nctid,status,why_stop,label,phase,diseases,icdcodes,drugs,smiless,criteria
NCT02578121,withdrawn,"
    investigator decided to close study without enrollment
  ",0,phase 2,['multiple myeloma'],"[""['C90.01', 'C90.02', 'C90.00']""]","['ixazomib', 'pomalidomide', 'dexamethasone']","['B(C(CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O', 'C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N', 'CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C']","
        Inclusion Criteria:

          -  Each patient must meet all of the following inclusion criteria to be enrolled in the
             study:

               -  Male or female patients 18 years or older.

               -  Voluntary written consent must be given before performance of any study related
                  procedure not part of standard medical care, with the understanding that consent
                  may be withdrawn by the patient at any time without prejudice to future medical
                  care.

               -  Female patients who:

        Are postmenopausal for at least 1 year before the screening visit, OR Are surgically
        sterile, OR If they are of childbearing potential, agree to practice 2 effective methods of
        contraception, at the same time, from the time of signing the informed consent form through
        90 days after the last dose of study drug, AND Agree to practice true abstinence when this
        is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg,
        calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not
        acceptable methods of contraception.)

          -  Male patients, even if surgically sterilized (ie, status post-vasectomy), must agree
             to one of the following: Agree to practice effective barrier contraception during the
             entire study treatment period and through 90 days after the last dose of study drug,
             OR Agree to practice true abstinence when this is in line with the preferred and usual
             lifestyle of the subject. (Periodic abstinence (eg, calendar, ovulation,
             symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of
             contraception.)

          -  Patients must have a diagnosis of relapsed and/or refractory multiple myeloma and must
             have received at least one line of prior therapy. Patients must be at least 14 days
             beyond the last multiple myeloma therapy and have recovered from acute toxicities of
             prior therapies measured by CTCAE (Version 4.0)

          -  Patients must have life expectancy of at least 3 months.

          -  Eastern Cooperative Oncology Group (ECOG) performance status and/or other performance
             status 0, 1, or 2.

          -  Patients must meet the following clinical laboratory criteria:

        Absolute neutrophil count (ANC) > 1,000/mm3 and platelet count> 50,000/mm3. Platelet
        transfusions to help patients meet eligibility criteria are not allowed within 3 days
        before study enrollment. Total bilirubin <1.5 x the upper limit of the normal range (ULN).
        Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 x ULN. Calculated
        creatinine clearance > 30 mL/min (see APPENDIX C for the Cockcroft-Gault Equation).,

        Exclusion Criteria:

        - Patients meeting any of the following exclusion criteria are not to be enrolled in the
        study:

          -  Female patients who are lactating or have a positive serum pregnancy test during the
             screening period.

          -  Failure to have fully recovered (ie, < Grade 1 toxicity) from the reversible effects
             of prior chemotherapy.

          -  Major surgery within 14 days before enrollment.

          -  Radiotherapy within 14 days before enrollment. If the involved field is small, 7 days
             will be considered a sufficient interval.

          -  Central nervous system involvement.

          -  Infection requiring systemic antibiotic therapy or other serious infection within 14
             days before study enrollment.

          -  Evidence of current uncontrolled cardiovascular conditions, including uncontrolled
             hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure,
             unstable angina, or myocardial infarction within the past 6 months.

          -  Ongoing or active systemic infection, active hepatitis B or C virus infection, or
             known human immunodeficiency virus (HIV) positive.

          -  Any serious medical or psychiatric illness that could, in the investigator's opinion,
             potentially interfere with the completion of treatment according to this protocol.

          -  Known allergy to any of the study medications, their analogues, or excipients in the
             various formulations of any agent.

          -  Known GI disease or GI procedure that could interfere with the oral absorption or
             tolerance of oral medications including difficulty swallowing.

          -  Diagnosed or treated for another malignancy within 2 years before study enrollment or
             previously diagnosed with another malignancy and have any evidence of residual
             disease. Patients with non-melanoma skin cancer or carcinoma in situ of any type are
             not excluded if they have undergone complete resection.

          -  Patient has > Grade 3 peripheral neuropathy, or Grade 2 with pain on clinical
             examination during the screening period.

          -  Participation in other clinical trials, including those with other investigational
             agents not included in this trial, within 21 days of the start of this trial and
             throughout the duration of this trial.
      "
NCT02574598,completed,,1,phase 2,"['carcinoma, non-small-cell lung']","[""['D02.20', 'D02.21', 'D02.22']""]","['mk-3475', 'docetaxel']",['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O'],"
        Inclusion Criteria:

          1. Signed written informed consent

               1. Patients should be signed and dated form of written informed consent approved by
                  the IRB / IEC in accordance with regulatory and institutional guidelines. This
                  must be obtained before performing any procedure related to the protocol that are
                  not part of the normal care of the patient.

               2. Patients must be willing and able to comply with scheduled visits , treatment
                  program , laboratory testing including filling of questionnaires the results
                  reported by the patient and other study requirements .

          2. Target Population

               1. Subjects with locally advanced NSCLC of squamous cell and non-squamous cell
                  (adenocarcinoma and big cells) histological or cytologically documented , those
                  who submit Stage IIIB / IV or recurrent disease after receiving radiation
                  treatment or surgical resection

               2. Men and women ≥ 18 years of age.

               3. Performance status Eastern Cooperative Oncology Group ( ECOG ) ≤ 1.

               4. Subjects must have measurable disease by CT or MRI according to RECIST 1.1
                  criteria Radiographic Evaluation of Tumor on in the span of 28 days before
                  randomization.

               5. The target lesions may be located on a previously irradiated field exists if
                  documented progression of disease (radiographic) in that site. Subjects
                  progression or recurrence of the disease must have experienced during or after
                  prior chemotherapy regimen containing platinum in metastatic disease.

                  This includes individuals who meet the following criteria:

                    1. Subjects who received pemetrexed, bevacizumab or erlotinib as maintenance
                       therapy (non-progressors double platinum-based chemotherapy) and progressed
                       are eligible However, patients who received a wild EGFR tyrosine kinase
                       inhibitor after failure of prior platinum-based therapy were excluded.

                    2. Eligible patients who received double- platinum -based chemotherapy in
                       adjuvant or neo adjuvant (after surgery and / or radiation) and developed
                       recurrent or metastatic disease within 6 months after treatment ends

                    3. Eligible individuals with recurrent disease > 6 months after adjuvant
                       chemotherapy or neoadjuvant platinum-based , who also subsequently
                       progressed during or after one platinum-based doublet regimen to treat
                       recurrences

                    4. Subjects with a known mutation of EGFR and received EGFR TKI (erlotinib ,
                       gefitinib or experimental) and double platinum-based chemotherapy (
                       regardless of the order of administration).

                    5. subjects with known ALK translocation double receiving platinum-based
                       chemotherapy and ALK inhibitor ( crizotinib or experimental )

                    6. patients who have received >30Gy to the chest should have waited at least 6
                       months from completing radiation to starting pembrolizumab.

               6. must be available a blood sample, for evaluation of biomarkers. Samples must be
                  received by the central laboratory before randomization.

               7. All baseline laboratory requirements will be evaluated , and must be obtained -14
                  days of randomization. The screening laboratory values must meet the following
                  criteria:

             i) WBC ≥ 2000/μL ii) iNeutrophils ≥ 1500/μL iii) Platelets ≥ 100 x 10 ³ / uL iv)
             Hemoglobin ≥ 9.0 g / dL v) Serum creatinine ≤ 1.5 x ULN or creatinine clearance > 40
             mL / min (using the Cockcroft / Gault ) Women : CrCl = (140 - age in years) x weight
             in kg x 0.85 72 x serum creatinine in mg / dL Males: CrCl = (140 - age in years) x
             weight in kg x 1.00 72 x serum creatinine in mg / dL vi) ≤ 1.5 X ULN AST vii) ≤ 1.5 X
             ULN ALT viii) Total bilirubin ≤ 1.5x ULN (except for subjects with Gilbert 's Syndrome
             who must have total bilirubin < 3.0 mg / dL ) h ) pretreatment with radiotherapy or
             radiosurgery at least 3 weeks must be completed before randomization.

             i ) Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis. Subjects with previously treated brain metastases may participate provided
             they are stable (without evidence of progression by imaging for at least four weeks
             prior to the first dose of trial treatment and any neurologic symptoms have returned
             to baseline), have no evidence of new or enlarging brain metastases, and are not using
             steroids for at least 7 days prior to trial treatment. This exception does not include
             carcinomatous meningitis which is excluded regardless of clinical stability.

          3. Age and Reproductive Status

               1. Women with reproductive potential ( WOCBP ) should use contraceptive methods
                  based on tables found in Appendix 2 . When a teratogenic drug test is used , and
                  / or a drug for which there is not enough information to assess teratogenicity (
                  have not been conducted preclinical studies) are required to use a highly
                  effective method of contraception ( failure rate less than 1 % per year).
                  Individual methods of contraception should be determined in consultation with the
                  researcher.

               2. The WOCBP must have a negative pregnancy test in serum or urine ( minimum
                  sensitivity 25 IU / L or equivalent units of HCG ) 24 hours before starting the
                  investigational product .

               3. Women should not be breastfeeding .

          4. Subjects must:

               1. Be willing and able to provide written informed consent/assent for the trial.

               2. Be > 18 years of age on day of signing informed consent.

               3. Have measurable disease based on RECIST 1.1.

               4. Have provided tissue from an archival tissue sample or newly obtained core or
                  excisional biopsy of a tumor lesion.

               5. Have a performance status of 0 or 1 on the ECOG Performance Scale.

        6. Demonstrate adequate organ function as defined in Table 1, all screening labs should be
        performed within 10 days of treatment initiation.

        Exclusion Criteria:

        The subject must be excluded from participating in the trial if the subject:

          1. Is currently participating in or has participated in a study of an investigational
             agent or using an investigational device within 4 weeks of the first dose of
             treatment.

          2. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
             other form of immunosuppressive therapy within 7 days prior to the first dose of trial
             treatment.

          3. Has had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not
             recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents
             administered more than 4 weeks earlier.

          4. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy
             within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at
             baseline) from adverse events due to a previously administered agent.

               -  Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and
                  may qualify for the study.

               -  Note: If subject received major surgery, they must have recovered adequately from
                  the toxicity and/or complications from the intervention prior to starting
                  therapy.

          5. Has a known additional malignancy that is progressing or requires active treatment.
             Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the
             skin, or in situ cervical cancer that has undergone potentially curative therapy.

          6. Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis. Subjects with previously treated brain metastases may participate provided
             they are stable (without evidence of progression by imaging for at least four weeks
             prior to the first dose of trial treatment and any neurologic symptoms have returned
             to baseline), have no evidence of new or enlarging brain metastases, and are not using
             steroids for at least 7 days prior to trial treatment.

          7. Has an active autoimmune disease requiring systemic treatment within the past 3 months
             or a documented history of clinically severe autoimmune disease, or a syndrome that
             requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or
             resolved childhood asthma/atopy would be an exception to this rule. Subjects that
             require intermittent use of bronchodilators or local steroid injections would not be
             excluded from the study. Subjects with hypothyroidism stable on hormone replacement or
             Sjorgen's syndrome will not be excluded from the study.

          8. Has evidence of interstitial lung disease or active, non-infectious pneumonitis.

          9. Has an active infection requiring systemic therapy.

         10. Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the subject's
             participation for the full duration of the trial, or is not in the best interest of
             the subject to participate, in the opinion of the treating investigator.

         11. Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial.

         12. Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the pre-screening or screening visit
             through 120 days after the last dose of trial treatment.

         13. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or
             anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including
             ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation
             or checkpoint pathways).

         14. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).

         15. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA
             [qualitative] is detected).

         16. Has received a live vaccine within 30 days prior to the first dose of trial treatment.
      "
NCT02573935,terminated,"
    suspected side effects to the combination of clarithromycin and vcd (bortezomib,
    cyclophosphamide and dexamethasone)
  ",0,phase 2,['multiple myeloma'],"[""['C90.01', 'C90.02', 'C90.00']""]","['clarithromycin', 'placebo', 'vcd induction therapy']",['CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OC)C)C)O)(C)O'],"
        Inclusion Criteria:

          -  Myeloma diagnosis according to IMWG criteria

          -  Treatment demanding disease

          -  High-dose melphalan with stem cell support scheduled as a part of the treatment

          -  Signed informed consent given prior to any study related activities

          -  Age > 18 years

        Exclusion Criteria:

          -  Allogeneic transplantation scheduled as a part of the treatment

          -  Myeloma treatment prior to entry in the study, except radiotherapy,
             bisphosphonates/denosumab or corticosteroids for symptom control

          -  Concurrent disease making clarithromycin treatment unsuitable

          -  Positive pregnancy test (only applicable for women with childbearing potential)

          -  Known or suspected hypersensitivity or intolerance to clarithromycin

          -  Prolonged QT corrected (QTc) interval ( > 500 msec on screening ECG)

          -  Concurrent treatment with cabergoline, fluconazole, ketoconazole, pimozide,
             quetiapine, sirolimus, verapamil, tacrolimus, ergot alkaloid, simvastatin or other
             statins

          -  Uncontrolled or severe cardiovascular disease including myocardial infarction within 6
             months of enrolment, uncontrolled angina or known cardiac amyloidosis

          -  Severe renal dysfunction (estimated creatinine clearance <10 mL/min)

          -  Serious medical or psychiatric illness which, in the judgment of the investigator,
             would make the patient inappropriate for entry into the study
      "
NCT02572492,unknown status,,1,phase 2,['multiple myeloma'],"[""['C90.01', 'C90.02', 'C90.00']""]","['induction with car-cy-dex and conditioning with carfilzomib and highdose melphalan', 'carfilzomib/dexamethasone maintenance', 'observation without carfilzomib/dexamethasone maintenance']",['Status: 400'],"
        Inclusion Criteria:

          -  Myeloma diagnosis according to IMWG criteria

          -  First treatment demanding relapse after HDT according to IMWG criteria

          -  More than 2.0 x 10m CD34+ stem cells / kg body weight in the freezer for stem cell
             support

          -  Signed informed consent given prior to any study related activities have been
             performed

          -  Age > 18 years

        Exclusion Criteria:

        Demographic

          -  Allogeneic transplantation scheduled as a part of the treatment

          -  Treatment demanding relapse less than one year after HDT

          -  Myeloma treatment after the first HDT, except radiotherapy, bisphosphonates, denosumab
             and corticosteroids less than 6 days for symptom control

          -  Patients not having received HDT as first line treatment

          -  Previous treatment with carfilzomib

          -  Expected survival of less than six months

          -  Performance status (WHO) ≥ 3

        Laboratory

          -  Serum M-component < 5 g/l and urine M-component < 200 mg/l

          -  Any of the following laboratory abnormalities:

               -  Absolute neutrophil count (ANC) < 1.0 × 109/L

               -  Hemoglobin < 5 mmol/L (<80 g/L) (prior RBC transfusion or recombinant human
                  erythropoietin use is permitted)

               -  Platelet count < 50 × 109/L (< 30 × 109/L if myeloma involvement in the bone
                  marrow is > 50%)

               -  Serum ALT or AST > 3.5 times the upper limit of normal and serum direct bilirubin
                  > 34 µmol/L (2 mg/dL)

               -  Creatinine clearance (CrCl) < 15 mL/minute, either measured or calculated using a
                  standard formula

        Concurrent conditions

          -  Concurrent disease making treatment with carfilzomib, cyclophosphamide or
             dexamethasone unsuitable

          -  Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to
             enrolment

          -  Major surgery within 21 days prior to enrolment

          -  Acute active infection requiring treatment

          -  Known or suspected hypersensitivity or intolerance to melphalan, dexamethasone or
             Captisol® (a cyclodextrin derivative)

          -  Uncontrolled or severe cardiovascular disease including myocardial infarction within 6
             months of enrolment, NYHA Class III or IV heart failure, uncontrolled angina,
             clinically significant pericardial disease, uncontrolled severe arrhythmias, or
             cardiac amyloidosis

          -  LVEF <40%, determined by 2-D transthoracic echocardiogram (ECHO) or Multigated
             Acquisition Scan (MUGA)

          -  Pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14
             days prior to enrolment

          -  Serious hepatic disorder, including active hepatitis B or C infection

          -  Other serious medical or psychiatric illness likely to interfere with participation in
             this clinical study

          -  Use of any investigational agents or experimental medical device within 28 days prior
             to enrolment into the study

        Ethical/other

          -  Pregnant or lactating females

          -  Females of childbearing potential must agree to ongoing pregnancy testing and to
             practice contraception

          -  Male subjects must agree to practice contraception
      "
NCT02575300,completed,,0,phase 2,"['carcinoid tumors', 'pancreatic net']","[""['C7A.00', 'C7A.010', 'C7A.011', 'C7A.012', 'C7A.020', 'C7A.021', 'C7A.026']""]",['ibrutinib'],['C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N'],"
        Inclusion Criteria:

          -  Locally unresectable or metastatic carcinoid or pancreatic neuroendocrine tumors
             (pNETs)

          -  Measureable disease by Response Evaluation Criteria in Solid Tumors (RECIST)

          -  Tumors must be histologically or cytologically proven and considered low or
             intermediate grade. Patients with high grade neuroendocrine carcinomas or small cell
             carcinomas are excluded from the study.

          -  Evidence of progressive disease within 12 months of study entry

          -  Allowed prior therapies include: a) Surgery (major surgery at least more than four
             weeks prior to baseline assessment); b) Locoregional therapy such as:
             chemoembolization, radio-embolization, radiofrequency ablation, radiotherapy as long
             as there is progressive measurable disease outside the area of locoregional therapy or
             there is progression in the previously treated areas; c) Any number of previous lines
             of systemic therapy. Last treatment before enrollment must have occurred more than 4
             weeks for chemotherapy, 6 weeks for antibodies or more than 5 half-lives of prior
             tyrosine kinase inhibitors (TKIs) or small molecules.

          -  Prior or concurrent therapy with somatostatin analogs is permitted for patients with
             secretory NET

          -  All patients with gastroenteropancreatic NETs must have progressed on (or are
             intolerant of) prior somatostatin analog.

          -  Patients with pancreatic NETs must have progressed on (or are intolerant of) either
             everolimus or sunitinib.

          -  Age ≥ 18 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          -  Life expectancy 12 weeks or more

          -  Adequate bone marrow function as shown by: absolute neutrophil count ≥ 1,000/mm^3,
             Platelets ≥ 100,000/mm^3, Hb > 10 g/dl

          -  Adequate liver function as shown by: serum bilirubin ≤ 1.5 x ULN, and serum
             transaminases activity ≤ 2.5 x ULN, with the exception of serum transaminases (< 3 x
             ULN) if the patient has liver metastases

          -  Adequate renal function as shown by serum creatinine ≤ 2 mg/dl

          -  Women of childbearing potential must have a negative serum pregnancy test within 7
             days of the administration of the first study treatment. Women must not be lactating.
             Both men and women of childbearing potential must be advised of the importance of
             using effective birth control measures during the course of the study.

          -  Signed informed consent to participate in the study must be obtained from patients
             after they have been fully informed of the nature and potential risks by the
             investigator (or his/her designee) with the aid of written information.

        Exclusion Criteria:

          -  High grade NET or small cell neuroendocrine carcinoma

          -  Clinically apparent central nervous system metastases or carcinomatous meningitis

          -  Known positive test for human immunodeficiency virus (HIV), hepatitis B virus (HBV),
             or hepatitis C virus (HCV)

          -  History of stroke or intracranial hemorrhage within 6 months prior to the first dose
             of study drug

          -  Clinically significant cardiovascular disease such as uncontrolled or symptomatic
             arrhythmias, congestive heart failure, or myocardial infarction within 6 months of
             screening, or any class III or IV cardiac disease as defined by the New York Heart
             Association (NYHA) functional classification

          -  Requirement for anticoagulation with warfarin or similar vitamin K antagonists.

          -  Requirement for treatment with a strong cytochrome P450 (CYP) 3A4/5

          -  Prior antitumor therapy within 2 weeks of enrollment (with the exception of
             somatostatin analogs)

          -  No other active malignancy within 3 years of enrolment except adequately treated basal
             cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I
             or II cancer from which the patient is currently in complete remission, or any other
             cancer from which the patient has been disease free for at least three years

          -  Any medical condition or organ system dysfunction which, in the investigator's
             opinion, could compromise the patient's safety, interfere with the absorption or
             metabolism of ibrutinib

          -  Known hypersensitivity to ibrutinib or any component of the ibrutinib formulation

          -  History of noncompliance to medical regimens or unwillingness to comply with the
             protocol

          -  Currently active, clinically significant hepatic impairment Child-Pugh class B or C
             according to the Child Pugh classification
      "
NCT02579616,completed,,1,phase 2,['biliary tract cancer'],"[""['C24.9', 'C24.8']""]",['lenvatinib'],['COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl'],"
        Inclusion Criteria:

          1. Pathologically or cytologically confirmed adenocarcinoma of biliary tract cancer
             (intrahepatic, extrahepatic cholangiocarcinoma, gall bladder cancer, and ampulla of
             Vater cancer)

          2. Unresectable (eg, locally advanced or metastatic) BTC

          3. One prior gemcitabine-based doublet chemotherapy (eg, gemcitabine and cisplatin) to
             unresectable BTC and not treated by any other chemotherapy to BTC

               -  Participants who received adjuvant chemotherapy are eligible if this therapy was
                  completed and recurrent has not been shown for 6 months after the completion of
                  the therapy

          4. Measurable disease meeting the following criteria:

               -  At least 1 lesion of ≥ 1.0 cm in the longest diameter for a non-lymph node or ≥
                  1.5 cm in the short-axis diameter for a lymph node that is serially measurable
                  according to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST1.1) using
                  computerized tomography/magnetic resonance imaging (CT/MRI)

               -  Lesions that have had external beam radiotherapy (EBRT) or locoregional therapies
                  such as radiofrequency (RF) ablation must show evidence of progressive disease
                  based on RECIST 1.1 to be deemed a target lesion

          5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1

          6. Survival expectation of 3 months or longer after beginning of study treatment

          7. Males or females age ≥ 20 years at the time of informed consent

          8. All chemotherapy- or radiation-related toxicities must have resolved to Grade 0-1 per
             Common Terminology Criteria for Adverse Events (CTCAE v 4.03), except alopecia,
             infertility, and the adverse events listed in inclusion criteria

          9. Adequately controlled blood pressure (BP) with or without antihypertensive medications
             (defined as BP ≤ 150/90 mm Hg at Screening and no change in antihypertensive
             medications within 1 week prior to the first dose of study drug)

         10. Participants with adequate function of major organs and blood coagulation:

               -  Absolute neutrophil count (ANC) ≥ 1500/mm^3 ( ≥ 1.5×103/μl)

               -  Platelets ≥ 100,000/mm3 ( ≥ 100×10^9/L)

               -  Hemoglobin ≥ 9.0 g/dL

               -  Bilirubin ≤ 2.0 mg/dL except for unconjugated hyperbilirubinemia or Gilbert's
                  syndrome

               -  Alkaline phosphatase (ALP), aspartate aminotransferase (AST), and alanine
                  aminotransferase (ALT) ≤ 3.0 × upper limit of normal (ULN) ( ≤ 5.0 × ULN for
                  participants with the liver metastasis)

               -  Creatinine clearance ≥ 40 mL/min per the Cockcroft and Gault formula

               -  Prothrombin time-International Normalized Ratio (PT-INR) ≤ 1.5

         11. Participants must voluntarily agree to provide written informed consent

         12. Participants must be willing and able to comply with all aspects of the protocol

        Exclusion Criteria:

          1. Any anti-cancer treatment (except BSC) within 21 days prior to the first dose of study
             drug

          2. Major surgery (any surgical procedure that involves anesthesia or respiratory
             assistance) within 21 days prior to the first dose of study drug or scheduled surgery
             during the study (except for bile duct drainage)

          3. Ascites of moderate, severe, or requiring drainage

          4. Proteinuria of ≥ 2+ on dipstick testing (Grade ≤ 1 confirmed by quantitative
             assessment is eligible)

          5. Gastrointestinal malabsorption or any other condition that in the opinion of the
             investigator might affect the absorption of study drug

          6. New York Heart Association congestive heart failure of class II or above, unstable
             angina, myocardial infarction, or serious cardiac arrhythmia associated with
             significant cardiovascular impairment within the past 6 months from the first dose of
             study drug

          7. A prolonged QT/QTc interval (QTcF > 480 ms)

          8. Known to be human immunodeficiency virus (HIV) positive

          9. Active infection requiring systemic treatment

         10. Bleeding or thrombotic disorders or chronic systemic use of anticoagulants requiring
             therapeutic INR monitoring, eg, warfarin or similar agents (treatment with low
             molecular weight heparin is permitted)

         11. Gastrointestinal bleeding event or active hemoptysis (bright red blood of at least 0.5
             teaspoon) within 21 days prior to the first dose of study drug

         12. Active malignancy (except for BTC or definitively treated melanoma in-situ, basal or
             squamous cell carcinoma of the skin, carcinoma in-situ of the cervix, or early stage
             gastric/colorectal cancer) within the past 24 months prior to the first dose of study
             drug

         13. Diagnosed with meningeal carcinomatosis

         14. Participants with brain or subdural metastases are not eligible, unless they have
             completed local therapy and have discontinued the use of corticosteroids for this
             indication for at least 28 days prior to the first dose of study drug. Any signs (eg,
             radiologic) or symptoms of brain metastases must be stable for at least 28 days prior
             to the first dose of study drug.

         15. Known intolerance to the study drug or any of the excipients

         16. History of drug or alcohol dependency or abuse within the last 24 months prior to the
             first dose of study drug

         17. Any medical or other condition that in the opinion of the investigator(s) would
             preclude the participant's participation in a clinical study

         18. Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a
             positive human chorionic gonadotropin [hCG or B-hCG]). A separate baseline assessment
             is required if a negative screening pregnancy test was obtained more than 3 days
             before the first dose of study drug.

         19. For either males unless undergoing a successful vasectomy (confirmed azoospermia) or
             females of childbearing potential, the participant and his/her partner do not agree to
             use a medically appropriate method of contraception throughout the entire study period

               -  the use of condom, contraceptive sponge, contraceptive foam, contraceptive jelly,
                  diaphragm, or intrauterine device, otherwise using oral contraceptive
                  (percutaneous or transvaginal also allowed) for at least 28 days before the first
                  dose of study drug
      "
NCT02579811,completed,,1,phase 2,['metastatic renal cell cancer'],"[""['C96.20', 'C96.29', 'D47.09']""]",['axitinib'],['CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4'],"
        Inclusion Criteria:

          -  Histologically confirmed, locally recurrent or metastatic clear cell renal cell
             carcinoma

          -  Has received one prior systemic therapy regimen for Metastatic Renal Cell Carcinoma
             (mRCC) directed against PD-1 and/or PD-L1 which must have been the most recent regimen

               -  Prior high-dose interleukin-2 therapy is permitted in addition to anti-PD(L)1
                  therapy, but is not required

               -  Prior bevacizumab or Vascular Endothelial Growth Factor (VEGF) Tyrosine Kinas
                  Inhibitor (TKI) is permitted either in combination with anti-PD(L)1 therapy OR as
                  monotherapy when given PRIOR to anti-PD(L)1 therapy

               -  Prior treatment with combined ipilimumab and nivolumab is permitted

               -  Prior axitinib in any setting is not permitted

               -  A minimum of two weeks since last dose of most recent renal cell cancer therapy
                  assuming resolution of clinically significant treatment-related toxicities to
                  grade 1, baseline, or controlled with supportive medications

          -  Evidence of measurable disease per RECIST 1.1.

          -  Karnofsky performance status ≥ 70 %.

          -  Adequate organ function as defined by:

               -  Absolute neutrophil count (ANC) ≥1,000/μL

               -  Platelets ≥100,000/μL

               -  Hemoglobin ≥9.0 g/dL

               -  Serum calcium ≤12.0 mg/dL

               -  Serum creatinine ≤2.0 x Upper Limit of Normal (ULN)

               -  Total serum bilirubin ≤1.5 x ULN

               -  SGOT≤2.5 x ULN and Serum Glutamic Pyruvic Transaminase (SGPT) ≤2.5x ULN

          -  Signed informed consent and willingness/ability to comply with scheduled visits,
             treatment plans, laboratory tests, and other study procedures

        Exclusion Criteria:

          -  Non clear cell Renal Cell Carcinoma (RCC)

          -  Major surgery within 4 weeks of starting the study treatment.

          -  Radiation therapy within 2 weeks of starting the study treatment. Prior palliative
             radiotherapy to metastatic lesion(s) is permitted, provided there is at least one
             measurable lesion that has not been irradiated.

          -  NCI CTCAE Version 4.03 grade 3 hemorrhage within 4 weeks of starting the study
             treatment.

          -  Any of the following within the 6 months prior to study drug administration:
             myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass
             graft, symptomatic congestive heart failure, cerebrovascular accident or transient
             ischemic attack.

          -  Ongoing cardiac dysrhythmias of NCI CTCAE Version 4.03 grade ≥2. Controlled atrial
             fibrillation is permitted.

          -  Uncontrolled hypertension (>160/100 mm Hg despite optimal medical therapy)

          -  Concurrent treatment on another clinical trial. Supportive care trials or
             non-treatment trials, e.g. QOL, and imaging trials, are allowed.

          -  Pregnancy or breastfeeding. Female subjects must be surgically sterile or be
             postmenopausal, or must agree to use effective contraception during the period of
             therapy. All female subjects with reproductive potential must have a negative
             pregnancy test (serum) prior to enrollment. Male subjects must be surgically sterile
             or must agree to use effective contraception during the period of therapy. The
             definition of effective contraception will be based on the judgment of the principal
             investigator or a designated associate

          -  Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or study
             drug administration, or may interfere with the interpretation of study results, and in
             the judgment of the investigator would make the subject inappropriate for entry into
             this study.

          -  Uncontrolled Central Nervous System (CNS) metastases. Patients are considered to have
             controlled CNS metastases (and thus eligible) if they have completed local therapy
             (XRT and/or surgery) and are off steroids with clinical and radiographic stability 3
             months from the end of CNS-directed therapy.
      "
NCT02642042,"active, not recruiting",,1,phase 2,"['kras gene mutation', 'recurrent lung non-small cell carcinoma', 'stage iv lung non-small cell cancer ajcc v7']","[""['D02.20', 'D02.21', 'D02.22']"", ""['C96.20', 'C96.29', 'D47.09']""]","['docetaxel', 'trametinib']","['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O', 'CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5']","
        Inclusion Criteria:

          -  DISEASE RELATED CRITERIA: Patients must have pathologically confirmed KRAS mutation
             (at codon 12, 13 and 61) positive non-small cell lung cancer (NSCLC) that is stage IV
             or recurrent; the specific subtype of KRAS mutation must be known; KRAS mutation
             testing must have been performed in a Clinical Laboratory Improvement Act (CLIA)
             certified laboratory; CLIA certified commercially available tests are acceptable

          -  DISEASE RELATED CRITERIA: Patients must have measurable disease documented by computed
             tomography (CT) or magnetic resonance imaging (MRI) within 28 days prior to
             registration; the CT from a combined positron emission tomography (PET)/CT may be used
             only if it is of diagnostic quality; non-measurable disease must be assessed within 42
             days prior to registration; all known sites of disease must be assessed and documented
             on the baseline tumor assessment form (Response Evaluation Criteria in Solid Tumors
             [RECIST 1.1])

          -  DISEASE RELATED CRITERIA: Patients must not have known brain metastases,
             leptomeningeal carcinomatosis or spinal cord compression unless: (1) metastases have
             been locally treated (including stereotactic body radiation therapy [SBRT], whole
             brain radiotherapy [WBRT], and surgical resection) and have remained clinically
             controlled and asymptomatic for at least 14 days following treatment and prior to
             registration, AND (2) patient has no residual neurological dysfunction and has been
             off corticosteroids for at least 2 days prior to registration

          -  PRIOR/CONCURRENT THERAPY CRITERIA: Patients must have documented progressive cancer
             following at least one but no more than two prior regimens of systemic therapy for
             lung cancer, one of which must have been platinum based combination chemotherapy;
             treatment with an immune therapy or targeted therapy for advanced disease will be
             considered a separate regimen and will count toward the prior regimens; maintenance
             therapy will not be counted as a separate regimen; adjuvant chemotherapy or
             chemotherapy administered as part of concurrent chemotherapy and radiation therapy for
             the treatment of lung cancer will not count as a prior regimen of systemic therapy as
             long as recurrence of patient's lung cancer occurred more than 12 months after the
             last day of chemotherapy

          -  PRIOR/CONCURRENT THERAPY CRITERIA: Patients must not have received any chemotherapy,
             biologic agent, or any investigational agent within 14 days prior to registration.
             Patients must have recovered from any adverse events to Common Terminology Criteria
             for Adverse Events (CTCAE) grade 0-1 prior to registration

          -  PRIOR/CONCURRENT THERAPY CRITERIA: Prior treatment with an anti-PD-1 or anti-PDL1 is
             not required

          -  PRIOR/CONCURRENT THERAPY CRITERIA: Patients must not have received prior docetaxel;
             patients must not have received therapy with a drug known to be either a
             mitogen-activated protein kinase (MEK) inhibitor or a phosphatidylinositol 3 kinase
             (PI3K)/v-akt murine thymoma viral oncogene homolog 1 (AKT)/mammalian target of
             rapamycin (mTOR) pathway inhibitor

          -  PRIOR/CONCURRENT THERAPY CRITERIA: Patients must have recovered from any adverse
             effects from prior therapy (except alopecia) to =< CTCAE grade 1 prior to registration

          -  PRIOR/CONCURRENT THERAPY CRITERIA: Patients may have had prior radiation therapy as
             long as it has not affected greater than 25% of the bone marrow and at least one
             measurable lesion is outside the area of prior radiation; at least 7 days must have
             elapsed since last radiation treatment; patients must have recovered from any adverse
             events from prior radiation therapy to =< CTCAE grade 1

          -  PRIOR/CONCURRENT THERAPY CRITERIA: Patients must not have had a major surgery within
             28 days prior to registration; patients must have recovered from any adverse effects
             of prior surgery to the satisfaction of the treating physician; biopsies and central
             IV access placement are not considered major surgery

          -  PRIOR/CONCURRENT THERAPY CRITERIA: Because the composition, pharmacokinetics (PK), and
             metabolism of many herbal supplements are unknown, the concurrent use of all herbal
             supplements is prohibited during the study (including but not limited to St. John's
             wort, kava, ephedra [ma huang], ginko biloba, dehydroepiandrosterone [DHEA], yohimbe,
             saw palmetto, or ginseng)

          -  CLINICAL/LABORATORY CRITERIA: Patients must have Zubrod performance status of 0-2

          -  CLINICAL/LABORATORY CRITERIA: Absolute neutrophil count (ANC) >= 1500/mcL; these
             results must be obtained within 28 days prior to registration

          -  CLINICAL/LABORATORY CRITERIA: Platelet count >= 100,000/mcL; these results must be
             obtained within 28 days prior to registration

          -  CLINICAL/LABORATORY CRITERIA: Hemoglobin >= 9 grams/dl; these results must be obtained
             within 28 days prior to registration

          -  CLINICAL/LABORATORY CRITERIA: Total bilirubin =< 1.5 x institutional upper limit of
             normal (IULN); these results must be obtained within 28 days prior to registration

          -  CLINICAL/LABORATORY CRITERIA: Aspartate aminotransferase (AST) and alanine
             aminotransferase (ALT) =< 2.5 x IULN (or =< 5 x IULN for patients with known liver
             metastases); these results must be obtained within 28 days prior to registration

          -  CLINICAL/LABORATORY CRITERIA: Serum creatinine =< 1.5 x IULN OR measured or calculated
             creatinine clearance >= 40 mL/min; this result must have been obtained within 28 days
             prior to registration

          -  CLINICAL/LABORATORY CRITERIA: Patients must be able to swallow oral medications and
             must not have a gastro-intestinal disorder with diarrhea as a major symptom or that
             may alter absorption such as malabsorption syndromes or gastric resection

          -  CLINICAL/LABORATORY CRITERIA: Patient must not have prior history of interstitial lung
             disease or pneumonitis

          -  CLINICAL/LABORATORY CRITERIA: Patients must not have history of significant co-morbid
             illness inclusive of but not restricted to New York Heart Association class II,
             congestive cardiac failure, uncontrolled hypertension, history of myocardial
             infarction, unstable angina, coronary angioplasty, stenting or cerebrovascular
             accident within 6 months prior to registration or any other illness that in the
             assessment of the treating physician would compromise the ability of the patient to
             participate in this study

          -  CLINICAL/LABORATORY CRITERIA: Patients must have corrected QT (QTc) interval =< 480
             msec (using the Bazett's formula) on electrocardiogram (ECG) performed within 42 days
             prior to registration; history or evidence of current clinically significant
             uncontrolled arrhythmias are not eligible; however, patients with controlled atrial
             fibrillation for > 30 days prior to randomization are eligible; patients must not have
             atrial fibrillation > grade 2 on the screening ECG; patients with CTCAE grade 1-2
             atrial fibrillation on their screening ECG must have a second ECG performed prior to
             registration and more than 30 days from the screening ECG (either before or after)
             with the most recent ECG showing stable or improving grade of atrial fibrillation

          -  CLINICAL/LABORATORY CRITERIA: Patients must have a left ventricular ejection fraction
             (LVEF) >= institutional lower limit of normal (ILLN) by echocardiography (ECHO) or
             multi-gated acquisition scan (MUGA) within 42 days prior to registration

          -  CLINICAL/LABORATORY CRITERIA: Patients must not have untreated or unresolved
             retinopathy or have a history (or current evidence) of retinal vein occlusion
             determined by an ophthalmology exam within 42 days prior to registration

          -  CLINICAL/LABORATORY CRITERIA: Patients must not have an immediate or delayed
             hypersensitivity reaction or idiosyncrasy to drugs chemically related to trametinib,
             or excipients, or to dimethyl sulfoxide (DMSO) or other agents used in the study

          -  CLINICAL/LABORATORY CRITERIA: Patients must not have a known history of active
             hepatitis B or C infection (defined as presence of hepatitis [Hep] B surface antigen
             [sAg] and/or Hep B deoxyribonucleic acid [DNA] and/or Hep C ribonucleic acid [RNA]);
             patients must not have a known history of human immunodeficiency virus (HIV)
             seropositivity

          -  CLINICAL/LABORATORY CRITERIA: No other prior malignancy is allowed except for the
             following: adequately treated basal cell or squamous cell skin cancer, in situ
             cervical cancer, adequately treated stage I or II cancer from which the patient is
             currently in complete remission, or any other cancer from which the patient has been
             disease free for three years; patients with localized prostate cancer who are being
             followed by an active surveillance program are also eligible

          -  CLINICAL/LABORATORY CRITERIA: Patients must not be pregnant or nursing due to the risk
             of fetal or nursing infant harm; women/men of reproductive potential must have agreed
             to use an effective contraceptive method (hormonal or barrier method of birth control;
             abstinence) prior to study entry, during the study participation and for 4 months
             after the last dose of the drug; a woman is considered to be of ""reproductive
             potential"" if she has had menses at any time in the preceding 12 consecutive months;
             in addition to routine contraceptive methods, ""effective contraception"" also includes
             heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect
             of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or
             bilateral tubal ligation; however, if at any point a previously celibate patient
             chooses to become heterosexually active during the time period for use of
             contraceptive measures outlined in the protocol, he/she is responsible for beginning
             contraceptive measures

          -  SPECIMEN SUBMISSION CRITERIA: Patients must be offered optional participation in
             banking of specimens for future research

          -  REGULATORY CRITERIA: Patients must be informed of the investigational nature of this
             study and must sign and give written informed consent in accordance with institutional
             and federal guidelines

          -  REGULATORY CRITERIA: As a part of the Oncology Patient Enrollment Network (OPEN)
             registration process the treating institution's identity is provided in order to
             ensure that the current (within 365 days) date of institutional review board approval
             for this study has been entered in the system
      "
NCT02642965,completed,,1,phase 1/phase 2,"['recurrent childhood acute myeloid leukemia', 'secondary acute myeloid leukemia', 'therapy-related acute myeloid leukemia']","[""['G47.13', 'J01.41', 'K11.22', 'K12.0', 'N96', 'F33.8', 'G03.2']"", ""['D75.1', 'E26.1', 'N91.1', 'N91.4', 'N94.5', 'A51.41', 'A51.43']"", ""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']""]","['cytarabine', 'fludarabine phosphate', 'liposome-encapsulated daunorubicin-cytarabine']","['C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O', 'C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)COP(=O)(O)O)O)O)F)N']","
        Inclusion Criteria:

          -  Patients must have had histologic verification of AML at original diagnosis

          -  Patient must have one of the following:

               -  Recurrent disease with >= 5% blasts in the bone marrow (M2/M3 bone marrow), with
                  or without extramedullary disease.

               -  Recurrent disease with an absolute blast count greater than 1,000 per microliter
                  in the peripheral blood with or without extramedullary disease

          -  To be eligible for the dose-finding phase: (the dose-finding phase completed in
             12/2016)

               -  Relapsed patients

                    -  Patients must be in first relapse, and

                    -  Patients must not have received prior re-induction therapy

               -  Refractory patients

                    -  Patients must not have received more than one attempt at remission
                       induction, which may consist of up to two different therapy courses;
                       Children Oncology Group (COG) AAML1031 de novo therapy including induction I
                       and induction II is an example

               -  Treatment-related AML (t-AML)

                    -  Patients must be previously untreated for secondary AML

          -  To be eligible for the phase 2 efficacy phase:

               -  Relapse patients:

                    -  Patients must be in first marrow relapse, and

                    -  Patients must not have received prior re-induction therapy; donor lymphocyte
                       infusion (DLI) is considered a re-induction attempt

          -  Patients must have the status of CNS1 or CNS2 only, and no clinical signs or
             neurologic symptoms suggestive of CNS leukemia, such as cranial palsy

          -  Patients must have a performance status corresponding to an Eastern Cooperative
             Oncology Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients > 16 years of
             age and Lansky for patients =< 16 years of age; Note: patients who are unable to walk
             because of paralysis, but who are up in a wheelchair, will be considered ambulatory
             for the purpose of assessing the performance score

          -  Patients must have recovered from the acute toxic effects of all prior chemotherapy,
             immunotherapy, stem cell transplant or radiotherapy prior to entering this study; all
             prior treatment-related toxicities must have resolved to =< grade 2 prior to
             enrollment

          -  Myelosuppressive chemotherapy: must not have received myelosuppressive chemotherapy
             within 3 weeks of entry onto this study (excluding hydroxyurea)

               -  Cytoreduction with hydroxyurea can be initiated and continued for up to 24 hours
                  prior to the start of CPX-351

          -  Biologic (anti-neoplastic agent): at least 7 days since the completion of therapy with
             a biologic agent such as steroids, retinoids; Note: for agents that have known adverse
             events occurring beyond 7 days after administration (i.e. monoclonal antibodies), this
             period must be extended beyond the time during which acute adverse events are known to
             occur

          -  Radiation therapy (RT): >= 2 weeks for local palliative RT (small port); >= 6 months
             must have elapsed if prior craniospinal RT or if >= 50% radiation of pelvis; >= 6
             weeks must have elapsed if other substantial bone marrow (BM) radiation; Note:
             patients must have received =< than 13.6 Gray (Gy) prior radiation to the mediastinum

          -  Stem cell transplant (SCT): no evidence of active graft vs. host disease for at least
             4 weeks; for allogeneic SCT patients, >= 3 months must have elapsed since transplant

               -  Must have received no more than 1 prior autologous or allogeneic stem cell
                  transplant.

               -  Patients must be off all systemic immunosuppressive therapy for at least 2 weeks,
                  excluding hydrocortisone for physiologic cortisol replacement

          -  Intrathecal cytotoxic therapy:

               -  No waiting period is required for patients having received intrathecal
                  cytarabine, methotrexate, and/or hydrocortisone

               -  At least 14 days must have elapsed since receiving liposomal cytarabine
                  (DepoCyte) by intrathecal injection

          -  Growth factors:

               -  Patients must not have received growth factors for 7 days prior to CPX-351

               -  Patients must not have received pegfilgrastim for 14 days prior to CPX-351

          -  Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70
             mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows:

               -  Age 1 to < 2 years: maximum serum creatinine 0.6 mg/dL (males and females)

               -  Age 2 to < 6 years: maximum serum creatinine 0.8 mg/dL (males and females)

               -  Age 6 to < 10 years: maximum serum creatinine 1.0 mg/dL (males and females)

               -  Age 10 to < 13 years: maximum serum creatinine 1.2 mg/dL (males and females)

               -  Age 13 to < 16 years: maximum serum creatinine 1.5 mg/dL (males) and 1.4 mg/dL
                  (females)

               -  Age >= 16 years: maximum serum creatinine 1.7 mg/dL (males) and 1.4 mg/dL
                  (females)

          -  Direct bilirubin < 1.5 x upper limit of normal (ULN) for age and institution

          -  Serum glutamate pyruvate (SGPT) (alanine aminotransferase [ALT]) =< 3.0 x upper limit
             of normal (ULN) for age and institution (unless it is related to leukemic involvement)

          -  Shortening fraction of >= 27% by echocardiogram, or

          -  Ejection fraction of >= 50% by radionuclide angiogram or echocardiogram

          -  Corrected QT (using Bazett's formula [QTcB]) interval < 500 msecs

          -  Patients with seizure disorder may be enrolled if on anticonvulsants and if seizures
             are well controlled

          -  Central nervous system (CNS) toxicity =< grade 2

          -  Patients with a known history of human immunodeficiency virus (HIV) are eligible, if
             they meet all of the following conditions:

               -  No history of HIV complications with the exception of cluster of differentiation
                  (CD)4 count < 200 cells/mm^3

               -  No antiretroviral therapy with overlapping toxicity such as myelosuppression

               -  HIV viral loads below the limit of detection

               -  No history of highly active antiretroviral therapy (HAART)-resistant HIV

          -  All patients and/or their parents or legal guardians must sign a written informed
             consent

          -  All institutional, Food and Drug Administration (FDA), and National Cancer Institute
             (NCI) requirements for human studies must be met

        Exclusion Criteria:

          -  Patients who have received > 450 mg/m^2 daunorubicin equivalents; patients who relapse
             after receiving AAML0531/AAML1031 therapy will be eligible for this study, provided
             they have not received any additional anthracyclines; NOTE: for the purposes of
             determining eligibility for this protocol, the following cardiotoxicity multipliers
             will be used to determine daunorubicin equivalents:

               -  Doxorubicin (doxorubicin hydrochloride): 1

               -  Mitoxantrone: 3

               -  Idarubicin: 3

               -  Epirubicin: 0.5

          -  Patients who are currently receiving another investigational drug

          -  Patients receiving medications for treatment of left ventricular systolic dysfunction

          -  Patients with any of the following diagnoses:

               -  Acute promyelocytic leukemia (APL)

               -  Down syndrome

               -  Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone
                  marrow failure syndrome

               -  Wilson's disease and any other disorder of copper metabolism

               -  Juvenile myelomonocytic leukemia (JMML)

          -  Patients with documented active, uncontrolled infection at the time of study entry

          -  Patients with known active hepatitis B virus (HBV) and hepatitis C virus (HCV)
             infections

          -  Patients with prior allergy to daunorubicin and/or cytarabine

          -  Female patients who are pregnant are ineligible

          -  Lactating females are not eligible

          -  Female patients of childbearing potential are not eligible unless a negative pregnancy
             test result has been obtained

          -  Sexually active patients of reproductive potential are not eligible unless they have
             agreed to use an effective contraceptive method for the duration of their study
             participation and for 6 months after the last dose of chemotherapy
      "
NCT02649361,completed,,1,phase 2,['esophageal squamous cell carcinoma'],"[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]","['anlotinib', 'placebo']",['CC1=CC2=C(N1)C=CC(=C2F)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC'],"
        Inclusion Criteria:

          -  Histological documentation of esophageal squamous cell carcinoma；

          -  Advanced esophageal squamous cell carcinoma with distant metastasis(Stage IV),at least
             one measurable lesion (by RECIST1.1)

          -  Patients who at least have failed to a platinum-based chemotherapy treatment or
             chemotherapy containing paclitaxel.

        Note: (1) Each line treatment refers to treatment duration at least one cycle using
        monotherapy or drug combination; (2)Adjuvant chemotherapy or neoadjuvant chemoradiation is
        permitted before the study (if disease recurred during adjuvant chemotherapy/neoadjuvant
        chemoradiation or recurred within 6 months after stopping treatment, adjuvant
        chemotherapy/neoadjuvant chemoradiation can be considered as first line systemic
        chemotherapy;

          -  18-75 years,ECOG PS:0-2,Life expectancy of more than 3 months

          -  4 weeks or more from the last cytotoxic therapy, radiation therapy or surgery

          -  Main organs function is normal

          -  Women of childbearing potential should agree to use and utilize an adequate method of
             contraception (such as intrauterine device，contraceptive and condom) throughout
             treatment and for at least 6 months after study is stopped；the result of serum or
             urine pregnancy test should be negative within 7 days prior to study enrollment，and
             the patients required to be non-lactating；Man participants should agree to use and
             utilize an adequate method of contraception throughout treatment and for at least 6
             months after study is stopped

          -  Patients should participate in the study voluntarily and sign informed consent

        Exclusion Criteria:

          -  Patients whose primary lesion with active bleeding within 2 months

          -  Primary lesion not resected and has not shrinked after radiation therapy

          -  Patients who have been failure with anti-tumor angiogenesis drug treatment

          -  Patients with factors that could affect oral medication (such as dysphagia，chronic
             diarrhea, intestinal obstruction etc.)

          -  Brain metastases patients with symptoms or symptoms controlled < 3 months

          -  Patients with any severe and/or unable to control diseases，including：

               1. Blood pressure unable to be controlled ideally(systolic pressure≥150
                  mmHg，diastolic pressure≥100 mmHg);

               2. Patients with Grade 1 or higher myocardial ischemia, myocardial infarction or
                  malignant arrhythmias(including QT≥480ms) and patients with Grade 1 or higher
                  congestive heart failure (NYHA Classification);

               3. Patients with active or unable to control serious infections;

               4. Patients with cirrhosis, decompensated liver disease, or active hepatitis;

               5. Patients with poorly controlled diabetes (fasting blood glucose(FBG)>10mmol/L)

               6. Urine protein ≥ ++，and 24-hour urinary protein excretion>1.0 g confirmed

          -  Patients with non-healing wounds or fractures

          -  Patients with any CTC AE Grade 1 or higher bleeding events occurred in the lungs or
             any CTC AE Grade 2 or higher bleeding events occurred within 4 weeks prior to
             assignment;Patients with any physical signs of bleeding diathesis or receiving
             thrombolysis and anticoagulation

          -  Patients with arterial or venous thromboembolic events occurred within 6 months, such
             as cerebrovascular accident (including transient ischemic attack), deep vein
             thrombosis and pulmonary embolism

          -  Patients with drug abuse history and unable to get rid of or Patients with mental
             disorders

          -  Imaging showed tumors have involved important blood vessels or by investigators
             determine likely during the follow-up study and cause fatal hemorrhage

          -  Patients participated in other anticancer drug clinical trials within 4 weeks

          -  History of immunodeficiency

          -  Patients with concomitant diseases which could seriously endanger their own safety or
             could affect completion of the study according to investigators' judgment
      "
NCT01824823,terminated,"
    slow accrual
  ",0,phase 2,['head and neck squamous cell carcinoma'],"[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]",['afatinib'],['CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4'],"
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Patients must have pathological evidence of persistent primary and/or lymph node
             disease with viable tumor cells following primary concurrent chemoradiotherapy of
             locoregionally advanced (stage III/IV) HNSCC of the oral cavity, oropharynx, larynx,
             hypopharynx or p16-positive unknown primary of the head and neck region; persistent
             primary and/or lymph node disease with viable tumor cells will be determined by the
             histological determination of tumor viability defined as tumor cells with intact
             cellular compartments (i.e. cytoplasm and nucleus) that do not exhibit karyolysis,
             pyknosis, or karyorrhexis on haematoxylin and eosin (H&E) staining

          -  Patients must have undergone a neck dissection following completion of
             chemoradiotherapy and must have involved at the minimum a compartment dissection of
             nodal levels with residual abnormalities on post-treatment imaging studies and/or
             received a complete resection of the residual primary lesion with negative margins

          -  Patients must have achieved a complete response at the primary disease site after
             chemoradiotherapy or complete resection of the residual primary site disease with
             negative margins

          -  All persistent lymph node disease must have received at least 66 Gy of radiotherapy
             and must have been completely surgically resected prior to registration, and surgical
             incisions should be adequately healed

          -  Patients with extracapsular lymph node extension, perineural or lymphovascular
             invasion will be eligible

          -  Patients must be at least 6 weeks (42 days) and no more than 36 weeks (252 days) from
             completion of chemoradiation at the time of registration

          -  Patients will be eligible regardless of ability to swallow; patients with dysphagia
             may have afatinib/placebo administered via gastrostomy tube

          -  Absolute neutrophil count >= 1,000/mm^3

          -  Platelets >= 100,000/mm^3

          -  Total bilirubin =< 1.5 x the upper limit of normal (ULN)

          -  Aspartate amino transferase (AST) =< 3 x the ULN

          -  Alanine amino transferase (ALT) =< 3 x the ULN

          -  Calculated creatinine clearance must be >= 50 ml/min using the Cockcroft-Gault formula

          -  Prior cetuximab or any epidermal growth factor receptor (EGFR) inhibitors will not be
             permitted including cetuximab administered with a chemoradiotherapy or radiotherapy
             regimen

          -  As all patients in this study will have received prior full dose, curative-intent
             external-beam radiotherapy to the involved neck, no additional external-beam
             radiotherapy will be permitted prior to or during study participation

          -  Women of childbearing potential and sexually active males must be strongly advised to
             use an accepted and effective method of contraception

          -  Patients must have electrocardiogram (ECG) within 8 weeks prior to randomization to
             the study

          -  Patients must be assessed for cardiac function by echocardiogram (ECHO) or multi-gated
             acquisition scan (MUGA) within 8 weeks prior to randomization

        Exclusion Criteria:

          -  Patients with known distant metastatic disease or with any gross residual disease
             following salvage primary tumor resection or neck dissection

          -  Known hypersensitivity to afatinib or any of the excipients of this product

          -  Prior adjuvant chemotherapy (aside from the initial induction chemotherapy followed by
             chemoradiotherapy or chemoradiotherapy regimen)

          -  History of acute myocardial infarction within 3 months prior to registration, and any
             history of uncontrolled angina, uncontrolled arrhythmia, or uncontrolled heart failure

          -  Pregnant or breast-feeding women

          -  Active infections, other cancers, or history of other cancers

          -  Participation in any other clinical trials or taking any other experimental
             medications

          -  Left ventricular dysfunction

          -  Evidence of interstitial lung disease
      "
NCT04051853,terminated,"
    slow accrual.
  ",0,phase 2,"['bclc stage c hcc', 'cp-b liver cirrhosis']","[""['Z52.6', 'K71.8', 'K71.7', 'A06.4', 'C22.0', 'C22.3', 'K70.0']""]",['sorafenib'],['CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F'],"
        Inclusion Criteria:

          -  Male or female, 18 years of age or older

          -  Diagnosis of HCC: diagnosis based on the following criteria:

               1. 1 radiologic technique: Focal lesion >1 cm with arterial hypervascularization in
                  4-phase CT or dynamic contrast enhanced MRI OR

               2. 2 coincidental dynamic radiologic techniques (CT or MRI) in case one imaging
                  technique is non-conclusive and lesion > 1 cm OR

               3. biopsy proven HCC

          -  Patients with advanced HCC - BCLC stage C

          -  Cancer related symptoms (symptomatic tumors, ECOG Performance status 1-2),
             macrovascular invasion (either segmental or portal invasion) or extrahepatic spread
             (lymph node involvement or distant metastases)

          -  Not eligible for TACE (; i.e. diffuse tumors, tumors larger than 5 cm)

          -  Not eligible for curative resection or RFA

          -  Patients with CP-B liver cirrhosis (CP-B score 7 or 8)

          -  Capable of giving written informed consent

          -  History of organ transplant (including prior liver transplantation) is allowed

          -  HIV, congenital immune defect, any immunosuppressive therapy for autoimmune disease
             (rheumatoid arthritis) is allowed

        Exclusion Criteria:

        Subjects will not be enrolled in the study if any of the following criteria apply:

          -  CP-B9 liver cirrhosis

          -  CP-C liver cirrhosis

          -  Mental conditions rendering the subject incapable to understand the nature, scope, and
             consequences of the trial

          -  Concurrent antitumoral treatment for HCC or other malignancies

          -  Not eligible for sorafenib treatment

          -  Bilirubin > 51 micromol/L

          -  If female, pregnant or breast feeding (females of child-bearing potential must use
             adequate contraception and must have a negative pregnancy test performed within 7 days
             prior to inclusion into this study)

          -  If male, not using adequate birth control measures

          -  One or more of the following: - WBC <2,500 cells/mm3, - ANC <1,500 cells/mm3, -
             platelets <50,000/mm3,

          -  ECOG performance status >2

          -  Patients with known GFR <30 mL/min/1.73m2

          -  Significant cardiovascular disease; e.g., myocardial infarction within 6 months of
             inclusion, chronic heart failure (New York Heart Association class III or IV),
             unstable coronary artery disease

          -  Uncontrolled hypertension i.e. systolic blood pressure > 150 mm Hg and/or diastolic
             blood pressure > 90 mm Hg despite optimal medical management (2 classes of
             antihypertensive drugs)

          -  History of hemorrhage / bleeding events of grade 3 or worse within 30 days before
             inclusion into this study

          -  Previous variceal bleeding within the past 3 months

        Additional exclusion criteria for cocktail test

          -  Consumption of grapefruit or grapefruit juice and/or kumquats, pummelos, exotic citrus
             fruit (i.e., star fruit, bitter melon) or grapefruit hybrids from seven days prior to
             the first dose of cocktail.

          -  Use of herbal medicine or medication that induce or inhibit CYP3A4/5, CYP2C9, CYP2D6,
             CYP1A2 and CYP2C19

          -  Use of omeprazole, warfarin, metoprolol, caffeine or midazolam (=medication of the
             probe cocktail)

          -  Concurrent anticoagulant therapy
      "
NCT02720510,terminated,"
    a study was terminated due to low enrollment.
  ",0,phase 2,['multiple myeloma'],"[""['C90.01', 'C90.02', 'C90.00']""]","['revlimid', 'velcade', 'dexamethasone', 'farydak']","['C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N', 'B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O', 'CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C', 'CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)C=CC(=O)NO']","
        Key Inclusion Criteria:

          -  Patient newly diagnosed with multiple myeloma, based on following IMWG 2014 definition
             (Rajkumar et al 2014):

          -  Clonal bone marrow plasma cells ≥ 10% or biopsy-proven bony or extramedullary
             plasmacytoma and any one or more of the following myeloma defining events:

          -  Evidence of end organ damage that can be attributed to the underlying plasma cell
             proliferative disorder

          -  Any one or more of the following biomarkers of malignancy:

               1. Clonal bone marrow plasma cell percentage ≥ 60%

               2. Involved: uninvolved serum free light chain ratio ≥ 100

               3. >1 focal lesions on MRI studies

          -  Patient with measurable disease defined by at least 1 of the following conditions
             present at screening:

          -  Serum M-protein by Protein Electrophoresis (PEP) ≥ 1.0 g/dL (≥ 10 g/L).

          -  Urine M-protein by PEP ≥ 200 mg/24 hours. Involved serum free light chain level ≥ 10
             mg/dL (≥ 100 mg/L), provided that the serum free light chain ratio is abnormal.

          -  Patient eligible for autologous stem cell transplantation based on the investigator's
             clinical judgment.

          -  Patient with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2

          -  Patient's age ≥ 18 and <75 years at time of signing the informed consent

          -  Patient provided written informed consent prior to any screening procedures

          -  Women of childbearing potential (WOCBP) with a negative serum pregnancy test at
             screening and a negative urine pregnancy test at baseline

        Key Exclusion Criteria:

        Patients eligible for this study must not meet any of the following criteria:

          -  Any concomitant anti-cancer therapy (other than bortezomib/lenalidomide/dexamethasone;
             bisphosphonates are permitted only if commenced prior to the start of screening
             period)

          -  Unresolved diarrhea ≥ CTCAE grade 2 or presence of medical condition associated with
             chronic diarrhea (such as irritable bowel syndrome, inflammatory bowel disease).

          -  Allogeneic stem cell transplant recipient presenting with graft versus host disease
             either active or requiring immunosuppression

          -  Patient shown intolerance to bortezomib or to dexamethasone or components of these
             drugs or has any contraindication to one or the other drug, following locally
             applicable prescribing information

          -  Patient with rade ≥ 2 peripheral neuropathy or grade 1 peripheral neuropathy with pain
             on clinical examination at screening

          -  Patient received prior treatment with DAC inhibitors including Panobinostat

          -  Patient needing valproic acid for any medical condition during the study or within 5
             days prior to first administration of panobinostat/study treatment.

          -  Patient taking any anti-cancer therapy concomitantly (bisphosphonates are permitted
             only if commenced prior to the start of screening period)

          -  Patient who received:

               1. prior anti-myeloma chemotherapy or medication including Immunomodulator (IMiDs)
                  and Dex ≤ 3 weeks prior to start of study.

               2. experimental therapy or biologic immunotherapy including monoclonal antibodies ≤
                  4 weeks prior to start of study.

               3. prior radiation therapy ≤ 4 weeks or limited field radiotherapy ≤ 2 weeks prior
                  start of study.

          -  Patient has not recovered from all therapy-related toxicities associated with above
             listed treatments to < grade 2 CTCAE.

          -  Patient undergone major surgery ≤ 2 weeks prior to starting study drug or who have not
             recovered from side effects of such therapy to < grade 2 CTCAE

          -  Patients with evidence of mucosal or internal bleeding

          -  Clinically significant, uncontrolled heart disease and/or recent cardiac event (within
             6 month prior to screening)

          -  Inability to determine the Fridericia's Correction Formula (QTc) F interval

          -  Patient with an impairment of gastrointestinal (GI) function or GI disease that may
             significantly alter the absorption of panobinostat (e.g. ulcerative disease,
             uncontrolled nausea, vomiting, malabsorption syndrome, obstruction, or stomach and/or
             small bowel resection)

          -  Sexually active males unless they use a condom during intercourse while taking the
             drug during treatment, and for 6 months after stopping treatment

          -  Pregnant or nursing (lactating) women.
      "
NCT02721979,terminated,"
    terminated due to slow accrual
  ",0,phase 2,['prostate adenocarcinoma'],"[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]",['apalutamide'],['CNC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CC(=C(N=C4)C#N)C(F)(F)F)F'],"
        Inclusion Criteria:

          -  Have signed an informed consent document

          -  Be willing/able to adhere to the prohibitions and restrictions specified in this
             protocol

          -  Written authorization for use and release of health and research study information has
             been obtained

          -  Life expectancy >= 10 years (as determined by the treating physician)

          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 1

          -  Histologically confirmed adenocarcinoma of the prostate as documented by a minimum 12
             core prostate biopsy completed within 1-year of enrollment (note: most recent prostate
             biopsy must have demonstrated prostatic adenocarcinoma)

          -  Favorable risk prostate cancer as defined by:

               -  Very low-risk:

                    -  Clinical stage T1c disease

                    -  PSA density (PSAD) < 0.15 ng/mL

                    -  Gleason score 6

                    -  =< 2 core biopsies with =< 50% involvement of any biopsy core with cancer,
                       or unilateral disease =< 2 core biopsies with any percentage involvement OR

               -  Low risk:

                    -  Clinical stage =< T2a

                    -  PSA < 15 ng/mL

                    -  Gleason score 6 OR

               -  Low-intermediate risk:

                    -  Clinical stage T1c

                    -  PSA < 15 ng/ml

                    -  Gleason 3+4 present in =< 50% of one core/site as detected by systematic
                       biopsy or MRI/transrectal ultrasound (TRUS) fusion guided biopsy

                    -  Gleason 6 disease in all other cores / sites

          -  Willing and qualified for active surveillance at Johns Hopkins or the University of
             Washington

          -  Serum testosterone >= 150 ng/dL

          -  Able to swallow the study drugs whole as a tablet

          -  Hemoglobin >= 9.0 g/dL, (at screening), independent of transfusion and/or growth
             factors within 3 months prior to registration

          -  Platelet count >= 100,000 x 10^9/uL (at screening) independent of transfusion and/or
             growth factors within 3 months prior to registration

          -  Serum albumin >= 3.0 g/dL (at screening)

          -  Glomerular filtration rate (GFR) >= 45 mL/min (at screening)

          -  Serum potassium >= 3.5 mmol/L (at screening)

          -  Serum total bilirubin =< 1.5 x upper limit of normal (ULN) (at screening) (note: in
             subjects with Gilbert's syndrome, if total bilirubin is > 1.5 x ULN, measure direct
             and indirect bilirubin and if direct bilirubin is =< 1.5 x ULN, subject may be
             eligible)

          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 × ULN (at
             screening)

          -  Medications known to lower the seizure threshold must be discontinued or substituted
             at least 4 weeks prior to study entry

          -  Agrees to use a condom (even men with vasectomies) and another effective method of
             birth control if he is having sex with a woman of childbearing potential or agrees to
             use a condom if he is having sex with a woman who is pregnant while on study drug and
             for 3 months following the last dose of study drug; must also agree not to donate
             sperm during the study and for 3 months after receiving the last dose of study drug

        Exclusion Criteria:

          -  Prior local therapy to treat prostate cancer (e.g. radical prostatectomy, radiation
             therapy, brachytherapy)

          -  Prior use of ARN-509 (apalutamide)

          -  Have known allergies, hypersensitivity, or intolerance to ARN-509 (apalutamide) or its
             excipients

          -  Prior or ongoing systemic therapy for prostate cancer including, but not limited to:

               -  Hormonal therapy (e.g. leuprolide, goserelin, triptorelin)

               -  Cytochrome P450 (CYP)-17 inhibitors (e.g. abiraterone, ketoconazole)

               -  Antiandrogens (e.g. bicalutamide, nilutamide)

               -  Second generation antiandrogens (e.g. enzalutamide)

               -  Immunotherapy (e.g. sipuleucel-T, ipilimumab)

               -  Chemotherapy (e.g. docetaxel, cabazitaxel)

          -  Have any condition that, in the opinion of the investigator, would compromise the
             well-being of the subject or the study or prevent the subject from meeting or
             performing study requirements

          -  History of any of the following:

               -  Seizure or known condition that may pre-dispose to seizure (including but not
                  limited to prior stroke, transient ischemic attack, loss of consciousness within
                  1 year prior to registration, brain arteriovenous malformation; or intracranial
                  masses such as schwannomas and meningiomas that are causing edema or mass effect)

               -  Severe or unstable angina, myocardial infarction, symptomatic congestive heart
                  failure, arterial or venous thromboembolic events (e.g., pulmonary embolism,
                  cerebrovascular accident including transient ischemic attacks), or clinically
                  significant ventricular arrhythmias within 6 months prior to registration

               -  Any condition that in the opinion of the investigator, would preclude
                  participation in this study

          -  Current evidence of any of the following:

               -  Uncontrolled hypertension

               -  Gastrointestinal disorder affecting absorption

               -  Active infection (e.g. human immunodeficiency virus [HIV] or viral hepatitis) or
                  other medical condition that would make prednisone/prednisolone (corticosteroid)
                  use contraindicated

               -  Any condition that in the opinion of the investigator, would preclude
                  participation in this study

          -  The use of drugs known to lower the seizure threshold, including: atypical
             antipsychotics (e.g. clozapine, olanzapine, risperidone, ziprasidone), bupropion,
             lithium, meperidine, pethidine, phenothiazine antipsychotics (e.g. chlorpromazine,
             mesoridazine, thioridazine), and tricyclic antidepressants (e.g. amitriptyline,
             desipramine, doxepin, imipramine, maprotiline, mirtazapine)

          -  The use of strong CYP3A4 inhibitors, including: itraconazole, clarithromycin,
             erythromycin, diltiazem, verapamil, delavirdine, atazanavir, indinavir, nefazodone,
             nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, grapefruit juice (or
             grapefruits)

               -  Note: If a patient is on a strong CYP3A4 inhibitor, they can be reconsidered for
                  enrollment if they can safely stop said medication; a two week or 5 half-lives,
                  whichever is longer, washout will be required prior to enrolling on study;
                  subject may not resume medication while receiving apalutamide

          -  Strong CYP3A4 inducers, including: phenytoin, carbamazepine, rifampin, rifabutin,
             rifapentine, phenobarbital, efavirenz, tipranavir, St. John's wort

             **Note: If a patient is on a strong CYP3A4 inhibitor, they can be reconsidered for
             enrollment if they can safely stop said medication; a two week or 5 half-lives,
             whichever is longer, washout will be required prior to enrolling on study; subject may
             not resume medication while receiving apalutamide

          -  Any psychological, familial, sociological, or geographical condition that could
             potentially interfere with compliance with the study protocol and follow-up schedule
      "
NCT02723578,completed,,0,phase 2,['metastatic colorectal cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['pemetrexed', 'erlotinib']","['C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O', 'COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC']","
        Inclusion Criteria:

          1. Male or female, aged ≥ 19 years

          2. Histologic or cytologic confirmed diagnosis of colorectal carcinoma with metastatic
             (STAGE IV) disease.

          3. Confirmed KRAS(codon 12 or 13) status

          4. Prior chemotherapy for metastatic disease is required; prior regimens must include
             fluoropyrimidine, oxaliplatin and irinotecan

          5. Eastern Cooperative Oncology Group performance status ≤ 2

          6. Patients who can swallow oral medication.

          7. Life expectancy of greater than 3 months

          8. Patients must have normal organ and marrow function as defined below:

               -  absolute neutrophil count ≥ 1,500/mm3

               -  hemoglobin ≥ 9 g/dl

               -  platelets ≥ 100,000/mm3

               -  serum total bilirubin ≤ 1.5 X institutional upper limit of normal

               -  aspartate aminotransferase(SGOT)/alanine aminotransferase(SGPT) ≤ 3.0 X
                  institutional upper limit of normal (≤ 5 times the upper institutional limits of
                  normal if hepatic metastases are present)

               -  serum creatinine ≤ 1.5 times the institutional upper limits of normal or
                  Creatinine Clearance ≥ 50ml/min

          9. The effects of Pemetrexed and Erlotinib on the developing human fetus at the
             recommended therapeutic dose are unknown. For this reason and because therapeutic
             agents used in this trial are known to be teratogenic, female participants of child
             bearing potential and male participants whose partner is of child bearing potential
             must be willing to ensure that they or their partner use effective contraception
             (hormonal or barrier method of birth control; abstinence) during the study and for 6
             months thereafter. Should a woman become pregnant or suspect she is pregnant while
             participating in this study, she should inform her treating physician immediately.

         10. Participant is willing and able to give informed consent for participation in the
             study. Voluntary signed and dated written informed consent form in accordance with
             regulatory and institutional guidelines obtained before the performance of any
             protocol-related procedures not part of normal patient care.

        Exclusion Criteria:

          1. Previous treatment with Pemetrexed and Erlotinib

          2. History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to Pemetrexed or Erlotinib or other agents used in the study

          3. Patients who can not allow the administration of Folic acid or Vitamin B12.

          4. Past or current history of neoplasm other than colorectal carcinoma with a
             disease-free interval of less than 5 years, except for non-melanoma skin cancer or
             curatively treated carcinoma in situ of the cervix.

          5. Systemic chemotherapy within three weeks after the administration of the last before
             the test treatment

          6. Major surgical operation or major trauma within 4 weeks.

          7. Patients who have had wide-ranged radiotherapy within 4 weeks or limited radiotherapy
             within 2 2 weeks.

          8. Persistent toxicity (> CTCAE grade 1) related to previous treatment except for the
             hair loss.

          9. Patients with active brain metastases should be excluded from this clinical trial
             because of their poor prognosis and because they often develop progressive neurologic
             dysfunction that would confound the evaluation of neurologic and other adverse events.

         10. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

         11. Breast-feeding or pregnant female
      "
NCT02722369,terminated,"
    low recruitment, lack of efficacy and increased adverse events in investigational arm.
  ",0,phase 2,['small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['gemcitabine', 'carboplatin', 'etoposide', 'hydroxychloroquine']","['C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F', 'C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]', 'CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O', 'CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO']","
        Inclusion Criteria:

          -  Histologically or cytologically confirmed SCLC

          -  Stage IV disease

          -  Performance status ECOG 0-2

          -  Life expectancy >8 weeks

          -  Age 18 or over

          -  Willing and able to give informed consent

          -  Patient considered able to tolerate chemotherapy

          -  Adequate renal function - defined by GFR ≥50mL/min as measured by EDTA or C&G

          -  Adequate bone marrow reserve: Absolute neutrophil count ≥1.5 x 109/L, haemoglobin ≥90
             g/L, platelet count ≥100 x 109/L

          -  Negative pregnancy test for WCBP

          -  Highly effective contraception is mandatory for all patients of reproductive potential

          -  At least one site of measurable disease (target lesion) for RECIST 1.1 evaluation

          -  Hypersensitivity or history of severe allergic reaction to any of the IMPs

          -  Able to swallow medication

        Exclusion Criteria:

          -  Mixed cell histology (i.e. NSCLC and SCLC)

          -  Prior macular degeneration or diabetic retinopathy

          -  History of glaucoma

          -  Patients with abnormal LFTs (ALP, ALT/AST*) that are ≥3 x ULN (≥5 x ULN for patients
             with liver metastases)

          -  Patients with abnormal bilirubin levels that are ≥1.5 x ULN

          -  Prior treatment for this disease e.g. chemotherapy, surgery, radiotherapy (except
             palliative radiotherapy to bone metastases)

          -  Documented side effects to chloroquine or related agents

          -  Treatment with chloroquine or related agents within the last year prior to
             randomisation

          -  Evidence of significant medical condition or laboratory finding which, in the opinion
             of the investigator, makes it undesirable for the patient to participate in the trial

          -  Previous medical history of prolonged QT interval

          -  A history of prior malignant tumour, unless the patient has been without evidence of
             disease for at least 3 years or the tumour was a non-melanoma skin tumour or early
             cervical cancer

          -  Patients with symptomatic brain metastases

          -  Women who are breastfeeding

          -  Concurrent cytochrome P450 enzyme-inducing anticonvulsant drugs e.g. phenytoin,
             carbamazepine, phenobarbital, primidone or oxcarbazepine

          -  Patients who are unable to have their digoxin levels regularly monitored

               -  if both ALT and AST performed then both need to be recorded
      "
NCT02726399,terminated,"
    low accrual rate
  ",0,phase 2,"['gastric cancer', 'gastroesophageal junction cancer']","[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['C19', 'D12.7', 'Z85.048']""]","['ramucirumab', 'trastuzumab', 'capecitabine', 'cisplatin']","['CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O', 'N.N.Cl[Pt]Cl']","
        Inclusion Criteria:

          -  Patients must have pathologically or cytologically MSKCC confirmed diagnosis of
             gastric or GEJ adenocarcinoma.

          -  Patients must have Stage IV gastric or GEJ adenocarcinoma with HER2 overexpression
             and/or amplification as determined by next generation sequencing assay,
             immunohistochemistry (IHC 3+) or fluorescent in situ hybridization (FISH+ is defined
             as HER2:CEP17 ratio ≥ 2.0). MSKCC confirmation of HER2 status is not mandatory prior
             to enrollment and treatment on study. For patients with outside HER2 testing, if
             sufficient tissue is available HER2 testing will be repeated at MSKCC for purpose of
             analysis and will not impact the patient's eligibility.

          -  Available archival tumor tissue should be submitted to MSKCC for IMPACT analysis, but
             will not be required prior to registration. Note: if tissue is depleted, patient will
             still be eligible after discussion with the PI.

          -  Patients must have disease that can be evaluated radiographically. This may be
             measurable disease or non-measurable disease per RECIST 1.1.

          -  Patients may have received no prior chemotherapy for Stage IV disease. Patients may
             have received prior adjuvant therapy (chemotherapy and/or chemoradiation) if more than
             6 months have elapsed between the end of adjuvant therapy and registration.

          -  Age of 18 years or older.

          -  ECOG performance status 0-1.

          -  Peripheral neuropathy ≤ grade 1

          -  Patients who have adequate hepatic function as defined by a total bilirubin ≤1.5 times
             upper limit of institutional normal value (ULN) mg/dL (except patients with Gilbert's
             disease), and aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 times
             ULN or ≤ 5.0 times the ULN in the setting of liver metastases.

          -  Patients who have adequate hematologic function, as evidenced by absolute neutrophil
             count (ANC) ≥1500/μL, hemoglobin ≥9 g/dL (5.58 mmol/L), and platelets ≥100,000/μL.

          -  Patients who have adequate renal function as defined by calculated creatinine
             clearance ≥60 mL/minute using the Cockcroft-Gaul formula or equivalent method.

          -  Patients whose urinary protein is ≤2+ on routine urinalysis (UA; if routine analysis
             is >2+, a 24-hour urine collection for protein must demonstrate <2g of protein in 24
             hours to allow participation in this protocol).

          -  The patient must have adequate coagulation function as defined by International
             Normalized Ratio (INR) ≤ 1.5, and a partial thromboplastin time (PTT) ≤ 5 seconds
             above the ULN (unless receiving anticoagulation therapy). Patients receiving warfarin
             must be switched to low molecular weight heparin and have achieved stable coagulation
             profile prior to first dose of protocol therapy.

          -  Patients, must be postmenopausal, surgically sterile, or using effective contraception
             (hormonal or barrier methods).

          -  Female patients of childbearing potential must have a negative serum pregnancy test
             within 7 days of study entry.

        Exclusion Criteria:

          -  Patients who have uncontrolled or poorly-controlled hypertension (>160 mmHg systolic
             or >100 mmHg diastolic for >4 weeks) despite standard medical management.

          -  Patients receiving any concurrent anticancer therapy or investigational agents with
             the intention of treating gastric/GEJ cancer. Previously received trastuzumab as part
             of a regimen in the metastatic setting with evidence of progression. 89Zr-trastuzumab
             use as imaging agent for 89Zr-trastuzumab PET permitted.

          -  Patients having:

               -  Cirrhosis at a level of Child-Pugh B (or worse) or

               -  Cirrhosis (any degree) and a history of hepatic encephalopathy or clinically
                  meaningful ascites resulting from cirrhosis. Clinically meaningful ascites is
                  defined as ascites from cirrhosis requiring diuretics or paracentesis.

          -  Active or clinically significant cardiac disease including:

               -  Congestive heart failure - New York Heart Association (NYHA) > Class II.

               -  Active coronary artery disease.

               -  Left ventricular function <50%.

               -  Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or
                  digoxin.

               -  Unstable angina (anginal symptoms at rest), new-onset angina within 3 months
                  before randomization, or myocardial infarction within 6 months before
                  randomization.

               -  Patients who have experienced any arterial thromboembolic events, including but
                  not limited to myocardial infarction, transient ischemic attack, cerebrovascular
                  accident, or unstable angina, within 6 months prior to enrollment.

               -  Patients who are receiving chronic antiplatelet therapy, including aspirin,
                  nonsteroidal anti-infalmmatory drugs (NSAIDs, inluding ibuprofen, naproxen, and
                  others), dipyridamole or clopidogrel, or similar agents. Once-daily aspirin
                  (maximum dose 325 mg/day is permitted.

          -  Evidence or history of bleeding diathesis or coagulopathy.

          -  Patients who have experienced any Grade 3-4 GI bleeding within 3 months prior to
             enrolment.

          -  Unwillingness to give written informed consent, unwillingness to participate, or
             inability to comply with the protocol for the duration of the study.

          -  Patients with prior trastuzumab treatment.

          -  Patients with known active brain or central nervous system metastases, including
             leptomeningeal disease. Patients with treated and asymptomatic brain metastases may be
             eligible after discussion with PI.

          -  Patients who are pregnant or breast-feeding.

          -  Patients with a serious or nonhealing wound, ulcer, or bone fracture within 28 days
             prior to enrollment.

          -  The patient has undergone major surgery within 28 days prior to first dose of protocol
             therapy

          -  Patients may not have had major surgical procedure within 2 weeks of registration.

          -  Patients who have elective or planned major surgery to be performed during the course
             of the clinical trial.Minor surgery/subcutaneous venous access device placement within
             7 days prior to first dose of protocol therapy is permitted.

          -  Patients may not have had radiation within 28 days prior to first dose weeks of
             registration.

          -  Patients may not have any other medical condition or reason, in that investigator's
             opinion, makes the patient unstable to participate in a clinical trial.
      "
NCT02514447,terminated,"
    primary analysis and survival follow up completed per protocol. not stopped due to safety
    concerns.
  ",1,phase 1/phase 2,['small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['trilaciclib', 'placebo', 'topotecan']","['CN1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6', 'CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O']","
        Key Inclusion Criteria:

          -  Male or female subjects aged ≥18 years

          -  Confirmed diagnosis of SCLC by histology or cytology, preferably including the
             presence of neuroendocrine features by immunohistochemistry

          -  Progression during or after prior first- or second-line chemotherapy and eligible to
             receive topotecan therapy

          -  At least 1 target lesion that is measurable by RECIST, Version 1.1

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2

          -  Adequate organ function

        Key Exclusion Criteria:

          -  Presence of brain metastases requiring immediate treatment with radiation therapy or
             steroids.

          -  Uncontrolled ischemic heart disease or uncontrolled symptomatic congestive heart
             failure

          -  Known history of stroke or cerebrovascular accident within 6 months prior to
             enrollment

          -  Other uncontrolled serious chronic disease or conditions that in the investigator's
             opinion could affect compliance or follow-up in the protocol

          -  Concurrent radiotherapy to any site or radiotherapy within 2 weeks prior to enrollment
             or previous radiotherapy to the target lesion sites

          -  Receipt of any systemic chemotherapy regimen within 4 weeks prior to enrollment or a
             noncytotoxic investigational medication within 2 weeks prior to enrollment

          -  History of topotecan treatment for SCLC
      "
NCT02518750,terminated,"
    due to slow accrual
  ",0,phase 2,"['acute lymphoblastic leukemia', ""lymphoma, non-hodgkin's"", 'leukemia, t-cell', 'leukemia, b-cell']","[""['C91.01', 'C91.02', 'C91.00']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['C91.61', 'C91.62', 'C91.51', 'C91.52', 'C91.60', 'C91.50']"", ""['C91.31', 'C91.32', 'C91.A1', 'C91.A2', 'C91.11', 'C91.12', 'C91.30']""]","['dexamethasone', 'panobinostat', 'liposomal vincristine', 'mitoxantrone', 'peg-asparaginase', 'bortezomib', 'intrathecal triples', 'high-dose methotrexate', '6-mercaptopurine', 'high-dose cytarabine', 'nelarabine', 'cyclophosphamide', 'etoposide', 'clofarabine']","['CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C', 'CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)C=CC(=O)NO', 'CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O', 'C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO', 'B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O', 'C1=NC2=C(N1)C(=S)N=CN2', 'COC1=NC(=NC2=C1N=CN2C3C(C(C(O3)CO)O)O)N', 'C1CNP(=O)(OC1)N(CCCl)CCCl', 'CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O', 'C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)F)Cl)N']","
        Inclusion Criteria:

          -  Participants must have relapsed or refractory acute lymphoblastic leukemia or lymphoma
             (ALL):

               -  Stratum I: T-cell lymphoblastic leukemia or lymphoma in first relapse or
                  refractory to one or two courses of frontline induction therapy.

               -  Stratum II: B-cell or T-cell lymphoblastic leukemia or lymphoma in second or
                  third relapse or refractory to 2 or 3 induction or re-induction attempts.
                  Patients with Ph+ ALL must be refractory or relapsed after treatment with regimen
                  that included a tyrosine kinase inhibitor (TKI).

          -  Relapse in ALL is defined as the reappearance (in a patient who has previously
             achieved remission) of leukemic blasts in the bone marrow.

               -  Should flow cytometric analyses suggest relapse (by the reappearance of a similar
                  immunophenotype to the original leukemia) in the presence of <5% blasts
                  morphologically, a repeat bone marrow test is recommended to confirm relapse.

               -  Molecular or genetic relapse is characterized by the reappearance of a
                  cytogenetic or molecular abnormality.

          -  Age is ≤ 21 years (participant has not yet reached 22nd birthday).

          -  Able to swallow capsules.

          -  Karnofsky or Lansky performance score is ≥ 60%. The Lansky performance score should be
             used for participants < 16 years and the Karnofsky performance score for participants
             ≥ 16 years.

          -  Prior therapy:

               -  There is no waiting period for participants who relapse while receiving therapy
                  if they are free from side effects attributable to such therapy.

               -  Emergent radiation therapy, one dose of intrathecal chemotherapy and up to 7 days
                  of steroids or hydroxyurea are permitted before start of treatment in
                  participants who relapse after completion of frontline therapy. Other
                  circumstances must be cleared by PI or medical designee.

               -  At least 90 days have elapsed since bone marrow transplant and participant is off
                  immune suppression for ≥ 2 weeks, if applicable.

          -  Adequate renal function defined as glomerular filtration rate ≥ 60 cc/min/1.73m^2 or
             serum creatinine based on age as follows:

               -  If age is 1 to 2 years, then maximum serum creatinine (mg/dL) is 0.6 for males or
                  females.

               -  If age is 2 to 6 years, then maximum serum creatinine (mg/dL) is 0.8 for males or
                  females.

               -  If age is 6 to 10 years, then maximum serum creatinine (mg/dL) is 1 for males or
                  females.

               -  If age is 10 to <13 years, then maximum serum creatinine (mg/dL) is 1.2 for males
                  or females.

               -  If age is 13 to 16 years, then maximum serum creatinine (mg/dl) is 1.5 for males
                  or 1.4 for females.

               -  If age is > 16 years, then maximum serum creatinine (mg/dl) is 1.7 for males or
                  1.4 for females.

          -  Adequate hepatic function defined as:

               -  Direct bilirubin ≤ 1.4 mg/dL (if total bilirubin > 1.4 mg/dL) AND

               -  AST and ALT < 5 x ULN for age.

          -  Adequate cardiac function defined as shortening fraction of ≥ 27% or ejection fraction
             ≥ 45%.

          -  Lymphoma participants without bone marrow involvement must have:

               -  Absolute neutrophil count (ANC) >1,000/mm3, AND

               -  Platelet count ≥50,000/mm^3 (without transfusion support)

               -  NOTE: These criteria are waived for participants with leukemia or lymphoma
                  participants with bone marrow involvement.

          -  Written, informed consent and assent following Institutional Review Board, NCI, FDA
             and OHRP guidelines.

        Exclusion Criteria:

          -  Prior histone deacytylases (HDAC), DAC, HSP90 inhibitors or valproic acid for
             treatment of cancer.

          -  Patients who will need valproic acid for any medical condition during the study or
             within 5 days prior to first panobinostat treatment.

          -  Impaired cardiac function or clinically significant cardiac diseases, history of
             arrhythmia (including ventricular fibrillation or torsade de pointes), bradycardia <50
             bpm, screening ECG with prolonged QTc or uncontrolled hypertension.

          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly
             alter the absorption of panobinostat.

          -  Patients with diarrhea > CTCAE grade 2.

          -  Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled
             diabetes or active or uncontrolled infection) including abnormal laboratory values,
             that could cause unacceptable safety risks or compromise compliance with the protocol.

          -  Patients using medications that have a relative risk of prolonging the QT interval or
             inducing torsade de pointes if treatment cannot be discontinued or switched to a
             different medication prior to starting treatment.

          -  Patients who have received targeted agents within 2 weeks or within 5 half-lives of
             the agent and active metabolites (whichever is longer) and who have not recovered from
             side effects of those therapies.

          -  Patients who have undergone major surgery ≤ 4 weeks prior to starting treatment or who
             have not recovered from side effects of such therapy.

          -  Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis
             B/C.

          -  Inability to swallow capsules.

          -  Active, uncontrolled infection or severe concurrent medical disease, including but not
             limited to congestive heart failure, cardiac arrhythmias, or psychiatric illness.

          -  Isolated extramedullary relapse (leukemia) or isolated CNS lymphoma.

          -  Pregnant or lactating (female participant of childbearing potential must have negative
             serum or urine pregnancy test required within 7 days prior to start of treatment).
             Male or female of reproductive potential has agreed to use effective contraception
             method for duration of study treatment.

          -  Down syndrome.

          -  Inability or unwillingness or research participant or legal guardian/representative to
             give written informed consent.
      "
NCT03687125,terminated,"
    sponsor decision based on adverse events limiting administration of higher doses required to
    achieve myeoblative conditioning necessary in this population
  ",0,phase 1/phase 2,"['multiple myeloma in relapse', 'multiple myeloma progression', 'multiple myeloma with failed remission']","[""['C90.02']""]",['tinostamustine'],['CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCCCCC(=O)NO'],"
        Inclusion Criteria:

          1. Participants has Multiple Myeloma (MM) and:

             a. Has received prior ASCT after standard first-line induction treatment. b. Has
             evidence of progressive disease (PD), with progression-free interval greater than or
             equal to (>=) 6 months in Phase 1 >= 18 months in Phase 2.

               -  Progression Free Interval is defined as the time from date of ASCT to PD. c.
                  Received treatment with lesser than or equal to (<=) 3 prior lines of therapy.

               -  A line of therapy is defined as 1 or more cycles of a planned treatment program.
                  When participants have undergone sequential phases of treatment without
                  intervening progression, such as induction, collection of peripheral blood stem
                  cells (PBSCs), transplantation and consolidation/maintenance, this is considered
                  to be 1 line of treatment. A new line of therapy is initiated as a result of PD
                  or relapse.

          2. Complete response (CR), very good partial response (VGPR), partial response (PR), or
             minimal response (MR) to salvage chemotherapy, as determined by the International
             Myeloma Working Group (IMWG) criteria.

          3. Is, in the Investigator's opinion, a candidate for consolidation therapy with
             tinostamustine followed by ASCT. (Note that participants planned to receive tandem
             ASCT are not eligible for the Phase 1 portion of the study.)

          4. Has available autologous peripheral blood stem cell (PBSC) product with CD34 cell dose
             >= 2×106 cells/kg. The product could be from a collection prior to first ASCT or later
             second collection. (Note that, although not required, in Phase 1, the Investigator
             should consider enrolling participant with a large number of available PBSCs to permit
             subsequent ASCT, as participants in Stage 1 may received a dose lower than that
             determined to be effective.)

          5. Age 18-75 years.

          6. Eastern Cooperative Oncology Group (ECOG) performance status score lesser than (<) 3
             at Screening.

          7. Creatinine clearance >= 40 milliliter per minute (mL/min), as determined by a local
             laboratory using the Cockcroft-Gault equation within 28 days before ASCT.

          8. Left ventricular ejection fraction (LVEF) >= 40 percent (%) within 28 days before
             ASCT.

          9. Adequate pulmonary function, defined as forced expiratory volume in 1 second (FEV1),
             forced vital capacity (FVC), and carbon monoxide diffusing capacity (DLCO) greater
             than (>) 50% predicted within 28 days before ASCT.

         10. Adequate liver function, as defined by an alanine aminotransferase (ALT) and aspartate
             aminotransferase (AST) <= 2.5 × the upper limit of normal (ULN) and bilirubin <= 1.5 ×
             ULN within 28 days before ASCT.

         11. Potassium within the local laboratory's normal range. (Potassium supplementation is
             permissible.)

        Exclusion Criteria:

        Participants meeting any of the following criteria are not eligible for study entry:

          1. History of central nervous system (CNS) disease involvement.

          2. Primary or secondary plasma cell leukemia at any time point prior to transplant.

          3. Myocardial infarction (MI) or stroke within 6 months before Screening.

          4. Uncontrolled acute infection.

          5. Hematopoietic cell transplantation-comorbidity index (HCT-CI) > 6 points.

          6. Concurrent malignant disease with the exception of treated basalioma/spinalioma of the
             skin or early-stage cervix carcinoma, or early-stage prostate cancer. Previous
             treatment for other malignancies (not listed above) must have been terminated at least
             24 months before registration and no evidence of active disease shall be documented
             since then.

          7. Major coagulopathy or bleeding disorder.

          8. Other serious medical condition that could potentially interfere with the completion
             of treatment according to this protocol or that would impair tolerance to therapy or
             prolong hematological recovery.

          9. Lack of cooperation to allow study treatment as outlined in this protocol.

         10. Pregnancy or lactating female participants.

         11. The use of any anti-cancer investigational agents within 21 days prior to the expected
             start of trial treatment and interval of 14 days to last administration of salvage
             treatment.

         12. Receiving treatment with drugs known to prolong the QT/QTc interval.

         13. QTc interval (Fridericia's formula) > 450 millisecond (msec), based on the mean of
             triplicate Screening 12-lead electrocardiograms (ECGs).
      "
NCT03566485,terminated,"
    low accrual/loss of funding
  ",0,phase 1/phase 2,"['stage iii breast cancer', 'stage iiia breast cancer', 'stage iiib breast cancer', 'stage iiic breast cancer', 'stage iv breast cancer', 'estrogen receptor-positive', 'her2/neu negative']","[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['Z17.0']"", ""['A41.50', 'A41.59', 'E70.320', 'Z17.1', 'Z67.11', 'Z67.21', 'Z67.31']""]","['atezolizumab', 'cobimetinib', 'idasanutlin']","['C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O', 'CC(C)(C)CC1C(C(C(N1)C(=O)NC2=C(C=C(C=C2)C(=O)O)OC)C3=C(C(=CC=C3)Cl)F)(C#N)C4=C(C=C(C=C4)Cl)F']","
        -  Signed and dated written informed consent.

          -  Subjects ≥ 18 years of age.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

          -  Clinical stage IV invasive mammary carcinoma or unresectable locoregional recurrence
             of invasive mammary carcinoma that is:

               -  ER/PR-positive (> 1% cells) by IHC and HER2 negative per ASCO guidelines (by IHC
                  or FISH)

               -  Previously exposed to an aromatase inhibitor (AI) or a selective
                  estrogen-receptor modulator/ downregulator (SERM; SERD) + a CDK4/6 inhibitor

               -  Appropriate candidates for chemotherapy

               -  Amenable to biopsy at the time of study entry

          -  Adequate organ function including:

               -  Absolute neutrophil count (ANC) ≥ 1.5 × 109/L

               -  Platelets ≥ 100 × 109/L

               -  Hemoglobin ≥ 9/g/dL (may have been transfused)

               -  Total serum bilirubin ≤ 1.5 times upper limit of normal (ULN)

               -  Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤
                  2.5 × ULN (or ≤ 5 × ULN if liver metastases are present)

               -  Serum creatinine ≤ 1.5 x ULN or estimated creatinine clearance ≥ 50 mL/min as
                  calculated using the Cockcroft-Gault (CG) equation

               -  Thyroid Stimulating Hormone (TSH) ≤ 1 x ULN

               -  Amylase ≤ 1 x ULN

               -  Lipase ≤ 1 x ULN

               -  CPK ≤ 1.5 x ULN

               -  LVEF (echo) ≥ LLN (Cobi arm only)

          -  Female patients of childbearing potential must agree to use at least two methods of
             acceptable contraception with a failure rate of < 1% per year from 15 days prior to
             first trial treatment administration until at least 5 months after study participant's
             final dose of study drugs. See appendix C for details.

        Note: Females of childbearing potential are defined as those who are not surgically sterile
        or post-menopausal (i.e. patient has not had a bilateral tubal ligation, a bilateral
        oophorectomy, or a complete hysterectomy; or has not been amenorrheic for 12 months without
        an alternative medical cause). Post-menopausal status in females under 55 years of age
        should be confirmed with a serum follicle-stimulating hormone (FSH) level within laboratory
        reference range for postmenopausal women.

          -  Patients unable to read/write in English are eligible to participate in the overall
             study but will not participate in the Patient-Reported Outcome questionnaires
             throughout the trial

          -  Re-enrollment of a subject that has discontinued the study as a pre-treatment screen
             failure (i.e. a consented patient who did not receive study drugs) is permitted. If
             re-enrolled, the subject must be re-consented. Only the screening procedures performed
             outside of protocol-specified timing must be repeated.

        Exclusion Criteria:

          -  Prior therapy with anti-PD-L1 and anti-PD1 antibodies, MEK inhibitors or MDM2
             antagonists.

          -  No more than 3 lines of chemotherapy in the metastatic setting

          -  No concurrent anticancer therapy. Required washout from prior therapy:

               -  Endocrine therapy: no required wash-out

               -  Chemotherapy: 14 days

               -  Major surgery: 14 days (provided wound healing is adequate)

               -  Radiation: 7 days

               -  Investigational/Biologic Therapy (half -life ≤ 40 hours): 14 days

               -  Investigational/Biologic Therapy (half -life > 40 hours): 28 days

               -  Use of corticosteroids or immunosuppressive medication is exclusionary, except
                  the following in the absence of active autoimmune disease:

                    -  Subjects are permitted the use of corticosteroids with minimal systemic
                       absorption (e.g. topical, ocular, intra-articular, intranasal, and inhaled);

                    -  Systemic corticosteroids at physiologic doses ≤10 mg/day of prednisone or
                       equivalent are permitted;

                    -  Adrenal replacement steroid doses including doses > 10 mg daily prednisone
                       are permitted;

                    -  A brief (less than 3 weeks) course of corticosteroids for prophylaxis (e.g.
                       CT scan premedication against contrast dye allergy) or for treatment of
                       non-autoimmune conditions (e.g. delayed-type hypersensitivity reaction
                       caused by a contact allergen) is permitted.

          -  Previous malignant disease other than breast cancer within the last 5 years, with the
             exception of basal or squamous cell carcinoma of the skin, cervical carcinoma in situ,
             or low-risk cancers considered curatively treated (i.e. complete remission achieved at
             least 2 years prior to first dose of study drugs AND additional therapy not required
             while receiving study treatment).

          -  All subjects with brain metastases, except those meeting the following criteria:

               -  Brain metastases that have been treated locally and are clinically stable for at
                  least 2 weeks prior to enrollment

               -  No history of intracranial or spinal cord hemorrhage

               -  No evidence of interim CNS disease progression

               -  Metastasis to the midbrain, pons, and medulla

               -  No ongoing neurological symptoms that are related to the brain localization of
                  the disease (sequelae that are a consequence of the treatment of the brain
                  metastases are acceptable.

               -  Subjects must be either off steroids or on a stable or decreasing dose of ≤ 10 mg
                  daily prednisone (or equivalent)

          -  Receipt of any organ transplantation including allogeneic stem-cell transplantation.

          -  Significant acute or chronic infections including, among others:

               -  Known history of testing positive for human immunodeficiency virus (HIV), or
                  acquired immunodeficiency syndrome (AIDS).

               -  Active tuberculosis

               -  Positive test for hepatitis B virus (HBV) surface antigen (and/or core antibody)
                  and/or confirmatory hepatitis C virus (HCV) RNA (if anti-HCV antibody tested
                  positive).

          -  Active autoimmune disease with reasonable possibility of clinically significant
             deterioration when receiving an immunostimulatory agent:

               -  Subjects with Type 1 diabetes mellitus, vitiligo, psoriasis, hypo- or
                  hyperthyroid disease not requiring immunosuppressive treatment are eligible.

               -  Subjects requiring hormone replacement with corticosteroids are eligible if the
                  steroids are administered only for the purpose of hormonal replacement and at
                  doses ≤ 10 mg or 10 mg equivalent prednisone per day.

               -  Administration of steroids through a route known to result in a minimal systemic
                  exposure (topical, intranasal, intro-ocular, or inhalation) are acceptable.

          -  Interstitial lung disease that is symptomatic or which may interfere with the
             detection or management of suspected drug-related pulmonary toxicity.

          -  Uncontrolled asthma [defined as having 3 or more of the following features of
             partially controlled asthma within 28 days prior to starting study treatment: Daytime
             symptoms more than twice per week, any limitation of activities, any nocturnal
             symptoms/awaking, need for reliever/rescue inhaler more than twice per week, or known
             lung function (PEF or FEV1) without administration of a bronchodilator that is < 80%
             predicted or personal best (if known)].

          -  Current symptomatic congestive heart failure (New York Heart Association > class II),
             unstable cardiac arrhythmia requiring therapy (e.g. medication or pacemaker), unstable
             angina (e.g. new, worsening or persistent chest discomfort), or uncontrolled
             hypertension (systolic > 160 mmHg or diastolic > 100mmHg). Or any of the following
             occurring within 6 months (180 days) prior to first dose of study drugs: Myocardial
             infarction, coronary/peripheral artery bypass graft, cerebrovascular accident or
             transient ischemic attack. (Use of antihypertensive medication to control blood
             pressure is allowed.)

          -  Concurrent treatment with a non-permitted drug (refer to prohibited medication list)
             as well as foods or supplements that are strong or moderate CYP3A4 enzyme inducers or
             inhibitors. Any of the above has to be discontinued at least 7 days prior to Cycle 1/
             Day 1 of study treatment.

          -  Requirement of anticoagulant therapy with oral vitamin K antagonists such as Coumadin
             (warfarin). Low-dose anticoagulants for the maintenance of patency in a central venous
             access device or the prevention of deep vein thrombosis or pulmonary embolism is
             allowed. Therapeutic use of low molecular weight heparin is allowed provided patients
             are safely able to interrupt it prior to biopsy procedures.

          -  Persisting toxicity related to prior therapy that has not reduced to Grade 1 [National
             Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 5.0];
             however, alopecia and sensory neuropathy Grade ≤ 2 are acceptable and Grade ≤ 2
             non-hematological toxicities well controlled with medical management are allowed (for
             example: hypomagnesemia well controlled on magnesium replacement).

          -  Known severe (Grade ≥ 3 NCI-CTCAE) hypersensitivity reactions to monoclonal
             antibodies, or history of anaphylaxis.

          -  Vaccination within 28 days of the first dose of study drugs and while on trial is
             prohibited, except for administration of inactivated vaccines (for example,
             inactivated influenza vaccine).

          -  Pregnant or breastfeeding females.

          -  Known current alcohol or drug abuse

          -  Prisoners or subjects who are involuntarily incarcerated.

          -  Known psychiatric condition, social circumstance, or other medical condition
             reasonably judged by the patient's study physician to unacceptably increase the risk
             of study participation; or to prohibit the understanding or rendering of informed
             consent or anticipated compliance with scheduled visits, treatment schedule,
             laboratory tests and other study requirements.

          -  Known risk factors for ocular toxicity, consisting of any of the following (Cobi arm
             only):

               -  presence of serous retinopathy within 6 months of protocol enrollment

               -  presence of retinal vein occlusion (RVO) within 6 months of protocol enrollment
      "
NCT03520985,terminated,"
    feasibility (low patient accrual and financial reasons)
  ",0,phase 2,['refractory multiple myeloma'],"[""['D46.4', 'I20.2', 'D46.1', 'D46.A', 'D46.0', 'D46.20', 'D46.21']""]","['pomalidomide', 'dexamethasone']","['C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N', 'CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C']","
        Key inclusion criteria:

          -  Patient was diagnosed with multiple myeloma based on standard IMWG criteria

          -  Prior treatment with ≥ 2 treatment lines of anti-myeloma therapy

          -  Patients must have been exposed to both lenalidomide and bortezomib

          -  Measurable disease for myeloma defined as one of the following: serum M-protein ≥ 5
             g/L; urine M-protein ≥ 0.2 g/24 hours

          -  Refractory or relapsed and refractory disease defined as documented disease
             progression during or within 60 days of completing their last myeloma therapy.

          -  Adequate hematological and hepatic function

          -  A negative pregnancy test before inclusion into the trial is required for all women
             with child-bearing potential

        Key exclusion criteria:

          -  History of hematologic or primary solid tumor malignancy, unless in remission for at
             least 3 years from registration, with the exception of pT1-2 prostate cancer Gleason
             score ≤6, adequately treated, cervical carcinoma in situ or localized non-melanoma
             skin cancer.

          -  Polyneuropathy grade > 2

          -  Patients who received any of the following within the last 14 days of initiation of
             trial treatment:

               -  Plasmapheresis

               -  Major surgery (kyphoplasty is not considered major surgery)

               -  Radiation therapy

               -  Use of any anti-myeloma drug therapy

          -  Known or clinically suspected myeloma manifestations in the central nervous system

          -  Severe or uncontrolled cardiovascular disease
      "
NCT04190056,terminated,"
    low accrual
  ",0,phase 2,"['anatomic stage iv breast cancer ajcc v8', 'prognostic stage iv breast cancer ajcc v8']","[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['tamoxifen', 'vorinostat']","['CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3', 'C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO']","
        Inclusion Criteria:

          -  Pre and postmenopausal women or men with stage IV ER+ breast cancer histological or
             cytological confirmation

          -  > 10% expression of PD-1/Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) dual
             staining in Cluster of differentiation 8 (CD8) cells in tumor or blood or >5%
             expression of PD-1/CTLA-4 dual staining in CD4 in blood (only).

          -  Eastern Cooperative Oncology Group (ECOG) performance status of =< 1

          -  Understand and voluntarily sign an informed consent prior to any study-related
             assessments or procedures are conducted and are able to adhere to the study visit
             schedule and other protocol requirements

          -  Consent to paired tumor biopsy

          -  Measurable tumor by Response Evaluation Criteria in Solid Tumors (RECIST) criteria

          -  Per Good Clinical Practice, any toxicity related to prior therapies that, in the
             opinion of the investigator, would potentially be worsened with anti-PD1 therapy
             should be resolved to less than grade 1

          -  Absolute neutrophil count (ANC) >= 1.5 X 10^9/L

          -  Hemoglobin (Hgb) >= 9 g/dL (may transfuse if clinically indicated)

          -  Platelets (plt) >= 100 x 10^9/L

          -  Potassium within normal range, or correctable with supplements

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper
             limit normal (ULN) or =< 5.0 x ULN if liver tumor is present

          -  Serum total bilirubin =< 1.5 x ULN

          -  Serum creatinine =< 1.5 x ULN, or 24-hr clearance >= 60 ml/min

          -  Females of childbearing potential (defined as sexually mature women who):

               -  Has not undergone a hysterectomy (the surgical removal of the uterus) or
                  bilateral oophorectomy (the surgical removal of both ovaries) or,

               -  Has not been naturally postmenopausal for at least 24 consecutive months (i.e.,
                  has had menses at any time during the preceding 24 consecutive months) must have

                    -  Negative serum pregnancy test within 14 days before starting study treatment
                       in females of childbearing potential (FCBP) and willingness to adhere to
                       acceptable forms or birth control (a physician-approved contraceptive method
                       (oral, injectable, or implantable hormonal contraceptive; tubal ligation;
                       intra-uterine device; barrier contraceptive with spermicide; or vasectomized
                       partner)

          -  All female and male participants must agree to use approved contraception during the
             treatment period and for at least 18 weeks after the last dose of study treatment and
             refrain from donating sperm during this period

        Exclusion Criteria:

          -  Prior treatment with pembrolizumab or other PD-(L)1

          -  Any significant medical condition, laboratory abnormalities, which places the subject
             at unacceptable risk if he/she were to participate in the study

          -  Has a history of (non-infectious) pneumonitis/interstitial lung disease that required
             steroids or current pneumonitis/ interstitial lung disease

          -  Has known active hepatitis B (e.g., hepatitis B surface antigen (HBsAg) reactive) or
             hepatitis C (e.g., hepatitis C virus (HCV) ribonucleic acid (RNA) [qualitative] is
             detected)

          -  Has a history of hepatitis B virus (HBV)

          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the study, interfere with the subject's
             participation for the full duration of the study, or is not in the best interest of
             the subject to participate, in the opinion of the treating investigator

          -  Symptomatic central nervous system metastases. Subjects with brain metastases that
             have been previously treated and are stable for 6 weeks are allowed

          -  Persistent diarrhea or malabsorption >= National Cancer Institute (NCI) Common
             Terminology Criteria for Adverse Events (CTCAE) grade 2, despite medical management

          -  Unstable angina, significant cardiac arrhythmia, or New York Heart Association (NYHA)
             class 3 or 4 congestive heart failure

          -  Prior systemic cancer-directed treatments or investigational modalities =< 5
             half-lives or 4 weeks, whichever is shorter, prior to starting study drug or who have
             not recovered from side effects of such therapy (except alopecia)

          -  Active autoimmune disease except for vitiligo or hypothyroidism

          -  Active and ongoing steroid use, except for non-systemically absorbed treatments (such
             as inhaled or topical steroid therapy for asthma, chronic obstructive pulmonary
             disease (COPD), allergic rhinitis)

          -  Major surgery =< 2 weeks prior to starting a study drug or who have not recovered from
             side effects of such therapy

          -  Pregnant or breastfeeding

          -  Known human immunodeficiency virus (HIV) infection

          -  Known history of tuberculosis

          -  Known allergic reaction or intolerability to tamoxifen

          -  Patients with prior history of deep vein thrombosis (DVT)s must be on therapeutic or
             preventive anticoagulation
      "
NCT04190433,withdrawn,"
    administratively closed due to low/no accrual
  ",0,phase 2,"['breast carcinoma', 'hematopoietic and lymphoid cell neoplasm', 'lymphoma', 'sarcoma']","[""['C4A.52', 'C44.511', 'C44.521', 'D05.00', 'D05.01', 'D05.02', 'D05.10']"", ""['C96.20', 'C96.29', 'D47.09']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['C96.A', 'C46.9', 'C96.22', 'C46.0', 'C46.2', 'C92.31', 'C92.32']""]","['carvedilol', 'lisinopril', 'pravastatin', 'spironolactone']","['COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O', 'C1CC(N(C1)C(=O)C(CCCCN)NC(CCC2=CC=CC=C2)C(=O)O)C(=O)O', 'CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)O)O)O)O', 'CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C']","
        Inclusion Criteria:

          -  >= 18 years of age.

          -  New diagnosis of reduced cardiac function.

          -  Any prior anthracycline-based cancer therapy for hematological malignancy, breast
             cancer, or sarcoma.

        Exclusion Criteria:

          -  History of heart failure (HF) of any class and type, or diagnosis of cardiomyopathy
             prior to anthracycline therapy.

          -  On active therapy with a fibrate, niacin or eplerenone, or statin.

          -  History of myopathy/rhabdomyolysis.

          -  History of statin intolerance.

          -  Active treatment for hyperlipidemia.

          -  History of gout.

          -  Active treatment for liver disease.

          -  Unexplained persistent elevations of serum transaminases (above upper limit of normal
             over two weeks).

          -  Pregnancy.

          -  Breast-feeding.

          -  Hyperkalemia (above upper limit of normal).

          -  Addison disease.

          -  Estimated glomerular filtration rate (eGFR) < 30 mL/minute/1.73 m^2.
      "
NCT03439215,unknown status,,1,phase 2,"['carcinoma, non-small-cell lung']","[""['D02.20', 'D02.21', 'D02.22']""]",['lorlatinib'],['CC1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C'],"
        Inclusion Criteria:

          1. Written informed consent;

          2. Male or female patient ages ≥ 18 years;

          3. Histologically/cytologically confirmed diagnosis of NSCLC with evidence of ROS1
             rearrangement;

          4. Possibility to perform a new tumor biopsy or tumor tissue collected at the time or
             after crizotinib failure;

          5. Patient pretreated with crizotinib with evidence of disease progression during
             crizotinib therapy;

          6. At least one radiological measurable disease according to RECIST criteria;

          7. At least 1 previous standard chemotherapy regimen;

          8. Performance status 0-2 (ECOG);

          9. Patient compliance to trial procedures

         10. Adequate bone marrow function (ANC ≥ 1.5x109/L, platelets ≥ 100x109/L, haemoglobin > 9
             g/dl);

         11. Adequate liver function (bilirubin < grade 2, transaminases no more than 3xULN/<5xULN
             in present of liver metastases);

         12. Normal level of alkaline phosphatase and creatinine;

         13. If female: childbearing potential either terminated by surgery, radiation, or
             menopause, or attenuated by use of approved contraceptive method [intrauterine
             contraceptive device (IUD), birth control pills, or barrier device] during and for
             ninety (90) days after end of treatment.

        Exclusion Criteria:

        1. No ROS1 rearrangement 2. No previous therapy with crizotinib; 3. No evidence of
        crizotinib failure; 4. No post-crizotinib tumor tissue available; 5. Absence of any
        measurable lesions; 6. No previous chemotherapy; 7. Concomitant radiotherapy or
        chemotherapy; 8. Symptomatic brain metastases; 9. Diagnosis of any other malignancy during
        the last 5 years, except for in situ carcinoma of cervix uteri and squamous cell carcinoma
        of the skin; 10. Predisposing factors for acute pancreatitis (e.g., uncontrolled
        hyperglycaemia, current gallstone disease, alcoholism); 11. History of extensive
        disseminated/bilateral or known presence of Grade 3 or 4 interstitial fibrosis or
        interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis,
        interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis and pulmonary
        fibrosis (but not history of prior radiation pneumonitis); 12. Pregnancy or lactating
        female; 13. Other serious illness or medical condition potentially interfering with the
        study.

        -
      "
NCT03436420,terminated,"
    terminated due to lack of efficacy and safety concerns.
  ",0,phase 2,['non-alcoholic fatty liver disease'],"[""['Z52.6', 'K71.8', 'K71.7', 'A06.4', 'C22.0', 'C22.3', 'K70.0']""]",['gemcabene'],['CC(C)(CCCCOCCCCC(C)(C)C(=O)O)C(=O)O'],"
        Inclusion Criteria:

          1. Provision of signed and dated informed consent form

          2. Provision of signed and dated assent, if indicated

          3. Stated willingness to comply with all study procedures and availability for the
             duration of the study

          4. Children aged 12-17 years at the time of informed consent

          5. History of clinical diagnosis of NAFLD including a, b and c below:

               1. Medical history eliminating, other chronic liver diseases (for example
                  mitochondrial diseases, hepatotoxic drugs, anorexia nervosa)

               2. Laboratory studies: negative testing for hepatitis C and normal ceruloplasmin

               3. Either liver biopsy confirming NAFLD or MRI > 10% steatosis within the past three
                  years

          6. ALT ≥ 54 U/L for boys or ≥ 46 U/L for girls and ≤ 250 U/L at screening visit and
             within past three months (prior to screening). If ALT at screening is more than two
             times the historic value (or a historic value is not available), the subject will be
             asked to repeat the ALT after four weeks. If the repeat ALT is more than 50% increased
             or decreased over the screening ALT a third ALT may be obtained. If a third ALT is not
             within 50% of the previous value then the subject is ineligible, but may be rescreened
             at a later date.

          7. Body weight ≥ 60 kg at the time of screening

          8. Able to take oral medication and be willing to adhere to the study drug regimen

          9. Minimum of three months of attempted lifestyle modification to treat the NAFLD and
             agreement to adhere to Lifestyle Considerations (dietary improvement and physical
             activity) throughout study duration

        Exclusion Criteria:

          1. Heart disease (e.g., myocardial infarction, heart failure, unstable arrhythmias)

          2. Seizure disorder

          3. Active coagulopathy (international normalized ratio (INR) > 1.4)

          4. Renal dysfunction with an estimated glomerular filtration rate (eGFR) <60ml/min/1.73
             calculated using Schwartz Bedside GFR calculator for children

          5. History of active malignant disease requiring chemotherapy or radiation

          6. History of significant alcohol intake (AUDIT questionnaire) or inability to quantify
             alcohol consumption

          7. Use of new medications or supplements with the intent to treat NAFLD/nonalcoholic
             steatohepatitis (NASH) during the 30 days prior to screening, including statin
             therapy. Medications or supplements (including metformin and vitamin E) that they have
             been on and are on a stable dose are acceptable

          8. History of bariatric surgery or planning to undergo bariatric surgery during study
             duration

          9. Clinically significant depression

         10. Any girl nursing, planning a pregnancy, known or suspected to be pregnant, or who has
             a positive pregnancy screen

         11. Non-compensated liver disease defined as cirrhosis and any one of the following
             hematologic, biochemical, and serological criteria on entry into protocol:

               -  Hemoglobin < 10 g/dL;

               -  White blood cell (WBC) < 3,500 cells/mm3;

               -  Neutrophil count < 1,500 cells/mm3;

               -  Platelets < 150,000 cells/mm3;

               -  Total bilirubin > 1.3 mg/dL unless due to Gilbert's syndrome (subjects with a
                  history of Gilbert's syndrome may be included if both direct bilirubin and the
                  reticulocyte count do no exceed the upper limit of normal (ULN) [reflexive direct
                  bilirubin testing will be used to confirm Gilbert's syndrome])

               -  Albumin < 3.2 g/dL

               -  INR > 1.3

               -  Abnormal alkaline phosphatase

               -  Any history of ascites, variceal bleeding, hepatic encephalopathy, or
                  hepatocellular carcinoma (HCC)

         12. Poorly controlled diabetes mellitus (hemoglobin A1c (HbA1c) > 8%) or requiring insulin

         13. Patients with type I diabetes mellitus

         14. Chronic liver disease other than NAFLD

         15. Patients on Cytochrome P450 3A4 (CYP3A4) inhibitors such as itraconazole or macrolide
             antibiotics are excluded

         16. Patients who are on thiazolidinediones, fibrates or fish oils are excluded

         17. Patients who are on daily prescription medications are excluded except for allergy
             medications, Attention Deficit Hyperactivity Disorder (ADHD) medications, asthma
             medications, or any other acceptable medication in the opinion of the investigator

         18. Abnormal creatinine kinase levels at screening (may be repeated if the elevation is
             thought to be exercise related)

         19. Sexually active female participants of childbearing potential and Tanner stage ≥ 4 or
             menstruating unwilling to utilize two acceptable forms of contraception from screening
             through completion of the study or unwilling to complete pregnancy tests throughout
             the study

         20. Currently enrolled in a clinical trial or who received an investigational study drug
             within 90 days of screening

         21. Participants who are not able or willing to comply with the protocol or have any other
             condition that would impede compliance or hinder completion of the study, in the
             opinion of the investigator
      "
NCT04634110,terminated,"
    low accrual
  ",0,phase 2,"['brain metastases', 'lung cancer']","[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]",['brigatinib'],['CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)NC4=NC=C(C(=N4)NC5=CC=CC=C5P(=O)(C)C)Cl)OC'],"
        Inclusion Criteria:

          1. Provision to sign and date the consent form.

          2. Stated willingness to comply with all study procedures and be available for the
             duration of the study.

          3. Ability to take and retain oral medications.

          4. Age ≥18 years.

          5. Patients with ALK+ lung cancer with evidence of ≥1 previously untreated brain
             metastases on brain MRI. Prior therapy (radiation or surgery) for brain metastases is
             allowed. However, patients must have ≥1 previously untreated at the time of
             enrollment.

          6. Patients may be ALK TKI naïve OR have had prior crizotinib therapy.

          7. Patients may be included if they are asymptomatic from their brain metastases
             (RTOG/EORTC grade 0) or if they have mild symptoms from their brain metastases not to
             exceed RTOG/ EORTC grade 1 or 2 (Grade 1: Fully functional status (i.e. able to work)
             with minor neurological findings, no medication needed; Grade 2: Neurological findings
             present sufficient to require home care / nursing assistance may be required /
             medications including steroids/anti-seizure agents may be required) (Cox, James D., et
             al ""Toxicity criteria of the radiation therapy oncology group (RTOG) and the European
             organization for research and treatment of cancer (EORTC)."" International Journal of
             Radiation Oncology• Biology• Physics 31.5 (1995): 1341-1346).

          8. Neurologically symptomatic patients must not require immediate surgical or radiation
             therapy for their symptoms, as decided by an investigator.

          9. Have an Eastern Cooperative Oncology Group (ECOG) performance status ≤2.

         10. Have adequate organ function, as determined by

               -  ALT/AST ≤2.5 × upper limit of normal (ULN); ≤5 × ULN is acceptable if liver
                  metastases are present

               -  Total serum bilirubin ≤1.5 × ULN (<3.0×ULN for patients with Gilbert syndrome)

               -  Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2, using the
                  modification of diet in renal disease (MDRD) equation

               -  Serum lipase/amylase ≤1.5 × ULN

               -  Absolute neutrophil count (ANC) ≥1.5 × 109/L

               -  Platelet count ≥75 × 109/L

               -  Hemoglobin ≥9 g/dL

         11. For females of childbearing potential, have a negative pregnancy test documented prior
             to initiating brigatinib.

         12. For female and male patients who are fertile, agree to use 2 effective methods of
             contraception with their sexual partners from the time of signing the informed consent
             through 4 months after the last dose of study drug, or agree to completely abstain
             from heterosexual intercourse. Brigatinib may decrease effectiveness of hormonal
             contraceptives, therefore, women are recommended to use non-hormonal methods of
             contraception. Highly effective non-hormonal birth control for women of child bearing
             potential with male partners includes:

               -  Sexual abstinence (no sexual intercourse)

               -  Intrauterine device (IUD) or intrauterine system (IUS)

               -  Bilateral tubal ligation (both tubes tied)

               -  Vasectomized partner

         13. Male patients, even if surgically sterilized (i.e., status post-vasectomy) must agree
             to 1 of the following:

               -  Practice effective barrier contraception during the entire study treatment period
                  and through 4 months after the last dose of study drug, or completely abstain
                  from heterosexual intercourse.

        Exclusion Criteria:

          1. Patients who have received prior brigatinib therapy or other CNS-penetrant ALK TKIs,
             including alectinib, lorlatinib, or ceritinib.

          2. RTOG/EORTC Acute CNS symptoms, grade 3 and 4 (Grade 3: Neurological findings requiring
             hospitalization for initial management; Grade 4: Serious neurological impairment that
             includes paralysis, coma, or seizures > 3 per week despite medication /
             hospitalization required).

          3. Currently pregnant, planning a pregnancy during the study period, or breastfeeding.

          4. Have clinically significant, uncontrolled cardiovascular disease per investigator,
             specifically including, but not restricted to:

               1. Myocardial infarction (MI) within 6 months prior to the first dose of study drug

               2. Unstable angina within 6 months prior to first dose of study drug

               3. Clinically significant congestive heart failure (CHF) within 6 months prior to
                  first dose of study drug

               4. History of clinically significant atrial or ventricular arrhythmia (including
                  clinically significant bradyarrhythmia), as determined by the treating physician

               5. Cerebrovascular accident or transient ischemic attack within 6 months prior to
                  first dose of study drug

          5. Have uncontrolled hypertension per the investigator. Patients with persistent
             hypertension of systolic ≥140 or diastolic ≥90 mm Hg should be under treatment on
             study entry to control blood pressure.

          6. Have a history or the presence at baseline of pulmonary interstitial disease,
             drug-related pneumonitis, or radiation pneumonitis.

          7. Have an ongoing or active infection, including, but not limited to, the requirement
             for intravenous (IV) antibiotics.

          8. Have a known history of human immunodeficiency virus (HIV) infection. Testing is not
             required in the absence of history.

          9. Have a known or suspected hypersensitivity to brigatinib or its excipients.

         10. Additional systemic therapies for the treatment of lung cancer may not be taken
             concomitantly with brigatinib (eg, TKIs, immunotherapy, chemotherapy). No washout
             period is required for prior therapy.

         11. Have malabsorption syndrome or other GI illness that could affect oral absorption of
             brigatinib.

         12. Have any condition or illness that, in the opinion of the investigator, would
             compromise patient safety or interfere with the evaluation of brigatinib.

         13. Received systemic treatment with strong cytochrome p-450 (cyp)3a inhibitors, strong
             cyp3a inducers, or moderate cyp3a inducers within 14 days before enrollment.

         14. Had major surgery within 30 days of the first dose of brigatinib. Minor surgical
             procedures such as catheter placement or minimally invasive biopsies are allowed.

         15. Have been diagnosed with another primary malignancy other than NSCLC, except for
             adequately treated nonmelanoma skin cancer or cervical cancer in situ; definitively
             treated nonmetastatic prostate cancer; or patients with another primary malignancy who
             are definitively relapse-free with at least 3 years elapsed since the diagnosis of the
             other primary malignancy.
      "
NCT04630730,suspended,"
    temporarily suspended for accrual due to ""out of specification"" notification for imp batch.
  ",0,phase 2,['bladder cancer'],"[""['D30.3', 'C67.5', 'C67.9', 'C79.11', 'C67.0', 'C67.1', 'D41.4']""]","['recombinant intravesical bcg (bacillus calmette-guérin vpm1002bc)', 'atezolizumab', 'cisplatin', 'gemcitabine']","['N.N.Cl[Pt]Cl', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F']","
        Inclusion Criteria:

          -  Written informed consent according to ICH/GCP regulations before registration and
             prior to any trial specific procedures

          -  Histologically proven urothelial cell carcinoma of the bladder (cT2, cT3 or cT4a and ≤
             cN1 (defined as a solitary lymph node ≤ 2 cm in the greatest dimension) and cM0) and
             be considered suitable for curative multimodality treatment including radical
             cystectomy by a multidisciplinary tumor board

          -  All histological subtypes eligible with the exception of small cell component

          -  Age ≥ 18 years

          -  WHO performance status 0-1

          -  Hematological function: hemoglobin ≥ 90 g/L, neutrophils ≥ 1.5 x 109/L, platelets ≥
             100 x 109/L

          -  Hepatic function: total bilirubin ≤ 1.5 x ULN (except for patients with Gilbert's
             disease ≤ 3.0 x ULN), AST ≤ 2.5 x ULN and ALT ≤ 2.5 x ULN, AP ≤ 2.5 x ULN

          -  Renal function: estimated glomerular filtration rate (eGFR) > 50 mL/min/1.73m²,
             according to CKD-EPI formula

          -  Women of childbearing potential must use effective contraception, are not pregnant or
             lactating and agree not to become pregnant during trial treatment and until 5 months
             after the last dose of investigational drug

          -  Men agree not to donate sperm or to father a child during trial treatment and until 5
             months after the last dose of investigational drug (www.swissmedicinfo.ch).

        Exclusion Criteria:

          -  Any pathological evidence of small-cell carcinoma component

          -  Presence of any distant metastasis

          -  History of hematologic or primary solid tumor malignancy, unless in remission for at
             least 3 years after registration, with the exception of adequately treated cervical
             carcinoma in situ, localized non-melanoma skin cancer or low risk localized prostate
             cancer (T1-T2a, Gleason <7, PSA <10ng/ml)

          -  Residual urinary bladder volume after micturition > 150ml (measured by ultrasound of
             bladder or inserted catheter)

          -  Prior treatment for bladder cancer including BCG instillations. Single dose
             intravesical chemotherapy instillation after TURB is allowed

          -  Bladder surgery or traumatic catheterization or TURB within 14 days prior to the
             expected start of BCG trial treatment

          -  Uncontrollable urinary tract infection, macroscopic haematuria, suspicion of bladder
             perforation, urethral strictures (if interfering with trial procedures)

          -  Any conditions preventing the patient from keeping BCG instillation in the bladder for
             at least 1 hour; anticholinergics are allowed to achieve this criterion

          -  Any previous treatment with a PD-1 or PD-L1 inhibitor, including atezolizumab

          -  Concomitant or prior use of immunosuppressive medication within 28 days before
             registration, with the exceptions of intranasal and inhaled corticosteroids, or
             systemic corticosteroids which must not exceed 10 mg/day of prednisone (or a dose
             equivalent corticosteroid) and the premedication for chemotherapy

          -  Concurrent treatment with other experimental drugs or other anticancer therapy,
             treatment in a clinical trial within 28 days prior to registration

          -  Major surgical procedure within 28 days prior to registration

          -  Preexisting peripheral neuropathy (> grade 1)

          -  Active or prior documented autoimmune or inflammatory disorders (including
             inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with
             the exception of diverticulosis], systemic lupus erythematosus, sarcoidosis syndrome,
             or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid
             arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this
             criterion:

               -  Patients with vitiligo or alopecia

               -  Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on
                  hormone replacement

               -  Any chronic skin condition that does not require systemic therapy

               -  Patients without active disease in the last 5 years may be included but only
                  after consultation with the coordinating investigator

               -  Patients with celiac disease controlled by diet alone

          -  Known history of human immunodeficiency virus (HIV) or active chronic Hepatitis C or
             Hepatitis B Virus infection or any uncontrolled active systemic infection requiring
             intravenous (iv) antimicrobial treatment

          -  Known history of tuberculosis, known history of primary immunodeficiency, known
             history of allogeneic organ transplant, or receipt of live attenuated vaccine within
             28 days prior to registration

          -  Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or
             IV), unstable angina pectoris, history of myocardial infarction within the last six
             months, serious arrhythmias requiring medication (with exception of atrial
             fibrillation or paroxysmal supraventricular tachycardia), significant QT-prolongation,
             uncontrolled hypertension

          -  Any concomitant drugs contraindicated for use with the trial drugs according to the
             approved product information

          -  Known hypersensitivity to trial drugs or to any component of the trial drugs

          -  Any other serious underlying medical, psychiatric, psychological, familial or
             geographical condition, which in the judgment of the investigator may interfere with
             the planned staging, treatment and follow-up, affect patient compliance or place the
             patient at high risk from treatment-related complications.
      "
NCT04639245,terminated,"
    terminated due to slow accrual.
  ",0,phase 1/phase 2,"['anatomic stage iv breast cancer ajcc v8', 'metastatic lung non-small cell carcinoma', 'metastatic malignant solid neoplasm', 'metastatic triple-negative breast carcinoma', 'metastatic urothelial carcinoma', 'stage iv lung cancer ajcc v8']","[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['D02.20', 'D02.21', 'D02.22']"", ""['R18.0', 'C17.3', 'G21.0', 'J91.0', 'C05.2', 'C10.0', 'C16.0']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['atezolizumab', 'cyclophosphamide', 'fludarabine']","['C1CNP(=O)(OC1)N(CCCl)CCCl', 'C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N']","
        Inclusion Criteria:

          -  Tissue confirmation of triple negative breast cancer (TNBC), urothelial carcinoma or
             non-small cell lung cancer (NSCLC) and expression of MAGEA1: Participants must have
             metastatic disease. Confirmation of diagnosis must be or have been performed by
             internal pathology review of archival, initial or subsequent biopsy or other
             pathologic material at Fred Hutchinson Cancer Research Center (FHCRC)/Seattle Cancer
             Care Alliance (SCCA)/University of Washington Medical Center (UWMC). Patients with
             TNBC must meet the American Society of Clinical Oncology - College of American
             Pathologists (ASCO-CAP) definition of negative estrogen, progesterone and HER2
             receptor expression. Baseline tissue will be stained to confirm MAGE-A1 expression

          -  Measurable disease by RECIST 1.1 criteria: Participants must have measurable disease,
             defined as at least one target lesion that can be measured in at least one dimension
             (longest diameter to be recorded) as >= 10 mm, unless lymph node in which case short
             axis must be >= 15 mm. Baseline imaging (for example diagnostic computed tomography
             [CT] chest/abdomen/pelvis and imaging of the affected extremity as appropriate), brain
             imaging (magnetic resonance imaging [MRI] or CT scan) must be obtained within 45 days
             of prior to start of first planned FH-MAGEA1-A2TCR infusion. MRI can be substituted
             for CT in patients unable to have CT contrast. Measurable disease is not required for
             purposes of leukapheresis /cell manufacturing storage for patients who meet HLA and
             expression criteria but not standard treatment criteria

          -  Previous treatment with standard of care (SOC) Food and Drug Administration
             (FDA)-approved therapies. Patients with NSCLC who have actionable somatic mutations or
             alterations in EGFR, ROS1 and ALK with FDA-approved drug therapy options will be
             eligible for study only after treatment with targeted therapies for those mutations
             have been offered or received. Patients with urothelial carcinoma who are candidates
             for enfortumab vedotin (enfortumab vedotin-ejfv) will be eligible for study after
             prior treatment with enfortumab vedotin-ejfv has been offered or received

             * Note: Participants will be eligible to enroll before standard therapy is received in
             order to expedite leukapheresis/cell manufacturing as long as the aforementioned agent
             is administered prior to lymphodepletion and/or cell infusion

          -  Previous treatment with PD-1 axis inhibitor: Patients in Phase I/2 must have been
             offered or been previously treated with at least one dose of a PD-L1 axis inhibitor
             (e.g. PD-1 or PD-L1 inhibiting monoclonal antibody such as pembrolizumab, nivolumab,
             avelumab, atezolizumab, durvalumab). If received, they must have either developed
             progression or still have detectable disease and not have developed Common Terminology
             Criteria for Adverse Events (CTCAE) grade 3 or higher toxicity while on treatment.
             Patients may have received 1 or more prior systemic regimens for metastatic TNBC or
             NSCLC. There is no upper limit on prior regimens. Patients may have received prior
             anti-PD-1/anti-PD-L1 in the neoadjuvant or adjuvant setting

          -  HLA type HLA-A*02:01: Participants must be HLA-A*02:01 in order for infused transgenic
             T cells in order to insure recognition of antigen-MHC complexes. HLA typing should be
             determined though a molecular approach in a clinical laboratory licensed for HLA
             typing

          -  Life expectancy must be anticipated to be > 3 months at trial entry

          -  18 years or older

          -  Capable of understanding and providing a written informed consent

          -  If fertile, willingness to comply with reproductive requirements

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

          -  Tumor tissue amenable to safe biopsy and subject willing to undergo serial tumor
             biopsies: Should there be no tumor tissue that is accessible for biopsy, patients will
             still be considered for participation, at discretion of the sponsor and in
             consultation with the investigator. Similarly, should an investigator determine that a
             biopsy cannot be performed safely for clinical reasons biopsies may be cancelled or
             retimed after confirming plan with the sponsor

          -  Participants must be at least three weeks from last systemic treatment at the time of
             cell collection: At least 3 weeks must have passed since any: immunotherapy (for
             example, T-cell infusions, immunomodulatory agents, interleukins, vaccines), small
             molecule or chemotherapy cancer treatment, other investigational agents. There is no
             washout period for radiation, so long as radiated lesion is not the lesion being
             evaluated for RECIST measurements on the protocol. Bisphosphonates are permitted but
             the concurrent treatment with RANK ligand inhibitors (i.e., denosumab) is not
             permitted within 8 weeks of treatment

          -  Serum creatine < 2.5 mg/dL or estimated glomerular filtration rate (eGFR) > 30 mL/min

          -  Total bilirubin (tBili) < 3.0 mg/dL. Patients with suspected Gilbert syndrome may be
             included if Tbili > 3 but no other evidence of hepatic dysfunction

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 5 x upper limit
             of normal (ULN)

          -  =< grade 1 dyspnea and oxygen saturation (SaO2) >= 92% on ambient air. If pulmonary
             function tests (PFTs) are performed based on the clinical judgement of the treating
             physician, patients with forced expiratory volume in 1 second (FEVI) >= 50% of
             predicted and carbon monoxide diffusing capability test (DLCO) (corrected) of >= 40%
             of predicted will be eligible

          -  Patients 60 years of age or older are required to have left ventricular ejection
             fraction (LVEF) evaluation performed within 60 days prior to enrollment. LVEF may be
             established with echocardiogram or multigated acquisition scan (MUGA) scan, and left
             ejection fraction must be >= 35%. Cardiac evaluation for other patients is at the
             discretion of the treating physician

          -  Absolute neutrophil count (ANC) > 500 cells/ mm^3

        Exclusion Criteria:

          -  Expression of HLA B*4901: participants will be excluded due to the risk of
             alloreactivity

          -  Participants of childbearing potential must have a negative serum pregnancy test
             within 14 days prior to enrollment. Childbearing potential is defined as women who
             have not been surgically sterilized and who are not postmenopausal (free of menses for
             at least 1 year)

          -  Patients with active autoimmune disease requiring immunosuppressive therapy are
             excluded. Case-by-case exemptions are possible with approval by principal investigator
             (PI)

          -  Prior solid organ transplant or allogenic hematopoietic stem cell transplant: Kidney
             transplant patients will be considered on a case-by-case basis requiring discussion
             with PI. If kidney transplant, patient must have dialysis access, dialysis plan,
             supportive nephrologist, willingness to stop transplant immunosuppression, and express
             understanding that rejection is possible outcome. Dialysis or costs related to
             transplant kidney will not be supported by the study. Participants having had any
             other solid organ transplants will be excluded, as will those with any history of
             allogeneic stem cell transplant

          -  Corticosteroid therapy at a dose equivalent of > 0.5 mg/kg of prednisone-equivalent
             per day

          -  Concurrent use of other investigational anti-cancer agents

          -  Chronic lymphocytic leukemia (CLL) or other active hematologic malignancy

          -  Active uncontrolled infection: Human immunodeficiency virus (HIV) positive
             participants on highly active anti-retroviral therapy (HAART) with a CD4 count > 500
             cells/mm^3 are considered controlled, as are individuals with a history of hepatitis C
             who have successfully completed antiviral therapy with an undetectable viral load, and
             those with hepatitis B who have, per standard practice, hepatitis well-controlled on
             medication (e.g., AST and ALT < 5 x ULN)

          -  Participants may not have uncontrolled or concurrent illness including, but not
             limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Participants with small asymptomatic brain metastases (< 1 cm) or those with brain
             metastases previously treated with surgery or radiotherapy will be considered for
             inclusion at discretion of principal investigator, so long as other eligibility
             criteria are met.

          -  For patients in phase 1/2, grade 3 or higher immune-mediated toxicity to any prior
             PD-L1 axis blocking agent

          -  Active treatment for prior immune related adverse event to any immunotherapy:
             Participants receiving ongoing treatment for prior serious immune related adverse
             events are excluded, with exception of hormone supplementation or corticosteroid
             therapy at equivalent of up to 0.5 mg/kg prednisone per day, unless otherwise approved
             by PI

          -  Study participants must not have significant active underlying neurologic disease,
             unless approved by PI. Neuropathy related to diabetes or prior chemotherapy is
             acceptable

          -  Other medical, social, or psychiatric factor that interferes with medical
             appropriateness and/or ability to comply with study, as determined by the PI
      "
NCT02008318,completed,,0,phase 2/phase 3,['myelodysplastic syndromes'],"[""['D46.9', 'D46.C', 'D46.Z']""]","['galunisertib', 'placebo']",['CC1=NC(=CC=C1)C2=NN3CCCC3=C2C4=C5C=C(C=CC5=NC=C4)C(=O)N'],"
        Inclusion Criteria:

          -  Confirmed diagnosis of MDS based on the World Health Organization (WHO) criteria

          -  Participants with 5q deletions are allowed only if they have failed or are intolerant
             of lenalidomide treatment

          -  Participants must have a Revised International Prognostic Scoring System (IPSS-R)
             category of very low-, low-, or intermediate-risk disease

          -  In the 8 weeks prior to registration, participants in phase 2 should have anemia with
             Hb ≤10.0 g/dL (based on the average of 2 baseline measurements and untransfused for at
             least 1 week) with or without red blood cell (RBC) transfusion dependence confirmed
             for a minimum of 8 weeks before enrollment

          -  For phase 3, participants should have anemia with RBC transfusion dependence confirmed
             within 8 weeks before enrollment

          -  Performance status ≤2 on the Eastern Cooperative Oncology Group (ECOG) scale

        Exclusion Criteria:

          -  No history of moderate or severe cardiac disease

          -  No prior history of acute myeloid leukemia (AML)
      "
NCT02037230,completed,,1,phase 1/phase 2,['adenocarcinoma of the pancreas'],"[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['mk-1775', 'gemcitabine']","['CC(C)(C1=NC(=CC=C1)N2C3=NC(=NC=C3C(=O)N2CC=C)NC4=CC=C(C=C4)N5CCN(CC5)C)O', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F']","
        Inclusion Criteria:

          -  Patients must have pathologically confirmed adenocarcinoma of the pancreas.

          -  Patients will have unresectable disease, defined radiographically as >180 degrees
             involvement of the superior mesenteric artery or celiac trunk or SMV/portal vein
             impingement that cannot be surgically reconstructed, in the absence of distant
             metastasis..

          -  Patients must have a Zubrod performance status (measure of general well being that
             ranges from 0 to 5 where 0 represents perfect health) of < 2.

          -  Patients must have adequate organ function defined as follows: absolute neutrophil
             count of ≥ 1500/mm3, platelets ≥ 100,000/mm3, serum creatinine ≤ 2 mg/dl, total
             bilirubin ≤ 3, (with relief of biliary obstruction if present (PTC tube or endobiliary
             stent)) and AST < 5 times the upper limit of normal.

          -  Patients of reproductive potential must agree to use an effective contraceptive method
             during participation in this trial and for 6 months after the trial. Patients must not
             be breastfeeding.

          -  Patients must be aware of the investigational nature of the therapy and provide
             written informed consent.

          -  Patients must be at least 18 years old.

        Exclusion Criteria:

          -  Other serious uncontrolled concomitant systemic disorders or psychiatric condition
             that would interfere with the safe delivery of protocol therapy.

          -  A history of previous chemotherapy for pancreatic cancer or abdominal radiation
             therapy.

          -  The use of any investigational agent in the month before enrollment into the study.

          -  Inability to discontinue a prescription or non-prescription drugs or other products
             known to be metabolized by CYP3A4, or to inhibit or induce CYP3A4 prior to Day 1 of
             dosing and to withhold throughout the study until 2 weeks after the last dose of study
             medication. Medications of particular concern are the following inhibitors of CYP3A4:
             azole antifungals (ketoconazole itraconazole, fluconazole and voriconazole), macrolide
             antibiotics (erythromycin, clarithromycin), cimetidine, aprepitant, HIV protease
             inhibitors, nefazodone and the following inducers of CYP3A4: phenytoin, barbiturates
             and rifampicin. Substrates of CYP3A4 include statins (lovastatin, simvastatin),
             midazolam, terfenadine, astemizole, and cisapride.
      "
NCT02038647,completed,,1,phase 2,['small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['alisertib', 'placebo', 'paclitaxel']","['COC1=C(C(=CC=C1)F)C2=NCC3=CN=C(N=C3C4=C2C=C(C=C4)Cl)NC5=CC(=C(C=C5)C(=O)O)OC', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C']","
        Inclusion Criteria

        Each participant must meet all the following inclusion criteria to be enrolled in the
        study:

          1. Male or female participants ≥ 18 years old.

          2. Have a pathologically (histology or cytology) confirmed diagnosis of SCLC.

          3. Have received and progressed after a platinum-based standard chemotherapy regimen for
             first line treatment of SCLC, either limited stage (LS) or extensive stage (ES).

          4. Have measurable disease within ≤ 2 weeks before randomization. Clear radiographic
             evidence of disease progression after initial therapy should have been documented.

          5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 (PS 0-1).

          6. Participants with treated brain metastases (surgery, whole or stereotactic brain
             radiation) are allowed provided the lesions have been stable for at least 2 weeks and
             the participant is off steroids or is on a stable dose of steroids. Participants
             should be without neurologic dysfunction that would confound the evaluation of
             neurological and/or other AEs.

        Exclusion Criteria

        Participants meeting any of the following exclusion criteria are not to be randomized to
        treatment:

          1. Any prior therapy for second-line treatment of SCLC.

          2. Participants who relapsed ≥ 180 days after their response to first-line treatment.

          3. Prior treatment with an Aurora A specific-targeted or pan-Aurora-targeted agent,
             including alisertib, or any other investigational agent.

          4. Prior treatment with paclitaxel or any other taxane agent.

          5. Known hypersensitivity to Cremophor® EL, paclitaxel, or its components.

          6. Any comorbid condition or unresolved toxicity that would preclude administration of
             alisertib or weekly paclitaxel.

          7. Prior history of ≥ Grade 2 neurotoxicity that is not resolved to ≤ Grade 1.

          8. Participants with symptomatic and/or progressive brain metastases or with
             carcinomatous meningitis.

          9. Treatment with clinically significant enzyme inducers within 14 days prior to the
             first dose of alisertib and during study conduct. Major prohibited enzyme inducers
             include: phenytoin, carbamazepine, phenobarbital, rifampin, rifabutin, rifapentine,
             and St. John's wort.

         10. Inability to swallow alisertib or other orally administered medications.

         11. Requirement for administration of proton pump inhibitor (PPI), H2 antagonist, or
             pancreatic enzymes.

         12. Diagnosed with or treated for another malignancy within 2 years before the first dose
             of study drug, or previously diagnosed with another malignancy and have any evidence
             of residual disease.

         13. Other severe acute or chronic medical or psychiatric condition(s) per protocol.

         14. History of myocardial infarction, unstable symptomatic ischemic heart disease,
             uncontrolled hypertension despite appropriate medical therapy, any ongoing cardiac
             arrhythmias of Grade > 2, thromboembolic events (eg, deep vein thrombosis, pulmonary
             embolism, or symptomatic cerebrovascular events), or any other cardiac condition (eg,
             pericardial effusion or restrictive cardiomyopathy) within 6 months before receiving
             the first dose of study drug.

         15. Known history of human immunodeficiency virus (HIV) infection, hepatitis B or
             hepatitis C.

         16. Surgery within 3 weeks (or 2 weeks for a minor surgery) before study enrollment and
             not fully recovered to baseline or to a stable clinical status.

         17. Participants who are pregnant, lactating, or do not agree to use effective methods of
             contraception during the study treatment period through 6 months after the last dose
             of study drug per protocol.
      "
NCT02033993,completed,,1,phase 2,['urothelial cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['nab-paclitaxel', 'paclitaxel']","['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C', 'Status: 503']","
        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of TCC of the urinary tract
             (bladder, urethra, ureter, renal pelvis) and metastatic or locally advanced inoperable
             disease extent (T4, N2, N3 or M1 disease)

        Note: Mixed histologies (except small cell) permitted if predominately TCC by IHC.

          -  Patients must have evidence of metastatic disease, but measurable disease is not
             mandatory. To be considered evaluable for the overall response rate (complete and
             partial response), patients must have at least one measurable lesion as follows:

               -  X-ray, physical exam ≥ 20 mm

               -  Conventional CT scan, MRI ≥ 20 mm

               -  Spiral CT scan ≥ 10 mm

          -  Male or female, 18 years of age or older.

          -  ECOG performance status ≤ 2 at study entry

          -  Adequate hematological, renal and hepatic functions as defined by the following
             required laboratory values obtained within 14 days prior to randomization. If anemic,
             patients should be asymptomatic and should not be decompensated.

               -  Absolute neutrophil count (ANC) ≥ 1.5 x10^9/L (1,500 cells/mm3)

               -  Platelet count ≥ 90 x10^9/L (100,000/mm3)

               -  Hemoglobin ≥ 90 g/L

               -  Calculated creatinine clearance > 25 mL/min (Cockcroft and Gault formula)

               -  Total bilirubin ≤ 1.5 times the upper limit of normal (≤ 2.5X if Gilbert's
                  disease)

               -  ALT (SGPT) ≤ 3 x ULN or ≤ 5 x ULN if hepatic metastases are present

          -  Patients may have had prior neoadjuvant or adjuvant therapy for completely resected
             disease, provided it was completed at least 12 months prior to randomization. Patients
             must have recovered from any acute toxic effects to ≤ Grade 2 from any prior
             treatments. Neoadjuvant or adjuvant chemotherapy will be considered to have been first
             line therapy in the metastatic setting if the patient progressed within 12 months of
             the last dose.

          -  Patients must have received one and only one prior chemotherapeutic regimen which
             included a platinum (at least one cycle) for metastatic/recurrent disease. Treatment
             must have been discontinued at least 4 weeks prior to randomization in this study.
             Patients must have recovered from any acute toxic effects to ≤ Grade 2 from any prior
             treatments

          -  Patients may not have had any prior therapy with a taxane in any setting.

          -  Patients may have had prior investigational agents but these must have been
             discontinued at least 4 weeks prior to randomization. Patients must have recovered
             from any acute toxic effects to ≤ Grade 2 from any prior treatments.

          -  Prior treatments with radiation therapy in the adjuvant and/or metastatic setting are
             permitted provided that at least 2 weeks have elapsed since the last fraction of
             radiation therapy and all treatment related adverse events are ≤ Grade 1 at the time
             of randomization.

          -  Patients may have had prior surgery provided that at least 4 weeks elapsed between the
             end of surgery and randomization onto the study. Patients must have recovered from any
             acute toxic effects to ≤ Grade 2 from any prior treatments.

          -  Patients may have peripheral neuropathy from previous treatments providing that it is
             ≤ Grade 1.

          -  Patient is able (i.e. sufficiently fluent) and willing to complete the health and
             demographic, quality of life, and health utilities questionnaires in either English or
             French. The baseline assessment must be completed within required timelines, prior to
             registration/randomization. Inability (illiteracy in English or French, loss of sight,
             or other equivalent reason) to complete the questionnaires will not make the patient
             ineligible for the study. However, ability but unwillingness to complete the
             questionnaires will make the patient ineligible.

          -  Patient consent must be appropriately obtained in accordance with applicable local and
             regulatory requirements. Each patient must sign a consent form prior to enrollment in
             the trial to document their willingness to participate.

          -  Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy
             test within 7 days prior to randomization. In addition to routine contraceptive
             methods, ""effective contraception"" also includes heterosexual celibacy and surgery
             intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined
             as a hysterectomy, bilateral oophorectomy, bilateral tubal ligation or
             vasectomy/vasectomized partner. However, if at any point a previously celibate patient
             chooses to become heterosexually active during the time period for use of
             contraceptive measures outlined in the protocol, he/she is responsible for beginning
             contraceptive measures.

          -  Patients must be accessible for treatment and follow up. Patients registered on this
             trial must be treated and followed at the participating centre. This implies there
             must be reasonable geographical limits (for example: 1 ½ hour's driving distance)
             placed on patients being considered for this trial. Investigators must assure
             themselves the patients registered on this trial will be available for complete
             documentation of the treatment, adverse events, response assessment and follow-up.

          -  In accordance with CCTG policy, protocol treatment is to begin within 5 working days
             of patient randomization.

        Exclusion Criteria:

          -  A candidate for potentially curative surgery or radiotherapy.

          -  Patients with brain metastases are ineligible if they meet at least one of the
             following criteria:

               1. diagnosis within 3 months from randomization

               2. untreated brain metastases

               3. unstable brain metastasis as defined by:

                    -  cavitation or hemorrhage in the brain lesion

                    -  symptomatic state

                    -  daily prednisone or equivalent use greater than 10 mg

        Patients do not need CT/MRI scans to rule out brain metastases unless there is a clinical
        suspicion of CNS metastases.

          -  Patients with serious illness or medical condition which would not permit the patient
             to be managed according to the protocol including, but not limited to:

               1. . any evidence of severe or uncontrolled systemic disease (i.e. known cases of
                  hepatitis B or C or human immunodeficiency virus (HIV)).

               2. patients with active or uncontrolled infections.

                  Screening for chronic conditions is not required, although patients known to have
                  such conditions at screening should not be included.

          -  Women who are pregnant or breastfeeding.

          -  Patients with history of allergic or hypersensitivity reactions to any study drug or
             their excipients or with a history of allergic reactions attributed to compounds with
             similar chemical composition to any of the study drugs.

          -  Planned concomitant participation in another clinical trial of an experimental agent,
             vaccine or device. Concomitant participation in observational studies is acceptable.

          -  Patients with a history of other malignancies, except: adequately treated non-melanoma
             skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours
             curatively treated with no evidence of disease for ≥ 5 years. Prior prostate cancer is
             allowed provided that it is an incidental finding at cystoprostatectomy with a PSA
             <0.5 ng/mL at randomization or a prior diagnosis of low risk prostate cancer at any
             time as defined by ≤T2, a Gleason Score of 6 or less and PSA <10 ng/mL.
      "
NCT02039947,completed,,1,phase 2,['melanoma and brain metastases'],"[""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']""]","['dabrafenib', 'trametinib']","['CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F', 'CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5']","
        Inclusion Criteria:

          -  ECOG Performance Status range of 0-2

          -  Histologically confirmed cutaneous metastatic melanoma of V600 E, K, D or R.

          -  May be systemic naïve or received up to two previous systemic treatment regimens for
             metastatic melanoma.

          -  Must be able to undergo MRI and have at least one measurable intracranial lesion for
             which specific criteria have to be met.

        Exclusion Criteria:

          -  Prior treatment with any BRAF inhibitor or any mitogen-activated protein/extracellular
             signal-regulated kinase inhibitor.

          -  Anti-cancer therapy or investigational anti-cancer therapy or chemotherapy without
             delayed toxicity within treatment specific timeframe.

          -  Treatment with stereotactic radiosurgery or treatment with whole-brain radiation
             within treatment specific timeframe.

          -  Any presence of leptomeningeal disease or any parenchymal brain metastasis

          -  History of another malignancy, some exceptions may apply.

          -  A history or evidence of cardiovascular risk- specific criteria have to be met

          -  A history or current evidence/risk of retinal vein occlusion or retinal pigment
             epithelial detachment - specific criteria have to be met.
      "
NCT02035124,withdrawn,"
    study withdrawn due to slow accrual. no patients were enrolled.
  ",0,phase 2,['advanced prostate cancer'],"[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]","['bkm 120', 'cabazitaxel']","['C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC)C)OC']","
        Inclusion Criteria:

          1. Adenocarcinoma of the prostate confirmed histologically.

          2. Metastatic disease confirmed by biopsy or imaging studies.

          3. Patients must have received treatment with docetaxel as the only previous chemotherapy
             regimen. In addition, previous treatment with hormonal agents and/or immune therapy is
             allowed (e.g., abiraterone). (Previous treatment with MDV3100 will also be allowed.)

          4. Patients must be castrate-resistant (i.e. developed progression of metastases
             following surgical castration or during medical androgen ablation therapy) with
             documented castrate levels of testosterone (<50 ng/dl).

          5. Patients receiving medical castration therapy with gonadotropin-releasing hormone
             (GnRH) analogues should continue this treatment during this study.

          6. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 to 2.

          7. Patient must have progressive metastatic prostate cancer by at least 1 of the
             following criteria:

               -  Soft tissue disease progression defined by Response Evaluation Criteria in Solid
                  Tumors (RECIST) version 1.1.

               -  Bone scan progression defined by 2 or more new lesions on bone scan.

               -  Prostate specific antigen (PSA) progression is determined by a minimum of three
                  rising PSA levels with an interval of ≥1 week between each determination. The
                  screening PSA measurement (documenting progression) must be ≥2 ng/mL.

          8. Screening PSA ≥2 ng/mL.

          9. Adequate hematologic, renal and hepatic function:

         10. Adequate serum chemistries.

         11. Ability to swallow and retain oral medication.

         12. Life expectancy of ≥6 months.

         13. Patients must be ≥18 years of age.

         14. Patients entering this study must be willing to provide tissue from a previous tumor
             biopsy or 15 unstained slides (if available) for correlative testing. If tissue is not
             available, a patient will still be eligible for enrollment into the study.

         15. Ability to understand the nature of this study and give written informed consent.

        Exclusion Criteria:

          1. Previous treatment with PI3K inhibitors.

          2. Known hypersensitivity to BKM120 or polysorbate-80 or any of the excipients or
             taxanes.

          3. Use of an investigational drug ≤21 days or 5 half-lives (whichever is shorter) prior
             to the first dose of BKM120. For investigational drugs for which 5 half-lives is ≤21
             days, a minimum of 10 days between termination of the investigational drug and
             administration of BKM120 is required.

          4. Previous chemotherapy with any agent other than docetaxel. All patients must be ≥28
             days after their most recent chemotherapy and have recovered from side effects.

          5. Patient has received wide field radiotherapy (including therapeutic radioisotopes such
             as strontium 89) ≤28 days or limited field radiation for palliation ≤7 days prior to
             starting study drug or has not recovered from side effects of such therapy.

          6. Major surgical procedures ≤28 days of beginning study drug, or minor surgical
             procedures ≤7 days. No waiting required following port-a-cath placement.

          7. Clinical significant peripheral neuropathy (defined as CTCAE v4.0 Grade ≥2) regardless
             of causality.

          8. Mood disorders as judged by the Investigator or a Psychiatrist, or who meets the
             cut-off score of ≥12 in the Patient Health Questionnaire (PHQ)-9 or a cut-off score of
             ≥ 15 in the Generalized Anxiety Disorder (GAD)-7 mood scale, respectively, or selects
             a positive response of '1, 2, or 3' to question 9 regarding potential for suicidal
             thoughts in the PHQ-9 (independent of the total score or the PHQ-9)

               -  anxiety or depression ≥ Grade 3

               -  medically documented history of or active major depressive episode, bipolar
                  disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of
                  suicidal attempt or ideation, or homicidal ideation, or patients with active
                  severe personality disorders (defined according to DSM- IV) are not eligible.
                  Note: for patients with psychotropic treatments ongoing at baseline, the dose and
                  the schedule should not be modified

          9. Previously untreated brain metastases. Patients who have received radiation or surgery
             for brain metastases are eligible if there is no evidence of central nervous system
             (CNS) disease progression, and at least 28 days (4 weeks) have elapsed since
             treatment. Patients are not permitted to receive enzyme inducing anti-epileptic drugs
             (EIAEDs) during the study and should not be receiving chronic corticosteroid therapy
             for CNS metastases.

         10. Leptomeningeal metastases or spinal cord compression due to disease.

         11. Acute or chronic liver, renal disease or pancreatitis.

         12. Uncontrolled diabetes mellitus. Type II diabetics are eligible if they require only
             oral hypoglycemic agents and fasting blood glucose level is ≤120. Type I diabetics are
             eligible if HbAlc is <8.

         13. Presence of active gastrointestinal (GI) disease or other condition that will
             interfere significantly with the absorption, distribution, metabolism, or excretion of
             oral therapy (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea Grade
             ≥2, and malabsorption syndrome).

         14. Any of the following cardiac diseases currently or within the last 6 months:

               -  Left Ventricular Ejection Fraction (LVEF) <50% as determined by Multiple Gated
                  acquisition (MUGA) scan or echocardiogram (ECHO)

               -  QTc > 480 ms on screening ECG

               -  Unstable angina pectoris

               -  Congestive heart failure (New York Heart Association [NYHA] ≥ Grade 2

               -  Acute myocardial infarction

               -  Conduction abnormality not controlled with pacemaker or medication

               -  Significant ventricular or supraventricular arrhythmias (Patients with chronic
                  rate-controlled atrial fibrillation in the absence of other cardiac abnormalities
                  are eligible.)

               -  Valvular disease with significant compromise in cardiac function.

         15. Family history of congenital long or short QT, or known history of QT/QTc prolongation
             or Torsades de Pointes (TdP). Patients who are currently receiving treatment with
             medication that has the potential to prolong the QT interval or induce TdP and the
             treatment cannot either be discontinued or switched to a different medication prior to
             starting study treatment.

         16. Inadequately controlled hypertension (i.e., SBP>180 mmHg or DBP>100mmHg). (Patients
             with values above these levels must have their BP controlled with medication prior to
             starting treatment)

         17. Patient receiving chronic treatment with systemic steroids or another
             immunosuppressive agent at the start of study treatment.

             Note: Topical applications (e.g. rash), inhaled sprays (e.g. obstructive airways
             diseases), eye drops or local injections (e.g. intra-articular) are allowed.

         18. Patients receiving drugs known to be moderate and strong inhibitors or inducers or
             isoenzyme cytochrome P450 (CYP) 3A (CYP3A) that cannot be discontinued or switched to
             different medication prior to starting study drug.

         19. Patients who have taken herbal medications and certain fruits ≤7 days prior to
             starting study drug. Herbal medications include, but are not limited to St. John's
             wort, Kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe,
             saw palmetto, and ginseng. Fruits include the CYP3A inhibitors Seville oranges,
             grapefruit, pummelos, or exotic citrus fruits.

         20. Patients currently receiving treatment with therapeutic doses of warfarin sodium.
             Patients receiving low molecular weight heparin are allowed.

         21. A serious active infection at the time of treatment, or another serious underlying
             medical condition that would impair the ability of the patient to receive protocol
             treatment.

         22. Known diagnosis of human immunodeficiency virus (HIV), Hepatitis B (HBV) or Hepatitis
             C (HCV).

         23. Presence of other active cancers, or history of treatment for invasive cancer ≤5
             years. Patients with stage I cancer who have received definitive local treatment at
             least 3 years previously, and are considered unlikely to recur are eligible. All
             patients with previously treated in situ carcinoma (i.e. non-invasive) are eligible,
             as are patients with history of non-melanoma skin cancer.

         24. Psychological, familial, sociological, or geographical conditions that do not permit
             compliance with the protocol.

         25. Inability or unwillingness to comply with study and/or follow-up procedures outlined
             in the protocol.

         26. Fertile male patients, defined as all males physiologically capable of conceiving
             offspring must use a highly effective contraception during dosing any study agent + [5
             x T1/2] +12 weeks = contraception through 16 weeks after final dosing of study therapy
             and should not father a child during this period. In addition, female partners of male
             patients must use a highly effective contraception during dosing of any study agent +
             [5 x T1/2] +12 weeks = contraception through 16 weeks after the final dose of study
             therapy.
      "
NCT02036476,terminated,"
    lack of accrual.
  ",0,phase 2,"['merkel cell carcinoma', 'skin cancer']","[""['C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8', 'Z85.821']"", ""['C79.2', 'C44.500', 'C44.90', 'D23.9', 'D48.5', 'C44.00', 'C44.301']""]",['cabozantinib'],['COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F'],"
        Inclusion Criteria:

          -  Must have histologically or cytologically confirmed Merkel Cell Carcinoma that is
             metastatic or unresectable and for which standard curative measures do not exist or
             are no longer effective

          -  Must have measurable disease, defined as at least one lesion that can be accurately
             measured in at least one dimension (longest diameter to be recorded) as ≥ 20 mm with
             conventional techniques or as ≥10 mm with spiral CT scan (see section 10 for the
             evaluation of measureable disease). Tumors within a previously irradiated field will
             be designated as ""non-target"" lesions unless progression is documented

          -  Must have had one prior platinum-based chemotherapeutic regimen for management of
             primary disease containing carboplatin, cisplatin or another organoplatinum compound.
             Patients are also eligible if they received curative intent platinum-based therapy and
             progressed within a year of therapy

          -  No prior MET inhibitor is allowed

          -  At least 2 weeks since prior chemotherapy or radiation therapy. At least 3 weeks since
             prior biologics or investigational agents

          -  Recovery from effects of recent treatment to baseline or CTCAE ≤ grade 1 toxicity from
             all prior therapies except alopecia and other non-clinically significant AEs

          -  Participants must be ≥18 years of age

          -  ECOG performance status ≤1

          -  Participants must have normal organ and marrow function

          -  Women of child-bearing potential and men must agree to use adequate contraception
             prior to study entry and for the duration of study participation

          -  Ability to understand and the willingness to sign a written informed consent document

          -  Collection of archival tissue specimens for confirmation of Merkel Cell Carcinoma

        Exclusion Criteria:

          -  Participants who have had chemotherapy or radiotherapy within 2 weeks prior to
             entering the study or those who have not recovered from adverse events due to agents
             administered more than 2 weeks earlier

          -  Participants may not be receiving any biologics or investigational agents within 3
             weeks

          -  The subject has active brain metastases or epidural disease

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to cabozantinib

          -  Has prothrombin time (PT)/ International Normalized Ratio (INR) or partial
             thromboplastin time (PTT) test ≥ 1.3 the institutional ULN within 7 days before the
             first dose of study treatment, unless PT/PTT prolongation known to be secondary to
             conditions not associated with increased bleeding risk (as on antiphospholipid
             antibody syndrome)

          -  Requires concomitant treatment, in therapeutic doses, with anticoagulants

          -  Active bleeding or pathologic conditions that carry high risk of bleeding

          -  Have experienced clinically significant gastrointestinal bleeding within 6 months
             before first dose of study treatment

          -  Requires chronic concomitant treatment of strong CYP3A4 inducers

          -  Is unable or unwilling to swallow tablets

          -  Has a corrected QT interval calculated by the Fridericia formula (QTcF)>500 ms within
             28 days before initiation of cabozantinib

          -  Has evidence of tumor invading the GI tract or any evidence of endotracheal or
             endobronchial tumor within 28 days before the first dose of cabozantinib

          -  Has radiographic evidence of cavitating pulmonary lesion(s)

          -  Has uncontrolled, significant intercurrent or recent illness

          -  Other disorders associated with a high risk of fistula formation including PEG tube
             placement within 3 months before the first dose of study therapy

          -  History of major surgery within 3 months or minor surgery within 1 month of the first
             dose of cabozantinib

          -  Pregnant women

          -  Individuals with a history of other malignancies are eligible if they have been
             disease-free for at least 5 years and are deemed by the investigator to be at low risk
             for recurrence of that malignancy

          -  HIV-positive individuals on combination antiretroviral therapy
      "
NCT02031536,terminated,"
    slow accrual
  ",0,phase 2,"['gastrinoma', 'glucagonoma', 'insulinoma', 'liver metastases', 'pancreatic polypeptide tumor', 'recurrent islet cell carcinoma', 'somatostatinoma']","[""['Z52.6', 'K71.8', 'K71.7', 'A06.4', 'C22.0', 'C22.3', 'K70.0']"", ""['K90.3', 'K86.81', 'Q45.2', 'C25.3', 'E16.9', 'E16.8', 'Q45.3']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]",['everolimus'],['CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC'],"
        INCLUSION CRITERIA:

          -  Patients must have histologically or pathologically confirmed metastatic low or
             intermediate grade pancreatic neuroendocrine tumor(s) to the liver as per the Klimstra
             guidelines

          -  Patients must have recovered from an R0 or R1 resection of all disease (including
             resection of a primary primitive neuroectodermal tumor [PNET] if present); patients
             may have had resection plus microwave or radiofrequency ablation, provided that no
             ablated lesion was >= 5 cm prior to ablation

          -  Patients must be within 4 to 8 weeks from the completion of surgery at time of
             randomization

          -  Patients must have paraffin-embedded fixed metastatic tumor tissue available for
             submission for central review; core biopsy or surgical specimens required

          -  Patients must have post-operative computed tomography (CT) or magnetic resonance
             imaging (MRI) prior to randomization and =< 4 weeks after completion of surgery to
             confirm disease status; patients must be able to tolerate CT or MRI imaging including
             contrast agents as required for the protocol

          -  Women of child-bearing potential and sexually active males must be strongly advised to
             use an accepted and highly effective method of contraception or abstain from sexual
             intercourse for the duration of their treatment through 8 weeks after their last dose
             of protocol therapy; women of child-bearing potential, sexually active males, and the
             female partners of male participants should be advised of the risk of becoming
             pregnant or fathering a child while receiving protocol treatment; should a woman
             become pregnant while participating in this study, she should inform her treating
             physician immediately; if a man impregnates a woman while participating in this study,
             he should inform his treating physician immediately

          -  Prior treatment with sunitinib and/or cytotoxic chemotherapy are allowed provided last
             dose was > 30 days prior to randomization

          -  Prior chemoembolization is allowed provided last dose was > 30 days prior to
             randomization

          -  Total bilirubin =< 1.5 X institutional upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =< 5 X institutional ULN

          -  Serum creatinine =< 1.5 X institutional ULN or creatinine clearance >= 60 mL/min for
             patients with creatinine levels above 1.5 X institutional normal

          -  Fasting serum cholesterol =< 300 mg/dL OR =< 7.75 mmol/L AND fasting triglycerides =<
             2.5 x ULN

          -  Absolute neutrophil count >= 1,500/mm^3

          -  Leukocytes >= 3,000/mm^3

          -  Platelets >= 100,000/mm^3

          -  Hemoglobin >= 9 g/dL

          -  Patients with a history of the following within =< 12 months of randomization are not
             eligible

               -  Arterial thromboembolic events

               -  Unstable angina

               -  Myocardial infarction

          -  Patients with known history of abnormal pulmonary function must have documentation of
             diffusing capacity of the lung for carbon monoxide (DLCO) of > 50% predicted and
             oxygen saturation (SaO2) of > 87% at rest on room air =< 4 weeks prior to
             randomization

          -  Patients with unexplained pulmonary infiltrates must have pulmonary function tests
             within the institutional limits of normal =< 4 weeks prior to randomization

          -  Patients with poorly controlled diabetes mellitus as defined by hemoglobin A1c (HbA1c)
             > 8% despite adequate therapy are ineligible; patients with a known history of
             impaired fasting glucose or diabetes mellitus must have blood glucose and antidiabetic
             treatment monitored closely throughout the trial and adjusted as necessary

          -  Patients may not be receiving any other investigational agents while on study
             treatment; prior treatment with other investigational agent is allowed provided last
             dose was >= 30 days prior to randomization

          -  Patients must NOT have received live attenuated vaccines =< 1 week prior to
             randomization; patients should also be advised not to receive live attenuated vaccines
             during the study and to avoid close contact with others who have received live
             attenuated vaccines; examples of live attenuated vaccines include intranasal
             influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Guerin (BCG), yellow
             fever, varicella and TY21a typhoid vaccines

          -  Patients must have Eastern Cooperative Oncology Group (ECOG) performance status =< 1

          -  Patients must have life expectancy >= 12 weeks

          -  Patients should be advised to avoid drugs or foods that are known potent cytochrome
             P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inhibitors or inducers

        EXCLUSION CRITERIA:

          -  Patients have received prior everolimus

          -  Patients have either clinically apparent central nervous system metastases or
             carcinomatous meningitis =< 6 months prior to randomization

          -  Women are pregnant or breast-feeding; all females of childbearing potential must have
             a blood test within 2 weeks prior to randomization to rule out pregnancy

          -  Patients are on chronic treatment with corticosteroids or other immunosuppressive
             agents; topical or inhaled corticosteroids are allowed

          -  Patients have history of allergic reactions attributed to compounds of similar
             chemical or biologic composition to everolimus

          -  Patients have known intolerance or hypersensitivity to everolimus or other rapamycin
             analogs (e.g. sirolimus, temsirolimus)

          -  Patients have absorption issues that would limit the ability to absorb everolimus

          -  Patients have a history of non-compliance to medical regimens or who are considered
             potentially unreliable or will not be able to complete the entire study

          -  Patients have previous or concurrent malignancy; exceptions are made for patients who
             meet any of the following conditions:

               -  Non-melanoma skin cancer, in situ cervical cancer, breast cancer in situ, or
                  superficial bladder cancer (noninvasive papillary carcinoma or carcinoma in
                  situ); OR

               -  Prior malignancy completely excised or removed and patient has been continuously
                  disease free for > 5 years

          -  Patients have severe and/or uncontrolled medical conditions such as:

               -  Unstable angina pectoris, symptomatic congestive heart failure, myocardial
                  infarction =< 6 months prior to randomization, serious uncontrolled cardiac
                  arrhythmia, or any other clinically significant cardiac disease

               -  Symptomatic congestive heart failure of New York Heart Association class III or
                  IV

               -  Active (acute or chronic) or uncontrolled severe infection, liver disease such as
                  cirrhosis, decompensated liver disease, and chronic hepatitis (i.e. quantifiable
                  hepatitis B virus [HBV]-deoxyribonucleic acid [DNA] and/or positive hepatitis B
                  surface antigen [HbsAg], quantifiable hepatitis C virus [HCV]-ribonucleic acid
                  [RNA])

               -  Active, bleeding diathesis

          -  Patients have known history of human immunodeficiency virus (HIV) seropositivity

          -  Patients have experienced thrombotic events (deep vein thrombosis, pulmonary embolism)
             =< 3 months prior to randomization

          -  Patients have liver disease such as cirrhosis, chronic active hepatitis, or chronic
             persistent hepatitis at randomization; patients at increased risk for hepatitis B or
             hepatitis C must be screened for hepatitis prior to randomization

          -  Patients have ongoing cardiac dysrhythmia of National Cancer Institute (NCI) Common
             Terminology Criteria for Adverse Events (CTCAE) version 4.0 (v4.0) grade >= 2,
             uncontrolled atrial fibrillation of any grade, or corrected QT (QTc) interval > 470
             msec

          -  Patients have history of severely impaired pulmonary function for their age
      "
NCT02038699,withdrawn,"
    protocol not activated.
  ",1,phase 1/phase 2,"['advanced glioblastoma', 'advanced colorectal cancer', 'advanced triple-negative breast cancer', 'advanced non-small cell lung cancer']","[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]",['onc201'],['CC1=CC=CC=C1CN2C(=O)C3=C(CCN(C3)CC4=CC=CC=C4)N5C2=NCC5'],"
        Inclusion Criteria:

          1. Patients must have histologically confirmed glioblastoma multiforme, triple-negative
             breast cancer, colorectal cancer, or non-small cell lung cancer patients with advanced
             disease and limited therapeutic options.

          2. Patients must have measurable disease, defined as at least one lesion that can be
             accurately measured in at least one dimension (longest diameter to be recorded for
             non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional
             techniques or as ≥10 mm with spiral CT scan, MRI, or calipers by clinical exam. For
             lymph nodes to be considered measurable, the short axis must be ≥15 mm when assessed
             by CT scan. All other lesions (or sites of disease), including small lesions (longest
             diameter <10 mm or pathological lymph nodes with ≥10 to <15 mm short axis), are
             considered non-measurable disease. Bone lesions, leptomeningeal disease, ascites,
             pleural/pericardial effusions, lymphangitis cutis/pulmonitis, inflammatory breast
             disease, and abdominal masses (not followed by CT or MRI), are considered
             non-measurable. See Section 11 for the evaluation of measurable disease.

          3. Patients are eligible for enrollment if they have not had prior chemotherapy,
             radiotherapy, anticancer therapy, or investigational agent within 28 days prior to the
             first dose (Week 1, Day 1); 42 days weeks in the case of alkylating agents. Patients
             are eligible for enrollment if they have had no surgery within 6 weeks prior to the
             first dose. Any number of prior therapies is allowable.

          4. All adverse events Grade > 1 related to prior therapies (chemotherapy, radiotherapy,
             and/or surgery) must be resolved, except for alopecia.

          5. Age ≥18 years.

          6. ECOG performance status ≤ 2 (Karnofsky ≥ 60%, see Appendix A).

          7. Life expectancy of greater than 10 weeks.

          8. Patients must have normal organ and marrow function as defined below:

               -  leukocytes ≥ 3,000/mcL

               -  absolute neutrophil count ≥ 1,500/mcL

               -  platelets ≥ 100,000/mcL

               -  hemoglobin > 8.0 mg/dL

               -  total bilirubin < 2.0 x upper limit of normal

               -  AST (SGOT)/ALT (SGPT) ≤2.5 × upper limit of normal creatinine OR creatinine
                  clearance ≥60 mL/min/1.73 m2 for patients with creatinine levels above normal.

          9. The effects of ONC201 on the developing human fetus are unknown. For this reason,
             women of childbearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for
             the duration of study participation. Should a woman become pregnant or suspect she is
             pregnant while she or her partner is participating in this study, she should inform
             her treating physician immediately.

         10. Tumor specimen (paraffin-embedded block or frozen tissue) from prior resection or
             biopsy available that is sufficient to perform pharmacodynamic assays (>3 slides for
             IHC)

         11. Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          1. Patients who have received bevacizumab therapy.

          2. Patients with known brain metastases will be excluded from the phase I portion of the
             study. In the phase II portion, patients with known CNS metastases will be limited to
             20% of the patient population to accrue proportionately. Patients with CNS metastases
             must be stable after therapy for CNS metastases (such as surgery, radiotherapy or
             stereotactic radiosurgery) for > 3 month and must be off steroid treatment prior to
             study enrollment and must have a life expectancy of 3 months or greater to be
             eligible.

          3. History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to ONC201 or its excipients.

          4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection or psychiatric illness/social situations that would limit compliance with
             study requirements

          5. Pregnant women are excluded from this study because ONC201 is novel agent with unknown
             potential for teratogenic or abortifacient effects. Because there is an unknown but
             potential risk for adverse events in nursing infants secondary to treatment of the
             mother with ONC201, breastfeeding should be discontinued if the mother is treated with
             ONC201.

          6. Patients with a known HIV-positive test on combination antiretroviral therapy are
             ineligible for the initial first-in-man trial because of the potential for
             pharmacokinetic interactions with ONC201. In addition, these patients are at increased
             risk of lethal infections when treated with marrow-suppressive therapy. Appropriate
             studies will be undertaken in patients receiving combination antiretroviral therapy
             when indicated.

          7. Patients with known history of cardiac arrhythmias including atrial fibrillation,
             tachyarrhythmias or bradycardia will be excluded. Patients receiving therapeutic
             agents known to prolong QT interval will be excluded. Patients with history of CHF, or
             MI or stroke in the last 3 months will be excluded. Patients with a history of
             seizures will be excluded form the initial trial because ONC201 crosses the
             blood-brain barrier and this may affect their anti-seizure therapy.

          8. Active drug use or alcoholism.
      "
NCT02038816,terminated,"
    accrual too slow, insufficient patients
  ",0,phase 2,['myelodysplastic syndromes'],"[""['D46.9', 'D46.C', 'D46.Z']""]","['deferasirox + azacitidine', 'azacitidine']",['C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N'],"
        Inclusion Criteria:

          -  Adults >18 yrs of age

          -  WHO defined MDS with Higher risk MDS (IPSS int-2/high)

          -  Azacitidine X at least 6 cycles with no hematologic improvement/no disease progression
             as per IWG 2006 criteria

          -  Ferritin >500 µg/L

          -  If transfusion independent, must have Hb <110 g/L OR Neutrophils < 1,000/mL OR
             Platelets < 100,000/mL

          -  ECOG ≤2

          -  CrCl >40 ml/min

        Exclusion Criteria:

          -  Increased ALT (>300 U/L)

          -  Uncontrolled infection

          -  HIV+

          -  Pregnant or breast-feeding

          -  Previous and concurrent iron chelation

          -  Concurrent use of hematopoietic growth factors including erythropoietin, darbepoietin
             and granulocyte colony stimulating factor

          -  Concurrent use of other disease modifying agents including cytotoxic chemotherapy,
             histone deacetylase inhibitors, other hypomethylating agents or lenalidomide
      "
NCT02382406,terminated,"
    the study was completed. it was fully accrued.
  ",0,phase 1/phase 2,['non-small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['carboplatin', 'nab-paclitaxel', 'mk-3475 (phase i)', 'mk-3475 (phase ii)']","['C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C']","
        Inclusion Criteria:

          -  Subjects must be willing and able to provide written informed consent for the trial
             and HIPAA authorization for release of personal health information. NOTE: HIPAA
             authorization may be included in the informed consent or obtained separately.

          -  Subjects must be ≥ 18 years of age.

          -  Individuals with stage IIIB or IV, unresectable non-small cell lung cancer (NSCLC) who
             have not received prior chemotherapy for Stage IIIB or IV disease, and who are not
             candidates for curative surgery or radiation therapy.

          -  ECOG performance status (PS) 0-1

          -  Measurable disease by RECIST v1.1 criteria

          -  Prior to registration, all subjects must have archival tissue available. For subjects
             who have no archival tissue, but have PD-L1 testing results using the Dako 22C3
             antibody, subjects will be permitted to enroll without submitting tissue. If the
             patient has not had prior testing and no acceptable archival tissue is available,
             subjects must be willing to consent to providing a pre-treatment biopsy for PD-L1
             testing. Regardless of PD-L1 testing status, archival tissue will be requested for
             research testing if available.

          -  Phase II subjects must be willing to consent to providing a mandatory post-treatment
             core biopsy for research if clinical feasible.

          -  Women are eligible to participate if they are of non-childbearing potential or have
             documentation of a negative pregnancy test (serum or urine β-hCG) within 3 days of
             registration. Sexually active pre-menopausal women of childbearing potential must
             agree to use adequate, highly effective contraceptive measures, starting with the
             first dose of study drug and for 120 days after the last dose of last study drug.
             Effective birth control includes (a) intrauterine device (IUD) plus one barrier
             method; (b) oral, implantable, or injectable contraceptives plus one barrier method;
             or (c) 2 barrier methods. Effective barrier methods are male or female condoms,
             diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm).
             Women of childbearing potential are those who have not been surgically sterilized or
             have not been free from menses for ≥ 1 year.

          -  Male participants should agree to use an adequate method of contraception starting
             with the first dose of study drug through 120 days after the last dose of last study
             drug.

        Exclusion Criteria:

          -  Individuals with the presence of symptomatic CNS metastases requiring radiation
             treatment, surgery, or ongoing use of corticosteroids.

          -  Untreated or brain metastasis causing any symptoms, such as neurologic deficits or
             headache. Individuals with previously treated brain metastases may participate
             provided they are stable (without evidence of progression by imaging for at least four
             weeks prior to the first dose of study drug and any neurologic symptoms have returned
             to baseline and whole brain radiation or stereotactic radiosurgery completed over 4
             weeks prior to registration), have no evidence of new or enlarging brain metastases,
             and are not using steroids for at least 7 days prior to study treatment.

          -  History of solid organ or stem cell transplant requiring immunosuppressive
             medications.

          -  Any prior adjuvant cytotoxic chemotherapy within 12 months of registration. Subjects
             who received chemotherapy for earlier stage disease more than 12 months prior to study
             registration are eligible for this trial.

          -  Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or
             anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including
             ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation
             or checkpoint pathways).

          -  Any radiotherapy within 2 weeks prior to registration (4 weeks for brain radiotherapy
             as noted above).

          -  Is currently participating in or has participated in a study of an investigational
             agent or using an investigational device within 4 weeks of the first dose of
             treatment.

          -  History of other invasive malignancy that is currently active and/or has been treated
             within 12 months of registration. (Notable exceptions include: basal cell carcinoma,
             squamous cell carcinoma of the skin, localized prostate cancer, in situ carcinomas of
             the cervix and breast, and superficial bladder cancers [non-muscle-invasive]).

          -  Has known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).

          -  Active autoimmune disease that has required systemic treatment in past 2 years (i.e.
             with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
             Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
             form of systemic treatment.

          -  Pulmonary conditions such as sarcoidosis, silicosis, idiopathic pulmonary fibrosis, or
             hypersensitivity pneumonitis.

          -  Has a history of pneumonitis that required steroids or current pneumonitis.

          -  Pre-existing peripheral neuropathy that is ≥ Grade 2 by CTCAE v 4.0 criteria.

          -  Known significant liver disease including viral, alcoholic, active hepatitis B or C,
             and/or cirrhosis.

          -  Abnormal liver or renal function as defined as: bilirubin ≥ 1.5 mg/dL; AST or ALT ≥
             2.5 x the ULN; alkaline phosphatase > 2.5 x the ULN, there is no upper limit if bone
             metastasis is present in the absence of liver metastasis; creatinine > 1.5 mg/dL

          -  Abnormal baseline hematologic or coagulation parameters as defined as: absolute
             neutrophil count (ANC) <1.5 x 10^9/L; hemoglobin < 9.0 g/dL; platelets < 100 x 10^9/L;
             International Normalized Ratio (INR) of prothrombin time (PT) ≥ 1.5 x ULN unless
             subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic
             range of intended use of anticoagulants; Activated Partial Thromboplastin Time (aPTT)
             ≥ 1.5 x ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is
             within therapeutic range of intended use of anticoagulants

          -  Has received a live vaccine within 30 days prior to the first dose of study drug.

          -  Known activating EGFR mutation or ALK translocation

          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the pre-screening or screening visit
             through 120 days after the last dose of pembrolizumab.
      "
NCT02384382,completed,,1,phase 2,"['prostate carcinoma metastatic to the bone', 'castration resistant prostate cancer']","[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]",['enzalutamide'],['CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C'],"
        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate without
             neuroendocrine differentiation, or signet cell or small cell features;

          -  Presence of bone metastatic disease as assessed by at least two lesions on whole body
             metastable technetium-methylene diphosphonate (99mTc-MDP) bone scintigraphy;

          -  Throughout the study, ongoing androgen deprivation therapy with a luteinizing
             hormone-releasing hormone (LHRH) analogue or prior bilateral orchiectomy (medical or
             surgical castration);

          -  Testosterone ≤ 1.73 nmol/L (≤ 50 ng/dL) at screening;

          -  Progressive disease on androgen deprivation therapy at screening defined as a minimum
             of two sequentially rising prostate-specific antigen (PSA) values (PSA1 < PSA2 <
             PSA3);

          -  The screening PSA (PSA3) must be ≥ 2 μg/L (≥ 2 ng/mL).

        Exclusion Criteria:

          -  Prior enzalutamide, abiraterone acetate, aminoglutethimide, ketoconazole, radium Ra
             223 dichloride or other bone-targeting radionuclides, or cytotoxic chemotherapy in the
             CRPC setting for the treatment of prostate cancer or participation in a clinical trial
             of an investigational agent that inhibits the androgen receptor or androgen synthesis
             (unless treatment was placebo);

          -  Treatment with hormonal therapy (eg, androgen receptor inhibitors, 5-alpha reductase
             inhibitors) or biologic therapy for prostate cancer (other than LHRH analogue therapy)
             within 4 weeks before enrollment;

          -  Initiation of new treatment with denosumab, bisphosphonates, or systemic
             corticosteroids for treatment of prostate cancer within 4 weeks before enrollment;

          -  Use of an investigational agent within 4 weeks before the screening visit;

          -  Radiation therapy to bone within 4 weeks before enrollment;

          -  Use of opiate analgesics for prostate cancer pain within 4 weeks before enrollment;

          -  Screening 99mTc-MDP bone scintigraphy showing a superscan;

          -  Visceral (eg, lung, liver) metastatic disease. Adenopathy is allowed;

          -  Current or previously treated brain metastasis or active leptomeningeal disease;

          -  History of seizure any time in the past for any reason or any condition that may
             predispose to seizures.
      "
NCT02383433,terminated,,0,phase 2,['metastatic pancreatic adenocarcinoma'],"[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['regorafenib', 'gemcitabine hydrochloride']","['CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F.Cl']","
        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed metastatic pancreatic
             adenocarcinoma (or any mixed pathology if adenocarcinoma is predominant)

          -  Patients must have measurable disease, defined as at least one lesion that can be
             accurately measured in at least one dimension (longest diameter to be recorded) as >
             20 mm with conventional techniques or as > 10 mm with spiral computed tomography (CT)
             scan

          -  Prior Therapies: Patients must have received at least one prior systemic chemotherapy
             regimen for metastatic pancreatic cancer. They should have experienced disease
             progression or intolerable toxicity from that regimen.

          -  Patients who have received prior non-gemcitabine-based systemic chemotherapy for
             metastatic disease at any time 4 weeks prior to enrollment, or those who are beyond 12
             months of exposure to gemcitabine-based chemotherapy regimen are allowed.

          -  Prior chemotherapy, radiation therapy, concurrent chemoradiation are allowed if used
             for treatment of non-metastatic disease.

          -  Any chemotherapy must have been completed 4 weeks prior to enrollment

          -  Any radiotherapy must have been completed 2 weeks prior to enrollment

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Life expectancy of at least 12 weeks (3 months)

          -  Subjects must be able to understand and be willing to sign the written informed
             consent form; a signed informed consent form must be appropriately obtained prior to
             the conduct of any trial-specific procedure

          -  All acute toxic effects of any prior treatment have resolved to National Cancer
             Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version (v)4.0
             grade 1 or less at the time of signing the informed consent form (ICF)

          -  Total bilirubin =< 1.5 x the upper limits of normal (ULN)

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5
             x ULN for subjects with liver involvement of their cancer)

          -  Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver
             involvement of their cancer)

          -  Lipase =< 1.5 x the ULN

          -  Serum creatinine =< 1.5 x the ULN

          -  International normalized ratio (INR)/partial thromboplastin time (PTT) 1.5 x ULN;
             (subjects who are therapeutically treated with an agent such as warfarin or heparin
             will be allowed to participate provided that no prior evidence of underlying
             abnormality in coagulation parameters exists; close monitoring of at least weekly
             evaluations will be performed until INR/PTT is stable based on a measurement that is
             pre-dose as defined by the local standard of care)

          -  Platelet count >= 100000/mm^3, hemoglobin (Hb) ≥ 9 g/dL, absolute neutrophil count
             (ANC) ≥ 1500/mm^3; blood transfusion to meet the inclusion criteria will not be
             allowed

          -  Women of childbearing potential must have a negative serum pregnancy test performed
             within 7 days prior to the start of study drug; post-menopausal women (defined as no
             menses for at least 1 year) and surgically sterilized women are not required to
             undergo a pregnancy test

          -  Subjects (men and women) of childbearing potential must agree to use adequate
             contraception beginning at the signing of the ICF until at least 3 months after the
             last dose of study drug; the definition of adequate contraception will be based on the
             judgment of the principal investigator or a designated associate

          -  Subject must be able to swallow and retain oral medication

        Exclusion Criteria:

          -  Chemotherapy within 4 weeks prior to entering the study, radiotherapy within 2 weeks
             prior to entering the study or failure to recover from adverse events to grade 1 or
             less due to agents administered more than 4 weeks earlier

          -  Use of any other investigational agents

          -  Previous assignment to treatment during this study; subjects permanently withdrawn
             from study participation will not be allowed to re-enter study

          -  Uncontrolled hypertension (systolic pressure > 140 mm Hg or diastolic pressure > 90 mm
             Hg [NCI-CTCAE v4.0] on repeated measurement) despite optimal medical management

          -  Active or clinically significant cardiac disease including:

               -  Congestive heart failure - New York Heart Association (NYHA) > class II

               -  Active coronary artery disease

               -  Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or
                  digoxin

               -  Unstable angina (anginal symptoms at rest), new-onset angina within 3 months
                  before randomization, or myocardial infarction within 6 months before
                  randomization

          -  Evidence or history of bleeding diathesis or coagulopathy

          -  Any hemorrhage or bleeding event >= NCI CTCAE grade 3 within 4 weeks prior to start of
             study medication

          -  Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular
             accident (including transient ischemic attacks) deep vein thrombosis or pulmonary
             embolism within 6 months of informed consent

          -  Subjects with any previously untreated or concurrent cancer that is distinct in
             primary site or histology from pancreatic cancer except cervical cancer in-situ,
             treated basal cell carcinoma, or superficial bladder tumor; subjects surviving a
             cancer that was curatively treated and without evidence of disease for more than 3
             years before randomization are allowed; all cancer treatments must be completed at
             least 3 years prior to study entry (i.e., signature date of the informed consent form)

          -  Patients with phaeochromocytoma

          -  Known history of human immunodeficiency virus (HIV) infection or current chronic or
             active hepatitis B or C infection requiring treatment with antiviral therapy

          -  Any infection requiring ongoing intravenous antibiotics for management

          -  Symptomatic metastatic brain or meningeal tumors; treated and stable, asymptomatic
             brain metastases, as long as treatment was greater than 4 weeks prior to informed
             consent, are allowed

          -  Presence of a non-healing wound, non-healing ulcer, or bone fracture

          -  Renal failure requiring hemo-or peritoneal dialysis

          -  Dehydration grade >= 1 NCI-CTCAE v4.0

          -  Patients with seizure disorder requiring medication

          -  Persistent proteinuria >= grade 3 NCI-CTCAE v4.0 (> 3.5 g/24 hrs, measured by urine
             protein:creatinine ratio on a random urine sample)

          -  Interstitial lung disease with ongoing signs and symptoms at the time of informed
             consent

          -  Pleural effusion or ascites that causes respiratory compromise (>= NCI-CTCAE version
             4.0 grade 2 dyspnea)

          -  History of organ allograft (including corneal transplant)

          -  Known or suspected allergy or hypersensitivity to any of the study drugs, study drug
             classes, or excipients of the formulations given during the course of this trial

          -  Any malabsorption condition

          -  Women who are pregnant or breast-feeding

          -  Any condition which, in the investigator's opinion, makes the subject unsuitable for
             trial participation

          -  Substance abuse, medical, psychological or social conditions that may interfere with
             the subject's participation in the study or evaluation of the study results
      "
NCT02389764,terminated,"
    slow accrual
  ",0,phase 2,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]",['bibf 1120'],['CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O'],"
        Inclusion Criteria:

          1. Patients are 18 years of age or older

          2. Patients are female or male.

          3. Have histological confirmation of breast carcinoma with a clinical diagnosis of IBC
             based on presence of inflammatory changes in the involved breast, including diffuse
             erythema and edema (peau d'orange), with or without an underlying palpable mass
             involving the majority of the skin of the breast. Pathological evidence of dermal
             lymphatic invasion should be noted but is not required at diagnosis.

          4. Have confirmed distant metastasis with or without local recurrence.

          5. Have negative HER2 expression by IHC (defined as 0 or1+), or FISH. If HER2 is 2+,
             negative HER2 expression must be confirmed by FISH.

          6. Patients may undergo an optional biopsy of the metastatic disease at baseline and
             after 2 cycles of BIBF-1120.

          7. Estimated life expectancy of at least 3 months

          8. Have ECOG performance status score 0-2

          9. Have received at least one any prior treatment for local recurrence or metastatic
             disease and have relapsed.

         10. Signed and dated written informed consent prior to admission to the study

         11. If Patients have been treated with anti-VEGF agents, such as Bevacizumab, last dose
             must be >/= 4 weeks.

         12. Have tissues from a biopsy, or have up to 20 unstained slides available from archived
             metastatic tissue block for biomarker evaluation

         13. Patients are able to swallow and retain oral medication

        Exclusion Criteria:

          1. Patients have an active infection and require IV or oral antibiotics.

          2. Patients have impaired cardiac function or clinically significant cardiac diseases,
             including any of the following: a) History or presence of serious uncontrolled
             ventricular arrhythmias or presence of atrial fibrillation; b) Clinically significant
             resting bradycardia (< 50 beats per minute); c) LVEF assessed by 2-D echocardiogram
             (ECHO) or multiple gated acquisition scan (MUGA) < 45%; d). pericardial effusion

          3. Any of the following within 6 months prior to study entry: myocardial infarction (MI),
             severe/unstable angina, Coronary Artery Bypass Graft (CABG), Congestive Heart Failure
             (CHF) > NYHA II, Cerebrovascular Accident (CVA), Transient Ischemic Attack (TIA),
             Pulmonary Embolism (PE),

          4. Uncontrolled hypertension defined by an SBP>150 and/or a DBP>100 mm Hg with or without
             anti-hypertensive medication

          5. History of gastrointestinal disorders (medical disorders or extensive surgery) which
             may interfere with the absorption of the study drug as determined by the investigator.

          6. Patients have a concurrent disease or condition that would make them inappropriate for
             study participation, or any serious medical disorder that would interfere with
             patients' safety as determined by the investigator.

          7. Patients with only locally or regionally confined disease without evidence of
             metastatic disease

          8. Prior treatment with BIBF 1120 or any other VEGFR inhibitor within 4 weeks

          9. Known hypersensitivity to the trial drugs , to their excipients or to contrast media

         10. Chemotherapy, hormonal therapy, radiotherapy (except for brain and extremities) or
             immunotherapy or therapy with monoclonal antibodies or small tyrosine kinase
             inhibitors within the past 4 weeks prior to treatment with the trial drug

         11. Persistence of toxicity from previous chemo and/or radiotherapy > grade 2.

         12. Active brain metastases (e.g. stable for <4 weeks, no adequate previous treatment with
             radiotherapy, symptomatic, requiring treatment with anti-convulsants; dexamethasone
             therapy will be allowed if administered as stable dose for at least one month before
             randomisation).

         13. Radiographic evidence of cavitary or necrotic tumors

         14. Centrally located tumors with radiographic evidence (CT or MRI) of local invasion of
             major blood vessels

         15. Treatment with other investigational drugs or treatment in another clinical trial
             within the past 4 weeks before start of therapy or concomitantly with the trial

         16. Therapeutic anticoagulation( except low-dose heparin and/or heparin flush as needed
             for maintenance of an in-dwelling intravenous devise) or anti-platelet therapy (except
             for low-dose therapy with acetylsalicylic acid < 325mg per day

         17. Major injuries within the past 10 days prior to start of study treatment with
             incomplete wound healing and/or planned surgery during the on-treatment study period

         18. History of clinically significant haemorrhagic or thromboembolic event in the past 6
             months

         19. Known inherited predisposition to bleeding or thrombosis

         20. Proteinuria CTCAE grade 2 or greater

         21. Creatinine >/= 1.5 x ULN or GFR < 45 ml/min

         22. Hepatic function: total bilirubin outside of normal limits; ALT or AST >1.5 x ULN in
             pts without liver metastasis. For Pts with liver metastasis: total bilirubin outside
             of normal limits, ALT or AST >2.5 x ULN

         23. Coagulation parameters: International normalised ratio ( INR) > 2, prothrombin time
             (PT) and partial thromboplastin time (PTT) > 50% of deviation of institutional ULN

         24. Absolute neutrophil count ( ANC) < 1500/ml, platelets < 100000/ml, Haemoglobin < 9.0
             g/dl

         25. Other malignancies within the past 5 years other than basal cell skin cancer or
             carcinoma in situ of the cervix

         26. Known history of active or chronic hepatitis C and/or B infection

         27. Serious illness or concomitant non-oncological disease such as neurologic,
             psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or
             laboratory abnormality that may increase the risk associated with study participation
             or study drug administration and in the judgment of the investigator would make the
             patient inappropriate for entry into the study.

         28. Patients who are sexually active and unwilling to use a medically acceptable method of
             contraception (e.g. such as implants, injectables, combined oral contraceptives, some
             intrauterine devices or vasectomized partner for participating females) during the
             trial and for at least three months after end of active therapy (Contraception in
             patients with preserved reproductive capacity, patients will be considered to be of
             childbearing potential unless surgically sterilised by hysterectomy or bilateral tubal
             ligation/salpingectomy, or post-menopausal for at least two years.)

         29. Patients with child bearing potential must have a negative pregnancy test (urine or
             serum) prior to study treatment

         30. Psychological, familial, sociological or geographical factors potentially hampering
             compliance with the study protocol and follow-up schedule

         31. Active alcohol or drug abuse

         32. Significant weight loss (> 10% of BW) within past 6 months prior to inclusion into the
             trial
      "
NCT02387216,terminated,"
    based on the preliminary results seen during interim analysis, which were confirmed in the
    final analysis, the sponsor terminated the study
  ",0,phase 2,"['non-small cell lung cancer', 'nsclc', 'adenocarcinoma', 'heregulin']","[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['mm-121', 'docetaxel']",['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O'],"
        Inclusion Criteria:

          -  Patients with a diagnosis of cytologically or histologically documented adenocarcinoma
             of the lung with either metastatic disease (stage IV), Stage IIIB or Stage IIIC
             disease not amenable to surgery with curative intent

          -  Not received more than 2 prior systemic therapies- one of which must have been a
             platinum based regimen- for primary or recurrent disease

          -  Tissue submitted for HRG-biomarker testing

          -  ECOG performance status (PS) of 0 or 1

        Exclusion Criteria:

          -  Known ALK mutation

          -  Presence of exon 19 deletion or exon 21 (L858R) substitution of the EGFR gene

          -  Received >2 prior systemic anti-cancer drug regimen for locally advanced disease

          -  Prior treatment with an anti-ErbB3 antibody

          -  CTCAE grade 3 or higher peripheral neuropathy

          -  Symptomatic CNS metastases or CNS metastases requiring steroids

          -  Any other active malignancy requiring systemic therapy

          -  Clinically significant cardiac disease
      "
NCT02388919,completed,,1,phase 2/phase 3,['non-small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['anlotinib', 'placebo']",['CC1=CC2=C(N1)C=CC(=C2F)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC'],"
        Inclusion Criteria:

          1. Signed and dated informed consent

          2. Diagnosed with advanced NSCLC (phase IIIB/IV) through pathology, with measurable
             nidus(using RECIST 1.1)

          3. at least two systematic chemotherapy with upwards of 3-line treatments or cannot
             suffer

          4. Patients must provide detectable specimen (from tumor tissue or hydrothorax) before
             participating, who negative in EGFR&ALK can participate or who positive in EGFR&ALK,
             have or have not drug tolerance after the treatment with relative targeted drugs

          5. ECOG PS：0-1,Expected Survival Time: Over 3 months

          6. main organs function is normal

          7. The woman patients of childbearing age who must agree to take contraceptive methods
             (e.g. intrauterine device, contraceptive pill or condom) during the research and
             within another 6 months after it; who are not in the lactation period and examined as
             negative in blood serum test or urine pregnancy test within 7 days before the
             research; The man patients who must agree to take contraceptive methods during the
             research and within another 6 months after it

        Exclusion Criteria:

          1. have used Anlotinib before

          2. Small Cell Lung Cancer (including small cell cancer and other kinds of cancer mixed
             with non-small cell cancer)

          3. examined as positive in EGFR&ALK mutation detection and never take the treatment of
             TKIs

          4. central lung squamous carcinoma along with cavum, or non-small cell lung cancer along
             with hemoptysis (>50ml/day)

          5. other kinds of malignancies within 5 years or for now

          6. plan to take systemic anti-tumor therapy within 4 weeks before grouping or during the
             medicine-taking period of this research, including Cytotoxic Therapy, Signal
             Transduction Inhibitor, and Immunotherapy (or who use Mitomycin C within 6 weeks
             before taking the treatment with experimental drug); The patients who have already
             taken Extended Field Radiotherapy (EF-RT) within 4 weeks before grouping or Limited
             Field Radiotherapy with proposed assessment of nidus within 2 weeks before grouping

          7. have got non remissive toxic reactions derived from previous therapies, which is over
             level 1 in CTC AE (4.0), alopecia NOT included

          8. with kinds of factors which affect oral medicine (e.g. failing to swallow,
             gastrointestinal tract getting resected, chronic diarrhea and ileus)

          9. pleural effusion or ascites, resulting in respiratory syndrome (≥CTC AE level 2)

         10. symptoms of brain metastases cannot be controlled and treated within less than 2
             months

         11. get any severe diseases or the ones that cannot be controlled

         12. take major surgical treatments, open biopsy, or get overt traumatic injury within 28
             days before grouping

         13. have any habitus or medical history of hemorrhage, however severe it is; the patients
             who have non healing wounds, ulcer or fracture after any events with hemorrhage or
             bleeding (≥CTCAE level 3)

         14. get arterial/venous thrombosis within 6 months, such as cerebrovascular accidents
             (including temporary ischemic stoke), deevenous thrombosis, and pulmonary embolism

         15. ever abuse psychiatric drugs and cannot abstain or who are diagnosed with mental
             disorder

         16. have participated in other clinical trials of anti-tumor medicine within 4 weeks

         17. diagnosed with disease which will severely endanger the security of patients or
             influence the completion of this research.
      "
NCT02952573,terminated,"
    low patient accrual
  ",0,phase 2,"['multiple myeloma', 'relapsed/refractory']","[""['C90.01', 'C90.02', 'C90.00']""]","['jnj-42756493', 'dexamethasone']","['CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC', 'CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C']","
        Inclusion Criteria:

          -  A diagnosis of MM and documentation of at least 1 prior line of therapy including
             proteasome and immunomodulatory agents.

          -  Documented lab results confirming FGFR3 expression and mutational status determined by
             a clinical grade, next generation sequencing platform approved by the
             Sponsor-Investigator, the results of which must be obtained prior to registration.

          -  Patients with measurable disease by laboratory studies for determining eligibility
             must be obtained within 28 days prior to start of study drug):

          -  Must have an Eastern Cooperative Oncology Group (ECOG) performance status score 0, 1,
             or 2.

          -  Negative pregnancy status in women of childbearing potential must be confirmed within
             7 days prior to start of study drug. Participants must use medically acceptable
             methods of birth control before the study entry, during the study, and until 3 months
             after taking the last dose of the study drug.

          -  Patient must sign the informed consent documents indicating that they understand the
             purpose of and procedures required for the study and are willing to participate in the
             study.

          -  Life Expectancy of ≥ 3 months.

          -  Able to take oral medications.

          -  Acceptable laboratory results must be met within 7 days of first study drug
             administration.

        Exclusion Criteria:

          -  Patients in whom FGFR3 expression or mutational status cannot be determined.

          -  Chemotherapy, limited palliative radiotherapy or other anti-myeloma therapy within 14
             days prior to the first dose of study drug. In addition, any treatment related
             toxicity should have recovered < Grade 1 unless deemed to be irreversible.

          -  Patients who are receiving any other investigational agent.

          -  Patients with known CNS involvement, plasma cell leukemia or amyloidosis.

          -  Use of an investigational drug within 21 days or five-half-lives, whichever is shorter
             but not less than 14 days, preceding the first dose of study drug.

          -  History of allogeneic stem cell transplant.

          -  Autologous, peripheral stem cell transplant within 12 weeks of the first dose of study
             drug.

          -  Prior major surgical procedure or extensive radiation therapy within 4 weeks of the
             first dose of study treatment.

          -  Current use of corticosteroids, with the exception of inhaled or topical steroids.

          -  Previous or concurrent malignancies are allowed if it is clear that the patient is not
             symptomatic from the other tumor. The subject must not be receiving active therapy for
             the other tumor and the other tumor must be considered medically stable.

          -  Has a history of or current uncontrolled cardiovascular disease.

          -  Patients with evidence of mucosal or internal bleeding and/or platelet transfusion
             refractory. Patients cannot use growth factors within 7 days of start of study drug,
             or transfusion of blood or platelets within 7 days of start of study drug.

          -  Has impaired wound healing capacity defined as skin/decubitus ulcers, chronic leg
             ulcers, known gastric ulcers, or unhealed incisions.

          -  Serious psychiatric illness, active alcoholism, or drug addiction that may hinder or
             confuse follow-up evaluations.

          -  Any other condition that, in the Investigator's opinion, would contraindicate the
             patient's participation in the clinical study due to safety concerns or compliance
             with clinical study procedures.

          -  Received prior FGFR inhibitor treatment or if the subject has known allergies,
             hypersensitivity, or intolerance to JNJ-42756493 or its excipients.

          -  Pregnant, breast feeding, or planning to become pregnant within 3 months after the
             last dose of study drug and males who plan to father a child while enrolled in this
             study or within 5 months after the last dose of study drug.

          -  Known HIV or active hepatitis B or C viral infection.

          -  History of cerebrovascular accident (CVA) within 6 months prior to registration.

          -  Gastrointestinal abnormalities, including bowel obstruction, inability to take oral
             medication, requirement for intravenous (IV) alimentation, active peptic ulcer or
             prior surgical procedures or bowel resection affecting absorption.

          -  Peripheral neuropathy ≥ Grade 2.

          -  Has persistent phosphate level >ULN during screening (within 14 days of treatment and
             prior to Cycle 1 Day 1) despite medical management.

          -  Any corneal or retinal abnormality likely to increase the risk of eye toxicity.

          -  Patients that require the following prohibited therapy:

               1. Medicines known to have a risk of causing QTc prolongation and Torsades de
                  Pointes

               2. Medications known to increase serum levels of phosphate and calcium

               3. Medications or substances known to be strong inhibitors or strong inducers of
                  CYP3A4 or CYP2C9 before the recommended 5 half-life washout period
      "
NCT02958163,terminated,"
    lack of recruitment
  ",0,phase 2,"['liver neoplasms', 'hepatocellular cancer']","[""['D13.4', 'Z85.05', 'C22.8', 'C78.7', 'C22.9', 'D37.6']"", ""['P59.20', 'P59.29']""]",['doxorubicin'],['CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O'],"
        Inclusion Criteria:

          -  Hepatocellular carcinoma larger than 3 cm and non-resectable, with a diagnosis
             established either by:

               -  dynamic imaging (non-invasively), showing a typical contrast enhancement and
                  wash-out

               -  histopathology

          -  satellite lesions are allowed (at most three lesions) as long as the doses constraints
             are still achievable

          -  Hepatocellular carcinoma belonging to Barcelona Clinic Liver Cancer Stage System class
             B

          -  Tumor must be measurable on a multi-phase MRI according to mRECIST criteria

          -  Non-tumoral liver volume ≥ 800 cc

          -  Child-Pugh (CP) A to B7 cirrhosis

          -  HCC Patients can be included if they require treatment prior to liver transplantation

          -  ECOG performance status 0-1

          -  AST/ALT < 5 times ULN

          -  Initial platelets ≥ 50 000 x 10E9/l, neutrophils > 1500 x 10E9/l, Hb > 9 g/dl

          -  Serum creatinine < 1.5 X normal, or calculated Creatinine clearance rate ≥ 60 mL/min

          -  As tumor biopsy can be performed after inclusion, pure hepatocellular carcinoma but
             also mixed hepatocellular carcinoma will be allowed in this trial. Cholangiocarcinoma
             cannot be included.

          -  Written informed consent form to be signed,

          -  Patient willing and able to comply to the follow-up schedule

          -  Patients in fertile age should use a contraceptive method during treatment and 4
             months after.

        Exclusion Criteria:

          -  Eligibility for resection or ablative treatments

          -  Extra hepatic spread of the disease

          -  Previous treatment of the same lesion with TACE

          -  Previous treatment with selective internal radiotherapy or radiotherapy to the upper
             abdomen

          -  Uncontrolled Ascites

          -  Uncontrolled Encephalopathy

          -  Any clinical sign of acute viral or non-viral hepatitis (new serological testing are
             not required)

          -  Known current pregnancy

          -  Uncontrolled active co-morbidity
      "
NCT02950480,terminated,"
    low accrual.
  ",0,phase 2,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]",['zafirlukast'],['CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC'],"
        Inclusion Criteria:

          1. Patients who are scheduled to undergo therapeutic or prophylactic mastectomy with
             immediate placement of tissue expanders and have a strong family history or hereditary
             cancer

          2. Age ≥ 18 years

          3. Zafirlukast is pregnancy category B. There are no adequate and well-controlled trials
             in pregnant women. Therefore, the effects of zafirlukast on the developing human fetus
             are unknown. For this reason, women of child-bearing potential must agree to use
             adequate contraception: 2 methods of birth control, prior to study entry ad for the
             duration of study participation. Should a woman become pregnant or suspect she is
             pregnant while she is participating in this study, she should inform her treating
             physician immediately.

          4. Ability to understand a written informed consent document, and the willingness to sign
             it

          5. At least 4 weeks post-completion of chemotherapy

          6. Adequate organ function within 14 days start of study start:

               1. Absolute neutrophil count (ANC) ≥ 1.5 X 10^9/L

               2. Hemoglobin (Hgb) ≥9g/dL

               3. Platelets (plt) ≥ 100 x 10^9/L

               4. Potassium within normal range, or correctable with supplements;

               5. AST and ALT ≤2.5 x Upper Limit Normal (ULN) or ≤5.0 x ULN if liver tumor is
                  present;

               6. Serum total bilirubin ≤ 1.5 x ULN

               7. Serum creatinine ≤ 1.5 x ULN, or 24-hr clearance ≥ 60ml/min

        Exclusion Criteria:

          1. Any significant medical condition, laboratory abnormalities, which places the subject
             at unacceptable risk if he/she were to participate in the study

          2. Currently on a leukotriene inhibitor or used within the past 6 months

          3. Prior chest wall radiation

          4. Pregnant or breastfeeding

          5. Hepatic impairment as defined by:

             • AST(SGOT) > 2.5X institutional ULN and ALT(SGPT) > 2.5X institutional ULN

          6. Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial.
      "
NCT02951819,completed,,1,phase 2,['multiple myeloma'],"[""['C90.01', 'C90.02', 'C90.00']""]","['daratumumab', 'cyclophosphamide', 'bortezomib', 'dexamethasone']","['C1CNP(=O)(OC1)N(CCCl)CCCl', 'B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O', 'CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C']","
        Inclusion Criteria:

          -  Subjects with documented multiple myeloma (MM) as defined by the International Myeloma
             Working Group (IMWG) 2015 criteria: Clonal bone marrow plasma cells greater than or
             equal to (>=) 10 percent (%) or biopsy-proven bony or extramedullary plasmacytoma and
             any one or more of the following CRAB (calcium level, renal dysfunction, anemia, and
             destructive bone lesions) features and myeloma defining events as in the protocol

          -  Subjects with previously untreated myeloma or relapsed myeloma with one prior line of
             therapy including an induction regimen which may be followed by autologous stem cell
             transplantation and single agent maintenance therapy. For previously untreated
             subjects an emergency course of steroids (defined as no greater than 40 milligram (mg)
             of dexamethasone, or equivalent per day for a maximum of 4 days) is permitted. In
             addition, radiation therapy is permitted prior to study entry, during screening, and
             during Cycles 1-2 of study treatment as needed for lytic bone disease

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or
             2

          -  A woman of childbearing potential must have 2 negative serum (beta (β) human chorionic
             gonadotropin) or urine pregnancy tests during screening, the first one within 28 days
             prior to the first dose of study drug and the second within 24 hours prior to the
             first dose of study drug

          -  A man who is sexually active with a woman of childbearing potential and has not had a
             vasectomy must agree to use a barrier method of birth control example, either condom
             with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap
             (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository,
             and all men must also not donate sperm during the study and for 3 months after
             receiving the last dose of study drug

        Exclusion Criteria:

          -  Refractory to any proteasome inhibitor (PI) or the combination of PI and
             immunomodulatory drug (IMiD) agents (such as lenalidomide), defined as failure to
             respond or progression within 60 days of the end of PI therapy

          -  Exhibiting clinical signs of or has a known history of meningeal or central nervous
             system involvement by multiple myeloma

          -  Has known chronic obstructive pulmonary disease with a forced expiratory volume in 1
             second (FEV1) less than (<) 50 percent (%) of predicted normal

          -  Has known moderate or severe persistent asthma within the past 2 years, or currently
             has uncontrolled asthma of any classification

          -  Is known to be seropositive for human immunodeficiency virus, known to have hepatitis
             B surface antigen positivity, or known to have a history of hepatitis C
      "
NCT02461836,unknown status,,0,phase 2,['pancreatic cancer'],"[""['C25.3']""]",['gemcitabine'],['C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F'],"
        Inclusion Criteria:

          1. Male/Female subjects, age ≥ 18 years and ≤ 75 years old at the time informed consent
             is signed

          2. Pathologically confirmed pancreatic adenocarcinoma or mixed-type pancreatic carcinoma
             (adenocarcinoma predominantly)

          3. The operation must be radical resection (R0), with all margins negative.

          4. Eastern Cooperative Oncology Group (ECOG) score: 0-2

          5. Without large volume ascites or pleural effusion

          6. Lab tests:

             a Complete blood cell count: HGB≥100g/L, WBC≥4×109/L, PLT≥100×109/L b Liver function:
             Total bilirubin≤3 x upper limit of normal range (ULN) with direct bilirubin within
             normal range, alanine aminotransferase (ALT) / aspartate aminotransferase (AST)≤3 c
             Renal function: Creatine≤1.5 x ULN or creatine clearance≥60 ml/min

          7. Heart and lung function well (Eject function>55%)

          8. Females of child-bearing potential must demonstrate a negative serum pregnancy test
             result at screening confirmed by local negative urine pregnancy dipstick within 72
             hours prior to the first dose of Gemcitabine.

          9. At least 30 days from major surgery before randomization, with full recovery

         10. Understand and voluntarily sign an informed consent document prior to any study
             related assessments/procedures are conducted

         11. Able to adhere to the study visit schedule and other protocol requirements

        Exclusion Criteria:

          1. Margin positive resections (R1 or R2)

          2. Resection of recurrence pancreatic cancer

          3. Other types of pancreatic cancer (non-adenocarcinoma)

          4. Subjects with severe complications, can't tolerate chemotherapy in 4-12 weeks after
             surgery

          5. Subjects with severe bone marrow suppression

          6. Subjects with a history of severe lung diseases (interstitial lung disease,
             sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity
             pneumonitis), severe liver diseases (active hepatitis, liver cirrhosis), renal
             dysfunction, uncontrolled diabetes and hypertension, or multiple and severe allergies
             which may lead to serious complications

          7. Subjects with severe heart diseases (congested heart failure, systematic coronary
             disease, uncontrolled arrhythmia, or myocardial infarction in 6 months)

          8. Under treatment with steroids for a long time

          9. Subjects with early recurrence of pancreatic cancer before initiation of chemotherapy

         10. Subjects with diarrhea and infection (body temperature >38.5℃)

         11. Subjects who was enrolled into another clinical study or finished another clinical
             study within the previous 4 weeks prior to randomization

         12. Pregnant or nursing women

         13. Subjects with other type of malignancies, except of curated basal cell carcinoma and
             carcinoma in situ of cervix which finished treatments more than half one year ago

         14. Subjects having any significant medical condition, laboratory abnormality, or
             psychiatric illness that would prevent them from participating in the study

         15. Any condition that confounds interpreting data from the study
      "
NCT02465814,completed,,1,phase 2,['leiomyoma'],"[""['D25.0', 'D25.1', 'D25.2', 'D25.9']""]","['vilaprisan (bay1002670)', 'vilaprisan (bay1002670', 'vilaprisan (bay1002670', 'vilaprisan (bay1002670)', 'ulipristal', 'ulipristal', 'ulipristal']","['CC(=O)C1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O', 'CC(=O)C1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O', 'CC(=O)C1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O']","
        Inclusion Criteria:

          -  Women, 18 to 50 years of age at the time of screening

          -  Diagnosis of uterine fibroid(s) documented by transvaginal or abdominal ultrasound at
             screening with at least 1 fibroid with largest diameter >/=3.0 cm

          -  Heavy menstrual bleeding (HMB) >80 mL documented by menstrual pictogram (MP) in a
             bleeding episode during the screening period. Women who did not suffer from perceived
             HMB during the 3 months prior to Visit 1 due to any effective medical treatment, e.g.
             with a hormonal contraceptive, are not considered appropriate candidates and should
             not undergo further screening procedures. Women suffering from perceived HMB despite
             medical treatment, e.g. with a hormonal contraceptive, are appropriate candidates for
             further screening, if rules on stopping prior medication are followed. Heavy menstrual
             bleeding /HMB) > 80 mL should be documented within 10 consecutive days.

          -  Good general health (except for findings related to uterine fibroids) as proven by
             medical history, physical and gynecological examinations, and laboratory test results

          -  Normal or clinically insignificant cervical smear not requiring further follow-up.
             Human papilloma virus (HPV) testing in subjects with atypical squamous cells of
             undetermined significance (ASCUS) can be used as an adjunctive test. Subjects with
             ASCUS can be included if they are negative for high-risk HPV strains.

          -  An endometrial biopsy performed during the screening period, without significant
             histological disorder such as endometrial hyperplasia (including simple hyperplasia)
             or other significant endometrial pathology.

          -  Use of an acceptable nonhormonal method of contraception (i.e. either male condom,
             cap, diaphragm or sponge, each in combination with spermicide) starting at the
             bleeding episode following the screening visit 1 (Visit 1) until the end of the study.
             This is not required if safe contraception is achieved by a permanent method, such as
             bilateral fallopian tube blockage of the subject or vasectomy of the partner(s).

        Exclusion Criteria:

          -  Pregnancy or lactation (less than 3 months since delivery, abortion, or lactation
             before start of treatment)

          -  Uterine fibroid with largest diameter >10.0 cm

          -  Hypersensitivity to any ingredient of the study drugs

          -  Hemoglobin values </= 6 g/dL or any condition requiring immediate blood transfusion
             (subjects with hemoglobin values </=10.9 g/dL will be offered iron supplementation).

          -  Any diseases or conditions that can compromise the function of the body systems and
             could result in altered absorption, excessive accumulation, impaired metabolism, or
             altered excretion of the study drug

          -  Any diseases or conditions that might interfere with the conduct of the study or the
             interpretation of the results

          -  Abuse of alcohol, drugs, or medicines (e.g. laxatives)

          -  Use of other treatments that might interfere with the conduct of the study or the
             interpretation of the results

          -  Undiagnosed abnormal genital bleeding.
      "
NCT02102490,completed,,1,phase 2,['metastatic breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]",['abemaciclib'],['CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F'],"
        Inclusion Criteria.

          -  Have a diagnosis of Hormone Receptor Positive (HR+), Human Epidermal Growth Factor
             Receptor 2 Negative (HER2-) breast cancer.

          -  Recurrent, locally advanced, unresectable or metastatic breast cancer with disease
             progression following anti-estrogen therapy.

          -  Prior treatment with at least 2 chemotherapy regimens:

               -  At least 1 of these regimens must have been administered in the metastatic
                  setting.

               -  At least 1 of these regimens must have contained a taxane.

               -  No more than 2 prior chemotherapy regimens in the metastatic setting.

          -  Have a performance status (PS) of 0 to 1 on the Eastern Cooperative Oncology Group
             scale.

          -  Have discontinued all previous therapies for cancer.

          -  Have the presence of measureable disease as defined by Response Evaluation Criteria in
             Solid Tumors Version 1.1.

        Exclusion Criteria:

          -  Have either a history of central nervous system (CNS) metastasis or evidence of CNS
             metastasis on the magnetic resonance image of brain obtained at baseline.

          -  Received prior therapy with another cyclin-dependent kinases 4 and 6 (CDK4/6)
             inhibitor.

          -  Have received treatment with a drug that has not received regulatory approval for any
             indication within 14 or 21 days of the initial dose of study drug.

          -  Have had major surgery within 14 days of the initial dose of study drug.

          -  Have a history of any other cancer (except non-melanoma skin cancer or carcinoma
             in-situ of the cervix).
      "
NCT02101775,"active, not recruiting",,1,phase 2,"['ovarian brenner tumor', 'ovarian carcinosarcoma', 'ovarian clear cell cystadenocarcinoma', 'ovarian endometrioid adenocarcinoma', 'ovarian mucinous cystadenocarcinoma', 'ovarian seromucinous carcinoma', 'ovarian serous cystadenocarcinoma', 'ovarian serous surface papillary adenocarcinoma', 'ovarian undifferentiated carcinoma', 'recurrent fallopian tube carcinoma', 'recurrent ovarian carcinoma', 'recurrent primary peritoneal carcinoma']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['adavosertib', 'gemcitabine hydrochloride']","['CC(C)(C1=NC(=CC=C1)N2C3=NC(=NC=C3C(=O)N2CC=C)NC4=CC=C(C=C4)N5CCN(CC5)C)O', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F.Cl']","
        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed epithelial ovarian,
             primary peritoneal and fallopian tube carcinoma; all histologic subtypes of epithelial
             ovarian cancer are eligible, but only patients with high grade serous ovarian cancer
             will be considered for the statistical analysis; non-high grade serous cancers will be
             allowed in an exploratory cohort

          -  Patients must be platinum-resistant (platinum-free interval < 6 months) or have
             platinum-refractory disease as per Gynecologic Cancer Intergroup Committee (GCIC)
             criteria; disease progression has to be radiologic or clinical; biomarker progression
             with CA125 after a platinum based regimen would not be sufficient evidence of disease
             progression; the patients must have had radiological progression to that regimen

          -  Patients must have measurable disease, defined as at least one lesion that can be
             accurately measured in at least one dimension (longest diameter to be recorded for
             non-nodal lesions and short axis for nodal lesions) as > 10 mm with computed
             tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam

          -  There is no limitation in the number of prior lines of therapy

          -  Patients must have completed any prior chemotherapy, radiotherapy or major surgery at
             least 4 weeks before receiving study treatment; ongoing toxicities related to
             treatment must be =< grade 1 and patients with grade 2 alopecia or peripheral
             neuropathy can also be included; palliative radiation to < 10% of bone marrow is
             permissible if completed within one week of commencing study treatment as long as the
             toxicities secondary to palliative radiotherapy are limited to grade 1; the lesions
             that have received radiation treatment immediately before will be excluded as target
             lesions; previously irradiated lesions can be considered as targeted lesions, as long
             as there is prove of radiological progression

          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)

          -  Life expectancy of greater than 3 months

          -  Leukocytes >= 3,000/mcL

          -  Absolute neutrophil count >= 1,500/mcL

          -  Platelets >= 100,000/mcL

          -  Hemoglobin >= 90 g/L

               -  Blood transfusions are allowed at any time during the screening, treatment or
                  follow-up period, according to the center recommendations

          -  Prothrombin time (PT), partial thromboplastin time (PTT) and international normalized
             ratio (INR) =< 1.5 upper limit of normal (ULN)

          -  Total bilirubin =< 1.5 x institutional upper limit of normal; unless due to Gilbert's
             syndrome

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x
             institutional upper limit of normal (5 x if liver metastases)

          -  Creatinine =< 1.5 × institutional upper limit of normal OR creatinine clearance >= 40
             mL/min/1.73 m^2 for patients with creatinine levels above 1.5 x institutional limit of
             normal

          -  Patients must be able to tolerate oral medication and not have evidence of active
             bowel obstruction

               -  Note: patients can have a history of prior bowel obstruction, provided the
                  patient is not having symptoms of bowel obstruction at the time of enrolment and
                  the bowel obstruction is not anticipated to recur during the participation in the
                  study

          -  Patients must have disease amenable to biopsy and must be willing to undergo a paired
             biopsy for correlative analyses (the first biopsy within 28 days prior to start of
             treatment and the second biopsy while on treatment)

          -  Women of child-bearing potential must agree to use adequate contraception (hormonal or
             barrier method of birth control; abstinence) prior to study entry and for the duration
             of study participation; should a woman become pregnant or suspect she is pregnant
             while she is participating in this study, she should inform her treating physician
             immediately

               -  Women of childbearing potential include women who have experienced menarche and
                  who have not undergone successful surgical sterilization (hysterectomy, bilateral
                  tubal ligation, or bilateral oophorectomy) or are not postmenopausal;
                  postmenopause is defined as amenorrhea >= 12 consecutive months; Note: women who
                  have been amenorrheic for 12 or more months are still considered to be of
                  childbearing potential if the amenorrhea is possibly due to prior chemotherapy,
                  anti-estrogens, ovarian suppression or any other reversible reason

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients who previously received gemcitabine for the treatment of recurrent disease

          -  Patients who are receiving any other investigational agents

          -  Patients with clinically or radiologically unstable brain metastases are excluded from
             this clinical trial

               -  Note: patients with stable brain metastases after treatment, for at least 3
                  months prior to enrolling on this trial, could participate in the study; patients
                  should be off, or on a stable dose of steroids

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to AZD 1775 (MK-1775) or gemcitabine

          -  Patients taking the following prescription or non-prescription drugs or other products
             (i.e. grapefruit juice) are ineligible: sensitive cytochrome P450 family 3, subfamily
             A, polypeptide 4 (CYP3A4) substrates, CYP3A4 substrates with a narrow therapeutic
             index, moderate to potent inhibitors/inducers of CYP3A4; patients would be eligible if
             the medications can be discontinued two weeks prior to day 1 of dosing and withheld
             throughout the study until 2 weeks after the last dose of study medication

          -  Pregnant and breastfeeding women are excluded from this study

          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
             therapy are ineligible

          -  Uncontrolled intercurrent illness including, but not limited to, myocardial infarction
             within 6 months, congestive heart failure, symptomatic congestive heart failure,
             unstable angina pectoris, active cardiomyopathy, unstable ventricular arrhythmia,
             uncontrolled hypertension, uncontrolled psychotic disorders, serious infections,
             active peptic ulcer disease, active liver disease or cerebrovascular disease with
             previous stroke, or psychiatric illness/social situations that would limit compliance
             with study requirements
      "
NCT02109016,terminated,,0,phase 2,"['non-small cell lung cancer', 'squamous non-small cell lung cancer', 'nsclc', 'small cell lung cancer', 'sclc', 'lung cancer', 'advanced lung cancer', 'metastatic lung cancer', 'stage iv lung cancer']","[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]",['lucitanib'],['CNC(=O)C1=CC=CC2=C1C=CC(=C2)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC'],"
        Inclusion Criteria:

          -  Histologically or cytologically confirmed advanced/metastatic SCLC or NSCLC

          -  Any of the following tumor tissue based genetic alterations: FGFR1, FGFR2, FGFR3,
             VEGFA, or PDGFRα amplification; Any FGFR1, FGFR2, or FGFR3 gene fusion; FGFR1, FGFR2,
             or FGFR3 activating mutation

          -  Availability of tumor tissue sample suitable for the central confirmation of the
             genetic alteration and exploratory analyses

          -  Eastern Cooperative Oncology Group (ECOG) of 0 or 1

          -  Measurable disease per RECIST 1.1

          -  Documented radiographic disease progression following at least one line of therapy in
             the advanced/metastatic setting

        Exclusion Criteria:

          -  Tumors that are invading a major vessel; NSCLC tumors abutting to a major vessel

          -  Uncontrolled hypertension, defined as SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg with
             optimized anti-hypertensive therapy

          -  Uncontrolled hypothyroidism defined as serum thyroid stimulating hormone (TSH) higher
             than 5 mIU/mL while receiving appropriate thyroid hormone therapy

          -  Symptomatic and/or untreated central nervous system metastases

          -  Presence of another active cancer

          -  Ongoing adverse events from surgery or prior anti-cancer therapies, including
             radiation, targeted, or cytotoxic therapies

          -  Pregnant or breastfeeding women
      "
NCT02104661,completed,,0,phase 2,['multiple sclerosis'],"[""['G35', 'C81.18']""]","['oxcarbazepine', 'placebo']",['C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N'],"
        Inclusion Criteria:

          -  A diagnosis of definite multiple sclerosis

          -  Treatment with DMDs for at least 6 months prior to baseline visit*

          -  CSF NFL level ≥ 0.380ng/mL

          -  EDSS score between 3.5 and 6.0

          -  No history of relapses in the 6 months prior to the baseline visit

          -  A history of slow progression of disability, objective or subjective, over a period of
             at least 6 months prior to baseline

          -  Age 18-60 years

               -  [Temporary interruption is permitted at the discretion of the investigator for a
                  period of up to 8 weeks to prevent inflammatory MS reactivation. The cases where
                  this could happen include for example switching DMDs that require a washout
                  period as per clinical practice. When there are safety concerns, as in
                  Lymphopenia or other side effects induced by the DMD, the interruption period can
                  exceed 8 weeks as per clinical need. If reactivation of MS occurs with a relapse
                  the investigator will assess if this meets withdrawal criteria 6.]

        Exclusion Criteria:

          -  Pregnant or breastfeeding or unwilling to use adequate contraception.*

          -  Participants with a diagnosis of primary progressive PP MS or primary relapsing PR MS.

          -  A clinical relapse or pulsed intravenous or oral steroids in the 6 months preceding
             the baseline assessment.

          -  Participants presenting with medical disorder deemed severe or unstable by the CI such
             as poorly controlled diabetes or arterial hypertension, severe cardiac insufficiency,
             unstable ischemic heart disease, abnormal liver function tests (>2.5 times ULN) and
             abnormal complete blood count (in particular leukopenia, as defined by a lymphocyte
             count <500, neutrophil count <1.5 or platelet count <100, or thrombocytopenia <1.5
             LLN), or any medical condition which, in the opinion of the investigator, would pose
             additional risk to the participant.

          -  Infection with hepatitis B or hepatitis C or human immunodeficiency virus.

          -  Exposure to any other investigational drug within 30 days of enrolment in the study.

          -  Judged clinically to have a suicidal risk in the opinion of the investigator based
             upon a clinical interview and the Columbia Suicide-Severity Rating Scale (CSSRS).

          -  Prior history of malignancy unless an exception is granted by the Investigator.

          -  History of uncontrolled drug or alcohol abuse within 6 months prior to screening.

          -  Past untoward reactions to OxCbz or Cbz

          -  Participants receiving OxCbz or Cbz in the previous 12 weeks from baseline

               -  [Adequate methods of contraception are non hormonal methods such as barrier
                  methods, intrauterine devices, surgical sterilisation (undergone by the
                  participant or their partner). Female participants using hormonal only forms of
                  contraception will be required to use an additional barrier method. True
                  abstinence can be considered an acceptable method of contraception when this is
                  in line with the preferred and usual lifestyle of the subject. Periodic
                  abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods),
                  declaration of abstinence for the duration of a trial, and withdrawal are not
                  acceptable methods of contraception. Non sexually active participants or those in
                  same sex relationships will not be required to commence contraception.]
      "
NCT02103062,completed,,0,phase 2,['colorectal neoplasms'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]",['abi-007'],['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C'],"
        Inclusion Criteria: - 1. Subject is ≥ 18 years old at the time of signing the Informed
        Consent Form 2. Subject has histological or cytological diagnosis of adenocarcinoma of the
        colon or rectum, with evidence of metastasis 3. Subject has a known KRAS mutation status
        (mutated or wild-type). NRAS mutation status may be unknown. 4. Subject has documented
        disease progression ≤ 2 months after the last administration of the last standard therapy.
        a. Subjects treated with oxaliplatin in the adjuvant setting, should have progressed during
        or within 6 months of completion of adjuvant therapy 5. Subject has either received prior
        treatment or was not a candidate for prior treatment, with fluoropyrimidine, oxaliplatin,
        irinotecan and an anti-VEGF therapy (e.g. bevacizumab or ziv-aflibercept); and if RAS
        wild-type tumors, an anti-EGFR therapy (e.g. cetuximab or panitumumab). 6. Subject has
        Eastern Cooperative Oncology Group performance status 0 or 1 7. Subject has
        radiographically-documented measurable disease, as per Response Evaluation Criteria in
        Solid Tumors version 1.1 criteria 8. Subject has adequate organ functions, evidenced by the
        following: a. Aspartate Aminotransferase (SGOT), Alanine Transaminase (SGPT) ≤ 2.5 × upper
        limit of normal range, or < 5 x upper limit of normal range if liver metastasis present b.
        Total bilirubin ≤ 1.5 × upper limit of normal range c. Creatinine ≤ 1.5 × upper limit of
        normal range 9. Subject has adequate bone marrow function, evidenced by the following: a.
        Absolute neutrophil count ≥ 1.5 × 109 cells/millimeters3 b. Platelets ≥ 100 × 109
        cells/millimeters3 (transfusion independent, defined as not receiving platelet transfusions
        within 7 days prior to laboratory sample) c. Hemoglobin ≥ 9 grams/decilitre (transfusion is
        permitted to fulfill this criterion) 10. Females of child-bearing potential (defined as a
        sexually mature woman who (1) has not undergone hysterectomy [the surgical removal of the
        uterus] or bilateral oophorectomy [the surgical removal of both ovaries] or (2) has not
        been naturally postmenopausal for at least 24 consecutive months [i.e., has had menses at
        any time during the preceding 24 consecutive months]) must: a. Either commit to true
        abstinence* from heterosexual contact (which must be reviewed on a monthly basis), or agree
        to use, and be able to comply with, effective contraception without interruption, 28 days
        prior to starting Investigational Product therapy (including dose interruptions), and for 3
        months following the last dose of Investigational Product; and b. Have a negative serum
        pregnancy test (β -human Chorionic Gonadotrophin) result at screening and agree to ongoing
        pregnancy testing during the course of the study, and after the end of study therapy. This
        applies even if the subject practices true abstinence* from heterosexual contact. * True
        abstinence is acceptable when this is in line with the preferred and usual lifestyle of the
        subject. Note: Periodic abstinence (e.g, calendar, ovulation, symptothermal, post-ovulation
        methods) and withdrawal are not acceptable methods of contraception. 11. Male subjects must
        practice true abstinence* or agree to use a condom during sexual contact with a pregnant
        female or a female of childbearing potential while participating in the study, during dose
        interruptions and for 6 months following Investigational Product discontinuation, even if
        he has undergone a successful vasectomy. 12. Subject must understand and voluntarily sign
        an Informed Consent Form prior to any study related assessments or procedures being
        conducted. 13. Subject must be able to adhere to the study visit schedule and other
        protocol requirements. Exclusion Criteria: - 1. Subject has current or a history of brain
        metastasis. In subjects who are symptomatic, a brain scan is required to exclude
        metastasis. 2. Subject has ≥ National Cancer Institute Common Terminology Criteria for
        Adverse Events grade 2 peripheral neuropathy at screening 3. Subject has had prior
        treatment with regorafenib 4. Subject has received radiotherapy ≤ 4 weeks or limited field
        radiation for palliation ≤ 2 weeks prior to starting Investigational Product, and/or from
        whom ≥ 30% of the bone marrow was irradiated. Radiation therapy to a target lesion is
        permitted only if there has been clear progression of the lesion since radiation was
        completed. 5. Subject has had major surgery within 14 days prior to starting
        Investigational Product or has not recovered from postoperative complications 6. Subject
        has not recovered from the acute toxic effects of prior anticancer therapy, radiation or
        major /significant trauma 7. Subject has a history of allergy or hypersensitivity to
        nab-paclitaxel or any of the excipients 8. Subject has a known history of the following
        within 6 months prior to enrollment (the decision to include the subject in the study): a
        myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass
        graft, New York Heart Association Class III-IV heart failure, uncontrolled hypertension,
        clinically significant cardiac dysrhythmia or Electrocardiogram abnormality,
        cerebrovascular accident, transient ischemic attack, or seizure disorder 9. Subject has a
        known infection with hepatitis B or C, or history of human immunodeficiency virus
        infection, or subject receiving immunosuppressive or myelosuppressive medications that
        would in the opinion of the investigator, increase the risk of serious neutropenic
        complications 10. Subject has an active, uncontrolled bacterial, viral, or fungal
        infection(s) requiring systemic therapy, defined as ongoing signs/symptoms related to the
        infection without improvement despite appropriate antibiotics, antiviral therapy, and/or
        other treatment 11. Subject has any other malignancy within 5 years prior to enrolment,
        with the exception of adequately treated in-situ carcinoma of the cervix, uteri, or
        non-melanomatous skin cancer (all treatment of which should have been completed 6 months
        prior to enrollment) 12. Subject has a history of connective tissue disorders (eg, lupus,
        scleroderma, arteritis nodosa) 13. Subject has a history of interstitial lung disease ,
        history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis,
        idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies
        14. Subject has any other concurrent severe and/or uncontrolled medical condition that
        would, in the investigator's judgment, contraindicate subject participation in the clinical
        study (e.g. chronic pancreatitis, chronic active hepatitis, etc.) 15. Subject is enrolled
        in any other clinical protocol or investigational study with an interventional agent or
        assessments that may interfere with study procedures 16. Subject has any significant
        medical condition, laboratory abnormality, or psychiatric illness that would prevent the
        subject from participating in the study 17. Subject has any condition that confounds the
        ability to interpret data from the study 18. Subject is unwilling or unable to comply with
        study procedures 19. Subject is a pregnant or nursing female
      "
NCT02109445,terminated,"
    the study was terminated on 24jun15 due to change in strategy of pf-03084014 development.no
    safety/efficacy concerns were behind the reason of trial termination
  ",0,phase 2,['metastatic cancer pancreas'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['pf-03084014', 'gemcitabine', 'nab-paclitaxel', 'pf-03084014', 'gemcitabine', 'nab-paclitaxel', 'gemcitabine', 'nab-paclitaxel']","['CCCC(C(=O)NC1=CN(C=N1)C(C)(C)CNCC(C)(C)C)NC2CCC3=C(C2)C(=CC(=C3)F)F', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C', 'CCCC(C(=O)NC1=CN(C=N1)C(C)(C)CNCC(C)(C)C)NC2CCC3=C(C2)C(=CC(=C3)F)F', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C']","
        Inclusion Criteria:

          -  Histologically or cytologically diagnosis of metastatic ductal adenocarcinoma of the
             pancreas.

          -  No prior radiotherapy, surgery chemotherapy or investigational therapy for metastatic
             disease. Prior adjuvant therapy with 5-FU or gemcitabine (± gemcitabine post
             radiation) administered as radiosensitizer allowed, provided at least 6 months have
             elapsed between the last dose and study registration

          -  Tumor tissue available (Archival 6 months old or de novo biopsy)

          -  Measurable disease as per RECIST 1.1

          -  Performance Status (ECOG) 0 or 1

        Exclusion Criteria:

          -  Symptomatic brain metastases requiring steroids

          -  Prior therapy with gamma secretase inhibitors or other Notch pathway inhibitor

          -  Major surgery within 4 weeks of registration in the current study

          -  Known hypersensitivity to gemcitabine or nab-paclitaxel or any of the excipients

          -  Current or anticipated need for food or drugs that are strong/moderate CYP3A4
             inhibitors or inducers

          -  Diagnosis of any second malignancy within 3 years prior to registration
      "
NCT02106884,completed,,1,phase 2,['pancreatic cancer'],"[""['C25.3']""]","['nab-paclitaxel', 'gemcitabine']","['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F']","
        Inclusion Criteria:

          -  Written informed consent (+ optional for TR) must be given according to ICH/GCP and
             national/local regulations.

          -  Patient is at least 18 years of age .

          -  Unresectable locally advanced or metastatic pancreatic cancer.

          -  Histologically or cytologically confirmed adenocarcinoma of the pancreas. Islet cell
             neoplasms are excluded.

          -  Evaluable or measurable disease, not in a previously irradiated area.

          -  Life expectancy of at least 12 weeks.

          -  WHO ECOG performance status ≤ 2

          -  Adequate organ function.

          -  Adequate bone marrow, hepatic and renal function. Acceptable coagulation (prothrombin
             time and partial thromboplastin time within +/- 15% of normal limits).

          -  No clinically significant abnormalities in urinalysis.

          -  Effective contraception for both male and female patients if applicable. Women of
             childbearing potential must have negative blood pregnancy test at screening visit.

        Exclusion criteria:

          -  Prior chemotherapy, radiotherapy, surgery or other investigational therapy for the
             treatment for metastatic disease. Adjuvant treatment with gemcitabine or 5-FU is
             allowed provided at least 6 months have elapsed since completion of the last dose.

          -  Major surgery within 4 weeks of the start of the study.

          -  Irradiation within 3 weeks prior to study entry.

          -  Brain metastasis (known or suspected).

          -  Serious medical risk factors involving any of the major organ systems, including high
             cardiovascular risk including coronary stenting or myocardial infarction in the last
             year and psychiatric disorders.

          -  Historical or active infection with HIV, hepatitis B or C.

          -  History of connective tissue disorders (eg. lupus, scleroderma, arteritis nodosa,
             etc).

          -  History of interstitial lung disease.

          -  History of peripheral artery disease.

          -  Previous (within 5 years) or concurrent malignancies at other sites with the exception
             of surgically cured or adequately treated carcinoma in-situ of the cervix and basal
             cell carcinoma of the skin.

          -  Known allergy or any other adverse reaction to any of the drugs or to any related
             compound.

          -  Use of Coumadin.

          -  Organ allografts requiring immunosuppressive therapy.

          -  Pregnancy or breast-feeding.

          -  Medical, social or psychological condition which, in the opinion of the investigator,
             would not permit the patient to complete the study or sign meaningful informed
             consent.
      "
NCT02100748,completed,,1,phase 2,['acute pain'],"[""['G89.12', 'G89.18', 'G89.11', 'G89.3']""]","['trv130', 'morphine', 'placebo']","['COC1=C(SC=C1)CNCCC2(CCOC3(C2)CCCC3)C4=CC=CC=N4', 'CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O']","
        Inclusion Criteria:

          -  Has undergone primary, unilateral, first metatarsal bunionectomy (osteotomy and
             internal fixation) with no additional collateral procedures.

          -  Experiences a pain intensity rating of ≥ 4 on an 11 point NRS

          -  Able to provide written informed consent before any study procedure.

        Exclusion Criteria:

          -  ASA Physical Status Classification System classification of P3 or worse

          -  Has surgical or post-surgical complications.

          -  Has clinically significant medical conditions or history of such conditions that may
             interfere with the interpretation of efficacy, safety, or tolerability data obtained
             in the trial, or may interfere with the absorption, distribution, metabolism, or
             excretion of drugs.

          -  Has previously participated in another TRV130 clinical study.
      "
NCT02100423,completed,,0,phase 2,"['contiguous stage ii small lymphocytic lymphoma', 'noncontiguous stage ii small lymphocytic lymphoma', 'stage 0 chronic lymphocytic leukemia', 'stage i chronic lymphocytic leukemia', 'stage i small lymphocytic lymphoma', 'stage ii chronic lymphocytic leukemia']","[""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['C91.11', 'C91.12', 'C91.10']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['C91.11', 'C91.12', 'C91.10']""]",['curcumin'],['COC1=C(C=CC(=C1)C=CC(=O)CC(=O)C=CC2=CC(=C(C=C2)O)OC)O'],"
        Inclusion Criteria:

          -  Have a diagnosis of CLL based on peripheral blood flow cytometry and/or bone marrow
             aspiration and biopsy OR diagnosis of SLL based on lymph node or bone marrow biopsy;
             patients with SLL need to have measurable disease

          -  Performance status (Eastern Cooperative Oncology Group [ECOG]) 0-2

          -  Patients must have not received any prior treatment for CLL or SLL

          -  Patients must be stage 0-II based on Rai staging system; must have no indication for
             treatment for SLL per NCI-WG criteria

          -  Absolute neutrophil count (ANC) >= 1,500/mm^3

          -  Platelet count >= 100,000/mm^3

          -  Hemoglobin >= 10 g/dL

          -  Serum creatinine =< 2.0 g/dL or calculated creatinine clearance (CrCl) >= 60mL/min
             (Cockcroft-Gault method)

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x
             institutional upper limit of normal (ULN)

          -  Bilirubin < 2.0 x ULN, unless subject has Gilbert's disease

          -  Calcium < 10.1 mg/dL (corrected to serum albumin)

          -  Females will be either postmenopausal for at least 1 year or surgically sterile for at
             least 3 months OR females of child-bearing potential must have a negative pregnancy
             test at screening and agree to take appropriate precautions to avoid pregnancy (double
             barrier method of birth control or abstinence) from screening through 3 months after
             the last dose of treatment

          -  Able to comprehend and willing to sign an Informed Consent Form (ICF)

          -  Subjects must be off any steroids 7 days prior to the initiation of treatment

          -  Subjects must be off any curcumin, tumeric, or vitamin D supplements for 14 days prior
             to the initiation of treatment

          -  Subjects must be able to take oral medications

        Exclusion Criteria:

          -  Presence of malignancy (other than the one treated in this study) which required
             systemic treatment within the past 3 years

          -  Any indication to start treatment for CLL based on NCI-WG criteria

          -  Prior therapy for CLL/SLL

          -  Subjects who are pregnant or breast-feeding; breastfeeding should be discontinued if
             the mother is treated with curcumin

          -  Concurrent medical condition which may increase the risk of toxicity, including:

               -  Hypercalcemia of any cause

               -  Untreated hyperparathyroidism

               -  Paget's disease of bone

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situation that would limit compliance with
             study requirements as judged by treating physician; subjects receiving antibiotics
             that are under control may be included in the study

          -  Inability to take oral medications

          -  Patients receiving other investigational agent

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to curcumin or vitamin D or other agents used in this study

          -  Patients on therapeutic anticoagulation, with heparin (or low-molecular weight
             heparin), warfarin, or a direct thrombin inhibitor as the safety of concurrent
             administration of curcumin has not been established

          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
             therapy are ineligible
      "
NCT02013128,completed,,1,phase 1/phase 2,"['chronic lymphocytic leukemia', 'mantle cell lymphoma']","[""['C91.11', 'C91.12', 'C91.10']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']""]","['ublituximab', 'ibrutinib']",['C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N'],"
        Inclusion Criteria:

          -  Confirmed Mantle Cell lymphoma (MCL) open for enrollment. The Chronic Lymphocytic
             Leukemia (CLL) enrollment arm is now closed.

          -  Refractory to or relapsed after at least 1 prior treatment regimen

          -  Eastern Cooperative Oncology Group (ECOG) score of 0 to 2

        Exclusion Criteria:

          -  Any major surgery, chemotherapy or immunotherapy within the last 21 days

          -  Known hepatitis B virus, hepatitis C virus or HIV infection

          -  Autologous hematologic stem cell transplant within 3 months of study entry. Prior
             Allogeneic hematologic stem cell transplant is excluded.

          -  Richter's transformation, prolymphocytic leukemia or primary central nervous system
             lymphoma
      "
NCT02016534,terminated,"
    amgen decision following interim review of efficacy and safety data from the amg 337 program.
  ",0,phase 2,['stomach neoplasms'],"[""['D13.1', 'C16.9', 'C16.1', 'C16.2', 'D37.1', 'C16.8', 'C16.5']""]",['amg 337'],['CC(C1=NN=C2N1C=C(C=C2F)C3=CN(N=C3)C)N4C=CC5=C(C4=O)C=C(C=N5)OCCOC'],"
        Inclusion Criteria:

          -  Able to daily self-administer AMG 337 orally as a whole capsule

          -  Male or female 18 years of age or over.

          -  Pathologically confirmed advanced G/GEJ/E adenocarcinoma (Cohort 1) or other solid
             tumor (Cohort 2) for which subject has received prior therapy for advanced disease,
             for which no standard therapy exists, or subject refuses standard therapy

          -  Tumor MET amplified by protocol-specified centralized testing.

          -  Measurable disease per RECIST 1.1 guidelines. Cohort 2 may include up to 10 subjects
             with advanced MET amplified, G/GEJ/E adenocarcinoma with non-measurable tumor per
             RECIST v1.1

          -  (ECOG) Performance Status of 0, 1 or 2

        Exclusion Criteria:

          -  Known central nervous system metastases

          -  Candidate for curative surgery or definitive chemoradiation

          -  Peripheral edema > grade 1

          -  Persistent gastric outlet obstruction, complete dysphagia or are dependent upon
             jejunostomy for feeding. Significant gastrointestinal disorder(s) that in the opinion
             of the Investigator may influence drug absorption

          -  Acute Hepatitis B. Chronic Hepatitis B eligible if condition is stable and, in the
             opinion of the investigator or Amgen physician, if consulted, would not pose a risk to
             subject safety

          -  Detectable Hepatitis C virus (indicative of active Hepatitis C)

          -  Currently receiving any anti-tumor treatments, or less than 14 days prior to
             enrollment since ending anti-tumor treatment

          -  Prior treatment with small molecule inhibitors of the MET pathway.

        Other protocol defined inclusion criteria may apply.
      "
NCT02877082,terminated,,0,phase 2,"['acute leukemia', 'chronic lymphocytic leukemia', 'chronic myelogenous leukemia, bcr-abl1 positive', 'diffuse large b-cell lymphoma', 'follicular lymphoma', 'graft versus host disease', 'mantle cell lymphoma', 'marginal zone lymphoma', 'myelodysplastic syndrome', 'myelofibrosis', 'myeloproliferative neoplasm', 'small lymphocytic lymphoma']","[""['C91.01', 'C91.02', 'C92.01', 'C92.02', 'C92.41', 'C92.42', 'C92.51']"", ""['C91.11', 'C91.12', 'C91.10']"", ""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['D89.810', 'D89.811', 'D89.813', 'D89.812']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['D46.9', 'D46.C', 'D46.Z']"", ""['D75.81', 'C94.41', 'C94.42', 'C94.40']"", ""['D47.1']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']""]","['bortezomib', 'tacrolimus']","['B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O', 'CC1CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC(=O)C(C=C(C1)C)CC=C)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC']","
        Inclusion Criteria:

          -  Patients with acute leukemia, chronic myelogenous leukemia, myeloproliferative
             disorder and myelodysplasia with no circulating blasts and with less than 5% blasts in
             the bone marrow within 4 weeks of the start of transplant conditioning regimen

          -  Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma; follicular,
             marginal zone, diffuse large B-cell or mantle cell lymphoma with chemo-sensitive
             disease at time of transplant

          -  Patients must have a related or unrelated peripheral blood stem cell donor; sibling
             donor must be a 6/6 match for human leukocyte antigen (HLA)-A and -B at intermediate
             (or higher) resolution, and -DRB1 at high resolution using deoxyribonucleic acid
             (DNA)-based typing, and must be willing to donate peripheral blood stem cells and meet
             institutional criteria for donation; unrelated donor must be 8/8 match at HLA-A, -B,
             -C and -DRB1 at high resolution using DNA-based typing; unrelated donor must be
             willing to donate peripheral blood stem cells and be medically eligible to donate stem
             cells according to National Marrow Donor Program (NMDP) criteria

          -  Cardiac function: ejection fraction > 40%

          -  Estimated creatinine clearance greater than 50 mL/minute (using the Cockcroft-Gault
             formula and actual body weight)

          -  Pulmonary function: carbon monoxide diffusing capability test (DLCO) ≥ 40% (adjusted
             for hemoglobin) and forced expiratory volume in 1 second (FEV1) ≥ 50%

          -  Total bilirubin < 1.5 x the upper limit of normal; patients who have been diagnosed
             with Gilbert's disease are allowed to exceed the defined bilirubin value of 1.5 x the
             upper limit of normal

          -  Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 2.5 x the upper
             normal limit

          -  Female subjects (unless postmenopausal for at least 1 year before the screening visit,
             or surgically sterilized), agree to practice two effective methods of contraception or
             agree to completely abstain from heterosexual intercourse from the time of signing the
             informed consent through 12 months post-transplant

          -  Male subjects (even if surgically sterilized), of partners of women of childbearing
             potential must agree to practice effective barrier contraception or abstain from
             heterosexual intercourse from the time of signing the informed consent through 12
             months post-transplant

          -  Signed informed consent

        Exclusion Criteria:

          -  Prior allogeneic transplant

          -  Karnofsky performance score < 70%

          -  Active central nervous system (CNS) involvement by malignant cells

          -  Patients with uncontrolled bacterial, viral, or fungal infections (currently taking
             medication and with progression or no clinical improvement) at time of enrollment

          -  Patients with transformed lymphoma (e.g., Richter's transformation arising in
             follicular lymphoma or chronic lymphocytic leukemia)

          -  Patients seropositive for the human immunodeficiency virus (HIV)

          -  Patient with active hepatitis B or C

          -  Patients with hypersensitivity to bortezomib, boron, or mannitol

          -  Patients with > grade 2 sensory peripheral neuropathy

          -  Myocardial infarction within 6 months prior to enrollment or New York Heart
             Association (NYHA) class III or IV heart failure, uncontrolled angina, severe
             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
             ischemia or active conduction system abnormalities; prior to study entry, any
             electrocardiography (ECG) abnormality at screening must be documented by the
             investigator as not medically relevant

          -  Female patients who are lactating or pregnant

          -  Patients with a serious medical or psychiatric illness likely to interfere with
             participation in this clinical study

          -  Patients with prior malignancies, except resected basal cell carcinoma or treated
             cervical carcinoma in situ; cancer treated with curative intent > 5 years previously
             will be allowed; cancer treated with curative intent < 5 years previously will not be
             allowed unless approved by the protocol officer or one of the protocol chairs
      "
NCT02874742,completed,,1,phase 2,['multiple myeloma'],"[""['C90.01', 'C90.02', 'C90.00']""]","['lenalidomide', 'bortezomib', 'dexamethasone', 'daratumumab']","['C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N', 'B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O', 'CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C']","
        Inclusion Criteria:

          -  Considered by the investigator to be eligible for high-dose chemotherapy (HDT) and
             autologous stem cell transplantation (ASCT) according to the institution's criteria
             based on age, medical history, cardiac and pulmonary status, overall health and
             condition, co-morbid condition(s), physical examination, and laboratory studies

          -  Has not had prior systemic therapy for multiple myeloma. An emergency course of
             steroids (defined as no greater than 40 milligram [mg] of dexamethasone, or equivalent
             per day for a maximum of 4 days (that is, a total of 160 mg) is permitted. In
             addition, radiation therapy is permitted prior to study entry, during screening, and
             during Cycles 1-2 of study treatment as needed for lytic bone disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2

          -  Woman of childbearing potential must have 2 negative highly sensitive serum
             (beta-human chorionic gonadotropin [b-hCG]) during screening, the first one within 10
             to 14 days prior to the first dose of any component of study treatment and the second
             within 24 hours prior to the first dose of any component of study treatment

          -  A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted
             reproduction during the study (including during dose interruptions), and for 4 weeks
             following discontinuation of lenalidomide, and if receiving daratumumab, for 3 months
             after the last dose

        Exclusion Criteria:

          -  Diagnosed or treated for malignancy other than multiple myeloma, except: a) Malignancy
             treated with curative intent and with no known active disease present for more than
             equal to (>= )3 years before randomization; b) Adequately treated non-melanoma skin
             cancer, lentigo maligna or in situ malignancies (including but not limited to,
             cervical, breast) with no evidence of disease

          -  Exhibiting clinical signs of or has a known history of meningeal or central nervous
             system involvement by multiple myeloma

          -  Known chronic obstructive pulmonary disease with a forced expiratory volume in 1
             second (FEV1) less than (<)50 percent (%) of predicted normal

          -  Known moderate or severe persistent asthma within the past 2 years or currently has
             uncontrolled asthma of any classification

          -  Known to be seropositive for human immunodeficiency virus, known to have hepatitis B
             surface antigen positivity, or known to have a history of hepatitis C. Participants
             who completed treatment for hepatitis C at least 6 months prior to screening and have
             no detectable circulating hepatitis C virus (HCV) at screening, may participate in the
             study. Such participants will be required to undergo regular assessment for HCV
             reactivation during their participation in the study. Participants who test positive
             for HCV at any time during these assessments will be withdrawn from the study
      "
NCT02873338,completed,,1,phase 2,['acute myeloid leukemia'],"[""['C92.A1', 'C92.A2', 'C92.61', 'C92.62', 'C92.A0', 'C92.60']""]","['cx-01', 'idarubicin', 'cytarabine']","['CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O']","
        Inclusion Criteria:

          -  Newly diagnosed, de novo or secondary, previously untreated AML

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

        Exclusion Criteria:

          -  Acute promyelocytic leukemia

          -  Prior chemotherapy for AML

          -  Prior intensive chemotherapy or stem cell transplantation for the treatment of
             myelodysplastic syndrome

          -  CNS leukemia
      "
NCT02870920,completed,,1,phase 2,['colorectal cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['tremelimumab', 'durvalumab']",['Status: 503'],"
        Inclusion Criteria:

          -  Must have histologically or pathologically confirmed advanced (metastatic or locally
             advanced) colorectal cancer that is unresectable.

          -  Received a prior thymidylate synthase inhibitor (e.g. 5-fluorouracil (5-FU),
             capecitabine, raltitrexed, UFT) for metastatic disease or as adjuvant therapy. A
             thymidylate synthase inhibitor may have been given in combination with oxaliplatin or
             irinotecan.

          -  Received and failed an irinotecan -containing regimen (i.e. single-agent or in
             combination) for treatment of metastatic disease, OR relapsed within 6 months of
             completion of an irinotecan-containing adjuvant therapy, OR have documented
             unsuitability for an irinotecan-containing regimen.

          -  Received and failed an oxaliplatin-containing regimen (i.e. single-agent or in
             combination) for treatment of metastatic disease, OR relapsed within 6 months of
             completion of an oxaliplatin-containing adjuvant therapy OR have documented
             unsuitability for an oxaliplatin-containing regimen.

          -  For patients with colorectal cancer that is RAS-wild type:

        Received and failed a cetuximab or panitumumab-containing regimen (i.e. single-agent or in
        combination) for treatment of metastatic disease OR have documented unsuitability for a
        cetuximab or panitumumab-containing regimen

          -  Patient prior treatment with VEGF targeting therapy, such as bevacizumab, aflibercept,
             ramucirumab, or regorafenib, is permitted but not mandatory. Reasons not used are to
             be documented.

          -  Patient prior treatment with TAS-102 (an agent composed of a combination of
             trifluorothymidine (FTD) and tipiracil hydrochloride (TPI)), is permitted but not
             mandatory.

          -  The only remaining standard available therapy as recommended by the Investigator, in
             consultation with the patient, is best supportive care.

          -  Must have presence of measurable or evaluable disease as defined by Response
             Evaluation Criteria in Solid Tumours (RECIST 1.1).

          -  Imaging investigations including CT/MRI of chest/abdomen/pelvis or other scans as
             necessary to document all sites of disease done within 28 days prior to randomization.

          -  Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Life expectancy of ≥ 12 weeks at the time of study entry.

          -  Must be ≥ 18 years of age.

          -  Women/men of childbearing potential must have agreed to use a highly effective
             contraceptive method.

          -  Patient must consent to provision of, and investigator(s) must confirm adequacy of
             tissue, and confirm access to and agree to submit within 4 weeks of randomization to
             the CCTG Central Tumour Bank, a representative formalin fixed paraffin block of tumour
             tissue in order that the specific correlative marker assays may be conducted.

          -  Patient must consent to provision of samples of blood in order that the specific
             correlative marker assays

          -  Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life
             questionnaires in either English or French.

        Patients must be accessible for treatment and follow-up. Investigators must assure
        themselves the patients randomized on this trial will be available for complete
        documentation of the treatment, adverse events, and follow-up.

          -  In accordance with CCTG policy, protocol treatment is to begin within 2 working days
             of patient randomization.

          -  The patient is not receiving therapy in a concurrent clinical study and the patient
             agrees not to participate in other clinical studies during their participation in this
             trial while on study treatment.
      "
NCT03316573,suspended,"
    low accrual
  ",0,phase 2,"['lymphoma', 'histiocytic sarcoma', 'follicular dendritic cell sarcoma', 'interdigitating dendritic cell sarcoma']","[""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['C96.A']"", ""['L73.9', 'C82.97', 'H10.013', 'H10.433', 'L73.8', 'C82.07', 'C82.17']"", ""['C96.4']""]",['pembrolizumab'],['Status: 503'],"
        Inclusion Criteria:

          -  Be willing and able to provide written informed consent for the trial.

          -  Histologically confirmed diagnosis of a histiocyte/dendritic cell neoplasm or
             relapsed/refractory aggressive lymphoma with at least one of the following features
             (with review required at a participating study center):

               -  Diffuse large B cell lymphoma with EBV positive tumor cells (defined as positive
                  EBV-encoded RNA in tumor cells)

               -  Plasmablastic lymphoma

               -  T cell/histiocyte rich DLBCL

               -  EBV+ T cell lymphoma of any histology; note, patients with angioimmunoblastic T
                  cell lymphoma will be eligible regardless of EBV status

               -  Histiocytic sarcoma

               -  Follicular dendritic cell sarcoma

               -  Interdigitating dendritic cell sarcoma

          -  For patients with histiocytic sarcoma, interdigitating dendritic cell sarcoma, or
             follicular dendritic cell sarcoma only: disease that is not amenable to surgical
             resection and/or radiation therapy with curative intent.

          -  For lymphoma patients only: At least one prior systemic chemotherapy including an
             alkylating agent and anthracycline (unless contraindicated), and an anti-CD20
             monoclonal antibody if the tumor is CD20+.

          -  For lymphoma patients only: Participants must have received and relapsed after
             autologous stem cell transplantation (ASCT), or be ineligible for ASCT (including on
             the basis of refractory disease), or have declined ASCT

          -  Age 18 years or older at the time of signing consent.

          -  ECOG performance status of 0 or 1 (Karnofsky ≥70%, see Appendix A)

          -  Participants must have normal organ and marrow function as defined below:

               -  absolute neutrophil count ≥ 1,000/mcL

               -  platelets ≥75,000/mcL (> 30,000 if there is bone marrow involvement with
                  lymphoma)

               -  total bilirubin < 1.5 times the institutional upper limit of normal (ULN) OR
                  direct bilirubin < the normal in subjects with total bilirubin >1.5 times the ULN

               -  AST(SGOT)/ALT(SGPT) ≤2.5 × institutional ULN or < 5 times ULN in patients with
                  known hepatic involvement with lymphoma

               -  albumin > 2.5 mg/dl

               -  creatinine < 1.5 times the normal upper institutional limit OR creatinine
                  clearance ≥60 mL/min/1.73 m2 in participants with creatinine levels > 1.5 times
                  the normal upper institutional limit

               -  INR, aPTT or PT < 1.5 times the ULN unless subject is receiving anticoagulation
                  therapy as long as PT or aPTT are within therapeutic range of intended use of
                  anticoagulant

          -  Be willing to provide tissue from a newly obtained core needle or excisional biopsy.
             Newly-obtained is defined as a specimen obtained up to and including 90 days prior to
             treatment day 1. Subjects for whom newly obtained samples cannot be provided may be
             enrolled only with agreement by the overall PI.

          -  No prior allogeneic transplant unless all of the following apply:

               -  At least 5 years from time of transplant

               -  Absence of clinically significant graft-versus-host disease (GVHD)

               -  Not on immune suppression

               -  Approval of overall PI

          -  Not a candidate for potentially curative therapy at the time of enrollment

          -  Measurable disease per the Lugano criteria.

          -  Female subjects of childbearing potential should have a negative urine or serum
             pregnancy test within 72 hours prior to receiving the first dose of study medication.
             If the urine test is positive or cannot be confirmed as negative, a serum pregnancy
             test will be required.

          -  Female subjects of childbearing potential must be willing to use an adequate method of
             contraception as outlined in Section 5.4.3 - Contraception for the course of the study
             through 120 days after the last dose of study medication.

          -  Abstinence is acceptable if this is the usual lifestyle and preferred contraception
             for the subject.

          -  Male subjects of childbearing potential must agree to use an adequate method of
             contraception as outlined in Section 5.4.3- Contraception, starting with the first
             dose of study therapy through 120 days after the last dose of study therapy.

          -  Abstinence is acceptable if this is the usual lifestyle and preferred contraception
             for the subject

          -  The effects of pembrolizumab on the developing human fetus are unknown. Should a woman
             become pregnant or suspect she is pregnant while she or her partner is participating
             in this study, she should inform her treating physician immediately.

        Exclusion Criteria:

          -  Prior treatment with a PD-1, PD-L1 or PD-L2 inhibitor

          -  Has had a prior anti-cancer monoclonal antibody within 4 weeks prior to study day 1 or
             has not recovered (i.e., < grade 1 or at baseline) from adverse events due to a
             previously administered agent.

          -  Participants who have had chemotherapy, targeted small molecule therapy, or
             radiotherapy within 2 weeks prior to study day 1 (6 weeks for nitrosoureas or
             mitomycin C) or who has not recovered (i.e., < grade 1 or at baseline) from adverse
             events due to previously administered agents. Note: subjects with < grade 2 peripheral
             neuropathy are an exception to this criterion and may qualify for the study.

          -  Radiation therapy within 2 weeks of study treatment

          -  Is currently participating and receiving study therapy or has participated in a study
             of an investigational agent and received study therapy or used an investigational
             device within 4 weeks of the first dose of treatment.

          -  Has a known history of active tuberculosis

          -  Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial.

          -  Has an active infection requiring systemic therapy.

          -  Has active autoimmune disease that has required systemic treatment in the past 2 years
             (i.e., with the use of disease modifying agents, corticosteroids, or immunosuppressive
             drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid
             replacement therapy for adrenal her pituitary insufficiency, etc.) is not considered a
             form of systemic treatment.

          -  Has a diagnosis of immunodeficiency or is receiving any form of immunosuppressive
             therapy within 7 days prior to the first dose of trial treatment or is taking chronic
             systemic steroids (in doses exceeding 10 mg daily of prednisone equivalent) within 7
             days prior to the first dose of trial treatment. Note: Subjects with asthma or chronic
             obstructive pulmonary disease that require intermittent use of bronchodilators,
             inhaled steroids, or local steroid injections are not excluded from the study.

          -  Has a history of non-infectious pneumonitis that required systemic corticosteroid
             treatment or has active pneumonitis.

          -  Known active central nervous system involvement and/or carcinomatous meningitis.
             Subjects with previously treated brain metastases may participate provided they are
             stable (without evidence of progression by imaging for at least 4 weeks prior to the
             first dose of trial treatment and any neurologic symptoms have returned to baseline),
             have no evidence of new or enlarging brain metastases, and are not using steroids for
             at least 7 days prior to trial treatment. This exception does not include
             carcinomatous meningitis which is excluded regardless of clinical stability.

          -  Known additional malignancy that is progressing or requires active treatment.
             Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the
             skin that has undergone potentially curative therapy or in situ cervical cancer

          -  Active hepatitis B (e.g., hepatitis B surface antigen reactive) or hepatitis C (e.g.,
             hepatitis C virus RNA detectable).

          -  Human immunodeficiency virus (HIV 1/2).

          -  Is pregnant or breast-feeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the screening visit until 120 days
             after the last dose of trial treatment.

          -  Has received a live vaccine within 30 days of planned start of study therapy. (Note:
             seasonal influenza vaccines for injection are allowed as they are inactivated;
             however, intranasal influenza vaccines are live attenuated vaccines and are NOT
             allowed)

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to pembrolizumab.

          -  Baseline pulse oximetry <94% or requires oxygen supplementation of any kind

          -  If subject underwent major surgery they must have recovered adequately from the
             toxicity and/or complications from the procedure prior to starting therapy.

          -  Uncontrolled intercurrent illness including, but not limited to symptomatic congestive
             heart failure, unstable angina pectoris, or cardiac arrhythmia
      "
NCT03414229,"active, not recruiting",,0,phase 2,['sarcoma'],"[""['C96.A', 'C46.9', 'C96.22', 'C46.0', 'C46.2', 'C92.31', 'C92.32']""]","['epacadostat', 'pembrolizumab']",['C1=CC(=C(C=C1N=C(C2=NON=C2NCCNS(=O)(=O)N)NO)Br)F'],"
        Inclusion Criteria:

          -  Male or female age ≥ 18 years at the time of informed consent

          -  Be willing and able to provide written informed consent/assent for the trial

          -  Be willing to comply with treatment protocol

          -  Subjects must have a histologically confirmed metastatic and/or locally advanced
             sarcoma

          -  Adequate performance status: ECOG 0 or 1/KPS 100-70%

          -  Subjects must have at least one prior line of systemic therapy (e.g. chemotherapy,
             immunotherapy, targeted or biological therapy) for their sarcoma. An exception to this
             criterion will be made for patients with sarcoma histological subtypes for which there
             is no known standard systemic therapy (e.g., chondrosarcoma). Any patient that refuses
             standard chemotherapy for the treatment of their disease is also considered eligible.
             Prior adjuvant therapy will not count provided it was completed more than 6 months
             previously.

          -  Presence of measureable disease per RECIST v1.1.Target lesions must not be chosen from
             a previously irradiated field unless there has been radiographically and/or
             pathologically documented tumor progression in that lesion prior to enrollment.

          -  All subjects must agree to pre-treatment tumor biopsy. Subjects in whom biopsy is
             technically not feasible or in whom would result in unacceptable risk, in the opinion
             of the investigator, may be exempted from the biopsy requirement with discussion with
             the principal investigator.

          -  Adequate organ function determined within 21 days of treatment initiation

          -  Hematological

               -  Absolute neutrophil count (ANC) ≥1,000 /mcL

               -  Platelets ≥75,000 / mcL

               -  Hemoglobin ≥8 g/dL or ≥5.0 mmol/L

          -  Renal

             °Serum creatinine OR Measured or calculateda creatinine clearance (GFR can also be
             used in place of creatinine or CrCl) ≤1.5 X upper limit of normal (ULN) OR

             ≥60 mL/min for subject with creatinine levels > 1.5 X institutional ULN aCreatinine
             clearance should be calculated per institutional standard.

          -  Hepatic

               -  Serum total bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with
                  total bilirubin levels > 1.5 ULN

               -  AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver
                  metastases

               -  Albumin ≥ 2.5 mg/dL

          -  Coagulation

               -  International Normalized Ratio 52 or Prothrombin Time ≤1.5 X ULN unless subject
                  is receiving anticoagulant therapy as long as PT or PTT is within therapeutic
                  range of intended use of anticoagulants

               -  Activated Partial Thromboplastin Time (aPTT) ≤1.5 X ULN unless subject is
                  receiving anticoagulant therapy as long as PT or PTT is within therapeutic range
                  of intended use of anticoagulants

          -  Women of childbearing potential must have a negative serum pregnancy test at screening
             and ≤ 72 hours prior to day 1 of study treatment.

          -  Male and female subjects of childbearing potential must be willing to use an adequate
             method of contraception as outlined in Section 11.7, for the course of the study
             through 120 days after the last dose of study medication.

        Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception
        for the subject.

        Exclusion Criteria:

          -  Uncontrolled intercurrent illness including current active infection requiring
             systemic therapy or symptomatic congestive heart failure within 6 months

          -  Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis. Subjects with previously treated brain metastases may participate provided
             they are stable (without evidence of progression by imaging for at least four weeks
             prior to the first dose of trial treatment and any neurologic symptoms have returned
             to baseline), have no evidence of new or enlarging brain metastases, and are not using
             steroids for at least 7 days prior to trial treatment. This exception does not include
             carcinomatous meningitis which is excluded regardless of clinical stability.

          -  Evidence of clinically significant immunosuppression such as the following:

               -  Primary immunodeficiency state such as Severe Combined Immunodeficiency Disease

               -  Concurrent opportunistic infection

               -  Receiving systemic immunosuppressive therapy (> 2 weeks) including oral steroid
                  doses > 10 mg/day of prednisone or equivalent within 7 days prior to enrollment.
                  However, in the setting of non-immune mediated indications for steroid use,
                  chronic/active low dose steroid use may be permitted at the discretion of the
                  principal investigator. The dose of steroid allowed in this setting is also at
                  the discretion of the principal investigator. (Use of inhaled or topical steroids
                  is permitted.)

          -  History or evidence of symptomatic autoimmune disease (e.g., pneumonitis,
             glomerulonephritis, vasculitis, or other), or history of active autoimmune disease
             that has required systemic treatment (i.e., use of corticosteroids, immunosuppressive
             drugs or biological agents used for treatment of autoimmune diseases) in past 2 years
             prior to enrollment. Replacement therapy (e.g., thyroxine for hypothyroidism, insulin
             for diabetes or physiologic corticosteroid replacement therapy for adrenal or
             pituitary insufficiency) is not considered a form of systemic treatment for autoimmune
             disease.

          -  Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies) disease

          -  Has known active Hepatitis B (e.g., Hepatitis B Virus PCR is detected) or Hepatitis C
             (e.g., HCV RNA [qualitative] is detected).

          -  Patients who have received a live vaccine within 30 days of the start date of the
             planned study therapy. Examples of live vaccines include, but are not limited to, the
             following: measles, mumps, rubella, chicken pox, yellow fever, rabies, Bacillus
             Calmette-Guérin (BCG), and typhoid vaccine. Note: Seasonal influenza vaccines for
             injection are generally inactivated flu vaccines and are allowed; however intranasal
             influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not
             allowed.

          -  Has a known history of active TB (Bacillus Tuberculosis)

          -  Is currently participating and receiving study therapy or has participated in a study
             of an investigational agent and received study therapy or used an investigational
             device within 2 weeks of the first dose of treatment.

          -  Has had a prior chemotherapy, immunotherapy, biological therapy, targeted small
             molecule therapy, or radiation therapy within 3 weeks prior to study Day 1 or who has
             not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to previously
             administered agent.

               -  Note: Subjects with ≤ Grade 2 neuropathy, alopecia or hypothyroidism are an
                  exception to this criterion and may qualify for the study.

               -  Note: If subject received major surgery, they must have recovered adequately from
                  the toxicity and/or complications from the intervention prior to starting therapy
                  events due to a previously administered agent.

          -  Presence of a gastrointestinal condition that may affect drug absorption

          -  Known allergy or reaction to any component of either study drug formulation

          -  Women who are pregnant or breast feeding

          -  Subjects expecting to conceive or father children within the projected duration of the
             trial, starting with the pre-screening or screening visit through 120 days after the
             last dose of study treatment(s).

          -  Inability to comply with protocol required procedures

          -  Subjects receiving Monoamine Oxidase Inhibitors (MAOIs) or drug which has significant
             MAOI activity (meperidine, linezolid, methylene blue) within the 21 days before
             screening.

          -  Any history of Serotonin Syndrome (SS) after receiving serotonergic drugs.

          -  History or presence of an abnormal electrocardiogram (ECG) that, in the investigator's
             opinion, is clinically meaningful. Screening QTc interval 480 milliseconds is
             excluded. In the event that a single QTc is ≥ 480 milliseconds, the subject may enroll
             if the average QTc for the 3 ECGs is < 480 milliseconds. For subjects with an
             intraventricular conduction delay (QRS interval > 120 milliseconds), the JTc interval
             may be used in place of the QTc with the approval of the principal investigator. The
             JTc must be < 340 milliseconds if JTc is used in place of the QTc. Subjects with left
             bundle branch block are excluded.

        Note: QTc prolongation due to pacemaker may enroll if the JTc is normal.

          -  Use of any UGT1A9 inhibitor from screening through follow-up period, including the
             following: diclofenac, imipramine, ketoconazole, mefenamic acid, and probenecid.

          -  History of prior therapy with an IDO1 inhibitor in combination with an
             anti-PD-1/anti-PD-L1 agent/any other drug specifically targeting checkpoint pathways.
             Patients who have received prior therapy with single agent anti-PD-1/anti-PD-L1
             therapy or single agent IDO1 inhibitor will be eligible for this study.

          -  Presence of any other concurrent active malignancy
      "
NCT03506048,terminated,"
    study has been abandoned for lack of accrual
  ",0,phase 2,"['differentiated thyroid gland carcinoma', 'thyroid gland follicular carcinoma', 'thyroid gland papillary carcinoma']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]",['lenvatinib'],['COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl'],"
        Inclusion Criteria:

          -  Prior treatment with therapeutic dose of radioactive iodine (> 50 mCi) with evidence
             of RAI uptake on delayed scan and with progression (biochemical or anatomic) within 12
             months of RAI

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Karnofsky ≥ 80%)

          -  Leukocytes ≥ 3,000/µL

          -  Absolute neutrophil count ≥ 1,500/µL

          -  Platelets ≥ 100,000/µL

          -  Total bilirubin within normal institutional limits

          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             ≤ 2.5 x institutional upper limit of normal

          -  Creatinine within normal institutional limits OR

          -  Creatinine clearance ≥ 60 mL/min/1.73 m² for patients with creatinine levels above
             institutional normal

          -  Confirmed diagnosis of differentiated thyroid cancer (follicular or papillary thyroid
             cancer and their variants)

          -  Ability and willingness to use appropriate contraception; women of child-bearing
             potential and men must agree to use adequate contraception (hormonal or barrier method
             of birth control; abstinence) prior to study entry and for the duration of study
             participation; should a woman become pregnant or suspect she is pregnant while she or
             her partner is participating in this study, she should inform her treating physician
             immediately; men treated or enrolled on this protocol must also agree to use adequate
             contraception prior to the study, for the duration of study participation, and for 2
             weeks after completion of lenvatinib administration

          -  Patients must have measurable disease, defined as at least one lesion that can be
             accurately measured in at least one dimension (longest diameter to be recorded for
             non-nodal lesions and short axis for nodal lesions) as ≥ 20 mm (≥ 2 cm) by chest x-ray
             or as ≥ 10 mm (≥ 1 cm) with computed tomography (CT) scan, magnetic resonance imaging
             (MRI), or calipers by clinical exam

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients who have received RAI within 12 weeks of planned retreatment

          -  Prior receipt of cumulative RAI doses in excess of 1000 mCi

          -  Patients who have not recovered from adverse events due to prior anti-cancer therapy
             (i.e., have residual toxicities > grade 1)

          -  Patients who are receiving any other investigational agents

          -  Patients with previously untreated and or symptomatic brain metastases are excluded
             from this clinical trial because of the risk of intracranial bleeding with angiogenic
             agents and tumoral swelling from RAI

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to lenvatinib

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Patients with uncontrolled hypertension (requirement for more than 2 blood pressure
             [BP] medications or grade 2 or higher BP elevation while on adequate doses of not more
             than 2 antihypertensive agents) are excluded from the study because one of the
             significant adverse events of lenvatinib is worsening hypertension

          -  Fridericia's corrected QT (QTcF) interval prolongation greater than 500 ms

          -  Recent arterial thromboembolic event within the previous 6 months

          -  Urine dipstick proteinuria ≥ 2+ or nephrotic range proteinuria on ≥ 2 gram in 24-hour
             urine

          -  History of gastrointestinal perforation, abscess or fistula

          -  History of and or medical condition (e.g. diverticular disease; aneurysm) that
             predisposes to risk of major hemorrhage

          -  Pregnant women are excluded from this study because lenvatinib is a tyrosine kinase
             inhibitor agent with the potential for teratogenic or abortifacient effects; because
             there is an unknown but potential risk for adverse events in nursing infants secondary
             to treatment of the mother with lenvatinib, breastfeeding should be discontinued if
             the mother is treated with lenvatinib

          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
             therapy are ineligible because of the potential for pharmacokinetic interactions with
             lenvatinib
      "
NCT02215161,terminated,"
    risk to benefit ratio is not acceptable
  ",0,phase 2,"['castration levels of testosterone', 'hormone-resistant prostate cancer', 'metastatic prostate carcinoma in the soft tissue', 'prostate carcinoma metastatic in the bone', 'psa progression', 'stage iv prostate adenocarcinoma ajcc v7']","[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]",['selinexor'],['C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F'],"
        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the prostate

          -  Patients must have castrate levels of testosterone (< 50 ng/dL) on
             gonadotropin-releasing hormone (GnRH) analogues or have had prior orchiectomy; GnRH
             analogues must be continued while on study

          -  Tumor tissue submitted for molecular and genetic analysis through the companion
             Stand-up 2 Cancer (SU2C) radiologically guided biopsy of abiraterone and/or
             enzalutamide refractory mCRPC protocol

               -  Patients who consent to participate in the companion biopsy protocol and are
                  subsequently determined to be ineligible for biopsy are eligible to participate
                  in the current protocol

          -  Progressive disease as demonstrated by a rising PSA (at least two determinations)
             prior to study entry, and/or radiographic evidence of tumor progression in soft tissue
             according to modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria
             or identification of new lesions by bone scan (i.e., >= 2 new lesions)

          -  Primary resistance or acquired resistance (i.e., acquired resistance will be defined
             as disease progression following a period of response defined as >= 50% decline in PSA
             within 12 weeks of starting therapy and not otherwise meeting criteria for primary
             resistance) to any of the following agents/combinations of therapy:

          -  Abiraterone acetate; primary resistance to abiraterone will be defined as:

               -  No PSA decline

               -  PSA decline less than 50% after 12 weeks of abiraterone therapy

               -  PSA progression within 12 weeks of abiraterone acetate (AA) treatment (by
                  Prostate Cancer Working Group-2 [PCWG2] criteria), after initial response to
                  therapy

               -  Objective progression, by RECIST criteria for soft tissue lesions and by modified
                  PCWG2 criteria for bone lesions within 12 weeks of starting abiraterone treatment

               -  Unequivocal clinical progression (per the treating provider's discretion) within
                  12 weeks of starting abiraterone treatment

          -  Enzalutamide; primary resistance to enzalutamide will be defined as:

               -  No PSA decline

               -  PSA decline less than 50% after 12 weeks of enzalutamide therapy

               -  PSA progression within 12 weeks of enzalutamide treatment (by PCWG2 criteria),
                  after initial response to therapy

               -  Objective progression, by RECIST criteria for soft tissue lesions and by modified
                  PCWG2 criteria for bone lesions within 12 weeks of starting enzalutamide
                  treatment

               -  Unequivocal clinical progression (per the treating provider's discretion) within
                  12 weeks of starting enzalutamide treatment

          -  Other second-generation investigational anti-androgen/androgen-receptor targeted
             therapies, including apalutamide (ARN-509); primary resistance will be defined as:

               -  No PSA decline

               -  PSA decline less than 50% after 12 weeks of enzalutamide therapy

               -  PSA progression within 12 weeks of enzalutamide treatment (by PCWG2 criteria),
                  after initial response to therapy

               -  Objective progression, by RECIST criteria for soft tissue lesions and by modified
                  PCWG2 criteria for bone lesions within 12 weeks of starting enzalutamide
                  treatment

               -  Unequivocal clinical progression (per the treating provider's discretion) within
                  12 weeks of starting enzalutamide treatment

          -  Combination therapy with abiraterone, enzalutamide and/or other second- generation
             investigational anti-androgen/androgen-receptor targeted therapies, including ARN-509;
             primary resistance to combination therapy will be defined as:

               -  No PSA decline

               -  PSA decline less than 50% after 12 weeks of abiraterone and enzalutamide therapy

               -  PSA progression within 12 weeks of abiraterone and enzalutamide treatment (by
                  PCWG2 criteria), after initial response to therapy

               -  Objective progression, by RECIST criteria for soft tissue lesions and by modified
                  PCWG2 criteria for bone lesions within 12 weeks of starting abiraterone and
                  enzalutamide treatment

               -  Unequivocal clinical progression (per the treating provider?s discretion) within
                  12 weeks of starting abiraterone and enzalutamide treatment

          -  Sequenced therapy, including any of the following:

               -  Abiraterone acetate followed by enzalutamide

                    -  Primary resistance will be defined per criteria for abiraterone monotherapy
                       primary resistance

               -  Enzalutamide followed by abiraterone acetate

                    -  Primary resistance will be defined per criteria for enzalutamide monotherapy
                       primary resistance

               -  Other second-generation investigational anti-androgen/androgen- receptor targeted
                  therapies, including ARN-509

                    -  Primary resistance will be defined per criteria for other investigational
                       anti-androgen monotherapy primary resistance

          -  Presence of 1 or more bone metastasis

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Prior and ongoing zoledronic acid or denosumab therapy is allowed

          -  Prior therapy with radium-223 is allowed

          -  Discontinuation of prior therapy for mCRPC: a washout period of 28 days for the
             following therapies is required: abiraterone, enzalutamide, fluconazole, itraconazole,
             flutamide, bicalutamide, nilutamide, and other experimental hormonal agents (ARN509,
             orteronel [TAK-700], etc.), sipuleucel-T (Provenge), other experimental vaccines
             (PROSTVAC-V/F, etc.), strontium-89, samarium, and radium-223 chloride

          -  Leukocytes > 3,000/mcL

          -  Absolute neutrophil count > 1,500/mcL

          -  Platelets > 125,000/mcL

          -  Hemoglobin >= 5.59 mmol/L or 9 g/dL; up to 5% deviation is tolerated; transfusions and
             growth factors are allowed

          -  Total bilirubin within normal institutional limits

          -  Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT]) < 3 X
             institutional upper limit of normal

          -  Alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]) < 3 X
             institutional upper limit of normal

          -  Creatinine within normal institutional limits OR creatinine clearance > 60 mL/min/1.73
             m^2 for patients with creatinine levels above institutional normal

          -  Ability to understand a written informed consent document, and the willingness to sign
             it

          -  Life expectancy of at least 12 weeks

          -  Able to swallow and retain oral medication

        Exclusion Criteria:

          -  Untreated brain metastases; brain metastases =< 1 cm and not associated with any focal
             neurologic deficits are allowed

          -  Prior docetaxel or other chemotherapy for mCRPC; patients who have received docetaxel
             for metastatic hormone-sensitive prostate cancer are eligible

          -  Active or symptomatic viral hepatitis or chronic liver disease

          -  Clinically significant heart disease as evidenced by myocardial infarction, or
             arterial thrombotic events in the past 6 months, severe or unstable angina, or New
             York Heart Association (NYHA) class II-IV heart disease or known cardiac ejection
             fraction measurement of < 50 % at baseline

          -  Patients with significantly diseased or obstructed gastrointestinal tract or
             uncontrolled vomiting or diarrhea or other gastrointestinal disorders (medical
             disorders or extensive surgery) that may interfere with the absorption of the study
             agents

          -  Pure small cell carcinoma of the prostate or any mixed histology cancer of the
             prostate (eg: neuroendocrine) that contains < 50% adenocarcinoma, as observed on
             biopsy obtained at the time of diagnosis or on any subsequent biopsies

          -  Any ?currently active? second malignancy, other than non-melanoma skin cancer;
             patients are not considered to have a ""currently active? malignancy, if they have
             completed therapy and are considered by their physician to be at least less than 30%
             risk of relapse over next year

          -  Any condition, which in the opinion of the investigator, would preclude participation
             in this trial

          -  Active psychiatric illnesses/social situations that would limit compliance with
             protocol requirements

          -  Patients in whom urgent treatment with docetaxel is indicated, per clinician
             discretion; this includes, but is not limited to patients with symptomatic visceral
             metastatic disease

          -  Uncontrolled infection or concomitant medical illness that is not adequately
             controlled with current medical management, as determined per clinician discretion

          -  Active bleeding disorders or evidence of evidence of chronic or acute disseminated
             intravascular coagulation (DIC)

          -  Severely compromised immunological state, including known human immunodeficiency virus
             (HIV)

          -  Any acute toxicities due to prior anti-cancer treatments and/or radiotherapy that have
             not resolved to a National Cancer Institute (NCI) Common Terminology Criteria for
             Adverse Events (CTCAE) grade of =< 1 (except alopecia)

          -  Prior radiation therapy completed < 3 weeks or single fraction of palliative
             radiotherapy < 14 days prior to first dose of KPT-330 (selinexor)

          -  Initiation of bisphosphonate therapy < 4 weeks prior to first dose of KPT-330;
             patients receiving bisphosphonate or denosumab therapy must be on stable doses for at
             least 4 weeks prior to first dose of KPT-330

          -  Men unable or unwilling to employ 2 forms of highly effective contraception throughout
             the study and for 8 weeks after the end of study treatment
      "
NCT02216149,terminated,"
    slow accrual
  ",0,phase 2,"['esophagus cancer', 'stomach cancer', 'small bowel cancer', 'colon cancer', 'rectum cancer']","[""['D13.0', 'C15.9', 'C15.3', 'C15.4', 'C15.5', 'C15.8', 'Z85.01']"", ""['D13.1', 'C16.9', 'C16.1', 'C16.2', 'D37.1', 'C16.8', 'C16.5']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['C18.2', 'C18.4', 'C18.6', 'C18.7', 'C18.9', 'D12.2', 'D12.3']"", ""['C20', 'D12.8', 'D37.5', 'C78.5', 'Z12.12', 'C21.8', 'Z85.048']""]","['s-1', 'capecitabine', 'oxaliplatin']","['CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O', 'C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]']","
        Inclusion Criteria:

          -  Has given written informed consent.

          -  Is at least 18 years of age.

          -  Has advanced or metastatic gastrointestinal tract adenocarcinoma.

          -  No previous cancer chemotherapy for cancer.

          -  Measurable or evaluable lesions according to RECIST v1.1 criteria.

          -  Is able to take medications orally.

          -  Has ECOG performance status 0 or 1.

          -  Has a life expectancy of at least 3 months.

          -  Has adequate organ function.

        Exclusion Criteria:

          -  Cancer considered operable without prior chemotherapy.

          -  Prior chemotherapy to cancer.

          -  Previous therapy with fluoropyrimidines or anthracyclines for any indication.

          -  Inability to swallow tablets.

          -  Known brain metastasis or leptomeningeal metastasis.

          -  History of myocardial infarction, coronary stenting/graft.

          -  History of unstable angina, coronary/peripheral artery bypass graft.

          -  History of cerebrovascular accident or transient ischemic attack.

          -  History of pulmonary embolism or deep vein thrombosis.

          -  Symptomatic congestive heart failure.

          -  Ongoing cardiac dysrhythmias.

          -  Patients with any cardiac disease that requires regular medication.

          -  Hypertensive crisis or severe hypertension that is not controlled.

          -  Is a pregnant or lactating female.

          -  The cardiac arterial flow tests cannot be done.
      "
NCT02213744,terminated,"
    felt not to show benefit over control per dmc and confirmed via futility analysis
  ",0,phase 2/phase 3,"['breast cancer', 'her2 positive breast cancer']","[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['mm-302', 'gemcitabine', 'capecitabine', 'vinorelbine', 'trastuzumab']","['C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F', 'CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O', 'CCC1=CC2CC(C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC']","
        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed invasive cancer of the
             breast

          -  Patients must have documented locally advanced/metastatic disease, defined by the
             investigator, which is not amenable to resection with curative intent.

          -  Patients must have HER2-positive breast cancer as defined by ASCO/CAP 2013 guidelines
             that is confirmed by a Sponsor-designated central laboratory

          -  Patients must have progressed on, or be intolerant to pertuzumab in the LABC/MBC
             setting or had disease recurrence within 12 months of pertuzumab treatment in the
             neoadjuvant or adjuvant setting.

          -  Patients must have progressed on, or be intolerant to ado-trastuzumab emtansine in the
             LABC/MBC setting

          -  Patients must have been previously treated with trastuzumab in any setting (which may
             have been previously administered with or without pertuzumab)

          -  ECOG Performance Status of 0 or 1

        Exclusion Criteria:

          -  Patients who have previously been treated with doxorubicin, liposomal doxorubicin,
             epirubicin, mitoxantrone, or any other anthracycline derivative

          -  Subjects with central nervous system (CNS) metastases, unless they have been treated
             and are stable without symptoms for 4 weeks after completion of treatment and must be
             off steroids for at least 4 weeks prior to enrollment

          -  Patients with any class of New York Heart Association (NYHA) CHF or heart failure with
             preserved ejection fraction (HFPEF)

          -  Patients with a history of known coronary artery disease or a myocardial infarction
             within the last 12 months

          -  Patients with a known history of serious cardiac arrhythmias requiring treatment
             (exception: controlled atrial fibrillation, paroxysmal supraventricular tachycardia)

          -  Patients who previously discontinued trastuzumab due to unacceptable cardiac toxicity

          -  Patients with a history of LVEF decline to below 50% during or after prior
             trastuzumab/lapatinib or other HER2 directed therapy.
      "
NCT02213133,terminated,"
    due to enrollment challenges and availability of other options for lung cancer patients. the
    termination is not a consequence of any safety concern.
  ",0,phase 2,['squamous cell carcinoma'],"[""['C44.520', 'C44.92', 'C44.02', 'C44.321', 'C44.521', 'C44.82', 'C44.42']""]",['selinexor (kpt-330)'],['C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F'],"
        Inclusion Criteria:

          -  18 years of age or older

          -  confirmed SCC of the head and neck, lung, or esophagus

          -  1 to 2 prior therapies

          -  measurable disease at screening and documented progression within the past 6 weeks

        Exclusion Criteria:

          -  patients requiring total parenteral nutrition

          -  unstable cardiovascular function

          -  substantially impaired gastrointestinal function

          -  Symptomatic brain metastases

          -  another malignancy within 3 years except adequately treated in situ carcinoma of any
             type, basal or non-melanomatous skin cancer
      "
NCT02212197,completed,,1,phase 2,['prostate cancer'],"[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]","['leuprolide acetate fluidcrystal® injection depot', 'leuprolide acetate']",['CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O'],"
        Inclusion Criteria:

          -  Men ≥40 and ≤85 years of age

          -  Histological or cytological proven adenocarcinoma of the prostate requiring hormone
             therapy

          -  Life expectancy over 12 months

          -  World Health Organisation/ The Eastern Cooperative Oncology Group (WHO/ECOG)
             performance status of 0, 1 or 2

          -  Adequate and stable renal function

          -  Adequate and stable hepatic function

        Exclusion Criteria:

          -  Evidence of brain metastasis, spinal cord compression, or urinary tract obstruction

          -  Serum Testosterone levels below 150 ng/dL at Screening visit

          -  Medical or radiological prostate cancer treatments within 2 months prior to the
             Screening visit

          -  Surgical treatment of prostate cancer within 2 weeks prior to the Screening visit

          -  Prior orchiectomy, hypophysectomy, or adrenalectomy

          -  Prior use of LHRH agonists within 12 months prior to the Screening visit and during
             the study
      "
NCT02674568,completed,,0,phase 2,['small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]",['rovalpituzumab tesirine'],['CC1=CN2C(C1)C=NC3=CC(=C(C=C3C2=O)OC)OCCCCCOC4=C(C=C5C(=C4)N(C(C6CC(=CN6C5=O)C)O)C(=O)OCC7=CC=C(C=C7)NC(=O)C(C)NC(=O)C(C(C)C)NC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCNC(=O)CCN8C(=O)CC(C8=O)SCC(C(=O)O)N)OC'],"
        Inclusion Criteria:

          1. Adult aged 18 years or older

          2. Histologically confirmed SCLC with documented disease progression after at least 2
             prior systemic regimens, including at least one platinum-based regimen

          3. DLL3-expressing SCLC based on central immunohistochemistry (IHC) assessment of banked
             or otherwise representative tumor tissue. Positive is defined as staining in ≥ 1% of
             tumor cells

          4. Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)
             version 1.1

          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          6. Minimum life expectancy of at least 12 weeks

          7. Subjects with a history of central nervous system (CNS) metastases must have
             documentation of stable or improved status based on brain imaging for at least 2 weeks
             after completion of definitive treatment and within 2 weeks prior to first dose of
             study drug, off or on a stable dose of corticosteroids

          8. Recovery to Grade 1 of any clinically significant toxicity (excluding alopecia) prior
             to initiation of study drug administration

          9. Adequate hematologic and organ function as confirmed by laboratory values

         10. Last dose of any prior therapy administered by the following time intervals before the
             first dose of study drug:

               -  Chemotherapy, small molecule inhibitors, radiation, and/or other investigational
                  anticancer agents (excluding investigational monoclonal antibodies): 2 weeks

               -  Immune-checkpoint inhibitors (i.e., anti-PD-1, anti-PD-L1, or anti-CTLA-4): 4
                  weeks

               -  Other monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or
                  T-cell or other cell-based therapies: 4 weeks (2 weeks with documented disease
                  progression)

         11. Females of childbearing potential must have a negative beta human chorionic
             gonadotropin (β-hCG) pregnancy test result within 7 days prior to the first dose of
             study drug. Females of non-childbearing potential are those who are postmenopausal
             greater than 1 year or who have had a bilateral tubal ligation or hysterectomy.

        Exclusion Criteria:

          1. Any significant medical condition, including any suggested by screening laboratory
             findings that, in the opinion of the investigator or sponsor, may place the subject at
             undue risk from the study, including but not necessarily limited to uncontrolled
             hypertension and/or diabetes, clinically significant pulmonary disease (e.g., chronic
             obstructive pulmonary disease requiring hospitalization within 6 months) or
             neurological disorder (e.g., seizure disorder active within 6 months)

          2. Documented history of a cerebral vascular event (stroke or transient ischemic attack),
             unstable angina, myocardial infarction, or cardiac symptoms consistent with New York
             Heart Association (NYHA) Class III-IV within 6 months prior to their first dose of
             study drug

          3. Recent or ongoing serious infection, including:

               -  Any active grade 3 or higher (per National Cancer Institute's Common Terminology
                  Criteria for Adverse Events [NCI CTCAE] version 4.03) viral, bacterial, or fungal
                  infection within 2 weeks of the first dose of the study drug. Routine
                  antimicrobial prophylaxis is permitted.

               -  Known seropositivity for or active infection by human immunodeficiency virus
                  (HIV)

               -  Active Hepatitis B (by surface antigen expression or polymerase chain reaction)
                  or C (by polymerase chain reaction) infection or on hepatitis-related antiviral
                  therapy within 6 months of first dose of study drug.

          4. Women who are breastfeeding

          5. Systemic therapy with corticosteroids at >20 mg/day prednisone or equivalent within 1
             week prior to the first dose of study drug

          6. History of another invasive malignancy that has not been in remission for at least 3
             years. Exceptions to the 3 year limit include nonmelanoma skin cancer, curatively
             treated localized prostate cancer, and cervical cancer in situ on biopsy or squamous
             intraepithelial lesion on pap smear

          7. Prior exposure to a pyrrolobenzodiazepine (PBD)-based drug, or known hypersensitivity
             to rovalpituzumab tesirine or excipient contained in the drug formulation, unless
             undergoing retreatment with rovalpituzumab tesirine in the context of this protocol
      "
NCT02678780,completed,,1,phase 2,['neuroendocrine tumors'],"[""['C7A.1', 'C7A.8', 'C7B.8', 'D3A.8']""]",['lenvatinib'],['COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl'],"
        INCLUSION CRITERIA

        Subjects must meet all of the following criteria to be included in this study:

          1. Subjects must have histologically confirmed diagnosis of one of the following
             advanced/metastatic neuroendocrine tumor types:

               1. WHO Classification G1/G2 (Ki67<20% and mitotic count ≤20 mitoses x 10 HPF)
                  pancreatic neuroendocrine tumor

               2. WHO Classification G1/G2 (Ki67<20% and mitotic count ≤20 mitoses x 10 HPF)
                  gastrointestinal neuroendocrine tumor (including stomach, small intestine and
                  colorectal origins).

          2. Subjects must have evidence of measurable disease meeting the following criteria:

               1. At least 1 lesion of ≥ 1.0 cm in the longest diameter for a non-lymph node, or ≥
                  1.5 cm in the short-axis diameter for a lymph node, which is serially measurable
                  according to RECIST 1.1 (Appendix I) using computerized tomography/magnetic
                  resonance imaging (CT/MRI). If there is only one target lesion and it is a
                  non-lymph node, it should have a longest diameter of ≥ 1.5 cm.

               2. Lesions that have had external beam radiotherapy (EBRT) or loco-regional
                  therapies such as radiofrequency (RF) ablation or liver embolization must show
                  evidence of progressive disease based on RECIST 1.1 to be deemed a target lesion.

          3. Subjects must show evidence of disease progression by radiologic image techniques
             within 12 months (an additional month will be allowed to accommodate actual dates of
             performance of scans, i.e., within ≤ 13 months) prior to signing informed consent,
             according to RECIST 1.1 (Appendix I)

          4. Subjects must meet the following inclusion criterion regarding primary tumor site:

               1. Pancreatic origin: progression after a previous targeted agent (including mTOR
                  inhibitors, such as everolimus or antiangiogenic therapies, such as sunitinib,
                  sorafenib, axitinib, bevacizumab within others). Combination therapies in the
                  same treatment line (such as sorafenib plus bevacizumab, chemotherapy plus
                  antiangiogenic drugs) are considered one treatment line and are allowed to be
                  included in the study. Patients must be treated with only one previous line of
                  targeted agent(s)-based therapy.

                  Previous therapy with somatostatin analogues and/or interferon is allowed and is
                  not considered as a previous targeted agent therapy.

               2. Gastrointestinal origin: progression after therapy with antitumoral doses of
                  somatostatin analogs (octreotide LAR 30 mg every 28 days or Lanreotide 120 mg
                  every 28 days) and/or interferon treatment.

          5. Only for patients with pancreatic origin neuroendocrine tumors, one previous line with
             chemotherapy is allowed.

          6. Concomitant somatostatin analogues are allowed in both cohorts during the study.

          7. Patients with known brain metastases who have completed whole brain radiotherapy,
             stereotactic radiosurgery or complete surgical resection, will be eligible if they
             have remained clinically stable, asymptomatic and off of steroids for at least one
             month.

          8. All prior chemotherapy or radiation-related toxicities must have resolved to < Grade 2
             (following CTCAE V 4.03 grade levels), except alopecia and infertility.

          9. Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of
             0 - 1 (Appendix II).

         10. Previous liver locoregional therapies, such as (chemo) embolization, radiofrequency or
             liver-directed (radio) embolization, or systemic peptide-receptor radionucleotide
             therapy are allowed if the procedure was performed at least 6 months previous the
             informed consent form signature.

         11. Adequately controlled blood pressure with or without antihypertensive medications,
             defined as BP < 150/90 mmHg at screening and no change in antihypertensive medications
             within 1 week prior to the Screening Visit.

         12. Adequate renal function defined as calculated creatinine clearance ≥ 30 mL/min per the
             Cockcroft and Gault formula (Appendix III).

         13. Adequate bone marrow function, defined as:

               1. Absolute neutrophil count (ANC) ≥ 1500/mm3 (≥ 1.5 ×103/μL).

               2. Platelets ≥ 100,000/mm3 (≥ 100 × 109/L).

               3. Hemoglobin ≥ 9.0 g/dL.

         14. Adequate blood coagulation function as evidenced by an International Normalized Ratio
             (INR) ≤ 1.5. Prophylactic low molecular weight heparin therapy is allowed.

         15. Adequate liver function:

               1. Bilirubin ≤ 1.5 × the upper limit of normal (ULN) except for unconjugated
                  hyperbilirubinemia or Gilbert's syndrome.

               2. Alkaline phosphatase, alanine aminotransferase (ALT), and aspartate
                  aminotransferase (AST) ≤ 3 × the ULN (≤ 5 × ULN if subject has liver metastases).

         16. Males or females age ≥ 18 years at the time of informed consent.

         17. All females must have a negative serum or urine pregnancy test (minimum sensitivity 25
             IU/L or equivalent units of beta human chorionic gonadotropin (β-hCG) at the baseline
             visit (and/or within 72h prior to the first dose of study drug).

             Females of childbearing potential must agree to use a highly effective method of
             contraception (e.g., total sexual abstinence*, an intrauterine device, a
             double-barrier method such as condom + spermicide or condom + diaphragm with
             spermicide or have a vasectomized partner with confirmed azoospermia*) throughout the
             entire study period and for 30 days after study drug administration. The only subjects
             who will be exempt from this requirement are postmenopausal women (defined as women
             who have been amenorrheic for at least 12 consecutive months, in the appropriate age
             group, without other known or suspected primary cause) or subjects who have been
             sterilized surgically or who are otherwise proven sterile (i.e., bilateral tubal
             ligation with surgery at least 1 month prior to dosing, hysterectomy, or bilateral
             oophorectomy with surgery at least 1 month prior to dosing).

             The women using oral hormonal contraceptives should add an additional barrier method
             as there is unknown whether lenvatinib may reduce the effectiveness of the hormonal
             contraceptives. All women who are of reproductive potential and who are using hormonal
             contraceptives must have been on a stable dose of the same hormonal contraceptive
             product for at least 4 weeks prior to dosing and must continue to use the same
             contraceptive during the study and for 30 days after study drug discontinuation.

             ** Sexual abstinence will be acceptable only when this is in line with the preferred
             and usual lifestyle of the subject.

         18. Male subjects who are partners of women of childbearing potential must use or their
             partners must use a highly effective method of contraception (e.g., condom +
             spermicide, condom + diaphragm with spermicide, IUD) beginning at least 1 menstrual
             cycle prior to starting study drug(s), throughout the entire study period, and for 30
             days after the last dose of study drug, unless they are sexually abstinent or have
             undergone a successful vasectomy. Those with partners using hormonal contraceptives
             must also be using an additional approved method of contraception, as described
             previously.

         19. Voluntary provision of written informed consent and the willingness and ability to
             comply with all aspects of the protocol.

        EXCLUSION CRITERIA

          1. WHO Classification G3 neuroendocrine tumors of the pancreas and gastrointestinal
             tract.

          2. Two or more prior lines of targeted agents-based therapy in pancreatic origin and any
             previous line of targeted therapy for gastrointestinal origin or any ongoing
             antiproliferative treatment for advanced/metastatic neuroendocrine tumors, with the
             exception of somatostatin analogues therapy.

          3. More than one previous line of chemotherapy in pancreatic neuroendocrine tumors.

          4. Previous chemotherapy in gastrointestinal neuroendocrine tumors.

          5. Prior treatment with lenvatinib.

          6. Subjects who have received any anti-cancer treatment within 21 days or any
             investigational agent within 30 days prior to the first dose of study drug and should
             have recovered from any toxicity related to previous anti-cancer treatment. This does
             not apply to the use of somatostatin analogues for symptomatic therapy.

          7. Major surgery within 3 weeks prior to the first dose of study drug.

          8. Subjects having > 1+ proteinuria on urine dipstick testing will undergo 24h urine
             collection for quantitative assessment of proteinuria. Subjects with urine protein ≥ 1
             g/24h will be ineligible.

          9. Gastrointestinal malabsorption, or any other condition in the opinion of the
             investigator that might affect the absorption of lenvatinib.

         10. Significant cardiovascular impairment: history of congestive heart failure greater
             than New York Heart Association (NYHA) Class II, unstable angina; myocardial
             infarction or stroke within 6 months prior to the first dose of study drug, or cardiac
             arrhythmia requiring medical treatment. The left ventricular ejection fraction in the
             echocardiogram must be of at least 50%.

         11. Prolongation of QTcF interval to > 480 msec.

         12. Bleeding or thrombotic disorders or use of anticoagulants, such as warfarin, or
             similar agents requiring therapeutic international normalized ration (INR) monitoring.
             Treatment with low molecular weight heparin (LMWH) is allowed.

         13. Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to
             the first dose of study drug.

         14. Active infection (any infection requiring treatment).

         15. Active malignancy within the past 5 years (except for definitely treated melanoma
             in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the
             cervix).

         16. Known intolerance or hypersensitivity to the active substance (or any of the
             excipients).

         17. Any medical or other condition which, in the opinion of the investigator, would
             preclude participation in a clinical trial.

         18. Females who are pregnant or breastfeeding.

         19. Documented active alcohol or drug abuse.

         20. Patients with a prior history of non-compliance with medical regimens.
      "
NCT02674204,terminated,"
    closed due to low accrual
  ",0,phase 2,"['breast cancer', 'heart disease', 'cardiotoxicity', 'myocardial dysfunction']","[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['I11.0', 'I11.9', 'I27.1', 'I51.9', 'I09.9', 'I27.9', 'I01.8']"", ""['Q93.81', 'B33.4', 'A36.81', 'A50.54', 'A52.00', 'A52.09', 'B33.24']"", ""['E28.8', 'E28.9', 'E29.8', 'E29.9', 'E31.8', 'E31.9', 'H83.2X3']""]","['atorvastatin', 'placebo']",['CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4'],"
        Inclusion Criteria:

          -  Female patients with newly diagnosed stage 1-3 breast cancer

          -  Histologically confirmed HER2, ER, and PR status

          -  Recommended to undergo trastuzumab treatment, with or without anthracycline. Patients
             will be eligible for up to 3 weeks after starting treatment.

          -  Age minimum 18 years

          -  Able and willing to read, understand, and sign an informed consent form (ICF) and
             medical release form

          -  Willing and able to comply with trial protocol and follow-up

          -  ECOG performance status 0-1 (Karnofsky ≥ 70%)

        Exclusion Criteria:

          -  Prior use of statin medication within the past year

          -  Not using statin medication but is eligible for statin therapy based on the 2013
             ACC/AHA guidelines (LDL cholesterol >190, or LDL <190 and ASCVD risk >7.5%;
             http://tools.acc.org/ASCVD-Risk-Estimator/) and is > 50 years old; or is eligible for
             statin therapy based on the 2013 ACC/AHA guidelines and is 40-50 years old and wishes
             to be placed on statin therapy

          -  History of adverse effects, intolerance, or allergic reactions attributed to statin
             medication

          -  Current use of gemfibrozil, cyclosporine, clarithromycin, itraconazole, erythromycin,
             the hepatitis C protease inhibitor telaprevir, HIV protease inhibitors, colchicine, or
             red yeast rice

          -  Current use of any other investigational agent

          -  Pregnant or intention to get pregnant during the next 18 months. Pregnant women are
             excluded from this study because atorvastatin is a lipid-lowering agent with the
             potential for teratogenic or abortifacient effects, and MRI is contraindicated in
             pregnant women.

          -  History of diabetes, severe lung disease, renal disease (creatinine > 1.8 mg/dL or
             CrCl ≤ 50 mL/min), or hepatic disease (AST and ALT > 3 times upper normal limits)

          -  Abnormal baseline echocardiogram or cardiac MRI (detection of congenital heart
             disease; ischemic heart disease; moderate or severe valvular heart disease;
             cardiomyopathy; EF < 55%)

          -  Previously known or diagnosed heart disease (e.g. congenital; valvular; coronary
             artery disease; history of myocardial infarction or acute coronary syndrome;
             cardiomyopathy, including infiltrative, hypertensive, hypertrophic, dilated,
             constrictive pericarditis, or other cardiomyopathy)

          -  Left ventricular dysfunction (EF < 55%)

          -  Prior non-cardiac illness with an estimated life expectancy < 4 years

          -  Known active infection with HIV

          -  Allergy or contraindication to MRI testing, including claustrophobia, metallic parts
             in body the prohibiting MRI, prior gadolinium contrast reaction, or uncontrolled
             moderate hypertension (sitting blood pressure >160/95 mm Hg with measurements recorded
             on at least 2 occasions).

          -  Has metallic breast expanders in place at the time of screening

          -  Concurrent illness which in the opinion of the investigators would compromise either
             the patient or the integrity of the data
      "
NCT02675231,"active, not recruiting",,1,phase 2,"['hormone receptor positive breast cancer', 'her-2 positive breast cancer']","[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['abemaciclib', 'trastuzumab', 'fulvestrant', 'standard of care single agent chemotherapy']","['CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F', 'CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F']","
        Inclusion Criteria:

          -  diagnosis of HR+, HER2+ breast cancer (BC)

          -  unresectable locally advanced recurrent BC or metastatic BC

          -  adequate tumor tissue available prior to randomization

          -  measurable and/or non-measurable disease according to Response Evaluation Criteria in
             Solid Tumors (RECIST) version 1.1

          -  previously received:

               -  at least 2 HER2-directed therapies for advanced disease

               -  participant must have received trastuzumab emtansine (T-DM1) in any disease
                  setting

          -  must have received a taxane in any disease setting

          -  may have received any endocrine therapy (excluding fulvestrant)

          -  have postmenopausal status due to surgical / natural menopause or chemical ovarian
             suppression

          -  performance status (PS) of 0 to 1 on the Eastern Cooperative Oncology Group scale

          -  left ventricular ejection fraction (LVEF) of 50% or higher at baseline

          -  adequate organ function

          -  negative serum pregnancy test at baseline (within 14 days prior to randomization) and
             agree to use medically approved precautions to prevent pregnancy during the study and
             for 12 weeks following the last dose of abemaciclib if menopause induced by
             gonadotropin-releasing hormone (GnRH) agonist or radiation

          -  discontinued previous localized radiotherapy for palliative purposes or for lytic
             lesions at risk of fracture at least 2 weeks prior to randomization and recovered from
             the acute effects of therapy

          -  discontinued all previous therapies for cancer (including chemotherapy, radiotherapy,
             immunotherapy, and endocrine therapy), except trastuzumab, for at least 21 days for
             myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving
             study drug, and recovered from the acute effects of therapy

          -  are able to swallow capsules

        Exclusion Criteria:

          -  have visceral crisis

          -  known central nervous system (CNS) metastases that are untreated, symptomatic, or
             require steroids to control symptoms

          -  had major surgery within 14 days prior to randomization

          -  received prior treatment with any cyclin-dependent kinase (CDK) 4 and CDK 6 inhibitor

          -  received treatment with a drug that has not received regulatory approval for any
             indication within 14 or 21 days of randomization for a nonmyelosuppressive or
             myelosuppressive agent, respectively

          -  have serious preexisting medical conditions that, in the judgment of the investigator,
             would preclude participation in this study

          -  history within the last 6 months of symptomatic congestive heart failure, myocardial
             infarction, or unstable angina

          -  history within the last 12 months of any of the following conditions: syncope of
             cardiovascular etiology, ventricular tachycardia, ventricular fibrillation, or sudden
             cardiac arrest

          -  history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of
             the cervix), unless in complete remission with no therapy for a minimum of 3 years

          -  active bacterial, fungal infection, or detectable viral infection

          -  have received any recent (within 28 days prior to randomization) live virus
             vaccination

          -  hypersensitivity to trastuzumab, murine proteins, fulvestrant, or to any of the
             excipients
      "
NCT02244502,unknown status,,1,phase 1/phase 2,['ovarian carcinoma'],"[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]",['paclitaxel'],['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C'],"
        Inclusion Criteria:

          1. Histologically or cytologically confirmed ovarian carcinoma, fallopian tube carcinoma
             or primary peritoneal carcinoma

          2. Recurrent ovarian cancer with any number of prior therapies

          3. 18 years of age and older

          4. Life expectancy of at least 12 weeks

          5. Measurable disease according to the revised RECIST criteria version 1.1. A lesion in a
             previously irradiated field is considered ""non-measurable"" and cannot be a ""target
             lesion"".

          6. ECOG score 0-1 (see Appendix A)

          7. Adequate bone marrow, liver and renal functions:

               1. Absolute neutrophil count ≥ 1.5 x 10 9/L

               2. Platelet count ≥ 100 x 10 9/L

               3. Hemoglobin ≥ 10 g/dL

               4. AST and/or ALT ≤ 3 x upper limit of normal range (ULN) or ≤ 5 x ULN if patient
                  has documented liver metastases

               5. Bilirubin ≤1.5 x ULN

               6. Serum creatinine ≤ 1.5 x ULN

               7. Coagulation status: PT and PTT within normal limits or within therapeutic limits
                  for patients receiving anticoagulation.

          8. Able to operate the NovoTTF-100L(O) System independently or with the help of a
             caregiver

          9. No concurrent anti-tumor therapy (beyond weekly paclitaxel and NovoTTF Therapy as per
             protocol)

         10. At least 4 weeks since major surgery

        Exclusion Criteria:

          1. Meningeal carcinomatosis or known brain metastases which have not been treated,
             require steroid treatment, or are symptomatic.

          2. Any other malignancy requiring anti-tumor treatment in the past three years, except
             resected non-melanomatous skin cancer, breast carcinoma in situ, adequately treated
             stage I breast cancer or in situ cervical cancer.

          3. Chemotherapy within 4 weeks prior to treatment start.

          4. Radiotherapy within 4 weeks prior to treatment start.

          5. Significant comorbidity which is expected to affect patient's prognosis or ability to
             receive the combined therapy:

               1. History of significant cardiovascular disease unless the disease is well
                  controlled. Significant cardiac disease includes second/third degree heart block;
                  significant ischemic heart disease; poorly controlled hypertension; congestive
                  heart failure of the New York Heart Association (NYHA) Class II or worse (slight
                  limitation of physical activity; comfortable at rest, but ordinary activity
                  results in fatigue, palpitation or dyspnea).

               2. History of arrhythmia that is symptomatic or requires treatment. Patients with
                  stable atrial fibrillation or flutter controlled by medication are not excluded
                  from participation in the trial.

               3. Active infection or any serious underlying medical condition that would impair
                  the ability of the patient to receive protocol therapy.

               4. History of any psychiatric condition that might impair the patient's ability to
                  understand or comply with the requirements of the study or to provide consent.

          6. Implantable electronic medical devices including pacemaker, implantable automatic
             defibrillator, etc.

          7. Known history of sensitivity to taxanes or drugs containing Cremophor

          8. Grade 2 or greater peripheral neuropathy

          9. Known allergies to medical adhesives or hydrogel

         10. Pregnant or breast feeding
      "
NCT02246049,completed,,1,phase 2,['colorectal neoplasms'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['5-fluorouracil', 'irinotecan hydrochloride', 'leucovorin calcium', 'oxaliplatin']","['C1=C(C(=O)NC(=O)N1)F', 'CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl', 'C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)[O-])C(=O)[O-].[Ca+2]', 'C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]']","
        Inclusion Criteria:

          1. Written Informed consent.

          2. Histopathologically proven diagnosis of colorectal cancer (adenocarcinoma) excluding
             vermiform appendix cancer and proctos cancer.

          3. Not resectable metastatic colorectal cancer

          4. Age at enrollment is >= 20 and <= 75 years

          5. ECOG PS < 2 if age < 70 years, ECOG PS = 0 if age = 71-75 years

          6. One or more measurable lesion in RECIST ver.1.1 criteria according to contrast
             enhanced CT chest / abdomen / pelvis diagnosis.

          7. Not previously treated with chemotherapy. ( Previous adjuvant by fluoropyrimidine
             monotherapy is allowed if more than 24 weeks have elapsed between the end of adjuvant
             therapy and first relapse.)

          8. Vital organ functions (listed below) are preserved within 2 weeks prior to entry. Data
             recorded nearest to the entry should be referred. Blood transfusion or erythropoiesis
             stimulating agents less than 2 weeks prior to the tests are not allowed.

             Neu. >= 1,500/cubicmillimeter Pt. >= 100,000/cubicmillimeter Hb. >= 9.0 g/dL T-bil. <=
             upper limit of normal (ULN)*1.5 AST and ALT,ALP <= upper limit of normal (ULN)*2.5 (<=
             ULN*5 in case of liver metastasis) Serum creatinine <= upper limit of normal (ULN)
             *1.5 PT-INR < 1.5 Proteinuria <= 2+

          9. UGT1A1 genotype tested. Categorized into Wild or single Hetero.

        Exclusion Criteria:

          1. Previously treated with irradiation to bone marrow constituting 20% or more of
             irradiation field.

          2. Untreated brain metastases or spinal cord compression or primary brain tumors.

          3. History of CNS disease.[except for asymptomatic Lacunar stroke]

          4. Requiring chronic systemic corticosteroid treatment.

          5. Current or recent ongoing treatment with anticoagulants.

          6. Clinically significant cardiovascular disease for example cerebrovascular accidents,
             myocardial infarction, unstable angina, congestive heart failure, serious cardiac
             arrhythmia requiring medication.

          7. Treatment with any investigational drug within 4 weeks.

          8. Patient with Uncontrolled hypertension, Uncontrolled diabetes, Uncontrolled diarrhea,
             >=grade 1 peripheral neuropathy, Active peptic ulcer, Non-healing wound, Clinically
             important diseases.

          9. Major surgical procedure within 28 days prior to study treatment start, open biopsy,
             or significant traumatic injury, or anticipation of the need for major surgical
             procedure.[except for implantation of central venous catheter and port system.]

         10. Lack of physical integrity of the upper gastrointestinal tract.

         11. Pregnant women, lactating woman , positive by pregnancy test , wishing to become
             pregnant, and Sexually active males.

         12. Hepatitis B or hepatitis C. Evidence of HIV infection.

         13. Previous Chemotherapy for other organs.

         14. Other active co-existing malignancies.

         15. History / Presence of thrombosis within 1 year requiring medication.

         16. History / Presence of paralytic ileus, obstruction or gastrointestinal perforation.

         17. Malignant coelomic fluid required drainage.

         18. History of allergy to Chinese hamster ovary cell proteins, or any of the components of
             the study medications.

         19. History of fluoropyrimidine severe side effects caused by DPD defect.

         20. Interstitial pneumonitis or pulmonary fibrosis.

         21. Evidence or requiring systemic treatment for Infectious disease.

         22. Patient who is judged by the investigator to be inappropriate for study participation
             for any reason.
      "
NCT02243007,terminated,"
    slow accrual
  ",0,phase 2,"['resectable pancreatic cancer', 'pancreatic ductal carcinoma']","[""['C25.3']""]","['folfirinox', 'gemcitabine/nab-paclitaxel', 'capecitabine']","['CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.C1CCC(C(C1)[NH-])[NH-].C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O.C1=C(C(=O)NC(=O)N1)F.C(=O)(C(=O)[O-])[O-].[Pt+4]', 'Status: 400', 'CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O']","
        Inclusion Criteria:

          -  Cytologic or histologic proof of pancreatic ductal carcinoma is required prior to
             study entry.

          -  No evidence of metastatic disease as determined by chest CT scan, and abdominal CT
             scan (or MRI with gadolinium and/or manganese) and laparoscopy. All patients must be
             staged with a physical exam, chest CT, abdominal CT with intravenous contrast (or
             abdominal MRI with gadolinium and/or manganese). Only potentially resectable patients
             are eligible. Potentially resectable is defined as a) no extrapancreatic disease, b)
             no evidence (on CT) of involvement of the celiac axis or SMA, c) no evidence (CT or
             MRI) of occlusion of the SMV or SMPV confluence, and d) no evidence of gross
             peritoneal or distant metastases by laparoscopy.

          -  Patients must be 18 years old or older. There will be no upper age restriction.

          -  ECOG Performance Status of 0 or 1 are eligible.

          -  Life expectancy of greater than 3 months.

          -  Lab Values:

               -  ANC ≥ 1500 cells/mm3

               -  Platelet count at least 100,000 cells/mm3.

               -  AST and ALT ≤2.5 x upper limit of normal

               -  Total Bilirubin ≤ 5 x upper limit of normal if patient is s/p biliary stenting
                  AND decreasing at least two time points after stenting.

               -  Total Bilirubin ≤ 1.5 x upper limit of normal if no biliary stenting was done

               -  Serum Creatinine ≤1.5mg/dl OR

               -  Creatinine Clearance greater than or equal to 30ml/min (as estimated by Cockroft
                  Gault Equation) (140 - age [yrs]) (body wt [kg])

                    -  Creatinine clearance for males = ------------ (72) (serum creatinine
                       [mg/dL])

                    -  Creatinine clearance for females = 0.85 x male value

          -  The effects of radiation on the developing human fetus are known to be teratogenic.
             Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for
             the duration of study treatment plus 30 days from the last date of study drug
             administration. Should a woman become pregnant or suspect she is pregnant while
             participating in this study, she should inform her treating physician immediately.

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

        Patients who fulfill any of the following criteria will be excluded:

          -  The presence of metastatic disease on imaging or laparoscopy.

          -  Serious concomitant systemic disorders incompatible with the study (at the discretion
             of the investigator), such as significant cardiac or pulmonary morbidity e.g.
             congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias
             not well controlled with medication) or myocardial infarction within the last 12
             months, ongoing infection as manifested by fever.

          -  Pregnant or lactating women. Women of childbearing potential with either a positive or
             no pregnancy test (serum or urine) at baseline. (Postmenopausal woman must have been
             amenorrheic for at least 12 months to be considered of non-childbearing potential).

          -  Any prior chemotherapy or radiation for treatment of the patient's pancreatic tumor.

          -  Diagnosis for other invasive carcinomas (except basal cell carcinoma/squamous cell
             carcinoma of the skin) within the last five years. Carcinoma in-situ is allowed.

          -  Other serious uncontrolled medical conditions that the investigator feels might
             compromise study participation.

          -  Unwillingness to participate or inability to comply with the protocol for the duration
             of the study.

          -  Participation in any investigational drug study within 4 weeks preceding the start of
             study treatment.

          -  History of uncontrolled seizures, central nervous system disorders or psychiatric
             disability judged by the investigator to be clinically significant, precluding
             informed consent, or interfering with compliance or oral drug intake.

          -  Major surgery, excluding laparoscopy, within 4 weeks of the start of study treatment,
             without complete recovery.
      "
NCT02494713,terminated,"
    slow enrollment; resource re-allocation
  ",0,phase 2,['prostate cancer'],"[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]","['degarelix', 'doxorubicin', 'ketoconazole', 'docetaxel', 'estramustine']","['CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)NC(=O)N)NC(=O)C(CC3=CC=C(C=C3)NC(=O)C4CC(=O)NC(=O)N4)NC(=O)C(CO)NC(=O)C(CC5=CN=CC=C5)NC(=O)C(CC6=CC=C(C=C6)Cl)NC(=O)C(CC7=CC8=CC=CC=C8C=C7)NC(=O)C', 'CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O', 'CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O', 'CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)OC(=O)N(CCCl)CCCl']","
        Inclusion Criteria:

          -  Pathologic proof of prostatic adenocarcinoma without evidence of regional and/or
             distant metastasis, clinical stage T1c or T2a with high grade disease (Gleason 8-10)
             on initial biopsy, clinical stage T2b-T2c with Gleason grade 7 (4+3), or clinical
             stage T3. No neuroendocrine differentiation or small cell features.

          -  Recent (<6 weeks prior to study entry) negative bone scan and CT of the chest and
             abdomen.

          -  Appropriate surgical candidate for radical prostatectomy and a performance status of
             <2 (ECOG scale).

          -  Adequate bone marrow function as defined as an absolute peripheral granulocyte count
             >1500 and platelet count >100,000.

          -  Adequate hepatic function per the following criteria:

               -  Albumin ≥2.8 g/dL

               -  AST and ALT ≤5 x ULN

               -  Total bilirubin <2 mg/dL

          -  Adequate renal function per the following criteria:

             o Serum creatinine ≤1.5 x ULN

          -  Normal coagulation profile (INR ≤ 1.5, aPTT ≤ 1.5 x ULN for the lab) and no history of
             substantial non-iatrogenic bleeding diatheses. Use of anticoagulants is limited to
             local use only (for control of central line patency).

          -  Age ≥ 18 years

          -  Written informed consent to participate in this study.

        Exclusion Criteria:

          -  Prostatic adenocarcinoma with neuroendocrine differentiation or small cell features

          -  Surgical resection or major surgery within 4 weeks or stereotactic biopsy within 1
             week of first ADT and chemotherapy treatment

          -  Previous or current hormonal treatment, chemotherapy, radiation therapy,
             immunotherapy, or investigational study drug.

          -  Unable to tolerate multiparametric MRI or is contraindicated.

          -  Patients not appropriate surgical candidates for radical prostatectomy based on the
             evaluation of coexistent medical diseases and competing causes of death.

          -  Patients with uncontrolled cardiac, hepatic, renal, or neurologic/psychiatric
             disorder.

          -  Severe gastrointestinal bleeding within 12 weeks of treatment with ADT and
             chemotherapy

          -  Patients who are HIV positive or have chronic hepatitis B or C infections.

          -  Congestive heart failure New York Heart Association (NYHA) class 3 or 4, or history of
             congestive heart failure New York Heart Association (NYHA) class 3 or 4, unless a 2D
             echocardiogram or multi-gated acquisition scan (MUGA) performed within 3 months of
             enrollment demonstrates a left ventricular ejection fraction >45%.

          -  Sensory neuropathy grade >1.

          -  History of another malignancy within the previous 5 years other than curatively
             treated non-melanoma skin cancer.

          -  Use of herbal products that may decrease PSA levels (e.g., saw palmetto) or systemic
             corticosteroids greater than the equivalent of 10 mg of prednisone per day within 4
             weeks of enrollment.

          -  Any other condition, including concurrent medical condition, social circumstance or
             drug dependency, which in the opinion of the investigator could compromise patient
             safety and/or compliance with study requirements
      "
NCT02495233,terminated,"
    study terminated due to adverse events related to the combination therapy
  ",0,phase 1/phase 2,['non-small-cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['gilteritinib', 'erlotinib']","['CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5', 'COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC']","
        IInclusion Criteria:

          -  Participant had histologically or cytologically confirmed metastatic or locally
             advanced, unresectable non-small-cell lung cancer (NSCLC).

          -  Participant had a documented exon 19 deletion or exon 21 L858R EGFR activating
             mutation.

          -  Participant had received prior treatment with any EGFR tyrosine kinase inhibitor

          -  Participant had Eastern Cooperative Oncology Group (ECOG) performance status of less
             than or equal to 2 at screening.

          -  Participant had adequate organ function.

          -  Female participant must either:

               -  Be of nonchildbearing potential:

               -  Or, if of childbearing potential,

                    1. Agree not to try to become pregnant during the study and for 45 days after
                       the final study drug administration

                    2. And had a negative serum pregnancy test at screening

                    3. And, if heterosexually active, agreed to consistently use 2 forms of highly
                       effective birth control

          -  Male participant and their female spouse/partners who were of childbearing potential
             must be using highly effective contraception consisting of 2 forms of birth control

          -  Phase 1b Participants only:

               -  Participant was not expected to show a therapeutic response to existing available
                  treatment.

               -  Intervening anticancer treatment subsequent to the EGFR TKI was allowed (but not
                  required).

          -  Additional inclusion criteria for phase 2 Participants only:

               -  Participant had a NSCLC tissue sample obtained after participant developed
                  resistance to EGFR TKI therapy that was available for central testing.

               -  Participant's baseline tumor specimen (obtained after participant developed
                  resistance to EGFR TKI therapy) is T790M negative.

               -  Participant received an EGFR TKI for at least 6 months and progressed on this
                  therapy within the past 28 days.

               -  Participant had not had any intervening anticancer treatment subsequent to the
                  EGFR TKI with the exception of radiotherapy which was allowed if it occurred at
                  least 14 days prior to the first dose of study drug.

               -  Participant had at least 1 measureable lesion (not including any lesion that was
                  irradiated) based on Response Evaluation Criteria in Solid Tumors (RECIST)
                  version 1.1.

        Exclusion Criteria:

          -  Participant had an ongoing toxicity greater than or equal to grade 3 (NCI CTCAE
             version 4.03) attributable to prior NSCLC treatment at the time of screening.

          -  Participant received any agent with antitumor activity (other than an EGFR inhibitor,
             including a T790M inhibitor) including chemotherapy, radiotherapy, immunotherapy,
             within 14 days prior to the first dose of study drug (palliative radiotherapy is
             allowed).

          -  Participant received ASP2215 previously.

          -  Participant received blood transfusions or hematopoietic growth factor therapy within
             14 days prior to the first dose of study drug.

          -  Participant had a major surgical procedure (other than study-related biopsy) within 14
             days prior to the first dose of study drug, or a major surgical procedure was planned
             to occur during the study.

          -  Participant had active hepatitis B or C or other active hepatic disorder.

          -  Participant t was known to have human immunodeficiency virus (HIV) infection.

          -  Participant had symptomatic central nervous system (CNS) metastasis. Participants with
             asymptomatic, untreated CNS metastases were allowed. Participants with previously
             treated and currently asymptomatic CNS metastases were eligible provided they met the
             following:

               -  Any whole brain radiotherapy (WBRT) was completed at least 2 weeks prior to the
                  first dose of study drug.

               -  Any stereotactic radiosurgery (SRS) was completed at least 1 week prior to the
                  first dose of study drug.

               -  Participant did not require steroids or did not require escalating doses of
                  steroids for at least 2 weeks prior to the first dose of study drug.

          -  Participant had evidence of active infection requiring systemic therapy within 14 days
             prior to the first dose of study drug.

          -  Participant had uncontrolled hypertension.

          -  Participant had severe or uncontrolled systemic diseases or active bleeding diatheses.

          -  Participant had history of drug-induced interstitial lung disease or any evidence of
             active interstitial lung disease.

          -  Participant had ongoing cardiac arrhythmia (including atrial fibrillation) that was
             grade ≥ 2.

          -  Participant currently had Class 3 or 4 New York Heart Association congestive heart
             failure.

          -  Participant had history of severe/unstable angina, myocardial infarction or
             cerebrovascular accident within 6 months prior to the first dose of study drug.

          -  Participant had history of gastrointestinal ulcer within 28 days prior to the first
             dose of study drug.

          -  Participant had a history of gastrointestinal bleeding within 90 days prior to the
             first dose of study drug.

          -  Participant had concurrent corneal disorder or any ophthalmologic condition which
             makes the participant unsuitable for study participation .

          -  Participant had any condition which made the participant unsuitable for study
             participation.

          -  Participant had hypokalemia or hypomagnesemia at screening.

          -  Participant had QTcF interval > 450 ms on 12-lead ECG at screening.

          -  Participant was known to have long QT syndrome.

          -  Participant was taking medication known to prolong the QT interval.
      "
NCT02499120,completed,,1,phase 2,['squamous cell carcinoma of the head and neck (scchn)'],"[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]","['palbociclib', 'cetuximab', 'placebo']",['CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C'],"
        Key Inclusion Criteria:

          -  Histologically or cytologically confirmed squamous cell carcinoma of the oral cavity,
             oropharynx, hypopharynx or larynx, not amenable for salvage surgery or radiotherapy.

          -  Measurable disease as defined per RECIST v. 1.1. Tumor lesions previously irradiated
             or subjected to other locoregional therapy will only be deemed measureable if disease
             progression at the treated site after completion of therapy is clearly documented.

          -  HPV- negative SCCHN tumor as determined per institutional standard (eg, p16 IHC;
             multiplex nucleic acid sequence based amplification [NASBA] or other polymerase chain
             reaction [PCR]-based assays).

          -  Documented progressive disease according to RECIST v1.1 (Appendix 2) following receipt
             of at least 2 cycles of one platinum-containing chemotherapy regimen administered for
             R/M disease (min. 50 mg/m2 for cisplatin, minimum area under the curve [AUC] > 4 for
             carboplatin).

          -  Availability of a tumor tissue specimen (ie, archived formalin fixed paraffin embedded
             tissue [block preferred, or 15 unstained slides]), which will be used for centralized,
             retrospective biomarker analysis. If archived tumor tissue is not available, then a de
             novo biopsy will be required for patient participation.

        Key Exclusion Criteria:

          -  Prior nasopharyngeal cancer, salivary gland or sinus tumors.

          -  More than one chemotherapeutic regimen given for R/M disease. Prior treatment with
             immunotherapy is allowed.

          -  Known active uncontrolled or symptomatic central nervous system (CNS) metastases,
             carcinomatous meningitis, or leptomeningeal disease as indicated by clinical symptoms,
             cerebral edema, and/or progressive growth. Patients with a history of CNS metastases
             or cord compression are eligible if they have been definitively treated with local
             therapy (eg, radiotherapy, stereotactic surgery) and are clinically stable off
             anticonvulsants and steroids for at least 4 weeks before randomization.

          -  Progressive disease within 3 months after completion of curatively intended treatment
             for locoregionally advanced SCCHN.

          -  Difficulty swallowing capsules.

          -  Prior use of cetuximab in the R/M disease treatment setting (except cetuximab during
             curative radiotherapy)
      "
NCT02499770,completed,,1,phase 1/phase 2,['small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['carboplatin', 'placebo', 'trilaciclib', 'etoposide']","['C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]', 'CN1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6', 'CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O']","
        Inclusion Criteria:

          -  Male or female subjects aged ≥18 years

          -  Unequivocally confirmed diagnosis of SCLC by histology or cytology, preferably
             including the presence of neuroendocrine features by immunohistochemistry

          -  At least 1 target lesion that is unirradiated and measurable by RECIST, Version 1.1

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2

          -  Adequate organ function

        Exclusion Criteria:

          -  Prior chemotherapy for extensive-stage SCLC

          -  Presence of symptomatic brain metastases requiring immediate treatment with radiation
             therapy or steroids.

          -  Uncontrolled ischemic heart disease or uncontrolled symptomatic congestive heart
             failure

          -  Known history of stroke or cerebrovascular accident within 6 months prior to
             enrollment

          -  Other uncontrolled serious chronic disease or conditions that in the investigator's
             opinion could affect compliance or follow-up in the protocol

          -  Concurrent radiotherapy to any site or radiotherapy within 2 weeks prior to enrollment
             or previous radiotherapy to the target lesion sites (the sites that are to be followed
             for determination of a response)

          -  Receipt of any investigational medication within 4 weeks prior to enrollment
      "
NCT03644589,withdrawn,"
    no participants enrolled.
  ",0,phase 2,"['estrogen receptor negative', 'her2/neu negative', 'metastatic breast cancer', 'progesterone receptor negative', 'recurrent breast carcinoma', 'triple negative breast cancer']","[""['Z17.1']"", ""['A41.50', 'A41.59', 'E70.320', 'Z17.1', 'Z67.11', 'Z67.21', 'Z67.31']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['Z17.0', 'Z17.1', 'T47.0X6S', 'T50.7X6S', 'T47.0X3S', 'T47.0X4S', 'T47.0X5S']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]",['cisplatin'],['N.N.Cl[Pt]Cl'],"
        Inclusion Criteria:

          -  Have histologically confirmed diagnosis of metastatic or locally recurrent and
             inoperable triple negative breast cancer (estrogen receptor [ER] < 10%, progesterone
             receptor [PR] < 10% and HER2 negative by IHC or fluorescence in situ hybridization
             [FISH]).

          -  Be willing and able to provide written informed consent for the trial.

          -  Have measurable disease based on RECIST 1.1.

          -  Be willing to provide tissue from a newly obtained core or excisional biopsy of a
             tumor lesion. Newly-obtained is defined as a specimen obtained up to 6 weeks (42 days)
             prior to initiation of treatment on day 1. Participants for whom newly-obtained
             samples cannot be provided (e.g. inaccessible or participant safety concern) may
             submit an archived specimen only upon agreement from the principal investigator. *
             Participants that are screening for second course phase (retreatment period) do not
             need to comply with the tumor tissue collection eligibility criteria.

          -  Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)
             performance scale. Evaluation of ECOG is to be performed within 10 days prior to the
             date of treatment initiation.

          -  Absolute neutrophil count (ANC) >= 1500/uL, performed within 10 days of treatment
             initiation.

          -  Platelets >= 100 000/uL, performed within 10 days of treatment initiation.

          -  Hemoglobin >= 9.0 g/dL or >= 5.6 mmol/L, performed within 10 days of treatment
             initiation.

          -  Creatinine =< 1.5 x upper limit of normal (ULN) OR measured or calculated creatinine
             clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or
             creatinine clearance [CrCl]) >= 30 mL/min for participant with creatinine levels > 1.5
             x institutional ULN, performed within 10 days of treatment initiation.

          -  Total bilirubin =< 1.5 x ULN OR direct bilirubin =< ULN for participants with total
             bilirubin levels > 1.5 x ULN, performed within 10 days of treatment initiation.

          -  Aspartate aminotransferase (AST) serum glutamic oxaloacetic transaminase ([SGOT]) and
             alanine aminotransferase (ALT) serum glutamate pyruvate transaminase ([SGPT]) =< 2.5 x
             ULN (=< 5 x ULN for participants with liver metastases), performed within 10 days of
             treatment initiation.

          -  International normalized ratio (INR) OR prothrombin time (PT) =< 1.5 x ULN unless
             participant is receiving anticoagulant therapy as long as PT or activated partial
             thromboplastin time (aPTT) is within therapeutic range of intended use of
             anticoagulants, performed within 10 days of treatment initiation.

          -  Activated partial thromboplastin time (aPTT) =< 1.5 x ULN unless participant is
             receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of
             intended use of anticoagulants, performed within 10 days of treatment initiation.

          -  Female participants of childbearing potential should have a negative serum pregnancy
             test performed at the screening visit and a urine pregnancy test performed on cycle 1
             day 1 (within 72 hours of receiving the first dose of study medication). If the urine
             test is positive or cannot be confirmed as negative, a serum pregnancy test will be
             required.

          -  A female participant is eligible to participate if she is not pregnant, not
             breastfeeding, and at least one of the following conditions applies: * Not a woman of
             childbearing potential (WOCBP), OR * A WOCBP who agrees to follow the contraceptive
             guidance during the treatment period and for at least 120 days after the last dose of
             study treatment. ** Note: abstinence is acceptable if this is the usual lifestyle and
             preferred contraception for the participant.

          -  A male participant must agree to use a contraception during the treatment period and
             for at least 120 days after the last dose of study treatment and refrain from donating
             sperm during this period. * Note: abstinence is acceptable if this is the usual
             lifestyle and preferred contraception for the participant.

        Exclusion Criteria:

          -  Has received greater than 3 lines of cytotoxic chemotherapy for metastatic breast
             cancer.

          -  Documented disease progression on prior cisplatin therapy.

          -  Is currently participating in or has participated in a study of an investigational
             agent or using an investigational device within 4 weeks of the first dose of
             treatment. * Note: participants who have entered the follow-up phase of an
             investigational study may participate as long as it has been 4 weeks after the last
             dose of the previous investigational agent.

          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
             (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
             immunosuppressive therapy within 7 days prior to the first dose of study drug.

          -  Has had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not
             recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents
             administered more than 4 weeks earlier.

          -  Has received prior systemic anti-cancer therapy including investigational agents
             within 2 weeks prior to first dose of study treatment. * Note: participants must have
             recovered from all adverse events (AEs) due to previous therapies to =< grade 1 or
             baseline. Participants with =< grade 2 neuropathy may be eligible. * Note: if
             participant received major surgery, they must have recovered adequately from the
             toxicity and/or complications from the intervention prior to starting study treatment.

          -  Has a known additional malignancy that is progressing or requires active treatment.
             Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the
             skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that has
             undergone potentially curative therapy.

          -  Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis. Participants with previously treated brain metastases may participate
             provided they are radiologically stable, i.e. without evidence of progression for at
             least 4 weeks by repeat imaging (note that the repeat imaging should be performed
             during study screening), clinically stable and without requirement of steroid
             treatment for at least 14 days prior to first dose of study treatment.

          -  Has severe hypersensitivity (>= grade 3) to pembrolizumab and/or any of its
             excipients.

          -  Has received prior radiotherapy within 2 weeks of start of study treatment.
             Participants must have recovered from all radiation-related toxicities, not require
             corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted
             for palliative radiation (=< 2 weeks of radiotherapy) to non-CNS disease.

          -  Has active autoimmune disease that has required systemic treatment in the past 2 years
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive
             drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
             form of systemic treatment.

          -  Has a history of (non-infectious) pneumonitis that required steroids or has current
             pneumonitis.

          -  Has an active infection requiring systemic intravenous therapy.

          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the participant's
             participation for the full duration of the trial, or is not in the best interest of
             the participant to participate, in the opinion of the treating investigator.

          -  Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial.

          -  A WOCBP who has a positive urine pregnancy test within 72 hours prior to first dose of
             study treatment. If the urine test is positive or cannot be confirmed as negative, a
             serum pregnancy test will be required.

          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the pre-screening or screening visit
             through 120 days after the last dose of trial treatment.

          -  Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with
             an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g.,
             CTLA-4, OX 40, CD137).

          -  Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies).

          -  Has a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg]
             reactive) or known active hepatitis C virus (defined as hepatitis C virus [HCV]
             ribonucleic acid (RNA) [qualitative] is detected) infection. * Note: no testing for
             hepatitis B and hepatitis C is required unless mandated by local health authority.

          -  Has received a live vaccine within 30 days prior to the first dose of trial treatment.
      "
NCT03649841,terminated,"
    terminated due to low accrual.
  ",0,phase 2,"['castration-sensitive prostate carcinoma', 'metastatic malignant neoplasm in the bone', 'metastatic prostate carcinoma', 'prostate adenocarcinoma', 'prostate small cell neuroendocrine carcinoma', 'stage iv prostate cancer ajcc v8', 'stage iva prostate cancer ajcc v8', 'stage ivb prostate cancer ajcc v8']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']"", ""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']"", ""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]","['antiandrogen therapy', 'abiraterone acetate', 'prednisone']","['CC(=O)OC1CCC2(C3CCC4(C(C3CC=C2C1)CC=C4C5=CN=CC=C5)C)C', 'CC12CC(=O)C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C']","
        Inclusion Criteria:

          -  Pathologically proven (either histologic or cytologic) diagnosis of prostate
             adenocarcinoma with < 50% neuroendocrine differentiation or small cell histology.

          -  At least one site of nodal or distant metastatic disease that is measurable by
             Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, or a bony
             metastasis that is evaluable on both computed tomography (CT) and bone scan.

          -  No prior orchiectomy.

          -  No androgen deprivation therapy such as treatment with antiandrogens, luteinizing
             hormone-releasing hormone (LHRH) agonists or antagonists for at least one year prior
             to trial enrollment, and testosterone must be inside normal range prior to trial
             enrollment if there is prior history of ADT.

          -  No other systemic anti-cancer therapy for at least 1-year prior to enrollment.

          -  Prior prostate-directed therapies such as prostatectomy or cryotherapy are allowed.

          -  Prior radiation treatments are allowed (prostate or metastatic sites) but must have
             been completed at least 3 months prior to starting ADT for this trial.

          -  White blood cell (WBC) > 3000/mm^3.

          -  Absolute neutrophil count (ANC) > 1000/mm^3.

          -  Platelets > 100,000/mm^3.

          -  Creatinine < 1.5 institutional upper limit of normal (ULN) or calculated creatinine
             clearance > 30 ml/min.

          -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin
             < 3 x institutional ULN (unless patient has documented Gilbert's syndrome).

          -  No steroids for at least 2 weeks prior to enrollment, and patient must not be expected
             to require steroids during the study period, other than the typical low dose steroid
             that is given with abiraterone (typically prednisone or prednisolone at 5 mg twice
             daily).

          -  Zubrod performance status 0-2.

          -  Patient must sign study specific informed consent prior to study entry.

          -  Men who are sexually active must use medically acceptable forms of contraception.

        Exclusion Criteria:

          -  Other illnesses with a life expectancy of less than 6 months, including but not
             limited to unstable angina, symptomatic congestive heart failure, cardiac arrhythmias.

          -  Psychological or social issues that would prevent patients from informed consent or
             complying with study requirements.

          -  Subject has a history of unexplained loss of consciousness or transient ischemic
             attack within 12 months of treatment start.

          -  Individuals on active treatment for a different cancer are excluded. Individuals with
             a history of other malignancies are eligible if they are deemed by the investigator to
             be at low risk for recurrence of that malignancy.

          -  Known brain metastasis.

          -  Known allergies, hypersensitivity, or intolerance to abiraterone or prednisone.

          -  Prior ADT less than a year, or greater than two months, prior to trial enrollment or
             prior ADT with testosterone less than normal.

          -  There is a potential drug interaction when abiraterone is concomitantly used with a
             CYP2D6 substrate narrow therapeutic index (e.g., thioridazine, dextromethorphan), or
             strong CYP3A4 inhibitors (e.g., atazanavir, erythromycin, indinavir, itraconazole,
             ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and
             voriconazole) or strong inducers (e.g., carbamazepine, phenobarbital, phenytoin,
             rifabutin, rifampin, rifapentine). Caution should be used when patients are on one of
             these drugs.

          -  Patients with a history of pituitary or adrenal dysfunction, active or symptomatic
             viral hepatitis, human immunodeficiency virus (HIV), or chronic liver disease are not
             eligible.

          -  Any chronic medical condition requiring a higher dose of corticosteroid than 10 mg
             prednisone/prednisolone once daily.
      "
NCT01975935,completed,,1,phase 2,"['diabetes mellitus type 2', 'non-alcoholic fatty liver disease', 'obesity']","[""['E11.65', 'E11.9', 'E11.21', 'E11.36', 'E11.41', 'E11.42', 'E11.44']"", ""['Z52.6', 'K71.8', 'K71.7', 'A06.4', 'C22.0', 'C22.3', 'K70.0']"", ""['E66.8', 'E66.9', 'E66.1', 'O99.214', 'O99.215', 'O99.210', 'O99.211']""]","['amlexanox', 'placebo']",['CC(C)C1=CC2=C(C=C1)OC3=NC(=C(C=C3C2=O)C(=O)O)N'],"
        Inclusion Criteria:

          -  ≥ 18 years old at baseline.

          -  Is male, female not of childbearing potential, or meets all the following criteria if
             female of childbearing potential (including perimenopausal women who have had a
             menstrual period within one year):

               -  Not breastfeeding.

               -  Negative pregnancy test result (human chorionic gonadotropin, beta subunit
                  [βhCG]) at baseline (not applicable to hysterectomized females).

               -  Must practice and be willing to continue to practice appropriate birth control
                  (defined as a method which results in a low failure rate when use consistently
                  and correctly, such as implants, injectables, oral contraceptives, some
                  intrauterine contraceptive devices, sexual abstinence, tubal ligation, or a
                  vasectomized partner) during the entire duration of study period.

          -  Has physician-confirmed diabetes mellitus with a clear diagnosis or per ADA criteria
             with fasting glucose>126 mg/dL or HbA1c >6.4% or 2 hour GTT >200 mg/dL.

          -  BMI ≥27 and <45 kg/m2.

          -  On no medications or only on first line oral medications (such as Metformin and/or DPP
             IV inhibitors) for treatment of Type 2 diabetes mellitus with a stable regimen for >12
             weeks.

          -  Alcohol consumption of less than 40 grams/week.

          -  A liver US confirming presence of fatty infiltration of the liver.

          -  Is able to read, understand and sign the U of M IRBMED approved informed consent form
             (ICF), communicate with study physician and study team, understand and comply with
             protocol requirements.

        Exclusion Criteria:

          -  On insulin, or other injectables for treatment of Type 2 diabetes.

          -  Unable to conduct home based glucose monitoring.

          -  HbA1c <6.5% and >10.0% (set to achieve uniformity in the study population).

          -  Presence of advanced liver disease (as evidenced by abnormal synthetic function,
             abnormal PT or albumin).

          -  Evidence of other etiologies of viral hepatitis.

          -  Presence of hematologic, bone marrow and/or other abnormalities.

          -  Presence of hemoglobinopathy or other hematological abnormalities that will interfere
             with accurate measurement of HbA1c.

          -  Presence of HIV infection.

          -  Inability to give informed consent.

          -  Presence of ESRD, any type of active cancer, or >class 2 congestive heart failure
             ((New York Heart Association Functional Classification System), based on medical
             history and physical examination.

          -  Active chronic infection such as known chronic osteomyelitis or tb, etc. (may be
             transient).

          -  Creatinine >1.5 mg/dL.

          -  Proliferative diabetic retinopathy, nonproliferative retinopathy is allowed.

          -  Unable to ambulate.

          -  Clinically relevant CAD: history of stent, CABG or cardiologist confirmed angina.

          -  Any other condition in the opinion of the investigators that may impede successful
             data collection.
      "
NCT01972347,"active, not recruiting",,1,phase 2,['melanoma'],"[""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']""]","['dabrafenib', 'trametinib']","['CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F', 'CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5']","
        Inclusion Criteria:

          -  Age ≥18 years

          -  Histologically confirmed AJCC Stage IIIB or IIIC (Tx, T1-4, N1b, N2b, N2c, N3, Mo)
             cutaneous melanoma or unknown primary determined to be BRAF V600 mutation positive,
             with sufficient nodal or in-transit disease to enable biopsies prior to
             surgery.Patients must have disease that is measurable per RECIST version 1.1

          -  Able to swallow and retain oral medication and must not have any clinically
             significant gastrointestinal abnormalities that may alter absorption

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1

          -  Adequate baseline organ function

          -  Women of childbearing potential must have a negative serum pregnancy test within 7
             days of first dose of study treatment and agree to use effective contraception from 14
             days prior to commencing study treatment, throughout the treatment period and for 4
             months after the last dose of study treatment

          -  Men with any female partner of childbearing potential must agree to use effective
             contraception from 14 days prior to commencing study treatment, throughout the
             treatment period and for 4 months after the last dose of study treatment

        Exclusion Criteria:

          -  Known mucosal or ocular melanoma or any unresectable in-transit metastases

          -  Evidence of distant metastatic disease on screening evaluation

          -  Prior anti-cancer treatment for melanoma (chemotherapy, immunotherapy, biologic
             therapy, vaccine therapy, investigational treatment or radiotherapy). Prior surgery
             for melanoma is allowed.

          -  Taken an investigational drug within 28 days or 5 half-lives, whichever is longer,
             prior to commencing study treatment.

          -  Current or expected use of a prohibited medication(s)

          -  Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
             chemically related to the study treatments, their excipients, and/or dimethyl
             sulfoxide (DMSO)

          -  Known HIV

          -  A history of known glucose-6-phosphate dehydrogenase (G6PD) deficiency

          -  History of another malignancy or a concurrent malignancy except:

               1. Patients who have been disease-free for 3 years and have a life expectancy of > 5
                  years;

               2. Patients with a history of completely resected non-melanoma skin cancer or
                  successfully treated in situ carcinoma are eligible, for example cervical cancer
                  in situ, atypical melanocytic hyperplasia or melanoma in situ, multiple primary
                  melanomas.

          -  A history or evidence of cardiovascular risk including any of the following: a. QT
             interval corrected for heart rate using the Bazett's formula ≥480 msec or ≥ 450 msec
             for patients with bundle branch block; b. History or evidence of current clinically
             significant uncontrolled arrhythmias; c. History of acute coronary syndromes
             (including myocardial infarction or unstable angina), coronary angioplasty, or
             stenting within 6 months prior to commencement of study treatment; d. History or
             evidence of current ≥ Class II congestive heart failure; e. Abnormal cardiac valve
             morphology documented by echocardiogram which in the opinion of the investigator could
             interfere with the patient's safety.

             f. Treatment refractory hypertension defined as a blood pressure of systolic > 140 mm
             Hg and/or diastolic > 90 mm Hg which cannot be controlled by anti-hypertensive
             therapy.

          -  A history or current evidence/risk of retinal vein occlusion (RVO) or central serous
             retinopathy (CSR)

          -  Any serious or unstable pre-existing medical conditions (aside from the malignancy
             exceptions specified above), psychiatric disorders, or other conditions that, in the
             opinion of the treating clinician, could interfere with the patient's safety,
             obtaining informed consent, or compliance with study procedures.

          -  Breastfeeding females
      "
NCT01972217,"active, not recruiting",,1,phase 2,['metastatic castration-resistant prostate cancer'],"[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]","['olaparib', 'placebo', 'abiraterone', 'prednisone or prednisolone']","['C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F', 'CC12CCC(CC1=CCC3C2CCC4(C3CC=C4C5=CN=CC=C5)C)O']","
        Inclusion Criteria:

          1. Provision of signed and dated written informed consent prior to any study specific
             procedures.

          2. Male aged 18 years and older.

          3. Histologically or cytologically proven diagnosis of prostate cancer.

          4. Candidate for abiraterone therapy with documented evidence of metastatic
             castration-resistant prostate cancer. Metastatic status is defined as at least one
             documented metastatic lesion on either bone scan or CT/MRI scan. Castration resistant
             prostate cancer is defined as rising PSA or other signs of disease progression despite
             treatment with androgen deprivation therapy and the presence of a castrate level of
             testosterone (≤50 ng/dL).

          5. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 with no
             deterioration over the previous 2 weeks.

          6. Patients must have a life expectancy ≥12 weeks.

          7. Patients are willing and able to comply with the protocol for the duration of the
             study including undergoing treatment and scheduled visits and examinations, and
             completing PRO instruments.

          8. Patients must be on a stable concomitant medication regimen, defined as no changes in
             medication or in dose within 2 weeks prior to start of olaparib dosing, except for
             bisphosphonates, denosumab and corticosteroids, which should be stable for at least 4
             weeks prior to start of olaparib dosing.

          9. For the randomised phase only, patients must have received chemotherapy in the form of
             docetaxel treatment for metastatic castration-resistant prostate cancer. Note:
             patients who discontinued docetaxel for toxicity reasons and without completing the
             full course will still be eligible to enter this study provided they received at least
             2 cycles of chemotherapy.

        Provide informed consent for the pharmacogenetic sampling and analyses.

        Exclusion Criteria:

          1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca
             staff, its agents and/or staff at the study site).

          2. Previous treatment in the present study.

          3. Treatment with any of the following:

               -  Previous exposure to any 2nd generation anti-hormonal including abiraterone and
                  enzalutamide

               -  More than 2 prior courses of chemotherapy for metastatic prostate cancer

               -  Previous use of immunotherapy or radium-223 for the treatment of metastatic
                  prostate cancer

               -  Any investigational agents or study drugs from a previous clinical study within
                  30 days of the first dose of study treatment;

               -  Any previous exposure to a CYP17 (17α-hydroxylase/C17,20-lyase) inhibitor;

               -  Substrates of CYP2D6 with a narrow therapeutic index (eg, thioridazine);

               -  Potent inhibitors or inducers of CYP3A4 within 2 weeks before the first dose of
                  study treatment (3 weeks for St John's Wort).

               -  Any previous treatment with a PARP inhibitor, including olaparib.

          4. With the exception of alopecia or toxicities related to the use of
             gonadotropinreleasing hormone agonists, any unresolved toxicities from prior therapy
             greater than CTCAE Grade 2 at the time of starting study treatment.

          5. Spinal cord compression or brain metastases unless asymptomatic, treated and stable
             and not requiring steroids for at least 4 weeks prior to start of study treatment.

          6. As judged by the Investigator, any evidence of severe or uncontrolled systemic
             diseases, including uncontrolled hypertension, active bleeding diatheses, or active
             infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV).
             Screening for chronic conditions is not required.

          7. Any of the following cardiac criteria:

               -  Mean resting QTc >470 msec obtained from 3 ECGs

               -  Any clinically important abnormalities in rhythm, conduction or morphology of
                  resting ECG eg, complete left bundle branch block, third degree heart block

               -  Any factors that increase the risk of QTc prolongation or risk of arrhythmic
                  events such as heart failure, hypokalaemia, congenital long QT syndrome, family
                  history of long QT syndrome or unexplained sudden death under 40 years of age or
                  any concomitant medication known to prolong the QT interval.

          8. Other malignancy within the last 5 years except: adequately treated non-melanoma skin
             cancer or other solid tumours including lymphomas (without bone marrow involvement)
             curatively treated with no evidence of disease for ≥5 years.

          9. Inadequate bone marrow reserve or organ function as demonstrated by any of the
             following laboratory values:

               -  Absolute neutrophil count (ANC) <1.5 x 109/L

               -  Platelet count <100 x 109/L

               -  Haemoglobin (Hb) <100 g/L

               -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 x upper
                  limit of normal (ULN) if no demonstrable liver metastases or >5 x ULN in the
                  presence of liver metastases

               -  Total bilirubin >1.5 x ULN if no liver metastases or >3 x ULN in the presence of
                  liver metastases (except in the case of Gilbert's disease)

               -  Creatinine >1.5 x ULN concurrent with creatinine clearance <50 mL/min (measured
                  or calculated by Cockcroft and Gault equation); confirmation of creatinine
                  clearance is only required when creatinine is >1.5 x ULN

               -  If bone metastases are present and liver function is otherwise considered
                  adequate by the Investigator then elevated alkaline phosphatase (ALP) will not
                  exclude the patient.

         10. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to
             swallow the formulated product or previous significant bowel resection that would
             preclude adequate absorption of olaparib or abiraterone.

         11. History of hypersensitivity to active or inactive excipients of olaparib or
             abiraterone or drugs with a similar chemical structure or class to olaparib or
             abiraterone.

         12. Patients with myelodysplastic syndrome/acute myeloid leukaemia.

         13. Current disease or condition known to interfere with absorption, distribution,
             metabolism, or excretion of drugs, at the Investigator's discretion.

         14. Major surgery within 2 weeks of starting study treatment and patients must have
             recovered from any effects of any major surgery.

         15. Judgment by the Investigator that the patient should not participate in the study if
             the patient is unlikely to comply with study procedures, restrictions and
             requirements.

             Exclusion from the genetic research may be for any of the exclusion criteria specified
             in the main study or any of the following:

         16. Previous allogeneic bone marrow transplant.

         17. Non-leukocyte depleted whole blood transfusion within 120 days of the date of the
             pharmacogenetic sample collection.
      "
NCT01883362,completed,,1,phase 2,['acute myeloid leukemia'],"[""['C92.A1', 'C92.A2', 'C92.61', 'C92.62', 'C92.A0', 'C92.60']""]",['midostaurin'],['CC12C(C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC'],"
        Inclusion Criteria:

          -  Patients between 18 and 70 years of age

          -  Patients with ECOG Performance Status of ≤ 2

          -  Patients with a documented unequivocal diagnosis of AML according to WHO 2008
             classification (>20% blasts in the bone marrow), excluding M3 (acute promyelocytic
             leukemia).

          -  Patients with a documented FLT3 ITD mutation, determined by local laboratory for
             eligibility (historical tissue will be requested for central analysis confirmation)

          -  Patients who undersent allogeneic HSCT in CR1 from a matched related or matched
             unrelated donor. All of the following criteria had to be met: HLA typing to include
             available 8/8 or 7/8 allele HLA matched donor (at A,B,C, DRB1) Single allelic mismatch
             allowed

          -  Patients who had received a conditioning regimen which included one of the following:

        Busulfan/Fludarabine (Bu/Flu) Busulfan (16 mg/kg PO or 12.8 mg/kg IV) Fludarabine (120-180
        mg/m2) Fludarabine / Melphalan (Flu/Mel) Fludarabine (120-180 mg/m2) Melphalan (≤ 150
        mg/m2) Busulfan/Cyclophosphamide (Bu/Cy) Busulfan (16 mg/kg PO or 12.8 mg/kg IV)
        Cyclophosphamide (120 mg/kg) Cyclophosphamide/Total Body Irradiation (Cy/TBI)
        Cyclophosphamide (120 mg/kg) TBI (1200-1420 cGy)

        • Recovery of counts by day 42 and was able to start midostaurin by day 60 post-HSCT (first
        dose of midostaurin to start no earlier than 28 days post-HSCT); ANC >1000µL, platelets
        ≥20,000 without platelet transfusion

        Exclusion Criteria:

        Patients eligible for this study must not have met any of the following criteria:

          -  Patients who failed prior attempts at allogeneic HSCT

          -  Patients who had received an autologous transplant

          -  Patients with Acute GVHD Grade III-IV

          -  Patients with a known confirmed diagnosis of HIV infection or active viral hepatitis.

          -  Impaired cardiac function including any of the following:

               -  Screening ECG with a QTc > 450 msec. If QTc > 450 and electrolytes were not
                  within normal ranges, electrolytes should be corrected and then the patient
                  rescreened for QTc.

               -  Patients with congenital long QT syndrome

               -  History or presence of sustained ventricular tachycardia

               -  Any history of ventricular fibrillation or torsades de pointes

               -  Bradycardia defined as HR. < 50 bpm

               -  Right bundle branch block + left anterior hemiblock (bifascicular block)

               -  Patients with myocardial infarction or unstable angina < 6 months prior to
                  starting study

               -  Congestive Heart Failure NY Heart Association class III or IV

               -  Patients with an ejection fraction < 45% assessed by MUGA or ---ECHO within 28
                  days prior to starting study cycle 1 (of midostaurin or control group)

          -  Patients with any pulmonary infiltrate including those suspected to be of infectious
             origin (unless resolves to ≤ Grade 1 within screening timeframe)

          -  Patient required treatment with strong CYP3A4 inhibitors or moderate or strong CYP3A4
             inducers other than those required for GVH or infection prophylaxis or treatment

        Pregnant or nursing (lactating) women, or women of child-bearing potential, must have used
        highly effective methods of contraception during dosing and for 30 days after treatment
        completion
      "
NCT01923168,completed,,0,phase 2,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['alpelisib', 'buparlisib', 'placebo']","['CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F', 'C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4']","
        Inclusion Criteria:

          1. Patient is an adult, female ≥ 18 years old at the time of informed consent

          2. Patient has a histologically and/or cytologically confirmed diagnosis of breast cancer

          3. Patient is postmenopausal.

          4. Patient has T1c-T3, any N, M0, operable breast cancer

          5. Patients must have measurable disease

          6. Patient has diagnostic biopsy available for the analysis of PIK3CA mutation and Ki67
             level.

          7. Patient has estrogen-receptor and/or progesterone positive breast cancer as per local
             laboratory testing

          8. Patient has HER2 negative breast cancer defined as a negative in situ hybridization
             test or an IHC status of 0 or 1+ as per local laboratory testing

        Exclusion Criteria:

          1. Patient has locally recurrent or metastatic disease

          2. Patient has received any systemic therapy (e.g. chemotherapy, targeted therapy,
             immunotherapy) or radiotherapy for current breast cancer disease before randomization.

          3. Patient with type 1 diabetes mellitus or not adequately controlled type 2 diabetes
             mellitus

          4. History of acute pancreatitis within 1 year of study entry

          5. Uncontrolled hypertension
      "
NCT03922724,suspended,"
    the study was halted to further accrual while smc discusses the two recent deaths on the ric
    arm of this study.
  ",0,phase 2,"['peripheral t-cell lymphomas', 'lymphoproliferative disorders', 'immune system diseases']","[""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['D47.Z1']""]","['ioc', 'gvhd prophylaxis', 'ric', 'mric', 'atl-ric']",['C1=CC(=CC=C1C(=O)NCC2=C(C(=C(C=C2)F)F)F)S(=O)(=O)N'],"
        -  INCLUSION CRITERIA-RECIPIENT:

               1. Age greater than or equal to 12 years

               2. Diagnosis of PTCL, confirmed by NCI pathology review, that is relapsed or
                  refractory to prior therapy, and/or PTCL where upfront allo HCT in first
                  remission is reasonable (PIT score of intermediate-low risk or higher or
                  supported by clinical practice guidelines1)

                  --ALK-positive ALCL patients will only be eligible if relapsed or refractory

               3. At least one potential 7-8/8 HLA-matched related (excluding an identical twin) or
                  unrelated donor (at HLA-A, -B, -C, and DR), or an HLA-haploidentical related
                  donor, based on initial low resolution unrelated donor search and/or at least one
                  iologicallyrelated family member who has at least a 25% chance of being at
                  minimum an HLAhaploidentical match and is potentially suitable to donate based on
                  reported family history. HLA typing of potential donors and/or mutation testing
                  does not need to be completed for eligibility.

               4. Adequate end-organ function, as measured by:

                    -  For RIC: Left ventricular ejection fraction (LVEF) greater than or equal to
                       40% by 2D echocardiogram (ECHO) or MUGA, left ventricular shortening
                       fraction greater than or equal to 20% by ECHO, or LVEF greater than or equal
                       to 30% if the patient has radiologic evidence of aortic, renal, or coronary
                       artery vasculitis. For IOC: LVEF greater than or equal to 30% by 2D ECHO or
                       MUGA.

                    -  Pulmonary function tests: DLco (corrected for hemoglobin) and FEV1 greater
                       than or equal to 40% of predicted for the RIC arm, and greater than or equal
                       to 30% predicted for the IOC arm; or in pediatric patients, if unable to
                       perform pulmonary function tests, there should be no evidence of dyspnea at
                       rest, no requirement for supplemental oxygen, and oxygen saturation >92% on
                       room air. Calculations will be based on the USA-ITS-NIH reference.

                    -  Bilirubin less than or equal to 3.0 mg/dL (unless due to Gilbert s syndrome
                       or hemolysis) for patients receiving RIC and bilirubin less than or equal to
                       5.0 mg/dL for patients receiving IOC (unless due to Gilbert s syndrome or
                       hemolysis); ALT and AST less than or equal to 10 x ULN for patients
                       receiving RIC or IOC. Patients who are above these bilirubin, ALT, or AST
                       thresholds may be eligible for the RIC or IOC arm if evaluated by a
                       hepatologist who deems the liver function test abnormalities to be
                       potentially disease related, either because of direct involvement by PTCL,
                       due to an associated process such as hemophagocytic lymphohistiocytosis, or
                       as sequelae of prior chemotherapy that is thought to improve with time.

                    -  Estimated creatinine clearance of greater than or equal to 50 mL/min/1.73
                       m2, calculated using eGFR in the clinical lab for adults and the Schwartz
                       formula for pediatrics.

               5. Adequate central venous access potential

               6. Karnofsky (adults) or Lansky (children) performance status of greater than or
                  equal to 50% or ECOG performance status of 2 or less for the RIC arm and
                  Karnofsky (adults) or Lansky (children) greater than or equal to 30% or ECOG
                  performance status of 3 or less for the IOC arm

               7. Ability of subject or parent/guardian to understand and the willingness to sign a
                  written informed consent document

               8. Not pregnant or breastfeeding.

               9. As therapeutic agents used in this trial may be harmful to a fetus, women of
                  childbearing potential and men must agree to use adequate contraception (hormonal
                  or barrier method of birth control; abstinence) prior to study entry and for at
                  least one year post-allo HCT. Should a woman become pregnant or suspect she is
                  pregnant while she or her partner is participating in the study, she should
                  inform her treating physician immediately.

        EXCLUSION CRITERIA-RECIPIENT:

          1. Patients who are receiving any other investigational agents, with the exception of
             virus specific cytotoxic T-cells for the treatment of viral infection/reactivation
             prior to allo HCT.

          2. Prohibitive allergy to a study drug or to compounds of similar chemical or biologic
             composition of the agents (e-ATG, steroids, cyclophosphamide, busulfan, pentostatin,
             sirolimus, MMF, G-CSF) used in the study

          3. Lack of central venous access potential

          4. Active psychiatric disorder which is deemed by the PI to have significant risk of
             compromising compliance with the transplant protocol or which does not allow for
             appropriate informed consent

        INCLUSION CRITERIA-RELATED DONOR:

        1 Related donor deemed suitable and eligible, and willing to donate, per clinical
        evaluations who are additionally willing to donate blood and/or marrow/peripheral blood
        stem cells for research. Related donors will be evaluated in accordance with existing
        Standard Policies and Procedures for determination of eligibility and suitability for
        clinical donation.

        EXCLUSION CRITERIA-RELATED DONOR:

        None

        INCLUSION CRITERIA (UNRELATED DONOR):

        1 Unrelated donors will be evaluated in accordance with existing NMDP Standard Policies and
        Procedures, available at: http://bethematch.org/About-Us/Global-transplantnetwork/
        Standards/, except for the additional requirement of EBV serostatus testing for clinical
        purposes of donor selection. Note that participation in this study is offered to all
        unrelated donors but not required for clinical donation, so it is possible that not all
        unrelated donors will enroll on this study. Unrelated donors only enroll if they contribute
        research specimens, which is optional

        EXCLUSION CRITERIA (UNRELATED DONOR):

        1 Unrelated donors: failure to qualify as a National Marrow Donor Program (NMDP) donor per
        current NMDP Standards, available at: http://bethematch.org/About-Us/Globaltransplant-
        network/Standards/. Exceptions to donor eligibility (e.g. foreign travel, tattoos) do not
        automatically exclude the donor and will be reviewed by the PI.
      "
NCT03377556,completed,,0,phase 2,"['atm gene mutation', 'atr gene mutation', 'bard1 gene mutation', 'brca1 gene mutation', 'brca2 gene mutation', 'brip1 gene mutation', 'chek1 gene mutation', 'chek2 gene mutation', 'fanca gene mutation', 'fancc gene mutation', 'fancd2 gene mutation', 'fancf gene mutation', 'fancm gene mutation', 'nbn gene mutation', 'palb2 gene mutation', 'rad51 gene mutation', 'rad51b gene mutation', 'rad54l gene mutation', 'recurrent squamous cell lung carcinoma', 'rpa1 gene mutation', 'stage iv squamous cell lung carcinoma ajcc v7']","[""['D02.20', 'D02.21', 'D02.22']""]",['talazoparib'],['CN1C(=NC=N1)C2C(NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F'],"
        Inclusion Criteria:

          -  Patients must meet all SCREENING/PRE-SCREENING and SUB-STUDY REGISTRATION COMMON
             ELIGIBILITY CRITERIA as specified in S1400: Phase II/III Biomarker-Driven Master
             Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)

          -  Patients must be assigned to S1400G; S1400G biomarker eligibility defined as
             homologous recombination repair deficiency (HRRD) positive is as follows

               -  Biomarker-positive group

                    -  HRRD by FMI

                         -  Homologous recombination repair deficiency by Foundation Medicine Inc.,
                            criteria

               -  Alteration type

                    -  Truncating mutation, frameshift deletions, indels missense and nonsense
                       mutations predicted to have functional consequence in any of the specified
                       genes

               -  Eligible alteration

                    -  Mutation in any one of the following critical HRR pathway genes: ATM, ATR,
                       BARD1, BRCA1, BRCA2, BRIP1, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCF,
                       FANCM, NBN (NBS1), PALB2, RAD51, RAD51B (RAD51L1), RAD54L, RPA1

          -  Patients must not have had prior exposure to any agent with a PARP inhibitor (e.g.,
             veliparib, olaparib, rucaparib, niraparib, talazoparib [BMN 673]) as its primary
             pharmacology

          -  Patients must have achieved stable disease, a partial response, or a complete response
             at their first disease assessment after initiating first-line platinum-based
             chemotherapy; patients determined to have progressed (in the opinion of the treating
             physician) at their first disease assessment are not eligible

          -  Patients may not have any impairment of gastrointestinal function or gastrointestinal
             disease that may significantly alter the absorption of talazoparib (BMN 673) (e.g.,
             ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome,
             small bowel resection, or active peptic ulcer disease); patients must not have active
             small or large intestine inflammation such as Crohn's disease or ulcerative colitis
             (within 12 months of sub-study registration)

          -  Patients must be able to take oral medications; patients must be able to swallow
             capsules whole without crushing or altering them in any way

          -  Patients must not be taking, nor plan to take while on protocol treatment strong
             P-glycoprotein (P-gp) inhibitors, P-gp inducers, or breast cancer resistance protein
             (BCRP) inhibitors; the language ?P-gp or BCRP inhibitors or inducers? is reworded to
             ?strong P-gp inhibitors, P-gp inducers, or BCRP inhibitors? for consistency with the
             investigator brochure

          -  Patients must agree to have blood specimens submitted for pharmacokinetic analysis
      "
NCT03374852,withdrawn,"
    pi left institution on 8/6/2018 and study has been final reported with irb. never opened to
    accrual
  ",0,phase 2,['pancreatic ductal adenocarcinoma'],"[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['cpi-613', 'mfolfirnox']",['C1=CC=C(C=C1)CSCCC(CCCCC(=O)O)SCC2=CC=CC=C2'],"
        Inclusion Criteria:

          -  Cytologically confirmed pancreatic adenocarcinoma

          -  Locally advanced (including unresectable or borderline resectable) pancreatic cancer
             based on CT imaging, as determined by the PI

          -  Eastern Cooperative Oncology Group (ECOG) performance status being 0-1 within 1 week
             of planned start of therapy.

          -  Expected survival >3 months.

          -  Male and female patients 18 to not older than 80 years of age

          -  Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically
             sterile) must use accepted contraceptive methods (abstinence, intrauterine device
             (IUD), oral contraceptive or double barrier device) during the study, and must have a
             negative serum or urine pregnancy test within 1 week prior to treatment initiation.

          -  Fertile men must practice effective contraceptive methods during the study, unless
             documentation of infertility exists.

          -  Laboratory values ≤2 weeks must be:

               -  Adequate hematologic (granulocyte count ≥1500/mm3; white blood cell [WBC] ≥3500
                  cells/mm3; platelet count ≥100,000 cells/mm3; absolute neutrophil count [ANC]
                  ≥1500 cells/mm3; and hemoglobin ≥9 g/dL).

               -  Adequate hepatic function (aspartate aminotransferase [AST/SGOT] ≤3x upper normal
                  limit [UNL], alanine aminotransferase [ALT/SGPT] ≤3x UNL, bilirubin ≤1.5x UNL).

               -  Adequate renal function (serum creatinine ≤2.0 mg/dL or 177 μmol/L).

               -  Adequate coagulation (""International Normalized Ratio"" or INR must be <1.5)
                  unless on therapeutic blood thinners.

          -  No evidence of clinically significant active infection and no serious infection within
             the past month.

          -  Mentally competent, ability to understand and willingness to sign the informed consent
             form.

        Exclusion Criteria:

          -  Patients under the age of 18 or older than 80 years of age

          -  Endocrine or acinar pancreatic carcinoma

          -  Resectable pancreatic cancer

          -  Metastatic pancreatic cancer based on imaging

          -  Prior surgical or medical treatment for pancreatic cancer

          -  Patients receiving any other standard or investigational treatment for their cancer
             with a primary goal of improving survival within the past 2 weeks prior to initiation
             of CPI-613 treatment.

          -  Serious medical illness that would potentially increase patients' risk for toxicity

          -  Any active uncontrolled bleeding, and any patients with a bleeding diathesis (e.g.,
             active peptic ulcer disease).

          -  Pregnant women, or women of child-bearing potential not using reliable means of
             contraception (because the teratogenic potential of CPI-613 is unknown).

          -  Lactating females.

          -  Fertile men unwilling to practice contraceptive methods during the study period.

          -  Life expectancy less than 3 months.

          -  Any condition or abnormality which may, in the opinion of the investigator, compromise
             the safety of patients.

          -  Unwilling or unable to follow protocol requirements.

          -  Active including but not limited to symptomatic congestive heart failure, symptomatic
             coronary artery disease, symptomatic angina pectoris, or symptomatic myocardial
             infarction.

          -  Patients with a history of myocardial infarction that is <3 months prior to
             registration.

          -  Evidence of active infection, or serious infection within the past month.

          -  Patients with known HIV infection.

          -  Any condition or abnormality which may, in the opinion of the investigator, compromise
             the safety of the patient.
      "
NCT03303950,terminated,"
    slow accrual
  ",0,phase 2,"['anemia', 'asxl1 gene mutation', 'ezh2 gene mutation', 'idh1 gene mutation', 'idh2 gene mutation', 'plasma cell myeloma', 'primary myelofibrosis', 'recurrent plasma cell myeloma', 'secondary myelofibrosis', 'thrombocytopenia']","[""['D53.2', 'D64.9', 'D46.4', 'D53.0', 'D53.9', 'D61.3', 'D61.9']"", ""['D68.52', 'J84.83']"", ""['D68.52', 'J84.83']"", ""['D68.52', 'J84.83']"", ""['D68.52', 'J84.83']"", ""['D75.81', 'C94.41', 'C94.42', 'C94.40']"", ""['G47.13', 'J01.41', 'K11.22', 'K12.0', 'N96', 'F33.8', 'G03.2']"", ""['D75.81', 'C94.41', 'C94.42', 'C94.40']"", ""['D69.6', 'D69.49', 'D69.59', 'P61.0', 'D75.829', 'D69.42', 'D75.821']""]","['busulfan', 'cyclophosphamide', 'fludarabine']","['CS(=O)(=O)OCCCCOS(=O)(=O)C', 'C1CNP(=O)(OC1)N(CCCl)CCCl', 'C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N']","
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Participants must have one of the following diagnoses of multiple myeloma (MM) or
             primary/secondary myelofibrosis (MF)

          -  Participants must have histologically documented multiple myeloma (MM)

               -  Participants in early relapse (less than 24 months from initiation of systemic
                  anti-myeloma therapy which may include single or planned tandem autologous
                  transplant) after primary therapy that included and autologous HSCT; OR

               -  Later stage; OR

               -  High risk factors defined by the presence of any one of the following detected at
                  any time prior to enrollment: deletion of chromosome 13 by conventional
                  cytogenetics, hypodiploidy, abnormality in chromosome 1 (1q amplification or 1p
                  deletion), t(4;14), t(14;16), t(14;20) or deletion of 17p by fluorescence in situ
                  hybridization (FISH) or conventional karyotyping; high risk criteria based on
                  commercially available gene expression profiling; OR

               -  Extramedullary disease, plasma cell leukemia or high lactate dehydrogenase (LDH)

          -  Participants must have histologically documented myelofibrosis (MF)

               -  Participants with Dynamic International Prognostic Scoring System (DIPSS) plus
                  intermediate stage 2 or higher risk MF; OR

               -  Subset of intermediate stage 1 participants; defined by:

                    -  Poor-risk molecular profile (triple negative: JAK2, CALR, MPL); OR

                    -  Presence of any of the following mutations: ASXL1, SRSF2, EZH2, IDH1/2; OR

                    -  Severe thrombocytopenia, severe anemia, high peripheral blood blasts
                       percentage; OR

                    -  Unfavorable cytogenetic abnormalities (rearrangements of chromosome 5 or 7
                       or >= 3 abnormalities

          -  Able to provide informed consent and willing to sign an approved consent form that
             conforms to federal and institutional guidelines

          -  DONOR: A related donor - fully matched

          -  DONOR: A related donor - haploidentical

          -  DONOR: An unrelated donor - fully matched

          -  DONOR: An unrelated donor -9/10 matched

        Exclusion Criteria:

          -  Cardiac-left ventricular ejection fraction < 40%, symptomatic coronary artery disease,
             or uncontrolled arrhythmias

          -  Pulmonary-forced expiratory volume at one second (FEV1) or diffusion capacity of lung
             for carbon dioxide (DLCO) < 40% or history of chronic use of supplemental oxygen.
             Temporary use of supplemental oxygen at the time of screening or registration is
             allowed if the investigator feels that the underlying cause of requiring oxygen is
             reversible by the time treatment begins.

          -  Renal-calculated or measured glomerular filtration rate (GFR) < 30 ml/min,
             dialysis-dependent, or history of renal transplant

          -  Hepatic-bilirubin > 2 X upper limit of normal (ULN)

          -  Alanine aminotransferase (ALT) > 2.5 X ULN or cirrhosis

          -  Participants with active or uncontrolled bacterial, viral, or fungal infections
             requiring systemic therapy

          -  Pregnant women, nursing mothers or women of child-bearing potential who are unwilling
             to use medically accepted methods of contraception

          -  Male and female subjects not willing to agree to medically accepted methods of
             contraception
      "
NCT02597062,completed,,0,phase 2,['multiple myeloma'],"[""['C90.01', 'C90.02', 'C90.00']""]","['carfilzomib', 'cyclophosphamide', 'dexamethasone']","['CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3)NC(=O)CN4CCOCC4', 'C1CNP(=O)(OC1)N(CCCl)CCCl', 'CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C']","
        Inclusion Criteria:

          -  Relapsed symptomatic multiple myeloma as per the International Myeloma Working group
             criteria [Palumbo 2009].

          -  Measurable disease, as defined by one or more of the following (assessed within 21
             days prior to registration):

               -  Serum M-protein ≥ 5 g/L (0.5g/dL)

               -  Urine Bence-Jones protein ≥ 200 mg/24 hours

               -  Involved serum free light chain (FLC) measurement ≥ 100 mg/L (10 mg/dL), provided
                  serum FLC ratio is abnormal (abnormal if FLC ratio is <0.26 or >1.65)

               -  Biopsy proven plasmacytoma

               -  For IgA patients whose disease can only be reliably measured by serum
                  quantitative immunoglobulin (qIgA) ≥ 750 mg/dL (0.75 g/dL)

          -  Prior treatment with at least one, but no more than three, regimens for multiple
             myeloma

          -  Documented relapse or progressive disease on or after any regimen (subjects refractory
             to the most recent line of therapy are eligible except those who are refractory to
             bortezomib and cyclophosphamide as described in exclusion criteria 1.

          -  Achieved a response to at least one prior regimen (defined as ≥ 25% decrease in
             M-protein)

          -  Age ≥ 18 years.

          -  Life expectancy ≥ 3 months.

          -  ECOG performance status 0-2.

          -  Laboratory Requirements (must be done within 21 days of registration):

          -  Hematology:

               -  Absolute neutrophil count (ANC) ≥ 1.0 × 10^9/L

               -  Hemoglobin ≥ 8 g/dL (80 g/L) (subjects may be receiving red blood cell (RBC)
                  transfusions in accordance with institutional guidelines)

               -  Platelet count ≥ 50 × 10^9/L, independent of platelet transfusions for 7 days. (≥
                  30 × 10^9/L if myeloma involvement in the bone marrow is ≥ 50%)

          -  Biochemistry:

               -  ALT ≤ 3.5 x UNL

               -  Serum direct bilirubin ≤ 2 mg/dL (34 μmol/L) (only required if total bilirubin ≥
                  2mg/dL (34μmol/L)

               -  Creatinine clearance (CrCl) ≥ 30 mL/minute (Crockcroft and Gault formula) and not
                  on dialysis.

          -  Patient consent must be appropriately obtained in accordance with applicable local and
             regulatory requirements. Each patient must sign a consent form prior to enrollment in
             the trial to document their willingness to participate.

          -  Patients must be accessible for treatment and follow up. Patients registered on this
             trial must be treated and followed at the participating centre.

          -  In accordance with CRO policy, protocol treatment is to begin within 2 working days of
             patient registration.

          -  Women/men of childbearing potential must have agreed to use a highly effective
             contraceptive method.

        Exclusion Criteria:

          -  Refractory to any proteasome inhibitor therapy (bortezomib, ixazomib, etc.) Refractory
             disease is defined as failure to respond to the proteasome inhibitor, initial response
             followed by progression while on a proteasome inhibitor, or relapse within 60 days of
             stopping proteasome inhibitor therapy.

          -  Prior carfilzomib treatment.

          -  POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and
             skin changes)

          -  Waldenström's macroglobulinemia or IgM myeloma

          -  Current or previous Plasma cell leukemia defined as (> 2.0 × 10^9/L circulating plasma
             cells by standard differential)

          -  Chemotherapy or investigational agent within 3 weeks prior to registration or antibody
             therapy within 6 weeks prior to registration

          -  Radiotherapy to multiple sites within 28 days prior to registration; localized
             radiotherapy to a single site within 7 days prior to registration

          -  Plasmapheresisis within 14 days of registration.

          -  Pregnant or lactating females.

          -  Major surgery within 21 days prior to registration.

          -  Active, uncontrolled bacterial, fungal, or viral infection.

          -  Concurrent amyloidosis

          -  Known human immunodeficiency virus infection.

          -  Active hepatitis B or C infection.

          -  Myocardial infarction within 4 months prior to registration, NYHA Class III or IV
             heart failure, uncontrolled angina, history of severe coronary artery disease, severe
             uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic
             evidence of acute ischemia or grade 3 conduction system abnormalities unless subject
             has a pacemaker.

          -  Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to
             registration.

          -  Other malignancy, including MDS, within the past 3 years with the exception of
             adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer;
             carcinoma in situ of the cervix or breast; prostate cancer of Gleason Score 6 or less
             with stable prostate-specific antigen levels; or cancer considered cured by surgical
             resection or unlikely to impact survival during the duration of the study, such as
             localized transitional cell carcinoma of the bladder or benign tumours of the adrenal
             or pancreas.

          -  Significant neuropathy (≥ grade 3, or grade 2 with pain) within 14 days prior to
             registration.

          -  Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize
             carfilzomib).

          -  Contraindication to any of the required concomitant drugs or supportive treatments,
             including hypersensitivity antiviral drugs, or intolerance to hydration due to
             preexisting pulmonary or cardiac impairment.

          -  Ongoing graft-versus-host disease.

          -  Subjects with pleural effusions requiring thoracentesis or ascites requiring
             paracentesis within 14 days prior to registration.

          -  Any other clinically significant medical disease or condition that, in the
             Investigator's opinion, may interfere with protocol adherence or a subject's ability
             to give informed consent.
      "
NCT02598310,terminated,,1,phase 2,"['breast cancer', 'estrogen receptor negative neoplasm', 'her-2 positive breast cancer']","[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['nab-paclitaxel', 'trastuzumab']",['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C'],"
        Inclusion Criteria:

          1. Histologically confirmed invasive breast cancer

          2. Tumor size of 3cm or less and N0

          3. Hormone receptors have been identified as negative

          4. HER2 positive confirmed by IHC 3+ or FISH+

          5. LVEF > 50% by echocardiogram or MUGA

          6. Adequate EKG

          7. No prior treatment for breast cancer

          8. PS 0-1

          9. Required baseline laboratory data WBC > 4,000/mm3 and Neut > 2,000/mm3 PLT >
             100,000/mm3 Hb > 9.0g/dl AST and ALT < ULNx2.5 T-Bil < 1.5mg/dl Serum creatinin <
             1.5mg/dl

         10. Written informed consent

        Exclusion Criteria:

          1. With history of hypersensitivity reaction for important drug in this study

          2. With history of invasive breast cancer

          3. Bilateral invasive breast cancer

          4. Patients with medical conditions that renders them intolerant to primary chemotherapy
             and related treatment, including infection, diarrhea, intestinal paralysis, severe
             Diabetes Mellitus

          5. Positive for HBs antigen or HCV antibody

          6. With history of congestive heart failure, uncontrolled or symptomatic angina pectoris,
             arrhythmia or myocardial infarction, poorly controlled hypertension

          7. With severe edema

          8. With severe peripheral neuropathy

          9. With severe psychiatric disorder

         10. Pregnant or nursing women

         11. The case that is judged to be unsuitable for this study by physician
      "
NCT02590003,terminated,"
    trial was stopped after non-response to treatment.
  ",0,phase 2,"['carcinoma, non-small cell lung']","[""['D02.20', 'D02.21', 'D02.22']""]","['carboplatin', 'nab-paclitaxel']","['C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C']","
        Inclusion Criteria:

          1. Patient able and willing to comply with study procedures as per protocol, including
             the geriatric assessment at the time of study enrollment.

          2. Patient able to understand and willing to sign and date the written voluntary informed
             consent form (ICF) at screening visit prior to any protocol-specific procedures.

          3. Patients must have histological or cytological confirmed primary non-small cell lung
             cancer (adenocarcinoma, large cell carcinoma, squamous, or unspecified). Disease must
             be stage IV Non-Small Cell Lung Cancer (NSCLC). Disease may be either newly diagnosed
             or recurrent after previous surgery and/or irradiation. Primary or metastatic site for
             biopsy is allowed

          4. Patients may have measurable or non-measurable disease documented by CT or MRI. The CT
             from a combined PET/CT may be used to document only non-measurable disease. Measurable
             disease must be assessed within 30 days prior to registration per response evaluation
             criteria in solid tumors (RECIST) v1.1. Pleural effusions, ascites and laboratory
             parameters are not acceptable as the only evidence of disease. Non- measurable disease
             must be assessed within 30 days prior to registration. All disease must be assessed
             and documented on the Baseline Tumor Assessment Form.

          5. Prior chemotherapy for curative intent is permitted providing the cytotoxic
             chemotherapy was completed ≥12 months prior to enrollment. Patients must have a CT or
             MRI scan of the brain to evaluate for CNS disease within 30 days prior to
             registration. Patient must not have brain metastases unless: (1) metastases have been
             treated and have remained controlled for at least two weeks following treatment, AND
             (2) patient has no residual neurological dysfunction off corticosteroids for at least
             1 day. Any radiation therapy completed prior to chemotherapy, except gamma-knife
             radiosurgery, 1 week prior to chemotherapy.

          6. Age >70 years of age at time of signing of the informed consent form.

          7. Life expectancy of greater than 12 weeks.

          8. ECOG performance status 0-2 (See Appendix A)

          9. Patients must have a comprehensive geriatric assessment and chemotherapy toxicity
             assessment score between 7-17 (See Appendix B, D)

         10. Patients must have normal organ and marrow function as defined below:

               -  Leukocytes >3,000/mcL

               -  ANC > 1,500 cells/mm3Hemoglobin > 9.0g/dL

               -  Platelets >100,000 cells/mm3

               -  Total bilirubin < 1.5 mg/dL (unless there is a known history of Gilberts
                  Syndrome).

               -  AST(SGOT)/ALT(SGPT) ≤2.5 X institutional upper limit of normal

               -  Alkaline phosphatase < 2.5 X upper limit of normal in the absence of liver or
                  bone metastasis, or ≤ 5.0 × upper limit of normal range if bone or liver
                  metastases

               -  Creatinine clearance >25 mL/min or creatinine <1.5 mg/dL

         11. HIV-positive patients on combination antiretroviral therapy are eligible if they have
             been on ARVs for ≥6 months and undetectable viral loads.

         12. Patients must not have documented evidence of acute hepatitis or have an active or
             uncontrolled infection.

         13. No other priormalignancy is allowed except for the following: adequately treated basal
             cell or squamous cell skin cancer, in-situ cervical cancer, adequately treated Stage I
             or II cancer from which the patient is currently in complete remission, or any other
             cancer from which the patient has been disease-free for 5 years.

         14. Ability to understand and the willingness to sign a written informed consent document
             in English or a Spanish consent ""short form"". If language other than English or
             Spanish, then interpreter will be used to sign English consent form.

         15. Patients must have < Grade 2 pre-existing peripheral neuropathy (per CTCAE)

        Exclusion Criteria

          1. Patients who have had palliative chemotherapy prior to entering the study <12 months
             from enrollment or those who have not recovered from adverse events due to agents
             administered more than 4 weeks earlier.

          2. Patients may not be receiving any other investigational agents or have received
             immunotherapy.

          3. Known EGFR or ALK mutated disease (molecular testing not required prior to study
             entry)

          4. History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to carboplatin, or nab-paclitaxel.

          5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          6. Preexisting peripheral neuropathy of Grade 2, 3, or 4 (per Common Terminology Criteria
             for Adverse Events v4.0)

          7. Evidence of active brain metastases, including leptomeningeal involvement (prior
             evidence of brain metastasis are permitted only if treated and stable and off therapy
             for ≥ 2 weeks prior to signing Informed consent form. Magnetic Resonance Imaging of
             the brain (or Computed Tomography scan w/contrast) is preferred for diagnosis.
      "
NCT02590965,completed,,1,phase 2,['non-small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['fruquintinib', 'placebo']",['CC1=C(C2=C(O1)C=C(C=C2)OC3=NC=NC4=CC(=C(C=C43)OC)OC)C(=O)NC'],"
        Inclusion Criteria:

          1. Fully understand the study and sign the informed consent form voluntarily;

          2. Histologically and/or cytologically diagnosed with local advanced and/or metastatic
             stage IIIB/IV non-squamous NSCLC;

          3. Previously failed to two chemotherapy regimens(treatment failure is defined as disease
             progression or intolerable toxicity), patients with positive EGFR mutation permitted
             to treated by EGFR-TKI previously; patients with EGFR wild type or unknown whether or
             not treated by EGFR-TKI previously;

          4. Aged 18-75 years (inclusive);

          5. Body weight ≥40 kg;

          6. Evident measurable lesion(s) (according to RECIST1.1);

          7. ECOG Performance Status 0-1;

          8. Expected survival >12 weeks

        Exclusion Criteria:

          1. Treatment in another clinical trials in the past 3 weeks; or treatment with systemic
             anti-tumor chemotherapy, radiotherapy or biotherapy within 3 weeks prior to
             administration of the study drug;

          2. Previous therapy with VEGF/VEGFR inhibitors;

          3. Unrecovered from toxicity caused by previous anti-cancer treatment (CTCAE >grade 1),
             or not completely recovered from previous surgery;

          4. Previous active brain metastasis (without radiotherapy previously, or symptoms stable
             < 4 weeks, or with clinical symptoms, or with medication to control symptoms);

          5. Other malignancies except basal cell carcinoma or cervical carcinoma in situ in the
             past 5 years;

          6. Uncontrolled clinical active infection, e.g. acute pneumonia and active hepatitis B;

          7. Dysphagia or known drug malabsorption;

          8. Present active duodenal ulcer, ulcerative colitis, intestinal obstruction and other
             gastrointestinal diseases or other conditions that may lead to gastrointestinal
             bleeding or perforation according to the investigators' judgment; or with a history of
             intestinal perforation or intestinal fistula;

          9. Have evidence or a history of thrombosis or bleeding tendency, regardless of
             seriousness;

         10. Stroke and/or transient ischemic attack within 12 months prior to enrollment;

         11. Appropriate organ function. Patients with any of the following conditions will be
             excluded:

               -  Absolute neutrophil count (ANC) <1.5×109/L, platelet <100×109/L or hemoglobin <9
                  g/dL within 1 week prior to enrollment;

               -  Serum total bilirubin >1.5 upper limit of normal (ULN), alanine transaminase and
                  aspartate transferase >1.5×ULN; ALT and AST > 3×ULN in patients with liver
                  metastasis;

               -  Electrolyte abnormality of clinical significance;

               -  Blood creatinine >ULN and creatinine clearance <60 ml/min;

               -  Urine protein 2+ or above, or 24 h urine protein quantification ≥1.0 g/24 h;

               -  Activated partial thromboplastin time (APTT) or/and INR and prothrombin time (PT)
                  >1.5×ULN (according to reference range in each clinical study center);

         12. Uncontrolled hypertension, systolic blood pressure ≥140 mmHg and/or diastolic blood
             pressure ≥90 mmHg with medication; or heart failure NYHA classification ≥ grade 2;

         13. Heart function evaluation: left ventricular ejection fraction <50% (echocardiography);

         14. Acute myocardial infarction, severe/unstable angina or coronary bypass surgery within
             6 months prior to enrollment; history of arterial thrombosis or deep venous
             thrombosis;

         15. Skin wound, surgical site, wound site, severe mucosal ulcer or fracture without
             complete healing;

         16. Female subjects who are pregnant or lactating or of child bearing potential with
             positive pregnancy test result before the first dose;

         17. Patients with child bearing potential who or whose sexual partners are not willing to
             take contraceptive measures;

         18. Any clinical or laboratory abnormalities unfit to participate in this clinical trial
             according to the investigator's judgment;

         19. Serious psychological or psychiatric disorders which may affect subject compliance in
             this clinical study;

         20. Allergy to Fruquintinib and/or excipient contained in trial drugs.
      "
NCT02591615,completed,,0,phase 2,['non-small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['mk-3475', 'carboplatin', 'paclitaxel', 'pemetrexed']","['C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C', 'C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O']","
        Inclusion Criteria:

          1. Be ≥ 18 years of age on day of signing informed consent.

          2. Have a life expectancy of at least 3 months.

          3. Have a histologically or cytologically confirmed diagnosis of stage IV NSCLC.

          4. Have a performance status of 0 or 1 on the ECOG.

          5. Have a measurable disease based on RECIST 1.1.

          6. Have provided tissue from an archival tissue sample or newly obtained core or
             excisional biopsy of tumor lesion.

          7. In patients with non-squamous non-small cell lung cancer, investigators must be able
             to produce source documentation of the EGFR mutation status or ALK translocation
             status.

          8. Demonstrate adequate organ function.

          9. Female patient of childbearing potential should have a negative urine or serum
             pregnancy test within 72 hours.

         10. Female parents of childbearing potential must be willing to use 2 methods of birth
             control or be surgically sterile.

         11. Male patients must agree to use an adequate method of contraception.

         12. Patients with sensitizing EGFR mutation or ALK rearrangement must have progressed on
             an appropriate tyrosine kinase inhibitor (TKI)

        Exclusion Criteria:

          1. Has received prior treatment with chemotherapy or biologic therapy for stage IV NSCLC.

          2. Is currently participating in or has participated in a study of an investigational
             agent or using an investigational device.

          3. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
             other form of immunosuppressive therapy.

          4. Has had a prior mAb within 4 weeks prior to study Day 1 or who has not recovered from
             adverse events due to agents administered more than 4 weeks earlier.

          5. Has had prior chemotherapy or radiation.

          6. Has a known additional malignancy that is progressing or requires active treatment.

          7. Has known active CNS metastases and/or carcinomatous meningitis.

          8. Has an active autoimmune disease requiring systemic treatment within the past 3 months
             or a documented history of clinically severe autoimmune disease, or a syndrome that
             requires systemic steroids or immunosuppressive agents.

          9. Has evidence of interstitial lung disease or active, non-infectious pneumonitis.

         10. Has an active infection requiring systemic therapy.

         11. Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial.

         12. Has known psychiatric or substance abuse disorders.

         13. Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial.

         14. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or
             CTLA-4 antibody.

         15. Has a known history of HIV.

         16. Has known active Hepatitis B or Hepatitis C.

         17. Has received a live vaccine within 30 days prior to the planned first dose of study
             therapy.

         18. Has a known history of active TB.

         19. Hypersensitivity to pembrolizumab or any of it's excipients.
      "
NCT02596256,unknown status,,1,phase 2,['gastric cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['apatinib', 'docetaxel']","['C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O']","
        Inclusion Criteria:

          1. Age: more than 18 years old, male or female;

          2. Pathologically diagnosed with advanced gastric cancer (including adenocarcinoma of the
             gastroesophageal junction) with measurable metastases outside the stomach (measuring ≥
             10mm on spiral computed tomography(CT) scan, satisfying the criteria in Response
             Evaluation Criteria In Solid Tumors (RECIST) 1.1);

          3. Failure of prior therapy (during or after treatment) in patients who have received at
             first line chemotherapy regimens(platinum - based regimens);

          4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1;

          5. Major organ function has to meet the following criteria; (1) For results of blood
             routine test and biochemical tests:

               1. Hemoglobin (HB) ≥ 80g / L,

               2. ANC ≥ 1.5 × 109 / L,

               3. PLT ≥ 90 × 109 / L,

               4. ALT and AST ≤ 2.5 × ULN, liver metastases, if any, the ALT and AST≤5 × ULN,

               5. Bilirubin ≤ 1.5 times the upper limit of normal (ULN),

               6. Serum creatinine ≤ 1.5 times the upper limit of normal (ULN),

               7. Serum albumin ≥ 30g / L;

          6. An expected survival of ≥ 3 months;

          7. Pregnancy test (serum or urine) has to be performed for woman of childbearing age
             within 7 days before enrolment and the test result must be negative. They shall take
             appropriate methods for contraception during the study until the 8th week post the
             last administration of study drug. For men, (previous surgical sterilization
             accepted), shall agree to take appropriate methods of contraception during the study
             until the 8th week post the last administration of study drug;

          8. Patient has to voluntarily join the study and sign the Informed Consent Form for the
             study.

        Exclusion Criteria:

          1. Confirmed that apatinib and/or its accessories allergy;

          2. Subjects with poor-controlled arterial hypertension (systolic blood pressure> 140 mmHg
             and diastolic blood pressure > 90 mm Hg) despite standard medical management; Coronary
             heart disease greater than Class Ⅰ; Ⅰ-level arrhythmia (including QT interval
             prolongation, for man ≥ 450 ms, for woman ≥ 470 ms) together with Class Ⅰ cardiac
             dysfunction; Patients with positive urinary protein;

          3. Factors that could have an effect on oral medication (such as inability to swallow,
             chronic diarrhea and intestinal obstruction);

          4. Subjects with high gastrointestinal bleeding risk, including the following conditions:
             local active ulcer lesions with positive fecal occult blood test (++); history of
             black stool, or vomiting blood in the past 2 months;unresected primary lesion in
             stomach with positive fecal occult blood test (+), ulcerated gastric carcinoma with
             massive alimentary tract bleeding risk judged by PIs based on gastric endoscopy
             result;

          5. Abnormal Coagulation (INR>1.5、APTT>1.5 UNL), with tendency of bleed;

          6. Associated with CNS (central nervous system) metastases;

          7. Pregnant or lactating women;

          8. Pts with other malignant tumor within 5 years;

          9. With psychotropic drug abuse history and can't get rid of or mental disorder patients;

         10. Participated in other clinical trials within 4 weeks;

         11. Pts received VEGFR inhibitor treatment(i.e. sorafenib, sunitinib);

         12. Any other condition that might place the patient at undue risk or preclude a patient
             from completing the study;

         13. Other conditions regimented at investigators' discretion.
      "
NCT02596867,terminated,"
    poor accrual
  ",0,phase 2,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]",['propanolol'],['CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O'],"
        Inclusion Criteria:

          -  Ages 18- 65

          -  diagnosis of stage I-III breast cancer , confirmed by a core biopsy

          -  Planning to undergo definitive surgery including mastectomy or breast conserving
             surgery

          -  Systolic blood pressure must be >100 mmHg but no more than 140 mmHg and/or diastolic >
             60 mmHg and no more than 95 mmHg.

          -  normal baseline EKG

        Exclusion criteria:

          -  Pregnancy; potential subjects of female bearing age will have to complete a pregnancy
             test during screening to ensure that they are not pregnant. Potential patients who are
             post-menopausal must have confirmed one year without menstrual cycle.

          -  Free of major medical illnesses including:

          -  Uncontrolled Diabetes (HbA1c of ≤ 8 if previously tested)

          -  Uncontrolled hypertension: BP >systolic 140/ diastolic > 95

          -  Cardiac diseases (history of cardiac valve disease, coronary artery disease,
             congestive heart failure, A-V block, peripheral vascular disease, any cardiac
             arrhythmia/bradycardia) with the exception of the diagnosed cancer.

          -  Histories of asthma, bronchospastic disease, or obstructive pulmonary disease

          -  Previously diagnosed thyrotoxicosis

          -  Severe allergic reactions to medications which are included in the beta blocker family

          -  Previously or currently treated with a beta adrenergic receptor antagonist

          -  Patients with locally advanced or inflammatory breast cancer not amenable to surgical
             resection

          -  Patients taking any of the following medications will be excluded:

               -  Drugs that are categorized as digitalis glycosides, beta-blockers and calcium
                  channel blockers, ACE inhibitors and alpha blockers

               -  Amiodarone

               -  Cimetidine

               -  Ciprofloxacin

               -  Delavudin

               -  Dobutamine

               -  Ethanol

               -  Fluconazole

               -  Fluoxetine

               -  Fluvoxamine

               -  Haloperidol

               -  Imipramine

               -  Isoniazid

               -  Isoproterenol

               -  Luvoxamine

               -  Paroxetine

               -  Phenytoin

               -  Phenobarbital.

               -  Propafenone.

               -  Quinidine

               -  Reserpine

               -  Rifampin

               -  Ritonavir

               -  Rizatriptan.

               -  Tenioposide

               -  Theophylline

               -  Thyroxine

               -  Tolbutamide.

               -  Warfarin

               -  Zileuton

               -  Zolmitriptan
      "
NCT02542137,withdrawn,"
    no recruitment.
  ",0,phase 2,"['small cell lung cancer', 'radiotherapy', 'thymalfasin']","[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]",['thymalfasin'],['CCC(C)C(C(=O)NC(C(C)O)C(=O)NC(C(C)O)C(=O)NC(CCCCN)C(=O)NC(CC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCC(=O)O)C(=O)NC(C(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CCC(=O)O)C(=O)NC(CC(=O)N)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC(=O)O)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C'],"
        Inclusion Criteria:

          1. Patients with histologically confirmed small cell lung cancer which is persistent and
             metastatic or recurrent and metastatic;

          2. Patients must have at least 3 distinct measurable metastatic sites at least 1 cm of
             larger in their largest diameter;

          3. Age ≥18 years;

          4. Metastatic disease measurable on a CT/MRI scan. The primary tumor is not considered
             measurable disease. Metastatic lesions within a prior radiation field are acceptable
             as long as disease has progressed in the radiation field by RECIST criteria. The same
             imaging modality performed at baseline (CT or MRI) will be repeated at subsequent
             imaging.

          5. ECOG performance status: 0-1;

          6. Life expectancy ≥ 3 months.

          7. Patients have adequate baseline organ and marrow function as defined by an absolute
             neutrophil count greater than 1500 cells per μL, platelet concentration of greater
             than 50 000 per μL, total bilirubin less than 1•5 times the upper limit of normal
             (ULN), aspartate aminotransferase and alanine aminotransferase less than 2•5 times the
             ULN, and serum creatinine less than 1•5 times the ULN;

          8. Signed consent forms voluntarily;

        Exclusion Criteria:

          1. Patients undergoing therapy with other investigational agents.

          2. Women who are pregnant or breastfeeding;

          3. Patients with known brain metastases can be included in this clinical trial but brain
             lesions are not eligible as target or non target lesion;

          4. Active severe infection or known chronic infection with HIV, hepatitis B virus, or
             hepatitis C virus;

          5. Cardiovascular disease problems including unstable angina, therapy for
             life-threatening ventricular arrhythmia, myocardial infarction, stroke or congestive
             heart failure within the last 6 months;

          6. The subject has had another active malignancy within the past five years except for
             cervical cancer in site, in situ carcinoma of the bladder or non-melanoma carcinoma of
             the skin;

          7. Clinically significant and uncontrolled major medical conditions including but not
             limited to: active uncontrolled infection, symptomatic congestive heart failure,
             Unstable angina pectoris or cardiac arrhythmia, psychiatric illness/ social situation
             that would limit compliance with study requirements; any medical condition, which in
             the opinion of the study investigator places the subject at an unacceptably high risk
             for toxicities;

          8. Patients with any other concurrent disease which, in the judgment of the investigator,
             would make the patient inappropriate for participation in the study.
      "
NCT02546986,"active, not recruiting",,0,phase 2,"['carcinoma, non-small-cell lung']","[""['D02.20', 'D02.21', 'D02.22']""]","['cc-486', 'pembrolizumab', 'placebo']",['CN(C)CC1=CC=C(C=C1)C2=NC3=CC=CC4=C3N2CCNC4=O'],"
        Inclusion Criteria:

          1. Participant is ≥ 18 years of age at the time of signing the informed consent form.

          2. Participant has histologically or cytologically confirmed squamous or non-squamous
             non-small cell lung cancer (NSCLC).

          3. Participant has stage IIIB or IV NSCLC (American Joint Committee on Cancer [AJCC]
             Staging Manual, 7th edition [Edge, 2009]) and was pretreated with only 1 prior
             systemic platinum based chemotherapy.

          4. Participant has provided a formalin fixed tumor tissue sample from a biopsy of a tumor
             lesion either at the time of or after the diagnosis of metastatic disease has been
             made and from a site not previously irradiated to assess for a protein known as
             Programmed death-ligand 1( PD-L1) status. Fine needle aspirates, endobronchial
             ultrasound (EBUS) or cell blocks are not acceptable. Needle or excisional biopsies, or
             resected tissue is required. Archival tissue may be acceptable. Submission of
             formalin-fixed paraffin embedded tumor tissue sample blocks are preferred; if
             submitting unstained slides, the slides should be freshly cut and submitted to the
             testing laboratory within 14 days from site slide sectioning date otherwise a new
             specimen will be requested.

          5. Participant has radiographically-documented measurable disease, as per Response
             Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1).

          6. Particiapant has an Eastern Cancer Oncology Group (ECOG) performance status of 0 to 1.

          7. Participant has adequate organ functions, evidenced by the following:

               1. Aspartate aminotransferase (AST), Serum glutamic oxaloacetic transaminase (SGOT),
                  alanine aminotransferase (ALT), serum glutamic pyruvic transaminase (SGPT) ≤ 2.5
                  x upper limit of normal range (ULN), or ≤ 5 x ULN range if liver metastasis
                  present

               2. Total bilirubin ≤ 1.5 x ULN

               3. Serum creatinine ≤ 1.5 x ULN

               4. Potassium within normal range, or correctable with supplements

          8. Participant has adequate bone marrow function, evidenced by the following:

               1. Absolute neutrophil count ≥ 1.5 x 10^9 cells/L

               2. Platelets ≥ 100 x 10^9 cells/L

               3. Hemoglobin ≥ 9 g/dL

               4. International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 x ULN unless
                  participant is receiving anticoagulant therapy as long as prothrombin time (PT)
                  or partial thromboplastin time (PTT) is within therapeutic range of intended use
                  of anticoagulants

               5. Activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN unless participant is
                  receiving anticoagulant therapy as long as PT or PTT is within therapeutic range
                  of intended use of anticoagulants

          9. Female of childbearing potential (FCBP) (defined as a sexually mature woman who 1) has
             not undergone a hysterectomy (the surgical removal of the uterus) or bilateral
             oophorectomy (the surgical removal of both ovaries) or, 2) if ≥ 45 years old has not
             been naturally postmenopausal for at least 24 consecutive months (ie, has had menses
             at any time during the preceding 24 consecutive months) must:

               1. Have two negative pregnancy tests as verified by the Investigator prior to
                  starting study therapy. She must agree to ongoing pregnancy testing during the
                  course of the study, and after end of study treatment. This applies even if the
                  participant practices true abstinence* from heterosexual contact.

               2. Either commit to true abstinence* from heterosexual contact (which must be
                  reviewed on a monthly basis) or agree to use, and be able to comply with two
                  effective methods of contraception without interruption, 28 days prior to
                  starting IP, during the study therapy (including dose interruptions), and for 120
                  days after discontinuation (or longer if required by local requirements) of study
                  therapy. The two methods of contraception can either be two barrier methods or a
                  barrier method plus a hormonal method to prevent pregnancy.

         10. Male participants must practice true abstinence* (which must be reviewed on a monthly
             basis) or agree to the use a condom during sexual contact with a pregnant female or a
             female of childbearing potential while participating in the study, during dose
             interruptions and for at least 3 months following investigational product
             discontinuation (or longer if required by local requirements), even if he has
             undergone a successful vasectomy.

             * True abstinence is acceptable when this is in line with the preferred and usual
             lifestyle of the participant. Note: Periodic abstinence (eg, calendar, ovulation,
             symptothermal, postovulation methods) and withdrawal are not acceptable methods of
             contraception.

         11. Participant is willing to adhere to the study visit schedule and other protocol
             requirements.

         12. Participant understands and voluntarily signs an informed consent document prior to
             any study related assessments or procedures are conducted.

        Exclusion Criteria:

          1. Participants with non-squamous histology has known or unknown sensitizing epidermal
             growth factor receptor (EGFR) and/or anaplastic lymphoma kinase positive (ALK)
             mutation. Note: Participants with squamous histology and unknown EGFR and ALK
             mutational status are eligible.

          2. Participant has received more than one line of therapy for stage IIIB or IV disease

          3. Participant has been previously treated with azacitidine (any formulation),
             decitabine, or any other hypomethylating agent.

          4. Particpant has received prior therapy with any other anti-PD-1, or PD-L1 or PD-L2
             agent or an antibody targeting other immuno-regulatory receptors or mechanism,
             including participation in any other pembrolizumab trial and treatment with
             pembrolizumab.

             a. Examples of such antibodies include (but are not limited to) antibodies against
             indoleamine 2,3-dioxygenase (IDO), PD-L1, IL-2R, glucocorticoid-induced tumor necrosis
             factor receptor (GITR).

          5. Participant has had a prior monoclonal antibody within 4 weeks prior to study Day 1 or
             who has not recovered (i.e. ≤ Grade 1 or at baseline) from adverse events due to
             agents administered more than 4 weeks earlier.

          6. Participant is currently participating and receiving study therapy or has participated
             in a study of an investigational agent and received study therapy or used an
             investigational device within 4 weeks prior to administration of pembrolizumab and
             CC-486

          7. Participant has previous severe hypersensitivity reaction to another monoclonal
             antibody (mAb).

          8. Participant has a known or suspected hypersensitivity to azacitidine, mannitol, or any
             other ingredient used in the manufacture of CC-486 (see the Azacitidine IB).

          9. Participant has had radiotherapy ≤ 4 weeks or limited field radiation for palliation

         10. Participant has received radiation therapy to the lung that is > 30 Gy within 6 months
             of the first dose of trial treatment

         11. Participant has received a live-virus vaccination within 30 days of planned treatment
             start. Seasonal flu vaccines that do not contain live virus are permitted.

         12. Participant has not recovered from the acute toxic effects of prior anticancer
             therapy, radiation, or major surgery/significant trauma.

         13. Participant has an active infection requiring therapy.

         14. Participant has had an allogenetic tissue/solid organ ransplant.

         15. Participant has active autoimmune disease that has required systemic treatment within
             the past 2 years (eg, with use of disease modifying agents, corticosteroids or
             immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic
             corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is
             not considered a form of systemic treatment.

         16. Participant has known active Hepatitis B, Hepatitis C or tuberculosis. Active
             Hepatitis B is defined as a known positive HBsAg result. Active Hepatitis C is defined
             by a known positive Hepatitis C antibody result and known quantitative Hepatitis C
             virus (HCV) ribonucleic acid (RNA) results greater than the lower limits of detection
             of the assay.

         17. Participant has had any other malignancy within 5 years prior to randomization, with
             the exception of adequately treated in situ carcinoma of the cervix, uterus, or
             nonmelanomatous skin cancer (all treatment of which should have been completed 6
             months prior to enrollment).

         18. Participant has a history of inflammatory bowel disease (eg, Crohn's disease,
             ulcerative colitis), celiac disease (ie, sprue), prior gastrectomy or upper bowel
             removal, or any other gastrointestinal disorder or defect that would interfere with
             the absorption, distribution, metabolism, or excretion of the IP and/or predispose the
             participant to an increased risk of gastrointestinal toxicity.

         19. Participant has persistent diarrhea or clinically significant malabsorption syndrome
             or known sub-acute bowel obstruction ≥ Grade 2, despite medical management

         20. Participant has significant active cardiac disease within the previous 6 months
             including unstable angina or angina requiring surgical or medical intervention,
             significant cardiac arrhythmia, or New York Heart Association (NYHA) class 3 or 4
             congestive heart failure.

         21. Participant has history of interstitial lung disease (ILD) OR a history of pneumonitis
             that has required oral or IV steroids. Participants whose pneumonitis was solely as a
             result of radiation therapy for their NSCLC would not be excluded from the study
             unless they received oral/IV steroids to manage the pneumonitis.

         22. Participant has a known history or current diagnosis of human immunodeficiency virus
             (HIV) infection, regardless of treatment status.

         23. Participant has any other concurrent severe and/or uncontrolled medical condition that
             would, in the Investigator's judgment, contraindicate patient participation in the
             clinical study (eg, chronic pancreatitis, etc.).

         24. Participant with uncontrolled or symptomatic central nervous system (CNS) metastases
             and/or carcinomatous meningitis Participants with controlled and asymptomatic CNS
             metastases may participate in this trial. The patient must have completed any prior
             treatment for CNS metastases (must include radiotherapy and/or surgery) ≥ 28 days (≥
             14 days for stereotactic radiosurgery) and, if on corticosteroid therapy, should be
             receiving a stable dose of no greater than 4 mg/d dexamethasone (or equivalent
             anti-inflammatory potency of another corticosteroid) for at least 14 days before start
             of study treatment). Patients must not be receiving corticosteroids for brain
             metastases.

         25. Partcipant has not recovered from the acute toxic effects (Common Terminology Criteria
             for Adverse Events [CTCAE] grade ≤ 1) of prior anticancer therapy, radiation, or major
             surgery/significant trauma (except alopecia or other toxicities not considered a
             safety risk for the particiapants at the Investigator's discretion).

         26. Participant has an impaired ability to swallow oral medication.

         27. Participant is pregnant or breast feeding.

         28. Participant has any condition that confounds the ability to interpret data from the
             study.

         29. Participant is or has an immediate family member (spouse or children) who is
             investigational site or sponsor staff directly involved with this trial, unless
             prospective Institutional Review Board (IRB) approval (by chair or designee) is given
             allowing exception to this criterion for a specific participant.
      "
NCT02541903,terminated,"
    poor overall accrual
  ",0,phase 2,['penile squamous cell carcinoma (pscc)'],"[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]",['gilotrif'],['CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O'],"
        Inclusion Criteria:

          1. Histologically or cytologically confirmed PSCC.

          2. Patients with metastatic or locally advanced unresectable PSCC.

          3. Progressive disease after ≥1 prior chemotherapy regimens.

          4. Measurable disease by RECIST 1.1 criteria.

          5. Prior regimen within 6 months

          6. ECOG performance status 0-2.

          7. Adequate organ function, defined as all of the following:

               -  Absolute neutrophil count (ANC) >1500 /mm3. Platelet count >100,000/ mm3.

               -  Estimated creatinine clearance ≥ 45ml/min.

               -  Total Bilirubin <1.5 times upper limit of institutional normal; Aspartate amino
                  transferase (AST) or alanine amino transferase (ALT) <2.5 times the upper limit
                  of institutional normal (ULN).

               -  Hemoglobin ≥8.5 g/dl.

          8. Resolution of all acute toxic effects of prior chemotherapy or surgical procedures to
             NCI CTCAE version 4.03 grade <1, in the opinion of the Treating Physician.

          9. Ability to understand and willingness to sign a written informed consent. Age ≥18
             years or age of majority at the participating site, whichever is greater.

         10. Availability of 20 archival formalin-fixed paraffin embedded tumor tissue slides.

        Exclusion Criteria:

          1. Patients will have recovered from toxicities from prior systemic anticancer treatment
             or local therapies.

          2. Prior EGFR inhibitors.

          3. Major surgery within 4 weeks or minor surgery within 2 weeks before registration or
             scheduled for surgery during the projected course of the study. Wounds will be
             completely healed prior to study entry and patients recovered from all toxicities from
             surgery. Placement of vascular access device is not considered major or minor surgery
             in this regard.

          4. Prior radiation therapy is allowed as long as the irradiated area was not the sole
             source of measurable disease and radiotherapy was completed with recovery from
             toxicity, at least 3 weeks prior to enrollment. If the irradiated area is the only
             site of disease, there will be progressive disease.

          5. History or presence of clinically relevant cardiovascular abnormalities such as
             uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA)
             classification of 3, unstable angina or poorly controlled arrhythmia as determined by
             the investigator. Myocardial infarction within 6 months prior to registration.

          6. Any history of or concomitant condition that, in the opinion of the Investigator,
             would compromise the patient's ability to comply with the study or interfere with the
             evaluation of the efficacy and safety of the test drug.

          7. Previous or concomitant malignancies at other sites, except effectively treated
             non-melanoma skin cancers, ductal carcinoma in situ or effectively treated malignancy
             that has been in remission for more than 3 years and is considered to be cured.

          8. Requiring treatment with any of the prohibited concomitant medications listed in the
             protocol that cannot be stopped for the duration of trial participation.

          9. Known pre-existing interstitial lung disease.

         10. Any history or presence of poorly controlled gastrointestinal disorders that could
             affect the absorption of the study drug (e.g. Crohn's disease, ulcerative colitis,
             chronic diarrhea, malabsorption).

         11. Active hepatitis B infection (defined as presence of Hep BsAg and/ or Hep B DNA),
             active hepatitis C infection (defined as presence of Hep C RNA) and/or known HIV
             carrier.

         12. Meningeal carcinomatosis.

         13. Patients with active brain or subdural metastases are not eligible, unless they have
             completed local (radiation) therapy and have discontinued the use of corticosteroids
             or have been on stable dose of corticosteroids for at least 4 weeks before starting
             study treatment. Any symptoms attributed to brain metastases will be stable for at
             least 4 weeks before starting study treatment.

         14. Any active or uncontrolled infection.
      "
NCT02542930,withdrawn,"
    no recruitment.
  ",0,phase 2,"['non-small cell lung cancer', 'metastatic non-small cell lung cancer', 'radiotherapy', 'thymalfasin']","[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]",['thymalfasin'],['CCC(C)C(C(=O)NC(C(C)O)C(=O)NC(C(C)O)C(=O)NC(CCCCN)C(=O)NC(CC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCC(=O)O)C(=O)NC(C(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CCC(=O)O)C(=O)NC(CC(=O)N)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC(=O)O)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C'],"
        Inclusion Criteria:

          1. Patients with histologically confirmed colorectal cancer which is persistent and
             metastatic or recurrent and metastatic;

          2. Patients must have at least 3 distinct measurable metastatic sites at least 1 cm of
             larger in their largest diameter;

          3. Age ≥18 years;

          4. Metastatic disease measurable on a CT/MRI scan. The primary tumor is not considered
             measurable disease. Metastatic lesions within a prior radiation field are acceptable
             as long as disease has progressed in the radiation field by RECIST criteria. The same
             imaging modality performed at baseline (CT or MRI) will be repeated at subsequent
             imaging.

          5. ECOG performance status: 0-1;

          6. Life expectancy ≥ 3 months.

          7. Patients have adequate baseline organ and marrow function as defined by an absolute
             neutrophil count greater than 1500 cells per μL, platelet concentration of greater
             than 50 000 per μL, total bilirubin less than 1•5 times the upper limit of normal
             (ULN), aspartate aminotransferase and alanine aminotransferase less than 2•5 times the
             ULN, and serum creatinine less than 1•5 times the ULN;

          8. Signed consent forms voluntarily;

        Exclusion Criteria:

          1. Patients who have had prior allergic reaction to Apatinib;

          2. Patients undergoing therapy with other investigational agents.

          3. Women who are pregnant or breastfeeding;

          4. Patients with known brain metastases can be included in this clinical trial but brain
             lesions are not eligible as target or non target lesion;

          5. Anticipated patient survival under 3 months;

          6. Active severe infection or known chronic infection with HIV, hepatitis B virus, or
             hepatitis C virus;

          7. Cardiovascular disease problems including unstable angina, therapy for
             life-threatening ventricular arrhythmia, myocardial infarction, stroke or congestive
             heart failure within the last 6 months;

          8. The subject has had another active malignancy within the past five years except for
             cervical cancer in site, in situ carcinoma of the bladder or non-melanoma carcinoma of
             the skin;

          9. Clinically significant and uncontrolled major medical conditions including but not
             limited to: active uncontrolled infection, symptomatic congestive heart failure,
             Unstable angina pectoris or cardiac arrhythmia, psychiatric illness/ social situation
             that would limit compliance with study requirements; any medical condition, which in
             the opinion of the study investigator places the subject at an unacceptably high risk
             for toxicities;

         10. Patients with any other concurrent disease which, in the judgment of the investigator,
             would make the patient inappropriate for participation in the study.
      "
NCT02541396,completed,,1,phase 2,['acute pain'],"[""['G89.12', 'G89.18', 'G89.11', 'G89.3']""]","['wafermine', 'oxycodone', 'placebo']",['CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O'],"
        Inclusion Criteria:

          -  Scheduled for a bunionectomy (with no additional procedures).

          -  Healthy, ambulatory subjects able to understand and willing to comply with study
             procedures, study restrictions and requirements.

          -  Body mass index (BMI) ≥19 to ≤33 kg/m2.

          -  Females: Not pregnant, not lactating, and not planning to become pregnant during the
             study.

          -  Females: Be abstinent, surgically sterile, at least two years post-menopausal; or
             medically acceptable contraception.

          -  Able to read and understand English.

          -  Able to swallow oral capsules whole.

        Exclusion Criteria:

          -  Allergy, intolerance, or contraindication to ketamine, oxycodone, morphine, ibuprofen
             or surgical medications.

          -  Clinically significant medical condition.

          -  History of illicit drug use or alcohol abuse and not in full remission.

          -  Positive test for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or
             hepatitis C virus (HCV) at the screening visit.

          -  Clinically significant 12 lead ECG abnormalities at screening.

          -  Smokers who are unwilling to abstain during the inpatient stay.
      "
NCT02207309,terminated,"
    poor recruitment
  ",0,phase 2,['sarcoma'],"[""['C96.A', 'C46.9', 'C96.22', 'C46.0', 'C46.2', 'C92.31', 'C92.32']""]","['pazopanib', 'placebo (for pazopanib)']",['CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N'],"
        Inclusion Criteria:

          -  Subjects must provide written informed consent prior to performance of study-specific
             procedures or assessments and must be willing to comply with treatment and follow up

          -  Patients must have histological evidence of high-grade soft tissue sarcoma (grade 2 -
             3) according to the FNLCC grading system, tumor size ≥ 5 cm and deep localization with
             regard to the superficial fascia, excluding the following tumor types:

               -  Embryonal rhabdomyosarcoma

               -  Chondrosarcoma (excluding extraskeletal myxoid chondrosarcoma)

               -  Osteosarcoma (excluding extraskeletal osteosarcoma)

               -  Ewing tumors / primitive neuroectodermal tumor (PNET)

               -  Gastro-intestinal stromal tumors (GIST)

               -  Dermatofibrosarcoma protuberans

          -  Patients who had undergone previous surgery with inadequate margins (tumour-free
             margins ≤1 cm or margins contaminated) are eligible if thermochemotherapy has been
             started within 8 weeks after surgery

          -  Unstained slides and ideally tumour blocks must be available for histological central
             review

          -  Completed 4 to 8 cycles of thermochemotherapy with doxorubicin and ifosfamide at least
             21 days but no more than 42 days prior to study entry

          -  No evidence of disease following completion of first-line thermochemotherapy and
             within ≤ 21 days of study entry

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  No other prior chemotherapy except thermochemotherapy with doxorubicin and ifosfamide

          -  Adequate organ system function

        Exclusion Criteria:

          -  No prior or concurrent second primary malignant tumors (except adequately treated in
             situ carcinoma of cervix, or basal cell carcinoma)

          -  No symptomatic or known Central nervous system (CNS) metastases at baseline

          -  Clinically significant gastrointestinal abnormalities that may increase the risk for
             gastrointestinal bleeding including, but not limited to:

               -  Active peptic ulcer disease

               -  Known intraluminal metastatic lesion/s with risk of bleeding

               -  Inflammatory bowel disease (e.g. ulcerative colitis, Chrohn's disease), or other
                  gastrointestinal conditions with increased risk of perforation

               -  History of abdominal fistula, gastrointestinal perforation, or intra abdominal
                  abscess within 28 days prior to beginning study treatment.

          -  Clinically significant gastrointestinal abnormalities that may affect absorption of
             investigational product including, but not limited to:

               -  Malabsorption syndrome

               -  Major resection of the stomach or small bowel.

          -  Corrected QT interval (QTc) > 480 msecs

          -  History of any one or more of the following cardiovascular conditions within the past
             6 months:

               -  Cardiac angioplasty or stenting

               -  Myocardial infarction

               -  Unstable angina

               -  Coronary artery bypass graft surgery

               -  Symptomatic peripheral vascular disease

               -  Class III or IV congestive heart failure, as defined by the New York Heart
                  Association (NYHA) (See Appendix D for description)

          -  Poorly controlled hypertension (SBP of ≤ 150 mmHg or DBP of ≤95 mmHg is acceptable
             provided that BP will be treated and monitored at least weekly. The goal is to attain
             controlled hypertension within 4 weeks of start of IMP which is defined as grade ≤1
             hypertension CTCAE Version 4.0)

          -  NYHA II at Screening for Patients > 65 years

          -  History of cerebrovascular accident including transient ischemic attack (TIA),
             pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.

        Note: Subjects with recent DVT who have been treated with therapeutic anti-coagulating
        agents for at least 6 weeks are eligible

          -  Major surgery or trauma within 28 days prior to first dose of investigational product
             and/or presence of any non-healing wound, fracture, or ulcer (procedures such as
             catheter placement not considered to be major surgery).

          -  Evidence of active bleeding or bleeding diathesis.

          -  Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that
             increase the risk of pulmonary hemorrhage Note: Lesions infiltrating major pulmonary
             vessels (contiguous tumour and vessels) are excluded; however, the presence of a tumor
             that is touching, but not infiltrating (abutting) the vessels is acceptable (CT with
             contrast is strongly recommended to evaluate such lesions).

               -  Large protruding endobronchial lesions in the main or lobar bronchi are excluded;
                  however, endobronchial lesions in the segmented bronchi are allowed.

               -  Lesions extensively infiltrating the main or lobar bronchi are excluded; however,
                  minor infiltrations in the wall of the bronchi are allowed.

          -  Recent hemoptysis (≥½ teaspoon of red blood within 8 weeks before first dose of study
             drug).

          -  Any serious and/or unstable pre-existing medical, psychiatric, or other condition that
             could interfere with subject's safety, provision of informed consent, or compliance to
             study procedures.

          -  Treatment with any of the following anti-cancer therapies:

               -  radiation therapy, surgery or tumor embolization within 14 days prior to the
                  first dose of pazopanib OR

               -  chemotherapy, immunotherapy, biologic therapy, investigational therapy or
                  hormonal therapy within 14 days or five half-lives of a drug (whichever is
                  longer) prior to the first dose of pazopanib

          -  Administration of any non-oncologic investigational drug within 30 days or 5 half
             lives whichever is longer prior to receiving the first dose of study treatment

          -  Any ongoing toxicity from prior anti-cancer therapy that is >Grade 1 and/or that is
             progressing in severity, except alopecia
      "
NCT02208037,completed,,1,phase 2,"['acute leukemia', 'chronic myelogenous leukemia', 'myelodysplasia', 'chronic lymphocytic leukemia', 'small lymphocytic lymphoma', 'lymphoma, b-cell', 'lymphoma, follicular', 'lymphoma, large b-cell, diffuse', ""hodgkin's lymphoma""]","[""['C91.01', 'C91.02', 'C92.01', 'C92.02', 'C92.41', 'C92.42', 'C92.51']"", ""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']"", ""['C91.11', 'C91.12', 'C91.10']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']""]","['tacrolimus (arm with methotrexate)', 'tacrolimus (arm with mmf and cyclophosphamide)', 'methotrexate (arm with maraviroc)', 'methotrexate (arm with bortezomib)', 'maraviroc', 'bortezomib', 'mycophenolate mofetil', 'cyclophosphamide']","['CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C', 'B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O', 'CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)OCCN3CCOCC3)O', 'C1CNP(=O)(OC1)N(CCCl)CCCl']","
        Inclusion Criteria:

          1. Age 18-75 years (patient is older than 18.0 and less than 76.0 years old)

          2. Patients with acute leukemia, chronic myelogenous leukemia or myelodysplasia with no
             circulating blasts and with less than 5% blasts in the bone marrow.

          3. Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular,
             marginal zone, diffuse large B-cell, Hodgkin's Lymphoma,or mantle cell lymphoma with
             chemosensitive disease at time of transplantation

          4. Planned reduced intensity conditioning regimen (see eligible regimens in Table 2.4a)

          5. Patients must have a related or unrelated peripheral blood stem cell donor as follows:

               1. Sibling donor must be a 6/6 match for HLA-A and -B at intermediate (or higher)
                  resolution, and -DRB1 at high resolution using DNA-based typing, and must be
                  willing to donate peripheral blood stem cells and meet institutional criteria for
                  donation.

               2. Unrelated donor must be a 7/8 or 8/8 match at HLA-A, -B, -C and -DRB1 at high
                  resolution using DNA-based typing. Unrelated donor must be willing to donate
                  peripheral blood stem cells and be medically cleared to donate stem cells
                  according to National Marrow Donor Program (NMDP) criteria.

          6. Cardiac function: Ejection fraction at rest ≥ 45%

          7. Estimated creatinine clearance greater than 50 mL/minute (using the Cockcroft-Gault
             formula and actual body weight)

          8. Pulmonary function: Diffusing capacity of the lung for carbon monoxide (DLCO) ≥ 40%
             (adjusted for hemoglobin) and forced expiratory volume in one second (FEV1) ≥ 50%

          9. Liver function: total bilirubin < 1.5 x the upper limit of normal and alanine
             aminotransferase (ALT)/aspartate aminotransferase (AST) < 2.5x the upper normal limit.
             Patients who have been diagnosed with Gilbert's Disease are allowed to exceed the
             defined bilirubin value of 1.5x the upper limit of normal.

         10. Female subjects (unless postmenopausal for at least 1 year before the screening visit,
             or surgically sterilized), agree to practice two (2) effective methods of
             contraception at the same time, or agree to completely abstain from heterosexual
             intercourse, from the time of signing the informed consent through 12 months post
             transplant (see Section 2.6.4 for definition of postmenopausal).

         11. Male subjects (even if surgically sterilized), of partners of women of childbearing
             potential must agree to one of the following: practice effective barrier contraception
             (see Section 2.6.4 for list of barrier methods), or abstain from heterosexual
             intercourse from the time of signing the informed consent through 12 months post
             transplant.

         12. Signed informed consent

        Exclusion Criteria:

          1. Prior allogeneic transplant

          2. Karnofsky Performance Score < 70%

          3. Active central nervous system (CNS) involvement by malignant cells

          4. Patients with uncontrolled bacterial, viral or fungal infections (currently taking
             medication and with progression or no clinical improvement) at time of enrollment.

          5. Presence of fluid collection (ascites, pleural or pericardial effusion) that
             interferes with methotrexate clearance or makes methotrexate use contraindicated

          6. Patients with transformed lymphoma (e.g., Richters transformation arising in
             follicular lymphoma or chronic lymphocytic leukemia)

          7. Patients seropositive for the human immunodeficiency virus (HIV)

          8. Patient with active Hepatitis B or C determined by serology and/or nucleic acid
             amplification tests (NAAT)

          9. Patients with hypersensitivity to bortezomib, boron or mannitol

         10. Patients with ≥ grade 2 sensory peripheral neuropathy

         11. Myocardial infarction within 6 months prior to enrollment or New York Heart
             Association (NYHA) Class III or IV heart failure (see Appendix D), uncontrolled
             angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence
             of acute ischemia or active conduction system abnormalities. Prior to study entry, any
             ECG abnormality at screening must be documented by the investigator as not medically
             relevant.

         12. Female patients who are lactating or pregnant

         13. Patients with a serious medical or psychiatric illness likely to interfere with
             participation in this clinical study

         14. Patients with prior malignancies except resected basal cell carcinoma or treated
             cervical carcinoma in situ. Cancer treated with curative intent ≥ 5 years previously
             will be allowed. Cancer treated with curative intent < 5 years previously will not be
             allowed unless approved by the Protocol Officer or one of the Protocol Chairs.

         15. Planned use of anti-thymocyte globulin (ATG) or alemtuzumab in conditioning regimen.

         16. Planned post-transplant therapy, including use of tyrosine-kinase inhibitors (TKI).

         17. Inability to withhold agents that may interact with hepatic cytochrome P450 enzymes
             (CYP3A4), or glutathione S-transferases involved in bortezomib and/or busulfan
             metabolism during day -5 through day +7. It is acceptable to use alternative
             non-interacting medications during this period, and then resume prior medications.

         18. Patients with secondary acute myeloid leukemia arising from myeloproliferative
             disease, including Chronic myelomonocytic leukemia (CMML), with evidence of active
             myeloproliferative features or myelofibrosis in the background.
      "
NCT02322853,terminated,"
    lack of recruitment
  ",0,phase 2,"['postmenopausal', 'metastatic breast cancer']","[""['N95.0', 'N95.2']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['tamoxifen', 'ralimetinib (ly2228820 dimesylate)']",['CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3'],"
        Inclusion Criteria:

          -  Women with histologically confirmed breast cancer

          -  18 < age < 80 years old

          -  Menopausal status Women are considered post-menopausal and not of child bearing
             potential if they have had

               -  12 months of spontaneous amenorrhea with an appropriate clinical profile (e.g.,
                  age appropriate, history of vasomotor symptoms) or

               -  6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL and
                  estradiol < 20 pg/mL or

               -  surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks
                  ago. In the case of oophorectomy alone, only when the reproductive status of the
                  woman has been confirmed by follow up hormone level assessment is she considered
                  not of child bearing potential

          -  ER-positive status by local laboratory testing (>10% by IHC) and HER2-negative status
             (IHC 0 or 1+ or 2+ and FISH negative) on the last biopsy or surgical specimen
             available.

          -  Disease progression defined as inoperable locally advanced or metastatic breast cancer
             (MBC) excluding aggressive visceral disease requiring other approaches, such as
             chemotherapy

          -  Disease refractory to aromatase inhibitors (AI) defined as:

               -  recurrence while on, or within 12 months of end of adjuvant treatment with
                  aromatase inhibitor, or

               -  progression while on, or within 3 months of end of AI for locally advanced or MBC

          -  Patients who have received fulvestrant are eligible

          -  Maximum 2 previous lines of chemotherapy for MBC

          -  Performance Status (PS) ≤ 2

          -  Patient able to swallow and retain oral medication

          -  Measurable or evaluable lesions as per RECIST 1.1

               -  Measurable disease (≥ 20 mm by conventional techniques or ≥ 10 mm by spiral
                  computed tomography scan) or

               -  Non-measurable lytic or mixed (lytic + blastic) bone lesions in the absence of
                  measurable disease.

               -  Patients with only pleural effusion and/or ascites are not eligible.

          -  Adequate bone marrow and organ function as defined by the following laboratory values:

               -  Absolute Neutrophil Count (ANC) ≥ 1.0 x 109/L

               -  Platelets (plt) ≥ 100 x 109/L

               -  Hemoglobin (Hgb) ≥ 9 g/dl

               -  INR ≤ 1.5 without any anticoagulation treatment

               -  Serum creatinine ≤ 1.5 x ULN

               -  Alanine aminotransferase (AST) and aspartate aminotransferase (ALT) within normal
                  range (or < 3.0 x ULN if liver metastases are present)

               -  Total serum bilirubin within normal range (or ≤ 1.5 x ULN if liver metastases are
                  present; or total bilirubin ≤ 3.0 x ULN with direct bilirubin within normal range
                  in patients with well documented Gilbert's Syndrome, which is defined as presence
                  of several episodes of unconjugated hyperbilirubinemia with normal results from
                  CBC count (including normal reticulocyte count and blood smear), normal liver
                  function test results, and absence of other contributing disease processes at the
                  time of diagnosis

          -  Patient has signed informed consents obtained before any trial related activities and
             according to local guidelines

        Exclusion Criteria:

          -  • Previous treatment with p38 MAPK inhibitors or Tamoxifen in metastatic setting
             (adjuvant treatment by tamoxifen is allowed)

               -  More than 2 lines of chemotherapy for locally advanced and/or metastatic breast
                  cancer

               -  Brain metastasis

               -  Other malignancy (with the exception of adequately treated, basal or squamous
                  cell carcinoma, non-melanomatous skin cancer or curatively resected cervical
                  cancer).

               -  Clinically significant (i.e. active) cardiovascular disease: cerebro-vascular
                  accident/stroke or myocardial infarction within 6 months prior to first study
                  medication; unstable angina; CHF of New York Heart Association (NYHA) Grade II or
                  higher; or serious cardiac arrhythmia requiring medication.

               -  Have had a major bowel resection that would alter oral drug absorption.

               -  Have a diagnosis of inflammatory bowel disease (Crohn's disease or ulcerative
                  colitis).

               -  Are receiving concurrent administration of immunosuppressive therapy

               -  Concurrent participation in any therapeutic clinical trial

               -  Assessed by the investigator to be unable or unwilling to comply with the
                  requirements of the protocol
      "
NCT02325986,unknown status,,1,phase 2,['esophageal squamous cell carcinoma'],"[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]","['fluorouracil', 'cisplatin']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          1. R0 resection for primary esophageal squamous cell carcinoma with two-incision
             esophagectomy (Ivor Lewis approach)25 or three-incision (right thoracotomy, midline
             laparotomy and left cervical incisions) esophagectomy with cervical esophagogastric
             anastomosis.

          2. Absence of previous thoracic radiotherapy.

          3. Cervical and/or thoracic postoperative recurrence (biopsy proven or positron emission
             tomography/computed tomography (PET/CT) proven or follow-up computed tomography (CT)
             showed progression of disease).

          4. Absence of distant metastasis at recurrence.

          5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2

        Exclusion Criteria:

          1. Younger than 18 or older than 70 years of age.

          2. Eastern Cooperative Oncology Group (ECOG) performance status of 3 or above

          3. Other cancer history.

          4. Serious cardiac, liver, or pulmonary disease.

          5. Previous radiotherapy history
      "
NCT02320487,completed,,1,phase 2,['chronic lymphocytic leukemia'],"[""['C91.11', 'C91.12', 'C91.10']""]","['bendamustine', 'obinutuzumab']",['CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O'],"
        Inclusion Criteria:

          -  Participants must satisfy one of the criteria for treatment initiation, as outlined in
             the iwCLL NCI-WG guidelines. The criteria include: (a) Evidence of progressive marrow
             failure as manifested by the development of, or worsening of, anemia and/or
             thrombocytopenia, (b) Massive (i.e., greater than or equal to [>=] 6 centimeters [cm]
             below the left costal margin) or progressive or symptomatic splenomegaly, (c) Massive
             nodes (i.e., >= 10 cm in longest diameter) or progressive or symptomatic
             lymphadenopathy, (d) Progressive lymphocytosis with an increase of greater than (>) 50
             percent (%) over a 2-month period or lymphocyte doubling time (LDT) of less than (<) 6
             months, (e) Autoimmune anemia and/or thrombocytopenia that is poorly responsive to
             corticosteroids or other standard therapy, (f) Constitutional symptoms, defined as any
             one or more of the following disease-related symptoms or signs: unintentional weight
             loss of >=10% within the previous 6 months, significant fatigue (i.e., Eastern
             Cooperative Oncology Group Performance Status [ECOG PS] of 2 or worse or the inability
             to work or perform usual activities), fevers higher than 100.5 degrees Fahrenheit
             (°F)/38.0 degrees Celsius (°C) for >= 2 weeks without other evidence of infection, or
             night sweats for >1 month without evidence of infection

          -  Absolute neutrophil count (ANC) >=1.5 × 10^9 per liter (/L) and platelets >=75 ×
             10^9/L unless cytopenia is caused by the underlying disease, i.e., no evidence of
             additional bone marrow dysfunction (e.g., myelodysplastic syndrome, hypoplastic bone
             marrow)

          -  Life expectancy >6 months

          -  ECOG PS of 0, 1, or 2

          -  Willing to use acceptable contraceptive measures as defined by the protocol during and
             at least for 6 months (male participants) or 12 months (female participants) after the
             last dose of study drug

        Exclusion Criteria:

          -  Pregnant or lactating, or intending to become pregnant during the study: Women who are
             not postmenopausal (>=12 months of non-therapy-induced amenorrhea) or surgically
             sterile must have a negative serum pregnancy test result within 14 days prior to
             initiation of study drug

          -  Participants who have received previous CLL therapy, including investigational
             therapies

          -  Transformation of CLL to aggressive non-Hodgkin's lymphoma (Richter's transformation)

          -  Inadequate renal function

          -  Inadequate liver function: National Cancer Institute Common Terminology Criteria for
             Adverse Events (NCI CTCAE) Grade 3 liver function tests (aspartate aminotransferase
             [AST] or alanine aminotransferase [ALT] >5× upper limit of normal [ULN] for >2 weeks;
             bilirubin >3× ULN) unless due to underlying disease

          -  History of other malignancy, which could affect compliance with the protocol or
             interpretation of results

          -  Participants with active bacterial, viral, or fungal infection requiring systemic
             treatment

          -  Participants with known infection with human immunodeficiency virus (HIV) or human
             T-cell leukemia virus 1 (HTLV-1)

          -  Positive hepatitis serology: (a) Participants with positive serology for hepatitis B,
             defined as positivity for hepatitis B surface antigen (HBsAg), or participants who are
             HBsAg negative but are hepatitis B core antibody (anti-HBc) positive, (b) Participants
             positive for anti-HBc, but with negative hepatitis B Virus (HBV) deoxyribonucleic acid
             (DNA), will be considered for inclusion by the Medical Monitor on a case-by-case basis
             in order to ensure feasibility of monthly DNA testing and availability of appropriate
             care in case of hepatitis B reactivation, (c) Participants with positive serology for
             hepatitis C (HCV) unless HCV (by ribonucleic acid [RNA]) is confirmed negative

          -  History of severe allergic or anaphylactic reactions to monoclonal antibodies

          -  Evidence of significant, uncontrolled concomitant diseases that could affect
             compliance with the protocol or interpretation of results, including significant
             cardiovascular disease (such as New York Heart Association Class III or IV cardiac
             disease, myocardial infarction within the previous 6 months, unstable arrhythmias, or
             unstable angina) or pulmonary disease (including obstructive pulmonary disease and
             history of symptomatic bronchospasm)

          -  Vaccination with a live vaccine a minimum of 30 days prior to study treatment

          -  Use of investigational agents of any kind within 30 days before study treatment
      "
NCT02324803,unknown status,,1,phase 2,"['self efficacy', 'adverse drug event', 'carcinoma, renal cell']","[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]",['pazopanib'],['CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N'],"
        Inclusion Criteria:

          1. Written informed consent

          2. Diagnosis of renal cell carcinoma with clear-cell component histology.

          3. Locally advanced/metastatic renal cell carcinoma

          4. Measurable lesion (RECIST 1.1) on physical exam or as CT/MRI

          5. No prior systemic therapy for advanced/metastatic RCC

          6. Karnofsky performance scale >=70

          7. Age >=18 years

          8. A female is eligible to enter and participate in this study if she is of:
             non-childbearing/agrees to use adequate contraception

          9. A male with female partner of childbearing potential must have vasectomy/agree to use
             effective contraception from two weeks prior to administration of the 1st dose of
             study treatment for a period of time after the last dose of study treatment

         10. Adequate organ function

         11. Able to swallow and retain orally administered medication and must not have clinically
             significant GIT abnormalities that may alter absorption

         12. The date of disease progression must be within six months of stopping sunitinib or
             during treatment with sunitinib

         13. Measurable lesion at pazopanib baseline as per the RECIST 1.1 criteria

        Exclusion Criteria:

          1. Pregnant/lactating

          2. History of another malignancy (unless have been disease-free for 3 years)

          3. History or clinical evidence of Central nervous system metastases (unless have
             previously-treated CNS metastases and who meet both of the following criteria: a) are
             asymptomatic and b) have no requirement for steroids or enzyme-inducing
             anticonvulsants in prior 6 month time interval.

          4. Clinically significant gastrointestinal abnormalities including, but not limited to:
             malabsorption syndrome, major resection of the stomach or small bowel that could
             affect the absorption of study drug, active peptic ulcer disease, known intraluminal
             metastatic lesion/s with suspected bleeding, Inflammatory bowel disease, ulcerative
             colitis, or other gastrointestinal conditions with increased risk of perforation,
             history of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess

          5. Moderate to severe hepatic impairment (Child-Pugh Class C)

          6. Any serious and/or unstable pre-existing medical, psychiatric, or other conditions
             that could interfere with patient's safety, obtaining informed consent or compliance
             to the study.

          7. Subjects receiving chronic treatment with corticosteroids/other immunosuppressive
             agents

          8. Subjects with a known history of HIV seropositivity

          9. Subjects with active bleeding, bleeding diathesis or on oral anti-vitamin K medication
             (except low dose coumadin)

         10. Presence of any severe or uncontrolled medical conditions/infection.

         11. Currently receiving chemotherapy, immunotherapy or radiotherapy

         12. Corrected QT interval (QTc) > 480 milliseconds

         13. History of any one or more of the following cardiovascular conditions within the past
             12 months: cardiac angioplasty or stenting, myocardial infarction, unstable angina,
             coronary artery by-pass graft surgery, symptomatic peripheral vascular disease, Class
             III or IV congestive heart failure, as defined by the New York Heart Association

         14. Poorly controlled hypertension (defined as systolic blood pressure of >=140mmHg or
             diastolic blood pressure of >=90mmHg).

         15. History of cerebrovascular accident including transient ischemic attack, pulmonary
             embolism or untreated deep venous thrombosis (DVT) within the past 6 months (unless
             recent DVT have been treated with therapeutic anti-coagulating agents for at least 6
             weeks)

         16. Major surgery or trauma within 28 days prior to first dose of study drug and/or
             presence of any non-healing wound, fracture, or ulcer.

         17. Evidence of active bleeding or bleeding susceptibility.

         18. Known endobronchial lesion and/or lesions infiltrating major pulmonary vessels that
             increase the risk of pulmonary hemorrage
      "
NCT02324335,completed,,1,phase 2,"['head and neck neoplasms', 'mucositis']","[""['C76.0', 'C47.0', 'C49.0', 'C77.0', 'D17.0', 'D21.0', 'D36.11']"", ""['J34.81', 'K92.81', 'K12.30', 'K12.39', 'K12.33', 'N76.81', 'K12.31']""]",['brilacidin'],['C1CNCC1OC2=C(C=C(C=C2NC(=O)C3=CC(=NC=N3)C(=O)NC4=CC(=CC(=C4OC5CCNC5)NC(=O)CCCCN=C(N)N)C(F)(F)F)C(F)(F)F)NC(=O)CCCCN=C(N)N'],"
        Inclusion Criteria:

          1. Willing and able to read, understand and sign an informed consent form (ICF)

          2. Have recently diagnosed (within previous 6 months) pathologically confirmed,
             non-metastatic squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or
             supraglottic larynx that will be treated with CRT therapy as first line non-surgical
             treatment. Scans (CT, PET, and/or MRI) obtained within 120 days prior to consent for
             screening can be used to determine the subject's eligibility.

          3. Have a plan to receive a continuous course of conventional external beam irradiation
             delivered by intensity-modulated radiotherapy (IMRT) as single daily fractions of 2.0
             Gy to 2.2 Gy with a cumulative radiation dose ≥55 Gy and ≤72 Gy. Planned radiation
             treatment fields must include at least two oral sites (buccal mucosa, floor of mouth,
             ventral/lateral tongue, soft palate). [Note: the independent RTQA consultant must
             confirm that the planned radiation treatment meets the protocol criteria]

          4. Have a plan to receive a standard cisplatin chemotherapy regimen administered weekly
             (30-40 mg/m2) or approximately every 21 days (80-100 mg/m2)

          5. Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2.
             However, potential subjects with an ECOG of 3 may be enrolled provided their condition
             does not preclude performing the actions required by study participation (e.g.,
             opening medication bottles, swishing the oral rinse and spitting out, completing or
             participating in completion of daily diaries and FACT-H&N forms).

          6. Have adequate hematopoietic, hepatic, and renal function at a screening visit

          7. Urine or serum pregnancy test: negative for female patients of childbearing potential

          8. Agree to utilize medically accepted methods of birth control during study
             participation and for 90 days following the last treatment with study drug if a female
             subject is of childbearing potential or if a male subject has an opposite sex partner
             of child bearing potential.

          9. Males or females aged ≥18 years on day of consent.

        Exclusion Criteria:

          1. Has tumor(s) of the lips, sinuses, salivary glands, nasopharynx, glottic larynx,
             subglottic larynx or unknown primary tumor

          2. Has metastatic disease (M1) Stage IV C

          3. Has had prior radiation to the head and neck

          4. Plan to be treated with cetuximab (Erbitux®)

          5. Planned use of cisplatin as induction chemotherapy.

          6. Has a history of other malignant tumors within the last 5 years, except non melanoma
             skin cancer or in situ cervical carcinoma curatively excised

          7. Has had a major surgical procedure, other than for HNC, or significant traumatic
             injury within 4 weeks prior to the initiation of RT; anticipation of need for major
             surgical procedure during the course of the study

          8. Has incompletely healed sites of dental extractions

          9. Has an 12-lead ECG obtained at screening visit which shows medically significant
             abnormality(ies) (e.g. left bundle branch block, frequent premature ventricular
             contractions, QTc interval prolongation > 450 msec for males and > 470 msec for
             females)

         10. Has untreated hypertension or has hypertension under treatment that meets protocol
             definitions.

         11. Has active infectious disease undergoing systemic treatment excluding oral candidiasis

         12. Has oral mucositis (of any severity) prior to initiation of radiation therapy

         13. Has a diagnosis of an immunosuppressive illness or a condition requiring chronic
             immunosuppression

         14. Has known seropositivity for HIV or hepatitis C antibody, or known to be hepatitis B
             surface antigen positive (testing for these serologic markers is not required for
             enrollment in this protocol)

         15. Use of any investigational agent within 30 days of randomization

         16. Is pregnant or breastfeeding

         17. Has known allergies or intolerance to brilacidin, cisplatin or carboplatin

         18. Has inability to give informed consent or comply with study requirements

         19. Has any other condition or prior therapy that in the opinion of the Investigator would
             make the patient unsuitable for the study and/or unable to comply with requirements
             for follow-up visits.

         20. Is unwilling or unable to agree to swish and spit the study oral rinse three times per
             day during the study period
      "
NCT02323113,terminated,"
    business decision; no safety or efficacy concerns.
  ",0,phase 1/phase 2,['acute myelogenous leukemia'],"[""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']""]",['tak-659'],['CN1C=C(C=N1)C2=NC(=C(C3=C2C(=O)NC3)F)NC4CCCCC4N'],"
        Inclusion Criteria:

          1. Male or female participants 18 years or older.

          2. Must have a histopathologically documented diagnosis of primary or secondary AML
             (excluding acute promyelocytic leukemia), as defined by World Health Organization
             (WHO) criteria (Jaffe et al, 2001), for whom no standard therapies are anticipated to
             result in a durable remission according to the clinical judgment of the principal
             investigator, or who refuses standard therapies (phase 1b and 2).

          3. Participants for the phase 2 portion of the study must, in addition, meet the
             following:

             o Must be refractory to or relapsed after no more than 2 prior chemotherapy regimens.
             Re-induction with the same regimen or stem cell transplant will not be considered a
             separate regimen.

          4. Eastern Cooperative Oncology Group performance status of 0 to 1.

          5. Female participants who:

               -  Are postmenopausal for at least 1 year before the screening visit, or

               -  Are surgically sterile, or

               -  If they are of childbearing potential, agree to practice 2 effective methods of
                  contraception, at the same time, from the time of signing the informed consent
                  through 180 days after the last dose of study drug, or

               -  Agree to practice true abstinence, when this is in line with the preferred and
                  usual lifestyle of the participant. (Periodic abstinence [example, calendar,
                  ovulation, symptothermal, postovulation methods], withdrawal, spermicides only,
                  and lactational amenorrhea are not acceptable methods of contraception. Female
                  and male condoms should not be used together).

             Male participants, even if surgically sterilized (that is, status postvasectomy), who:

               -  Agree to practice effective barrier contraception during the entire study
                  treatment period and through 180 days after the last dose of study drug, or

               -  Agree to practice true abstinence, when this is in line with the preferred and
                  usual lifestyle of the participant. (Periodic abstinence [example, calendar,
                  ovulation, symptothermal, postovulation methods for the female partner],
                  withdrawal, spermicides only, and lactational amenorrhea are not acceptable
                  methods of contraception. Female and male condoms should not be used together).

          6. Voluntary written consent must be given before performance of any study-related
             procedure not part of standard medical care, with the understanding that consent may
             be withdrawn by the participant at any time without prejudice to future medical care.

          7. In the absence of rapid progressive disease, the interval from prior systemic
             anticancer treatment to time of TAK-659 administration should be at least 2 weeks for
             cytotoxic agents (other than hydroxyurea), or at least 5 half-lives for noncytotoxic
             agents, and participants have to have recovered from acute toxicities of these
             therapies. Participants who are on hydroxyurea may be included in the study and may
             continue on hydroxyurea for the first 28 days while participating in this study.

          8. Suitable venous access for the study-required blood sampling, including
             pharmacokinteic (PK) and pharmacodynamic (PD) sampling and blood transfusion support.

          9. Clinical laboratory values as specified in the following:

               -  Total bilirubin must be less than or equal to (<=) 1.5* the upper limit of normal
                  (ULN).

               -  Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be
                  less than or equal to (<=) 2.5*the ULN.

               -  Lipase <=1.5*ULN and amylase <=1.5*ULN with no clinical symptoms suggestive of
                  pancreatitis or cholecystitis.

               -  Creatinine clearance greater than or equal to (>=) 60 milliliter per minute
                  (mL/min) either as estimated by the Cockcroft-Gault equation or based on urine
                  collection (12 or 24 hours).

        Exclusion Criteria:

          1. Clinically active central nervous system leukemia.

          2. Female participants who are lactating and breastfeeding or have a positive serum
             pregnancy test during the Screening period or a positive urine pregnancy test on Day 1
             before first dose of study drug.

          3. Any serious medical or psychiatric illness, including drug or alcohol abuse that
             could, in the investigator's opinion, potentially jeopardize the safety of the
             participant or interfere with the objectives of the study.

          4. Systemic anti-cancer treatment (including investigational agents) <=21 days or <=
             5*their half-lives before the first dose of study treatment. (For example, if the
             5*the half-life is shorter than 21 days, 5*half-life should be used as the washout
             period. However, a minimum of 10 days should elapse from prior therapy to initiating
             protocol therapy).

          5. Persistent clinically significant toxicity from prior chemotherapy that is Grade 2 or
             higher by the National Cancer Institute Common Terminology Criteria for Adverse Events
             (NCI CTCAE) (v4.03).

          6. Receipt of hematopoietic stem cell transplant (HSCT) within 60 days of the first dose
             of TAK-659; clinically significant graft-versus-host disease (GVHD) requiring ongoing
             immunosuppressive therapy post HSCT at the time of screening (use of topical steroids
             for ongoing skin GVHD is permitted).

          7. Active, systemic infection requiring intravenous (IV) antibiotic, antifungal, or
             antiviral therapy or other serious infection within 14 days before the first dose of
             study drug.

          8. Major surgery within 14 days before the first dose of study drug and have not
             recovered fully from any complications from surgery.

          9. Radiotherapy less than 2 weeks before the first dose of study treatment or have not
             recovered from acute toxic effects from radiotherapy.

         10. Known human immunodeficiency virus (HIV) positive (testing not required).

         11. Known hepatitis B surface antigen-positive, known or suspected active hepatitis C
             infection (testing not required).

         12. Evidence of currently uncontrolled cardiovascular conditions as listed in the
             protocol; acute myocardial infarction with 6 months before starting study drug;
             baseline QT interval (QTcF) greater than (>) 450 milliseconds (msec) (males) or > 475
             msec (females); or abnormalities on baseline 12-lead electrocardiogram (ECG) that are
             considered clinically significant per investigator.

         13. Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral
             absorption or tolerance of TAK-659 including difficulty swallowing tablets; diarrhea >
             Grade 1 despite supportive therapy.

         14. Use or consumption of any of the following substances:

               -  Medications or supplements that are known to be inhibitors of P-glycoprotein
                  (P-gp) or strong inhibitors or inducers of Cytochrome (CY) P3A within 5 times the
                  inhibitor half-life (if a reasonable half-life estimate is known) or within 7
                  days (if a reasonable half-life estimate is unknown) before the first dose of
                  study drug. In general, the use of these agents is not permitted during the study
                  except for AE management.

               -  Medications or supplements that are known to be strong CYP3A mechanism based
                  inhibitors or strong CYP3A inducers and/or P-gp inducers within 7 days or within
                  5 times the inhibitor or inducer half-life (whichever is longer) before the first
                  dose of study drug. In general, the use of these agents is not permitted during
                  the study except for AE management.

               -  Grapefruit-containing food or beverages within 5 days before the first dose of
                  study drug. Note that grapefruit-containing food and beverages are not permitted
                  during the study.

         15. White blood cell count > 50,000 per micro liter (/µL); hydroxyurea may be used to
             control the level of circulating leukemic blast cell counts prior to study entry and,
             if needed, concomitantly while on TAK-659 treatment during the first 28 days of the
             study. Hydroxyurea can be used up to a maximum dose of 5 gram per (g/) day.
      "
NCT04337827,terminated,"
    slow accrual
  ",0,phase 2,['post-transplant lymphoproliferative disorder'],"[""['D47.Z1']""]","['rituximab', 'acalabrutinib']",['CC#CC(=O)N1CCCC1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5'],"
        Inclusion Criteria:

          -  Subjects must have a biopsy confirmed newly diagnosed CD20 positive B cell PTLD.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. ECOG 3 will be
             permitted if the decline in performance status is due to lymphoma. [See Appendix 1]

          -  Subjects must have adequate hematologic, hepatic, and renal function as defined below:

               -  Hemoglobin ≥ 8 gm/dL

               -  Absolute neutrophil count ≥500/mcL (unless documented bone marrow involvement
                  with lymphoma)

               -  Platelet count ≥50000/mcL (unless there is documented bone marrow involvement
                  with lymphoma)

               -  Prothrombin time/international normalized ratio (INR) or activated partial
                  thromboplastin time (aPTT) (in the absence of Lupus anticoagulant) < 2x ULN.

               -  Total bilirubin ≤1.5X upper limit of normal (ULN)

               -  Creatinine ≤2.5X upper limit of normal (ULN)

               -  Alanine aminotransferase/aspartate aminotransferase (ALT/AST) < 2.5 X or ≤5X ULN
                  for patients with document hepatic involvement with lymphoma

          -  Women of childbearing potential and men must agree to use adequate contraception
             (double barrier method of birth control or abstinence) during treatment and for 12
             months after last dose of study treatment. Women who have undergone surgical
             sterilization or who have been postmenopausal for at least 2 years are not considered
             to be of childbearing potential.

          -  Subjects must be willing and able to participate in all required evaluations and
             procedures in this study protocol including swallowing capsules without difficulty

          -  Subjects must have the ability to understand the purpose and risks of the study and
             provide signed and dated informed consent and authorization to use protected health
             information

        Exclusion Criteria:

          -  Prior treatment with any BTK inhibitor

          -  Subjects receiving any other investigational agents or participating in another
             therapeutic clinical trial.

          -  Subjects with active (treated or untreated) brain metastases/ central nervous system
             (CNS) disease (including but not limited to CNS PTLD) will be excluded from this
             clinical trial

          -  Prior malignancy (or any other malignancy that requires active treatment), except for
             adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer,
             early stage prostate cancer or other cancer from which the subject has been disease
             free for ≥ 3 years

          -  Clinically significant cardiovascular disease such as uncontrolled or symptomatic
             arrhythmias, congestive heart failure, or myocardial infarction within 6 months of
             screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart
             Association Functional Classification. Subjects with controlled, asymptomatic atrial
             fibrillation during screening can enroll in the study.

          -  Has difficulty with or is unable to swallow oral medication, or has significant
             gastrointestinal disease that would limit absorption of oral medication.

          -  Known history of infection with HIV. HIV-positive subjects on combination
             antiretroviral therapy are ineligible because of the potential for pharmacokinetic
             interactions with acalabrutinib.

          -  Patients with uncontrolled concurrent illness like active infection (eg, bacterial,
             viral, or fungal) requiring IV antibiotics or psychiatric illness/social situations
             that would limit compliance with study requirements

          -  Known history of drug-specific hypersensitivity or anaphylaxis to acalabrutinib or
             rituximab (including active product or excipient components).

          -  Active bleeding, history of bleeding diathesis (eg, hemophilia or von Willebrand
             disease).

          -  Uncontrolled AIHA (autoimmune hemolytic anemia) or ITP (idiopathic thrombocytopenic
             purpura).

          -  Requires treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor/inducer

          -  Requires or receiving anticoagulation with warfarin or equivalent vitamin K
             antagonists (eg, phenprocoumon)

          -  Requires treatment with proton pump inhibitors (eg, omeprazole, esomeprazole,
             lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Subjects receiving
             proton pump inhibitors who switch to H2-receptor antagonists or antacids are eligible
             for enrollment to this study.

          -  History of significant cerebrovascular disease or event, including stroke or
             intracranial hemorrhage, within 6 months before the first dose of study drug.

          -  Major surgical procedure within 28 days of first dose of study drug. Note: If a
             subject had major surgery, they must have recovered adequately from any toxicity
             and/or complications from the intervention before the first dose of study drug.

          -  Hepatitis B or C serologic status: subjects who are hepatitis B core antibody
             (anti-HBc) positive and who are surface antigen negative will need to have a negative
             polymerase chain reaction (PCR). Those who are hepatitis B surface antigen (HbsAg)
             positive or hepatitis B PCR positive will be excluded. Subjects who are hepatitis C
             antibody positive will need to have a negative PCR result. Those who are hepatitis C
             PCR positive will be excluded.

          -  History of progressive multifocal leukoencephalopathy (PML)

          -  Breastfeeding or pregnant. Pregnant or breastfeeding women are excluded from this
             study because it is unknown how acalabrutinib and rituximab can affect the fetus or
             infant. Rituximab can cross the placenta and is found in breast milk. Acalabrutinib
             has been found in the breast milk of animals and there is not significant data
             regarding its effect during pregnancy.

          -  Vaccination with live virus vaccines is not allowed within 4 weeks of study treatment
             of or during treatment.
      "
NCT04331717,withdrawn,"
    accrual on hold
  ",0,phase 2,"['prostate adenocarcinoma', 'obesity, morbid']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['E66.2', 'E66.01']""]",['lupron'],['CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O'],"
        Inclusion Criteria:

          -  Willing and able to provide written informed consent and HIPAA authorization for the
             release of personal health information (HIPAA authorization will be included in the
             informed consent)

          -  Males aged 18 years of age and above

          -  Histological proof of adenocarcinoma of the prostate

          -  Non-metastatic disease by computed tomography (CT), magnetic resonance imaging (MRI)
             or Nuclear medicine (NM) bone scan. Patients must have CT abdomen/pelvis with contrast
             prior to enrollment.

          -  Metastatic disease may be permitted if NOT starting on any concomitant therapy (ie
             chemotherapy, anti-androgens)

          -  Prior local therapy with prostatectomy or radiotherapy (including brachytherapy) or
             both

          -  BMI >30 kg/m2 with a concurrent obesity related comorbidity

        Obesity related comorbidity is defined as:

          -  hypertension (resting blood pressure >130/80 millimeters of mercury (mmHg) or being on
             medication to treat high blood pressure50),

          -  coronary artery disease (defined as prior myocardial infarction, elevated coronary
             artery calcium score, positive stress test history),

          -  dyslipidemia (triglyceride level of >150mg/dL or being on medicine to treat high
             triglycerides; HDL < 40mg/dL or being on medicine to treat cholesterol)51,

          -  diabetes (fasting glucose >126mg/dL, A1c > 6.5% or on medication for diabetes)52,

          -  pre-diabetes (fasting plasma glucose 100-125mg/dL)52,

          -  elevated waist circumference (>40 inches in men),

          -  obstructive sleep apnea,

          -  arthritis, or

          -  non-alcoholic steatohepatitis.

          -  Prior salvage or adjuvant radiation therapy is allowed but must have been completed at
             least 3 months prior to enrollment

          -  Non-castrate levels of testosterone (>50 ng/dL required)

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening

          -  Vascular anatomy (including celiac, hepatic and gastric arteries) that in the opinion
             of the interventional radiologist is amenable to bariatric embolization as assessed on
             3D CT angiography

          -  Participants must have normal organ and bone marrow function measured within 28 days
             prior to administration of study treatment as defined below:

        Hemoglobin ≥ 10.0 g/dL with no blood transfusion in the past 28 days Absolute neutrophil
        count (ANC) ≥ 1.0 x 109/L Platelet count ≥ 50 x 109/L Total bilirubin ≤ 1.5 x institutional
        upper limit of normal (ULN) Aspartate aminotransferase (AST) / Alanine aminotransferase
        (ALT) < 2.5 x institutional upper limit of normal Estimated Glomerular filtration rate
        (GFR) >60ml/min

        Exclusion Criteria:

          -  Prior hormonal therapy within 12 months of enrollment

          -  Planned concurrent cytotoxic chemotherapy or antiandrogens (ex. bicalutamide,
             abiraterone acetate, enzalutamide or any investigational agent).

          -  Contraindication to the use of leuprolide, such as a previous hypersensitivity
             reaction to an Luteinizing hormone-releasing hormone (LHRH) analogue or any of the
             excipients in the leuprolide injection

          -  Prior history of gastric, pancreatic, hepatic and/or splenic surgery

          -  Prior radiation therapy to the upper abdomen (pelvic radiation is not an exclusion)

          -  Prior embolization to the stomach, spleen or liver

          -  Cirrhosis or known portal venous hypertension

          -  Active peptic ulcer disease or significant risk factors for peptic ulcer disease
             including daily NSAID use or daily smoking

          -  Hiatal hernia >5cm in size

          -  Active h.pylori infection (patients will be required to have negative h.pylori
             testing)

          -  Weight >400 pounds or BMI >45kg/m2

          -  Known aortic arch pathology such as aneurysm or dissection

          -  Major comorbidity that precludes procedure including significant cardiovascular
             disease or peripheral arterial disease including the following:

        Myocardial infarction within 6 months before screening Unstable angina within 3 months
        before screening New York Heart Association class III or IV congestive heart failure or a
        history of New York Heart Association class III or IV congestive heart failure unless a
        screening echocardiogram or multi-gated acquisition scan performed within 3 months before
        the randomization date demonstrates a left ventricular ejection fraction ≥ 45% History of
        clinically significant ventricular arrhythmias (eg, sustained ventricular tachycardia,
        ventricular fibrillation, torsades de pointes) Uncontrolled hypertension as indicated by a
        minimum of 2 consecutive blood pressure measurements showing systolic blood pressure > 170
        mm Hg or diastolic blood pressure > 105 mm Hg at screening Peripheral arterial stenting or
        bypass procedure within 6 months before screening Active claudication

          -  Diabetes with A1c >7% or requiring medication other than metformin

          -  Known gastric motility dysfunction

          -  Preexisting chronic abdominal pain

          -  Positive stool occult study

          -  Inflammatory bowel disease

          -  Known history of allergy to iodinated contrast media

          -  American Society of Anesthesiology (ASA) physical status classification system Class 4
             of 5 (very high risk surgical candidates: class 4 = incapacitating disease that is a
             constant threat to life) at the time of screening for enrollment

          -  Any condition in which the principle investigator feels participation in the trial
             would put the patient and undue risk
      "
NCT02071225,completed,,1,phase 2,['chronic lymphocytic leukemia'],"[""['C91.11', 'C91.12', 'C91.10']""]","['bendamustine', 'obinutuzumab']",['CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O'],"
        Inclusion Criteria:

          -  Age 18 years or older

          -  Diagnosed CD20+ B- chronic lymphocytic leukemia (CLL) according to National Cancer
             Institute (NCI) criteria

          -  Active disease meeting at least 1 of the International Workshop on CLL (IWCLL) 2008
             criteria for treatment

          -  Refractory CLL (i.e. treatment failure or progression during treatment or within 6
             months after the last treatment) or relapse CLL (i.e. participants who met criteria
             for CR or PR, but progressed beyond 6 months post-treatment)

          -  At least 1 prior purine analogue or bendamustine containing therapy

          -  Life expectancy greater than (>) 6 months

          -  Use of effective contraception as described in the study protocol

        Exclusion Criteria:

          -  Prior Alogenic Bone Marrow Transplant

          -  Greater than or equal to (>/=) 3 previous lines of chemotherapy and/or immunotherapy
             for the CLL

          -  Previous obinutuzumab-containing regimen

          -  Treatment failure or progression within 6 months of bendamustine-containing regimen

          -  Transformation of CLL to aggressive non-Hodgkin lymphoma (NHL; Richter's
             transformation) Patients with prolymphocytic transformation cannot entry the study
             either

          -  Active haemolytic anaemia

          -  Inadequate liver function

          -  History of other malignancy which could affect compliance with the protocol or
             interpretation of results. Patients with a history of malignancy that has been treated
             but not with curative intent will be excluded, unless the malignancy has been in
             remission without treatment for >/= 2 years prior to enrolment. Patients with a
             history of adequately treated carcinoma in situ of the cervix; basal or squamous cell
             skin cancer; low grade, early stage localized prostate cancer treated surgically with
             curative intent; good prognosis ductal carcinoma in situ (DCIS) of the breast treated
             with lumpectomy alone with curative intent are eligible

          -  Evidence of significant, uncontrolled concomitant diseases that could affect
             compliance with the protocol or interpretation of results, including significant
             cardiovascular disease or pulmonary disease

          -  Recent major surgery (within 4 weeks prior to the start of Cycle 1), other than for
             diagnosis

          -  Regular treatment with corticosteroids during the 4 weeks prior to study start, unless
             administered for another condition at a dose equivalent to less than or equal to (</=)
             30 milligrams per day (mg/day) prednisone

          -  Known active infection or any infection requiring treatment with IV antibiotics or
             hospitalization within 4 weeks prior to study start

          -  Patients with HIV, human T cell leukemia virus 1 (HTLV-1), hepatitis B or hepatitis C

          -  Pregnancy or breast-feeding

          -  Vaccination with a live vaccine within 4 weeks prior to baseline visit

          -  Receipt of any other study drug within 4 weeks prior to study start
      "
NCT02075463,terminated,,0,phase 2,['anemia'],"[""['D53.2', 'D64.9', 'D46.4', 'D53.0', 'D53.9', 'D61.3', 'D61.9']""]","['gsk1278863', 'placebo']",['C1CCC(CC1)N2C(=O)C(C(=O)N(C2=O)C3CCCCC3)C(=O)NCC(=O)O'],"
        Inclusion Criteria:

          -  Hemodialysis (HD) frequency: Stable HD regimen of three to four times weekly for a
             minimum of 12 weeks. Note: The type and frequency of dialysis must be stable during
             the study. Isolated ultrafiltration sessions for the purposes of fluid removal are
             permitted.

          -  Dialysis Adequacy: Single-pool dialyzer clearance multiplied by dialyzer time divided
             by volume of distribution of urea (Kt/Vurea) of >=1.2 based on a historical value
             obtained within the prior month.

          -  rhEPO hyporesponsiveness: Historical and current intravenous (IV) rhEPO and Hgb
             values. Average epoetin alfa dose and Hgb level for three 4-week periods for a total
             of 12 weeks prior to Week -4, and during the 4 week run-in period, must be within the
             following ranges: average epoetin alfa dose >4000 and <=6000 units per session and Hgb
             >=8.0 and <=9.5 g/dL; average epoetin alfa dose >6000 and <=8000 units per session and
             Hgb >=8.0 and <=10.0 g/dL; average epoetin alfa dose >8000 and <=10000 units per
             session and Hgb >=8.0 and <=10.5 g/dL; and average epoetin alfa dose >10000 units per
             session and Hgb >=8.0 and <=11.0 g/dL.

          -  Absolute difference between the Hgb value at Week -4 and Week 0 (Day 1), must be <1.3
             g/dL. Note: Subjects who do not meet the criteria after being rescreened twice, should
             not be entered into the GSK1278863 treatment period and should be withdrawn from the
             study.

          -  Age: >=18 years of age.

          -  Q-T Interval Corrected for Heart Rate (QTc): Bazett's Correction of QT Interval (QTcB)
             <470 msec or QTcB <480 milliseconds (msec) in subjects with bundle branch block. There
             is no corrected QT interval (QTc) inclusion criterion for a subject with a
             predominantly paced rhythm.

          -  Gender: Female and male subjects. Females: If of childbearing potential, must agree to
             use one of the approved contraception methods from Screening until completion of the
             Follow-up Visit OR, of non-childbearing potential defined as pre-menopausal females
             with a documented tubal ligation, hysterectomy or oophorectomy; or postmenopausal
             defined as 12 months of spontaneous amenorrea [in questionable cases a blood sample
             with simultaneous follicle stimulating hormone (FSH) 23.0-116.3 milliinternational
             units (MIU)/milliliter (mL) (23.0-116.3 international units (IU)/liter (L)) and
             estradiol <=10 picograms (pg)/mL (<=37 picomole (pmol)/L) is confirmatory]. Females on
             hormone replacement therapy (HRT) whose menopausal status is in doubt will be required
             to use one of the approved contraception methods if they wish to continue their HRT
             during the study. Otherwise they must discontinue HRT to allow confirmation of
             post-menopausal status prior to study enrollment. For most forms of HRT, at least 2
             weeks will elapse between the cessation of therapy and the blood draw; this interval
             depends on the type and dosage of HRT. Following confirmation of their post-menopausal
             status, they can resume use of HRT during the study without use of a contraceptive
             method.

        Exclusion Criteria:

          -  Dialysis modality: Planned change in dialysis modality within the study time period.

          -  rhEPO: Use of methoxy polyethylene glycol epoetin beta or darbepoetin within the prior
             8 weeks prior to Week -4.

          -  Renal transplant: Scheduled renal transplant.

          -  Transferrin saturation (TSAT): <20% on the most recent sample taken over the last 12
             weeks.

          -  Ferritin: <100 nanograms (ng)/mL (<100 micrograms/L) on the most recent sample taken
             over the last 12 weeks.

          -  Vitamin B12: At or below the lower limit of the reference range (may rescreen in a
             minimum of 8 weeks).

          -  Folate: <2.0 ng/mL (<4.5 nanomoles (nmol)/L) (may rescreen in a minimum of 4 weeks).

          -  Myocardial infarction or acute coronary syndrome: Within the 8 weeks prior to Week -4.

          -  Stroke or transient ischemic attacks (TIAs): Within the 8 weeks prior to Week -4.

          -  Heart failure: Class III/IV heart failure, as defined by the New York Heart
             Association (NYHA) functional classification system diagnosed prior to Week -4.

          -  Hypertension: Defined using pre-dialysis vitals (Week -4) of diastolic blood pressure
             >100 millimeters of mercury (mmHg) or systolic blood pressure >170 mmHg.

          -  Thrombotic disease: History of thrombotic disease (e.g., venous thrombosis such as
             deep vein thrombosis or pulmonary embolism, or arterial thrombosis such as new onset
             or worsening limb ischemia requiring intervention) within the 8 weeks prior to Week
             -4, except vascular access thrombosis.

          -  Inflammatory disease: Active chronic inflammatory disease that could impact
             erythropoiesis (e.g., scleroderma, systemic lupus erythematosis, rheumatoid arthritis,
             celiac disease) diagnosed prior to Week -4.

          -  Hematological disease: Any hematological disease including those affecting platelets,
             white or red blood cells (e.g., antibody-mediated pure red cell aplasia, sickle cell
             anemia, myelodysplastic syndromes, hematological malignancy, myeloma, hemolytic
             anemia), coagulation disorders (e.g., antiphospholipid syndrome, Protein C or S
             deficiency), or any other cause of anemia other than renal disease diagnosed prior to
             Week -4.

          -  Liver disease: Current liver disease, known hepatic or biliary abnormalities (with the
             exception of Gilbert's syndrome or asymptomatic gallstones) or evidence at Screening
             of abnormal liver function tests [alanine transaminase (ALT) or aspartate transaminase
             (AST) > 2.0 x upper limit of normal (ULN) or total bilirubin > 1.5 x ULN]; or other
             hepatic abnormalities that in the opinion of the investigator would preclude the
             subject from participation in the study. NOTE: Those with Hepatitis B or Hepatitis C
             are eligible provided these exclusions are not met.

          -  Major surgery: (excluding vascular access surgery) within the 8 weeks prior to Week
             -4, or planned during the study.

          -  Transfusion: Blood transfusion within the 8 weeks prior to Week -4, or an anticipated
             need for blood transfusion during the study.

          -  Gastrointestinal (GI) Bleeding: Evidence of actively bleeding peptic, duodenal, or
             esophageal ulcer disease or clinically significant GI bleeding within the 8 weeks
             prior to Week -4.

          -  Ophthalmology disease: History of proliferative retinopathy requiring treatment within
             the prior 12 months or macular edema requiring treatment.

          -  Acute infection: Clinical evidence of acute infection, evidence of underlying
             infection or history of infection requiring IV antibiotic therapy within the 8 weeks
             prior to Week -4, and also through to Day 1. Note: IV antibiotics as prophylaxis are
             allowed.

          -  Malignancy: Subjects with a history of malignancy within the prior 5 years, who are
             receiving treatment for cancer, or who have a strong family history of cancer (e.g.,
             familial cancer disorders), with the exception of squamous cell or basal cell
             carcinoma of the skin that has been definitively treated prior to Week -4.

          -  Severe allergic reactions: History of severe allergic or anaphylactic reactions or
             hypersensitivity to excipients in the investigational product.

          -  Drugs and supplements: Use of any prescription or non-prescription drugs or dietary
             supplements that are prohibited from Week -4 until the Follow-up Visit.

          -  Prior investigational product exposure: The subject has participated in a clinical
             trial and has received an experimental investigational product within the prior 30
             days to Week -4.

          -  Life Expectancy: Life expectancy is considered by the investigator to be less than 6
             months.

          -  Other conditions: Any other conditions, clinical or laboratory abnormality, or
             examination finding that the Investigator considers would put the subject at
             unacceptable risk, or an unwillingness or inability to follow the procedures, or
             lifestyle and/or dietary restrictions outlined in the protocol.

          -  Pregnancy and lactation: Pregnant females as determined by positive serum human
             chorionic gonadotrophin (hCG) test or women who are lactating at Week -4 or during the
             trial.

          -  Laboratory eligibility criteria will be assessed according to the central laboratory
             result for the screening samples

          -  Subjects who fail screening may be rescreened as soon as the investigator feels they
             may have subsequently become eligible. However, an individual subject may not be
             rescreened more than twice. There is no predetermined amount of time required to wait
             to rescreen a previously ineligible subject. Exceptions are those failing on Hgb or
             folate who may rescreen in 4 weeks and those failing for Vitamin B12 where rescreening
             may occur in 8 weeks.
      "
NCT02073487,completed,,1,phase 2,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['t-dm1', 'trastuzumab', 'lapatinib', 'abraxane', 'paclitaxel', 'pertuzumab']","['CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C']","
        Inclusion Criteria:

          -  Female gender;

          -  Age ≥18 years;

          -  Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1

          -  Histologically confirmed invasive breast cancer:

          -  Primary tumor greater than 1 cm diameter, measured by clinical examination and
             mammography or ultrasound.

          -  Any N,

          -  No evidence of metastasis (M0) (isolated supra-clavicular node involvement allowed);

          -  Over expression and/or amplification of HER2 in the invasive component of the primary
             tumor and confirmed by a certified laboratory prior to randomization.

          -  Known hormone receptor status.

          -  Hematopoietic status:

          -  CBC not less than .75 of institutional lower limit. Absolute neutrophil count ≥ 1,5 x
             10^9/L, Platelet count ≥ 100 x 10^9/L, Hemoglobin at least 9 g/dl,

          -  Hepatic status:

        Serum total bilirubin ≤ 2 x upper limit of normal (ULN). In the case of known Gilbert's
        syndrome, a higher serum total bilirubin (< 1.5 x ULN) is allowed, Aspartate
        Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 3.5 times ULN, Alkaline
        phosphatase ≤ 2.5 times ULN, • Renal status: Creatinine ≤ 1.5mg/dL,

        • Cardiovascular: Baseline left ventricular ejection fraction (LVEF) ³ ≥50% measured by
        echocardiography (ECHO) or Multiple Gate Acquisition (MUGA) scan,

          -  Negative serum or urine β-hCG pregnancy test at screening for patients of childbearing
             potential within 2-weeks (preferably 7 days) prior to randomization.

          -  Fertile patients must use effective contraception (barrier method - condoms, diaphragm
             - also in conjunction with spermicidal jelly, or total abstinence. Oral, injectable,
             or implant hormonal contraceptives are not allowed)

          -  Signed informed consent form (ICF)

          -  Patient accepts to make available tumor samples for submission to central laboratory
             to conduct translational studies as part of this protocol.

        Exclusion Criteria:

          -  Previous (less than 5 years) or current history of malignant neoplasms, except for
             curatively treated: Basal and squamous cell carcinoma of the skin; Carcinoma in situ
             of the cervix.

          -  Patients with a prior malignancy diagnosed more than 5 years prior to randomization
             may enter the study.

          -  Preexisting peripheral neuropathy ≥ grade 2

          -  Known history of uncontrolled or symptomatic angina, clinically significant
             arrhythmias, congestive heart failure, transmural myocardial infarction, uncontrolled
             hypertension (≥180/110), unstable diabetes mellitus, dyspnea at rest, or chronic
             therapy with oxygen;

          -  Concurrent disease or condition that would make the subject inappropriate for study
             participation or any serious medical disorder that would interfere with the subject's
             safety;

          -  Unresolved or unstable, serious adverse events from prior administration of another
             investigational drug;

          -  Dementia, altered mental status, or any psychiatric condition that would prevent the
             understanding or rendering of ICF;

          -  Malabsorption syndrome, disease significantly affecting gastrointestinal function, or
             resection of the stomach or small bowel. Subjects with ulcerative colitis are also
             excluded;

          -  Concurrent neoadjuvant cancer therapy (chemotherapy, radiation therapy, immunotherapy,
             biologic therapy other than the trial therapies);

          -  Concurrent treatment with an investigational agent or participation in another
             therapeutic clinical trial;

          -  Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
             chemically related to trastuzumab Emtansine, trastuzumab, lapatinib, paclitaxel,
             abraxane or their components;

          -  Pregnant or lactating women;

          -  Concomitant use of CYP3A4 inhibitors or inducers

          -  Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g.
             active or uncontrolled infection, uncontrolled diabetes) that could cause unacceptable
             safety risks or compromise compliance with the protocol

          -  Patients have an active infection and require IV or oral antibiotics.

          -  Pregnant or breast-feeding women

          -  Patients unwilling or unable to comply with the protocol
      "
NCT02078960,terminated,"
    inability to accrue additional sites and enroll an adequate number of subjects.
  ",0,phase 1/phase 2,['chronic myeloid leukemia'],"[""['C92.11', 'C92.12', 'C92.21', 'C92.22', 'C92.10', 'C92.20']""]",['omacetaxine mepesuccinate'],['CC(C)(CCCC(CC(=O)OC)(C(=O)OC1C2C3=CC4=C(C=C3CCN5C2(CCC5)C=C1OC)OCO4)O)O'],"
        Inclusion Criteria:

          -  The patient has a confirmed diagnosis of Philadelphia chromosome (Ph) positive chronic
             myelogenous leukemia in either CP or AP. Accelerated phase will be defined as disease
             having 1 of the following: ≥15% to <30% blasts in peripheral blood or bone marrow;
             ≥30% blasts + promyelocytes in peripheral blood or bone marrow; ≥20% basophils in
             peripheral blood or bone marrow; platelet count <100x109/L unrelated to therapy; or
             clonal evolution.

          -  The patient has either failed, demonstrated intolerance, or a combination of prior
             failure and intolerance, to prior treatments with at least 2 tyrosine kinase
             inhibitors (TKI's). Failure of TKI treatment may either be primary (never achieved a
             response) or secondary resistance (loss of response).

          -  TKI treatment failure will be defined as 1 of the following:

               -  no CHR by 12 weeks (whether lost or never achieved)

               -  no partial cytogenetic response by 24 weeks (ie, 1 to 35% Ph-positive) (whether
                  lost or never achieved) no major cytogenetic response by 52 weeks (ie, ≤35%
                  Ph-positive) (whether lost or never achieved)

               -  progressive leukocytosis, defined as increasing white blood cell (WBC) count on
                  at least 2 consecutive evaluations, at least 2 weeks apart and doubling from the
                  nadir to ≥20000/μL or absolute increase in WBC by ≥50000/μL above the
                  post-treatment nadir

          -  Intolerance to TKI therapy will be defined as 1 of the following:

               -  grade 3 to 4 nonhematologic toxicity that does not resolve with adequate
                  intervention

               -  grade 4 hematologic toxicity lasting more than 7 days, or a documented inability
                  to sustain the TKI therapy because of recurrent grade 3 or 4 hematologic toxicity
                  with re-initiation of the same therapy

               -  any grade 2 or greater toxicity that is unacceptable to the patient

          -  Patients must have completed all previous anticancer therapy for at least 2 weeks
             prior to the first planned dose of omacetaxine, except as noted below, and must have
             fully recovered from side effects of a previous therapy.

          -  In patients with rapidly proliferating disease, hydroxyurea may be administered before
             study entry, if clinically indicated, to control disease. In such cases, complete
             hematologic response (CHR) must be sustained for at least 4 weeks for accelerated CML,
             and at least 8 weeks for chronic phase CML, following the discontinuation of
             hydroxyurea, to be considered as a CHR.

          -  Patients may receive anagrelide for up to 28 days (in countries where the product is
             registered). Leukapheresis is allowed up to 24 hours prior to the first treatment
             cycle with omacetaxine.

          -  Patients must have adequate hepatic and renal function as evidenced by bilirubin 2.0
             times the upper limit of the normal range (ULN) or lower, alanine aminotransferase
             (ALT) and asparate aminotransferase (AST) 3 times the ULN or lower, serum creatinine
             1.5 times the ULN or lower. Patients with nonclinically significant elevations of
             bilirubin up to 5.0 g/dL (85500 μmol/L) due to known or suspected Gilbert's disease
             are eligible; this must be documented on the medical history page of the case report
             form (CRF).

          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of
             0 to 2

          -  Patients are men or women at least 18 years of age.

          -  Patients must be able and willing to provide written informed consent prior to any
             study related procedure.

          -  The patient must take precautions to not become pregnant or produce offspring. Women
             must be of non-childbearing potential (surgically sterile or postmenopausal for at
             least 12 months, confirmed by follicle-stimulating hormone [FSH] >40 IU/L) or agree to
             use a medically accepted method of contraception for the duration of the study and 90
             days after treatment. Men must be surgically sterile or agree to use a medically
             accepted method of contraception for the duration of the study and 90 days after
             treatment. Acceptable methods of contraception include abstinence, barrier method with
             spermicide (excluding cervical cap and sponge), intrauterine device (IUD), or
             steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction
             with a barrier method.

               -  Other criteria may apply, please contact the investigator for additional
                  information

        Exclusion Criteria:

          -  The patient has New York Heart Association (NYHA) class III or IV heart disease,
             active ischemia, or any other uncontrolled cardiac condition such as angina pectoris,
             clinically significant cardiac arrhythmia requiring therapy, uncontrolled
             hypertension, or congestive heart failure.

          -  The patient has had a myocardial infarction in the previous 12 weeks. (Prior to study
             entry, electrocardiogram [ECG] abnormalities at screening must be documented by the
             investigator as not medically relevant.)

          -  The patient has received radiotherapy within 30 days prior to the start of study drug,
             or has not recovered from the acute toxicities associated with prior approved
             therapies including investigational drugs.

          -  The patient has another concurrent illness that would preclude study conduct and
             assessment, including, but not limited to, another active malignancy (excluding
             squamous or basal cell skin cancer and in situ cervical cancer), uncontrolled medical
             conditions, uncontrolled and active infection (considered opportunistic, life
             threatening, or clinically significant), uncontrolled risk of bleeding, or
             uncontrolled diabetes mellitus.

          -  The patient underwent autologous or allogeneic stem cell transplant within 60 days
             prior to receiving the first dose of omacetaxine and has any evidence of ongoing graft
             versus host disease (GVHD), or GVHD requiring immunosuppressive therapy.

          -  The patient has a human leukocyte antigen (HLA)-matched donor and is eligible for
             allogeneic transplantation for CML treatment.

          -  The patient has known positive human immunodeficiency virus (HIV) or known active
             human t-cell lymphotropic virus (HTLV) I/II disease, whether on treatment or not.

          -  The patient has known active hepatitis B or C. The determination of active hepatitis B
             or C is left to the investigator.

          -  The patient has lymphoid Ph+ blast crisis or blast phase CML.

          -  The patient participated in another clinical investigation within 30 days of
             enrollment or is receiving another investigational agent.

          -  The patient received omacetaxine or has a history of hypersensitivity.

               -  Other criteria may apply, please contact the investigator for additional
                  information
      "
NCT02073123,completed,,1,phase 1/phase 2,"['metastatic melanoma', 'stage iii melanoma', 'stage iv melanoma']","[""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']"", ""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']"", ""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']""]","['indoximod', 'ipilimumab', 'nivolumab', 'pembrolizumab']",['CN1C=C(C2=CC=CC=C21)CC(C(=O)O)N'],"
        Inclusion Criteria:

          -  Unresectable Stage III or Stage IV melanoma.

          -  Patients must have measurable disease, defined as lesions that can be accurately
             measure in in 2 perpendicular diameters with at least one diameter > 20mm and the
             other >10mm on conventional CT or MRI or 10mm x 10 mm by spiral CT.

          -  No systemic treatment in the previous 28 days.

          -  Age ≥18 years. Because no dosing or adverse event data are currently available on the
             use of ipilimumab or indoximod in patients <18 years of age, children are excluded
             from this study.

          -  ECOG performance status ≤2 (Karnofsky ≥60% )

          -  Patients with known brain metastases will only be eligible after their tumors have
             been treated with definitive resection and/or radiotherapy and they are neurologically
             stable for at least 1 month off steroids.

        Exclusion Criteria:

          -  Patients who have had molecular targeted therapy (including vemurafenib) or
             radiotherapy within 4 weeks prior to entering the study or those who have not
             recovered from adverse events due to agents administered more than 4 weeks earlier.

          -  Patients who have had prior therapy with immune checkpoint inhibition or or indoximod
             are excluded from the trial.

          -  Any other cancer, unless the patient has been disease-free for ≥5 years

          -  Patients with laboratory evidence of pancreatitis are excluded.

          -  Patients with autoimmune disease

          -  Chronic use of immune-suppressive drugs (ie, systemic corticosteroids used in the
             management of cancer or non-cancer related illnesses, eg, COPD).
      "
NCT02077881,completed,,0,phase 1/phase 2,"['metastatic pancreatic adenocarcinoma', 'metastatic pancreatic cancer']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C25.3']""]","['nab-paclitaxel', 'gemcitabine', 'indoximod']","['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F', 'CN1C=C(C2=CC=CC=C21)CC(C(=O)O)N']","
        Inclusion Criteria:

          -  Patient has definitive histologically or cytologically confirmed metastatic
             adenocarcinoma of the pancreas. Patients with islet cell or neuroendocrine neoplasms
             are excluded.

          -  Initial diagnosis of metastatic disease must have occurred ≤8 weeks prior to entry in
             the study.

          -  Patient has one or more metastatic tumors measurable per RECIST 1.1 by CT scan ≤4
             weeks prior to entry into the study

          -  Male or non-pregnant and non-lactating female, and ≥18 years of age.

          -  Patients must have received no previous radiotherapy, surgery, chemotherapy or
             investigational therapy for the treatment of metastatic disease.

          -  Prior treatment with gemcitabine and/or nab-paclitaxel in the adjuvant setting is
             allowed, provided at least 6 months have elapsed since completion of the last dose and
             no lingering toxicities are present.

          -  Patients cannot have received any other immunomodulatory therapies (including
             vaccines) as treatment for this or any other cancer.

          -  Patient has a Karnofsky performance status (KPS) ≥ 70.

          -  Patients should be asymptomatic for jaundice prior to Day 1.

        Exclusion Criteria:

          -  Patients may not be receiving (or received prior to enrollment) any other
             investigational agents for metastatic disease.

          -  Patient has known brain metastases,

          -  Patient has only locally advanced disease.

          -  Lymph node only metastases even if considered M1 disease by official staging criteria.

          -  History of malignancy in the last 3 years. Patients with prior history of in situ
             cancer or basal or squamous cell skin cancer are eligible. Patients with other
             malignancies are eligible if they were cured by surgery alone or surgery plus
             radiotherapy and have been continuously disease-free for at least 3 years.

          -  Patients with any active autoimmune disease

          -  Patient has undergone major surgery, other than diagnostic surgery (ie, surgery done
             to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to
             Day 1 of treatment in this study.
      "
NCT02077374,completed,,1,phase 2,"['nonalcoholic steatohepatitis', 'non-alcoholic fatty liver disease']","[""['K75.81']"", ""['Z52.6', 'K71.8', 'K71.7', 'A06.4', 'C22.0', 'C22.3', 'K70.0']""]",['idn-6556'],['CC(C(=O)NC(CC(=O)O)C(=O)COC1=C(C(=CC(=C1F)F)F)F)NC(=O)C(=O)NC2=CC=CC=C2C(C)(C)C'],"
        Inclusion Criteria:

          -  Male or female subjects of minimum adult legal age (according to local laws for
             signing the informed consent document), able to provide written informed consent, and
             understand and comply with the requirements of the study

          -  Diagnosis of non-alcoholic fatty liver disease (NAFLD) as evidenced by imaging or
             other diagnostic assessments

          -  Alanine aminotransferase (ALT) levels ≥1.5 x ULN on at least two occasions, seven or
             more days apart, during the Screening period

          -  alpha-fetoprotein (AFP) ≤ 100 ng/mL

          -  Hemoglobin ≥10 g/dL, a platelet count ≥ 100 x 10^9/L, and a white blood cell count ≥
             3.0 x 10^9/L

          -  If on metformin, sulfonylureas, statins, or fibrates, subjects must be on a stable
             dose of these drugs for at least three months prior to Screening and during the study

        Exclusion Criteria:

          -  Known infection with HIV, HCV, or HBV

          -  Decompensated or severe liver disease as evidenced by one or more of the following:

               1. Confirmed cirrhosis or suspicion of cirrhosis

               2. Esophageal varices

               3. Ascites

               4. Suspicion of portal hypertension

               5. Hospitalization for liver disease within 60 days of screening

               6. Bilirubin >2 x ULN, or ALT or AST > 10 x ULN

          -  Inflammatory bowel disease

          -  Diagnosed or suspected systemic lupus erythematosus (SLE) and/or rheumatoid arthritis
             (RA)

          -  Hepatocellular carcinoma (HCC) at entry into the study

          -  History of or active non-liver malignancies other than curatively treated skin cancer
             (basal cell or squamous cell carcinomas)

          -  Significant systemic or major illness other than liver disease, including coronary
             artery disease, cerebrovascular disease, pulmonary disease, renal insufficiency,
             and/or serious psychiatric disease, that, in the opinion of the Investigator would
             preclude the subject from participating in and completing the study

          -  History or presence of alcohol abuse, defined as consumption of more than 210 mL of
             alcohol per week (the equivalent of 14 4-ounce glasses of wine or 14 12-ounce
             cans/bottles of beer or wine coolers), or other substance abuse within the prior two
             years
      "
NCT02070120,unknown status,,1,phase 2,['bladder cancer'],"[""['D30.3', 'C67.5', 'C67.9', 'C79.11', 'C67.0', 'C67.1', 'D41.4']""]",['mitomycin c'],['CC1=C(C(=O)C2=C(C1=O)N3CC4C(C3(C2COC(=O)N)OC)N4)N'],"
        Inclusion Criteria:

          -  Written informed consent

          -  NMIBC recurrence following original diagnosis of low risk NMIBC (defined as Ta G1 or
             Ta G2 (Ta low grade) with a risk of recurrence score of ≤6 using EORTC risk tables

          -  Histologically confirmed Transitional-cell carcinoma (TCC) at original diagnosis

          -  Aged 16 or over

          -  Satisfactory pre-treatment haematology values and serum creatinine < 1.5 x Upper Limit
             of Normal (ULN)

          -  Negative pregnancy test for women of child-bearing potential

        Exclusion Criteria:

          -  Any history of: grade 3/high grade or ≥T1 transitional cell carcinoma, concomitant
             carcinoma in situ, more than 7 tumours at one diagnosis or more than 1 recurrence per
             year since initial diagnosis or in the past five years, whichever is shorter

          -  Any history of histologically confirmed non-TCC bladder cancer

          -  Trial entry recurrence identified within 11.5 months of the date of the original
             diagnosis

          -  Any prior treatment of the trial entry recurrence (including biopsy)

          -  Previous MMC chemotherapy other than a single instillation at diagnostic surgery

          -  Known allergy to MMC

          -  Carcinoma involving the prostatic urethra or upper urinary tract (participants should
             have had imaging of the upper urinary tract within 2 years prior to randomisation)

          -  Known or suspected reduced bladder capacity (<100ml)

          -  Significant bleeding disorder

          -  Female patients who are breast-feeding or are of childbearing potential and unwilling
             or unable to use adequate non-hormonal contraception. Male patients should also use
             contraception if sexually active.

          -  Active or intractable urinary tract infection

          -  Urethral stricture or anything impeding the insertion of a catheter

          -  Large narrow neck diverticula

          -  Significant urinary incontinence

          -  Any other conditions that in the Principal Investigator's opinion would contraindicate
             protocol treatment

          -  Unable or unwilling to comply with study procedures or follow up schedule
      "
NCT03454919,unknown status,,1,phase 2,['melanoma'],"[""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']""]",['palbociclib'],['CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C'],"
        Inclusion Criteria:

          1. Age from 18 to 75 years;

          2. ECOG performance status 0 or 1 before treatment;

          3. Metastatic melanoma or unresectable acral melanoma;

          4. Histologically confirmed melanoma.

          5. Bearing gene aberrations in cell cycle pathways [including CDK4 amplification and/or
             CCND1 amplification and/or P16 (CDKN2A) loss].;

          6. Anticipated life expectancy ≥ 3 month;

          7. Adequate organ function, defined as following criteria:

               1. Platelets 75 x 109/L, Hemoglobin 9.0 g/dL, Absolute Neutrophils(ANC) ≥ 1.5x109/L;

               2. Serum bilirubin ≤ 1.5*upper limit of normal (ULN) (could be ignored in the case
                  of Gilbert's syndrome) ，Serum aspartate transaminase (AST) and serum alanine
                  transaminase (ALT) ≤ 1.5 * ULN;

               3. Blood urea nitrogen (BUN) ≤ 1.5 * ULN, serum creatinine (Cr) ≤ 1.5 * ULN.

               4. Left ventricular ejection fraction (LVEF) ≥ lower limit of normal (LLN) as
                  assessed by multigated acquisition (MUGA) scan or echocardiography;

               5. QTc interval: male < 450msec, female < 470msec (via Fridericia method)

          8. Willingness and ability to comply with scheduled visits, treatment plans, laboratory
             tests, and other study procedures.

          9. Written informed consent signed.

        Exclusion Criteria:

          1. Previous or current administration of any kind of CDK4/6 inhibitors;

          2. Administration of any other anti-tumor therapy (including but not limited to
             radiotherapy, chemotherapy, endocrinal therapy, surgery, molecular targeted therapy,
             immunotherapy or biological therapy) 4 weeks before inclusion; administration of
             mitocycin or nitrosamines 8 weeks before inclusion;

          3. Non-treated brain metastasis (treatment controlled stable brain metastasis judged by
             investigators excluded);

          4. Presence of third space fluid that cannot be controlled by drainage or other means
             (i.e. pleural effusion or ascites);

          5. Long-term steroid therapy required;

          6. Uncorrectable hypokalemia or hypomagnesaemia before inclusion;

          7. Concurrent administration of drugs with potential of QT interval prolongation (such as
             antiarrhythmic drugs);

          8. Allergies or previous history of severe allergies;

          9. Active HBV or HCV infection (HBV viral copy number ≥ 104 copies/ml, HCV ≥ 103
             copies/ml);

         10. NCICTCAE Grade 2 toxicity before inclusion;

         11. Diagnosed as any second primary malignant tumor in 5 years before inclusion;

         12. Following conditions occur in the 6 months before drug administration: severe/
             unstable angina pectoris, myocardial infarction, congestive heart failure with
             symptoms, cerebrovascular accident, including transient ischemic attack, pulmonary
             embolism, ≥ grade II renal dysfunction, and other severe diseases that investigators
             judged to be unsuitable for this trial;

         13. Administration of potent CYP3A4 inhibitors in 7 days before inclusion , or
             administration of potent CYP3A4 inhibitors in 12 days before randomization ；

         14. NCICTCAE Grade ≥ 2 Active arrhythmias;

         15. Hypertension, defined as systolic blood pressure >150mmHg and/or diastolic blood
             pressure >100mmHg，and cannot be controlled by medication;

         16. No recommendation to receive >2 mg Warfarin treatment in 2 weeks before study
             beginning. It is permitted to use low dose Warfarin(<2 mg／3day) to prevent deep venous
             thrombosis. Low molecular weight heparin (fractionated) or aspirin are also allowed;

         17. Existence of any disease affecting drug absorption, including but not limited to: no
             ability to swallow oral medications, active inflammatory bowel disease, partial or
             complete obstruction, partial or total gastrectomy, extensive bowel resection or
             chronic diarrhea;

         18. Known infection of human immunodeficiency virus (HIV) or acquired immunodeficiency
             syndrome (AIDS)-related illness, or congenital immune deficiency diseases, organ
             transplantation history;

         19. Pregnancy, breastfeeding, childbearing age female who is reluctant to take effective
             contraceptive measures throughout trial period. All female patients with reproductive
             potential must have a negative pregnancy test (serum or urine) within 7 days before
             randomization and at first day of every cycle on visit.

         20. Other severe acute or chronic physiological or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or study
             drug administration, or may interfere with the interpretation of study results, and in
             the judgment of the investigator would make the patient inappropriate for entry into
             this study.

         21. Current treatment on another clinical trial. Supportive care or non-therapeutic
             clinical trials are allowed.
      "
NCT04470674,withdrawn,"
    lack of accrual
  ",0,phase 2,"['lung cancer', 'non-small cell lung cancer', 'pd-l1 gene mutation', 'kras activating mutation']","[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['durvalumab', 'carboplatin', 'pemetrexed']","['C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]', 'C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O']","
        Inclusion Criteria

          -  Written informed consent and HIPAA authorization for release of personal health
             information. NOTE: HIPAA authorization may be included in the informed consent or
             obtained separately.

          -  Age ≥ 18 years at the time of consent.

          -  Body weight > 30 kg. If body weight falls to 30 kg or below during the study, the
             subject will be removed from study drugs.

          -  ECOG Performance Status of 0-1 within 7 days prior to registration.

          -  Life expectancy of ≥ 12 weeks.

          -  Histological or cytological evidence of stage IV Kras mutation positive non-squamous
             NSCLC.

          -  Patients who have recurrence following treatment for earlier stages of NSCLC are
             eligible provided the recurrence has not occurred within 12 months of completing prior
             therapy.

          -  Patient's tumor must be known to be PD-L1 high (≥ 50%). SP-142 assay will not be
             accepted. See Section 8.1 for additional information regarding this result.

          -  Measurable disease according to RECIST v1.1 criteria within 4 weeks of study
             registration.

          -  Demonstrate adequate organ function as defined in the table below; all screening labs
             to be obtained within 14 days prior to registration.

               -  Absolute Neutrophil Count (ANC) ≥ 1.5 K/mm3

               -  Hemoglobin (Hgb) ≥ 9.0 g/dL

               -  Platelets ≥ 75 k/mm3

               -  Calculated creatinine clearance ≥ 45 cc/min using the Cockcroft-Gault formula

               -  Bilirubin ≤ 1.5 × upper limit of normal (ULN) This will not apply to subjects
                  with clinical diagnosis of Gilbert's syndrome (persistent or recurrent
                  hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis
                  or hepatic pathology)

               -  Aspartate aminotransferase (AST) ≤ 2.5 × ULN, unless patients has liver
                  metastases in which case it must be ≤5 × ULN

               -  Alanine aminotransferase (ALT) ≤ 2.5 × ULN, unless patients has liver metastases
                  in which case it must be ≤5 × ULN

          -  Evidence of post-menopausal status or negative urine or serum pregnancy test for
             female pre-menopausal patients. NOTE: Women will be considered post-menopausal if they
             have been amenorrheic for 12 months without an alternative medical cause. See section
             5.4 for age-specific requirements (<50 year old vs. ≥50 year old).

          -  Females of childbearing potential randomized to Arm A and males randomized to Arm A or
             Arm B must be willing to abstain from heterosexual activity or agree to use a highly
             effective method of contraception from the time of informed consent until 90 days
             after treatment discontinuation. Females of childbearing potential randomized to Arm B
             must be willing to abstain from heterosexual activity or agree to use a highly
             effective method of contraception until 180 days after treatment discontinuation. See
             section 5.4 for definition of childbearing potential.

          -  As determined by the enrolling physician or protocol designee, ability of the subject
             to understand and comply with study procedures for the entire length of the study

        Exclusion Criteria

          -  Patient must not have received any prior systemic therapy for stage IV NSCLC. Patients
             must not have received prior anti-PD-1 or anti-PD-L1.

          -  Active infection including tuberculosis (clinical evaluation that includes clinical
             history, physical examination and radiographic findings, and TB testing in line with
             local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result),
             hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients
             with a past or resolved HBV infection (defined as the presence of hepatitis B core
             antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for
             hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative
             for HCV RNA. Testing is not required at screening.

          -  Patients with history of non-infectious pneumonitis that required steroids or has
             current pneumonitis. Has known history of Interstitial Lung Disease (ILD) or radiation
             pneumonitis which required therapy with steroids.

          -  Active or prior documented autoimmune or inflammatory (including inflammatory bowel
             disease [eg, colitis or Crohn's disease], diverticulitis, systemic lupus
             erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with
             polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]) and
             pneumonitis. The following are exceptions to this criterion:

               -  Diverticulosis

               -  Patients with vitiligo or alopecia

               -  Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone
                  replacement

               -  Any chronic skin condition that does not require systemic therapy

               -  Patients without active disease in the last 5 years may be included but only
                  after consultation with the study sponsor investigator.

               -  Patients with celiac disease controlled by diet alone

          -  History of allogenic progenitor/stem cell or organ transplantation.

          -  History of immunodeficiency. Patient should not be on any immunosuppressive therapy or
             steroids > prednisone 10mg/day or its equivalent on the day of the start of therapy.

          -  Patients with current or prior use of immune suppressive therapy within 7 days of
             starting study therapy. Following exceptions are allowed

               -  Intranasal, local (eg. Intraarticular injections), inhaled or topical steroids

               -  Steroids to prevent hypersensitivity reactions, eg. IV contrast for CT scans

               -  Systemic steroids not to exceed 10mg of prednisone or its equivalent.

          -  Any concurrent chemotherapy, investigational product, biologic, or hormonal therapy
             for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related
             conditions (e.g., hormone replacement therapy) is acceptable.

          -  Patients who have received live attenuated vaccine within 30 days of the first dose of
             study therapy. Patients should not receive live vaccines while on therapy and for 30
             days after the last dose.

          -  Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the
             mother is being treated on study).

          -  History of another primary malignancy except for

               -  Malignancy treated with curative intent and with no known active disease ≥2 years
                  before the first dose of IP and of low potential risk for recurrence. Patients
                  with elevated PSA (prostate specific antigen) as the only evidence of prostate
                  cancer may be considered for enrolment after discussion with the
                  sponsor-investigator.

               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
                  of disease

               -  Adequately treated carcinoma in situ without evidence of disease

          -  Patients with leptomeningeal carcinomatosis are not eligible. Patients with
             symptomatic brain metastases are eligible only after receiving appropriate therapy,
             are clinically stable and do not require steroids equivalent to 10 mg of prednisone
             daily. Patients with asymptomatic brain metastases are eligible if the treating
             physician determines that the brain metastases do not require immediate directed
             therapy, they are clinically stable, and are not using steroids equivalent to >10mg of
             prednisone day prior to trial treatment.

          -  Any unresolved toxicity from previous anticancer therapy Grade ≥2 except for alopecia,
             vitiligo, and the laboratory values defined in the inclusion criteria.

               -  Patients with Grade ≥ 2 neuropathy will be evaluated on a case-by-case basis
                  after consultation with the sponsor-investigator.

               -  Patients with irreversible toxicity not reasonably expected to be exacerbated by
                  treatment with durvalumab may be included only after consultation with the
                  sponsor-investigator.

          -  Patients who have radiation therapy within 1 week prior to Day 1. Patients should have
             recovered from any adverse events related to radiation therapy to ≤ grade 1 or
             baseline. Patients must be considered stable to receive study therapy.

          -  Participation in another clinical study with an investigational product within 30 days
             prior to study registration.

          -  Concurrent enrolment in another clinical study, unless it is an observational
             (non-interventional) clinical study or during the follow-up period of an
             interventional study.

          -  Major surgery as determined by the treating physician within 4 weeks of study
             registration. Placement of a central access device (port) is not considered major
             surgery.

          -  Uncontrolled intercurrent illness as determined by the treating physician, including
             but not limited to, symptomatic congestive heart failure, uncontrolled hypertension,
             unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious
             chronic gastrointestinal conditions associated with diarrhea, or psychiatric
             illness/social situations that would limit compliance with study requirement,
             substantially increase risk of incurring AEs or compromise the ability of the patient
             to give written informed consent.

          -  History or hypersensitivity reaction to carboplatin, cisplatin or other
             platinum-containing compounds, pemetrexed, or durvalumab.
      "
NCT02776163,unknown status,,1,phase 2,"['salivary gland tumors', 'head and neck cancer']","[""['C76.0', 'C47.0', 'C49.0', 'C77.0', 'D17.0', 'D21.0', 'D36.11']""]","['cisplatin', 'docetaxel']","['N.N.Cl[Pt]Cl', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O']","
        Inclusion Criteria:

          1. Pathologically proven diagnosis of a malignant salivary gland tumor of intermediate or
             high-grade

          2. Pathologic stage T3-4 or N1-3 or T1-2, N0 with a close (≤ 5mm) or microscopically
             positive surgical margin

          3. Surgical resection with curative intent within 8 weeks prior to registration, with no
             evidence of gross tumor residual

          4. No evidence of distant metastases

          5. No synchronous or concurrent head and neck primary tumors

          6. Karnofsky score over 60

          7. Adequate organ function including the following:

               1. Absolute neutrophil count (ANC) >= 1.5 * 10^9/l

               2. Platelets count >= 100 * 10^9/l

               3. Hemoglobin >= 10 g/dl

               4. AST and ALT <= 2.5 times institutional upper limit of normal (ULN)

               5. Total bilirubin <= 1.5 times institutional ULN

               6. Creatinine clearance >= 50 ml/min

               7. Serum creatine <= 1 times ULN

          8. Signed written informed consent

        Exclusion Criteria:

          1. Evidence of distant metastasis

          2. Prior chemotherapy or anti-cancer biologic therapy for any type of cancer, or prior
             radiotherapy to the head and neck region

          3. Other previous cancer, except for in situ cervical cancer and cutaneous basal cell
             carcinoma

          4. Pregnant or breast-feeding females, or females and males of childbearing potential not
             taking adequate contraceptive measures

          5. Presence of an uncontrolled concomitant illness including, but not limited to, ongoing
             or active infection, symptomatic congestive heart failure, unstable angina pectoris,
             or cardiac arrhythmia
      "
NCT02774681,terminated,"
    slow accrual
  ",0,phase 2,"['breast carcinoma metastatic in the brain', 'estrogen receptor negative', 'her2/neu negative', 'her2/neu positive', 'progesterone receptor negative', 'recurrent breast carcinoma', 'stage iv breast cancer']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['Z17.1']"", ""['A41.50', 'A41.59', 'E70.320', 'Z17.1', 'Z67.11', 'Z67.21', 'Z67.31']"", ""['E70.321', 'Z17.0', 'Z67.10', 'Z67.20', 'Z67.30', 'Z67.40', 'Z67.90']"", ""['Z17.0', 'Z17.1', 'T47.0X6S', 'T50.7X6S', 'T47.0X3S', 'T47.0X4S', 'T47.0X5S']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]",['palbociclib'],['CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C'],"
        Inclusion Criteria:

          -  Histologically confirmed HER2-positive metastatic breast cancer (estrogen and
             progesterone receptor 0%, HER-2 3+ by immunohistochemistry (IHC); if IHC score of 2,
             fluorescence in situ hybridization (FISH) ratio must be greater than 2.0; if FISH less
             than 2.0, HER2 copy number must be greater than 6; NOTE: Brain lesions are not
             required to have pathologic confirmation

          -  Patients should not have received > 2 lines of chemotherapy for metastatic disease

          -  Patients must have a life expectancy of at least 12 weeks at the time of registration

          -  Eastern Cooperative Oncology Group (ECOG) performance status >= 2

          -  Measurable disease in the brain, defined as at least 1 lesion measuring >= 5 mm on
             imaging at the time of registration

          -  If patients are on corticosteroids, they must have been on a stable or decreasing dose
             >= 5 days prior to obtaining their baseline gadolinium (Gd)-magnetic resonance imaging
             (MRI) of brain; this MRI is to be obtained within 28 days of registration; NOTE: If
             patient needs escalation of steroids prior to therapy, or are on unstable doses of
             steroids they are not eligible

          -  Patients who underwent neurosurgery (NSGY) or stereotactic radiosurgery (SRS) to a
             brain lesion must have a new measureable lesion; NOTE: SRS may be done to a lesion
             that will not be used for response evaluation and should be done > 2 weeks prior to
             registration; any NSGY procedure must have been completed > 3 weeks prior to
             registration

          -  Patients must not have received systemic therapy within 2 weeks of initiating
             palbociclib; NOTE: For the HER2-positive cohort, patients on trastuzumab can remain on
             the drug; no break or washout period required; however, lapatinib,
             ado-trastuzumab-emtansine, and pertuzumab are prohibited and a minimum wash out period
             of 2 weeks is required

          -  Patients must exhibit adequate bone marrow, liver, and renal function, within 14 days
             prior to registration, defined as:

               -  Absolute neutrophil count (ANC) >= 1,000/mm^3 (growth factor support is
                  permitted)

               -  Platelets >= 100,000/mm^3 (may be reached by transfusion)

               -  Hemoglobin >= 10 gm/dl (may be reached by transfusion)

               -  Glutamate pyruvate transaminase (GPT)/glutamate oxaloacetate transaminase (GOT) <
                  3 x upper limit of normal (ULN) (or < 5 x ULN in case of liver metastasis)

               -  Bilirubin < 3 x ULN (or < 5 x ULN in case of liver metastasis)

               -  Creatinine < 1.5 x ULN

          -  Females of child-bearing potential (FOCBP) and males must agree to use adequate
             contraception prior to study entry, for the duration of study participation, and for 2
             weeks following completion of therapy; should a female patient become pregnant or
             suspect she is pregnant while participating in this study, she should inform her
             treating physician immediately; likewise, if the female partner of a male patient
             becomes pregnant while participating in this study, he should inform his treating
             physician immediately; NOTE: A FOCBP is any woman (regardless of sexual orientation,
             having undergone a tubal ligation, or remaining celibate by choice) who meets the
             following criteria:

               -  Has not undergone a hysterectomy or bilateral oophorectomy

               -  Has had menses at any time in the preceding 12 consecutive months (and therefore
                  has not been naturally postmenopausal for > 12 months)

          -  Female patients must have a negative urine pregnancy test within 7 days prior to
             registration; if urine test is positive, it should be followed by serum pregnancy test

          -  Patients must sign an informed consent prior to registration and before undergoing any
             study-specific procedures indicating that they are aware of the investigational nature
             of this study

          -  Patient must have the ability to swallow and retain oral medication

          -  Patient must have the ability to comply with all study requirements

        Exclusion Criteria:

          -  Any uncontrolled neurological symptom attributed to CNS metastasis

          -  Brain metastasis must not be impending herniation or other significant vasogenic edema
             requiring increasing steroid doses; lesions must not have frank hemorrhage

          -  Patients with leptomeningeal disease are not eligible for participation

          -  Any significant medical illnesses or infection that, in the investigator's opinion,
             cannot be adequately controlled with appropriate therapy or would compromise the
             patient's ability to tolerate this therapy are not eligible for participation

          -  Known human immunodeficiency virus (HIV) positive status

          -  Known active hepatitis B and/or C

          -  Previous treatment with palbociclib

          -  Patients who have a history of allergic reactions attributed to compounds of similar
             chemical or biologic composition to palbociclib are not eligible; AND/OR patients who
             have had prior exposure to compounds of similar chemical or biologic composition to
             palbociclib are not eligible hypersensitivity to any component of palbociclib are not
             eligible for participation

          -  Patients being treated with any other experimental agents/clinical trials are not
             eligible for participation; if the patient is on any investigational agent, a wash-out
             period of minimum 2 weeks prior to registration is mandatory for the patient to be
             eligible for the study

          -  Patients who are on any prohibited medication; a wash-out period of minimum 2 weeks
             prior to registration is mandatory for the patient to be eligible for the study

          -  Inability to swallow capsules, malabsorption syndrome or gastrointestinal disease that
             severely affects the absorption of study drugs, major resection of the stomach or
             small bowel, or gastric bypass procedure

          -  Patients who have an uncontrolled intercurrent illness including, but not limited to
             any of the following, are not eligible:

               -  Ongoing or active infection requiring systemic treatment

               -  Symptomatic congestive heart failure

               -  Unstable angina pectoris

               -  Cardiac arrhythmia: except atrial fibrillation (AF) and supraventricular
                  tachycardia (SVT) that are controlled by medication

               -  Psychiatric illness/social situations that would limit compliance with study
                  requirements

               -  Any other illness or condition that the treating investigator feels would
                  interfere with study compliance or would compromise the patient's safety or study
                  endpoints

          -  Female patients who are pregnant or nursing are not eligible
      "
NCT02778685,suspended,"
    accrual on hold
  ",0,phase 2,"['metastatic breast carcinoma', 'stage iv breast cancer ajcc v6 and v7']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['fulvestrant', 'letrozole', 'palbociclib']","['CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F', 'C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3', 'CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C']","
        Inclusion Criteria:

          -  Willing and able to provide written informed consent/assent for the trial

          -  Men or women >= 18 years of age on day of signing informed consent

          -  Willing and able to comply with all aspects of the treatment protocol

          -  Postmenopausal patients defined by at least one of the following criteria:

               -  Prior bilateral oophorectomy OR amenorrheic for >= 12 months (if =< 55 years of
                  age and prior to chemotherapy, or on medical ovarian ablative therapy OR

               -  Previous hysterectomy with one or both ovaries left in place (previous
                  hysterectomy in which documentation of bilateral oophorectomy is unavailable AND
                  follicle stimulating hormone [FSH] values consistent with the institutional
                  normal values for the post-menopausal state; FSH levels must be obtained within
                  28 days prior to registration)

          -  Presence of measurable disease meeting the following criteria: at least 1 lesion of >
             10 mm in long axis diameter for non-lymph nodes or > 15 mm in short axis diameter for
             lymph nodes that is serially measurable according to RECIST version 1.1 using
             computerized tomography, magnetic resonance imaging, or panoramic and close-up color
             photography

          -  Stage IV metastatic ER+HER2- breast cancer histologically proven per current American
             Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines;
             allow up to 30 days prior use of CDK4/6 inhibitors and up to 60 days of letrozole or
             other aromatase inhibitors for treatment of metastatic ER+ breast cancer

          -  Life expectancy of >= 3 months

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2

          -  Willing to provide tissue from a newly obtained core or excisional biopsy of a tumor
             lesion; newly-obtained is defined as a specimen obtained up-to 6 weeks (42 days) prior
             to initiation of treatment on day 1 and day -28 for cohort 3; subjects for whom
             newly-obtained samples cannot be provided (e.g. inaccessible or subject safety
             concern) may submit an archived specimen only upon agreement from the study principal
             investigator (PI)

          -  For Cohort 3, willing to undergo tumor biopsies at baseline (within 6 weeks of study
             onset), cycle 2 day 1 (C2D1) (+/-1 week) and at time-of-progression or
             end-of-treatment when feasible

          -  Absolute neutrophil count (ANC) >= 1,000 /mcL (performed within 10 days of treatment
             initiation)

          -  Platelets >= 100,000 /mcL (performed within 10 days of treatment initiation)

          -  Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO)
             dependency (within 7 days of assessment) (performed within 10 days of treatment
             initiation)

          -  Serum creatinine =< 1.5 X upper limit of normal (ULN) OR measured or calculated
             creatinine clearance (glomerular filtration rate [GFR] can also be used in place of
             creatinine or creatinine clearance [CrCl]) >= 60 mL/min for subject with creatinine
             levels > 1.5 x institutional ULN (performed within 10 days of treatment initiation)

               -  Creatinine clearance should be calculated per institutional standard

          -  Serum total bilirubin =< 1.5 X ULN OR direct bilirubin =< ULN for subjects with total
             bilirubin levels > 1.5 ULN (performed within 10 days of treatment initiation)

          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and
             alanine aminotransferase (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X ULN
             OR =< 5 X ULN for subjects with liver metastases (performed within 10 days of
             treatment initiation)

          -  Albumin >= 2.5 mg/dL (performed within 10 days of treatment initiation)

          -  International normalized ratio (INR) or prothrombin time (PT) =< 1.5 X ULN unless
             subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic
             range of intended use of anticoagulants

          -  Activated partial thromboplastin Time (aPTT) =< 1.5 X ULN unless subject is receiving
             anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use
             of anticoagulants

          -  Female subjects of childbearing potential should have a negative urine or serum
             pregnancy within 72 hours prior to receiving the first dose of study medication; if
             the urine test is positive or cannot be confirmed as negative, a serum pregnancy test
             will be required

          -  Female subjects of childbearing potential should be willing to use two methods of
             birth control or be surgically sterile, or abstain from heterosexual activity for the
             course of the study through 120 days after the last dose of study medication; subjects
             of childbearing potential are those who have not been surgically sterilized or have
             not been free from menses for > 1 year

               -  Cohort 1 (accrual to 6 patients) is for patients who had ongoing stable disease
                  (SD) on letrozole + palbociclib, enrolled on prior version of eligibility
                  criteria to receive pembrolizumab after obtaining stable disease on letrozole +
                  palbociclib; these patients must have been on treatment with letrozole and
                  palbociclib for 6 months with SD per RECIST 1.1; received up to 3 lies of
                  previous therapy including endocrine and/or chemotherapy in advanced setting
                  prior to initiation of letrozole and palbociclib; no grade 3 toxicities except
                  alopecia

        Exclusion Criteria:

          -  Patients currently participating and receiving study therapy or who have participated
             in a study of an investigational agent and received study therapy or used and
             investigational device within 4 weeks of the first dose of treatment

          -  Previously received pembrolizumab or other anti-programmed cell death-1 (PD-1) or
             anti-PD-L1 immunotherapy

          -  Does not have measurable disease per RECIST 1.1

          -  For cohort 2, received > 30 days of prior treatment with CDK4/6 inhibitors or > 60
             days of letrozole before screening

          -  Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other
             form of immunosuppressive therapy within 7 days prior to the first dose of trial
             treatment

          -  Known history of active TB (Bacillus tuberculosis)

          -  Hypersensitivity to pembrolizumab or any of its excipients

          -  Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or has
             not recovered (i.e., =< grade 1 or at baseline) for adverse events (AEs) due to agents
             administered > 4 weeks earlier

          -  Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2
             weeks prior to study day 1 or has not recovered (i.e. =< grade 1 or at baseline) from
             AEs due to a previously administered agent

               -  Note: Patients with =< grade 2 neuropathy are an exception to this criterion and
                  may qualify for the study

               -  Note: If patient received major surgery, she must have recovered adequately from
                  the toxicity and/or complications from the intervention prior to starting therapy

          -  Known additional malignancy that is progressing or requires active treatment;
             exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the
             skin that has undergone potentially curative therapy or in situ cervical cancer

          -  Known active central nervous system (CNS) metastases and/or carcinomatous meningitis;
             patients with previously treated brain metastases may participate provided they are
             stable (without evidence of progression by imaging for at least 4 weeks prior to the
             first dose of trial treatment and any neurologic symptoms have returned to baseline),
             have no evidence of new or enlarging brain metastases, and are not using steroids for
             at least 7 days prior to trial treatment; this exception does not include
             carcinomatous meningitis, which is excluded regardless of clinical stability

          -  Active autoimmune disease that has required systemic treatment in the past 2 years
             (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive
             drugs); replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
             form of systemic treatment

          -  History of (non-infectious) pneumonitis that required steroids or current pneumonitis

          -  History of interstitial lung disease

          -  Clinically active diverticulitis, intra-abdominal abscess, gastrointestinal (GI)
             obstruction, or abdominal carcinomatosis (known risks factors for bowel perforation)

          -  Active infection requiring systemic therapy

          -  History of significant cardiovascular disease, defined as: congestive heart failure
             greater than New York Heart Association (NYHA) class II according to the NYHA
             functional classification; unstable angina or myocardial infarction within 6 months of
             enrollment; or serious cardiac arrhythmia

          -  Clinically significant electrocardiogram (ECG) abnormality, including a marked
             baseline prolonged QT/corrected QT (QTc) ([QT interval/corrected QT interval], e.g., a
             repeated demonstration of a QTc interval > 480 ms), a family or personal history of
             long or short QT syndrome, Brugada syndrome or known history of QTc prolongation, or
             torsade de pointes (TdP)

          -  Concurrent use of drugs that are known to be moderate or strong cytochrome P450,
             family 3, subfamily A (CYP3A) inhibitors or inducers or drugs that are known to
             prolong the QT interval

          -  History or current evidence of any condition, therapy, or laboratory abnormality that
             might confound the results of the trial, interfere with the patient's participation
             for the full duration of the trial, or is not in the best interests of the patient to
             participate, in the opinion of the treating investigator

          -  Pregnant, breastfeeding, or expecting to conceive children within the projected
             duration of the trial, starting with the pre-screening or screening visit through 120
             days after the last dose of trial treatment

          -  Known psychiatric or substance abuse disorders that would interfere with cooperation
             with the requirements of the trial

          -  Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)

          -  Known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or
             hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is
             detected)

          -  Received a live vaccine within 30 days of planned start of study therapy;

               -  Note: Seasonal influenza vaccines for injection are generally inactivated flu
                  vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist)
                  are live attenuated vaccines, and are not allowed
      "
NCT02776137,completed,,0,phase 2,"['head-and-neck cancer', 'squamous cell carcinoma']","[""['C44.520', 'C44.92', 'C44.02', 'C44.321', 'C44.521', 'C44.82', 'C44.42']""]",['docetaxel'],['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O'],"
        Inclusion Criteria:

          1. Histologically confirmed squamous cell carcinoma of the head and neck.Site of tumor
             origin in the oral cavity, oropharynx, larynx, or hypopharynx (excluding nasopharynx,
             or sinuses)

          2. Gross total resection, with pathology demonstrating one or more of the following risk
             factors:

               1. Histologic extracapsular nodal extension

               2. Histologic involvement of ≥ 2 regional lymph nodes

               3. Invasive cancer seen on microscopic evaluation of the resection margin, with no
                  evidence of gross tumor residual

          3. No evidence of distant metastases

          4. No synchronous or concurrent head and neck primary tumors

          5. Karnofsky score over 60

          6. Adequate organ function including the following:

               1. Absolute neutrophil count (ANC) >= 1.5 * 10^9/l

               2. Platelets count >= 100 * 10^9/l

               3. Hemoglobin >= 10 g/dl

               4. AST and ALT <= 2.5 times institutional upper limit of normal (ULN)

               5. Total bilirubin <= 1.5 times institutional ULN

               6. Creatinine clearance >= 50 ml/min

               7. Serum creatine <= 1 times ULN

          7. Signed written informed consent

        Exclusion Criteria:

          1. Evidence of distant metastasis

          2. Prior chemotherapy or anti-cancer biologic therapy for any type of cancer, or prior
             radiotherapy to the head and neck region

          3. Other previous cancer, except for in situ cervical cancer and cutaneous basal cell
             carcinoma

          4. Pregnant or breast-feeding females, or females and males of childbearing potential not
             taking adequate contraceptive measures

          5. Presence of an uncontrolled concomitant illness including, but not limited to, ongoing
             or active infection, symptomatic congestive heart failure, unstable angina pectoris,
             or cardiac arrhythmia
      "
NCT02771626,terminated,"
    lack of efficacy
  ",0,phase 1/phase 2,"['clear cell renal cell carcinoma (ccrcc)', 'melanoma', 'non-small cell lung cancer (nsclc)']","[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['cb-839', 'nivolumab']",['C1=CC=NC(=C1)CC(=O)NC2=NN=C(S2)CCCCC3=NN=C(C=C3)NC(=O)CC4=CC(=CC=C4)OC(F)(F)F'],"
        Addition eligibility criteria based on tumor type apply

        Inclusion Criteria:

          -  Ability to provide written informed consent in accordance with federal, local, and
             institutional guidelines

          -  Histological or cytological diagnosis of metastatic cancer or locally advanced cancer
             that is not amenable to local therapy

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1

          -  Life Expectancy of at least 3 months

          -  Adequate hepatic, renal, cardiac, and hematologic function

          -  Measurable disease by Response Evaluation Criteria in Solid Tumours (RECIST) v1.1
             criteria

          -  Resolution of treatment-related toxicities except alopecia

        Exclusion Criteria:

          -  Unable to receive oral medications

          -  Unable to receive oral or intravenous (IV) hydration

          -  Intolerance to prior anti-PD-1/PD-L1 therapy

          -  Prior severe hypersensitivity reaction to another monoclonal antibody (mAb)

          -  Any other current or previous malignancy within 3 years except protocol allowed
             malignancies

          -  Chemotherapy, TKI therapy, radiation therapy or hormonal therapy within 2 weeks

          -  Immunotherapy or biological therapy, or investigational agent within 3 weeks (Note:
             Some cohort exceptions allow anti-PD-1 therapy)

          -  Active known or suspected exclusionary autoimmune disease

          -  Any condition requiring systemic treatment with either corticosteroids (> 10 mg daily
             prednisone equivalent) or other systemic immunosuppressive medications within 2 weeks

          -  History of known risks factors for bowel perforation

          -  Symptomatic ascites or pleural effusion

          -  Major surgery within 28 days before Cycle 1 Day 1

          -  Active infection requiring parenteral antibiotics, antivirals, or antifungals within 2
             weeks prior to first dose of study drug

          -  Patients who have human immunodeficiency virus (HIV), Hepatitis B or C

          -  Conditions that could interfere with treatment or protocol-related procedures

          -  Active and/or untreated central nervous system (CNS) disease or non-stable brain
             metastases
      "
NCT02779777,terminated,"
    lack of efficacy
  ",0,phase 2,['myelodysplastic syndromes'],"[""['D46.9', 'D46.C', 'D46.Z']""]",['tipifarnib'],['CN1C=NC=C1C(C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=CC(=CC=C5)Cl)C)N'],"
        Inclusion Criteria:

          -  Subject is at least 18 years of age.

          -  Documented pathological evidence of MDS as defined by the World Health Organization
             (WHO) criteria

          -  Must have transfusion-dependent anemia that meets the following criteria:

               1. Average transfusion requirement of ≥ 2 units per 28 days of packed RBCs confirmed
                  for a minimum of 112 days immediately preceding Cycle 1 Day 1.

               2. No consecutive 56 days that was RBC transfusion-free during the 112 days
                  immediately preceding Cycle 1 Day 1.

               3. Hemoglobin levels at the time of or within 7 days prior to transfusions must have
                  been ≤ 9.0 g/dL for the transfusions to qualify as required for the purpose of
                  providing evidence of transfusion-dependent anemia.

          -  Must be unresponsive or refractory to erythropoiesis-stimulating agents (ESA), based
             on one of the following:

               1. Transfusion-dependence in subjects previously treated with an ESA (requires a
                  minimum ESA trial of > 40,000 U/week recombinant human erythropoietin (rHuEPO) x
                  8 weeks or equivalent dose of darbepoetin or other erythropoietin agent), or

               2. Serum erythropoietin level of > 500 mU/mL in subjects not previously treated with
                  an ESA.

          -  Risk category very low, low or intermediate (Revised International Prognostic Scoring
             System, IPSS-R)

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

          -  Subjects have no known curative treatment.

          -  At least 1 week since the last systemic therapy regimen prior to Cycle 1 Day 1.
             Subjects must have recovered to NCI CTCAE v. 4.03 < Grade 2 from all acute toxicities
             (excluding Grade 2 toxicities that are not considered a safety risk by the Sponsor and
             Investigator) or toxicity must be deemed irreversible by the Investigator.

          -  Acceptable hematological function:

               1. Absolute neutrophil count > 500/mm3

               2. Platelet count > 25,000/mm3

          -  Acceptable liver function:

               1. Total or direct bilirubin ≤ 1.5 times upper limit of normal (x ULN); does not
                  apply to subjects with Gilbert's syndrome diagnosed as per institutional
                  guidelines.

               2. AST (SGOT) and ALT (SGPT) ≤ 2.5 x ULN.

          -  Acceptable renal function with serum creatinine ≤ 1.5 x ULN or a calculated creatinine
             clearance ≥ 60 mL/min using the Cockcroft-Gault or Modification of Diet in Renal
             Disease formulas.

          -  Female subjects must be either:

               1. Of non-child-bearing potential (surgically sterilized or at least 2 years
                  post-menopausal); or

               2. If of child-bearing potential, subject must use an adequate method of
                  contraception consisting of two-barrier method or one barrier method with a
                  spermicide or intrauterine device. Both females and male subjects with female
                  partners of child-bearing potential must agree to use an adequate method of
                  contraception for 2 weeks prior to screening, during, and at least 4 weeks after
                  last dose of study medication. Female subjects must have a negative serum or
                  urine pregnancy test within 72 hours prior to start of study medication.

               3. Not breast feeding at any time during the study.

        Exclusion Criteria:

          -  Known prior progression to acute myeloid leukemia (AML), defined by at least 20%
             blasts in the blood or bone marrow.

          -  Myelodysplastic or myeloproliferative syndrome other than MDS.

          -  More than two prior systemic treatments for MDS. Prior systemic therapies are those
             that have been received at standard doses for at least one full treatment cycle.

          -  Prior cytoreductive therapy.

          -  Use of an ESA within the 4 weeks prior to Cycle 1 Day 1.

          -  Participation in any interventional study within 4 weeks or 5 half lives (whichever is
             longer) of Cycle 1 Day 1.

          -  Ongoing treatment with an anticancer agent for MDS not contemplated in this protocol.

          -  Prior treatment (at least 1 full treatment cycle) with a farnesyltransferase
             inhibitor.

          -  Clinically significant anemia due to iron, B12, or folate deficiencies, or autoimmune
             or hereditary hemolytic anemia, or gastrointestinal bleeding. If marrow stain for iron
             is not available, the transferrin saturation (iron/total iron binding capacity
             Fe/TIBC) must be >20% or serum ferritin must be >100 ng/dL.

          -  Active coronary artery disease requiring treatment, myocardial infarction within the
             prior year, New York Heart Association grade III or greater congestive heart failure,
             cerebro-vascular attack within the prior year, or current serious cardiac arrhythmia
             requiring medication except atrial fibrillation.

          -  Major surgery, other than diagnostic surgery, within 2 weeks prior to Cycle 1 Day 1,
             without complete recovery.

          -  Active, concurrent malignancy requiring radiation, chemotherapy, or immunotherapy
             (excluding non-melanoma skin cancer, adjuvant hormonal therapy for breast cancer and
             hormonal treatment for castration sensitive prostate cancer).

          -  Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic
             therapy. Known infection with human immunodeficiency virus (HIV), or an active
             infection with hepatitis B or hepatitis C.

          -  Subjects who have exhibited allergic reactions to tipifarnib, or structural compounds
             similar to tipifarnib or to its excipients.

          -  Concomitant disease or condition that could interfere with the conduct of the study,
             or that would, in the opinion of the investigator, pose an unacceptable risk to the
             subject in this study.

          -  The subject has legal incapacity or limited legal capacity.

          -  Significantly altered mental status that would limit the understanding or rendering of
             informed consent and compliance with the requirements of this protocol. Unwillingness
             or inability to comply with the study protocol for any reason.
      "
NCT03351231,terminated,"
    inability to meet protocol objectives
  ",0,phase 1/phase 2,['cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]",['bms-986242'],['CC(C1CCC(CC1)C2=C3C=C(C=CC3=NC=C2)F)NC(=O)C4=CC=C(C=C4)Cl'],"
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Histologic or cytological confirmation of a malignancy that is advanced (metastatic
             and/or unresectable) with measureable disease per RECIST v1.1

          -  Participants must have received and then progressed or been intolerant to at least 1
             standard treatment regimen in the advanced or metastatic setting if such a therapy
             exists

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

          -  Ability to swallow tablets

          -  Adequate bone marrow and organ function, as defined by the protocol

        Exclusion Criteria:

          -  Participants with known or suspected CNS metastases, untreated CNS metastases, or with
             the CNS as the only site of disease (patients with controlled brain metastasis allowed
             to enroll)

          -  Ocular melanoma

          -  Any significant acute or chronic medical illness

          -  Prior malignancy

          -  Other active malignancy requiring concurrent intervention

          -  Prior organ allograft or allogeneic bone marrow transplantation

          -  Participants with active, known, or suspected autoimmune disease

          -  Requirement for daily supplemental oxygen

          -  Uncontrolled or significant cardiovascular disease

          -  Pre-existing liver disease

          -  Gastrointestinal disease known to interfere with absorption

        Other protocol defined inclusion/exclusion criteria could apply
      "
NCT03358004,terminated,"
    low accrual rate
  ",0,phase 2,['triple negative breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['vinorelbine tartrate', 'capecitabine 500 mg']",['CCC1=CC2CC(C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC.C(C(C(=O)O)O)(C(=O)O)O.C(C(C(=O)O)O)(C(=O)O)O'],"
        Inclusion Criteria:

          -  Female, aged ≥ 18 years old;

          -  Eastern Cooperative Oncology Group performance status (ECOG -PS) ≤ 1;

          -  Locally advanced or metastatic triple-negative breast cancer, i.e. HER2-negative
             status and ER and PgR negative status (as per local assessment);

          -  Treatment with 1st line chemotherapy (with any drug excepted Bevacizumab-based
             regimens) as per clinical practice, and non-progressive when the treatment was
             terminated;

          -  No more than 6 cycles of the previous chemotherapy;

          -  At least one measurable lesion according to Response Evaluation Criteria in Solid
             Tumors (RECIST, version 1.1);

          -  Willingness and ability to comply with the study protocol as judged by the
             Investigator;

          -  For women who are not postmenopausal (i.e., < 2 years after last menstruation) and who
             are sexually active: agreement to use an adequate method of contraception (oral
             contraceptives, intrauterine contraceptive device, barrier method of contraception in
             conjunction with spermicidal jelly) during the treatment period and for at least 6
             months after the last dose of study drug;

          -  Provision of a written informed consent signed prior to enrolment according to
             ICH/GCP.

        Exclusion Criteria:

          -  Previous treatment with vinorelbine or capecitabine;

          -  1st line therapy with a bevacizumab-based regimen;

          -  Presence of brain metastases;

          -  Any other investigational drug or any anti-cancer treatment (except for radiotherapy,
             if the treatment field does not include the liver);

          -  Inadequate bone marrow, hepatic or renal function including the following:

               1. absolute neutrophils count of < 1.5 cells x 109/L, platelet count < 100 cells x
                  109/L, or hemoglobin < 8 g/L;

               2. serum total bilirubin >1.5 × institution upper limit of normal [ULN], aspartate
                  aminotransferase and alanine aminotransferase >2.5 × ULN, or >5 × ULN for
                  patients with liver metastases, alkaline phosphatase >2.5 × ULN, or >5 × ULN for
                  patients with liver metastases, or >10 × ULN for patients with bone metastases;

               3. serum creatinine concentration >1.5 × ULN, creatinine clearance <50 mL/min
                  calculated according to Cockcroft-Gault equation, and coagulation parameters
                  international normalized ratio >1.5;

          -  With the exception of basal cell carcinoma or cervical cancer in situ, history of
             another malignancy, unless in remission for 5 years or more and judged of negligible
             potential of relapse;

          -  Known dihydropyrimidine dehydrogenase deficiency;

          -  Treatment with sorivudine or its chemically related analogues, such as brivudine,
             within 4 weeks prior to randomization;

          -  Evidence of any significant clinical disorder or concurrent illness or laboratory
             finding that, at the judgment of the Investigator, contra-indicate the inclusion of
             the patient in the study;

          -  Psychiatric disorders or altered mental status precluding understanding of the
             informed consent process and/or completion of the necessary study assessment and
             procedures;

          -  Unable to swallow tablets;

          -  Previous significant surgical resection of stomach or small bowel

          -  Patients requiring long-term oxygen therapy

          -  Known hypersensitivity to any excipients of oral vinorelbine, oral capecitabine and to
             fluoropyrimidine.
      "
NCT03407430,terminated,"
    low patient accrual
  ",0,phase 2,"['breast cancer', 'lymphoma', 'pain']","[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['N50.82', 'R07.2', 'R07.82', 'R10.13', 'R10.33', 'R14.1', 'R52']""]","['pregabalin', 'placebo']",['CC(C)CC(CC(=O)O)CN'],"
        Inclusion Criteria:

          -  Age ≥18 years

          -  Diagnosis of a non-myeloid hematologic malignancy scheduled to initiate a cycle of
             chemotherapy that requires prophylactic use of a granulocyte colony-stimulating growth
             factor (based on the provider's discretion), provided the schedule of chemotherapy
             cycles allows the use of pegfilgrastim at a dose of 6 mg SC once per cycle OR
             Diagnosis of breast cancer scheduled to initiate dose-dense doxorubicin and
             cyclophosphamide (AC) chemotherapy or docetaxel and cyclophosphamide (TC) chemotherapy
             that requires prophylactic use of a granulocyte colony-stimulating growth factor,
             provided the schedule of chemotherapy cycles allows the use of pegfilgrastim, at a
             dose of 6 mg SC once per cycle; pegfilgrastim scheduled for 24 hours post
             chemotherapy.

          -  Schedule of chemotherapy and pegfilgrastim initiation can accommodate initiation of
             pregabalin 4 days prior to pegfilgrastim dose.

          -  Baseline pain scores <7 as measured via 10-point numerical scale for pain (see section
             11.1); pain score and use of any non-opioid pain medication must be self-reported as
             stable (same dose and frequency) over the 7 days prior to screening; for opioids,
             patient must self-report the same dose and frequency over the 28 days prior to
             screening. Patients who are receiving peri-procedural short-acting analgesics will
             still be included as long as they are no longer receiving analgesics by D1 of
             chemotherapy.

        Exclusion Criteria:

          -  A history of (within one month) or current pregabalin use.

          -  Baseline pain scores ≥7 as measured via 10-point numerical scale for pain (see section
             11.1).

          -  Unwilling to discontinue use of antihistamines from 7 days prior to D1 of study
             medication.

          -  Creatinine clearance (CrCl) ≤60 ml/min (as measured via Cockcroft-Gault) based on
             serum creatinine measured as part of standard of care prior to administration of
             chemotherapy

          -  Women of childbearing potential must have a negative serum pregnancy test prior to
             initiating therapy (note, this test should be standard of care prior to administration
             of chemotherapy).

          -  Patient is unable or unwilling to abide by the study protocol or cooperate fully with
             the investigator.

          -  Eligible and agrees to enroll into therapeutic trial ongoing at the Lineberger
             Comprehensive Cancer Center (LCCC) (i.e., the treatment trial will take precedence
             over LCCC1314).

          -  Currently receiving therapeutic doses of anticoagulants (ie, prophylactic use of
             anticoagulants is allowed) due to possibility of dizziness and falls while on
             pregabalin.

          -  Currently receiving aromatase inhibitors or agents targeted against Ph+ leukemias
             (i.e., imatinib, dasatinib, nilotinib, and ponatinib) or scheduled to start these
             drugs during cycle 1 of scheduled chemotherapy.

          -  Presence of bone metastases.

          -  History of angioedema.

          -  History of a seizure disorder.
      "
NCT03402880,withdrawn,"
    no patients enrolled
  ",0,phase 2,['extensive stage small cell lung carcinoma'],"[""['D02.20', 'D02.21', 'D02.22']""]",['epacadostat'],['C1=CC(=C(C=C1N=C(C2=NON=C2NCCNS(=O)(=O)N)NO)Br)F'],"
        Inclusion Criteria:

          -  Be willing and able to provide written informed consent/assent for the trial

          -  Subjects with histologically or cytologically confirmed small cell lung cancer and
             radiographic evidence of extensive stage disease

          -  Previous treatment with platinum based therapy for small cell lung cancer (eligibility
             not dependent on stage at time of platinum based therapy)

          -  Have measurable disease based on RECIST v1.1

          -  Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)
             performance scale

          -  Absolute neutrophil count (ANC) >= 1,500/mcL (performed within 10 days of treatment
             initiation)

          -  Platelets >= 100,000/mcL (performed within 10 days of treatment initiation)

          -  Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO)
             dependency (within 7 days of assessment) (performed within 10 days of treatment
             initiation)

          -  Serum creatinine =< 1.5 X upper limit of normal (ULN) OR measured or calculated
             creatinine clearance >= 60 mL/min for subject with creatinine levels > 1.5 X
             institutional ULN (glomerular filtration rate [GFR] can also be used in place of
             creatinine or creatinine clearance [CrCl]) (performed within 10 days of treatment
             initiation)

          -  Serum total bilirubin =< 1.2 X ULN OR conjugated bilirubin =< 1.2 x ULN; if an
             institutional ULN for conjugated bilirubin is not available, then conjugated bilirubin
             should be < 40% of total bilirubin to be considered eligible (performed within 10 days
             of treatment initiation)

          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X
             ULN OR =< 5 X ULN for subjects with liver metastases (performed within 10 days of
             treatment initiation)

          -  Albumin >= 2.5 mg/dL (performed within 10 days of treatment initiation)

          -  International normalized ratio (INR) or prothrombin time (PT) =< 1.5 X ULN unless
             subject is receiving anticoagulant therapy as long as PT or partial thromboplastin
             time (PTT) is within therapeutic range of intended use of anticoagulants (performed
             within 10 days of treatment initiation)

          -  Activated partial thromboplastin time (aPTT) =< 1.5 X ULN unless subject is receiving
             anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use
             of anticoagulants (performed within 10 days of treatment initiation)

          -  Female subject of childbearing potential should have a negative urine or serum
             pregnancy within 72 hours prior to receiving the first dose of study medication; if
             the urine test is positive or cannot be confirmed as negative, a serum pregnancy test
             will be required

          -  Female subjects of childbearing potential must be willing to use an adequate method of
             contraception for the course of the study through 120 days after the last dose of
             study medication

             * Note: abstinence is acceptable if this is the usual lifestyle and preferred
             contraception for the subject

          -  Male subjects of childbearing potential must agree to use an adequate method of
             contraception starting with the first dose of study therapy through 120 days after the
             last dose of study therapy

               -  Note: abstinence is acceptable if this is the usual lifestyle and preferred
                  contraception for the subject

        Exclusion Criteria:

          -  Is currently participating and receiving study therapy or has participated in a study
             of an investigational agent and received study therapy or used an investigational
             device within 4 weeks of the first dose of treatment

          -  Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy > 10
             mg/day prednisone equivalents or any other form of immunosuppressive therapy within 7
             days prior to the first dose of trial treatment

          -  Has a known history of active TB (Bacillus tuberculosis); recommend documentation of
             inadequate treatment of latent or active TB

          -  Hypersensitivity to pembrolizumab, epacadostat or any of its excipients

          -  Corrected QT (QTc) > 480 ms: history or presence of an abnormal electrocardiogram
             (ECG) that, in the investigators opinion, is clinically meaningful; screening QTc
             interval > 480 milliseconds is excluded; in the event that a single QTc is > 480
             milliseconds, the subject may enroll if the average QTc for the 3 ECGs is < 480
             milliseconds; for subjects with an intraventricular conduction delay (QRS interval >
             120 milliseconds), the corrected JT (JTc) interval may be used in place of the QTc
             with sponsor approval; the JTc must be < 340 milliseconds if JTc is used in place of
             the QTc; subjects with left bundle branch block are excluded; QTc prolongation due to
             pacemaker may enroll if the JTc is normal

          -  Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study
             day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events
             due to agents administered more than 4 weeks earlier

          -  Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy
             within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at
             baseline) from adverse events due to a previously administered agent

               -  Note: subjects with =< grade 2 neuropathy are an exception to this criterion and
                  may qualify for the study

               -  Note: if subject received major surgery, they must have recovered adequately from
                  the toxicity and/or complications from the intervention prior to starting therapy

          -  Has a known additional malignancy that is progressing or requires active treatment;
             exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the
             skin that has undergone potentially curative therapy or in situ cervical cancer

          -  Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis; subjects with previously treated brain metastases may participate provided
             they are stable (without evidence of progression by imaging for at least four weeks
             prior to the first dose of trial treatment and any neurologic symptoms have returned
             to baseline), have no evidence of new or enlarging brain metastases, and are not using
             steroids for at least 7 days prior to trial treatment; this exception does not include
             carcinomatous meningitis which is excluded regardless of clinical stability

          -  Has active autoimmune disease that has required systemic treatment in the past 2 years
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive
             drugs); exceptions include vitiligo, controlled asthma, type I diabetes, Graves'
             disease, Hashimoto's disease, or with medical monitor approval; replacement therapy
             (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for
             adrenal or pituitary insufficiency, etc.) is not considered a form of systemic
             treatment

          -  Subjects who have had prior radiotherapy within 2 weeks of therapy; subjects must have
             recovered from all radiation-related toxicities, not require corticosteroids, and not
             have had radiation pneumonitis; a 1-week wash out is permitted for palliative
             radiation to non-CNS disease with medical monitor approval

          -  Has known history of non-infectious pneumonitis that required steroids, evidence of
             interstitial lung disease or active, non-infectious pneumonitis

          -  Has an active infection requiring systemic therapy

          -  Presence of a gastrointestinal condition that may affect drug absorption

          -  Subjects receiving monoamine oxidase inhibitors (MAOIs) within the 21 days before
             screening

          -  Any history of serotonin syndrome after receiving 1 or more serotonergic drugs

          -  Has a history of other malignancy within 2 years of study entry, with the exception of
             cured basal cell or squamous cell carcinoma of the skin, superficial bladder cancer,
             prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other
             noninvasive or indolent malignancy, or cancers from which the subject has been
             disease-free for >= 1 year following treatment with curative intent

          -  Clinically significant cardiac disease, including unstable angina, acute myocardial
             infarction within 6 months from day 1 of study drug administration, New York Heart
             Association class III or IV congestive heart failure, and arrhythmia requiring therapy

          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the subjects
             participation for the full duration of the trial, or is not in the best interest of
             the subject to participate, in the opinion of the treating investigator

          -  Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial

          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the pre-screening or screening visit
             through 120 days after the last dose of trial treatment

          -  Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-IDO1
             agent

          -  Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)

          -  Has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive or
             hepatitis B virus [HBV] DNA detected) or hepatitis C (e.g., hepatitis C virus [HCV]
             RNA [qualitative] is detected)

          -  Has received a live vaccine within 30 days of planned start of study therapy

               -  Note: seasonal influenza vaccines for injection are generally inactivated flu
                  vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist)
                  are live attenuated vaccines, and are not allowed
      "
NCT02362230,terminated,"
    difficulty accruing subjects the study accrual was closed
  ",0,phase 2,['metastatic breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]",['icotinib'],['C#CC1=CC(=CC=C1)NC2=NC=NC3=CC4=C(C=C32)OCCOCCOCCO4'],"
        Inclusion Criteria:

          -  Age 18 years or older

          -  ECOG 0 or 1

          -  Primary or metastatic tumor onfirmed as triple negative

          -  Measurable disease per RECIST version 1.1

          -  normal organ function, including bone marrow function, renal function, liver function,
             and cardiac function

          -  Two or more prior chemotherapy

          -  signed and dated an informed consent form

          -  Life expectancy of at least 12 weeks

        Exclusion Criteria:

          -  Pregnant or breast feeding

          -  ECOG score ≧2

          -  Uncontrolled medical problems

          -  Hepatic, renal, or bone marrow dysfunction as detailed above

          -  Concurrent malignancy or history of other malignancy within the last five years except
             as noted above

          -  Patients were unable or unwilling to comply with program requirements
      "
NCT02368691,terminated,"
    lack of efficacy
  ",0,phase 2,['triple negative breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]",['gtx-024'],['CC(COC1=CC=C(C=C1)C#N)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O'],"
        Inclusion Criteria:

          -  Able and willing to give voluntary, written and signed, informed consent

          -  Women ≥ 18 years of age

          -  Women with TNBC who have received at least one but no more than two prior chemotherapy
             regimens for TNBC

          -  Confirmation of AR+ (defined as ≥ 10% nuclear AR staining by immunohistochemistry
             [IHC]) TNBC in either the primary or metastatic lesion, assessed during the screening
             period by a local laboratory or by medical history

          -  TNBC confirmed by medical history as: human epidermal growth factor receptor 2
             [HER2]-negative (confirmed by IHC 0, 1+ regardless of fluorescence in situ
             hybridization [FISH] ratio; IHC 2+ with FISH ratio lower than 2.0 or HER2 gene copy
             less than 6.0; FISH ratio of 0, indicating gene deletion, when positive and negative
             in situ hybridization [ISH] controls are present); estrogen receptor (ER) negative
             (confirmed as ER expression less than or equal to 1% positive tumor nuclei);
             progesterone receptor negative (confirmed as progesterone receptor expression less
             than or equal to 1% positive tumor nuclei)

          -  Availability of paraffin embedded or formalin fixed tumor tissue; OR, a minimum of 10
             and up to 20 slides of archived tumor tissue for central laboratory confirmation of AR
             status and molecular subtyping. Metastatic tumor tissue is preferred when possible

          -  Subjects must have either measurable disease or bone-only non-measurable disease,
             evaluable according to RECIST 1.1

          -  Subjects with bone metastases should be treated with intravenous bisphosphonates or
             subcutaneous denosumab (or investigator preferred standard of care) prior to and
             during the trial, unless there is a contraindication or subject intolerance to these
             therapies

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 at the time of
             screening and enrollment

          -  Negative pregnancy test in women of childbearing potential (premenopausal or less than
             12 months of amenorrhea post-menopause, and who have not undergone surgical
             sterilization), no more than 7 days before the first dose of study treatment

          -  For women of childbearing potential who are sexually active, agreement to use a highly
             effective, non-hormonal form of contraception during and for at least 6 months after
             completion of study treatment; OR, a fertile male partner willing and able to use
             effective non-hormonal of contraception (barrier method of contraception in
             conjunction with spermicidal jelly, or surgical sterilization) during and for at least
             6 months after completion of study treatment

          -  Adequate organ function as shown by:

               -  Absolute neutrophil count ≥ 1,000 cells/mm3

               -  Platelet count ≥ 100,000 cells/mm3

               -  Hemoglobin ≥ 9 g/dL

               -  Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5
                  Upper Limit of the Normal range (ULN) (or ≤ 5 if hepatic metastases are present)

               -  Total serum bilirubin ≤ 2.0 × ULN (unless the subject has documented Gilbert
                  Syndrome)

               -  Alkaline phosphatase levels ≤ 2.5 × ULN (≤ 5 × ULN in subjects with liver
                  metastasis)

               -  Serum creatinine < 2.0 mg/dL or 177 μmol/L

               -  International normalized ratio (INR), activated partial thromboplastin time
                  (aPTT), or partial thromboplastin time (PTT) < 1.5 × ULN (unless on anticoagulant
                  treatment at screening)

          -  Able to swallow capsules

          -  Any toxicity from prior chemotherapy has resolved or Grade 1 (NCI-CTCAE, Version 4.0)

        Exclusion Criteria:

          -  Life expectancy < 4 months;

          -  Subjects with radiographic evidence of central nervous system (CNS) metastases as
             assessed by computerized tomography (CT) or magnetic resonance imaging (MRI) that are
             not well controlled (symptomatic or requiring control with continuous corticosteroid
             therapy [e.g., dexamethasone]). Note: Subjects with CNS metastases are permitted to
             participate in the study if the CNS metastases are medically well controlled prior to
             screening (as assessed by the Investigator) after receiving local therapy
             (irradiation, surgery, etc.)

          -  Radiotherapy within 14 days prior to first dose of study treatment

          -  Have, in the judgment of the Investigator, a clinically significant concurrent illness
             or psychological, familial, sociological, geographical, or other concomitant condition
             that would not permit adequate follow-up and compliance with the study protocol

          -  Positive hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection at screening

          -  Positive human immunodeficiency virus (HIV) infection at screening

          -  Prior treatment with any anti-androgens, including but not limited to, enzalutamide
             and bicalutamide

          -  Major surgery within 28 days of the first dose of study treatment

          -  Be currently taking or have previously taken testosterone, methyltestosterone,
             oxandrolone (Oxandrin®), oxymetholone, danazol, fluoxymesterone (Halotestin®),
             testosterone-like agents (such as dehydroepiandrosterone, androstenedione, and other
             androgenic compounds, including herbals), or anti-androgens

          -  Treatment with any of the following hormone replacement therapies, unless discontinued
             at least 14 days prior to the first dose of study treatment:

               -  Estrogens

               -  Megesterol acetate

          -  Treatment with any investigational agent within 28 days before the first dose of study
             treatment

          -  Another active cancer (excluding adequately treated basal cell carcinoma or cervical
             intraepithelial neoplasia [CIN]/cervical carcinoma in situ or melanoma in situ). Prior
             history of other cancer is allowed as long as there is no active disease within the
             prior 5 years

          -  Subject has a concomitant medical condition that precludes adequate study treatment
             compliance or assessment, or increases subject risk, in the opinion of the
             Investigator, such as but not limited to:

               -  Myocardial infarction or arterial thromboembolic events within 6 months prior to
                  baseline or severe or unstable angina, New York Heart Association (NYHA) Class
                  III or IV disease, or a QTcB (corrected according to Bazett's formula) interval >
                  470 msec; serious uncontrolled cardiac arrhythmia grade II or higher according to
                  NYHA; uncontrolled hypertension (systolic > 150 and/or diastolic > 100 mm Hg)

               -  Acute and chronic active infectious disorders and non-malignant medical illnesses
                  that are uncontrolled or whose control may be jeopardized by the complications of
                  this study therapy

               -  Impairment of gastrointestinal function or gastrointestinal disease that may
                  significantly alter the absorption of study drugs (e.g., ulcerative disease,
                  uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome)

          -  Current treatment with intravenous bisphosphonate or denosumab with elevated serum
             calcium corrected for albumin or ionized calcium levels outside institutional normal
             limits at screening

          -  History of non-compliance to medical regimens

          -  Subjects unwilling to or unable to comply with the protocol procedures as assessed by
             the Investigator

          -  Concurrent participation in another therapeutic clinical trial
      "
NCT02360059,terminated,"
    low accrual
  ",0,phase 2,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]",['metformin'],['CN(C)C(=N)N=C(N)N'],"
        Inclusion Criteria:

          1. Patients with histologically confirmed invasive breast cancer, stage I - IV, treated
             at Lyndon B. Johnson General Hospital in the Harris Health System.

          2. Patients = or > 18 years old and < 75 years old.

          3. Patients scheduled to undergo paclitaxel chemotherapy for breast cancer.

          4. Patients with adequate renal function, as evidenced in laboratory values = or < 3
             months old: epidermal growth factor receptor (eGFR) = or > 60 mL/min/1.73m2.

          5. Patients with adequate hepatic function per institutional testing standards, as
             evidenced in laboratory values = or < 3 months old: (1) The screening results for
             total bilirubin must be < 1.5 times the upper limit of normal. (2) The screening
             results for aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must
             be < 2 times the upper limit of normal.

          6. Patients who speak English and/or Spanish.

          7. Patients who are willing and able to review, understand, and provide written consent.

          8. Patients with an Eastern Cooperative Oncology performance status of 0 or 1.

        Exclusion Criteria:

          1. Patients with a history of or known diagnosis of diabetes according to national
             guidelines (fasting plasma glucose > or = 126 mg/dL or random plasma glucose > or =
             200 mg/dL), as evidenced in laboratory values < or = 3 months old).

          2. Patients using carbonic anhydrase inhibitors (acetazolamide [Diamox®], brinzolamide
             [Azopt®], methazolamide [Neptazane®], dorzolamide [Trusopt®], pomegranate
             ellagitannins), cimetidine, or topiramate.

          3. Patients who are enrolled in another symptom management trial.

          4. Patients with nerve pathology or clinically identified neuropathy.

          5. Patients with a history of clinically significant cutaneous drug reaction,
             hypersensitivity reaction, anaphylaxis, or any other serious adverse reaction to the
             medication used in the study.

          6. Patients with any condition associated with increased risk of metformin-associated
             lactic acidosis (e.g., congestive heart failure defined as New York Heart Association
             Class III or IV functional status, history of acidosis of any type).

          7. Patients with intestinal issues, including malabsorption syndrome, disease
             significantly affecting gastrointestinal function, or resection of the stomach or
             small bowel.

          8. Patients who are pregnant are excluded. Pre-menopausal women must have a negative
             pregnancy test. Patients that are post menopausal, or that have had a hysterectomy do
             not need to have a pregnancy test.

          9. Patients with any condition that precludes use of the study medication as determined
             by the treating physician.

         10. Patients with a diagnosis of hepatitis or HIV.

         11. Patients currently receiving or scheduled to receive a chemotherapy infusion other
             than Adriamycin/Cyclophosphamide prior to initiation of the metformin adaptation phase
             are not eligible. Patients who are receiving Adriamycin/Cyclophosphamide must be
             scheduled to be at least 8 days post-chemotherapy infusion prior to initiation of the
             metformin adaptation phase in order to be eligible.

         12. Patients who are currently using metformin (eg, Fortamet, Glucophage, Glucophage XR,
             Glumetza, Riomet).
      "
NCT02368886,completed,,1,phase 2,"['colon adenocarcinoma', 'rectal adenocarcinoma', 'stage iii colorectal cancer ajcc v7', 'stage iiia colorectal cancer ajcc v7', 'stage iiib colorectal cancer ajcc v7', 'stage iiic colorectal cancer ajcc v7', 'stage iv colorectal cancer ajcc v7', 'stage iva colorectal cancer ajcc v7', 'stage ivb colorectal cancer ajcc v7']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['clobetasol propionate', 'regorafenib']","['CCC(=O)OC1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)C(=O)CCl', 'CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F']","
        Inclusion Criteria:

          -  Histological or cytological documentation of adenocarcinoma of the colon or rectum

          -  Advanced or metastatic colorectal cancer with no curative options available and
             progression on previous standard therapy, including an EGFR inhibitor if KRAS
             wild-type

          -  Measurable or non-measurable disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

          -  Life expectancy of >= 3 months

          -  Absolute neutrophil count (ANC) > 1500/mm^3 (obtained =< 7 days prior to
             randomization)

          -  Platelet count > 100,000/mm^3 (obtained =< 7 days prior to randomization)

          -  Hemoglobin > 9.0 g/dL (obtained =< 7 days prior to randomization)

          -  Total bilirubin =< 1.5 x upper limit of normal (ULN) (obtained =< 7 days prior to
             randomization)

          -  Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) =< 2.5 x ULN (=<
             5 x ULN for subjects with liver involvement of their cancer) (obtained =< 7 days prior
             to randomization)

          -  Serum creatinine =< 1.5 x ULN (obtained =< 7 days prior to randomization)

          -  International normalized ratio (INR)/partial thromboplastin time (PTT) =< 1.5 x ULN
             (obtained =< 7 days prior to randomization)

               -  NOTE: patients who are therapeutically treated with an agent such as warfarin or
                  heparin will be allowed to participate provided that no prior evidence of
                  underlying abnormality in coagulation parameters exists; close monitoring of at
                  least weekly evaluations will be performed until INR/PTT is stable based on a
                  measurement that is pre-dose as defined by the local standard of care

          -  Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for patients with liver
             involvement of their cancer) (obtained =< 7 days prior to randomization)

          -  Negative serum pregnancy test done =< 7 days prior to randomization, for women of
             childbearing potential only; note: post-menopausal women (defined as no menses for at
             least 1 year) and surgically sterilized women are not required to undergo a pregnancy
             test; the definition of adequate contraception will be based on the judgment of the
             investigator

          -  Ability to complete questionnaire(s) by themselves or with assistance

          -  Provide informed written consent

          -  Willing to return to enrolling institution for follow-up (during the active monitoring
             phase of the study)

          -  Willing to provide blood samples for correlative research and banking purposes

        Exclusion Criteria:

          -  Prior treatment with regorafenib

          -  Major surgical procedure, open biopsy, or significant traumatic injury =< 28 days
             prior to randomization

          -  Congestive heart failure > New York Heart Association (NYHA) class 2

          -  Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3
             months) or myocardial infarction less than 6 months prior to randomization

          -  Cardiac arrhythmias requiring anti-arrhythmic therapy; Note: pace makers, beta
             blockers, or digoxin are permitted

          -  Uncontrolled hypertension; (systolic blood pressure > 140 mmHg or diastolic pressure >
             90 mmHg despite optimal medical management)

          -  History of or current pheochromocytoma

          -  Arterial or venous thrombotic or embolic events such as cerebrovascular accident
             (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism =<
             6 months prior to randomization

          -  Ongoing infection > grade 2 National Cancer Institute (NCI)-Common Terminology
             Criteria for Adverse Events (CTCAE) version 4.0

          -  Known history of chronic hepatitis B or C

          -  Patients with seizure disorder requiring medication

          -  Symptomatic metastatic brain or meningeal tumors unless the patient is > 6 months from
             definitive therapy, has a negative imaging study within 4 weeks of randomization and
             is clinically stable with respect to the tumor at the time of randomization; note:
             patient must not be undergoing acute steroid therapy or taper (chronic steroid therapy
             is acceptable provided that the dose is stable for one month prior to and following
             screening radiographic studies)

          -  History of organ allograft (including corneal transplant)

          -  Evidence or history of bleeding diathesis or any hemorrhage or bleeding event > CTCAE
             grade 3 =< 4 weeks prior to randomization

          -  Non-healing wound, ulcer, or bone fracture

          -  Renal failure requiring hematological (hemo-) or peritoneal dialysis

          -  Dehydration CTCAE (version 4.0) grade >= 1

          -  Substance abuse, medical, psychological or social conditions that may interfere with
             the patient?s participation in the study or evaluation of the study results

          -  Known hypersensitivity to any of the study drugs, study drug classes, or excipients in
             the formulation

          -  Interstitial lung disease with ongoing signs and symptoms at the time of informed
             consent

          -  Persistent proteinuria of Common Toxicity Criteria (CTC) grade 3 or higher (>= 3.5
             g/24 hours [hrs])

          -  Patients unable to swallow oral medications

          -  Any malabsorption condition

          -  Unresolved toxicity greater than CTCAE (version 4.0) grade 1 attributed to any prior
             therapy/procedure excluding alopecia and oxaliplatin induced neurotoxicity =< grade 2

          -  Albumin levels < 2.5 g/dl

          -  Any of the following:

               -  Pregnant women

               -  Nursing women

               -  Men or women of childbearing potential who are unwilling to employ adequate
                  contraception

                    -  NOTE: men and women of childbearing potential must agree to use adequate
                       contraception beginning at the signing of the informed consent form (ICF)
                       until at least 3 months after the last dose of study drug; the definition of
                       adequate contraception will be based on the judgment of the principal
                       investigator or a designated associate

          -  Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment
             of the investigator, would make the patient inappropriate for entry into this study or
             interfere significantly with the proper assessment of safety and toxicity of the
             prescribed regimens

          -  Immunocompromised patients and patients known to be human immunodeficiency virus (HIV)
             positive and currently receiving antiretroviral therapy; NOTE: patients known to be
             HIV positive, but without clinical evidence of an immunocompromised state, are
             eligible for this trial

          -  Receiving any other investigational agent which would be considered as a treatment for
             the primary neoplasm

          -  Previous or concurrent cancer that is distinct in primary site or histology from
             colorectal cancer within 3 years prior to randomization EXCEPT for curatively treated
             cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors (Ta
             [non-invasive tumor], Tis [carcinoma in situ] and T1 [tumor invades lamina propria]);
             note: all cancer treatments for cancers that were distinct in a primary site other
             than colorectal must be completed at least 3 years prior to randomization (i.e.,
             signature date of the informed consent form)

          -  Pleural effusion or ascites that causes respiratory compromise (>= CTCAE version 4.0
             grade 2 dyspnea)

          -  Concurrent anti-cancer therapy =< 4 weeks from registration (chemotherapy, radiation
             therapy, surgery, immunotherapy, biologic therapy, or tumor embolization)

          -  Current use of clobetasol propionate

          -  Use of any herbal remedy (e.g. St. John?s wort [Hypericum perforatum])

          -  Patients unable to ambulate or who have amputations or paralysis of any extremity

          -  History of contact dermatitis to clobetasol propionate or similarly fluorinated
             steroids or other steroids with the propionate ester
      "
NCT02885324,terminated,"
    failure to meet accrual goals.
  ",0,phase 2,"['glioblastoma multiforme', 'anaplastic astrocytoma', 'malignant brain tumor', 'high grade glioma']","[""['L51.0', 'L51.8', 'L51.9']"", ""['C84.67', 'C84.77', 'C84.7A', 'C84.60', 'C84.70', 'C84.62', 'C84.66']"", ""['C71.7', 'C71.9', 'C79.31', 'C71.8', 'Z85.841']""]",['cabozantinib'],['COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F'],"
        Inclusion Criteria

          1. Age: Patients must be ≥2 years and ≤21 years of age

          2. Diagnosis: Patients with relapsed or refractory central nervous system tumors.
             Patients must have had histological verification of malignancy at original diagnosis
             or relapse. Metastatic disease to the spine or primary tumors in the spine are
             eligible. Patients may be in first, second, or third relapse. Subjects with intrinsic
             brain stem gliomas may be eligible with or without histological confirmation. Please
             contact study chair prior to enrollment.

          3. Disease Status: Patients must have measurable disease. Linear enhancement of
             leptomeningeal without measurable mass is excluded.

          4. Therapeutic Options: Patient's current disease state must be one for which there is no
             accepted standard therapy, no known curative therapy or therapy proven to prolong
             survival with an acceptable quality of life. For patients in whom surgery is feasible,
             maximal surgical resection must have occurred.

          5. Performance Level: Karnofsky ≥ 50% for patients > 16 years of age and Lansky ≥ 50 for
             patients ≤ 16 years of age (See Appendix 1). Note: Neurologic deficits in patients
             must have been relatively stable for at least 7 days prior to study enrollment.
             Patients who are unable to walk because of paralysis, but who are in a wheelchair,
             will be considered ambulatory for the purpose of assessing the performance score.

          6. Subjects must have a reasonable life expectancy of at least 2 months.

          7. Prior Therapy

             a. Patients must have fully recovered from the acute toxic effects of all prior
             anti-cancer chemotherapy i. Cytotoxic chemotherapy (including investigational agents)
             or biologic agents (eg. Cytokines or antibodies): At least 3 weeks after the last
             dose.

             ii. Nitrosoureas/mitomycin C: At least 6 weeks from the last dose. iii. XRT: At least
             14 days after local palliative XRT (small port); At least 150 days must have elapsed
             if prior TBI, craniospinal XRT or if ≥ 50% radiation of pelvis; At least 42 days must
             have elapsed if other substantial BM radiation. e.g. Stem cell Infusion without TBI:
             No evidence of active graft vs. host disease and at least 56 days must have elapsed
             after transplant or stem cell infusion.

          8. Organ Function Requirements:

             a. Adequate bone marrow function defined as: absolute neutrophil count (ANC ≥1000/mm3)
             i. Platelet count ≥ 100,000/ mm3 (transfusion independent, defined as not receiving
             platelet transfusions for at least 7 days prior to enrollment) ii. Patients with bone
             marrow metastatic disease will not be eligible. b. Adequate renal function defined as:
             i. Creatinine clearance or radioisotope GFR ≥ 70mL/min/1.73 m² or a serum creatinine
             based on age/gender as follows:

             Age Maximum Serum Creatinine (mg/dL) Male Female 2 to < 6 years 0.8 0.8 6 to < 10
             years 1 1 10 to < 13 years 1.2 1.2 13 to < 16 years 1.5 1.4

             ≥ 16 years 1.7 1.4 The threshold creatinine values in this table were derived from the
             Schwartz formula for estimating GFR (Schwartz et al. J. Peds, 106:522, 1985) utilizing
             child length and stature data published by the CDC.

             ii. Urine protein: ≤ 30 mg/dL in urinalysis or ≤ 1+ on dipstick, unless quantitative
             protein is < 1000 mg in a 24 hour urine sample.

             c. Adequate Liver Function Defined as:

             i. Bilirubin (sum of conjugated + unconjugated) ≤ 1.5 x upper limit of normal (ULN)
             for age ii. SGPT (ALT) ≤ 110 U/L. For the purpose of this study, the ULN for SGPT is
             45 U/L.

             iii. Serum albumin ≥ 2.8 g/dL. d. Adequate coagulation status defined as: PT and INR ≤
             1.5x ULN e. Adequate pancreatic function defined as: Serum amylase and lipase ≤ 1.5 x
             ULN f. Adequate blood pressure control defined as: A blood pressure (BP) ≤ the 95th
             percentile for age, height and gender (Appendix II) despite optimal antihypertensive
             treatment within 7 days of the first dose of the study treatment. Please note that 3
             serial blood pressures should be obtained and averaged to determine baseline BP.

             g. Central nervous system function defined as: Patients with seizure disorder may be
             enrolled if receiving non-enzyme inducing anticonvulsants and well controlled. See
             Appendix III for a list of recommended non-enzyme inducing anticonvulsants.

             h. Adequate cardiac function defined as: i. No history of congenital QTc syndrome,
             NYHA Class III or IV congestive heart failure (CHF) ii. No clinical significant
             cardiac arrhythmias, stroke or myocardial infarction within 6 months prior to
             enrollment iii. QTc

             ≤ 480 msec. Note: One ECG must be performed for eligibility determination. If the QTc
             is > 480 msec, two additional ECGs must be performed and the average of the three ECGs
             will be used to determine eligibility. Patients with Grade 1 prolonged QTc (450-480
             msec) at the time of study enrollment should have correctable causes of prolonged QTc
             addressed if possible (i.e. electrolytes, medications). See Appendix IV for a list of
             drugs that prolong QTc.

          9. Informed consent: All patients and/or their parents or legally authorized
             representatives must sign a written informed consent. Assent, when appropriate will be
             obtained according to institutional guidelines.

         10. Archival tumor tissue slides must be sent or available, except for patients with
             intrinsic pontine glioma meeting the remainder of the inclusion criteria.

        Exclusion Criteria

          1. Pregnancy or Breast-Feeding: Pregnant or breast-feeding women will not be entered on
             this study due to risks of fetal and teratogentic adverse events as seen in
             animal/human studies. Pregnancy tests must be obtained in girls who are
             post-menarchal. Males or females of reproductive potential may not participate unless
             they have agreed to use two methods of birth control- a medically accepted barrier
             method of contraceptive method (e.g., male or female condom) and a second effective
             method of birth control- during protocol therapy and for at least 4 months after the
             last dose of cabozantinib. Abstinence is an acceptable method of birth control.

          2. Concomitant Medications:

               1. Corticosteroids: Patients receiving corticosteroids who have not been on a stable
                  or decreasing dose of corticosteroid for at least 7 days prior to enrollment are
                  not eligible.

               2. Investigational drugs: Patients who are currently receiving another
                  investigational drug are not eligible.

               3. Anti-cancer agents: patients who are currently receiving other anti-cancer agents
                  are not eligible.

               4. CYP3A4 active agents: Patients must not be receiving any of the following potent
                  CYP3A4 inducers or inhibitors: erythromycin, clarithromycin, ketoconazole,
                  azithromycin, itraconazole, grapefruit juice or St. John's wort. A list of other
                  known CYP3A4 inducers and inhibitors that should be discontinued prior to
                  initiation of protocol therapy and should be avoided during study therapy if
                  reasonable alternatives exist is included in Appendix V.

               5. Patients who are receiving systemic therapeutic treatment anticoagulation are not
                  eligible. Patients receiving prophylactic systemic anticoagulation will be
                  allowed with heparin or LMWH as long as eligibility PT/INR requirements are met.
                  Concomitant anticoagulation with oral anticoagulations (e.g. warfarin, direct
                  thrombin and Factor Xa inhibitors) or platelet inhibitors (eg. Clopidogrel) are
                  not allowed.

               6. Enzyme-inducing anticonvulsants: Patients must not have received enzyme-inducing
                  anticonvulsants within 14 days prior to enrollment (See Appendix III for a list
                  of unacceptable enzyme inducing anticonvulsants).

               7. QTc Agents: Patients who are receiving drugs that prolong QTc are not eligible
                  (See Appendix IV for a list of agents).

          3. Patients must be able to swallow intact tablets. Patients who cannot swallow intact
             tablets are not eligible.

          4. Patients with active bleeding are not eligible. Specifically, no clinically
             significant GI bleeding, GI perforation, intra-abdominal abscess or fistula for 6
             months prior to enrollment, no hemoptysis or other signs of pulmonary hemorrhage for 3
             months prior to enrollment.

          5. Patients with evidence of an acute intracranial or intratumoral hemorrhage on CT or
             MRI are not eligible (patients with evidence of resolving hemorrhage will be
             eligible).

          6. Major surgery within 28 days of enrollment. Complete wound healing from major or minor
             surgery must have occurred prior to enrollment. Minor surgery (including uncomplicated
             tooth extractions) within 7 days of enrollment. Subjects with clinically relevant
             ongoing complications from prior surgery are not eligible;

          7. Concurrent uncontrolled hypertension defined as sustained blood pressure>95% for age,
             height and gender (systolic or diastolic) despite optimal antihypertensive treatment
             within 7 days of the first dose of study treatment.

          8. Patients with any medical or surgical conditions that would interfere with
             gastrointestinal absorption of this oral agent are not eligible.

          9. Infection: Patients who have an uncontrolled infection are not eligible.

         10. Patients who have received a prior solid organ transplantation are not eligible.

         11. Patients who in the opinion of the investigator may not be able to comply with the
             safety monitoring requirements of the study are not eligible.

         12. Subjects who have received cabozantinib or have an allergy to cabozantinib are
             excluded. Subjects who have previously received tyrosine kinase inhibitors are
             allowed.

         13. Subjects who have not received radiation therapy as part of their prior treatment are
             excluded.
      "
NCT02888665,completed,,1,phase 1/phase 2,['sarcoma'],"[""['C96.A', 'C46.9', 'C96.22', 'C46.0', 'C46.2', 'C92.31', 'C92.32']""]",['doxorubicin hydrochloride'],['CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl'],"
        Inclusion Criteria:

          -  Be willing and able to provide written informed consent/assent for the trial

          -  Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST)
             1.1

          -  Have metastatic or unresectable sarcoma

          -  Have a performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG)
             performance scale

          -  Absolute neutrophil count (ANC) >= 1,500/mcL (within 10 days of treatment initiation)

          -  Platelets >= 100,000/mcL (within 10 days of treatment initiation)

          -  Hemoglobin >= 9 g/dL (within 10 days of treatment initiation) or >= 5.6 mmol/L without
             transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

          -  Serum creatinine =< 1.5 X upper limit of normal (ULN) OR measured or calculated
             creatinine clearance (glomerular filtration rate [GFR] can also be used in place of
             creatinine or creatinine clearance [CrCl]) >= 60 mL/min for subject with creatinine
             levels > 1.5 X institutional ULN (within 10 days of treatment initiation)

          -  Serum total bilirubin =< 1.5 X ULN OR direct bilirubin =< ULN for subjects with total
             bilirubin levels > 1.5 ULN (within 10 days of treatment initiation)

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X
             ULN OR =< 5 X ULN for subjects with liver metastases (within 10 days of treatment
             initiation)

          -  Albumin >= 2.5 mg/dL (within 10 days of treatment initiation)

          -  International normalized ratio (INR) or prothrombin time (PT) =< 1.5 X ULN unless
             subject is receiving anticoagulant therapy as long as PT or partial thromboplastin
             time (PTT) is within therapeutic range of intended use of anticoagulants (within 10
             days of treatment initiation)

          -  Activated partial thromboplastin time (aPTT) =< 1.5 X ULN unless subject is receiving
             anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use
             of anticoagulants (within 10 days of treatment initiation)

          -  Female subject of childbearing potential should have a negative urine or serum
             pregnancy within 72 hours prior to receiving the first dose of study medication; if
             the urine test is positive or cannot be confirmed as negative, a serum pregnancy test
             will be required

          -  Female subjects of childbearing potential should be willing to use 2 methods of birth
             control or be surgically sterile, or abstain from heterosexual activity for the course
             of the study through 120 days after the last dose of study medication; subjects of
             childbearing potential are those who have not been surgically sterilized or have not
             been free from menses for > 1 year

          -  Male subjects should agree to use an adequate method of contraception starting with
             the first dose of study therapy through 120 days after the last dose of study therapy

          -  Ejection fraction > 45% by either multi-gated acquisition scan (MUGA) scan or
             echocardiogram

        Exclusion Criteria:

          -  Has prior treatment using an anthracycline

          -  Has one of the following sarcoma subtypes where combining anthracyclines with other
             chemotherapies is established as the standard of care: osteosarcoma, Ewings sarcoma,
             embryonal rhabdomyosarcoma, alveolar rhabdomyosarcoma

          -  Is currently participating and receiving study therapy or has participated in a study
             of an investigational agent and received study therapy or used an investigational
             device within 4 weeks of the first dose of treatment

          -  Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
             other form of immunosuppressive therapy within 7 days prior to the first dose of trial
             treatment

          -  Has a known history of active TB (bacillus tuberculosis)

          -  Hypersensitivity to pembrolizumab or any of its excipients

          -  Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study
             day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events
             due to agents administered more than 4 weeks earlier

          -  Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy
             within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at
             baseline) from adverse events due to a previously administered agent

               -  Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and
                  may qualify for the study

               -  Note: If subject received major surgery, they must have recovered adequately from
                  the toxicity and/or complications from the intervention prior to starting therapy

          -  Has a known additional malignancy that is progressing or requires active treatment;
             exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the
             skin that has undergone potentially curative therapy or in situ cervical cancer

          -  Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis; subjects with previously treated brain metastases may participate provided
             they are stable (without evidence of progression by imaging for at least four weeks
             prior to the first dose of trial treatment and any neurologic symptoms have returned
             to baseline), have no evidence of new or enlarging brain metastases, and are not using
             steroids for at least 7 days prior to trial treatment; this exception does not include
             carcinomatous meningitis which is excluded regardless of clinical stability

          -  Has active autoimmune disease that has required systemic treatment in the past 2 years
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive
             drugs); replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
             form of systemic treatment

          -  Has known history of, or any evidence of active, non-infectious pneumonitis

          -  Has an active infection requiring systemic therapy

          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the subject's
             participation for the full duration of the trial, or is not in the best interest of
             the subject to participate, in the opinion of the treating investigator

          -  Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial

          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the pre-screening or screening visit
             through 120 days after the last dose of trial treatment

          -  Has received prior therapy with an anti-programed death receptor 1 (PD-1), anti-PD-L1,
             anti-program death receptor ligand 2 (PD-L2) agent or anti-CTLA4

          -  Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)

          -  Has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or
             hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is
             detected)

          -  Has received a live vaccine within 30 days of planned start of study therapy

               -  Note: Seasonal influenza vaccines for injection are generally inactivated flu
                  vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist)
                  are live attenuated vaccines, and are not allowed
      "
NCT03121534,terminated,"
    the study was closed for slow accrual
  ",0,phase 2,"['hematopoietic/lymphoid cancer', ""richter's transformation""]","[""['C96.9', 'D47.9', 'C96.Z', 'D47.Z9', 'Z80.7', 'Z85.79']"", ""['R85.616', 'R87.616']""]","['blinatumomab', 'dexamethasone', 'ibrutinib', 'nivolumab']","['Status: 503', 'Status: 503', 'C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N']","
        Inclusion Criteria:

          1. Patients with previously treated CLL and biopsy-proven Richter's transformation with
             DLBCL histology according to IWCLL criteria (Richter Transformation - RT) and CD19
             positive by flow cytometry OR immunohistochemistry.

          2. Eastern Co-operative Oncology Group (ECOG) performance status < or =2.

          3. Age > or =18 years at the time of informed consent.

          4. Able to provide informed consent and be willing to participate in study schedule and
             events.

        Exclusion Criteria:

          1. Other active malignancy receiving systemic therapy.

          2. History or presence of clinically relevant disorder affecting the CNS such as
             epilepsy, childhood or adult seizure, paresis, aphasia, stroke, severe brain injuries,
             dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or
             psychosis, with the exception of a history of CNS lymphoma that is controlled with
             intrathecal therapy.

          3. Known active DLBCL in the CNS (confirmed by CSF analysis).

          4. Current autoimmune disease requiring >/= 20mg/day of prednisone or systemic
             immunosuppressive therapy (eg. with cyclosporine or azathioprine).

          5. Allogeneic HSCT within 24 weeks before the start of protocol-specified therapy.

          6. Active Graft-versus-Host Disease (GvHD), grade 2-4 according to the Glucksberg
             criteria, active chronic GvHD requiring systemic treatment or requirement for GvHD
             prophylaxis with cyclosporine or tacrolimus.

          7. Cancer chemotherapy within 2 weeks before start of protocol-specified therapy, with
             the exception of intrathecal chemotherapy, dexamethasone, and oral small molecule
             inhibitors such as BTK-inhibitor, PI3K-inhibitor, or Bcl-2-inhibitor, which are
             allowed until the start of protocol-specified therapy). In addition, any subject whose
             organ toxicity (excluding hematologic) from prior treatment has not resolved to no
             more than CTCAE grade 1.

          8. Radiotherapy within 2 weeks before the start of protocol-specified therapy.

          9. Abnormal screening laboratory values as defined as following: a) ALT (SGOT) and/or ALT
             (SGPT) and/or ALP > or =5 x upper limit of normal (ULN); b) Total bilirubin > or = 1.5
             x ULN, unless due to Gilbert's disease; c) Creatinine > or = 2.0 x ULN or creatinine
             clearance <50 mL/min (calculated).

         10. Known infection with human immunodeficiency virus (HIV) or chronic infection with
             hepatitis B virus (HBsAg positive) or hepatitis C virus (anti-HCV positive).

         11. Patient is pregnant or breast feeding.

         12. Woman of childbearing potential and is not willing to use 2 highly effective methods
             of contraception while receiving protocol-specified therapy and for an additional 24
             hours after the last dose of protocol-specified therapy.

         13. Male who has a female partner of childbearing potential, and is not willing to use 2
             highly effective forms of contraception while receiving protocol-specified therapy and
             for at least an additional 24 hours after the last dose of protocol-specified therapy.

         14. Male who has a pregnant partner, and is not willing to use a condom during sexual
             activity while receiving protocol-specified therapy and for 3 months after the last
             dose of protocol-specified therapy.

         15. Currently receiving treatment in another investigational device or drug study.

         16. Subject previously treated with blinatumomab.

         17. History or evidence of any other clinically significant disorder, condition or disease
             (with the exception of those outlined above) that, in the opinion of the Principal
             Investigator would pose a risk to subject safety or interfere with the study
             evaluation, procedures or completion.
      "
NCT02089802,terminated,"
    early termination due to lack of recruitment
  ",0,phase 2,"['locally advanced renal cell carcinoma', 'metastatic renal cell carcinoma']","[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]",['pazopanib'],['CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N'],"
        Inclusion Criteria:

          -  signature of informed consent

          -  age ≥ 18 years

          -  histologically confirmed renal cell carcinoma with clear cell component and either
             locally progressed or metastasized

          -  ECOG ≤ 2

          -  No previous systemic therapy for locally progressed or metastasized renal cell
             carcinoma (previous adjuvant or neo-adjuvant therapy is permitted)

          -  Adequate organ function

          -  Female patients with child-bearing potential with negative serum pregnancy test within
             2 weeks prior to first dose of study medication and adequate contraception

          -  Lactating females

        Exclusion Criteria:

          -  Clinically suspected and known metastases of the central nervous system or
             carcinomatous meningitis except in asymptomatic patients with previously treated
             CNS-metastases and no necessity of steroids or anti-epileptic medication ≥ 6 months
             prior to start of the study medication

          -  Clinically significant gastrointestinal conditions with risk of increase of
             gastrointestinal bleeding due to (but not limited to)

          -  active peptic ulceration

          -  known intraluminal metastases with risk of bleeding

          -  chronic-inflammatory intestinal disease (like Morbus Crohn, ulcerative colitis) or
             another gastrointestinal disease with increased risk of perforation

          -  abdominal fistulas in anamnesis

          -  Clinically significant gastrointestinal conditions which can influence absorption of
             the IMP, among others (but not limited to)

          -  malabsorption syndrome

          -  resection of stomach or small bowel

          -  Current uncontrolled infection

          -  QTc corrected for heart frequency according to the Bazett formula

          -  One or more of the following cardiovascular diseases within the last 6 months in the
             anamnesis:

          -  cardiac angioplasty or coronary stent implantation

          -  myocardial infarction

          -  instable angina pectoris

          -  coronary-arterial bypass surgery

          -  symptomatic peripheral arterial occlusive disease

          -  Heart failure NYHA III or IV

          -  Poorly controlled high blood pressure

          -  Cerebrovascular disease, including transitory ischemic attacks, pulmonary artery
             embolism or untreated deep vein thrombosis within 6 months of study inclusion

          -  Previous major surgery or traumas within 28 days prior to start if study treatment or
             non-healing wound, fracture or ulcer

          -  Clinical signs of active bleeding or bleeding diathesis

          -  Known endobronchial lesions or lesions infiltrating the large lung arteries

          -  Haemoptyses of > 2.5 mL within 8 weeks prior to first intake of study medication

          -  Any other severe and/or instable medical or psychiatric pre-existing or other
             condition influencing patient safety, consent capacity or compliance within the study

          -  Incapacity or rejection to stop not allowed medication prior to first intake of study
             drug and pause for the duration of the trial

          -  Treatment with one of the following anti-tumour therapies:

          -  Radiation or tumour embolism within 14 days before first intake of study drug

          -  Chemotherapy, Immunotherapy, biological therapy, study medication or hormonal therapy
             within 14 days or 5 half-lives of the respective substance (whichever is longer)
             before first intake of the study drug. Neo-adjuvant or adjuvant therapy must have been
             completed for at least 6 months.

          -  Any present toxicity > CTC 1° from prior anti-tumour therapy and/or toxicities
             worsening in severity except alopecia
      "
NCT02088541,completed,,0,phase 2,['acute myeloid leukemia (aml)'],"[""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']""]","['selinexor', 'hydroxyurea', 'ara-c']","['C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F', 'C(=O)(N)NO', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O']","
        Inclusion Criteria:

          -  Age ≥ 60 years with relapsed or refractory AML of any type except for acute
             promyelocytic leukemia (APL; AML M3), after at least 1 prior AML therapy , who have
             never undergone, and who are not currently eligible for, stem cell transplantation,
             and are currently deemed unfit for intensive chemotherapy.

          -  Eastern Cooperative Oncology Group (ECOG) ≤ 2.

          -  Must have available archival or recently acquired bone marrow biopsy/aspiration or
             tumor tissue for central review to be eligible.

          -  Relapsed or refractory AML, defined as either: recurrence of disease after a complete
             remission (CR), or failure to achieve CR with initial therapy.

          -  Must have received at least 1 prior line of AML therapy given at standard doses and
             must have progressed after their most recent therapy. Prior therapy must have
             included: a hypomethylating agent with at least 2 cycles.

          -  At least 2 weeks must have elapsed since the last anti-leukemia treatment (with the
             exception of hydroxyurea) before first dose in this study.

        Exclusion Criteria:

          -  Treatment with any investigational agent within 3 weeks prior to first dose in this
             study.

          -  Presence of central nervous system (CNS) leukemia.

          -  In blast transformation of chronic myeloid leukemia (CML). Prior myelodysplastic
             syndrome (MDS) is acceptable; prior treatment for MDS does not count as an AML
             therapy.

          -  Major surgery within 2 weeks of first dose of study drug. Participants must have
             recovered from the effects of any surgery performed greater than 2 weeks previously.

          -  Concurrent active malignancy under treatment.

          -  Known active hepatitis B virus (HBV) or C virus (HCV) infection; or known to be
             positive for HCV ribonucleic acid (RNA) or HBsAg (HBV surface antigen).

          -  Known HIV infection.

          -  Unable to swallow tablets, or participants with malabsorption syndrome, or any other
             disease significantly affecting gastrointestinal function.

          -  Participants whose AML is classified as favorable according to the European
             LeukemiaNet (ELN) disease risk assessment.
      "
NCT02080260,completed,,0,phase 2,['pancreatic cancer'],"[""['C25.3']""]",['regorafenib'],['CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F'],"
        Inclusion Criteria:

          -  Adenocarcinoma of the exocrine pancreas with metastatic disease.

          -  The site of the primary tumor confirmed to have been within the pancreas.

          -  Progression on at least one prior line of chemotherapy for locally-advanced or
             metastatic pancreatic cancer.

          -  Progression while on treatment with a gemcitabine regimen for advanced pancreatic
             cancer, or within 12 months of treatment with gemcitabine as part of adjuvant therapy.

          -  Measurable disease on axial imaging.

          -  Age greater than or equal to 18 years.

          -  Life expectancy of at least 8 weeks.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2. Enrollment of
             patients with PS = 2 will be capped at 7 patients.

          -  Subjects must be able to understand and be willing to sign the written informed
             consent form.

          -  Acute toxic effects except alopecia of any prior treatment must have resolved to
             National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)
             v4.0 Grade 1 or less.

          -  Adequate bone marrow, renal, and liver function.

          -  Warfarin or heparin will be allowed provided that there is no prior evidence of
             underlying coagulation abnormality.

          -  Women of childbearing potential must have a negative pregnancy test performed within 7
             days prior to the start of study drug. Post-menopausal women (defined as no menses for
             at least 1 year) and surgically sterilized women are not required to undergo a
             pregnancy test.

          -  Patients (men and women) of childbearing potential must agree to use adequate
             contraception

          -  Patient must be able to swallow and retain oral medication.

        Exclusion Criteria:

          -  Previous assignment to treatment during this study.

          -  Uncontrolled hypertension.

          -  Active clinically significant cardiac disease.

          -  Cerebrovascular arterial event within 6 months.

          -  Evidence or history of bleeding diathesis or coagulopathy.

          -  Any bleeding event greater than or equal to NCI CTCAE Grade 3 within 4 weeks.

          -  New venous thrombotic or embolic events, such as deep vein thrombosis or pulmonary
             embolism within 3 months.

          -  Previously untreated or concurrent cancer that is distinct in primary site or
             histology except cervical cancer in-situ, treated basal cell carcinoma, or superficial
             bladder tumor. Patients surviving a cancer that was curatively treated and without
             evidence of disease for more than 3 years are allowed.

          -  Patients with pheochromocytoma.

          -  Known history of HIV infection or current chronic or active hepatitis B or C,
             requiring antiviral medication.

          -  Ongoing infection greater than or equal to Grade 2 NCI-CTCAE v4.0.

          -  Symptomatic metastatic brain or meningeal tumors.

          -  Presence of a non-healing wound, non-healing ulcer, or bone fracture.

          -  Renal failure requiring dialysis.

          -  Dehydration Grade greater than or equal to 1 NCI-CTCAE v4.0.

          -  Patients with seizure disorder requiring medication.

          -  Persistent proteinuria greater than or equal to Grade 3 NCI-CTCAE v4.0.

          -  Symptomatic interstitial lung disease.

          -  Pleural effusion or ascites that cause respiratory compromise.

          -  History of organ allograft except corneal transplant.

          -  Known or suspected allergy or hypersensitivity to the study drugs.

          -  Any severe, uncontrolled malabsorption condition.

          -  Women who are pregnant or breast-feeding.

          -  Substance abuse, medical, psychological or social conditions that may interfere with
             the subject's participation in the study.

          -  Concurrent anti-cancer therapy other than study treatment (regorafenib).

          -  Prior use of regorafenib.

          -  Concurrent use of another investigational drug or device therapy (i.e., outside of
             study treatment) during, or within 4 weeks.

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days.

          -  Prior radiation therapy or hepatic arterial therapy is permitted if more than 4 weeks
             have passed since completion and measurable disease outside of the treated area is
             present, or if progression since treatment has occurred.

          -  Use of St. John's Wort.
      "
NCT02083185,completed,,1,phase 2,['prostate cancer'],"[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]","['relugolix', 'leuprorelin']","['CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC', 'CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6']","
        Inclusion Criteria

        Each participant must meet all of the following inclusion criteria to be enrolled in the
        study:

          1. Male participant 18 years or older.

          2. Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma.

          3. Candidate for androgen deprivation therapy (ADT) for the management of
             hormone-sensitive prostate cancer with 1 of the following clinical disease states: 1)
             advanced localized disease not suitable for primary therapy, 2) evidence of
             prostate-specific antigen (PSA) biochemical or clinical relapse following primary
             surgery or radiation therapy of curative intent, or 3) newly diagnosed metastatic
             disease that is asymptomatic or not threatening to vital organs.

          4. Appropriate serum testosterone and serum PSA concentration at screening as specified
             in the protocol.

          5. A body mass index (BMI) ≥ 18.0 at screening and/or baseline.

          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening
             and/or baseline.

          7. Male participants, even if surgically sterilized, who agree to practice effective
             barrier contraception or agree to practice true abstinence.

          8. Voluntary written consent must be given before performance of any study-related
             procedure not part of standard medical care, with the understanding that consent may
             be withdrawn by the participant at any time without prejudice to future medical care.

          9. Suitable venous access for the study-required blood sampling, including
             pharmacokinetic (PK) and pharmacodynamic (PD) Sampling.

        Exclusion Criteria

        Participants meeting any of the following exclusion criteria are not to be enrolled in the
        study:

          1. In participants with advanced, localized M0N1 or M1 disease, the presence of
             clinically significant symptoms or threat to vital organs requiring immediate
             gonadotropin-releasing hormone (GnRH) /combined or complete androgen blockade (CAB)
             therapy, chemotherapy, or radiotherapy.

          2. Previously received androgen deprivation therapy (ADT) for more than 8 months total
             duration (if ADT was received for 8 months or less, then that ADT must have been
             completed at least 2 years prior to screening).

          3. Visceral metastases (liver or lung).

          4. Features of the participant's medical condition that may make ADT unnecessary or not
             indicated.

          5. Scheduled for additional surgical or (salvage) radiation therapy within 6 months after
             baseline evaluations.

          6. History of surgical castration.

          7. Diagnosis of or treatment for another malignancy within the 2 years before the first
             dose of study drug, or previously diagnosed with another malignancy and have any
             evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma
             in situ of any type are not excluded if they have undergone complete resection.

          8. Abnormal screening and/or baseline laboratory values as specified in the protocol.

          9. History of any significant cardiac condition within 6 months before receiving the
             first dose of study drug.

         10. Electrocardiogram (ECG) abnormalities as specified in the protocol

         11. Congenital long QT syndrome.

         12. Current use of Class IA (e.g., quinidine, procainamide) or Class III (e.g.,
             amiodarone, sotalol) antiarrhythmic medications.

         13. Uncontrolled hypertension despite appropriate medical therapy. Participants may be
             re-screened after referral and further management of hypertension.

         14. Known, previously diagnosed human immunodeficiency virus (HIV) infection, active
             chronic hepatitis B or C, life-threatening illness unrelated to prostate cancer, or
             any serious medical or psychiatric illness that could, in the investigator's opinion,
             potentially interfere with participation in this study. Specific screening for chronic
             viral illness is at the discretion of the site and/or local institutional review board
             (IRB).

         15. Treatment with any investigational products within 3 months before the first dose of
             study drug.

         16. A primary family member (spouse, parent, child, or sibling of the participant) is
             involved in the conduct of the study or is a study site employee.

         17. Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral
             absorption or tolerance of TAK-385, including difficulty swallowing tablets.

         18. Use of any medication, or food products listed in the excluded medications and dietary
             products table within 2 weeks before the first dose of study drug. Participant must
             have no history of amiodarone use in the 6 months before the first dose of TAK-385.

         19. Admission or evidence of alcohol or drug abuse or use of illicit drugs.
      "
NCT02086591,terminated,"
    lack of accrual
  ",0,phase 2,"['adult diffuse large b-cell lymphoma', 'mantle cell lymphoma recurrent', 'lymphoma, follicular', 'marginal zone b-cell lymphoma', 'malignant lymphoma - lymphoplasmacytic', 'waldenstrom macroglobulinemia', 'small lymphocytic lymphoma', 'chronic lymphocytic leukemia (cll)', 't-cell lymphoma']","[""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['C88.0']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['A87.2', 'K52.832', 'D72.111', 'C91.11', 'C91.12', 'C91.10']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']""]",['doxycycline'],['CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O'],"
        Inclusion Criteria:

          -  Relapsed aggressive or indolent NHL following any prior treatment of the following
             etiologies:

               -  Diffuse large B cell lymphoma (DLBCL)

               -  Mantle cell lymphoma (MCL)

               -  Follicular lymphoma (FL)

               -  Marginal zone lymphoma (MZL)

               -  Lymphoplasmacytic lymphoma (LPL)

               -  Waldenstrom's macroglobulinemia (WM)

               -  Small lymphocytic lymphoma (SLL)

               -  Chronic lymphocytic leukemia (CLL)

               -  T cell lymphoma (TCL)

          -  Ages ≥ 18

          -  Karnofsky Performance Status (KPS) ≥ 60% or Eastern Cooperative Oncology Group
             Performance Status (ECOG PS) ≤2

          -  Life expectancy of at least 3 months

          -  Measurable disease in at least one target lesion, assessable by radiographic
             examination with Fludeoxyglucose-Positron Emission Tomography (FDG-PET) or computed
             tomography (CT), bone marrow evaluation showing involvement, or peripheral blood
             showing involvement of lymphoma

          -  Adequate organ function:

               -  Absolute neutrophil count (ANC) > 500 cells/mL and platelet count > 50,000
                  cells/mL unless felt to be secondary to lymphoma at which any count is
                  permissible.

               -  Adequate renal function as determined by Creatinine (Cr) < 1.5x upper limit of
                  normal (ULN) or estimated creatinine clearance of ≥ 60mL/min

               -  Adequate hepatic function as determined by total bilirubin < 1.5x upper limit of
                  normal (ULN) (unless known Gilbert syndrome), alanine aminotransferase (ALT)and
                  aspartate aminotransferase (AST) < 2.5x upper limit of normal (ULN)

        Exclusion Criteria:

          -  Known sensitivity or allergy to tetracyclines

          -  Lack of measurable disease by computed tomography (CT) or Fludeoxyglucose-Positron
             Emission Tomography (FDG-PET)

          -  Karnofsky Performance Status (KPS) <60% or Eastern Cooperative Oncology Group
             Performance Status (ECOG PS) >2

          -  Curative treatment is indicated or possible

          -  Inadequate organ function as measured by not fulfilling above criteria

          -  Pregnancy, positive serum human chorionic gonadotropin (hCG) within 28 days of
             enrollment, or breast-feeding.
      "
NCT02083653,completed,,0,phase 2,['metastatic colorectal cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['sym004 (12 mg/kg)', 'sym004 (9/6 mg/kg)', 'fluorouracil (5-fu)', 'capecitabine']",['CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O'],"
        Inclusion Criteria:

          -  Written informed consent obtained before undergoing any study-related activities

          -  Male or female, at least 18 years of age

          -  Subjects with histologically or cytologically confirmed mCRC, Kirsten rat sarcoma
             wild-type (KRAS WT) at initial diagnosis

          -  Failure of or intolerance to 5-FU, Oxaliplatin, and Irinotecan

          -  Acquired resistance to marketed anti-EGFR mAbs as defined in the protocol

          -  Measurable disease defined as one or more target lesions according to RECIST

          -  Life expectancy of at least 3 months

          -  Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 1

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Pretreatment with regorafenib.

          -  Subjects who in the opinion of the subject and investigator would benefit more from
             regorafenib treatment (except where regorafenib is not reimbursed in the country)

          -  Skin rash Common Terminology Criteria for AEs (CTCAE) Grade greater than 1 from
             previous anti-EGFR therapy at time of randomization

          -  Magnesium less than 0.9 milligram per deciliter (mg/dL)

          -  Known hypersensitivity to any of the treatment ingredients. Known previous Grade 3-4
             infusion related reactions with anti-EGFR mABs

          -  Other protocol defined exclusion criteria could apply
      "
NCT01984242,completed,,1,phase 2,['renal cell carcinoma'],"[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]","['atezolizumab (mpdl3280a), an engineered anti-pd-l1 antibody', 'bevacizumab', 'sunitinib']",['CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C'],"
        Inclusion Criteria:

          -  Unresectable advanced or metastatic renal cell carcinoma with component of clear cell
             histology and/or component of sarcomatoid histology that has not been previously
             treated with any systemic agents, including treatment in the adjuvant setting

          -  Measurable disease, as defined by RECIST v1.1

          -  Karnofsky performance score greater than or equal to (>/=) 70

          -  Adequate hematologic and end-organ function as defined by protocol

          -  Women of childbearing potential and male participants with partners of childbearing
             potential must agree to use highly effective methods of contraception as defined by
             protocol

        Exclusion Criteria:

        Disease-Specific Exclusions:

          -  Radiotherapy for renal cell carcinoma within 14 days prior to Cycle 1, Day 1 with the
             exception of single-fraction radiotherapy given for the indication of pain control

          -  Known active malignancies or metastasis of the brain or spinal cord or leptomeningeal
             disease, as determined by computed tomography (CT) or magnetic resonance imaging (MRI)
             evaluation during screening and prior radiographic assessments

          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent
             drainage procedures (once monthly or more frequently)

          -  Uncontrolled hypercalcemia or symptomatic hypercalcemia

          -  Malignancies other than renal cell carcinoma within 5 years prior to Cycle 1, Day 1,
             with the exception of those with a negligible risk of metastasis or death, treated
             with expected curative outcome

        General Medical Exclusions:

          -  Life expectancy of less than (<) 12 weeks

          -  Pregnant and lactating women

          -  History of severe allergic, anaphylactic, or other hypersensitivity reactions to
             chimeric or humanized antibodies or fusion proteins

          -  History of autoimmune disease

          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening
             chest CT scan

          -  Participants with active or chronic hepatitis B, active hepatitis C, Human
             Immunodeficiency Virus (HIV) positive test, significant cardiovascular disease

          -  Prior allogeneic stem cell or solid organ transplant

        Exclusion Criteria Related to Medications:

          -  Prior treatment with Cluster of Differentiation 137 (CD137) agonists, anti-Cytotoxic
             T-Lymphocyte Antigen-4 (anti-CTLA-4), anti-programmed death-1 (anti-PD-1), or
             anti-PD-L1 therapeutic antibody or pathway-targeting agents

          -  Treatment with systemic immunostimulatory agents for any reason within 6 weeks or five
             half-lives of the drug, whichever is shorter, prior to Cycle 1, Day 1

          -  Treatment with systemic immunosuppressive medications within 2 weeks prior to Cycle 1,
             Day 1

        Bevacizumab- and Sunitinib-Specific Exclusions:

          -  Inadequately controlled hypertension

          -  Prior history of hypertensive crisis or hypertensive encephalopathy

          -  New York Heart Association Class II or greater congestive heart failure

          -  History of myocardial infarction or unstable angina, stroke or transient ischemic
             attack within 3 months prior to Cycle 1, Day 1
      "
NCT01988493,completed,,1,phase 1/phase 2,"['carcinoma, hepatocellular']","[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]","['tepotinib 300 mg', 'tepotinib 500 mg', 'tepotinib 1000 mg', 'tepotinib', 'sorafenib']","['Status: 503', 'Status: 503', 'CN1CCC(CC1)COC2=CN=C(N=C2)C3=CC=CC(=C3)CN4C(=O)C=CC(=N4)C5=CC=CC(=C5)C#N', 'CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F']","
        Inclusion Criteria:

          -  Histologically or cytologically confirmed HCC

          -  Participants were either intermediate HCC of BCLC Stage B, who were not eligible for
             surgical and/or local-regional therapies or who had progressive disease (PD) after
             surgical and/or local-regional therapies (note: the local-regional therapy must not
             contain sorafenib), or advanced HCC of BCLC Stage C

          -  Participants who had disease progression on or were intolerant to the prior standard
             treatment for advanced HCC (phase Ib Korean subjects only)

          -  A tumor biopsy was required for determining MET status

          -  MET+ status (Phase 2 only), as determined by the central laboratory (Phase 1b
             retrospectively, Phase 2 for participant selection) were defined in the protocol

          -  Child-Pugh class A with no encephalopathy according to the screening assessment

          -  Asian male or female, 18 years of age or older

          -  Measurable disease in accordance with RECIST v1.1 (Phase 2 only)

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2

          -  Eligible for treatment with sorafenib, was assessed by investigators according to the
             Package Insert and clinical judgment (Phase 2 only)

          -  Signed and dated informed consent indicating that the participants had been informed
             of all the pertinent aspects of the trial prior to enrollment

          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory
             tests, and other trial procedures

          -  Life expectancy was judged by the investigator of at least 3 months

        Exclusion Criteria:

          -  Prior systemic anticancer treatment for advanced HCC, included targeted therapy (for
             example, sorafenib), chemotherapy, or any other investigational agent (Phase 2 only)

          -  Prior treatment with any agent targeting the hepatocyte growth factor (HGF)/c-Met
             pathway

          -  Prior local-regional therapy within 4 weeks prior to Day 1 of trial treatment

          -  Prior history of liver transplant

          -  Laboratory index at baseline were defined in the protocol

          -  Past or current history of neoplasm other than HCC, except for curatively treated
             non-melanoma skin cancer, in situ carcinoma of the cervix, or other cancer curatively
             treated and with no evidence of disease for at least 5 years

          -  Known central nervous system (CNS) or brain metastasis that is either symptomatic or
             untreated

          -  Medical history of difficulty swallowing, malabsorption, or other chronic
             gastrointestinal disease, or conditions that may hamper compliance and/or absorption
             of the tested products

          -  Clinically significant gastrointestinal bleeding within 4 weeks before trial entry

          -  Peripheral neuropathy Grade greater than or equal to 2 (Common Terminology Criteria
             for Adverse Events [CTCAE] v4.0)

          -  Impaired cardiac function was defined in the protocol

          -  Hypertension uncontrolled by standard therapies

          -  Participants with a family history of long QT syndrome or who take any agent that is
             known to prolong QT/QTc interval

          -  Known human immunodeficiency virus (HIV) infection

          -  Particpants who had acute pancreatitis and/or chronic pancreatitis, with elevated
             lipase and/or amylase, clinical symptoms, and/or imaging studies that are indicative
             of the diagnosis (Mainland Chinese participants only)

          -  Known or suspected drug hypersensitivity to any ingredients of sorafenib (Phase 2
             only) and MSC2156119J

          -  Female participants who were pregnant or lactating, or males and females of
             reproductive potential not willing or not able to employ a highly effective method of
             birth control/contraception to prevent pregnancy from 2 weeks before receiving study
             drug until 3 months after receiving the last dose of study drug

          -  Concurrent treatment with a non-permitted drug

          -  Substance abuse, other acute or chronic medical or psychiatric condition, or
             laboratory abnormalities that may increase the risk associated with trial
             participation in the opinion of the investigator

          -  Participation in another clinical trial within the past 28 days

          -  Previous anticancer treatment-related toxicities not recovered to baseline or Grade
             0-1 (except alopecia and peripheral neuropathy)

          -  Participants with any concurrent medical condition or disease that will potentially
             compromise the conduct of the study at the discretion of the investigators
      "
NCT03147196,withdrawn,"
    lack of accrual
  ",0,phase 2,"['stage i prostate adenocarcinoma', 'stage ii prostate adenocarcinoma']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['bicalutamide', 'raloxifene hydrochloride']","['CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O', 'C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O.Cl']","
        Inclusion Criteria:

          -  Histological confirmation of adenocarcinoma of the prostate, >= Gleason 6, clinical
             stage T1a-T2c and planned for radical prostatectomy

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2

          -  Platelet count >= 50,000/mm^3

          -  Hemoglobin > 9.0 g/dL

          -  Creatinine =< 2.0 mg/dL

          -  Provide informed written consent

          -  Willing to return to enrolling institution for follow-up (during the Active Monitoring
             Phase of the study); Note: during the Active Monitoring Phase of a study (i.e., active
             treatment and observation), participants must be willing to return to the consenting
             institution for follow-up

          -  Patients must also provide written consent for biospecimens collection on
             Institutional Review Board (IRB) 08-000980

        Exclusion Criteria:

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Receiving any other investigational agent which would be considered as a treatment for
             the primary neoplasm

          -  History of myocardial infarction =< 6 months, or congestive heart failure requiring
             use of ongoing maintenance therapy for life-threatening ventricular arrhythmias

          -  History of a venous thromboembolic event, cerebrovascular accident (CVA), hepatic
             impairment, or heart failure
      "
NCT03269552,terminated,"
    terminated due to low accrual.
  ",0,phase 2,"['marginal zone lymphoma', 'recurrent marginal zone lymphoma', 'recurrent waldenstrom macroglobulinemia', 'refractory marginal zone lymphoma', 'refractory waldenstrom macroglobulinemia', 'waldenstrom macroglobulinemia']","[""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['C88.0']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['C88.0']"", ""['C88.0']""]",['carfilzomib'],['CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3)NC(=O)CN4CCOCC4'],"
        Inclusion Criteria:

          -  Waldenstrom's macroglobulinemia (WM) or marginal zone lymphoma (MZL) based on
             institutional pathology review; patients may have either previously untreated or
             relapsed/refractory disease

          -  Measurable disease: for WM presence of monoclonal IgM immunoglobulin concentration on
             serum electrophoresis, with lymphoplasmacytic marrow infiltrate; for MZL: measurable
             nodal disease measuring at least 1.5 cm in longest dimension, or splenomegaly

          -  Indication for initiation of therapy

          -  Absolute neutrophil count (ANC) > 1,000/uL unless disease-related (due to marrow
             infiltration or splenomegaly)

          -  Platelet count > 75,000/uL unless disease-related (due to marrow infiltration or
             splenomegaly)

          -  Serum creatinine < 2.5 mg/dL or creatinine clearance > 30 cc/min

          -  Bilirubin < 2 x upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN

          -  All patients must be informed of the investigational nature of this study and have
             given written consent in accordance with institutional and federal guidelines

          -  Expected survival of > 90 days

          -  Females of childbearing potential (FCBP) must agree to pregnancy testing and to
             practice contraception

          -  Male subjects must agree to practice contraception

        Exclusion Criteria:

          -  Known human immunodeficiency virus (HIV), hepatitis C, or hepatitis B positivity
             (subjects with hepatitis B surface antigen [SAg] or core antibody positivity, who are
             receiving and responding to antiviral therapy directed at hepatitis B or are negative
             for hepatitis B virus [HBV] deoxyribonucleic acid [DNA], are allowed)

          -  Candidate for potentially curative antibiotic therapy for gastric mucosa-associated
             lymphoid tissue (MALT); (gastric MALT lymphoma patients with stage I/II helicobacter
             [H.] pylori positive lymphoma must fail therapy with H.-pylori directed therapy before
             being considered for this study)

          -  Eastern Cooperative Oncology Group (ECOG) performance status 3 or higher

          -  Known active central nervous system (CNS) involvement

          -  Pregnant or lactating females

          -  Inadequate cardiac function, as measured by left ventricular ejection fraction (LVEF)
             that is less than or equal to 40%, or the presence of New York Heart Association
             (NYHA) classification of greater than stage II congestive heart failure

          -  Significant neuropathy (grades 3-4, or grade 2 with pain) within 14 days prior to
             screening

          -  Uncontrolled inter-current illness including, but not limited to, unstable angina,
             recent myocardial infarction within 6 months of screening and uncontrolled cardiac
             arrhythmias, psychiatric illness, or psychosocial difficulty that would limit
             compliance with study requirements

          -  Non-hematologic malignancy within the past 3 years with the exception of a) adequately
             treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b)
             carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason grade 6 or
             less with stable prostate-specific antigen levels; or d) cancer considered cured by
             surgical resection or unlikely to impact survival during the duration of the study
      "
NCT03059446,terminated,"
    this study was terminated early due to lack of efficacy based on the results of part i of the
    aurora study.
  ",0,phase 2,"['nonalcoholic steatohepatitis', 'liver cirrhosis', 'non-alcoholic fatty liver disease']","[""['K75.81']"", ""['K74.60', 'K74.69', 'P78.81', 'K71.7', 'K70.30', 'K70.31']"", ""['Z52.6', 'K71.8', 'K71.7', 'A06.4', 'C22.0', 'C22.3', 'K70.0']""]",['cenicriviroc'],['CCCCOCCOC1=CC=C(C=C1)C2=CC3=C(C=C2)N(CCCC(=C3)C(=O)NC4=CC=C(C=C4)S(=O)CC5=CN=CN5CCC)CC(C)C'],"
        Inclusion Criteria:

          -  Successful completion of both Treatment Period 1 and Treatment Period 2, of the
             CENTAUR Study (652-2-203), including a Year 2 liver biopsy.

          -  Completed the AURORA study (3152-301-002) as a result of reaching an adjudicated
             liver-related clinical outcome in Part 1 or Part 2 of the study of:

          -  Histopathological progression to cirrhosis

          -  Model for end-stage liver disease (MELD) score ≥ 15

          -  Ascites (requiring intervention, ie, large volume paracentesis ≥ 1L or initiation of a
             diuretic)

          -  Hospitalization (as defined by a stay of ≥ 24 hours) for onset of variceal bleed,
             hepatic encephalopathy (defined by a West Haven Stage of ≥ 2), spontaneous bacterial
             peritonitis (confirmed by diagnostic paracentesis with positive ascitic fluid
             bacterial culture).

        Exclusion Criteria:

          -  Prior or planned liver transplantation

          -  Other know causes of chronic liver disease such as: Alcoholic liver disease, Primary
             biliary cirrhosis, Primary sclerosing cholangitis, Autoimmune hepatitis, Wilson's
             disease, hemochromatosis, or iron overload, or Alpha-1 antitrypsin (A1AT) deficiency.
      "
NCT03053856,unknown status,,0,phase 2,['stage iiia non-small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['pembrolizumab', 'cisplatin', 'paclitaxel']","['N.N.Cl[Pt]Cl', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C']","
        Inclusion Criteria:

          -  In order to be eligible for participation in this trial, the subject must:

               1. Be willing and able to provide written informed consent for the trial

               2. Be 18 years of age

               3. Be within 6 weeks after complete resection after neoadjuvant CCRT

               4. Have a performance status of 0 or 1 on the ECOG Performance Scale.

               5. Patients who completed neoadjuvant CCRT regimen includes 5 cycles of weekly
                  Paclitaxel (50 mg/m2 + 5DW200 MIV over 1hr) plus Cisplatin (25 mg/m2 + N/S 150 mL
                  MIV over 1hr) concurrent with radiotherapy (44 Gy/22fx daily fraction).

               6. Be willing to provide tissue from a obtained before neoadjuvant CCRT and surgical
                  specimen (at least 10 slides from each surgically resected primary tumors and
                  surgically resected metastatic lymph nodes)

               7. Demonstrate adequate organ function as defined in Table 1, all screening labs
                  should be performed within 14 days of treatment initiation.

               8. Female subject of childbearing potential should have a negative urine or serum
                  pregnancy within 72 hours prior to receiving the first dose of study medication.
                  If the urine test is positive or cannot be confirmed as negative, a serum
                  pregnancy test will be required.

               9. Female subjects of childbearing potential (Section 5.7.2) must be willing to use
                  an adequate method of contraception as outlined in Section 5.7.2 - Contraception,
                  for the course of the study through 120 days after the last dose of study
                  medication.

                  Note: Abstinence is acceptable if this is the usual lifestyle and preferred
                  contraception for the subject.

              10. Male subjects of childbearing potential (Section 5.7.1) must agree to use an
                  adequate method of contraception as outlined in Section 5.7.1- Contraception,
                  starting with the first dose of study therapy through 120 days after the last
                  dose of study therapy.

        Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception
        for the subject.

        Exclusion Criteria:

          -  The subject must be excluded from participating in the trial if the subject:

               1. Is currently participating and receiving study therapy or has participated in a
                  study of an investigational agent and received study therapy or used an
                  investigational device within 4 weeks of the first dose of treatment.

               2. Participation in another clinical study with PD-1 or PD-L1 inhibitors at any time

               3. Any previous treatment with a PD-1, PD-L1 inhibitor or any anti-cancer therapy
                  after complete resection of lung cancer

               4. Current or prior use of immunosuppressive medication within 28 days before the
                  first dose of pembrolizumab, with the exceptions of intranasal and inhaled
                  corticosteroids or systemic corticosteroids at physiological doses, which are not
                  to exceed 10 mg/day of prednisone, or an equivalent corticosteroid

               5. Mean QT interval corrected for heart rate (QTc) ≥470 ms using Bazett's correction

               6. Has a known history of active TB (Bacillus Tuberculosis)

               7. Active or prior documented inflammatory bowel disease (Crohn's disease or
                  ulcerative colitis)

               8. History of allogenic organ transplant

               9. Hypersensitivity to pembrolizumab or any of its excipients.

              10. Prior history of malignancy within 2 years from study entry except for adequately
                  treated basal cell or squamous cell skin cancer or in situ cervical cancer, or
                  early gastric cancer. The incidentally detected, non-metastatic well
                  differentiated thyroid cancer can be enrolled irrespective of the treatment,
                  because the prognosis of this type of cancer is known much better than the study
                  disease, even it is untreated. For the debatable double primary cancer, the
                  enrolment can be discussed with the principal investigator in a manner of case by
                  case, and if it is not expected to affect the study outcome, the subjects can be
                  enrolled.

              11. Has active autoimmune disease that has required systemic treatment in the past 2
                  years (i.e. with use of disease modifying agents, corticosteroids or
                  immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or
                  physiologic corticosteroid replacement therapy for adrenal or pituitary
                  insufficiency, etc.) is not considered a form of systemic treatment.

              12. Has known history of, or any evidence of active, non-infectious pneumonitis.

              13. Evidence of interstitial lung disease.

              14. Has an active infection requiring systemic therapy.

              15. Has a history or current evidence of any condition, therapy, or laboratory
                  abnormality that might confound the results of the trial, interfere with the
                  subject's participation for the full duration of the trial, or is not in the best
                  interest of the subject to participate, in the opinion of the treating
                  investigator.

              16. Has known psychiatric or substance abuse disorders that would interfere with
                  cooperation with the requirements of the trial.

              17. Is pregnant or breastfeeding, or expecting to conceive or father children within
                  the projected duration of the trial, starting with the pre-screening or screening
                  visit through 120 days after the last dose of trial treatment.

              18. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).

              19. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA
                  [qualitative] is detected).

              20. Has received a live vaccine within 30 days of planned start of study therapy.
                  Note: Seasonal influenza vaccines for injection are generally inactivated flu
                  vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®)
                  are live attenuated vaccines, and are not allowed
      "
NCT03059667,completed,,0,phase 2,"['small cell lung cancer', 'small cell lung cancer limited stage', 'small cell lung cancer extensive stage']","[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['atezolizumab', 'topotecan', 'carboplatin', 'etoposide']","['CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O', 'Status: 503', 'CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O']","
        Inclusion Criteria:

          1. Histologically confirmed small-cell lung cancer.

          2. Extensive or limited disease according to the criteria of the Veteran's Administration
             Lung Cancer Group: (disease extended is defined as a disease beyond hemi thorax and
             supraclavicular lymph node areas. Tumor pleural effusion will be considered as
             extended disease).

          3. Targetable tumor lesions according to RECIST 1.1. Tumor involvement encompassed into a
             radiotherapy field is eligible as target pending that progression is documented.

          4. Tumor sample sent to IFCT for PD-L1 immunohistochemistry

          5. Previous platinum - etoposide treatment for at least 2 cycles.

          6. Demonstrated progression of the disease other than brain metastasis or carcinomatous
             meningitis.

             For the patient relapsing more than one year after the end of the previous treatment,
             a new histological confirmation is required before randomization.

          7. Age over 18 years.

          8. Weight loss ≤ 10% during the last three months.

          9. Patients with brain metastases at diagnosis will be eligible pending that they have
             achieved brain response during the first line therapy (including brain radiotherapy is
             required) and remain in brain tumor response during the two months prior to
             randomization.

         10. Performance Status 0-2

         11. Creatinine clearance > 40 mL/min.

         12. Neutrophils ≥ 2,000 µL-1 and platelets ≥ 100,000 µL-1.

         13. Bilirubin ≤ 1.5 x normal.

         14. Transaminases, alkaline phosphatases ≤ 2.5 x ULN except in case of liver metastases (5
             x ULN).

         15. Electrocardiogram without sign of progressive coronaropathy.

         16. No approved or investigational anti-cancer therapy concurrently or in the 5 years
             prior to start of study drug except the first line of treatment of the SCLC, including
             tumor embolization, chemotherapy, radiation therapy, immunotherapy, hormone therapy,
             biologic therapy, or anti angiogenic therapy (e.g., inhibitors of VEGF or VEGFR
             (Vascular Endothelial Growth Factor Receptor).

         17. Signed informed consent

         18. A female is eligible to enter and participate in this study if she is of:

        Non-childbearing potential (i.e., physiologically incapable of becoming pregnant),
        including any female who has undergone:

          -  Hysterectomy.

          -  Bilateral oophorectomy (ovariectomy).

          -  Bilateral tubal ligation.

          -  Or who is post-menopausal:

          -  Patients not using hormone replacement therapy (HRT) must have experienced total
             cessation of menses for ≥1 year and be greater than 45 years in age, OR, in
             questionable cases, have a follicle stimulating hormone value >40 mIU/mL and an
             estradiol value <40 pg/mL (<140 pmol/L).

          -  Subject using HRT must have experienced total cessation of menses for ≥ 1 year and be
             greater than 45 years of age OR have had documented evidence of menopause based on FSH
             (Follicle Stimulating Hormone) and estradiol concentrations prior to initiation of HRT
             (Hormone Replacement Therapy).

        Childbearing potential, including any female who has had a negative serum pregnancy test
        within 1 week prior to the first dose of study treatment, preferably as close to the first
        dose as possible, and agrees to use adequate contraception. Contraceptive methods
        acceptable to the IFCT, when used consistently and in accordance with both the product
        label and the instructions of the physician, are as follow:

          -  An intrauterine device with a documented failure rate of less than 1% per year.

          -  Male partner sterilization (vasectomy with documentation of azoospermia) prior to the
             female subject's entry and is the sole sexual partner for that female.

          -  Complete abstinence from sexual intercourse for 14 days before exposure to
             investigational product, through the dosing period, and for at least 21 days after the
             last dose of investigational product.

          -  Double-barrier contraception: condom and an occlusive cap (diaphragm or cervical/vault
             caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository)

          -  Oral contraceptive, either combined or progestogen alone

          -  Injectable progestogen

          -  Implant of levonorgestrel

          -  Estrogenic vaginal ring

          -  Percutaneous contraceptive patches The contraceptive methods must be used during all
             the time of the treatment and must be maintained during 5 months after the end of the
             treatment in the Atezolizumab arm and 30 days for women, 90 days for men, after the
             end of the treatment in the chemotherapy arm.

        Female patients who are lactating should discontinue nursing prior to the first dose of
        study drug and should refrain from nursing throughout the treatment period and for 15 days
        following the last dose of study drug.

        A male with a female partner of childbearing potential is eligible to enter and participate
        in the study if he uses a barrier method of contraception or abstinence during the study.

        Exclusion Criteria:

          1. Non-small cell lung cancer or mixed small-cell lung cancer - non small cell cancer.

          2. Prior immunotherapy

          3. Last dose of the previous treatment received less than 21 days before randomization
             (washout period).

          4. Corticosteroid with a daily dose over 10 mg prednisolone or equivalent for more than
             10 days during the previous month.

          5. Unstable angina or uncontrolled cardiac disease.

          6. Progressive infection (suggested by a fever associated with hyperleukocytosis,
             increase procalcitonin, and increase of C reactive protein without link with a
             paraneoplastic syndrome).

          7. Patient not able to follow the therapeutic program.

          8. Natremia < 125 mmol/L except in case of corrective treatment before the beginning of
             the therapy.

          9. Hypercalcemia despite corrective treatment (corrected calcemia = Ca++ (mmol) +
             [(40-alb (g)) x 0.025].

         10. Psychic or mental disease that do not allow the patient to give informed consent.

         11. Pregnant or lactating female.

         12. Systemic immunosuppressive therapy (eg cyclophosphamide, azathioprine, methotrexate,
             thalidomide and anti-tumor necrosis factor [TNF]) during the two weeks preceding the
             day 1 of cycle 1.

         13. Auto-immune disease. History of autoimmune disease, including myasthenia gravis,
             myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis,
             inflammatory bowel disease, vascular thrombosis associated with anti-phospholipid
             syndrome, Wegener's granulomatosis, Sjögren's syndrome, syndrome Guillain-Barré,
             multiple sclerosis, vasculitis or glomerulonephritis. Patients with a history of
             hypothyroidism origin autoimmune treated with a stable dose replacement therapy may be
             eligible for this study. Patients with controlled type 1 diabetes treated with insulin
             are eligible in this study.

         14. Idiopathic pulmonary fibrosis history, organizing pneumonia (eg, bronchiolitis
             obliterans), drug-induced lung disease, idiopathic pulmonary or active signs of
             pneumonia or interstitial lung infiltrate (any cause) detected on the lung scan
             selection

         15. Prior malignancy. Note: Patients who have had another malignancy and were treated more
             than 5 years ago and have since been considered cured, or patients with a history of
             basocellular skin carcinoma or in situ carcinoma of the uterine cervix are eligible.

         16. Presence of any concurrent disease or condition that would make the subject
             inappropriate for study participation including any unresolved or unstable, serious
             toxicity from prior administration of another investigational drug or any serious
             medical disorder that would interfere with the subject's safety, obtaining informed
             consent, or compliance with all study related procedures.

         17. Administration of a live attenuated vaccine during the four weeks preceding the day 1
             of cycle 1, or administration of a vaccine of this type scheduled during the study. An
             influenza vaccine should be administered during the influenza season (approximately
             from October to March). Patients should not receive a live attenuated influenza
             vaccine during the four weeks preceding the day 1 of cycle 1, and shall not receive a
             vaccine of this type during the study.

         18. History of human immunodeficiency virus infection or chronic hepatitis B or C.

         19. Presence of active or uncontrolled infection.

         20. Psoriasis patients

         21. History of any one or more of the following cardiovascular conditions within the past
             6 months:

               -  Coronary/peripheral artery bypass graft, cardiac angioplasty or stenting.

               -  Myocardial infarction.

               -  Severe/unstable angina pectoris.

               -  Symptomatic peripheral vascular disease, pulmonary embolism or untreated deep
                  venous thrombosis (DVT), cerebrovascular accident or transient ischemic attack.

               -  Note: Subject with recent DVT who have been treated with therapeutic
                  anti-coagulating agents for at least 6 weeks are eligible

               -  Class III or IV congestive heart failure, as defined by the New York Heart
                  Association.

         22. Concurrent treatment with an investigational agent or participation in another
             clinical trial.
      "
NCT03059797,completed,,1,phase 2,['small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['anlotinib', 'placebo']",['CC1=CC2=C(N1)C=CC(=C2F)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC'],"
        Inclusion Criteria:

          -  Histological documentation of small cell lung cancer

          -  Advanced small cell lung cancer who had at least two chemotherapy regimens,at least
             one measurable lesion (by RECIST1.1)

          -  18-75 years,ECOG PS:0-2,Life expectancy of more than 3 months

          -  Main organs function is normal

          -  Women of childbearing potential should agree to use and utilize an adequate method of
             contraception (such as intrauterine device，contraceptive and condom) throughout
             treatment and for at least 6 months after study is stopped；the result of serum or
             urine pregnancy test should be negative within 7 days prior to study enrollment，and
             the patients required to be non-lactating；Man participants should agree to use and
             utilize an adequate method of contraception throughout treatment and for at least 6
             months after study is stopped

          -  Patients should participate in the study voluntarily and sign informed consent

        Exclusion Criteria:

          -  Patients who have been used anlotinib

          -  Patients who have been used targeted drugs(such as
             sunitinib,bevacizumab,endostar),Immune targeted drugs

          -  4 weeks or less from the last cytotoxic therapy, radiation therapy or surgery

          -  Patients whose primary lesion with active bleeding within 4 months

          -  Carcinomatous meningitis

          -  Patients who known to the central nervous system

          -  Patients with factors that could affect oral medication (such as dysphagia，chronic
             diarrhea, intestinal obstruction etc.)

          -  Patients with any severe and/or unable to control diseases，including：

               1. Blood pressure unable to be controlled ideally(systolic pressure≥150
                  mmHg，diastolic pressure≥100 mmHg);

               2. Patients with Grade 1 or higher myocardial ischemia, myocardial infarction or
                  malignant arrhythmias(including QTc≥450ms(male),QTc≥470ms（female）) and patients
                  with Grade 1 or higher congestive heart failure (NYHA Classification);

               3. Patients with active or unable to control serious infections;

               4. Patients with cirrhosis, decompensated liver disease, or active hepatitis;

               5. Patients with poorly controlled diabetes (fasting blood glucose(FBG)>10mmol/L)

               6. Urine protein ≥ ++，and 24-hour urinary protein excretion>1.0 g confirmed;

          -  Patients with non-healing wounds or fractures

          -  Patients with arterial or venous thromboembolic events occurred within 6 months, such
             as cerebrovascular accident (including transient ischemic attack), deep vein
             thrombosis and pulmonary embolism

          -  Patients with drug abuse history and unable to get rid of or Patients with mental
             disorders

          -  Imaging showed tumors have involved important blood vessels or by investigators
             determine likely during the follow-up study and cause fatal hemorrhage

          -  History of immunodeficiency

          -  Patients with concomitant diseases which could seriously endanger their own safety or
             could affect completion of the study according to investigators' judgment
      "
NCT03054350,completed,,1,phase 2,"['anemia', 'dialysis dependent chronic kidney disease']","[""['D53.2', 'D64.9', 'D46.4', 'D53.0', 'D53.9', 'D61.3', 'D61.9']"", ""['N26.2', 'Q63.0', 'Q63.2', 'Z52.4', 'I75.81', 'N19', 'N20.0']""]","['vadadustat', 'placebo']",['C1=CC(=CC(=C1)Cl)C2=CC(=C(N=C2)C(=O)NCC(=O)O)O'],"
        Inclusion Criteria:

          -  Male and female Japanese participants ≥20 years of age

          -  Receiving chronic maintenance hemodialysis for end-stage kidney disease

          -  Hemoglobin (Hb) <10.0 grams per deciliter (g/dL)

        Exclusion Criteria:

          -  Anemia due to a cause other than chronic kidney disease (CKD) or presence of active
             bleeding or recent blood loss

          -  Sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic
             malignancy, myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia

          -  Red blood cell transfusion within 4 weeks prior to or during screening

          -  Anticipated to recover adequate kidney function to no longer require hemodialysis
             during study participation
      "
NCT03054337,completed,,1,phase 2,"['anemia', 'non-dialysis dependent chronic kidney disease']","[""['D53.2', 'D64.9', 'D46.4', 'D53.0', 'D53.9', 'D61.3', 'D61.9']"", ""['N26.2', 'Q63.0', 'Q63.2', 'Z52.4', 'I75.81', 'N19', 'N20.0']""]","['vadadustat', 'placebo']",['C1=CC(=CC(=C1)Cl)C2=CC(=C(N=C2)C(=O)NCC(=O)O)O'],"
        Inclusion Criteria:

          -  Male and female Japanese participants ≥20 years of age

          -  Diagnosis of chronic kidney disease (CKD) based on an estimated glomerular filtration
             rate ≤60 milliliters per minute per 1.73 meters squared (mL/min/1.73 m^2)

          -  Hemoglobin (Hb) ≤10.5 grams per deciliter (g/dL)

          -  Not currently being treated with dialysis and not expected to start dialysis within 3
             months of screening

        Exclusion Criteria:

          -  Anemia due to a cause other than CKD or presence of active bleeding or recent blood
             loss

          -  Sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic
             malignancy, myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia

          -  Red blood cell transfusion within 4 weeks prior to or during screening

          -  Intravenous iron within 4 weeks prior to or during screening

          -  Any use of erythropoiesis-stimulating agents within 6 weeks prior to or during
             screening
      "
NCT03051659,"active, not recruiting",,0,phase 2,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['eribulin mesylate', 'pembrolizumab']",['CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O2)OC(C9OC)CC(CN)O.CS(=O)(=O)O'],"
        Inclusion Criteria

          -  Patients must have histologically or cytologically confirmed Stage IV invasive breast
             cancer. Patients without pathologic or cytologic confirmation of metastatic disease
             should have unequivocal evidence of metastasis from physical examination or radiologic
             evaluation.

          -  Subjects must have at least one lesion that is not within a previously radiated field
             that is evaluable on computerized tomography (CT) or magnetic resonance imaging (MRI)
             scan per RECIST version 1.1. If the subject's only evaluable disease is within a
             previously radiated field, it must have demonstrated progression since the time of
             radiation.

          -  Participants must have HR positive, HER2-negative breast cancer (ER>1% and/or, PR>1%,
             HER2-negative per ASCO CAP guidelines, 2013 resulted on the primary tumor and/or a
             metastatic lesion).

          -  Participants must have already received or been intolerant to at least two lines of
             hormonal therapies (including the adjuvant or metastatic setting) or be appropriate
             candidates for chemotherapy

          -  Prior chemotherapy: Participants are allowed to have received up to 2 prior lines of
             chemotherapy in the metastatic setting. If a prior chemotherapy was given for less
             than 1 cycle, it will not be counted as a prior line. The last dose of chemotherapy
             must be ≥14 days prior to initiation of study therapy. Participants should be
             adequately recovered from acute toxicities of prior treatment. No prior treatment with
             eribulin mesylate is allowed.

          -  Prior biologic therapy: The last dose of biologic or investigational therapy must be
             ≥21 days prior to initiation of study therapy.

          -  Prior hormonal therapy: Hormonal therapy must have been discontinued ≥14 days prior to
             initiation of study therapy. However, continuation of ovarian suppression is allowed.

          -  Prior radiation therapy: Participants may have received prior radiation therapy in
             either the metastatic or early-stage setting. Radiation therapy must be completed ≥14
             days prior to initiation of study therapy.

          -  Prior targeted therapy: Targeted therapy must have been discontinued ≥ 14 days prior
             to initiation of study therapy.

          -  Biphosphonates/Denosumab: Participants on bisphosphonates/denosumab may continue
             receiving bisphosphonate therapy during study treatment.

          -  Participants must have an archival tumor sample available (1 block or 20 unstained
             slides). If no archival tissue is available, participants must be willing to undergo a
             research biopsy of their disease if it is safely accessible.

          -  Age ≥ 18 years of age

          -  ECOG performance status ≤2 (Karnofsky ≥60%)

          -  Participants must have normal organ and marrow function as defined below:

          -  absolute neutrophil count ≥1,500/mcL

          -  platelets ≥100,000/mcL

          -  hemoglobin ≥ 8 g/dl

          -  total bilirubin ≤1.5 × institutional upper limit of normal (ULN)

          -  AST(SGOT)/ALT(SGPT) ≤2.5 × institutional ULN (≤ 5 × institutional ULN with documented
             liver metastases,

          -  serum creatinine ≤1.5mg/dL or calculated GFR ≥60 mL/min

          -  INR/PT ≤1.5 times ULN unless participant is receiving anticoagulant therapy, as long
             as PT or PTT is within therapeutic range of intended use of anticoagulants

          -  aPTT/PTT ≤1.5 times ULN unless participant is receiving anticoagulant therapy, as long
             as PT or PTT is within therapeutic range of intended use of anticoagulants

          -  The effects of eribulin mesylate and pembrolizumab on the developing human fetus are
             unknown. Pre-clinical data was suggestive of a teratogenic effect of eribulin
             mesylate. For these reasons women of child-bearing potential and men must agree to use
             adequate contraception (hormonal or barrier method of birth control; abstinence) for
             the duration of study participation and 4 months after the last dose of eribulin
             mesylate and/or pembrolizumab. Note: abstinence is acceptable if this is the usual
             lifestyle and preferred contraception for the subject.

               -  Should a woman become pregnant or suspect she is pregnant while she or her
                  partner is participating in this study, the treating physician and principal
                  investigator should be informed immediately.

               -  While on the study, women must not breastfeed.

               -  Subjects of childbearing potential are defined as those who have not been
                  surgically sterilized and/or have had a menstrual period in the past year

          -  Female subjects of childbearing potential, as defined above, must have a either a
             negative urine or a negative serum pregnancy test within seven (7) days of first dose
             of pembrolizumab. If a urine test is positive or cannot be confirmed as negative, a
             serum pregnancy test will be required.

          -  Ability to understand and willingness to sign a written informed consent document.

        Exclusion Criteria

          -  Chemotherapy-related or radiation-related toxicities that have not resolved to Grade 1
             severity or lower, except for stable sensory neuropathy (≤ Grade 2) and alopecia.

          -  Participants who are receiving any other investigational agents.

          -  Previous treatment with eribulin mesylate or any anti-PD-1, PD-L1, or PD-L2 agent or
             participation in any MK-3475 Merck studies.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to eribulin mesylate or pembrolizumab.

          -  Known brain metastases that are untreated, symptomatic, or require therapy to control
             symptoms. Participants with previously diagnosed brain metastases are eligible if they
             have completed treatment at least 4 weeks prior to registration, are neurologically
             stable and absence of new neurologic symptoms for the last 4 weeks prior to study
             entry, and have recovered from the effects of radiotherapy or surgery. Any
             corticosteroid use for brain metastases must have been discontinued without the
             subsequent appearance of symptoms for ≥2 weeks before the first study drug. Treatment
             for brain metastases may have included whole brain radiotherapy, radiosurgery, or a
             combination as deemed appropriate by the treating physician.

          -  Uncontrolled intercurrent illness, including, but not limited to uncontrolled
             hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, congestive
             heart failure-New York Heart Association Class III or IV, active ischemic heart
             disease, myocardial infarction within the previous six months, uncontrolled diabetes
             mellitus, gastric or duodenal ulceration diagnosed within the previous 6 months,
             chronic liver or renal disease, severe malnutrition or psychiatric illness/social
             situations that would limit compliance with study requirements.

          -  Clinically significant electrocardiogram (ECG) abnormality, including a marked
             baseline prolonged QT/QTc ([QT interval/corrected QT interval], eg, a repeated
             demonstration of a QTc interval >500 ms).

          -  Medcial condition that requires chronic systemic steroid therapy or on any other form
             of immunosuppressive medication. For example, participants with autoimmune disease
             that requires systemic steroids or immunosuppression agents should be excluded.
             Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
             form of systemic treatment.

          -  History or evidence of active, noninfectious pneumonitis that required treatment with
             steroids.

          -  History of interstitial lung disease.

          -  Participants known to be positive for the human immunodeficiency virus (HIV),
             Hepatitis B antigen (HepBsAg), or Hepatitis C virus (HCV) RNA. HIV-positive
             participants on combination antiretroviral therapy are ineligible because of the
             potential for pharmacokinetic interactions with Pembrolizumab and/or eribulin
             mesylate. In addition, these participants are at increased risk of lethal infections.

          -  Individuals with a history of a second malignancy are ineligible except for the
             following circumstances. Individuals with a history of other malignancies are eligible
             if they have been disease-free for at least 5 years and are deemed by the investigator
             to be at low risk for recurrence of that malignancy. Individuals with the following
             cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer
             in situ, and non-melanoma cancer of the skin. Patients with other cancers diagnosed
             within the past 5 years and felt to be at low risk of recurrence should be discussed
             with the study sponsor to determine eligibility.

          -  Has received a live vaccine within 28 days of planned start of study therapy.
      "
NCT03050060,terminated,"
    terminated due to slow accrual
  ",0,phase 2,"['metastatic kidney carcinoma', 'recurrent lung non-small cell carcinoma', 'stage iv cutaneous melanoma ajcc v6 and v7', 'stage iv renal cell cancer ajcc v7', 'stage iv lung non-small cell cancer ajcc v7']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['D02.20', 'D02.21', 'D02.22']"", ""['A06.7', 'A22.0', 'A26.0', 'A32.0', 'A36.3', 'A43.1', 'B38.3']"", ""['C96.20', 'C96.29', 'D47.09']"", ""['C96.20', 'C96.29', 'D47.09']""]","['atezolizumab', 'nelfinavir mesylate']",['CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O.CS(=O)(=O)O'],"
        Inclusion Criteria:

          -  Disease eligibility and stage

               -  Histologically confirmed diagnosis of melanoma, non-small cell lung cancer
                  (NSCLC), or renal carcinoma

               -  Previously treated or previously untreated stage IV melanoma, stage IV or
                  recurrent lung cancer, and metastatic renal cancer by American Joint Committee on
                  Cancer (AJCC) staging criteria

               -  Presence of a lesion that is suitable for hypofractionated radiotherapy

          -  Subjects must have measurable disease by Response Evaluation Criteria in Solid Tumors
             (RECIST) criteria independent of the lesion to be irradiated. Prior checkpoint
             inhibitor immunotherapy or chemotherapy is allowed as long as the last dose was
             received > 14 days prior to enrollment

          -  Eastern Cooperative Oncology Group (ECOG) 0-2

          -  Acceptable marrow function and hematologic indices for PD1/PDL1 immune checkpoint
             inhibitor and nelfinavir as per standard of care

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Subjects who have had immunotherapy, chemotherapy, or radiation therapy within 14 days
             (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who
             have not recovered from adverse events due to agents administered more than 4 weeks
             earlier

          -  Subjects may not be receiving other investigational agents

          -  Patients with untreated/active brain metastases as documented by computed tomography
             (CT) or magnetic resonance imaging (MRI) within 2 months of study enrollment; by
             active brain metastases - we mean - actively symptomatic brain metastases requiring
             steroids

          -  Allergy or intolerance to nelfinavir or selected PD1/PDL1 immune checkpoint inhibitor

          -  Patients requiring steroids or other immunosuppressive therapy; low-dose or topical
             steroids are allowable if being used as replacement therapy

          -  Patients receiving anti-retroviral therapy or other agents that are contra-indicated
             with nelfinavir due to drug-drug interactions*

          -  Pregnant or lactating patients

          -  Prior radiation that precludes delivery of hypofractionated radiotherapy

               -  *For a study regarding the safety and efficacy of high dose nelfinavir on
                  patients with Kaposi's Sarcoma (KS), exclusion criteria included participants who
                  were receiving any ""strong inhibitors or inducers of cytochrome P450, family 3,
                  subfamily A (CYP3A) or cytochrome P450, family 2, subfamily C, polypeptide 19
                  (2C19)""

        Strong Inhibitors of CYP3A4:

          -  Antibiotics: clarithromycin, erythromycin, telithromycin, troleandomycin

          -  HIV: non-nucleoside reverse transcriptase inhibitors (delavirdine, nevirapine),
             protease inhibitors (ritonavir, indinavir, lopinavir/ritonavir, saquinavir),
             cobicistat-boosted antiretrovirals (e.g., elvitegravir); NOTE: Clinical trials have
             demonstrated that there are no clinically significant drug-drug interactions between
             nelfinavir and the following antiretrovirals: efavirenz (strong CYP3A4 inhibitor),
             etravirine (strong CYP3A4 inhibitor); therefore, these antiretrovirals will not be
             excluded. • Antifungals: itraconazole, ketoconazole, voriconazole, fluconazole,
             posaconazole

          -  Antidepressants: nefazodone

          -  Antidiuretic: conivaptan

          -  GI: cimetidine, aprepitant

          -  Hepatitis C: boceprevir, telaprevir

          -  Miscellaneous: seville oranges, grapefruit, or grapefruit juice and/or pomelos, star
             fruit, exotic citrus fruits, or grapefruit hybrids.

        Strong Inducers of CYP3A4:

          -  Glucocorticoids: cortisone (> 50 mg), hydrocortisone (> 40 mg), prednisone (> 10 mg),
             methylprednisolone (> 8 mg), dexamethasone (> 1.5 mg)

          -  Anticonvulsants: phenytoin, carbamazepine, primidone, phenobarbital and other enzyme
             inducing anti-convulsant drugs (EIACD)

          -  Antibiotics: rifampin (rifampicin), rifabutin, rifapentine

          -  Miscellaneous: St. John's Wort, modafinil

        Strong Inhibitors of CYP2C9:

        • Antifungals: fluconazole; lists including medications and substances known or with the
        potential to interact with the CYP3A or 2C19
      "
NCT03803761,withdrawn,"
    inadequate accrual rate
  ",0,phase 1/phase 2,"['anatomic stage iv breast cancer ajcc v8', 'metastatic breast carcinoma', 'metastatic malignant neoplasm in the brain', 'prognostic stage iv breast cancer ajcc v8']","[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['copanlisib', 'fulvestrant']","['COC1=C(C=CC2=C3NCCN3C(=NC(=O)C4=CN=C(N=C4)N)N=C21)OCCCN5CCOCC5', 'CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F']","
        Inclusion Criteria:

          -  Postmenopausal women with estrogen receptor positive (ER+), human epidermal growth
             factor receptor 2 (HER2) negative metastatic breast cancer (MBC) who have progressed
             on combination therapy with an aromatase inhibitor and cyclin-dependent kinase 4/6
             (CDK 4/6) inhibitor

               -  Note: Postmenopausal females are considered of childbearing potential unless they
                  are surgically or permanently sterile (have undergone a hysterectomy, bilateral
                  tubal ligation, or bilateral oophorectomy) or they are naturally postmenopausal
                  for at least 12 consecutive months. A high follicle stimulating hormone (FSH)
                  level in the postmenopausal range may be used to confirm a post-menopausal state
                  in women not using hormonal contraception or hormonal replacement therapy.
                  Documentation of postmenopausal status must be provided

          -  Measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1
             (RECIST1.1)

          -  Patients must have had tumor sequencing for evaluation of actionable PIK3CA or PTEN
             mutations performed in a Clinical Laboratory Improvement Act (CLIA) certified, College
             of American Pathologist (CAP) tested and bioinformatics-validated testing lab PRIOR to
             enrollment in this current protocol. If available patient tumor sequencing status must
             be provided to University of North Carolina (UNC) principal investigator (PI) at
             consent, and prior to any additional screening procedures. The testing may have been
             done at any time prior to enrollment. For patients who have not yet had tumor genomic
             assessment, after consultation with the PI, tumor specimens will be sent to the UNC
             Hospitals Clinical Molecular Genetics Laboratory for assessment of the Solid Tumor
             Mutation Panel. In this case, results of genetic testing by the UNC lab must be
             available prior to the first on study disease assessment (i.e., prior to day 1 of
             cycle 4). In this case, the study will cover the cost of the Solid Tumor Panel

          -  Female subjects who are not of childbearing potential

               -  Note: Because no dosing or adverse event data are currently available on the use
                  of copanlisib in combination with fulvestrant in patients <18 years of age, and
                  only postmenopausal women with ER+/HER2 negative MBC are eligible or appropriate
                  for treatment with fulvestrant, children and pregnant or pre-menopausal women are
                  excluded from this study

          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)

          -  No prior treatment history with fulvestrant or a PI3K inhibitor

          -  Subject has not received more than 2 prior lines of chemotherapy in the metastatic
             setting

          -  Subject must have washout period from prior systemic anti-cancer therapy of at least
             21 days (or 5 half-lives of the systemic anti-cancer therapy, whichever is shorter)
             before the start of study treatment

          -  Subject must have washout period from prior radiation therapy of at least 2 weeks
             before the start of study treatment

          -  Subjects with a history of brain metastases are allowed if they are not on steroid
             therapy and there is no evidence of intracranial disease progression symptomatically
             or by imaging within 28 days prior to study registration

          -  Hemoglobin >= 9.0 g/dL (collected no more than 7 days before starting treatment)

          -  Leukocytes >= 3,000/mcL (collected no more than 7 days before starting treatment)

          -  Absolute neutrophil count >= 1,500/mcL (collected no more than 7 days before starting
             treatment)

          -  Platelets >= 100,000/mcL (collected no more than 7 days before starting treatment)

          -  Total bilirubin =< 1.5 x upper limit of normal (ULN) (collected no more than 7 days
             before starting treatment) (< 3 x ULN for patients with Gilbert syndrome, patients
             with cholestasis due to compressive adenopathies of the hepatic hilum or documented
             liver involvement)

          -  Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT])
             =< 2.5 x institutional upper limit of normal (ULN) OR =< 5 x institutional ULN if
             liver metastases present (collected no more than 7 days before starting treatment)

          -  Glomerular filtration rate (GFR) >= 60 mL/min/1.73 m^2 unless data exists supporting
             safe use at lower kidney function values, no lower than 30 mL/min/1.73 m^2 (collected
             no more than 7 days before starting treatment)

          -  Fasting blood glucose < 120 mg/dL (collected no more than 7 days before starting
             treatment)

          -  Lipase =< 1.5 x ULN (collected no more than 7 days before starting treatment)

          -  International normalized ratio (INR) and partial thromboplastin time (PTT) =< 1.5 x
             ULN (collected no more than 7 days before starting treatment)

          -  Left ventricular ejection fraction (LVEF) >= 50%

          -  Subject must agree to provide archival tumor material for research and/or agree to
             undergo a tumor biopsy for research if the tumor is accessible for biopsy prior to
             study treatment

          -  Ability to understand and the willingness to comply with study procedures and to sign
             a written informed consent document

          -  Patients with a prior or concurrent malignancy whose natural history or treatment does
             not have the potential to interfere with the safety or efficacy assessment of the
             investigational regimen are eligible for this trial

        Exclusion Criteria:

          -  Previous assignment to treatment during this study. Patients permanently withdrawn
             from study participation will not be allowed to re-enter the study

          -  Concomitant participation in another clinical study with investigational medicinal
             product

          -  Subjects who have not recovered from adverse events due to prior anti-cancer therapy
             (i.e., have residual toxicities > grade 1) with the exception of alopecia

          -  Immunosuppressive therapy is not allowed while on study

          -  Subjects who are receiving any other investigational agents

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to copanlisib, fulvestrant, or PI3K inhibitors

          -  Subjects with moderate or severe hepatic impairment (ie, Child-Pugh B or C)

          -  Copanlisib is primarily metabolized by CYP3A4. Therefore, the concomitant use of
             strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, clarithromycin,
             ritonavir, indinavir, nelfinavir and saquinavir), and strong inducers of CYP3A4 (e.g.
             rifampin, phenytoin, carbamazepine, phenobarbital, St. John's Wort) are not permitted
             from 14 days prior to enrollment until the end of the study. Other medications that
             are prohibited while on copanlisib treatment:

               -  Herbal medications/preparations (except for vitamins)

               -  Anti-arrhythmic therapy other than beta blockers or digoxin

          -  Systemic corticosteroid therapy at a daily dose higher than 15 mg prednisone or
             equivalent is not permitted while on study. Previous corticosteroid therapy must be
             stopped or reduced to the allowed dose at least 7 days prior to the computed
             tomography (CT)/magnetic resonance imaging (MRI) screening; if a patient is on chronic
             corticosteroid therapy, corticosteroids should be de-escalated to the maximum allowed
             dose before the screening; patients may be using topical or inhaled corticosteroids;
             short-term (up to 7 days) systemic corticosteroids above 15 mg prednisolone or
             equivalent will be allowed for the management of acute conditions (e.g., treatment
             non-infectious pneumonitis); the use of corticosteroids as antiemetics prior to
             copanlisib administration will not be allowed

          -  Uncontrolled intercurrent illness, including but not limited to, psychiatric
             illness/social situations that would limit compliance with study requirements

          -  Major surgical procedure or significant traumatic injury (as judged by the
             investigator) within 28 days prior to start of treatment, or not recovered from major
             side effects, or open biopsy within 7 days before start of study treatment

          -  Patients with non-healing wound, ulcer, or bone fracture not due to breast cancer

          -  Patients with active, clinically serious infections > grade 2 (Common Terminology
             Criteria for Adverse Events [CTCAE] version [v]5.0)

          -  Patients with glycosylated hemoglobin (HbA1c) > 8.5% at screening

          -  Proteinuria of >= CTCAE grade 3 as assessed by a 24 hour (h) protein quantification or
             estimated by urine protein: creatinine ratio > 3.5 on a random urine sample

          -  Arterial or venous thrombotic or embolic events such as cerebrovascular accident
             (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism
             within 3 months before the start of study medication

          -  Congestive heart failure > New York Heart Association (NYHA) class 2

               -  Note: Class III NYHA Heart failure classification: Patients with cardiac disease
                  resulting in marked limitation of physical activity. They are comfortable at
                  rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or
                  anginal pain

               -  Note: Class IV NYHA Heart failure classification: Patients with cardiac disease
                  resulting in the inability to carry on any physical activity without discomfort.
                  Symptoms of heart failure or the anginal syndrome may be present even at rest. If
                  any physical activity is undertaken, discomfort is increased.

        Other cardiovascular-related abnormalities or therapy that prohibit study participation
        are:

          -  Myocardial infarction less than 6 months before start of study medications

          -  Unstable angina (angina symptoms at rest), new onset angina (begun within the last 3
             months)

          -  Uncontrolled arterial hypertension despite optimal medical management

          -  Anti-arrhythmic therapy (exceptions: beta blockers or digoxin are permitted)

               -  Pregnant or lactating (Pregnant women or women who are breastfeeding are excluded
                  from this study because copanlisib is a PI3K inhibitor agent with the potential
                  for teratogenic or abortifacient effects; there is no safety data in pregnancy;
                  because there is an unknown but potential risk for adverse events in nursing
                  infants secondary to treatment of the mother with copanlisib, breastfeeding
                  should be discontinued if the mother is treated with copanlisib and/or
                  fulvestrant; fulvestrant may also cause fetal harm and based on animal studies,
                  may impair fertility in females of reproductive potential)

               -  Hepatitis B virus (HBV) or hepatitis C virus (HCV). All patients must be screened
                  for HBV and HCV up to 28 days prior to study drug start using the routine
                  hepatitis virus lab panel; patients positive for hepatitis B virus surface
                  antigen (HBsAg) and/or hepatitis B virus core antibody (HBcAb) will be eligible
                  if they are negative for deoxyribonucleic acid (DNA), these patients should
                  receive prophylactic antiviral therapy; patients positive for anti-HCV antibody
                  will be eligible if they are negative for HCV ribonucleic acid (RNA)

               -  Human immunodeficiency virus (HIV)-positive patients on combination
                  antiretroviral agents that are strong CYP3A4 inhibitors or inducers and who are
                  unwilling or unable to change to antiretroviral therapies without such
                  interactions are ineligible because of the potential for pharmacokinetic
                  interactions with copanlisib

               -  Subjects with seizure disorder requiring medication

               -  Subjects with evidence or history of bleeding diathesis; any hemorrhage or
                  bleeding event >= CTCAE grade 3 within 4 weeks prior to the start of study
                  medication

               -  Blood or platelet transfusion less than 7 days before start of study treatment or
                  myeloid growth factors within 14 days prior to treatment

               -  History of concurrent condition of interstitial lung disease of any severity
                  and/or severely impaired lung function (as judged by the investigator)

               -  History of, or current autoimmune disease

               -  Concurrent diagnosis of pheochromocytoma
      "
NCT02630368,recruiting,,0,phase 1/phase 2,"['solid tumors', 'soft-tissue sarcoma', 'breast cancer']","[""['C46.1']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['cyclophosphamide and jx-594 dose escalation', 'cyclophosphamide and jx-594', 'cyclophosphamide', 'avelumab and jx-594 and cyclophosphamide']",['C1CNP(=O)(OC1)N(CCCl)CCCl'],"
        Main Inclusion Criteria:

          1. Histology:

               -  Phase Ib : Patient with histologically confirmed solid tumor

               -  Phase II :

                    -  Patients with histologically confirmed HER2 negative breast cancer
                       (treatment by CP+JX-594), or triple negative (treatment by avelumab +
                       CP+JX-594)

                    -  Patients with histologically confirmed soft tissue sarcoma confirmed by the
                       RRePS Network, b)Progressive disease or relapse, after standard therapy
                       according to RECIST v1.1 criteria diagnosed on the basis of two CT scan or
                       MRI obtained at an interval less than 6 months in the period of 12 months
                       prior to inclusion and confirmed by central review

          2. Metastatic or unresectable locally advanced disease

          3. Age ≥ 18 years

          4. ECOG ≤ 1 (Phase Ib), ≤ 2 (Phase II JX+CP) and ≤ 1 (Phase II avelumab+JX+CP).

          5. Life expectancy > 3 months,

          6. Measurable disease according to RECIST v1.1 outside any previously irradiated field.
             For patients treated by avelumab+JX+CP, at least one injectable site ≥ 2 cm and ≤ 8 cm
             in diameter and one distant non-injected measurable site (target site)

          7. At least three weeks since last chemotherapy, immunotherapy or any other
             pharmacological treatment and/or radiotherapy.

          8. Adequate hematological, renal, metabolic and hepatic functions.

          9. Women of childbearing potential must have a negative serum pregnancy test before study
             entry. Both women and men must agree to use a medically acceptable method of
             contraception throughout the treatment period and for six months after discontinuation
             of treatment.

         10. Patients informed of risks regarding drug interactions: patients receiving any
             substances that are inhibitors or inducers of CYP450 2B6 are ineligible

         11. Voluntarily signed and dated written informed consent prior to any study specific
             procedure.

         12. Patients with a social security in compliance with the French law.

        Main Exclusion Criteria:

          1. Previous treatment with JX-594 or other vaccina vector based treatment .

          2. Concomitant diseases/conditions (non exhaustive list):

               1. Clinically significant immunodeficiency, such as HIV or active Hepatite B or C

               2. Any other major illness that, in the Investigator's judgment, will substantially
                  increase the risk associated with the patient's participation in this study.

               3. History of severe exfoliative skins condition requiring systemic treatment for
                  more than 4 weeks in the last two years.

               4. active autoimmune disease for patients treated by avelumab

          3. Active central nervous system metastasis (CNS)

          4. Participation to a study involving a medical or therapeutic intervention in the last
             30 days.

          5. Previous enrolment in the present study.

          6. Patient unable to follow and comply with the study procedures because of any
             geographical, social or psychological reasons.

          7. Known hypersensitivity to any involved study drug or any of its formulation
             components.

          8. Use of steroids (any route of administration), interferon/pegylated interferon or
             ribavirin that cannot be discontinued within 14 days prior to any JX-594 dose.

          9. No prior malignancy except for the following: adequately treated basal or squamous
             cell skin cancer, in situ cervical cancer, adequately treated Stage 1 or Stage 2
             cancer from which the patient is currently in complete remission or any other cancer
             from which the patient has been disease-free for 3 years.

         10. Active cardiovascular disease, including but not limited to significant coronary
             artery disease (e.g. requiring angioplasty or stenting) or congestive heart failure
             within the preceding 12 months. (treatment by CP+JX)

         11. Inability to suspend treatment with anti-hypertensive medication for 48 hours prior to
             and 48 hours after all JX-594 treatments.

         12. Pulse oximetry O2 saturation < 90% at rest on room air.

         13. Experienced a severe systemic reaction or side-effect as result of previous smallpox
             vaccination.

         14. Cardiac disease: LVEF out of normal limits ; cumulative dose of anthracyclines in
             excess of 450 mg/m²

         15. Known urinary tract obstruction

         16. Household contact exclusions for patients enrolled: children< 1 year old ; People with
             skin disease (e.g., eczema, atopic dermatitis and related diseases…),
             Immunocompromised hosts (severe deficiencies in cell-mediated immunity, including
             AIDS, organ transplant recipients, hematologic malignancies)

         17. Vaccination within 4 weeks of the first dose of study treatment and while on trial is
             prohibited except for administration of inactivated vaccines.
      "
NCT02639559,completed,,1,phase 2,"['acute myelogenous leukemia', 'acute lymphoblastic leukemia', 'chronic myelogenous leukemia', ""non-hodgkin's lymphoma"", 'non-hodgkin lymphoma', 'hodgkin disease', 'hodgkins disease', ""hodgkin's disease"", 'multiple myeloma', 'myelodysplastic syndrome', 'myeloproliferative neoplasm']","[""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']"", ""['C91.01', 'C91.02', 'C91.00']"", ""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['C81.77', 'C81.97', 'C81.17', 'C81.27', 'C81.37', 'C81.47', 'C81.70']"", ""['C81.77', 'C81.97', 'C81.17', 'C81.27', 'C81.37', 'C81.47', 'C81.70']"", ""['C90.01', 'C90.02', 'C90.00']"", ""['D46.9', 'D46.C', 'D46.Z']"", ""['D47.1']""]",['bl-8040'],['C1CC2C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2C1)CCCCN)CCCCN)CCCNC(=O)N)CC3=CC=C(C=C3)O)NC(=O)C(CC4=CC5=CC=CC=C5C=C4)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C6=CC=C(C=C6)F)C(=O)NC(CCCNC(=N)N)C(=O)N)CCCNC(=O)N)CCCNC(=N)N)CC7=CC=C(C=C7)O'],"
        Inclusion Criteria (DONOR):

          -  Age 18 to 70 years of age.

          -  ECOG performance status of 0 or 1.

          -  PART 1: Donor must be a 5/6 or 6/6 HLA-matched sibling willing to donate PBSC for
             transplant.

          -  PART 2: Donor must be a 5/6 or 6/6 HLA-matched sibling or 3/6 or 4/6 HLA
             haploidentical donor willing to donate PBSC for transplant. Haploidentical donors will
             be allowed to participate upon investigator decision and based on the data reached
             from 5/6 or 6/6 HLA matched transplant done during Part 1 of the study.

          -  Adequate organ function defined by:

               -  serum creatinine within normal limits or a minimum creatinine clearance (CrCl)
                  value of ≥ 60 ml/min calculated using the Modification of Diet in Renal Disease
                  (MDRD) Study equation

               -  AST, ALT and total bilirubin ≤ 2x institutional upper limit of normal.

          -  Women of childbearing potential and men must agree to use adequate contraception with
             two different forms, including one barrier method, during participation in the study
             and for 2 weeks following dosing with BL-8040. Abstinence is acceptable if this is the
             established and preferred contraception for the subject.

          -  Female subjects must have a negative urine or serum pregnancy test within 10 days
             prior to taking study medication if of childbearing potential or must be of
             non-childbearing potential. If the urine test is positive or cannot be confirmed as
             negative, a serum pregnancy test will be required. The serum pregnancy test must be
             negative for the subject to be eligible. Non-childbearing potential is defined as:

             -≥ 45 years of age and has not had menses for > 2 years

          -  Amenorrheic for > 2 years without a hysterectomy and oophorectomy and a FSH value in
             the postmenopausal range upon pretrial (screening) evaluation

          -  Post-hysterectomy, oophorectomy, or tubal ligation.

          -  Able and willing to comply with the requirements of the protocol.

          -  Able to understand and willing to sign an IRB-approved written informed consent
             document.

        Inclusion Criteria (RECIPIENT):

          -  Age 18 to 75 years

          -  ECOG performance status of 0-2 (inclusive)

          -  One of the following diagnoses:

               -  Acute myelogenous leukemia (AML) in 1st or subsequent remission

               -  Acute lymphoblastic leukemia (ALL) in 1st or subsequent remission

               -  Chronic myelogenous leukemia (CML) in chronic or accelerated phase

               -  Non-Hodgkin lymphoma (NHL) or Hodgkin's disease (HD) in 2nd or greater complete
                  remission, partial remission

               -  Chronic lymphocytic leukemia (CLL)

               -  Multiple myeloma (MM)

               -  Myelodysplastic syndrome (MDS)

               -  Myeloproliferative neoplasm (MPN) excluding primary or secondary myelofibrosis

          -  Adequate organ function defined by:

               -  a creatinine clearance (CrCl) value of ≥ 60 ml/min by MDRD study equation

               -  AST, ALT and a total bilirubin ≤ 2x institutional upper limit of normal.

          -  Adequate cardiac function with a left ventricular ejection fraction ≥ 40%.

          -  Adequate pulmonary function defined as NO severe or symptomatic restrictive or
             obstructive lung disease, and formal pulmonary function testing showing an FEV1 ≥50%
             of predicted and a DLCO ≥ 40% of predicted, corrected for hemoglobin.

          -  Female subjects must have a negative urine or serum pregnancy test if of childbearing
             potential or be of non-childbearing potential. If the urine test is positive or cannot
             be confirmed as negative, a serum pregnancy test will be required. The serum pregnancy
             test must be negative for the subject to be eligible. Non-childbearing potential is
             defined as:

             *≥ 45 years of age and has not had menses for > 2 years

               -  Amenorrheic for > 2 years without a hysterectomy and oophorectomy and a FSH value
                  in the postmenopausal range upon pretrial (screening) evaluation

               -  Post-hysterectomy, oophorectomy, or tubal ligation.

          -  Able to understand and willing to sign an IRB-approved written informed consent
             document.

        Exclusion Criteria (DONOR):

          -  Received any investigational agent within 30 days and/or 5 half-lives (of the other
             investigational agent), whichever is longer, of receiving BL-8040.

          -  Active HIV or hepatitis B or C infection

          -  Pregnant or breastfeeding.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Known allergy or hypersensitivity to any of the test compounds, materials, or
             contraindication to test products.

          -  Any malignancies in the 2 years prior to baseline, excluding: basal cell carcinoma, in
             situ malignancy, low-risk prostate cancer, cervix cancer after curative therapy.

          -  A comorbid condition which, in the view of the investigators, renders the subject at
             high risk from treatment complications.

        Exclusion Criteria (RECIPIENT):

          -  Recipient must not have received any investigational drug within 30 days of starting
             conditioning treatment.

          -  Pregnant or breastfeeding.

          -  Active HIV or hepatitis B or C infection.

          -  Any medical condition which, in the opinion of the clinical investigator, would
             interfere with the evaluation of the patient. Subjects with a clinically significant
             or unstable medical or surgical condition or any other condition that cannot be
             well-controlled by the allowed medications permitted in the study protocol that would
             preclude safe and complete study participation, as determined by medical history,
             physical examinations, ECG, laboratory tests, or chest-X-ray and according to the
             investigator's judgment.
      "
NCT02638909,terminated,"
    lack of enrollment
  ",0,phase 2,"['colorectal adenocarcinoma', 'cholangiocarcinoma', 'pancreatic adenocarcinoma', 'hepatocellular adenocarcinoma', 'gastric adenocarcinoma', 'esophageal adenocarcinoma']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]",['ceritinib'],['CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl'],"
        Inclusion Criteria:

          1. Histologically or cytologically confirmed diagnosis of inoperable colorectal
             adenocarcinoma, pancreatic, hepatocellular, cholangiocarcinoma, small bowel, gastric
             or esophageal adenocarcinoma that carries an activated ALK or ROS1 pathway

          2. Age 18 years or older at the time of informed consent.

          3. Patients must have received at least 1 line of cytotoxic chemotherapy

          4. Patients must have archival tissue sample available, collected either at the time of
             diagnosis or any time since.

             - If archival tissue is unavailable, patient must be eligible and willing to undergo a
             fresh tissue biopsy

          5. Patients must have recovered from all toxicities related to prior anticancer therapies
             to grade ≤ 2 (CTCAE v 4.03) provided that concomitant medication is given prior to
             initiation of treatment with LDK378, except for patients with grade 2 nausea/vomiting
             and/or grade 2 diarrhea despite optimal supportive therapy who will not be allowed to
             participate in the study. Additionally, patients with any grade of alopecia are
             allowed on treatment.

          6. Cohort Expansion Phase: Patient must have measurable lesions as defined by RECIST
             version 1.1 criteria.

          7. ECOG performance status 0-2

          8. Patients must have normal organ and marrow function as defined below: Bone marrow
             function defined as the following: An absolute neutrophil count ≥ (ANC) 1,500/mcl.
             Platelets ≥ 75,000/mcl. Hemoglobin ≥ 8 g/dl.

          9. Renal function defined as the following: Serum creatinine less than or equal to 1.5 x
             institutional upper limit normal (ULN). Calculated or measured creatinine clearance
             (CrCL) ≥ 30 mL/min

         10. Hepatic function defined as the following: Serum total bilirubin < 1.5 x ULN. AST
             (SGOT), ALT (SGPT), and alkaline phosphatase ≤ 3.0 x ULN. Serum albumin ≥ 2.5 g/dl. If
             liver involvement, AST, ALT, and alkaline phosphatase ≤ 5.0 x ULN.

         11. Serum amylase ≤ 2 x ULN and serum lipase ≤ 1 x ULN

         12. Fasting plasma glucose ≤175 mg/dL (≤9.8 mmol/L)

         13. Patient must have the following laboratory values or have the following laboratory
             values corrected with supplements to be within normal limits at screening:

               -  Potassium ≥ lower limit of normal (LLN)

               -  Magnesium ≥ LLN

               -  Phosphorus ≥ LLN

               -  Total calcium (corrected for serum albumin) ≥ LLN

         14. A male subject of fathering potential must use an adequate method of contraception to
             avoid conception throughout the study [and for up to 12 weeks after the last dose of
             study drug] to minimize the risk of pregnancy. If the partner is pregnant or
             breastfeeding, the subject must use a condom. A condom is required to be used also by
             vasectomized men in order to prevent delivery of the drug via seminal fluid.

         15. Women of childbearing potential (WOCBP) must be using an adequate method of
             contraception to avoid pregnancy throughout the study and for up to 12 weeks after the
             last dose of study drug to minimize the risk of pregnancy. WOCBP must have a negative
             serum or urine pregnancy test within 72 hours before the start of the investigational
             product. Highly effective contraception methods include:

               -  Total abstinence (when this is in line with the preferred and usual lifestyle of
                  the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal,
                  post-ovulation methods) and withdrawal are not acceptable methods of
                  contraception.

               -  Female sterilization (have had surgical bilateral oophorectomy with or without
                  hysterectomy) or tubal ligation at least six weeks before taking study treatment.
                  In case of oophorectomy alone, only when the reproductive status of the woman has
                  been confirmed by follow up hormone level assessment.

               -  Male sterilization (at least 6 months prior to screening) with the appropriate
                  post-vasectomy documentation of the absence of sperm in the ejaculate. For female
                  subjects on the study the vasectomized male partner should be the sole partner
                  for that subject.

               -  Combination of any two of the following (a+b or a+c or b+c):

               -  Use of oral, injected or implanted hormonal methods of contraception or other
                  forms of hormonal contraception that have comparable efficacy (failure rate <
                  1%), for example hormone vaginal ring or transdermal hormone contraception.

               -  Placement of an intrauterine device (IUD) or intrauterine system (IUS).

             Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault
             caps) with spermicidal foam/gel/film/cream/vaginal suppository.

             In case of use of oral contraception, women should have been stable on the same pill
             for a minimum of 3 months before taking study treatment.

             Women are considered post-menopausal and not of child bearing potential if they have
             had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile
             (e.g., age appropriate, history of vasomotor symptoms) or have had surgical bilateral
             oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior
             to screening. In the case of oophorectomy alone, only when the reproductive status of
             the woman has been confirmed by follow up hormone level assessment is she considered
             not of child bearing potential.

         16. Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          1. Patients who have had chemotherapy or radiotherapy within 3 weeks (4 weeks for
             radiotherapy to the lung fields and 6 weeks for nitrosoureas or mitomycin C) prior to
             entering the study or those who have not recovered from adverse events due to agents
             administered more than 4 weeks earlier.

          2. Patients with known hypersensitivity to any of the excipients of ceritinib
             (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and
             magnesium stearate)

          3. Prior therapy with ceritinib or other ALK or ROS1 inhibitor agents

          4. Patients who are currently receiving treatment with warfarin sodium (Coumadin®) or any
             other coumarin-derivative anti-coagulants.

          5. Patients with symptomatic CNS metastases who are neurologically unstable or have
             required increasing doses of steroids within the 1 week prior to study entry to manage
             CNS symptoms.

          6. Impairment of GI function or GI disease that may significantly alter the absorption of
             ceritinib

          7. History of pancreatitis or history of increased amylase or lipase that was due to
             pancreatic disease.

          8. Patients with known history of extensive disseminated bilateral interstitial fibrosis
             or interstitial lung disease, including a history of pneumonitis, hypersensitivity
             pneumonitis, interstitial pneumonia, obliterative bronchiolitis, and clinically
             significant radiation pneumonitis (i.e. affecting activities of daily living or
             requiring therapeutic intervention).

          9. Cardiac conditions as follows:

               -  Active coronary artery disease, unstable or newly diagnosed angina or myocardial
                  infarction less than 6 months prior to first study drug administration.

               -  Class II-IV New York Heart Association (NYHA) congestive heart failure.

               -  Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or
                  digoxin

               -  QTc (Frederica) prolongation > 470 msec.

               -  Subjects with valvular heart disease CTCAE (Version 4.0) Grade 2.

               -  Known left ventricular ejection fraction (LVEF) < 50%.

               -  Uncontrolled hypertension defined by a Systolic Blood Pressure (SBP) ≥ 160 mm Hg
                  and/or Diastolic Blood Pressure (DBP) ≥ 100 mm Hg, with or without
                  anti-hypertensive medication

         10. Receiving medications that meet one of the following criteria and that cannot be
             discontinued at least 1 week prior to the start of treatment with LDK378 and for the
             duration of participation:

               -  Medication with a known risk of prolonging the QT interval or inducing Torsades
                  de Pointes (please refer to
                  http://www.azcert.org/medical-pros/drug-lists/drug-lists.cfm)

               -  Strong inhibitors or strong inducers of CYP3A4/5 (please refer to
                  http://medicine.iupui.edu/flockhart/table.htm or
                  http://www.druginteractioninfo.org)

               -  Medications with a low therapeutic index that are primarily metabolized by
                  CYP3A4/5, and/or CYP2C9 (please refer to
                  http://medicine.iupui.edu/flockhart/table.htm or
                  http://www.druginteractioninfo.org)

               -  Therapeutic doses of warfarin sodium (Coumadin) or any other coumarin-derived
                  anti-coagulant. Anti-coagulants not derived from warfarin are allowed (e.g.,
                  dabigatran, rivaroxaban, apixaban).

               -  Unstable or increasing doses of corticosteroids

               -  Enzyme-inducing anti-convulsive agents

               -  Herbal supplements

         11. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris (Canadian
             Cardiovascular Society grade II-IV despite medical therapy), cardiac arrhythmia,
             active bleeding diatheses, or psychiatric illness/social situations that would limit
             compliance with study requirements.

         12. Major surgical procedure, open biopsy, or significant traumatic injury less than 4
             weeks or those who receive minor surgical procedures (e.g. core biopsy or fine needle
             aspiration) within 1 week from first dose of first study drug administration.

         13. Known inability to swallow up to five LDK378 capsules daily.

         14. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive hCG laboratory test.
      "
NCT02633800,terminated,"
    trial was terminated by sponsor due to lack of efficacy.
  ",0,phase 2,['head and neck neoplasms'],"[""['C76.0', 'C47.0', 'C49.0', 'C77.0', 'D17.0', 'D21.0', 'D36.11']""]","['patritumab', 'cetuximab', 'cisplatin', 'carboplatin', 'placebo']","['N.N.Cl[Pt]Cl', 'C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]']","
        Inclusion Criteria:

          -  Has histologically confirmed recurrent disease or metastatic SCCHN tumor and/or from
             its lymph nodal metastases originating from the oral cavity, oropharynx, hypopharynx,
             and larynx

          -  Has or be willing to provide tumor tissue for testing

          -  Has measurable disease per Response Evaluation Criteria in Solid Tumor (RECIST)
             version 1.1

          -  Has Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Has adequate hematological function per protocol

          -  Has adequate renal function per protocol

          -  Has adequate hepatic function per protocol

          -  Agrees to use effective contraception while on the study and for 6-months after the
             end of the study

          -  Provides written informed consent(s)

        Exclusion Criteria:

          -  Has left ventricular ejection fraction (LVEF) <50%

          -  Had prior epidermal growth factor receptor (EGFR) targeted regimen

          -  Had prior anti-human epidermal growth factor receptor 3 (anti-HER3) therapy

          -  Had prior chemotherapy for recurrent/metastatic disease

          -  Had anti-cancer therapy between biopsy and submission of sample

          -  Has history of other malignancies, except adequately treated non-melanoma skin cancer,
             curatively treated in-situ disease, or other solid tumors curatively treated with no
             evidence of disease for ≥ 2 years

          -  Has known history of brain metastases or active brain metastases

          -  Has uncontrolled hypertension

          -  Has clinically significant electrocardiograph (ECG) findings

          -  Had myocardial infarction within 1 year before enrollment, symptomatic congestive
             heart failure, unstable angina, or arrhythmia requiring medication

          -  Had platinum-containing drug therapy with radiotherapy less than 6 months before study
             drug treatment

          -  Had therapeutic or palliative radiation therapy or major surgery within 4 weeks before
             study drug treatment
      "
NCT02732119,completed,,1,phase 1/phase 2,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['ribociclib', 'everolimus', 'exemestane']","['CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5', 'CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC', 'CC12CCC3C(C1CCC2=O)CC(=C)C4=CC(=O)C=CC34C']","
        Inclusion Criteria:

          -  Adult men and women

          -  Patient has a confirmed diagnosis of estrogen-receptor positive and/or progesterone
             receptor positive breast cancer by local laboratory and has HER2-negative breast
             cancer

          -  Patient must have either measurable disease by RECIST 1.1 or bone lesions in absence
             of measurable disease.

          -  ECOG Performance Status 0 - 1

          -  Disease refractory to either, AI, tamoxifen or fulvestrant

          -  Previously treated on any CDK 4/6 inhibitor.

          -  Patient has adequate bone marrow and organ function.

        Exclusion Criteria:

          -  Patient with symptomatic visceral disease or any disease burden that makes the patient
             ineligible for endocrine therapy per the investigator's best judgment.

          -  Patient has received more than one line of chemotherapy for advanced disease.

          -  Previous treatment with mTOR inhibitors, or exemestane for advanced disease.

          -  Progressed on more than one CDK 4/6 inhibitor

          -  Patient with CNS involvement unless they are at least 4 weeks from prior therapy
             completion.

          -  Clinically significant, uncontrolled heart disease and/or recent cardiac events.
      "
NCT02731352,completed,,1,phase 2,['thyroid cancer'],"[""['C73', 'D34', 'D44.0', 'Z85.850']""]","['apatinib', 'apatinib']","['C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4', 'C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4']","
        Inclusion Criteria:

          1. Locally advanced or metastatic differentiated thyroid cancer (papillary, follicular,
             Hurthle cells, poorly differentiated carcinoma). At least one measurable lesion
             (helical CT scan long diameter ≥10mm, meet the requirements of the standard Response
             Evaluation Criteria In Solid Tumors（RESCIST） version 1.1);

          2. Disease progression within 14 months before inclusion;

          3. Subjects must be 131I-refractory / resistant as defined by at least one of the
             following;

               -  Lesions that do not demonstrate iodine uptake on any radioiodine scan

               -  Subjects received a single radioactive iodine therapy within 12 months (≥ 3.7
                  Giga Becquerel (GBq) [≥ 100 millicurie (mCi) ]) and target lesion disease
                  progression

               -  Every two radioactive iodine treatment interval <12 months, doses ≥ 3.7 GBq [≥100
                  mCi], disease progress more than 12 months after at least once iodine therapy;

               -  Received a total dose of radioactive iodine therapy ≥ 22.2 GBq (≥ 600 mCi)

          4. main organs function is normal;

          5. Eastern Cooperative Oncology Group（ECOG）Performance Status（PS） :0-2;

          6. An expected survival of ≥ 3 months;

          7. Pregnancy test (serum or urine) has to be performed for woman of childbearing age
             within 7 days before enrolment and the test result must be negative. They shall take
             appropriate methods for contraception during the study until the 8th week post the
             last administration of study drug. For men, (previous surgical sterilization
             accepted), shall agree to take appropriate methods of contraception during the study
             until the 8th week post the last administration of study drug;

          8. Patient has to voluntarily join the study and sign the Informed Consent Form for the
             study;

        Exclusion Criteria:

          1. Other thyroid cancer histological subtypes (such as medullary carcinoma, lymphoma or
             sarcoma);

          2. Received VEGFR inhibitor treatment within 1 month;

          3. Subjects with poor-controlled arterial hypertension (systolic blood pressure> 140 mmHg
             and diastolic blood pressure > 90 mm Hg) despite standard medical management; Coronary
             heart disease greater than ClassII; II-level arrhythmia (including QT interval
             prolongation, for man ≥ 450 ms, for woman ≥ 470 ms) together with Class II cardiac
             dysfunction;

          4. Factors that could have an effect on oral medication (such as inability to swallow,
             chronic diarrhea and intestinal obstruction);

          5. Subjects with high gastrointestinal bleeding risk, including the following conditions:
             local active ulcer lesions with positive fecal occult blood test (++); history of
             black stool, or vomiting blood in the past 3 months;

          6. Abnormal Coagulation (INR>1.5、APTT>1.5 UNL), with tendency of bleed;

          7. Received anti-thyroid cancer chemotherapy treatment (allows the use of low-dose
             chemotherapy with radiation sensitizer) or thalidomide(or derivative) therapy;

          8. Pregnant or lactating women;

          9. Other conditions regimented at investigators' discretion.
      "
NCT02730884,terminated,"
    terminated per pis request due to low accrual
  ",0,phase 2,"['leukemia', 'myelofibrosis', 'anemia', 'splenomegaly']","[""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']"", ""['D75.81', 'C94.41', 'C94.42', 'C94.40']"", ""['D53.2', 'D64.9', 'D46.4', 'D53.0', 'D53.9', 'D61.3', 'D61.9']"", ""['D73.81', 'D73.2', 'R16.1', 'R16.2']""]",['rigosertib'],['COC1=C(C=C(C=C1)CS(=O)(=O)C=CC2=C(C=C(C=C2OC)OC)OC)NCC(=O)O'],"
        Inclusion Criteria:

          1. >/= 18 years of age;

          2. Diagnosis of primary myelofibrosis (PMF) or post-polycythemia vera (post-PV) MF or
             post-essential thrombocythemia (post-ET) MF based on the World Health Organization
             (WHO) criteria or the International Working Group-Myeloproliferative Neoplasms
             Research and Treatment (IWG-MRT) criteria, which must be confirmed by BM aspirate
             and/or biopsy within 6 weeks prior to Screening. Measurement of JAK2 V617F allele
             burden in Bone Marrow (BM) samples, if not done within 6 months prior to Screening,
             must be provided with the Screening BM biopsy/aspirate report (patients are eligible
             regardless of JAK2 mutation status);

          3. Anemia or RBC-transfusion dependence defined as follows: a) Anemia: defined for the
             purpose of this protocol as 1) a hemoglobin level <10 g/L on every determination over
             84 days before study-entry, without red blood cell (RBC)-transfusions, or 2) a
             hemoglobin level <10 g/L on a patient that is receiving RBC-transfusions periodically
             but not meeting criteria for transfusion-dependent patient as defined below. The
             baseline hemoglobin value for these subjects is the lowest hemoglobin level during the
             antecedent 84 days; b) RBC-transfusion-dependence: RBC-transfusion-frequency of >/=2
             units packed red blood cells (PRBC)/28 days averaged over 84 days immediately
             pre-study-entry. There must not be any consecutive 42 days without an RBC-transfusion
             during this interval.

          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2;

          5. Willing to adhere to the prohibitions and restrictions specified in this protocol
             (Notation: the subject's willingness to adhere to prohibitions and restrictions must
             be clearly communicated in the on-study note);

          6. The patient must signed an informed consent form (ICF) indicating that s/he
             understands the purpose of, and procedures required for, the study and is willing to
             participate.

        Exclusion Criteria:

          1. Ongoing clinically significant anemia due to factors such as known iron, vitamin B12,
             or folate deficiencies, auto-immune or hereditary hemolysis, or gastrointestinal (GI)
             bleeding;

          2. Serum ferritin < 50 ng/mL;

          3. Any active malignancy within the past year, except basal cell or squamous cell skin
             cancer or carcinoma in situ of the cervix or breast; patients with history of prior
             malignancies should be free of disease for at least 3 years to be eligible for this
             study.

          4. Uncontrolled intercurrent illness, including, but not limited to symptomatic
             congestive heart failure, unstable angina pectoris, or cardiac arrhythmia;

          5. Active infection not adequately responding to appropriate therapy;

          6. Direct bilirubin >/= 2.0 mg/dL not related to hemolysis or Gilbert's disease;

          7. Alanine transaminase (ALT) or aspartate transaminase (AST)>/= 2.5 x the upper limit of
             normal (ULN);

          8. Serum creatinine >/= 2.5 mg/dL;

          9. Ascites requiring active medical management including paracentesis;

         10. Hyponatremia (defined as serum sodium level < 130 mEq/L);

         11. Female patients who are pregnant or lactating;

         12. Patients of childbearing potential (ie, women of childbearing potential and men with
             female partners of childbearing potential) who are unwilling to follow strict
             contraception requirements (including 2 reliable methods in combination: 1
             non-hormonal, highly-reliable method [diaphragm, condoms with spermicidal foam or
             jelly, or sterilization] plus 1 additional reliable method [birth control pills,
             intrauterine device, contraceptive injections, or contraceptive patches]) before entry
             and throughout the study, up to and including the 30-day non-treatment follow-up
             period;

         13. Female patients of childbearing potential who have a positive blood or urine pregnancy
             test at Screening;

         14. Major surgery without full recovery or major surgery within 3 weeks of Screening;

         15. Uncontrolled hypertension (defined as a sustained systolic pressure >/= 160 mmHg
             and/or a diastolic pressure >/= 110 mmHg);

         16. New onset seizures (within 3 months prior to Screening) or poorly controlled seizures;

         17. Any other concurrent investigational agent or chemotherapy, radiotherapy, or
             immunotherapy;

         18. Chronic use (> 2 weeks) of corticosteroids (prednisone >/= 10 mg/24 hr equivalent)
             within 4 weeks of Screening;

         19. Investigational therapy within 2 weeks of Screening;

         20. Psychiatric illness or social situation that would limit the patient's ability to
             tolerate and/or comply with study requirements.
      "
NCT03851081,withdrawn,"
    no accrual
  ",0,phase 1/phase 2,"['allogeneic hematopoietic stem cell transplantation recipient', 'blasts 5 percent or more of bone marrow nucleated cells', 'blasts 5 percent or more of peripheral blood white cells', 'cd22 positive', 'lymphoblasts 20 percent or more of bone marrow nucleated cells', 'lymphoblasts 20 percent or more of peripheral blood white cells', 'recurrent b acute lymphoblastic leukemia', 'refractory b acute lymphoblastic leukemia']","[""['M31.11']"", ""['A18.2', 'H11.043', 'H11.053', 'H18.463', 'H35.40', 'H81.393', 'I73.9']"", ""['E70.321', 'Z17.0', 'Z67.10', 'Z67.20', 'Z67.30', 'Z67.40', 'Z67.90']"", ""['A18.2', 'H11.043', 'H11.053', 'H18.463', 'H35.40', 'H81.393', 'I73.9']"", ""['C83.57', 'C83.50', 'C91.01', 'C91.02', 'C83.52', 'C83.56', 'C83.53']"", ""['C83.57', 'C83.50', 'C91.01', 'C91.02', 'C83.52', 'C83.56', 'C83.53']""]",['vincristine sulfate liposome'],['CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O'],"
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group performance status between 0-2

          -  Serum creatinine =< 1.5 x upper limit of normal (ULN) or calculated creatinine
             clearance (Cockcroft and Gault) > 30 mL/min

          -  Alanine aminotransferase (ALT) =< 5 x ULN

          -  Total bilirubin= < 1.5 x ULN

          -  Left ventricular ejection fraction (LVEF) >= 40% as assessed by echocardiogram (ECHO)
             or multiple-gated acquisition (MUGA) scan performed within 28 days of enrollment

          -  Diagnosis of relapsed/refractory CD22+ B-cell ALL with disease in the bone marrow
             and/or peripheral blood by morphology (>=5% blasts). CD22-positive B-ALL is defined as
             expression by at least 20% of malignant lymphoblasts as determined by local flow
             cytometry and/or immunohistochemistry from a peripheral blood and/or bone marrow
             sample obtained within 2 weeks of screening

          -  Relapsed or refractory disease, defined as second or greater bone marrow relapse from
             CR or overall response or, disease has progressed following two or more anti-leukemia
             therapies. Specifically:

               -  Any bone marrow relapse after allogeneic HSCT: subjects must be at least 1 month
                  from HSCT at the time of screening and off immunosuppressive medication for at
                  least 2 weeks at time of initial treatment (with the exception of low-dose
                  steroids =< 20 mg prednisone equivalent) and have no active graft versus (vs.)
                  host disease (GVHD);

               -  Philadelphia chromosome (Ph) negative B-ALL which has not achieved CR or CRi
                  after at least 2 attempts at remission induction using standard intensive
                  chemotherapy regimen(s);

               -  Philadelphia chromosome (Ph) positive B-cell ALL intolerant to or ineligible for
                  BCR-ABL tyrosine kinase inhibitor (TKI) therapy or with disease which has
                  progressed after at least two lines of prior TKI therapy

          -  Participants of childbearing potential must agree to use adequate contraceptive
             methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study
             entry and for females, at least 8 months after the final dose of inotuzumab
             ozogamicin. Males with female partners of childbearing potential must agree to use
             adequate contraceptive prior to study entry and for at least 5 months after the final
             dose of inotuzumab ozogamicin. Should a woman become pregnant or suspect she is
             pregnant while she or her partner is participating in this study, she should inform
             her treating physician immediately

          -  Participant must understand the investigational nature of this study and sign an
             Independent Ethics Committee/Institutional Review Board approved written informed
             consent form prior to receiving any study related procedure

        Exclusion Criteria:

          -  Receipt of chemotherapy, radiotherapy, or investigational drug therapy within 2 weeks
             prior to treatment on study or those who have not recovered from adverse events due to
             agents administered > 2 weeks earlier

          -  Participants on oral or injectable calcineurin inhibitors (e.g., cyclosporin,
             tacrolimus) within 4 weeks prior to study enrollment

               -  Active central nervous system involvement; patients who have a history of central
                  nervous system (CNS) disease which has been effectively treated (as defined by at
                  least one negative cerebrospinal sample prior to screening) are eligible

          -  Prior malignancy, unless treated with curative intent and with no evidence of active
             disease present for > 5 years before screening, with the following exceptions:

               -  Subjects with stage I breast cancer that has been completely and successfully
                  treated, requiring no therapy or only anti-hormonal therapy

               -  Subjects with T1N0M0 or T2N0M0 colorectal cancer who have been completely and
                  successfully resected and who are disease-free for > 2 years prior to screening

               -  Subjects with indolent prostate cancer, defined as clinical stage T1 or T2a,
                  Gleason score =< 6, and prostate-specific antigen (PSA) < 10 ng/mL, requiring no
                  therapy or only anti-hormonal therapy

               -  Subjects with a history of basal cell or squamous cell carcinoma of the skin, or
                  carcinoma in situ of the cervix, fully resected, and with no evidence of active
                  disease

          -  Uncontrolled intercurrent medical illness including, but not limited to, symptomatic
             congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric
             illness/social situations that in the opinion of the investigator would limit
             compliance with study requirements

          -  Uncontrolled systemic fungal, bacterial, viral, or other infection defined as
             exhibiting ongoing signs and symptoms due to infection despite appropriate
             anti-infective therapy at time of screening

          -  Pregnant or nursing female participants

          -  Known active hepatitis B, known active hepatitis C, or any human immunodeficiency
             virus (HIV) infection at the time of screening

          -  Presence of grade II-IV acute or extensive chronic graft versus host disease (GVHD) at
             time of screening

          -  Unwilling or unable to follow protocol requirements

          -  Any condition which in the investigator's opinion deems the participant an unsuitable
             candidate to receive study drug including, but not limited to, medical, psychological,
             familial, social, or geographical considerations
      "
NCT04025567,withdrawn,"
    slow/insufficient accrual.
  ",0,phase 2,"['metastatic hepatocellular carcinoma', 'hepatocellular carcinoma']","[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]",['vancomycin'],['CC1C(C(CC(O1)OC2C(C(C(OC2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)C(C(C(=O)NC(C(=O)NC5C(=O)NC7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)C(NC(=O)C(C(C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)CO)O)O)(C)N)O'],"
        -  INCLUSION CRITERIA:

          -  Patients must have histopathological confirmation of FLC by the NCI Laboratory of
             Pathology.

          -  Patients must have disease that is not amenable to potentially curative resection,
             transplantation or ablation.

          -  Patients must be greater than or equal to 18 years of age. Children are excluded from
             this study because this study has two mandatory biopsies performed for research
             purposes only and we do not want to put children into additional risk of biopsies.

          -  Patients must have evaluable or measurable hepatic disease per RECIST 1.1

          -  Patients must have hepatic lesion accessible for biopsy and be willing to undergo pre-
             and post-treatment mandatory biopsies.

          -  ECOG performance status of less than or equal to 2

          -  Adequate renal function defined by:

               -  Creatinine <1.5 x institution upper limit of normal (ULN)

               -  Creatinine clearance (CrCl) greater than or equal to 50 mL/min/1.73 m2 by 24
                  hours urine collection or eGFR as estimated using the chronic kidney disease
                  (CKD)-EPI equation for participant with creatinine levels > 1.5 X institutional
                  ULN.

          -  Adequate hepatic function defined by:

               -  Total bilirubin level with upper limit of normal less than or equal to 1
                  (SqrRoot) ULN,

               -  AST level <5(SqrRoot) ULN, and

               -  ALT level <5 (SqrRoot) ULN.

          -  Adequate hematological function defined by:

             --Absolute neutrophil count (ANC) greater than or equal to 1.5 (SqrRoot) 109/L.

          -  Subjects must be co-enrolled onto protocol 11C0112.

          -  Ability of subject or Legally Authorized Representative to understand and the
             willingness to sign a written informed consent document.

        EXCLUSION CRITERIA:

          -  Patients who have had standard-of-care anti-cancer therapy (e.g.,
             chemotherapy,immunotherapy, endocrine therapy, targeted therapy, biologic therapy,
             tumor embolization, monoclonal antibodies or other investigation agents) within 2
             weeks of enrollment; or, therapy with investigational agents, large field
             radiotherapy, or major surgery within 4 weeks prior to enrollment.

          -  Patients who are currently receiving any other investigational agents for any
             indication.

          -  Patients who are actively receiving broad-spectrum antibiotics or have received such
             within 4 weeks prior to enrollment.

          -  Patients with history of recurrent C. diff colitis

          -  Patients who are on anti-coagulation or anti-platelet medication that cannot be
             interrupted prior to study-specified biopsies, including:

               -  Aspirin that cannot be discontinued for 7 days prior to biopsy

               -  Clopidogrel and ticagrelor that cannot be discontinued for 5 days prior to biopsy

               -  Ticlopidine that cannot be discontinued for 10 days prior to biopsy

               -  Prasugrel that cannot be discontinued for 7 days prior to biopsy

               -  Dipyridamole that cannot be discontinued for at least 2 days prior to biopsy

               -  Cilostazol that cannot be discontinued for at least 3 days prior to biopsy

               -  Coumadin that cannot be discontinued for 7 days prior to biopsy

               -  Low molecular weight heparin (LMWH) that cannot be discontinued >24 hours prior
                  to biopsy and unfractionated heparin (UFH) that cannot be discontinued >4 hours
                  prior to biopsy. NOTE: LMWH or UFH may be used to transition patients on and off
                  the above anti-coagulants, if deemed appropriate by the treating physician.

               -  Oral direct thrombin inhibitor (dabigatran) or direct Factor Xa inhibitor
                  (rivaroxaban, apixaban, and edoxaban) that cannot be discontinued for 4 days
                  prior to biopsy

          -  Any other uncontrolled intercurrent illness or medical condition that per PI
             discretion would limit compliance with study requirements.

          -  Pregnant women are excluded from this study because this study has two mandatory
             biopsies performed for research purposes only and biopsies can have abortifacient
             effect.
      "
NCT02626481,completed,,1,phase 2,['multiple myeloma'],"[""['C90.01', 'C90.02', 'C90.00']""]","['daratumumab', 'dexamethasone']",['CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C'],"
        Inclusion Criteria:

          1. Must be able to understand and voluntarily sign an informed consent form

          2. Must be able to adhere to the study visit schedule and other protocol requirements

          3. Age ≥18 years

          4. Life expectancy > 6 months

          5. Patients must have relapsed myeloma, and previously treated with Bortezomib,
             Lenalidomide, and Pomalidomide treatment, and being resistant or refractory to
             Bortezomib and Lenalidomide and Pomalidomide treatment, defined as follows:

             5.1. Any number of prior therapies 5.2. Patients must have Progressive Disease as
             defined by the IMWG as one of the following (Kyle, 2009):

             Increase of 25% from lowest response value in any one or more of the following:

               -  Serum M-component (absolute increase must be ≥ 0.5 g/100 ml)b and/or Urine
                  M-component (absolute increase must be ≥ 200 mg per 24 h) and/or

               -  Only in patients without measurable serum and urine M-protein levels: the
                  difference between involved and uninvolved

               -  FLC levels (absolute increase must be > 10 mg/l). Bone marrow plasma cell
                  percentage (absolute % must be ≥ 10%)

               -  Definite development of new bone lesions or soft tissue plasmacytomas or definite
                  increase in the size of existing bone lesions or soft tissue plasmacytomas

               -  Development of hypercalcemia (corrected serum calcium > 11.5 mg/100 ml) that can
                  be attributed solely to the plasma cell proliferative disorder 5.3. Patients must
                  have undergone prior treatment with Bortezomib and Lenalidomide and Pomalidomide:

               -  They must have received at least two cycles of therapy

               -  Either at diagnosis or relapse

               -  Either in separate regimens or within the same regimen

               -  The line of treatment with Bortezomib and/or Lenalidomide and/or Pomalidomide
                  does not need to be the very last line of prior therapy

          6. Patients must have a clearly detectable and quantifiable monoclonal M-component value:

             IgG (serum M-component > 10g/l) IgA (serum M-component >5g/l) IgD (serum M-component >
             0.5g/l) Light chain (serum M-component >1g/l or Bence Jones > 200mg/24H) In patients
             without measurable serum and urine M-protein levels when the absolute serum FreeLight
             chain (sFLC) is ≥100 mg/l and an abnormal sFLC K/λ ratio (<0.26 and >1.65) is found
             (Dispenzieri, 2008).

          7. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2

          8. Adequate bone marrow function within 5 days prior to 1st drug intake (cycle1, day 1,
             C1D1), without transfusion nor growth factor support within 5 days prior to 1st drug
             intake , defined as:

             Absolute neutrophils ≥ 1000/mm3 Platelets ≥ 50000/mm3 Haemoglobin ≥ 8.5g/dl

          9. Adequate organ function defined as:

             Serum creatinine clearance (Cockcroft-Gault formula) ≥30 ml/min Serum SGOT or SGPT <
             3.0 X upper limit of normal (ULN) Serum total bilirubin < 2.0 mg/dL

         10. Wash out period of at least 2 weeks from previous antitumor therapy or any
             investigational treatment or 5 half-lives from previous antibodies.

         11. Women who are partners of men and of childbearing potential must be practicing one of
             the following methods of birth control: subcutaneous hormonal implant, levonorgestrel
             releasing intra-uterine system, medroxyprogesterone acetate depot, tubal
             sterilization, ovulation inhibitory progesterone only pills, or sexual intercourse
             with a vasectomized male partner (vasectomy must be confirmed by 2 negative semen
             analyses). Or women will commit to absolute and continuous abstinence confirmed to her
             physician on a monthly basis. Childbearing potential*. Contraception will start during
             therapy including dose interruptions, for 4 months after discontinuation of
             Daratumumab.

               -  Criteria for women of childbearing potential :

        This protocol defines a female of childbearing potential as a sexually mature woman who:

          1. has not undergone a hysterectomy or bilateral oophorectomy or

          2. has not been naturally postmenopausal (amenorrhea following cancer therapy does not
             rule out childbearing potential) for at least 24 consecutive months (ie, has had
             menses at any time in the preceding 24 consecutive months) 12. A woman of childbearing
             potential must have 2 negative serum or urine pregnancy tests at Screening, first
             within 28 days prior to dosing and the second within 48 hours prior to dosing, and
             remain on a highly effective method of birth control. The two methods of reliable
             contraception must include one highly effective method and one additional effective
             (barrier) method. FCBP must be referred to a qualified provider of contraceptive
             methods if needed. The following are examples of highly effective and additional
             effective methods of contraception:

               -  Highly effective methods:

                    -  Intrauterine device (IUD)

                    -  Hormonal (birth control pills, injections, implants)

                    -  Tubal ligation

                    -  Partner's vasectomy

               -  Additional effective methods:

                    -  Male condom

                    -  Diaphragm

                    -  Cervical Cap 13. Serum (urine in the case where serum is not possible in a
                       timely manner) pregnancy test to be performed for all women of childbearing
                       potential regularly during the study,. In addition, a pregnancy test may be
                       done at any time during the study at the discretion of the investigator if a
                       subject misses a period or has unusual menstrual bleeding.

                       14. A woman of childbearing potential must remain on a highly effective
                       method of birth control. Contraception must begin 4 weeks before initiating
                       treatment with Daratumumab, during therapy, during dose interruptions and
                       continuing for 4 months following discontinuation of Daratumumab. Reliable
                       contraception is indicated even where there has been a history of
                       infertility, unless due to hysterectomy.

                       15. A man who has not had a vasectomy and who is sexually active with a
                       woman of childbearing potential must agree to use a barrier method of birth
                       control eg, condom with spermicidal foam/gel/film/cream/suppository, and all
                       men must also not donate sperm during the study, for 4 months following
                       discontinuation of Daratumumab. The exception to this restriction is that if
                       the subject's female partner is surgically sterile, a second method of birth
                       control is not required.

                       16. Subjects affiliated with an appropriate social security system.

        Exclusion Criteria:

          1. Target disease exceptions:

               -  Solitary bone/solitary extramedullary plasmocytoma

               -  Patients with non-secretory MM and non-measurable MM

               -  Evidence of central nervous system (CNS) involvement

          2. Medical history and Concurrent disease:

             o Subjects with prior (≤ 5 years) or concurrent invasive malignancies except the
             following: Adequately treated basal cell or squamous cell skin cancer Incidental
             finding of low grade (Gleason 3+3 or less) prostate cancer Any cancer from which the
             subject has been disease free for at least 3 years.

               -  Subject with known/underlying medical conditions that, in the investigator's
                  opinion would make the administration of the study drug hazardous (ie:
                  uncontrolled diabetes or uncontrolled coronary artery disease)

               -  Any uncontrolled or severe cardiovascular or pulmonary disease determined by the
                  investigator including:

             NYHA functional classification III or IV congestive heart failure LVEF ( Left
             Ventricular Ejection Fraction) ≥45% Uncontrolled angina, hypertension or arrhythmia
             Myocardial infarction in the past 6 months

               -  Subjects with grade 2 or greater peripheral neuropathy (as per NCI-CTCAEv4.0)

               -  Subject is a woman who is pregnant, or breast-feeding, or planning to become
                  pregnant while enrolled in this study or within 4 months after the last dose of
                  any component of the treatment regimen. Or, subject is a man who plans to father
                  a child while enrolled in this study or within 4 months after the last dose of
                  any component of the treatment regimen.

               -  Known positive for HIV or active hepatitis B or C.

               -  Subjects with psychiatric illnesses or social situations that would preclude them
                  understanding the informed consent, study compliance or the ability to tolerate
                  study procedures and/or study therapy

               -  Subjects with known chronic obstructive pulmonary disease (COPD) with a Forced
                  Expiratory Volume in 1 second (FEV1) < 50% of predicted normal. Note that FEV1
                  testing is required for patients suspected of having COPD and subjects must be
                  excluded if FEV1 <50% of predicted normal.

               -  Subjects with a history of moderate or severe persistent asthma within the past 2
                  years (see appendix), or with uncontrolled asthma of any classification at the
                  time of screening (Note that subjects who currently have controlled intermittent
                  asthma or controlled mild persistent asthma are allowed in the study).

          3. Physical and laboratory test findings:

               -  Patients on dialysis or with a Creatinine clearance < 30mL/min

               -  SGOT or SGPT >3ULN

          4. Prohibited prior therapies

               -  Prior local irradiation within two weeks before first dose

               -  Previous anti-CD38 therapy.

          5. Allergies and Adverse Drug Reaction:

             o Hypersensitivity to Dexamethasone that would prohibit treatment with study therapy

          6. Refusal to consent or protected by a legal regime (guardianship, trusteeship)
      "
NCT02626754,terminated,"
    in most sites had difficult to recruitting subjects.
  ",0,phase 2,['renal cell carcinoma'],"[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]",['sunitinib malate'],['CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C.C(C(C(=O)O)O)C(=O)O'],"
        Inclusion Criteria:

          -  Advanced renal cell carcinoma with histology confirmation

          -  Grade III/IV AEs happen during first cycle of sunitinib 50mg/day 4 weeks on followed
             by 2 weeks of rest

          -  ECOG performance status 0 or 1

          -  Appropriate vital organ functions

        Exclusion Criteria:

          -  Prior systemic treatment of mRCC

          -  Patients treated with any neoadjuvant or adjuvant systemic therapy

          -  Major surgery <4 weeks or radiation therapy <2 weeks of starting the study treatment.
             Prior palliative radiotherapy to metastatic lesion(s) is permitted, provided there is
             at least one measurable lesion that has not been irradiated

          -  Pregnant

          -  Allergic history to sunitinib
      "
NCT02627573,terminated,"
    poor recruitment
  ",0,phase 2,"['leukemia, chronic myeloid', 'myelodysplastic syndromes', 'leukemia, myeloid, chronic, atypical, bcr-abl negative']","[""['D46.9', 'D46.C', 'D46.Z']""]","['busulfan', 'fludarabine monophosphate', 'tacrolimus', 'mycophenolate mofetil', 'cyclophosphamide', 'thymoglobulin']","['CS(=O)(=O)OCCCCOS(=O)(=O)C', 'C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)COP(=O)(O)O)O)O)F)N', 'CC1CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC(=O)C(C=C(C1)C)CC=C)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC', 'CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)OCCN3CCOCC3)O', 'C1CNP(=O)(OC1)N(CCCl)CCCl', 'Status: 503']","
        Inclusion Criteria:

          -  Patients must have an indication for allogeneic hematopoietic stem cell
             transplantation

          -  Diagnosis: Chronic myeloid leukemia Myelodysplastic Syndromes Myeloprolipherative
             neoplsm unclassified Atypical chronic myelogenous leukemia

          -  Signed informed consent

          -  Patients with 10/10 HLA-matched unrelated donor available. The donor and recipient
             must be identical by the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and
             HLA-DQB1. Mismatches in these loci are not allowed.

          -  Peripheral blood stem cells as graft source

          -  No second tumors

          -  No prior history of Thymoglobulin exposure or no history of anaphylactic shock after
             Thymoglobulin administration

          -  No severe concurrent illness

        Exclusion Criteria:

          -  Moderate or severe cardiac dysfunction, left ventricular ejection fraction <50%

          -  Moderate or severe decrease in pulmonary function, FEV1 <70% or DLCO<70% of predicted

          -  Respiratory distress >grade I

          -  Severe organ dysfunction: AST or ALT >5 upper normal limits, bilirubin >1.5 upper
             normal limits, creatinine >2 upper normal limits

          -  Creatinine clearance < 60 mL/min

          -  Uncontrolled bacterial or fungal infection at the time of enrollment

          -  Requirement for vasopressor support at the time of enrollment

          -  Karnofsky index <30%

          -  Pregnancy

          -  Somatic or psychiatric disorder making the patient unable to sign informed consent
      "
NCT02628951,completed,,1,phase 2,"['gastric adenocarcinoma', 'gastroesophageal junction adenocarcinoma']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['ramucirumab', 'paclitaxel']",['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C'],"
        Inclusion Criteria:

          1. The patient has histologically or cytologically confirmed gastric carcinoma, including
             gastric adenocarcinoma or GEJ adenocarcinoma. (Patients with adenocarcinoma of the
             distal esophagus are eligible if the primary tumor involves the GEJ.)

          2. The patient has metastatic disease or locally recurrent, unresectable disease.

          3. The patient has measureable or evaluable disease as determined by standard computed
             tomography (CT) or magnetic resonance imaging (MRI) imaging. Examples of evaluable,
             nonmeasurable disease include gastric, peritoneal, or mesenteric thickening in areas
             of known disease, or peritoneal nodules that are too small to be considered measurable
             by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) (48).

          4. The patient has experienced disease progression during treatment or within 4 months
             after the last dose of first-line therapy for metastatic disease.

               -  Acceptable prior chemotherapy regimens for this protocol are combination
                  chemotherapy regimens that include platinum and/or fluoropyrimidine components
                  (acceptable prior platinum agents are cisplatin, carboplatin, or oxaliplatin;
                  acceptable prior fluoropyrimidine agents are 5-FU, capecitabine, or S-1).
                  Regimens including a third agent, such as an anthracycline or a taxane, are
                  acceptable provided a fluoropyrimidine and/or a platinum were used.

               -  Recurrence during or within 6 months of completion of adjuvant chemotherapy
                  (capecitabine, 5-FU, or TS-1) will be considered as first-line chemotherapy.

          5. The patient's disease is not amenable to potentially curative resection.

          6. The patient is ≥18 years of age.

          7. The patient has resolution to Grade ≤1 (or to Grade ≤2 in the case of neuropathy) by
             the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-
             CTCAE), Version 4.03, of all clinically significant toxic effects of prior
             chemotherapy, surgery, radiotherapy, or hormonal therapy (with the exception of
             alopecia).

          8. The patient has an Eastern Cooperative Oncology Group performance status (ECOG PS)
             score of 0 or 1.

          9. The patient has adequate hepatic function as defined by a total bilirubin ≤1.5 mg/dL
             (25.65 µmol/L), and aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0
             times the upper limit of normal (ULN; or 5.0 times the ULN in the setting of liver
             metastases).

         10. The patient does not have:

               -  cirrhosis at a level of Child-Pugh B (or worse) or

               -  cirrhosis (any degree) and a history of hepatic encephalopathy or clinically
                  meaningful ascites resulting from cirrhosis. Clinically meaningful ascites is
                  defined as ascites from cirrhosis requiring diuretics or paracentesis.

         11. The patient has adequate renal function as defined by a serum creatinine ≤1.5 times
             the ULN, or creatinine clearance (measured via 24-hour urine collection) ≥40 mL/minute
             (that is, if serum creatinine is >1.5 times the ULN, a 24-hour urine collection to
             calculate creatinine clearance must be performed).

         12. The patient's urinary protein is ≤1+ on dipstick or routine urinalysis (UA; if urine
             dipstick or routine analysis is ≥2+, a 24-hour urine collection for protein must
             demonstrate <1000 mg of protein in 24 hours to allow participation in this protocol).

         13. The patient has adequate hematologic function, as evidenced by an absolute neutrophil
             count (ANC) ≥1000/µL, hemoglobin ≥9 g/dL (5.58 mmol/L), and platelets ≥100,000/µL.

         14. The patient must have adequate coagulation function as defined by international
             normalized ratio (INR) ≤1.5 and a partial thromboplastin time (PTT) ≤5 seconds above
             the ULN (unless receiving anticoagulation therapy). Patients on full-dose
             anticoagulation must be on a stable dose (minimum duration 14 days) of oral
             anticoagulant or low molecular weight heparin. If receiving warfarin, the patient must
             have an INR ≤3.0 and no active bleeding (that is, no bleeding within 14 days prior to
             first dose of protocol therapy) or pathological condition present that carries a high
             risk of bleeding (for example, tumor involving major vessels or known varices).
             Patients on anticoagulation therapy with unresected primary tumors or local tumor
             recurrence following resection are not eligible.

         15. If the patient has received prior anthracycline therapy as part of his or her
             first-line regimen, the patient is able to engage in ordinary physical activity
             without significant fatigue or dyspnea (equivalent to New York Heart Association Class
             I function) (49).

         16. Because the teratogenicity of ramucirumab is not known, the patient, if sexually
             active, must be postmenopausal, surgically sterile, or using effective contraception
             (hormonal or barrier methods).

         17. Female patients of childbearing potential must have a negative serum pregnancy test
             within 7 days prior to enrollment.

         18. The patient is able to provide informed written consent.

         19. Feasible biopsy site

        Exclusion Criteria:

          1. The patient has documented and/or symptomatic brain or leptomeningeal metastases.

          2. The patient has experienced any Grade 3 to 4 GI bleeding within 3 months prior to
             enrollment.

          3. The patient has experienced any arterial thromboembolic events, including but not
             limited to myocardial infarction, transient ischemic attack, cerebrovascular accident,
             or unstable angina, within 6 months prior to enrollment.

          4. The patient has an ongoing or active infection, symptomatic congestive heart failure,
             unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia,
             uncontrolled thrombotic or hemorrhagic disorder, or any other serious uncontrolled
             medical disorders in the opinion of the treating physician.

          5. The patient has ongoing or active psychiatric illness or social situation that would
             limit compliance with treatment.

          6. The patient has uncontrolled or poorly controlled hypertension (>160 mmHg systolic or
             >100 mmHg diastolic for >4 weeks) despite standard medical management.

          7. The patient has a serious or nonhealing wound, ulcer, or bone fracture within 28 days
             prior to enrollment.

          8. The patient has received chemotherapy, radiotherapy, immunotherapy, or targeted
             therapy for gastric cancer within 2 weeks prior to enrollment.

          9. The patient has received any investigational therapy within 30 days prior to
             enrollment.

         10. The patient has undergone major surgery within 28 days prior to enrollment, or
             subcutaneous venous access device placement within 7 days prior to enrollment.

         11. The patient has received prior therapy with an agent that directly inhibits VEGF
             (including bevacizumab), or VEGF Receptor 2 activity, or any antiangiogenic agent.

         12. The patient is receiving chronic antiplatelet therapy, including aspirin, nonsteroidal
             anti- inflammatory drugs (NSAIDs; including ibuprofen, naproxen, and others),
             dipyridamole or clopidogrel, or similar agents. Once-daily aspirin use (maximum dose
             325 mg/day) is permitted.

         13. The patient has elective or planned major surgery to be performed during the course of
             the clinical trial.

         14. The patient has a known allergy to any of the treatment components.

         15. The patient is pregnant or breastfeeding.

         16. The patient is known to be positive for infection with the human immunodeficiency
             virus (HIV).

         17. The patient has known alcohol or drug dependency.

         18. The patient has a concurrent active malignancy other than adequately treated
             nonmelanomatous skin cancer, other noninvasive carcinoma, or in situ neoplasm.

         19. The patient has a known hypersensitivity to ramucirumab or any of the excipients.

         20. The patient may not have received more than 1 prior therapy in the metastatic setting.
      "
NCT02239926,terminated,"
    difficulty in enrolling subjects
  ",0,phase 2/phase 3,['diarrhea predominant irritable bowel syndrome'],"[""['C81.07', 'C81.00', 'C81.02', 'C81.06', 'C81.03', 'D83.1', 'C81.08']""]","['ranolazine', 'placebo']",['CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O'],"
        Inclusion Criteria

          -  Males and non-pregnant, non-breastfeeding females with established diagnosis of IBS-D
             by modified Rome III criteria (Abdominal Pain Intensity: weekly average of worst daily
             score of >3.0 on a 0 to 10 point scale and Stool Consistency: at least one stool with
             a consistency of Type 5, 6 or 7 Bristol stool score on at least 2 days per week)

          -  18-70 years old

          -  U.S. resident

          -  English-speaking (to provide consent and complete questionnaires)

        Exclusion Criteria

          -  Structural or metabolic diseases/conditions that affect the gastrointestinal system

          -  Unable to withdraw the following medications 48 hours prior to the study:

               -  Drugs that alter GI transit including Lomotil, and bile acid binders such as
                  cholestyramine, prokinetics (e.g. metoclopramide, cisapride and erythromycin),
                  narcotics (e.g. oxycodone, morphine) and anticholinergics (dicyclomine,
                  hyoscyamine).

               -  Analgesic drugs including narcotics, NSAID, cyclooxygenase-2 ( COX2) inhibitors
                  (celecoxib, rofecoxib, and valdecoxib)

               -  GABAergic agents (baclofen)

               -  Benzodiazepines (e.g. lorazepam, alprazolam, and diazepam). Low stable doses of
                  thyroid replacement, estrogen replacement, and low dose aspirin for
                  cardioprotection and birth control pills or depot injections are permissible.

          -  Unable to withdraw the following medications, which are contraindications of
             ranolazine:

               -  Strong Cytochrome P450, Family 3, Subfamily A (CYP3A) inhibitors (e.g.
                  ketoconazole, clarithromycin, and nelfinavir)

               -  CYP3A inducers (e.g. rifampin, phenobarbital, St. John's wort)

          -  Female subjects who are pregnant or breastfeeding.

          -  Current symptoms of severe depression, as measured by Hospital Anxiety And Depression
             Scale ( HADS) score greater than 15.

          -  Clinical evidence (including physical exam, ECG, laboratory studies and review of the
             medical history) of significant cardiovascular, respiratory, renal, hepatic,
             gastrointestinal, hematological, neurological, psychiatric, or other disease that
             interfere with the objectives of the study.

          -  The Corrected QT Interval (QTc) > 490 msec.

          -  Active alcoholics not in remission or known substance abusers.

          -  Liver cirrhosis

          -  Patients with clinically significant hepatic disease.

          -  Major cardiovascular events in the last 6 months.

          -  Participation in another clinical trial (within 30 days).

          -  Incarcerated.
      "
NCT02238925,completed,,1,phase 2,"['acute myeloid leukemia (aml)', 'acute lymphoblastic leukemia (all)', 'myelodysplastic syndrome (mds)']","[""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']"", ""['D46.Z', 'D46.9', 'C94.6', 'D46.C']""]",['cpx-351'],['CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O.C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O'],"
        Inclusion Criteria:

          -  Ability to understand and voluntarily sign an informed consent form

          -  Age ≥ 18 to ≤ 80 years at the time of signing the informed consent form

          -  Life expectancy of at least 3 months

          -  Pathological confirmation by bone marrow documenting the following:

               -  Newly Diagnosed De novo AML according to WHO criteria except for Acute
                  Promyelocytic Leukemia or patients with known favorable cytogenetics (see
                  exclusion)

               -  Newly Diagnosed Secondary AML age <60 years and ≥76 to 80 years, defined as
                  having a history of an antecedent hematologic disorder (myelodysplastic syndromes
                  [MDS], myeloproliferative disease [MPD]or history of cytotoxic treatment for
                  non-hematologic malignancy)

               -  Patients with relapsed/refractory AML regardless of cytogenetic risk

               -  Patients with relapsed/refractory ALL

               -  Patients with MDS (IPSS score ≥ 1.5)

          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2

          -  Able to adhere to the study visit schedule and other protocol requirements

          -  Laboratory values fulfilling the following:

               -  Serum Creatinine ≤ 2.0mg/dL

               -  Hepatic function with a score of < 7 points according to the Child-Pugh System

               -  Serum alanine aminotransferase or aspartate aminotransferase < 3 times the ULN.
                  Note: If elevated liver enzymes are related to disease; contact medical monitor
                  to discuss.

          -  Cardiac ejection fraction ≥50% by ECHO or MUGA

          -  Screening and Baseline QTcF (Fridericia's) less than 470 msec

          -  Patients with second malignancies in remission may be eligible if there is clinical
             evidence of disease stability for a period of greater than 6 months off cytotoxic
             chemotherapy, documented by imaging, tumor marker studies, etc., at screening.
             Patients maintained on long-term non-chemotherapy treatment, e.g., hormonal therapy,
             are eligible.

          -  All men and women must agree to practice effective contraception during the study
             period if not otherwise documented to be infertile.

        Exclusion Criteria:

          -  Patients eligible for participation in Study CLTR0310-301 (Phase III study of CPX-351
             NCT01696084) or who have already participated in that study are not eligible for this
             study.

          -  Patients taking medications known to prolong the QTc interval directly or that
             interact pharmacodynamically with medicines to prolong the QTc interval.

          -  Rhythm abnormalities (other than sinus bradycardia with HR < 50 bpm)

          -  AV block (other than 1o AV Block with PR > 200 msec)

          -  Bundle branch block or QRS ≥ 120 msec

          -  Abnormal T wave morphology (other than slight flattening)

          -  Pathological U waves

          -  Other QRS or T/U morphology preventing accurate determination of QT interval

          -  Patients with unexplained syncope, history of or known risk factors for torsade des
             pointes, including congenital long QT syndrome, or family history of LQTS.

          -  Patients with history of and/or current evidence of myocardial impairment (e.g.
             cardiomyopathy, ischemic heart disease, significant valvular dysfunction, hypertensive
             heart disease, and congestive heart failure) resulting in heart failure by New York
             Heart Association Criteria (Class III or IV staging)

          -  Newly diagnosed patients with Acute promyelocytic leukemia [t(15;17)] or favorable
             cytogenetics, including t(8;21) or inv16

          -  Clinical evidence of active CNS leukemic involvement

          -  Chemotherapy or other investigational anticancer therapeutic drugs within 1 week prior
             to study entry unless AEs have resolved and there is no interference with the
             assessment of efficacy or safety; in the event of rapidly proliferative disease,
             however, the use of hydroxyurea is permitted up to 12 hours before study entry.
             Patients with prior bone marrow or stem cell transplant, considered for inclusion,
             should be discussed with the medical monitor first.

          -  Any serious medical condition or psychiatric illness that would prevent the patient
             from providing informed consent

          -  Patients with prior cumulative anthracycline exposure of greater than 368 mg/m2
             daunorubicin (or equivalent)

          -  Active or uncontrolled infection. Patients with any infection receiving treatment
             (antibiotic, antifungal or antiviral treatment) may be entered into the study but must
             be afebrile and hemodynamically stable for ≥72 hrs. Patients with fevers believed to
             be due to leukemia or MDS are eligible provided a thorough infection work-up is
             negative and the patient is clinically and hemodynamically stable.

          -  Pregnant or lactating women

          -  Hypersensitivity to cytarabine, daunorubicin or liposomal products

          -  History of Wilson's disease or other copper-related metabolic disorder
      "
NCT02230306,terminated,"
    closed due to slow accrual
  ",0,phase 2,['active melanoma brain metastases'],"[""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']""]","['cobimetinib', 'vemurafenib']","['C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O', 'CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F']","
        Inclusion Criteria:

          -  Signed informed consent

          -  Histologically confirmed metastatic melanoma (Stage IV), carrying BRAF V600-mutation

          -  Melanoma must be documented to contain a BRAFV600 mutation by a CLIA approved
             laboratory

          -  At least one measurable intracranial target lesion for which all of the following
             criteria are met:

               1. previously untreated or progressive according to RECIST 1.1 (equal to or greater
                  than 20% increase in longest diameter on baseline scan) after previous local
                  therapy (SRS and/or craniotomy)

               2. immediate local therapy clinically not indicated or patient is not a suitable
                  candidate to receive immediate local therapy (SRS and/or craniotomy)

               3. largest diameter of ≥ 0.5cm but ≤ 4 cm as determined by contrast-enhanced MRI

          -  Prior therapies for extracranial metastatic melanoma including chemo-, cytokine-,
             immuno-, biological- and vaccine-therapy will be allowed but prior BRAF or MEK not
             allowed

          -  ECOG PS 0-2

          -  Life expectancy >12 weeks

          -  Age 18 years or older

          -  Adequate bone marrow function as indicated by the following:

               1. ANC > 1500/µL

               2. Platelets ≥ 100,000/µL

               3. Hemoglobin > 9 g/dL

          -  Adequate renal function, as indicated by creatinine =/< 1.5 x the upper limit of
             normal (ULN)

          -  Adequate liver function, as indicated by bilirubin =/< 1.5 x ULN

          -  AST or ALT < 3 x ULN (patients with documented liver metastases: AST and/or ALT =/< 5
             x ULN)

          -  Able to swallow pills

          -  Negative serum pregnancy test within 7 days prior to commencement of dosing in
             premenopausal women. Women of non-childbearing potential may be included without serum
             pregnancy test if they are either surgically sterile or have been postmenopausal for ≥
             1 year

          -  Fertile men and women must use an effective method of contraception during treatment
             and for at least 6 months after completion of treatment as directed by their
             physician. Effective methods of contraception are defined as those which result in a
             low failure rate (i.e., less than 1% per year) when used consistently and correctly
             (for example implants, injectables, combined oral contraception or intra-uterine
             devices). At the discretion of the Investigator, acceptable methods of contraception
             may include total abstinence in cases where the lifestyle of the patient ensures
             compliance. (Periodic abstinence [e.g., calendar, ovulation, symptothermal,
             post-ovulation methods] and withdrawal are not acceptable methods of contraception.)

        Exclusion Criteria:

          -  Active infection

          -  Prior therapy with BRAFi and/or MEKi

          -  Leptomeningeal disease

          -  Symptomatic brain metastases requiring immediate local interventions such as
             craniotomy or SRS

          -  Increasing corticosteroid dose in 7 days prior to administration of first dose of
             study drug. Symptomatic patients that have stable or decreasing corticosteroid use in
             the past 7 days will be allowed

          -  Current use of therapeutic warfarin

          -  Unresolved toxicity of National Cancer Institute Common Terminology Criteria for
             Adverse Events, version 4.0 (NCI v4.0) [NCI, 2009] Grade 2 or higher from previous
             anti-cancer therapy, except alopecia

          -  Conditions that will interfere significantly with the absorption of drugs

          -  Inability to undergo MRI secondary to metal, claustrophobia, Gadolinium Contrast
             allergy

          -  Pregnant, lactating, or breast feeding women

          -  Prior radiation therapy within the last 14 days

          -  Concomitant malignancies or previous malignancies within the last 5 years, with the
             exception of adequately treated basal or squamous cell carcinoma of the skin or
             carcinoma in situ of the cervix

          -  Unwillingness or inability to comply with study and follow-up procedures

          -  The following foods/supplements are prohibited at least 7 days prior to initiation of
             and during study treatment:

               1. St. John's wort or hyperforin

               2. Grapefruit juice

          -  History of or evidence of retinal pathology on ophthalmologic examination that is
             considered a risk factor for neurosensory retinal detachment, Retinal Vein Occlusion
             (RVO), or neovascular macular degeneration

          -  Uncontrolled glaucoma with intra-ocular pressures > 21mmHg

          -  Serum cholesterol ≥ Grade 2

          -  Hypertriglyceridemia ≥ Grade 2

          -  Hyperglycemia (fasting) ≥ Grade 2

          -  History of clinically significant cardiac dysfunction, including the following:

               1. Current unstable angina

               2. Current symptomatic congestive heart failure of NYHA class 2 or higher

               3. History of congenital long QT syndrome or mean QTcF > 450 msec at baseline or
                  uncorrectable electrolyte abnormalities

               4. Uncontrolled hypertension ≥ Grade 2 (patients with a history hypertension
                  controlled with anti-hypertensives to ≤ Grade 1 are eligible)

               5. Left ventricular ejection fraction (LVEF) below 50%

               6. Uncontrolled Arrhythmias

               7. Myocardial infarction, severe/unstable angina, symptomatic congestive heart
                  failure, cerebrovascular accident or transient ischemic attack within the
                  previous 6 months
      "
NCT03232892,terminated,"
    low accrual
  ",0,phase 2,['non-small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]",['trametinib'],['CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5'],"
        Inclusion Criteria:

          1. Histologically or cytologically confirmed metastatic or unresectable locally advanced,
             non-squamous, NSCLC.

          2. Documented non-synonymous somatic mutation in NF1 in any tumor specimen or cell-free
             DNA assay by Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory.

          3. Received at least one prior line of cancer therapy for the treatment of NSCLC; this
             should include at least one of the following: platinum (carboplatin or cisplatin)
             doublet chemotherapy (acceptable combinations include: paclitaxel, docetaxel,
             abraxane, pemetrexed, gemcitabine, vinorelbine, or etoposide), anti-PD1/PDL1 therapy
             (pembrolizumab, nivolumab, or atezolizumab), or appropriate targeted therapy in
             patients with activating EGFR (osimertinib, erlotinib, gefitinib, or afatinib), ALK
             (alectinib, crizotinib, ceritinib, brigatinib, or loralatinib), or ROS-1 (crizotininb
             or entrectinib) alterations; therapy may be given as monotherapy or in combination
             with other cancer therapy (e.g. bevacizumab, ipilumimab)

          4. Patients with a known activating mutation in epidermal growth factor receptor (EGFR)
             (Exon 19 deletion, G719A, S768I, V769L, T790M, L833F, L858R, L861Q), must have
             progressed or been intolerant to treatment with a first-line EGFR tyrosine kinase
             inhibitor (TKI) (erlotinib, afatinib, or gefitinib). Patients whose tumors were found
             to have an EGFR T790M mutation must also have progressed or been intolerable to
             treatment with osimertinib.

          5. Patients with a known Anaplastic lymphoma kinase (ALK)-rearrangement must have
             progressed or been intolerant to treatment with at least one ALK TKI: crizotinib
             ceritinib, alectinib,brigatinib, or loralatinib

          6. Patients with a known ROS-1-rearrangement must have progressed or been intolerant to
             treatment with crizotinib or entrectinib

          7. Patients with PDL1 level of >= 50%, who do not have an ALK-rearrangement or
             EGFR-mutation, must have progressed or been intolerant to treatment with anti-PD1/PDL1
             therapy (pembrolizumab, nivolumab, or atezolizumab)

          8. Documented disease progression or intolerance to treatment either during or after
             treatment with most recent therapy.

          9. Willingness to undergo research biopsy.

         10. Measurable disease defined by RECIST 1.1 criteria.

         11. Life expectancy of at least 3 months.

         12. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

         13. Age ≥ 18 years.

         14. Resolution of all acute toxic effects of prior chemotherapy, immunotherapy,
             radiotherapy or surgical procedures to National Cancer Institute (NCI) Common
             Terminology Criteria for Adverse Events (CTCAE) Version 4.03 grade 1.

         15. Adequate baseline organ function defined as follows:

             Hematologic:

               -  Absolute neutrophil count: ≥ 1.2 x 10^9/L

               -  Hemoglobin: ≥ 9 g/dL

               -  Platelets: ≥ 100 x 10^9/L

               -  PT/INR and PTT: ≤ 1.5 x upper limit of normal (ULN)

             Hepatic:

               -  Albumin: ≥ 2.5 g/dL

               -  Total bilirubin: ≤ 1.5 x ULN

               -  AST and ALT: ≤ 2.5 x ULN

             Renal:

               -  Creatine: ≤ 1.5 ULN or

               -  Calculated creatinine clearance (calculated by the Cockcroft-Gault formula): ≥ 50
                  mL/min

             Cardiac:

             - Left Ventricular Ejection Fraction (LVEF): ≥ lower limit of normal (LLN) by
             echocardiogram (ECHO) or multiple-gated acquisition (MUGA)

         16. Women of childbearing potential must have a negative serum or urine pregnancy test
             within 3 days prior to study enrollment. The effects of trametinib on the developing
             human fetus are unknown. For this reason and because animal studies with trametinib
             have shown reproductive toxicity, women of child-bearing potential and men must agree
             to use effective methods of contraception (hormonal or barrier method of birth
             control) prior to study entry, for the duration of study participation, and for 4
             months following discontinuation of trametinib. Should a woman become pregnant or
             suspect she is pregnant while she or her partner is participating in this study, she
             should inform her treating physician immediately. Men treated or enrolled on this
             protocol must also agree to use adequate contraception prior to the study, for the
             duration of study participation, and 4 months after completion of study drug
             administration.

         17. Able to swallow and retain orally administered medication and does not have any
             clinically significant gastrointestinal abnormalities that may alter absorption such
             as malabsorption syndrome or major resection of the stomach or bowels.

         18. All prior treatment- related toxicities must be CTCAE (Version 4.03) ≤ Grade 1 (except
             alopecia) at the time of randomization

         19. Ability to understand a written informed consent document, and the willingness to sign
             it.

        Exclusion Criteria:

          1. Known mutation in KRAS at position G12, G13, or Q61.

          2. Symptomatic or untreated leptomeningeal or brain metastases or spinal cord
             compression. Treated brain metastases are allowed as long as they are stable for at
             least 28 days post-treatment.

          3. Pregnant women are excluded from this study; breastfeeding should be discontinued if
             the mother is treated with trametinib . Because there is an unknown but potential risk
             for adverse events in nursing infants secondary to treatment of the mother with
             trametinib, breastfeeding should be discontinued if the mother is treated with
             trametinib.

          4. History of another malignancy. Exception: Subjects who have been disease-free for 3
             years, or subjects with a history of completely resected non-melanoma skin cancer
             and/or subjects with indolent second malignancies are eligible.

          5. Any serious and/or unstable pre-existing medical disorder (aside from malignancy
             exception above), psychiatric disorder, or other conditions that could interfere with
             subject's safety, obtaining informed consent or compliance to the study procedures.

          6. The subject has received cytotoxic chemotherapy, molecular targeted therapy, or
             immunotherapy within 21 days before the first dose of study drug (trametinib).

          7. Prior treatment with MEK inhibitor.

          8. History of interstitial lung disease or pneumonitis.

          9. Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
             chemically related to study drug, or excipients or to dimethyl sulfoxide (DMSO).

         10. Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity,
             biologic therapy, or immunotherapy within 21 days prior to study enrollment and/or
             daily or weekly chemotherapy without the potential for delayed toxicity within 14 days
             prior to study enrollment.

         11. History of retinal vein occlusion (RVO).

         12. Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C
             Virus (HCV) infection (subjects with laboratory evidence of cleared HBV and HCV
             infection will be permitted).

         13. History or evidence of cardiovascular risk including any of the following:

               -  LVEF < LLN

               -  A QT interval corrected for heart rate using the Bazett's formula (QTcB) ≥ 480
                  msec;

               -  History or evidence of current clinically significant uncontrolled arrhythmias.

               -  Clarification: Subjects with atrial fibrillation controlled (defined as not
                  requiring change in cardiac drug dosing, emergency room visit, or hospital
                  admission) for > 30 days prior to dosing are eligible.

               -  History of acute coronary syndromes (including myocardial infarction and unstable
                  angina), coronary angioplasty, or stenting within 6 months prior to study
                  enrollment.

               -  History or evidence of current ≥ Class II congestive heart failure as defined by
                  New York Heart Association (NYHA).

               -  Treatment refractory hypertension defined as a blood pressure of systolic > 140
                  mmHg and/or diastolic > 90 mm Hg which cannot be controlled by anti-hypertensive
                  therapy;

               -  Patients with intra-cardiac defibrillators.
      "
NCT03231176,completed,,1,phase 2,['biliary tract cancer'],"[""['C24.9', 'C24.8']""]","['varlitinib', 'capecitabine']","['CC1COC(=N1)NC2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=NC=CS5)Cl', 'CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O']","
        Inclusion Criteria:

          1. Patients with histologically or cytologically confirmed advanced (unresectable) or
             metastatic biliary tract cancer, including intrahepatic or extrahepatic
             cholangiocarcinoma, gallbladder cancer and carcinoma of the Ampulla of Vater. This
             includes clinical diagnosis of biliary tract cancer with histological confirmation of
             adenocarcinoma.

          2. Patients who have received and failed one and only one prior line of systemic
             treatment or advanced or metastatic disease with radiologic evidence of disease
             progression. This prior line of systemic treatment must also contain gemcitabine

          3. Patients with radiographically measurable disease based on RECIST v1.1.

          4. Patients with no evidence of biliary duct obstruction, unless obstruction is
             controlled by local treatment or, in whom the biliary tree can be decompressed by
             endoscopic or percutaneous stenting with subsequent reduction in bilirubin to below
             1.5 x upper level of normal (ULN).

          5. Patients who are or older than 18 years of age and of or younger than 99 years of age
             at the time when written informed consent is obtained, and are able to understand and
             willing to sign the informed consent form.

          6. Patients have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
             1.

          7. Patients with adequate organ and hematological function:

               1. Hematological function, as follows:

                    -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L

                    -  Platelet count ≥ 100 x 109/L

               2. Renal functions, as follows:

                    -  Estimated glomerular filtration rate or creatinine clearance > 50
                       mL/min/1.73m2

               3. Hepatic function, as follows:

                    -  Total bilirubin ≤ 1.5 x ULN

                    -  AST and ALT ≤ 5 x ULN

        Exclusion Criteria:

          1. Patients are currently on or have received anti-cancer therapy within the past 3
             weeks.

          2. Patients are currently on or have received radiation or local treatment within the
             past 3 weeks for the target lesion(s).

          3. Patients have had major surgical procedures within 14 days prior to study entry.

          4. Patients have a metastatic brain lesion(s), including asymptomatic and well controlled
             lesion(s).

          5. Patients have malabsorption syndrome, diseases significantly affecting
             gastrointestinal function, resection of the stomach or small bowel, or difficulty in
             swallowing and retaining oral medications.

          6. Patients have any history or presence of clinically significant condition which in the
             opinion of the Investigator could jeopardize the safety of the patient or the validity
             of the study results.

          7. Patients have any history of other malignancy unless in remission for more than 1
             year. (skin carcinoma and carcinoma-in-site of uterine cervix treated with curative
             intent is not exclusionary).

          8. Female patients are pregnant or breast feeding.

          9. Patients who been previously treated with varlitinib or have been previously treated
             with capecitabine as first line therapy for advanced or metastatic disease. For
             patients who have previously received capecitabine as radiosensitizer or as part of
             their adjuvant therapy and their disease has relapsed for more than 6 months after
             their last dose of capecitabine adjuvant therapy, their capecitabine therapy will not
             be considered as a line of systemic chemotherapy for metastatic/advanced disease, and
             thus they can participate in the study.

         10. Patients have received any investigational drug (or have used an investigational
             device) within the last 14 days before receiving the first dose of study medication.

         11. Patients have unresolved or unstable serious toxicity (≥CTCAE 4.03 Grade 2), with the
             exception of anemia, asthenia, and alopecia, from prior administration of another
             investigational drug and/or prior cancer treatment.

         12. Patients have a known positive test for HIV, active hepatitis C, or hepatitis B
             infection with hepatitis B virus deoxyribonucleic acid exceeding 2000 IU/mL.

         13. Patients have a known history of drug addiction within last 1 year, on the basis that
             there could be a higher risk of non-compliance to investigational product.

         14. Patients need continuous treatment with proton pump inhibitors during the study
             period.

         15. Patients have a baseline corrected QT interval QTc> 450 ms or patients with known long
             QT syndrome, torsade de pointes, symptomatic ventricular tachycardia, an unstable
             cardiac syndrome in the past 3 months before screening visit, > class 2 New York Heart
             Association heart failure, > grade 2 Canadian cardiovascular society angina pectoris,
             or receiving quinidine, procainamide, disopyramide, amiodarone, dronedarone, arsenic,
             dofetilide, or sotalol methadone.
      "
NCT03256721,terminated,"
    due to the enrollment was slow and exceeded the expected enrollment time
  ",1,phase 2,['nonsmall cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['apatinib/docetaxel/pemetrexed', 'docetaxel/pemetrexed']","['Status: 400', 'Status: 503']","
        Inclusion Criteria:

          1. Age：18~75 years;

          2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          3. Subjects with histologically or cytologically confirmed locally advanced or advanced
             NSCLC who have previously received no more than one lines treatment before
             participating；

          4. Subjects with at least one measurable lesion as defined by RECIST (version 1.1),which
             is confirmed by computed tomography (CT) scan or MRI .

          5. EGFRˉ,and ALK mutation in the negative or unknown；

          6. Subjects without brain metastases or asymptomatic brain metastases, and not needing
             for dehydrating agents or corticosteroids to control intracranial symptoms;

          7. Survival expectation≥ 3 months;

          8. The main organ function is normal;

          9. Females of childbearing potential must be a pregnancy test in 7 days before
             participating ( including serum or urine), and the results were negative.

         10. Subjects provided written informed consent before participating,Willing and able to
             comply with all aspects of the protocol

        Exclusion Criteria:

          1. Small Cell Lung Cancer;

          2. Subjects with symptomatic brain metastases;

          3. Survival expectation < 3 months;

          4. Blood transfusion is required in the first dose of drug treatment within 14 days ;

          5. The interval of subjects had received chemotherapy, biotherapy, radiotherapy or other
             anticancer therapies in the first dose of drug treatment within 21 days(excluding
             palliative radiotherapy);

          6. The risk of active bleeding;

          7. Subjects with uncontrolled blood pressure with medication (140/90 mmHg)

          8. Laboratory values and organ functions ： （1）Hematologic insufficiency:

               1. Hemoglobin (Hb)<8.5 g/dL，

               2. Absolute neutrophil count (ANC)≤1.5×109/L，

               3. Platelet count (PLT)< 100×109/L； （2）Insufficient liver function:

               1. Bilirubin > 1.5×the upper limit of normal (ULN)

               2. Alanine aminotransferase (ALT), or Aspartate aminotransferase (AST) >3.0×(ULN),
                  When liver metastases,Bilirubin > 1.5×ULN, ALT or AST >5.0×(ULN.

               3. serum creatinine ≤1.0×（ULN）, or creatinine clearance > 50 mL/min( calculated per
                  the Cockcroft and Gault formula) (3) Subjects with positive for HBV
                  surfaceantigen ( HBsAg)or anti-hcv (4)Subjects with Interstitial lung disease
                  (5)Insufficient renal function: serum creatinine≥ 1.5×（ULN）, or creatinine
                  clearance <60 mL/min

          9. impairment of heart function: (1)Left ventricular ejection fraction (LVEF) <45% (LVEF
             evaluation is not required for subjects have no history of congestive heart failure),
             (2)Unstable angina, (3)Severe arrhythmia, (4)NYHA III or IVgrade of congestive heart
             failure, (5) Subjects with miocardial infarction within the last 12 months before
             entering the trial, (6)Pericardial effusion,

         10. Subjects with liver fibrosis or hepatic cirrhosis

         11. (1)Subjects with other active malignancy (except for definitively treated non melanoma
             skin cancer,carcinoma in-situ of the cervix,or other cancers that are treated with
             curative treatment and have no signs of recurrence for at least 5 years ) ,
             (2)Subjects with dysphagia,malabsorption,chronic gastrointestinal diseases,or other
             medical history may hinder compliance and / or experimental drug absorption,

         12. Subjects with major surgery in the first dose of drug treatment within 28 days,

         13. Subjects with positive foknown human immunodeficiency virus。
      "
NCT03259516,terminated,"
    slow recruitment rate
  ",0,phase 1/phase 2,['myelodysplastic syndromes'],"[""['D46.9', 'D46.C', 'D46.Z']""]","['nivolumab', 'azacitidine', 'fludarabine', 'cyclophosphamide', 'cytarabine', 'all trans retinoic acid', 'sildenafil', 'melphalan']","['Status: 503', 'C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N', 'C1CNP(=O)(OC1)N(CCCl)CCCl', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O', 'CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C', 'CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C', 'C1=CC(=CC=C1CC(C(=O)O)N)N(CCCl)CCCl']","
        Inclusion Criteria:

          -  Patients with myelodysplastic syndrome (MDS) (up to 20% blasts) of any risk. Patients
             with lower risk MDS (low and int-1 by IPSS) should have failed prior
             non-hypomethylating agent therapy (ie growth factors or lenalidomide). Patients with
             higher risk MDS (int-2 or high by IPSS) should have failed prior at least one therapy
             with a hypomethylating agent or Ara-C.

          -  Age 18 years or older.

          -  No severe organ dysfunction: creatinine <=2.5 x ULN; serum bilirubin <=2.5 x ULN; AST
             and ALT <=5 x ULN.

          -  Karnofsky index >=70%

          -  Females of childbearing potential must have a negative serum or urine beta human
             chorionic gonadotrophin (beta-hCG) pregnancy test result within 24 hours prior to the
             first dose of treatment and must agree to use an effective contraception to avoid
             pregnancy for 24 weeks

          -  Males who have partners of childbearing potential must agree to use an effective
             contraceptive method during the study and for 24 weeks after the last dose of
             nivolumab.

        Exclusion Criteria:

          -  Another malignancy requiring treatment at the time of inclusion

          -  History of interstitial lung disease or pneumonitis

          -  Patients with any other known concurrent severe and/or uncontrolled medical condition
             (e.g. uncontrolled diabetes; cardiovascular disease including congestive heart failure
             NYHA Class III or IV, myocardial infarction within 6 months, and poorly controlled
             hypertension; chronic renal failure; or active uncontrolled infection) which, in the
             opinion of the investigator could compromise participation in the study

          -  Active, known or suspected autoimmune disease requiring treatment at the time of
             inclusion

          -  Pregnancy or breastfeeding

          -  Patients unwilling or unable to comply with the protocol

          -  Somatic or psychiatric disorder making the patient unable to sign informed consent

          -  Prior treatment with anti-PD-1, anti-PD-L1, or anti-CTLA4 therapy
      "
NCT02585388,terminated,"
    treatment toxicity
  ",0,phase 2,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['vinorelbine', 'letrozole', 'anastrozole']","['CCC1=CC2CC(C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC', 'C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3', 'CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N']","
        Inclusion Criteria:

          1. Age ≥ 50 years.

          2. Histologically proven breast cancer.

          3. Progesterone and /or oestrogene receptors positive.

          4. HER2 negative on primary tumour.

          5. Patient taking hormonotherapy, in progression, already treated by at least one line of
             anti-aromatase non-steroidal hormonotherapy and by at least on line of chemotherapy.

          6. Patient having to begin a second or third line of chemotherapy.

          7. Presence of one or several measurable(s) or assessable(s) metastatic lesion(s).In case
             of isolated bone lesion (s): need to have a non-irradiated with an osteolytic
             component for be considered as lesion (s) target (s) and having an elevation of the
             CA15-3.

          8. Post menopausal woman.

          9. ECOG 0, 1 or 2.

         10. Adequate biological function.

               -  Neutrophil ≥ 1,5.E9/L

               -  Platelets ≥ 100.E9/L

               -  Creatinine clearance ≥ 30 mL/min

               -  Total bilirubin ≤ 1,5 x the upper limit of normal (ULN)

               -  Alkaline phosphatase ≤ 2,5 x ULN

               -  ALT, AST ≤ 1,5 x ULN in the absence of liver metastases or ≤ 3 x ULN if liver
                  metastases.

         11. Patient with a life expectancy greater than 3 months.

         12. Signed informed consent before enrollment.

         13. affiliation to a social security scheme

        Exclusion Criteria:

          1. Patient with located or single metastatic tumoral relapse, accessible to a surgical
             treatment.

          2. Patient having already received more 2 lines of chemotherapy for metastatic or
             advanced decease

          3. Patient having already received a treatment by Navelbine®

          4. Patient requiring an immediate located radiotherapy for analgesic action

          5. Patient with non-irradiated cerebral or symptomatic metastasis, symptomatic pulmonary
             carcinomatosis lymphangitis

          6. Simultaneous administration of another chemotherapy hormonotherapy or anti-tumoral
             drug

          7. Patient having already received another treatment ongoing evaluation within the 30
             days before the screening visit

          8. Known positive serology HIV

          9. Previous cancer within 5 years before the entry in the study, excepted an in situ
             carcinoma of the cervix or a spino or basal cell carcinoma of the skin or a
             nonmelanoma skin cancer with an adequate treatment.

         10. Any serious concomitant pathology and / or uncontrolled could compromise participation
             in the study (including uncontrolled diabetes, uncontrolled hypertension, severe
             infection, profound malnutrition, unstable angina or congestive heart failure - class
             III or IV according to the New York Heart Association - ventricular arrhythmias,
             progressive coronary artery disease, myocardial infarction within the last six months,
             chronic liver or kidney disease, a progressive ulceration of the digestive tract
             above, CNS disorders).

         11. Disorder of gastrointestinal function (GI) or pathology likely to significantly
             interfere with the absorption of Navelbine, of Letrozole or Anastrozole (eg.
             Ulcerative disease, uncontrolled nausea, vomiting, diarrhea, syndrome malabsorption,
             or resection of the small intestine).

         12. Known hypersensitivity to letrozole, anastrozole, vinorelbine or other vinco-alkaloids
             or any other component.

         13. Patient with fructose intolerance, galactose, a Lapp lactase deficiency or
             malabsorption of glucose and galactose (rare hereditary disease).

         14. Patient with a history of poor compliance with medical treatment.

         15. Patient can not be monitored regularly for family reasons, geographical, social or
             psychological.

         16. Patient with altered mental status would not allow him to understand the study or give
             informed consent .
      "
NCT02581930,"active, not recruiting",,0,phase 2,"['metastatic melanoma', 'recurrent cutaneous melanoma', 'stage iv cutaneous melanoma ajcc v6 and v7']","[""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']"", ""['G47.13', 'J01.41', 'K11.22', 'K12.0', 'N96', 'F33.8', 'G03.2']"", ""['A06.7', 'A22.0', 'A26.0', 'A32.0', 'A36.3', 'A43.1', 'B38.3']""]",['ibrutinib'],['C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N'],"
        Inclusion Criteria:

          -  Histologically confirmed melanoma of cutaneous primary; metastatic melanoma from
             unknown primary are allowed

          -  Measurable disease, defined as at least one lesion that can be accurately measured in
             at least one dimension (longest diameter to be recorded for non-nodal lesions and
             short axis for nodal lesions) as >= 10 mm (>= 1 cm) with spiral computed tomography
             (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam

          -  Stage IV disease

          -  If BRAFV600-mutant, documented refractory disease to at least one BRAF inhibitor
             (dabrafenib or vemurafenib) and/or a MEK inhibitor (trametinib or cobimetinib),
             defined as progression of measurable disease as per Response Evaluation Criteria in
             Solid Tumors (RECIST) criteria while on treatment; subjects with MAPK
             inhibitor-intolerance are eligible if they meet criteria

          -  Documented disease refractory to at least one PD1/PD-L1 inhibitor, defined as disease
             progression following at least 2 infusions of the same drug; radiographic disease
             progression will be documented by the institutional radiologist based on any
             radiographic evidence (magnetic resonance imaging [MRI], computed tomography [CT],
             positron emission tomography [PET], or other modalities, etc.) of disease progression
             on two separate radiographic scans assessment obtained at least 4 weeks apart; this
             minimum 4-week interval is required to define PD-1 inhibitor resistance based on
             imaging; alternatively, clinical disease progression may be documented on examination
             by the treating investigator

          -  Prior treatment-related toxicity resolved to =< grade 1 or baseline with the exception
             of alopecia and permanent grade =< 2 toxicities related to prior immune checkpoint
             inhibitor treatment (e.g. PD-1/PD-L1, CTLA-4, CD40, LAG3) treatment with the review
             and approval by the lead principal investigator (PI)

          -  Prior radiation allowed (no restriction on amount); measurable lesion(s) may not have
             been previously irradiated

          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)

          -  Life expectancy of greater than 3 months

          -  Hemoglobin >= 9.0 g/dL

          -  Absolute neutrophil count (ANC) > 1,500/uL

          -  Platelets > 100,000/uL

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =< 2 x upper limit of normal (ULN); =< 5 x ULN, if liver metastasis

          -  Total bilirubin =< 1.5 x ULN unless Gilbert's syndrome of disease infiltration of the
             liver is present

          -  Creatinine clearance estimated glomerular filtration rate (GFR) >= 30 mL/min/1.73 m^2
             (Cockcroft-Gault)

          -  Patients with brain metastases are allowed provided that:

               -  No leptomeningeal disease is present

               -  Intracranial disease is controlled by prior local therapies (craniotomy,
                  stereotactic radiosurgery, whole brain irradiation), as evidenced by brain MRI 4
                  weeks post treatment indicating no new intracranial disease

               -  Stable or decreasing dose of steroids provided patient on =< 20 mg of prednisone
                  or its equivalent daily

          -  Ibrutinib should be held at least 3 to 7 days pre- and post-surgery, depending upon
             the type of surgery and risk of bleeding

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry, for
             the duration of study participation and for 90 days after completion of ibrutinib
             administration; should a woman become pregnant or suspect she is pregnant while she or
             her partner is participating in this study, she should inform her treating physician
             immediately; men treated or enrolled on this protocol must also agree to use adequate
             contraception prior to the study, for the duration of study participation, and 90 days
             after completion of ibrutinib administration

          -  Negative serum pregnancy test within 7 days of treatment initiation with ibrutinib in
             women of childbearing potential (WOCBP)

          -  Ability to swallow oral medications

          -  Patients with autoimmune disease requiring systemic corticosteroid treatment (and
             previously ineligible to receive systemic immunotherapies for melanoma) are allowed on
             condition that they do not receive more than 20 mg of daily dose methylprednisolone,
             prednisone, or its equivalent; this does not include autoimmune diseases caused by
             previous immunotherapy treatments for melanoma that require ongoing treatment with
             corticosteroids (e.g. autoimmune colitis or autoimmune hepatitis receiving
             corticosteroids)

          -  Willing to consent to allow access to known archival tumor tissue (NOTE: designated
             pathologist from participating site OR lead principal investigator must sign-off to
             ensure ""sufficient"" tumor should be available for support of tumor imaging studies
             [multi-color immunofluorescence])

          -  If archival tumor tissue from a metastatic melanoma lesion is unavailable OR
             designated pathologist from participating site cannot sign-off to ensure that
             ""sufficient"" tumor is available from existing archival tumor block for support of
             tumor imaging studies, patients must be willing to consent to undergo a biopsy to
             collect metastatic tumor tissue; collection of fresh biopsy tissue does not guarantee
             enrollment, unless the pathologist from the participating site signs-off that
             ""sufficient"" tumor has been collected

          -  Ability to understand and the willingness to sign a written informed consent document

          -  Subjects who are unable to tolerate BRAF inhibitor and/or MEK inhibitor therapy due to
             grade >= 2 toxicity (Common Terminology Criteria for Adverse Events [CTCAE] version
             [v]4.0) from these agents, irrespective of antitumor response, are eligible on
             condition that: (a) toxicities persisted despite change from doublet to singlet
             therapy (i.e. from concurrent BRAF inhibition plus MEK inhibition to BRAF inhibition
             alone), (b) toxicities are attributed to a class effect, and therefore switch from one
             drug to another is expected to induce the same type of toxicity (e.g. ocular
             toxicities or cardiac dysfunction from MEK inhibitor), (c) drug-specific toxicities
             that do not resolve with switch from one BRAF inhibitor to another (i.e. dabrafenib to
             vemurafenib, or vice versa), will be eligible for enrollment in 9922; in other words,
             patients will be allowed to enroll into the NCI9922 study despite lack of progression
             to MAPK inhibitor treatments, on condition that grade 2 or higher toxicities
             attributed to MAPK inhibitors resolve to grade 1, or less, at the time of study
             enrollment

        Exclusion Criteria:

          -  Patients with melanoma of mucosal or ocular primary

          -  Patients who have had chemotherapy or immunotherapy within 4 weeks (6 weeks for
             nitrosoureas or mitomycin C) or radiotherapy within 2 weeks prior to cycle 1 day 1;
             patients who have had tyrosine kinase inhibitors (such as Braf or MEK inhibitors)
             within 15 days of cycle 1 day 1

          -  Patients who are receiving any other biologic, cytotoxic or investigational agents

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to ibrutinib (difficulty breathing, lip swelling, itching or rash)

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Pregnant and breastfeeding women are excluded from this study; breastfeeding should be
             discontinued if the mother is treated with ibrutinib

          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
             therapy are eligible; unless the patient's cluster of differentiation (CD)4+ count is
             below the institutional lower limit of normal

          -  Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura (ITP)
             resulting in (or as evidenced by) declining platelet or hemoglobin (Hgb) levels within
             the 4 weeks prior to first dose of study drug

          -  Presence of transfusion-dependent thrombocytopenia

          -  Need for daily corticosteroids at high doses (prednisone >= 20 mg daily, or an
             equivalent) is prohibited from 28 days prior to first dose and during treatment with
             ibrutinib; brief (up to 7 days) and episodic use of systemic corticosteroids for other
             general conditions (e.g. pre-medication for radiographic imaging due to intravenous
             [IV] contrast allergy, chronic obstructive pulmonary disease [COPD] exacerbation,
             poison ivy, etc.) is allowed

          -  Prior exposure to ibrutinib or other ITK inhibitors

          -  History of prior malignancy, with the exception of the following:

               -  Non-melanoma skin cancers, non-invasive bladder cancer, and carcinoma in situ of
                  the cervix

               -  Prostate cancer not under active systemic treatment other than hormonal therapy
                  and with documented undetectable prostate-specific antigen (PSA) (< 0.2 ng/mL)

               -  Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) provided
                  patient has isolated lymphocytosis (Rai stage O), and does not require systemic
                  treatment (for ""B"" symptoms, Richter's transformation, lymphocyte doubling time
                  [< 6 months], lymphadenopathy or hepatosplenomegaly)

               -  Lymphoma of any type of hairy-cell leukemia provided patient is not on active
                  systemic treatment and is in complete remission, as evidenced by PET/CT scans and
                  bone marrow biopsies for at least 3 months

               -  History of malignancy provided that patient has completed therapy and is free of
                  disease for >= 2 years; if patient had other malignancy within the last 2 years
                  from which he may have been completely cured by surgery alone, he may be
                  considered to be enrolled on condition that the risk of development of distant
                  metastatic disease based on American Joint Committee on Cancer (AJCC) staging
                  system is less than 30%

          -  Currently active clinically significant cardiovascular disease, such as uncontrolled
             arrhythmia, congestive heart failure, any class 3 or 4 cardiac disease, as defined by
             the New York Heart Association Functional Classification, or history of myocardial
             infarction within 6 months prior to first dose with study drug

          -  Unable to swallow capsules, or disease significantly affecting gastrointestinal
             function and/or inhibiting small intestine absorption, such as malabsorption syndrome,
             resection of portions of small bowel larger than 3 feet, or poorly controlled
             inflammatory bowel disease affecting the small intestine

          -  Known serologic status reflecting active hepatitis B or C infection; patients that are
             hepatitis B core antibody positive, but antigen negative, will need a negative
             polymerase chain reaction (PCR) prior to enrollment (NOTE: hepatitis B antigen or PCR
             positive patients will be excluded)

          -  History of stroke or intracranial hemorrhage within 6 months prior to enrollment

          -  Current life-threatening illness, medical condition, or organ system dysfunction,
             which, in the investigator's opinion, could compromise the patient's safety, or put
             the study at risk

          -  Received anticoagulation therapy with warfarin, or equivalent vitamin K antagonists,
             within the last 28 days prior to day 1 of ibrutinib; patients with familial
             coagulopathic diseases (e.g. hemophilia, von Willebrand disease) are also excluded; if
             applicable, subjects must discontinue fish oil and vitamin E supplements within 7 days
             prior to initiating ibrutinib therapy

          -  Subjects with known hepatic insufficiency (i.e. Child-Pugh score A [mild], Child-Pugh
             score B [moderate] or Child-Pugh score C [severe]) according to Child-Pugh criteria

          -  Subjects who received a strong cytochrome P450 (CYP) 3A inhibitor within 7 days prior
             to the first dose of ibrutinib or subjects who require continuous treatment with a
             strong CYP 450 3A inhibitor
      "
NCT02581839,completed,,0,phase 2,"['metastatic breast cancer', 'brain metastases']","[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['eribulin mesylate', 'pre-medication: zofran', 'pre-medication: decadron']",['CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O2)OC(C9OC)CC(CN)O.CS(=O)(=O)O'],"
        Inclusion Criteria:

          -  Female with histologically confirmed breast cancer.

          -  Patients must have evidence of metastatic disease (non measurable disease is
             eligible).

          -  Radiologically confirmed metastatic brain lesion by MRI.

          -  Brain metastases from breast cancer with or without prior WBRT, STS of surgical
             resection. Progression must be documented in an at least one lesion untreated by SRS
             or in any site after surgery or WBRT.

          -  Patients must be neurologically stable and with stable dose steroids and
             anticonvulsants for at least 1 week prior to obtaining the baseline MRI of the brain,
             and/or at least 1 week prior to beginning study treatment.

          -  No presence of uncontrolled systemic disease or tumor related complication which, in
             opinion of the investigator, might restrict life expectancy to less than 3 months.

          -  Patients may not be on any cytotoxic chemotherapy or hormonal treatment for breast
             cancer during protocol treatment. Trastuzumab is allowed in HER2 positive patients).

          -  Able to comprehend and willing to sign an Informed Consent Form (ICF)

          -  Karnofsky performance status ≥ 60

          -  No brain radiation therapy > 4 weeks

          -  No chemotherapy for > 3 weeks before planned start of protocol treatment

          -  Adequate bone marrow, renal, and hepatic function, per local reference laboratory
             ranges as follows:

               -  Absolute neutrophil count (ANC) ≥ 1,500/mm3

               -  Platelet count ≥ 100,000/mm3

               -  Hemoglobin ≥ 9 g/dL

               -  Calculated creatinine clearance (CrCl) ≥ 30mL/min (Cockcroft-Gault method)

               -  Patients with normal, mild or moderate hepatic dysfunction are eligible.

               -  Calcium <10.1 mg/dL (corrected to serum albumin as follows: Corrected Calcium =
                  (0.8 x (4 - patient albumin)) + serum Ca

          -  Females of child-bearing potential must have a negative pregnancy test at screening
             and agree to take appropriate precautions to avoid pregnancy (double barrier method of
             birth control or abstinence) from screening through 3 months after the last dose of
             treatment

          -  Able to undergo MRI evaluation with and without gadolinium contrast

        Exclusion Criteria:

          -  Patients with the presence of an active infection, abscess or fistula

          -  Known leptomeningeal disease or CNS midline shifts.

          -  Any evidence of severe or uncontrolled systemic disease such as clinically significant
             cardiovascular, pulmonary, hepatic, renal or metabolic disease.

          -  Severe conduction abnormality including significant QTc prolongation >450ms.

          -  Patients with grade 3/4 peripheral neuropathy.

          -  Patients with pacemaker or an ICD devices.

          -  Previous treatment with eribulin mesylate.
      "
NCT02588781,"active, not recruiting",,1,phase 2,['colorectal cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]",['pemetrexed'],['C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O'],"
        Inclusion Criteria:

          1. Subject is at least 20 years of age.

          2. Written and voluntary informed consent understood, signed and dated.

          3. They must have refractory or progressive colorectal cancer for which there is no
             further curative therapy available.

          4. Subject able to adhere to the study visit schedule and other protocol requirements.

          5. ECOG 0-2

          6. At least one measurable lesion that can be accurately assessed by imaging or physical
             examination at baseline and following up visits.

          7. Must have a life expectancy of 3 months or more

          8. Demonstrate adequate organ function

          9. Negative urine or serum pregnancy test within 28 days of study treatment

         10. Be willing to provide fresh tissue for biomarker analysis, and, based on the adequacy
             of the tissue sample quality for assessment of biomarker status.

        Exclusion Criteria:

          1. ECOG ≥ 3

          2. History of malignancy in the last 5 years.

          3. Subject has known historical or active infection with HIV, hepatitis B, or hepatitis
             C.

          4. Breast-feeding or pregnant female

          5. Patients can not the administration of Folic acid or Vitamin B12.

          6. Before treatment with Pemetrexed.

          7. Patients who can not swallow oral medication.

          8. The most recent treatment with the clinical trial for the drug for 14 days prior to
             enrollment.

          9. Systemic chemotherapy within three weeks after the administration of the last before
             the test treatment, radiation therapy patients who had been administered.

         10. Except for the hair loss, it is induced before cancer treatment, all of toxicity in
             progress (> CTCAE1 grade).

         11. Upper GI bleeding within registration before 4 weeks of Bowel obstruction or CTCAE3 or
             4 grade.

         12. Subject who experienced a recent myocardial infarction, including severe/unstable
             angina pectoris, coronary/peripheral artery bypass graft, uncontrolled hypertension,
             clinically significant cardiac dysrhythmia or clinically significant electrocardiogram
             (ECG) abnormality, significant or uncontrolled cardiovascular disease CHF, and
             cerebrovascular accident or transient ischemic attack, or seizure disorder in the past
             year.
      "
NCT02586350,completed,,1,phase 2/phase 3,['medullary thyroid carcinoma'],"[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['anlotinib', 'placebo']",['CC1=CC2=C(N1)C=CC(=C2F)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC'],"
        Inclusion Criteria:

          1. Signed and dated informed consent

          2. Histological documentation of medullary thyroid carcinoma(MTC),Unable to surgery(Stage
             IV) or metastasis ,With measurable disease (using RECIST1.1)

          3. ECOG PS:0-1,Life expectancy of more than 6 months

          4. main organs function is normal

        Exclusion Criteria:

          1. Prior treatment with Anlotinib or VEGFR-targeted therapies(such as
             Vandetanib,Cabozantinib,Lenvatinib,Sunitinib,Sorafenib etc.)

          2. Subjects received radiotherapy external exposure within 3 months prior to the first
             dose of study drug or plan to be received any anti-cancer treatment during study

          3. Patients suffering from other malignancies currently or within 5 years, except for
             cured cervical carcinoma in situ, non-melanoma skin cancers and superficial bladder
             cancer [ Ta (non-invasive carcinoma), Tis (carcinoma in situ) and T1 (carcinoma
             invasion into lamina propria) ]

          4. CTCAE(4.0) Grade 1 or higher non-remission toxicity induced by any other previous
             treatments，excluding alopecia and Grade 2 or lower neurotoxicity induced by
             oxaliplatin

          5. Patients with factors that could affect oral medication (such as dysphagia etc.)

          6. Patients with pleural effusion or ascites, causing respiratory syndrome (CTCAE Grade 2
             or higher dyspnea [Grade 2 dyspnea refers to Shortness of breath with a small amount
             of activities, affecting Instrumental activities of daily life])

          7. Patients underwent major surgical treatment，open biopsy or significant traumatic
             injury within 28 days prior to assignment
      "
NCT02426281,completed,,1,phase 2,['pancreatic ductal adenocarcinoma'],"[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['nab-paclitaxel', 'gemcitabine']","['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F']","
        Inclusion Criteria:

          1. Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma
             (Islet cell neoplasms or neuroendocrine carcinomas are excluded)

          2. ≥ 18 years of age at the time of signing the informed consent document

          3. ECOG 0-1

          4. At least one measurable lesion according to recist v1.1

          5. No prior palliative chemotherapy for the treatment of metastatic pancreatic cancer
             (Prior treatment with 5-FU or gemcitabine administered as a radiation sensitizer in
             the adjuvant setting is allowed if the treatment had been received at least 6 months
             before enroll).

          6. Adequate BM function: ANC ≥1.5 × 109/L; Platelet count ≥100,000/mm2 (100 × 109/L); Hb
             (Hb) ≥9 g/dL.

          7. Adequate liver and renal function (obtained ≤14 days prior to enroll): AST (SGOT), ALT
             (SGPT) ≤2.5 × upper limit of normal range (ULN), unless liver metastases are clearly
             present, then ≤5 × ULN is allowed; Total bilirubin 1.5 ≤ ULN; Serum creatinine within
             normal limits or calculated clearance ≥ 60 mL/min/1.73 m2

          8. Albumin level ≥ 3 g/dl

          9. Subjects should be asymptomatic for jaundice prior to Cycle 1 Day 1

         10. Subject with signed the Informed Consent Form (ICF) prior to participation in any
             study-related activities.

         11. Female of childbearing potential (FCBP) (defined as a sexually mature woman who (1)
             has not undergone hysterectomy [the surgical removal of the uterus] or bilateral
             oophorectomy [the surgical removal of both ovaries] or (2) has not been naturally
             postmenopausal for at least 24 consecutive months [ie, has had menses at any time
             during the preceding 24 consecutive months]) must:

               -  Either commit to true abstinence or agree to the use of 2 physician-approved
                  contraceptive methods (oral, injectable, or implantable hormonal contraceptive;
                  tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or
                  vasectomized partner) while on IP; and for 3 months following the last dose of
                  IP; and

               -  Has a negative serum pregnancy test (β-hCG) result at screening

         12. Male subjects must practice true abstinence or agree to use a condom during sexual
             contact with a pregnant female or a female of childbearing potential while
             participating in the study, during dose interruptions, and for 6 months following IP
             discontinuation, even if he has undergone a successful vasectomy

         13. Subject able to adhere to the study visit schedule and other protocol requirements.

        Exclusion Criteria:

          1. Subject has known symptomatic brain metastases.

          2. History of malignancy in the last 5 years.

          3. Breast-feeding or pregnant female

          4. Patients with plastic biliary stent (Metal biliary stents are allowed.)

          5. Subject has active, uncontrolled bacterial, viral, or fungal infection(s) requiring
             systemic therapy.

          6. Subject has known historical or active infection with HIV, hepatitis B, or hepatitis
             C.

          7. Subject has undergone major surgery within 4 weeks prior to Cycle 1 Day 1 of treatment
             in this study.

          8. Subject who experienced a recent myocardial infarction, including severe/unstable
             angina pectoris, coronary/peripheral artery bypass graft, uncontrolled hypertension,
             clinically significant cardiac dysrhythmia or clinically significant electrocardiogram
             (ECG) abnormality, significant or uncontrolled cardiovascular disease CHF, and
             cerebrovascular accident or transient ischemic attack, or seizure disorder in the past
             year.

          9. Subject has a history of allergy or hypersensitivity to any of the study drugs

         10. Subjects with history of connective tissue disorders (eg, lupus, scleroderma,
             arteritis nodosa).

         11. Subjects with a history of interstitial lung disease

         12. Any other malignancy within 5 years prior to enrollment, with the exception of
             adequately treated in-situ carcinoma of the prostate (Gleason score ≤ 7), cervix,
             uteri, or nonmelanomatous skin cancer (all treatment of which should have been
             completed 6 months prior to enrollment).

         13. Patients has > Grade 1 pre-existing peripheral neuropathy (per CTCAE)

         14. Subject has serious medical risk factors involving any of the major organ systems, or
             serious psychiatric disorders, which could compromise the subject's safety or the
             study data integrity.

         15. Subject is enrolled in any other clinical protocol or investigational trial with an
             interventional agent or assessments that may interfere with study procedures.

         16. Subject is unwilling or unable to comply with study procedures

         17. Any significant medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subject from participating in the study.
      "
NCT02425605,completed,,1,phase 2,['hepatocellular carcinoma'],"[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]",['sorafenib'],['CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F'],"
        Inclusion Criteria:

          -  Subjects must have confirmed diagnosis of unresectable hepatocellular carcinoma (HCC)
             categorized to stage C based on Barcelona Clinic Liver Cancer (BCLC) staging system
             with any of following criteria: 1) Lesion limited to a single lobe that is within the
             radiotherapy field, 2) Lesion not limited to a single lobe, but the lesion that is not
             within the radiotherapy field can be controlled by transarterial chemoembolization or
             radiofrequency ablation, 3) Presence of metastatic lesions that measure < 1.0 cm in
             the long axis, 4) The lesion can be accurately measured in at least one dimension as ≥
             1.0 cm

          -  Males or females aged at least 20 years and below 76 years

          -  Eastern Cooperative Oncology Group performance status (ECOG-PS) 0 or 1

          -  Adequate liver function, defined as: 1) Child-Pugh score ≤ 7, 2) Bilirubin ≤ 3.0 mg/dL

          -  Adequate bone marrow function, defined as: 1) Absolute neutrophil count (ANC) ≥ 1.5 ×
             109/L, 2) White blood cell count (WBC) ≥ 4.0 × 109/L, 3) Platelet count ≥ 60 × 109/L

          -  Adequate renal function, defined as serum creatinine < 2.0 mg/dL

          -  Subjects with hepatitis B virus (HBV)-related HCC must have adequately controlled HBV
             replication status

          -  Adequate blood coagulation factors, defined as international normalized ratio (INR) ≤
             2.3

          -  Provide written informed consent

          -  Willing and able to comply with all aspects of the protocol

        Exclusion Criteria:

          -  Significant liver function impairment, defined as bilirubin > 3.0 mg/dL or
             uncontrolled ascites

          -  Imaging findings for HCC corresponding to any of the following: 1) Diffuse HCC with >
             50% liver occupation, that is not adequate for external radiotherapy, 2) Presence of
             metastatic lesions that measure ≥ 1.0 cm in the long axis

          -  Uncontrolled significant active infection

          -  Presence of active malignancy (except for HCC)

          -  Females who are lactating or pregnant; females of childbearing potential who have not
             received pregnancy test or shown positive on pregnancy test

          -  Any medical or other condition that in the opinion of the investigator would preclude
             the subject's participation in a clinical study

          -  Major surgery within 4 weeks prior to enrollment
      "
NCT02422381,"active, not recruiting",,1,phase 1/phase 2,"['carcinoma, non-small-cell lung']","[""['D02.20', 'D02.21', 'D02.22']""]","['mk-3475', 'gemcitabine']","['Status: 503', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F']","
        Inclusion Criteria:

          -  Women or men with advanced, histologically proven NSCLC.

          -  Patients must have received at least one but no more than three prior systemic
             therapies for advanced disease.

          -  Any toxicity related to prior therapies that, in the opinion of the investigator,
             would potentially be worsened with anti-PD1 therapy or gemcitabine should be resolved
             to less than Grade 1.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

          -  Women of childbearing potential must have a negative pregnancy test

          -  Ability to give informed consent and comply with the protocol.

          -  Anticipated survival minimum 3 months.

          -  Prior therapy with investigational agents must have been completed at least 3 weeks
             prior to study enrollment.

          -  Patients must have normal organ and marrow function as seen on protocol-defined blood
             test results

          -  Archived tumor tissue (minimum of 8 slides for paraffin-embedded tumor tissue)
             available

          -  Measurable disease by RECIST 1.1 criteria.

          -  Treated brain metastases will be allowed, provided they are asymptomatic.

          -  Radiation for symptomatic lesions outside the Central nervous system (CNS) must have
             been completed at least 2 weeks prior to study enrollment.

        Exclusion Criteria:

          -  Prior therapy with any anti-PD-1, anti-PD-L1, or anti-CTLA4 antibody.

          -  Prior therapy with gemcitabine.

          -  Prior complications from radiation, such as history of radiation pneumonitis or
             pulmonary edema that, in the opinion of the investigator, may have risk of increasing
             toxicity with anti-PD1 therapy.

          -  Active autoimmune disease except vitiligo or stable hypothyroidism.

          -  Active and ongoing steroid use, except for non-systemically absorbed treatments (such
             as inhaled or topical steroid therapy for asthma, cardiopulmonary disease (COPD),
             allergic rhinitis).

          -  Active other malignancy, except for controlled basal cell skin carcinoma.

          -  HIV positive and/or Hepatitis B or C positive.

          -  Other medical or psychiatric conditions that in the opinion of the Principal
             Investigator would preclude safe participation in this protocol.
      "
NCT02420652,terminated,"
    slow accrual
  ",0,phase 2,"['recurrent prostate carcinoma', 'stage i prostate cancer', 'stage iia prostate cancer', 'stage iib prostate cancer', 'stage iii prostate cancer']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']"", ""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']"", ""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']"", ""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]","['aspirin', 'metformin hydrochloride']","['CC(=O)OC1=CC=CC=C1C(=O)O', 'CN(C)C(=N)N=C(N)N.Cl']","
        Inclusion Criteria:

          -  Patients with histologically proven prostate cancer treated with surgery, radiation,
             or the combination of surgery and radiation for prostate cancer (metastatic to
             regional lymph nodes) with resection of the nodes, who now has a rising PSA value
             after definitive local therapy, and no visible metastatic disease on conventional
             imaging studies

          -  Patients must have undergone local treatment via prostatectomy or radiation therapy

          -  Patients must have PSA progression after local treatment:

               -  PSA values for patients after surgery (or surgery and salvage/adjuvant radiation)
                  must be greater than or equal to 0.2 ng/mL, determined by two measurements, at
                  least 1 month apart and at least 6 months after prostatectomy

               -  PSA values for patients after radiation must be greater than or equal to 2.0
                  ng/ml greater than the nadir achieved after radiation, determined by two
                  measurements at 1 month apart and at least 6 months after the radiation treatment
                  is completed; (patients who received adjuvant or salvage radiation after
                  prostatectomy must have PSA of greater than or equal to 0.2)

               -  The first two PSA values, along with a third (study baseline) value must all be
                  rising (i.e., there must be an overall rising trajectory, such that the third
                  value cannot be lower than the first value)

               -  PSA must be less than 50 ng/mL at study entry

               -  PSA doubling time using the mkscc.org PSA doubling time calculator must be
                  greater than 4 months

          -  Baseline bone scan, chest x-ray and computed tomography (CT)/magnetic resonance
             imaging (MRI) of abdomen/pelvis demonstrating no metastatic disease

          -  Estimated life expectancy of at least 6 months

          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 2

          -  White blood cells (WBC) > 3500/ul

          -  Absolute neutrophil count (ANC) > 1500/ul

          -  Hemoglobin > 10 g/dl

          -  Platelet count > 100,000/ul

          -  Adequate renal function with estimated glomerular filtration rate (GFR) by Cockcroft
             Gault of greater than 40 ML per minute

          -  Total bilirubin must be within 1.5 X the normal institutional limits; if total
             bilirubin is outside the normal institutional limits, assess direct bilirubin

          -  The direct bilirubin must be within normal parameters

          -  Transaminases (serum glutamic oxaloacetic transaminase [SGOT] and/or serum glutamate
             pyruvate transaminase [SGPT]) must be less than 2.5 X the institutional upper limit of
             normal

          -  Patients must have a serum total testosterone level >= 150 ng/dL at the time of
             enrollment within 4 weeks prior to randomization

          -  Patients must sign informed consent

        Exclusion Criteria:

          -  Serious concomitant systemic disorder that would compromise the safety of the patient
             or compromise the patient's ability to complete the study, at the discretion of the
             investigator

          -  Patients may have received prior androgen deprivation therapy (ADT) in the
             neoadjuvant, adjuvant and/or salvage setting, but must be off therapy for at least 3
             months and have a testosterone level > 150 ng/dl

          -  Second primary malignancy except most situ carcinoma (e.g. adequately treated
             non-melanomatous carcinoma of the skin) or other malignancy treated at least 2 years
             previously with no evidence of recurrence

          -  Patients with type II diabetes currently already on metformin

          -  Patients taking aspirin for previously diagnosed cardiovascular disease

          -  Patients who received aspirin or metformin within the past 28 days

          -  Patients taking medications with known interactions with metformin or aspirin

          -  Patients taking warfarin or platelet inhibitors

          -  Patients requiring chronic use of nonsteroidal anti-inflammatory drugs (NSAIDS)

          -  Other concurrent experimental or investigational drugs

          -  Prior history of lactic acidosis or metabolic acidosis

          -  Patients with history of gastrointestinal (GI) bleeding and peptic ulcer disease

          -  Any unstable, serious co-existing medical conditions including but not limited to
             myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias,
             clinically evident congestive heart failure, or cerebrovascular accident within 6
             months prior to screening
      "
NCT02423603,unknown status,,1,phase 2,['metastatic breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['paclitaxel', 'azd5363', 'placebo']","['Status: 503', 'C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4']","
        Inclusion Criteria:

          1. Written informed consent prior to admission to this study

          2. Women, age > 18 years

          3. Histologically confirmed breast cancer

          4. Metastatic or locally recurrent disease; locally recurrent disease must not be
             amenable to resection with curative intent (patients who are considered suitable for
             surgical or ablative techniques following potential down-staging with study treatment
             are not eligible)

          5. Patient must have

               -  At least one lesion, not previously irradiated, that can be measured accurately
                  at baseline as ≥ 10mm in the longest diameter (except lymph nodes which must have
                  short axis ≥15mm) with CT, or magnetic resonance imaging (MRI) which is suitable
                  for accurate repeated measurements, OR

               -  lytic or mixed bone lesions in the absence of measurable disease as defined
                  above; patients with sclerotic/osteoblastic bone lesions only in the absence of
                  measurable disease are not eligible.

          6. Radiological or clinical evidence of recurrence or progression

          7. Triple-negative disease

          8. Formalin fixed paraffin embedded tumour sample from the primary or recurrent cancer
             must be available for central testing

          9. Patients must be able to swallow and retain oral medication

         10. Haematologic and biochemical indices within protocol specified ranges

         11. ECOG performance status 0-2

         12. Non-childbearing potential. If patient is of childbearing potential, she must have a
             negative serum pregnancy test and agree to use adequate contraception

         13. Willing and able to provide written informed consent

        Exclusion Criteria:

          1. Patients with confirm brain metastases or a history of primary central nervous system
             tumours or who have signs/symptoms attributable to brain metastases and have not been
             assessed with radiologic imaging to rule out the presence of brain metastases.

          2. Prior chemotherapy for metastatic breast cancer

          3. Radiotherapy with a wide field of radiation within 4 weeks before the first dose of
             study medication

          4. Prior treatment with PI3K inhibitors, AKT inhibitors or mTOR inhibitors

          5. Prior treatment with paclitaxel or docetaxel in the (neo)adjuvant setting within 12
             months from inclusion into this study

          6. Pre-existing sensory or motor polyneuropathy ≥ Grade 2 according to CTCAE

          7. Malabsorption syndrome or other condition that would interfere with enteral absorption

          8. Clinically significant pulmonary dysfunction

          9. Prolongation defined as a QTc interval >470msecs or other significant abnormalities in
             rhythm, conduction or morphology of resting ECG including 2nd degree (Type II) or 3rd
             degree AV block or bradycardia (ventricular rate <50 beats/min)

         10. Any factors that increase risk of QTc prolongation or risk of arrythmic events

         11. Experience of any of the following procedures or conditions in the preceding 6 months:
             coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction,
             angina pectoris, congestive heart failure NYHA Grade ≥2, or cardiac ejection fraction
             outside institutional range of normal or <50%

         12. Clinically significant abnormalities of glucose metabolism

         13. Patients with proteinuria or creatine >1.5xULN concurrent with creatinine clearance
             <50mL/min

         14. Exposure to potent inhibitors or inducers or substrates of CYP3A4 or substrates of
             CYP2D6 within 2 weeks before the first dose of study treatment

         15. Concurrent treatment with other experimental drugs or participation in another
             clinical trial with any investigational drug within 30 days prior to study entry

         16. Psychological, familial, sociological or geographical conditions that do not permit
             compliance with the study protocol.

         17. Detained persons or prisoners

         18. Pregnant or nursing women
      "
NCT02425306,terminated,"
    slow accrual to part 2 of the study. accrual to part 1 is complete.
  ",0,phase 1/phase 2,['melanoma'],"[""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']""]","['montanide isa-51', 'polyiclc', 'cyclophosphamide']",['C1CNP(=O)(OC1)N(CCCl)CCCl'],"
        Inclusion Criteria:

          -  Part 1 only: Participants with stage IIB, IIC, III, or IV melanoma at original
             diagnosis or at restaging after recurrence. Patients with high-risk stage IIA melanoma
             (by DecisionDx Melanoma test, Castle Biosciences, Inc,;Friendswood, TX) also may be
             eligible. These participants may have had cutaneous, uveal, mucosal primary melanoma,
             or an unknown primary melanoma. Diagnosis of melanoma must be confirmed by cytological
             or histological examination. Staging of cutaneous melanoma will be based on version 7
             AJCC staging system.

          -  Part 2 only: Patients with a diagnosis of stage IIIB-IV melanoma with one or more
             tumor deposits accessible for biopsy and/or excision. These participants may have had
             cutaneous, uveal, mucosal primary melanoma, or an unknown primary melanoma. Diagnosis
             of melanoma must be confirmed by cytological or histological examination. Staging of
             cutaneous melanoma will be based on version 7 AJCC staging system.

        Patients must have adequate cutaneous, subcutaneous, soft tissue, or nodal metastases of
        melanoma readily accessible for biopsy

          -  Participants will be required to have radiological studies to rule out radiologically
             evident disease. Required studies include:

               -  Chest CT scan,

               -  Abdominal and pelvic CT scan, and

               -  Head CT scan or MRI

               -  PET/CT fusion scan may replace scans of the chest, abdomen, and pelvis.

          -  Participants who have had brain metastases will be eligible if all of the following
             are true:

               -  Each brain metastasis must have been completely removed by surgery or each
                  unresected brain metastasis must have been treated with stereotactic
                  radiosurgery.

               -  There has been no evident growth of any brain metastasis since the most recent
                  treatment.

               -  No brain metastasis is > 2 cm in diameter at the time of registration.

               -  The most recent surgical resections or gamma-knife therapy for malignant melanoma
                  must have been completed ≥ 1 week and for Part 1, ≤ 6 months prior to
                  registration.

          -  All participants must have:

               -  ECOG performance status of 0 or 1 (Appendix 3)

               -  Ability and willingness to give informed consent

          -  Laboratory parameters as follows:

               -  ANC > 1000/mm3

               -  Platelets > 100,000/mm3

               -  Hgb > 9 g/dL

               -  HgbA1c ≤ 7.5%

               -  Hepatic:

               -  AST and ALT ≤ 2.5 x upper limits of normal (ULN)

               -  Bilirubin ≤ 2.5 x ULN (except in patients with Gilbert's disease, where bilirubin
                  to 4x ULN is allowed)

               -  Alkaline phosphatase ≤ 2.5 x ULN

               -  Renal

               -  Creatinine ≤ 1.5 x ULN

               -  Serology (within 6 months of study entry)

               -  HIV negative

               -  Hepatitis C negative (no evidence of active virus)

          -  Blood is to be collected for HLA typing (Class I and Class II), which will be analyzed
             as part of the immunologic endpoints, but HLA type will not be an inclusion/exclusion
             criterion.

          -  Age 18 years or older at registration.

          -  Part 1 only: Participants must have at least two intact (undissected) axillary and/or
             inguinal lymph node basins.

          -  Part 2 only: Participants must have at least one intact (undissected) axillary and/or
             inguinal lymph node basin.

        Exclusion Criteria:

          -  Participants who have received the following medications or treatments at any time
             within 4 weeks of registration:

               -  Chemotherapy

               -  Interferon (e.g. Intron-A®)

               -  Radiation therapy (Stereotactic radiotherapy, such as gamma knife, can be used ≥
                  1 week and ≤ 6 months prior to registration)

               -  Allergy desensitization injections

               -  High doses of systemic corticosteroids, with the following qualifications and
                  exceptions:

                    -  In patients with adrenal or pituitary insufficiency replacement steroid
                       doses are allowed; however, daily doses of 10 mg or more of prednisone (or
                       equivalent) per day administered parenterally or orally are not allowed in
                       patients with normal adrenal and pituitary function.

                    -  Inhaled steroids (e.g.: Advair®, Flovent®, Azmacort®) are permitted at low
                       doses (less than 500 mcg fluticasone per day, or equivalent) (76,77).

                    -  Topical, nasal, and intra-articular corticosteroids are acceptable.

               -  Growth factors (e.g. Procrit®, Aranesp®, Neulasta®)

               -  Interleukins (e.g. Proleukin®)

               -  Any investigational medication

               -  Targeted therapies specific for mutated BRAF or for MEK

          -  Participants who are currently receiving nitrosoureas or who have received this
             therapy within the preceding 6 weeks

          -  Participants who are currently receiving a checkpoint molecule blockade therapy, or
             who have received this therapy within the preceding 12 weeks.

          -  Participants with known or suspected allergies to any component of the vaccine.

          -  Participants may not have been vaccinated previously with any of the synthetic
             peptides included in this protocol. Participants who have received vaccinations
             containing agents other than the synthetic peptides included in this protocol and have
             recurred during or after administration of the vaccine will be eligible to enroll 12
             weeks following their last vaccination.

          -  Pregnancy. Female participants of childbearing potential must have a negative
             pregnancy test (urinary or serum beta-HCG) obtained within 2 weeks prior to
             registration. Males and females must agree, in the consent form, to use effective
             birth control methods during the course of vaccination.

          -  Female participants must not be breastfeeding

          -  Participants in whom there is a medical contraindication or potential problem in
             complying with the requirements of the protocol in the opinion of the investigator.

          -  Participants classified according to the New York Heart Association classification as
             having Class III or IV heart disease (Appendix 4).

          -  Participants with uncontrolled diabetes, defined as having a HgbA1c ≥ 7.5%.

          -  Participants must not have had prior autoimmune disorders requiring cytotoxic or
             immunosuppressive therapy, or autoimmune disorders with visceral involvement.
             Participants with an active autoimmune disorder requiring these therapies are also
             excluded. The following will not be exclusionary:

               -  The presence of laboratory evidence of autoimmune disease (e.g. positive ANA
                  titer) without symptoms

               -  Clinical evidence of vitiligo

               -  Other forms of depigmenting illness

               -  Mild arthritis requiring NSAID medications

          -  Participants who have another cancer diagnosis, except that the following diagnoses
             will be allowed:

               -  squamous cell cancer of the skin without known metastasis

               -  basal cell cancer of the skin without known metastasis

               -  carcinoma in situ of the breast (DCIS or LCIS)

               -  carcinoma in situ of the cervix

               -  any cancer without distant metastasis that has been treated successfully, without
                  evidence of recurrence or metastasis for over 5 years

          -  Participants with known addiction to alcohol or drugs who are actively taking those
             agents, or participants with recent (within 1 year) or ongoing illicit IV drug use.

          -  Body weight < 110 pounds (without clothes) at registration, due to the amount and
             frequency with which blood will be drawn.
      "
NCT02428270,completed,,0,phase 2,"['pancreatic cancer', 'adenocarcinoma']","[""['C25.3']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['gsk2256098', 'trametinib']","['CC1=NN(C(=C1)NC2=NC=C(C(=C2)NC3=CC=CC=C3C(=O)NOC)Cl)C(C)C', 'CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5']","
        Inclusion Criteria:

          -  Male or female, 18 years or older, able to give written consent

          -  Pancreatic adenocarcinoma that is not responsive to standard therapies or for which
             there is no approved or curative therapy or for patients who refuse standard therapy

          -  Have clinical, radiographic, or serologic progression after one prior line of
             chemotherapy for advanced disease. Patients who have received two or more prior lines
             of chemotherapy for advanced disease are not eligible.

          -  Performance Status score of 0 or 1

          -  Measureable disease by RECIST version 1.1

          -  Able to swallow and retain oral medication

          -  Have malignant disease that is amenable to biopsy and agree to collection of mandatory
             tumor biopsy samples.

          -  Agrees to use contraception

          -  Not pregnant

          -  Adequate organ system function

        Exclusion Criteria:

          -  Chemotherapy, radiotherapy, immunotherapy, or other anti-cancer therapy including
             investigational drugs within 28 days or 5 half lives. No prior MEK inhibitor, RAF
             inhibitors or a FAK inhibitors

          -  Current use of a prohibited medication

          -  Unresolved toxicity greater than Grade 1 from previous anticancer therapy unless the
             ongoing toxicity will not introduce additional risk factors and will not interfere
             with the study procedures.

          -  Presence of active GI disease or other condition that could affect gastrointestinal
             absorption or predisposed to GI ulceration

          -  Evidence of mucosal or internal bleeding

          -  Anticoagulation with warfarin

          -  Major surgery within the last four weeks

          -  Malignancies related to HIV or HBV/HCV

          -  Known active infection requiring parenteral or oral anti-infective treatment

          -  Leptomeningeal disease.

          -  Brain metastases

          -  QTcF interval ≥ 480 msecs

          -  History or evidence of current clinically significant uncontrolled arrhythmias

          -  History of acute coronary syndromes, myocardial infarction, coronary angioplasty, or
             stenting or bypass grafting within six months of screening.

          -  Class II, III, or IV heart failure as defined by the New York Heart Association (NYHA)
             functional classification system.

          -  Other clinically significant ECG abnormalities

          -  Intra-cardiac defibrillators.

          -  Presence of cardiac metastases.

          -  Serious or unstable pre-existing medical, psychiatric, or other condition that could
             interfere with patient's safety or providing informed consent.

          -  Known immediate or delayed hypersensitivity to any of the components of the study
             treatment(s).

          -  Evidence of severe or uncontrolled systemic diseases

          -  Pregnant or lactating

          -  History of retinal vein occlusion

          -  History of interstitial lung disease or pneumonitis
      "
NCT02425683,terminated,"
    insufficient accrual
  ",0,phase 2,"['colorectal neoplasms', 'adenocarcinoma of the colon', 'adenocarcinoma of the rectum']","[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]",['regorafenib'],['CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F'],"
        Inclusion Criteria:

          -  A signed Patient Authorization Form (HIPAA) has been obtained prior to registration

          -  Subjects must be able to understand and be willing to sign the written informed
             consent form. A signed informed consent form must be appropriately obtained prior to
             the conduct of any trial-specific procedure.

          -  Age ≥ 18 years.

          -  Stage IIIC colorectal cancer (T4a, N2a, M0) or (T3-4a, N2b, M0), or (T4b, N1- N2, M0)
             (per AJCC 7th ed).

          -  Must have started adjuvant FOLFOX chemotherapy within 8 weeks of resection for
             colorectal carcinoma

          -  CT scan that demonstrates no evidence of disease (NED) after completion of adjuvant
             therapy Note: This CT scan will also be used for Texture analysis.

          -  Received FOLFOX within 6 weeks before starting regorafenib

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Life expectancy of at least 12 weeks (3 months).

          -  Complete Metabolic Profile (CMP) within normal limits

          -  Adequate bone marrow, liver, and renal function as assessed by the following
             laboratory requirements:

               -  Total bilirubin ≤ 1.5 x the upper limits of normal (ULN)

               -  Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) ≤ 2.5 x ULN

               -  Alkaline phosphatase limit ≤ 2.5 x ULN

               -  Lipase ≤ 1.5 x ULN

               -  Serum creatinine ≤ 1.5 x ULN

               -  International normalized ratio (INR)/ Partial thromboplastin time (PTT) ≤ 1.5 x
                  ULN. (Subjects who are prophylactically treated with an agent such as warfarin or
                  heparin will be allowed to participate provided that no prior evidence of
                  underlying abnormality in coagulation parameters exists. Close monitoring of at
                  least weekly evaluations will be performed until INR/PTT is stable based on a
                  measurement that is pre-dose as defined by the local standard of care.

               -  Platelet count ≥ 100,000 /mm3, hemoglobin (Hb) ≥ 9 g/dL, absolute neutrophil
                  count (ANC) ≥ 1500/mm3. Blood transfusion to meet the inclusion criteria will not
                  be allowed.

          -  Normal carcinoembryonic antigen (CEA) prior to study entry

          -  Glomerular filtration rate (GFR) ≥ 60 mL/min/1.73 m2 according to the Modified Diet in
             Renal Disease (MDRD) abbreviated formula.

          -  Women of childbearing potential must have a negative serum pregnancy test performed
             within 7 days prior to the start of study drug. Post-menopausal women (defined as no
             menses for at least 1 year) and surgically sterilized women are not required to
             undergo a pregnancy test. The definition of adequate contraception will be based on
             the judgment of the investigator.

          -  Subjects (men and women) of childbearing potential must agree to use adequate
             contraception beginning at the signing of the informed consent form (ICF) until at
             least 3 months after the last dose of study drug. The definition of adequate
             contraception will be based on the judgment of the principal investigator or a
             designated associate.

          -  Subject must be able to swallow and retain oral medication.

          -  Discretionary use of growth factors allowed

        Exclusion Criteria:

          -  Previous assignment to treatment during this study. Subjects permanently withdrawn
             from study participation will not be allowed to re-enter study.

          -  Uncontrolled hypertension (systolic pressure >140 mm Hg or diastolic pressure > 90 mm
             Hg [NCI-Common Toxicity Criteria for Adverse Effects (CTCAE) v4.03] on repeated
             measurement) despite optimal medical management.

          -  Evidence of remaining tumor

          -  Has local or distant metastasis

          -  Previous antiangiogenic treatment

          -  Abnormal hematological, renal, or liver function

          -  Impaired pulmonary function

          -  Evidence of ≥ Grade 2 neuropathy

          -  Active or clinically significant cardiac disease including:

               -  Congestive heart failure - New York Heart Association (NYHA) > Class II.

               -  Active coronary artery disease.

               -  Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or
                  digoxin.

               -  Unstable angina (anginal symptoms at rest), new-onset angina within 3 months
                  before randomization, or myocardial infarction within 6 months before
                  randomization.

          -  Evidence or history of bleeding diathesis or coagulopathy.

          -  Any hemorrhage or bleeding event ≥ NCI CTCAE Grade 3 within 4 weeks prior to start of
             study medication.

          -  Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular
             accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary
             embolism within 6 months of start of study treatment.

          -  Subjects with any previously untreated or concurrent cancer that is distinct in
             primary site or histology from breast cancer except cervical cancer in-situ, treated
             basal cell carcinoma, or superficial bladder tumor. Subjects surviving a cancer that
             was curatively treated and without evidence of disease for more than 3 years before
             randomization are allowed. All cancer treatments must be completed at least 3 years
             prior to study entry (ie, signature date of the informed consent form).

          -  Patients with phaeochromocytoma.

          -  Known history of human immunodeficiency virus (HIV) infection or current chronic or
             active hepatitis B or C infection requiring treatment with antiviral therapy.

          -  Ongoing infection > Grade 2 NCI-CTCAE v4.03.

          -  Presence of a non-healing wound, non-healing ulcer, or bone fracture.

          -  Dehydration Grade ≥ 1 NCI-CTCAE v4.03.

          -  Patients with seizure disorder requiring medication.

          -  Persistent proteinuria ≥ Grade 3 NCI-CTCAE v4.03 (> 3.5 g/24 hrs, measured by urine
             protein: creatinine ratio on a random urine sample).

          -  Interstitial lung disease with ongoing signs and symptoms at the time of informed
             consent.

          -  Pleural effusion or ascites that causes respiratory compromise (≥ NCI-CTCAE version
             4.03 Grade 2 dyspnea).

          -  History of organ allograft (including corneal transplant).

          -  Known or suspected allergy or hypersensitivity to any of the study drugs, study drug
             classes, or excipients of the formulations given during the course of this trial.

          -  Any malabsorption condition.

          -  Women who are pregnant or breast-feeding.

          -  Any condition which, in the investigator's opinion, makes the subject unsuitable for
             trial participation.

          -  Substance abuse, medical, psychological or social conditions that may interfere with
             the subject's participation in the study or evaluation of the study results.

          -  Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery,
             immunotherapy, biologic therapy, or tumor embolization) other than study treatment
             (regorafenib, other agents being investigated in combination with regorafenib).

          -  Prior use of regorafenib.

          -  Concurrent use of another investigational drug or device therapy (ie, outside of study
             treatment) during, or within 4 weeks of trial entry (signing of the informed consent
             form).

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             before start of study medication.

          -  Therapeutic anticoagulation with Vitamin-K antagonists (eg, warfarin) or with heparins
             and heparinoids.

             o However, prophylactic anticoagulation as described below is allowed:

               -  Low dose warfarin (1 mg orally, once daily) with PT-INR ≤ 1.5 x ULN is permitted.
                  Infrequent bleeding or elevations in PT-INR have been reported in some subjects
                  taking warfarin while on regorafenib therapy. Therefore, subjects taking
                  concomitant warfarin should be monitored regularly for changes in PT, PT-INR, or
                  clinical bleeding episodes.

               -  Low dose aspirin (≤ 100 mg daily).

               -  Prophylactic doses of heparin.

          -  Use of any herbal remedy (eg, St. John's wort [Hypericum perforatum]) Note:
             Granulocyte colony-stimulating factor (G-CSF) and other hematopoietic growth factors
             may be used in the management of acute toxicity, such as febrile neutropenia, when
             clinically indicated or at the investigator's discretion. However, they may not be
             substituted for a required dose reduction. Subjects are permitted to take chronic
             erythropoietin.
      "
NCT02420717,terminated,"
    study was closed early due to low accrual and lack of response.
  ",0,phase 2,"['recurrent b acute lymphoblastic leukemia', 'recurrent ph-like acute lymphoblastic leukemia', 'refractory b acute lymphoblastic leukemia', 'refractory ph-like acute lymphoblastic leukemia']","[""['C83.57', 'C83.50', 'C91.01', 'C91.02', 'C83.52', 'C83.56', 'C83.53']"", ""['C83.57', 'C83.50', 'C91.01', 'C91.02', 'C83.52', 'C83.56', 'C83.53']"", ""['C83.57', 'C83.50', 'C91.01', 'C91.02', 'C83.52', 'C83.56', 'C83.53']"", ""['C83.57', 'C83.50', 'C91.01', 'C91.02', 'C83.52', 'C83.56', 'C83.53']""]","['cyclophosphamide', 'cytarabine', 'dasatinib', 'dexamethasone', 'doxorubicin', 'leucovorin', 'mercaptopurine', 'methotrexate', 'prednisone', 'ruxolitinib phosphate', 'vincristine']","['C1CNP(=O)(OC1)N(CCCl)CCCl', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O', 'CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO', 'CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C', 'CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O', 'C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O', 'C1=NC2=C(N1)C(=S)N=CN2', 'CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O', 'CC12CC(=O)C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C', 'C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3.OP(=O)(O)O', 'CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O']","
        Inclusion Criteria:

          -  Patients with previously treated B-cell ALL (relapsed and/or refractory after prior
             therapy)

          -  Bone marrow involvement with >= 5% lymphoblasts

          -  Documented genetic lesion(s) known to confer susceptibility to inhibition by either
             ruxolitinib or dasatinib or cytokine receptor-like factor 2 (CRLF2) positivity by flow
             cytometry (for the ruxolitinib cohort)

          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 2

          -  Total bilirubin < 2.0 mg/dL

          -  Serum glutamate pyruvate transaminase (SGPT) or serum glutamic oxaloacetic
             transaminase (SGOT) < 3 x upper limit of normal (ULN)

          -  Creatinine < 2 mg/dL

          -  Females of childbearing potential must have a negative serum or urine beta human
             chorionic gonadotropin (beta-hCG) pregnancy test result within 14 days prior to the
             first dose of study drugs and must agree to use an effective contraception method
             during the study and for 30 days following the last dose of study drug; females of
             non-childbearing potential are those who are postmenopausal greater than 1 year or who
             have had a bilateral tubal ligation or hysterectomy; appropriate methods of birth
             control include the following: any 2 of the following methods used together: birth
             control implants, injections, or pills (except for progesterone only pills),
             intrauterine device (IUD), vasectomy, tubal ligation, barrier method (female or male
             condom with spermicide, cervical cap with spermicide, diaphragm with spermicide); male
             condom with spermicide and diaphragm; male condom with spermicide and cervical cap;
             unacceptable methods of birth control include using no birth control, withdrawal,
             rhythm method, vaginal sponge, any barrier method that does not use spermicide,
             progesterone only pills, and using male and female condoms at the same time

          -  Males who have partners of childbearing potential must agree to use an effective
             contraceptive method during the study and for 30 days following the last dose of study
             drug

          -  Patients or their legally authorized representative must provide written informed
             consent

        Exclusion Criteria:

          -  Burkitt's leukemia or lymphoma, T-cell ALL or lymphoblastic lymphoma

          -  Patients having undergone prior allogeneic stem cell transplant within 3 months or
             having active graft versus host disease

          -  Patient is pregnant or breastfeeding

          -  Patients with uncontrolled active infections (fever >= 38 degrees Celsius [C], septic
             shock)

          -  Isolated extramedullary relapse (i.e. testicular, central nervous system)

          -  Current or chronic hepatitis B or C infection, or known seropositivity for human
             immunodeficiency virus (HIV)

          -  Concurrent chemotherapy (except intrathecal chemotherapy)

          -  Major surgery within 4 weeks prior to first study dose

          -  Systemic chemotherapy/radiotherapy/investigational therapy within 14 days (with the
             exception of hydroxyurea and steroids) prior to starting therapy; for patients
             receiving ALL maintenance with 6-mercaptopurine, methotrexate, vincristine, and
             steroids - these agents should be discontinued at least 48 hours prior to start of
             study drugs; for patients on oral targeted therapies (such as imatinib, dasatinib,
             ponatinib), - these agents should be discontinued at least 48 hours prior to start of
             study drugs

          -  Patients must have recovered from acute non hematologic toxicity (to =< grade 1) of
             all previous therapy prior to enrollment

          -  Known active central nervous system (CNS) leukemia, as defined by unequivocal
             morphologic evidence of lymphoblasts in the cerebrospinal fluid (CSF), use of
             CNS-directed local treatment for active disease within the prior 28 days, symptomatic
             CNS leukemia (i.e., cranial nerve palsies or other significant neurologic dysfunction)
             within 28 days; patients may have history of CNS leukemic involvement if definitively
             treated with prior therapy and no evidence of active disease (defined as >= 2
             consecutive spinal fluid assessments with no evidence of disease) at the time of
             registration; prophylactic intrathecal chemotherapy is not a criterion for exclusion

          -  Patients with active heart disease (New York Heart Association [NYHA] class 3-4 as
             assessed by history and physical examination, unstable angina/stroke/myocardial
             infarction within the last 6 months)

          -  Patients with a cardiac ejection fraction (as measured by either multi-gated
             acquisition [MUGA] scan or echocardiogram) < 40%; (Note: patients who have had prior
             anthracycline exposure of > 250 mg/m^2 may be eligible after discussion with the
             principal investigator [PI])

          -  Second malignancy other than basal cell or squamous cell carcinoma of the skin or in
             situ carcinoma of the cervix or the breast, unless they are successfully treated with
             curative intent for more than 2 years before entering the study

          -  Malabsorption syndrome or other conditions that preclude enteral route of
             administration

          -  Patients requiring strong cytochrome P450, family 3, subfamily A, polypeptide 4
             (CYP3A4) inhibitors

          -  Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that in the opinion of the investigator may increase the risk associated
             with study participation or investigational product administration or may interfere
             with the interpretation of study results and/or would make the patient inappropriate
             for enrollment into this study
      "
NCT02423590,unknown status,,0,phase 2,['squamous cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['apatorsen (ogx-427)', 'gemcitabine', 'carboplatin']","['C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F', 'C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]']","
        Inclusion Criteria:

          1. Written informed consent prior to admission to this study

          2. Histological or cytological diagnosis of squamous non-small cell lung cancer. Patients
             with adenosquamous or mixed histology are not eligible for this study.

          3. Stage IIIB disease that is unsuitable to radio-chemotherapy or Stage IV disease or
             recurrent NSCLC; recurrent disease must not be amenable to resection or radical
             radiotherapy with curative intent.

          4. Patients must have:

               -  at least one lesion, not previously irradiated, that can be measured accurately
                  at baseline as ≥10 mm in the longest diameter (except lymph nodes which must have
                  short axis ≥15 mm) OR

               -  lytic or mixed (lytic + sclerotic) bone lesions in the absence of measurable
                  disease as defined above

          5. Willing to donate archival diagnostic tissue for translational research, if available.

          6. Haematologic and biochemical indices within the ranges shown below. These measurements
             must be performed within one week prior to randomisation

               -  ANC ≥1.5 x 109/L;, platelet count ≥100 x 109/L,

               -  Serum creatinine < 1.5 times the upper limit of normal (ULN)

               -  Bilirubin level < 1.5 X ULN

               -  AST or ALT <3.0 X ULN or <5 X ULN in the presence of liver metastases

          7. ECOG performance status 0-2

          8. Non-childbearing potential (i.e., physiologically incapable of becoming pregnant)

          9. Male or Female aged ≥18 years

        Exclusion Criteria:

          1. Symptomatic CNS involvement or CNS involvement requiring steroid therapy; patients
             with treated brain metastases that are asymptomatic and have been clinically stable
             for 1 month will be eligible for protocol participation

          2. Previous systemic treatment for lung cancer (exception for patients who have
             previously received immunotherapy without chemotherapy, and for patients with
             recurrent disease: adjuvant chemotherapy is allowed as long as this was finished at
             least 1 year prior to enrolment and did not contain gemcitabine)

          3. Known tumour EGFR mutation, unless contraindication to EGFR-directed therapy

          4. Known tumour ALK rearrangements, unless contraindication to Alk-directed therapy or
             Alk-directed therapy not available 1

          5. Pre-existing sensory or motor polyneuropathy >Grade 2 according to NCI CTCAE

          6. Significant cardiovascular disease, such as

               -  History of myocardial infarction, acute coronary syndromes (including unstable
                  angina), or history of coronary angioplasty/stenting/bypass grafting within past
                  6 months.

               -  History of symptomatic congestive heart failure (CHF) New York Heart Association
                  (NYHA) Classes III-IV.

               -  Severe cardiac arrhythmia requiring medication or severe conduction abnormalities

               -  Poorly controlled hypertension (resting diastolic blood pressure >115 mmHg)

               -  Clinically significant valvular disease, cardiomegaly, ventricular hypertrophy,
                  or cardiomyopathy

          7. Active second malignancy (except non-melanomatous skin cancer): active secondary
             malignancy is defined as a current need for cancer therapy or a high possibility
             (>30%) of recurrence during the study.

          8. Concurrent treatment with other experimental drugs or participation in another
             clinical trial with any investigational drug within 30 days prior to study entry.

          9. Any other disease, metabolic dysfunction, physical examination finding, or clinical
             laboratory finding that, in the investigator's opinion, gives reasonable suspicion of
             a disease or condition that contraindicates the use of an investigational drug, may
             affect the interpretation of the results, render the patient at high risk from
             treatment complications or interferes with obtaining informed consent.

         10. Psychological, familial, sociological or geographical conditions that do not permit
             compliance with the study protocol.
      "
NCT02422199,unknown status,,1,phase 1/phase 2,['her2 positive metastatic breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['pyrotinib', 'lapatinib', 'capecitabine']","['CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CC5CCCN5C', 'CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl', 'CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O']","
        Inclusion Criteria:

          -  Aged ≥18 and ≤70 years.

          -  ECOG performance status of 0 to 1.

          -  Life expectancy of more than 12 weeks.

          -  At least one measurable lesion exists.(RECIST 1.1).

          -  Histologically or cytologic confirmed HER2 positive advanced breast cancer which
             failed prior therapies.

          -  Required laboratory values including following parameters:

        ANC: ≥ 1.5 x 10^9/L;Platelet count: ≥ 100 x 10^9/L;Hemoglobin: ≥ 9.0 g/dL;Total bilirubin:
        ≤ 1.5 x upper limit of normal (ULN);ALT and AST: ≤ 1.5 x ULN;BUN and creatine clearance
        rate: ≥ 50 mL/min;LVEF: ≥ 50%;QTcF: < 470 ms for female and < 450 ms for male.

          -  Signed informed consent

        Exclusion Criteria:

          -  Received previous therapy with lapatinib, neratinib, pyrotinib or any other HER2
             directe tyrosine kinase inhibitor.

          -  Received previous therapy with capecitabine within 3 months.
      "
NCT02296242,completed,,1,phase 1/phase 2,"['acute myelogenous leukemia', 'myelodysplastic syndrome']","[""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']"", ""['D46.9', 'D46.C', 'D46.Z']""]",['bvd-523'],['CC(C)NC1=NC=C(C(=C1)C2=CNC(=C2)C(=O)NC(CO)C3=CC(=CC=C3)Cl)Cl'],"
        Inclusion Criteria:

          -  Have either of the following diagnoses:

               1. Morphologically confirmed acute myeloid leukemia (AML), except acute
                  promyelocytic leukemia (APL), including leukemia secondary to prior therapy or
                  antecedent hematologic disorder (e.g., MDS or myeloproliferative disorders), who
                  have failed to achieve CR or who have relapsed after prior therapy and are not
                  candidates for potentially curative therapy

               2. Intermediate-2 or High-grade risk MDS (including chronic myelomonocytic leukemia
                  (CMML))

          -  Have received at least one prior therapy. Patients who are over age 65 and have not
             received therapy for AML are also eligible, if they are not candidates for induction
             chemotherapy

          -  ECOG performance status of 0 to 2

          -  Predicted life expectancy of ≥ 3 months

          -  Adequate liver, renal and cardiac function

        For Group 1 in Part 2 of the Study ONLY:

        • Positive for RAS mutation at a Clinical Laboratory Improvement Amendments
        (CLIA)-certified laboratory prior to study entry

        Exclusion Criteria:

          -  Concomitant malignancies except carcinoma in situ, basal or squamous cell skin
             carcinoma; low grade prostate cancer treated with prostatectomy more than 10 years
             ago; early stage melanoma treated with complete surgical excision more than 5 years
             ago; carcinoma in situ of cervix treated with cone procedure more than 8 years ago

          -  Gastrointestinal condition which could impair absorption of study medication

          -  Uncontrolled or severe intercurrent medical condition

          -  Patients with rapidly increasing peripheral blood blast counts

          -  Known uncontrolled central nervous system involvement

          -  Any cancer-directed therapy within 28 days or 5 half-lives, whichever is shorter

          -  Any concurrent or prior use of an investigational drug (including MEK inhibitors)
             within previous 28 days or 5 half-lives, whichever is shorter

          -  Received chemotherapy regimens with delayed toxicity within the last four weeks (six
             weeks for prior nitrosourea or mitomycin C). Received chemotherapy regimens given
             continuously or on a weekly basis with limited potential for delayed toxicity within
             the last two weeks.

          -  Ongoing anticoagulant therapy that cannot be held if necessary to permit bone marrow
             sampling.

          -  Major surgery within 4 weeks prior to first dose

          -  Pregnant or breast-feeding women

          -  Any evidence of serious active infections

          -  Any important medical illness or abnormal laboratory finding that would increase the
             risk of participating in this study

          -  A history or current evidence/risk of retinal vein occlusion or central serous
             retinopathy

          -  Concurrent therapy with drugs known to be strong inhibitors of CYP1A2, CYP2D6, and
             CYP3A4, or strong inducers of CYP3A4
      "
NCT02296801,completed,,0,phase 2,"['breast cancer', 'breast carcinoma', 'breast tumors']","[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C4A.52', 'C44.511', 'C44.521', 'D05.00', 'D05.01', 'D05.02', 'D05.10']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['letrozole', 'palbociclib']","['C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3', 'CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C']","
        Inclusion Criteria:

          -  Patients must be postmenopausal women defined as: Age 56 or older with no spontaneous
             menses for at least 12 months prior to study entry; or Age 55 or younger with no
             menses for at least 12 months prior to study entry (e.g., spontaneous or secondary to
             hysterectomy) and with a documented estradiol level in the postmenopausal range
             according to local institutional/laboratory standard; or Age greater than or equal to
             18 with documented bilateral oophorectomy.

          -  Operable ER-positive/HER2- negative, invasive early breast cancer, suitable for
             neoadjuvant AI treatment. HER2-negative as determined by American Society of Clinical
             Oncology - College of American Pathologists (ASCO-CAP) guidelines.

          -  No known severe hypersensitivity reactions to compounds similar to palbociclib or
             palbociclib excipients or to endocrine treatments.

          -  A breast tumor with an ultrasound size of at least 2.0 cm.

          -  Patients must have the ability to swallow oral medication.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  At the time of randomization, blood counts performed within 4 weeks prior to
             randomization must meet the following criteria: absolute neutrophil count (ANC) must
             be greater than or equal to 1500/mm3; Platelet count must be greater than or equal to
             100,000/mm3; Hemoglobin must be greater than or equal to 10 g/dL.

          -  international normalized ratio (INR) must be within normal limits of the local
             laboratory ranges.

          -  The following criteria for evidence of adequate hepatic function performed within 4
             weeks prior to study entry must be met: total bilirubin must be less than or equal to
             upper limit of normal (ULN) for the lab unless the patient has a bilirubin elevation
             greater than ULN to 1.5 x ULN due to Gilbert's disease or similar syndrome involving
             slow conjugation of bilirubin; and alkaline phosphatase must be must be less than or
             equal to 1.5 x ULN for the lab; and aspartate aminotransferase (AST) and alanine
             aminotransferase (ALT) must be less than or equal to 1.5 x ULN for the lab.

          -  Serum creatinine performed within 4 weeks prior to study entry must be less than or
             equal to 1.25 x ULN or estimated creatinine clearance less than 60 mL/min (as
             calculated using the method standard for the institutions).

        Exclusion Criteria:

          -  Active hepatitis B or hepatitis C with abnormal liver function tests.

          -  HIV positive patients receiving antivirals.

          -  Premenopausal or peri-menopausal women.

          -  Inflammatory/inoperable breast cancer.

          -  HER2-positive as determined using ASCO-CAP Guidelines.

          -  Concurrent use (defined as use within 4 weeks prior to baseline tissue sample being
             taken) of hormone replacement therapy (HRT) or any other estrogen-containing
             medication (including vaginal estrogens)

          -  Prior endocrine therapy for breast cancer.

          -  Any invasive malignancy within previous 5 years (other than basal cell carcinoma or
             cervical carcinoma in situ).

          -  Other nonmalignant systemic disease that would preclude the patient from receiving
             study treatment or would prevent required follow up such as: Active infection or
             chronic infection requiring chronic suppressive antibiotics; Malabsorption syndrome,
             ulcerative colitis, inflammatory bowel disease, resection of the stomach or small
             bowel, or other disease or condition significantly affecting gastrointestinal
             function; Chronic daily treatment with corticosteroids with a dose of greater than or
             equal to 10 mg/day methylprednisolone equivalent (excluding inhaled steroids); Seizure
             disorders requiring medication.

          -  Diagnosis by fine needle aspiration (FNA) alone or excisional biopsy or lumpectomy
             performed prior to study entry.

          -  Surgical axillary staging procedure prior to study procedure (with exception of FNA or
             core biopsy).

          -  Definitive clinical or radiologic evidence of metastatic disease.

          -  History of ipsilateral invasive breast cancer regardless of treatment or ipsilateral
             ductal carcinoma in situ (DCIS) treated with radiotherapy or contralateral invasive
             breast cancer at any time.

          -  Any treatment, including radiotherapy, chemotherapy, and/or targeted therapy,
             administered for the currently diagnosed breast cancer prior to study entry.

          -  Use of any medication or substances that are strong inhibitors or inducers of CYP3A
             isoenzymes.

          -  Class III or Class IV myocardial disease as described by the New York Heart
             Association; a recent history (within 6 months) of myocardial infarction, or
             symptomatic arrhythmia at the time of randomization. Class III: Patients with cardiac
             disease resulting in marked limitation of physical activity. Such patients are
             comfortable at rest. Less than ordinary physical activity that causes fatigue,
             palpitation, dyspnea, or anginal pain. Class IV: Patients with cardiac disease
             resulting in inability to perform any physical activity without discomfort. Symptoms
             of cardiac insufficiency or anginal syndrome may be present even at rest.

          -  QTc greater than 480 msec or a family or personal history of long or short QT
             syndrome, Brugada syndrome or know history of QTc prolongation, or Torsade de Pointes
             (TdP).

          -  The investigator should assess the patient to determine if she has any psychiatric or
             addictive disorder or other condition that, in the opinion of the investigator, would
             preclude her from meeting the study requirements.
      "
NCT02296203,unknown status,,1,phase 2,['metastatic colorectal cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['cetuximab', 'irinotecan']",['CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7'],"
        Inclusion Criteria:

          -  Histologically proven diagnosis of colorectal adenocarcinoma;

          -  RAS and BRAF wild-type status;

          -  First-line irinotecan-based (FOLFIRI or FOLFOXIRI) cetuximab-containing therapy
             producing at least a partial response;

          -  First-line progression-free survival in response to cetuximab-containing therapy ≥6
             months;

          -  Documentation of progression to first-line cetuximab within 4 weeks after last
             cetuximab administration;

          -  Time between the end of first-line therapy and the start of third-line treatment with
             cetuximab plus irinotecan ≥4 months;

          -  Second-line oxaliplatin-based (FOLFOXIRI, FOLFOX or XELOX) bevacizumab-containing
             therapy;

          -  Documentation of progression to second-line treatment;

          -  Measurable disease according to RECIST criteria v1.1;

          -  Have tumor tissue (of primary tumor and metastases or at least one of the two)
             available for biomarker analysis;

          -  Male or female patients > 18 years of age;

          -  ECOG Performance Status ≤ 2;

          -  Life expectancy of at least 3 months;

          -  Adequate bone marrow, liver and renal function assessed within 14 days before starting
             study treatment;

          -  Women of childbearing potential must have a negative blood pregnancy test at the
             baseline visit. For this trial, women of childbearing potential are defined as all
             women after puberty, unless they are postmenopausal for at least 12 months, are
             surgically sterile or are sexually inactive;

          -  Subjects and their partners must be willing to avoid pregnancy during the trial and
             until 6 months after the last trial treatment. Male subjects with female partners of
             childbearing potential and female subjects of childbearing potential must, therefore,
             be willing to use adequate contraception as approved by the investigator, such as a
             two-barrier method or one-barrier method with spermicidal or intrauterine device. This
             requirement begins 2 weeks before receiving the first trial treatment and ends 6
             months after receiving the last treatment;

          -  Signed informed consent obtained before any study specific procedure.

        Exclusion Criteria:

          -  Active uncontrolled infections or active disseminated intravascular coagulation;

          -  Past or current history of malignancies other than colorectal carcinoma, except for
             curatively treated basal and squamous cell carcinoma of the skin cancer or in situ
             carcinoma of the cervix;

          -  Fertile women (< 12 months after last menstruation) and men of childbearing potential
             not willing to use effective means of contraception

          -  Women who are pregnant or are breastfeeding;

          -  Previous grade 3/4 infusion related reaction to cetuximab.
      "
NCT02299635,terminated,"
    the study was terminated on june 24th, 2015 due to change in strategy of pf-03084014
    development. there were no safety/efficacy concerns behind the decision.
  ",0,phase 2,['triple negative breast neoplasms'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['pf-03084014', 'pf-03084014', 'pf-03084014']","['CCCC(C(=O)NC1=CN(C=N1)C(C)(C)CNCC(C)(C)C)NC2CCC3=C(C2)C(=CC(=C3)F)F', 'CCCC(C(=O)NC1=CN(C=N1)C(C)(C)CNCC(C)(C)C)NC2CCC3=C(C2)C(=CC(=C3)F)F', 'CCCC(C(=O)NC1=CN(C=N1)C(C)(C)CNCC(C)(C)C)NC2CCC3=C(C2)C(=CC(=C3)F)F']","
        Inclusion Criteria:

          -  Histological or cytological diagnosis of triple negative breast cancer (TNBC) with
             evidence of a) metastatic or b) locally recurrent advanced disease that is not
             amenable to resection or radiotherapy with curative intent.

          -  Availability of an original diagnostic tumor tissue or the most recent metastatic
             tumor biopsies (archival biopsy or de novo biopsy) and a peripheral blood sample for
             Notch receptors genomic profiling

        Exclusion Criteria:

          -  Known brain metastases.

          -  Prior treatment with gamma secretase inhibitor or other Notch signaling inhibitor.
      "
NCT03970616,terminated,"
    the study was terminated due to regulatory approval of newer therapeutic options and slower
    than anticipated accrual.
  ",0,phase 1/phase 2,['hepatocellular carcinoma'],"[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]","['tivozanib', 'durvalumab']",['CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl'],"
        Subjects to be included

          1. ≥ 18 years old

          2. Signed and dated written informed consent

          3. Histologically or cytologically or radiologically confirmed unresectable locally
             advanced or metastatic hepatocellular carcinoma. Measurable or evaluable disease by
             RECIST 1.1 criteria. Patients can be either untreated or have progressed on both
             bevacizumab and atezolizumab or both bevacizumab and atezolizumab in combination with
             a second immune checkpoint inhibitor.

             o Patients who may have progressed on bevacizumab and atezolizumab who have any
             suggestion of pseudo-progression, should remain on bevacizumab and atezolizumab until
             progression is confirmed.

          4. Child-Pugh Class A.

          5. ECOG performance status ≤ 1 (see Appendix A) and life expectancy ≥ 3 months.

          6. Body weight > 30 kg

          7. Measured creatinine clearance (crCL) >40 mL/min or calculated crCL >40 mL/min as
             determined by Cockcroft-Gault (using actual body weight) Males CrCL = Weight (kg) ×
             (140 - Age) 72 × serum creatinine (mg/dL) Females CrCL = Weight (kg) × (140 - Age) 85
             × serum creatinine (mg/dL)

          8. Sexually active pre-menopausal female subjects (and female partners of male subjects)
             must use highly effective contraceptive measures, while on study and for at least 90
             days after the last dose of study drug. Sexually active male subjects must use
             adequate contraceptive measures, while on study and for at least 90 days after the
             last dose of study drug. All fertile male and female subjects and their partners must
             agree to use a highly effective method of contraception.

        Note - COVID-19 testing is not required prior to enrollment into the protocol, however,
        institutional guidelines on testing should be followed.

        Subjects to be excluded

          1. Subjects who have received prior systemic treatment for HCC except for both
             bevacizumab and atezolizumab or both bevacizumab and atezolizumab in combination with
             a second immune checkpoint inhibitor.

          2. Female subjects who are pregnant or breastfeeding or male or female subjects of
             reproductive potential who are not willing to employ effective birth control from
             screening to 90 days after the last dose of study drug.

          3. Brain metastases or spinal cord compression. Subjects with suspected brain metastases
             at screening should have an MRI (preferred) or CT scan each preferable with IV
             contrast of the brain prior to study entry. Brain metastases will not be recorded on
             RECIST Target Lesions at baseline.

          4. Any of the following hematologic abnormalities:

               -  Hemoglobin < 9.0 g/dL

               -  Absolute neutrophil count (ANC) < 1500 per mm3

               -  Platelet count < 75,000 per mm3

          5. Any of the following serum chemistry or urinalysis abnormalities:

               -  Total bilirubin > 2 × ULN (>2.5 mg/dL in subjects with Gilbert's syndrome)

               -  AST or ALT > 5 × ULN

               -  Alkaline phosphatase > 2.5 × ULN (or > 5 × ULN for subjects with liver or bone
                  metastasis)

               -  Serum creatinine > 1.5 × ULN •> 2+ proteinuria

          6. History of hepatic encephalopathy within past 12 months or requirement for medications
             to prevent or control encephalopathy (eg, no lactulose, rifaximin, etc if used for
             purposes of hepatic encephalopathy).

          7. GI Bleeding (eg, esophageal varices or ulcer bleeding) within 12 months. (Note: For
             patients with a history of GI bleeding for more than 12 months or assessed as high
             risk for esophageal variceal bleed by the Investigator, adequate endoscopic therapy
             according to institutional standards is required).

          8. Clinically meaningful ascites defined as ascites requiring non-pharmacologic
             intervention (eg, paracentesis) to maintain symptomatic control, within 6 months prior
             to the first scheduled dose. Subjects on stable doses of diuretics for ascites for ≥ 2
             months are eligible.

          9. Main portal vein thrombosis (Vp4) as documented on imaging. (VP4 is defined as portal
             vein thrombosis in the main trunk of the portal vein or a portal vein branch
             contralateral to the primarily involved lobe (or both).

         10. For subjects who require ongoing therapeutic anti-coagulation or anti-platelet
             therapy; the subject must be off either therapy for at least 7 days prior to the first
             dose of investigational product. Low-dose aspirin for cardiac prophylaxis/protection
             is permitted per local institutional standards.

         11. Patients co-infected with HBV and HCV. HBV positive [presence of hepatitis B surface
             antigen (HBsAg) and/or hepatitis B core antibodies (anti-HBcAb) with detectable HBV
             DNA (≥10IU/ml)]; HCV positive (presence of anti-HCV antibodies).

         12. Major surgery (as defined by the investigator) within 28 days prior to first dose of
             IP or still recovering from prior surgery. Local procedures (eg, core needle biopsy,
             and prostate biopsy) are allowed if completed at least 3 days prior to the
             administration of the first dose of study treatment.

         13. Significant cardiovascular disease, including:

               -  Clinically symptomatic heart failure. Subjects with a history of heart failure
                  must have an ECHO or MUGA scan to document left ventricular ejection fraction
                  (LVEF) > 45% prior to start of protocol therapy

               -  Any New York Heart Association classification ≥ Class 2 (prefer Class 0 or 1)

               -  Any stenting procedure within the last 3 months

               -  Venous thromboembolism or arterial thromboembolism within the last 3 months

               -  Any IVC tumor thrombosis

               -  History of a hemorrhagic event (i.e., GI bleed within 6 months)

               -  Uncontrolled hypertension: blood pressure >150/95 mmHg on more than 2
                  antihypertensive medications, on two consecutive measurements obtained at least
                  24 hours apart. Subjects with a history of hypertension must have been on stable
                  doses of anti-hypertensive drugs for ≥ 2 weeks prior to start of protocol
                  therapy.

               -  Myocardial infarction within 3 months prior to start of protocol therapy

         14. Subjects with delayed healing of wounds, ulcers, and/or bone fractures

         15. Serious/active infection or infection requiring parenteral antibiotics

         16. Inadequate recovery from any prior surgical procedure; major surgical procedure within
             4 weeks prior to start of protocol therapy.

         17. Inability to comply with protocol requirements

         18. History of another primary malignancy except for:

               -  Malignancy treated with curative intent and with no known active disease ≥ 5
                  years before the first dose of study drug and low potential risk for recurrence

               -  Adequately treated non-melanoma skin cancer of lentigo maligna without evidence
                  of disease

         19. Active infection including tuberculosis (clinical evaluation that includes clinical
             history, physical examination and radiographic findings, and tuberculosis testing in
             line with local practice), hepatitis C, or human immunodeficiency virus (positive HIV
             1/2 antibodies). Subjects positive for hepatitis C (HCV) antibody are eligible only if
             polymerase chain reaction is negative for HCV RNA.

         20. Patients with a history or current HBV infection (detectable HBV DNA), should be
             placed on anti-viral treatment and tested at every cycle for HBV DNA viral load.

         21. Palliative radiotherapy with a limited field of radiation within 2 weeks or with wide
             field of radiation or to more than 30% of the bone marrow within 4 weeks before the
             first dose of study intervention.

         22. Treatment with systemic hormonal therapy within 3 weeks prior to start of protocol
             therapy, with the exception of:

               -  Hormonal therapy for appetite stimulation or contraception

               -  Nasal, ophthalmic, inhaled and topical steroid preparations

               -  Oral replacement therapy for adrenal insufficiency

               -  Low-dose maintenance steroid therapy (equivalent of prednisone 10mg/day) for
                  other conditions

               -  Hormone replacement therapy such as testosterone

         23. Strong CYP3A4 inducers (see Appendix B) within 2 weeks prior to start of, or during,
             protocol therapy.

         24. Prior exposure to tivozanib or durvalumab. For subjects who have received prior
             atezolizumab:

               -  Must not have experienced a toxicity that led to permanent discontinuation of
                  prior immunotherapy.

               -  All AEs while receiving prior immunotherapy must have completely resolved or
                  resolved to baseline prior to screening for this study.

               -  Must not have experienced a Grade ≥ 3 immune-related AE or an immune-related
                  neurologic or ocular AE of any grade while receiving prior immunotherapy. Note:
                  Participants with an endocrine AE of Grade ≤ 2 are permitted to enroll if they
                  are stably maintained on appropriate replacement therapy and are asymptomatic.

               -  Must not have required the use of additional immunosuppression other than
                  corticosteroids for the management of an AE, not have experienced recurrence of
                  an AE if re-challenged, and not currently require maintenance doses of > 10 mg
                  prednisone or equivalent per day.

         25. History of allogeneic organ transplantation

         26. Active or prior documented autoimmune or inflammatory disorders (including
             inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with
             the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome,
             or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid
             arthritis, hypophysitis, uveitis, etc.]). The following are exceptions to this
             criterion:

               -  Subjects with vitiligo or alopecia

               -  Subjects with hypothyroidism (e.g., following Hashimoto syndrome) stable on
                  hormone replacement

               -  Any chronic skin condition that does not require systemic therapy

               -  Subjects without active disease in the last 5 years may be included but only
                  after consultation with Medical Monitor

               -  Subjects with celiac disease controlled by diet alone

         27. Uncontrolled intercurrent illness, including but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable
             angina pectoris, uncontrolled cardiac arrhythmia, active interstitial lung disease,
             serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric
             illness/social situations that would limit compliance with study requirement,
             substantially increase risk of incurring AEs or compromise the ability of the subject
             to give written informed consent

         28. History of leptomeningeal carcinomatosis

         29. History of active primary immunodeficiency

         30. Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms
             calculated from 3 ECGs (within 15 minutes at 5 minutes apart)

         31. Known allergy or hypersensitivity to any of the study drugs or any of the study drug
             excipients

         32. Concurrent enrollment in another clinical study, unless it is an observational (non
             interventional) clinical study or during the follow-up period of an interventional
             study

         33. Receipt of live attenuated vaccine within 30 days prior to the first dose of study
             drug. Note: Subjects, if enrolled, should not receive live vaccine whilst receiving
             study drug and up to 30 days after the last dose of study drug.

         34. Current or prior use of immunosuppressive medication within 14 days before the first
             dose of durvalumab. The following are exceptions to this criterion:

               -  Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra
                  articular injection)

               -  Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of
                  prednisone or its equivalent

               -  Steroids as premedication for hypersensitivity reactions (e.g., CT scan
                  premedication)

         35. Previous study drug assignment in the present study.
      "
NCT02829918,"active, not recruiting",,1,phase 2,"['biliary tract cancer', 'biliary tract neoplasms']","[""['C24.9', 'C24.8']"", ""['C24.9', 'C24.8']""]",['nivolumab'],['Status: 503'],"
        Inclusion Criteria:

          -  Must have histologically or cytologically documented carcinoma primary to the intra-
             or extra-hepatic biliary system or gall bladder with clinical and/or radiologic
             evidence of unresectable, locally advanced or metastatic disease. Patients with
             ampullary carcinoma are not eligible.

          -  Must have failed or are intolerant to one line of systemic treatment but no more than
             2 prior lines of systemic chemotherapy for advanced BTC. Patients who received
             adjuvant chemotherapy and had evidence of disease recurrence within 6 months of
             completion of the adjuvant treatment are also eligible. If the patient received
             adjuvant treatment and had disease recurrence after 6 months, patients will only be
             eligible after failing or having intolerance to one line of systemic chemotherapy used
             to treat the disease recurrence.

          -  Age ≥ 18

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status Assessment of 0 or 1.

          -  Must have radiographic measurable disease per Response Evaluation Criteria in Solid
             Tumors (RECIST) 1.1.

          -  Life expectancy of at least 12 weeks (3 months).

          -  For patients who have received prior radiation, cryotherapy, radiofrequency ablation,
             therasphere, ethanol injection, transarterial chemoembolization (TACE) or photodynamic
             therapy, the following criteria must be met: 28 days have elapsed since that therapy;
             Lesions that have not been treated with local therapy must be present and measureable.

          -  Must be able to understand and be willing to sign the written informed consent form.
             Must be willing and able to comply with scheduled visits, treatment schedule,
             laboratory testing, and other study requirements.

          -  All acute toxic effects of any prior treatment have resolved to NCI-CTCAE v4.0 Grade 1
             or less at the time of signing the Informed Consent Form (ICF) except for alopecia.

          -  Adequate bone marrow, liver and liver function.

          -  Women of childbearing potential must have a negative serum or urine pregnancy test
             (minimum sensitivity of 25 IU/L or equivalent units of HCG) performed within24 hours
             prior to the start of nivolumab Post-menopausal women (defined as no menses for at
             least 1 year) and surgically sterilized women are not required to undergo a pregnancy
             test.

          -  Men and women of childbearing potential must agree to use adequate contraception
             beginning at the signing of the ICF until at least 3 months after the last dose of
             study drug.

          -  Patients with history of hepatitis B and hepatitis C will be eligible but patients
             with hepatitis B must be started on antiviral therapy prior to beginning study
             therapy.

          -  Availability of archival tumor tissue for biomarkers analysis (FFPE block or cell
             block will be required).

        Exclusion Criteria:

          -  Active central nervous system (CNS). If CNS metastases are treated and potential
             participants are at neurologic baseline for at least 2 weeks prior to enrollment, they
             will be eligible but will need a Brain MRI prior to enrollment. Must be off
             corticosteroids or on a dose of less than 10 mg per day.

          -  Active, known or suspected autoimmune disease. Potential participants with vitiligo,
             type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only
             requiring hormone replacement, or conditions not expected to recur in the absence of
             an external trigger are permitted to enroll.

          -  A condition requiring systemic treatment with either corticosteroids (>10 mg daily
             prednisone equivalent) or other immunosuppressive medications within 14 days of
             enrollment. Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg
             daily prednisone equivalent, are permitted in the absence of active autoimmune
             disease.

          -  Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4
             antibody (including ipilimumab or any other antibody or drug specifically targeting
             T-cell costimulation or checkpoint pathways).

          -  Previous or concurrent cancer within 3 years prior to treatment start EXCEPT for
             curatively treated cervical cancer in situ, non-melanoma skin cancer, superficial
             bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades
             lamina propria)].

          -  Known history of human immunodeficiency virus (HIV) infection or acquired
             immunodeficiency syndrome (AIDS).

          -  Child Pugh B or C disease.

          -  History of severe hypersensitivity reactions to other monoclonal antibodies.

          -  History of allergy or intolerance to study drug components or
             Polysorbate-80-containing Infusions.

          -  Substance abuse, medical, psychological or social conditions that may interfere with
             the patient's participation in the study or evaluation of the study results.

          -  History or concurrent condition of interstitial lung disease of any grade or severely
             impaired pulmonary function.

          -  Unresolved toxicity higher than CTCAE grade1 attributed to any prior therapy/procedure
             excluding alopecia.

          -  Pregnant or breast-feeding patients. Women of childbearing potential must have a
             negative serum or urine pregnancy test (minimum sensitivity of 25 IU/L or equivalent
             units of HCG) performed within 24 hours prior to the start of nivolumab and a negative
             results must be documented before start of treatment.

          -  Any illness or medical conditions that are unstable or could jeopardize the safety of
             the patient and his/her compliance in the study.

          -  Excluded Therapies and Medications for Cancer: 1) Anticancer chemotherapy during the
             study or within 4 weeks of study enrollment. Must have recovered from the toxic
             effects of the previous anti-cancer chemotherapy (with the exception of alopecia).
             Anti-cancer therapy is defined as any agent or combination of agents with clinically
             proven anti-tumor activity administered by any route with the purpose of affecting the
             malignancy, either directly or indirectly, including palliative and therapeutic
             endpoints. 2) Hormonal therapy during the study or within 2 weeks of first study
             enrollment. 3) Radiotherapy to target lesions during study or within 2 weeks of
             enrollment. 4) An irradiated lesion is considered evaluable only if it has shown
             enlargement since the completion of last radiation. 5) Bone marrow transplant or stem
             cell rescue. 6) Investigational drug therapy outside of this trial during or within 4
             weeks of first study treatment.
      "
NCT03869762,terminated,"
    insufficient accrual
  ",0,phase 2,"['castration-resistant prostate cancer', 'metastatic cancer', 'bone metastases']","[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['xgeva', 'xtandi']",['CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C'],"
        Inclusion Criteria:

          1. Written informed consent obtained prior to any study-related procedures.

          2. Age ≥ 18 years and male.

          3. ECOG performance status ≤ 2.

          4. Histologically/cytologically confirmed adenocarcinoma of the prostate, and without
             neuroendocrine differentiation or small cell histology.

          5. Documented metastatic disease with at least 1 bone metastasis on bone scan and
             confirmed, if necessary, by CT scan or MRI, if results of the bone scans are
             ambiguous. Patients with or without visceral involvement / lymph nodes (documented by
             RECIST 1.1) are allowed.

          6. Patients must have documented Progressive disease (PD) either by radiographic or PSA
             criteria as defined in a) and b) below:

               1. For the Radiographic PD assessment, 2 sets of scans using the same imaging
                  modality (ie CT/MRI or bone scan) and taken at separate time points are required
                  to document radiographic disease progression during or following the patient's
                  most recent anti-neoplastic therapy, (note: the 1st bone scan can be from before
                  most recent therapy but the 2nd scan must show disease progression during or
                  after the most recent therapy).

                  For patients with bone disease, progression will be assessed following
                  recommendations by the Prostate Cancer Working Group (PCWG3) (Appendix I):
                  appearance of 2 or more new lesions on bone scan, confirmed, if necessary, by
                  other imaging modalities (such as CT scan or MRI), if results of the bone scans
                  are ambiguous).

                  For patients with soft tissue lesions progression will be assessed using RECIST
                  1.1 criteria, (see Appendix C). Patients may have measurable or non-measurable
                  disease according to RECIST criteria version 1.1 (see Appendix C)

               2. PSA progression as per PCWG3 (Appendix I) is defined as an increase in PSA, as
                  determined by 2 separate measurements taken at least 1 week apart and confirmed
                  by a third. If the third measurement is not greater than the second measurement,
                  then a fourth measurement must be taken and must be greater than the second
                  measurement for the patient to be eligible for the study. Furthermore, the
                  confirmatory PSA measurement (i.e. the third or, if applicable, fourth PSA
                  measurement) must be defined. If a patient has received prior anti-androgen
                  therapy (e.g. bicalutamide), PSA progression must be evident and documented after
                  discontinuation of anti-androgen therapy, (note: The 1st PSA reading taken to
                  document disease progression when the patient presents can be while the patient
                  is on Casodex or other ADT).

          7. Prior surgical castration or concurrent use of an agent for medical castration (e.g.
             GnRH analogue) with testosterone at screening less than 1.73 nmol /l (50ng/dL).

          8. Screening PSA ≥ 2 ng/mL.

          9. Patients must agree to:

               -  abstain from intercourse or

               -  if the patient engages in sexual intercourse with a woman of childbearing
                  potential, a condom and a highly effective birth control must be used (i.e.
                  hormonal contraception associated with inhibition of ovulation, intrauterine
                  device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal
                  occlusion or a vasectomy that has received medical assessment of the surgical
                  success) during treatment and for 5 months after treatment.

         10. Stable medical condition, including the absence of acute exacerbations of chronic
             illnesses, serious infections, or major surgery within 28 days prior to registration.

         11. Life expectancy of 12 months or more based on general health and prostate cancer
             disease status as judged by the investigator.

         12. Able to swallow study drug as whole tablet.

         13. Adequate haematological, hepatic, and renal function.

               -  Haemoglobin ≥ 10g/dL.

               -  Neutrophils (ANC/AGC) ≥ 1500/mm³ (1.5 x 109/L).

               -  Platelets ≥ (100 x 109/L).

               -  Total bilirubin ≤ 1.5mg/dL (25.65 μmol/L) with the exception of Gilberts
                  syndrome.

               -  Both Alanine aminotransferase (ALT (SGPT)) and Aspartate aminotransferase (AST
                  (SGOT) ≤ 3 x ULN with or without liver Metastasis.

               -  Calculated creatinine clearance (CrCl) ≥ 30mL/min according to the Cockcroft and
                  Gault formula (Appendix D).

               -  Serum corrected Calcium within normal range and > 2 mmol/L

         14. Continuous daily use of oral prednisone, oral dexamethasone, or other systemic
             corticosteroids is allowed prior to study entry but must be discontinued a minimum of
             2 weeks prior to start of study treatment.

        Exclusion Criteria:

          1. Patients should not be receiving any other investigational agents for the treatment of
             prostate cancer or other diseases (within 30 days prior to registration).

          2. Patients with GI tract disease resulting in an inability to take oral medication,
             malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures
             affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's disease,
             ulcerative colitis).

          3. Have current active hepatic or biliary disease (with exception of patients with
             Gilbert's syndrome, asymptomatic gallstones, or stable chronic liver disease per
             investigator assessment).

          4. Prior therapy with orteronel, ketoconazole, aminoglutethimide, abiraterone or
             enzalutamide, denosumab or radium 223.

          5. All anti-androgen therapy (including bicalutamide) is excluded within 6 weeks prior to
             first dose of study drug. Any other therapies for prostate cancer, other than GnRH
             analogue therapy, such as progesterone, medroxyprogesterone, progestins (megesterol),
             or 5-alpha reductase inhibitors (eg, finasteride or dutasteride), must be discontinued
             2 weeks before the first dose of study drug. No prior bisphosphonates/Rank ligand
             inhibitors are allowed except when administered for bone density preservation in
             association with androgen deprivation therapy.

          6. Prior chemotherapy for prostate cancer, with the exception of:

               -  neoadjuvant/ adjuvant therapy as part of initial primary treatment for local
                  disease that was completed 2 or more years prior to screening.

               -  Patients who received prior docetaxol for castrate sensitive metastatic prostate
                  cancer commencing with 120 days of ADT initation where total dose received did
                  not exceed 450mg/m2

          7. Diagnosis of or treatment for another systemic malignancy within 2 years before the
             first dose of study drug, or previously diagnosed with another malignancy and have any
             evidence of residual disease. Patients with non-melanoma skin cancer or carcinoma in
             situ of any type are not excluded if they have undergone complete resection.

          8. History of myocardial infarction, unstable symptomatic ischemic heart disease/
             unstable angina, uncontrolled on-going arrhythmias of Grade >2 (National Cancer
             Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5),
             pulmonary embolism, or any other cardiac condition (e.g. pericardial effusion
             restrictive cardiomyopathy) within 6 months prior to first dose of study drug.
             Patients with long QT, QTcF >470ms or uncontrolled hypertension are excluded.

          9. New York Heart Association Class III or IV heart failure (see Appendix F).

         10. History of seizure, underlying brain injury with loss of consciousness, stroke,
             transient ischaemic attack (TIA), cerebral vascular accident, primary brain tumours or
             brain metastases, brain arteriovenous malformation, alcoholism, or the use of
             concomitant medications that may lower the seizure threshold.

         11. Known human immunodeficiency virus (HIV) infection, active chronic hepatitis B or C,
             life-threatening illness unrelated to cancer, or any ongoing serious medical or
             psychiatric illness that could, in the investigator's opinion, potentially interfere
             with participation in this study. Patients will be tested for hepatitis B or C or HIV
             infection during screening if they are considered by the investigator to be at higher
             risk for these infections and have not been previously tested, or if testing is
             required by the independent ethics committee or institutional review board.

         12. Prohibited medications, including drugs that are known to lower the seizure threshold
             or prolong QT interval are not permitted see section 7.4.2.

         13. Patients with prior history of ONJ or osteomyelitis of the jaw, an active dental or
             jaw condition requiring oral surgery, non-healed dental/oral surgery, or any planned
             invasive dental procedure are excluded as confirmed by dental examination.

         14. Patients with rare hereditary problems of fructose intolerance.
      "
NCT03185871,withdrawn,"
    slow accrual
  ",0,phase 2,['breast carcinoma'],"[""['C4A.52', 'C44.511', 'C44.521', 'D05.00', 'D05.01', 'D05.02', 'D05.10']""]",['celecoxib'],['CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F'],"
        Inclusion Criteria:

          -  Participants must have biopsy proven invasive breast carcinoma stages T1cN0 to T3N0,
             ER or PR positive with tumors greater than 1cm without lymph node spread.

          -  Participants must have a mammographic breast composition category (density) of c or d.

          -  Participants must be willing to participate and provide signed informed consent.

          -  Participants must have no immediate requirements for chemotherapy, radiotherapy or
             hormonal therapy.

          -  Participants must be willing to discontinue any use of NSAIDs like aspirin or
             ibuprofen until the tumor is removed

          -  Participants cannot be taking the following medications because of major
             pharmacokinetic interactions with celecoxib while being enrolled in the study:
             Abciximab, Argatroban, Bivalirudin, Cilostazol, Dabigatran, Etexilate, Dipyridamole,
             Fondaparinux, Heparin, Lepirudin, Pemetrexed, Protein C, Rivaroxaban, Sibutramine,
             Ticlopidine, Tirofiban, Vilazodone and Warfarin.

          -  Participants should pass MRI screening questionnaire

        Exclusion Criteria:

          -  Prior history of cancer, neo-adjuvant chemotherapy and radiation therapy

          -  No daily NSAIDs intake within the past 4 weeks. Intermittent non-daily NSAIDs is
             allowed under PI discretion.

          -  Current or prior systemic use of corticosteroids in the past month.

          -  Participants with history of hypertension, congestive heart failure, edema, stroke or
             other cardiac disease or condition.

          -  Participants with type 2 diabetes, documented stomach ulcers and pulmonary embolism.

          -  Participants with aspirin or other NSAIDs-induced asthma or hypersensitivity reaction,
             sulfonamide allergy

          -  Participants who are currently pregnant

          -  Participants with known human immunodeficiency virus (HIV) infection, hepatitis B
             carrier state or with clinical evidence of hepatitis B.

          -  Participants who are not able to understand or provide written informed consent.

          -  Participants with standard contraindications to non-contrast MRI will be excluded,
             including claustrophobia and metallic implants incompatible with MRI.

          -  Participants whose girth exceeds the bore of the MRI scanner.

          -  Participants requiring conscious sedation for MR imaging.
      "
NCT03381118,terminated,"
    unexpected toxicity
  ",0,phase 2,['acute myeloid leukemia'],"[""['C92.A1', 'C92.A2', 'C92.61', 'C92.62', 'C92.A0', 'C92.60']""]","['cytarabine', 'nivolumab', 'cytarabine', 'nivolumab']","['C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O']","
        Inclusion Criteria:

          -  Patients with a diagnosis of acute myeloid leukemia with the confirmed first or second
             complete remission

          -  ≥ 55 years of age

          -  Not candidates for allogeneic stem cell transplantation as decided by the panel of
             hematologists at the transplant center

          -  Patients with a HLA-haploidentical donor who should be able to provide informed
             consent for peripheral blood apheresis

          -  No severe concurrent illness that limits life expectancy to less than 2 years

        Exclusion Criteria:

          -  Uncontrolled bacterial or fungal infection at the time of enrollment

          -  Karnofsky index <70%

          -  Acute promyelocytic leukemia

          -  Other tumor requiring treatment at the time of enrollment

          -  Active or prior documented autoimmune disease requiring systemic treatment

          -  Somatic or psychiatric disorder making the patient unable to sign informed consent
      "
NCT02021370,completed,,1,phase 2,"['anemia', 'renal insufficiency, chronic']","[""['D53.2', 'D64.9', 'D46.4', 'D53.0', 'D53.9', 'D61.3', 'D61.9']"", ""['N25.0', 'Q61.4', 'N23', 'N26.9', 'P96.0', 'Q60.0', 'Q60.1']""]","['bay85-3934', 'placebo']",['C1COCCN1C2=NC=NC(=C2)N3C(=O)C(=CN3)N4C=CN=N4'],"
        Inclusion Criteria:

          -  Women without childbearing potential

          -  Male or female subjects ≥ 18 years of age with anemia of chronic kidney disease (CKD)
             at screening

          -  Estimated glomerular filtration rate of < 60 mL/min/1.73 m2 (Modification of Diet in
             Renal Disease [MDRD] or the formula according to Matsuo, et al)

          -  Not on dialysis and not expected to begin dialysis during the treatment period of the
             study (at least 16 weeks from randomization)

          -  Not treated with any erythropoiesis-stimulating agent (ESA) within 8 weeks before
             randomization

          -  Mean screening Hb concentration </= 10.5 g/dL

          -  Body weight of 45 kg to 125 kg, inclusive, at screening

        Exclusion Criteria:

          -  Subjects with significant acute or chronic bleeding, such as overt gastrointestinal
             bleeding

          -  Chronic inflammatory disease that could impact erythropoiesis (e.g., systemic lupus
             erythematosis, rheumatoid arthritis, celiac disease) even if it is currently in
             remission

          -  Previous or concurrent cancer except cervical carcinoma in situ, treated basal cell
             carcinoma, superficial bladder tumors (Ta, Tis, and T1) or any cancer curatively
             treated > 3 years prior to randomization

          -  Subjects treated with any ESA within the 8 weeks before randomization

          -  Red blood cell (RBC) containing transfusion within the 8 weeks before randomization

          -  History of cardio- (cerebro-) vascular events (e.g., unstable angina, myocardial
             infarction, stroke, transient ischemic attack, deep vein thrombosis, pulmonary
             embolism) within the last 6 months from initial screening visit

          -  Severe rhythm or conduction disorders (e.g., HR < 50 or > 110 bpm, atrial flutter,
             prolonged QT > 500 msec, third degree atrioventricular [AV] block)

          -  New York Heart Association Class III or IV congestive heart failure

          -  Severe hepatic insufficiency (defined as alanine aminotransferase [ALT] or aspartate
             aminotransferase [AST] > 3 x the upper limit of normal [ULN], total bilirubin > 2
             mg/dL, or Child-Pugh B and C) or active hepatitis, in the investigator's opinion
      "
NCT02025985,completed,,1,phase 2,"['ovarian carcinoma', 'endometrial carcinoma', 'cervical carcinoma']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]",['selinexor'],['C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F'],"
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

          -  Adequate hematologic function defined as:

               -  platelets ≥125*10^9 per liter (/L)

               -  hemoglobin ≥5.59 millimoles per liter (mmol/L) or 9 grams per deciliter (g/dL)

               -  Absolute neutrophil count (ANC) ≥1.5*10^9/L

               -  White blood cells (WBC) count ≥3.0*10^9/L

               -  Up to 5 percent (%) deviation is tolerated. Transfusions and growth factors are
                  allowed.

          -  Adequate liver function defined as adequate hepatic function within 14 days prior to
             Cycle 1 Day 1: total bilirubin <2 times the upper limit of normal (ULN) (except
             participants with Gilbert's syndrome, who must have a total bilirubin of <3 times
             ULN), aspartate aminotransferase (AST) <2.0 times ULN, and alanine aminotransferase
             (ALT) <2.0 times ULN. In the case of known (radiologically and/or biopsy- documented)
             liver metastasis, AST <5.0 times ULN and ALT <5.0 times ULN is acceptable. Up to 10%
             deviation is acceptable.

          -  Renal function defined as a calculated or measured glomerular filtration rate ≥30
             milliliter per minute (mL/min).

          -  The participant has recovered to Grade less than or equal to (≤) 1 by the National
             Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03
             (NCI-CTCAE v4.03) from the effects of recent surgery, radiotherapy, chemotherapy,
             hormonal therapy, or other targeted therapies, with the exception of alopecia. The
             exceptions for such effects are allowed lab values of ≤Grade 2 specified elsewhere in
             these inclusion criteria.

          -  Life expectancy of at least 12 weeks.

          -  Able to swallow and retain oral medication.

          -  Participants must give informed consent according to the rules and regulations of the
             individual participating sites.

          -  Negative serum pregnancy test in women of childbearing potential within 14 days of
             first dose of treatment, and participants of childbearing potential must agree to use
             effective contraception during treatment up to 3 months from last dose. Fertile male
             partners must be willing and able to use effective non-hormonal means of contraception
             (barrier method of contraception in conjunction with spermicidal jelly, or surgical
             sterilization) during and for at least 6 months post-study treatment.

          -  The participant must be recovered from any prior treatment/major operation. The
             treatment/major operation must be performed at least 4 weeks prior to start of study
             drug. Palliative radiotherapy is permitted until one week prior to the start of study
             drug.

          -  Only incurable participants with histologically or cytologically proven primary tumor
             and objective documentation of disease progression on prior treatment by computerized
             tomography (CT)/ magnetic resonance imaging (MRI) may be enrolled.

          -  Ovarian, fallopian tube, or peritoneal carcinoma: both platinum refractory* and
             platinum resistant** participants, who have received ≥1 line of chemotherapy for
             relapsed disease (i.e., ≥2 lines of chemotherapy in total).

             *Platinum refractory is defined as progression during or within 4 weeks of last
             treatment with a platinum-containing therapy.

             **Platinum resistant is defined as relapse 4 weeks to <6 months after a
             platinum-containing therapy.

          -  Endometrial carcinoma: participants must have received ≥1 line of chemotherapy for
             relapsed or advanced (Stage IV, IIIc) disease.

          -  Cervical carcinoma: participants must have received ≥1 line of chemotherapy for
             relapsed or advanced (Stage IV b) disease.

          -  Carcinosarcomas (Malignant Mixed Mullerian Tumor) are allowed, but all other
             nonepithelial cancers of the ovary, fallopian tube, endometrium, or cervix are
             excluded.

          -  Participants must have either measurable disease per RECIST 1.1 or evaluable disease
             outside irradiated field on CT/MRI. For ovarian cancer: Participants must have disease
             that is measurable according to RECIST or assessable according to the Gynecological
             Cancer Intergroup (GCIG) CA-125 criterion. A rise in CA-125 or other tumor marker
             alone is not sufficient.

        Exclusion Criteria:

          -  Disease-Specific Exclusions:

               -  Evidence of complete or partial bowel obstruction.

               -  Need of Total Parenteral Nutrition.

          -  Participants who are pregnant or breast feeding.

          -  Radiation (except planned or on-going palliative radiation to bone outside of the
             region of measurable disease) ≤3 weeks prior to Cycle 1 Day 1.

          -  Chemotherapy, endocrine therapy, immunotherapy or any other systemic anti-cancer
             therapy (including investigational anti-cancer therapy) ≤3 weeks prior to Cycle 1 Day
             1.

          -  Diagnosis or recurrence of invasive cancer other than the present cancer within 3
             years (except basal or squamous cell carcinoma of the skin that has been definitively
             treated).

          -  Unstable cardiovascular function:

               -  Symptomatic ischemia, or

               -  Uncontrolled clinically significant conduction abnormalities (e.g. ventricular
                  tachycardia on anti-arrhythmics are excluded and 1st degree atrioventricular (AV)
                  block or asymptomatic left anterior fascicular block (LAFB)/ right bundle branch
                  block (RBBB) will not be excluded), or

               -  Congestive heart failure (CHF) of New York Heart Association (NYHA) Class ≥3, or
                  myocardial infarction (MI) within 3 months of Cycle 1 Day 1.

          -  Uncontrolled active infection requiring parenteral antibiotics, antivirals, or
             antifungals within one week prior to the first dose. Active infection with concurrent
             treatment is acceptable only if the participant is clinically stable.

          -  Significantly diseased or obstructed gastrointestinal tract or uncontrolled vomiting
             or diarrhea.

          -  Concurrent therapy with approved or investigational anti-cancer therapeutics.

          -  Medical, psychological, or social conditions that may interfere with the participant's
             participation in the study or evaluation of the study results.

          -  Known brain metastases unless adequately treated (surgery or radiotherapy) with no
             evidence of progression and neurologically stable off anticonvulsants and
             glucocorticoids.

          -  All non-epithelial cancers of the ovary, fallopian tube, peritoneum, endometrium or
             cervix as well as neuro-endocrine tumors are excluded.
      "
NCT02021409,completed,,1,phase 2,"['anemia', 'renal insufficiency, chronic']","[""['D53.2', 'D64.9', 'D46.4', 'D53.0', 'D53.9', 'D61.3', 'D61.9']"", ""['N25.0', 'Q61.4', 'N23', 'N26.9', 'P96.0', 'Q60.0', 'Q60.1']""]",['bay85-3934'],['C1COCCN1C2=NC=NC(=C2)N3C(=O)C(=CN3)N4C=CN=N4'],"
        Inclusion Criteria:

          -  Male or female subjects ≥ 18 years of age with anemia of chronic kidney disease (CKD)
             at screening

          -  Estimated glomerular filtration rate (eGFR) of < 60 mL/min/1.73 m2 (Modification of
             Diet in Renal Disease or the formula according to Matsuo, et al.)

          -  Not on dialysis and not expected to begin dialysis during the treatment period of the
             study (at least 16 weeks from randomization)

          -  Treated with darbepoetin via intravenous (IV) or subcutaneous (SC) route with a
             weekly, bi-weekly, or monthly dose, having had no more than one dose change within 8
             weeks prior to randomization

          -  At least one kidney

          -  Mean screening hemoglobin (Hb) concentration of 10.0 to 12.0 g/dL

          -  Men who agree to use adequate contraception when sexually active or women without
             childbearing potential

        Exclusion Criteria:

          -  Subjects with significant acute or chronic bleeding, such as overt gastrointestinal
             bleeding

          -  Active hemolysis or diagnosis of hemolytic syndrome

          -  History of myelodysplastic syndrome, multiple myeloma, marrow fibrosis, or pure
             red-cell aplasia (PRCA)

          -  History of hemosiderosis or hemochromatosis

          -  Hereditary hemoglobinopathies (such as sickle cell disease and thalassemia major)

          -  Aplastic anemia

          -  Chronic lymphoproliferative diseases

          -  Proliferative choroidal or retinal disease, such as neovascular age-related macular
             degeneration or proliferative diabetic retinopathy that is likely to require invasive
             treatment (intraocular injections or laser photocoagulation) during the study

          -  Chronic inflammatory disease that could impact erythropoiesis (e.g., systemic lupus
             erythematosis, rheumatoid arthritis, celiac disease) even if it is currently in
             remission

          -  Known hypersensitivity to the study drugs (active substances or excipients of the
             preparations)

          -  Uncontrolled and symptomatic hyperparathyroidism

          -  Uncontrolled active infection

          -  Previous or concurrent cancer except cervical carcinoma in situ, treated basal cell
             carcinoma, superficial bladder tumors (Ta, Tis, and T1) or any cancer curatively
             treated > 3 years prior to randomization

          -  Any allograft (including renal allograft) in place and on immunosuppressive therapy or
             a scheduled kidney transplant within the next 16 weeks (being on a waiting list does
             not exclude the subject)
      "
NCT04576208,withdrawn,"
    business decision (no safety or efficacy concerns)
  ",0,phase 2,['non-small cell lung cancer (nsclc)'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['tak-788', 'antidiarrheal prophylaxis']",['CC(C)OC(=O)C1=CN=C(N=C1C2=CN(C3=CC=CC=C32)C)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC'],"
        Inclusion Criteria:

          1. Diagnosed with histologically or cytologically confirmed nonsquamous cell locally
             advanced (not suitable for definitive therapy) or metastatic non-small-cell lung
             cancer (NSCLC) (Stage IIIB or IV) NSCLC; and, has received at least 1 prior line of
             therapy for this disease.

          2. A documented epidermal growth factor receptor (EGFR) mutation with in-frame exon 20
             insertion, confirmed as follows:

               -  For sites located in the United States (US): assessment must be done by a
                  certified laboratory functioning under the guidelines of the Clinical Laboratory
                  Improvements Amendment (CLIA).

               -  For site located outside of the US: assessment must be done by an accredited
                  local laboratory.

             Note: A documented EGFR in-frame exon 20 insertion or insertion-duplication includes
             but is not limited to one of the following:

               -  A763_Y764insFQEA,

               -  V769_D770insASV (also referred to as ASV duplication)

               -  D770_N771insNPG

               -  D770_N771insSVD (also referred to as SVD duplication)

               -  H773_V774insNPH (also referred to as NPH duplication), or

               -  Any other in-frame insertion mutation in the exon 20 [amino acids 739 -823].

             The EGFR exon 20 insertion mutation can be either alone or in combination with other
             EGFR or HER2 mutations. The reported insertion-duplication can have been detected on
             either tissue or liquid biopsy using a well-validated test based on either polymerase
             chain reaction, sequencing or next-generation sequencing (NGS).

          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

          4. Minimum life expectancy of ≥3 months.

          5. All toxicities from prior therapy have been resolved to ≤Grade 1, according to the
             National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
             v5.0 or have resolved to baseline, at the time of first dose of TAK-788.

        Exclusion Criteria:

          1. Has been diagnosed with another primary malignancy other than NSCLC, except for the
             following:

               1. Adequately treated non-melanoma skin cancer or cervical cancer in situ.

               2. Definitively treated non-metastatic prostate cancer.

               3. Non-NSCLC primary malignancies that are definitively relapse-free for ≥3 years.

          2. Has unstable brain metastases to include previously untreated intracranial central
             nervous system (CNS) metastases or previously treated intracranial CNS metastases with
             radiologically documented new or progressing CNS lesions.

             - Brain metastases that are stable do not preclude eligibility if they have been
             treated with surgery and/or radiation, and have been stable without requiring
             corticosteroids to control symptoms within 7 days before randomization, and have no
             evidence of new or enlarging brain metastases.

          3. Has a current spinal cord compression (symptomatic or asymptomatic that is detectable
             by radiographic imaging) or leptomeningeal disease (symptomatic or asymptomatic).

          4. Currently has or has had a history of interstitial lung disease, to include radiation
             or drug related pneumonitis that requires/required steroid treatment.

          5. Has an ongoing or active infection, to include but not limited to infections requiring
             intravenous antibiotics or has a known history of HIV. Testing for HIV is not required
             in the absence of history.

             Note: Hepatitis B surface antigen-positive participants are allowed to enroll if
             hepatitis B virus (HBV) deoxyribonucleic acid (DNA) is below 1000 copies/mL in the
             plasma. Patients who are positive for anti-hepatitis C virus antibody can be enrolled
             but must not have detectable hepatitis C virus (HCV) RNA in the plasma.

          6. Have uncontrolled hypertension. Participants with hypertension should be under
             treatment on study entry to control blood pressure.

          7. A prolonged QTcF interval, or is being treated with medications known to be associated
             with the development of Torsades de Pointes.

          8. Has a GI illness or disorder, including but not limited to a history of GI
             perforation, that could affect oral absorption of TAK-788.
      "
NCT02769286,completed,,1,phase 2,"['lung neoplasms', 'egfr gene mutations']","[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]",['osimertinib'],['CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC'],"
        Inclusion Criteria:

        < Cohort 1 >

          1. Provision of informed consent prior to any study specific procedures

          2. Patients (male/female) must be > 18 years of age.

          3. Locally advanced or metastatic non-small cell lung cancer, not amenable to curative
             surgery or radiotherapy with or without pathologic diagnosis

          4. No prior exposure to EGFR TKI (multiple lines of prior cytotoxic chemotherapy are
             permitted.)

          5. Activating EGFR mutation (G719X, exon 19 deletion, L858R, L861Q) detected from
             circulating tumor DNA either by PANA mutyper® or Cobas® EGFR mutation test.

          6. Activating EGFR mutation (G719X, exon 19 deletion, L858R, L861Q) detected from tumor
             tissue or cytology specimen.

          7. World Health Organization (WHO) performance status 0-2.

          8. Patients must have a life expectancy ≥ 12 weeks.

          9. Females should be using adequate contraceptive measures, should not be breast feeding
             and must have a negative pregnancy test prior to start of dosing if of child-bearing
             potential or must have evidence of non-child-bearing potential by fulfilling one of
             the following criteria at screening:

               -  Post-menopausal defined as aged more than 50 years and amenorrheic for at least
                  12 months following cessation of all exogenous hormonal treatments

               -  Women under 50 years old would be consider postmenopausal if they have been
                  amenorrheic for 12 months or more following cessation of exogenous hormonal
                  treatments and with luteinizing hormone (LH) and follicle stimulating hormone
                  (FSH) levels in the post-menopausal range for the institution

               -  Documentation of irreversible surgical sterilisation by hysterectomy, bilateral
                  oophorectomy or bilateral salpingectomy but not tubal ligation

         10. Male patients should be willing to use barrier contraception.

         11. Patient is willing and able to comply with the protocol for the duration of the study
             including undergoing treatment and scheduled visits and examinations including follow
             up.

         12. At least one lesion, not previously irradiated, that can be accurately measured at
             baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have short
             axis ≥ 15 mm) with computed tomography (CT)

        < Cohort 2 >

          1. Provision of informed consent prior to any study specific procedures

          2. Patients (male/female) must be > 18 years of age.

          3. Locally advanced or metastatic non-small cell lung cancer, not amenable to curative
             surgery or radiotherapy with or without pathologic diagnosis

          4. Progression after prior exposure to gefitinib, erlotinib, afatinib or dacomitinib.
             Multiple lines of prior cytotoxic chemotherapy are permitted and there is no specified
             order of treatment.

          5. Patients must fulfil one of the following:

             5.1) Activating EGFR mutation (G719X, exon 19 deletion, L858R, L861Q) from tumor
             tissue or cytology or circulating tumor DNA 5.2) Must have experienced clinical
             benefit from prior EGFR-TKI, according to the Jackman criteria (Jackman 2010) followed
             by systemic objective progression (RECIST) while on continuous treatment with EGFR-TKI

          6. T790M mutation detected from circulating tumor DNA either by PANA mutyper® or Cobas®
             EGFR mutation test.

          7. World Health Organization (WHO) performance status 0-2.

          8. Patients must have a life expectancy ≥ 12 weeks.

          9. Females should be using adequate contraceptive measures, should not be breast feeding
             and must have a negative pregnancy test prior to start of dosing if of child-bearing
             potential or must have evidence of non-child-bearing potential by fulfilling one of
             the following criteria at screening:

               -  Post-menopausal defined as aged more than 50 years and amenorrheic for at least
                  12 months following cessation of all exogenous hormonal treatments

               -  Women under 50 years old would be consider postmenopausal if they have been
                  amenorrheic for 12 months or more following cessation of exogenous hormonal
                  treatments and with LH and FSH levels in the post-menopausal range for the
                  institution

               -  Documentation of irreversible surgical sterilisation by hysterectomy, bilateral
                  oophorectomy or bilateral salpingectomy but not tubal ligation

         10. Male patients should be willing to use barrier contraception.

         11. Patient is willing and able to comply with the protocol for the duration of the study
             including undergoing treatment and scheduled visits and examinations including follow
             up.

         12. At least one lesion, not previously irradiated, that can be accurately measured at
             baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have short
             axis ≥ 15 mm) with computed tomography (CT)

        Exclusion Criteria:

          1. Previous treatment with AZD9291, or other 3rd generation EGFR TKI

          2. Treatment with an investigational drug within five half-lives of the compound

          3. Patients currently receiving (or unable to stop use prior to receiving the first dose
             of study treatment) medications or herbal supplements known to be potent inhibitors of
             CYP3A4 (at least 1 week prior) and potent inducers of CYP3A4 (at least 3 week prior)
             (Appendix A). All patients must try to avoid concomitant use of any medications,
             herbal supplements and/or ingestion of foods with known inducer/inhibitory effects on
             CYP3A4.

          4. Any unresolved toxicities from prior therapy greater than Common Terminology Criteria
             for Adverse Events (CTCAE) grade 1 at the time of starting study treatment with the
             exception of alopecia and grade 2, prior platinum-therapy related neuropathy.

          5. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled
             hypertension and active bleeding diatheses, which in the investigator's opinion makes
             it undesirable for the patient to participate in the trial or which would jeopardise
             compliance with the protocol, or active infection including hepatitis B, hepatitis C
             and human immunodeficiency virus (HIV). Screening for chronic conditions is not
             required.

          6. Patients with symptomatic central nervous system (CNS) metastases who are
             neurologically unstable

          7. Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation
             pneumonitis requiring steroid treatment, or any evidence of clinically active ILD

          8. Inadequate bone marrow reserve or organ function as demonstrated by any of the
             following laboratory values:

             Absolute neutrophil count <1.5 x 109/L Platelet count <100 x 109/L Haemoglobin <90 g/L
             Alanine aminotransferase >2.5 times the upper limit of normal (ULN) if no demonstrable
             liver metastases or >5 times ULN in the presence of liver metastases Aspartate
             aminotransferase >2.5 times ULN if no demonstrable liver metastases or >5 times ULN in
             the presence of liver metastases Total bilirubin >1.5 times ULN if no liver metastases
             or >3 times ULN in the presence of documented Gilbert's Syndrome (unconjugated
             hyperbilirubinaemia) or liver metastases Creatinine >1.5 times ULN concurrent with
             creatinine clearance <50 ml/min (measured or calculated by Cockcroft and Gault
             equation); confirmation of creatinine clearance is only required when creatinine is
             >1.5 times ULN.

          9. Any of the following cardiac criteria:

               1. Mean resting corrected QT interval (QTc using Fredericia's formula) > 470 msec

               2. Any clinically important abnormalities in rhythm, conduction or morphology of
                  resting ECG (e.g., complete left bundle branch block, third degree heart block,
                  second degree heart block)

               3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic
                  events such as heart failure, hypokalemia, congenital long QT syndrome, family
                  history of long QT syndrome or unexplained sudden death under 40 years of age in
                  first degree relatives or any concomitant medication known to prolong the QT
                  interval

         10. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to
             swallow the formulated product or previous significant bowel resection that would
             preclude adequate absorption of AZD9291

         11. History of hypersensitivity to AZD9291 (or drugs with a similar chemical structure or
             class to AZD9291) or any excipients of these agents

         12. Males and females of reproductive potential who are not using an effective method of
             birth control and females who are pregnant or breastfeeding or have a positive (urine
             or serum) pregnancy test prior to study entry

         13. Judgment by the Investigator that the patient should not participate in the study if
             the patient is unlikely to comply with study procedures, restrictions and requirements

         14. Previous allogeneic bone marrow transplant.

         15. Non-leukocyte depleted whole blood transfusion within 120 days of the date of the
             genetic sample collection.
      "
NCT02768415,unknown status,,1,phase 2,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['apatinib', 'oral vinorelbine']",['C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4'],"
        Inclusion Criteria:

          1. Age between 18 and 75 year-old women; HER2 negative(immunohistochemistry or
             fluorescence in situ hybridization);

          2. ECOG score: 0-1, expected survival time ≥ 3months;

          3. Pathologically or cytologically confirmed breast cancer;

          4. Anthracycline- / taxane- pretreated (adjuvant, neoadjuvant) breast cancer patients who
             have failed from 1-2 standard chemotherapies after recurrence and metastasis;

          5. According to RECIST 1.1, exist at least ≥1 measurable lesion(CT >1cm，other examination
             >2cm) ;

          6. The patients have enough organ function. The laboratory test indexes must comply with
             the following requirements:

             Blood routine: neutrophil≥1.5G/L, platelet count ≥80G/L, hemoglobin ≥90g/L Liver
             function: serum bilirubin ≤ 1.5 times the upper limit of normal value; ALT and AST≤2.5
             times the upper limit of normal value; ALT and AST≤5 times the upper limit of normal
             value when liver metastasis Renal function: serum creatinine ≤ 1.0times the upper
             limit of normal value, creatinine clearance >50ml/min（Cockcroft-Gault formula)

          7. Women of child-bearing age should be carried out pregnancy test (serum or urine)
             within 7 days before recruit, the results should be negative; and are willing to adopt
             the appropriate methods of contraception during the trial and 8 weeks after last
             administration；

          8. Can swallow oral drugs;

          9. The patients have good compliance to the therapy and follow-up to be scheduled and are
             able to understand the study protocol and sign the Informed Consent Form.

        Exclusion Criteria:

          1. The patients in pregnancy or lactation growth period and did not take effective
             contraception;

          2. The patients who received ≥3 chemotherapies（Do not include endocrine therapy）after
             recurrence and metastasis; involved in other clinical trials four weeks prior to the
             start of the study;

          3. The patients with a variety of factors that affect the oral administration and
             absorption of drugs；

          4. The patients previously received anti-VEFG of anti-VEGFR therapies；

          5. The patients with rapid progression of viscera invasion(liver lesion >1/2 viscera area
             or liver dysfunction);

          6. The patients have uncontrollable mental illness.

          7. The patients who had serious adverse effect to oral vinorelbine or were allergic to
             vinorelbine.

          8. The patients who have only bone metastasis without other measurable lesion;

          9. The patients experience severe cardiovascular diseases;

         10. The patients experience severe upper gastrointestinal ulcer or malabsorption syndrome.

         11. Abnormal bone marrow functions(neutrophil<1.5G/L, platelet count <75G/L, hemoglobin
             <90g/L)；

         12. Abnormal renal function(serum creatinine > 1.5 times the upper limit of normal value)；

         13. Abnormal liver function(serum bilirubin ≤ 1.5 times the upper limit of normal value);

         14. The patients have uncontrollable brain metastasis;

         15. The patients do not have good compliance to the therapy.
      "
NCT02767752,terminated,"
    poor accrual and change of soc (folfirinox in adjuvant setting)
  ",0,phase 2,['pancreatic cancer'],"[""['C25.3']""]","['gemcitabine', 'capecitabine']","['C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F', 'CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O']","
        Inclusion Criteria:

          1. Signed informed consent

          2. Histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic
             complete resection (R0 and R1). Subjects with neuroendocrine (and mixed type) tumors
             are excluded

          3. Subject should be able to start treatment no later than 12 weeks post-surgery

          4. Male or non-pregnant, non-lactating females who are ≥18 years of age at the time of
             signing the informed consent form (ICF)

          5. ECOG/WHO Performance Status (PS) 0-1

          6. Females of child-bearing potential (defined as a sexually mature woman who (1) has not
             undergone hysterectomy [the surgical removal of the uterus] or bilateral oophorectomy
             [the surgical removal of both ovaries] or (2) has not been naturally postmenopausal
             for at least 24 consecutive months [i.e., has had menses at any time during the
             preceding 24 consecutive months]) must:

               -  Agree to the use of two physician-approved contraceptive methods (oral,
                  injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine
                  device; barrier contraceptive with spermicide; or vasectomized partner) while on
                  study IP; and for 3months following the last dose of IP

               -  Has negative serum pregnancy test (β-hCG) result at screening

          7. Male subjects:

             • Must practice true abstinence or agree to use a condom during sexual contact with a
             pregnant female or a female of childbearing potential while participating in the
             study, during dose interruptions and for 6 months following IP discontinuation, even
             if he has undergone a successful vasectomy

          8. Understand and voluntarily sign an ICF prior to any study related assessments or
             procedures being conducted

          9. Be able to adhere to the study visit schedule and other protocol requirements

         10. Acceptable hematology parameters defined as:

               -  Absolute neutrophil count (ANC) ≥ 1.5 x 10⁹/L

               -  Platelet count ≥ 100 x 10⁹/L

               -  Haemoglobin ≥ 5.6 mmol/L

         11. Acceptable liver function defined as:

               -  Serum bilirubin < 1.5 x upper limit of normal (ULN)

               -  ASAT/ALAT < 2.5 x ULN

         12. Acceptable renal function with a creatinine clearance ≥ 50 mL/min/ (e.g., using the
             Cockroft-Gault formula)

        Exclusion Criteria:

          1. Prior neo-adjuvant treatment, radiation therapy, or systemic therapy for pancreatic
             adenocarcinoma

          2. Presence of or history of metastatic or locally recurrent pancreatic adenocarcinoma

          3. Other malignancies, except adequately treated basal carcinoma or squamous cell
             carcinoma of the skin or in situ cervix carcinoma or incidental prostate cancer (T1a,
             Gleason score ≤ 6, PSA < 0.5 ng/ml), or any other tumor with a DSF survival of ≥ 5
             years

          4. History of serious or concurrent illness or uncontrolled medical disorder; any medical
             condition that might be aggravated by chemotherapy treatment or which could not be
             controlled; including, but not restricted to:

               -  Active infection requiring antibiotics within 2 weeks before the study inclusion

               -  Concurrent congestive heart failure NYHA class III - IV

               -  Unstable angina pectoris, or myocardial infarction within 6 months and/or prior
                  poorly controlled hypertension

               -  History of interstitial lung disease, slowly progressive dyspnea and unproductive
                  cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary
                  hypersensitivity pneumonitis or multiple allergies

               -  Concomitant use of immunosuppressive or myelosuppressive medications that would
                  in the opinion of the investigator, increase the risk of serious neutropenic
                  complications

          5. Known or suspected allergy to the investigational agents or any agents given in
             association with this trial

          6. Any psychological, familial, sociological, or geographical condition which does not
             permit protocol compliance and medical follow-up

          7. Enrollment in any other clinical protocol or investigational study with an
             interventional agent or assessments that may interfere with study procedures

          8. Any condition including the presence of laboratory abnormalities, which places the
             subject at unacceptable risk if he/she were to participate in the study

          9. Any condition that confounds the ability to interpret data from the study

         10. Unwillingness or inability to comply with study procedures

         11. Current use of anticoagulation therapy such as heparins both unfractionated and low
             molecular weighted
      "
NCT02760667,"active, not recruiting",,1,phase 2,['head and neck cancer'],"[""['C76.0', 'C47.0', 'C49.0', 'C77.0', 'D17.0', 'D21.0', 'D36.11']""]","['cisplatinum', 'docetaxel', 'carboplatin']","['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O', 'C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]']","
        Inclusion Criteria:

          -  Biopsy proven squamous cell carcinoma of the oropharynx (tonsil, base of tongue,
             vallecula, soft palate) and supraglottis.

          -  Stages III (T1N1, T2N1, T3N0, T3N1) and stage IVA (T1N2, T2N2, T3N2, very select
             earlyT4) disease not previously treated with any method (Surgery, Radiation or
             Chemotherapy)

          -  No evidence of distant metastatic disease

          -  Fit for surgery and primary tumor assessed surgically resectable (by surgical PI) via
             transoral approach

          -  Age > 18 years

          -  Karnofsky performance status > 60%, or ECOG < 2

          -  ANC > 2,000, platelets > 100,000 and calculated creatinine clearance >50 cc/min

          -  Signed study specific consent form

          -  Protocol begins within 4 weeks of biopsy and within 3 weeks of the latest medical
             imaging.

               -  No other malignancies except cutaneous basal or squamous cell cancer within the
                  last 5 years

               -  Patients must have measurable disease based on RECIST.

          -  Men and women of child bearing potential must agree to use effective contraception
             while on the study, and women must have a negative pregnancy test, and not be
             lactating.

        Exclusion Criteria:

          -  Patients with advanced T4 cancer judged unresectable by transoral approach by surgical
             PI.

          -  Patients with N3 disease (Stage IVB).

          -  Patients with distant metastatic disease (Stage IVC).

          -  Patients with radiologically positive neck nodes with radiological evidence of
             extracapsular nodal tumor invasion.

          -  Patients having anatomy not allowing transoral access and exposure for surgery(Judged
             by the surgical PI at the time of biopsy under general anesthesia)

          -  Patients with prior head and neck cancer at any time (other than basal or squamous
             cell cancer of the skin)

          -  Coexistent second malignancy or history within 5 years of prior malignancy (other than
             basal or squamous cell cancer of the skin or curatively treated Stage I carcinoma of
             the cervix) renders the patient ineligible.

          -  Patients with peripheral neuropathy >/= grade 1 will not be eligible for the study.

          -  Patients who have had prior Taxanes or Cisplatin

          -  Patients with concurrent infection are not eligible. All patients must be afebrile for
             at least 3 days prior to start of therapy unless fever is due to tumor.

          -  Patients with coexisting medical illness of a severity that might interfere with
             treatment or follow-up, or who do not have the ability to give informed consent.

          -  Patients who have received prior radiation therapy, surgery and chemotherapy for the
             tumor being treated.

          -  Patients must not be receiving any other investigational agent while on the study.
      "
NCT02766335,completed,,1,phase 2/phase 3,"['recurrent squamous cell lung carcinoma', 'stage iv squamous cell lung carcinoma ajcc v7']","[""['D02.20', 'D02.21', 'D02.22']""]",['docetaxel'],['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O'],"
        Inclusion Criteria:

          -  Patients must meet all SCREENING/PRE-SCREENING and SUB-STUDY REGISTRATION COMMON
             ELIGIBILITY CRITERIA as specified in S1400: Phase II/III Biomarker-Driven Master
             Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)

          -  Patients must have been assigned to S1400A

          -  Patients must not have any prior exposure to immunotherapy such as, but not limited to
             anti-programmed death 1 (PD-1) or anti-PD-L1 antibodies; prior exposure to the
             following is allowed: anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) antibodies, live
             attenuated vaccines, anti-EGFR agents and sargramostim (GM-GSF)

          -  Patients must not have received nitrosoureas or mitomycin-C within 42 days prior to
             sub-study registration

          -  Patients must not have any active or prior documented autoimmune or inflammatory
             disease (including inflammatory bowel disease, diverticulitis with the exception of
             diverticulosis, celiac disease, irritable bowel disease; Wegener syndrome; Hashimoto
             syndrome) within 3 years prior to sub-study registration; patients with vitiligo,
             alopecia, Grave's disease, or psoriasis requiring systemic treatment within the past 3
             years are not eligible

          -  Patients must not have any history of primary immunodeficiency

          -  Patients must not have received any immunosuppressive medication within 28 days prior
             to sub-study registration and must not be planning to receive any such agents while on
             protocol treatment; however, intranasal and inhaled corticosteroids or systemic
             corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or
             equivalent are allowed

          -  Patients must not have any prior grade >= 3 immune-related adverse event (irAE) or any
             unresolved irAE > grade 1

          -  Patients must not have any history of organ transplant that requires use of
             immunosuppressives

          -  Patients must not have any known allergy or reaction to any component of the MEDI4736
             formulation

          -  Patients must not have a known history of tuberculosis

          -  Patients must not have received a live attenuated vaccination within 28 days prior to
             sub-study registration

          -  Patients must not have known human immunodeficiency virus (HIV), hepatitis B or C
             positivity

          -  Patients must also be offered participation in banking for future use of specimens

          -  STEP 2 TO MEDI4736 RE-TREATMENT REGISTRATION:

          -  Patient must have progressed following 12 months of treatment with MEDI4736; patients
             who discontinue MEDI4736 prior to the completion of 12 months (for any reason) are not
             eligible; patients who have already completed two 12-month periods of treatment are
             not eligible

          -  Patients may have measurable or non-measurable disease documented by computed
             tomography (CT) or magnetic resonance imaging (MRI); the CT from a combined positron
             emission tomography (PET)/CT may be used to document only non-measurable disease
             unless it is of diagnostic quality; measurable disease must be assessed within 28 days
             prior to re-treatment registration; pleural effusions, ascites and laboratory
             parameters are not acceptable as the only evidence of disease; non-measurable disease
             must be assessed within 42 days prior to re-treatment registration; all disease must
             be assessed and documented on the Baseline Tumor Assessment Form; patients whose only
             measurable disease is within a previous radiation therapy port must demonstrate
             clearly progressive disease (in the opinion of the treating investigator) prior to
             RE-TREATMENT registration

          -  Patients must have a CT or MRI scan of the brain to evaluate for central nervous
             system (CNS) disease within 42 days prior to RE-TREATMENT registration; patient must
             not have leptomeningeal disease, spinal cord compression or brain metastases unless:
             metastases have been locally treated and have remained clinically controlled and
             asymptomatic for at least 14 days following treatment and prior to RE-TREATMENT
             registration, AND patient has no residual neurological dysfunction and has been off
             corticosteroids for at least 24 hours prior to RE-TREATMENT registration

          -  Patients must not have received any treatment after discontinuing MEDI4736 with the
             following exceptions; localized palliative radiation therapy is allowed for symptom
             management, provided and treatment is completed >= 14 days prior to RE-TREATMENT
             registration; local treatment for brain metastases is allowed

          -  Patients must not have received any immunosuppressive medication within 28 days prior
             to RE-TREATMENT registration and must not be planning to receive any such agents while
             on protocol treatment; however, intranasal and inhaled corticosteroids or systemic
             corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or
             equivalent are allowed

          -  Patients must not have any prior grade >= 3 immune-related adverse event (irAE) or any
             unresolved irAE > grade 1 (MEDI4736 RE-TREATMENT)

          -  Patients must not have received a live attenuated vaccination within 28 days prior to
             RE-TREATMENT registration

          -  Patients must not have known HIV, hepatitis B or hepatitis C positivity

          -  Patients must not be planning to receive any concurrent chemotherapy, immunotherapy,
             biologic or hormonal therapy for cancer treatment; concurrent use of hormones for
             non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement
             therapy) is acceptable

          -  Absolute neutrophil count (ANC) >= 1,500/mcl obtained within 28 days prior to
             RE-TREATMENT registration

          -  Platelet count >= 100,000 mcl obtained within 28 days prior to RE-TREATMENT
             registration

          -  Hemoglobin >= 9 g/dL obtained within 28 days prior to RE-TREATMENT registration

          -  Serum bilirubin =< institutional upper limit of normal (IULN) within 28 days prior to
             RE-TREATMENT registration; for patients with liver metastases, bilirubin must be =< 5
             x IULN

          -  Either alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 2 x IULN
             within 28 days prior to RE-TREATMENT registration (if both ALT and AST are done, both
             must be =< 2 IULN); for patients with liver metastases, either ALT or AST must be =< 5
             x IULN (if both ALT and AST are done, both must be =< 5 x IULN)

          -  Patients must have a serum creatinine =< the IULN OR measured or calculated creatinine
             clearance >= 50 mL/min using the Cockcroft-Gault formula

          -  Patients must have Zubrod performance status of 0-1 documented within 28 days prior to
             RE-TREATMENT registration

          -  Prestudy history and physical exam must be obtained within 28 days prior to
             RE-TREATMENT registration

          -  Patients must not be pregnant or nursing; women/men of reproductive potential must
             have agreed to use an effective contraceptive method; a woman is considered to be of
             ""reproductive potential"" if she has had menses at any time in the preceding 12
             consecutive months; in addition to routine contraceptive methods, ""effective
             contraception"" also includes heterosexual celibacy and surgery intended to prevent
             pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy,
             bilateral oophorectomy or bilateral tubal ligation; however, if at any point a
             previously celibate patient chooses to become heterosexually active during the time
             period for use of contraceptive measures outlined in the protocol, he/she is
             responsible for beginning contraceptive measures

          -  As a part of the Oncology Patient Enrollment Network (OPEN) registration process the
             treating institution's identity is provided in order to ensure that the current
             (within 365 days) date of institutional review board approval for this study has been
             entered in the system

          -  Patients with impaired decision-making capacity are eligible as long as their
             neurological or psychological condition does not preclude their safe participation in
             the study (e.g., tracking pill consumption and reporting adverse events to the
             investigator)

          -  Patients must be informed of the investigational nature of this study and must sign
             and give written informed consent in accordance with institutional and federal
             guidelines
      "
NCT02763384,terminated,"
    low accrual
  ",0,phase 2,"['t-acute lymphoblastic leukemia', 'adult t lymphoblastic lymphoma']","[""['C83.57', 'C83.50', 'C91.01', 'C91.02', 'C83.52', 'C83.56', 'C83.53']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']""]","['bl-8040', 'nelarabine']","['C1CC2C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2C1)CCCCN)CCCCN)CCCNC(=O)N)CC3=CC=C(C=C3)O)NC(=O)C(CC4=CC5=CC=CC=C5C=C4)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C6=CC=C(C=C6)F)C(=O)NC(CCCNC(=N)N)C(=O)N)CCCNC(=O)N)CCCNC(=N)N)CC7=CC=C(C=C7)O', 'COC1=NC(=NC2=C1N=CN2C3C(C(C(O3)CO)O)O)N']","
        Inclusion Criteria:

          -  Diagnosis of T-acute lymphoblastic leukemia/ lymphoblastic lymphoma according to WHO
             criteria which has relapsed or is refractory to chemotherapy.

          -  Peripheral blood lymphoblasts ≤ 50,000 mcL. Hydroxyurea and/or leukapheresis is
             permitted to reduce the peripheral blast count prior to enrollment and treatment.

          -  Age ≥ 18 years

          -  ECOG performance status ≤ 2.

          -  Adequate organ function defined as:

               -  Calculated creatinine clearance ≥ 50 ml/min using the Cockroft-Gault formula

               -  AST, ALT, total bilirubin ≤ 2 x institutional ULN except for Gilbert's disease or
                  when in the opinion of treating physician elevated levels are due to direct
                  involvement of leukemia (e.g., hepatic infiltration or biliary obstruction due to
                  leukemia), in which case ALT and AST may be elevated up to ≤ 5 x IULN.

          -  Women of childbearing potential and men must agree to use adequate contraception with
             a highly effective method (hormonal or barrier method of birth control, abstinence)
             prior to study entry and for the duration of study participation. Abstinence is
             acceptable if this is the established and preferred contraception for the subject.

          -  Female subjects must have a negative urine or serum pregnancy test within 72 hours
             prior to start of study treatment if of childbearing potential or be of
             non-childbearing potential. If the urine test is positive or cannot be confirmed as
             negative, a serum pregnancy test will be required. The serum pregnancy test must be
             negative for the subject to be eligible. Non-childbearing potential is defined as:

             *≥ 45 years of age and has not had menses for > 2 years

               -  Amenorrheic for > 2 years without a hysterectomy and oophorectomy and a FSH value
                  in the postmenopausal range upon pretrial (screening) evaluation

               -  Post-hysterectomy, oophorectomy, or tubal ligation. Documented hysterectomy or
                  oophorectomy must be confirmed with medical records of the actual procedure or
                  confirmed by an ultrasound. Tubal ligation must be confirmed with medical records
                  of the actual procedure.

          -  Able to understand and willing to sign an IRB-approved written informed consent
             document.

        Exclusion Criteria:

          -  Previous treatment with nelarabine for relapsed or refractory disease.

          -  Pregnant or nursing.

          -  Received any other investigational agent or systemic cytotoxic chemotherapy within the
             preceding 2 weeks.

          -  Active CNS involvement with leukemia

          -  Active HIV or hepatitis B or C infection.

          -  Any medical condition which, in the opinion of the clinical investigator, would
             interfere with the evaluation of the patient. Subjects with a clinically significant
             or unstable medical or surgical condition or any other condition that cannot be
             well-controlled by the allowed medications permitted in the study protocol that would
             preclude safe and complete study participation, as determined by medical history,
             physical examinations, laboratory tests, and according to the investigator's judgment.
      "
NCT02229981,withdrawn,"
    study was discontinued due to lack of recruitment.
  ",0,phase 1/phase 2,"['diffuse large b cell lymphoma', 'kaposi sarcoma']","[""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['C46.9', 'C46.0', 'C46.2', 'C46.1', 'C46.3', 'C46.4', 'C46.50']""]",['abc294640'],['C1C2CC3(CC1CC(C2)(C3)C(=O)NCC4=CC=NC=C4)C5=CC=C(C=C5)Cl'],"
        Inclusion Criteria

          1. Pathologically confirmed DLBCL or KS. In the case of patients with DLBCL, the disease
             must be radiographically refractory to standard therapy, or relapsed following
             standard therapy (one or more tumors measurable on PET-CT scan). In the case of
             patients with KS, the disease must be either radiographically or clinically refractory
             (persistent skin lesions) to standard therapy or relapsed following standard therapy
             (one or more tumors measurable on CT scan or through direct measurement of skin
             tumors). Please see caveats for antineoplastic therapies in Exclusion criteria below.

          2. For patients with DLBCL, the patient is not a candidate for hematopoietic stem cell
             transplantation (as determined by medical oncologists at participating institutions)
             or has failed stem cell transplantation.

          3. Tumor progression after receiving standard/approved chemotherapy, or lack of candidacy
             for standard therapy.

          4. One or more tumors measurable on PET-CT scan (DLBCL), CT scan (KS), or by clinical
             exam of skin (KS).

          5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3.

          6. Life expectancy of at least 3 months.

          7. Age ≥ 18 years.

          8. Signed, written IRB-approved informed consent.

          9. A negative pregnancy test (if female).

         10. Acceptable liver function:

               -  Bilirubin ≤ 3 times upper limit of normal (CTCAE Grade 2 baseline)

               -  AST (SGOT), ALT (SGPT) ≤ 3 x ULN (CTCAE Grade 1 baseline)

               -  Serum creatinine ≤ 1.5 X ULN (CTCAE Grade 1 baseline)

         11. Acceptable hematologic status:

               -  Absolute neutrophil count ≥ 1000 cells/mm3

               -  Platelet count ≥ 75,000 (plt/mm3) (CTCAE Grade 1 baseline)

               -  Hemoglobin ≥ 8 g/dL

         12. Urinalysis: No clinically significant abnormalities.

         13. PT and PTT ≤ 1.5 X ULN after correction of nutritional deficiencies that may
             contribute to prolonged PT/PTT.

         14. For men and women of child-producing potential, willingness to use of effective
             contraceptive methods during the study. If female (or female partner of male subject),
             is either not of childbearing potential (defined as postmenopausal for ≥ 1 year or
             surgically sterile [bilateral tubal ligation, bilateral oophorectomy or hysterectomy])
             or practicing one of the following medically acceptable methods of birth control and
             agrees to continue with the regimen throughout the duration of the study:

               -  Oral, implantable or injectable contraceptives for 3 consecutive months before
                  the Baseline/Randomization Visit.

               -  Total abstinence from sexual intercourse (≥ 1 complete menstrual cycle before the
                  Baseline/Randomization Visit).

               -  Intrauterine device (IUD).

               -  Double barrier method (condoms, sponge, diaphragm or vaginal ring with
                  spermicidal jellies or cream).

        Exclusion Criteria

          1. New York Heart Association Class III or IV, cardiac disease, myocardial infarction
             within the past 6 months, unstable arrhythmia, or evidence of ischemia on ECG.

          2. Pregnant or nursing women. NOTE: Women of child-bearing potential and men must agree
             to use barrier methods (preferably condoms) or other methods of birth control at your
             doctor's discretion, or abstain from sexual activity, prior to study entry and for the
             duration of study participation. Should a woman become pregnant or suspect she is
             pregnant while participating in this study, she should inform her treating physician
             immediately.

          3. Patients with active, life-threatening bacterial or fungal infections.

          4. Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy
             within one month prior to study entry.

          5. Unwillingness or inability to comply with procedures required in this protocol.

          6. Serious nonmalignant disease (e.g., hydronephrosis, liver failure, or other
             conditions) that could compromise protocol objectives in the opinion of the
             Investigator and/or the Sponsor.

          7. Patients who are currently receiving any other investigational agent.

          8. Patients who are receiving drugs other than highly active antiretroviral therapy
             (HAART) or trimethoprim-sulfamethoxazole that are sensitive substrates of CYP450 1A2,
             3A4, 2C9, 2D6, or 2C19, or strong inhibitors or inducers of these isozymes that cannot
             be stopped at least 7 days or 5 half-lives (whichever is longer) before starting
             treatment with ABC294640 and either replaced with another appropriate medication or
             not given for the duration of the clinical study. Patients on HAART will be restricted
             to preferred, potent agents with no demonstrated interactions with CYP450 isoforms for
             which significant interactions are predicted with ABC294640 (1A2, 2C9, or 2C19 for
             which ABC294640 IC50 < 1uM). These include tenofovir, FTC, 3TC, abacavir, darunavir,
             atazanavir, norvir, raltegravir, dolutegravir, elvitegravir, cobicistat, and
             maraviroc. Switching of ART prior to study entry is permitted given significant data
             for improvement/maintenance of HIV suppression when switching regimens in other
             contexts.

          9. Patients who are currently taking Coumadin or Coumadin derivatives.

         10. Patients who have received any antineoplastic therapy within 1 month of starting
             treatment with ABC294640 or who have not adequately recovered from side effects and
             toxicities of previous antineoplastic therapy.

         11. Patients who are currently participating in any other clinical trial of an
             investigational product.

         12. Allergy to radiographic contrast
      "
NCT02225275,terminated,"
    due to slow accrual
  ",0,phase 2,"['recurrent chronic lymphocytic leukemia', 'recurrent small lymphocytic lymphoma', 'refractory chronic lymphocytic leukemia', 'refractory small lymphocytic lymphoma']","[""['A87.2', 'K52.832', 'D72.111', 'C91.11', 'C91.12', 'C91.10']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['A87.2', 'K52.832', 'D72.111', 'C91.11', 'C91.12', 'C91.10']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']""]",['lenalidomide'],['C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N'],"
        Inclusion Criteria:

          -  Able to understand and to provide voluntarily informed consent

          -  Have documented chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
             according to National Cancer Institute (NCI) criteria

          -  Recurrent or refractory disease according to NCI criteria

          -  Patient are eligible if they have received one or more prior treatment

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          -  Life expectancy > 6 months

          -  Serum creatinine less or equal to 2 mg/dl

          -  Total bilirubin less or equal to 2 mg/dl

          -  Alanine aminotransferase (ALT)/serum glutamate pyruvate transaminase (SGPT) less or
             equal to two times the upper normal limit

          -  Disease free of prior malignancies for 3 years with exception of currently treated
             basal cell squamous cell carcinoma of the skin, or carcinoma ""in situ"" of the cervix
             or breast; patients with malignancies with indolent behavior such as prostate cancer
             treated with radiation or surgery can be enrolled in the study as long as they have a
             reasonable expectation to have been cured with the treatment modality received

          -  No prior history of myelodysplastic syndrome or other myeloid malignancy

          -  All participants must be registered into the mandatory Revlimid Risk Evaluation and
             Mitigation Strategy (REMS) program, and be willing and able to comply with the
             requirements of the Revlimid REMS

          -  Females of childbearing potential (FCBP) must have a negative serum and/or urine
             pregnancy test with a sensitive of at least 50 mIU/mL within 10-14 days and again
             within 24 hours prior to prescribe lenalidomide for cycle 1 (prescriptions must be
             filled within 7 days as required by Revlimid REMS) and must either commit to continued
             abstinence from heterosexual intercourse or begin TWO acceptable methods of birth
             control, one highly effective method and one additional effective method AT THE SAME
             TIME, at least 28 days before she starts taking lenalidomide; FCBP must also agree to
             ongoing pregnancy testing; men must agree to use a latex condom during sexual contact
             with a FCBP even if they have had a successful vasectomy

        Exclusion Criteria:

          -  Known sensitivity to lenalidomide or other thalidomide derivatives or anti cluster of
             differentiation (CD)20

          -  Documented prolymphocytic leukemia (prolymphocytes more than 55% in the blood)

          -  Known history of infection with human immunodeficiency virus (HIV) or human T cell
             leukemia virus 1 (HTLV-1)

          -  Serologic status reflecting active hepatitis B or C; patients with hepatitis B (HBV)
             antibody positive but who have positivity for hepatitis B surface antigen (HBsAg) or
             anti hepatitis B core antibody (anti-HBc) and patients who are positive for
             anti-hepatitis C (HCV) will need to have a negative polymerase chain reaction (PCR)
             (viral HBV deoxyribonucleic acid [DNA] or HCV ribonucleic acid [RNA]) result prior to
             enrollment; those who are HBsAg positive or HBV DNA positive and those who are
             positive for HCV (RNA) will be excluded

          -  Pregnant or breast feeding females

          -  History of tuberculosis treated within the last five years or recent exposure to
             tuberculosis

          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that
             places the subject unacceptable risk if he/she were to participate to the study

          -  Patients with a recent history of deep vein thrombosis or pulmonary embolus, in the
             six months prior to enrollment are not eligible for this study
      "
NCT02186847,"active, not recruiting",,0,phase 2,"['adenosquamous lung carcinoma', 'bronchioloalveolar carcinoma', 'large cell lung carcinoma', 'lung adenocarcinoma', 'non-small cell lung carcinoma', 'recurrent non-small cell lung carcinoma', 'squamous cell lung carcinoma', 'stage iiia non-small cell lung cancer', 'stage iiib non-small cell lung cancer']","[""['D02.20', 'D02.21', 'D02.22']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['D02.20', 'D02.21', 'D02.22']"", ""['D02.20', 'D02.21', 'D02.22']"", ""['D02.20', 'D02.21', 'D02.22']"", ""['D02.20', 'D02.21', 'D02.22']"", ""['D02.20', 'D02.21', 'D02.22']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['carboplatin', 'metformin', 'paclitaxel']","['C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]', 'CN(C)C(=N)N=C(N)N', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C']","
        Inclusion Criteria:

          -  Pathologically (histologically or cytologically) proven diagnosis of stage IIIA or
             IIIB non-small cell lung cancer within 84 days of registration; eligible histologies
             include adenocarcinoma, adenosquamous, large cell carcinoma, squamous carcinoma,
             non-lobar and non-diffuse bronchoalveolar cell carcinoma or non-small cell lung cancer
             not otherwise specified)

          -  Patients must have measurable disease

          -  Patients must have unresectable disease, be medically inoperable, or unwilling to
             undergo surgical management

          -  Appropriate stage for protocol entry, including no distant metastases, based upon the
             following minimum diagnostic workup:

               -  History/physical examination, including documentation of height, weight, body
                  surface area, and vital signs, within 30 days prior to registration

               -  Computed tomography (CT) with IV contrast or magnetic resonance imaging (MRI)
                  imaging (if CT scan with contrast is medically contraindicated) of the lung and
                  upper abdomen through the adrenal glands, required within 45 days prior to
                  registration (recommended within 30 days prior to registration

               -  MRI of the brain with contrast (or CT with contrast if MRI is medically
                  contraindicated) within 45 days prior to registration; note: the use of
                  intravenous contrast is required for the MRI or CT; an MRI without contrast is
                  only permitted if the patient has a contrast allergy

               -  Whole-body fludeoxyglucose (FDG)-positron emission tomography (PET)/CT required
                  within 45 days prior to registration (recommended within 30 days prior to
                  registration; note: patients do not need to have a separate CT of the chest and
                  upper abdomen with contrast if PET/CT imaging includes a high quality CT with
                  contrast

          -  Zubrod performance status 0-1

          -  Absolute neutrophil count (ANC) >= 1,500 cells/mm^3

          -  Complete blood count(CBC)/differential obtained within 14 days prior to registration
             on study, with adequate bone marrow function defined as follows:

               -  Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3

               -  Platelets >= 100,000 cells/mm^3

               -  Hemoglobin >= 8.0 g/dl (note: the use of transfusion or other intervention to
                  achieve hemoglobin [Hgb] >= 8.0 g/dl is acceptable)

          -  Adequate renal function within 14 days prior to registration, defined as serum
             creatinine within normal institutional limits or creatinine clearance must be at least
             60 ml/min;

          -  Adequate hepatic function within 14 days prior to registration, defined as total
             bilirubin ≤ 1.5 x upper limit of normal (ULN) for the institution and alanine
             aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase ≤
             2.5 x ULN for the institution;

          -  Fasting blood glucose ≤ 125 mg/dL within 14 days prior to registration;

          -  Serum albumin > 3.0 g/dl within 14 days prior to registration;

          -  For women of childbearing potential, a serum pregnancy test within 72 hours prior to
             registration;

          -  Patients with post-obstructive pneumonia are eligible provided they no longer require
             intravenous antibiotics at registration;

          -  Patients must be at least 3 weeks from prior thoracotomy (if performed);

          -  If a pleural effusion is present, the following criteria must be met at registration
             to exclude malignant involvement (incurable M1a disease):

               -  When pleural fluid is visible on both the CT scan and on a chest x-ray, a
                  pleuracentesis is required to confirm that the pleural fluid is cytologically
                  negative;

               -  Effusions that are minimal (i.e. not visible under ultrasound guidance) and that
                  are too small to safely tap are eligible.

          -  Women of childbearing potential and male participants must practice adequate
             contraception throughout the study;

        Exclusion Criteria:

          -  Patients with mixed small cell and non-small cell histologies

          -  Patients with distant metastasis

          -  Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free
             for a minimum of 3 years (for example, carcinoma in situ of the breast, oral cavity,
             or cervix are all permissible)

          -  Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a
             different cancer is allowable

          -  Prior radiotherapy to the region of the study cancer that would result in overlap of
             radiation therapy fields

          -  Patients currently using metformin (metformin hydrochloride), other oral hypoglycemic
             agents or insulin

          -  Patients with any history of allergic reaction to paclitaxel or other taxanes or
             carboplatin

          -  Patients with a history of chronic kidney disease or lactic acidosis

          -  Patients with >= 10% weight loss within the past month

          -  Severe, active co-morbidity, defined as follows:

               -  Diagnosis of type I or type II diabetes mellitus

               -  Uncontrolled neuropathy >= grade 2 regardless of cause

               -  Unstable angina and/or congestive heart failure requiring hospitalization within
                  the last 6 months

               -  Transmural myocardial infarction within the last 6 months

               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the time
                  of registration

               -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness
                  requiring hospitalization or precluding study therapy within 30 days of
                  registration

               -  Severe hepatic disease, defined as a diagnosis of Child-Pugh class B or C hepatic
                  disease

               -  Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4
                  count < 200 cells/microliter; note that patients who are HIV positive are
                  eligible, provided they are under treatment with highly active antiretroviral
                  therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior
                  to registration; note also that HIV testing is not required for eligibility for
                  this protocol

               -  End-stage renal disease (ie, on dialysis or dialysis has been recommended)

          -  Pregnancy or women of childbearing potential and men who are sexually active and not
             willing/able to use medically acceptable forms of contraception
      "
NCT02181738,completed,,1,phase 2,['hodgkin disease'],"[""['C81.77', 'C81.97', 'C81.17', 'C81.27', 'C81.37', 'C81.47', 'C81.70']""]","['nivolumab', 'doxorubicin', 'vinblastine', 'dacarbazine']","['Status: 503', 'CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O', 'CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O', 'CN(C)N=NC1=C(NC=N1)C(=O)N']","
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Must have received prior high-dose conditioning chemotherapy followed by autologous
             stem cell transplant (ASCT) as a part of salvage therapy for cHL (cohort A, B & C -
             enrollment closed)

          -  Participants may be Brentuximab vedotin- naïve, or may have had prior Brentuximab
             vedotin treatment (cohort A, B & C - enrollment closed)

          -  Newly diagnosed and previously untreated classical Hodgkin Lymphoma (cohort D)

        Exclusion Criteria:

          -  Known central nervous system lymphoma

          -  Participants with nodular lymphocyte-predominant Hodgkin Lymphoma

          -  Prior allogeneic stem cell transplantation (SCT)

          -  Chest radiation ≤ 24 weeks prior to first dose

          -  Carmustine ≥ 600 mg/m² received as part of the pre-transplant conditioning regimen
      "
NCT02187302,completed,,0,phase 2,['metastatic renal cell carcinoma'],"[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]","['crlx101', 'bevacizumab', 'standard of care (investigator choice)']",['CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O'],"
        Inclusion Criteria:

          -  Must have histologically confirmed renal cell carcinoma of any pathologic subtype.

          -  Must have unresectable metastatic disease, and have tumor(s) present that is (are)
             evaluable by the RECIST, v1.1; may have spinal-associated metastases but must have
             concluded dexamethasone therapy and be evaluated by the Investigator to have stable
             CNS disease.

          -  Must have received 2 or 3 prior lines of conventional molecularly targeted therapy

          -  Must have full recovery from any toxicities from prior therapy CTCAE Grade 1 or less
             with the exception of Grade 2 alopecia) prior to randomization.

          -  ECOG performance status 0 or 1.

          -  Age 18 years and older.

          -  Life expectancy of at least 3 months.

          -  Must have normal organ and marrow function reported within 14 days prior to
             randomization

          -  Ability to understand and willingness to sign a written informed consent document.

          -  Able to comply with study visit schedule and assessments.

        Exclusion Criteria:

          -  Any conventional molecularly targeted therapy within 2 weeks or, chemotherapy or
             radiotherapy within 2 weeks (local) or 4 weeks (systemic) prior to entering the study.

          -  Failure to recover to grade 1 or less all prior adverse events.

          -  Any major surgery within 4 weeks of study randomization.

          -  Any prior treatment with topoisomerase I therapy.

          -  Prior treatment with any drugs or therapies that will be administered during the
             course of this trial including CRLX101, any topoisomerase 1 inhibitor, bevacizumab or
             the conventional molecularly targeted agent intended for use as standard of care
             treatment.

          -  Patients receiving any other current investigational therapeutic agent.

          -  Other active malignancies

          -  Patients with brain metastasis treated or untreated, or other CNS disease

          -  Any clinically significant cardiac disease defined as NYHA class III or IV.

          -  Uncontrolled hypertension

          -  Uncontrolled concurrent illness

          -  History of non-healing wounds or ulcers.

          -  Pregnancy, or inadequate contraception for men or women of childbearing age, or
             lactating / breast-feeding

          -  Patients with known HIV or with solid organ transplant
      "
NCT02186834,completed,,0,phase 1/phase 2,['multiple myeloma'],"[""['C90.01', 'C90.02', 'C90.00']""]","['selinexor', 'liposomal doxorubicin', 'dexamethasone']","['C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F', 'CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O', 'CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C']","
        Inclusion Criteria:

          -  Patients with relapsed and refractory multiple myeloma who have received at least 2
             prior therapies which must include lenalidomide and a proteasome inhibitor. Patients
             must have disease refractory to the most recent therapy. Refractory myeloma is defined
             as progressive disease during or within 60 days of last therapy. Patients must have
             previously received or be ineligible for (or refused) autologous stem cell transplant.

          -  Must have measurable myeloma paraprotein levels in serum (≥ 0.5 g/dL) or urine (≥ 0.2
             g excreted in a 24-hour urine collection sample) or by free light chain (involved free
             light chain greater than 100 mg/L).

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. ECOG 2 allowed if
             due to bone disease

          -  Must have an echocardiogram or multigated acquisition (MUGA) scan indicating left
             ventricular ejection fraction (LVEF) ≥ 50% within 42 days prior to first dose of study
             drug

          -  Adequate hematological function

          -  Adequate hepatic function within 14 days prior to loading phase (day -14)

          -  Adequate renal function within 14 days prior to loading: estimated creatinine
             clearance of ≥ 30 mL/min, (Cockcroft and Gault)

          -  Female patients of child-bearing potential must agree to use dual methods of
             contraception and have a negative serum pregnancy test at screening. Male patients
             must use an effective barrier method of contraception if sexually active with a female
             of child-bearing potential. For both male and female patients, effective methods of
             contraception must be used throughout the study and for three months following the
             last dose.

        Exclusion Criteria:

          -  Women who are pregnant or lactating

          -  Radiation, chemotherapy, or immunotherapy or any other approved anticancer therapy ≤2
             weeks prior to day -7 (beginning of loading phase)

          -  Major surgery within four weeks before Day -7

          -  Myocardial infarct within 6 months before enrollment, New York Heart Association
             (NYHA) Class II or greater heart failure, uncontrolled angina, severe uncontrolled
             ventricular arrhythmias, clinically significant pericardial disease, or
             electrocardiographic evidence of acute ischemic or active conduction system
             abnormalities

          -  Prior cumulative exposure to doxorubicin (including liposomal preparation) > 350mg/m^2

          -  Uncontrolled infection requiring parenteral antibiotics, antivirals, or antifungals
             within one week prior to first dose; patients with controlled infection or on
             prophylactic antibiotics are permitted in the study

          -  Known to be HIV seropositive

          -  Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C
             virus (HCV) RNA or HBsAg (HBV surface antigen)

          -  Any underlying condition that would significantly interfere with the absorption of an
             oral medication

          -  Grade >2 peripheral neuropathy at baseline (within 14 days prior to loading phase (day
             -7))

          -  Serious psychiatric or medical conditions that could interfere with treatment

          -  Participation in an investigational anti-cancer study within 3 weeks prior to day
             -7(beginning of loading phase)

          -  Concurrent therapy with approved or investigational anticancer therapeutic

          -  Coagulation problems and active bleeding in the last month

          -  Previous allogeneic transplant within 6 months and have evidence of clinically
             significant graft versus host disease
      "
NCT02183805,terminated,"
    difficulty accruing subjects the study accrual was closed
  ",0,phase 2,['carcinoma breast stage iv'],"[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['abraxane,cyclophosphamide,carboplatin']",['Status: 503'],"
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) 0 or 1.

          -  Histologically or cytologically proven diagnosis of breast cancer with evidence of
             locally recurrent or metastatic disease.

          -  Documentation of estrogen and progestin receptor (ER/PR) negative status and HER2/neu
             receptor negative status (ie, FISH negative or immunohistochemistry 0 or +1).

          -  Obtained complete response or Good partial response after first line chemotherapy.

          -  Normal organ function required prior to study entry.

          -  Willingness to comply with treatment plans and other study procedures.

        Exclusion Criteria:

          -  Uncontrolled central nervous system (CNS) involvement with disease

          -  Fertile women unwilling to use contraceptive techniques during treatment

          -  Females who are pregnant

          -  Organ dysfunction.

          -  Patients may not be receiving any other investigational agents.
      "
NCT02188537,completed,,1,phase 2,['myeloma'],"[""['C90.01', 'C90.02', 'C90.00']""]","['nelfinavir', 'bortezomib', 'dexamethasone']","['CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O', 'B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O', 'CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C']","
        Inclusion Criteria:

          -  Patient must give written informed consent prior to any protocol-specific procedure.

          -  Patient was diagnosed with multiple myeloma based on standard IMWG criteria, and has
             received at least one previous line of chemotherapy.

          -  Patient has been exposed to or is intolerant to at least one IMID (thalidomide,
             lenalidomide, pomalidomide).

          -  A therapy with bortezomib in the approved dose and schedule, based on Swissmedic
             approval (treatment of patients with relapsed/refractory multiple myeloma who have
             received at least one prior line of therapy), is indicated and intended.

          -  Patient is refractory to his/her most recent proteasome inhibitor-containing regimen,
             based on divers criteria.

          -  WHO performance status ≤ 3.

          -  Age ≥ 18 years.

          -  Adequate hematological values: platelets ≥ 50 x 109/L, hemoglobin ≥ 80 g/L (both may
             be achieved by transfusion).

          -  Adequate hepatic function: bilirubin ≤ 1.5 x ULN (for patients with suspected
             hemolysis: direct bilirubin ≤ 1.5 x ULN), ALT ≤ 3 x ULN (≤ 5 x ULN if liver
             infiltration by myeloma suspected, based on imaging results).

          -  Calculated creatinine clearance ≥ 15 mL/min, according to the formula of
             Cockcroft-Gault, see Appendix 1).

          -  Women are not breastfeeding. Women with child-bearing potential are using effective
             contraception (see 9.8), are not pregnant and agree not to become pregnant during
             participation in the trial and during the 12 months thereafter. A negative pregnancy
             test before inclusion (within 7 days) into the trial is required for all women with
             child-bearing potential. Men agree not to father a child during participation in the
             trial and during 12 months thereafter.

          -  Completed baseline QoL questionnaire.

        Exclusion Criteria:

          -  Evidence of ongoing uncontrolled systemic infections.

          -  History of chronic active HCV or HBV.

          -  Evidence of myeloma within the CNS.

          -  Psychiatric disorder precluding understanding of information on trial related topics,
             giving informed consent, filling out quality of life (QoL) forms, or interfering with
             compliance for oral drug intake.

          -  Exposure to another experimental drug within 3 weeks prior to trial entry.

          -  Any serious underlying medical condition (at the judgment of the investigator) which
             may impair the ability of the patient to participate in the trial, in particular any
             uncontrolled clinically significant active disease (e.g. active autoimmune disease,
             uncontrolled diabetes, uncontrolled cardiac disease).

          -  Non-hematologic active malignancy within the past 5 years with the exception of a)
             adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer;
             b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or
             less with stable prostate-specific antigen levels; or d) cancer considered cured by
             surgical resection or unlikely to impact survival during the duration of the study,
             such as localized transitional cell carcinoma of the bladder or benign tumors of the
             adrenal or pancreas.

          -  Concomitant use of other anti-cancer medication or radiotherapy except for local pain
             control. The use of bisphosphonates is allowed.

          -  Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to
             enrollment.

          -  Known hypersensitivity to bortezomib or nelfinavir or hypersensitivity to components
             of these drugs.

          -  Any psychological, familial, sociological or geographical condition likely hampering
             compliance with the trial protocol and follow-up.

          -  Patient who takes the following drugs during the trial therapy, which cannot be
             replaced or paused.
      "
NCT02183870,completed,,1,phase 2,"['lung cancer', 'adenocarcinoma', 'nsclc']","[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]",['crizotinib'],['CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N'],"
        Inclusion Criteria:

          -  Patients with adenocarcinoma of the lung that is locally advanced or metastatic
             independent from the number of prior lines of therapy, i.e. including non-pretreated
             patients (UICC stage IIIB or IV)

          -  Positive for ROS1 translocation by central FISH-testing

          -  Ability to swallow pills

          -  Age > 18 years

          -  ECOG performance status 0 to 2

          -  Life expectancy of at least 12 weeks

          -  Disease measurable per Response Evaluation Criteria in Solid Tumors (RECIST, version
             1.1)

          -  Any prior treatment (chemotherapy, radiation or surgery) must have been completed at
             least 2 weeks prior to initiation of study medication

          -  Adequate bone marrow, liver and renal function as assessed by the following laboratory
             requirements to be conducted within 14 days prior to screening:

          -  Hemoglobin ≥ 8.0 g/dL

          -  Absolute neutrophil count (ANC) ≥ 1,000 /mm3

          -  Platelet count ≥ 50 000/µL

          -  Total bilirubin ≤ 2 x upper limit of normal (ULN)

          -  Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline
             phosphatase (AP) ≤ 2,5 x ULN or ≤ 5 x ULN in case of liver involvement

          -  PT-INR/PTT ≤ 1.5 x ULN

          -  Serum creatinine ≤ 2 times ULN

          -  Calculated creatinine clearance (CLcr) ≥ 40 ml/min (Cockcroft-Gault formula)

          -  Written informed consent

          -  Negative serum pregnancy test within 3 days prior to start of dosing premenopausal
             women. Women of non-childbearing potential may be included without serum pregnancy
             test if they are either surgically sterile or have been postmenopausal for ≥ 1 year.

        Fertile men and women must have an effective method of contraception during treatment and
        for at least 3 months after completion of treatment as directed by their physician.
        Effective methods of contraception result in a low failure rate (i.e. less than 1% per
        year) when used consistently and correctly (for example implants, injectables, combined
        oral contraception or intra-uterine devices). At the discretion of the investigator,
        acceptable methods of contraception may include total abstinence where lifestyle of the
        patient ensures compliance (Periodic abstinence and withdrawal are not acceptable methods
        of contraception).

        Exclusion Criteria:

          -  Previous treatment with specific ALK or ROS1 inhibitors

          -  Current treatment within another therapeutic clinical trial

          -  Other history of ongoing malignancy that would potentially interfere with the
             interpretation of efficacy (early stage or chronic disease is allowed if not requiring
             active therapy or intervention and being under control)

          -  Pregnancy or breastfeeding

          -  Use of drugs or foods that are known potent CYP3A4 inhibitors, including but not
             limited to atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole,
             nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin,
             voriconazole and grapefruit or grapefruit juice

          -  Use of drugs that are known potent CYP3A4 inducers, including but not limited to
             carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, and St. John's wort

          -  Use of drugs that are CYP3A4 substrates with narrow therapeutic indices, including but
             not limited to dihydroergotamine, ergotamine, pimozide, astemizole, cisapride, and
             terfenadine

          -  Active CNS metastases. Patients with brain metastasis are eligible if asymptomatic for
             ≥ 14 days before starting study medication and off corticosteroids.

          -  History of or known carcinomatous meningitis or leptomeningeal disease

          -  Known diagnosis of HIV, active hepatitis B and/or C (testing is not mandatory)

          -  Any person being in an institution on assignment of the respective authority against
             his/her own will

          -  Any medical, mental or psychological condition which in the opinion of the
             investigator would not permit the patient to complete the study or understand the
             patient information

          -  Ongoing cardiac dysrhythmias of CTCAE grade ≥2, uncontrolled atrial fibrillation of
             any grade or QTcF interval > 470ms

          -  Patients with known interstitial fibrosis or interstitial lung disease

          -  Any of the following within 3 months prior to first crizotinib administration:

        Myocardial infarction, severe/unstable angina, symptomatic congestive heart failure,
        cerebrovascular accident or transient ischemic attack
      "
NCT02185768,completed,,0,phase 2,['liver cancer'],"[""['D13.4', 'Z85.05', 'C22.8', 'C78.7', 'C22.9', 'D37.6']""]",['idarubicin'],['Status: 503'],"
        Inclusion Criteria:

          -  - Histologically diagnosed HCC or HCC diagnosed according to the EASL criteria

          -  Measurable targets according to the mRECIST v1.1 criterion

          -  Preserved liver function (in case of Child-Pugh A or B7 cirrhosis)

          -  Tumour not subject to interventive care (liver transplant, surgical resection or
             percutaneous destruction)

          -  BCLC A/B without portal or extra-hepatic invasion

          -  No prior treatment by chemotherapy, radiotherapy or transarterial embolisation (with
             or without chemotherapy)

          -  Age ≥ 18 years

          -  WHO 0 or 1

          -  Laboratory test: platelets ≥ 50,000 mm3, N ≥ 1,000/mm3, creatininaemia ≤ 150 µmol/L,
             PT ≥ 50%

          -  No heart failure (isotope or ultrasound VEF > 50%)

        Exclusion Criteria:

          -  - Advanced tumour (vascular or extra-hepatic invasion including brain metastasis or
             diffuse HCC with liver invasion > 50%)

          -  History of other type of cancer except cancer known to be in remission for more than 5
             years (in this case, HCC histological proof is required), or basal-cell carcinoma or
             in situ cervix uteri cancer properly treated with curative treatment

          -  Advanced liver disease (Child B8, B9 and C, bilirubinaemia > 3 mg/dL, SGOT and SGPT >
             5 x ULN or 250 U/L)

          -  Previous treatment by idarubicin and/or doxorubicin

          -  Idarubicin contraindications (cardiopathy with myocardial failure, serious kidney or
             liver failure, yellow fever vaccine)

          -  Concurrent disease or uncontrolled severe clinical condition

          -  Uncontrolled severe infection

          -  Patient requiring long-term anticoagulant treatment

          -  Thrombosis of the portal vein or a 3-segment region or more

          -  Hepatofugal portal venous flow

          -  Presence of serious atheromatosis

          -  Presence of collateral vascular ways potentially affecting the normal regions during
             embolisation

          -  Presence of arthritis of the hepatic artery branches to be treated

          -  Presence of arterioportal or arterial subhepatic fistula that cannot be embolised by
             coils

          -  Pregnancy or breastfeeding

          -  Absence of effective contraception (for men and women of childbearing age)

          -  Patient who cannot be regularly monitored on account of psychological, social, family-
             or geography-related reasons

          -  Concomitant participation of a patient in another study
      "
NCT02605863,terminated,"
    low enrollment, sponsor withdrew support for study
  ",0,phase 2,['bladder cancer'],"[""['D30.3', 'C67.5', 'C67.9', 'C79.11', 'C67.0', 'C67.1', 'D41.4']""]",['enzalutamide'],['CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C'],"
        Inclusion Criteria:

          1. Subjects with histologically confirmed NMIBC who have undergone their TURBT.

          2. Per the European Association of Urology (EAU) guidelines, only subjects with
             ""Intermediate"" or ""High risk"" bladder cancer will be enrolled21:

             For patients with ""high risk"" bladder cancer, only those who undergo BCG therapy
             following their TURBT will be eligible for enrollment.

          3. Subjects who receive BCG instillations post-operatively will be eligible for
             enrollment.

          4. Subjects whose tumors are AR(+) as well as AR(-) will be included, but we will
             restrict inclusion of AR(-) subjects so that they represent no more than 1/3 of the
             total study population, or any single cohort (ie. the intermediate or high-risk
             groups).

          5. Subjects of child-bearing potential must agree to 2 acceptable forms of birth control.

        Exclusion Criteria:

          1. Subjects with ""low risk"" bladder cancer, as defined by the EAU guidelines21, will be
             ineligible for enrollment.

          2. Subjects with ""high risk"" bladder cancer who do not undergo BCG therapy following
             their TURBT will be ineligible for enrollment.

          3. Subjects who have ""failed"" BCG therapy in the past (had a recurrence of bladder cancer
             despite prior use of BCG) will be ineligible for enrollment.

          4. Subjects who receive an immediate post-TURBT single instillation of intravesical
             chemotherapy will be ineligible for enrollment.

          5. Subjects who receive a post-operative induction course of intravesical chemotherapy
             (ie. more than just a single immediate post-operative dose of intravesical
             chemotherapy) will be ineligible for enrollment.

          6. Subjects who undergo blue-light/fluorescence cystoscopy will be ineligible for
             enrollment.

          7. Subjects with a history of heart attack within the previous 12 months or who have
             unstable cardiovascular status will be ineligible for enrollment.

          8. Subjects who have uncontrolled hypertension (for our purposes, defined as those having
             a systolic blood pressure > 160 documented on 2 occasions despite appropriate medical
             therapy) will similarly be ineligible.

          9. Subjects with a history of venous thrombo-embolism (DVT/PE) within the past 3 years.

         10. Subjects with a history of seizure disorders, or those with a history of stroke or
             transient ischemic attacks (TIA) within the previous 12 months will be ineligible.

         11. Subjects with a history of liver disease whose hepatic enzymes, alkaline phosphatase
             or bilirubin are greater than twice the upper limit of normal will be ineligible.

         12. Subjects with kidney disease with an estimated glomerular filtration rate (eGFR) < 30
             will be ineligible.

         13. Subjects with neutropenia will be ineligible.

         14. Subjects with clinical hypogonadism, those on androgen replacement therapy, or those
             with prostate cancer or other diseases treated with various forms of hormonal therapy
             (not including 5-alpha reductase inhibitors) will also be ineligible for study
             enrollment.

         15. Subjects who have undergone therapy for any malignancy within the past 5 years except
             for basal and squamous cell carcinomas of the skin will also be ineligible.

         16. Subjects with prior histories of prostate cancer treated by definitive local therapy >
             5 years ago will only be eligible if they have had no clinical or biochemical evidence
             of recurrent prostate cancer.
      "
NCT02607423,withdrawn,"
    the study failed to meet its accrual targets.
  ",0,phase 2,['stage iiia non-small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['cisplatin', 'docetaxel', 'gemcitabine hydrochloride', 'pemetrexed disodium']","['N.N.Cl[Pt]Cl', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F.Cl', 'C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)[O-])C(=O)[O-].[Na+].[Na+]']","
        Inclusion Criteria:

          -  Patient must have stage IIIA non-small cell lung cancer (T1-3N2) per American Joint
             Committee on Cancer (AJCC) 7th edition and must be considered to be surgically
             resectable

          -  Patients must be assessed by surgeons and are considered surgically resectable

          -  Mediastinal nodal metastases (N2) disease must be confirmed histologically

          -  Easter Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Required imaging studies obtained within four weeks prior to registration

          -  White blood cell (WBC) >= 4000 mm^3 or granulocyte count at least 2,000/mm^3

          -  Platelets >= 100,000/mm^3

          -  Hemoglobin >= 10.0g/dL

          -  Total bilirubin < 1.5 mg/dL

          -  Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) < 3
             x upper limit of normal (ULN)

          -  Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 3 x
             ULN

          -  Alkaline phosphatase < 3 x ULN

          -  Calculated/estimated or measured creatinine clearance at least 50 ml/min; note:
             creatinine clearance should be calculated using the Cockcroft-Gault formula; patients
             who will receive pemetrexed/cisplatin therapy must be obtained within 2 weeks of
             registration

          -  Patients cannot have hormonal cancer therapy or radiation therapy as prior cancer
             treatment within 5 years of registration; (prior surgery, biologic therapy, hormonal
             therapy, or radiation therapy for a malignancy over 5 years prior to enrollment that
             is not considered cured is acceptable)

          -  Patients must not have any history of other cancer within 5 years from registration
             with the exception of in situ carcinoma of the cervix, in situ carcinoma of the breast
             or completely resected non-melanoma skin cancer

          -  Patients may not have received prior chemotherapy or radiation therapy for lung cancer

          -  Patients with a history of myocardial infarction are eligible if the event occurred >
             6 months prior to entry

          -  Patients must not have any clinically significant ongoing, active or serious
             infection, symptomatic or uncontrolled congestive heart failure, active angina,
             symptomatic or uncontrolled cardiac arrhythmia or any other medical condition or
             psychiatric illness/social situations that would limit compliance with study
             requirements

          -  Patents must have no contraindication to cisplatin chemotherapy including no
             clinically significant hearing loss unless willing to accept the potential of further
             loss of hearing, no symptomatic peripheral neuropathy

          -  Women must not be pregnant or breast-feeding

          -  All females of childbearing potential must have a blood test or urine study within 2
             weeks prior to registration to rule out pregnancy

          -  A female of childbearing potential is any woman, regardless of sexual orientation or
             whether they have undergone tubal ligation, who meets the following criteria: 1) has
             not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally
             postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in
             the preceding 24 consecutive months)

          -  Women of childbearing potential and sexually active males must be strongly advised to
             use an accepted and effective method of contraception or to abstain from sexual
             intercourse for the duration of their participation in the study

          -  Patients must not have received any study therapies prior to registration

          -  Pemetrexed/cisplatin therapy; note: patients who will receive pemetrexed/cisplatin
             therapy must meet all eligibility criteria below:

               -  Patients assigned to pemetrexed/cisplatin therapy must NOT have squamous cell
                  histology

               -  Calculated creatinine clearance must be obtained within 2 weeks of registration
                  and calculated creatinine clearance (CrCl) must be >= 45mL/min using the standard
                  Cockcroft and Gault formula, or the measured glomerular filtration rate (GFR)
                  using the appropriate radiolabeled method (51-CrEDTA or Tc99m-DTPA) must be used
                  to calculate CrCl

          -  Patients should have no contraindications for FDG-PET/CT
      "
NCT02604511,completed,,1,phase 2,"[""waldenstrom's macroglobulinemia""]","[""['C88.0']""]",['ibrutinib'],['C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N'],"
        Inclusion Criteria:

          -  Clinicopathological diagnosis of Waldenstrom's Macroglobulinemia and meeting criteria
             for treatment using consensus panel criteria from the Second International Workshop on
             Waldenstrom's macroglobulinemia (Kyle et al, 2003).

          -  Measurable disease, defined as presence of serum immunoglobulin M (IgM) with a minimum
             IgM level of ≥ 2 times the upper limit of normal is required.

          -  Age ≥ 18 years.

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (see Appendix A.).

          -  Participants must have normal organ and marrow function as defined below:

               -  Absolute neutrophil count ≥ 1,000/μL

               -  Platelets ≥ 50,000/μL

               -  Hemoglobin ≥ 8 g/dL

               -  Total bilirubin ≤ 2.0. mg/dL or < 2.5 mg/dL if attributable to hepatic
                  infiltration by neoplastic disease or Gilbert's syndrome.

               -  Aspartate aminotransferase (AST or SGOT) and Alanine aminotransferase (ALT or
                  SGPT) ≤ 2.5 X institutional upper limit of normal

               -  Estimated Creatinine Clearance ≥30ml/min

          -  Not on any active therapy for other malignancies with the exception of topical
             therapies for basal cell or squamous cell cancers of the skin.

          -  Females of childbearing potential (FCBP) must agree to use two reliable forms of
             contraception simultaneously or have or will have complete abstinence from
             heterosexual intercourse during the following time periods related to this study: 1)
             while participating in the study; and 2) for at least 28 days after discontinuation
             from the study. Men must agree to use a latex condom during sexual contact with a FCBP
             even if they have had a successful vasectomy. FCBP must be referred to a qualified
             provider of contraceptive methods if needed.

          -  Able to adhere to the study visit schedule and other protocol requirements.

          -  Ability to understand and the willingness to sign a written informed consent document.

          -  Both men and women of all races and ethnic groups are eligible for this trial.

        Exclusion Criteria:

          -  Prior systemic therapy for WM

          -  Any serious medical condition, laboratory abnormality, uncontrolled intercurrent
             illness, or psychiatric illness/social condition that would prevent the participant
             from signing the informed consent form.

          -  Concurrent use of any other anti-cancer treatments or any other investigational
             agents.

          -  Concomitant use of warfarin or other Vitamin K antagonists.

          -  Concomitant treatment with strong CYP3A4/5 inhibitor.

          -  Any condition, including the presence of laboratory abnormalities, which places the
             participant at unacceptable risk if he/she were to participate in the study or
             confounds the ability to interpret data from the study.

          -  Any life-threatening illness, medical condition, or organ system dysfunction which, in
             the investigator's opinion could interfere with the absorption or metabolism of
             ibrutinib.

          -  Known Central nervous system (CNS) lymphoma.

          -  Concomitant use of medication known to cause QT prolongation.

          -  Currently active, clinically significant cardiovascular disease such as uncontrolled
             or symptomatic arrhythmias, Class 3 or 4 congestive heart failure as defined by the
             New York Heart Association Functional Classification, or history of myocardial
             infarction, unstable angina or acute coronary syndrome within 6 months of screening.

          -  Malabsorption, disease significantly affecting gastrointestinal function, or resection
             of the stomach or small bowel, ulcerative colitis, symptomatic inflammatory bowel
             disease, or partial or complete bowel obstruction.

          -  Known history of Human Immunodeficiency Virus (HIV), active infection with Hepatitis B
             Virus (HBV), and/or Hepatitis C Virus (HCV). Subjects who are positive for hepatitis B
             core antibody or hepatitis B surface antigen must have a negative polymerase chain
             reaction (PCR) result before enrollment. Those who are PCR positive will be excluded.

          -  Lactating or pregnant women.

          -  Inability to swallow capsules.

          -  History of non-compliance to medical regimens.

          -  Unwilling or unable to comply with the protocol.

          -  Major surgery within 4 weeks of first dose of study drug.

          -  No active infections requiring systemic therapy.

          -  Known bleeding disorders with the exception of acquired Von Willebrand Disorder
             suspected on the basis of WM.

          -  History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
      "
NCT02605083,terminated,"
    the study was terminated after determination of the rp2d, prior to opening expansion cohorts)
  ",1,phase 1/phase 2,['cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]",['eft508'],['CC1=C2C(=O)NC3(N2C(=O)C(=C1)NC4=NC=NC(=C4)N)CCCCC3'],"
        Inclusion Criteria:

          1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          2. Pathologically documented diagnosis of advanced solid tumor malignancy that progressed
             after appropriate prior therapy or has no potential for cure with currently available
             treatments.

          3. Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST)
             outside of any prior radiation field.

          4. At least 3 weeks post any treatments/therapies at the time of first dose.

          5. Adequate bone marrow function.

          6. Adequate hepatic function.

          7. Adequate renal function.

          8. Normal coagulation panel.

          9. Negative antiviral serology.

         10. Willingness to use effective contraception.

        Exclusion Criteria:

          1. Known central nervous system malignancy.

          2. Gastrointestinal disease that may interfere with drug absorption.

          3. Significant cardiovascular disease.

          4. Significant ECG abnormalities.

          5. Ongoing risk of bleeding due to active peptic ulcer disease, bleeding diathesis, or
             requirement for systemic anticoagulants. Use of heparin or thrombolytic agents for
             local maintenance or clearance of a central venous catheter is permitted.

          6. Ongoing systemic bacterial, fungal or viral infection (with the exception of fungal
             infections of the skin or nails).

          7. Pregnancy or breastfeeding.

          8. Major surgery within 4 weeks before the start of study therapy.

          9. Prior solid organ or bone marrow progenitor cell transplantation.

         10. Prior therapy with any known inhibitor of MNK1 or MNK2.

         11. Ongoing immunosuppressive therapy, including systemic or enteric corticosteroids (can
             be using topical or inhaled corticosteroids).

         12. Use of drugs that might pose a risk of a drug-drug interaction within 4-7 days before
             the start of study therapy.
      "
NCT02607332,completed,,1,phase 2,['gastrointestinal stromal tumors'],"[""['C49.A0', 'C49.A1', 'C49.A2', 'C49.A5', 'C49.A3', 'C49.A4', 'C49.A9']""]",['paclitaxel'],['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C'],"
        Inclusion Criteria:

          -  Age 20 years or older

          -  Histologically confirmed metastatic and/or advanced GIST with CD117(cluster of
             differentiation 117)(+), DOG-1(+), or mutation in KIT or PDGFRα gene(Platelet Derived
             Growth Factor Receptor)

          -  Failed (progressed and/or intolerable) after prior treatments for GIST, including at
             least both imatinib and sunitinib .

          -  Eastern Cooperative Oncology Group performance status of 0~2

          -  Resolution of all toxic effects of prior treatments to grade 0 or 1 by NCI-Common
             Toxicity Criteria for Adverse Effects version 3.0

          -  At least one measurable lesion as defined by Response Evaluation Criteria In Solid
             Tumors version 1.0

          -  Adequate bone marrow, hepatic, renal, and other organ functions

               -  Neutrophil > 1,500/mm3

               -  Platelet > 100,000/mm3

               -  Hemoglobin > 8.0 g/dL

               -  Total bilirubin < 1.5 x upper limit of normal (ULN)

               -  Aspartate aminotransferase /Alanine transferase< 2.5 x ULN (or < 5 x ULM in case
                  of liver metastases)

               -  Creatinine < 1.5 x ULN

          -  Life expectancy > 12 weeks

          -  Washout period of previous TKIs(Tyrosine Kinase Inhibitor) or chemotherapy for more
             than 4 times the half life.

          -  Provision of a signed written informed consent

        Exclusion Criteria:

          -  Women of child-bearing potential who are pregnant or breast feeding or adults of
             reproductive potential not employing an effective method of birth control.

          -  have the presence of cardiac disease,including a myocardial infarction within 6 months
             prior to study entry,Clinically significant cardiac disease (New York Heart
             Association, Class III or IV) or severe unstable angina pectoris, stroke or transient
             ischemic attack, Arrhythmia in need of treatment

          -  Uncontrolled infection

          -  Diabetes mellitus (insulin dependent or independent disease, requiring chronic
             medication) with signs of clinically significant peripheral vascular disease.

          -  Acute and chronic liver disease and all chronic liver impairment.(Patients with stable
             and chronic viral hepatitis are eligible are acceptable)

          -  Uncontrolled gastrointestinal toxicities with toxicity greater than NCI Common
             Toxicity Criteria for Adverse Effects grade 2

          -  Other severe, acute, or chronic medical or psychiatric condition or laboratory
             abnormality.

          -  The patient experienced any bleeding episode considered life-threatening, or any grade
             3 or 4 bleeding event.

          -  Major surgery ≤ 28 days prior to starting study drug or who have not recovered from
             side effects of such therapy.

          -  Known diagnosis of HIV infection .

          -  History of another primary malignancy that is currently clinically significant or
             currently requires active intervention.

          -  Patients with brain metastases as assessed by radiologic imaging

          -  Alcohol or substance abuse disorder.
      "
NCT02965378,completed,,0,phase 2/phase 3,"['fgfr1 gene amplification', 'fgfr1 gene mutation', 'fgfr2 gene amplification', 'fgfr2 gene mutation', 'fgfr3 gene amplification', 'fgfr3 gene mutation', 'recurrent squamous cell lung carcinoma', 'stage iv squamous cell lung carcinoma ajcc v7']","[""['D02.20', 'D02.21', 'D02.22']""]","['docetaxel', 'fgfr inhibitor azd4547']",['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O'],"
        Inclusion Criteria:

          -  Patients must meet all SCREENING/PRE-SCREENING and SUB-STUDY REGISTRATION COMMON
             ELIGIBILITY CRITERIA as specified in S1400: Phase II/III Biomarker-Driven Master
             Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)

          -  Patients must be assigned to S1400D

          -  Patients must not be taking, nor plan to take while on protocol treatment and for 14
             days after the last dose of study treatment, drugs, herbal supplements or foods that
             are known to be strong/moderate CYP3A4 or CYP2D6 inhibitors and/or inducers

          -  Patients must not have received nitrosourea or mitomycin C within 42 days prior to
             sub-study registration

          -  Patients must not have had any prior exposure to any agent with FGFR inhibition as its
             primary pharmacology

          -  Patients must not have a mean resting corrected QT interval (QTc) > 450 msec obtained
             from 3 consecutive electrocardiograms (ECGs); performed within 28 days prior to
             sub-study registration; patients must not have any clinically important abnormalities
             in rhythm, conduction or morphology of resting ECG (e.g. complete left bundle branch
             block, third degree heart block); patients must not have any factors that increase the
             risk of QTc prolongation or risk of arrhythmic events such as heart failure,
             hypokalemia, congenital long QT syndrome, family history of long QT syndrome or
             unexplained sudden death under 40 years of age

          -  Patients must not be planning to receive any concomitant medication known to prolong
             QT interval

          -  Patients must be able to take oral medications; patient may not have any impairment of
             gastrointestinal function or gastrointestinal disease that may significantly alter the
             absorption of AZD4547 (e.g. ulcerative disease, uncontrolled nausea, vomiting,
             diarrhea, malabsorption syndrome or small bowel resection)

          -  Patients must not have a history of hypersensitivity to active or inactive excipients
             of AZD4547 or drugs with a similar chemical structure or class to AZD4547

          -  Patients must not have any of the following ophthalmological criteria: current
             evidence or previous history of retinal pigmented epithelium detachment (RPED);
             previous laser treatment or intra-ocular injection for treatment of macular
             degeneration; current evidence or previous history of dry or wet age-related macular
             degeneration; current evidence or previous history of retinal vein occlusion (RVO);
             current evidence or previous history of retinal degenerative diseases (e.g.
             hereditary); or current evidence or previous history of any other clinically relevant
             chorioretinal defect

          -  Patients must have an eye exam performed within 28 days prior to sub-study
             registration; patients with uncontrolled glaucoma or intra-ocular pressure >= 21 mm Hg
             at screening should be referred for ophthalmological management and the condition
             controlled prior to registration

          -  Patients must have albumin, urinalysis, and Troponin I obtained within 7 days prior to
             sub-study registration

          -  Patients must have corrected calcium and phosphate < upper limit or normal (ULN)
             obtained within 7 days prior to sub-study registration

          -  Patients must have multigated acquisition (MUGA)/echocardiogram performed within 28
             days prior to sub-study registration

          -  Patients must also be offered participation in banking for future use of specimens

          -  STEP 2 TO AZD4547 RE-REGISTRATION:

          -  Patients must have progressed on Arm 2 (docetaxel) of this sub-study

          -  Patients must not have received any prior systemic therapy (systemic chemotherapy,
             immunotherapy or investigational drug) within 21 days prior to re-registration;
             patients must have recovered (=< grade 1) from any side effects of prior therapy

          -  Patients must have measurable disease documented by computed tomography (CT) or
             magnetic resonance imaging (MRI); the CT from a combined positron emission tomography
             (PET)/CT may be used to document only non-measurable disease unless it is of
             diagnostic quality; measurable disease must be assessed within 28 days prior to
             re-registration; pleural effusions, ascites and laboratory parameters are not
             acceptable as the only evidence of disease; non-measurable disease must be assessed
             within 42 days prior to re-registration; all disease must be assessed and documented
             on the Baseline Tumor Assessment Form; patients whose only measurable disease is
             within a previous radiation therapy port must demonstrate clearly progressive disease
             (in the opinion of the treating investigator) prior to registration

          -  Patients must have a CT or MRI scan of the brain to evaluate for central nervous
             system (CNS) disease within 42 days prior to Step 2 Re-registration; patient must not
             have leptomeningeal disease, spinal cord compression or brain metastases unless: (1)
             metastases have been locally treated and have remained clinically controlled and
             asymptomatic for at least 14 days following treatment prior to re-registration, AND
             (2) patient has no residual neurological dysfunction and has been off corticosteroids
             for at least 24 hours prior to re-registration

          -  Patients must not be planning to receive any concurrent chemotherapy, immunotherapy,
             biologic or hormonal therapy for cancer treatment; concurrent use of hormones for
             non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement
             therapy) is acceptable

          -  Patients must have albumin, urinalysis, and Troponin I obtained within 7 days prior to
             substudy registration

          -  Patients must have corrected calcium and phosphate < ULN obtained within 7 days prior
             to sub-study registration

          -  Patients must have MUGA/echocardiogram performed within 28 days prior to sub-study
             registration

          -  Patients must not have any of the following ophthalmological criteria: current
             evidence or previous history of retinal pigmented epithelium detachment (RPED);
             previous laser treatment or intra-ocular injection for treatment of macular
             degeneration; current evidence or previous history of dry or wet age-related macular
             degeneration; current evidence or previous history of retinal vein occlusion (RVO);
             current evidence or previous history of retinal degenerative diseases (e.g.
             hereditary); or current evidence or previous history of any other clinically relevant
             chorioretinal defect; patients must have an eye exam performed within 28 days prior to
             Step 2 re-registration; patients with uncontrolled glaucoma or intra-ocular pressure
             >= 21 mm Hg at screening should be referred for ophthalmological management and the
             condition controlled prior to crossover registration

          -  Patients must not be taking, nor plan to take while on protocol treatment and for 14
             days after the last dose of study treatment, drugs, herbal supplements or foods that
             are known to be strong/moderate CYP3A4 or CYP2D6 substrates

          -  Patients must not have a mean resting corrected QT interval (QTc) > 450 msec obtained
             from 3 consecutive electrocardiograms (ECGs); performed within 28 days prior to Step 2
             re-registration; patients must not have any clinically important abnormalities in
             rhythm, conduction or morphology of resting ECG (e.g. complete left bundle branch
             block, third degree heart block); patients must not have any factors that increase the
             risk of QTc prolongation or risk of arrhythmic events such as heart failure,
             hypokalemia, congenital long QT syndrome, family history of long QT syndrome or
             unexplained sudden death under 40 years of age

          -  Absolute neutrophil count (ANC) >= 1,500/mcl obtained within 28 days prior to Step 2
             re-registration

          -  Platelet count >= 100,000 mcl obtained within 28 days prior to Step 2 re-registration

          -  Hemoglobin >= 9 g/dL obtained within 28 days prior to Step 2 re-registration

          -  Serum bilirubin =< institutional upper limit of normal (IULN); for patients with liver
             metastases, bilirubin must be =< 5 x IULN within 28 days prior to Step 2
             re-registration

          -  Either alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 2 x IULN
             within 28 days prior to Step 2 re-registration (if both ALT and AST are done, both
             must be =< 2 IULN); for patients with liver metastases, either ALT or AST must be =< 5
             x IULN (if both ALT and AST are done, both must be =< 5 x IULN)

          -  Patients must have a serum creatinine =< the IULN OR measured or calculated creatinine
             clearance >= 50 mL/min using the Cockroft-Gault formula

          -  Patients must have Zubrod performance status of 0-1 documented within 28 days prior to
             Step 2 re-registration

          -  Patients must not have any grade III/IV cardiac disease as defined by the New York
             Heart Association Criteria (i.e., patients with cardiac disease resulting in marked
             limitation of physical activity or resulting in inability to carry on any physical
             activity without discomfort), unstable angina pectoris, and myocardial infarction
             within 6 months, or serious uncontrolled cardiac arrhythmia

          -  Patients must not have documented evidence of acute hepatitis or have an active or
             uncontrolled infection

          -  Patients with a known history of human immunodeficiency virus (HIV) seropositivity: 1.
             Must have undetectable viral load using standard HIV assays in clinical practice; 2.
             Must have cluster of differentiation (CD)4 count >= 400/mcL; 3. Must not require
             prophylaxis for any opportunistic infections (i.e., fungal, mycobacterium avium
             complex [mAC], or pneumocystis pneumonia [PCP] prophylaxis); 4. Must not be newly
             diagnosed within 12 months prior to re-registration

          -  Prestudy history and physical exam must be obtained within 28 days prior to
             re-registration

          -  No other prior malignancy is allowed except for the following: adequately treated
             basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated
             stage I or II cancer from which the patient is currently in complete remission, or any
             other cancer from which the patient has been disease free for five years

          -  Patients must not be pregnant or nursing; women/men of reproductive potential must
             have agreed to use an effective contraceptive method; a woman is considered to be of
             ""reproductive potential"" if she has had menses at any time in the preceding 12
             consecutive months; in addition to routine contraceptive methods, ""effective
             contraception"" also includes heterosexual celibacy and surgery intended to prevent
             pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy,
             bilateral oophorectomy or bilateral tubal ligation; however, if at any point a
             previously celibate patient chooses to become heterosexually active during the time
             period for use of contraceptive measures outlined in the protocol, he/she is
             responsible for beginning contraceptive measures

          -  As a part of the Oncology Patient Enrollment Network (OPEN) registration process the
             treating institution's identity is provided in order to ensure that the current
             (within 365 days) date of institutional review board approval for this study has been
             entered in the system

          -  Patients with impaired decision-making capacity are eligible as long as their
             neurological or psychological condition does not preclude their safe participation in
             the study (e.g., tracking pill consumption and reporting adverse events to the
             investigator)

          -  Patients must be informed of the investigational nature of this study and must sign
             and give written informed consent in accordance with institutional and federal
             guidelines
      "
NCT03935347,withdrawn,"
    no accrual
  ",0,phase 2,"['metastatic bladder urothelial carcinoma', 'metastatic renal pelvis urothelial carcinoma', 'metastatic ureter urothelial carcinoma', 'metastatic urethral urothelial carcinoma', 'unresectable renal pelvis urothelial carcinoma', 'unresectable ureter urothelial carcinoma']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['cyclophosphamide', 'fludarabine', 'fludarabine phosphate']","['C1CNP(=O)(OC1)N(CCCl)CCCl', 'C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N', 'C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)COP(=O)(O)O)O)O)F)N']","
        Inclusion Criteria:

          -  The subject must understand the requirements of the study and voluntarily sign the
             informed consent form (ICF)

          -  All subjects must have a histologically confirmed unresectable TCC (including renal
             pelvis, ureters, urinary bladder, and urethra)

          -  Failed one and only one line of cisplatin-based chemotherapy per FDA guidelines.

          -  Subjects must have an area of tumor amenable to excisional biopsy for the generation
             of TIL separate from, and in addition to , a target lesion to be used for response
             assessment.Have at least one resectable lesion to generate TILs

          -  At least one measurable target lesion as defined by RECIST version 1.1

          -  An Eastern Cooperative Oncology Group (ECOG) performance status of =< 1

          -  Estimated life expectancy of >= 6 months

          -  Adequate bone marrow function

          -  Adequate organ function

          -  Subjects must be seronegative for the human immunodeficiency virus (HIV)

          -  Recovered from all prior anticancer therapy-related AEs to grade 1 or less

          -  Negative serum pregnancy test (female subjects of childbearing potential)

          -  Subjects of childbearing potential must be willing to practice an approved method of
             birth control starting at the time of informed consent and for 12 months after the
             completion of the study treatment regimen

          -  Must be able and willing to comply with the study visit schedule and protocol
             requirements including long-term follow-up

        Exclusion Criteria:

          -  Have had another primary malignancy within the previous 3 years (with the exception of
             carcinoma in situ of the breast, cervix, or localized prostate cancer and non-melanoma
             skin cancer that has been adequately treated)

          -  Have received prior cell transfer therapy that included a nonmyeloablative or
             myeloablative chemotherapy regimen

          -  Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody, or
             pathway-targeting agents

          -  Chemotherapy or radiotherapy with projected completion within 4 weeks of initiating
             study treatment

          -  Bisphosphonate therapy for symptomatic hypercalcemia

          -  Have had treatment with systemic immunostimulatory agents (including, but not limited
             to, interferon [IFN]-alpha or interleukin [IL]-2) within 6 weeks before initiation of
             study treatment

          -  Active or prior documented autoimmune or inflammatory disorders

          -  Subjects who have any form of human immondeficiency virus (HIV)infection

          -  Have severe infections within 4 weeks before initiation of study treatment

          -  Have received a live or attenuated vaccine within 28 days of the non-myeloablative
             lymphodepletion (NMA-LD regimen)

          -  Subjects with a history of hypersensitivity reaction(s) to any component of the LN-145
             therapy and/or the other study drugs

               -  Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) >=
                  450 msec for males (and >= 470 msec for females) calculated from 3
                  electrocardiograms (ECGs) (within a 30-minute timeframe) or history of familiar
                  long-QT syndrome

          -  Subjects who have a left ventricular ejection fraction (LVEF) < 45% or who are New
             York Heart Association functional classification class II or higher

          -  Serious illnesses or medical conditions, which would pose increased risk for study
             participation and/or compliance with the protocol

          -  Known clinically significant liver disease

          -  Have obstructive or restrictive pulmonary disease and have a documented FEV1 (forced
             expiratory volume in 1 second) of =< 60%

          -  Subjects with known primary central nervous system (CNS) malignancy or symptomatic CNS
             metastases

          -  Subjects who are pregnant or breastfeeding

          -  Active infection including tuberculosis (TB), hepatitis B, hepatitis C, or human
             immunodeficiency virus

          -  Treatment with any other investigational agent within 4 weeks before initiation of
             study treatment
      "
NCT02569957,terminated,"
    the trial was halted prematurely due to slow accrual.
  ",0,phase 2,"['malignant ovarian endometrioid tumor', 'malignant ovarian serous tumor', 'recurrent fallopian tube carcinoma', 'recurrent ovarian carcinoma', 'recurrent primary peritoneal carcinoma']","[""['R18.0', 'C17.3', 'G21.0', 'J91.0', 'C05.2', 'C10.0', 'C16.0']"", ""['R18.0', 'C17.3', 'G21.0', 'J91.0', 'C05.2', 'C10.0', 'C16.0']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['topotecan hydrochloride', 'topotecan hydrochloride', 'acetylcysteine']","['CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl', 'CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl', 'CC(=O)NC(CS)C(=O)O']","
        Inclusion Criteria:

          1. Patient must have persistent or recurrent high grade endometrioid or serous ovarian,
             primary peritoneal or fallopian tube carcinoma. Histologic documentation of the
             original primary tumor is required via the pathology report.

          2. All patients must have measurable disease that is amenable to biopsy. Measurable
             disease is defined as at least one lesion that can be accurately measured in at least
             one dimension (longest dimension to be recorded). Each lesion must be ≥20 mm when
             measured by conventional techniques including palpation, plain film x-ray, CT, and
             MRI, or ≥ 10 mm when measured by high resolution CT.

          3. Patient must have at least one target lesion to be used to assess response on this
             protocol as defined by RECIST 1.1. Tumors within a previously irradiated field will be
             designated as non-target lesions unless progression is documented or a biopsy is
             obtained to confirm persistent disease at least 90 days following completion of
             radiation therapy.

          4. Patients must have a GOG performance status of 0, 1, or 2.

          5. Patients must be free of active infections requiring antibiotics, with the exception
             of uncomplicated urinary tract infections (UTIs).

          6. Any hormonal therapy directed at the tumor must be discontinued at least one week
             prior to initiation of therapy. Continuation of hormone replacement therapies is
             permitted.

          7. Any other prior therapy directed at the tumor, including immunologic agents, must be
             discontinued at least 3 weeks prior to initiation of therapy.

          8. Patients must have had at least one prior platinum/taxane combination chemotherapeutic
             regimen for management of primary disease containing carboplatin, cisplatin, or
             another organoplatin compound. This initial treatment may include intraperitoneal
             therapy, high dose therapy, consolidation, noncytotoxic agents, or extended therapy.

          9. Patients must be platinum resistant- defined as progressive disease while receiving
             platinum therapy or within 6 months of completing first line platinum therapy or
             patients who have progressive disease after two lines of platinum based treatment.

               1. Cytotoxic regimens are any that include agents that target the genetic and/or
                  mitotic apparatus of the dividing cells, resulting in dose limiting toxicity to
                  the bone marrow or gastrointestinal mucosa

               2. Patients are allowed to receive, but not required to receive biologic
                  (noncytotoxic) therapy as part of their treatment regimen, e.g. bevacizumab.

         10. Patients Must Have Adequate:

               1. Bone Marrow Function: Absolute Neutrophil Count greater than or equal to
                  1000/mcl. Platelets greater than or equal to 100,000/mcl. Hemoglobin greater than
                  10 g/dl. (Patients may be transfused to achieve this hemoglobin.)

               2. Renal Function: creatinine less than or equal to 1.5 x upper limit of normal,
                  CTCAE v 4.0 grade 1.

               3. Hepatic Function: bilirubin less than or equal to 1.5 x upper limit of normal,
                  CTCAE v 4.0 grade 1. Asparate transaminase (AST) and alkaline phosphatase less
                  than or equal to 2.5 x upper limit of normal, CTCAE v 4.0 grade 1.

               4. Coagulation: PT, PTT less than or equal to 1 to 1.5 x upper limit of normal CTCAE
                  v 4.0 grade 1 except for patients on therapeutic anticoagulation.

               5. Neurologic Function: neuropathy (sensory and motor) less than or equal to CTCAE v
                  4.0 grade 1.

         11. Patients must have signed an approved informed consent and authorization permitting
             release of personal health information.

         12. Patients must meet pre-entry requirements as specified.

         13. In the unlikely event that patients are still of childbearing potential, these
             patients must have a negative serum pregnancy test within 72 hours prior to initiating
             protocol therapy and be practicing an effective form of contraception during protocol
             therapy and for at least 4 weeks following completion of protocol therapy.

         14. Patients must be 18 years of age or older.

         15. Patients must not be receiving any other investigational agent.

         16. Patients must be able to swallow whole pills. -

        Exclusion Criteria:

          1. Patients who have had previous treatment with topotecan.

          2. Patients who have had more than 4 prior chemotherapy regimens.

          3. Patients who have received radiation to more than 25% of marrow-bearing areas.

          4. Patients with a history of other invasive malignancies are excluded if there is any
             evidence of other malignancy being present within the last 3 years.

          5. Patients who have received prior chemotherapy for any abdominal or pelvic tumor other
             than for treatment of ovarian carcinoma within the last 3 years are excluded. Patients
             may have received prior chemotherapy for localized breast cancer, provided that it was
             completed more than three years prior to registration and the patient remains free of
             recurrent of metastatic disease.

          6. Pregnant or nursing women or women of childbearing potential unless using effective
             contraception as determined by the investigator. -
      "
NCT02568839,"active, not recruiting",,1,phase 2/phase 3,"['early-stage breast carcinoma', 'her-2 positive breast cancer']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['docetaxel + trastuzumab sc + pertuzumab', 'trastuzumab emtansin']",['Status: 503'],"
        Inclusion Criteria:

          1. Written informed consent

          2. Patients with breast cancer confirmed by histology, characterized by
             immunohistochemistry for ER, PR, HER2 and proliferation marker

          3. Tumor and blood samples available. HER2 type confirmed by ISH

          4. Age 18 years or older. Elderly patients in condition adequate for planned therapy

          5. Primary breast cancer >20mm in diameter and/or verified lymph node metastases

          6. Adequate bone marrow, renal, hepatic and cardiac functions and no other uncontrolled
             medical or psychiatric disorders

          7. LVEF ≥55%

          8. ECOG performance status 0-1

          9. Primary breast cancer as defined in p. 5 plus at most 2 morphologically characterized
             well-defined distant metastases accessible for stereotactic radiotherapy, provided
             that this treatment is available

        Exclusion Criteria:

          1. Distant metastases, including node metastases in the contralateral thoracic region or
             in the mediastinum

          2. Other malignancy diagnosed within the last five years, except for radically treated
             basal or squamous cell carcinoma of the skin or CIS of the cervix

          3. Patients in child-bearing age without adequate contraception

          4. Pregnancy or lactation

          5. Uncontrolled hypertension, heart, liver, kidney related or other medical or
             psychiatric disorders
      "
NCT02560038,terminated,"
    slow enrollment; resource re-allocation
  ",0,phase 2,['urinary bladder neoplasms'],"[""['D30.3', 'C67.5', 'C67.9', 'C79.11', 'C67.0', 'C67.1', 'D41.4']""]","['gemcitabine', 'paclitaxel', 'cisplatin']","['C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C', 'N.N.Cl[Pt]Cl']","
        Inclusion Criteria:

          -  All patients must have histologic demonstration of metastatic or locally unresectable
             transitional cell carcinoma of the urothelium. Minor components (<50% overall) of
             variants such as glandular or squamous differentiation, or evolution to more
             aggressive phenotypes, such as sarcomatoid, or small cell changes are acceptable.
             However, when these atypical histologies are dominant, other treatment approaches may
             be more appropriate, and such patients are not eligible.

          -  All patients must have measurable or evaluable disease. In general, liver and lung
             lesions should be at least 1 cm, and patients with node-only disease should have
             lesions of ≥ 1.5 cm in the largest dimension. Patients with disease confined to bone
             may be eligible if a measurable lytic defect is present. Patients with a 3-dimensional
             mass or pelvic sidewall fixation on bladder examination under anesthesia are
             considered to have measurable disease.

          -  All patients must have adequate physiologic reserves as evidenced by:

          -  Life expectancy of at least 12 weeks.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.

          -  No clinical history of heart disease and a normal EKG or an ejection fraction measured
             by echocardiogram or MUGA scan of at least 45%.

          -  Transaminase less than twice the upper limit of normal. Bilirubin <1.5 mg%.

          -  Serum creatinine ≤2.0 mg/dL. Patients presenting with obstructive uropathy may be
             eligible if they show excellent response to nephrostomy drainage.

          -  Absolute neutrophil count ≥1500; platelet count ≥100,000.

          -  Patients must not have had any previous systemic chemotherapy for bladder cancer,
             including neoadjuvant or adjuvant treatment given remotely. Gemcitabine/cisplatin is
             the standard of care for metastatic urothelial cancer. Patients who have received
             treatment would be either resistant or refractory to additional doses. In addition,
             they would have residual adverse effects from treatment and would be particularly
             susceptible to further neuropathic adverse events. Any prior intravesicular therapy is
             allowed.

          -  Women of childbearing potential must have a negative pregnancy test prior to starting
             therapy. Men and women of childbearing potential must be willing to consent using
             effective contraceptive while on treatment and for a reasonable period thereafter.

          -  Patients must not have an active, or likely to become active, second malignancy.

          -  Patients must be at least 6 weeks out from pelvic irradiation, and must not have had
             more than 10% of the bone marrow irradiated.

        Exclusion Criteria:

          -  Patients with uncontrolled CNS metastasis are not eligible.

          -  Patients with a history of peripheral neuropathy greater than grade 1 are not
             eligible.

          -  Pregnant women are excluded.
      "
NCT02560025,completed,,1,phase 2,['acute myeloid leukemia'],"[""['C92.A1', 'C92.A2', 'C92.61', 'C92.62', 'C92.A0', 'C92.60']""]","['alisertib', 'cytarabine', 'idarubicin', 'daunorubicin']","['COC1=C(C(=CC=C1)F)C2=NCC3=CN=C(N=C3C4=C2C=C(C=C4)Cl)NC5=CC(=C(C=C5)C(=O)O)OC', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O', 'CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O', 'CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O']","
        Inclusion Criteria:

          -  Participants must have pathologically confirmed, newly diagnosed high-risk acute
             myeloid leukemia, as defined by at least one of the following criteria

               -  Age greater than or equal to 65 years

               -  Poor risk karyotype, as per Leukemianet criteria

               -  Antecedent or underlying myelodysplastic syndrome or myeloproliferative neoplasm

               -  AML with MDS-related changes

          -  Adults, age 18 years or older at the time of diagnosis, eligible for standard
             induction chemotherapy according to their treating physician.

          -  ECOG performance status 0-2 (Karnofsky ≥60%, see Appendix A)

          -  Left ventricular ejection fraction > 50% as measured by echocardiogram or MUGA scan

          -  Must not have received systemic antineoplastic therapy including radiation therapy
             within 14 days of the study enrollment, except hydroxyurea or 6-mercaptopurine for the
             purposes of cytoreduction. Patients may also have received all-trans retinoic acid
             (ATRA) if there is an early suspicion of acute promyelocytic leukemia (APL, M3-AML),
             although if confirmed to have APL these patients will be excluded from the study.

          -  Adequate renal function as defined by: calculated creatinine clearance ≥40 mL/min
             (Cockcroft-Gualt Formula)

          -  Direct bilirubin < 2.0 x upper limit of normal (ULN), SGOT (AST) and SGPT (ALT)< 2.5 x
             ULN. AST and/or ALT may be up to 5X ULN if thought to be secondary to leukemia.

          -  The effects of alisertib on the developing human fetus are unknown. For this reason
             and because other chemotherapeutic agents are known to be teratogenic, women of
             child-bearing potential and men must agree to use adequate contraception (hormonal or
             barrier method of birth control; abstinence) prior to study entry and for the duration
             of study participation. Should a woman become pregnant or suspect she is pregnant
             while she or her partner is participating in this study, she should inform her
             treating physician immediately. Men treated or enrolled on this protocol must also
             agree to use adequate contraception for the duration of study participation, and 6
             months after completion of therapy.

          -  Subject must be able to take oral medication and to maintain a fast as required for 2
             hours before and 1 hour after alisertib administration.

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Patients will be excluded from this study if they do not otherwise fulfill criteria
             mentioned in bullet 3.1.1, and are found to harbor ""intermediate"" or ""favorable"" risk
             cytogenetics 41:

          -  In such patients, a sample to evaluate patient cytogenetics will be sent at the time
             of diagnosis per standard clinical care and the absence of favorable or
             intermediate-risk cytogenetics must be confirmed by Day 8. If the cytogenetic analysis
             reveals that the patient harbors non-poor risk cytogenetics, or if the cytogenetic
             results are not received prior to Day 8, the participant will be removed from the
             study.

          -  Patients with acute bilineal/biphenotypic leukemia

          -  Participants who have had chemotherapy or radiotherapy within 14 days prior to
             entering the study, except for hydroxyurea or 6-MP as noted.

          -  Participants who are receiving or have received any other investigational agents
             within 14 days of enrollment.

          -  Chemo-, hormono-, radio- or immunotherapy or therapy with monoclonal antibodies or
             small tyrosine kinase inhibitors within the past 4 weeks prior to treatment with the
             trial drug

          -  Persistence of clinically relevant therapy related toxicity from previous anti-cancer
             therapy

          -  Prior allogeneic bone marrow or organ transplantation

          -  Individuals with a history of a different malignancy are ineligible except for the
             following circumstances. Individuals with a history of other malignancies are eligible
             if they have been disease-free for at least 5 years and are deemed by the investigator
             to be at low risk for recurrence of that malignancy. Individuals with the following
             cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer
             in situ, and basal cell or squamous cell carcinoma of the skin.

          -  Current clinical central nervous system (CNS) symptoms deemed by the investigator to
             be related to leukemic CNS involvement (no lumbar puncture required, clinical
             assessment per investigator's judgment is sufficient).

          -  If applicable, patient with ≥Grade 2 peripheral neuropathy within 14 days before
             enrollment

          -  Prior treatment with alisertib

          -  Known history of hepatitis C infection or suspected currently active hepatitis C
             infection. Known or suspected history of hepatitis B infection will be excluded when
             any of the following conditions are met:

               -  Received hematopoietic stem cell transplantation (either allogenic or
                  autologous), or

               -  Received any rituximab-containing treatment regimen in the last 12 months before
                  entering the study, or

               -  Tested positive for the presence of at least 1 of the following 3 markers in
                  blood (evaluated at screening): hepatitis B surface antigen (HBsAG), antibodies
                  against hepatitis B core antigen (anti-HBc), or hepatitis B viral load (HBV DNA).

          -  Current or history of congestive heart failure New York Heart Association (NYHA) class
             3 or 4, or any history of documented diastolic or systolic dysfunction (LVEF <50%, as
             measured by MUGA scan or echocardiogram). Prior to study entry, any ECG abnormality at
             screening has to be documented by the investigator as not medically relevant

          -  Known hypersensitivity to the trial drugs or other contraindication to standard ""7+3""
             induction chemotherapy.

          -  Known history of uncontrolled sleep apnea syndrome, or sleep apnea requiring
             supplemental oxygen, and other conditions that could result in excessive daytime
             sleepiness.

          -  A medical condition requiring use of proton pump inhibitors (PPIs); or histamine 2
             (H2) receptor antagonists. Patients who intermittently use these medications, must
             meet the following criteria:

               -  No use of PPIs within 5 days before the first dose of alisertib

               -  No use of H2 antagonist or pancreatic enzymes within 24 hours before the first
                  dose of alisertib

          -  Patients with mental deficits or psychiatric conditions that preclude them from giving
             informed consent or following protocol.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection requiring intravenous antibiotics, symptomatic congestive heart failure,
             unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations
             that would limit compliance with study requirements.

          -  Known GI disease or GI procedures that could interfere with the oral absorption or
             tolerance of alisertib. Examples include, but are not limited to partial gastrectomy,
             history of small intestine surgery, and celiac disease.

          -  Pregnant women are excluded from this study because alisertib, along with standard
             induction chemotherapy, carries the potential for teratogenic or abortifacient
             effects. Because there is an unknown but potential risk for adverse events in nursing
             infants secondary to treatment of the mother with alisertib as well as cytarabine and
             idarubicin, breastfeeding should be avoided. Confirmation that the subject is not
             pregnant must be established by a negative serum ß-human chorionic gonadotropin (
             ß-hCG) pregnancy test result obtained during screening. Pregnancy testing is not
             required for post-menopausal or surgically sterilized women.

          -  Although not absolute exclusion criteria, because of known drug-drug interactions,
             below are issues that should be considered during enrollment:

          -  Treatment with clinically significant enzyme-inducing drugs, including known
             P-glycoprotein inducers (including St John's wort and rifampicin) should be used only
             if absolutely necessary and considered to be the best available choice for the
             patient. If possible, it is recommended that alternatives to known substrates,
             inhibitors or inducers of P-glycoprotein be considered. Cases should be discussed with
             the principal investigator, and may be allowed as per his/her discretion.

               -  Patients with psychological, familial, social, or geographic factors that
                  otherwise preclude them from giving informed consent, following the protocol, or
                  potentially hamper compliance with study treatment and follow-up.

               -  Patients who are otherwise felt unable to comply with the protocol, in the
                  opinion of the investigator.
      "
NCT02124369,terminated,"
    poor accrual
  ",0,phase 2,['pancreatic adenocarcinoma'],"[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['abraxane', 'gemcitabine']","['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F']","
        Inclusion Criteria:

          -  Patients with borderline unresectable advanced pancreatic adenocarcinoma, defined as
             Category 2 by central radiological review.

          -  Aged 18 years or over at the time of signing the informed consent form.

          -  Documented histological or cytological diagnosis of pancreatic ductal adenocarcinoma.

          -  ECOG performance status 0-1.

          -  Life expectancy of at least 12 weeks.

          -  Willing and able to comply with scheduled visits, treatment plans, laboratory tests
             and other study procedures.

          -  Adequate haematological function defined by:

          -  Absolute neutrophil count (ANC) ≥1,500 cells/mm3 (1.5 x 109/L).

          -  Haemoglobin ≥8.0 g/dL (80 g/L) (may be increased to this level with transfusion as
             long as there is no evidence of active bleeding).

          -  Platelets ≥100x 109/L

          -  Adequate renal function defined by serum creatinine≤1.5 x ULN or calculated creatinine
             clearance by Cockcroft-Gault of ≥50 ml/min.

          -  Adequate hepatic function defined by:

          -  Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ≤2.5 x upper
             limit of normal (ULN)

          -  Total bilirubin ≤1.5 x ULN

          -  Patients may have endoscopic or radiologic stenting to treat biliary obstruction. If
             so, bilirubin must return to ≤1.5 x ULN prior to enrolment.

          -  Received no prior therapy for their disease.

          -  Measurable disease by RECIST 1.1 criteria. Tumour assessments and measurements must be
             done within 28 days before the patient receives the first dose of ABX/GEM.

          -  All Women of Child Bearing Potential (WoCBP) and all sexually active male patients
             must agree to use effective contraception methods throughout the study and for 6
             months after the final dose of trial drug.

        Exclusion Criteria:

          -  Patients with metastatic PDAC, or disease which is amenable to resection with curative
             intent. These include tumours which are defined as Category 1 or 3 by central
             radiological review.

          -  Other invasive malignancies diagnosed within the last 5 years, with the exceptions of
             adequately treated localized cured prostate cancer, in situ carcinoma of the cervix
             uteri and basal or squamous cell carcinoma of the skin. Cancer survivors, who have
             undergone potentially curative therapy for a prior malignancy, have no evidence of
             that disease for three years or more and are deemed at negligible risk for recurrence,
             are eligible for the trial.

          -  Known allergy or hypersensitivity to ABX or GEM.

          -  Routine use of oral anti-oxidant supplements: beta-carotene, selenium, lutein,
             zeaxanthin, lycopene, pycnogenol, fernblock, omega-3S, vitamin C, vitamin E,
             astaxanthin. If recent use, a washout period of 5 half-lives is required.

          -  Patients with pre-existent ischemic heart disease particularly those under active
             treatment for coronary disease, will be excluded from Sonuvue dynamic contrast
             enhanced ultrasound investigation due to sporadic reports of cardiac ischemia in this
             population. They will be eligible for the rest of the study, as long as their cardiac
             status does not preclude surgery.

          -  Significant acute or chronic medical or psychiatric condition, disease or laboratory
             abnormality which in the judgment of the Investigator would place the patient at undue
             risk or interfere with the study. Examples include, but are not limited to:

          -  Patients who have had a venous thromboembolic event (e.g., pulmonary embolism or deep
             vein thrombosis) requiring anticoagulation who are not appropriately anti-coagulated
             or have had a NCI CTCAE (version 4.0) Grade 2 or greater bleeding episode in the 4
             weeks before Day 1.

          -  Patients taking warfarin, unless it is possible for the patient to be switched to a
             low molecular weight heparin for the duration of the study

          -  Patients with a significant history of stroke, unstable angina, myocardial infarction,
             or ventricular arrhythmia requiring medication or mechanical control within the last 6
             months.

          -  Cirrhotic liver disease, ongoing alcohol abuse, or known chronic active or acute
             hepatitis B, or hepatitis C.

          -  Known infection with HIV.

          -  Women, who are pregnant, plan to become pregnant or are lactating (during the study or
             for up to 6 months after the last dose).
      "
NCT02129257,completed,,1,phase 2,['metastatic colorectal cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['aflibercept', 'irinotecan', '5-fluorouracil', 'folinic acid']","['CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7', 'C1=C(C(=O)NC(=O)N1)F', 'C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O']","
        Inclusion Criteria

          -  Histologically proven adenocarcinoma of the colon and/or rectum

          -  Metastatic disease confirmed clinically/radiologically

          -  Signed written informed consent

          -  No prior therapy for metastatic disease

          -  Duly documented inoperable metastatic disease, ie not suitable for complete curative
             surgical resection

          -  At least one measurable or evaluable lesion as assessed by Computed Tomography (CT)
             scan or MRI (Magnetic Resonance Imaging) according to Response Evaluation Criteria In
             Solid Tumors (RECIST) v1.1

          -  Age ≥18 years

          -  Eastern Cooperative Oncology Group (ECOG) Performance status (PS) 0-2

          -  Adequate hematological status:

               -  neutrophils (ANC) ≥1.5x109/L

               -  platelets ≥100x109/L

               -  haemoglobin ≥9g/dL

          -  Adequate renal function: serum creatinine level <1.5 mg/dl and Glomerular Filtration
             Rate>50 ml/min by Cockroft/Gault formula

          -  Adequate liver function:

               -  serum bilirubin ≤1.5 x upper normal limit (ULN)

               -  alkaline phosphatase

               -  aspartate aminotransferase (AST)

               -  alanine aminotransferase (ALT) < 5 x ULN

          -  Proteinuria <2+ (dipstick urinalysis) or ≤1g/24hour

          -  Regular follow-up feasible

          -  Baseline evaluations performed before registration: clinical and blood evaluations no
             more than 2 weeks (14 days) prior to registration, tumor assessment (chest X-ray,
             CT-scan or MRI, evaluation of non-measurable lesions) no more than 3 weeks (21 days)
             prior to registration

          -  First course of treatment planned less than 1 week (7 days) after registration

          -  For female patients of childbearing potential, negative serum pregnancy test within 1
             week (7 days) prior of starting study treatment

          -  Female patients must commit to using reliable and appropriate methods of contraception
             until at least three months after the end of study treatment (when applicable). Male
             patients with a partner of childbearing potential must agree to use contraception in
             addition to having their partner use another contraceptive method during the trial.

        Exclusion Criteria

          -  Exclusive presence of bone metastasis only

          -  Uncontrolled hypercalcemia

          -  Uncontrolled hypertension (defined as systolic blood pressure >150 mmHg and/or
             diastolic blood pressure >100 mmHg despite medical therapy), or history of
             hypertensive crisis, or hypertensive encephalopathy

          -  Concomitant unplanned antitumor therapy (e.g. chemotherapy, molecular targeted
             therapy, immunotherapy)

          -  Treatment with any other investigational medicinal product within 28 days prior to
             study entry

          -  Other serious and uncontrolled non-malignant chronic disease

          -  History or presence of Central Nervous System (CNS) metastasis unless adequately
             treated (e.g. non irradiated CNS metastasis, seizures not controlled with standard
             medical therapy)

          -  Gilbert's syndrome

          -  Intolerance to atropine sulfate or loperamide

          -  Known dihydropyrimidine dehydrogenase deficiency

          -  Treatment with Cytochrome P450 3A4 (CYP3A4) inducers unless discontinued > 7 days
             prior to randomization

          -  Any of the following in 3 months prior to inclusion: grade 3-4 gastrointestinal
             bleeding (unless due to resected tumor), treatment resistant peptic ulcer disease,
             erosive esophagitis or gastritis, infectious or inflammatory bowel disease, or
             diverticulitis

          -  Other concomitant or previous malignancy, except:

               -  adequately treated in-situ carcinoma of the uterine cervix

               -  basal or squamous cell carcinoma of the skin

               -  cancer in complete remission for >5 years

          -  Any other serious and uncontrolled non-malignant disease, major surgery or traumatic
             injury within the last 28 days

          -  Pregnant or breastfeeding women

          -  Patients with known allergy to any excipients to study drugs

          -  History of myocardial infarction and/or stroke or other arterial thrombotic events or
             pulmonary embolism or unstable angina pectoris within 6 months prior to registration

          -  Poorly controlled cardiac arrhythmias

          -  Bowel obstruction

          -  History of severe tumour bleeding or bleeding disorders

          -  Poorly controlled anti-coagulation therapy (INR>3.0 on coumadin or heparin compounds)

          -  Palliative radiation therapy within 4 weeks prior to registration
      "
NCT02128958,completed,,0,phase 2,['hepatocellular carcinoma'],"[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]","['cf102', 'placebo']",['CNC(=O)C1C(C(C(O1)N2C=NC3=C(N=C(N=C32)Cl)NCC4=CC(=CC=C4)I)O)O'],"
        Inclusion Criteria:

          1. Males and females at least 18 years of age.

          2. Diagnosis of HCC:

               -  For subjects without underlying cirrhosis at the time of diagnosis, diagnosis of
                  HCC documented by cytology and/or histology.

               -  For subjects with underlying cirrhosis at the time of diagnosis, diagnosis of HCC
                  established according to the American Association for the Study of Liver Diseases
                  Practice Guideline algorithm (Appendix E).

          3. HCC is advanced, ie, treatment-refractory or metastatic, and no standard therapies are
             expected to be curative.

          4. Receipt of 1 previous systemic drug therapy for at least 3 weeks and withdrawal from
             treatment due either to intolerability or to radiographic disease progression. If
             treatment was withdrawn due to intolerability manifested as a Grade 3 or 4 event by
             National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE v4.0),
             less than 3 weeks of continuous prior administration prior to withdrawal is acceptable
             (see also Exclusion Criterion #3).

          5. Prior systemic treatment was discontinued for at least 2 weeks prior to the Baseline
             Visit.

          6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≤ 2 (Appendix B).

          7. Cirrhosis classified as Child-Pugh Class B (Appendix C).

          8. The following laboratory values must be documented within 3 days prior to the first
             dose of study drug:

               -  Absolute neutrophil count (ANC) ≥ 1.5 × 109/L

               -  Platelet count ≥ 75 × 109/L

               -  Serum creatinine ≤ 2.0 mg/dL

               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 × the
                  upper limit of normal (ULN)

               -  Total bilirubin ≤ 3.0 mg/dL

               -  Serum albumin ≥ 2.8 g/dL

               -  Prothrombin time (PT) no greater than 6 seconds longer than control.

          9. Life expectancy of ≥ 6 weeks.

        Exclusion Criteria:

          1. Receipt of no, or of >1, prior systemic drug therapies for HCC.

          2. Receipt of systemic cancer therapy, immunomodulatory drug therapy, immunosuppressive
             therapy, or corticosteroids > 20 mg/day prednisone or equivalent within 14 days prior
             to the Baseline Visit or concurrently during the trial.

          3. Presence of an acute or chronic toxicity of prior chemotherapy that has not resolved
             to ≤ Grade 1, as determined by CTCAE v 4.0.

          4. Locoregional treatment within 4 weeks prior to the Baseline Visit.

          5. Major surgery or radiation therapy within 4 weeks prior to the Baseline Visit.

          6. Use of any investigational agent within 4 weeks prior to the Baseline Visit.

          7. Child-Pugh Class A or C cirrhosis, or hepatic encephalopathy.

          8. Occurrence of esophageal or other gastrointestinal hemorrhage requiring transfusion
             within 4 weeks prior to the Baseline Visit.

          9. Active bacterial, viral, or fungal infection requiring systemic therapy or operative
             or radiological intervention.

         10. Known human immunodeficiency virus- or acquired immunodeficiency syndrome-related
             illness.

         11. Liver transplant.

         12. Active malignancy other than HCC.

         13. Uncontrolled arterial hypertension or congestive heart failure (New York Heart
             Association Classification 3 or 4) (Appendix B).

         14. Angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery
             bypass graft surgery, transient ischemic attack, or pulmonary embolism within 3 months
             prior to initiation of study drug.

         15. History of or ongoing cardiac dysrhythmias requiring treatment, atrial fibrillation of
             any grade, or persistent prolongation of the QTc (Fridericia) interval to > 450 msec
             for males or > 470 msec for females.

         16. Pregnant or lactating female.

         17. Any severe, acute, or chronic medical or psychiatric condition, or laboratory
             abnormality that may increase the risk associated with trial participation or study
             drug administration; may interfere with the informed consent process and/or with
             compliance with the requirements of the trial; or may interfere with the
             interpretation of trial results and, in the Investigator's opinion, would make the
             subject inappropriate for entry into this trial.
      "
NCT02125357,completed,,1,phase 2,['metastatic castration-resistant prostate cancer'],"[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]","['abiraterone acetate', 'enzalutamide']","['Status: 503', 'CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C']","
        Inclusion Criteria:

          1. Willing and able to provide informed consent

          2. Adult males ≥ 18 years age

          3. History of adenocarcinoma of the prostate diagnosed histologically without evidence of
             neuroendocrine or small cell differentiation

          4. Prior surgical orchiectomy or if on luteinizing hormone-releasing hormone (LHRH)
             agonist/antagonist then testosterone < 1.7 nmol/L at screening visit (patients must
             maintain LHRH agonist/antagonist therapy for duration of study treatment if not
             surgically castrated)

          5. Evidence of metastatic disease on bone scan or CT scan

          6. Evidence of biochemical or imaging progression in the setting of surgical or medical
             castration. Progressive disease for study entry is defined by one of the following
             three criteria:

               1. PSA progression: minimum of two rising PSA values from a baseline measurement
                  with an interval of ≥ 1 week between each measurement. Minimum PSA at screening
                  visit is > 2.0 ug/L

               2. Soft tissue or visceral disease progression (see Appendix B for definition of
                  measurable disease as per Response Evaluation Criteria in Solid Tumours (RECIST)
                  1.1 criteria)

               3. Bone progression: ≥ 2 new lesions on bone scan

          7. ECOG performance status 0-2 (see Appendix C)

          8. Eligible for treatment with either abiraterone acetate or enzalutamide as per standard
             of care guidelines

          9. Adequate organ function defined as:

               1. Absolute neutrophil count ≥ 1.5 x 109/L, platelet count ≥ 100 x 109/L and
                  hemoglobin ≥ 80 g/L

               2. Creatinine clearance ≥ 30 ml/min (calculated by Cockcroft-Gault formula, see
                  Appendix D)

               3. Serum potassium within normal limits

               4. Total bilirubin ≤ 1.5 x upper limit of normal (ULN) except for patients with
                  known Gilbert's syndrome (direct bilirubin ≤ 1.5 x ULN)

               5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN

         10. Able to swallow study drug and comply with study requirements including provision of
             peripheral blood samples at specified time points for correlative studies

         11. Recovery from all prior treatment-related toxicity to grade ≤ 2 (as per Common
             Terminology Criteria for Adverse Events 4.0)

        Exclusion Criteria:

          1. Severe concurrent illness or co-morbid disease that would make the subject unsuitable
             for enrolment

          2. Prior therapy with CYP17 inhibitors (including abiraterone acetate, TAK-700, TOK-001
             and ketoconazole), enzalutamide or other experimental anti-androgens (e.g. ARN-509,
             TOK-001)

          3. Prior systemic chemotherapy for mCRPC

          4. Life expectancy < 6 months

          5. Active concurrent malignancy (with the exception of non-melanomatous skin cancer)

          6. Wide-field radiotherapy or radioisotopes such as Strontium-89 or Radium-223 ≤ 28 days
             prior to starting study drug (limited-field palliative radiotherapy for 1-5 fractions
             is permitted at anytime prior to commencement protocol therapy)

          7. Brain metastases or active epidural disease (treated epidural disease is permitted)

          8. Use of herbal products that may lower PSA level (e.g. saw palmetto)

          9. Contraindication to prednisone therapy including poorly controlled diabetes mellitus

         10. History of seizure or seizure disorder, or history of any cerebrovascular event within
             6 months of study entry.

         11. Gastrointestinal disorder affecting absorption

         12. Major surgery within 4 weeks of starting study treatment
      "
NCT02129062,terminated,"
    slow accrual.
  ",0,phase 2,"['adult b acute lymphoblastic leukemia', 'adult b acute lymphoblastic leukemia with t(9;22)(q34;q11.2); bcr-abl1', 'recurrent adult acute lymphoblastic leukemia']","[""['C83.57', 'C83.50', 'C91.01', 'C91.02', 'C83.52', 'C83.56', 'C83.53']"", ""['C83.57', 'C83.50', 'C91.01', 'C91.02', 'C83.52', 'C83.56', 'C83.53']"", ""['C83.57', 'C83.50', 'C91.01', 'C91.02', 'C83.52', 'C83.56', 'C83.53']""]",['ibrutinib'],['C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N'],"
        Inclusion Criteria:

          -  Relapsed or refractory B-ALL due to receive salvage 1, 2, 3, 4, 5, or 6; half of the
             patients, i.e. 5 out of the first 10 patients, and 5 out of 10 patients thereafter,
             need to be in earlier line of salvage therapy, defined as 1st, 2nd, or 3rd line of
             salvage therapy; Philadelphia chromosome-positive (Ph+) B-ALL patients must have
             failed treatment with at least 1 second generation tyrosine kinase inhibitor; patients
             in salvage 1 with late relapse should be deemed poor candidates for reinduction with
             initial therapy; patients with ALL of T cell origin (T-ALL) can not be treated

          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)

          -  Total bilirubin =< 1.5 × upper limit of normal (ULN) (unless Gilbert's syndrome or
             disease infiltration of the liver is present)

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =< 2.0 × institutional ULN

          -  Creatinine clearance (Cockcroft-Gault) greater than or equal to 30 mL/min or estimated
             (est) glomerular filtration rate (GFR) greater than or equal to 30 mL/min/1.73 m^2

          -  For any surgery or invasive procedure requiring sutures or staples for closure,
             ibrutinib should be held at least 7 days prior to the intervention and should be held
             at least 7 days after the procedure, and restarted at the discretion of the
             investigator when the surgical site is reasonably healed without serosanguineous
             drainage or the need for drainage tubes

          -  Bone marrow involvement with >= 5% lymphoblasts, peripheral blast count less than
             5,000 per uL

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for
             the duration of study participation; should a woman become pregnant or suspect she is
             pregnant while she or her partner is participating in this study, she should inform
             her treating physician immediately; female patients need a negative serum or urine
             pregnancy test within 14 days of study start (applies only if patient is of
             childbearing potential); non-childbearing is defined as >= 1 year postmenopausal or
             surgically sterilized; men treated or enrolled on this protocol must also agree to use
             adequate contraception prior to the study, for the duration of study participation,
             and 4 months after completion of ibrutinib administration

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients who receive other chemotherapy; patients must have been off previous therapy
             for >= 2 weeks and must have recovered from clinically significant toxicity (to grade
             1 or less) of all previous therapy prior to enrollment (consent signing) with the
             following exceptions: steroids, hydroxyurea, oral mercaptopurine, methotrexate,
             vincristine (including prophylactic intrathecal medication), thioguanine, and tyrosine
             kinase inhibitors are permitted within 2 weeks of randomization as maintenance or to
             reduce the peripheral blood blast counts; during ibrutinib therapy, only steroids and
             hydroxyurea are permitted to reduce peripheral blood blast counts; patients who have
             had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin
             C) prior to entering the study or those who have not recovered from adverse events due
             to agents administered more than 2 weeks earlier

          -  Patients who are receiving any other investigational agents

          -  Active central nervous system (CNS) leukemia, as defined by unequivocal morphologic
             evidence of lymphoblasts in the cerebrospinal fluid (CSF), use of CNS-directed local
             treatment for active disease within the prior 28 days, symptomatic CNS leukemia (i.e.,
             cranial nerve palsies or other significant neurologic dysfunction) within 28 days;
             prophylactic intrathecal medication is not a reason for exclusion; patients with known
             brain metastases should be excluded from this clinical trial

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to ibrutinib

          -  Concomitant use of drugs that strongly inhibit cytochrome P450, family 3, subfamily A,
             polypeptide 4/5 (CYP3A4/5)

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection or an infection requiring systemic antibiotics, symptomatic congestive heart
             failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social
             situations that would limit compliance with study requirements

          -  Pregnant and breastfeeding women are excluded from this study; breastfeeding should be
             discontinued if the mother is treated with ibrutinib

          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
             therapy are eligible, unless the patient's cluster of differentiation (CD)4 count is
             below the institutional lower limit of normal, or the patient is taking prohibited
             CYP3A4/5 strong inhibitors or inducers

          -  Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura (ITP)
             resulting in (or as evidenced by) declining platelet or hemoglobin (Hgb) levels within
             the 4 weeks prior to first dose of study drug

          -  Presence of transfusion-dependent thrombocytopenia

          -  Prior exposure to ibrutinib

          -  History of prior malignancy, with the exception of the following:

               -  Malignancy treated with curative intent and with no evidence of active disease
                  present for more than 3 years prior to screening and felt to be at low risk for
                  recurrence by treating physician

               -  Adequately treated non-melanomatous skin cancer or lentigo maligna melanoma
                  without current evidence of disease

               -  Adequately treated cervical carcinoma in situ without current evidence of disease

          -  Burkitt's or mixed lineage leukemia, T cell ALL

          -  Isolated extramedullary relapse (i.e., testicular or CNS)

          -  Patients with a cardiac ejection fraction (as measured by either multi gated
             acquisition scan [MUGA] or echocardiogram) < 45% are excluded; currently active
             clinically significant cardiovascular disease such as uncontrolled arrhythmia,
             congestive heart failure, any class 3 or 4 cardiac disease as defined by the New York
             Heart Association Functional Classification, or history of myocardial infarction
             within 6 months prior to first dose with study drug

          -  Unable to swallow capsules, or disease significantly affecting gastrointestinal
             function and/or inhibiting small intestine absorption, such as malabsorption syndrome,
             resection of the small bowel, or poorly controlled inflammatory bowel disease
             affecting the small intestine

          -  Serologic status reflecting active hepatitis B or C infection; patients that are
             hepatitis B core antibody positive but antigen negative will need a negative
             polymerase chain reaction (PCR) prior to enrollment; (hepatitis B antigen or PCR
             positive patients will be excluded;) (this may not be a necessary exclusion for an
             ibrutinib monotherapy protocol)

          -  History of stroke or intracranial hemorrhage within 6 months prior to enrollment

          -  Current life-threatening illness, medical condition, or organ system dysfunction
             which, in the Investigator's opinion, could compromise the patient's safety, or put
             the study at risk; any other severe concurrent disease, or have a history of serious
             organ dysfunction or disease involving the heart, kidney, liver or other organ system
             that may place the subject at undue risk to undergo therapy with ibrutinib

          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that
             places the subject at unacceptable risk if he/she were to participate in the study

          -  Received anticoagulation therapy with warfarin or equivalent vitamin K antagonists
             within the last 28 days

          -  Evidence of clinically significant bleeding diathesis or coagulopathy

          -  Major surgical procedure, open biopsy, or significant traumatic injury, within 28 days
             prior to day 1, anticipation of need for major surgical procedure during the course of
             the study; (minor surgical procedures, fine needle aspirations or core biopsies within
             7 days prior to day 1; bone marrow aspiration +/- biopsy is allowed)

          -  Prior allogeneic stem cell transplant in previous 3 months
      "
NCT01757327,withdrawn,"
    poor accrual
  ",0,phase 2,['breast neoplasms'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['erismodegib', 'placebo']",['CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F'],"
        Pre-Registration Inclusion Criteria

          -  Diagnosis of pathologic stage II or III ER, PR, and HER2 negative primary invasive
             ductal or invasive lobular breast carcinoma. ER negative is defined as an Allred score
             of 0-2. PR negative is defined as an Allred score of 0-4. HER2 negative is defined as
             an IHC score of 0-1 and/or not-amplified by FISH testing.

          -  All surgery for breast cancer (as defined by surgical excision of the cancer with a
             negative margin or mastectomy) must be complete.

          -  Undergone axillary lymph node surgery (either sentinel lymph node biopsy or axillary
             lymph node dissection) per institutional standard.

          -  Completed all (neo) adjuvant chemotherapy and radiation therapy as recommended by the
             treating physicians.

          -  Completed the most recent cancer therapy (surgery, radiation, or chemotherapy) no less
             than 3 and no more than 24 weeks prior to registration. Note: patients who received
             experimental neoadjuvant or adjuvant therapy or surgical therapy (with the exception
             of Hh inhibitors) through participation in clinical trial are NOT excluded from this
             study as long as the other trial does not exclude patients from enrolling into an
             additional adjuvant clinical trial and enrolling into this trial will not compromise
             the endpoints (primary and secondary) of the primary clinical trial. In addition,
             patients must have completed the experimental therapy no less than 4 weeks or 5 half
             lives (whichever is longer) and no more than 24 weeks prior to registration. For those
             patients who have enrolled into a neoadjuvant / adjuvant / surgical trial, all
             endpoints of these trials will be reviewed prior to consenting the patient for the
             sonidegib trial.

          -  At least 18 years of age.

          -  ECOG performance status ≤ 1

          -  Patient (or legally authorized representative if applicable) must be able to
             understand and willing to sign an IRB approved written informed consent document.

        Pre-Registration Exclusion Criteria

          -  Concurrent treatment with any other standard therapy (e.g. chemotherapy, targeted
             therapy or radiotherapy) or within 3 weeks of starting sonidegib.

          -  Treatment with investigational anti-cancer agent within 4 weeks or 5 half-lives
             whichever is longer, of initializing treatments with sonidegib.

          -  Previous treatment with systemic sonidegib or with other Hh pathway inhibitors.

          -  Diagnosis of a neuromuscular disorder (e.g., inflammatory myopathies, muscular
             dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy) or on concomitant
             treatment with drugs that are recognized to cause rhabdomyolysis (such as HMG CoA
             inhibitors (statins), clofibrate and gemfibrozil) and that cannot be discontinued at
             least 2 weeks prior to starting sonidegib treatment. If it is essential that the
             patient stays on a statin to control hyperlipidemia, only pravastatin may be used with
             extra caution.

          -  Known to be HIV-positive on combination antiretroviral therapy because of the
             potential for pharmacokinetic interactions with sonidegib. In addition, these patients
             are at increased risk of lethal infections when treated with marrow-suppressive
             therapy. Appropriate studies will be undertaken in patients receiving combination
             antiretroviral therapy when indicated.

        Registration Inclusion Criteria

          -  Presence of bone marrow DTCs after the completion of all intended breast cancer
             therapy including surgery, (neo) adjuvant chemotherapy therapy, and radiation as
             indicated. Note: Bone marrow aspiration will be performed in consented patients to
             evaluate DTCs provided patients meet all eligibility criteria as described in this
             section.

          -  ECOG performance status ≤ 1

          -  Normal bone marrow and organ function as defined below:

               -  Leukocytes ≥ 3,000/mcL

               -  Absolute neutrophil count ≥ 1,500/mcL

               -  Hemoglobin ≥ 9.0 g/dL

               -  Platelets ≥ 80,000/mcL

               -  Total bilirubin ≤ 1.5 x IULN

               -  AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN

               -  Plasma creatine phosphokinase (CK) < 1.5 x ULN

               -  Creatinine ≤ 1.5 x ULN OR Creatinine clearance ≥ 50 mL/min/1.73 m2 for patients
                  with creatinine levels above institutional normal

          -  Able to swallow capsules.

          -  Women of childbearing potential must have a negative serum pregnancy test ≤ 7 days
             from date of registration. Women of childbearing potential must agree to use dual
             forms of adequate contraception (barrier method of birth control, non-hormonal IUD or
             IUS, abstinence) prior to study entry duration of study participation and 20 months
             after final dose of study treatment. Should a woman become pregnant or suspect she is
             pregnant while participating in this study, she must inform her treating physician
             immediately.

        Registration Exclusion Criteria

          -  Evidence of distant metastasis present by CT scan, bone scan, or physical exam within
             one year prior to entry into the trial.

          -  History of other malignancy ≤ 5 years previous with the exception of basal cell or
             squamous cell carcinoma of the skin which were treated with local resection only or
             carcinoma in situ of the cervix.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to sonidegib or other agents used in the study.

          -  Planning to embark on a new strenuous exercise regimen after initiation of study
             treatment. Muscular activities, such as strenuous exercise, that can result in
             significant increases in plasma CK levels should be avoided while on sonidegib
             treatment.

          -  Diagnosis of a medical condition that would lead to lack of physical integrity of the
             upper gastrointestinal tract or known malabsorption syndrome.

          -  Taking warfarin and Coumadin derivatives because of potential interactions with
             sonidegib.

          -  Receiving treatment with medications known to be moderate or strong inhibitors or
             inducers of CYP3A4/5 or drugs metabolized by CYP2B6 or CYP2C9 that have narrow
             therapeutic indices and that cannot be discontinued before starting treatment with
             sonidegib. Medications that are strong CYP3A4/5 inhibitors should be discontinued at
             least 7 days and strong CYP3A4/5 inducers at least 2 weeks prior to starting treatment
             with sonidegib.

          -  Concurrent uncontrolled medical conditions that may interfere with participation in
             the study or potentially affect the interpretation of the study data.

          -  Impaired cardiac function or clinically significant heart disease, including any one
             of the following:

               -  Angina pectoris within 3 months

               -  Acute myocardial infarction within 3 months

               -  QTcF > 450 msec for males and > 470 msec for females on the screening ECG

               -  A past medication history of clinically significant ECG abnormalities or a family
                  history of prolonged QT-interval syndrome

               -  Other clinically significant heart disease (e.g., congestive heart failure,
                  uncontrolled hypertension, history of labile hypertension, or history of poor
                  compliance with an antihypertensive regimen)

          -  Pregnant and/or breastfeeding. Pregnant women are excluded from this study because
             sonidegib is an Hh inhibitor with the potential for teratogenic or abortifacient
             effects. Because there is an unknown but potential risk for adverse events in nursing
             infants secondary to treatment of the mother with sonidegib, breastfeeding should be
             discontinued if the mother is treated with sonidegib.
      "
NCT02744768,unknown status,,1,phase 2,['acute lymphoblastic leukemia'],"[""['C91.01', 'C91.02', 'C91.00']""]","['dasatinib', 'blinatumomab']",['CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO'],"
        Inclusion Criteria:

          -  Newly diagnosed adult B-precursor Ph+ ALL patients.

          -  Age greater or equal to18 years,

          -  Signed written informed consent according to ICH/EU/GCP and national local laws.

          -  ECOG Performance Status 0 or 1 and/or WHO performance status less or equal to 2.

          -  Renal and hepatic function as defined below:

               -  AST (GOT), ALT (GPT), and AP <2 x upper limit of normal (ULN).

               -  Total bilirubin <1.5 x ULN.

               -  Creatinine clearance equal or greater than 50 mL/min.

          -  Pancreatic function as defined below:

               -  Serum amylase less or equal to 1.5 x ULN

               -  Serum lipase less or equal to1.5 x ULN.

          -  Normal cardiac function.

          -  Negative HIV test, negative HBV DNA and HCV RNA.

          -  Negative pregnancy test in women of childbearing potential.

          -  Bone marrow specimen from primary diagnosis available.

        Exclusion Criteria:

          -  History of or current relevant CNS pathology (current ≥grade 2 epilepsy, seizure,
             paresis, aphasia, clinically relevant apoplexia, severe brain injuries, dementia,
             Parkinson's disease, organic brain syndrome, psychosis).

          -  Impaired cardiac function, including any one of the following:

               -  LVEF <45% as determined by MUGA scan or echocardiogram.

               -  Complete left bundle branch block.

               -  Use of a cardiac pacemaker.

               -  ST depression of >1mm in 2 or more leads and/or T wave inversions in 2 or more
                  contiguous leads.

               -  Congenital long QT syndrome.

               -  History of or presence of significant ventricular or atrial arrhythmia.

               -  Clinically significant resting bradycardia (<50 beats per minute).

               -  QTc >450 msec on screening ECG (using the QTcF formula).

               -  Right bundle branch block plus left anterior hemiblock, bifascicular block.

               -  Myocardial infarction within 3 months prior to starting Dasatinib.

               -  Angina pectoris.

          -  Other clinically significant heart disease (e.g., congestive heart failure,
             uncontrolled hypertension, history of labile hypertension, or history of poor
             compliance with an antihypertensive regimen).

          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly
             alter the absorption of Dasatinib (e.g., ulcerative diseases, uncontrolled nausea,
             vomiting, diarrhea, malabsorption syndrome, or small bowel resection).

          -  History of or current autoimmune disease.

          -  Systemic cancer chemotherapy within 2 weeks prior to study.

          -  Known hypersensitivity to immunoglobulins or to any other component of the study drug
             formulation.

          -  Active malignancy other than ALL with the exception of basal cell or squamous cell
             carcinoma of the skin, or carcinoma ""in situ"" of the cervix.

          -  Active infection, any other concurrent disease or medical conditions that are deemed
             to interfere with the conduct of the study as judged by the investigator.

          -  Nursing women or women of childbearing potential not willing to use an effective form
             of contraception during participation in the study and at least 3 months thereafter or
             male patients not willing to ensure effective contraception during participation in
             the study and at least three months thereafter.
      "
NCT02742090,completed,,1,phase 2,['chronic lymphocytic leukemia'],"[""['C91.11', 'C91.12', 'C91.10']""]",['tgr-1202'],['Status: 503'],"
        Inclusion Criteria:

          -  Confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL)

          -  Discontinuation on prior BTK inhibitor or PI3K delta inhibitor due to adverse events
             within prior 9 months

          -  Presence of measurable disease

        Exclusion Criteria:

          -  Progression on prior BTK or PI3K delta inhibitor

          -  Prior treatment with TGR-1202

          -  Richter's transformation or CLL transformation to aggressive lymphoma
      "
NCT02747004,"active, not recruiting",,0,phase 2,['metastatic breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['abemaciclib', 'tamoxifen', 'prophylactic loperamide']","['CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F', 'CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3']","
        Inclusion Criteria:

          -  Have a diagnosis of HR+, HER2- breast cancer.

          -  Relapsed or progressed following endocrine therapy.

          -  Have received prior treatment with at least 2 chemotherapy regimens, of which at least
             1 but no more than 2 have been administered in the metastatic setting.

          -  Have the presence of measureable disease as defined by the Response Evaluation
             Criteria in Solid Tumors (RECIST 1.1).

          -  Have a performance status ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale.

          -  Have discontinued previous therapies for cancer (including specifically, aromatase
             inhibitors, anti-estrogens, chemotherapy, radiotherapy, and immunotherapy) for at
             least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents
             prior to receiving study drug, and recovered from the acute effects of therapy (until
             the toxicity resolves to either baseline or at least Grade 1) except for residual
             alopecia or peripheral neuropathy.

          -  Have adequate organ function.

          -  Have negative serum pregnancy test within 7 days prior to the first dose of study
             treatment and agree to use highly effective precautions to prevent pregnancy during
             the study and for 3 weeks following last dose of study treatment.

          -  Are able to swallow oral medication.

        Exclusion Criteria:

          -  Have clinical evidence or history of central nervous system metastasis.

          -  Have a personal history of any of the following conditions: syncope of either
             unexplained or cardiovascular etiology, ventricular tachycardia, ventricular
             fibrillation, or sudden cardiac arrest.

          -  Have active bacterial or fungal infection (that is, requiring intravenous antibiotics
             at the time of initiating study treatment) and/or detectable viral infection.

          -  Have received treatment with a prior cyclin-dependent kinase (CDK4) and CDK 6
             inhibitor.

          -  Have a preexisting chronic condition resulting in persistent diarrhea.

          -  Have a history of any other cancer (except nonmelanoma skin cancer or carcinoma
             in-situ of the cervix or breast), unless in complete remission with no therapy for a
             minimum of 3 years.
      "
NCT02743221,completed,,1,phase 2,['metastatic colorectal cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['trifluridine/tipiracil + bevacizumab', 'capecitabine + bevacizumab']",['Status: 503'],"
        Inclusion Criteria:

          -  Written informed consent obtained.

          -  Has ECOG (Eastern Cooperative Oncology Group) performance status of 0, 1 or 2 at the
             time of the randomisation.

          -  Has definitive histologically or cytologically confirmed adenocarcinoma of the colon
             or rectum.

          -  RAS status must have been determined (mutant or wild).

          -  Has at least one measurable metastatic lesion.

          -  No previous systemic anticancer therapy for unresectable metastatic colorectal cancer.

          -  Previous adjuvant (or neoadjuvant for patients with rectal cancer) chemotherapy is
             allowed only if if it has been completed more than 6 months before start of study
             treatment.

          -  Patient is not a candidate for combination chemotherapy with irinotecan or
             oxaliplatin, or for curative resection of metastatic lesions.

          -  Is able to take medication orally (i.e., no feeding tube).

          -  Has adequate organ function.

          -  Coagulation parameters in normal limit (or in therapeutic limit for patients treated
             with anticoagulant drugs).

          -  Women of childbearing potential must have been tested negative in a serum pregnancy
             test. Female participants of childbearing potential and male participants with
             partners of childbearing potential must agree to use a highly effective method of
             birth control. Women and female partners using hormonal contraceptive must also use a
             barrier method.

        Exclusion Criteria:

          -  Is a pregnant or lactating female.

          -  Has certain serious illness or serious medical condition(s) as described in the
             protocol.

          -  Has had certain other recent treatment e.g. major surgery, field radiation, received
             investigational agent, within the specified time frames prior to randomisation.

          -  Has previously received Trifluridine/tipiracil or history of allergic reactions
             attributed to compounds of similar composition to Trifluridine/tipiracil or any of its
             excipients.

          -  Has rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or
             glucose-galactose malabsorption.

          -  Has contra-indication to bevacizumab or capecitabine.
      "
NCT02347163,terminated,"
    the study stopped prematurely due to the low accrual rate
  ",0,phase 2,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]",['zoledronate'],['C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O'],"
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of non-metastatic operable primary invasive TN
             breast cancer subjected to diagnostic core biopsy

          -  TNBC defined as HER2/ER/PgR negative receptors

          -  Ki67 and p53 expression determined by IHC

          -  Tumour tissue availability at time of diagnosis for IHC evaluation of p53/PIN1,
             YAP/TAZ and Ki67 protein expression and for RT-PCR molecular testing of critical
             genes: p53/PIN1, YAP/TAZ

          -  Age ≥ 18 years old

          -  ECOG (Eastern Cooperative Oncology Group) performance status ≤ 1

          -  Patients with reproductive potential. Female patients must have a negative serum
             pregnancy test within 7 days prior to start of trial. Patients must agree to use a
             medically acceptable method of contraception throughout the treatment period and for 3
             months (female patients) and 6 months (male patients) after discontinuation of
             treatment

          -  Written informed consent signed prior to enrolment according to ICH/GCP.

        Exclusion Criteria:

          -  Presence of metastatic disease

          -  Clinical indication of debulking neo-adjuvant treatment

          -  Previous investigational treatment for any condition within 4 weeks from study
             registration

          -  Treatment with bisphosphonates, denosumab or other drug that, in the Investigator's
             judgment, affects bone metabolism

          -  Treatment with statins or other drugs that, in the Investigator's judgment,
             potentially affect the mevalonate pathway

          -  Any previous treatment for the currently diagnosed breast cancer, including radiation
             therapy, chemotherapy, biotherapy and/or hormonal therapy

          -  Inadequate bone marrow, hepatic or renal function including the following

               1. Hb< 9.0 g/dL, absolute neutrophil count < 1.5 x 109/L, platelets <100 x 109/L

               2. Total bilirubin > 1.5 x ULN, excluding cases where elevated bilirubin can be
                  attributed to Gilberts Syndrome

               3. AST (SGOT), ALT (SGPT) > 2.5 x ULN Creatinine > 1.2 x ULN, calcium <8.6mg/dL

          -  Co-existing active infection or serious concurrent illness that, at the judgment of
             the investigator, contra-indicate the inclusion of the patient in the study

          -  Co-existing dental diseases that form a contraindication to the use of zol or need for
             immediate dental work

          -  Any medical or other condition that in the investigator's opinion renders the patient
             unsuitable for this study due to unacceptable risk

          -  Psychiatric disorders or altered mental status precluding understanding of the
             informed consent process and/or completion of the necessary study assessment and
             procedures

          -  Anticipation of need for major surgical procedure during the course of the trial

          -  Known hypersensitivity to any excipients of zoledronate

          -  Pregnant or breast feeding women.
      "
NCT02348281,terminated,"
    it's too slow to enroll suitable patients into this study
  ",0,phase 2,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]",['bicalutamide'],['CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O'],"
        Inclusion Criteria:

          1. Females elder than 18

          2. Histological proven unresectable or metastatic breast cancer patients who underwent at
             least one chemotherapy regimen for metastatic disease

          3. Patients with androgen Receptor (AR) positive (IHC >10% nuclear staining) either for
             primary tumor or metastatic lesion

          4. Triple-negative for estrogen receptor (ER), progestogen receptor (PR), and human
             epithelial receptor-2 (HER2) by IHC (ER <1%, PR <1% and Her2 negative). A negative
             Her2 gene amplification should be verified by FISH test for those patients with Her2
             (2+). For those with Her2 (1+), FISH test might be considered by the investigator.

          5. At least one measurable disease according to the response evaluation criteria in solid
             tumor (RECIST 1.1)

          6. Performance status no more than 2

          7. All patients enrolled are required to have adequate hematologic, hepatic, and renal
             function

          8. Life expectancy longer than 12 weeks

          9. No serious medical history of heart, lung, liver and kidney

         10. Be able to understand the study procedures and sign informed consent.

         11. Patients with good compliance

        Exclusion Criteria:

          1. Pregnant or lactating women

          2. Women of child-bearing potential, unwilling to use adequate contraceptive protection
             during the process of the study

          3. Patients treated with an investigational product within 4 weeks before the enrollment

          4. Patients who received chemotherapy within 4 weeks before the enrollment

          5. Patients with symptomatic central nervous system metastases are not permitted, except
             for those with stable and asymptomatic brain metastases who have completed cranial
             irradiation, and have at least one measurable lesion outside the brain. Radiotherapy
             should be completed within 4 weeks prior to the registration

          6. Other active malignancies (including other hematologic malignancies) or other
             malignancies within the last 5 years, except for cured nonmelanoma skin cancer or
             cervical intraepithelial neoplasia.

          7. Patients having a history of clinically significant cardiovascular, hepatic,
             respiratory or renal diseases, clinically significant hematological and endocrinal
             abnormalities, clinically significant neurological or psychiatric conditions

          8. Uncontrolled serious infection
      "
NCT02349178,terminated,"
    low accrual
  ",0,phase 2,"['leukemia, acute lymphoblastic', 'acute myeloid leukemia']","[""['C91.01', 'C91.02', 'C91.00']"", ""['C92.A1', 'C92.A2', 'C92.61', 'C92.62', 'C92.A0', 'C92.60']""]","['clofarabine', 'cyclophosphamide', 'etoposide']","['C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)F)Cl)N', 'C1CNP(=O)(OC1)N(CCCl)CCCl', 'CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O']","
        Inclusion Criteria:

          -  Diagnosis of acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) with <
             5% blasts in the bone marrow (M1) by morphology and that meets one of the following
             criteria:

        Flow cytometric evidence of MRD (≥ 0.01% leukemic blasts for ALL or ≥ 0.5% leukemic blasts
        for AML detected in the bone marrow) OR Molecular/cytogenetic evidence of disease (FISH or
        PCR methodology) performed within 7 days And with the intent of going on to an allogeneic
        hematopoietic cell transplantation (HCT) independent of this study

          -  Patients must have an available donor and have intention of proceeding directly to
             ALL-HCT after completion of 1 cycle of Bridging therapy.

          -  Age 0 to 39 years

          -  Karnofsky Performance Status ≥ 50% for patients 16 years and older and Lansky Play
             Score ≥ 50 for patients under 16 years of age (see Appendix 2)

          -  Patients must have a life expectancy ≥ 8 weeks as determined by the enrolling
             investigator

          -  Have acceptable organ function as defined within 7 days of study registration

        Renal: creatinine clearance ≥ 60 mL/min/1.73 m2 or serum creatinine based on age/gender as
        follows:

        Hepatic: ALT < 5 x upper limit of normal (ULN) and total bilirubin ≤ 1.5 x upper limit of
        normal (ULN) for age Cardiac: left ventricular ejection fraction ≥ 40% by ECHO/MUGA

          -  Patients must have fully recovered from the acute toxic effects of all prior
             chemotherapy, immunotherapy, or radiotherapy prior to entering this study. At least 7
             days must have elapsed from prior chemotherapy.

          -  Hematopoietic Growth Factors: At least 7 days since the completion of therapy with a
             growth factor and at least 14 days since pegfilgrastim (Neulasta®) administration.

          -  Sexually active females of child bearing potential must agree to use adequate
             contraception (diaphragm, birth control pills, injections, intrauterine device [IUD],
             surgical sterilization, subcutaneous implants, or abstinence, etc.) for the duration
             of treatment and for 2 months after the last dose of chemotherapy. Sexually active men
             must agree to use barrier contraceptive for the duration of treatment and for 2 months
             after the last dose of chemotherapy.

          -  Voluntary written consent before performance of any study-related procedure not part
             of normal medical care, with the understanding that consent may be withdrawn by the
             subject at any time without prejudice to future medical care.

        Exclusion Criteria:

          -  Acute Promyelocytic Leukemia (APL)

          -  Active extramedullary disease (CNS ≥ CNS2 and/or testicular leukemia) or presence of
             chloromatous disease

          -  Receiving concomitant chemotherapy, radiation therapy; immunotherapy or other
             anti-cancer therapy other than is specified in the protocol

          -  Systemic fungal, bacterial, viral, or other infection not controlled (defined as
             exhibiting ongoing signs/symptoms related to the infection and without improvement,
             despite appropriate antibiotics or other treatment)

          -  Pregnant or lactating. The agents used in this study are known to be teratogenic to a
             fetus and there is no information on the excretion of agents into breast milk. All
             females of childbearing potential must have a blood test or urine study within 2 weeks
             prior to registration to rule out pregnancy.

          -  Known allergy to any of the agents or their ingredients used in this study

          -  Participating in a concomitant Phase 1 or 2 study
      "
NCT02344810,withdrawn,"
    the study did not open to accrual. no start date and no completion dates.
  ",0,phase 1/phase 2,"['adenocarcinoma of the esophagus', 'adenocarcinoma of the gastroesophageal junction', 'diffuse adenocarcinoma of the stomach', 'gastrointestinal cancer', 'intestinal adenocarcinoma of the stomach', 'mixed adenocarcinoma of the stomach', 'stage iiia esophageal cancer', 'stage iiia gastric cancer', 'stage iiib esophageal cancer', 'stage iiib gastric cancer', 'stage iiic esophageal cancer', 'stage iiic gastric cancer', 'stage iv esophageal cancer', 'stage iv gastric cancer']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C49.A0', 'C49.A1', 'C49.A2', 'C49.A5', 'C49.A3', 'C49.A4', 'C49.A9']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['K22.2', 'K22.81', 'Q39.4', 'P78.83', 'I85.00', 'I85.01', 'I85.10']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['K22.2', 'K22.81', 'Q39.4', 'P78.83', 'I85.00', 'I85.01', 'I85.10']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['K22.2', 'K22.81', 'Q39.4', 'P78.83', 'I85.00', 'I85.01', 'I85.10']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['K22.2', 'K22.81', 'Q39.4', 'P78.83', 'I85.00', 'I85.01', 'I85.10']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['c-met inhibitor amg 337', 'oxaliplatin', 'leucovorin calcium', 'fluorouracil']","['C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]', 'C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)[O-])C(=O)[O-].[Ca+2]', 'C1=C(C(=O)NC(=O)N1)F']","
        Inclusion Criteria:

          -  Patients must have a life expectancy >= 12 weeks

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Women must not be pregnant or breast-feeding; all females of childbearing potential
             must have a blood test or urine study within 48 hours prior to randomization to rule
             out pregnancy; a female of childbearing potential is any woman, regardless of sexual
             orientation or whether they have undergone tubal ligation, who meets the following
             criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not
             been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses
             at any time in the preceding 24 consecutive months)

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) for the duration of study
             therapy and for 3 months after the last dose of AMG 337 plus mFOLFOX6 chemotherapy;
             should a woman become pregnant or suspect she is pregnant while participating in this
             study, she should inform her treating physician immediately; should a man impregnate
             or suspect that he has impregnated a woman while participating in this study, he
             should inform his treating physician immediately

          -  Patients must NOT have a known immediate or delayed hypersensitivity reaction to drugs
             chemically related to fluorouracil, platins or their excipients nor have a known
             history of dihydropyrimidine dehydrogenase (DPD) deficiency

          -  Patients must be able to swallow tablets whole

          -  Leukocytes >= 3,000/mcL

          -  Absolute neutrophil count >= 1,500/mcL

          -  Hemoglobin >= 9 g/dL

          -  Platelets >= 100,000/mcL

          -  Total bilirubin =< 1.5 X institutional upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =< 3 X institutional upper limit of normal (ULN) or =< 5 X ULN if the patient has
             liver metastases

          -  Creatinine =< 1.5 X institutional ULN or creatinine clearance >= 50 mL/min for
             patients with creatinine levels above institutional normal

          -  Patients must NOT be taking current medications or substances that are inhibitors or
             inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4)

          -  Patients with known human immunodeficiency virus (HIV) are not eligible if cluster of
             differentiation (CD)4 count is =< 200 cell/mm^3 or if receiving antiretroviral therapy

          -  Patients must not have a pre-existing > grade 1 (Common Terminology Criteria for
             Adverse Events version 4 [CTCAEv4]) motor or sensory neuropathy

          -  Patients must not have an uncontrolled infection, active hepatic, biliary disease or
             other uncontrolled intercurrent illnesses including, but not limited to: uncontrolled
             ascites, uncontrolled hypertension, symptomatic congestive heart failure, unstable
             angina pectoris, cardiac arrhythmia or psychiatric illness/addictive disorders that
             would limit compliance with study requirements

          -  PHASE I:

          -  Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors
             (RECIST) 1.1 criteria within 4 weeks prior to registration; patients must not have
             clinical or radiographic evidence of brain metastasis

          -  Patients must have histologically or cytologically confirmed adenocarcinoma
             originating from anywhere in the gastrointestinal tract

          -  Patients must have progression on standard therapies, for which effective therapy is
             not available (or patients are not a candidate for or are intolerant of such
             therapies)

          -  Patients must NOT have previous or concurrent malignancy; exceptions are made for
             patients who meet any of the following conditions:

               -  Non-melanoma skin cancer, in situ cervical cancer, breast cancer in situ, or
                  superficial bladder cancer (noninvasive papillary carcinoma or carcinoma in situ)

               -  Prior malignancy completely excised or removed and patient has been continuously
                  disease free for > 5 years from registration

          -  Patients may have received prior surgery or radiotherapy if > 4 weeks prior to
             registration and patient does not have any unresolved or unstable serious toxicity

          -  Patients must not be receiving an investigational agent concurrently and must not have
             received any other investigational agents within 4 weeks prior to randomization

          -  PHASE II:

          -  Patients must have measurable disease by RECIST 1.1 criteria within 4 weeks prior to
             registration to Step 0; patients must not have clinical or radiographic evidence of
             brain metastasis because of their poor prognosis

          -  Patient disease status must be as follows:

               -  Adenocarcinoma or poorly differentiated carcinoma of the stomach, esophagus or
                  gastroesophageal (GE) junction

               -  Histologically or cytologically confirmed Her2/neu negative cancer prior to
                  pre-registration; Her2/neu status must be determined by a Clinical Laboratory
                  Improvement Amendments (CLIA) certified laboratory

               -  Locally advanced or metastatic disease that is inoperable and not amenable to
                  curative therapy; linitis plastica is permitted

               -  Patient must NOT have gastric carcinoid, sarcomas or squamous cell carcinoma

          -  Patients may have received prior surgery or radiotherapy if > 4 weeks prior to
             registration to Step 0 and patient does not have any unresolved or unstable serious
             toxicity

          -  Patients must NOT have previous or concurrent malignancy; exceptions are made for
             patients who meet any of the following conditions:

               -  Non-melanoma skin cancer, in situ cervical cancer, breast cancer in situ, or
                  superficial bladder cancer (noninvasive papillary carcinoma or carcinoma in situ)

               -  Prior malignancy completely excised or removed and patient has been continuously
                  disease free for > 5 years from registration to Step 0

          -  Patients must not be receiving an investigational agent concurrently and must not have
             received any other investigational agents within 4 weeks prior to registration to Step
             0

          -  Patient may not have received prior chemotherapy for advanced disease or prior
             oxaliplatin or anti-MET therapy

          -  Previous neo-adjuvant or adjuvant treatment is allowed provided that it was
             discontinued >= 6 months prior to registration to Step 0

          -  Patients must have paraffin-embedded tumor specimen available for submission for
             central determination of MET expression status

               -  NOTE: it is recommended that patients not be pre-registered until the required
                  tumor specimens are on hand and ready for submission; if submission of tissue
                  will be submitted more than 5 working days after pre-registration, immediately
                  notify the receiving laboratory

          -  Patients must have had MET expression status determined by the Immunohistochemistry
             Laboratory and Image Analysis Laboratory in the Department of Pathology of The
             University of Texas MD Anderson Cancer Center in Houston: the report from the central
             laboratory indicates tumor tissue has MET

               -  NOTE: for this protocol, 'MET High' will be defined as: >= 50% tumor cells with a
                  staining intensity of 2+ or 3+ in IHC utilizing the CONFIRM anti-total MET, SP44,
                  rabbit monoclonal primary antibody
      "
NCT02340949,completed,,1,phase 2,['rectal cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['aflibercept', '5-fluoruracil', 'oxaliplatin', 'leucovorin']","['C1=C(C(=O)NC(=O)N1)F', 'C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]', 'C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O']","
        Inclusion Criteria:

          1. Signed and dated informed consent, and willing and able to comply with protocol
             requirement;

          2. Male or female subjects with rectal cancer ≥18 and <70 years of age;

          3. High risk MRI-defined operable rectal cancer (with an inferior margin no more than 12
             cm above the anal verge as assessed by MRI). Presence of at least 1 of the following
             on high resolution, thin-slice MRI (3 mm):

             Middle Third Tumors

               -  mr T3

                    1. Extramural vascular invasion (EMVI) positive

                    2. Extramural extension > 5 mms into perirectal fat

                    3. Mesorectal fascia (MRF) threatened or involved*

               -  mr T4***

             Distal Third Tumors (≤5 cm from anal verge)

               -  mr T3 tumor at or below levators

               -  T4 as above N2**

                    -  tumor or lymph node < 1 mm from the mesorectal fascia **≥4 lymph nodes in
                       the mesorectum showing morphological signs on MRI indicating metastatic
                       disease. ≥4 nodes, whether enlarged or not, with a rounded, homogeneous
                       appearance is thus not sufficient.

                         -  T4a: overgrowth to an adjacent organ or structure or T4b: peritoneal
                            involvement.

          4. Histologically confirmed adenocarcinoma of the rectum. All other histological types
             are excluded;

          5. Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤1;

          6. Hematological status: neutrophils (ANC) ≥1.5x109/L; platelets ≥100x109/L; hemoglobin
             ≥9g/dL;

          7. Adequate renal function: serum creatinine level <1.5 x upper limit of normality (ULN);

          8. Adequate liver function: serum bilirubin ≤1.5 x ULN, alkaline phosphatase <5x ULN,
             AST/ALT < 3 x ULN;

          9. Proteinuria <2+ (dipstick urinalysis) or ≤1g/24hour;

         10. Regular follow-up feasible;

         11. For female patients of childbearing potential, negative serum pregnancy test within 1
             week (7 days) prior to starting study treatment;

         12. Female patients must commit to using reliable and appropriate methods of contraception
             until at least three months after the end of study treatment (when applicable). Male
             patients with a partner of childbearing potential must agree to use contraception in
             addition to having their partner use another contraceptive method during the trial.

        Exclusion Criteria:

          1. Prior treatment with aflibercept;

          2. History or evidence upon physical examination of metastasis;

          3. Uncontrolled hypercalcemia;

          4. Pre-existing permanent neuropathy (NCI grade ≥2);

          5. Uncontrolled hypertension (defined as systolic blood pressure >150 mmHg and/or
             diastolic blood pressure >100 mmHg), or history of hypertensive crisis, or
             hypertensive encephalopathy;

          6. Concomitant protocol unplanned antitumor therapy (e.g. chemotherapy, molecular
             targeted therapy, immunotherapy);

          7. Treatment with any other investigational medicinal product within 28 days prior to
             study entry;

          8. Other concomitant or previous malignancy, except: i/ adequately treated in-situ
             carcinoma of the uterine cervix, ii/ basal or squamous cell carcinoma of the skin,
             iii/ cancer in complete remission for >5 years;

          9. Any other serious and uncontrolled non-malignant disease, major surgery or traumatic
             injury within the last 28 days;

         10. Pregnant or breastfeeding women;

         11. Patients with known allergy to any excipient to study drugs;

         12. History of myocardial infarction and/or stroke within 6 months prior to randomization;
             Previous history of stable angina, uncontrolled arrhythmia, and acute coronary
             syndrome even if controlled with medication or with myocardial infarction within the
             last 12 months.

         13. Bowel obstruction.
      "
NCT02344550,completed,,1,phase 2,['metastatic breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['everolimus(afinitor)', 'letrozole', 'leuprolide(lorelin depot)']",['C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3'],"
        Inclusion Criteria:

          -  Age ≥ 20 years

          -  Histologically or cytologically confirmed, HER-2 negative breast cancer with recurrent
             or metastatic disease

          -  No HER2 overexpressing breast cancer

          -  Premenopausal status, defined as either

          -  ER and/or PR positive

          -  Progressive disease on tamoxifen treatment or sequential or combined treatment of
             tamoxifen and GnRH agonist as a palliative or an adjuvant endocrine treatment

          -  Duration of tamoxifen treatment should be at least 3 months or more

          -  No prior treatment with an aromatase inhibitor or inactivator or fulvestrant, or mTOR
             inhibitors

          -  One line of chemotherapy in metastatic setting is permitted

          -  ECOG performance status 0,1 or 2

          -  At least one measurable lesion or mainly lytic bone lesions in the absence of
             measurable disease

          -  Adequate hematologic, liver and kidney function

        Exclusion Criteria:

          -  Pregnant women or patients in lactation

          -  More than one line of prior chemotherapy for metastatic breast cancer

          -  GnRH agonist with tamoxifen treatment within 2 weeks.

          -  Active malignancy other than breast cancer, in situ carcinoma of the cervix,
             controlled resected thyroid well differentiated carcinoma or non-melanomatous skin
             cancer in the past 5 years

          -  Active cardiovascular disease such as angina, ventricular tachycardia, uncontrolled
             hypertension

          -  Active uncontrolled infection

          -  Symptomatic brain metastases

          -  Lymphangitic carcinomatosis involving >50% of the lungs

          -  Evidence of metastases involving more than one third of the liver on sonogram or CT

          -  Patients not able or unwilling to give informed consent
      "
NCT02340780,completed,,1,phase 2,['chronic lymphocytic leukemia'],"[""['C91.11', 'C91.12', 'C91.10']""]",['buparlisib'],['C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4'],"
        Inclusion Criteria:

          -  Previously documented CLL that is recurrent or relapsed after previous therapy and
             that requires treatment

          -  Age ≥ 18 years

          -  ECOG Performance Status score of 0, 1 or 2

          -  Patients must have a life expectancy of at least 12 weeks. Those who have previously
             completed curative treatment of a malignancy other than CLL will be eligible

          -  Patients must have at least ONE of: Lymphocyte count ≥ 10 x 10^9/L OR at least one
             pathologically enlarged lymph node (≥ 2 x 2 cm) by CT scan

          -  Previous therapy: Patients must have received at least 1 prior systemic treatment
             regimen (single agent or combination therapy). There is no upper limit on number of
             prior regimens. Patients who have received prior autologous or allogeneic stem cell
             transplantation are eligible.

          -  Patients must have recovered (to ≤ grade 2) from all reversible toxicity related to
             prior systemic therapy, and have adequate washout from prior chemotherapy and
             investigational agents defined as the longest of:

               -  two weeks

               -  standard cycle length of prior regimen (e.g. 28 days for FCR)

               -  5 half-lives for investigational drugs

        Not permitted:

        • prior treatment with buparlisib (BKM120)

          -  Patients may have had radiation, provided a minimum of 21 days has elapsed prior to
             enrollment. Patients must have recovered from any acute toxic effects from radiation
             prior to registration

          -  Previous surgery is permitted provided that wound healing has occurred and at least 14
             days have elapsed if surgery was major

          -  Absolute neutrophil counts (ANC): ≥ 1.0 x 10^9/L

          -  Platelets ≥ 50/min x 10^9/L and more than 5 days since last transfusion

          -  Creatinine clearance* ≥ 50 mL/min

          -  Bilirubin** ≤ 1.5 x upper normal limit (UNL)

          -  Alanine aminotransferase (AST) and aspartate aminotransferase (ALT) ≤ 1.5 x UNL or ≤ 3
             x UNL if hepatic involvement with CLL

          -  Potassium and calcium Within normal limits for laboratory (supplementation permitted)

          -  Glucose (fasting) < 7.8 mmol/L (AND HbA1c ≤ 8% if diabetic)

             * Creatinine clearance as calculated by Cockcroft-Gault formula or by 24 hour urine
             measurement: Females: GFR = 1.04 x (140-age) x weight in kg serum creatinine in μmol/L
             Males: GFR = 1.23 x (140-age) x weight in kg serum creatinine in μmol/L

             ** Direct if patient known to have Gilbert's syndrome

          -  Patient consent must be obtained according to local Institutional and/or University
             Human Experimentation Committee requirements

          -  Patients must be accessible for treatment and follow up. Patients registered on this
             trial must be treated and followed at the participating centre

          -  In accordance with CCTG policy, protocol treatment is to begin within 2 working days
             of patient registration

        Exclusion Criteria:

          -  Progression to high grade lymphoma (Richter's transformation) or myelodysplasia

          -  Patients with known hypersensitivity to the study drug or its excipients

          -  The following are exclusions for enrolment on the study:

               -  Pregnant or lactating women. (N.B. All women of childbearing potential must have
                  a negative serum or urine pregnancy test within 7 days prior to registration).

               -  Men and women of childbearing potential who do not agree to use adequate
                  contraception: prior to study entry; while taking buparlisib and after completion
                  of study therapy for 12 weeks in men and 4 weeks in women.

          -  Serious illness or medical condition which would not permit the patient to be managed
             according to the protocol, including, but not limited to:

               1. active uncontrolled or serious infection (viral, bacterial or fungal);

               2. pulmonary disease requiring oxygen;

               3. known HIV infection or other immune deficiency disorders (except for CLL);

               4. uncontrolled auto-immune hemolytic anemia (AIHA) or auto-immune thrombocytopenia
                  (ITP)

               5. acute or chronic pancreatitis

          -  Uncontrolled or significant cardiovascular disease including:

               -  Myocardial infarction within 12 months

               -  Uncontrolled angina within 6 months

               -  Clinically significant congestive heart failure (eligible if controlled and LVEF
                  ≥ 50%)

               -  Stroke, TIA or other ischemic event within 12 months

               -  Severe cardiac valve dysfunction

               -  Left ventricular ejection fraction < 50% (only required if symptoms suggestive or
                  history of cardiovascular disease)

               -  Uncontrolled hypertension

          -  Patient has any of the following mood disorders:

               -  Medically documented history of or active major depressive episode, bipolar
                  disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of
                  suicidal attempt or ideation, or homicidal ideation (e.g. risk of doing harm to
                  self or others)

               -  Score of ≥ 12 on the PHQ-9 questionnaire

               -  Score of ≥ 15 on the GAD-7 mood scale

               -  ≥ CTCAE grade 3 anxiety

               -  Patient selects a positive response of '1,2,3' to question 9 (suicidal ideation)
                  in the PHQ-9 questionnaire

          -  Patients who have received prior buparlisib (BKM120).

          -  Patients with impairment of gastrointestinal (GI) function or GI disease that may
             significantly alter the absorption of buparlisib (e.g. ulcerative diseases,
             uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel
             resection).

          -  Patients who are unable to swallow capsules

          -  Patients on strong CYP3A inhibitors/inducers or therapeutic doses of warfarin-like
             anticoagulants (must have discontinued > 7 days prior to day 1). Patients may receive
             low molecular weight heparin if indicated. See Appendix VII for a list of prohibited
             medications.

          -  Patients on drugs with a known risk to induce Torsades de Pointes

          -  Patients receiving high dose steroid therapy or another immunosuppressive agent. Note:
             Topical applications (e.g. rash), inhaled sprays (e.g. obstructive airways diseases),
             eye drops or local injections (e.g. intra-articular) are allowed. Patients who are on
             stable moderate dose corticosteroid treatment for treatment of conditions other than
             CLL (< dexamethasone 4 mg/day, prednisone 25 mg/day) for at least 14 days before start
             of study treatment are eligible.

          -  Patients with known HIV positivity.

          -  Patients with known CLL involvement of the central nervous system.

          -  Patients with a history of other malignancies, except those which have been curatively
             treated and require no ongoing therapy
      "
NCT02343549,terminated,"
    closed to accrual due to low accrual
  ",0,phase 2,['cancer of brain and nervous system'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['bevacizumab', 'temozolomide']",['CN1C(=O)N2C=NC(=C2N=N1)C(=O)N'],"
        Inclusion Criteria:

          -  At least 22 years of age

          -  Have undergone a brain biopsy via stereotactic or open technique

          -  Pathological evidence of GBM using WHO classification criteria

          -  Planned 6 weeks of concurrent chemoradiotherapy post-biopsy concomitant with
             temozolomide (45-70Gy)

          -  Karnofsky scale greater than or equal to 70

          -  Life expectancy at least 3 months

          -  Baseline hemoglobin of > 8.0 gm/dL (with or without transfusion)

          -  Adequate coagulation defined as PT and INR < 1.5 times the upper limit of normal

          -  Signed informed consent

          -  Able to start bevacizumab at least 2 weeks but no more than 4 weeks from date of
             biopsy

          -  Able to tolerate MRI of brain and have measurable disease.

          -  Participants of childbearing age must use effective contraception for at least 6
             months following completion of treatment.

        Exclusion Criteria

          -  Enrolled in another clinical treatment trial

          -  Pregnant or Breast-feeding

          -  Any other malignancy aside from localized basal cell or squamous cell carcinoma of the
             skin

          -  Significant co-morbidities at baseline which would prevent maintenance temozolomide

          -  Thrombocytopenia (platelet count < 100 x 103 )

          -  Neutropenia (absolute neutrophil count < 1.5 x 103 )

          -  CTC grade 4 non-hematological toxicity (except for alopecia, nausea, vomiting)

          -  Significant liver function impairment - AST or ALT > 3 times the upper limit of normal

          -  Total bilirubin> 2 times the upper limit of normal

          -  Significant renal impairment (serum creatinine> 1.7 mg/dL)

          -  Implanted pacemaker, programmable shunts, defibrillator, deep brain stimulator, other
             implanted electronic devices in the brain, or documented clinically significant
             arrhythmias.

          -  Infra-tentorial tumor

          -  Evidence of increased intracranial pressure (midline shift > 5mm, clinically
             significant papilledema, vomiting and nausea, or reduced level of consciousness)

          -  History of hypersensitivity reaction to temozolomide or a history of hypersensitivity
             to DTIC or hydrogel

          -  Inability to adequately cover treatment area with TTFields (Tumor Treating Fields)

          -  Inability to wear NovoTTF-100A System for an average of 18 hours per 24 hours

          -  Currently taking cytotoxic medications, non-steroidal ant-inflammatory drugs (NSAIDS),
             or enzyme inducing anticonvulsants.

          -  Currently taking anticoagulants or blood-thinners (Coumadin)

          -  Subjects meeting any of the following bevacizumab-specific contraindications are
             ineligible for study entry:

          -  Inadequately controlled hypertension (defined as systolic blood pressure greater than
             or equal to 150 and/or diastolic blood pressure > 100 mmHg)

          -  Prior history of hypertensive crisis or hypertensive encephalopathy

          -  New York Heart Association (NYHA) Grade II or greater congestive heart failure

          -  History of myocardial infarction or unstable angina within 6 months prior to study
             enrollment

          -  History of stroke or transient ischemic attack within 6 months prior to study
             enrollment

          -  Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or
             recent peripheral arterial thrombosis) within 6 months prior to study enrollment

          -  History of hemoptysis (greater than or equal to a half teaspoon of bright red blood
             per episode) within 1 month prior to study enrollment

          -  Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic
             anticoagulation)

          -  Major surgical procedure or significant traumatic injury within 28 days prior to 1st
             bevacizumab infusion or anticipation of need for major surgical procedure during the
             course of the study

          -  Core biopsy or other minor surgical procedure, excluding placement of a vascular
             access device, within 7 days prior to study enrollment

          -  History of abdominal fistula, gastrointestinal perforation within 6 months prior to
             study enrollment

          -  Serious, non-healing wound, active ulcer, or untreated bone fracture

          -  Proteinuria at screening as demonstrated by either urine protein: creatinine (UPC)
             ratio greater than or equal to 1.0 at screening OR urine dipstick for proteinuria
             greater than or equal to 2 or more (patients discovered to have greater than or equal
             to 2 or greater proteinuria on dipstick urinalysis at baseline should undergo a
             24-hour urine collection and must demonstrate less than or equal to 1g of protein in
             24 hours to be eligible).

          -  Known hypersensitivity to any component of bevacizumab
      "
NCT02346578,completed,,1,phase 2,['castration-resistant prostate cancer'],"[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]","['enzalutamide', 'flutamide']","['CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C', 'CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F']","
        Inclusion Criteria:

          -  Testosterone of less than 50 ng/dL

          -  Participants who was detected of disease progression on image or relapse of PSA (All
             PSA values measured 3 time at least one week interval are consecutively increased and
             final value is 2 ng/mL or more. If third value is not higher than second one, fourth
             measurement will be undertaken and its value must be higher than second one.)

          -  Participants who relapsed after CAB with bicalutamide

          -  Eastern Cooperative Oncology Group (ECOG) performance status is 0 or 1

          -  Aged 20 years or older

          -  Participants who provided written informed consent

        Exclusion Criteria:

          -  Any prior treatment with enzalutamide, flutamide, abiraterone or chemotherapy, except
             for neoadjuvant therapy

          -  With active double cancer

          -  Any prior treatment with bicalutamide within 6 weeks

          -  Participants who received systemic biological therapy (except for existing approved
             drug for bone or treatment with luteinizing hormone-releasing hormone (LHRH) analogue)
             or received treatment with other antitumor agent for prostate cancer

          -  With serious complication

          -  History of hypersensitivity to enzalutamide or any other excipient of enzalutamide

          -  History of hypersensitivity to flutamide-containing agent

          -  With liver dysfunction

          -  Participants who are considered as inadequate by the investigator
      "
NCT02348255,withdrawn,"
    poor accrual
  ",0,phase 2,"['adult brain glioblastoma', 'recurrent adult brain neoplasm']","[""['C71.7', 'C71.9', 'C79.31', 'D33.0', 'D33.1', 'D33.2', 'D49.6']""]",['carmustine'],['C(CCl)NC(=O)N(CCCl)N=O'],"
        Inclusion Criteria:

          -  Histologically confirmed GBM

          -  Progressive disease after temozolomide and radiation therapy (in ""first relapse"")

          -  At least 28 days since chemotherapy or radiation

          -  Karnofsky performance score at least 70%

          -  Platelet count >= 130/mm^3

          -  Absolute neutrophil count >= 1500/mm^3

          -  Calculated creatinine clearance greater than 45 mg/dl using the Cockcroft-Gault
             formula

          -  Aspartate aminotransferase (AST) < 2 times the upper limit of normal

          -  Bilirubin < 1.5 times the upper limit of normal

          -  Subjects with child-bearing potential agree to use effective means of contraception

        Exclusion Criteria:

          -  Prior systemically administered nitrosoureas or vascular endothelial growth factor
             (VEGF) targeted therapy

          -  Chemotherapy for glioma other than temozolomide or Gliadel wafers (steroids are
             allowed)

          -  Pregnant or breast feeding

          -  Active inflammatory bowel disease

          -  Abdominal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess
             within 6 months

          -  Hypertension: systolic blood pressure (SBP) > 150 or diastolic blood pressure (DBP) >
             100 mm mercury (Hg) despite antihypertensive medications

          -  New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF);
             myocardial infarction or unstable angina within 6 months

          -  History of thrombosis

          -  Symptomatic peripheral vascular disease, stroke or transient ischemic attack within 6
             months

          -  Bleeding risks: Required to be on therapeutic anticoagulation (aspirin is allowed),
             coagulopathy (e.g. hemophilia or von Willebrand's disease); any grade III or greater
             hemorrhage, major surgical procedure, or significant trauma within 28 days; core
             biopsy or other minor surgical procedure, excluding placement of a vascular access
             device, within 7 days

          -  Activated partial thromboplastin time (APTT) must not exceed 32.5 seconds (normal
             range 21.8-31.5 seconds); international normalized ratio (INR) must not exceed 1.30
             (normal range 0.87-1.18)

          -  Serious, non-healing wound, ulcer, or bone fracture

          -  Active implanted medical device (e.g. deep brain stimulators, spinal cord stimulators,
             vagus nerve stimulators, pacemakers, defibrillators, and programmable shunts), a skull
             defect (such as missing bone with no replacement), a shunt, or bullet fragments

          -  Known sensitivity to conductive hydrogels like the gel used on electrocardiogram (ECG)
             stickers or transcutaneous electrical nerve stimulation (TENS) electrodes

          -  Human immunodeficiency virus (HIV) positive

          -  Proteinuria at screening as demonstrated by urine dipstick >= 2+

          -  Prior organ transplantation

          -  Known hypersensitivity to Chinese hamster ovary cell products or other recombinant
             human antibodies

          -  Aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), clopidogrel or any other drug
             whose goal is to inhibit platelet function

          -  Unable to give signed informed consent
      "
NCT04437953,withdrawn,"
    lack of accrual
  ",0,phase 2,"['thrombocytopenia', 'cancer', 'liver diseases']","[""['D69.6', 'D69.49', 'D69.59', 'P61.0', 'D75.829', 'D69.42', 'D75.821']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['K76.9', 'K71.8', 'K70.9', 'K71.9', 'K75.9', 'P78.84', 'Q44.6']""]",['avatrombopag'],['C1CCC(CC1)N2CCN(CC2)C3=C(N=C(S3)NC(=O)C4=CC(=C(N=C4)N5CCC(CC5)C(=O)O)Cl)C6=CC(=CS6)Cl'],"
        Inclusion Criteria:

          -  Patients with history of locally advanced or metastatic solid tumor, with a plan to
             initiate cancer directed systemic therapy for adjuvant or palliative purposes.

          -  18 years of age or greater

          -  Known liver disease attributed to one of the following:

               1. Chronic HBV and/or chronic HCV with Cirrhosis

               2. Alcoholic Cirrhosis

               3. Nonalcoholic Fatty Liver Disease with Cirrhosis

               4. Primary Biliary Cholangitis

               5. Primary Sclerosing Cholangitis

               6. Autoimmune Hepatitis

               7. Hereditary Hemochromatosis

               8. Wilsons Disease

               9. Alpha-1 Antitrypsin Deficiency

              10. Congestive Hepatopathy

              11. Cirrhosis or known pre-existing liver dysfunction of unknown cause, or not
                  otherwise specified

          -  No specific Child-Pugh Score will be required for eligibility.

          -  Patients with liver involvement with primary or metastatic cancer are eligible, if the
             patient also has a diagnosis from list in eligibility

          -  Platelet count of < 80,000/mcL at time of enrollment, and no platelet count ≥
             80,000/mcL in the 4 weeks prior to enrollment. A platelet count ≥ 80,000/mcL in the
             prior 4 weeks within 72 hours of a platelet transfusion will not make a patient
             ineligible.

          -  No prior cancer directed therapy that is cytotoxic, marrow suppressive, or has
             thrombocytopenia as a known common side effect in the past 12 months.

             a. For purposes of this study, cytotoxic/marrow suppressive systemic cancer therapy
             drugs will include: i. Nucleoside Analogue, including gemcitabine and fluorouracil ii.
             Carboplatin or cisplatin iii. Anthracycline iv. Alkylating agent v. Other cancer
             directive therapies with thrombocytopenia as a known common toxicity even if not
             cytotoxic b. If a patient has received cytotoxic systemic cancer therapy at any time
             in the past, then patients will be evaluated for myelodysplastic syndrome and leukemia
             prior to enrollment

          -  ECOG Performance status ≤ 2.

        Exclusion Criteria:

          -  History of immune causes of thrombocytopenia (ITP).

          -  Presence of leukemia or myelodysplastic syndrome.

          -  Known bone metastases sufficient to result in at least one site of cortical bone
             destruction, osteolytic lesions, or osteoblastic lesions, on radiologic imaging.

          -  Patients who have previously received thrombopoietin mimetics such as romiplostim,
             eltrombopag, etc.

          -  Patients who require emergent systemic cancer therapy will be excluded.

          -  Patients who require emergent radiation therapy will be excluded.

             a. Note: Concomitant radiation therapy with systemic cancer therapy is permitted.

          -  Pancytopenia at enrollment (Hemoglobin <9 g/dL and/or Absolute Neutrophil Count <
             1500/mcL).

             a. G-CSF and Red Blood Cell transfusions to treat anemia and neutropenia and achieve
             adequate hemoglobin and ANC are permitted.

          -  Patients with serum sodium ≤130 mEq/L will be excluded.

          -  Patients with a known bleeding disorder or platelet dysfunction will be excluded

               1. Baseline Prothrombin Time (PT) that is greater than 2"" above the upper limit of
                  normal.

               2. Activated Partial Thromboplastin Time (aPTT) that is greater than 3"" above the
                  upper limit of normal.

          -  Patients with known genetic prothrombotic conditions (Factor V Leiden, Prothrombin
             20210A, Antithrombin deficiency or Protein C or S deficiency) or history of
             antiphospholipid syndrome.

          -  Patients on anticoagulation or NSAIDs within 7 days of enrollment will be excluded,
             with the exception of celecoxib.

          -  Patients with concurrent lymphoma will be excluded.

          -  Patients will be excluded if they have a known pre-existing portal vein thrombus,
             mesenteric thrombus, or splenic thrombus that is not in the context of tumor invasion.
             Pre-existing tumor-associated portal vein thrombus, mesenteric thrombus, or splenic
             thrombus are not excluded.

          -  Potential drug interactions: Moderate or strong inducers of cytochrome p450 (CYP)2C9
             or CYP3A4/5 and use of dual moderate inhibitors of CYP2C9 and CYP3A4/5 may interact
             with Avatrombopag. Patients will be ineligible if they are receiving any of the
             following drugs:

               1. Itraconazole, Fluconazole, Rifampin, Cyclosporine, Verapamil

               2. If patients had been previously receiving the above drugs, the last dose must
                  have been administered 7 or more days before initiation of the first dose of
                  Avatrombopag.

          -  Females who are pregnant or breastfeeding or planning to become pregnant or breastfeed
             during treatment and for an additional 30 days after treatment discontinuation or
             longer if required by prescribing information for systemic cancer therapy received
             during the study will be excluded.

          -  Patients unwilling to use highly effective contraception during the study period and
             for the duration required by prescribing information for systemic cancer therapy (ies)
             administered during the study.

               1. If a woman, before entry she must be: postmenopausal (for at least 12 months), or
                  surgically sterile (have had a total hysterectomy or bilateral oophorectomy,
                  tubal ligation, or otherwise be incapable of pregnancy), or practicing a highly
                  effective method of birth control, if sexually active, including hormonal
                  prescription oral contraceptives,contraceptive injections, contraceptive patch,
                  intrauterine device, double-barrier method for less effective methods of
                  contraception (eg,condoms, diaphragm, cervical cap, or sponge with spermicidal
                  foam, cream, or gel), or male partner sterilization, consistent with local
                  regulations regarding use of birth control methods for subjects participating in
                  clinical trials, for the duration of their participation in the study, or not
                  heterosexually active.

                  Note: subjects who are not heterosexually active at screening must agree to
                  utilize a highly effective method of birth control if they become heterosexually
                  active during their participation in the study.

               2. If a man, must agree to use an adequate contraception method as deemed
                  appropriate by the investigator (eg, vasectomy, condoms, partner using effective
                  contraception).
      "
NCT04439305,withdrawn,"
    zero accrual
  ",0,phase 2,"['advanced lymphoma', 'advanced malignant solid neoplasm', 'hematopoietic and lymphoid cell neoplasm', 'refractory lymphoma', 'refractory malignant solid neoplasm', 'refractory plasma cell myeloma']","[""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['R18.0', 'C17.3', 'G21.0', 'J91.0', 'C05.2', 'C10.0', 'C16.0']"", ""['C96.20', 'C96.29', 'D47.09']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['D46.4', 'I20.2', 'D46.1', 'D46.A', 'D46.0', 'D46.20', 'D46.21']"", ""['D46.4', 'I20.2', 'D46.1', 'D46.A', 'D46.0', 'D46.20', 'D46.21']""]",['dasatinib'],['CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO'],"
        Inclusion Criteria:

          -  Patients must have met applicable eligibility criteria in the Master MATCH Protocol
             prior to registration to treatment subprotocol

          -  Patients must have one of the following missense mutations in DDR2: S768R, I638F,
             L239R

          -  Patients must have an electrocardiogram (ECG) within 8 weeks prior to treatment
             assignment and must have no clinically important abnormalities in rhythm, conduction
             or morphology of resting ECG (e.g. complete left bundle branch block, third degree
             heart block)

          -  Patients with known left ventricular dysfunction must have an echocardiogram (ECHO) or
             a nuclear study (multigated acquisition scan [MUGA] or First Pass) within 4 weeks
             prior to registration to treatment and must not have left ventricular ejection
             fraction (LVEF) < institutional lower limit of normal (LLN). If the LLN is not defined
             at a site, the LVEF must be > 50% for the patient to be eligible

        Exclusion Criteria:

          -  Patients must not have known hypersensitivity to dasatinib or compounds of similar
             chemical or biologic composition

          -  Patients with prior use of dasatinib will be excluded

          -  Dasatinib should NOT be given in the presence of STRONG CYP 3A4 inhibitors/inducers.
             Patients who take these drugs concurrently are ineligible for treatment with
             dasatinib. These drugs must be discontinued prior to initiation of dasatinib

          -  Dasatinib should NOT be given in the presence of H2-antagonists or proton pump
             inhibitors. Patients who take these drugs concurrently are ineligible for treatment
             with dasatinib. These drugs must be discontinued prior to initiation of dasatinib.
             Antacids taken 2 hours before or after dasatinib administration can be used in place
             of H2-antagonists or proton pump inhibitors if some acid-reducing therapy is needed
      "
NCT02278783,terminated,"
    slow accrual
  ",0,phase 2,"['ovarian cancer', 'primary peritoneal cancer', 'fallopian tube cancer']","[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['K65.1', 'K66.0', 'N99.4', 'N73.6', 'R88.0', 'Z49.32', 'Z49.02']"", ""['C57.00', 'C57.01', 'C57.02']""]",['regorafenib'],['CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F'],"
        Inclusion Criteria:

        Age greater than or equal to 18 years. Life expectancy of at least 12 weeks (3 months).
        Diagnosis of recurrent epithelial ovarian, primary peritoneal or fallopian tube cancer.
        Histologic or cytologic confirmation of the original primary tumor is required.

        Patients must have measurable disease defined as at least one lesion that can be accurately
        measured in at least one dimension with longest diameter (LD) greater than or equal to 10
        mm using CT, MRI, or caliper measurements or greater than or equal to 20 mm with x-ray.

        Patients must have at least one target lesion to be used to assess response on this
        protocol as defined by RECIST 1.1.

        Prior therapy: Patients must have had at least one prior platinum-based chemotherapeutic
        regimen for management of primary disease containing Carboplatin, Cisplatin, or another
        organo-platinum compound. This initial treatment may have included intraperitoneal therapy,
        consolidation, non-cytotoxic agents (including anti-angiogenesis agents) or extended
        therapy (i.e. maintenance therapy) administered after surgical or non-surgical assessment.

        Patients are allowed to have previously received, but are not required to receive, one or
        two additional cytotoxic regimens for management of recurrent disease.

        Patients who have received only one prior cytotoxic regimen (platinum based regimen for
        management of primary disease), must have a platinum-free interval of at least 6 months.

        Patients must not have received any non-cytotoxic therapy for management of recurrent or
        persistent disease, except hormonal based therapy is allowed. Patients are allowed to have
        previously received, but are not required to have received non-cytotoxic therapy as part of
        their primary treatment regimen.

        ECOG score of 0-1. Adequate bone marrow, liver and renal function

        Exclusion Criteria:

        Patients who have progressed during initial platinum-based therapy in the upfront setting,
        who have persistent disease after this initial platinum-based therapy, or who have
        recurrence less than 6 months from adjuvant chemotherapy are excluded.

        Major surgical procedure or significant traumatic injury within 28 days before start of
        study medication.

        Patients who have received wide field radiotherapy less than or equal to 4 weeks or limited
        field radiation for palliation less than or equal to 2 weeks prior to starting study drug
        or who have not recovered from side effects of such therapy Patients who have received any
        continuous or intermittent small molecule therapeutics (excluding monoclonal antibodies)
        greater than or equal to 5 effective half-lives prior to starting study drug or who have
        not recovered from side effects of such therapy.

        Patients who have received chemotherapy or targeted anticancer therapy greater than or
        equal to 4 weeks (6 weeks for nitrosourea, antibodies or mitomycin-C, and 1 week for
        hormone therapy) prior to starting study drug or who have not recovered from side effects
        of such therapy.

        Active concurrent primary malignancy or prior malignancies occurring within 3 years (except
        cervical carcinoma in-situ, treated basal cell carcinoma, or superficial bladder tumor.

        Use of any investigational drugs, biologics, or devices within 28 days prior to study
        enrollment.

        Prior use of regorafenib. Strong inducers and inhibitors of CYP3A4 and therapeutic
        anticoagulation with Vitamin-K antagonists (e.g. warfarin) or with heparins and heparinoids
        Women who are pregnant or breastfeeding. Uncontrolled hypertension defined as systolic
        pressure greater than or equal to 140 mmHg or diastolic pressure greater than or equal to
        90 mmHg despite optimal medical management.

        Human immunodeficiency virus (HIV) positive diagnosis with a CD4 count of <100 mm3 or
        detectable viral load within the past 3 months, and is receiving combination
        anti-retroviral therapy.

        Active or clinically significant cardiac disease Evidence or history of bleeding diathesis
        or coagulopathy Any hemorrhage or bleeding event ≥ NCI CTCAE v4.0 Grade 3 within 4 weeks
        prior to start of study medication.

        Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular
        accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism
        within 6 months of start of study treatment.

        Patients with pheochromocytoma Symptomatic metastatic brain or meningeal tumors. Ongoing
        infection Presence of a non-healing wound, non-healing ulcer, or bone fracture Patient's
        with a history of kidney disease or persistent proteinuria must have less than Grade 3
        proteinuria per NCI CTCAE v4.0 at screening.

        Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g. active or
        uncontrolled infection) that could cause unacceptable safety risks or compromise compliance
        with the protocol.

        Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the
        absorption of drug (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea,
        malabsorption syndrome, or small bowel resection).
      "
NCT02271906,terminated,"
    poor accrual
  ",0,phase 2,['lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]",['bibw 2992'],['CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4'],"
        Inclusion Criteria:

          1. Histologically confirmed NSCLC, who are deemed to be surgical candidates by standard
             criteria. Patients with all types of NSCLC (e.g., adenocarcinoma, squamous cell
             carcinoma) will be allowed to enroll.

          2. Patients with Stage IA to IIB disease. Select patients with resectable stage IIIA
             disease (T3N1, T4N0, T4N1) will also be eligible if approved by the PI.

          3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1

          4. Measurable disease by RECIST 1.1 criteria

          5. Mediastinoscopy and/or Endoscopic Bronchial Ultrasound (EBUS) and/or Endoscopic
             Ultrasound (EUS) for complete surgical staging when clinically indicated

          6. Serious, active infections must be controlled. Patients may be enrolled while still on
             antibiotics as long as clinical signs of active infection have resolved.

          7. A signed informed consent document (ICD)

          8. Patients 18 years or older

          9. Able and willing to take oral medications

        Exclusion Criteria:

          1. Known preexisting interstitial lung disease, interstitial pulmonary fibrosis, or
             connective tissue disorder associated lung disease

          2. Known N2 nodal disease or distant metastatic disease

          3. History or presence of clinically relevant cardiovascular abnormalities such as
             uncontrolled hypertension, congestive heart failure NYHA classification of 3, unstable
             angina or poorly controlled arrhythmia. Myocardial infarction within 6 months prior to
             randomization.

          4. Patients with any of the following lab values at screening should be excluded:
             Absolute neutrophil count (ANC) < 1500 / mm^3; Platelet count < 100,000 / mm^3; Serum
             creatinine >/= 1.5 times the upper normal limit or calculated/measured creatinine
             clearance </= 60 mL/min; Bilirubin >/=1.5mg/dL (> 26 mol/L, SI unit equivalent);
             Aspartate amino transferase (AST) or Alanine amino transferase (ALT) >/= three (3)
             times the upper limit of normal.

          5. Active hepatitis B infection, active hepatitis C infection or known HIV carrier.

          6. Known or suspected active drug or alcohol abuse

          7. Significant or recent acute gastrointestinal disorders with diarrhea as a major
             symptom for example Crohn's disease, malabsorption or CTC grade >/= 2 diarrhea of any
             etiology.

          8. Baseline (< 1 month before treatment) cardiac left ventricular function with resting
             ejection fraction of less than 50% measured by multigated blood pool imaging of the
             heart (MUGA scan) or echocardiogram

          9. Patients receiving other investigational agent.

         10. History of allergic reactions to anilinoquinazolins like gefitinib, erlotinib, or
             BIBW2992

         11. Uncontrolled intercurrent illness that would preclude a patient from undergoing
             surgery

         12. Psychiatric illness/social situations that would limit compliance with study
             requirements

         13. Pregnant (positive pregnancy test) or lactating

         14. Inability to comply with study and/or follow-up procedures

         15. Patients who are not surgical candidates or refuse surgery
      "
NCT02273752,terminated,"
    slow accrual
  ",0,phase 2,"['estrogen receptor-positive breast cancer', 'gastrinoma', 'glucagonoma', 'her2-negative breast cancer', 'insulinoma', 'mucositis', 'oral complications', 'pancreatic polypeptide tumor', 'progesterone receptor-positive breast cancer', 'recurrent breast cancer', 'recurrent islet cell carcinoma', 'recurrent renal cell cancer', 'somatostatinoma', 'stage iii renal cell cancer', 'stage iiia breast cancer', 'stage iiib breast cancer', 'stage iiic breast cancer', 'stage iv breast cancer', 'stage iv renal cell cancer']","[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['J34.81', 'K92.81', 'K12.30', 'K12.39', 'K12.33', 'N76.81', 'K12.31']"", ""['E10.638', 'E11.638', 'E13.638', 'E08.638', 'E09.638']"", ""['K90.3', 'K86.81', 'Q45.2', 'C25.3', 'E16.9', 'E16.8', 'Q45.3']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C96.20', 'C96.29', 'D47.09']"", ""['C96.20', 'C96.29', 'D47.09']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C96.20', 'C96.29', 'D47.09']""]",['everolimus'],['CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC'],"
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Confirmed diagnosis of:

               -  Postmenopausal advanced hormone receptor-positive, human epidermal growth factor
                  receptor 2 (HER2)-negative breast cancer after failure of treatment with
                  letrozole or anastrozole

               -  Progressive neuroendocrine tumors of pancreatic origin (PNET) that is
                  unresectable, locally advanced or metastatic

               -  Advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or
                  sorafenib

          -  Histologically confirmed, measurable or evaluable disease. Patients should have at
             least one measurable lesion.

          -  Adequate bone marrow function as indicated by the following:

               -  Absolute neutrophil count (ANC) > 1,500/μL

               -  Platelets ≥ 100,000/μL

               -  Hemoglobin > 10 g/dL

          -  Adequate renal function, as indicated by creatinine clearance > 30 mL/min

          -  Adequate liver function, as indicated by:

               -  Bilirubin ≤ 1.5 x upper limit of normal (ULN)

               -  International normalized ratio (INR) ≤ 2

               -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2 x ULN
                  unless related to primary disease

          -  Signed informed consent

          -  Adequate birth control when appropriate

          -  Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 mmol/L AND fasting triglycerides ≤ 2.5
             x ULN. NOTE: in case one or both of these thresholds are exceeded, the patient can
             only be included after initiation of appropriate lipid lowering medication.

        Exclusion Criteria:

          -  Patients currently receiving anticancer therapies or who have received anticancer
             therapies within 4 weeks of the start of everolimus (including chemotherapy, radiation
             therapy, antibody based therapy, etc., but not including somatostatin analogues, e.g.,
             octreotide)

          -  Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g.
             sirolimus, temsirolimus)

          -  Known impairment of gastrointestinal (GI) function or GI disease that may
             significantly alter the absorption of oral everolimus

          -  Uncontrolled diabetes mellitus as defined by HbA1c >8% despite adequate therapy.
             Patients with a known history of impaired fasting glucose or diabetes mellitus (DM)
             may be included, however blood glucose and antidiabetic treatment must be monitored
             closely throughout the trial and adjusted as necessary.

          -  Patients who have any severe and/or uncontrolled medical conditions such as:

               -  Unstable angina pectoris, symptomatic congestive heart failure, myocardial
                  infarction ≤ 6 months prior to start of everolimus, serious uncontrolled cardiac
                  arrhythmia, or any other clinically significant cardiac disease

               -  Symptomatic congestive heart failure of New York Heart Association Class III or
                  IV

               -  Active (acute or chronic) or uncontrolled severe infection, liver disease such as
                  cirrhosis, decompensated liver disease, and active and chronic hepatitis (i.e.
                  quantifiable hepatitis B virus [HBV]-DNA and/or positive HbsAg, quantifiable
                  hepatitis C virus [HCV]-RNA)

               -  Known severely impaired lung function (spirometry and diffusing capacity of the
                  lung for carbon monoxide [DLCO] 50% or less of normal and O2 saturation 88% or
                  less at rest on room air)

               -  Active, bleeding diathesis

          -  Chronic treatment with corticosteroids or other immunosuppressive agents. Topical or
             inhaled corticosteroids are allowed.

          -  Known history of HIV seropositivity

          -  Patients who have received live attenuated vaccines within 1 week of start of
             everolimus and during the study. Patient should also avoid close contact with others
             who have received live attenuated vaccines. Examples of live attenuated vaccines
             include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus
             Calmette-Guérin (BCG), yellow fever, varicella and TY21a typhoid vaccines.

          -  Patients who have a history of another primary malignancy, with the exceptions of:
             nonmelanoma skin cancer, and carcinoma in situ of the cervix, uteri, or breast from
             which the patient has been disease free for ≥3 years

          -  Patients with a history of non-compliance to medical regimens or who are considered
             potentially unreliable or will not be able to complete the entire study

          -  Patients who are currently part of or have participated in any clinical investigation
             with an investigational drug within 1 month prior to dosing

          -  Pregnant or nursing (lactating) women

          -  Women of child-bearing potential (WOCBP), defined as all women physiologically capable
             of becoming pregnant, must use highly effective methods of contraception during the
             study and 8 weeks after. Highly effective contraception methods include combination of
             any two of the following:

               -  Use of oral, injected or implanted hormonal methods of contraception

               -  Placement of an intrauterine device (IUD) or intrauterine system (IUS)

               -  Barrier methods of contraception: condom or occlusive cap (diaphragm or
                  cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal suppository

               -  Total abstinence

               -  Male/female sterilization

          -  Women are considered post-menopausal and not of child-bearing potential if they have
             had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile
             (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral
             oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior
             to randomization. In the case of oophorectomy alone, only when the reproductive status
             of the woman has been confirmed by follow up hormone level assessment is she
             considered not of child-bearing potential.

          -  Male patients whose sexual partner(s) are WOCBP who are not willing to use adequate
             contraception, during the study and for 8 weeks after the end of treatment
      "
NCT02279524,completed,,1,phase 2,"['fatty liver', 'non-alcoholic steatohepatitis', 'liver diseases', 'liver fibroses']","[""['K70.0', 'K76.0']"", ""['K75.81']"", ""['K76.9', 'K71.8', 'K70.9', 'K71.9', 'K75.9', 'P78.84', 'Q44.6']"", ""['Z52.6', 'K71.8', 'K71.7', 'A06.4', 'C22.0', 'C22.3', 'K70.0']""]",['aramchol'],['CCCCCCCCCCCCCCCCCCCC(=O)NC1CCC2(C(C1)CC(C3C2CC(C4(C3CCC4C(C)CCC(=O)O)C)O)O)C'],"
        Inclusion Criteria:

          1. Male or female age 18 to 75 years.

          2. BMI between 25kg/m2 to 40kg/m2 or waist circumference between 88 cm to 200 cm for
             women, and between 102 cm to 200 cm for men. If there is deviation above the upper
             limit, please consult the MRI center, to ensure that the machine is suitable for the
             patient.

          3. Known type II Diabetes Mellitus or pre-Diabetes according to American Diabetes
             Association. One of the following 3 criteria is needed for pre-Diabetes: Fasting
             Plasma Glucose > 100mg/dl (5.5 mmol/l) or 2hPG following 75g OGTT > 140 (7.8 mmol/l)
             mg/dl or HbA1c > 5.7%. HbA1c can be repeated at Investigator's discretion.

          4. Histologically proven Steatohepatitis on a diagnostic liver biopsy performed either
             during screening or within 6 months before screening visit, confirmed by central
             laboratory reading of the slides.(Steatosis ≥1 + inflammation ≥1 + ballooning
             ≥1).Total activity NAS score of 4 or more.

          5. Liver fat concentration in the liver of 5.5% or more as measured by NMRS.

          6. Biopsies with an activity NAS score of 4 or more.

          7. Normal synthetic liver function (serum albumin >3.2g/dl, INR 0.8-1.2, conjugated
             bilirubin < 35 µmol/L).

          8. Understanding the nature of the study and signature of the written informed consent.

          9. Negative pregnancy test at study entry for females of child bearing potential.

         10. Females of child bearing potential practicing reliable contraception throughout the
             study period (including oral contraceptives) as well as negative pregnancy test at
             study entry.

         11. Hypertensive patients must be well controlled by stable dose of anti-hypertensive
             medication for at least 2 months prior to screening.

         12. Patients previously treated with vitamin E (>400IU/day), Polyunsaturated fatty acid
             (>2g/day) or Ursodeoxycholic acid or fish oil can be included if stopped or at least
             maintained on stable dose at least 3 months prior to diagnostic liver biopsy (and are
             not started during the trial). These treatments-dosages are allowed if they were
             stable for at least 12 months prior to biopsy and can remain stable throughout the
             study. (Dosages less than the amounts stated above are allowed without washout- or
             stable-period restrictions).

         13. For patients with type II Diabetes, glycaemia must be controlled (Glycosylated
             Hemoglobin A1c ≤9%) while any HbA1c change should not exceed 1.5% during 6 months
             prior to enrolment). Treatments with anti-diabetic medications (except for those
             mentioned in Exclusion 16) are permitted if glycaemia is self-monitored by the
             patient. HbA1c can be repeated at Investigator's discretion.

        Exclusion Criteria:

          1. Patients with other active (acute or chronic) liver disease other than NASH (e.g.
             viral hepatitis, unless eradicated at least 3 years prior to screening; genetic
             hemochromatosis; Wilson disease; alpha 1antitripsin deficiency; alcohol liver disease;
             drug-induced liver disease) at the time of randomization.

          2. Patients with clinically or histologically documented liver cirrhosis

          3. Known alcohol and/or any other drug abuse or dependence in the last five years.

          4. Known history or presence of clinically significant cardiovascular, gastrointestinal,
             metabolic other than Diabetes Mellitus, neurologic, pulmonary, endocrine, psychiatric,
             neoplastic disorder or nephrotic syndrome, that in the opinion of the Investigator
             warrant exclusion from the study.

          5. Patients with familial (i.e., genetic) hypertriglyceridemia and familial (i.e.,
             genetic) hypercholesterolemia.

          6. History or presence of any disease or condition known to interfere with the absorption
             distribution, metabolism or excretion of drugs including bile salt metabolites (e.g.
             inflammatory bowel disease (IBD)), previous intestinal (ileal or colonic) operation,
             chronic pancreatitis, celiac disease or previous vagotomy. Ongoing Chronic
             constipation

          7. Patients with heart or brain pacemaker (i.e., implantable neurological devices).

          8. Surgery during the last three month before screening which involved stent implantation
             of metal devices (e.g. knee, hip etc.)

          9. Weight loss of more than 5% within 6 months prior to randomization.

         10. History of bariatric surgery within 5 years of liver biopsy.

         11. Uncontrolled arterial hypertension.

         12. Women who are pregnant and breast feeding.

         13. Diabetes Mellitus other than type II (type I, endocrinopathy, genetic syndromes etc.).

         14. Patients with HIV infection.

         15. Daily alcohol intake >20 g/day for women and >30 g/day for men (on average per day) as
             per medical history.

         16. Treatment with other anti-diabetic medications:

             GLP-1 receptor agonists and Thiazolidinediones (TZDs), unless started at least 12
             months prior to biopsy and on stable dose for 6 months. In case of GLP-1 receptor
             agonists stopped, it should be at least 6 months before biopsy as per medical history.

         17. SGLT-2 Inhibitors, Metformin, fibrates, statins, insulin, DPP-4 inhibitors and
             sulfonylurea unless prescribed dose has been stable for the last 6 months prior to the
             biopsy.

         18. Treatment with Valproic acid, Tamoxifen, Methotrexate, Amiodarone or chronic treatment
             with anti-cholinergic agents, corticosteroids, high dose estrogen and tetracycline
             within 12 months prior to the screening visit.

         19. Chronic treatment with antibiotics (e.g. Rifaximin).

         20. Homeopathic and/or alternative treatments. Any treatment should be stopped during the
             screening period at least 48 hours before randomization.

         21. Uncontrolled hypothyroidism defined as Thyroid Stimulating hormone >2X the upper limit
             of normal (ULN). Thyroid dysfunction controlled for at least 6 months prior to
             screening is permitted.

         22. Patients with renal dysfunction eGFR< 40.

         23. Unexplained serum creatine phosphokinase (CPK) >3X the upper limit of normal (UNL).
             Patients with a reason for CPK elevation may have the measurement repeated prior to
             randomization; a CPK retest > 3X ULN leads to exclusion.

         24. Patients with condition(s) that makes them unsuitable to perform the NMRS (as
             determined by the PI or the MRI facility).

         25. Hypersensitivity to Aramchol or to any of the excipients in the tablets

         26. Hypersensitivity to cholic acid or bile acid sequestrants
      "
NCT02279407,completed,,1,phase 2,['t2 diabetes and fatty liver disease (non-alcoholic origin)'],"[""['Z52.6', 'K71.8', 'K71.7', 'A06.4', 'C22.0', 'C22.3', 'K70.0']""]","['placebo', 'omega-3 carboxylic acids', 'dapagliflozin', 'placebo']",['CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl'],"
        Inclusion Criteria: Provision of informed consent prior to any study specific procedures;
        Men or women ≥40 years and ≤75 years with suitable veins for cannulation or repeated
        venepuncture; Have liver fat content as assessed by MRI >5.5%; Diagnosis of Type 2 diabetes
        since at least 6 months in accordance with WHO criteria.

        Exclusion Criteria: Any condition when MRI is contraindicated such as, but not limited to,
        having a pacemaker or claustrophobia; Diagnosis or signs of Type 1 diabetes (e.g. history
        of positive islet antibodies); Creatinine clearance <60 mL/min at screening
        (Cockcroft-Gault formula).
      "
NCT02275286,recruiting,,1,phase 1/phase 2,"['liposarcoma, myxoid', 'sarcoma, soft tissue', 'leiomyosarcoma', 'liposarcoma', 'pleomorphic liposarcoma']","[""['C46.1']""]",['trabectedin'],['CC1=CC2=C(C3C4C5C6=C(C(=C7C(=C6C(N4C(C(C2)N3C)O)COC(=O)C8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O'],"
        Cohort A: STS

        Inclusion Criteria:

          1. The patient must sign voluntarily the informed consent form before any study test is
             conducted that is not part of routine patient care.

          2. Aged equal or over 18.

          3. Patients must have a diagnostic of Soft Tissue Sarcoma with metastasis limited to
             lung, and not suitable for metastasectomy or surgery resection or not oncologically
             recommended metastasectomy.A centralized diagnostic will be performed, the tumor
             sample must be available and sent prior to inclusion.

          4. Disease distribution allows meeting with normal tissue constraints of radiation
             therapy. Radiation oncologist must confirm this point.

          5. Metastatic spread could be present in two organs at maximum (i.e. lungs and pelvic
             fosa).

          6. Those lesions considered for radiation therapy have to be considered as target lesions
             as well. (i.e. in a patient with nodules in lungs, those lesions selected for
             radiation therapy have to include at least the target lesions)

          7. It is allowed that not all the lesions will be under radiation fields. As a general
             rule, it will be prioritized to select, as target-irradiating lesions, those with
             greater increase in size and those largest lesions. It should be discouraged to
             irradiate pulmonary lesions with infiltration of pleural serosa.

          8. Patients must have documentation of disease progression within 6 months prior to study
             entry.

          9. The patient must have been considered eligible for systemic chemotherapy. A maximum of
             two previous lines for advanced/metastatic disease are allowed as long as trabectedin
             has not been included.

         10. The following histological subtypes can be included:

             Undifferentiated pleomorphic sarcoma (previously, malignant fibrous histiocytoma)
             Leiomyosarcoma Angiosarcoma/ epithelial hemangioendothelioma Liposarcoma and its
             variants (well differentiated, dedifferentiated, myxoid/round cells, pleomorphic).

             Synovial sarcoma Fibrosarcoma and its variants (epithelial fibrosarcoma/low grade
             fibromyxoid sarcoma) Hemangiopericytoma/solitary fibroid tumor Neurogenic sarcoma
             (Malignant peripheral nerve sheath tumor, MPNST) Myxofibrosarcoma Epithelioid Sarcoma
             Unclassified sarcoma (spindle cell/epithelioid/pleomorphic/myxoid)

         11. Measurable disease, according to RECIST V 1.1 criteria

         12. Performance status ≤1 (ECOG).

         13. Adequate respiratory functions: FEV1 >1L; DLco > 40% (patients with pulmonary target
             lesions)

         14. Adequate bone marrow function (hemoglobin > 10 g/dl, leukocytes ≥ 3.000/mm3,
             neutrophils ≥ 1.500/mm3, platelets ≥ 100.000/mm3). Patients with plasma creatinine ≤
             1,6 mg/dl, transaminases ≤ 2.5 times the UNL, total bilirubin ≤ UNL, CPK ≤ 2.5 times
             UNL, alkaline phosphatase ≤ 2.5 times the UNL are acceptable. If the increase of
             alkaline phosphatase is > 2.5 times the UNL, then the alkaline phosphatase liver
             fraction and/or GGT must be ≤ UNL.

         15. Men or women of child bearing potential should be using an effective method of
             contraception before entry into the study and throughout the same and for 6 months
             after ending the study. Women of childbearing potential must have a negative urine
             pregnancy test before study entry.

         16. Normal cardiac function with a LVEF ≥ 50% by echocardiogram or MUGA.

         17. It should be performed HBV and HCV serologies prior to inclusion. If HbsAg is positive
             it is recommended to reject the existence of replicative phase (HbaAg+, DNA VHB+). If
             these were positives the inclusion is not recommended, remaining at investigators'
             discretion the preventive treatment with lamivudine. If a potential patient is
             positive for anti-HCV antibodies, presence of the virus should be ruled out with a
             qualitative PCR, or the patient should NOT be included in the study (if a qualitative
             PCR cannot be performed then patient will not be able to enter the study)

         18. Patient must have a Central Venous Catheter for treatment

        Exclusion Criteria:

          1. Previous treatment with trabectedin or previous treatment with radiotherapy (except if
             previous radiotherapy treatment plus planned study radiotherapy treatment allow
             tissues constrains)

          2. Performance status ≥ 2 (ECOG).

          3. Plasma bilirubin > UNL.

          4. Creatinine > 1.6 mg/dL.

          5. History of other neoplastic disease with less than 5 years free of disease with the
             exception of basal cell carcinoma or in situ cervical cancer adequately treated.

          6. Severe COPD or other severe pulmonary diseases.

          7. Significant cardiovascular disease (for example, dyspnea > 2 NYHA)

          8. Significant systemic diseases grade 3 or higher on the NCI-CTCAE v4.03 scale, that
             limit patient availability, or according to investigator judgment may contribute
             significantly to treatment toxicity.

          9. Uncontrolled bacterial, mycotic or viral infections.

         10. Known positive test for infection by human immunodeficiency virus (HIV).

         11. Women who are pregnant or breast-feeding.

         12. Psychological, familial, social or geographic circumstances that limit the patient""s
             ability to comply with the protocol or informed consent.

         13. Patients participating in another clinical trial or receiving any other
             investigational product

         14. Patients who had participated in another clinical trial and/or had received any other
             investigational product in the last 30 days prior to inclusion.

         15. Histologies other than those described in inclusion criteria.

        Cohort B: ML

        Inclusion criteria:

          1. The patient must sign voluntarily the informed consent form before any study test is
             conducted that is not part of routine patient care.

          2. Age ≥18 years old.

          3. Pathological diagnosis of Myxoid Liposarcoma, deep located and more than 5 cm or
             superficial more than 10 cm. A centralized diagnostic will be performed to confirm
             that the patient can be included in the study.

          4. Tumor must be resectable and without evidence of regional or distal spread after
             adequate staging procedure. Tumor must be located in limbs or superficial trunk wall.

          5. Disease distribution allows meeting with normal tissue constraints of radiation
             therapy. Radiation oncologist must confirm this point.

          6. Measurable disease, according to RECIST V 1.1 criteria

          7. Performance status 0-1 (ECOG).

          8. Adequate bone marrow function (hemoglobin > 10 g/dL, leukocytes ≥ 3.000/mm3,
             neutrophils ≥ 1.500/mm3, platelets ≥ 100.000/mm3). Patients with plasma creatinine ≤
             1,6 mg/dL, transaminases ≤ 2.5 times the UNL, total bilirubin ≤ UNL, CPK ≤ 2.5 times
             UNL, alkaline phosphatase ≤ 2.5 times the UNL are acceptable. If the increase of
             alkaline phosphatase is > 2.5 times the UNL, then the alkaline phosphatase liver
             fraction and/or GGT must be ≤ UNL.

          9. Men or women of child bearing potential should be using an effective method of
             contraception before entry into the study and throughout the same and for 6 months
             after ending the study. Women of childbearing potential must have a negative urine
             pregnancy test before study entry.

         10. Normal cardiac function with a LVEF ≥ 50% by echocardiogram or MUGA.

         11. It should be performed HBV and HCV serologies prior to inclusion. If HbsAg is positive
             it is recommended to reject the existence of replicative phase (HbaAg+, DNA HBV+). If
             these were positives the inclusion is not recommended, remaining at investigators'
             discretion the preventive treatment with lamivudine. If a potential patient is
             positive for anti-HCV antibodies, presence of the virus should be ruled out with a
             qualitative PCR, or the patient should NOT be included in the study (if a qualitative
             PCR cannot be performed then patient will not be able to enter the study).

         12. Patient may have had one previous chemotherapy line.

         13. Patient must have a Central Venous Catheter for treatment.

        Exclusion criteria:

          1. Unresectable tumors (with limb sparing surgery)

          2. More than one previous chemotherapy treatment for local disease including trabectedin.

          3. Radiotherapy involving the tumoral bed.

          4. Performance status ≥ 2 (ECOG).

          5. Presence of metastases or lymph node involvement by the tumor.

          6. Location other than limb or superficial trunk wall.

          7. Plasma bilirubin > UNL.

          8. Creatinine > 1.6 mg/dL.

          9. History of other neoplastic disease with less than 5 years free of disease with the
             exception of basal cell carcinoma or in situ cervical cancer adequately treated.

         10. Significant cardiovascular disease (for example, dyspnea > 2 NYHA)

         11. Significant systemic diseases grade 3 or higher on the NCI-CTCAE v4.03 scale, that
             limit patient availability, or according to investigator judgment may contribute
             significantly to treatment toxicity.

         12. Uncontrolled bacterial, mycotic or viral infections.

         13. Known positive test for infection by human immunodeficiency virus (HIV).

         14. Women who are pregnant or breast-feeding.

         15. Psychological, familial, social or geographic circumstances that limit the patient""s
             ability to comply with the protocol or informed consent.

         16. Patients who had participated in another clinical trial and/or had received any other
             investigational product in the last 30 days prior to inclusion.

        Cohorts C and D: Retroperitoneum sarcoma

        Inclusion criteria:

          1. The patient must voluntarily sign the informed consent form before performing any
             study-specific test that is not part of the patient's usual care.

          2. Aged between 18 and 75 years.

          3. The following histological subtypes may be included in the cohort C:

             High grade leiomyosarcoma (G2-3), liposarcoma (G2-3), if at least 30% of the tumour is
             dedifferentiated, pleomorphic liposarcoma.

             The following histological subtypes may be included in the cohort D:

             Well differentiated liposarcoma (WD liposarcoma) and G2 dedifferentiated
             liposarcorcoma, if less than 30% of the tumour is dedifferentiated.

             A centralised diagnosis will be made to confirm that the patient can be included in
             the study.

          4. The tumour must be located in the retroperitoneum and it must be resectable and
             without evidence of regional or distal spread after the appropriate staging process.
             This point must be confirmed by the central surgeon reviewer.

          5. The location and size of the disease in the retroperitoneum must allow for compliance
             with radiotherapy limitations in healthy tissue. This point must be confirmed by the
             site's radiation oncologist and the central radiation oncologist reviewer.

          6. Measurable disease according to CHOI criteria for cohort C and RECIST V 1.1 criteria
             for cohort D.

          7. ECOG performance status 0-1.

          8. Adequate haematological parameters (haemoglobin >10 g/dl, leukocytes ≥3,000/mm3,
             neutrophils ≥1,500/mm3, platelets ≥100,000/mm3). Patients with plasma creatinine ≤1.6
             mg/dl, transaminases ≤2.5 times the ULN, total bilirubin ≤ ULN, CPK ≤2.5 times ULN,
             alkaline phosphatase ≤2.5 times ULN are acceptable. If the increase in alkaline
             phosphatase is >2.5 times the ULN, the liver fraction of alkaline phosphatase and/or
             GGT should be ≤ULN.

          9. Fertile men or women must use an effective contraceptive method before starting the
             study, during the study and for 6 months following the conclusion thereof. Women of
             childbearing potential who participate in the study must undergo a pregnancy test
             before starting the study.

         10. Normal cardiac function with LVEF ≥50% by echocardiogram or MUGA.

         11. HBV and HCV serology must be performed before including the patient in the study. If
             HbsAg is positive, it is advisable to rule out a replicative phase (HbsAg*, DNA HBV+).
             If positive, the patient's inclusion in the trial is not recommended, and it is at the
             discretion of the investigator to administer preventive treatment with lamivudine. If
             a potential patient is positive to anti-HCV antibodies, the presence of the virus will
             be ruled out with a qualitative PCR, or the patient cannot be included in the study
             (if the qualitative PCR test cannot be performed on the patient, they cannot be
             included in the study).

         12. Patient may have had one previous chemotherapy line (cohort D only).

         13. The patient must have a central venous catheter for the administration of the
             treatment.

        Exclusion criteria

          1. Unresectable tumours.

          2. Location other than the retroperitoneum.

          3. Patients who have previously received systemic treatment with chemotherapy
             (trabectedin included). For cohort D, patients may have received one previous line of
             chemotherapy with any other agent.

          4. Patients who underwent prior local treatment for retroperitoneal sarcoma: surgery or
             radiotherapy in the tumour bed.

          5. ECOG performance status ≥2.

          6. Presence of metastasis or lymph node involvement of the tumour.

          7. Previous history of another neoplastic disease with less than 5 years free of disease
             except for basal cell carcinoma or properly treated in situ cervical cancer.

          8. Significant cardiovascular disease (e.g. dyspnoea >2 NYHA).

          9. A significant grade 3 or greater systemic disease on the NCI-CTCAE v4.03 scale, which
             may limit the availability of the patient or which, in the opinion of the
             investigator, may contribute to the toxicity caused by the study treatment.

         10. Uncontrolled viral, mycotic or bacterial infections.

         11. Known HIV-positive patients.

         12. Pregnant or breast-feeding women.

         13. Psychological, familial, social or geographical circumstances that limit the patient's
             ability to comply with the protocol or informed consent form.

         14. Patients who have participated in another clinical trial and/or have received another
             investigational product in the 30 days prior to inclusion in the trial.
      "
NCT02273973,completed,,1,phase 2,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['letrozole', 'taselisib']","['C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3', 'CC1=NN(C(=N1)C2=CN3CCOC4=C(C3=N2)C=CC(=C4)C5=CN(N=C5)C(C)(C)C(=O)N)C(C)C']","
        Inclusion Criteria:

          -  Female participants

          -  Postmenopausal status

          -  Histologically confirmed invasive breast carcinoma, with all of the following
             characteristics: (i) Primary tumor greater than or equal to (>/=) 2 centimeters (cm)
             in largest diameter (cT1-3) by MRI; (ii) Stage I to operable Stage III breast cancer;
             (iii) Documented absence of distant metastases (M0)

          -  Estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative
             (HER2-) breast cancer

          -  Breast cancer eligible for primary surgery

          -  Tumor tissue from formalin-fixed paraffin-embedded cores (FFPE) core biopsy of breast
             primary tumor that is confirmed as evaluable for phosphatidylinositol-4,5-bisphosphate
             3-kinase, catalytic subunit alpha (PIK3CA) mutation status by central histopathology
             laboratory

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Fasting glucose less than or equal to (</=) 125 milligrams per deciliter (mg/dL)

          -  Adequate hematological, renal, and hepatic function

          -  Absence of any psychological, familial, sociological, or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule

          -  Ability and willingness to comply with study visits, treatment, testing, and to comply
             with the protocol, in the investigator's judgment

        Exclusion Criteria:

          -  Any prior treatment for primary invasive breast cancer

          -  Participants with cT4 or cN3 stage breast tumors

          -  Bilateral invasive, multicentric, or metastatic breast cancer

          -  Participants who have undergone excisional biopsy of primary tumor and/or axillary
             lymph nodes or sentinel lymph node biopsy

          -  Type 1 or 2 diabetes requiring antihyperglycemic medication

          -  Inability or unwillingness to swallow pills

          -  Malabsorption syndrome or other condition that would interfere with enteric absorption

          -  History of prior or currently active small or large intestine inflammation (such as
             Crohn's disease or ulcerative colitis). Any predisposition for gastrointestinal (GI)
             toxicity requires prior approval from the Medical Monitor.

          -  Congenital long QT syndrome or QT interval corrected using Fridericia's formula (QTcF)
             >470 milliseconds (msec)

          -  Diffusing capacity of the lungs for carbon monoxide (DLCO) <60% of the predicted
             values

          -  Clinically significant (i.e., active) cardiovascular disease, uncontrolled
             hypertension, unstable angina, history of myocardial infarction, cardiac failure class
             II-IV

          -  Any contraindication to MRI examination

          -  Active infection requiring intravenous antibiotics

          -  Participants requiring any daily supplemental oxygen

          -  Clinically significant history of liver disease, including viral or other known
             hepatitis, current alcohol abuse, or cirrhosis

          -  Any other diseases, active or uncontrolled pulmonary dysfunction, metabolic
             dysfunction, physical examination finding, or clinical laboratory finding giving
             reasonable suspicion of a disease or condition that contraindicates the use of an
             investigational drug, that may affect the interpretation of the results, or renders
             the participants at high risk from treatment complications

          -  Significant traumatic injury within 3 weeks prior to initiation of study treatment

          -  Major surgical procedure within 4 weeks prior to initiation of study treatment

          -  Inability to comply with study and follow-up procedures

          -  History of other malignancy within 5 years prior to screening, except for
             appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or
             Stage I uterine cancer
      "
NCT02276989,withdrawn,"
    poor recruitment
  ",0,phase 2,"['compliance', 'chronic pain']","[""['G89.29', 'G89.4', 'R39.82', 'G89.22', 'G89.28', 'G89.21', 'G89.3']""]","['acetazolamide', 'quinine', 'riboflavin']","['CC(=O)NC1=NN=C(S1)S(=O)(=O)N', 'COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O', 'CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)CC(C(C(CO)O)O)O']","
        Inclusion Criteria:

          1. male and female English-speaking literate adults age 18- 50 years old,

          2. have medically diagnosed chronic pain condition,

          3. be on a stable dose of buprenorphine (clinic modal dose),

          4. history of prescription opioid abuse,

          5. adequate venous access,

          6. if female, a negative pregnancy test. Individuals will not be accepted who are
             unstable in buprenorphine treatment as evidence by continued illicit drug use and
             irregular clinic attendance in the previous trial,

          7. be otherwise in good physical health or in care of a physician who is wiling to take
             responsibility for such treatment. The same conditions apply in cases of patients with
             a psychiatric disorder needing ongoing treatment.

        Exclusion Criteria:

          1. physiologic drug dependence on benzodiazepines, barbiturates, and/or alcohol that
             would require medical management,

          2. significant ongoing medical problems (e.g., diabetes),

          3. history of head injury or seizure,

          4. serious psychiatric illness outside of drug use (e.g., schizophrenia),

          5. recent use of any agent that inhibits or induces cytochrome P450 3A4 or 2D6,

          6. nursing or pregnant female, or a female or male who does not agree to not become
             pregnant or father a child during the course of, and three months following completion
             of the study,

          7. have a cardiac conduction or blood clotting disorder,

          8. blood donation within the past 30 days prior to screening,

          9. clinically significant laboratory results (as judged by the
             investigator/sub-investigator)

         10. moderate to severe COPD,

         11. renal impairment, and

         12. severe renal hepatic impairment.
      "
NCT02277093,terminated,"
    fda issued a clinical hold as pacritinib had increased side effects
  ",0,phase 2,['colorectal cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]",['pacritinib'],['C1CCN(C1)CCOC2=C3COCC=CCOCC4=CC(=CC=C4)C5=NC(=NC=C5)NC(=C3)C=C2'],"
        Inclusion Criteria:

          -  Histologically or cytologically confirmed refractory colorectal cancer

          -  Measurable disease defined as lesions that can be accurately measured in at least one
             dimension (longest diameter to be recorded) as >10 mm with CT scan, as >20 mm by chest
             x-ray, or >10 mm with calipers by clinical exam.

          -  Refractory to or intolerant of standard systemic therapy, including having received
             two or more standard available therapies known to prolong survival for which s/he was
             eligible, including FOLFOX or FOLFIRI with or without bevacizumab, aflibercept,
             cetuximab, or panitumumab

          -  At least 18 years of age.

          -  ECOG performance status < 2

          -  Life expectancy ≥ 12 weeks.

          -  Normal bone marrow and organ function as defined below:

               -  Absolute neutrophil count ≥ 1,500/mcl

               -  Platelets ≥ 50,000/mcl

               -  Total bilirubin ≤ 2.0 x IULN

               -  AST (SGOT) / ALT (SGPT) ≤ 3.0 x IULN

               -  Serum creatinine ≤ 2.0 mg/dL OR creatinine clearance > 60 mL/min/1.73 m2 for
                  patients with creatinine levels above 2.0 mg/dL

               -  Women of childbearing potential and men must agree to use adequate contraception
                  (hormonal or barrier method of birth control, abstinence) prior to study entry
                  and for the duration of study participation. Should a woman become pregnant or
                  suspect she is pregnant while participating in this study, she must inform her
                  treating physician immediately.

               -  Able to understand and willing to sign an IRB approved written informed consent
                  document (or that of legally authorized representative, if applicable).

        Exclusion Criteria:

          -  Prior therapy with a JAK2 or FLT3 inhibitor.

          -  A history of other malignancy ≤ 5 years previous with the exception of basal cell or
             squamous cell carcinoma of the skin which were treated with local resection only or
             carcinoma in situ of the cervix.

          -  Received any chemotherapeutic or targeted agent for metastatic colorectal cancer
             within two weeks of initiation of study drug.

          -  Currently receiving any other investigational agents.

          -  Known brain metastases. Patients with known brain metastases must be excluded from
             this clinical trial because of their poor prognosis and because they often develop
             progressive neurologic dysfunction that would confound the evaluation of neurologic
             and other adverse events.

          -  A history of allergic reactions attributed to compounds of similar chemical or
             biologic composition to pacritinib or other agents used in the study.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Pregnant and/or breastfeeding. Patient must have a negative pregnancy test within 14
             days of study entry.

          -  Known HIV-positivity on combination antiretroviral therapy because of the potential
             for pharmacokinetic interactions with pacritinib. In addition, these patients are at
             increased risk of lethal infections when treated with marrow-suppressive therapy.
             Appropriate studies will be undertaken in patients receiving combination
             antiretroviral therapy when indicated.

          -  Use of potent cytochrome P450 3A4 (CYP3A4) inhibitor within one week of pacritinib
             initiation.

          -  Patients with CTCAE grade 2 cardiac arrhythmias may be considered for inclusion if the
             arrhythmias are stable, asymptomatic, and unlikely to affect patient safety. Patients
             will be excluded if they have ongoing cardiac dysrhythmias of CTCAE grade ≥ 3,
             corrected QT interval (QTc) prolongation >450ms, or other factors that increase the
             risk for QT interval prolongation (eg, heart failure, hypokalemia [defined as serum
             potassium <3.0mEq/L that is persistent and refractory to correction], or family
             history of long QT interval syndrome).

          -  Any gastrointestinal (GI) or metabolic condition that could interfere with absorption
             of oral medication such as ongoing grade 3 or higher diarrhea, constipation, nausea,
             or vomiting.

          -  Active viral hepatitis.
      "
NCT02272803,completed,,1,phase 2,['multiple myeloma'],"[""['C90.01', 'C90.02', 'C90.00']""]","['lenalidomide', 'dexamethasone']","['C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N', 'CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C']","
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Newly diagnosed with symptomatic Multiple Myeloma (MM)

          -  Have not received any prior systemic anti-myeloma therapy

          -  Have measurable disease

          -  Are not candidates for high-dose therapy plus stem-cell transplantation (SCT) because
             of age (≥ 65 years) or coexisting conditions. Refusal to undergo high dose therapy
             with SCT is NOT sufficient for entry onto CA204-116 for a subject < 65 years old.
             There must be a comorbidity that prevents SCT for a subject < 65 years old

        Exclusion Criteria:

          -  Non-secretory myeloma

          -  Smoldering MM, defined as asymptomatic MM with absence of lytic bone lesions

          -  Monoclonal Gammopathy of Undetermined Significance (MGUS)

          -  Active plasma cell leukemia

          -  Known Human Immunodeficiency Virus (HIV) infection or active hepatitis A, B, or C
      "
NCT02945813,terminated,"
    trial was prematurely closed for accrual by the sakk board and the follow-up period shortened
    to one year after last rt fraction of the last patient
  ",0,phase 2,['prostate cancer'],"[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]",['metformin'],['CN(C)C(=N)N=C(N)N'],"
        Inclusion Criteria:

          -  Written informed consent according to ICH/GCP regulations before registration and
             prior to any trial specific procedures

          -  Histologically confirmed adenocarcinoma of the prostate without small cell features

          -  Tumor stage pT2a-3b, pN0 or cN0, M0, R0-1 resection margins, according to UICC TNM
             2009, Gleason score available

          -  Radical prostatectomy (RP) at least 12 weeks before registration

          -  PSA progression after RP defined as two consecutive rises with the final PSA > 0.1
             ng/mL or three consecutive rises. The first value must be measured earliest 4 weeks
             after RP

          -  PSA ≤ 2 ng/mL within 14 days prior to registration

          -  Age ≥ 18 years at time of registration

          -  WHO performance status 0-1

          -  Adequate hepatic function within 14 days prior to registration: bilirubin ≤ 1.5 x ULN
             (exception if Gilbert's syndrome ≤ 3 x ULN), AST and ALT ≤ 2.5 x ULN

          -  Adequate renal function within 14 days prior to registration: calculated corrected
             creatinine clearance ≥ 60 mL/min, according to the formula of corrected
             Cockcroft-Gault Patient agrees not to father a child and to use effective
             contraceptive methods during salvage radiotherapy and until 6 months after the last
             fraction of radiotherapy

        Exclusion Criteria:

          -  Persistent PSA (> 0.4 ng/mL) 4 to 20 weeks after RP

          -  Pelvic lymph node enlargement > 0.8 cm in short axis diameter (cN positive) assessed
             by mpMRI within 12 weeks prior to registration, unless the enlarged lymph node is
             sampled and negative

          -  Evidence of macroscopic local recurrence assessed by mpMRI within 12 weeks prior to
             registration

          -  Palpable prostatic fossa mass suggestive of recurrence, unless an ultrasound guided
             biopsy is negative for malignancy

          -  Presence or history of prostate cancer metastases. In case of clinical suspicion (e.g.
             bone pain), imaging (e.g. bone scan, Choline-PET, PSMA-PET, whole body MRI) must be
             performed. The imaging method is at the discretion of the investigator.

          -  If PET/CT scan was performed, any metabolic uptake considered clinically suspicious
             for malignancy, unless biopsy proves to be negative.

          -  History of hematologic or primary solid tumor malignancy, unless in remission for at
             least 3 years from registration with the exception of curatively treated localized
             non-melanoma skin cancer

          -  Patients diagnosed with diabetes mellitus

          -  Treatment with metformin within the last 3 months prior to registration

          -  Prior pelvic radiotherapy

          -  Hormonal treatment as bilateral orchiectomy prior or following RP

          -  Usage of products known to affect PSA levels within 4 weeks prior to start of trial
             treatment

          -  Bilateral hip prosthesis

          -  Severe or active co-morbidity likely to impact on the advisability of salvage RT,
             e.g.:

               -  History of inflammatory bowel disease or any malabsorption syndrome or conditions
                  that would interfere with enteral absorption

               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the time
                  of registration

               -  Unstable angina and/or congestive heart failure requiring hospitalization within
                  the last 6 months

               -  Transmural myocardial infarction within the last 6 months

               -  Chronic Obstructive Pulmonary Disease (COPD) exacerbation or other respiratory
                  illness requiring hospitalization or precluding study therapy at the time of
                  registration

          -  Any condition associated with increased risk of lactic acidosis (e.g. alcohol abuse,
             congestive heart failure NYHA III or IV

          -  Clinically significant history of liver disease consistent with Child-Pugh Class B or
             C, including viral or other hepatitis, current alcohol abuse, or cirrhosis

          -  Severe or uncontrolled kidney disease resulted in impaired kidney function (GFR
             <60ml/min)

          -  Any acute or chronic condition that could cause tissue hypoxia (e.g. cardiac or
             respiratory insufficiency, recent myocardial infarction, shock)

          -  Treatment with any experimental drug or participation within a clinical trial within
             30 days prior to registration (exception: concurrent participation in the biobank
             project SAKK 63/12 is allowed)

          -  Any concomitant drug contraindicated for use with metformin according to the approved
             product information

          -  Known hypersensitivity to metformin/placebo or to any of its components

          -  Hereditary intolerance to fructose; known galactose-1-phosphate uridyl transferase
             deficiency, UDP galactose 4 epimerase deficiency, galactokinase deficiency,
             Fanconi-Bickel syndrome, congenital lactase deficiency, or glucose-galactose
             malabsorption (due to the lactose-containing placebo)

          -  Inability or unwillingness to swallow oral medication

          -  Any other serious underlying medical, psychiatric, psychological, familial or
             geographical condition, which in the judgment of the investigator may interfere with
             the planned staging, treatment and follow-up, affect patient compliance or place the
             patient at high risk from treatment-related complications
      "
NCT02943668,terminated,"
    terminated due to low accrual
  ",0,phase 2,"['anemia', 'myelodysplastic syndrome']","[""['D53.2', 'D64.9', 'D46.4', 'D53.0', 'D53.9', 'D61.3', 'D61.9']"", ""['D46.9', 'D46.C', 'D46.Z']""]",['deferasirox'],['C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O'],"
        Inclusion Criteria:

          -  Capable of giving written informed consent prior to any study-specific procedures

          -  Diagnosis of MDS as defined by the World Health Organization (WHO) diagnostic criteria

          -  Have very low, low or intermediate-risk disease by the Revised International
             Prognostic Scoring System (IPSS-R)

          -  Baseline serum ferritin level >= 100 ng/mL

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          -  Anemia defined as: hemoglobin =< 10.0 g/dL

          -  Bilirubin =< 1.5 times upper limit of normal (ULN)

          -  Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) =< 3.5 times ULN

          -  Serum creatinine =< 1.5 x ULN

          -  Estimated glomerular filtration rate (GFR) > 40 mL/min

          -  Males and females with reproductive potential must agree to use medically approved
             contraceptive precautions during the study and for 3 months following the last dose of
             deferasirox

               -  Women of child-bearing potential, defined as all women physiologically capable of
                  becoming pregnant, unless they are using effective methods of contraception
                  during dosing of study treatment; effective contraception methods include:

                    -  Placement of an intrauterine device (IUD) or intrauterine system (IUS)

                    -  Barrier methods of contraception: condom or occlusive cap (diaphragm or
                       cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal
                       suppository

                    -  Total abstinence or (when this is in line with the preferred and usual
                       lifestyle of the subject); periodic abstinence (e.g., calendar, ovulation,
                       symptothermal, post-ovulation methods) and withdrawal are not acceptable
                       methods of contraception

                    -  Female sterilization (have had surgical bilateral oophorectomy with or
                       without hysterectomy) or tubal ligation at least six weeks before taking
                       study treatment; in case of oophorectomy alone, only when the reproductive
                       status of the woman has been confirmed by follow up hormone level assessment

                    -  Male sterilization (at least 6 months prior to screening); for female
                       subjects on the study, the vasectomized male partner should be the sole
                       partner for that subject

               -  Women are considered post-menopausal and not of child bearing potential if they
                  have had 12 months of natural (spontaneous) amenorrhea with an appropriate
                  clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have
                  had surgical bilateral oophorectomy (with or without hysterectomy) or tubal
                  ligation at least six weeks ago; in the case of oophorectomy alone, only when the
                  reproductive status of the woman has been confirmed by follow up hormone level
                  assessment is she considered not of child bearing potential; sexually active
                  males must use a condom during intercourse while taking drug and for 28 days
                  after stopping study medication and should not father a child in this period; a
                  condom is required to be used also by vasectomized men in order to prevent
                  delivery of the drug via seminal fluid

          -  Females with childbearing potential* must have had a negative urine or serum pregnancy
             test =< 7 days before the first dose of deferasirox and must also not be breastfeeding

          -  Reliable and willing to make themselves available for the duration of the study and
             are willing to follow study procedures

        Exclusion Criteria:

          -  If the patient is currently receiving erythroid stimulating agents (ESA) with plans to
             continue during study, less than 2 months duration of ESA prior to starting study drug
             and no dose escalation within 2 months of start of study drug

          -  If the patient is being treated with granulocyte-colony stimulating factor (GCSF)
             and/or a TPO-mimetic (for example, eltrombopag or romiplostim) with plans to continue
             during the study: Less than 2 months duration of GCSF or the TPO-mimetic treatment
             prior to starting study drug; or GCSF and/or TPO-mimetic has been added to ESA therapy
             within 2 months of start of study drug

          -  If patient is being treated with lenalidomide with plans to continue during the study:
             Stable dose for less than 3 months prior to start of study drug

          -  If patient is being treated with hypomethylating agents (HMA) (for example,
             azacitidine or decitabine) with plans to continue during the study: Stable dose for
             less than 6 months prior to start of study drug

          -  Currently enrolled in, or discontinued within the last 14 days from a clinical trial
             involving an investigational product or non-approved use of a drug, or concurrently
             enrolled in any other type of medical research judged not to be scientifically or
             medically compatible with this study

          -  Presence of >= 10% blast by morphologic examination of bone marrow aspirate or biopsy

          -  Platelets =< 50,000

          -  Microcytosis on screening blood cell count (CBC) (mean corpuscular volume [MCV] < 81
             fL)

          -  Active gastrointestinal (GI) ulceration or hemorrhage

          -  Have a serious preexisting medical condition that, in the opinion of the investigator
             would preclude participation in the study (for example a GI disorder causing
             clinically significant symptoms such as nausea, vomiting, and diarrhea, or
             malabsorption syndrome) or that would result in a life expectancy of less than 1 year

          -  Known hypersensitivity to deferasirox

          -  History of non-transfusional hemosiderosis

          -  Prior hematopoietic stem cell transplant for the diagnosis of MDS

          -  A second primary malignancy that in the judgment of the principal investigator (PI) or
             designee may affect the interpretation of results

          -  Have an active fungal, bacterial, and/or known viral infection including human
             immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis

          -  Currently using aluminum-containing antacid products

          -  History of clinically significant auditory or ocular toxicity with ICT
      "
NCT02949843,terminated,"
    slow accrual, closed by irb
  ",0,phase 2,"['egfr activating mutation', 'recurrent non-small cell lung carcinoma', 'stage iv non-small cell lung cancer']","[""['D75.84']"", ""['D02.20', 'D02.21', 'D02.22']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['chemotherapy', 'targeted molecular therapy', 'tyrosine kinase inhibitor']",['C1CC1(C(=O)NC2=CC=C(C=C2)OC3=C4C=C(NC4=NC=C3)C(=O)NCCN5CCOCC5)C(=O)NC6=CC=C(C=C6)F'],"
        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed incurable non-small cell
             lung cancer that harbors an activating mutation in EGFR, MET, BRAF, V600E, RET, HER2,
             translocation in Alk, or translocation in ROS-1

          -  Patients must be receiving treatment or planning to start treatment with a tyrosine
             kinase inhibitor targeting the activated gene

          -  Patients may not be receiving the treatment targeting the activated gene as part of a
             clinical treatment trial other than the Precision Oncology Trial

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-3

          -  Total bilirubin =< 1.5 X institutional upper limit of normal

          -  Aspartate transaminase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine
             transaminase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X
             institutional upper limit of normal

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control) prior to study entry and for the
             duration of study participation; should a woman become pregnant or suspect she is
             pregnant while participating in this study, she should inform her treating physician
             immediately

          -  Ability to understand and the willingness to sign an Institutional Review Board
             (IRB)-approved informed consent document

        Exclusion Criteria:

          -  Emergent need for palliative radiation

          -  Patients may not be receiving any other investigational agents for the treatment of
             non-small cell lung cancer

          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Pregnant women are excluded; breastfeeding should be discontinued
      "
NCT02945852,completed,,1,phase 2,['small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]",['apatinib'],['C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4'],"
        Inclusion Criteria:

        Histologic or cytologic diagnosis of small cell lung caner(SCLC), Extensive Stage.

        Previous treatments including first-line therapy with EP or CE and second-line therapy with
        topotecan; Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2; Males or
        females between 18 Years to 75 Years. Expected survival is above three months. At least one
        measurable lung tumor lesion (according to RECIST criteria, the application of conventional
        technology, diameter length of the lesion >= 20mm or spiral CT >=10mm).

        Adequate hematologic (Leukocyte count >= 4.0×109/L, neutrophil count>=2.0×109/L,
        hemoglobin>=95g/L, platelets>=100×109/L), hepatic function (aspartate transaminase (AST) &
        alanine transaminase(ALT) =<upper normal limit(UNL) x1.5, bilirubin level =< UNL x 1.5).

        Patient can take oral medicine. Patients have the ability to understand and voluntarily
        sign the informed consent, and allow adequate follow-up.

        Exclusion Criteria:

        History of cardiovascular disease: congestive heart failure (CHF) > New York Heart
        Association (NYHA) II, active coronary artery disease(patients with myocardial infarction
        six months ago can be recruited), arrhythmias need to be treated (allow taking beta
        blockers or digoxin).

        Serious clinical infection (> NCI-CTCAE version 4.0 ,infection standard II). Patients with
        epilepsy who need to take medicine (such as steroids or anti epilepsy agents).

        The patients had accepted allogeneic organ transplantation. Bleeding tendency or
        coagulation disorders. Patients who need renal dialysis. Suffered from other tumor within 5
        years( Except: cervical carcinoma in situ, cured basal cell carcinoma, cured bladder
        epithelial tumor).

        Uncontrolled hypertension (systolic pressure>150 mmHg , or diastolic pressure> 90 mmHg).

        Thrombosis or embolism(cerebrovascular accidents including transient ischemic attack within
        the last 6 months).

        Pulmonary hemorrhage >CTCAE grade 2 within 4 weeks before first use of drugs. Other organ
        hemorrhage >CTCAE grade 3 within 4 weeks before first use of drugs. severe uncured wounds,
        ulcers or fracture. uncured dehydration. Factors influencing the safety and compliance of
        patients. Inability to comply with protocol or study procedures. Pregnant or
        breast-feeding. The researcher believe that the Patient is not suitable to participate in
        the study.
      "
NCT02941523,completed,,1,phase 1/phase 2,['cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['nox66', 'carboplatin']",['C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]'],"
        Inclusion Criteria:

          1. Provision of informed consent

          2. Male or female ≥18 years of age

          3. Histologic or cytologic confirmed locally advanced or metastatic cancer that has no
             standard therapeutic alternatives.

          4. ECOG Performance status 0-1

          5. A minimum life expectancy of 12 weeks

          6. Adequate bone marrow, hepatic and renal function as evidenced by:

               -  Absolute neutrophil count (ANC) > 1.5 x 109/L

               -  Platelet count > 100 x 109/L

               -  Hemoglobin > 9.0 g/dL

               -  Serum bilirubin < 1.5 x ULN

               -  AST/ALT (SGOT/SGPT) 2.5 x ULN for the reference laboratory or < 5 x ULN in the
                  presence of liver metastases

               -  Serum creatinine 1.5 x ULN

          7. Female patients who are known to be capable of conception should have a negative serum
             pregnancy test (beta-human chorionic gonadotropin (β-hCG)) within 1 week of starting
             the study

          8. All potentially fertile patients will agree to use an effective form of contraception
             during the study and for 90 days following the last dose of NOX66 (an effective form
             of contraception is defined as an oral contraceptive or a double barrier method

          9. At least 4 weeks must have elapsed prior to commencement of NOX66 treatment since
             prior chemotherapy, investigational drug or biologic therapy and any toxicity
             associated with these treatments has recovered to ≤ NCI-CTCAE Grade 1

         10. At least 21 days must have elapsed prior to Day 1 Cycle 1 since radiotherapy (limited
             palliative radiation is allowed > 2 weeks), immunotherapy or following major surgery
             and any surgical incision should be completely healed

        Exclusion Criteria:

          1. Patients who are pregnant or breastfeeding.

          2. Uncontrolled infection or systemic disease.

          3. Clinically significant cardiac disease not well controlled with medication (e.g.
             congestive heart failure, symptomatic coronary artery disease, angina, and cardiac
             arrhythmias) or myocardial infarction within the last 12 months.

          4. Patients with QTc of > 470 msec on screening ECG. (If a patient has QTc interval >470
             msec on screening ECG, the screening ECG may be repeated twice (at least 24 hours
             apart). The average QTc from the 3 screening ECGs must be <470 msec in order for the
             patient to be eligible for the study.

          5. Any major surgery, radiotherapy, or immunotherapy within the last 21 days (limited
             palliative radiation is allowed > 2 weeks).

          6. Chemotherapy regimens with delayed toxicity within the last 4 weeks. Chemotherapy
             regimens given continuously or on a weekly basis with limited potential or delayed
             toxicity within the last 2 weeks.

          7. No concurrent systemic chemotherapy or biologic therapy is allowed.

          8. Known human immunodeficiency virus (HIV) or Hepatitis B or C (active, previously
             treated or both).

          9. History of solid organ transplantation.

         10. Psychiatric disorder or social or geographic situation that would preclude study
             participation.

         11. Known unsuitability for treatment with carboplatin including renal disease where there
             is impaired glomerular filtration rate (GFR).
      "
NCT02948075,completed,,1,phase 2,['ovarian cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['quisinostat', 'paclitaxel', 'carboplatin']","['CN1C=C(C2=CC=CC=C21)CNCC3CCN(CC3)C4=NC=C(C=N4)C(=O)NO', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C', 'C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]']","
        Inclusion Criteria:

          1. Signed patient's information sheet and informed consent form to participate in the
             study.

          2. Histological confirmed diagnosis of serous epithelial ovarian, primarily peritoneal or
             fallopian tube carcinoma.

          3. Females aged ≥ 18 years.

          4. Patients must have an ECOG status of 0 or 1.

          5. Patients must have received only 1 prior line of platinum and Paclitaxel based
             chemotherapy.

          6. Tumor progression observed not less than 1 month and no more than 6 months after
             completion of the planned number of cycles of first line platinum/Paclitaxel based
             chemotherapy (Carboplatin in the dose AUC5-6 or Cisplatin in the dose ≥ 75 mg/m2, in
             combination with paclitaxel for 6 q3-4 wk cycles) and indications for undergoing the
             second line chemotherapy.

          7. The patients must have at least one measurable lesion according to RECIST 1.1
             criteria.

          8. Tissue block from archived material at diagnosis must be available and be submitted
             for predictive biomarker analysis.

          9. Patient's ability to carry out visits and study procedures and to comply with the
             protocol.

         10. Requirements for laboratory parameters determined below:

             Hematology: Absolute neutrophil count:

             Platelets:

             Hemoglobin: ≥ 1,500/mm3 (1.5 x 109 cells/L)

               -  100,000/mm3 (100 x 109 cells/L)

               -  9.0 g/dl Liver function: Total bilirubin: ≤ 1.5x upper limit of normal (ULN)

             Aspartate aminotransferase (AST) and alanine aminotransferase (ALT):

             Alkalinephosphatase:

               -  2.5x ULN, or ≤ 5.0 x ULN in the case of liver metastasis

               -  5.0 x ULN Renal function: Serum creatinine: ≤2 mg/dL Coagulation panel: Activated
                  partial thromboplastin time (aPTT): ≤ 1.5 x ULN

         11. The expected survival time not less than 6 months.

         12. Women of childbearing potential (not sterile or in menopause less than 2 years) must
             be practicing an effective method of birth control during the whole period of the
             study and 6 months after the last administration of the investigational product.
             Effective methods include usage of a condom or diaphragm (barrier method) with
             spermicide.

        Exclusion Criteria:

          1. Patients previously treated with an HDAC inhibitor. Patients, who have been treated
             with Valproate for convulsions can be included, however only if the treatment has
             taken place > 30 days before the screening.

          2. Have received treatment for ovarian cancer with any other prior chemotherapy than
             platinum (Carboplatin (AUC 5-6) or Cisplatin (≥ 75 mg/m2)) and paclitaxel (175-200
             mg/m2) q3-4 wk for 6 cycles. Additional first line chemotherapy or prior treatment
             with additional investigational anticancer therapy is also an exclusion criterion.

          3. Presence of specific toxicities of ≥ I grade, according to the NCI-CTCAE v.4.3,
             related to any prior anti-cancer therapy (excluding alopecia)

          4. Patients with subsequent debulking operation (after first line chemotherapy) or
             radiotherapy due to the disease recurrence.

          5. Patients who have undergone lower pelvis radiotherapy.

          6. Patients with active or uncontrolled infection.

          7. Patients with antibodies to human immunodeficiency virus (HIV), or hepatitis C virus
             (HCV), active hepatitis B virus (HBsAg).

          8. History of other malignancies with the exception of basal cell carcinoma of the skin
             or cervical cancer in situ, that had undergone surgical removal or treatment within ≥
             5 years before the screening.

          9. Patients with known cerebral metastases or clinical signs of cerebral metastases.

         10. Have a history of severe hypersensitivity reaction to carboplatin, paclitaxel or
             agents within the histone deacetylase inhibitor group.

         11. History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess
             during the year prior to inclusion.

         12. Clinically significant cardiovascular diseases including:

               -  Myocardial infarction within 12 months before screening

               -  Unstable angina within 12 months before screening

               -  Congestive heart failure Class III or IV according to the New York Heart
                  Association criteria (NYHA)

               -  Clinically significant ventricular arrhythmia including ventricular tachycardia,
                  ventricular fibrillation, history of cardiac arrest, atrioventricular block
                  (Mobitz II or III), use of cardiostimulator

               -  QTc interval > 470 ms (ECG) (calculated according to Fredericia formula), or a
                  diagnosis of long QTc syndrome

               -  Hypotension (systolic blood pressure < 86 mm Hg) or bradycardia with a heart rate
                  of < 50 beats per minute (ECG) except when caused by medications (e.g.
                  beta-blockers)

               -  Uncontrolled arterial hypertension (systolic arterial pressure > 170 mm Hg or
                  diastolic blood pressure > 105 mm Hg)

         13. Pregnancy and lactation

         14. Drug or alcohol abuse at the moment of screening or in the past which according to the
             opinion of the Investigator makes the patient unsuitable for participation in the
             study

         15. Inability to read or write; inability to understand and comply with the procedures of
             the study protocol; failure to comply with the treatment, which, in opinion of the
             Investigator, may affect the results of the study or the patient's safety and prevent
             the patient from further participation in the study; any other associated medical or
             serious mental conditions that make the patient unsuitable for participation in the
             clinical study, limit the validity of informed consent or may affect the patient's
             ability to participate in the study
      "
NCT02706691,terminated,"
    study stopped due to poor enrollment.
  ",0,phase 2,"['fgfr gene amplification', 'fgfr1 gene amplification', 'fgfr2 gene amplification', 'fgfr2 gene mutation', 'fgfr3 gene mutation', 'head and neck squamous cell carcinoma', 'human papillomavirus infection', 'recurrent head and neck carcinoma', 'recurrent nasopharynx carcinoma', 'recurrent oropharyngeal squamous cell carcinoma']","[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]",['bgj398'],['CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl'],"
        Inclusion Criteria:

          -  Histologically documented diagnosis of squamous cell carcinoma of the head/neck
             including nasopharyngeal carcinomas (lymphepithelioma histology is ok if criteria 2 is
             met)

               -  Patients must have progressed on prior platinum based therapy (or have become
                  intolerant) prior to enrollment on this study

               -  Prior anti-PD-1 or other immunotherapy is acceptable

          -  Known FGFR genetic alterations (specifically FGFR1-3 mutation, amplification, or
             translocation) via deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) based assay.

               -  The following genetic aberrations will be screened for:

                    -  FGFR1 amplification, FGFR1 somatic mutations, FGFR1 translocations

                    -  FGFR2 somatic mutations, FGFR2 translocations, FGFR2 amplification

                    -  FGFR3 somatic mutations, FGFR3 translocations, FGFR3 amplification

               -  Other genetic FGF/FGFR pathway aberrations may be acceptable should such genetic
                  changes be observed to emerge and require approval per the lead investigator for
                  enrollment.

               -  The number of enrolled patients with each type of genetic aberration may be
                  limited at the discretion of the lead investigator.

          -  Consent to undergo a fresh biopsy in case of benefit from therapy and subsequent
             progression

          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 1

          -  Patients must provide written informed consent prior to any screening procedures

          -  Aged 18 years or older

          -  Willing and able to comply with scheduled visits, treatment plan and laboratory tests

          -  Patient is able to swallow and retain oral medication, unless approval per the
             manufacturer of other administration routes/methods is provided

          -  Recovery from adverse events of previous systemic anti-cancer therapies to baseline or
             grade 1, except for:

               -  Alopecia

               -  Stable neuropathy of =< grade 2 due to prior cancer therapy

          -  HPV status in oropharyngeal carcinomas; while HPV status (e.g. via p16) does not have
             to be known prior to consenting, the HPV status (e.g. using p16 immunohistochemistry
             [IHC]) needs to be established prior to start of therapy

          -  Presence of measurable disease by Response Evaluation Criteria in Solid Tumors
             (RECIST) 1.1

          -  Availability of tumor tissue (e.g. formalin-fixed, paraffin-embedded [FFPE]) for
             genomic profile (typically 12 unstained FFPE 5-10 micron slides, minimum of 10)

        Exclusion Criteria:

          -  History of another primary malignancy except adequately treated in situ carcinoma of
             the cervix or non-melanoma carcinoma of the skin or any other curatively treated
             malignancy that has not been treated in the prior 3 months or expected to require
             treatment for recurrence during the course of the study

          -  Patients with metastatic central nervous system (CNS) tumors are allowed provided that
             they are clinically stable for a period of 30 days prior to study entry and there is
             not a requirement for steroid (other than close to physiologic doses) or
             anti-convulsant therapy; patients with leptomeningeal involvement are excluded

          -  Patients who received a prior selective FGFR inhibitor in the recurrent/metastatic
             disease setting; prior use of a multikinase inhibitor that includes anti-FGFR activity
             is acceptable after review by the lead investigator

          -  History and/or current evidence of tissue calcification including, but not limited to,
             the soft tissue, kidneys, intestine, myocardium and lung with the exception of
             calcified lymph nodes and asymptomatic coronary calcification

          -  Current evidence of corneal or retinal disorder/keratopathy including, but not limited
             to, bullous/band keratopathy, corneal abrasion, inflammation/ulceration,
             keratoconjuctivitis, confirmed by ophthalmologic examination

          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly
             alter the absorption of oral BGJ398 (e.g., ulcerative diseases, uncontrolled nausea,
             vomiting, diarrhea, malabsorption syndrome, small bowel resection)

          -  History and/or current evidence of endocrine alterations of calcium/phosphate
             homeostasis, e.g., parathyroid disorders, history of parathyroidectomy, tumor lysis,
             tumoral calcinosis, etc unless approval from lead investigator/ collaborator is
             obtained

          -  Treatment with any of the following anti-cancer therapies prior to the first dose of
             BGJ398 within the stated timeframes

               -  Cyclical chemotherapy (intravenous) within a period of 2 weeks unless there are
                  ongoing side effects > grade 2

               -  Biological therapy (including small molecules, and/or) within a period of time
                  that is =< 2 weeks prior to starting study drug unless there are ongoing side
                  effects > grade 2

               -  Any other investigational agents within a period =< 2 weeks prior to starting
                  study drug unless there are ongoing side effects > grade 2

               -  Wide field radiotherapy (including radioisotopes) =< 2 weeks prior to starting
                  study drug unless there are ongoing side effects > grade 2

          -  Patients who are currently receiving treatment with agents that are known strong
             inducers or inhibitors of cytochrome P450 family 3, subfamily A, polypeptide 4
             (CYP3A4) are prohibited

          -  Enzyme inducing anti-epileptic drugs

          -  Consumption of grapefruit, grapefruit juice, pomegranates, star fruits, Seville
             oranges or products within 7 days prior to first dose

          -  Use of medications that are known to prolong the QT interval and/or are associated
             with a risk of torsades de pointes 7 days prior to first dose

          -  Use of amiodarone within 90 days prior to first dose

          -  Use of medications that increase serum levels of phosphorus and/or calcium

          -  Current use of therapeutic doses of warfarin sodium or any other coumadin-derivative
             anticoagulants; heparin and/or low molecular weight heparins or other anticoagulants
             are allowed

          -  Insufficient bone marrow function

               -  Absolute neutrophil count (ANC) < 1,000/mm^3 [1.0 x 10^9/L]

               -  Platelets < 75,000/mm^3 [75 x 10^9/L]

               -  Hemoglobin < 10.0 g/dL

          -  Insufficient hepatic and renal function

               -  Total bilirubin > 1.5 x upper limit of normal (ULN) (unless evidence of Gilbert's
                  disease)

               -  Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT)
                  and alanine aminotransferase (ALT)/serum glutamate pyruvate transaminase (SGPT) >
                  2.5 x ULN

               -  Serum creatinine >= ULN and/or calculated or measured creatinine clearance < 75%
                  lower limit of normal (LLN)

          -  Calcium-phosphate homeostasis

               -  Inorganic phosphorus outside of normal limits

               -  Total and ionized serum calcium outside of normal limits

          -  Clinically significant cardiac disease including any of the following:

               -  Congestive heart failure requiring treatment (New York Heart Association [NYHA]
                  grade >= 2)

               -  Left ventricular ejection fraction (LVEF) < 50% as determined by multigated
                  acquisition (MUGA) scan or electrocardiogram (ECHO), or uncontrolled hypertension
                  (refer to World Health Organization-International Society of Hypertension
                  [WHO-ISH] guidelines)

               -  History or presence of clinically significant ventricular arrhythmias, atrial
                  fibrillation, resting bradycardia, or conduction abnormality

               -  Unstable angina pectoris or acute myocardial infarction =< 3 months prior to
                  starting study drug

               -  Corrected QT Interval Fridericia (QTcF) > 450 msec (both genders)

               -  History of congenital long QT syndrome

          -  Pregnant or nursing (lactating) women

          -  Known positive serology for human immunodeficiency virus (HIV), active hepatitis B,
             and/or active hepatitis C infection

          -  Study medication cannot be administered through gastric (G)-tube, unless additional
             information from the manufacturer becomes available in the future

          -  Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant, unless they are using highly effective methods of contraception
             during dosing and for 3 months following the discontinuation of study treatment must
             be used by both sexes (= female patients and their male partners)

               -  Post-menopausal women are allowed to participate in this study; women are
                  considered post-menopausal and not of child bearing potential if they have had 12
                  months of natural (spontaneous) amenorrhea with an appropriate clinical profile
                  (e.g. age appropriate, history of vasomotor symptoms) or have had surgical
                  bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least
                  six weeks ago; in the case of oophorectomy alone, only when the reproductive
                  status of the woman has been confirmed by follow up hormone level assessment is
                  she considered not of child bearing potential

          -  Sexually active males unless they use a condom during intercourse while taking drug
             and for 3 months after the last dose of the study drug and should not father a child
             in this period; a condom is required to be used also by vasectomized men in order to
             prevent delivery of the drug via seminal fluid
      "
NCT02703415,completed,,1,phase 2,['acute pain'],"[""['G89.12', 'G89.18', 'G89.11', 'G89.3']""]","['bupivacaine', 'tramadol']","['CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C', 'CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O']","
        Inclusion Criteria:

        lower abdominal operation

        Exclusion Criteria:

        Any systemic disease that might compromise the immune system severe coagulation disorder
        true allergy to local anesthetics patients with major malformations of the lower spine or
        meninges any cutaneous or subcutaneous lesion at the site of injection unplanned
        reoperation, or reoperation within three months Diabetes Melliutes
      "
NCT02700568,completed,,1,phase 2,"['carcinoma, renal cell', 'clear cell renal cell carcinoma']","[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]",['axitinib'],['CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4'],"
        Principle Inclusion Criteria:

          -  Histologic confirmation of Renal cell carcinoma with a clear cell component

          -  Patients must have measurable disease

          -  Previous treatment with sunitinib or pazopanib

          -  Favorable prognosis according to IMDC criteria

          -  Must have available tumor tissue for submission

          -  Subjects must also meet various laboratory parameters for inclusion

          -  Patients must give written informed consent prior to initiation of therapy

        Exclusion Criteria:

          -  Any underlying medical condition, which in the opinion of the Investigator, will make
             the administration of study drug hazardous or obscure the interpretation of adverse
             events

          -  Patients who have history of uncompensated diseases, metabolic dysfunction, physical
             examination finding, or clinical laboratory finding giving reasonable suspicion of a
             disease or condition that contraindicates the use of an investigational drug or that
             might affect the interpretation of the results of the study or render the subject at
             high risk from treatment complications.
      "
NCT02708680,completed,,0,phase 1/phase 2,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['entinostat', 'atezolizumab', 'placebo']",['C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3'],"
        Inclusion Criteria:

          1. Has histologically or cytologically confirmed triple negative breast carcinoma that is
             either metastatic (stage IV of the TNM classification) or locally recurrent and not
             amenable to local curative treatment.

          2. Evidence of measurable, locally recurrent or metastatic disease based on imaging
             studies within 28 days before the first dose of study drug.

          3. Has received at least 1, but no more than 2, prior lines of systemic therapy for
             locally recurrent and/or metastatic disease.

          4. If patient has a history of treated asymptomatic CNS metastases they are eligible,
             provided they meet all of the following criteria: Patient has measurable disease
             outside CNS; Patient does not have metastases to midbrain, pons, medulla or spinal
             cord; Patient is not on corticosteroids as therapy for CNS disease (anticonvulsants at
             a stable dose are allowed); Patient has not had whole-brain radiation within 6 weeks
             prior to study enrollment; Patient has stable CNS disease as demonstrated by at least
             4 weeks of stability between the last intervention scan and the study screening scan.

          5. ECOG performance status of 0 or 1.

          6. Has acceptable, applicable laboratory parameters.

          7. Female subjects must not be pregnant; willing to use 2 methods of birth
             control/abstinence if applicable through 120 days after the last dose of study drug.

          8. Experienced resolution of toxic effect(s) of the most recent prior anti-cancer therapy
             to Grade <1 (except alopecia or neuropathy).

          9. Able to understand and give written informed consent and comply with study procedures.

        Exclusion Criteria:

          1. Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form
             of immunosuppressive therapy within 7 days prior to the first dose of study drug.

          2. Active autoimmune disease including active diverticulitis, symptomatic peptic ulcer
             disease, colitis, or inflammatory bowel disease that has required systemic treatment
             in past 2 years.

          3. Previously treated with a PD-1/PD-L1-blocking antibody or a histone deacetylase
             inhibitor.

          4. History or current evidence of any condition, therapy, or laboratory abnormality that
             might confound the results of the study, interfere with the patient's participation
             for the full duration of the study, or is not in the best interest of the patient to
             participate, in the opinion of the treating Investigator, including, but not limited
             to: History of immune deficiencies or autoimmune disease; Myocardial infarction or
             arterial thromboembolic events within 6 months prior to screening or severe or
             unstable angina, New York Heart Association (NYHA) Class III or IV disease, or a QTc
             interval > 470 msec; Uncontrolled hypertension or diabetes mellitus; Another known
             malignancy that is progressing or requires active treatment; Active infection
             requiring systemic therapy; Known active central nervous system (CNS) metastases
             and/or carcinomatous meningitis.

          5. Any contraindication to oral agents or significant nausea and vomiting, malabsorption,
             or significant small bowel resection that, in the opinion of the investigator, would
             preclude adequate absorption.

          6. Received a live vaccine within 30 days of the first dose of treatment.

          7. Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to enrollment or who
             has not recovered from AEs due to mAb agents administered more than 4 weeks earlier.

          8. Prior chemotherapy within 3 weeks, targeted small molecule therapy or radiation
             therapy within 2 weeks prior to enrollment, or who has not recovered (i.e., ≤Grade 1
             at enrollment) from AEs due to a previously administered agent.

          9. Received transfusion of blood products or administration of colony stimulating factors
             within 4 weeks prior to the first dose of treatment.

         10. Currently participating and receiving study therapy or has participated in a study of
             an investigational agent and received study therapy or used an investigational device
             within 4 weeks of the first dose of study drug.

         11. Currently receiving treatment with any other agent listed on the prohibited medication
             list.

         12. If female, is pregnant, breastfeeding, or expecting to conceive starting with the
             screening visit through 120 days after the last dose of study drug.

         13. Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies).

         14. Known active hepatitis B or hepatitis C.

         15. Allergy to benzamide or inactive components of entinostat.

         16. History of allergies to any active or inactive ingredients of atezolizumab.

         17. Known psychiatric or substance abuse disorders that would interfere with cooperation
             with the requirements of the study.
      "
NCT02195011,completed,,0,phase 2,['colorectal neoplasms'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]",['regorafenib'],['CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F'],"
        Inclusion Criteria:

          1. Histologically confirmed metastatic adenocarcinoma of the colon or rectum.

          2. Patients who have been previously treated with or are not candidates for fluorouracil,
             oxaliplatin, irinotecan, and if Kras wild-type, anti EGFR therapy.

          3. Considered an appropriate candidate for regorafenib therapy.

          4. Measurable disease or evaluable disease as measured by Response Evaluation Criteria in
             Solid Tumors (RECIST) version 1.1.

          5. Measurable computed tomography (CT) scan evidence of liver metastases which are not
             treatable by surgical resection or local ablation with curative intent at the time of
             study entry.

          6. ECOG Performance Status score of 0-1.

          7. Adequate hematologic, renal and liver function.

          8. Male patients with female partners of childbearing potential and women female patients
             of childbearing potential are required to use two forms of acceptable contraception,
             including one barrier method, during their participation in the study and for 30 days
             following last dose.

          9. Life expectancy ≥ 3 months.

         10. Ability to understand the nature of this study and give written informed consent

        Exclusion Criteria:

          1. Most recent chemotherapy ≤14 days and ≥Grade 1 chemotherapy-related side effects, with
             the exception of alopecia.

          2. Use of a study drug ≤21 days or 5 half-lives (whichever is shorter) prior to
             initiation of study treatment. For study drugs for which 5 half-lives is ≤21 days, a
             minimum of 10 days between termination of the study drug and administration of study
             treatment is required.

          3. Wide field radiotherapy (including therapeutic radioisotopes such as strontium-89
             administered ≤28 days or limited field radiation for palliation ≤7 days prior to
             starting study drug or has not recovered from side effects of such therapy.

          4. Previous radiation delivered to the upper abdomen.

          5. Major surgical procedures ≤28 days of beginning study drug, or minor surgical
             procedures ≤7 days. No waiting required following port-a-cath placement.

          6. Previously untreated brain metastases. Patients who have received radiation or surgery
             for brain metastases are eligible if therapy was completed at least 2 weeks previously
             and there is no evidence of central nervous system disease progression, mild
             neurologic symptoms, and no requirement for chronic corticosteroid therapy.

          7. Leptomeningeal metastases or spinal cord compression due to disease.

          8. Pregnant or lactating.

          9. Evidence of ascites, cirrhosis, portal hypertension, or thrombosis as determined by
             clinical or radiologic assessment.

         10. History of abdominal fistula or gastrointestinal perforation ≤6 months prior to
             beginning study treatment.

         11. Serious non-healing wound, active ulcer, or untreated bone fracture.

         12. Presence of active gastrointestinal disease or other condition that will interfere
             significantly with the absorption, distribution, metabolism, or excretion of oral
             therapy (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea Grade ≥2,
             and malabsorption syndrome).

         13. Any of the following cardiac diseases currently or within the last 6 months:

               -  Unstable angina pectoris

               -  Congestive heart failure (NYHA ≥ Grade 2)

               -  Conduction abnormality not controlled with pacemaker or medication

               -  Significant ventricular or supraventricular arrhythmias (patients with chronic
                  rate-controlled atrial fibrillation in the absence of other cardiac abnormalities
                  are eligible)

               -  Valvular disease with significant compromise in cardiac function

         14. Inadequately controlled hypertension (i.e., systolic blood pressure [SBP] >180 mmHg or
             diastolic blood pressure (DBP) >100 mmHg) (patients with values above these levels
             must have their blood pressure (BP) controlled with medication prior to starting
             treatment).

         15. Serious active infection at the time of treatment, or another serious underlying
             medical condition that would impair the ability of the patient to receive protocol
             treatment.

         16. Known diagnosis of human immunodeficiency virus, hepatitis B, or hepatitis C.

         17. Presence of other active cancers, or history of treatment for invasive cancer ≤5
             years. Patients with Stage I cancer who have received definitive local treatment and
             are considered unlikely to recur are eligible. All patients with previously treated in
             situ carcinoma (i.e., non-invasive) are eligible, as are patients with history of
             non-melanoma skin cancer.

         18. Use of strong CYP34A inducers or inhibitors.

         19. The herbal medications St. John's wort, kava, ephedra (ma huang), gingko biloba,
             dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng will not be allowed
             during study treatment. Patients should stop using these herbal medications 7 days
             prior to first dose of study drug.

         20. Psychological, familial, sociological, or geographical conditions that do not permit
             compliance with the protocol.

         21. Inability or unwillingness to comply with study and/or follow-up procedures outlined
             in the protocol.
      "
NCT02192697,terminated,"
    following recommendation by solar study idmc, astellas closed enrollment in asp8273 studies.
  ",1,phase 1/phase 2,['non-small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]",['asp8273'],['CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC5CCN(C5)C(=O)C=C'],"
        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of NSCLC.

          -  Patients confirmed to have the del ex19, L858R, G719X, or L861Q mutation among the
             EGFR activating mutations (patients at the study site who are documented to have any
             of the above-stated EGFR activating mutations can be enrolled in the study).

          -  Life expectancy ≥ 12 weeks based on the investigator's/subinvestigator's judgment.

          -  [Phase I]

               -  Patients who have previously been treated with EGFR tyrosine-kinase inhibitors
                  (EGFR-TKIs)*

               -  Those who are not expected to show a therapeutic response to existing treatments
                  in the investigator's/subinvestigator's opinion.

          -  [Phase II]

               -  Patients who have been confirmed to have progressive disease (PD) after previous
                  treatment with EGFR-TKIs*; for those who have received 2 or more regimens of
                  previous treatment, the last regimen before enrollment should have included
                  EGFR-TKIs.

               -  *Erlotinib, gefitinib, and EGFR-TKIs under clinical investigation (e.g.,
                  neratinib, afatinib, dacomitinib)

               -  Expression of the EGFR-T790M mutation as confirmed by a tumor biopsy of the
                  primary or metastatic lesions after confirmation of PD following previous
                  treatment with EGFR-TKIs and before enrollment, or by a tumor tissue sample that
                  had been collected and archived after confirmation of PD following previous
                  treatment with EGFR-TKIs.

               -  At least 1 measurable lesion based on Response Evaluation Criteria in Solid
                  Tumors (RECIST) Version 1.1.

        Exclusion Criteria:

          -  Persistent clinical evidence of previous antitumor treatment related toxicity ≥ Grade
             2 using the Japan Clinical Oncology Group (JCOG) Japanese translation of the National
             Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version
             4.0 (NCI CTCAE v4.0 - JCOG) (except alopecia and skin toxicities considered irrelevant
             in study enrollment by the investigator/sub-investigator).

          -  History of or concurrent interstitial lung disease

          -  Received treatment with a reversible EGFR-TKI (erlotinib or gefitinib) within 8 days
             before the start of the study treatment.

          -  Received previous treatment (except reversible EGFR-TKIs) intended to have antitumor
             effects or treatment with another investigational drug or an investigational device
             within 14 days before the start of the study treatment.

          -  Previously received treatment with EGFR-TKIs (e.g., CO-1686, AZD9291) that can inhibit
             EGFR with the T790M mutation.

          -  It is planned that the subject will undergo a surgical procedure during the course of
             the study or the subject still has an unhealed wound after previous surgery

          -  Symptomatic central nervous system (CNS) lesions.
      "
NCT02199197,completed,,1,phase 2,['prostate cancer'],"[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]","['radium ra 223 dichloride', 'enzalutamide']",['CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C'],"
        Inclusion Criteria:

          -  Histologically documented adenocarcinoma of the prostate.

          -  Men at least 18 years of age and life expectancy of greater than or equal to 6 months.

          -  Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.

          -  Metastatic disease as evidenced by both lymphadenopathy and bony metastases or just
             bony metastases on baseline bone scan and/or computed tomography (CT) scan or MRI of
             the abdomen and pelvis within 28 days of registration. Chest imaging is only required
             if clinically indicated or if there is known disease in the chest.

          -  Castration resistant prostatic adenocarcinoma. Subjects must have castrate levels of
             serum testosterone (less than 50 ng/dL) achieved by orchiectomy or luteinizing
             hormone-releasing hormone (LHRH) agonist or antagonist therapy.

          -  Previously received docetaxel or are not healthy enough per clinical judgment or
             declined to receive it

          -  Evidence of disease progression on or after the most recent systemic treatment defined
             by the following criteria:

               -  Prostate-Specific Antigen (PSA): Increasing serum PSA levels as defined by the
                  Prostate Cancer Working Group 2 (PCWG2), determined by 2 consecutive measurements
                  (compared to a baseline or nadir value). If the third measurement is below the
                  second, then a fourth measurement must be greater than the second. The confirming
                  third or fourth measurement must be greater or equal to 2 ng/mL. PSA progression
                  must have occurred within 15 months of registration (with at least 7 days between
                  each PSA measurement). Additionally, the PSA progression as described above
                  should have occurred during or after the most recent systemic treatment for
                  prostate cancer.

               -  Measurable disease: greater than or equal to 20% increase in the sum of the short
                  axis diameter of all measurable lymph nodes or the development of any new
                  measurable lymphadenopathy by RECIST 1.1 and PCWG2 criteria.

               -  Non-measurable disease:

          -  Lymph node disease: The appearance of 1 or more new lymphadenopathy, and/or
             unequivocal worsening of non-measurable disease when compared to imaging studies
             acquired during castration therapy or against the pre-castration studies if there was
             no response.

          -  Bone disease: Appearance of 2 or more new areas of abnormal uptake on bone scan when
             compared to imaging studies acquired during castration therapy or against the
             pre-castration studies if there was no response. Increased uptake of pre-existing
             lesions on bone scan does not constitute progression.

          -  Symptomatic bone metastases

          -  Adequate hematologic, renal, and liver function as evidenced by laboratory test
             results. (Transfusion of blood products are not allowed to normalize blood parameters
             within 4 weeks of the first radium treatment.)

          -  Subjects who have previously received docetaxel or are ineligible for docetaxel and
             who are candidates for treatment with enzalutamide alone or enzalutamide in
             combination with Radium-223

          -  Men must agree to use adequate contraception beginning at the signing of the Informed
             Consent Form until at least 6 months after the last dose of study drug. Because of the
             potential side effect on spermatogenesis associated with radiation, men who are
             sexually active must agree to use condoms and their female partners of reproductive
             potential must agree to use a highly effective contraceptive method during and for 6
             months after completing treatment.

          -  Able to provide informed consent and have signed an approved consent form that
             conforms to federal and institutional guidelines to ensure compliance with HIPAA
             regulations.

        Exclusion Criteria:

          -  The presence of known brain metastases, malignant pleural effusions, or malignant
             ascites. Brain MRI is required at screening only if clinically indicated.

          -  Visceral metastases as assessed by chest, abdominal or pelvic computed tomography (CT)
             (or other imaging modality)

          -  Received systemic therapy with radionuclides (e.g., strontium-89, samarium-153,
             rhenium-186, or rhenium-188, or Radium Ra 223 dichloride) for the treatment of bony
             metastases

          -  Prior treatment with enzalutamide.

          -  Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery,
             immunotherapy, biologic therapy, or tumor embolization) other than the protocol based
             treatment. LHRH agonist or antagonist therapy, and supportive non-cancer directed
             therapies like bisphosphonates or denosumab are allowed.

          -  Prior cytoxic chemotherapy with the exception of docetaxel or cabazitaxel. Treatment
             with docetaxel or cabazitaxel must be discontinued greater than 4 weeks from the time
             of enrollment, and recovery of adverse events (AEs) to grade 1 or baseline (however,
             ongoing neuropathy is permitted).

          -  Major surgery within 30 days prior to start of study drug

          -  Current, untreated pathologic long-bone fractures, imminent pathologic long-bone
             fractures (cortical erosion on radiography greater than 50%).

          -  Prior hemi-body external radiotherapy. Subjects who received other types of prior
             external radiotherapy are allowed provided that bone marrow function is assessed and
             meets the protocol requirements for hemoglobin, absolute neutrophil count (ANC), and
             platelets.

          -  Use of biologic response modifiers, such as granulocyte macrophage colony-stimulating
             factor (GM-CSF) or granulocyte colony-stimulating factor (G-CSF) within 4 weeks prior
             to screening

          -  Lymphadenopathy exceeding 3 cm in short-axis diameter

          -  Any size pelvic lymphadenopathy if it is thought to be a contributor to concurrent
             hydronephrosis.

          -  Current or imminent spinal cord compression based on clinical findings and/or magnetic
             resonance imaging (MRI). Treatment should be completed for spinal cord compression.

          -  Any other serious illness or medical condition in the opinion of the investigator,
             such as but not limited to:

          -  Any greater than or equal to Grade 2 infection as defined by NCI-CTCAE version 4.03.

          -  Cardiac failure New York Heart Association (NYHA) III or IV

          -  Crohn's disease or ulcerative colitis

          -  Bone marrow dysplasia

          -  Fecal incontinence

          -  Concomitant use of narrow therapeutic index drugs that are metabolized by CYP3A4 (i.e.
             alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide,
             quinidine, sirolimus, tacrolimus), CYP2C9 (phenytoin, warfarin), and CYP2C19
             (S-mephenytoin). [Note: Patients on stable doses of anti-coagulation with warfarin and
             fentanyl will be eligible, as long as they are monitored closely with additional
             international normalized ratio (INR) monitoring].

          -  Any infection requiring parenteral antibiotic therapy or causing fever (temperature
             greater than 100.5 degrees F or 38.1 degrees C) within 1 week prior to registration.

          -  Concurrent other malignancy with the exception of: a) cutaneous squamous cell and
             basal carcinomas, b) adequately treated stage 1-2 malignancy , c) adequately treated
             stage 3-4 malignancy that had been in remission for greater than or equal to 2 years
             at the time of registration.

          -  Inability to comply with the protocol and/or not willing or not available for
             follow-up assessments

          -  Any medical intervention or other condition which, in the opinion of the Principal
             Investigator could compromise adherence with study requirements or otherwise
             compromise the study's objectives
      "
NCT02190838,terminated,"
    preliminary terminated due to inefficacy
  ",0,phase 2,['melanoma'],"[""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']""]","['metformin', 'melatonin', 'dacarbazine']","['CN(C)C(=N)N=C(N)N', 'CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC', 'CN(C)N=NC1=C(NC=N1)C(=O)N']","
        Inclusion Criteria:

          -  Age >18.

          -  Obtained Inform Consent

          -  Morphologically confirmed disseminated Stage IV melanoma

          -  Eastern Collaborative Oncology Group Performance Status Scale 0 - 2.

          -  Expected survival >3 month

        Exclusion Criteria:

          -  Evidence of active brain lesions (brain lesions after stereotaxic ray therapy allowed)

          -  Evidence of liver and bone marrow clinically meaningful disfunction

          -  Severe uncontrolled concomitant conditions and diseases

          -  Pregnancy or lactation

          -  Systemic therapy for disseminated melanoma

          -  Second malignancy

          -  Diabetes mellitus requiring drug therapy

          -  Any condition preventing study participation by investigator opinion
      "
NCT02196688,completed,,1,phase 2,['colorectal cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['fruquintinib', 'placebo']",['CC1=C(C2=C(O1)C=C(C=C2)OC3=NC=NC4=CC(=C(C=C43)OC)OC)C(=O)NC'],"
        Inclusion Criteria:

          -  ≥ 18 and ≤ 75 years of age , with ≥ 40 Kg

          -  Histological or cytological confirmed metastatic colorectal cancer

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

          -  Failed 2 or more lines of chemotherapy

          -  Adequate hepatic, renal, heart, and hematologic functions

          -  At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan)

          -  Signed and dated informed consent.

          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory
             tests, and other study procedure

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Any factors that influence the usage of oral administration

          -  Central nervous system (CNS) metastasis

          -  One of the following conditions: non-controlled hypertension, coronary artery disease,
             arrhythmia and heart failure

          -  Abuse of alcohol or drugs

          -  Less than 4 weeks from the last clinical trial - Previous treatment with VEGFR
             inhibition

          -  Disability of serious uncontrolled intercurrence infection

          -  Proteinuria ≥ 2+ (1.0g/24hr)

          -  Evidence or a history of bleeding tendency within two months of the enrollment,
             regardless of seriousness

          -  History of artery/venous thromboembolic events in 12 months, such as cerebral vascular
             accident (including transient ischemic attack) etc.

          -  History of acute myocardial infarction, acute coronary syndrome or coronary artery
             bypass graft (CABG) in 6 months

          -  Bone fracture or wounds that was not cured for a long time

          -  Coagulation dysfunction, hemorrhagic tendency or receiving anticoagulant therapy
      "
NCT02197897,completed,,1,phase 2,['bladder cancer'],"[""['D30.3', 'C67.5', 'C67.9', 'C79.11', 'C67.0', 'C67.1', 'D41.4']""]",['tamoxifen citrate'],['Status: 503'],"
        Inclusion Criteria:

        Males and females age 21 or older. Histologic evidence of urothelial carcinoma of the
        bladder. Low/Intermediate-risk papillary urothelial carcinoma of the bladder, at initial
        occurrence or recurrent with >6 months interval free of disease.

        Patients with multifocal tumors must have resectable lesions. Patients may be
        treatment-naïve or have failed 1 previous regimen of intravesical therapy.

        At least one endoscopically measurable tumor 6 - 10mm in diameter. Adequate hepatic and
        renal function. Patient or authorized proxy needs to have signed the informed consent form.

        -

        Exclusion Criteria:

        Patients with sessile appearing tumors, which may be invasive or high-grade. Diagnosis of
        urothelial carcinoma involving the prostatic urethra or upper urinary tract.

        Plans for pelvic radiation while participating in the study. Concurrent use of warfarin,
        heparin, or chronic use of NSAIDs, including aspirin (other than cardioprotective doses of
        80mg daily) within 30 days prior to registration or during the trial.

        Concurrent use of selective serotonin reuptake inhibitors or aromatase inhibitors.

        Chronic or acute renal or hepatic disorder or any other condition, medical or psychological
        that, in the opinion of the investigator, could jeopardize the subject's safe
        participation.

        Any other investigational drug within 30 days prior to registration and during the study.

        Women Exclusion Pregnant or lactating women. Personal history of endometrial cancer or any
        abnormal uterine bleeding. Previous or concurrent treatment with SERM and/or hormonal
        replacement therapy within 3 months of the study.

        -
      "
NCT02196168,terminated,"
    inadequate accrual rate
  ",0,phase 2,"['recurrent hypopharyngeal squamous cell carcinoma', 'recurrent laryngeal squamous cell carcinoma', 'recurrent laryngeal verrucous carcinoma', 'recurrent lip and oral cavity squamous cell carcinoma', 'recurrent metastatic squamous cell carcinoma in the neck with occult primary', 'recurrent nasal cavity and paranasal sinus squamous cell carcinoma', 'recurrent oral cavity verrucous carcinoma', 'recurrent oropharyngeal squamous cell carcinoma', 'squamous cell carcinoma metastatic in the neck with occult primary', 'stage iv hypopharyngeal squamous cell carcinoma', 'stage iva laryngeal squamous cell carcinoma', 'stage iva laryngeal verrucous carcinoma', 'stage iva lip and oral cavity squamous cell carcinoma', 'stage iva nasal cavity and paranasal sinus squamous cell carcinoma', 'stage iva oral cavity verrucous carcinoma', 'stage iva oropharyngeal squamous cell carcinoma', 'stage ivb laryngeal squamous cell carcinoma', 'stage ivb laryngeal verrucous carcinoma', 'stage ivb lip and oral cavity squamous cell carcinoma', 'stage ivb nasal cavity and paranasal sinus squamous cell carcinoma', 'stage ivb oral cavity verrucous carcinoma', 'stage ivb oropharyngeal squamous cell carcinoma', 'stage ivc laryngeal squamous cell carcinoma', 'stage ivc laryngeal verrucous carcinoma', 'stage ivc lip and oral cavity squamous cell carcinoma', 'stage ivc nasal cavity and paranasal sinus squamous cell carcinoma', 'stage ivc oral cavity verrucous carcinoma', 'stage ivc oropharyngeal squamous cell carcinoma', 'tongue carcinoma']","[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['D00.07']""]","['cisplatin', 'wee1 inhibitor azd1775']",['N.N.Cl[Pt]Cl'],"
        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed SCCHN that is recurrent
             and/or metastatic and not amendable to curative therapy by surgery or radiation; SCCHN
             originating from the following sites are eligible: oral cavity, oropharynx, larynx,
             hypopharynx and paranasal sinus; for patients with a diagnosis of SCCHN of unknown
             origin, their eligibility must be reviewed and approved by the principal investigator

          -  No prior systemic chemotherapy or WEE1 kinase inhibitor therapy for metastatic or
             recurrent disease will be allowed; patients are permitted to have received prior
             systemic chemotherapy as a part of the initial multimodality treatment for locally
             advanced disease if this treatment was completed more than 6 months prior to
             enrollment

          -  Patients must have disease amenable to biopsy and must be medically fit to undergo a
             biopsy

          -  Patients must have measurable disease, defined as at least one lesion that can be
             accurately measured in at least one dimension (longest diameter to be recorded) as >
             10 mm with computed tomography (CT) scan; indicator lesions must not have been
             previously treated with surgery, radiation therapy or radiofrequency ablation unless
             there is documented progression after therapy

          -  Patients must have completed any previous surgery or radiotherapy >= 4 weeks prior to
             enrollment

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Karnofsky > 60%)

          -  Life expectancy of greater than 12 weeks

          -  Leukocytes >= 3,000/mcL

          -  Absolute neutrophil count >= 1,500/mcL

          -  Platelets >= 100,000/mcL

          -  Hemoglobin >= 9 g/dL

          -  Total bilirubin within normal institutional limits

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =< 2.5 × institutional upper limit of normal

          -  Prothrombin time (PT)/partial thromboplastin time (PTT)/international normalized ratio
             (INR) =< 1.5 upper limit of normal (ULN)

          -  Creatinine within normal institutional limits OR calculated creatinine clearance >= 60
             mL/min/1.73 m^2 for patients with levels above institutional normal using modified
             Cockcroft-Gault

          -  Cardiac function: 12-lead electrocardiogram (ECG) with normal tracing, or
             non-clinically significant changes that do not require medical intervention; corrected
             QT (QTc) interval is to be < 470 msec

          -  Women of childbearing potential and men must be surgically sterilized, practicing
             abstinence, or agree to use 2 birth control methods prior to study entry and for the
             duration of study participation including up to 30 days after the last dose of
             MK-1775; the 2 methods of birth control can be either 2 barrier methods or a barrier
             method plus a hormonal method to prevent pregnancy; the following are considered
             adequate barrier methods of contraception: diaphragm or sponge, and condom; other
             methods of contraception such as copper intrauterine device or spermicide may be used;
             appropriate hormonal contraceptives will include any registered and marketed
             contraceptive agent that contains an estrogen and/or a progestational agent (including
             oral, subcutaneous, intrauterine, or intramuscular agents); should a woman become
             pregnant or suspect she is pregnant while participating in this study, she should
             inform her treating physician immediately

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Past or current malignancy other than SCCHN, except for:

               -  Cervical carcinoma stage 1B or less

               -  Non-invasive basal cell and squamous cell skin carcinoma

               -  Malignant melanoma with a complete response of a duration of > 10 years

               -  Radically treated prostate cancer (prostatectomy or radiotherapy) with normal
                  prostate specific antigen (PSA), and not requiring ongoing anti-androgen hormonal
                  therapy

               -  Other cancer diagnosis with a complete response of duration of > 5 years

          -  Patients may not be receiving any other investigational agents

          -  Patients with known brain metastases should be excluded from this clinical trial

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to MK-1775 or cisplatin

          -  Patients who are unable to take oral medications and/or who have a clinical or
             radiological diagnosis of bowel obstruction are ineligible

          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active
             infection, active peptic ulcer disease, myocardial infarction within 6 months prior to
             entry, congestive heart failure, symptomatic congestive heart failure, active
             cardiomyopathy, unstable angina pectoris, cardiac arrhythmia, uncontrolled
             hypertension or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if
             the mother is treated with MK-1775

          -  Human immunodeficiency virus (HIV)-positive patients are ineligible

          -  Patients taking the following prescription or non-prescription drugs or other products
             (i.e. grapefruit juice) are ineligible: sensitive cytochrome P450, family 3, subfamily
             A, polypeptide 4 (CYP3A4) substrates, CYP3A4 substrates with a narrow therapeutic
             index, moderate to potent inhibitors/inducers of CYP3A4; patients would be eligible if
             the medications can be discontinued two weeks prior to day 1 of dosing and withheld
             throughout the study until 2 weeks after the last dose of study medication
      "
NCT03015792,terminated,"
    per cs0139535 -submitter stated we can update status to admin complete- low accrual reasoning
  ",0,phase 1/phase 2,"['recurrent plasma cell myeloma', 'refractory plasma cell myeloma']","[""['G47.13', 'J01.41', 'K11.22', 'K12.0', 'N96', 'F33.8', 'G03.2']"", ""['D46.4', 'I20.2', 'D46.1', 'D46.A', 'D46.0', 'D46.20', 'D46.21']""]","['dexamethasone', 'ibrutinib', 'lenalidomide']","['CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C', 'C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N', 'C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N']","
        Inclusion Criteria:

          -  Age >= 18 years

          -  Diagnosis

               -  Phase I: confirmed diagnosis of relapsed or refractory multiple myeloma

               -  Phase II: confirmed diagnosis of active multiple myeloma and must be newly
                  diagnosed

               -  NOTE: all tests for establishing disease status must be completed =< 28 days
                  prior to registration

          -  Measurable disease =< 28 days prior to registration, defined by at least one of the
             following:

               -  Serum monoclonal protein >= 1.0 g/dL

               -  > 200 mg of monoclonal protein in the urine on 24-hour electrophoresis

               -  Serum immunoglobulin free light chain > 10 mg/dL AND abnormal serum
                  immunoglobulin kappa to lambda free light chain ratio

               -  Monoclonal bone marrow plasmacytosis > 30% (evaluable disease)

          -  Prior treatment

               -  Phase I: exposure to 2-3 prior lines of therapy or no therapeutic options

               -  Phase II: previously untreated for symptomatic MM

               -  EXCEPTION: =< 7 days with pulse steroids or localized radiation therapy, without
                  curative intent, for a myeloma-related complication prior to registration is
                  allowed, as considered necessary by the treating physician

          -  Myeloma Frailty Score:

               -  NOTE: this will include calculating a frailty score (based on age, activities of
                  daily living, instrumental activities of daily living and Charlson comorbidity
                  index)

                    -  Phase I: ""intermediate fitness"" or ""frail""; NOTE: no ""fit"" patients will be
                       included in the phase 1 portion of the trial which is being done to
                       determine the MTD of the 3-drug combination

                    -  Phase II: transplant-ineligible as per their treating physician; NOTE: all
                       the patients with ""intermediate fitness"" or ""frail"" status will be
                       considered transplant-ineligible; other reasons to consider transplant
                       ineligibility may include, but are not limited to: financial constraints or
                       patient preference; in case such patients have a frailty score of ""fit"", it
                       should be duly noted by the treating physician

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2

          -  Absolute neutrophil count (ANC) >= 1,000 cell/mm^3 without growth factor support
             (obtained =< 14 days prior to registration)

          -  Platelets >= 50,000 cells/mm^3 for patients who have bone marrow (obtained =< 14 days
             prior to registration)

          -  Plasmacytosis < 50% or >= 30,000 cells/mm^3 for patients who have bone marrow
             plasmacytosis of >= 50% (obtained =< 14 days prior to registration)

          -  Calculated or measured creatinine clearance >= 30 ml/min (obtained =< 14 days prior to
             registration)

          -  Total bilirubin =< 1.5 x upper limit of normal (ULN) unless due to Gilbert's syndrome
             (obtained =< 14 days prior to registration)

          -  Aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) and
             alanine aminotransferase (ALT)/serum glutamate pyruvate transaminase (SGPT) =< 3 x ULN
             (obtained =< 14 days prior to registration)

          -  Prothrombin time (PT)/international normalized ratio (INR) =< 1.5 X ULN (obtained =<
             14 days prior to registration)

          -  Provide informed written consent

          -  Willing to return to enrolling institution for follow-up (during the active monitoring
             phase of the study)

          -  Persons able to become pregnant must be willing to adhere to the scheduled pregnancy
             testing as required in the REVLIMID Risk Evaluation and Mitigation Strategy (REMS)
             program

          -  Willing to be registered into the mandatory REVLIMID REMS program, and willing and
             able to comply with the requirements of the REVLIMID REMS program

          -  Ability to complete study-related (QoL, pill diary) questionnaire(s) by themselves or
             with assistance

          -  Willing to provide bone marrow aspirate and core, and blood samples for correlative
             research purposes

        Exclusion Criteria:

          -  Non-secretory MM or known amyloid light-chain (AL) amyloidosis

          -  Clinically significant active infection requiring intravenous antibiotics =< 14 days
             prior to registration

          -  >= grade 3 neuropathy and/or POEMS syndrome (plasma cell dyscrasia with
             polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)

          -  Other prior malignancy; EXCEPTIONS:

               -  Adequately treated basal cell or squamous cell skin cancer

               -  Any in situ cancer

               -  Adequately treated stage I or II cancer from which the patient is currently in
                  complete remission, or

               -  Any other cancer from which the patient has been disease-free for >= at least
                  three years prior to registration

          -  Concurrent therapy considered to be investigational; NOTE: patients must not be
             planning to receive any radiation therapy (except localized radiation for palliative
             care that must be completed prior to starting cycle 1, day 1)

          -  Any of the following:

               -  Pregnant women

               -  Nursing women (lactating females are eligible provided that they agree not to
                  breast feed while taking lenalidomide)

               -  Men or women of childbearing potential who are unwilling to employ adequate
                  contraception

          -  Requires treatment with a strong cytochrome (CYP) 3A4/5 inhibitor

          -  Major surgery =< 4 weeks prior to registration

          -  History of stroke/intracranial hemorrhage =< 6 months prior to registration

          -  Requires use of therapeutic anticoagulation prior to registration

               -  NOTE: thromboprophylaxis with any agent is permitted

          -  History of clinically significant bleeding or known platelet or coagulation disorder

          -  Clinically significant cardiac illness including New York Heart Association (NYHA)
             class III or class IV heart failure, unstable angina pectoris, myocardial infarction
             within the past 6 months, or >= grade 3 cardiac arrhythmias noted =< 14 days prior to
             registration

          -  Hepatic impairment:

               -  Phase I: any currently active, clinically significant hepatic impairment
                  (Child-Pugh class A, B, or C according to the Child Pugh classification)

               -  Phase II: currently active, clinically significant hepatic impairment Child-Pugh
                  class B or C according to the Child Pugh classification

          -  Known human immunodeficiency virus (HIV) positive (+) patients; EXCEPTION: if they
             meet the following additional criteria =< 28 days prior to registration:

               -  CD4 cells >= 500/mm^3

               -  Viral load of < 50 copies HIV messenger (m) ribonucleic acid (RNA)/mm^3 if on
                  combination antiretroviral therapy (cART) or < 10,000 copies HIV mRNA if not on
                  cART • No zidovudine or stavudine as part of cART

          -  Known hepatitis B or hepatitis C infection; EXCEPTION: if viral load < 800,000 IU/L

          -  Phase I: active dermatologic disease >= grade 3
      "
NCT03010358,completed,,1,phase 1/phase 2,"['anemia', 'b-cell prolymphocytic leukemia', 'grade 1 follicular lymphoma', 'grade 2 follicular lymphoma', 'grade 3a follicular lymphoma', 'hairy cell leukemia', 'lymphoplasmacytic lymphoma', 'mantle cell lymphoma', 'marginal zone lymphoma', 'recurrent chronic lymphocytic leukemia', 'recurrent small lymphocytic lymphoma', 'refractory chronic lymphocytic leukemia', 'refractory small lymphocytic lymphoma', 'richter syndrome']","[""['D53.2', 'D64.9', 'D46.4', 'D53.0', 'D53.9', 'D61.3', 'D61.9']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['A87.2', 'K52.832', 'D72.111', 'C91.11', 'C91.12', 'C91.10']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['A87.2', 'K52.832', 'D72.111', 'C91.11', 'C91.12', 'C91.10']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']""]",['entospletinib'],['C1COCCN1C2=CC=C(C=C2)NC3=NC(=CN4C3=NC=C4)C5=CC6=C(C=C5)C=NN6'],"
        Inclusion Criteria:

          -  Phase I portion of the study: Histologically or flow cytometry confirmed diagnosis of
             B-CLL/SLL according to National Cancer Institute (NCI)-Working Group (WG) 1996
             guidelines

          -  Phase I portion of the study: The following types of NHL as documented by medical
             records and with histology based on criteria established by the World Health
             Organization (WHO):

               -  Mantle cell lymphoma (MCL)

               -  Follicular lymphoma (FL) - grades 1-3a

               -  Lymphoplasmacytic lymphoma (LPL)

               -  Marginal zone lymphoma (MZL)

               -  CLL in Richter's transformation

               -  B-cell prolymphocytic leukemia

          -  Phase I portion of the study: Patients with histologically confirmed classical hairy
             cell leukemia (HCL)

          -  Phase II portion of the study - histologically or flow cytometry confirmed diagnosis
             of BCLL/SLL according to NCI-WG 1996 guidelines; patients who lack CD23 expression on
             their leukemia cells should be examined for (and found NOT to have) either t(11;14) or
             cyclin D1 overexpression, to rule out mantle cell lymphoma

          -  Patients underwent >= 1 prior chemotherapy-based or immunotherapy-based regimen or
             targeted therapy (e.g., inhibitors of BTK, PI3K etc.) administered for >= 2 cycles,
             and have had either documented disease progression or no response (stable disease) to
             the most recent treatment regimen

          -  Patients with CLL/SLL must demonstrate active disease meeting at least 1 of the
             International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria for
             requiring treatment:

               -  A minimum of any one of the following constitutional symptoms:

                    -  Unintentional weight loss > 10% within the previous 6 months prior to
                       screening

                    -  Extreme fatigue (unable to work or perform usual activities)

                    -  Fevers of greater than 100.5 Fahrenheit (F) for >= 2 weeks without evidence
                       of infection

                    -  Night sweats without evidence of infection

               -  Evidence of progressive marrow failure as manifested by the development of, or
                  worsening of anemia or thrombocytopenia

               -  Massive (i.e., > 6 cm below the left costal margin), progressive or symptomatic
                  splenomegaly

               -  Massive nodes or clusters (i.e., > 10 cm in longest diameter) or progressive
                  lymphadenopathy

               -  Progressive lymphocytosis with an increase of > 50% over a 2-month period, or an
                  anticipated doubling time of less than 6 months

               -  Autoimmune anemia or thrombocytopenia that is poorly responsive to
                  corticosteroids

          -  Patients with HCL must be intolerant of or not candidates for purine analog-based
             therapy, or failed to achieve response (CR or partial response [PR]) or relapsed
             within 2 years of such therapy, AND meet the standard treatment initiation criteria
             (absolute neutrophil count [ANC] =< 1000/uL, hemoglobin [Hgb] =< 10 g/dL, platelet
             count =< 100,000/uL); patients with indolent lymphoma (FL, LPL, MZL) and patients with
             B-cell prolymphocytic leukemia must have an indication for treatment in the opinion of
             the investigator; patients with MCL and patients with CLL in Richter's transformation
             should have previously received or not be candidates for high dose
             chemotherapy/autologous stem cell transplant

          -  For diseases other than CLL, LPL, and HCL, presence of radiographically measurable
             lymphadenopathy or extra-nodal lymphoid malignancy (defined as the presence of >= 1
             lesion that measures >= 2.0 cm in the longest dimension [LD] and >= 1.0 cm in the
             longest perpendicular dimension [LPD] as assessed by computed tomography [CT] or
             magnetic resonance imaging [MRI]); for LPL, measurable disease will be defined as
             serum monoclonal IgM > 0.5 g/dL or meeting at least 1 of the recommendations from the
             Second International Workshop on LPL for requiring treatment

          -  Patients must have Eastern Cooperative Oncology Group (ECOG) performance status =< 2

          -  Direct bilirubin =< 2 X institutional upper limit of normal (ULN) (unless due to known
             Gilbert's syndrome or compensated hemolysis directly attributable to CLL)

          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) less than 2.5 X
             institutional ULN

          -  Estimated creatinine clearance (CrCL) using the Cockcroft-Gault equation >= 50 mL/min

          -  Platelets >= 50,000/mm^3 independent of transfusion support, with no active bleeding

          -  Absolute neutrophil count (ANC) >= 1000/mm^3, unless due to disease involvement in the
             bone marrow

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Prior therapeutic intervention with any of the following:

               -  Therapeutic anticancer antibodies within 4 weeks (rituximab), except within 6
                  months for obinutuzumab or a similar investigational type II monoclonal antibody;

               -  Radio- or toxin-immunoconjugates within 10 weeks;

               -  Inhibitors of BTK (ibrutinib), PI-3K (idelalisib), BH3-mimetic venetoclax,
                  lenalidomide and other ""targeted"" therapy (including but not limited to
                  investigational BTK and PI-3K inhibitors, etc.) - within 6 half-lives (i.e., 36
                  hours for ibrutinib)

               -  All other chemotherapy, radiation therapy within 3 weeks prior to initiation of
                  therapy

               -  SYK inhibitors at any time

          -  Inadequate recovery from adverse events related to prior therapy to grade =< 1
             (excluding grade 2 alopecia and neuropathy)

          -  Chronic use of corticosteroids in excess of prednisone 30 mg/day or its equivalent

          -  Stem cell transplant recipients must have no evidence of and not receive treatment for
             graft-versus-host disease

          -  Concomitant use or use in the prior two weeks of moderate or strong CYP3A and CYP2C9
             inducers or strong CYP2C9 inhibitors, including nutraceutical preparations, e.g.,
             grapefruit juice and St John's wort

          -  History prior malignancy except:

               -  Malignancy treated with curative intent and no known active disease present for
                  >= 2 years prior to initiation of therapy on current study

               -  Adequately treated non-melanoma skin cancer or lentigo maligna (melanoma in situ)
                  without evidence of disease

               -  Adequately treated in situ carcinomas (e.g., cervical, esophageal, etc.) without
                  evidence of disease

               -  Asymptomatic prostate cancer managed with ""watch and wait"" strategy

               -  Myelodysplastic syndrome which is clinically well controlled and no evidence of
                  the cytogenetic abnormalities characteristic of myelodysplasia on the bone marrow
                  at screening

          -  Uncontrolled immune hemolysis or thrombocytopenia (positive direct antiglobulin test
             in absence of hemolysis or history of immune-mediated cytopenias are not exclusions)

          -  History of human immunodeficiency virus (HIV) infection or active hepatitis B or C

          -  Major surgery (requiring general anesthesia) within 2 weeks prior to initiation of
             therapy

          -  Inability to swallow and retain an oral medication; patients with clinically
             significant medical condition of malabsorption, inflammatory bowel disease, chronic
             conditions which manifest with diarrhea, refractory nausea, vomiting or any other
             condition that will interfere significantly with drug absorption are excluded;
             patients must also have adequate venous access

          -  Need for ongoing therapy with proton pump inhibitors; H2 antagonists are allowed

          -  Active uncontrolled infection

          -  Women who are pregnant or lactating

          -  Fertile men or women of childbearing potential unless 1) permanently sterile or 2)
             using a highly effective measure of contraception such as condoms in males and
             consistent and correct use of one of the following in females: intrauterine device,
             tubal sterilization, Essure micro-insert system, vasectomy in the male partner;
             effective contraception is required for males during treatment with study drug and to
             continue for 3 months after the last dose of either entospletinib or obinutuzumab,
             whichever is later; for women, effective contraception is required to continue for 18
             months after the last dose of obinutuzumab or for 30 days after the last dose of
             entospletinib, whichever is later

               -  Definition of childbearing potential: for this study, a female subject is
                  considered of childbearing potential until becoming post-menopausal unless
                  permanently sterile or with medically documented ovarian failure; women are
                  considered to be in a postmenopausal state when >= 54 years of age with cessation
                  of previously occurring menses for >= 12 months without an alternative cause;
                  women of any age with amenorrhea of >= 12 months may also be considered
                  post-menopausal if their follicle stimulating hormone (FSH) level is in the
                  post-menopausal range and they are not using hormonal contraception or hormonal
                  replacement therapy; permanent sterilization in females includes hysterectomy,
                  bilateral oophorectomy, or bilateral salpingectomy in a female subject of any
                  age; permanent sterilization in males include bilateral orchiectomy or medical
                  documentation of alternative explanation

          -  Any condition for which participation in the study is judged by the Investigator to be
             detrimental to the patient with inter-current illness or psychiatric/social situations
             that would jeopardize compliance with study requirements
      "
NCT02504892,terminated,"
    study was terminated due to slow, insufficient accrual.
  ",0,phase 2,"['renal cancer', 'birt-hogg-dube syndrome']","[""['C65.1', 'C65.2', 'C65.9', 'D30.10', 'D30.11', 'D30.12', 'C64.1']"", ""['D68.61', 'D69.41', 'D81.4', 'E24.1', 'E26.01', 'E26.81', 'E34.0']""]",['everolimus'],['CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC'],"
        -  INCLUSION CRITERIA:

          -  Patients must have a clinical diagnosis of Birt-Hogg-Dub (Copyright) Syndrome
             (clinical features consistent with BHD and /or a germline Folliculin (FLCN) mutation)
             and the presence of localized, locally advanced or advanced, renal tumor(s).

          -  Patients must have measurable disease, as defined by Response Evaluation Criteria in
             Solid Tumors (RECIST) 1.1

          -  Age greater than or equal to 18 years.

          -  Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 1
             (Karnofsky greater than or equal to 70%).

          -  Patients must have normal organ and marrow function as defined below:

        leukocytes greater than or equal to 3,000/mcL

        absolute neutrophil count greater than or equal to 1,500/mcL

        platelets greater than or equal to 100,000/mcL

        total bilirubin less than or equal to 2mg/dL

        Aspartate aminotransferase (AST) Serum glutamic oxaloacetic transaminase(SGOT)/Alanine
        aminotransferase (ALT) Serum glutamic pyruvic transaminase(SGPT) greater than or equal to
        2.5 times institutional upper limit of normal (ULN) (greater than or equal to 5 times ULN
        in patients with liver metastases)

        creatinine less than or equal to 2.0 times ULN

        OR

        creatinine clearance greater than or equal to 30 mL/min/1.73 m(2)

        fasting serum cholesterol less than or equal to 300 mg/dL OR less than or equal to 7.75
        mmol/L

        AND

        fasting triglycerides less than or equal to 2.5 times ULN

        NOTE: In case one or both of these thresholds (for fasting serum cholesterol or
        triglyceride) are exceeded, the patient can only be included after initiation of
        appropriate lipid lowering medication.

          -  No history of major bleeding, recent or active myocardial ischemia, gastrointestinal
             (GI) perforation, cerebrovascular accidents or other significant illness.

          -  Recovery from acute toxicity of prior treatment for renal cell carcinoma (RCC) (to
             less than or equal to grade 1 the active version of Common Terminology Criteria for
             Adverse Events (CTCAE) or to a level permitted under other sections of Inclusion/
             Exclusion criteria). Additionally, in patients who have received standard or
             experimental treatments for their RCC at least approximately 5 half-lives should have
             elapsed from the last dose at the time of study entry.

          -  No prior therapy with an mTOR-pathway inhibitor.

          -  Ability of subject to understand and the willingness to sign a written informed
             consent document.

        EXCLUSION CRITERIA:

          -  Patients currently receiving anticancer therapies (including chemotherapy, radiation
             therapy, antibody based therapy, etc.).

          -  Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g.
             sirolimus, temsirolimus).

          -  Patients with known brain metastases unless treated with an appropriate modality with
             no evidence of progression/recurrence for >3months

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection requiring intravenous (IV) antibiotics, invasive fungal infection, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
             therapy are ineligible because of the potential for pharmacokinetic interactions with
             everolimus. Known impairment of gastrointestinal (GI) function or GI disease that may
             significantly alter the absorption of oral everolimus.

          -  Uncontrolled diabetes mellitus as defined by hemoglobin A1c (HbA1c) >8% despite
             adequate therapy. Patients with a known history of impaired fasting glucose or
             diabetes mellitus (DM) may be included, however blood glucose and antidiabetic
             treatment must be monitored closely throughout the trial and adjusted as necessary.

          -  Patients who have any severe and/or uncontrolled medical conditions such as:

               1. unstable angina pectoris, symptomatic congestive heart failure, myocardial
                  infarction less than or equal to 6 months prior to start of everolimus, serious
                  uncontrolled cardiac arrhythmia, or any other clinically significant cardiac
                  disease.

               2. Symptomatic congestive heart failure of New York heart Association Class III or
                  IV.

               3. known severely impaired lung function (spirometry and diffusing capacity of the
                  lung for carbon monoxide (DLCO) 50% or less of normal and oxygen (O2) saturation
                  88% or less at rest on room air).

               4. active, bleeding diathesis.

          -  Chronic (treatment > 1 month) or ongoing treatment with corticosteroids or other
             immunosuppressive agents. Topical or inhaled corticosteroids are allowed.

          -  Patients who have received live attenuated vaccines within 1 week of start of
             everolimus Examples of live attenuated vaccines include intranasal influenza, measles,
             mumps, rubella, oral polio, Bacillus Calmette-Guerin (BCG), yellow fever, varicella
             and typhoid vaccine) TY21a typhoid vaccines.

          -  Patients, who in the opinion of the investigator, are unlikely to comply with
             follow-up visits or other study requirements. Patients who are currently part of or
             have participated in any clinical investigation with an investigational drug within 1
             month prior to dosing.

          -  Pregnant or nursing (lactating) women.

          -  Women of child-bearing potential (WOCBP), defined as all women physiologically capable
             of becoming pregnant, who do not agree to use highly effective methods of
             contraception during the study and 8 weeks after.

               -  Highly effective contraception methods include combination of any two of the
                  following:

                    1. Use of oral, injected or implanted hormonal methods of contraception or;

                    2. Placement of an intrauterine device (IUD) or intrauterine system (IUS);

                    3. Barrier methods of contraception: condom or occlusive cap (diaphragm or
                       cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal
                       suppository;

                    4. Total abstinence or;

                    5. Male/female sterilization.

        Women are considered post-menopausal and not of child-bearing potential if they have had 12
        months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age
        appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy
        (with or without hysterectomy) or tubal ligation at least six weeks prior to randomization.
        In the case of oophorectomy alone, only when the reproductive status of the woman has been
        confirmed by follow up hormone level assessment is she considered not of child-bearing
        potential.

          -  Male patients whose sexual partner(s) are WOCBP who are not willing to use adequate
             contraception, during the study and for 8 weeks after the end of treatment.

          -  Prior invasive malignancy of other histology currently requiring treatment.

          -  Patients with active Hepatitis B (detectable hepatitis B virus-deoxyribonucleic acid
             (HBV-DNA) or hepatitis B virus surface antigen (HBsAg +) or Hepatitis C infection
             (detectable hepatitis C virus ribonucleic acid (HCV RNA) by polymerase chain reaction
             (PCR)

          -  Patients who are currently on or have used potent or moderate inhibitors or strong
             inducers Cytochrome P450 3A4 (CYP3A4) or P-glycoprotein (PgP) inhibitors in the past 2
             weeks
      "
NCT02504346,"active, not recruiting",,1,phase 2,"['lung cancer', 'targeted therapy']","[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]",['azd9291'],['CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC'],"
        Inclusion Criteria:

          1. Provision of signed and dated, written informed consent.

          2. Age > 18 years.

          3. Histologically or cytologically documented locally advanced or metastatic NSCLC not
             amenable to curative surgery or radiotherapy.

          4. Radiological disease progression following at least one prior EGFR TKI.

          5. Documented EGFR mutation known to be associated with EGFR TKI sensitivity (also
             including T790M).

          6. ECOG status 0-2 and a minimum life expectancy of 12 weeks.

          7. At least one lesion, not previously irradiated and not chosen for biopsy during the
             study screening period, that can be accurately measured at baseline according to
             RECIST 1.1.

          8. Females should be using adequate contraceptive measures, should not be breast feeding
             and must have a negative pregnancy test prior to start of dosing if of child-bearing
             potential or must have evidence of non-child-bearing potential by fulfilling one of
             the following criteria at screening:

               -  Post-menopausal defined as aged more than 50 years and amenorrhoeic for at least
                  12 months following cessation of all exogenous hormonal treatments

               -  Women under 50 years old would be considered postmenopausal if they have been
                  amenorrheic for 12 months or more following cessation of exogenous hormonal
                  treatments and with Luteinizing Hormone (LH) and Follicle-Stimulating Hormone
                  (FSH) levels in the post-menopausal range for the institution

               -  Documentation of irreversible surgical sterilisation by hysterectomy, bilateral
                  oophorectomy or bilateral salpingectomy but not tubal ligation.

          9. Male subjects must be willing to use barrier contraception.

             -

        Exclusion Criteria:

          -  1. Treatment with an EGFR-TKI within 8 days or approximately 5x half-life, whichever
             is the longer, of the first dose of study treatment.

             2. Treatment with cytotoxic chemotherapy, investigational agents or other anticancer
             drugs from a previous treatment regimen or clinical study within 14 days or
             approximately 5x half-life, whichever is the longer, of the first dose of study
             treatment.

             3. Previous treatment with AZD9291, or another EGFR TKI with similar profile, e.g.
             CO-1686 4. Major surgery within 4 weeks of inclusion 5. Radiotherapy treatment to more
             than 30% of the bone marrow or with a wide field of radiation within 4 weeks of
             inclusion 6. Subjects currently receiving (or unable to stop using) potent inhibitors
             or inducers of CYP3A4 7. Any unresolved toxicities from prior therapy greater than
             CTCAE grade 1 (with the exception of alopecia grade 2) at the time of starting study
             treatment.

             8. Spinal cord compression or brain metastases unless asymptomatic and on stable
             steroid dosage for at least 2 weeks prior to start of study treatment.

             9. Any evidence of severe or uncontrolled systemic diseases which in the
             investigator's opinion makes it undesirable for the subject to participate in the
             trial or which would jeopardise compliance with the protocol, or active infection
             including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening
             for chronic conditions is not required.

             10. Gastrointestinal conditions incompatible with swallowing or precluding absorption
             of AZD9291.

             11. Exclude based on any of the following cardiac criteria:

          -  Mean resting corrected QT interval (QTc using Fredericia's formula) > 470 msec

          -  Any clinically important abnormalities in rhythm, conduction or morphology of resting
             ECG (e.g., complete left bundle branch block, third degree heart block, second degree
             heart block)

          -  Any factors that increase the risk of QTc prolongation or risk of arrhythmic events
             such as heart failure, hypokalemia, congenital long QT syndrome, family history of
             long QT syndrome or unexplained sudden death under 40 years of age in first degree
             relatives or any concomitant medication known to prolong the QT interval 12. Current
             or previous significant interstitial lung disease or radiation pneumonitis 13.
             Absolute neutrophil count < 1.5 x 109/L 14. Platelet count < 100 x 109/L 15.
             Haemoglobin < 80 g/L 16. Alanine aminotransferase (ALT) > 2.5 times the upper limit of
             normal (ULN) if no demonstrable liver metastases or > 5 times ULN in the presence of
             liver metastases 17. Aspartate aminotransferase (AST) > 2.5 times ULN if no
             demonstrable liver metastases or > 5 times ULN in the presence of liver metastases 18.
             Total bilirubin > 1.5 times ULN if no liver metastases or > 3 times ULN in the
             presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinaemia) or liver
             metastases 19. Creatinine >1.5 times ULN concurrent with creatinine clearance < 50
             ml/min (measured or calculated by Cockcroft and Gault equation), 20. History of
             hypersensitivity of AZD9291 (or drugs with a similar chemical structure or class.

             21. Women who are pregnant or breast-feeding, or have a positive (urine or serum)
             pregnancy test prior to study entry 22. Judgment by the investigator that the subject
             should not participate in the study if the subject is unlikely to comply with study
             procedures, restrictions and requirements.
      "
NCT02500576,completed,,0,phase 2,"['metastatic melanoma', 'stage iiib cutaneous melanoma ajcc v7', 'stage iiic cutaneous melanoma ajcc v7', 'stage iv cutaneous melanoma ajcc v6 and v7']","[""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']"", ""['A06.7', 'A22.0', 'A26.0', 'A32.0', 'A36.3', 'A43.1', 'B38.3']"", ""['A06.7', 'A22.0', 'A26.0', 'A32.0', 'A36.3', 'A43.1', 'B38.3']"", ""['A06.7', 'A22.0', 'A26.0', 'A32.0', 'A36.3', 'A43.1', 'B38.3']""]","['cyclophosphamide', 'fludarabine phosphate']","['C1CNP(=O)(OC1)N(CCCl)CCCl', 'C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)COP(=O)(O)O)O)O)F)N']","
        Inclusion Criteria:

          -  TURNSTILE I - SCREENING:

          -  Patients must have metastatic melanoma or stage III in-transit, subcutaneous, or
             regional nodal disease

          -  Patients must have a lesion amenable to resection for the generation of TIL on MD
             Anderson protocol 2004-0069

          -  Patients must receive a magnetic resonance imaging (MRI)/computed tomography
             (CT)/positron emission tomography (PET) of the brain within 6 months of signing
             informed consent; if new central nervous system (CNS) lesions are present, patient
             must have definitive treatment (including surgery or radiation); principal
             investigator (PI) or his designee should make final determination regarding enrollment

          -  Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 - 1 within
             30 days of signing informed consent

          -  Patients previously treated with immunotherapy, targeted therapy, or no therapy
             (treatment naive) will be eligible

          -  Patients receiving cytotoxic agents will be evaluated by the PI or his designee for
             eligibility suitability

          -  Patients with a negative pregnancy test (urine or serum) must be documented within 14
             days of screening for women of childbearing potential (WOCBP); a WOCBP has not
             undergone a hysterectomy or who has not been naturally postmenopausal for at least 12
             consecutive months (i.e. who has not had menses at any time in the preceding 12
             consecutive months)

          -  TURNSTILE II - TREATMENT:

          -  Patients must sign the treatment consent document before Turnstile II screening
             procedures; before the treatment starts and at each visit, the patient will be asked
             to complete two quality of life questionnaires; It should take about 15 minutes to
             complete the questionnaires (Functional Assessment of Cancer Therapy General [FACT-G],
             FACT-Melanoma); patients must fulfill all of the following criteria to be eligible for
             Turnstile II of the study

          -  Patients must have adequate TIL that were previously harvested and then cryopreserved
             on MD Anderson Cancer Center (MDACC) protocol 2004-0069

          -  Patients who have had prior therapy (BRAF inhibitors, ipilimumab, anti PD-1 antibody
             or anti PD-L1 antibody) or treatment naive patients are eligible as long as toxicity
             from therapy is grade =< 1 or at baseline

          -  Patients must have at least one biopsiable measurable metastatic melanoma, lesion > 1
             cm and must be amenable to undergoing serial biopsies through the course of therapy;
             this lesion must not be documented as one of the target lesions

          -  Patients may have central nervous system (CNS) metastases which have been treated and
             are radiographically stable for at least 4 weeks

          -  Patients of both genders must practice birth control for four months after receiving
             the preparative regimen (lymphodepletion) and continue to practice birth control
             throughout the study; patients must have a documented negative pregnancy test (urine
             or serum) for women who have menstruated in the past 12 months and without
             sterilization surgery

          -  Unless surgically sterile by bilateral tubal ligation or vasectomy of partner(s), or
             if the patient is post-menopausal, the patient agrees to continue to use a barrier
             method of contraception throughout the study such as: condom, diaphragm, hormonal,
             intrauterine device (IUD), or sponge plus spermicide; abstinence is an acceptable form
             of birth control

          -  Pregnancy testing will be performed within 14 days of screening for women of
             childbearing potential (WOCBP); a WOCBP has not undergone a hysterectomy or who has
             not been naturally postmenopausal for at least 12 consecutive months (i.e. who has not
             had menses at any time in the preceding 12 consecutive months)

          -  Clinical performance status of ECOG 0-1 within 30 days of signing informed consent

          -  A stress cardiac test (stress thallium, stress multi-gated acquisition scan [MUGA],
             dobutamine echocardiogram or other stress test that will rule out cardiac ischemia)
             within 1 month of lymphodepletion

          -  12-lead electrocardiogram (EKG) showing no active ischemia and corrected QT (QTc)
             interval less than 480 msec

          -  Pulmonary function tests (forced expiratory volume in 1 second [FEV1] > 65% or forced
             vital capacity [FVC] > 65% of predicted) within 1 month of lymphodepletion

          -  Have measurable disease based on RECIST 1.1 and immune related response (irRC)
             criteria

          -  Absolute neutrophil count (ANC) >= 1,500 /mcL (within 10 days of treatment initiation)

          -  Platelets >= 100,000 /mcL (within 10 days of treatment initiation)

          -  Hemoglobin >= 9 g/dL or >= 5.6 mmol/L (within 10 days of treatment initiation)

          -  Serum creatinine OR measured or calculated creatinine clearance (glomerular filtration
             rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) =<
             1.5 X upper limit of normal (ULN) OR >= 60 mL/min for subject with creatinine levels >
             1.5 X institutional ULN (within 10 days of treatment initiation)

          -  Serum total bilirubin =< 1.5 X ULN (within 10 days of treatment initiation) OR

          -  Direct bilirubin =< ULN for subjects with total bilirubin levels > 1.5 ULN (within 10
             days of treatment initiation)

          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X
             ULN or =< 5 X ULN for subjects with liver metastases (within 10 days of treatment
             initiation)

          -  International normalized ratio (INR) or prothrombin time (PT)/activated partial
             thromboplastin time (aPTT) =< 1.5 X ULN unless subject is receiving anticoagulant
             therapy as long as PT or PTT is within therapeutic range of intended use of
             anticoagulants =< 1.5 X ULN unless subject is receiving anticoagulant therapy as long
             as PT or PTT is within therapeutic range of intended use of anticoagulants

        Exclusion Criteria:

          -  TURNSTILE I - SCREENING

          -  Active systemic infections requiring intravenous antibiotics, coagulation disorders or
             other major medical illnesses of the cardiovascular, respiratory or immune system; PI
             or his designee shall make the final determination regarding appropriateness of
             enrollment

          -  Primary immunodeficiency and need for chronic steroid therapy, exception: patients on
             chronic physiological dose of steroid equivalent to prednisone < 10 mg/day is allowed

          -  Patients who are pregnant or nursing

          -  Presence of a significant psychiatric disease, which in the opinion of the principal
             investigator or his designee, would prevent adequate informed consent

          -  TURNSTILE II - TREATMENT

          -  Is currently participating in or has participated in a study of an investigational
             agent or using an investigational device within 4 weeks of the first dose of treatment

          -  Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
             other form of immunosuppressive therapy within 7 days prior to initiation of
             lymphodepletion; exception: patients on chronic physiologic dose of steroid equivalent
             to prednisone < 10 mg/day is allowed

          -  Has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to
             investigational or standard agents administered more than 4 weeks earlier

          -  Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy
             within 2 weeks prior to lymphodepletion or who has not recovered (i.e., =< grade 1 or
             at baseline) from adverse events due to a previously administered agent

               -  Note: subjects with =< grade 2 neuropathy, alopecia, hypophysitis stable on
                  physiologic dose of steroid equivalent to prednisone < 10 mg/day, hypothyroidism
                  stable on hormone replacement are an exception to this criterion and may qualify
                  for the study

               -  Note: if subject received major surgery, they must have recovered adequately from
                  the toxicity and/or complications from the intervention prior to starting therapy

          -  Has a known additional malignancy that is progressing or requires active treatment;
             exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the
             skin, or in situ cervical cancer that has undergone potentially curative therapy

          -  Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis; subjects with previously treated brain metastases may participate provided
             they are stable (without evidence of progression by imaging for at least four weeks
             prior to the first dose of trial treatment and any neurologic symptoms have returned
             to baseline), have no evidence of new or enlarging brain metastases, and are not using
             steroids for at least 7 days prior to initiation of lymphodepletion

          -  Has an active autoimmune disease requiring systemic treatment within the past 3 months
             or a documented history of clinically severe autoimmune disease; subjects with
             vitiligo or resolved childhood asthma/atopy would be an exception to this rule;
             subjects that require intermittent use of bronchodilators or local steroid injections
             would not be excluded from the study; subjects with hypothyroidism stable on hormone
             replacement or Sjogren's syndrome will not be excluded from the study; subjects with
             hypophysitis stable on physiologic dose of steroid will not be excluded from the study

          -  Has evidence of interstitial lung disease or has a history of non-infectious
             pneumonitis that required steroids or current pneumonitis

          -  Has an active infection requiring systemic therapy

          -  Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial

          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the pre-screening or screening visit
             through 120 days after the last dose of trial treatment

          -  Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)

          -  Has known active hepatitis B (e.g., hepatitis B virus HBsAg surface protein antigen
             [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA]
             [qualitative] is detected)

          -  Has received a live vaccine within 30 days prior to the first dose of trial treatment

          -  Any active systemic infections requiring intravenous antibiotics, coagulation
             disorders or other major medical illnesses of the cardiovascular, respiratory or
             immune system, such as abnormal stress thallium or comparable test, myocardial
             infarction, cardiac arrhythmias, obstructive or restrictive pulmonary disease; PI or
             his designee shall make the final determination regarding appropriateness of
             enrollment
      "
NCT02508077,terminated,"
    poor accrual
  ",0,phase 2,"['recurrent colorectal carcinoma', 'stage iva colorectal cancer', 'stage ivb colorectal cancer']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['fluorouracil', 'irinotecan hydrochloride', 'leucovorin calcium']","['C1=C(C(=O)NC(=O)N1)F', 'CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl', 'C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)[O-])C(=O)[O-].[Ca+2]']","
        Inclusion Criteria:

          -  Participant must have the ability to understand and the willingness to sign a written
             informed consent document

          -  Participant must be willing to comply with study and/or follow-up procedures

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Life expectancy of 3 >= months

          -  Histologically confirmed colon or rectal cancer with metastatic disease

          -  Extended RAS and BRAF wild type status documented on archival tumor tissue or on fresh
             biopsy if no archival tissue present

          -  Measurable disease defined by at least 1 lesion >= 1 cm

          -  Documented objective response or stable disease lasting for 6 months or more to last
             prior anti-EGFR (cetuximab or panitumumab) in combination with irinotecan or FOLFIRI

          -  Progression within 6 weeks following their last dose of anti-EGFR therapy

          -  Treatment with a non-EGFR targeting regimen following progression on anti-EGFR plus
             irinotecan-based therapy

          -  At least 4 months from prior anti-EGFR therapy prior to start of study treatment

          -  At least three weeks from any non-anti-EGFR therapy prior to start of study treatment;
             any number of prior therapies is permitted

          -  Adequate recovery in the investigators opinion from any clinically significant
             toxicity from prior therapy

          -  Absolute neutrophil count (ANC) >= 1.5 x 10^9/L

          -  Hemoglobin (Hgb) >= 9 g/dL without transfusions

          -  Platelets (PLT) >= 100 x 10^9/L without transfusions

          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])
             and/or alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =< 2.5 x upper limit of normal (ULN); patient with liver metastases =< 5 x ULN

          -  Total bilirubin =< ULN

          -  Creatinine =< 1.5 mg/dL

          -  Magnesium >= 1.2mg/dL or 0.5 mmol/L

          -  Negative serum beta-human chorionic gonadotropin (HCG) test (female patient of
             childbearing potential only), to be performed locally within the screening period

          -  Agreement by females of childbearing potential and sexually active males to use an
             effective method of contraception (hormonal or barrier method of birth control or
             abstinence) prior to study entry and for three months following duration of study
             participation; should a woman become pregnant or suspect that she is pregnant while
             participating on the trial, she should inform her treating physician immediately

        Exclusion Criteria:

          -  History of severe anti-EGFR toxicity requiring drug discontinuation or
             dose-modification within the first 4 months of prior anti-EGFR therapy

          -  History of intolerance to irinotecan at dose-intensity of 125 mg/m^2/2 weeks or lower

          -  History of intolerance to 5-FU at dose-intensity of 1800 mg/m^2/2 weeks or lower

          -  Current use (or planned use during the treatment period) of other investigational
             agents, or biological, chemotherapy, radiation or other anti-tumor therapy

          -  Co-medication that may interfere with study results; e.g. immuno-suppressive agents
             other than corticosteroids, such as systemic cyclosporine and tacrolimus

          -  No St John's wort supplement or other herbal supplementation is allowed while on
             trial; patients are not to take grapefruit juice during study treatment

          -  Use of drugs known to inhibit UDP glycosyltransferase 1 family, polypeptide A1 gene
             (UGT1A1), such as Atazanavir, Gemfibrozil, Indinavir, or Ketoconazole while on study
             treatment; (patients using these drugs must not take these drugs on the day study
             treatment begins and for the duration of study treatment)

          -  Planned use of strong cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4)
             inhibitors or CYP3A4 inducers while on study treatment unless deemed clinically
             necessary with no reasonable alternatives and with expressed permission from the
             principal investigator

          -  If on anticoagulation, participant must be on stable therapeutic dose prior to
             enrollment

          -  Impairment of gastrointestinal function or gastrointestinal disease (e.g., active
             ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome,
             extensive small bowel resection)

          -  Major surgery =< 3 weeks prior to starting study drug or who have not recovered from
             side effects of such procedure

          -  Unstable pulmonary embolism, deep vein thrombosis, or other significant
             arterial/venous thromboembolic event =< 30 days before enrollment

          -  Clinically significant cardiovascular disease (including myocardial infarction,
             unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac
             arrhythmia) =< 6 months prior to enrollment

          -  History of interstitial lung disease (ILD) eg, interstitial pneumonitis, pulmonary
             fibrosis or evidence of ILD on baseline chest computed tomography (CT) or magnetic
             resonance imaging (MRI)

          -  Other active malignancies except cervical carcinomas in situ or clinically
             insignificant non-melanoma skin cancers

          -  Clinically significant uncontrolled illness or active infections

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to irinotecan, 5-FU, leucovorin or any of the products to be administered
             during dosing

          -  Pregnant women and women who are lactating; breastfeeding should be discontinued if
             the mother is enrolled on this study

          -  Any other condition that would, in the Investigator's judgment, contraindicate the
             patient's participation in the clinical study due to safety concerns or compliance
             with clinical study procedures, e.g., infection/inflammation, intestinal obstruction,
             unable to swallow medication, social/psychological issues, etc

          -  Prospective participants who, in the opinion of the investigator, may not be able to
             comply with all study procedures (including compliance issues related to
             feasibility/logistics)
      "
NCT02354690,completed,,0,phase 1/phase 2,['metastatic melanoma'],"[""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']""]","['vemurafenib', 'lymphodepleting chemotherapy', 'til infusion', 'interleukin-2']",['CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F'],"
        Inclusion Criteria:

          -  Histologically confirmed unresectable stage III or stage IV metastatic melanoma.

          -  Metastasis available for surgical resection (about 2 cm3) and residual measureable
             disease after resection.

          -  Pathologically verified BRAF mutation.

          -  ECOG performance status 0-1.

          -  Life expectancy ≥ 3 months.

          -  No significant toxicity (CTC ≤ 1) from prior treatments.

          -  Adequate renal, hepatic and hematologic function.

          -  Women of childbearing potential (WOCBP) and men in a sexual relationship with a WOCBP
             must be using an effective method of contraception during treatment and for at least 6
             months after completion of treatment.

          -  Able to comprehend the information given and willing to sign informed consent.

        Exclusion Criteria:

          -  Other malignancies, unless followed for ≥ 5 years with no sign of disease, except
             squamous cell carcinoma or adequately treated carcinoma in situ colli uteri.

          -  Cerebral metastasis. Patients with previously treated CNS metastasis can participate
             if surgically removed or treated with stereotactic radiotherapy if stable > 28 days
             after treatment measured by MRI. Patients with asymptomatic and untreated CNS
             metastasis can participate based on investigators evaluation.

          -  Patients with ocular melanoma.

          -  Previous treatment with a BRAF inhibitor.

          -  Severe allergies, history of anaphylaxis or known allergies to drugs administered.

          -  Serious medical or psychiatric comorbidity.

          -  QTc ≥ 450 ms.

          -  Clearance < 70 ml/min.

          -  Acute or chronic infection with e.g. HIV, hepatitis, tuberculosis

          -  Active autoimmune disease.

          -  Pregnant og nursing women.

          -  Need for immunosuppressive treatment, e.g. corticosteroids or methotrexate.

          -  Concomitant treatment with other experimental drugs.

          -  Patients with uncontrolled hypercalcemia

          -  More than four weeks must have elapsed since any prior systemic therapy at the time of
             treatment
      "
NCT02354131,completed,,1,phase 1/phase 2,['ovarian cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['niraparib', 'bevacizumab']",['C1CC(CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N'],"
        Inclusion Criteria:

        A patient will be eligible for inclusion only if all of the following criteria are
        fulfilled:

          1. Recurrent platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer
             (platinum sensitivity defined as no recurrence within 6 months of last receipt of
             platinum/chemotherapy).

          2. High-grade serious or high-grade endometrioid histology.

          3. Patient consents to perform HRD test.

               -  Patients with known BRCA status: BRCA positive patients must submit the tissue
                  for HRD test, though these patients need not to wait for HRD test results and can
                  be randomized in HRD positive stratum.

               -  If tumor tissue is not sufficient to perform HRD test: these patients shall be
                  randomized in HRD negative stratum as HRD unknown.

          4. Prior line of therapy: Patients must have received platinum-containing therapy for
             primary disease.

               -  No limits on number of platinum-based therapies. Population of patients who has
                  previously received ≥ 3 lines of therapy for relapsed disease will be capped at
                  40%.

               -  Up to one non-platinum-based line of therapy in recurrent setting.

               -  Patients who are treated with bevacizumab just prior to entering in the trial
                  must not have progressed under or within 3 months after bevacizumab.

               -  Patients may have participated in a PARP inhibitor trial as first-line
                  maintenance therapy and have not progressed within 3 months after PARP/placebo.
                  Patients who received PARP inhibitor after relapse (definitive or maintenance
                  therapy) are not eligible.

          5. Target group: Age 18+

          6. Histological confirmed ovarian, fallopian tube or peritoneal cancers

          7. Patients must give informed consent

          8. Patients may have undergone primary or interval debulking surgery

          9. Patients may have received bevacizumab though no other prior use of anti-angiogenic
             therapy

         10. Patients may have received a PARP inhibitor as first-line maintenance therapy.

         11. Patients must have disease that is measurable according to RECIST or assessable
             according to the GCIG criteria

         12. The patient agrees to complete PROs (QoL questionnaire) during study treatment AND at
             one additional time point 8 weeks following progression of disease

         13. ECOG performance status 0-2

         14. Adequate organ function

               -  Absolute neutrophil count (ANC) ≥1,5 x 109/L

               -  Platelets >100 x 109/L

               -  Hemoglobin ≥ 9g/dl

               -  Serum creatinine ≤1.5x upper limit of normal (ULN) or calculated creatinine
                  clearance ≥50mL/min using Cockcroft-Gault formula

               -  Total bilirubin ≤1.5x ULN

               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5x ULN
                  unless liver metastases are present, in which case they must be ≤5x ULN.

         15. Able to take oral medications

         16. Life expectancy of at least 12 weeks

         17. Patients must fulfill all inclusions criteria and according to investigator fit to
             receive niraparib and/or bevacizumab.

         18. Women of childbearing potential must use adequate birth control for the duration of
             study participation

        Exclusion Criteria:

        A patient will not be eligible for inclusion if any of the following criteria are
        fulfilled:

          1. Ovarian sarcomas, small cell carcinoma with neuroendocrine differentiation,
             non-epithelial cancers and cancer types not mentioned in the inclusion criteria

          2. Concurrent cancer therapy

          3. Concurrent treatment with an investigational agent or participation in another
             clinical trial

          4. Major injuries or surgery within the past 21 days prior to start of study treatment
             with incomplete wound healing and/or planned surgery during the on-treatment study
             period

          5. Previous malignant disease: patients are not eligible for the study if diagnosis,
             detection or treatment of invasive cancer (other than ovarian cancer; with the
             exception of basal or squamous cell carcinoma of the skin that was definitively
             treated) was detected within 2 years prior to randomization

          6. Active infections or other serious underlying significant medical illness, abnormal
             laboratory finding or psychiatric illness/social situation that would, in the
             Investigator's judgment, makes the patient inappropriate for this study

          7. Gastrointestinal disorders or abnormalities that would interfere with absorption of
             the study drug

          8. History of bowel obstruction, including sub-occlusive disease, related to the
             underlying disease and history of abdominal fistula, gastrointestinal perforation or
             intra-abdominal abscess. Evidence of recto-sigmoid involvement by pelvic examination
             or bowel involvement on CT scan or clinical symptoms of bowel obstruction

          9. Known contraindications to PARP inhibitors or VEGF directed therapy

         10. Known uncontrolled hypersensitivity to the investigational drugs

         11. History of major thromboembolic event defined as:

               -  Uncontrolled pulmonary embolism (PE)

               -  Deep venous thrombosis (DVT)

               -  Other related conditions, though patients with stable therapeutic anticoagulation
                  for more than three months prior randomization are eligible for this study. This
                  also apply to PE & DVT.

         12. History of a cerebral vascular accident, transient ischemic attack or subarachnoid
             hemorrhage within the past 3 months

         13. History of clinically significant hemorrhage in the past 3 months

         14. Uncontrolled and/or symptomatic CNS metastasis or leptomeningeal carcinomatosis
             (Dexamethasone/prednisone therapy will be allowed if administered as stable dose for
             at least one month prior randomization)

         15. Significant cardiovascular diseases, including uncontrolled hypertension, clinically
             relevant cardiac arrhythmia, unstable angina or myocardial infarction within 6 months
             prior to randomization, congestive heart failure > NYHA III, severe peripheral
             vascular disease, QT prolongation >470 msec ,clinically significant pericardial
             effusion

         16. Pregnancy or breastfeeding. Patients with preserved reproductive capacity, unwilling
             to use a medically acceptable method of contraception for the duration of the trial
             and for 3 months afterwards.

         17. Radiographic evidence of cavitation or necrotic tumors with invasion of adjacent major
             blood vessels

         18. Active or chronic hepatitis C and/or B infection

         19. Persistence of clinically relevant therapy related toxicity from previous chemotherapy

         20. Proteinuria as demonstrated by: (a) urine protein: creatinine (UPC) ratio >/= 1.0 at
             screening OR (b) urine dipstick for proteinuria >/=2+ (patients discovered to have
             >/=2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hr urine
             collection and must demonstrate </=1g of protein in24 hours to be eligible

         21. Patients must not have any known history of MDS

         22. Patients must not have known persistent (> 4 weeks) ≥ Grade 2 hematological toxicity
             from prior cancer therapy

         23. Patients must not have known ≥ Grade 3 thrombocytopenia or anemia with the last
             chemotherapy regimen.
      "
NCT02352337,completed,,1,phase 2,['metastatic pancreatic cancer'],"[""['C25.3']""]","['folfirinox', 'lv5fu2', 'folfiri.3', 'gemcitabine']","['CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.C1CCC(C(C1)[NH-])[NH-].C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O.C1=C(C(=O)NC(=O)N1)F.C(=O)(C(=O)[O-])[O-].[Pt+4]', 'Status: 503']","
        Inclusion Criteria:

          -  Metastatic disease

          -  At least one mesurable lesion according to RECIST V1.1 criteria

          -  No prior chemotherapy (excepted if there is at least on lestion out of the irradition
             area)

          -  Age > 18 years. A favorable adviced by an onco geriatrician would be mandatory for
             inclusion of patients older than 75 older

          -  Performance statut (WHO) 0-1

          -  Polynyclear ≥ 1500/mm3

          -  Bilirubine ≤ 1,5 fois la LSN, creatinin < 120μmol / L

          -  Signed informed consent form

        Exclusion Criteria:

          -  Another type of pancreas tumor, as endocrine tumor ou with acinous cells

          -  Ampulloma

          -  Cerebral or meningeal metastasis

          -  Gilbert disease

          -  Neuropathie > or = grade 1

          -  Study treatments contraindication

          -  Uncontrolled diarrhoea or inflamatory disease of colon or rectum, or bowel obstruction
             or bowel sub-obstruction no resolved with specific treatment

          -  Serious uncontrolled intercurrent infections or other serious uncontrolled concomitant
             disease prevent patient to receive study Cancer within the 5 years before inclusion,
             except for int situ cancer of the neck of the uterus or basal cell skin cancer

          -  Significant previous cardiac and respiratory disease

          -  Patient included in an other therapeutic study with experimental treatment

          -  Pregnancy or breast feeding

          -  Patient depreved of freedom or under gardianship

          -  Psychological, familial, sociological or geographical condition potentially hampering
             compliance with the study protocol and follow-up schedule
      "
NCT02354586,completed,,1,phase 2,"['ovarian neoplasms', 'ovarian cancer']","[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]",['niraparib'],['C1CC(CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N'],"
        Inclusion Criteria:

          -  Patients must agree to undergo tumor HRD testing and blood gBRCAmut status testing.

          -  Patients of childbearing potential must have negative pregnancy serum test within 72
             hours of being dosed

          -  Patients must have histologically diagnosed high-grade (Grade 2 or 3) serous
             epithelial ovarian, fallopian tube, or primary peritoneal cancer with recurrent
             disease and must have been previously treated with chemotherapy and experienced a
             response lasting at least 6 months to first-line platinum based therapy.

          -  Patients Must have completed 3 or 4 previous chemotherapy regimens.

          -  Patients must have completed their last chemotherapy regimen > 4 weeks prior to
             treatment initiation.

          -  Patients must have measurable disease according to RECIST (v.1.1).

          -  Patients must have formalin-fixed, paraffin-embedded tumor samples available from the
             primary or recurrent cancer or agree to undergo fresh biopsy prior to study treatment
             initiation.

          -  Patients must agree to blood samples during screening and at the end of treatment for
             cytogenetic analysis.

        Exclusion Criteria:

          -  Patients must not have any known, persistent (> 4 weeks), ≥Grade 3 hematologic
             toxicity during the last cancer therapy. Patients must not have any known, persistent
             (>4 weeks), ≥ Grade 3 fatigue during the last cancer therapy.

          -  Patients must not have received pelvic radiotherapy as treatment for primary or
             recurrent disease within 1 year of the first dose of study treatment.

          -  Patients must not have symptomatic uncontrolled brain or leptomeningeal metastases.

          -  Patients must not be considered a poor medical risk due to a serious, uncontrolled
             medical disorder, nonmalignant systemic disease or active, uncontrolled infection.

          -  Patients must not have received a transfusion (platelets or red blood cells) within 4
             weeks of the first dose of study treatment.

          -  Patients must not have known history or current diagnosis of myelodysplastic syndrome
             (MDS) or acute myeloid leukemia (AML).
      "
NCT02354976,completed,,0,phase 2,"['non-alcoholic fatty liver disease (nafld', 'hypertriglyceridemia']","[""['Z52.6', 'K71.8', 'K71.7', 'A06.4', 'C22.0', 'C22.3', 'K70.0']""]","['placebo', 'omega-3 carboxylic acid', 'fenofibrate 200mg', 'placebo']",['CCCCCC=CCC=CCCCCCCCC(=O)O.CCCCCC=CCC=CCC=CCCCCC(=O)O.CCCCCC=CCC=CCC=CCC=CCC=CCCC(=O)O.CCC=CCC=CCC=CCCCCCCCC(=O)O.CCC=CCC=CCC=CCC=CCCCCCCC(=O)O.CCC=CCC=CCC=CCC=CCC=CCCCCCC(=O)O.CCC=CCC=CCC=CCC=CCC=CCCCCC(=O)O.CCC=CCC=CCC=CCC=CCC=CCCCC(=O)O.CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)O'],"
        Inclusion Criteria: - Provision of informed consent

          -  Men or women ≥40 years and ≤75 years with suitable veins for cannulation or repeated
             venepuncture

          -  Have serum triglycerides ≥1.7 mM

          -  Have liver fat content as assessed by MRI >5.5%

          -  Have a body mass index (BMI) >25 and ≤40 kg/m2

             , Exclusion Criteria: - History of or presence of any clinically significant disease
             or disorder which, in the opinion of the investigator, may either put the subject at
             risk because of participation in the study, or influence the results or the subject's
             ability to participate in the study.

          -  Creatinine clearance <60 mL/min at screening (Cockcroft-Gault formula).

          -  Severe hepatic insufficiency and/or significant abnormal liver function defined as
             aspartate aminotransferase (AST) >3x upper limit of normal (ULN) and/or alanine
             aminotransferase (ALT) >3x ULN

          -  Total bilirubin >2.0 mg/dL (34.2 µmol/L)

          -  Type 2 diabetes, as defined by WHO criteria e.g. fasting plasma Glucose >7.0 mM or use
             of antidiabetic therapy

          -  Any clinically significant abnormalities in clinical chemistry, haematology or
             urinalysis results as judged by the investigator. This includes signs of liver disease
             other than NAFLD that motivates further investigations of treatment based on clinical
             judgement

          -  Recent history (past 12 months) of drug abuse or alcohol abuse. Alcohol abuse was to
             be defined as >14 drinks per week (1 drink = 35 cl beer, 14 cl wine, or 4 cl hard
             liquor) or as judged by the investigator
      "
NCT02351505,terminated,"
    low patient accrual
  ",0,phase 2,['recurrent small cell lung carcinoma'],"[""['D02.20', 'D02.21', 'D02.22']""]",['selinexor'],['C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F'],"
        Inclusion Criteria:

          -  Written informed consent in accordance with federal, local, and institutional
             guidelines

          -  Patients should have estimated life expectancy of > 3 months at study entry

          -  Patients with relapsed small cell lung cancer - diagnosis must be histologically
             confirmed

          -  Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 at the
             time of study entry

          -  Objective evidence of disease progression on study entry

          -  Prior systemic anticancer therapy: patients will have received no more than 2 prior
             chemotherapy regimens; the regimen(s) may have included biological, molecularly
             targeted or immune therapies; patients with primary refractory disease (i.e., those
             patients with progressive disease on first line chemotherapy) and patients with
             disease relapse within 90 days of completion of initial chemotherapy (chemotherapy
             resistant) are excluded; patients with limited stage small cell lung cancer (SCLC) and
             systemic relapse who are not felt to be candidates for repeat platinum-based
             chemotherapy at relapse are eligible for enrollment

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

          -  Absolute neutrophil count (ANC) > 1000/mm^3

          -  Platelet count > 75,000 mm^3

          -  Total bilirubin < 2 times the upper limit of normal (ULN) (except patients with
             Gilbert's syndrome who must have a total bilirubin of < 3 times ULN)

          -  Alanine aminotransferase (ALT) < 2.5 times ULN; in the case of known (radiological
             and/or biopsy documented) liver metastasis, ALT < 5.0 times ULN is acceptable

          -  Albumin >= 3.0 mg/dl

          -  Estimated creatinine clearance of >= 30 mL/min, calculated using the formula of
             Cockroft and Gault

          -  Amylase =< 1.5 x ULN

          -  Lipase =< 1.5 x ULN

          -  Alkaline phosphatase limit =< 2.5 x ULN

          -  Female patients of childbearing potential must agree to use dual methods of
             contraception and have a negative serum pregnancy test at screening; male patients
             must use an effective barrier method of contraception if sexually active with a female
             of child-bearing potential; acceptable methods of contraception are condoms with
             contraceptive foam, oral, implantable or injectable contraceptives, contraceptive
             patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is
             surgically sterilized or post-menopausal; for both male and female patients, effective
             methods of contraception must be used throughout the study and for three months
             following the last dose

          -  Resolution to grade =< 1 by National Cancer Institute (NCI) Common Terminology
             Criteria for Adverse Events (CTCAE v4.03) of all clinically significant toxic effects
             of prior anti-cancer therapy (with the exception neuropathy, which may be =< grade 2
             within 14 days prior to cycle 1 day 1)

          -  Available archival tumor tissue or willingness to undergo repeat biopsy is required at
             trial initiation

        Exclusion Criteria:

          -  Primary refractory disease (progressive disease on initial platinum based
             chemotherapy) or chemotherapy-resistant disease (disease progression within 90 days of
             completion of initial chemotherapy)

          -  Patients who are pregnant or lactating

          -  Radiation, chemotherapy, or immunotherapy or any other anticancer therapy =< 2 weeks
             prior to cycle 1 day 1; any clinical trial therapy (including investigational
             anti-cancer study) =< 3 weeks prior to cycle 1 day 1

          -  Prior treatment with selinexor

          -  Major surgery within 3 weeks before day 1

          -  Unstable cardiovascular function:

               -  Electrocardiogram (ECG) abnormalities requiring treatment, or

               -  Congestive heart failure (CHF) of New York Heart Association (NYHA) class >= 3

               -  Myocardial infarction (MI) within 3 months

               -  Symptomatic ischemia or angina

          -  Uncontrolled infection requiring parenteral antibiotics, antivirals, or antifungals
             within one week prior to first dose; patients with controlled infection or on
             prophylactic antibiotics are permitted in the study

          -  Known to be human immunodeficiency virus (HIV) seropositive

          -  Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C
             virus (HCV) RNA or hepatitis B surface antigen (HBsAg) (hepatitis B virus [HBV]
             surface antigen)

          -  Serious psychiatric or medical conditions that could interfere with treatment

          -  History of seizures, movement disorders or cerebrovascular accident within the past 5
             years prior to cycle 1 day 1

          -  Concurrent therapy with approved or investigational anticancer therapeutic other than
             steroids

          -  Patients with > 3 liver metastases at time of enrollment

          -  Patients with coagulation problems and active bleeding in the last month (peptic
             ulcer, epistaxis, spontaneous bleeding)

          -  Patients with significantly diseased or obstructed gastrointestinal tract,
             malabsorption, uncontrolled vomiting or diarrhea or inability to swallow oral
             medications

          -  Patients who are severely underweight (body mass index [BMI] less than 17) or patients
             with a body surface area (BSA) < 1.4 m^2 as calculated per Dubois 1916 or Mosteller
             1987

          -  Uncontrolled brain metastases or leptomeningeal involvement; patients with brain
             metastases are permitted if they have received appropriate therapy and demonstrated
             control of the brain metastases or leptomeningeal disease following therapy; patients
             with known brain metastases will require magnetic resonance imaging (MRI) brain to
             demonstrate disease control prior to enrollment (lack of symptom progression for two
             weeks off therapeutic doses of steroids, excluding chronic steroids used for control
             of chronic obstructive pulmonary disease [COPD])

          -  Prior cancer diagnosis is allowed if patient is disease-free for >= 3 years, or
             disease free for < 3 years for treated basal cell/ squamous cell skin cancer or in
             situ cervical cancer
      "
NCT02801487,terminated,"
    slow accrual of patients.
  ",0,phase 1/phase 2,['nasopharyngeal carcinoma'],"[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]",['cisplatin'],['N.N.Cl[Pt]Cl'],"
        Inclusion Criteria:

          -  -Pathologically confirmed NPC

          -  Completed a definitive course of intensity-modulated photon radiation therapy (IMXT)
             to a total dose of ≥ 66 Gy

          -  Recurrence diagnosed more than 12 months after the initial course of IMXT

          -  Age ≥ 18 and < 70 years of age

          -  Karnofsky Performance Score ≥70

          -  Willing to accept adequate contraception for women with childbearing potential

          -  Ability to understand character and individual consequences of the clinical trial

          -  Willing to sign the written informed consent; Informed consent must be signed before
             the enrollment in the trial

        Exclusion Criteria:

          -  Local recurrence of NPC diagnosed within 12 months from the completion of previous
             course of radiation therapy

          -  Presence of distant metastasis

          -  Technology used other than IMXT (including brachytherapy following IMXT) for the
             treatment of initial diagnosis of NPC

          -  Pregnant or lactating women

          -  Patients who have not yet recovered from acute toxicities of prior therapies

          -  A diagnosis of malignancy other than CIS of the cervix, BCC and SCC of the skin within
             the past 5 years

          -  Refusal of the patient to participate into the study
      "
NCT02802267,unknown status,,0,phase 2,['acute myelogenous leukemia'],"[""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']""]","['inecalcitol', 'placebo oral tablet']",['CC(CC#CC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3)O)O)C'],"
        Inclusion Criteria:

        • Patients aged 65 to < 75 years with at least one non severe comorbidity ie disease or
        syndrome with mild to moderate clinical or diagnostic observations or lab abnormalities
        which could increase the risk of toxicity and/or early death of intensive chemotherapy in
        the opinion of the investigator and are not contra-indicated for non-intensive
        chemotherapy.

        or ≥ 75 years with or without any comorbidity at the time of the informed consent
        signature;

        • Newly diagnosed, untreated de novo or secondary AML according to WHO classification;

        Exclusion Criteria:

          -  Prior or current treatment with chemotherapy for any myeloid disorder (excluding
             hydroxyurea) or radiotherapy for extramedullary involvement within 2 weeks of
             randomization;

          -  Prior treatment with decitabine, azacitidine, or cytarabine;

          -  Prior malignancies for 5 years with exception of basal cell, squamous cell carcinoma
             of the skin, or carcinoma "" in situ "" of the cervix or breast;

          -  Chronic myelogenous or acute promyelocytic leukaemia;

          -  Known CNS involvement;

          -  Patient eligible to bone marrow or stem cell transplant;

          -  WBC ≥ 30.000/mm3;

          -  Impaired renal function with Creatinine clearance < 30 mL/min/1.73m² according to the
             MDRD formula;

          -  Serum bilirubin ≥ 2.5 x ULN and/or AST and/or ALT ≥ 2.5 x ULN (upper limit of normal
             value);

          -  Calcemia ≥ 2.65 mmol/L (106 mg/L) at screening assessment (corrected with
             albuminemia);

          -  History of diseases known to be associated with calcium disorders: ongoing
             hyperparathyroidism, sarcoidosis….;

          -  Presence or history of symptomatic kidney stones in the last 5 years;

          -  Hypersensitivity to any of the excipients of decitabine (Potassium dihydrogen
             phosphate (E340) ; Sodium hydroxide (E524) ; Hydrochloric acid (for pH adjustment) or
             to the excipient of inecalcitol tablets (lactose);

          -  Current use of drugs known to influence serum calcium (such as thiazide diuretics,
             teriparatide, calcitonin and multivitamin supplements containing > 400 IU of vitamin D
             or calcium);

          -  Current use of digitalis;

          -  Current use of drugs which could influence bioavailability of inecalcitol (such as
             magnesium-containing antacids, bile-resin binders);

          -  Use of any other experimental drug or therapy or vitamin D supplementation within 4
             weeks of randomization;

          -  Known HIV;

          -  Patients who are eligible for intensive induction therapy with curative intent;

          -  Refractory congestive heart failure;

          -  Active infection resistant to anti-infective therapy;

          -  Documented pulmonary disease with DLCO ≤ 65% or FEV1≤ 65%, or dyspnea at rest or
             requiring oxygen, or any pleural neoplasm or uncontrolled lung neoplasm;

          -  Liver cirrhosis Child B or C or acute viral hepatitis;

          -  Current mental illness requiring psychiatric hospitalization, institutionalization or
             intensive outpatient management, or current cognitive status that produces dependence
             (as confirmed by the specialist) not controlled by the caregiver;

          -  Uncontrolled neoplasia;
      "
NCT02993822,completed,,1,phase 2,['chronic refractory cough'],"[""['D46.4', 'I20.2', 'D46.1', 'D46.A', 'D46.0', 'D46.20', 'D46.21']""]","['orvepitant maleate', 'placebo']",['CC1=C(C=CC(=C1)F)C2CC(CCN2C(=O)N(C)C(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN5C(C4)CCC5=O.C(=CC(=O)O)C(=O)O'],"
        Key Inclusion Criteria:

          -  Male and female subjects ≥18 years of age.

          -  Diagnosis of CRC or unexplained cough for at least 1 year (see ACCP/BTS guidelines
             attached).

          -  An awake average cough frequency of ≥10 coughs/ hour, as assessed using an ACM during
             the screening period.

        Key Exclusion Criteria:

          -  Subjects with respiratory tract infection (<4 weeks prior to study start)

          -  Current smokers or ex-smokers with <6 months' abstinence or cumulative history of >10
             pack years

          -  Treatment with Angiotensin Converting Enzyme (ACE) inhibitors within 3 months of
             screening

          -  FEV1 <80% predicted, measured at screening using spirometry

          -  History of cystic fibrosis, idiopathic pulmonary fibrosis, clinically significant
             bronchiectasis, moderate to severe asthma, chronic obstructive pulmonary disease
             (COPD)

          -  Any clinically significant abnormal laboratory test result(s)

          -  Inability to comply with the use of prohibited and allowed medications as described in
             the protocol.
      "
NCT02379247,completed,,1,phase 1/phase 2,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['byl-719 (alpelisib)', 'nab-paclitaxel']",['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C'],"
        Inclusion Criteria:

          1. Ability to understand and the willingness to sign a written Informed Consent Form.

          2. Age ≥ 18 years

          3. Histologically proven HER-2 negative breast cancer (HER-2 negative defined as HER IHC
             0 or 1+ and/or HER-2 FISH negative); HER-2 negative breast cancer includes hormone
             positive (ER and/or PR positive) breast cancer and TNBC

          4. HER-2 negative breast cancer that at the time of study entry is either stage III
             (locally advanced) disease not amenable to curative therapy or stage IV disease.
             Histological confirmation of recurrent/metastatic disease is encouraged but not
             required if clinical evidence of stage IV disease is available

          5. Have measurable (defined as at least one lesion that can be accurately measured in at
             least one dimension [longest diameter to be recorded] with minimum lesion size of ≥ 2
             cm on conventional measurement techniques or ≥ 1 cm on spiral computed tomography (CT)
             scan

          6. No limitations to number of prior chemotherapies for metastatic disease. Treatment
             with prior taxanes (except Nab-Paclitaxel) is allowed as long as it has been 6 months
             or more since exposure to prior taxane.

             NOTE: For subjects who are, or who have previously received endocrine therapy for
             breast cancer, the treating investigator will decide how many days should pass between
             the last dose of endocrine therapy and the first dose of study treatment.

          7. All patients should have received at least one line of chemotherapy in either the
             advanced or adjuvant setting and hormonal therapy (where appropriate)

          8. Performance status of 2 or better as per ECOG criteria (See Appendix A for details)

          9. Subject is able to swallow and retain oral medicines

         10. Adequate marrow and organ function as defined below (labs must be performed within 14
             days of subject registration)

               -  Absolute neutrophil count ≥ 1500/uL

               -  Platelets 100,000/uL (no transfusion allowed within 2 weeks)

               -  Hemoglobin > 9 g/dL (which may be reached by transfusion)

               -  Total bilirubin within normal range or ≤ 1.5X IULN if liver metastases are
                  present or total bilirubin ≤ 3.0X IULN with direct bilirubin within normal range
                  in subjects with well-documented Gilbert's Syndrome, which is defined as presence
                  of unconjugated hyperbilirubinemia with normal results from CBC (including normal
                  reticulocyte count and blood smear), normal liver function test results and
                  absence of other contributing disease processes at the time of diagnosis

               -  AST(SGOT)/ALT(SPGT) ≤ 2.5X IULN or ≤ 5X IULN if liver metastases are present

               -  Serum creatinine ≤ 1.5X IULN

               -  INR ≤ 1.5

               -  Fasting plasma glucose ≤ 140 mg/dL or 7.8 mmol/L (NOTE: Fasting whole blood
                  glucose testing is acceptable if fasting plasma glucose is not feasible.)

               -  HBA1c ≤ 8%

               -  Potassium, calcium (corrected for serum albumin) and magnesium within IULN

               -  Serum Amylase < 2 x ULN and serum lipase within normal limits

         11. IV bisphosphate and denosumab for bony metastatic disease will be allowed

         12. Prior palliative radiation therapy to bony metastases is allowed. There should be a
             minimum of 14 days between the end of radiation treatment and start of study treatment

         13. Subjects with previously treated brain metastases who are free of CNS symptoms and are
             > 3 months from treatment of brain metastases are eligible Subjects should be > 2
             weeks from prior systemic chemotherapy for breast cancer AND should have recovered to
             Grade 1 or better (except alopecia) from related side effects of any prior
             antineoplastic therapy prior to study entry NOTE: For subjects who are, or who have
             previously received endocrine therapy for breast cancer, the treating investigator
             will decide how many days should pass between the last dose of endocrine therapy and
             the first dose of study treatment.

         14. Women of child bearing potential (WOCBP) and their partners must agree to use adequate
             contraception (barrier method of birth control; abstinence) prior to study entry, for
             the duration of study participation, and for 90 days following completion of therapy.
             After confirmation of negative pregnancy test at screening, should a WOCBP become
             pregnant or suspect that she is pregnant while participating in this study, she should
             inform her treating physician and the investigator immediately.

               -  WOCBP are defined as any females (regardless of sexual orientation, having
                  undergone tubal ligation, or remaining celibate by choice) who meet the following
                  criteria:

                    -  Have not undergone a hysterectomy or bilateral oophorectomy OR

                    -  Have not been naturally postmenopausal for at least 12 consecutive months
                       (i.e. has had menses at any time in the preceding 12 consecutive months)

        Exclusion criteria:

          1. Subject has any other medical or psychiatric disorder that, in the opinion of the
             treating physician, would contraindicate the use of drugs in this protocol or place
             the subject at undue risk for treatment complications

          2. Subject is pregnant or lactating

          3. Subject has previously been treated with Nab-Paclitaxel NOTE: Subjects who have had
             previous treatment with Nab-Paclitaxel will NOT be excluded if given in the adjuvant
             or neoadjuvant setting Only in the metastatic setting, will subjects previously
             treated with Nab-Paclitaxel be excluded from this trial. Exceptions may be made for
             subjects who discontinued treatment with a previous Nab-Paclitaxel inhibitor for
             reasons other than progression and as long as it has been > 12 months since
             discontinuation of the previous Nab-Paclitaxel. This exception will require prior
             approval from the study PI at KUMC.

          4. Subject has inflammatory breast cancer

          5. Subject has a known hypersensitivity to any of the excipients of Nab-Paclitaxel or
             BYL719/alpelisib

          6. Subject has a concurrent malignancy or malignancy within 3 years of study enrollment
             (with the exception of adequately treated, basal or squamous cell carcinoma,
             non-melanomatous skin cancer or curatively resected cervical cancer)

          7. Subject has clinically manifest diabetes mellitus or documented steroid-induced
             diabetes mellitus

          8. Subject has impairment of gastrointestinal (GI) function or GI disease that may
             significantly alter the absorption of the study drugs (e.g. ulcerative diseases,
             uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel
             resection)

          9. Subject is classified into Child-Pugh class C

         10. Subject has a known history of HIV infection (testing not mandatory)

         11. Subject has active, uncontrolled infection

         12. Subject has symptomatic/untreated CNS disease

         13. Subject has ≥ Grade 2 peripheral neuropathy

         14. Subject has active cardiac disease or a history of cardiac dysfunction including any
             of the following:

               -  Unstable angina pectoris within 6 months prior to study entry

               -  Symptomatic peritonitis

               -  Documented myocardial infarction within 6 months prior to study entry

               -  History of documented congestive heart failure (New York Heart Association
                  functional classification III-IV)

               -  Documented cardiomyopathy

               -  Subject has a Left Ventricular Ejection Fraction (LVEF) < 50% as determined by
                  Multiple Gated Acquisition (MUGA) scan or echocardiogram (ECHO)

               -  Subject has any of the following cardiac conduction abnormalities

               -  Ventricular arrhythmias except for benign premature ventricular contractions

               -  Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled
                  with medicine

               -  Conduction abnormality requiring a pacemaker

               -  Other cardiac arrhythmia not controlled with medication

         15. Subject has a QTcF > 480 msec on the screening ECG (using the QTcF formula)

         16. Subject is currently receiving treatment with a medication that has a known risk to
             prolong the QT interval or induce Torsades de Pointes and the treatment cannot be
             discontinued or switched to a different medication prior to randomization

         17. Subject has had major surgery within 14 days prior to starting study drug or has not
             recovered from major side effects

         18. Subject is currently receiving or has received systemic corticosteroids ≤ 2 weeks
             prior to starting study drug or who have not fully recovered from side effects of such
             treatment

         19. Subject is currently receiving treatment with drugs known to be moderate or strong
             inhibitors or inducers of isoenzyme CYP3A. The subject must have discontinued strong
             inducers for at least one week and must have discontinued strong inhibitors before the
             start of treatment

         20. Subject is currently receiving warfarin or other coumarin-derived anti-coagulant for
             treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight
             heparin (LMWH), or fondaparinux is allowed

         21. Subject has received previous treatment with a PI3K inhibitor. Exceptions may be made
             for subjects who discontinued treatment with a previous PI3K inhibitor for reasons
             other than toxicity or progression and as long as it has been > 12 months since
             discontinuation of the previous PI3K inhibitor. This exception will require prior
             approval from the study PI at KUMC.

         22. Subjects who have received an investigational agent within 30 days OR within 5
             half-lives of the investigational agent (whichever is shorter) prior to the possible
             enrollment date on this study.

         23. Subject with history of acute within one year of study entry or past medical history
             of chronic pancreatitis.
      "
NCT02374489,terminated,"
    ros1 in ihc and gene rearrangement result can not match。no tumor response。
  ",0,phase 2,['cholangiocarcinoma'],"[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]",['ldk378'],['CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl'],"
        Inclusion Criteria:

          -  1.Histological or cytologically confirmed diagnosis of intrahepatic or hilar
             cholangiocarcinoma that demonstrates ALK and/or ROS1 over-expression by IHC (3+).

          -  2.Locally advanced with inoperable or metastatic disease status

          -  3.ECOG performance status 0-2.

          -  4.Aged no less than 20 years and no more than 75 years, at the time of acquisition of
             informed consent 5.Patients must have recovered from all toxicities related to prior
             anticancer therapies to ≤ grade 2 (CTCAE v 4.03), provided that concomitant medication
             is given prior to initiation of treatment with LDK378. Exception to this criterion:
             patients with any grade of alopecia are allowed to enter the treatment.

             6.The following laboratory criteria have been met:

             •Absolute neutrophil count (ANC) ≥1.5 x 109/L

               -  Hemoglobin (Hgb) ≥ 9 g/dL

               -  Platelets ≥ 75 x 109/L

               -  Serum total bilirubin ≤1.5 x upper limit of normal (ULN), except for patients
                  with biliary tract obstruction statis post drainage or stent may be included if
                  total bilirubin ≤3.0 x ULN and direct bilirubin≤ 1.5 x ULN

               -  Aspartate transaminase (AST) < 3.0 x ULN, except for patients with liver
                  metastasis, who are only included if AST < 5 x ULN; alanine transaminase (ALT) <
                  3.0 x ULN, except for patients with liver metastasis, who are only included if
                  ALT < 5 x ULN

               -  Calculated or measured creatinine clearance (CrCL) ≥ 30 mL/min 7.Patient must
                  have the following laboratory values or have the following laboratory values
                  corrected with supplements to be within normal limits at screening:

               -  Potassium ≥ 1.0 x lower limit of normal (LLN)

               -  Magnesium ≥ 1.0 x LLN

               -  Phosphorus ≥ 1.0 x LLN

               -  Total calcium (corrected for serum albumin) ≥ 1.0 x LLN 8.At least one, not
                  previously irradiated, measurable lesion according to RECIST (version 1.1)
                  9.Willingness and ability to comply with scheduled visits, treatment plans,
                  laboratory tests and other procedures.

        Exclusion Criteria:

          -  1.Patients with known hypersensitivity to any of the excipients of LDK378
             (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and
             magnesium stearate).

             2.Patients with symptomatic CNS metastases who are neurologically unstable or have
             required increasing doses of steroids within the 1 week prior to study entry to manage
             CNS symptoms.

             3.Prior therapy with LDK378. 4.Other anti-tumor agent such as systemic chemotherapy,
             immunotherapy or targeted therapy within 2 weeks before the commencement of study
             treatment.

             5.Presence or history of a malignant disease other than cholangiocarcinoma that has
             been diagnosed and/or required therapy within the past year and is not undergoing
             active anticancer treatment. Exceptions to this exclusion include the following:
             completely resected basal cell and squamous cell skin cancers, and completely resected
             carcinoma in situ of any type.

             6.Patients with known history of extensive disseminated bilateral interstitial
             fibrosis or interstitial lung disease, including a history of pneumonitis,
             hypersensitivity pneumonitis, interstitial pneumonia, obliterative bronchiolitis, and
             clinically significant radiation pneumonitis (i.e. affecting activities of daily
             living or requiring therapeutic intervention).

             7.Patient has clinically significant, uncontrolled heart disease and/or recent cardiac
             event (within 6 months), such as:unstable angina within 6 months prior to
             screening;myocardial infarction within 6 months prior to screening;history of
             documented congestive heart failure (New York Heart Association functional
             classification III-IV);uncontrolled hypertension defined by a Systolic Blood Pressure
             (SBP) ≥ 160 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 100 mm Hg, with or without
             antihypertensive medication ;initiation or adjustment of antihypertensive
             medication(s) is allowed prior to screening;ventricular arrhythmias; supraventricular
             and nodal arrhythmias not controlled with medication;other cardiac arrhythmia not
             controlled with medication;corrected QTc (male: QTc >450 msec; female: QTc> 470 msec )
             using Bazett correction on the screening ECG.

             8.Impaired GI function or GI disease that may alter absorption of LDK378 or inability
             to swallow up to five LDK378 capsules daily.

             9.Ongoing GI adverse events > grade 2 (e.g. nausea, vomiting, or diarrhea) at the
             start of the study.

             10.Receiving medications that meet one of the following criteria and that cannot be
             discontinued at least 1 week prior to the start of treatment with LDK378 and for the
             duration of participation:Medication with a known risk of prolonging the QT interval
             or inducing Torsades de Pointes .Strong inhibitors or strong inducers of CYP3A4/5
             ;Medications with a low therapeutic index that are primarily metabolized by CYP3A4/5,
             CYP2C8 and/or CYP2C9 ;Therapeutic doses of warfarin sodium (Coumadin) or any other
             coumadin-derived anti-coagulant. Anticoagulants not derived from warfarin are allowed
             (eg, dabigatran, rivaroxaban, apixaban).;increasing doses of
             corticosteroids;enzyme-inducing anticonvulsive agents;herbal supplements 11.Pregnant
             or nursing (lactating) women, where pregnancy is defined as the state of a female
             after conception and until the termination of gestation, confirmed by a positive hCG
             laboratory test.

             12.Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant, unless they are using highly effective methods of contraception
             during dosing and for 3 months after the last dose of study treatment. Highly
             effective contraception methods include:Total abstinence (when this is in line with
             the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar,
             ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable
             methods of contraception.

        Female sterilization (have had surgical bilateral oophorectomy with or without
        hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case
        of oophorectomy alone, only when the reproductive status of the woman has been confirmed by
        follow up hormone level assessment.

        Male sterilization (at least 6 months prior to screening) with the appropriate
        post-vasectomy documentation of the absence of sperm in the ejaculate. For female subjects
        on the study the vasectomized male partner should be the sole partner for that subject.

        Combination of any two of the following (a+b or a+c or b+c):

          1. Use of oral, injected or implanted hormonal methods of contraception or other forms of
             hormonal contraception that have comparable efficacy (failure rate < 1%), for example
             hormone vaginal ring or transdermal hormone contraception.

          2. Placement of an intrauterine device (IUD) or intrauterine system (IUS).

          3. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault
             caps) with spermicidal foam/gel/film/cream/vaginal suppository.

        In case of use of oral contraception, women should have been stable on the same pill for a
        minimum of 3 months before taking study treatment.

        13.Sexually active males unless they use a condom during intercourse while taking drug and
        for 3 months after the last dose of study treatment. Male patients for 3 months should not
        father a child in this period. A condom is required to be used also by vasectomized men in
        order to prevent delivery of the drug via seminal fluid.
      "
NCT02379195,completed,,1,phase 1/phase 2,['metastatic melanoma'],"[""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']""]","['cyclophosphamide', 'fludarabine', 'interleukin-2', 'peginterferon alfa-2b']","['C1CNP(=O)(OC1)N(CCCl)CCCl', 'C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N']","
        Inclusion Criteria:

        Histologically confirmed unresectable stage III or stage IV metastatic melanoma Metastasis
        available for surgical resection (about 2 cm3) and residual measurable disease after
        resection

        ECOG performance status 0-1

        Life expectancy ≥ 3 months

        No significant toxicity from prior treatments

        Adequate renal, hepatic and hematologic function

        Women of childbearing potential (WOCBP) and men in a sexual relationship with a WOCBP must
        be using an effective method of contraception during treatment and for at least 6 months
        after completion af treatment.

        Able to comprehend the information given and willing to sign informed consent

        -

        Exclusion Criteria:

        Other Malignancies, unless followed for ≥ 5 years with no sign of disease, except squamous
        cell carcinoma or adequately treated carcinoma in situ colli uteri.

        Cerebral metastasis. Patients with previously treated CNS metastases can participate if CNS
        metastases are surgically removed or treated with stereotactic radiosurgery and stable ≥ 28
        days after treatment measured by MRI. Patients with asymptomatic, stable and untreated CNS
        metastasis can in be included according to investigators and sponsors decision.

        Patients with ocular melanoma

        Severe allergies, history of anaphylaxis or known allergies to the administered drugs.

        Serious medical or psychiatric comorbidity

        Creatinine clearance < 70 ml/min

        Acute or chronic infection with e.g. HIV, hepatitis, tuberculosis

        Severe and active autoimmune disease

        Pregnant and nursing women

        Need for immunosuppressive treatment, e.g. corticosteroids or methotrexate

        Concomitant treatment with other experimental drugs

        Patients with uncontrolled hypercalcemia

        Less than four weeks since prior systemic antineoplastic treatment at the time of
        treatment.

        -
      "
NCT02379390,terminated,"
    unsatisfactory patient accrual
  ",0,phase 2,['prostate cancer metastatic'],"[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]","['cabazitaxel xrp6258', 'ezalutamide', 'abiraterone acetate', 'prednisone']","['CC(=O)OC1CCC2(C3CCC4(C(C3CC=C2C1)CC=C4C5=CN=CC=C5)C)C', 'CC12CC(=O)C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C']","
        Inclusion criteria:

          -  Diagnosis of histologically or cytologically confirmed prostate adenocarcinoma.

          -  Metastatic disease.

          -  Progressive disease (PD) while receiving AR targeted therapy with abiraterone acetate
             or enzalutamide within 12 months of treatment initiation (≤12 months) by at least one
             of the following:

          -  Progression in measurable disease Response Evaluation Criteria in Solid Tumors
             (RECIST) 1.1.

          -  Appearance of 2 or more new bone lesions according to Prostate Cancer Working Group 2
             (PCWG2).

          -  Rising PSA defined (PCWG2) as at least two consecutive rises in PSA to be documented
             over a reference value (measure 1) taken at least one week apart.

          -  A PSA value of at least 2 nanogram/milliliter (ng/mL) is required at study entry.

          -  Effective castration (serum testosterone levels ≤0.5 ng/mL).

          -  Prior AR targeted therapy (abiraterone acetate or enzalutamide) must be stopped at
             least 2 weeks before study treatment.

          -  Signed written informed consent.

        Exclusion criteria:

          -  Prior chemotherapy for prostate cancer, except estramustine and except
             adjuvant/neoadjuvant treatment completed >3 years ago. No further anti-cancer therapy
             after the previous AR targeted therapy and before inclusion. Prior docetaxel in
             hormone sensitive setting is allowed if completed >1 year before randomization. Prior
             immunotherapy is allowed.

          -  Less than 28 days elapsed from prior treatment with immunotherapy, radiotherapy, or
             surgery to the time of randomization.

          -  Adverse events (excluding alopecia and those listed in the specific exclusion
             criteria) from any prior anticancer therapy of grade >1(National Cancer Institute
             Common Terminology Criteria for Adverse Events [NCI CTCAE] v4.0) at the time of
             randomization.

          -  Eastern Cooperative Oncology Group (ECOG) performance status >1.

          -  History of brain metastases, uncontrolled spinal cord compression, or carcinomatous
             meningitis, or new evidence of brain or leptomeningeal disease.

          -  Prior malignancy. Adequately treated basal cell or squamous cell skin or superficial
             (pTis, pTa, and pT1) bladder cancer are allowed, as well as any other cancer for which
             treatment has been completed ≥5 years ago and from which the patient has been
             disease-free for ≥5 years.

          -  Participation in another clinical trial and any concurrent treatment with any
             investigational drug within 30 days prior to randomization.

          -  Acquired immunodeficiency syndrome (AIDS)-related illnesses or known Human
             immunodeficiency virus (HIV) disease requiring antiretroviral treatment.

          -  Any severe acute or chronic medical condition including uncontrolled diabetes
             mellitus, severe renal impairment, history of cardiovascular disease (uncontrolled
             hypertension, arterial thrombotic events in the past 6 months, congestive heart
             failure, severe or unstable angina pectoris, recent myocardial infraction within last
             6 months or uncontrolled cardiac arrhythmia), which could impair the ability of the
             patient to participate to the study or interfere with interpretation of study results,
             or patient unable to comply with the study procedures.

          -  Participants with reproductive potential who do not agree to use accepted and
             effective method of contraception during the study treatment period and up to 6 months
             after the last administered dose. The definition of ""effective method of
             contraception"" will be based on the Investigator's judgment.

          -  Known allergies, hypersensitivity or intolerance to prednisone or excipients of
             abiraterone acetate or enzalutamide. History of hypersensitivity to docetaxel or
             polysorbate 80.

          -  Known history of mineralocorticoid excess or deficiency (not applicable to
             participants who have already been treated with abiraterone acetate in first line
             before inclusion).

          -  History of seizure, underlying brain injury with loss of consciousness, transient
             ischemic attack within the past 12 months, cerebral vascular accident, brain
             arteriovenous malformation or the use of concomitant medications that may lower the
             seizure threshold (not applicable to participants who have already been treated with
             enzalutamide in first line before inclusion).

          -  Unable to swallow a whole tablet or capsule.

          -  Inadequate organ and bone marrow function as evidenced by:

          -  Hemoglobin <10.0 g/dL.

          -  Absolute neutrophil count <1.5 x 10^9/L.

          -  Platelet count <100 x 10^9/L.

          -  Aspartate aminotransferase (AST) and/or Alanine aminotransferase (ALT) >1.5 x Upper
             limit of normal (ULN).

          -  Total bilirubin >1.0 x ULN.

          -  Potassium <3.5 mmol/L.

          -  Serum albumin <3.0 g/dL.

          -  Child-Pugh Class B and C.

          -  Contraindications to the use of corticosteroid treatment.

          -  Symptomatic peripheral neuropathy grade ≥2 NCI CTCAE v4.0.

          -  Concomitant vaccination with yellow fever vaccine.

        The above information was not intended to contain all considerations relevant to a
        patient's potential participation in a clinical trial.
      "
NCT01806571,completed,,1,phase 2,['untreated adult acute myeloid leukemia'],"[""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']""]","['cytarabine', 'daunorubicin hydrochloride', 'nilotinib']","['C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O', 'CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O.Cl', 'CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5']","
        Inclusion Criteria:

          -  Untreated, histological confirmed acute myeloid leukemia (AML) based on World Health
             Organization (WHO) 2008 criteria with Kit expression (cluster of differentiation [CD]
             117) of myeloblasts >= 20% by flow cytometry from bone marrow aspirate at diagnosis

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2

          -  Magnesium within normal limits (WNL)

          -  Potassium WNL

          -  Phosphorus WNL

          -  Serum amylase =< 1.5 x upper limit of normal (ULN)

          -  Serum lipase =< 1.5 x ULN

          -  Total bilirubin =< 1.5 x ULN (does not apply to patients with isolated
             hyperbilirubinemia [e.g., Gilbert's disease], in that case direct bilirubin should be
             =< 2 x ULN)

          -  Alkaline phosphatase =< 3 x ULN

          -  Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 3
             x ULN

          -  Creatinine =<1.5 x ULN

          -  Negative pregnancy test done =< 7 days prior to registration, for women of
             childbearing potential only

          -  Provide informed written consent

          -  Willing to return to consenting Mayo Clinic (Mayo Clinic's campus in Rochester, Mayo
             Clinic's campus in Arizona, or Mayo Clinic's campus in Florida) institution for
             follow-up during the active monitoring phase of the study

          -  Willing to provide bone marrow aspirate and blood samples for correlative research
             purposes

        Exclusion Criteria:

          -  Any of the following because this study involves investigational agent(s) whose
             genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are
             unknown

               -  Pregnant women

               -  Nursing women

               -  Men or women of childbearing potential who are unwilling to employ adequate
                  contraception throughout the study and for 3 months after completion of study
                  treatment

          -  Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment
             of the investigator, would make the patient inappropriate for entry into this study or
             interfere significantly with the proper assessment of safety and toxicity of the
             prescribed regimens

          -  Immunocompromised patients (other than that related to the use of corticosteroids)
             including patients known to be human immunodeficiency virus (HIV) positive

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Receiving any other investigational agent which would be considered as a treatment for
             the primary neoplasm

          -  Other active malignancy =< 3 years prior to registration; EXCEPTIONS: non-melanotic
             skin cancer or carcinoma-in-situ of the cervix

          -  Previous treatment with chemotherapy or any other tyrosine kinase inhibitor for a
             hematological disorder; Exceptions: patients with prior diagnosis of myelodysplastic
             syndrome (MDS) and/or treatment with hypomethylating agent (azacytidine or decitabine)
             are not excluded, prior hydroxyurea allowed

          -  Impaired cardiac function including any one of the following:

               -  Inability to monitor the QT interval on electrocardiogram (ECG)

               -  Congenital long QT syndrome or a known family history of long QT syndrome

               -  Clinically significant resting brachycardia (< 50 beats per minute)

               -  Corrected QT (QTc) > 450 msec on baseline ECG; if QTc > 450 msec and electrolytes
                  are not within normal ranges, electrolytes should be corrected and then the
                  patient re-screened for QTc

               -  Myocardial infarction =< 12 months prior to starting study

               -  Other clinically significant uncontrolled heart disease (e.g. unstable angina,
                  congestive heart failure or uncontrolled hypertension)

               -  History of or presence of clinically significant ventricular, atrial
                  tachyarrhythmias or ejection fraction cutoff

               -  Left ventricle ejection fraction < 45%

               -  History of, congestive heart failure requiring use of ongoing maintenance therapy
                  for life-threatening ventricular arrhythmias

          -  Patients currently receiving treatment with strong cytochrome P450 family 3, subfamily
             A, polypeptide 4 (CYP3A4) inhibitors and treatment that cannot be either discontinued
             or switched to a different medication prior to starting study drug; patients receiving
             any medications or substances that are strong or moderate inhibitors of CYP3A4

               -  Use of the following strong or moderate inhibitors is prohibited < 7 days prior
                  to registration

                    -  Strong inhibitors of CYP3A4/5 > 5-fold increase in the plasma area under the
                       curve (AUC) values or more than 80% decrease in clearance

                         -  Boceprevir (Victrelis)

                         -  Clarithromycin (Biaxin, Biaxin XL)

                         -  Conivaptan (Vaprisol)

                         -  Grapefruit juice

                         -  Indinavir (Crixivan)

                         -  Itraconazole (Sporanox)

                         -  Ketoconazole (Nizoral)

                         -  Lopinavir/ritonavir (Kaletra)

                         -  Mibefradil

                         -  Nefazodone (Serzone)

                         -  Nelfinavir (Viracept)

                         -  Posaconazole (Noxafil)

                         -  Ritonavir (Novir, Kaletra)

                         -  Saquinivir (Fortovase, Invirase)

                         -  Telaprevir (Incivek)

                         -  Telithromycin (Ketek)

                         -  Voriconazole (Vfend)

                    -  Moderate inhibitors of CYP3A4/5 > 2-fold in the plasma AUC values or 50-80%
                       decrease in clearance

                         -  Amprenavir (Agenerase)

                         -  Aprepitant (Emend)

                         -  Atazanavir (Reyataz)

                         -  Ciprofloxacin (Cipro)

                         -  Darunavir (Prezista)

                         -  Diltiazem (Cardizem, Cardizem CD, Cardizem LA, Cardizem SR, Cartia XT,
                            Dilacor XR, Diltia XT, Taztia XT, Tiazac)

                         -  Erythromycin (Erythrocin, E.E.S. , Ery-Tab, Eryc, EryPed, PCE)

                         -  Fluconazole (Diflucan)

                         -  Fosamprenavir (Lexiva)

                         -  Imatinib (Gleevec)

                         -  Verapamil (Calan, Calan SR, Covera-HS, Isoptin SR, Verelan, Verelan PM)

          -  Receiving any medications or substances that are inducers of CYP3A4; use of the
             following inducers are prohibited =< 7 days prior to registration

               -  Strong inducers of CYP3A4/5 > 80% decrease in AUC

                    -  Avasimibe

                    -  Carbamazepine (Carbatrol, Epitol, Equetro, Tegretol, Tegretol-XR)

                    -  Phenytoin (Dilantin, Phenytek)

                    -  Rifampin (Rifadin)

                    -  St. John's wort

               -  Moderate inducers of CYP3A4/5 50-80% decrease in AUC

                    -  Bosentan (Tracleer)

                    -  Efavirenz (Sustiva)

                    -  Etravirine (Intelence)

                    -  Modafinil (Provigil)

                    -  Nafcillin

                    -  Nevirapine (Viramune)

                    -  Phenobarbital (Luminal)

                    -  Rifabutin (Mycobutin)

                    -  Troglitazone

          -  Patients currently receiving treatment with any medications that have the potential to
             prolong the QT interval and the treatment cannot be either discontinued or switched to
             a different medication prior to starting study drug

          -  Impaired gastrointestinal (GI) function or GI disease that may significantly alter the
             absorption of study drug (e.g., ulcerative diseases, uncontrolled nausea, vomiting,
             diarrhea, malabsorption syndrome, small bowel resection or gastric bypass surgery)

          -  Acute or chronic pancreatic disease

          -  Known cytopathologically confirmed central nervous system (CNS) infiltration

          -  Acute or chronic liver disease or severe renal disease considered unrelated to the
             cancer

          -  History of significant congenital or acquired bleeding disorder unrelated to cancer

          -  Major surgery =< 4 weeks prior to registration of the study or who have not recovered
             from prior surgery

          -  Treatment with other investigational agents =< 14 days of registration

          -  Diagnosis of AML-M3 (or acute promyelocytic leukemia)
      "
NCT03026166,terminated,"
    enrollment was stopped after the dose-limiting toxicity (dlt) evaluation phase of cohort 2.
  ",0,phase 1/phase 2,['small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['ipilimumab', 'nivolumab', 'rovalpituzumab tesirine']",['Status: 503'],"
        Inclusion Criteria:

          -  Participants with histologically or cytologically confirmed extensive-stage small cell
             lung cancer (SCLC) with progressive disease after at least one platinum-based
             chemotherapeutic regimen and with evaluable or measurable disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Adequate hematologic, hepatic, and renal function

        Exclusion Criteria:

          -  Has active, known, or suspected autoimmune disease

          -  Had prior exposure to an immuno-oncology or pyrrolobenzodiazepine (PBD)-based drug
      "
NCT03022578,terminated,"
    slow accrual
  ",0,phase 2,"['idh family wildtype', 'recurrent anaplastic astrocytoma', 'recurrent glioblastoma']","[""['E85.82']"", ""['C84.67', 'C84.77', 'C84.7A', 'C84.60', 'C84.70', 'C84.62', 'C84.66']"", ""['G47.13', 'J01.41', 'K11.22', 'K12.0', 'N96', 'F33.8', 'G03.2']""]",['lomustine'],['C1CCC(CC1)NC(=O)N(CCCl)N=O'],"
        Inclusion Criteria:

          -  Patients must have histologically-proven, recurrent supratentorial grade IV
             glioblastoma (or grade III IDH-wildtype anaplastic astrocytoma), for which a complete
             surgical resection is unsafe due to location, shape, or size of the tumor. Diagnosis
             of recurrence will be established by biopsy and frozen section immediately prior to
             initiating LITT procedure. If findings on frozen section are not consistent with
             recurrence (glioblastoma or recurrent IDH-wildtype anaplastic astrocytoma), decision
             to proceed with LITT procedure will be at the discretion of the neurosurgeon (only
             patients with histologically-proven recurrent tumor will be evaluable for efficacy).

          -  All patients must sign an informed consent indicating that they are aware of the
             investigational nature of this study. Patients must have signed an authorization for
             the release of their protected health information. Patients must be registered prior
             to treatment on study.

          -  Patients must have a Karnofsky performance score (KPS) > 60.

          -  Patients must have received standard of care therapy with chemoradiation with
             temozolomide followed by adjuvant chemotherapy with temozolomide. Patients may have
             received one additional chemotherapy regimen (other than lomustine) in addition to
             adjuvant temozolomide prior to study entry (patients at either first or second
             recurrence are eligible).

          -  In the context of this clinical trial, a lesion suitable for LITT is single,
             enhancing, supratentorial, at least 2 cm from inner table of skull over the
             hemispheric convexity, and > 1 cm, but < 4 cm in cross-sectional dimension, including
             thalamic tumor (=< 3 cm).

          -  Patients must have stable cardiovascular, neurovascular and neurological status, and
             be considered surgical candidates, as determined by any relevant pre-operative
             assessments, at the neurosurgeon's discretion.

          -  Patients must not be receiving concurrent anti-tumor treatment and must have recovered
             from toxicity of prior treatment. Minimum interval required: 1) > 6 weeks following
             nitrosourea chemotherapy; 2) > 4 weeks after recovering from any non-nitrosourea drug
             or systemic investigational agent; 3) > 2 weeks after receiving any non-cytotoxic
             anti-tumor drug; 4) > 4 weeks after receiving radiation therapy (> 12 weeks following
             upfront concurrent chemoradiation); 5) > 2 weeks following Optune device use.

          -  Patients must not have previously undergone an intracranial LITT procedure.

          -  White blood cell (WBC) > 3,000/ul (performed within 14 days (+ 3 working days) prior
             to registration)

          -  Absolute neutrophil count (ANC) > 1,500/mm^3 (performed within 14 days (+ 3 working
             days) prior to registration)

          -  Platelet count of > 100,000/mm^3 (may be reached by transfusion) (performed within 14
             days (+ 3 working days) prior to registration)

          -  Hemoglobin > 10 gm/dl (may be reached by transfusion) (performed within 14 days (+ 3
             working days) prior to registration)

          -  Serum glutamic-oxaloacetic transaminase (SGOT) and bilirubin < 2 times upper limit of
             normal (ULN) (performed within 14 days (+ 3 working days) prior to registration)

          -  Creatinine < 1.5 mg/dL (performed within 14 days (+ 3 working days) prior to
             registration)

          -  Women of childbearing potential must have a negative B-Human chorionic gonadotropin
             (HCG) documented within 7 days prior to registration and must agree to practice
             adequate contraception as defined below. Non-childbearing potential (i.e.,
             physiologically incapable of becoming pregnant), includes any female who has had:

               -  A hysterectomy

               -  A bilateral oophorectomy

               -  A bilateral tubal ligation

               -  Is post-menopausal: Subjects not using hormone replacement therapy (HRT) must
                  have experienced total cessation of menses for >= 1 year and be greater than 45
                  years in age, OR, in questionable cases, have a follicle stimulating hormone
                  (FSH) value > 40 mIU/mL and an estradiol value < 40 pg/mL (< 140 pmol/L).

          -  Subjects using HRT must have experienced total cessation of menses for >= 1 year and
             be greater than 45 years of age OR have had documented evidence of menopause based on
             FSH and estradiol concentrations prior to initiation of HRT.

          -  Childbearing potential includes any female who has had a negative serum pregnancy test
             within 7 days of study registration, and agrees to use adequate contraception.
             Acceptable contraceptive methods, when used consistently and in accordance with both
             the product label and the instructions of the physician, are as follows:

               -  Complete abstinence from sexual intercourse for 14 days before starting
                  treatment, through the treatment, and for at least 1 month after the last dose of
                  temozolomide

               -  Oral contraceptive, either combined or progestogen alone. A second barrier method
                  is required during the first month of treatment with oral contraceptives

               -  Injectable progesterone

               -  Implants of levonorgestrel

               -  Estrogenic vaginal ring

               -  Percutaneous contraceptive patches

               -  Intrauterine device (IUD) or intrauterine system (IUS) with a documented failure
                  rate of less than 1% per year

               -  Male partner sterilization (vasectomy with documentation of azoospermia) prior to
                  the female subject's entry into the study, and this male is the sole partner for
                  that subject

               -  Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault
                  caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository). Female
                  participants who are lactating should discontinue nursing prior to the first dose
                  of temozolomide and should refrain from nursing throughout the treatment period
                  and for 42 days following the last dose of lomustine.

        Exclusion Criteria:

          -  Patients must not have received prior treatment with bevacizumab.

          -  Patients must not have had prior treatment of glioblastoma with stereotactic
             radiosurgery, brachytherapy, or carmustine-impregnated wafers (Gliadel).

          -  Patients must not have symptoms attributed to mass effect of the tumor (despite
             corticosteroid treatment) that would be better treated with debulking surgery, or
             wherein surgical debulking in the first 30 days following LITT procedure would be
             anticipated for symptom management.

          -  Patients unable to undergo MRI are not eligible.

          -  Patients with progression of multifocal tumors or tumors involving the posterior fossa
             (brainstem and cerebellum) will be excluded, as will patients where the anticipated
             treatment margin will be within 5 mm of critical intracranial structures (e.g.,
             primary branches of cerebral vessels, dural sinuses, hypophysis or cranial nerves).

          -  Patients may not have undergone previous treatment with lomustine.

          -  Patients must not have any significant medical illnesses that in the investigator's
             opinion cannot be adequately controlled with appropriate therapy or would compromise
             the patient's ability to tolerate this therapy.

          -  Patients with a history of any other cancer (except non-melanoma skin cancer or
             carcinoma in-situ of the cervix), unless in complete remission and off of all therapy
             for that disease for a minimum of 3 years are ineligible.

          -  Patients must not have active infection or serious intercurrent medical illness.

          -  Patients must not be pregnant/breast feeding and must agree to practice adequate
             contraception.

          -  Patients must not have uncontrolled hypertension (systolic >180 mm hg or diastolic >
             100 mg Hg), angina pectoris, cardiac dysrhythmia, or recent (within 6 weeks)
             intracranial hemorrhage.
      "
NCT02929498,terminated,"
    the risk benefit in the study population does not favor continuation of the study
  ",0,phase 1/phase 2,"['myelodysplastic syndrome', 'myelodysplastic syndromes']","[""['D46.9', 'D46.C', 'D46.Z']"", ""['D46.9', 'D46.C', 'D46.Z']""]","['gsk2879552', 'azacitidine']","['C1CN(CCC1CNC2CC2C3=CC=CC=C3)CC4=CC=C(C=C4)C(=O)O', 'C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N']","
        Inclusion Criteria:

          -  >=18 years of age and provided signed written informed consent

          -  Subjects must have IPSS-R high or very high risk myelodysplastic syndromes (MDS) by
             World Health Organization (WHO) classification

          -  Subjects must have failed hypomethylating treatment where ""failure"" is defined as:
             Progression (according to 2006 International Working Group [IWG] criteria) at any time
             after initiation of the hypomethylating treatment OR Failure to achieve complete or
             partial response or hematological improvement (HI) (according to 2006 IWG) after at
             least 4 cycles treatment OR Relapse after initial complete or partial response or HI
             (according to 2006 IWG criteria).

          -  Subjects are not a candidate, or have failed allogeneic stem cell transplantation.
             Subjects who underwent allo-transplant in the past are eligible under following
             conditions: transplant was >2 year prior to enrolment, and no evidence of active
             graft-versus-host disease (GVHD)

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

          -  Subjects must have a life expectancy of at least 12 weeks, in the opinion of the
             investigator.

          -  Able to swallow and retain orally administered medication and does not have any
             clinically significant gastrointestinal abnormalities that may alter absorption such
             as malabsorption syndrome or major resection of the stomach or bowels.

          -  All prior treatment-related toxicities must be National Cancer Institute- Common
             Toxicity Criteria for Adverse Events (NCI-CTCAE), version 4.0 <=Grade 1 at the time of
             enrollment (except for alopecia).

          -  Adequate baseline organ function defined by: International Normalization Ratio (INR)
             and activated partial thromboplastin time (aPTT) <=1.3xupper limit of normal (ULN);
             platelet count (PLT) >=10,000 (transfusions permitted to bring PLT to >10,000); total
             bilirubin <=1.5xULN (Isolated bilirubin >1.5xULN is acceptable if bilirubin is
             fractionated and direct bilirubin <35% or subject has a diagnosis of Gilbert's
             syndrome); Alanine transaminase (ALT) <=2.5xULN; creatinine <=1.5xULN OR calculated
             creatinine clearance by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
             equation or measured from 24 hour urine >=50 milliliters (mL)/minute (min); and
             Ejection fraction >=lower limit of normal (LLN) by Echocardiogram (ECHO) or multigated
             acquisition scan (MUGA)

          -  Women of childbearing potential must have a negative serum pregnancy test within 7
             days of first dose of study treatment and agree to use effective contraception during
             the study and for 7 days following the last dose of study treatment.

          -  Men with a female partner of childbearing potential must have either had a prior
             vasectomy or agree to use effective contraception from the administration of the first
             dose of study treatment until 3 months after the last dose of study treatment to allow
             for clearance of any altered sperm.

        Exclusion Criteria:

          -  AML according to world health organization (WHO) criteria (i.e. bone marrow blasts
             >20%)

          -  Active hepatitis B or hepatitis C treatment

          -  Baseline Montreal Cognitive Assessment (MOCA) score of 22 or lower

          -  History of or concurrent malignancy of solid tumours, except for below:

        Exception: Subjects who have been disease-free for 2 years, or subjects with a history of
        completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are
        eligible.

          -  Prior treatment with temozolomide, dacarbazine or procarbazine

          -  Prior treatment with poly adenosine diphosphate (ADP) ribose polymerase (PARP)
             inhibitors (example (e.g.), olaparib, veliparib [ABT-888])

          -  Currently receiving other anti-cancer therapy (chemotherapy, radiation therapy,
             immuno- therapy, biologic therapy, hormonal therapy, surgery, and/or tumour
             embolization)

          -  Received major surgery, radiotherapy, or immunotherapy within 4 weeks of GSK2879552
             administration

          -  Evidence of severe or uncontrolled systemic diseases (e.g., severe/chronic infection,
             unstable or uncompensated respiratory, renal, or cardiac disease). Any serious and/or
             unstable pre-existing medical (aside from malignancy exception above), psychiatric
             disorder, or other conditions that could interfere with subject's safety, obtaining
             informed consent or compliance to the study procedures, in the opinion of the
             Investigator

          -  Current active liver or biliary disease (with the exception of Gilbert's syndrome or
             asymptomatic gallstones or otherwise stable chronic liver disease per investigator's
             assessment)

          -  Patients with any major bleeding current or within the past 4 weeks. (e.g. recent
             gastrointestinal [GI] hemorrhage or neurosurgery).

          -  Administration of an investigational drug within 14 days or 5 half-lives, whichever is
             shorter, preceding the first dose of study treatment(s) in this study.

          -  Cardiac abnormalities as evidenced by any of the following: clinically significant
             uncontrolled arrhythmias or uncontrolled hypertension; history or evidence of current
             >=Class II congestive heart failure as defined by New York Heart Association (NYHA);
             history of acute coronary syndromes (including unstable angina and myocardial
             infarction), coronary angioplasty, or stenting within the past 3 months; baseline
             Corrected QT (QTc) interval using Fridericia's formula >450 milliseconds (msec) or
             >480 msec in subjects with Bundle Branch Block. QTc value based on single or average
             of triplicate ECGs obtained over a brief recording period

          -  Current use of a prohibited medication including anticoagulants or platelet inhibitors
             or expected to require any of these medications during treatment with the
             investigational drug

          -  Consumption of Seville oranges, grapefruit, grapefruit hybrids, grapefruit juice,
             pommelos, or exotic citrus fruits, from 1 day prior to the first dose of study
             treatment(s) until the last dose of study drug

          -  Lactating female

          -  Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
             chemically related to GSK2879552 or lysine-specific demethylase 1 (LSD1) inhibitors
             that contraindicates their participation

          -  Known hypersensitivity to azacitidine or mannitol
      "
NCT02920450,terminated,"
    slow accrual
  ",0,phase 1/phase 2,['non-small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['gedatolisib', 'paclitaxel', 'carboplatin']","['CN(C)C1CCN(CC1)C(=O)C2=CC=C(C=C2)NC(=O)NC3=CC=C(C=C3)C4=NC(=NC(=N4)N5CCOCC5)N6CCOCC6', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C', 'C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]']","
        Inclusion Criteria:

          -  Signed Institutional Review Board (IRB)-approved informed consent prior to any
             study-related procedures

          -  Age of 18 years or older

          -  Advanced-stage unresectable NSCLC, as confirmed by pathological and/or radiological
             analysis (subjects will be classified as having advanced disease if they were not
             eligible for, or had disease progression after, surgical or locoregional therapies)

          -  Prior chemotherapy will be allowed for other invasive malignancies, provided therapy
             was completed at least five years before the start of protocol therapy, and
             participants have recovered from all toxicities of that prior therapy

          -  Participants may have received prior chemotherapy for NSCLC

          -  In the Phase II portion, subjects must have disease which lacks PTEN expression by
             immunohistochemistry, or has known prior activating PI3K or inactivating PTEN gene
             mutations (mutations will not be assayed for specifically)

          -  Eastern Cooperative Oncology Group (ECOG) performance status score < 2

          -  Life expectancy ≥ 12 week

          -  Participants must have measureable disease by RECIST criteria

          -  Absolute neutrophil count > 1500 mm3 (individuals with benign ethnic neutropenia may
             be enrolled if they have no evidence of infectious diathesis, or febrile neutropenia
             at the time of enrollment)

          -  Platelet count ≥ 100×109 L

          -  Hgb ≥ 8.5 g/dL (subjects may receive transfusions to achieve this, in the absence of
             overt bleeding)

          -  Total Bilirubin ≤ 2 mg/dL

          -  aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≤ 3 times the upper
             limit of normal range

          -  Serum creatinine ≤1.5 times the upper limit of the normal range

          -  Women of childbearing potential (WOCBP) must be using an adequate method of
             contraception to avoid pregnancy throughout the study and for at least 6 months after
             the last dose of study drug to minimize the risk of pregnancy. Prior to study
             enrollment, women of childbearing potential must be advised of the importance of
             avoiding pregnancy during trial participation and the potential risk factors for an
             unintentional pregnancy. WOCBP include any woman who has experienced menarche and who
             has not undergone successful surgical sterilization (hysterectomy, bilateral tubal
             ligation, or bilateral oophorectomy) or who is not post-menopausal. Post-menopause is
             defined as:

          -  Amenorrhea that has lasted for ≥ 12 consecutive months without another cause, or

          -  For women with irregular menstrual periods who are taking hormone replacement therapy
             (HRT), a documented serum follicle-stimulating hormone (FSH) level of greater than 35
             mIU/mL.

          -  Males with female partners of child-bearing potential must agree to use
             physician-approved contraceptive methods (e.g., abstinence, condoms, vasectomy)
             throughout the study and should avoid conceiving children for 6 months following the
             last dose of study drug

        Exclusion Criteria:

          -  Uncontrolled cardiac disease, congestive heart failure, angina, arrhythmias or
             hypertension.

          -  Myocardial infarction or unstable angina within 2 months of treatment.

          -  Known human immunodeficiency virus (HIV) infection or chronic active Hepatitis B
             (subjects will not be screened for this).

          -  Active clinically serious infection > CTCAE Grade 2.

          -  Thrombotic or embolic events such as a cerebrovascular accident including transient
             ischemic attacks within the past 6 months.

          -  Pulmonary hemorrhage/bleeding event ≥ CTCAE Grade 2 within 4 weeks of first dose of
             study drug.

          -  Any other hemorrhage/bleeding event ≥ CTCAE Grade 3 within 4 weeks of first dose of
             study drug.

          -  Serious non-healing wound, ulcer, or bone fracture.

          -  Evidence or history of bleeding diathesis or coagulopathy

          -  Major surgery, open biopsy or significant traumatic injury within 4 weeks of first
             study drug

          -  Women or men of childbearing potential who are unwilling or unable to use an
             acceptable method to avoid pregnancy for the entire study period and for at least 6
             months after the last dose of study drug

          -  Women who are pregnant or breastfeeding.

          -  History of any other disease, metabolic dysfunction, physical examination finding, or
             clinical laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates the use of protocol therapy or that might affect the interpretation of
             the results of the study or that puts the subject at high risk for treatment
             complications, in the opinion of the treating physician.

          -  Prisoners or subjects who are involuntarily incarcerated.

          -  Subjects who are compulsorily detained for treatment of either a psychiatric or
             physical illness.

          -  Subjects demonstrating an inability to comply with the study and/or follow-up
             procedures.
      "
NCT02928419,terminated,"
    ""the study has been closed due to a low rate of patient enrollment (2 patients since the start
    of the trial)""
  ",0,phase 2,['myelodysplastic syndromes'],"[""['D46.9', 'D46.C', 'D46.Z']""]","['eltrombopag/revolade', 'lenalidomide']","['Status: 400', 'C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N']","
        Inclusion Criteria:

          -  Adult subjects (18 years of age or older) with MDS and low or intermediate-1 IPSS risk
             and del5q as a single abnormality, at the time of their screening and enrollment into
             the study

          -  Subjects must not have received any prior treatment course with any immunomodulating
             agent nor TPO-R agonists

          -  Subjects must be dependent on regular packed RBC transfusions, as defined by
             international working group 2006 criteria, and must have a PLT count taken within the
             4 weeks prior to screening that is >25 Gi/L.

          -  Absolute Neutrophil Counts (ANC) ≥ 0.5 GiL

          -  Resistant or refractory to erythropoetic stimulating agents (ESAs) and/or serum
             erythropoetin levels > 500 miU/L

          -  Subjects must be ineligible or relapsed or refractory to receive treatment options of
             azacitidine and decitabine.

          -  Subjects must have PLT count and RBC and PLT transfusion data available over a period
             of 8 weeks prior to screening.

          -  During the 2 months prior to randomization, subjects must have a baseline BM
             examination including all of the following: cytomorphology, cytogenetics and histology

          -  ECOG Performance Status must be 0-3.

          -  The following clinical chemistries MUST NOT exceed the upper limit of normal (ULN)
             reference range: creatinine, ALT, AST, total bilirubin (except for Gilbert's
             Syndrome), gamma-gt and alkaline phosphatase. In addition, albumin must not be below
             the lower limit of normal (LLN) by more than 10%.

          -  If subject meets the criteria for childbearing potential:

               1. Negative pregnancy test in female subjects within the 3 days prior to Day 1 of
                  1st cycle and effective contraception for at least 4 weeks.

               2. Subject is practicing an acceptable method of contraception (documented in
                  chart). Female subjects (or female partners of male subjects) must either be of
                  non-childbearing potential (hysterectomy, bilateral oophorectomy, bilateral tubal
                  ligation or post-menopausal >1 year), or of childbearing potential and use of an
                  highly effective method of contraception from 2 weeks prior to administration of
                  study medication, throughout the study, and 28 days after completion or premature
                  discontinuation from the study.

          -  Criteria for women of non-childbearing potential: A female patient or a female partner
             of a male patient is considered to have childbearing potential unless she meets at
             least one of the following criteria:

               1. Age ≥ 50 years and naturally amenorrhoeic for ≥ 1 year (amenorrhoea following
                  cancer therapy or during lactation does not rule out childbearing potential).

               2. Premature ovarian failure confirmed by a gynaecologist

               3. Previous bilateral salpingo-oophorectomy, or hysterectomy

               4. XY genotype, Turner syndrome, uterine agenesis.

          -  Subject is able to understand and comply with protocol requirements and instructions.

          -  Subject has signed and dated informed consent.

        Exclusion Criteria:

          -  MDS with intermediate-2 or high IPSS risk

          -  Additional cytogenetic abnormalities

          -  Transfusion independence (TI) by IWG 2006 criteria

          -  Absolute Neutrophil Count < 0.5 Gi/L and/or Platelet counts < 25 Gi/L

          -  History of treatment for cancer with systemic chemotherapy and/or radiotherapy within
             the last 2 years

          -  History of treatment with immunomodulatory drugs or other TPO-R agonists.

          -  Thrombophilia, pre-existing history of thrombosis, cardiovascular disease (including
             congestive heart failure, New York Heart Association [NYHA] Grade III/IV), or
             arrhythmia known to increase the risk of thromboembolic events (e.g. atrial
             fibrillation), or subjects with a QTc >450 msec (QTc >480 msec for subjects with
             Bundle Branch Block)

          -  Bone Marrow fibrosis that leads to an inability to aspirate marrow for assessment.

          -  Leukocytosis >=25,000/uL prior to Day 1 of study medication.

          -  Monocytosis > 1000/ uL prior to Day 1 of study medication.

          -  Female subjects who are nursing or pregnant (positive serum or urine Beta-human
             chorionic gonadotropin [B-hCG] pregnancy test).

          -  Women of childbearing potential unless all of the conditions of the Pregnancy
             Prevention Programme illustrated in sections 6.4 are met (see sections 6.4).

          -  Known hypersensitivity to lenalidomide.

          -  Current alcohol or drug abuse.

          -  Treatment with an Investigational Product within 30 days or 5 half-lives (whichever is
             longer) preceding the first dose of study medication.

          -  Active and uncontrolled infections.

          -  Subjects infected with Hepatitis B, C or Human Immunodeficiency Virus (HIV).
      "
NCT01991210,terminated,"
    the primary objective of pfs did not meet pre-specified criteria.
  ",0,phase 2,['ovarian cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['dnib0600a', 'pld']",['CCCCCCCCCCCC[N+]1=C(C(=C(C(=C1)CO)C=O)O)C.[Cl-]'],"
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Histologically documented epithelial ovarian cancer, primary peritoneal cancer, or
             fallopian tube cancer

          -  Advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer that has
             progressed or relapsed during or within 6 months after the most recent treatment with
             a platinum-containing chemotherapy regimen and for whom PLD is appropriate therapy

          -  No more than 1 prior cytotoxic chemotherapy regimens for the treatment of PROC and not
             more than 2 total regimens (defined as any therapy [approved or investigational] with
             intent to treat the ovarian cancer)

          -  Adequate hematologic, renal and liver function

          -  Willing and able to perform a patient-reported outcome (PRO) survey (including the
             possibility of using an electronic PRO device)

          -  For women of childbearing potential, agreement to use 1 highly effective form of
             contraception as defined by protocol through the course of study treatment and for 6
             months after the last dose of study treatment

        Exclusion Criteria:

          -  Primary platinum-refractory disease defined as disease progression during or within 2
             months of a first-line, platinum-containing chemotherapy regimen

          -  Anti-tumor therapy, including chemotherapy, biologic, experimental, or hormonal
             therapy, within 4 weeks prior to Day 1

          -  Palliative radiation within 2 weeks prior to Day 1

          -  Prior anthracycline therapy, including prior treatment with PLD (for example, Doxil®,
             Caelyx®, or Lipodox®) in any setting (for example, in combination with carboplatin or
             as a single agent)

          -  Prior treatment with NaPi2b or SCL34A2 targeted therapy

          -  Major surgical procedure within 4 weeks prior to Day 1

          -  Current Grade greater than (>) 1 toxicity (except alopecia and anorexia) from prior
             therapy or Grade >1 neuropathy from any cause

          -  Left ventricular ejection fraction defined by multigated acquisition
             (MUGA)/echocardiogram below the institutional lower limit of normal

          -  Evidence of significant, uncontrolled, concomitant disease that could affect
             compliance with the protocol or interpretation of results, including significant
             cardiovascular disease or significant pulmonary disease

          -  Known active infection, or any major episode of infection requiring treatment with IV
             antibiotics or hospitalization (within 4 weeks prior to Cycle 1, Day 1)

          -  Clinically significant history of liver disease, including viral or other hepatitis,
             current alcohol abuse, or cirrhosis

          -  Presence of positive test results for hepatitis B or hepatitis C as detailed in the
             protocol

          -  Known history of HIV seropositive status

          -  Other malignancy within the last 5 years, except for adequately treated carcinoma in
             situ of the cervix, squamous carcinoma of the skin, adequately controlled limited
             basal cell skin cancer, or synchronous primary endometrial cancer or prior primary
             endometrial cancer

          -  Untreated or active central nervous system metastases (progressing or requiring
             anticonvulsants or corticosteroids for symptomatic control)

          -  Pregnancy or breastfeeding

          -  Known history of NaPi2b deficiency (for example, congenital alveolar microlithiasis or
             testicular microlithiasis)

          -  History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
             (or recombinant antibody-related fusion proteins)

          -  Metabolic dysfunction, physical examination finding, or clinical laboratory find
             giving reasonable suspicion of a disease or condition that contraindicated use of an
             investigational drug or may render the participant at high risk from treatment
             complications
      "
NCT01992952,"active, not recruiting",,1,phase 1/phase 2,['estrogen receptor positive breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['azd5363', 'placebo', 'fulvestrant']","['C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4', 'CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F']","
        Inclusion Criteria:

          -  Post-menopausal Women

          -  Life expectancy 3 months

          -  Histological confirmation of ER+ breast cancer

          -  Clinical or histological confirmation of metastatic or locally advanced disease not
             amenable to surgical resection

          -  Measurable or non-measurable disease

          -  Adequate bone marrow, renal and hepatic function

          -  Eastern Cooperative Oncology Group (ECOG) performance status < or equal to 2

          -  Progressive disease whilst receiving an aromatase inhibitor (AI) for metastatic breast
             cancer (MBC)

          -  Relapsed with metastatic disease whilst receiving an AI in adjuvant setting

          -  Up to 3 prior lines of endocrine therapy for Advanced Breast Cancer

          -  Up to 1 line of chemotherapy for Advanced Breast Cancer

          -  Patient willing to donate archival tumour sample

          -  Patient willing to donate baseline blood sample

          -  Suitable for further endocrine therapy

        Exclusion Criteria:

          -  Previous treatment with fulvestrant or PI3K/mTOR(mammalian target of rapamycin )/Akt
             inhibitor therapy

          -  Treatment with chemotherapy, immunotherapy or targeted, biologic or tumour
             embolisation within 21 days of study drug administration

          -  Palliative radiotherapy within 7 days of study drug

          -  Clinically significant abnormalities in glucose metabolism

          -  Rapidly progressive visceral disease not suitable for further endocrine therapy

          -  Known brain or leptomeningeal metastases

          -  Any co-existing medical condition precluding trial entry including significant cardiac
             disease (to be defined in the protocol)

          -  Concomitant medication unsuitable for combination with trial medication
      "
NCT02538965,completed,,0,phase 2,"['leukemia, myeloid']","[""['C92.Z1', 'C92.Z2', 'C92.91', 'C92.92', 'C92.Z0', 'C92.90', 'C92.11']""]",['lenalidomide'],['C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N'],"
        Inclusion Criteria:

        - Participants must satisfy the following criteria to be enrolled in the study:

          1. Male or female is 1 to ≤ 18 years of age at the time of signing the Informed Consent
             Form / Informed Assent Form (ICF/IAF).

          2. Participants (when applicable, parental/legal representative) must understand and
             voluntarily provide permission to the ICF/IAF prior to conducting any study-related
             assessments/procedures.

          3. Participants have relapsed or refractory acute myeloid leukemia after at least 2 prior
             induction attempts:

               -  Bone marrow aspirate or biopsy must have ≥ 5% blasts by morphology and/or flow
                  cytometry.

               -  Each block of chemotherapy is a separate reinduction attempt.

               -  Donor lymphocyte infusion (DLI) is considered a reinduction attempt.

          4. Participants are willing and able to adhere to the study visit schedule and other
             protocol requirements.

          5. Participants have a Karnofsky score of ≥ 50% (participants ≥ 16 years of age) or a
             Lansky score ≥ 50% (participants < 16 years of age).

          6. Participants have a resting left ventricular ejection fraction (LVEF) of ≥ 40%
             obtained by echocardiography.

          7. Participants have recovered from the acute toxic effects of all prior chemotherapy,
             immunotherapy, or radiotherapy prior to first dose. All prior treatment-related
             toxicities must have resolved to ≤ Grade 2 prior to enrollment.

          8. Regarding radiation therapy, time elapsed prior to first dose of lenalidomide:

               -  2 weeks for local palliative radiation therapy (XRT).

               -  8 weeks if prior craniospinal chemoradiation therapy (CRT) or if ≥ 50% radiation
                  of pelvis.

               -  6 weeks if other bone marrow radiation has been administered.

          9. Graft-versus-host disease criteria:

               -  Participants must be at least 2 months (from first dose of lenalidomide) from
                  stem cell infusion.

               -  Participants must have no evidence of active acute or chronic GVHD (Grade 0) for
                  4 weeks prior to the first dose of lenalidomide.

               -  If the participants have a history of maximum Grade 1 or 2 GVHD that was treated
                  with systemic steroid (≥ 0.5 mg/kg/day prednisone equivalents) or other
                  non-steroid systemic IST, the participant must be off all IST for at least 2
                  weeks, and must have ceased treatment doses of steroids for GVHD (≥ 0.5 mg/kg/day
                  prednisone equivalents) for at least 4 weeks.

                    -  If the participants have a history of Grade 3 or greater GVHD, the
                       participants must be off all systemic IST for 4 weeks

                    -  Topical therapy is permitted and does not imply the participants have active
                       acute or chronic GVHD.

               -  Physiologic dosing of hydrocortisone is permitted.

         10. At least 4 weeks (from first dose) elapsed from donor lymphocyte infusion (DLI)
             without conditioning.

         11. Participants have adequate renal function, which is defined as:

             - Creatinine clearance calculated using the Schwartz formula, or radioisotope
             glomerular filtration rate (GFR) > 70 mL/min/1.73 m2.

         12. Participants have adequate liver function, which is defined as:

               -  Total bilirubin is ≤ 2 mg/dL unless the increase in bilirubin is attributable to
                  Gilbert's Syndrome

               -  Aspartate aminotransferase (AST) is ≤ 3.0 x upper normal limit (ULN) for age. For
                  the purpose of this study, the ULN for AST is 50 U/L.

               -  Alanine transaminase (ALT) is ≤ 3.0 x upper normal limit (ULN) for age. For the
                  purpose of this study, the ULN for ALT is 45 U/L.

         13. Female Children of Childbearing Potential (FCCBP), Female of Childbearing Potential
             (FCBP) and male participants that have reached puberty must agree to undergo
             physician-approved reproductive education and discuss the side effects of the study
             therapy on reproduction with parent(s) and/or guardian(s).

         14. All participants and/or parents/guardians must have an understanding that lenalidomide
             could have a potential teratogenic risk. Female children of childbearing potential, is
             defined as females who have achieved menarche and/or breast development in Tanner
             Stage 2 or greater and have not undergone a hysterectomy or bilateral oophorectomy and
             FCBP defined as a sexually mature woman who has not undergone a hysterectomy or
             bilateral oophorectomy and has not been naturally postmenopausal for at least 24
             consecutive months (ie, has had menses at any time in the preceding 24 consecutive
             months) must meet the following conditions below (Note: Amenorrhea following cancer
             therapy does not rule out childbearing potential):

               -  Medically supervised serum pregnancy tests with a sensitivity of at least 25
                  mIU/mL must be conducted in FCCBP/FCBP, including those who commit to complete
                  abstinence*. FCCBP/FCBP must have two pregnancy tests (with a minimum sensitivity
                  of 25 mIU/mL) prior to starting treatment with lenalidomide. The first pregnancy
                  test must be performed within 10 - 14 days prior to the start of lenalidomide
                  treatment and the second pregnancy test must be performed within 24 hours prior
                  to starting treatment with lenalidomide.

        NOTE: The pregnancy test 10 to 14 days prior to initiation of lenalidomide may be omitted,
        at the discretion of the investigator, for any FCCBP/FCBP who has high acuity disease
        requiring immediate treatment with lenalidomide. The pregnancy test within 24 hours prior
        to the first dose of lenalidomide is required to be performed.

        The participants may not received Investigational Product (IP) until the investigator has
        verified that the results of these pregnancy tests performed on Cycle 1 Day 1 are negative.
        FCCBP/FCBP with regular or no menstrual cycles must agree to have pregnancy tests weekly
        for the first 28 days of study participation and then every 28 days while on study, at
        study Treatment Discontinuation Visit, and at Day 28 following IP discontinuation. If
        menstrual cycles are irregular, the pregnancy testing must occur weekly for the first 28
        days and then every 14 days while on study, at study Treatment Discontinuation Visit, and
        at Days 14 and 28 following IP discontinuation.

          -  Female participants must, as appropriate to age and at the discretion of the study
             Investigator, either commit to true abstinence* from heterosexual contact (which must
             be reviewed on a monthly basis) and/or agree to the use of two reliable forms of
             approved and effective contraceptive methods simultaneously. The two methods of
             reliable contraception must include one highly effective method and one additional
             effective (barrier) method (oral, injectable, or implantable hormonal contraceptive;
             tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or
             vasectomized partner) without interruption, 28 days prior to starting lenalidomide
             treatment, throughout the entire duration of study treatment including dose
             interruptions and 28 days after the end of study treatment.

          -  All male and female participants must follow all requirements defined in the Pregnancy
             Prevention Program.

             16. Male participants, as appropriate to age and the discretion of the study
             physician:

          -  Must practice true abstinence* or agree to use a condom during sexual contact with a
             pregnant female or a female of childbearing potential while participating in the
             study, during dose interruptions and for at least 28 days following lenalidomide
             discontinuation, even if he has undergone a successful vasectomy or practices complete
             abstinence.

        Exclusion Criteria:

          1. Participants have Down syndrome.

          2. Participants have French-American-British classification (FAB) type M3 leukemia (acute
             promyelocytic leukemia) or identification of t(15;17).

          3. Participants have isolated central nervous system (CNS) involvement or extramedullary
             relapse. (Participants with combined CNS/marrow relapse may be enrolled).

          4. Participants had prior treatment with cytotoxic chemotherapy within 2 weeks of the
             first dose of lenalidomide with the exception of hydroxyurea (allowed prior to the
             first dose of lenalidomide and through Day 14 of Cycle 1) and intrathecal (IT)
             cytarabine will be administered within 2 weeks prior to administration of
             lenalidomide.

          5. Participants have had prior treatment with biologic antineoplastic agents less than 7
             days before the first dose of lenalidomide. For agents that have known adverse events
             (AEs) occurring beyond 7 days after administration (ie, monoclonal antibodies), this
             period must be extended beyond the time during which acute AEs are known to occur.

          6. Participants have had prior treatment with lenalidomide.

          7. Participant is pregnant or lactating.

          8. Participants have an uncontrolled systemic fungal, bacterial, or viral infection
             (defined as ongoing signs/symptoms related to the infection without improvement
             despite appropriate antibiotics, antiviral therapy, and/or other treatment).

          9. Participants has known Human Immunodeficiency Virus (HIV) positivity (participants who
             are receiving antiretroviral therapy for HIV disease).

         10. Participants have a prior history of malignancies other than AML unless the subject
             has been free of the disease for ≥ 5 years from first dose of lenalidomide.

         11. The presence of any of the following will exclude a participant from enrollment:

               -  Participants have any significant medical condition, laboratory abnormality, or
                  psychiatric illness that would prevent the participant from participating in the
                  study.

               -  Participants have any condition including the presence of laboratory
                  abnormalities, which places the participant at unacceptable risk if he/she were
                  to participate in the study.

               -  Participants have any condition that confounds the ability to interpret data from
                  the study.

         12. Participants have cardiac disorders (Common Terminology Criteria for Adverse Events
             [CTCAE] version 4.03 Grade 3 or 4).

         13. Participants have a history of well-documented prior veno-occlusive disease (VOD).

         14. Participants have any other organ dysfunction (CTCAE version 4.03 Grade 4) that will
             interfere with the administration of the therapy according to this protocol.
      "
NCT02530424,completed,,1,phase 2,['breast neoplasms'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['trastuzumab', 'pertuzumab', 'palbociclib', 'fulvestrant']","['CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C', 'CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F']","
        Inclusion Criteria:

          1. Female patients aged 18 years or older with tumors suitable for neoadjuvant treatment

          2. Early (> 1.5 cm) or locally advanced untreated breast cancer

          3. Histologically confirmed invasive unilateral breast cancer

          4. HER2 status to be centrally confirmed (HER2 3+ of neu amplified for cohorts A and B;
             HER2 1+/2+ without amplification for cohort C)

          5. Positive estrogen receptor (ER) > 10% and known progesterone receptor (PgR). Note: PgR
             assessment must be positive for cohort C

          6. Ki67 > 20% for cohort C

          7. Available paraffin-embedded tumor block taken at diagnostic biopsy for central
             retrospective confirmation of HER2 and ER eligibility and for assessment of Ki67 value
             and apoptosis is mandatory

          8. All patients must agree to provide tumor tissues for centralized assessment of KI67
             values and apoptosis at the required timelines (2 weeks from starting protocol therapy
             and at surgery)

          9. ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1

         10. Written informed consent to participate in the trial (approved by the Institutional
             Review Board/ Independent Ethics Committee) obtained prior to any study specific
             screening procedures

         11. Willing and able to comply with the protocol

        Exclusion Criteria:

          1. Evidence of bilateral invasive breast cancer or metastatic disease (M1)

          2. Pregnant or lactating women.

          3. Women with childbearing potential unless (1) surgically sterile or (2) using adequate
             measures of contraception

          4. Previous treatment with chemotherapy, hormonal therapy or an investigational drug for
             any type of malignancy

          5. Previous extensive radiotherapy

          6. Previous investigational treatment for any condition within 4 weeks of registration
             date

          7. Known hypersensitivity reaction to one of the compounds or incorporated substances
             used in this protocol

          8. Previous or concomitant malignancy of any other type that could affect compliance with
             the protocol or interpretation of results.

          9. Other serious illness or medical condition including: history of documented congestive
             cardiac failure; angina pectoris requiring anti-anginal medication; evidence of
             transmural infarction on ECG; poorly controlled hypertension; clinically significant
             valvular heart disease; high-risk uncontrolled arrhythmias

         10. Baseline left ventricular ejection fraction (LVEF) < 55% by echocardiography or
             multi-gated scintigraphic scan (MUGA)

         11. QTc (corrected QT interval) >480 msec or a family or personal history of long or short
             QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de
             Pointes (TdP)

         12. Patients with a history of uncontrolled seizures, central nervous system disorders or
             psychiatric disability judged by the investigator to be clinically significant and
             precluding informed consent or adversely affecting compliance with study drugs

         13. Serious uncontrolled infections (bacterial or viral) or poorly controlled diabetes
             mellitus

         14. Current use or anticipated need for food or drugs that are known strong CYP3A4
             (cytochrome P450 3A4) inhibitors or inducers

         15. Uncontrolled electrolyte disorders that can compound the effects of a QTc prolonging
             drug (e.g., hypocalcemia, hypokalemia, hypomagnesemia)

         16. Abnormal baseline hematological values:

         17. Abnormal baseline liver function, bilirubin, creatinine and/or INR (international
             normalized ratio)
      "
NCT02538510,"active, not recruiting",,1,phase 1/phase 2,"['head and neck squamous cell carcinoma', 'recurrent nasal cavity and paranasal sinus squamous cell carcinoma', 'recurrent nasopharynx carcinoma', 'recurrent salivary gland carcinoma', 'squamous cell carcinoma metastatic in the neck with occult primary', 'stage iii major salivary gland carcinoma', 'stage iii nasal cavity and paranasal sinus squamous cell carcinoma', 'stage iii nasopharyngeal carcinoma', 'stage iv nasopharyngeal carcinoma', 'stage iva major salivary gland carcinoma', 'stage iva nasal cavity and paranasal sinus squamous cell carcinoma', 'stage ivb major salivary gland carcinoma', 'stage ivb nasal cavity and paranasal sinus squamous cell carcinoma', 'stage ivc major salivary gland carcinoma', 'stage ivc nasal cavity and paranasal sinus squamous cell carcinoma']","[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]",['vorinostat'],['C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO'],"
        Inclusion Criteria:

          -  Phase I run in: biopsy proven RMHNSCC with the following primary sites: nasopharynx,
             paranasal sinus, nasal cavity, skin/cutaneous sites; patients with unknown head and
             neck primary sites will be enrolled; patients with recurrent or metastatic squamous
             cell carcinomas of the head and neck (regardless of primary site) who are either
             unwilling to receive or have contraindications (deemed by treating physician) to
             standard systemic chemotherapy will also be eligible; patients with biopsy proven
             RMSGC be eligible as well

          -  Phase II expansion: biopsy proven RMHNSCC, of any primary site (including unknown
             primary) and RMSGC will be eligible

          -  Have evidence of disease progression by Response Evaluation Criteria in Solid Tumors
             (RECIST) 1.1 criteria within 3 months prior to study enrollment; if the patient was
             receiving a prior line of systemic therapy, he/she should have evidence of disease
             progression on that line of treatment prior to enrollment

          -  Have received any number lines of prior systemic therapy (including systemic therapy
             in the curative intent setting)

          -  Be willing and able to provide written informed consent for the trial and comply with
             the study visit requirements

          -  Have measurable disease based on RECIST 1.1

          -  Have provided tissue from an archival tissue sample or newly obtained core or
             excisional biopsy of a tumor lesion

          -  Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)
             performance scale

          -  Absolute neutrophil count (ANC) >= 1,500/mcL

          -  Platelets >= 100,000/mcL

          -  Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

          -  Serum creatinine =< 1.5 x upper limit of normal (ULN) OR measured or calculated*
             creatinine clearance >= 60 mL/min for subject with creatinine levels > 1.5 x
             institutional ULN (glomerular filtration rate [GFR] can also be used in place of
             creatinine or creatinine clearance [CrC])

               -  Creatinine clearance should be calculated per institutional standard

          -  Serum total bilirubin =< 1.5 x ULN

          -  Aspartate aminotransferase (AST) (glutamic oxaloacetic transaminase [SGOT]) and
             alanine aminotransferase (ALT) (glutamate pyruvate transaminase [SGPT]) =< 1.5 x ULN

          -  International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN unless
             subject is receiving anticoagulant therapy as long as PT or partial thromboplastin
             time (PTT) is within therapeutic range of intended use of anticoagulants

          -  Activated partial thromboplastin time (aPTT) =< 1.5 x ULN unless subject is receiving
             anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use
             of anticoagulants

          -  Female subjects of childbearing potential should have a negative urine or serum
             pregnancy within 72 hours prior to receiving the first dose of study medication; if
             the urine test is positive or cannot be confirmed as negative, a serum pregnancy test
             will be required

          -  Female subjects of childbearing potential should be willing to use 2 methods of birth
             control or be surgically sterile, or abstain from heterosexual activity for the course
             of the study through 120 days after the last dose of study medication; subjects of
             childbearing potential are those who have not been surgically sterilized or have not
             been free from menses for > 1 year

          -  Male subjects should agree to use an adequate method of contraception starting with
             the first dose of study therapy through 120 days after the last dose of study therapy

          -  Patient is < 5 years free of another primary malignancy, except: a) if the other
             malignancy is basal cell carcinoma or cervical carcinoma in situ or b) if the other
             primary malignancy is not considered clinically significant and is requiring no active
             intervention

          -  SECOND COURSE PHASE (RETREATMENT PERIOD FOR POST-COMPLETE RESPONSE RELAPSE ONLY)

          -  Subjects may be eligible to receive MK-3475 in the second course phase of this study
             if the study remains open and the subject meets the following conditions:

          -  Stopped initial treatment with MK-3475 after attaining an investigator-determined
             confirmed response according to RECIST1.1 response criteria

          -  Was treated for at least 24 weeks with MK-3475 before discontinuing therapy

          -  Received at least four treatments with MK-3475 beyond the date when the initial
             complete response (CR) was declared

          -  Experienced an investigator-determined confirmed cutaneous or radiographic disease
             progression after stopping their initial treatment with MK-3475

          -  Did not receive any anti-cancer treatment since the last dose of MK-3475

          -  Have a performance status of 0 or 1 on the ECOG performance scale

          -  Demonstrate adequate organ function as detailed above

          -  Female subject of childbearing potential should have a negative urine or serum
             pregnancy test within 72 hours prior to receiving retreatment with study medication

          -  Female subjects of childbearing potential should be willing to use 2 methods of birth
             control or be surgically sterile, or abstain from heterosexual activity for the course
             of the study through 120 days after the last dose of study medication; subjects of
             child bearing potential are those who have not been surgically sterilized or have not
             been free from menses for > 2 year; male subjects should agree to use an adequate
             method of contraception starting with the first dose of study therapy through 120 days
             after the last dose of study therapy

          -  Does not have a history or current evidence of any condition, therapy, or laboratory
             abnormality that might interfere with the subject's participation for the full
             duration of the trial or is not in the best interest of the subject to participate, in
             the opinion of the treating investigator

        Exclusion Criteria:

          -  Is currently participating in or has participated in a study of an investigational
             agent or using an investigational device within 4 weeks of the first dose of treatment

          -  Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
             other form of immunosuppressive therapy within 7 days prior to the first dose of trial
             treatment

          -  Has had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not
             recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents
             administered more than 4 weeks earlier

          -  Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy
             within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at
             baseline) from adverse events due to a previously administered agent

               -  Note: subjects with =< grade 2 neuropathy are an exception to this criterion and
                  may qualify for the study

               -  Note: if subject received major surgery, they must have recovered adequately from
                  the toxicity and/or complications from the intervention prior to starting therapy

          -  Has a known additional malignancy that is progressing or requires active treatment;
             exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the
             skin, or in situ cervical cancer that has undergone potentially curative therapy

          -  Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis; subjects with previously treated brain metastases may participate provided
             they are stable (without evidence of progression by imaging for at least four weeks
             prior to the first dose of trial treatment and any neurologic symptoms have returned
             to baseline), have no evidence of new or enlarging brain metastases, and are not using
             steroids for at least 7 days prior to trial treatment

          -  Has an active autoimmune disease requiring systemic treatment within the past 3 months
             or a documented history of clinically severe autoimmune disease, or a syndrome that
             requires systemic steroids or immunosuppressive agents; subjects with vitiligo or
             resolved childhood asthma/atopy would be an exception to this rule; subjects that
             require intermittent use of bronchodilators or local steroid injections would not be
             excluded from the study; subjects with hypothyroidism stable on hormone replacement or
             Sjogren's syndrome will not be excluded from the study

          -  Has evidence of interstitial lung disease or active, non-infectious pneumonitis

          -  Has an active infection requiring systemic therapy

          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the subject's
             participation for the full duration of the trial, or is not in the best interest of
             the subject to participate, in the opinion of the treating investigator

          -  Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial

          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the pre-screening or screening visit
             through 120 days after the last dose of trial treatment

          -  Has received prior therapy with an anti-programmed cell death 1 (PD-1), PD-L1,
             anti-programmed cell death ligand 2 (PD-L2), anti-cluster of differentiation (CD)137,
             or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including
             ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation
             or checkpoint pathways); patients who have previously received MK-3475 or participated
             in an MK-3475 clinical trial will be ineligible

          -  Has received prior therapy with vorinostat or other epigenetic agent

          -  Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)

          -  Has known active hepatitis B (e.g., hepatitis B virus surface antigen [HBsAg]
             reactive) or hepatitis C (HCV) (e.g., HCV RNA [ribonucleic acid] qualitative is
             detected)

          -  Has received a live vaccine within 30 days prior to the first dose of trial treatment

          -  Requires total parenteral nutrition and is unable to swallow pills or unable to take a
             suspension through a gastrostomy tube
      "
NCT02535988,withdrawn,"
    no recruitment.
  ",0,phase 2,"['colorectal cancer', 'metastatic colorectal cancer', 'thymalfasin']","[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]",['thymalfasin'],['CCC(C)C(C(=O)NC(C(C)O)C(=O)NC(C(C)O)C(=O)NC(CCCCN)C(=O)NC(CC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCC(=O)O)C(=O)NC(C(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CCC(=O)O)C(=O)NC(CC(=O)N)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC(=O)O)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C'],"
        Inclusion Criteria:

          1. Patients with histologically confirmed colorectal cancer which is persistent and
             metastatic or recurrent and metastatic;

          2. Patients must have at least 3 distinct measurable metastatic sites at least 1 cm of
             larger in their largest diameter;

          3. Age ≥18 years;

          4. Metastatic disease measurable on a CT/MRI scan. The primary tumor is not considered
             measurable disease. Metastatic lesions within a prior radiation field are acceptable
             as long as disease has progressed in the radiation field by RECIST criteria. The same
             imaging modality performed at baseline (CT or MRI) will be repeated at subsequent
             imaging.

          5. ECOG performance status: 0-1;

          6. Life expectancy ≥ 3 months.

          7. Patients have adequate baseline organ and marrow function as defined by an absolute
             neutrophil count greater than 1500 cells per μL, platelet concentration of greater
             than 50 000 per μL, total bilirubin less than 1•5 times the upper limit of normal
             (ULN), aspartate aminotransferase and alanine aminotransferase less than 2•5 times the
             ULN, and serum creatinine less than 1•5 times the ULN;

          8. Signed consent forms voluntarily;

        Exclusion Criteria:

          1. Patients who have had prior allergic reaction to Apatinib;

          2. Patients undergoing therapy with other investigational agents.

          3. Women who are pregnant or breastfeeding;

          4. Patients with known brain metastases can be included in this clinical trial but brain
             lesions are not eligible as target or non target lesion;

          5. Anticipated patient survival under 3 months;

          6. Active severe infection or known chronic infection with HIV, hepatitis B virus, or
             hepatitis C virus;

          7. Cardiovascular disease problems including unstable angina, therapy for
             life-threatening ventricular arrhythmia, myocardial infarction, stroke or congestive
             heart failure within the last 6 months;

          8. The subject has had another active malignancy within the past five years except for
             cervical cancer in site, in situ carcinoma of the bladder or non-melanoma carcinoma of
             the skin;

          9. Clinically significant and uncontrolled major medical conditions including but not
             limited to: active uncontrolled infection, symptomatic congestive heart failure,
             Unstable angina pectoris or cardiac arrhythmia, psychiatric illness/ social situation
             that would limit compliance with study requirements; any medical condition, which in
             the opinion of the study investigator places the subject at an unacceptably high risk
             for toxicities;

         10. Patients with any other concurrent disease which, in the judgment of the investigator,
             would make the patient inappropriate for participation in the study.
      "
NCT02539225,completed,,0,phase 2,"['metastatic gastric adenocarcinoma', 'gastroesophageal junction adenocarcinoma']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['ramucirumab', 'placebo', 's-1', 'oxaliplatin', 'paclitaxel']","['C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C']","
        Inclusion Criteria:

          -  Have a histopathologically or cytologically confirmed diagnosis of metastatic gastric
             or GEJ adenocarcinoma. Participants with esophageal cancer are not eligible.

          -  Have not received any prior first-line systemic therapy for gastric or GEJ
             adenocarcinoma (prior adjuvant or neoadjuvant therapy is permitted). Participants
             whose disease has progressed after >24 weeks following the last dose of systemic
             treatment in the adjuvant/neoadjuvant setting are eligible.

          -  Have measurable or nonmeasurable but evaluable disease determined using guidelines in
             Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v.1.1).

          -  Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)
             scale at baseline.

          -  Have adequate organ function.

          -  Have an estimated life expectancy of ≥12 weeks in the judgment of the investigator.

          -  Eligible participants of reproductive potential (both sexes) must agree to use
             contraception (hormonal or barrier methods) during the study period and at least 6
             months after the last dose of study treatment or longer if required per local
             regulations.

          -  Are willing to provide a blood sample for research purposes. Submission of a blood
             sample is mandatory for participation in this study unless restricted by local
             regulations or ethical review boards (ERBs); submission of a tumor tissue sample is
             optional.

        Exclusion Criteria:

          -  Participants with human epidermal growth factor receptor 2 (HER2)-positive status as
             determined per local standards. Participants with a negative test or having an
             indeterminate result due to any reason are eligible, provided these participants are
             not eligible for treatment directed against tumors which overexpress HER2.

          -  Have radiation therapy within 14 days prior to randomization. Any lesion requiring
             palliative radiation or which has been previously irradiated cannot be considered for
             response assessment.

          -  Have documented brain metastases, leptomeningeal disease, or uncontrolled spinal cord
             compression.

          -  Have undergone major surgery within 28 days prior to randomization.

          -  Are currently enrolled in, or discontinued study drug within the last 28 days from, a
             clinical trial involving an investigational product or non-approved use of a drug or
             device (other than the study drug used in this study), or are concurrently enrolled in
             any other type of medical research judged not to be scientifically or medically
             compatible with this study. Participants participating in surveys or observational
             studies are eligible to participate in this study.

          -  Are pregnant or breast feeding. Females of childbearing potential must have a negative
             serum or urine pregnancy test within 7 days prior to first dose of study treatment.

          -  Have any prior malignancies.

          -  Have any condition (eg, psychological, geographical, or medical) that does not permit
             compliance with the study and follow-up procedures or suggest that the participant is,
             in the investigator's opinion, not an appropriate candidate for the study.
      "
NCT02535650,"active, not recruiting",,1,phase 2,['urothelial carcinoma'],"[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]",['tipifarnib'],['Status: 503'],"
        Inclusion Criteria:

          1. Subject is at least 20 years of age.

          2. Subject has a histologically or cytologically confirmed diagnosis of urothelial
             carcinoma arising from urinary bladder or upper urinary tract.

          3. Subject has been treated with platinum-based chemotherapy for advanced disease. They
             must have refractory or progressive disease for which there is no further curative
             therapy available.

          4. Subject has been treated with platinum-based chemotherapy for advanced disease. They
             must have refractory or progressive disease for which there is no further curative
             therapy available.

             Subject has a tumor that carries a missense HRAS mutation according to a standard
             methodology using Illumina HiSeqTM. (missence non-synonymous HRAS mutation and/or
             STK11: rs2075606 (T>C))HRAS status may have been assessed either in primary tumor
             tissue, recurrent or metastatic disease.

          5. Subject has consented to provide at least 10 unstained tumor slides for retrospective
             testing of HRAS gene tumor status.

          6. Must have a life expectancy of 3 months or more

          7. Subject has measurable disease according to RECIST(Response Evaluation Criteria in
             Solid Tumors ) v1.1 and has relapsed (progressive disease) or is refractory to prior
             therapy.

          8. At least 2 weeks since the last systemic therapy regimen prior to enrolment. Subjects
             must have recovered to NCI CTCAE v. 4.03 < Grade 2 from all acute toxicities
             (excluding Grade 2 toxicities that are not considered a safety risk by the Sponsor and
             Investigator) or toxicity must be deemed irreversible by the Investigator.

          9. At least 2 weeks since last radiotherapy if radiation was localized to the only site
             of measurable disease, unless there is documentation of disease progression of the
             irradiated site. Patients must have recovered from all acute toxicities from
             radiotherapy.

         10. ECOG(Eastern Cooperative Oncology Group ) performance status of 0 or 1.

         11. Acceptable liver function:

               1. Bilirubin ≤ 1.5 times upper limit of normal (x ULN); does not apply to subjects
                  with Gilbert's syndrome diagnosed as per institutional guidelines.

               2. AST (SGOT,aspartate aminotransferase ) and ALT (SGPT,Alanine aminotransferase) ≤
                  3 x ULN; if liver metastases are present, then ≤ 5 x ULN is allowed.

         12. Acceptable renal function with serum creatinine ≤ 1.5 x ULN or a calculated creatinine
             clearance ≥ 60 mL/min using the Cockcroft-Gault or MDRD(Modification of Diet in Renal
             Disease ) formulas. Serum potassium with normal or ≤ CTCAE Grade 1 with or without
             supplementation.

         13. Acceptable hematologic status (without growth factor support or transfusion
             dependency):

               1. ANC(absolute neutrophil count )>1500 cells/μL.

               2. Platelet count >100,000/μL.

               3. Hemoglobin >9.0 g/dL.

         14. Female subjects must be either:

               1. Of non-child-bearing potential (surgically sterilized or at least 2 years
                  post-menopausal); or

               2. If of child-bearing potential, subject must use an adequate method of
                  contraception consisting of two-barrier method or one barrier method with a
                  spermicide or intrauterine device. Both females and male subjects with female
                  partners of child-bearing potential must agree to use an adequate method of
                  contraception for 2 weeks prior to screening, during, and at least 4 weeks after
                  last dose of trial medication. Female subjects must have a negative serum or
                  urine pregnancy test within 72 hours prior to start of trial medication.

               3. Not breast feeding at any time during the study.

         15. Written and voluntary informed consent understood, signed and dated.

        Exclusion Criteria:

          1. Ongoing treatment with an anticancer agent not contemplated in this protocol.

          2. Prior treatment (at least 1 full treatment cycle) with an FTase inhibitor.

          3. Any history of clinically relevant coronary artery disease or myocardial infarction
             within the last 3 years, New York Heart Association (NYHA) grade III or greater
             congestive heart failure, cerebrovascular attack within the prior year, or current
             serious cardiac arrhythmia requiring medication except atrial fibrillation.

          4. Known uncontrolled brain, leptomeningeal or epidural metastases (unless treated and
             well controlled for at least 4 weeks prior to Cycle 1 Day 1). Subjects that develop
             brain metastasis during the study may have their treatment interrupted to receive a
             course of cranial radiation and restart trial medication after a recovery period of at
             least 1 week. High dose corticosteroids may be employed for the management of cranial
             radiation but must be tapered off before resuming treatment.

          5. Non-tolerable > Grade 2 neuropathy or evidence of unstable neurological symptoms
             within 4 weeks of Cycle 1 Day 1.

          6. Major surgery, other than diagnostic surgery, within 4 weeks prior to Cycle 1 Day 1,
             without complete recovery.

          7. Double primary cancer of other site(s), except for cured ones at the discretion of
             investigator

          8. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic
             therapy. Known infection with HIV, or an active infection with hepatitis B or
             hepatitis C.

          9. Subjects who have exhibited allergic reactions to tipifarnib, structural compounds
             similar to tipifarnib or to its excipients.

         10. Concomitant disease or condition that could interfere with the conduct of the study,
             or that would, in the opinion of the Investigator, pose an unacceptable risk to the
             subject in this study.

         11. The subject has legal incapacity or limited legal capacity.

         12. Dementia or significantly altered mental status that would limit the understanding or
             rendering of informed consent and compliance with the requirements of this protocol.
             Unwillingness or inability to comply with the study protocol for any reason.

         13. QTcF interval ≥ 470 msecs
      "
NCT02530476,completed,,1,phase 1/phase 2,"['leukemia', 'acute myeloid leukemia']","[""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']"", ""['C92.A1', 'C92.A2', 'C92.61', 'C92.62', 'C92.A0', 'C92.60']""]","['selinexor', 'sorafenib']","['C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F', 'CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F']","
        Inclusion Criteria:

          1. FLT3-ITD and/or FLT3-D835 mutated patients 18 years of age or older with relapsed/
             refractory AML (any number of relapses) including patients who may have been
             previously exposed to one or more FLT3-inhibitor therapies will be eligible for the
             phase I portion of this study.

          2. Phase II FLT3-ITD and/or FLT3-D835 mutated relapsed/refractory patients: Patients
             should have a diagnosis of AML (de novo or transformed from hematologic malignancies).
             Patients with high-risk myelodysplastic syndrome (MDS) (defined as having >/= 10%
             blasts in the bone marrow) or patients with Chronic Myelomonocytic Leukemia (CMML)
             (having >/= 10% blasts in the bone marrow) may also be eligible after discussion with
             Principal Investigator (PI). The patients should have one of the following features:
             1. Patients with AML should have failed any prior induction therapy or have relapsed
             after prior therapy. 2. Patients with high-risk MDS or high-risk CMML should have
             failed any prior therapy for the MDS or CMML. 3. Patients with MDS or CMML who
             received therapy for the MDS or CMML and progress to AML are eligible at the time of
             diagnosis of AML regardless any prior therapy for AML. The World Health Organization
             (WHO) classification will be used for AML.

          3. Patients must be eligible for one of two cohorts: Cohort 1 (FLT3 and/or FLT3-D835
             inhibitor failure cohort) in FLT3-ITD and/or FLT3-D835 mutated relapsed/refractory AML
             who have failed therapy with up to two prior salvage regimens (SCT or stem cell
             therapy for patients who previously underwent SCT/stem cell therapy in remission will
             not be considered a salvage regimen) and have previously been exposed at least one
             prior FLT3 inhibitor. Cohort 2 (FLT3 inhibitor naive cohort) in FLT3-ITD and/or
             FLT3-D835 mutated relapsed/refractory who have failed therapy with up to two prior
             salvage regimens (SCT or stem cell therapy for patients who previously underwent
             SCT/stem cell therapy in remission will not be considered a salvage regimen) with no
             prior exposure to any FLT3 inhibitor.

          4. Age >/=18 years

          5. Eastern Cooperative Oncology Group (ECOG) Performance Status </=2

          6. Patients should have estimated life expectancy of >3 months at study entry

          7. Adequate hepatic (serum total bilirubin </= 2.0 x upper limit normal (ULN) (or </= 3.0
             x ULN if deemed to be elevated due to leukemia), alanine aminotransferase and/or
             aspartate transaminase </= 3.0 x ULN (or </= 5.0 x ULN if deemed to be elevated due to
             leukemia), and renal function (creatinine </= 2.0 mg/dL).

          8. Patients must provide written informed consent.

          9. In the absence of rapidly progressing disease, the interval from prior treatment to
             time of initiation of selinexor and sorafenib administration will be at least 2 weeks
             for cytotoxic agents or at least 5 half-lives for cytotoxic/noncytotoxic agents. The
             use of chemotherapeutic or anti-leukemic agents is not permitted during the study with
             the following exceptions: (1) intrathecal (IT) therapy for patients with controlled
             Central Nervous System (CNS) leukemia at the discretion of the PI and with the
             agreement of the Sponsor. Controlled CNS leukemia is defined by the absence of active
             clinical signs of CNS disease and no evidence of CNS leukemia on the most recent 2
             simultaneous CSF evaluations. (2) Use of one dose of cytarabine (up to 2 g/m2) or
             hydroxyurea for patients with rapidly proliferative disease is allowed before the
             start of study therapy and for the first four weeks on therapy. These medications will
             be recorded in the case-report form.

         10. Baseline ejection fraction must be >/= 40%.

         11. Females must be surgically or biologically sterile or postmenopausal (amenorrheic for
             at least 12 months) or if of childbearing potential, must have a negative serum or
             urine pregnancy test within 72 hours before the start of the treatment.

         12. Women of childbearing potential must agree to use an adequate method of contraception
             during the study and until 3 months after the last treatment. Males must be surgically
             or biologically sterile or agree to use an adequate method of contraception during the
             study until 3 months after the last treatment. Adequate methods of contraception
             include: Total abstinence when this is in line with the preferred and usual lifestyle
             of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal,
             post-ovulation methods) and withdrawal are not acceptable methods of contraception.
             Female sterilization (have had surgical bilateral oophorectomy with or without
             hysterectomy) or tubal ligation at least six weeks before taking study treatment. In
             case of oophorectomy alone, only when the reproductive status of the woman has been
             confirmed by follow up hormone level assessment

         13. (Continued from Criteria 12) Male sterilization (at least 6 months prior to
             screening). For female patients on the study, the vasectomized male partner should be
             the sole partner for that patient Combination of any of the two following (a+b or a+c
             or b+c) Use of oral, injected or implanted hormonal methods of contraception or other
             forms of hormonal contraception that have comparable efficacy (failure rate <1%), for
             example hormone vaginal ring or transdermal hormone contraception Placement of an
             intrauterine device (IUD) or intrauterine system (IUS) Barrier methods of
             contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with
             spermicidal foam/gel/film/cream/ vaginal suppository

         14. (Continued from Criteria 13) In case of use of oral contraception, women should have
             been stable on the same pill before taking study treatment. Note: Oral contraceptives
             are allowed but should be used in conjunction with a barrier method of contraception
             due to unknown effect of drug-drug interaction. Women are considered post-menopausal
             and not of child bearing potential if they have had 12 months of natural (spontaneous)
             amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of
             vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without
             hysterectomy) or tubal ligation at least six weeks ago. In the case of oophorectomy
             alone, only when the reproductive status of the woman has been confirmed by follow up
             hormone level assessment is she considered not of child bearing potential.

        Exclusion Criteria:

          1. Patients with known allergy or hypersensitivity to selinexor, sorafenib or any of its
             components.

          2. Subject has concurrent, uncontrolled medical condition, laboratory abnormality, or
             psychiatric illness, which could place him/her at unacceptable risk.

          3. Patients who have had any major surgical procedure within 14 days of Day 1.

          4. Patients currently receiving any other standard or investigational therapy for the
             treatment of AML.

          5. Patients unwilling or unable to comply with the protocol.

          6. Patients receiving concomitant treatment with strong CYP3A4 inhibitors, unless such
             drugs are considered critical for the well being of the patient and not adequate
             alternatives are available. Strong CYP3A4 inhibitors include the following
             medications: itraconazole, ketoconazole, miconazole, voriconazole; amprenavir,
             atazanavir, fosamprenavir, indinavir, nelfinavir, ritonavir; ciprofloxacin,
             clarithromycin, diclofenac, doxycycline, enoxacin, isoniazid, ketamine, nefazodone,
             nicardipine, propofol, quinidine, telithromycin.

          7. Patients with any severe gastrointestinal or metabolic condition that could interfere
             with absorption of oral medications.

          8. Patients who are in blast transformation of chronic myeloid leukemia (CML). Prior MDS
             or CMML is acceptable.

          9. Patient has a concurrent active malignancy under treatment.

         10. Unstable cardiovascular function: • Symptomatic ischemia, or • Uncontrolled clinically
             significant conduction abnormalities (i.e., ventricular tachycardia on antiarrhythmic
             agents are excluded; 1st degree atrioventricular (AV) block or asymptomatic left
             anterior fascicular block/right bundle branch block (LAFB/RBBB) will not be excluded),
             or • Congestive heart failure (CHF) New York Heart Association (NYHA) Class ≥ 3, or •
             Myocardial infarction (MI) within 3 months. • Left ventricular ejection fraction < 40
             %. • Hypertension > 140 mm Hg systolic or > 90 mm Hg diastolic with or without
             antihypertensive therapy.

         11. Uncontrolled infection at the time of enrollment. Infections controlled on concurrent
             anti-microbial agents are acceptable, and anti-microbial prophylaxis per institutional
             guidelines is acceptable.

         12. Known active hepatitis B virus (HBV) or C virus (HCV) infection; or known to be
             positive for HCV ribonucleic acid (RNA) or HBsAg (HBV surface antigen).

         13. Known human immunodeficiency virus (HIV) infection.

         14. Female subjects who are pregnant or breastfeeding.

         15. Acute promyelocytic leukemia.

         16. Any medical condition, which in the investigator's opinion, could compromise the
             patient's safety.
      "
NCT03071276,terminated,"
    due to slow enrollment
  ",0,phase 2,['acute myeloid leukemia (aml)'],"[""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']""]","['selinexor', 'fludarabine', 'cytarabine', 'methotrexate/hydrocortisone/cytarabine']","['C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F', 'C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O', 'Status: 400']","
        Inclusion Criteria:

          -  Participants must have a diagnosis of AML and must have disease that has relapsed or
             is refractory to chemotherapy, or that has relapsed after hematopoietic stem cell
             transplantation (HSCT)

               -  Refractory disease is defined as persistent disease after at least two courses of
                  induction chemotherapy.

               -  Patients are eligible at first or subsequent relapse or any relapse that is
                  refractory to salvage chemotherapy.

               -  Patients must have ≥ 5% leukemic blasts in the bone marrow and/or increasing
                  levels of MRD in the bone marrow as assessed by flow cytometry. If an adequate
                  bone marrow sample cannot be obtained, patients may be enrolled if there is
                  unequivocal evidence of leukemia in the peripheral blood.

          -  Adequate organ function defined as the following:

               -  Direct bilirubin ≤ 1.5 x institutional upper limit of normal (IULN)

               -  AST (SGOT)/ALT (SGPT) < 3 x IULN

               -  Creatinine within normal institutional limits for age

          -  Prothrombin time (PT) and partial thromboplastin (PTT) ≤ 1.5 x IULN.

          -  Age criteria: Patients treated at collaborating sites and current St. Jude patients
             who are on therapy or within 3 years of completion of therapy must be ≤ 24 years old.
             All other St. Jude patients must be ≤ 21 years old.

          -  Patients must be able to swallow tablets.

          -  Performance status: Lansky ≥ 50 for patients who are ≤ 16 years old and Karnofsky ≥
             50% for patients who are > 16 years old.

          -  Patients must have fully recovered from the acute effects of all prior therapy.

          -  For patients who have received prior HSCT, there can be no evidence of GVHD and
             greater than 60 days must have elapsed since the HSCT.

        Exclusion Criteria:

          -  History of cerebellar toxicity or cerebellar neurological findings on exam.

          -  Must not be pregnant or breastfeeding. Female patients of child-bearing potential must
             agree to use dual methods of contraception and have a negative serum pregnancy test at
             screening, and male patients must use an effective barrier method of contraception if
             sexually active with a female of child-bearing potential. Acceptable methods of
             contraception are condoms with contraceptive foam, oral, implantable or injectable
             contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal
             gel, or a sexual partner who is surgically sterilized or post-menopausal. For both
             male and female patients, effective methods of contraception must be used throughout
             the study and for three months following the last dose.

          -  Patients with Down syndrome, acute promyelocytic leukemia, juvenile myelomonocytic
             leukemia, Fanconi anemia, Kostmann syndrome, Shwachman syndrome, or other bone marrow
             failure syndromes are not eligible.

          -  Use of investigational agents, with the exception of gemtuzumab ozogamicin, within 30
             days.

          -  Any significant concurrent disease, illness, or psychiatric disorder that would
             compromise patient safety or compliance, study participation, follow up, or
             interpretation of study research.

          -  Unstable cardiovascular function:

               -  symptomatic ischemia

               -  congestive heart failure NYHA Class > 3

               -  myocardial infarction (MI) within 3 months

          -  Uncontrolled infection requiring parenteral antibiotics, antivirals, or antifungals
             within one week prior to first dose. Infections controlled on concurrent
             anti-microbial agents are acceptable, and anti-microbial prophylaxis per institutional
             guidelines are acceptable.

          -  Known human immunodeficiency virus (HIV) infection (pre-study testing not required).

          -  Patients with malabsorption syndrome, or any other disease significantly affecting
             gastrointestinal function.

          -  Prior treatment with selinexor.
      "
NCT03964337,terminated,"
    poor accrual.
  ",0,phase 2,"['prostate cancer', 'prostate cancer adenocarcinoma', 'non-metastatic']","[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']"", ""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]",['cabozantinib'],['COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F'],"
        Inclusion Criteria:

          1. Male, age ≥ 18 years old.

          2. ECOG performance status of 0 or 1

          3. Histologic evidence of adenocarcinoma of the prostate who are deemed candidates for
             curative radical prostatectomy.

          4. Planned robotic or laparoscopic prostatectomy technique.

          5. Low risk for conversion to open prostatectomy, in the opinion of the treating surgeon.

          6. Intermediate-high or high risk, clinically localized disease by the following
             criteria:

               -  Prostate cancer in at least 2 cores with a Gleason score ≥ 7 (4+3 or 3+4) in at
                  least 1 of those cores.

               -  No definite evidence of metastasis, in the opinion of the investigator.

          7. Adequate organ function as defined by the following criteria within 14 days prior to
             first dose of study treatment:

               -  Aspartate transaminase (AST) and alanine transaminase (ALT) ≤3 x local laboratory
                  upper limit of normal (ULN)

               -  Total serum bilirubin ≤1.5 x ULN, (for subjects with Gilbert's disease ≤ 3 x ULN)

               -  Absolute neutrophil count (ANC) ≥1500/L without granulocyte colony-stimulating
                  factor support.

               -  White blood cell count ≥ 2500/mm3

               -  Serum albumin ≥ 2.8 g/dl

               -  Platelets ≥100,000/mm3

               -  Hemoglobin ≥9.0 g/dL

               -  Serum calcium ≤12.0 mg/dL

               -  Serum creatinine ≤ 2.0 x ULN or calculated creatinine clearance ≥ 30mL/min.

               -  Urine protein/creatinine ratio (UPCR) ≤ 1 mg/mg (≤ 113.2 mg/mmol).

          8. Written Authorization for Use and Release of Health and Research Study Information
             (HIPAA authorization per institutional requirements)

          9. Evidence of a personally signed and dated informed consent document indicating that
             the subject has been informed of all pertinent aspects of the trial.

         10. Willing/able to adhere to the prohibitions and restrictions specified in this
             protocol.

         11. Agrees to use a condom (even men with vasectomies) and another effective method of
             birth control if subject is having sex with a woman who is pregnant or a woman of
             childbearing potential while on study drug and for 4 months following the last dose of
             study drug.

        Exclusion Criteria:

          1. Prior treatment for prostate cancer.

          2. Major surgery or radiation therapy within 4 weeks of Day 1 on study.

          3. Planned radiation therapy until at least 4 weeks after prostatectomy.

          4. NCI CTCAE v4.0 grade 3 hemorrhage within 4 weeks of Day 1 on study.

          5. Prothrombin time (PT)/INR or partial thromboplastin time (PTT) test ≥ 1.3 x the
             laboratory ULN within 14 days before Day 1 on study (Arm A subjects only) or within 14
             days of the completion of screening (Arm B subjects only).

          6. Concomitant anticoagulation with oral anticoagulants (e.g., warfarin, direct thrombin
             and Factor Xa inhibitors) or platelet inhibitors (eg, clopidogrel). However, low-dose
             aspirin for cardio protection is allowed (per local applicable guidelines).

          7. History of or known metastatic prostate cancer.

          8. QTcf interval > 500 msec on baseline EKG.

          9. The subject has uncontrolled, significant intercurrent or recent illness including,
             but not limited to, the following conditions:

             a. Cardiovascular disorders:

             i. Symptomatic congestive heart failure (CHF) New York Heart Association Class 3 or 4,
             unstable angina pectoris, ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2.
             coronary/peripheral artery bypass graft (CABG), within 6 months prior to screening.

             ii. Stroke (including transient ischemic attack [TIA]), cerebrovascular accident
             (CVA), myocardial infarction (MI), or other ischemic event, or thromboembolic event
             (eg, deep venous thrombosis, pulmonary embolism (PE)) within 6 months prior to
             screening.

             b. Gastrointestinal (GI) disorders including those associated with a high risk of
             perforation or fistula formation:

             i. Evidence of tumor invading the GI tract, active peptic ulcer disease, inflammatory
             bowel disease (eg, Crohn's disease), diverticulitis, cholecystitis, symptomatic
             cholangitis or appendicitis, acute pancreatitis, acute obstruction of the pancreatic
             duct or common bile duct, or gastric outlet obstruction.

             ii. Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess
             within 6 months before first dose.

             Note: Complete healing of an intra-abdominal abscess must be confirmed before first
             dose.

             c. Clinically significant hematuria, hematemesis, or hemoptysis of > 0.5 teaspoon (2.5
             ml) of red blood, or other history of significant bleeding (eg, pulmonary hemorrhage)
             within 12 weeks before first dose.

             d. Serious non-healing wound/ulcer/bone fracture. e. Other clinically significant
             disorders that would preclude safe study participation.

         10. Hypertension that cannot be controlled by medications (>140/90 mm Hg despite optimal
             medical therapy).

         11. Pre-existing thyroid abnormality with thyroid function that cannot be maintained in
             the normal range with medication.

         12. Concurrent treatment on another clinical trial. Supportive care trials or
             non-treatment trials, e.g. QOL, are allowed.

         13. Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or study
             drug administration, or may interfere with the interpretation of study results, and in
             the judgment of the investigator would make the subject inappropriate for entry into
             this study.

         14. Inability to swallow tablets.

         15. Diagnosis of another malignancy within 2 years before first dose of study treatment,
             except for superficial skin cancers, or localized, low grade tumors deemed cured and
             not treated with systemic therapy.
      "
NCT02473094,terminated,"
    slow accrual
  ",0,phase 2,"['rectal neoplasms', 'adenocarcinoma', 'carcinoma']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['capecitabine', 'metformin', 'placebo']","['CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O', 'CN(C)C(=N)N=C(N)N']","
        Inclusion Criteria:

          -  18 years or older;

          -  biopsy proven poorly differentiated carcinoma or adenocarcinoma of the rectum;

          -  lesions located within 12 cm of the anal verge (from colonoscopy assessment);

          -  ability to tolerate oral treatment;

          -  locally advanced tumor, classified by the presence of positive regional lymph nodes or
             primary tumor invasion beyond the serosa (T3 or T4), assessed by MRI;

          -  eligibility for curative surgery (no distant metastasis or invasion of bony structures
             of the pelvis);

          -  Performance Status (PS) Eastern Cooperative Oncology Group (ECOG) 0-2;

          -  adequate hematologic functions (hemoglobin ≥ 10 g / dL [5.6 mmol / L]; neutrophil
             count ≥ 1,500 / mm3 and platelet count ≥ 100,000 / mm3), adequate renal function
             (serum creatinine less than 1.5 times the UNL) and adequate hepatic function
             (bilirubin less than 1.5 times the UNL; aspartate aminotransferase and alanine
             aminotransferase less than 2.5 times the UNL);

        Exclusion Criteria:

          -  known hypersensitivity to metformin or its excipients;

          -  squamous carcinomas of the rectum or anal canal;

          -  chronic treatment with corticosteroids or other immunosuppressive agents;

          -  treatment with oral antidiabetic products;

          -  distant metastasis at diagnosis or tumor invasion of pelvic bone structures that may
             proscribe curative intent surgery;

          -  chronic or acute infections;

          -  use of drugs under study up to four weeks prior to randomization;

          -  pregnant or nursing patients;

          -  prior radiotherapy to the pelvic region;

          -  myocardial infarction up to six months prior to randomization, or uncontrolled
             ischemic heart disease;

          -  congestive heart insufficiency New York Heart Association (NYHA) III-IV.
      "
NCT02471222,completed,,1,phase 2,"['walking impairment', 'multiple sclerosis']","[""['Z73.82', 'M10.38', 'M10.30', 'M10.311', 'M10.312', 'M10.319', 'M10.321']"", ""['G35', 'C81.18']""]",['ads-5102'],['C1C2CC3CC1CC(C2)(C3)N.Cl'],"
        Inclusion Criteria:

          -  Signed a current IRB-approved informed consent form;

          -  Male or female subjects between 18 and 70 years of age, inclusive;

          -  Confirmed diagnosis of Multiple Sclerosis according to the 2010 Revised McDonald
             criteria;

          -  On a stable regimen of medications taken specifically to treat MS for at least 30 days
             prior to screening, and willing to continue the same doses and regimens for the
             duration of study participation;

          -  Stable physical activity level for at least 30 days prior to screening and willing to
             continue without change for the duration of study participation;

          -  Maximum EDSS score during screening of 6.5;

          -  Sufficient ambulatory ability to complete two trials of the Timed 25 Foot Walk (T25FW)
             at the screening visit;

          -  A score on each completed screening T25FW test between 8 and 45 seconds, inclusive;

          -  Any other current and allowed prescription/non-prescription medications and/or
             nutritional supplements taken regularly must have been at a stable dose and regimen
             for at least 30 days prior to screening, and subject must be willing to continue the
             same doses and regimens during study participation;

          -  If taking an antidepressant, must be on a stable dose for at least 60 days prior to
             screening.

        Exclusion Criteria:

          -  History of seizures within 2 years prior to screening;

          -  Clinically significant MS relapse with onset less than 30 days prior to screening;

          -  Presence of vertigo or other vestibular dysfunction that might compromise ability to
             safely perform the T25FW;

          -  Received physical therapy within 30 days prior to screening;

          -  Received systemic steroids within 30 days prior to screening;

          -  Received dalfampridine, methylphenidate, modafinil, armodafinil, amantadine, and/or
             any product containing amphetamines, or any treatment specifically for fatigue or to
             improve walking within 30 days prior to screening;

          -  Received any botulinum toxin containing product used as antispasmodic agent within 3
             months prior to screening;

          -  History of clinically significant hallucinations due to an MS medication or
             other/unknown cause, within 2 years prior to screening;

          -  History of Bipolar Disorder or Psychosis, regardless of treatment;

          -  Presence of cognitive impairment sufficient, in the opinion of the investigator, to
             affect the subject's ability to complete study assessments, or which would not be in
             the subject's best interest to participate in the study;

          -  History of stroke or TIA within 2 years prior to screening;

          -  History of cancer within 5 years;

          -  Presence of untreated angle closure glaucoma;

          -  If female, is pregnant or lactating;

          -  If a sexually active female, is not surgically sterile or at least 2 years
             post-menopausal, or does not agree to utilize a highly effective hormonal method of
             contraception (an IUD, or vasectomized male partner is also acceptable), in
             combination with a barrier method, from screening through at least 4 weeks after the
             completion of study treatment;

          -  Treatment with an investigational drug or device within 30 days prior to screening;

          -  Treatment with an investigational biologic within 6 months prior to screening;

          -  Current participation in another clinical trial;

          -  Planned elective surgery during study participation.
      "
NCT02472353,terminated,"
    did not meet target accrual
  ",0,phase 2,"['breast cancer', 'breast tumors']","[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['metformin', 'doxorubicin']","['CN(C)C(=N)N=C(N)N', 'CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O']","
        Inclusion Criteria:

          -  Breast cancer requiring neoadjuvant or adjuvant therapy with doxorubicin

          -  Complete metabolic panel demonstrating adequate organ functions as defined by the
             following: Aspartate transaminase (AST) less than 2.5 times Upper Limit of Normal
             (ULN); Alanine transaminase (ALT) less than 2.5 times ULN; alkaline phosphatase less
             than 2.5 times ULN; serum creatinine less than 1.5 mg/dL; serum bilirubin less than
             ULN

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Age greater than or equal to 21 years

        Exclusion Criteria:

          -  Known diabetes

          -  History of cardiac arrhythmias or symptomatic cardiac disease

          -  Currently taking antiarrhythmic medications, beta-blockers, or other rate controlling
             cardiac medications

          -  Currently taking metformin and/or sulfonylureas

          -  Known hypersensitivity or intolerance to metformin

          -  Baseline ejection fraction of less than 50% measured by echocardiogram

          -  Known hypersensitivity to contrast used during echocardiogram

          -  Risk factors associated with increased risk of metformin-associated lactic acidosis
             (e.g. congestive heard failure, history of acidosis, habitual intake of 3 or more
             alcoholic beverages per day)

          -  Pregnant or breast feeding
      "
NCT02477215,completed,,1,phase 1/phase 2,['multiple myeloma'],"[""['C90.01', 'C90.02', 'C90.00']""]","['mln9708', 'dexamethasone', 'bendamustine (multiple dose levels)', 'bendamustine (mtd)']",['CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C'],"
        INCLUSION CRITERIA:

          1. Male or female patients 18 years or older.

          2. Voluntary written consent must be given before performance of any study related
             procedure not part of standard medical care, with the understanding that consent may
             be withdrawn by the patient at any time without prejudice to future medical care.

          3. Female patients who:

               -  Are postmenopausal for at least one year before the screening visit, OR

               -  Are surgically sterile, OR

               -  If they are of childbearing potential, agree to practice two effective methods of
                  contraception, at the same time, from the time of signing the informed consent
                  form through 90 days after the last dose of study drug, OR • Agree to practice
                  true abstinence when this is in line with the preferred and usual lifestyle of
                  the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal,
                  post-ovulation methods] and withdrawal are not acceptable methods of
                  contraception.)

             Male patients, even if surgically sterilized (ie, status post-vasectomy), must agree
             to one of the following:

               -  Agree to practice effective barrier contraception during the entire study
                  treatment period and through 90 days after the last dose of study drug, OR

               -  Agree to practice true abstinence when this is in line with the preferred and
                  usual lifestyle of the subject. (Periodic abstinence (eg, calendar, ovulation,
                  symptothermal, postovulation methods] and withdrawal are not acceptable methods
                  of contraception.)

          4. Patients must have have histologically or cytologically confirmed symptomatic Multiple
             Myeloma, who are non-responsive to or ineligible for autologous stem cell transplant,
             and who progress after prior exposure to proteasome inhibitor (bortezomib,
             carfilzomib) and lenalidomide or pomalidomide or thalidomide (IMID); and
             refractory/progressing to at least one of these agents and must meet at least one of
             the following parameters of measurable disease:

               -  Measurable levels of monoclonal protein (M protein): > 1 g/dL of immunoglobin G
                  (IgG) or immunoglobin M (IgM) M-protein or > 0.5 g/dL immunoglobin A (IgA) or
                  immunoglobin D (IgD) M protein on serum protein electrophoresis OR > 200 mg/24h
                  of free light chain proteinuria on a 24 hour urine protein electrophoresis which
                  must be obtained within 4 weeks prior to registration OR > 10 mg/dL involved free
                  light chain on serum free light chain testing with an abnormal kappa:lambda light
                  chain ratio.

               -  Patients with lytic bone disease, defined as at least one lytic lesion that can
                  be accurately measured in at least one dimension.

          5. Eastern Cooperative Oncology Group (ECOG) performance status and/or other performance
             status 0, 1, or 2.

          6. Patients are eligible after autologous or allogeneic stem cell transplantation.
             Allogeneic transplantation can be enrolled only if they have no ongoing transplant
             related side effects.

          7. Patients must be at least 2 weeks from major surgery, radiation therapy, participation
             in other investigational trials and have recovered from clinically significant
             toxicities of these prior treatments

          8. Patients must meet the following clinical laboratory criteria:

               -  Absolute neutrophil count (ANC) ≥ 1,000/mm3 and platelet count ≥ 75,000/mm3.
                  Platelet transfusions or granulocyte-colony stimulating factor (G-CSF) can be
                  used to help patients meet eligibility criteria but are not allowed within 3 days
                  before study enrollment.

               -  Total bilirubin < 1.5 x the upper limit of the normal range (ULN), , OR, direct
                  bilirubin within normal limits (WNL), when total bilirubin is >>< 1.5 x the ULN.

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 x ULN.

               -  Calculated creatinine clearance ≥ 30 mL/min.

        EXCLUSION CRITERIA

        Patients meeting any of the following exclusion criteria are not to be enrolled in the
        study:

          1. Female patients who are lactating or have a positive serum pregnancy test during the
             screening period.

          2. Failure to have fully recovered (ie, ≤ Grade 1 toxicity) from the reversible effects
             of prior chemotherapy except for peripheral neuropathy, which is addressed in
             exclusion criteria no. #14.

          3. Major surgery within 14 days before enrollment.

          4. Radiotherapy within 14 days before enrollment. If the involved field is limited
             (single disease focus not involving pelvis and involving <36 Gy radiation), 7 days
             will be considered a sufficient interval between treatment and administration of
             Ixazomib provided hematologic inclusion parameters are met.

          5. Central nervous system involvement.

          6. Infection requiring systemic antibiotic therapy or other serious infection within 14
             days before study enrollment.

          7. Evidence of current uncontrolled cardiovascular conditions, including uncontrolled
             hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure,
             unstable angina, or myocardial infarction within the past 6 months.

          8. Systemic treatment, within 14 days before the first dose of IXAZOMIB, with strong
             inhibitors of cytochrome P1A2 (CYP1A2) (fluvoxamine, enoxacin, ciprofloxacin), strong
             inhibitors of cytochrome P3A (CYP3A) (clarithromycin, telithromycin, itraconazole,
             voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers
             (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of
             Ginkgo biloba or St. John's wort.

          9. Ongoing or active systemic infection, active hepatitis B or C virus infection, or
             known human immunodeficiency virus (HIV) positive.

         10. Any serious medical or psychiatric illness that could, in the investigator's opinion,
             potentially interfere with the completion of treatment according to this protocol.

         11. Known allergy to any of the study medications, their analogues, or excipients in the
             various formulations of any agent.

         12. Known GI disease or GI procedure that could interfere with the oral absorption or
             tolerance of IXAZOMIB including difficulty swallowing.

         13. Diagnosed or treated for another malignancy where the expected survival is less than
             two years will be excluded. Patients with nonmelanoma skin cancer or carcinoma in situ
             of any type are not excluded if they have undergone complete resection.

         14. Patient has ≥ Grade 2 peripheral neuropathy, or Grade 2 with pain on clinical
             examination during the screening period.

         15. Participation in other clinical trials, including those with other investigational
             agents not included in this trial, within 30 days of the start of this trial and
             throughout the duration of this trial.

         16. Patients that have previously been treated with IXAZOMIB, or participated in a study
             with IXAZOMIB whether treated with IXAZOMIB or not.

         17. Patients with a history of severe chronic obstructive pulmonary disease requiring
             ongoing oxygen support or those with a resting oxygen saturation <92% on room air
             irrespective of the cause.
      "
NCT02474290,completed,,1,phase 2/phase 3,"['acute myeloid leukemia', 'hematopoietic stem cell transplantation']","[""['C92.A1', 'C92.A2', 'C92.61', 'C92.62', 'C92.A0', 'C92.60']"", ""['M31.11']""]",['sorafenib'],['Status: 503'],"
        Inclusion Criteria:

          -  FLT3-ITD Positive AML

          -  Allo-HSCT Recipients

        Exclusion Criteria:

          -  cardiac dysfunction (particularly congestive heart failure)

          -  hepatic abnormalities (bilirubin ≥ 3 mg/dL, aminotransferase> 2 times the upper limit
             of normal)

          -  renal dysfunction (creatinine clearance rate < 30 mL/min)

          -  Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood
             pressure)

          -  Patients with any conditions not suitable for the trial (investigators' decision)
      "
NCT04061590,withdrawn,"
    low accrual
  ",0,phase 2,"['lung non-small cell carcinoma', 'stage i lung cancer ajcc v8', 'stage ia1 lung cancer ajcc v8', 'stage ia2 lung cancer ajcc v8', 'stage ia3 lung cancer ajcc v8', 'stage ib lung cancer ajcc v8', 'stage ii lung cancer ajcc v8', 'stage iia lung cancer ajcc v8', 'stage iib lung cancer ajcc v8', 'stage iiia lung cancer ajcc v8']","[""['D02.20', 'D02.21', 'D02.22']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['cisplatin', 'pemetrexed', 'pemetrexed disodium']","['N.N.Cl[Pt]Cl', 'C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O', 'C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)[O-])C(=O)[O-].[Na+].[Na+]']","
        Inclusion Criteria:

          -  Histologically or cytologically confirmed NSCLC, performed on a biopsy that occurred
             within the last 60 days

          -  Computed tomography (CT) within the last 30 days showing radiographic stage I to IIIa
             lung cancer (mediastinal staging biopsy is allowed but not required) by the American
             Joint Committee on Cancer (AJCC) 8th edition

          -  Documentation that the patient is a candidate for surgical resection of their lung
             cancer by an American Board of Thoracic Surgery-certified surgeon

          -  Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as
             assessed by the investigator

          -  Adequate tissue specimens for correlative biomarker analysis. The patient should be
             willing to provide tissue from a newly obtained core or excisional biopsy of a tumor
             lesion. Newly-obtained is defined as a specimen obtained up to 8 weeks (56 days) prior
             to initiation of treatment on day 1. Patients for whom newly-obtained samples cannot
             be provided (e.g. inaccessible or patient safety concern) may submit an archived
             specimen only upon agreement from the principal investigator

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Resolution of all acute toxic effects of prior chemotherapy, radiotherapy or surgical
             procedures to NCI CTCAE version (v)5.0 grade 1

          -  Be willing and able to provide written informed consent for the trial

          -  Absolute neutrophil count (ANC) >= 1500 cells/ microlitre(uL) (within 10 days prior to
             the start of trial treatment)

          -  Platelets >= 100 000 cells/uL (within 10 days prior to the start of trial treatment)

          -  Hemoglobin >= 9.0 g/dL or >= 5.6 mmol/L (criteria must be met without erythropoietin
             dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks)
             (within 10 days prior to the start of trial treatment)

          -  Creatinine =< 1.5 x upper limit of normal (ULN) OR measured or calculated creatinine
             clearance, glomerular filtration rate (GFR) can also be used in place of creatinine or
             creatinine clearance (CrCl) >= 30 mL/min for patients with creatinine levels > 1.5 x
             institutional ULN (within 10 days prior to the start of trial treatment)

          -  Total bilirubin =< 1.5 x ULN OR direct bilirubin =< ULN for patients with total
             bilirubin levels > 1.5 x ULN (within 10 days prior to the start of trial treatment)

          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase (SGOT)) and
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase (SGPT)) =< 2.5 x
             ULN (=< 5 x ULN for patients with liver metastases) (within 10 days prior to the start
             of trial treatment)

          -  International normalized ratio (INR) OR prothrombin time (PT) =< 1.5 x ULN unless
             patient is receiving anticoagulant therapy as long as PT or partial thromboplastin
             time (PTT) is within therapeutic range of intended use of anticoagulants (within 10
             days prior to the start of trial treatment)

          -  Activated partial thromboplastin time (aPTT)/PTT =< 1.5 x ULN unless patient is
             receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is
             within therapeutic range of intended use of anticoagulants (within 10 days prior to
             the start of trial treatment)

          -  Female patients of childbearing potential must have a negative urine or serum
             pregnancy test within 72 hours prior to receiving the first dose of trial medication.
             If the urine test is positive or cannot be confirmed as negative, a serum pregnancy
             test will be required

          -  Male and female patients of childbearing potential must be willing to use an adequate
             method of contraception as outlined, for the course of the trial through 120 days
             after the last dose of trial drug

               -  Note: Abstinence is acceptable if this is the usual lifestyle and preferred
                  contraception for the patient

          -  Be willing to provide newly obtained tissue (core biopsy of tumor) for PD-L1 biomarker
             analysis and, based on the adequacy of the tissue sample quality for assessment of
             PD-L1 status, received permission for enrollment from the core laboratory. Repeat
             samples may be required if adequate tissue is not provided. Newly obtained biopsy
             specimens are preferable to archived samples, and formalin-fixed paraffin-embedded
             (FFPE) block specimens are preferred to slides. A post-treatment biopsy after
             pembrolizumab treatment is desirable if patient agrees

               -  Collection of an archived tissue sample will also be requested available) to
                  support evaluation of the clinical utility of PD-L1 assessment in newly obtained
                  versus (vs.) archived tissue samples; however, a patient will not be precluded
                  from participating in the study if an archived tissue sample is not available for
                  collection or is otherwise insufficient for analysis

        Exclusion Criteria:

          -  Is ineligible for an operation based on medical or oncologic contraindications to
             surgery

          -  Is currently participating in or has participated in a trial of an investigational
             agent or has used an investigational device within 4 weeks prior to the first dose of
             trial treatment

               -  Note: Patients who have entered the follow-up phase of an investigational trial
                  may participate as long as it has been 4 weeks after the last dose of the
                  previous investigational agent

          -  Has any component of small cell tumor in the specimen, e.g. mixed NSCLC/small cell

          -  Has received prior therapy with an anti-Programmed cell death protein 1 (PD-1),
             anti-Programmed death-ligand 1 (PD-L1) , or anti-Programmed death-ligand 2 (PD-L2)
             agent or with an agent directed to another stimulatory or co-inhibitory T cell
             receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX-40, CD137)

          -  Has severe hypersensitivity >= grade 3) to pembrolizumab and/or any of its excipients

          -  Has a history of (non-infectious) pneumonitis / interstitial lung disease that
             required treatment with steroids or has current pneumonitis / interstitial lung
             disease that requires steroids

          -  Has a known history of human immunodeficiency virus (HIV) infection

               -  Note: No HIV testing is required unless mandated by local health authority

          -  Has a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg]
             reactive) or known active hepatitis C virus (HCV) (defined as HCV ribonucleic acid
             [RNA] [qualitative] is detected) infection

               -  Note: No testing for hepatitis B and hepatitis C is required unless mandated by
                  local health authority

          -  Has a known history of active tuberculosis (TB; Mycobacterium tuberculosis)

          -  Has received prior radiotherapy within 2 weeks of start of trial treatment. Patients
             must have recovered from all radiation-related toxicities, not require
             corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted
             for palliative radiation (=< 2 weeks of radiotherapy) to non-central nervous system
             (CNS) disease

          -  Has received a live vaccine within 30 days prior to the first dose of trial drug.
             Examples of live vaccines include, but are not limited to, the following: measles,
             mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus
             Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection
             are generally killed virus vaccines and are allowed; however, intranasal influenza
             vaccines (e.g., FluMist) are live attenuated vaccines and are not allowed

          -  Has evidence of clinically significant interstitial lung disease

          -  Has an active second malignancy, i.e. patient known to have potentially fatal cancer
             present for which he/she may be (but not necessarily) currently receiving treatment.
             Patients with a history of malignancy that has been completely treated, with no
             evidence of that cancer currently, are permitted to enroll in the trial if curative
             therapy has been completed, such as basal cell carcinoma of the skin or squamous cell
             carcinoma of the skin that has undergone potentially curative therapy or in situ
             cervical cancer

          -  Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (in
             dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
             immunosuppressive therapy within 7 days prior to the first dose of trial treatment

          -  Has active autoimmune disease that has required systemic treatment in the past 2 years
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive
             drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
             form of systemic treatment

          -  Has an active infection requiring systemic therapy

          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the patient?s
             participation for the full duration of the trial, or is not in the best interest of
             the patient to participate, in the opinion of the treating investigator, including
             dialysis

          -  Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial

          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the screening visit through 120 days
             after the last dose of trial treatment

          -  Has had an allogeneic tissue/solid organ transplant

        ADDITIONAL EXCLUSION CRITERIA For Arm B

          -  Has squamous cell carcinoma. Adenosquamous and adenocarcinoma with squamous features
             disease allowed

          -  Creatinine clearance < 45 ml/min as calculated by institutional standard

          -  Is taking any herbal/complementary oral or IV medicine within 4 weeks of first dose of
             treatment
      "
NCT02316496,terminated,,0,phase 2,['colorectal cancer metastatic'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['cetuximab', 'irinotecan']",['CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7'],"
        Inclusion Criteria:

          -  Signed and dated informed consent

          -  Histologically confirmed metastatic adenocarcinoma of the colon or rectum

          -  All Wild Type KRAS (exon 2 [codons 12-13], exon 3 [codons - 61]; exon 4 [codon 146]),
             NRAS (exon 2 [ codons 12-13] and exon 3 [codon 61) and BRAF (V600E) tumor ( local
             assessment performed either on primary tumor or metastasis)

          -  First line chemotherapy regimen with a fluoropyrimidine and Irinotecan (FOLFIRI) +
             cetuximab with initial partial or complete response and progressive disease (PD) with
             PD ≤ 6 weeks after the last administration of cetuximab

          -  Other line(s) of therapy(ies) including the following drugs: second line oxaliplatin
             based chemotherapy with fluoropyrimidines (5FU or capecitabine) + bevacizumab and
             eventually regorafenib (possible but not mandatory) and progression or limiting
             toxicity to the last therapy with a minimum of 4 months between last injection of
             cetuximab and inclusion in this study

          -  At least one measurable lesion ≥ 10 mm as assessed by CT-scan or MRI (Magnetic
             Resonance Imaging) according to RECIST v1.1 (All sites must be evaluated ≤ 28 days
             prior to the enrolment)

          -  Age ≥18 years

          -  World Health Organization (WHO) Performance status (PS) 0-2

          -  The patient has adequate organ function, defined as :

        Absolute neutrophil count (ANC) ≥ 1.5 x 109/L, hemoglobin ≥ 9 g/dL, and platelets ≥ 100 x
        109/L.Total bilirubin ≤ 1.5 times upper limit of normal value (ULN), serum alkaline
        phosphatase level < 5 times ULN, Serum creatinine level <150μM/l

          -  For female patients of childbearing potential, negative pregnancy test within 7 days
             before starting the study drug

          -  Men and women are required to use adequate birth control during the study (when
             applicable) and until 6 months after the end of study treatment

          -  Registration in a national health care system (CMU included)

        Exclusion Criteria:

          -  Previous chemotherapy other than adjuvant therapy with different combinations than
             those scheduled in first and second line treatment

          -  Presence of any KRAS, BRAF or NRAS mutation by allelic discrimination on tumor DNA

          -  Significant cardiovascular disease including unstable angina or myocardial infarction
             within 12 months before initiation of study treatment or a history of ventricular
             arrhythmia (treated or not)

          -  History or evidence of central nervous system metastasis (systematic CT-scan or MRI
             not mandatory if no clinical symptoms)

          -  Known allergy or hypersensitivity to cetuximab

          -  Previous or concurrent malignancy except for basal or squamous cell skin cancer, in
             situ carcinoma of the cervix, low-risk prostate cancer according to d'Amico
             classification or other solid tumors treated curatively and without evidence of
             recurrence for at least 5 years prior to the study

          -  Active or uncontrolled clinically serious infection

          -  Known human immunodeficiency virus (HIV) infection or acquired immunodeficiency
             syndrome (AIDS)-related illness

          -  Other serious and uncontrolled non-malignant disease

          -  Pregnancy

          -  Breast feeding

          -  Treatment with any other investigational medicinal product within 28 days prior to
             study entry

          -  Known Gilbert's syndrome

          -  Concomitant administration of live, attenuated virus vaccine such as yellow fever
             vaccine

          -  Concomitant use with St John's Wort

          -  Chronic inflammatory bowel disease and/or Bowel obstruction
      "
NCT02315625,terminated,"
    study closed due to poor accrual.
  ",0,phase 2,"['neuroendocrine tumors', 'neuroendocrine carcinoma', 'neuroendocrine neoplasms', 'carcinoma, neuroendocrine', 'neuroendocrine tumors of the gastrointestinal tract and pancreas']","[""['C7A.1', 'C7A.8', 'C7B.8', 'D3A.8']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C7A.1', 'C7A.8', 'C7B.8', 'D3A.8']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C7A.1', 'C7A.8', 'C7B.8', 'D3A.8']""]","['sunitinib', 'everolimus']","['CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C', 'CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC']","
        -INCLUSION CRITERIA:

          1. Progressive, histologically or cytologically diagnosed low or intermediate grade,
             neuroendocrine tumors confirmed by the Laboratory of Pathology, National Cancer
             Institute (NCI). Disease progression is defined according to Response Evaluation
             Criteria in Solid Tumors (RECIST) criteria for progression of disease or any new
             lesions seen on 68-Gallium DOTATATE within the 18 months prior to enrolment.

          2. Age greater than or equal 18 years, because the incidence and prevalence of metastatic
             pancreatic and gastrointestinal neuroendocrine tumors in the pediatric patient
             population is exceedingly rare (children are excluded from this study, but will be
             eligible for future pediatric trials).

          3. Patients must have measurable disease according to RECIST criteria on anatomic imaging
             studies (computed tomography (CT) scan or magnetic resonance imaging (MRI)).

          4. Willingness to undergo tumor biopsy if the patient does not have a known familial
             cancer syndrome (multiple endocrine neoplasia type 1 (MEN1), Von Hippel-Lindau (VHL)
             and neurofibromatosis type 1 (NF1)). Archival tissue available.

          5. Eastern Cooperative Oncology Group (ECOG) performance status <2.

          6. Patients must have normal organ and bone marrow function as defined below:

               -  hemoglobin greater than or equal 9 g/dL *

               -  leukocytes greater than or equal 3,000/mcL *

               -  absolute neutrophil count greater than or equal 1,500/mcL *

               -  platelets greater than or equal institutional lower limit of normal

               -  total bilirubin within normal institutional limits

               -  Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase
                  (SGOT)/alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT)
                  less than or equal 2.5 times institutional upper limit of normal

             (less than or equal 5 times upper limit of normal (ULN) in patients with liver
             metastases)

             - creatinine within normal institutional limits

             OR

               -  creatinine clearance greater than or equal 60 mL/min/1.73 m(2) for patients with
                  creatinine levels above institutional normal.

               -  International Normalized Ratio (INR) less than or equal 2;

                    -  If a patient's bone marrow function falls below the indicated values and it
                       is not thought to be related to prior treatments a hematology consult will
                       be ordered. If Hematology deems the patients safe to proceed with treatment
                       they will be allowed to enroll on study. In such cases, the patients
                       absolute neutrophil count must be greater than 1,000/mcl, hemoglobin must be
                       greater than 7.5 g/dL and the platelet count must be > 75,000 mcL. Each
                       patient will also be seen by a medical oncologist at follow-up visits if
                       possible.

          7. Fasting serum cholesterol less than or equal 300 mg/dL OR less than or equal 7.75
             mmol/L AND fasting triglycerides less than or equal 2.5x ULN. NOTE: In case one or
             both of these thresholds are exceeded, the patient can only be included after
             initiation of appropriate lipid lowering medication;

          8. Women of childbearing potential (WOCBP) or partners of WOCBP participating in this
             study must agree to use highly effective contraception while on treatment and for at
             least 8 weeks after end of treatment, because the effects of Sunitinib and Everolimus
             on the developing human fetus are unknown. Should a woman become pregnant or suspect
             she is pregnant while she or her partner is participating in this study, she should
             inform her treating physician immediately.

             Highly effective contraception methods include combination of:

               1. Any two of the following:

                    -  Use of oral, injected or implanted hormonal methods of contraception or;

                    -  Placement of an intrauterine device (IUD) or intrauterine system (IUS);

                    -  Barrier methods of contraception: condom or occlusive cap (diaphragm or
                       cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal
                       suppository;

               2. Total abstinence or;

               3. Male/female sterilization.

             Women are considered post-menopausal and not of child-bearing potential if they have
             had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile
             (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral
             oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior
             to enrollment. In the case of oophorectomy alone, only when the reproductive status of
             the woman has been confirmed by follow up hormone level assessment is she considered
             not of child-bearing potential.

          9. Must have fully recovered from toxicities of any prior treatment with cytotoxic drugs,
             radiotherapy, surgery, or other anti-cancer modalities (returned to baseline status as
             noted before most recent treatment or less than or equal grade 1).

         10. Ability of subject to understand and the willingness to sign a written informed
             consent document.

        EXCLUSION CRITERIA:

          -  Uncontrolled hypertension (>150/100 mmHg).

          -  Prior external beam radiation therapy to the target lesion(s) within 1 months prior to
             enrollment

          -  Prior systemic chemotherapy or therapy with one of the investigational agents within 1
             month prior to enrollment.

          -  Patients who had therapy with one of the investigational agents more than 1 month
             prior to enrollment in whom tumor genotyping show assignment to the same
             investigational agent.

          -  Patients who are receiving any other investigational agents.

          -  Patients with known brain metastases will be excluded from this clinical trial because
             of their poor prognosis and because they often develop progressive neurologic
             dysfunction that would confound the evaluation of neurologic and other adverse events.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to Sunitinib or Everolimus.

          -  Patients who have any severe and/or uncontrolled medical conditions such as:

               1. unstable angina pectoris, symptomatic congestive heart failure, myocardial
                  infarction less than or equal 6 months prior to start of Everolimus, serious
                  uncontrolled cardiac arrhythmia, or any other clinically significant cardiac
                  disease

               2. symptomatic congestive heart failure of New York heart Association Class III or
                  IV

               3. active (acute or chronic) or uncontrolled severe infection, liver disease such as
                  cirrhosis, decompensated liver disease

               4. known severely impaired lung function

               5. Corrected QT interval (QTc) interval > 450 msec for males or > 470 msec for
                  females

               6. active, bleeding diathesis;

               7. psychiatric illness/social situations that would preclude informed consent, limit
                  compliance with study requirements

          -  Pregnant or nursing patients will be excluded from the study, because the effects of
             Sunitinib and Everolimus on the developing human fetus are unknown. Because there is
             an unknown but potential risk for adverse events in nursing infants secondary to
             treatment of the mother with Sunitinib or Everolimus, breastfeeding should be
             discontinued if the mother is treated with Sunitinib or Everolimus.

          -  Current treatment with therapeutic doses of Coumadin-derivative anticoagulants (low
             dose Coumadin up to 2 mg by mouth (PO) daily for deep vein thrombosis prophylaxis is
             allowed).

          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
             therapy are ineligible because of the potential for pharmacokinetic interactions with
             study agents.

          -  Lack of physical integrity of the upper gastrointestinal tract or malabsorption
             syndrome, or the inability to take oral medication

          -  Uncontrolled diabetes mellitus as defined by hemoglobin A1C (HbA1c) >8% despite
             adequate therapy. Patients with a known history or diagnosis of diabetes mellitus who
             are on therapy and have had good blood sugar control may be included, even if the
             HbA1c is > 8% because this value can take up to 3-4 months to normalize

          -  Patients who have received live attenuated vaccines within 1 week of start of
             Everolimus and during the study. Patient should also avoid close contact with others
             who have received live attenuated vaccines. Examples of live attenuated vaccines
             include intranasal influenza, measles, mumps, rubella, oral polio, Bacille
             Calmette-Guerin (BCG), yellow fever, varicella and TY21a typhoid vaccines

          -  Patients who are on chronic treatment with corticosteroids or other immunosuppressive
             agents (topical or inhaled corticosteroids are allowed)

          -  Patients with a history of non-compliance to medical regimens or who are considered
             potentially unreliable or will not be able to complete the entire study

          -  Patients who are taking medications that are strong inhibitors of cytochrome P450 AA4
             (CYP3A4) or PgP and need to remain on these medications. For a current table of
             Substrates, Inhibitors and Inducers please access the following
             website:http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResourc
             es/DrugInteractionsLabeling/ucm093664.htm

          -  Patients who have a history of another primary malignancy from which the patient has
             been disease free for < 3 years at the time of enrolment, with the exceptions of: a
             patient with a familial cancer syndrome-associated NETs including MEN1, VHL, NF-1, and
             tuberous sclerosis (TS);
      "
NCT02316028,completed,,1,phase 1/phase 2,"['liver metastasis', 'colorectal cancer']","[""['Z52.6', 'K71.8', 'K71.7', 'A06.4', 'C22.0', 'C22.3', 'K70.0']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]",['decitabine'],['C1C(C(OC1N2C=NC(=NC2=O)N)CO)O'],"
        Inclusion Criteria:

          -  Histological documentation of colorectal adenocarcinoma CRC stage IV with predominant
             unresectable liver metastases and at least one measurable metastatic liver lesion

          -  Performance status WHO criteria of < 2.

          -  Laboratory values: absolute neutrophil count (ANC) count > 1500 /mm³, Platelet count >
             100 000 /mm³, Lymphocytes > 800 /mm³, Serum creatinine < 2.0 mg/dl or creatinine
             clearance >40 ml/min, Serum bilirubin < 2.0 mg/dl

          -  Progressive disease following standard of care palliative systemic chemotherapy

          -  able to give written informed consent.

        Exclusion Criteria:

          -  No prior radiotherapy to all target liver lesions

          -  No previous history of gastric or hepatobiliary surgery (except for simple
             cholecystectomy, No concurrent liver disease or other serious medical disease or
             condition

          -  No concomitant use of other investigational drugs.

          -  No pre-existing neuropathy with a severity of > grade 1 in the WHO toxicity scale.

          -  No previous or concurrent malignancies except for adequately treated in situ carcinoma
             of the cervix uteri, basal or squamous cell carcinoma of the skin or any other
             malignancy given potentially curative treatment more than 5 years before study entry

          -  No pregnant or breast-feeding female patients, use of an effective contraceptive if
             the risk of conception exists during study treatment.

          -  No candidate for the resection of all CRC metastases with curative intent.
      "
NCT02318368,terminated,"
    sponsor's decision
  ",0,phase 2,['non-small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['ficlatuzumab', 'erlotinib', 'placebo']",['COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC'],"
        Inclusion Criteria

          -  Histologically and/or cytologically confirmed primary diagnosis of Stage IV NSCLC
             (according to American Joint Committee on Cancer [AJCC] 7th edition lung cancer
             staging criteria).

          -  Measurable disease according to RECIST v.1.1.

          -  An EGFR exon 19 deletion and/or an exon 21 (L858R) substitution mutation.

          -  BDX004 Positive Label.

          -  Have received no prior systemic chemotherapy, immunotherapy, targeted therapy, or
             biologic therapy for metastatic NSCLC. Subjects may have previously been treated with
             postoperative adjuvant chemotherapy for early stage lung cancer or chemo radiotherapy
             for locally advanced disease provided this was completed at least 6 months prior to
             enrollment. No prior EGFR TKI therapy is allowed for any stage of NSCLC.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Exclusion
             Criteria

          -  History of severe allergic or anaphylactic reactions or hypersensitivity to
             recombinant proteins or excipients in the investigational agent or erlotinib.

          -  History of known brain metastases.

          -  Prior treatment with any other investigational drug or biologic agent within 5 half
             lives prior to randomization, or any investigational device within 2 weeks prior to
             randomization.

          -  Any unresolved toxicity from previous radiation therapy.

          -  Significant cardiovascular disease, including:

               -  Echocardiogram (ECHO) or multiple gated acquisition (MUGA) showing left
                  ventricular ejection fraction of less than 55%.

               -  Cardiac failure New York Heart Association class III or IV.

               -  Myocardial infarction, severe or unstable angina within 6 months prior to
                  randomization.

               -  History of serious ventricular arrhythmia (ie, ventricular tachycardia or
                  ventricular fibrillation).

               -  Significant thrombotic or embolic events within 3 months prior to randomization
                  (significant thrombotic or embolic events include but are not limited to stroke
                  or transient ischemic attack).

               -  Any uncontrolled or severe cardiovascular disease.

          -  History of prior malignancy within 3 years prior to randomization (except for
             adequately treated non-melanoma skin cancer, carcinoma in situ of the breast or
             cervix, superficial bladder cancer, or early stage prostate cancer, without evidence
             of recurrence).

          -  Radiographic evidence of interstitial lung disease.
      "
NCT02311569,completed,,0,phase 2,"['myeloproliferative neoplasm', 'primary myelofibrosis', 'essential thrombocythemia', 'polycythemia vera']","[""['D47.1']"", ""['D75.81', 'C94.41', 'C94.42', 'C94.40']"", ""['D47.3']"", ""['D45']""]",['mirabegron'],['C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O'],"
        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of JAK2-V617F positive ET, PV or
             PMF at primary diagnosis or pretreated

          -  JAK2-V617F mutant allele burden > 20% in the peripheral blood at study entry

          -  Patient must give written informed consent before registration

          -  WHO performance status 0-2

          -  Age ≥ 18 years

          -  Adequate hematological values: neutrophils ≥ 1.5 x 109/L, platelets ≥ 100 x 109/ L

          -  Adequate hepatic function: bilirubin ≤ 1.5 x ULN, AST/ALT/AP ≤ 2.5 x ULN

          -  Adequate renal function (calculated creatinine clearance > 50 mL/min, according to the
             formula of Cockcroft-Gault)

          -  Women are not breastfeeding. Women with child-bearing potential are using effective
             contraception, are not pregnant and agree not to become pregnant during participation
             in the trial and during 28 days thereafter. A negative pregnancy test before inclusion
             (within 7 days) into the trial is required for all women with child-bearing potential.
             Men agree not to father a child during participation in the trial and during 28 days
             thereafter.

          -  Patient compliance and geographic proximity allow proper staging and follow-up.

        Exclusion Criteria:

          -  Leukemic transformation (>20% blasts in blood, marrow or extramedullary site)

          -  Diabetic neuropathy

          -  Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or
             IV, unstable angina pectoris, history of myocardial infarction within the last twelve
             months, known cardiac rhythm disturbance including atrial fibrillation or QT
             prolongation

          -  Uncontrolled hypertension

          -  Treatment of ET, PV or PMF with IFNα or treatment of PMF with JAK inhibitors such as
             ruxolitinib within 3 months prior to trial entry.

          -  Previous malignancy within 5 years with the exception of adequately treated cervical
             carcinoma in situ or localized non-melanoma skin cancer.

          -  Psychiatric disorder precluding understanding of information on trial related topics,
             giving informed consent or interfering with compliance for oral drug intake.

          -  Treatment with hematopoietic stem cell transplantation

          -  Concurrent treatment with cytoreductive drugs, other experimental drugs or other
             anti-cancer therapy as well as treatment in a clinical trial within 2 months prior to
             trial entry.

          -  Any serious underlying medical condition (at the judgment of the investigator), which
             could impair the ability of the patient to participate in the trial (e.g. active
             autoimmune disease, uncontrolled diabetes, uncontrolled infection (HIV, Hepatitis B
             and C).

          -  Known hypersensitivity to trial drug or hypersensitivity to any other component of the
             trial drug.

          -  Any concomitant drugs contraindicated for use with the trial drug according to the
             approved product information.
      "
NCT03824704,terminated,"
    sponsor made a business decision to discontinue the study due to low accrual.
  ",0,phase 2,"['epithelial ovarian cancer', 'fallopian tube cancer', 'primary peritoneal carcinoma', 'high grade serous carcinoma', 'endometrioid adenocarcinoma']","[""['H18.523', 'H18.521', 'H18.522', 'H18.529']"", ""['C57.00', 'C57.01', 'C57.02']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['rucaparib', 'nivolumab']",['CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2'],"
        General Inclusion Criteria:

          -  ≥ 18 years of age

          -  Adequate organ function

          -  Life expectancy ≥ 16 weeks

          -  Women of childbearing potential must have a negative serum pregnancy test

          -  High-grade serous or endometrioid epithelial ovarian, fallopian tube, or primary
             peritoneal cancer

          -  Received 1 or 2 prior regimens, including ≥ 1 prior platinum-based therapy and have
             platinum-sensitive disease

          -  Relapsed/progressive disease (confirmed by radiologic assessment)

          -  Willing and able to have a biopsy of tumor at screening and after 4 weeks of
             treatment.

          -  Measurable disease (RECIST v1.1)- Cohort A1 only

          -  ECOG performance status of 0 to 1

        General Exclusion Criteria

          -  Active second malignancy

          -  Central nervous system brain metastases

          -  Evidence of interstitial lung disease, active pneumonitis, myocarditis, or history of
             myocarditis.

          -  Active, known or suspected autoimmune disease (eg, autoimmune hepatitis).

          -  Condition requiring systemic treatment with either corticosteroids

          -  Prior treatment with a PARP inhibitor or immune checkpoint inhibitor.

          -  Non-epithelial tumors (pure sarcomas) or ovarian tumors with low malignant potential
             (ie, borderline tumors) or mucinous tumors. Mixed Mullerian tumors/carcinosarcomas are
             allowed.
      "
NCT02812693,withdrawn,"
    poor accrual
  ",0,phase 1/phase 2,"['stage iiia skin melanoma', 'stage iiib skin melanoma', 'stage iiic skin melanoma', 'stage iv skin melanoma']","[""['C43.51', 'C43.9', 'C43.52', 'D03.51', 'C43.8', 'Z85.820', 'D03.52']"", ""['C43.51', 'C43.9', 'C43.52', 'D03.51', 'C43.8', 'Z85.820', 'D03.52']"", ""['C43.51', 'C43.9', 'C43.52', 'D03.51', 'C43.8', 'Z85.820', 'D03.52']"", ""['C43.51', 'C43.9', 'C43.52', 'D03.51', 'C43.8', 'Z85.820', 'D03.52']""]",['imatinib mesylate'],['CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)(=O)O'],"
        Inclusion Criteria:

          -  Patient must have histologically or cytologically confirmed diagnosis of stage III
             melanoma inoperable/not amenable to local treatment or stage IV melanoma.

          -  Patient must have either mutation or amplification of c-KIT gene tested by
             commercially available molecular or gene sequencing techniques

          -  Be willing and able to provide written informed consent/assent for the trial

          -  Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST)
             1.1

          -  Be willing to provide tissue from a newly obtained core or excisional biopsy of a
             tumor lesion; newly-obtained is defined as a specimen obtained up to 6 weeks (42 days)
             prior to initiation of treatment on day 1; subjects for whom newly-obtained samples
             cannot be provided (e.g. inaccessible or subject safety concern) may submit an
             archived specimen only upon agreement from the sponsor

          -  Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)
             performance scale

          -  Absolute neutrophil count (ANC) >= 1,500 /mcL

          -  Platelets >= 100,000 / mcL

          -  Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO)
             dependency (within 7 days of assessment)

          -  Serum creatinine =< 1.5 X upper limit of normal (ULN) or measured or calculated
             creatinine clearance (glomerular filtration rate [GFR] can also be used in place of
             creatinine or creatinine clearance [CrCl]) >= 60 mL/min for subject with creatinine
             levels > 1.5 X institutional ULN

          -  Serum total bilirubin =< 1.5 X ULN or direct bilirubin =< ULN for subjects with total
             bilirubin levels > 1.5 ULN

          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X
             ULN OR =< 5 X ULN for subjects with liver metastases

          -  Albumin >= 2.5 mg/dL

          -  International normalized ratio (INR) or prothrombin time (PT) =< 1.5 X ULN unless
             subject is receiving anticoagulant therapy as long as PT or partial thromboplastin
             time (PTT) is within therapeutic range of intended use of anticoagulants

          -  Activated Partial Thromboplastin Time (aPTT) =< 1.5 X ULN unless subject is receiving
             anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use
             of anticoagulants

          -  Female subject of childbearing potential must have a negative urine or serum pregnancy
             within 72 hours prior to receiving the first dose of study medication; if the urine
             test is positive or cannot be confirmed as negative, a serum pregnancy test will be
             required

          -  Female subjects of childbearing potential must be willing to use 2 methods of birth
             control or be surgically sterile, or abstain from heterosexual activity for the course
             of the study through 120 days after the last dose of study medication; subjects of
             childbearing potential are those who have not been surgically sterilized or have not
             been free from menses for > 1 year

          -  Male subjects must agree to use an adequate method of contraception starting with the
             first dose of study therapy through 120 days after the last dose of study therapy

        Exclusion Criteria:

          -  Is currently participating and receiving study therapy or has participated in a study
             of an investigational agent and received study therapy or used an investigational
             device within 4 weeks of the first dose of treatment

          -  Has a diagnosis of immunodeficiency or is receiving immunosuppressive therapy within 7
             days prior to the first dose of trial treatment; individuals who are receiving
             systemic steroid therapy at a stable dose less than or equal to 10mg of prednisone per
             day or its equivalent will be permitted to participate

          -  Has a known history of active TB (bacillus tuberculosis)

          -  Hypersensitivity to pembrolizumab, imatinib, or any of its excipients

          -  Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study
             day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events
             due to agents administered more than 4 weeks earlier

          -  Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy
             within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at
             baseline) from adverse events due to a previously administered agent

               -  Note: subjects with =< grade 2 neuropathy and/or alopecia are an exception to
                  this criterion and may qualify for the study

               -  Note: if subject received major surgery, they must have recovered adequately from
                  the toxicity and/or complications from the intervention prior to starting therapy

          -  Has a known additional malignancy that is progressing or requires active treatment;
             exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the
             skin that has undergone potentially curative therapy or in situ cervical cancer

          -  Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis; subjects with previously treated brain metastases may participate provided
             they are stable (without evidence of progression by imaging for at least four weeks
             prior to the first dose of trial treatment and any neurologic symptoms have returned
             to baseline), have no evidence of new or enlarging brain metastases, and are not using
             steroids at a dose exceeding 10mg of prednisone per day or its equivalent for at least
             7 days prior to trial treatment; this exception does not include carcinomatous
             meningitis, which is excluded regardless of clinical stability

          -  Has active autoimmune disease that has required systemic treatment in the past 2 years
             (i.e. with use of disease modifying agents, corticosteroids exceeding 10 mg prednisone
             per day or its equivalent, or immunosuppressive drugs); replacement therapy (eg.,
             thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or
             pituitary insufficiency, etc.) is not considered a form of systemic treatment

          -  Has known history of, or any evidence of, active, non-infectious pneumonitis

          -  Has an active infection requiring systemic therapy

          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the subject's
             participation for the full duration of the trial, or is not in the best interest of
             the subject to participate, in the opinion of the treating investigator

          -  Has decompensated congestive heart failure as defined by New York Heart Association
             (NYHA) functional classification III or IV

          -  Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial

          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the pre-screening or screening visit
             through 120 days after the last dose of trial treatment

          -  Has received prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, or
             anti-PD-L2 agent

          -  Has received prior therapy with imatinib or another tyrosine kinase inhibitor

          -  Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)

          -  Has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or
             hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is
             detected)

          -  Has received a live vaccine within 30 days of planned start of study therapy

               -  Note: seasonal influenza vaccines for injection are generally inactivated flu
                  vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist)
                  are live attenuated vaccines, and are not allowed
      "
NCT02338245,completed,,1,phase 2,['metastatic breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['aslan001', 'lapatinib', 'capecitabine']","['Status: 503', 'CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl', 'CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O']","
        Inclusion Criteria:

          -  Patients with documented histological confirmation of breast cancer with HER 2
             overexpression or gene amplification prior to study entry.

          -  Patients with HER 2-positive metastatic breast cancer that have failed on prior first
             line treatment with trastuzumab or who have progressed within 1 year of treatment with
             trastuzumab in adjuvant setting.

          -  Presence of at least one radiographically measurable disease (bone metastases and
             ascites are not considered measurable lesions).

          -  Patients of the respective country's legal age or older at the time of written
             informed consent.

          -  Patients with acceptable organ and hematological function

        Exclusion Criteria:

          -  Patients with radiation treatment or major surgical procedures within 21 days prior to
             study entry.

          -  Patients with malabsorption syndrome, diseases significantly affecting
             gastrointestinal function, resection of the stomach or small bowel, or difficulty in
             swallowing and retaining oral medications.

          -  Patients with an uncontrolled intercurrent illness including, but not limited to,
             ongoing or active infection, unstable angina pectoris, cardiac arrhythmia, diabetes,
             hypertension, or psychiatric illness/social situations that would limit compliance
             with study requirements.

          -  Patients with any history of other malignancy unless in remission for more than 1
             year. (Nonmelanoma skin carcinoma and carcinoma-in-situ of uterine cervix treated with
             curative intent is not exclusionary).

          -  Patients with symptomatic central nervous system metastasis and/or on systemic
             steroids or anticonvulsants within 3 months before the first dose of randomized
             therapy.

          -  Patients who are pregnant or breast-feeding.

          -  Patients who were previously treated with ASLAN001 and/or with lapatinib.

          -  Patients who have received more than 2 lines of any therapies in metastatic stage.

          -  Patients who have received any investigational drug (or have used an investigational
             device) within 21 days or received any antineoplastic monoclonal antibodies within a
             period of 5 half-lives before receiving the first dose of randomized therapy.

          -  Patients with unresolved or unstable serious toxicity from prior administration of
             another investigational drug and/or prior cancer treatment.
      "
NCT02333058,completed,,1,phase 2,"['acute lymphoblastic leukaemias (all)', 'acute myeloid leukaemias (aml)', 'myelodysplastic syndromes (mds)', 'juvenile myelomonocytic leukaemias (jmml)']","[""['D46.Z', 'D46.9', 'C94.6', 'D46.C']""]",['treosulfan'],['CS(=O)(=O)OCC(C(COS(=O)(=O)C)O)O'],"
        Inclusion Criteria:

          1. Haematological malignant disease i.e. ALL, AML, MDS or JMML, indicated for allo-HSCT.

          2. Indication for first allo-HSCT or second allo-HSCT due to disease relapse, graft
             failure, or secondary malignancy after previous HSCT.

          3. Available matched sibling donor (MSD), matched family donor (MFD) or matched unrelated
             donor (MUD). For bone marrow (BM) and peripheral blood (PB) match is defined as 9/10
             or 10/10 allele match after four digit typing in human leucocyte antigens (HLA)-A, B,
             C, DRB1 and DQB1.

          4. Patients with ALL or AML in complete morphologic remission (blast counts <5 % in BM)
             and patients with MDS or JMML with blast counts < 20 % in BM at study entry.

          5. Age at time of registration from 28 days to less than 18 years of age.

          6. Lansky (patients aged <16 years) or Karnofsky (patients aged ≥ 16 years) performance
             score of at least 70 %.

          7. Written informed consent of the parents/ legal guardians and patient's assent/consent
             according to national regulations.

          8. Females of child-bearing potential or male patients' partners with child-bearing
             potential must use a highly effective method of contraception (pearl index < 1 %) such
             as complete sexual abstinence, combined oral contraceptive, hormone intrauterine
             contraceptive device (IUCD), vaginal hormone ring, transdermal contraceptive patch,
             contraceptive implant or depot contraceptive injection in combination with a second
             method of contraception like a condom or a cervical cap / diaphragm with spermicide or
             surgical sterilisation (vasectomy) in male patients or male partners during the study
             and at least 6 months thereafter.

          9. Negative pregnancy test for females of child-bearing potential.

        Exclusion Criteria:

          1. Third or later allo-HSCT.

          2. HSCT from haploidentical or umbilical cord blood donor.

          3. Symptomatic involvement of central nervous system (CNS) at study entry.

          4. Treatment with cytotoxic drugs within 10 days prior to day 7.

          5. Obese paediatric patients with body mass index: weight (kg)/[height (m)]² > 30 kg/m².

          6. Solid tumours (e.g. neuroblastoma, peripheral neuroectodermal tumour [PNET], Ewing
             sarcoma).

          7. Fanconi anaemia and other deoxyribonucleic acid (DNA) breakage repair disorders.

          8. Impaired liver function indicated by Bilirubin > three times the upper limit of normal
             (ULN) or aspartate aminotransferase/alanine aminotransferase (AST/ALT) > five times
             ULN, or active infectious hepatitis.

          9. Impaired renal function indicated by estimated glomerular filtration rate ([GFR],
             according to the Schwartz formula) < 60 mL/min/1,73m2.

         10. Impaired cardiac function: severe cardiac insufficiency indicated by left ventricle
             ejection fraction (LVEF) < 35 %.

         11. Requirement for supplementary continuous oxygen.

         12. Severe active infection requiring deferral of conditioning.

         13. Human immunodeficiency virus (HIV) positivity.

         14. Known pregnancy, breast feeding.

         15. Known hypersensitivity to Treosulfan and/or Fludarabine.
      "
NCT02335411,completed,,1,phase 2,"['gastric adenocarcinoma', 'gastroesophageal junction adenocarcinoma']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['cisplatin', '5-fu', 'capecitabine']","['N.N.Cl[Pt]Cl', 'C1=C(C(=O)NC(=O)N1)F', 'CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O']","
        Inclusion Criteria - Cohort 1:

          -  Received and progressed on ≥2 prior chemotherapy regimens for their advanced disease;
             prior regimen must have included a cisplatin and a fluoropyridine

          -  Human epidermal growth factor receptor 2 (HER-2/neu) negative, or, if HER2/neu
             positive, must have previously received treatment with trastuzumab

        Inclusion Criteria - Cohort 2 or 3:

          -  HER2/neu negative

          -  Has not received prior systemic anti-cancer therapy for their advanced carcinoma
             (systemic therapy received in the neoadjuvant and adjuvant setting does not count)

        Inclusion Criteria - All Participants:

          -  Histologically- or cytologically-confirmed recurrent or metastatic gastric or
             gastroesophageal junction adenocarcinoma that is considered incurable by local
             therapies

          -  Willing to provide tissue for PD-L1 biomarker analysis from newly-obtained and/or
             archival tissue

          -  Measurable disease based on Response Evaluation Criteria in Solid Tumors version 1.1
             (RECIST 1.1)

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 3 days
             prior to first dose of study drug

          -  Life expectancy of at least 3 months

          -  Female participants of childbearing potential should have a negative pregnancy test
             and be willing to use 2 methods of birth control or be surgically sterile, or abstain
             from heterosexual activity for the course of the study through 120 days after the last
             dose of study drug (180 days for participants receiving cisplatin + 5FU)

          -  Male participants should agree to use an adequate method of contraception starting
             with the first dose through 120 days after the last dose of study drug (180 days for
             participants receiving cisplatin + 5FU)

          -  Adequate organ function

        Exclusion Criteria - All Participants:

          -  Currently participating and receiving study therapy or participated in a study of an
             investigational agent and received study therapy or used an investigation device
             within 4 weeks of the first dose of study drug

          -  Active autoimmune disease that has required systemic treatment in past 2 years

          -  Immunodeficiency or receiving systemic steroid therapy or any other form of
             immunosuppressive therapy within 7 days prior to the first dose of study drug

          -  Weight loss >10% over 2 months prior to first dose of study drug

          -  Clinical evidence of ascites by physical exam

          -  Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or not
             recovered from AEs due to agents administered more than 4 weeks earlier

          -  Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2
             weeks prior to study Day 1 or who has not recovered from AEs due to a previously
             administered agent

          -  Known additional malignancy that is progressing or requires active treatment excepting
             basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has
             undergone potentially curative therapy or in situ cervical cancer

          -  Known active central nervous system (CNS) metastases and/or carcinomatous meningitis

          -  Known history of, or any evidence of active, non-infectious pneumonitis

          -  Active infection requiring systemic therapy

          -  Psychiatric or substance abuse disorders that would interfere with cooperation with
             the requirements of the study

          -  Pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the study, starting with the screening visit through 120 days
             after the last dose of study drug (180 days for participants receiving cisplatin +
             5FU)

          -  Prior therapy with an anti-programmed death-1 (PD-1), anti-PD-L1, or anti-PD-L2 agent

          -  Human immunodeficiency virus (HIV)

          -  Hepatitis B or C

          -  Received live vaccine within 30 days of planned start of study drug
      "
NCT02336815,completed,,1,phase 2,['multiple myeloma'],"[""['C90.01', 'C90.02', 'C90.00']""]","['selinexor', 'dexamethasone']","['C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F', 'CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C']","
        Inclusion Criteria:

        Measurable MM based on modified IMWG guidelines. Defined by at least one of the following:

          1. Serum M-protein ≥ 0.5 g/dL by serum electrophoresis (SPEP) or for IgA myeloma, by
             quantitative IgA

          2. Urinary M-protein excretion ≥ 200 mg/24 hours

          3. Free Light Chain (FLC) ≥ 100 mg/L, provided that the FLC ratio is abnormal

          4. If serum protein electrophoresis is felt to be unreliable for routine M-protein
             measurement, then quantitative Ig levels by nephelometry or turbidimetry are
             acceptable

               -  Must have previously received ≥ 3 anti-MM regimens including: an alkylating
                  agent, lenalidomide, pomalidomide, bortezomib, carfilzomib, daratumumab, and a
                  glucocorticoid. There is no upper limit on the number of prior therapies provided
                  that all other inclusion/exclusion criteria are met.

               -  MM refractory to previous treatment with one or more glucocorticoids, parenteral
                  PI (i.e., bortezomib and/or carfilzomib), IMiD (i.e., lenalidomide and/or
                  pomalidomide), and the anti-CD38 mAb, daratumumab. Refractory is defined as ≤ 25%
                  response to therapy, or progression during therapy or progression within 60 days
                  after completion of therapy.

        Exclusion Criteria:

          -  Active smoldering MM.

          -  Active plasma cell leukemia.

          -  Documented systemic amyloid light chain amyloidosis.

          -  Active CNS MM.
      "
NCT02337946,completed,,1,phase 2,['colorectal carcinoma'],"[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['oxaliplatin (oxa), levofolinate calcium (l-lv), 5-fu, panitumumab', 'oxaliplatin (oxa), levofolinate calcium (l-lv), 5-fu, panitumumab']",['Status: 503'],"
        Inclusion Criteria for enrollment:

          1. Participants with unresectable adenocarcinoma originating in the large intestine
             (excluding carcinoma of the appendix and anal canal cancer)

          2. Participants with measurable lesion(s) according to the RECIST ver. 1.1

          3. Participants who have not received chemotherapy for colorectal cancer. Participants
             who experience relapse more than 6 months after the final dose of perioperative
             adjuvant chemotherapy with fluoropyrimidine agents may be enrolled.

          4. Aged ≥ 20 years at the time of enrollment

          5. Participants classified as KRAS wild-type. However, the criteria will be changed to
             all patients who are verified to be of KRAS and NRAS wild-type when the KRAS and NRAS
             tests come to be covered by National Health Insurance, and the tests become feasible
             at medical institutions.

          6. Participants who satisfy the following criteria for the major organ function in tests
             performed within 14 days prior to enrollment

               1. Neutrophil count ≥ 1.5 × 10^3/μL

               2. White blood cell count ≥ 3.0 × 10^3/μL

               3. Platelet count ≥ 10.0 × 10^4/μL

               4. Hemoglobin ≥ 9.0 g/dL

               5. Total bilirubin ≤ 2.0 mg/dL

               6. AST ≤ 100 U/L (≤ 200 U/L if liver metastases are present)

               7. ALT ≤ 100 U/L (≤ 200 U/L if liver metastases are present)

               8. Serum creatinine ≤ 1.5 mg/dL

          7. Participants who are assessed at Eastern Cooperative Oncology Group (ECOG) performance
             status (P.S.) of 0 or 1

          8. Life expectancy of ≥ 6 months after enrollment

          9. Participants who have given written consent to take part in the study after detailed
             explanation of the study prior to enrollment

        Inclusion criteria for randomization:

          1. Participants who have received 6 cycles of mFOLFOX6 + panitumumab combination therapy

          2. Participants who are assessed at ECOG P.S. of 0-1 in the 6th cycle.

          3. Participants for whom PD or not evaluable has been denied on the RECIST 1.1 based on
             imaging tests conducted after the day of administration in the 6th cycle within 14
             days (2 weeks).

        Exclusion Criteria for enrollment:

          1. Radiotherapy received for a measurable lesion

          2. Radiotherapy received within 28 days (4 weeks) prior to enrollment for a lesion other
             than measurable lesions. However, treatment to relieve pain associated with metastatic
             bone tumors was allowed.

          3. Known brain metastasis or strongly suspected of brain metastasis

          4. Synchronous cancers or metachronous cancers with a disease-free period of ≤ 5 years
             (excluding colorectal cancer) excluding mucosal cancers cured or be possibly cured by
             regional resection (esophageal, stomach, and cervical cancer, non-melanoma skin
             cancer, bladder cancer, etc.).

          5. Body cavity fluid that requires treatment (pleural effusion, ascites, pericardial
             effusion, etc.)

          6. Participants who do not want to use contraception to prevent pregnancy, and women who
             are pregnant or breast-feeding, or test positive for pregnancy

          7. Active hemorrhage requiring blood transfusion

          8. Disease requiring systemic steroids for treatment (excluding topical steroids)

          9. Intestinal resection and colostomy within 2 weeks prior to enrollment

         10. History or obvious and extensive CT findings of interstitial pulmonary disease
             (interstitial pneumonia, pulmonary fibrosis, etc.)

         11. Serious drug hypersensitivity

         12. Local or systemic active infection requiring treatment, or fever indicating infection

         13. Intestinal paralysis, gastrointestinal obstruction, or uncontrollable diarrhea
             (incapacitating symptoms despite adequate treatment)

         14. Active hepatitis B and/or active hepatitis C

         15. Known human immunodeficiency virus infection

         16. Other patients judged by the investigator or subinvestigator to be ineligible for
             enrollment in the study

        Exclusion criteria for randomization:

          1. Participants in whom interstitial pneumonia has been newly diagnosed during the period
             from registration to randomization

          2. Participants who have received radiotherapy during the period from registration to
             randomization

          3. Other Participants judged by the investigator or sub-investigator to be ineligible for
             enrollment in the study
      "
NCT02333890,unknown status,,0,phase 2,"['breast cancer', 'invasive breast cancer']","[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['chloroquine', 'placebo']",['CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl'],"
        Inclusion Criteria:

          -  newly diagnosed histologically confirmed primary invasive breast cancer who is
             currently not undergoing any treatment while awaiting surgery in the next 2-6 weeks

          -  tumour ≥ 1.5 cm by palpation or imaging

          -  ECOG performance status 0-2

          -  written informed consent for the study

        Exclusion Criteria:

          -  Known Metastatic breast cancer

          -  history of pre-existing known retinal or ocular pathology patient has only one
             functioning eye

          -  abnormal hepatic function (serum AST or ALT >3x upper limit of normal)

          -  currently on CQ or HCQ or has been on the drug within the past 3 months for other
             conditions

          -  known history of psoriasis

          -  known history of epilepsy or seizures

          -  electrocardiogram showing QT prolongation based on QTc interval >450 ms

          -  inability to comply with a study protocol (abuse of alcohol, drugs or psychotic
             states)

          -  current known pregnancy or actively nursing

          -  allergic reactions to quinolones or CQ

          -  inability to consent.
      "
NCT02419469,terminated,"
    slow accrual
  ",0,phase 2,"['leukemia', 'precursor-b acute lymphoblastic leukemia', 'lymphoblastic lymphoma', 'lymphoma']","[""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']""]","['cytarabine', 'daunorubicin', 'vincristine', 'prednisone', 'peg asparaginase', 'ofatumumab', 'rituximab', 'methotrexate', 'cyclophosphamide', 'mercaptopurine', 'doxorubicin', 'dexamethasone acetate', 'thioguanine']","['C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O', 'CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O', 'CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O', 'CC12CC(=O)C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C', 'CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O', 'C1CNP(=O)(OC1)N(CCCl)CCCl', 'C1=NC2=C(N1)C(=S)N=CN2', 'CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O', 'CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)COC(=O)C)O)C)O)F)C', 'C1=NC2=C(N1)C(=S)N=C(N2)N']","
        Inclusion Criteria:

          1. Patients must have precursor-B lymphoblastic leukemia or lymphoma.

          2. Patients must be untreated or have had only one prior chemotherapy regimen for ALL or
             LL . Previously treated patients will be analyzed separately.

          3. Age between 12 to 30 years old

          4. Patients with central nervous system (CNS) disease or testicular disease are eligible.

          5. Intrathecal therapy with cytarabine is allowed prior to registration for patient
             convenience. This is usually done at the time of the diagnostic bone marrow or venous
             line placement to avoid a second lumbar puncture. Systemic chemotherapy must begin
             within 72 hours of the first intrathecal treatment.

          6. Signed informed consent prior to the start of systemic therapy. In the event of
             enrollment of a minor patient, an attempt to obtain assent from the patient must be
             documented, and parental consent must be signed.

          7. Echocardiogram should be done within 7 days of starting therapy if there are cardiac
             risk factors (e.g., history of hypertension or of myocardial infarction)

          8. Creatinine should be < 3 mg/dL bilirubin < 3 mg/dl unless due to disease

          9. Zubrod Performance status of <3

         10. Patients who received steroids more than 72 hours prior to study enrollment are
             eligible but will be analyzed separately.

         11. Lymphoblasts may have any positive expression of cluster of differentiation antigen 20
             (CD20) for ofatumumab administration.

        Exclusion Criteria:

          1. Age less than twelve years of age or greater than 30 years.

          2. More than one prior treatment regimen for ALL or LL.

          3. The patient is pregnant or unwilling to practice appropriate birth control.

          4. Presence of the Philadelphia chromosome t(9;22)

          5. Laboratory or clinical evidence of active infectious hepatitis.
      "
NCT02413320,completed,,1,phase 2,['triple-negative breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['paclitaxel', 'carboplatin', 'doxorubicin', 'cyclophosphamide', 'docetaxel']","['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C', 'C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]', 'CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O', 'C1CNP(=O)(OC1)N(CCCl)CCCl', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O']","
        Inclusion Criteria:

          -  Patients with newly diagnosed stage I (T>1cm), II or III triple negative breast cancer
             who have not had definitive breast surgery or received systemic chemotherapy

          -  The invasive tumor must be hormone receptor-poor, defined as both estrogen receptor
             and progesterone receptor staining present in ≤ 10% of invasive cancer cells by
             Immunohistochemistry.

          -  HER- 2 negativity will be based on the current ASCO-CAP guidelines for HER testing

          -  No prior chemotherapy, endocrine therapy or radiation therapy with therapeutic intent
             for this cancer

          -  Female subjects age 18 - 70 years

          -  ECOG Performance Status of 0-1

          -  Adequate organ and marrow function as defined below:

               -  Leukocytes ≥ 3,000/uL

               -  Absolute neutrophil count ≥ 1500/uL

               -  Platelets ≥ 100,000/uL

               -  Total bilirubin ≤ 1.5mg/dL

               -  AST(SGOT)/ALT(SPGT) ≤ 2 x institutional upper limit of normal

               -  Creatinine ≤ 1.5mg/dl and/or Creatinine Clearance ≥ 60mL/min

               -  Serum albumin ≥ 3.0 g/dL

          -  Women of child-bearing potential must agree to use adequate contraception

          -  Pretreatment lab values must be performed within 14 days of treatment initiation, and
             other baseline studies performed within 30 days prior to registration

          -  Subjects should have LVEF ≥ 50% by echocardiogram or MUGA scan performed within 4
             weeks prior to treatment initiation

          -  Subjects should have breast and axillary imaging with breast MRI or breast and
             axillary ultrasound within 4 weeks prior to treatment initiation

          -  Subjects with clinically/radiologically abnormal axillary lymph nodes should have
             pathological confirmation of disease with image guided biopsy/fine needle aspiration.

          -  Subjects must be already enrolled in P.R.O.G.E.C.T observational registry

          -  Staging to rule out metastatic disease is recommended for subjects with clinical stage
             III disease

          -  Subjects with bilateral disease are eligible if they meet other eligibility criteria.

          -  Neuropathy: No baseline neuropathy grade > 2

        Exclusion Criteria:

          -  Current or anticipated use of other investigational agents

          -  Subject has received chemotherapy, radiotherapy or surgery for the treatment of breast
             cancer

          -  Subject with metastatic disease

          -  History of allergic reactions to compounds of similar chemical or biologic composition
             to carboplatin, docetaxel, doxorubicin, cyclophosphamide, paclitaxel, or other agents
             used in the study

          -  Subjects with inflammatory breast cancer

          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active
             infection or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Subject is pregnant or nursing

          -  Subjects with concomitant or previous malignancies within the last 5 years. Exceptions
             include: adequately treated basal or squamous cell carcinoma of the skin, carcinoma in
             situ of the cervix, and ductal carcinoma in situ (DCIS).

          -  Ejection Fraction <50% on ECHO or MUGA

          -  Cardiac function: Subjects with congestive heart failure, myocardial infarction,
             unstable angina pectoris, an arterial thrombotic event, stroke or transient ischemia
             attack within the past 12 months, uncontrolled hypertension (Systolic BP>160 or
             Diastolic BP>90), uncontrolled or symptomatic arrhythmia, or grade ≥ 2 peripheral
             vascular disease
      "
NCT02419755,terminated,"
    accrual goals were no longer feasible based on restrictions imposed by the dsmb.
  ",0,phase 2,"['mixed lineage acute leukemia', 'acute myeloid leukemia', 'acute lymphoid leukemia']","[""['C92.A1', 'C92.A2', 'C92.61', 'C92.62', 'C92.A0', 'C92.60']"", ""['J84.2', 'C91.Z1', 'C91.Z2', 'C91.91', 'C91.92', 'C91.Z0', 'C91.90']""]","['bortezomib', 'vorinostat', 'mitoxantrone', 'cytarabine', 'methotrexate', 'hydrocortisone', 'peg-l-asparaginase', 'erwinia l-asparaginase', 'dexamethasone', 'mercaptopurine', 'doxorubicin']","['B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O', 'C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO', 'C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O', 'CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O', 'CC12CCC(=O)C=C1CCC3C2C(CC4(C3CCC4(C(=O)CO)O)C)O', 'CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C', 'C1=NC2=C(N1)C(=S)N=CN2', 'CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O']","
        INCLUSION CRITERIA:

          -  Age: Patient is ≤ 21 years of age (i.e., eligible until 22nd birthday).

          -  Diagnosis: Participant has a hematologic malignancy that is positive for MLLr as
             determined by fluorescent in situ hybridization (FISH) or RT-PCR, and disease meets at
             least one of the following criteria:

               -  Relapsed after or is refractory to chemotherapy

               -  Relapsed after hematopoietic stem cell transplantation (HSCT)

               -  Relapsed or refractory secondary leukemia (Relapse is defined as reappearance of
                  leukemia cells after the attainment of complete remission and refractory is
                  defined as ≥5% blasts at the end of induction. Patients that achieved MRD
                  negative status followed by reappearance of blasts at less than 5% are eligible.)

          -  Patients must have had verification of the malignancy at relapse, including
             immunophenotyping, to confirm diagnosis.

          -  Performance Level: Karnofsky ≥50% for patients >16 years of age and Lansky ≥50 for
             patients ≤16 years of age (See Appendix III). Patients who are unable to walk because
             of paralysis, but who are up in a wheelchair, will be considered ambulatory for the
             purpose of assessing the performance score.

          -  Prior therapy:

               -  Patients who relapse while receiving standard ALL maintenance chemotherapy
                  consisting of daily 6MP, weekly methotrexate, monthly vincristine, and monthly
                  steroid pulse will not be required to have a waiting period before entry onto
                  this study.

               -  Patients who relapse on therapy other than standard ALL maintenance therapy must
                  have fully recovered from the acute toxic effects of all prior chemotherapy,
                  immunotherapy, or radiotherapy prior to entering this study.

               -  Cytotoxic therapy: At least 14 days since the completion of cytotoxic therapy
                  with the exception of hydroxyurea, low dose cytarabine, and intrathecal
                  chemotherapy which is permitted up to 24 hours prior to the start of protocol
                  therapy. For patients with aggressive disease that is in the peripheral blood and
                  rising, this 14 day washout period may be omitted.

               -  Biologic (anti-neoplastic) agent: At least 7 days since the completion of therapy
                  with a biologic agent or donor lymphocyte infusions (DLI). For agents that have
                  known adverse events occurring beyond 7 days after administration, this period
                  must be extended beyond the time during which adverse events are known to occur.

               -  Stem cell transplant or rescue: ≥2 months must have elapsed since the time of
                  transplant. Patients with active graft-vs-host disease (GVHD) are not eligible.

          -  Organ function requirements: All patients must have:

               -  Adequate renal function defined as: Creatinine clearance or radioisotope GFR ≥70
                  mL/min/1.73 m^2, OR adequate serum creatinine based on age/gender.

               -  Adequate liver function defined as: Total bilirubin ≤ ULN for age, or if total
                  bilirubin is > ULN, direct bilirubin is ≤ 1.4 mg/dL, AND SGPT (ALT) ≤4 x ULN for
                  age, unless elevation due to leukemic infiltration

               -  Adequate cardiac function defined as: Shortening fraction of ≥27% by
                  echocardiogram OR Ejection fraction of ≥50% by gated radionuclide study

               -  Central nervous system (CNS) function defined as: Patients with seizure disorder
                  may be enrolled if on allowed anti-convulsants and well controlled.
                  Benzodiazepines and gabapentin are acceptable. CNS toxicity ≤ Grade 2.

               -  Adequate pulmonary function defined as FVC>50% predicted OR, if unable to perform
                  pulmonary function testing, must maintain pulse oximetry oxygen saturation >92%
                  on room air.

        EXCLUSION CRITERIA:

          -  Patients requiring anticonvulsants known to activate the cytochrome p450 system, in
             particular anticonvulsants such as phenytoin, carbamazepine, and phenobarbital, are
             not eligible. Benzodiazepines and gabapentin are acceptable. Please see Appendix I for
             a list of drugs known to be potent inducers/inhibitors of the cytochrome p450 system
             and Appendix II for a list of anticonvulsants based on CYP3A4/5 enzyme induction.

          -  ALL patients who cannot receive any asparaginase products (E. Coli, PEG-asparaginase,
             or Erwinia asparaginase) on this study (eg, due to prior severe pancreatitis, stroke
             or other toxicity) are not eligible. Patients with clinically significant prior
             allergies to PEG-asparaginase are eligible if Erwinia L-asparaginase can be
             substituted.

          -  Pregnancy and breast feeding: patients who are pregnant or breast-feeding are not
             eligible for this study as there is as yet no available information regarding human
             fetal or teratogenic toxicities. Negative pregnancy tests must be obtained in girls
             who are post-menarchal. Males or females of reproductive potential may not participate
             unless they have agreed to use an effective birth control method.

          -  Investigational drugs: Patients who are currently receiving another investigational
             drug are not eligible.

          -  Anti-cancer agents: Patients who are currently receiving other anti-cancer agents with
             the exception of those delineated in the eligibility criteria.

          -  Infection: Patients who have an uncontrolled infection are not eligible. Infections
             controlled on concurrent anti-microbial agents are acceptable, and anti-microbial
             prophylaxis per institutional guidelines are acceptable.

          -  Known human immunodeficiency virus (HIV) infection (pre-study testing not required).

          -  Any significant concurrent disease, illness, or psychiatric disorder that would
             compromise patient safety or compliance, study participation, follow up, or
             interpretation of study research.

          -  Patients with Fanconi anemia, Kostmann syndrome, Shwachman syndrome, or other
             inherited bone marrow failure syndromes are not eligible.

          -  Patients who in the opinion of the investigator may not be able to comply with the
             safety monitoring requirements of the study are not eligible.
      "
NCT02416570,terminated,"
    at 6 months 1 participant recruited. study deemed not feasible and discontinued.
  ",0,phase 2,"['cachexia', 'lung cancer']","[""['R64']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['clarithromycin', 'placebo']",['CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OC)C)C)O)(C)O'],"
        Inclusion Criteria:

          -  Adults with stage IV, pathologically confirmed, NSCLC not suitable for/declining/not
             tolerating 1st/2nd-line palliative chemotherapy, or following completion of
             1st/2nd-line palliative chemotherapy

          -  A likely prognosis of ≥3 months.

          -  Cachexia on the basis of any of the following, weight loss >5% over past 6 months, or
             BMI <20kg/m2 and weight loss >2%, or appendicular skeletal muscle index determined by
             duel energy x-ray absorptiometry consistent with sarcopenia and weight loss >2%.

          -  Systemic inflammation on the basis of a C-reactive protein >10mg/L.

          -  Adequate renal function as defined by creatinine ≤132micromol/L and eGFR
             ≥30mL/min/1.73m2

          -  Adequate liver function as defined by the following parameters, bilirubin
             ≤25micromol/L, and AST and ALT ≤2 times upper limit of normal, unless liver
             metastases, in which case ≤5 times upper limit of normal

          -  Prepared to suspend, if necessary, the use of certain statins and/or substitute the
             use of domperidone for an alternative anti-emetic for the duration of the study

        Exclusion Criteria:

          -  ECOG Performance Status 3 or 4

          -  Little or no food intake

          -  Weight loss >10% in 1 month or >20% in total

          -  Known hypersensitivity to clarithromycin

          -  Inability to accurately measure QT interval, e.g. atrial fibrillation

          -  QTc prolongation >450 milliseconds in a male, or 470 milliseconds in a female

          -  History of ventricular arrhythmia

          -  Severe cardiac insufficiency (NYHA class >2)

          -  Untreated hypokalaemia/hypomagnesaemia

          -  Active infection requiring antibiotics

          -  Current or recent (within last 4 weeks) history of Clostridium difficile, eating
             disorder, dysphagia, malabsorption or diarrhoea

          -  Untreated adrenal or thyroid diseases

          -  Brain metastases

          -  Use of corticosteroids/progestogens

          -  Use of chemotherapy, other immunosuppressive, or antiviral (e.g. hepatitis C, HIV)
             drugs within 4 weeks

          -  Drugs which are contra-indicated (except certain statins which can be temporarily
             suspended and domperidone which can be substituted for an alternative anti-emetic) or
             should be avoided in patients receiving clarithromycin, either because of the risk of
             a drug-drug interaction and/or prolonged QT

          -  Pregnancy

          -  Breast Feeding
      "
NCT02415608,terminated,"
    slow accrual
  ",0,phase 2,"['aggressive systemic mastocytosis', 'mast cell leukemia', 'systemic mastocytosis']","[""['C96.21']"", ""['C94.31', 'C94.32', 'C94.30']"", ""['D47.02', 'C96.21']""]",['ibrutinib'],['C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N'],"
        INCLUSION CRITERIA

          -  Diagnosis of systemic mastocytosis per 2008 World Health Organization (WHO) criteria.
             Those with advanced systemic mastocytosis (ASM); mast cell leukemia (MCL); or systemic
             mastocytosis-associated hematological clonal non-mast cell lineage disease (SM-AHNMD)
             required to have at least 1 organ damage finding

          -  Serum aspartate transaminase (AST) or alanine transaminase (ALT) ≤ 3.0 x upper limit
             of normal (ULN); if considered related to ASM/MCL ≤ 5 x ULN

          -  Estimated creatinine clearance ≥ 30 mL/min (Cockcroft-Gault)

          -  Total bilirubin ≤ 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of
             non-hepatic origin); if considered related to ASM/MCL ≤ 3 x ULN

          -  Female subjects must be of non-reproductive potential, or if of childbearing potential
             must have a negative serum pregnancy test upon study entry

          -  Must agree to use highly effective methods of birth control

          -  Written informed consent

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3

          -  Life expectancy > 12 weeks

        EXCLUSION CRITERIA

          -  Received any investigational agent, chemotherapy, interferon-alpha, or
             2-chlorodeoxyadenosine (2-CdA, cladribine) within 30 days prior to day 1; or
             monoclonal antibody ≤ 6 weeks prior to first administration of study treatment
             (patients with an AHNMD with progressive leukocytosis who require control of their
             counts are permitted to receive hydroxyurea)

          -  Diagnosis of AHNMD requiring immediate cytoreductive therapy or targeted drugs (eg,
             acute myeloid leukemia [AML])

          -  History of other malignancies, except:

               -  Malignancy treated with curative intent and with no known active disease present
                  for ≥ 3 years before the first dose of study drug, and at low risk for recurrence

               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
                  of disease

               -  Adequately treated carcinoma in situ without evidence of disease

          -  Concurrent systemic immunosuppressant therapy (eg, cyclosporine A, tacrolimus, etc.,
             or chronic administration [> 14 days] of > 10 mg/day of prednisone) within 28 days of
             the first dose of study drug

          -  Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug

          -  Systemic treatment for infection completed ≤ 14 days before the first dose of study
             drug

          -  Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved
             to Common Terminology Criteria for Adverse Event (CTCAE, version 4), grade 0 or 1, or
             to the levels dictated in the inclusion/exclusion criteria with the exception of
             alopecia

          -  Known bleeding disorders (eg, severe von Willebrand's disease) or severe hemophilia

          -  History of stroke or intracranial hemorrhage within 6 months prior to enrollment

          -  Known history of human immunodeficiency virus (HIV) or

          -  Active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV)

          -  Major surgery within 4 weeks of first dose of study drug

          -  Any life-threatening illness, medical condition, or organ system dysfunction that
             could compromise the subject's safety or put the study outcomes at undue risk

          -  Currently active, clinically significant cardiovascular disease, such as uncontrolled
             arrhythmia or class 3 or 4 congestive heart failure as defined by the New York Heart
             Association Functional Classification; or a history of myocardial infarction, unstable
             angina, or acute coronary syndrome within 6 months prior to randomization

          -  Unable to swallow capsules or malabsorption syndrome

          -  Disease significantly affecting gastrointestinal function

          -  Resection of the stomach or small bowel

          -  Symptomatic inflammatory bowel disease

          -  Ulcerative colitis

          -  Partial or complete bowel obstruction

          -  Requires treatment with a strong cytochrome P450 (CYP) 3A4/5 inhibitor

          -  Lactating or pregnant

          -  Unwilling or unable to participate in all required study evaluations and procedures

          -  Unable to understand the purpose and risks of the study and to provide a signed and
             dated informed consent form (ICF) and authorization to use protected health
             information (in accordance with national and local subject privacy regulations)

          -  Known hypersensitivity to any excipient contained in the drug

          -  Received hematopoietic growth factor support within 14 days of day 1 of ibrutinib
             (Jehovah's witnesses may be given an erythropoiesis-stimulating agent before and
             during the trial in lieu of red blood cell transfusions but anemia and/or red blood
             cell (RBC) transfusion dependence cannot be used for response assessment in these
             patients)

          -  Presence of the factor interacting with poly(A) polymerase alpha (PAPOLA) and cleavage
             and polyadenylation specific factor 1 (CPSF1) (FIP1L1)-platelet-derived growth factor
             receptor, alpha polypeptide (PDGFRalpha) fusion even with resistance to imatinib (such
             patients are no longer defined as systemic mastocytosis by the WHO)

          -  Received any treatment with ibrutinib prior to study entry

          -  The concomitant use of warfarin or other vitamin K antagonists unless felt to be of
             significant clinical need; low molecular weight heparin or other anticoagulants may be
             used instead if anticoagulation is required
      "
NCT02410863,terminated,"
    lack of recruitment due to changed therapy options
  ",0,phase 2,['malignant melanoma'],"[""['C43.0', 'C43.31', 'C43.51', 'C43.9', 'C43.4', 'C43.52', 'C43.10']""]","['dabrafenib', 'trametinib']","['CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F', 'CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5']","
        Inclusion Criteria:

          1. ≥ 18 years of age.

          2. Signed written informed consent.

          3. Histologically confirmed cutaneous melanoma that is either Stage IIIc (unresectable)
             or Stage IV (metastatic), and determined to be BRAF V600E/K mutation-positive by the
             central laboratory. Subjects with ocular or mucosal melanoma are not eligible.

          4. Assessable lesion for biopsy at week 2 not inferring with RECIST measurements
             (Biopsies for genetic/biomarker analyses must be taken from lesions not required for
             disease assessment)

          5. Measurable disease, i.e., present with at least one measurable lesion per RECIST,
             version 1.1 for the definition of a measureable lesion.

          6. For Cohort A: Must NOT have received prior treatment with BRAF or MEK inhibitor.

             If a prior systemic therapy (such as but not limited to chemotherapy, immunotherapy,
             biologic, vaccine and/or investigational treatment) in metastatic disease has been
             administered, four weeks or more since last systemic treatment must have passed. Must
             have recovered from any acute toxicity associated with prior therapy.

          7. For Cohort B: Must have shown PR/CR during treatment with selective BRAF/MEK
             combination treatment that was discontinued due to tumor progression and received
             subsequent alternative treatment (such as but not limited to surgery, chemotherapy,
             immunotherapy, biologic, vaccine and/or investigational treatment), with a period of
             at least 3 months since last intake of BRAF/MEK inhibitor

          8. All prior treatment-related toxicities (except alopecia) must be ≤ Grade 1 according
             to the Common Terminology Criteria of Adverse Events (CTCAE, Version 9. Able to
             swallow and retain oral medication and must not have any clinically significant
             gastrointestinal abnormalities that may alter absorption such as malabsorption
             syndrome or major resection of the stomach or bowels.

        10. Women of childbearing potential must have a negative urin pregnancy test within 7 days
        prior to registration and agree to use effective contraception, as defined in Section 9.8
        throughout the treatment period, and for 4 months after the last dose of study treatment.

        Men with a female partner of childbearing potential must have either had a prior vasectomy
        or agree to use effective contraception as described in Section 9.8 throughout the
        treatment period, and for 4 months after the last dose of study treatment. 11. An Eastern
        Cooperative Oncology Group (ECOG) performance status of 0 or 1 12. Adequate baseline organ
        function defined as Absolute Neutrophil Count ≥1.2 × 109/L Hemoglobin ≥ 9 g/dL Platelet
        count ≥ 100 x 109/L Prothrombinzeit (PT/INR) and Partial thromboplastin time ≤ 1.3 x upper
        laboratory norm (ULN) Albumin ≥ 2.5 g/dL Total bilirubin ≤ 1.5 x ULN Aspartate
        aminotransferase and Alanine Aminotransferase ≤ 2.5 x ULN Serum creatinine ≤ 1.5 mg/dL 13.
        A left ventricular ejection fraction (LVEF) ≥ the institutional lower limit of normal as
        measured by ECHO

        Exclusion Criteria:

          1. Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity,
             biologic therapy, or immunotherapy within 21 days prior to registration and/or daily
             or weekly chemotherapy without the potential for delayed toxicity within 14 days prior
             to registration.

          2. Taken an investigational drug within 28 days or 5 half-lives (minimum 14 days),
             whichever is shorter, prior to registration.

          3. Current use of a prohibited medication

          4. History of another malignancy. Exception: Subjects who have been disease-free for 3
             years, subjects with a history of completely resected non-melanoma skin cancer, and/or
             subjects with successfully treated in situ carcinoma are eligible. Subjects with
             second malignancies that are indolent or definitively treated may be enrolled.

          5. Any serious or unstable pre-existing medical conditions (aside from malignancy
             exceptions specified above), psychiatric disorders, or other conditions that could
             interfere with the subject's safety, obtaining informed consent, or compliance with
             study procedures.

          6. Known Human Immunodeficiency Virus (HIV), active Hepatitis B Virus (HBV), or active
             Hepatitis C Virus (HCV). Subjects with chronic or cleared HBV and/or HCV are eligible.

          7. A history of glucose-6-phosphate dehydrogenase (G6PD) deficiency.

          8. Subjects with brain metastases are excluded, unless:

               -  All known lesions must be previously treated with surgery or stereotactic
                  radiosurgery, and

               -  Brain lesion(s), if present, must be confirmed stable (ie, no increase in lesion
                  size) for 90 days prior to first dose of study drug(s). This must be documented
                  with two consecutive MRI or CT scans using contrast, and

               -  Asymptomatic with no corticosteroids requirement for 30 days prior to first dose
                  of study drug(s), and

               -  No enzyme-inducing anticonvulsants for 30 days prior to first dose of study
                  drug(s).

             In addition, even in cases of no evidence of disease (NED), confirmation on two
             consecutive MRI or CT scans using contrast will be required. Enrollment of a subject
             with brain metastases who meet the above criteria requires approval of the sponsor

          9. A history or evidence of cardiovascular risk including any of the following:

               1. A QT interval corrected for heart rate using the Bazett's formula (QTcB; ³ 480
                  msec;

               2. A history or evidence of current clinically significant uncontrolled arrhythmias;
                  Exception: Subjects with controlled atrial fibrillation for > 30 days prior to
                  registration are eligible.

               3. A history of acute coronary syndromes (including myocardial infarction or
                  unstable angina), coronary angioplasty, or stenting within 6 months prior to
                  registration; or

               4. A history or evidence of current ≥ Class II congestive heart failure as defined
                  by the New York Heart Association (NYHA) guidelines.

         10. A history or current evidence/risk of retinal vein occlusion (RVO) or central serous
             retinopathy (CSR) including:

             Presence of predisposing factors to RVO or CSR (e.g., uncontrolled glaucoma or ocular
             hypertension, uncontrolled hypertension, uncontrolled diabetes mellitus, or a history
             of hyperviscosity or hypercoagulability syndromes); or

             Visible retinal pathology as assessed by ophthalmic examination that is considered a
             risk factor for RVO or CSR such as:

             i. Evidence of new optic disc cupping; ii. Evidence of new visual field defects on
             automated perimetry; iii. Intraocular pressure > 21 mmHg as measured by tonography.

         11. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
             chemically related to the study treatments, their excipients, and/or dimethyl
             sulfoxide (DMSO).

         12. Interstitial lung disease or pneumonitis

         13. Pregnant or breast-feeding females.
      "
NCT02414009,completed,,1,phase 2,['metastatic colorectal cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['capecitabine', 'temozolomide', 'irinotecan', 'fluorouracil', 'leucovorin']","['CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O', 'CN1C(=O)N2C=NC(=C2N=N1)C(=O)N', 'CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7', 'C1=C(C(=O)NC(=O)N1)F', 'C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O']","
        Inclusion Criteria:

          -  Signed Informed Consent Form

          -  Histologically or cytologically confirmed adenocarcinoma of the colon and/or rectum,
             with MGMT promoter methylation and RAS mutation.

          -  Progressive disease on or after a first-line oxaliplatin containing chemotherapy
             regimen for mCRC with or without bevacizumab or other anti-angiogenic drugs. Patients
             must have received oxaliplatin-containing chemotherapy for ≥ 3 months. No more than
             one prior chemotherapy regimen for metastatic disease is allowed. 8

          -  Disease measurableRECIST v1.1

          -  Age ≥ 18 years and ≤ 75 years

          -  Life expectancy ≥ 12 weeks

          -  ECOG Performance Status of 0 1

          -  Adequate hematologic and end-organ function, defined by laboratory results obtained
             within 14 days prior to first administration: ANC ≥ 1500/μL Platelet count ≥
             100,000/μL Hemoglobin ≥ 9.0 g/dL Albumin ≥ 2.5 g/dL

          -  Total bilirubin ≤ 1.5 × the upper limit of normal (ULN)

          -  AST, ALT, and/or alkaline phosphatase ≤ 2.5 × ULN, with the following exceptions:
             Patients with documented hepatic metastases are eligible with AST, ALT, and/or
             alkaline phosphatase ≤ 5 × ULN. Patients with documented bone metastases are eligible
             with alkaline phosphatase ≤ 5 × ULN.

          -  Serum creatinine ≤ 1.5 × ULN, or creatinine clearance ≥ 50 mL/min on the basis of the
             Cockcroft-Gault glomerular filtration rate estimation: (140 - age) × (weight in kg) ×
             (0.85 if female) 72 × (serum creatinine in mg/dL)

          -  INR and aPTT ≤ 1.5 × ULN

          -  documented agreement (by patient and/or partner) to use an effective means of
             contraception (e.g., surgical sterilization, a reliable barrier method, birth control
             pills, or contraceptive hormone implants) and to continue its use for the duration of
             the study and for 60 days for female patients or 150 days for male patients with
             partners of childbearing potential after the last infusion of study treatment.

          -  Consent to provide mandatory archival tumor tissue for biomarker testing

        Exclusion Criteria:

          -  Prior treatment with irinotecan and temozolomide

          -  Major surgical procedure within 4 weeks and radiotherapy within 2 weeks prior to Day 1
             Cycle 1

          -  Symptomatic hypercalcemia requiring continued use of bisphosphonate.

          -  Known clinically significant dihydropyrimidine 9 dehydrogenase deficiency

          -  Current severe, uncontrolled systemic disease Active infection requiring IV
             antibiotics

          -  History of heart failure of any New York Heart Association criteria or serious cardiac
             arrhythmia requiring treatment (except for atrial fibrillation and paroxysmal
             supraventricular tachycardia)

          -  History of myocardial infarction within 6 months prior to Cycle 1, Day 1, or history
             of unstable angina

          -  Known clinically significant liver disease,or current alcohol abuse

          -  History of bleeding diathesis or coagulopathy other than that due to anticoagulation
             therapy

          -  Patients receiving oral coumarin-derived anticoagulants

          -  Active haemoptysis within 30 days prior to Cycle 1, Day 1

          -  HIV infection

          -  Untreated/active CNS metastases (progressing or requiring anticonvulsants or
             corticosteroids for symptomatic control). Patients with a history of treated CNS
             metastases are eligible provided they meet all of the following criteria: Measurable
             disease outside the CNS as defined by RECIST v1.1.Radiotherapy completed ≥ 4 weeks
             prior to Cycle, 1 Day

          -  Pregnancy or lactation. Women of childbearing potential (including those who have had
             a tubal ligation) must have a documented negative serum pregnancy test within 14 days
             prior to Cycle 1, Day 1.

          -  Inability to take oral medications.

          -  Malignancies other than CRC within 3 years prior to randomization, with the exception
             of adequately treated basal or squamous cell skin cancer and carcinoma in situ of the
             cervix
      "
NCT02414165,terminated,"
    sponsor decision
  ",0,phase 2/phase 3,"['glioblastoma multiforme', 'anaplastic astrocytoma']","[""['L51.0', 'L51.8', 'L51.9']"", ""['C84.67', 'C84.77', 'C84.7A', 'C84.60', 'C84.70', 'C84.62', 'C84.66']""]","['toca fc', 'lomustine', 'temozolomide']","['C1CCC(CC1)NC(=O)N(CCCl)N=O', 'CN1C(=O)N2C=NC(=C2N=N1)C(=O)N']","
        Inclusion Criteria:

          1. Subject has given written informed consent

          2. Subject is between 18 years old and 75 years old, inclusive

          3. Subjects must have histologically proven GBM or AA and:

               1. Must have received first-line multimodal therapy with surgery followed by
                  temozolomide (unless MGMT promoter unmethylated) and radiation (subjects with GBM
                  must have received temozolomide and radiation concurrently)

               2. Must be in first or second recurrence (including this recurrence)

               3. Recurrence must be confirmed by diagnostic biopsy with local pathology review or
                  contrast-enhanced MRI. If first recurrence of GBM is documented by MRI, an
                  interval of at least 12 weeks after the end of prior radiation therapy is
                  required unless there is either: i) histopathologic confirmation of recurrent
                  tumor, or ii) new enhancement on MRI outside of the radiotherapy treatment field

          4. Subjects must have measurable disease preoperatively, defined as at least 1
             contrast-enhancing lesion, with 2 perpendicular measurements of at least 1 cm, as per
             RANO criteria

          5. Subjects must be at least 4 weeks post last dose of temozolomide

          6. Prior gamma knife, stereotactic radiosurgery, or other focal high-dose radiotherapy is
             allowed but the subject must have either histopathologic confirmation of recurrent
             tumor, or new enhancement on MRI outside of the radiotherapy treatment field

          7. Based on the pre-operative evaluation by neurosurgeon, the subject is a candidate for
             ≥ 80% resection of enhancing region

          8. IDH mutation status of the primary tumor must be available or tumor samples must be
             available for pre randomization testing

          9. Laboratory values adequate for patient to undergo surgery, including:

               -  Platelet count ≥ 60,000/mm3

               -  Hgb ≥ 10 g/dL

               -  Absolute neutrophil count (ANC) ≥ 1,500/mm3

               -  Absolute lymphocyte count (ALC) ≥ 500/mm3

               -  Adequate liver function, including:

                    -  Total bilirubin ≤ 1.5 x ULN (unless has Gilbert's syndrome)

                    -  ALT ≤ 2.5 x ULN f. Estimated glomerular filtration rate of at least 50
                       mL/min by the Cockcroft Gault formula

         10. Women of childbearing potential (≥12 months of non-therapy-induced amenorrhea or
             surgically sterile) must have had a negative serum pregnancy test within the past 21
             days and must use a birth control method in addition to barrier methods (condoms).

         11. Subject or subject's partner is willing to use condoms for 12 months after receiving
             Toca 511 or until there is no evidence of the virus in his/her blood, whichever is
             longer.

         12. The subject has a KPS ≥ 70

         13. The subject is willing and able to abide by the protocol

        Exclusion Criteria:

          1. History of more than 2 prior recurrences (including this recurrence) of GBM or AA

          2. History of other malignancy, unless the patient has been disease free for at least 5
             years. Adequately treated basal cell carcinoma or squamous cell skin cancer is
             acceptable regardless of time, as well as localized prostate carcinoma or cervical
             carcinoma in situ after curative treatment

          3. Histologically confirmed oligodendroglioma or mixed glioma

          4. Known 1p/19q co deletion

          5. A contrast enhancing brain tumor that is any of the following:

               -  Multi focal (defined as 2 separate areas of contrast enhancement measuring at
                  least 1 cm in 2 planes that are not contiguous on either fluid attenuated
                  inversion recovery (FLAIR) or T2 sequences);

               -  Associated with either diffuse subependymal or leptomeningeal dissemination; or

               -  > 5 cm in any dimension

          6. The subject has or had any active infection requiring systemic antibiotic, antifungal
             or antiviral therapy within the past 4 weeks

          7. The subject has any bleeding diathesis, or must take anticoagulants, or antiplatelet
             agents, including nonsteroidal anti inflammatory drugs (NSAIDs), at the time of the
             scheduled resection that cannot be stopped for surgery

          8. The subject is human immunodeficiency virus (HIV) positive

          9. The subject has a history of allergy or intolerance to flucytosine

         10. The subject has a gastrointestinal disease that would prevent him or her from being
             able to swallow or absorb flucytosine

         11. The subject received cytotoxic chemotherapy within the past 4 weeks (6 weeks for
             nitrosoureas) of the planned surgery date

         12. The subject received any investigational treatment within the past 30 days or prior
             immunotherapy or antibody therapy within the past 45 days.

         13. The subject is pregnant or breast feeding

         14. The subject intends to undergo treatment with the Gliadel® wafer at the time of this
             surgery or has received the Gliadel® wafer < 30 days from W1D1 (surgery)

         15. The subject has received bevacizumab for their disease unless in the context of
             primary therapy for newly diagnosed glioma

         16. For subjects planned to potentially receive bevacizumab, they have no evidence of
             uncontrolled hypertension (defined as a blood pressure of ≥ 150 mm Hg systolic and/or
             ≥ 100 mm Hg diastolic on medication) or active GI perforation

         17. The subject has received systemic dexamethasone continuously at a dose > 8 mg/day for
             8 weeks prior to the date of the screening assessment

         18. Severe pulmonary, cardiac or other systemic disease, specifically:

               -  New York Heart Association > Grade 2 congestive heart failure within 6 months
                  prior to study entry, unless asymptomatic and well controlled with medication

               -  Uncontrolled or significant cardiovascular disease, clinically significant
                  ventricular arrhythmia (such as ventricular tachycardia, ventricular
                  fibrillation, or Torsades des pointes), clinically significant pulmonary disease
                  (such as ≥ Grade 2 dyspnea, according to CTCAE 4.03)

               -  Subjects who have any other disease, either metabolic or psychological, which as
                  per Investigator assessment may affect the subject's compliance or place the
                  subject at higher risk of potential treatment complications
      "
NCT03131206,terminated,"
    study closed due to slow accrual and lack of efficacy.
  ",0,phase 1/phase 2,"['alk-positive non-small cell lung cancer (nsclc)', 'ret-positive non-small cell lung cancer (nsclc)', 'ret-positive thyroid cancer']","[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C73', 'D34', 'D44.0', 'Z85.850']""]",['alectinib'],['CCC1=CC2=C(C=C1N3CCC(CC3)N4CCOCC4)C(C5=C(C2=O)C6=C(N5)C=C(C=C6)C#N)(C)C'],"
        Inclusion Criteria:

          -  Tumor Types:

               -  Phase 1: Subjects must have a histologically or cytologically confirmed diagnosis
                  of locally advanced (AJCC Stage IIIB) not amenable to curative therapy or
                  metastatic (AJCC Stage IV) NSCLC that carries a RET rearrangement, as determined
                  by fluorescence in situ hybridization (FISH), reverse transcription polymerase
                  chain reaction (RT-PCR), or next generation sequencing (NGS) via a CLIA-certified
                  local diagnostic test (LDT).

                  --- OR-

               -  Phase 1: Subjects must have a histologically or cytologically confirmed diagnosis
                  of metastatic (AJCC Stage IV) NSCLC that carries an ALK rearrangement with CNS
                  metastases, as determined by FISH, RT-PCR, immunohistochemistry (IHC), or NGS via
                  a CLIA-certified LDT.

               -  Phase 2 Cohorts A&B: Subjects must have a histologically or cytologically
                  confirmed diagnosis of locally advanced (AJCC Stage IIIB) not amenable to
                  curative therapy or metastatic (AJCC Stage IV) NSCLC that carries a RET
                  rearrangement, as determined by FISH, RT-PCR, or NGS via a CLIA-certified LDT.

               -  Phase 2 Cohort C (thyroid cancer): Subjects must have a histologically or
                  cytologically confirmed diagnosis of metastatic thyroid cancer (Stage IV) that
                  carries either a RET rearrangement or activating RET mutation, as determined by
                  FISH, RT-PCR, or NGS via a CLIA-certified LDT.

          -  Disease Status Requirements:

               -  Phase 1: Subjects with a RET rearrangement must have had disease progression
                  after at least one prior line of systemic therapy. Subjects with an ALK
                  rearrangement may be either treatment naive or may have received prior treatment,
                  and must have CNS disease present at baseline. Subjects cannot have received more
                  than one prior RET TKI (such as, but not limited to, vandetanib, sorafenib,
                  sunitinib, ponatinib, or cabozantinib). Subjects enrolling to the Phase 1 portion
                  of the trial must not have received prior alectinib therapy.

               -  Phase 2:

                    -  Cohort A: RET-positive NSCLC subjects must have received at least one prior
                       line of therapy, but must be RET TKI-naive.

                    -  Cohort B: RET-positive NSCLC that has previously been treated with one RET
                       TKI. Subjects cannot have received more than one prior RET TKI and must not
                       have received prior alectinib.

                    -  Cohort C: RET-positive thyroid cancer, must be radioactive iodine
                       refractory.

          -  Subjects must have at least one measurable target lesion according to RECIST v1.1.

          -  Subjects enrolling to the phase 1 portion of the trial who have received a prior RET
             TKI must be able and willing to undergo a pre-treatment fresh tumor biopsy.

          -  Subjects enrolling to Cohort B or C of the phase 2 portion of the trial who have
             received a prior RET TKI must be able and willing to undergo a pre-treatment fresh
             tumor biopsy.

          -  All subjects must have archival tissue confirmed as available for enrollment. Subjects
             who are TKI naive who do not have archival tissue may undergo a fresh tumor biopsy in
             lieu of the archival tissue requirement. The archival tissue requirement may be waived
             for subjects after discussion with the principal investigator.

          -  Age ≥ 18 years.

          -  ECOG performance status ≤2 (See APPENDIX A)

          -  Subjects must have normal organ and marrow function as defined below:

        Adequate hematologic function

          -  Absolute neutrophil count ≥1,500/mcL

          -  Platelets ≥100,000/mcL

          -  Hemoglobin ≥ 9.0 g/dL -- Adequate renal function

          -  serum creatinine ≤1.5 x institutional ULN

             ---- OR-

          -  Estimated glomerular filtration rate (eGFR) ≥45 mL/min/1.73 m2 as calculated using the
             Modification of Diet Renal Disease Equation (See APPENDIX B)

               -  Subjects must have recovered from treatment toxicities to ≤ Grade 1 or to their
                  pretreatment levels. Subjects who have developed interstitial lung disease (ILD)
                  must have fully recovered.

               -  For all females of childbearing potential, a negative serum pregnancy test must
                  be obtained within 3 days prior to starting study treatment.

               -  For women who are not postmenopausal (≥12 months of non-therapy-induced
                  amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement
                  to remain abstinent or use single or combined contraceptive methods that result
                  in a failure rate of < 1% per year during the treatment period and for at least 3
                  months after the last dose of study drug. Abstinence is only acceptable if it is
                  in line with the preferred and usual lifestyle of the subject. Periodic
                  abstinence (e.g., calendar, ovulation, symptothermal or postovulation methods)
                  and withdrawal are not acceptable methods of contraception. Examples of
                  contraceptive methods with a failure rate of < 1% per year include tubal
                  ligation, male sterilization, hormonal implants, established, proper use of
                  combined oral or injected hormonal contraceptives, and certain intrauterine
                  devices.

               -  For men: agreement to remain abstinent or use a contraceptive method that results
                  in a failure rate of < 1% per year during the treatment period and for at least 3
                  months after the last dose of study drug. Abstinence is only acceptable if it is
                  in line with the preferred and usual lifestyle of the subject. Periodic
                  abstinence (e.g., calendar, ovulation, symptothermal or postovulation methods)
                  and withdrawal are not acceptable methods of contraception.

               -  Ability to understand and the willingness to sign a written informed consent
                  document.

        Exclusion Criteria:

          -  Cytotoxic chemotherapy or immunotherapy within 3 weeks of study entry.

          -  Oral targeted therapy within 5 half-lives (if known) or 3 weeks (if half-life is
             unknown) of study entry.

          -  Phase 1: subjects who have received prior alectinib therapy.

          -  For enrollment to the phase 1 portion of the trial: Administration of any cytochrome
             P450 (CYP)3A inhibitors or inducers within 14 days prior to the first dose of
             alectinib and from Cycle 1 Day 1 - Cycle 2 Day 8 of the phase 1 portion of the trial.
             Following completion of this period, strong/potent cytochrome P450 (CYP)3A inhibitors
             or inducers are prohibited while on study. Please see APPENDIX C.

          -  Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study
             entry. Palliative radiation (≤10 fractions) must have been completed at least 48 hours
             prior to study entry. Stereotactic or small field brain irradiation must have
             completed at least 2 weeks prior to study entry. Whole brain radiation must have
             completed at least 4 weeks prior to study entry.

          -  Major surgery within 4 weeks of study entry. Minor surgical procedures (e.g., port
             insertion) are not excluded, but sufficient time should have passed for wound healing
             (as determined by the treating investigator).

          -  Subjects who are receiving any other investigational agents.

          -  Liver disease characterized by:

             -- ALT or AST > 3 × institutional ULN (≥ 5 × ULN for subjects with concurrent liver
             metastasis) confirmed on two consecutive measurements

             --- OR-

          -  Absolute impaired excretory function (e.g., hyperbilirubinemia) or synthetic function
             or other conditions of decompensated liver disease such as coagulopathy, hepatic
             encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices

             --- OR-

          -  Impaired excretory function (e.g., hyperbilirubinemia) or synthetic function or other
             conditions of decompensated liver disease such as coagulopathy, hepatic
             encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices

             ---OR-

          -  Acute viral or active autoimmune, alcoholic, or other types of acute hepatitis

          -  Subjects with symptomatic CNS metastases who are neurologically unstable and/or
             require an increased dose of steroid to manage CNS symptoms within 1 week prior to the
             first day of treatment are excluded.

               -  Subjects with brain or leptomeningeal metastases that do not meet the above
                  criteria are allowed.

               -  Symptomatic disease is allowed as long as symptoms are controlled and stable.

          -  History of hypersensitivity to any of the additives in the alectinib drug formulation.

          -  Subjects with symptomatic bradycardia.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Pregnant or breastfeeding women.

          -  Any GI disorder that may affect absorption of oral medications in the opinion of the
             treating investigator, such as malabsorption syndrome or major bowel or stomach
             resection.

          -  Subjects who are unable to swallow pills.

          -  Subjects with a history of a second primary malignancy. Exceptions include: subjects
             with a history of malignancies that were treated curatively and have not recurred
             within 3 years prior to study entry; resected basal and squamous cell carcinomas of
             the skin, and completely resected carcinoma in situ of any type.

          -  NCI-CTCAE v4.03 Grade 3 or higher toxicities due to any prior therapy (excluding
             alopecia), which have not shown improvement and are strictly considered to interfere
             with current study medication.

          -  Known HIV positivity or AIDS-related illness.
      "
NCT03136627,completed,,1,phase 1/phase 2,"['carcinoma, renal cell']","[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]","['tivozanib', 'nivolumab']",['CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl'],"
        Inclusion Criteria:

          1. ≥ 18-year-old

          2. Histologically or cytologically documented renal cell carcinoma with a clear cell
             component, except in Phase 1b, where any histology will be permitted

          3. Metastatic renal cell carcinoma. Measurable or evaluable disease by RECIST 1.1
             criteria

          4. No prior exposure to tivozanib or nivolumab

          5. ECOG performance status ≤ 1 (see Appendix A) and life expectancy ≥ 3 months.

          6. Signed and dated written informed consent

          7. Sexually active pre-menopausal female subjects and female partners of male subjects
             must use adequate contraceptive measures, while on study and for at least 160 days
             after the last dose of study drug. Sexually active male subjects must use adequate
             contraceptive measures, while on study and for at least 160 days after the last dose
             of study drug. All fertile male and female subjects and their partners must agree to
             use a highly effective method of contraception. Effective birth control includes (a)
             intrauterine device (IUD) plus one barrier method; or (b) 2 barrier methods. Effective
             barrier methods are male or female condoms, diaphragms, and spermicides (creams or
             gels that contain a chemical to kill sperm). Note: Oral, implantable, or injectable
             contraceptives may be affected by cytochrome P450 interactions, and are not considered
             effective for this study.

        Exclusion Criteria:

          1. Pregnant or lactating women.

          2. Subjects with symptomatic CNS metastases. Subjects with treated brain metastases that
             have remained stable for at least 3 months without steroids are allowed. Subjects with
             signs or symptoms or history of brain metastasis must have a CT or MRI scan of the
             brain within 1 month prior to the start of protocol therapy. Subjects with spinal cord
             or nerve root compression who have completed treatment at least 4 weeks before the
             start of protocol therapy and are stable without steroid treatment for at least one
             week before start of protocol therapy are allowed. Subjects with leptomeningeal
             metastases are not allowed.

          3. Any of the following hematologic abnormalities:

               -  Hemoglobin < 9.0 g/dL

               -  ANC < 1500 per mm3

               -  Platelet count < 100,000 per mm3

          4. Any of the following serum chemistry abnormalities:

               -  Total bilirubin > 1.5 × ULN (>2.5 mg/dL in patients with Gilbert's syndrome)

               -  AST or ALT > 2.5 × ULN (or > 5 × ULN for subjects with liver metastasis)

               -  Alkaline phosphatase > 2.5 × ULN (or > 5 × ULN for subjects with liver or bone
                  metastasis)

               -  Serum creatinine > 1.5 × ULN

               -  Proteinuria > 2.5 g/24 hours or 3+ with urine dipstick

               -  Any other ³ Grade 3 laboratory abnormality at baseline (other than those listed
                  above)

          5. Significant cardiovascular disease, including:

               -  Clinically symptomatic heart failure. Subjects with a history of heart failure
                  must have an ECHO or MUGA scan to document left ventricular ejection fraction
                  (LVEF) > 45% prior to start of protocol therapy

               -  Uncontrolled hypertension: blood pressure >150/95 mmHg on more than 2
                  antihypertensive medications, on two consecutive measurements obtained at least
                  24 hours apart. Subjects with a history of hypertension must have been on stable
                  doses of anti-hypertensive drugs for ≥ 2 weeks prior to start of protocol
                  therapy.

               -  Myocardial infarction within 3 months prior to start of protocol therapy

          6. Subjects with delayed healing of wounds, ulcers, and/or bone fractures

          7. Serious/active infection or infection requiring parenteral antibiotics

          8. Inadequate recovery from any prior surgical procedure; major surgical procedure within
             4 weeks prior to start of protocol therapy.

          9. Inability to comply with protocol requirements

         10. Subjects with a ""currently active"" second primary malignancy other than non-melanoma
             skin cancers. Subjects are not considered to have a ""currently active"" malignancy if
             they have completed anti-cancer therapy and have been disease free for > 2 years.

         11. Known concomitant genetic or acquired immune suppression disease such as HIV

         12. Treatment with systemic hormonal therapy within 3 weeks prior to start of protocol
             therapy, with the exception of:

               -  Hormonal therapy for appetite stimulation or contraception

               -  Nasal, ophthalmic, inhaled and topical steroid preparations

               -  Oral replacement therapy for adrenal insufficiency

               -  Low-dose maintenance steroid therapy (equivalent of prednisone 10mg/day) for
                  other conditions

               -  Hormone replacement therapy

         13. Herbal preparations/supplements (except for a daily multivitamin/mineral supplement
             not containing herbal components) or CYP3A4 inhibitors or inducers (see Appendix B)
             within 2 weeks prior to start of or during protocol therapy.
      "
NCT03138083,terminated,"
    strategic reasons (not due to lack of efficacy or safety issues)
  ",0,phase 1/phase 2,['neoplasms'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]",['omo-1'],['C1=CC2=C(C=CC(=C2)C(C3=NN=C4N3N=C(C=C4)C5=CC=NC=C5)(F)F)N=C1'],"
        Inclusion Criteria:

          -  Aged at least 18 years

          -  Provision of signed and dated, written informed consent.

          -  Histological or cytological confirmation of locally advanced, unresectable or
             metastatic solid malignancy.

          -  Performance status: Eastern Co-operative Oncology Group (ECOG) ≤1 and life expectancy
             ≥3 months.

          -  Ability to swallow and retain oral medication.

          -  Adequate organ functions.

          -  Females of child-bearing potential:

               -  Must use a highly effective method contraceptive measures during the study and
                  for 1 month after the last dose of OMO 1.

               -  Must not be breast feeding.

               -  Must have a negative pregnancy test prior to start of dosing.

          -  Sexually active male patients must be willing to use barrier contraception

        Exclusion Criteria:

          -  Patients receiving other cancer therapy, or other investigational product apart from
             the combination agent(s) described in the relevant combination modules.

          -  Patients who have received radiotherapy for the primary tumour within 1 week from the
             screening visit.

          -  Patients receiving medications predominantly metabolized by CYP2B6.

          -  Patients receiving cannabinoid substances.

          -  Patients receiving St John's Wort.

          -  Patients receiving medications that are known to have potent aldehyde oxidase (AO)
             inhibitory activity.

          -  Patients with prior splenectomy.

          -  Patients testing positive for human immunodeficiency virus (HIV) infection, hepatitis
             B based on findings of persistent hepatitis B virus surface antigen (HBsAg) or other
             serology test, hepatitis C virus (HCV) or Epstein-Barr Virus (EBV) infection.

          -  Patients with current, or a history of uveitis.

          -  Patients with any known uncontrolled inter-current illness including ongoing or active
             infections, symptomatic congestive heart failure, conditions that could adversely be
             affected by hypertension or tachycardia, unstable angina pectoris, cardiac arrhythmia,
             or psychiatric illness/social situations that would limit compliance with study
             requirements.

          -  Patients with a history or clinical evidence of neoplastic central nervous system
             (CNS) involvement if not stable for 9 weeks prior to the first dose of study
             treatment.

          -  Patients with major and/or planned surgery within 12 weeks of the first dose of study
             treatment.

          -  Patients with any known severe allergies (e.g., anaphylaxis) to any active or inactive
             ingredients in OMO-1.

          -  Patients with nephrolithiasis.

          -  Patients with current, or a history of any seizure or seizure disorder. This includes
             receiving, or having received, seizure threshold-raising medication for the treatment
             of epilepsy.

        In addition to the main core eligibility criteria, Module specific eligibility criteria
        include:

        Module 1:

        Patient recruited into the paired biopsy cohorts of Part A must have:

          -  at least 1 lesion suitable for biopsy.

          -  tumours that are MET gene amplified and/or mutated.

          -  had no prior therapy with a selective MET inhibitor.

        Patients recruited into Part B cohorts must have:

          -  tumours that are MET gene amplified and/or mutated.

          -  at least one lesion, not previously irradiated, that can be accurately measured at
             baseline.

          -  had no prior therapy with a selective MET inhibitor.

          -  no coinciding malignancy that would impact on survival.

          -  no metastasis limited to the bone only.

        Module 2:

        Patients recruited into Part A and Part B cohorts must have:

          -  tumours that are EGFR gene mutant that are currently progressing on treatment with a
             small molecule EGFR-TKI. Enrolment must be restricted to patients that are resistant
             to all relevant EGFR TKI therapy according to their tumour mutated status.

          -  received the EGFR-TKI as monotherapy for at least 12 weeks.

          -  tolerated their current dose of EGFR-TKI for at least 12 weeks.

          -  tumours that are MET gene amplified.

          -  had no prior therapy with a selective MET inhibitor.

          -  had no prior EGFR-TKI treatment of >2 lines.

          -  no past medical history of ILD, drug-induced ILD, radiation pneumonitis which required
             steroid treatment, or any evidence of clinically active ILD.

          -  no significant GI disorders with diarrhoea as a major symptom e.g., Crohn's disease,
             mal-absorption, or CTCAE Grade >1 diarrhoea of any aetiology at the enrolment.

          -  no contra-indications (as per the relevant medication package insert) for therapy with
             the EGFR-TKI routinely used by their oncology unit.

        In addition, patients recruited into Module 2 Part B cohorts must have:

          -  at least one lesion, not previously irradiated, that can be accurately measured at
             baseline as ≥10 mm in the longest diameter (except lymph nodes which must have short
             axis ≥15 mm) with CT or MRI and which is suitable for accurate repeated assessment.

          -  no coinciding malignancy that would impact on survival.

          -  no metastasis limited to the bone only.
      "
NCT03130439,terminated,"
    slow accrual
  ",0,phase 2,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]",['abemaciclib'],['CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F'],"
        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed invasive breast cancer,
             which is recurrent, locally advanced, unresectable or metastatic.

          -  Patients must have at least one lesion that is not within a previously radiated field
             and that is measurable on computerized tomography (CT) or magnetic resonance imaging
             (MRI) scans per RECIST version 1.1. Bone lesions are not considered measurable.

          -  Either the primary tumor and/or metastatic tumor must be triple-negative on the most
             recent sample as defined below:

               -  Hormone receptor status: the invasive tumor must be ER- and PR-negative, or
                  staining present in <1% by immunohistochemistry (IHC)

               -  HER2 status: the invasive tumor must be Human Epidermal Growth Factor Receptor 2
                  Negative (HER2-negative) by the ASCO CAP guidelines

          -  Either the primary tumor and/or the metastatic tumor must be RB positive as defined
             below:

             --RB status: the invasive tumor must have greater than 50% of tumor cells staining
             positive for RB.

          -  Prior Chemotherapy:

               -  Patients may have received 1-3 prior systemic therapies for metastatic disease
                  (note: for patients who have first developed recurrent/metastatic disease within
                  12 months of completing any (neo)-adjuvant therapy for triple-negative breast
                  cancer, the (neo)-adjuvant therapy is counted as a prior line of therapy).

               -  Patients must have been off treatment with myelosuppressive chemotherapy for at
                  least 21 days or nonmyelosuppressive agents for 14 days before registration.
                  Patients should also be adequately recovered (to baseline or grade 1) from acute
                  toxicities of prior treatment except for residual alopecia and peripheral
                  neuropathy.

          -  Prior biologic therapy: Patients must have discontinued all biologic therapy at least
             21 days before registration.

          -  Prior radiation therapy: Patients may have received prior radiation therapy in either
             the metastatic or early-stage setting. Radiation therapy must be completed at least 14
             days prior to study registration.

          -  Patients on bisphosphonates or RANK-L inhibitors may continue receiving these
             therapies during study treatment. There is no washout period required between the last
             dose of these therapies and the start of abemaciclib.

          -  The patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Patients must have normal organ and marrow function as defined below:

               -  Absolute neutrophil count ≥1500/mm3

               -  Platelets ≥100,000/mm3

               -  Hemoglobin ≥8 g/dL

               -  Total Bilirubin ≤1.5x the upper limit of normal (ULN)

               -  Serum creatinine ≤1.5 mg/dL OR calculated GFR ≥60mL/min

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 times the
                  upper limit of normal. For patients with documented liver metastases, AST/ALT ≤
                  5.0 times the upper limit of normal.

          -  Female subjects of childbearing potential must have a negative serum pregnancy test at
             screening. Women of childbearing potential are defined as those who have not been
             surgically sterilized and have had a menstrual period in the past year

          -  The patient must be ≥18 years old

          -  Capable of understanding and complying with the protocol and has signed the informed
             consent document.

          -  Able to swallow study drug.

          -  Sexually active patients (male and female) must use medically acceptable methods of
             contraception during the course of the study and for 3 months after completion of
             study treatment. If a woman becomes pregnant or suspects she is pregnant while
             participating in this study, she should inform her treating physician immediately.
             While on the study and for 3 months after final drug administration, women may not
             breast-feed.

          -  Confirmed availability of formalin-fixed, paraffin-embedded (FFPE) tumor tissue

          -  Patients with tumor that is felt to be accessible to biopsy must be willing to provide
             tissue from a newly obtained core biopsy of a tumor lesion at baseline. Biopsies will
             be obtained up to 1 week (7 days) prior to initiation of treatment on Cycle 1, Day 1.
             Patients who undergo an attempted research biopsy procedure for the purpose of this
             protocol, and in whom inadequate tissue is obtained, are not required to undergo a
             repeat biopsy in order to continue on protocol.

        Exclusion Criteria:

          -  Received a prior CDK4/6 inhibitor.

          -  Undergone major surgery within 14 days of the initial dose of study drug

          -  Received another investigational agent (defined as any agent/device that has not
             received regulatory approval for any indication) within 14 days of the first dose of
             study drug for a nonmyelosupressive agent, or 21 days of the first dose of study drug
             for a myelosuppressive agent.

          -  Has any severe concurrent disease, infection, or comorbid condition that renders the
             patient inappropriate for enrollment in the opinion of the investigator.

          -  Has an active bacterial, fungal, and/or known viral infection. Patients with known HIV
             infection are excluded given the potential for interactions between antiretroviral
             agents and abemaciclib, and the potential for increased risk of life-threatening
             infection with therapy that is myelosuppressive. Patients with known Hepatitis B or
             Hepatitis C infection are excluded only if there is evidence of active infection
             (detectable Hepatitis B surface antigen, detectable Hepatitis C RNA)

          -  Documented brain metastases that are untreated, symptomatic, or require therapy to
             control symptoms. Participants with previously diagnosed brain metastases are eligible
             if they have completed treatment at least one month prior to trial registration, are
             neurologically stable, and have recovered from effects of radiotherapy or surgery.

               -  Any corticosteroid use for brain metastases must have been discontinued without
                  the subsequent appearance of symptoms for ≥2 weeks before the first study drug.

               -  Treatment for brain metastases may have included whole brain radiotherapy,
                  radiosurgery, or a combination as was deemed appropriate by the treating
                  physician.

               -  Patients who meet the above criteria and are clinically stable on anti-convulsant
                  medication are eligible only if their anti-convulsant does not alter hepatic
                  cytochrome P450 activity in a way that might interfere with metabolism of
                  abemaciclib.

          -  Pregnant women are excluded from this study because of the potential for teratogenic
             effects.

          -  Lactating women are excluding from the study.

          -  Individuals with a history of a second malignancy are ineligible except for the
             following circumstances: individuals with a history of other malignancies are eligible
             if they have been disease-free for at least 5 years and are deemed by the investigator
             to be at low risk for recurrence of that malignancy. Individuals with the following
             cancers are eligible if they are diagnosed and have completed treatment within the
             past 5 years: cervical cancer in situ, and non-melanoma cancer of the skin. Patients
             with other cancers diagnosed within the past 5 years and felt to be at low risk of
             recurrence should be discussed with the principle investigator to determine
             eligibility.

          -  Have received any live vaccination within 28 days of first dose of study drug.
      "
NCT03130270,unknown status,,1,phase 2,['nasopharyngeal carcinoma'],"[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]",['apatinib mesylate tablet'],['Status: 503'],"
        Inclusion Criteria:

          1. Male and female patients aged ranging from 18 to 70 years old.

          2. Patients with newly histologically proven nasopharyngeal carcinoma (NPC).

          3. Local recurrent NPC patients after comprehensive treatment, including clinical
             examination found a clear local area residue: electronic nasopharyngoscope found clear
             residual or enlarged cervical lymph nodes.

          4. Distant metastatic NPC patients after comprehensive treatment, including liver B
             ultrasound, chest X-ray, bone scan or other clinicians consider appropriate tests such
             as CT, MRI or PET/CT found distant metastases.

          5. Comprehensive treatment of local recurrence or distant metastasis after line or
             second-line therapy found progressive disease.

          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1.

          7. Patient who has the expected survival time more than 3 months.

          8. Adequate hematological function: hemoglobin >80 g/L (no transfusion within 14 days),
             neutrophil count > 1.5×109/L, platelet count 80×109/L.

          9. Adequate liver function (serum total bilirubin ≤ 1.5 mg/dL, serum transminase ≤ 2.5
             times higher than upper limit).

         10. Adequate renal function (creatinine clearance ≥ 50 mL/min).

         11. Participants volunteered to participate in this study, signed informed consent, good
             compliance and cooperated with us to complete the follow-up.

        Exclusion Criteria:

          1. Before treatment, MRI showed that the tumor might be an important risk factor (for
             example, wrapping around the internal carotid artery / vein); or researchers judged
             that the tumor is a high risk of serious blood vessel bleeding during the treatment.

          2. Patient who has serious hemorrhages, any serious bleeding events classification at 3
             degree or more (according to CTCAE4.0) within the last 4 weeks.

          3. Patient who has high blood pressure can not be controlled by a single antihypertensive
             drug treatment (Systolic pressure > 140 mmHg, diastolic pressure > 90 mmHg); any
             unstable angina pectoris; with a history of angina pectoris were newly diagnosed with
             angina pectoris within 3 months before screening; any myocardial infarction events
             occurred within 6 months before screening; arrhythmia (including QTcF: male ≥ 450ms,
             female ≥ 470 ms) need long time use of antiarrhythmic drugs and heart function
             insufficiency ≥II according to New York Heart Association class.

          4. Patient who has positive urine protein.

          5. Patient who has abnormal coagulation and bleeding tendency (signed informed consent
             before 14 days, and must be satisfied: INR is in the normal range without the use of
             anticoagulants); Application of anticoagulants or vitamin K antagonists such as Hua
             Falin, heparin or its analogues, with international normalized ratio (INR) is less
             than 1.5, allows the use of small dose Hua Falin (1 mg orally, once daily) or small
             dose aspirin (total dose ≤ 100 mg daily).

          6. Medical history of arteriovenous thrombosis event within the past year, such as
             cerebral vascular accident (including transient ischemic attack) and deep venous
             thrombosis (venous catheter thrombosis caused by chemotherapy and investigator judged
             that the patient had recovered, these patients should be except) and pulmonary
             embolism.

          7. A healed wound for long time or incomplete fracture.

          8. Any factors that affect the oral drug, such as the inability to swallow, diarrhea and
             intestinal obstruction.

          9. For females: patients should be surgical sterilization or postmenopausal patients, or
             willing to receive a medical approved contraception during treatment and 6 months
             after the end of the treatment; serum or urine pregnancy test must be negative, and
             must be non lactating period within 7 days before study; for males: patients should be
             treated with surgical sterilization or willing to receive a medical approved
             contraception during treatment and 6 months after the end of the treatment.

         10. History of psychotropic substance abuse and can not be removed or psychiatric
             disorders.

         11. Medical history of immunodeficiency, or other acquired, congenital immunodeficiency
             disease, or history of organ transplantation.

         12. Any serious harm to the subject's safety or evidence of significant medical illness
             that in the investigator's judgment will substantially increase the risk associated
             with the subject's participation in and completion of the study.
      "
NCT03139747,suspended,"
    lack of accrual reevaluating feasibility
  ",0,phase 2,['thyroid cancer'],"[""['C73', 'D34', 'D44.0', 'Z85.850']""]","['lenvatinib', 'everolimus']","['COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl', 'CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC']","
        Inclusion Criteria:

          -  Patients must be 18 years old or older.

          -  ECOG performance status < 2 (Appendix 1).

          -  Patients must have histologically confirmed differentiated thyroid cancer, that is
             metastatic or unresectable and for which standard curative or palliative measures do
             not exist or are no longer effective.

          -  Patients may have received multiple treatments of radioactive iodine. Patients may
             have received one or more prior MKI treatments that are not lenvatinib (note: all
             patients will have been required to have had lenvatinib for entry, see below). At
             least 4 weeks must have elapsed since prior non-lenvatinib MKI treatment.

          -  Patients are eligible immediately following progression on lenvatinib. Patients must
             have had documented progression while on the prior treatment with lenvatinib and must
             have had a minimum of stable disease for 4 months.

          -  Measurable disease defined as at least one malignant lesion that can be accurately and
             serially measured in at least one dimension (longest diameter to be recorded) using
             conventional methods (CT, MRI, x-ray, PE) (diameter > 20 mm) or spiral CT (diameter >
             10 mm).

          -  Life expectancy greater than 3 months.

          -  Adequate organ function that has been determined within 14 days prior to enrollment,
             defined as:

          -  Leukocyte count > 3,000/uL; Absolute neutrophil count (ANC) > 1,500/mm3, platelets >
             75,000/mm3, and hemoglobin > 9 g/dl.

          -  Serum creatinine < 1.5 times ULN, or 24-hour creatinine clearance > 75 cc/min. (Note:
             creatinine clearance need not be determined if the baseline serum creatinine is within
             normal limits).

          -  Serum bilirubin < 2.0mg/dL; ALT and AST < 2.5 ULN;

          -  INR < 2.0 or a PT/PTT within normal limits. Exception allowed for patients receiving
             anti-coagulation treatment with an agent such as warfarin or heparin who may be
             allowed to participate. For patients on warfarin, the INR should be measured prior to
             initiation of lenvatinib and monitored at least weekly, or as defined by the local
             standard of care, until INR is stable.

          -  Intellectual, emotional, and physical ability to comply with oral medication.

          -  Ability to understand and the willingness to sign a written informed consent

          -  Signed informed consent obtained prior to any screening procedures.

        Exclusion Criteria:

          -  Patients who have had any intervening systemic cancer treatment since the prior
             lenvatinib treatment.

          -  Patients with significant medical disease including: uncontrolled congestive heart
             failure; active symptoms of coronary artery disease, uncontrolled seizure disorder;
             active infection; uncontrolled diabetes mellitus; requirement for chronic high dose
             corticosteroid treatment (Topical or inhaled corticosteroids are allowed); requirement
             for concurrent immunosuppressive drug(s); active autoimmune disease.

          -  Patients with organ allografts.

          -  Patients with uncontrolled BP prior to the start of treatment

          -  Patients with known HIV-infection (HIV testing is not required for participation).

          -  Pregnant or nursing (lactating) women;

          -  Women of child-bearing potential (WOCBP), defined as all women physiologically capable
             of becoming pregnant, must use highly effective methods of contraception during the
             study and 8 weeks after. Highly effective contraception methods include any of the
             following:

          -  Use of oral, injected or implanted hormonal methods of contraception or;

          -  Placement of an intrauterine device (IUD) or intrauterine system (IUS);

          -  Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault
             caps) with spermicidal foam/gel/film/cream/ vaginal suppository;

          -  Total abstinence or;

          -  Male/female sterilization. Women are considered post-menopausal and not of
             child-bearing potential if they have had 12 months of natural (spontaneous) amenorrhea
             with an appropriate clinical profile (e.g. age appropriate, history of vasomotor
             symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy)
             or tubal ligation at least six weeks prior to randomization. In the case of
             oophorectomy alone, only when the reproductive status of the woman has been confirmed
             by follow up hormone level assessment is she considered not of child-bearing
             potential. Male patients whose sexual partner(s) are WOCBP who are not willing to use
             adequate contraception, during the study and for 8 weeks after the end of treatment

          -  Patients with a history of second cancer (except adequately non-melanoma skin cancer,
             in situ treated cancer of the cervix, uterus, colon cancer or melanoma, any benign
             cancer for which the patient does not require treatment, or any other cancer for which
             the patient has been disease-free for three or more years).

          -  Patients who have received live attenuated vaccines within 1 week of start of
             Everolimus and during the study. Patient should also avoid close contact with others
             who have received live attenuated vaccines. Examples of live attenuated vaccines
             include intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow fever,
             varicella and TY21a typhoid vaccines;

          -  Patients with uncontrolled diabetes mellitus as defined by HbA1c >8% despite adequate
             therapy. Patients with a known history of impaired fasting glucose or diabetes
             mellitus (DM) may be included, however blood glucose and antidiabetic treatment must
             be monitored closely throughout the trial and adjusted as necessary

          -  Patients with known intolerance or hypersensitivity to everolimus or other rapamycin
             analogs (e.g. sirolimus, temsirolimus);

          -  Patients who have any severe and/or uncontrolled medical conditions such as:

          -  unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction
             ≤6 months prior to start of Everolimus, serious uncontrolled cardiac arrhythmia, or
             any other clinically significant cardiac disease

          -  Symptomatic congestive heart failure of New York heart Association Class III or IV

          -  active (acute or chronic) or uncontrolled severe infection, liver disease such as
             cirrhosis, decompensated liver disease, and active and chronic hepatitis (i.e.
             quantifiable HBV-DNA and/or positive HbsAg, quantifiable HCV-RNA),

          -  known severely impaired lung function (spirometry and DLCO 50% or less of normal and
             O2 saturation 88% or less at rest on room air),

          -  active, bleeding diathesis;

          -  Patients requiring chronic treatment with corticosteroids or other immunosuppressive
             agents. Topical or Topical or inhaled corticosteroids are allowed;

          -  Patients with a known history of HIV seropositivity;

          -  Use of any experimental therapy within 4 weeks prior to baseline evaluations done
             prior to enrollment (with the exception of lenvatinib which may be continued until
             treatment start). Therefore, all experimental treatments other than lenvatinib must be
             discontinued 4 weeks prior to baseline studies or enrollment.

          -  Patients with known impairment of gastrointestinal (GI) function or GI disease that
             may significantly alter the absorption;

          -  Patients with a history of non-compliance to medical regimens or who are considered
             potentially unreliable or will not be able to complete the entire study;

          -  Patients already scheduled to have a lymph node dissection may have the procedure
             performed on-study as long as the lymph nodes are not followed as part of RECIST
             criteria and all study medications are held from three days prior to the procedure to
             one week following or until deemed safe by the treating physician

          -  Patients with carcinomatous meningitis are excluded from the study. Patients with
             treated sites of leptomeningeal disease may be included at the discretion of the
             principal investigator.

          -  Patients who are not expected to tolerate a starting dose of 18mg lenvatinib and 5mg
             everolimus daily will not be considered eligible for the study.

          -  Excludedtherapies and medications, previous or concomitant:

          -  Anticancer chemotherapy or immunotherapy during the study or within 4 weeks prior to
             the first dose of the study drug with the exception of lenvatinib

          -  Radiotherapy for the treatment of a symptomatic (e.g. bone metastasis) as clinically
             indicated is allowed as long as it is not evidence of progressive disease and is not
             required to be measured as a target lesion per RECIST Biological response modifiers,
             such as G-CSF, within 3 week prior to study entry. (G-CSF and other hematopoietic
             growth factors may be used in the management of acute toxicity such as febrile
             neutropenia when clinically indicated or at the discretion of the investigator;
             however they may not be substituted for a required dose reduction).

          -  Patients taking chronic erythropoietin are permitted provided no dose adjustment is
             undertaken within 2 months prior to the study or during the study.

          -  Investigational drug therapy outside of this trial during or within 4 weeks prior the
             screening assessment.

          -  Use of ketoconazole, itraconazole, and ritonavir.

          -  Use of carbamazepine, phenytoin, phenobarbital.

          -  Use of grapefruit juice products.

          -  Use of cyclosporin.

          -  Use of coumadin is discouraged, and patients where possible should be switched to
             lovanox.
      "
NCT03095079,unknown status,,1,phase 2,['melanoma'],"[""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']""]",['recombinant human endostatin'],['CN(CC(=O)C1=CC=CC=C1)N=O'],"
        Inclusion Criteria:

          -  1. Histologically confirmed melanoma with metastases and has no received any systemic
             treatment.

          -  2.At least one measurable site (diameter≥1cm) of disease (RECIST 1.1).

          -  3.Estimated life expectancy of 12 weeks or greater

          -  4. ECOG performance status 0, 1

          -  5.Adequate organ function

          -  6.Without symptoms of brain metastases and stable in neuro-functions

        Exclusion Criteria:

          -  1. Pregnant or lactation women

          -  2. Acute infections without control.

          -  3. Heart disease history, cardiac function class≥NYHA II.

          -  4. HIV positive or chronic HBV/HCV in active stage.

          -  5. Brain metastases or primary tumor with positive symptoms

          -  6. Need anti-epileptic treatments

          -  7. Organ transplantation history

          -  8. Hemorrhagic tendency or related history

          -  9. Renal dialysis patients

          -  10. Diagnosis of any second malignancy within the last 3 years, except for adequately
             treated.

          -  11. Current treatment on another clinical trial

          -  12. The other improper situations which investigator judged.
      "
NCT03090412,terminated,"
    low accrual
  ",0,phase 2,"['stage i oral cavity squamous cell carcinoma', 'stage ii oral cavity squamous cell carcinoma']","[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]","['hpph', 'photodynamic therapy']",['CCCCCCOC(C)C1=C(C2=NC1=CC3=NC(=CC4=C(C5=C(CC(=C6C(C(C(=C2)N6)C)CCC(=O)O)C5=N4)O)C)C(=C3C)CC)C'],"
        Inclusion Criteria:

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2

          -  Participants with previously untreated T1/T2 N0 squamous cell carcinoma of the oral
             cavity with or without extension to the oropharynx

          -  Histologically confirmed squamous cell carcinoma of the target tumor(s)

          -  Tumor thickness is 4 mm or less (measured clinically and/or by computed tomography
             [CT] or magnetic resonance imaging [MRI] scan)

          -  CT or MRI of the neck to confirm staging

          -  Tumor accessible for unrestricted illumination for photodynamic therapy (PDT)
             (accessibility as determined by the physician)

          -  Life expectancy of at least 12 months in the judgment of the physician

          -  Participants of child-bearing potential must agree to use adequate contraceptive
             methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study
             entry and for the duration of study participation; should a woman become pregnant or
             suspect she is pregnant while she is participating in this study, she should inform
             her treating physician immediately

          -  Participant or legal representative must understand the investigational nature of this
             study and sign an Institutional Review Board approved written informed consent form
             prior to receiving any study related procedure

        Exclusion Criteria:

          -  Those who have had chemotherapy or radiotherapy or targeted agents within 4 weeks (6
             weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have
             not recovered from adverse events due to agents administered more than 4 weeks earlier

          -  Those with known brain metastases should be excluded from this clinical trial because
             of their poor prognosis and because they often develop progressive neurologic
             dysfunction that would confound the evaluation of neurologic and other adverse events

          -  Those with porphyria or with known hypersensitivity to porphyrins or porphyrin-like
             compounds

          -  White blood cells (WBC) < 4,000

          -  Total serum bilirubin > 2 mg/dL

          -  Serum creatinine > 2 mg/dL

          -  Alkaline phosphatase (hepatic) or serum glutamic-oxaloacetic transaminase (SGOT) > 3
             times the upper normal limit

          -  Diagnostic biopsy reveals perineural invasion (PNI) and/or lymphovascular invasion
             (LVI)

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Nodal disease as detected by clinical exam or CT

          -  Pregnant or nursing females

          -  Unwilling or unable to follow protocol requirements

          -  Any condition which in the investigator's opinion deems the participant an unsuitable
             candidate to receive study drug

          -  Received an investigational agent within 30 days prior to enrollment

          -  Trismus or compromised airway

          -  Previous treatment in the target tumor area
      "
NCT01610869,completed,,1,phase 2,"['ovarian cancer', 'fallopian tube cancer']","[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['C57.00', 'C57.01', 'C57.02']""]",['bibf 1120'],['CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O'],"
        Inclusion Criteria:

          -  Female subjects, ≥18 years, histologically proven recurrent advanced epithelial
             ovarian, fallopian tube or primary peritoneal carcinomas

          -  Have either undergone a hysterectomy or bilateral oophorectomy/salpingectomy and/or
             have been postmenopausal for 24 consecutive months (i.e. who have not had menses at
             any time in the preceding 24 consecutive months without an alternative medical cause)

          -  Performance status 0-2

          -  Adequate organ function

          -  Life expectancy >6 weeks

          -  Has received 2 or more lines of chemotherapy for ovarian cancer and patient is
             platinum resistant or platinum intolerant or not suitable for any further standard
             intravenous chemotherapy

          -  No previous oral cyclophosphamide, nintedanib, or other tyrosine kinase inhibitors
             such as cediranib but patients can have received anti-VEGF therapies such as
             bevacizumab as they will be stratified for this

          -  Measurable lesions according to RECIST 1.1 criteria or serum CA125 levels for
             evaluation by GCIG CA125 criteria are welcomed but not a prerequisite for inclusion as
             response will only be assessed for those with evaluable disease

          -  Able to give written informed consent and to complete QoL

        Exclusion Criteria

          -  Carcinosarcoma or malignant tumour of non-epithelial origin (e.g. germ cell tumour,
             sex cord-stromal tumour) of the ovary, fallopian tube or peritoneum

          -  Clinically relevant non-healing wound, ulcer (intestinal tract, skin) or bone fracture

          -  Symptoms or signs of gastrointestinal obstruction requiring parenteral nutrition or
             hydration or any other GI disorders or abnormalities that would interfere with drug
             absorption or inability to take oral medication

          -  Active brain metastases (i.e. symptoms deteriorating, changing condition in < 4 weeks)
             or leptomeningeal disease. Trial entry is allowed if the brain metastases are stable
             (asymptomatic or condition stable for > 4 weeks).

          -  Dexamethasone for brain metastases is allowed if administered as stable dose for > 4
             weeks before randomisation (if < 4 weeks then the patient is not eligible)

          -  Clinically relevant therapy-related toxicity from previous chemotherapy and
             radiotherapy

          -  History of major thromboembolic event within the last 6 months, such as pulmonary
             embolism or proximal deep vein thrombosis, unless on stable therapeutic
             anticoagulation (>3 months if on warfarin, PT / INR needs to be monitored regularly as
             per table 8.1 in protocol)

          -  Known inherited or acquired bleeding disorder

          -  Significant cardiovascular diseases, including uncontrolled hypertension, clinically
             relevant cardiac arrhythmia, unstable angina or myocardial infarction within the past
             6 months, congestive heart failure > NYHA II, severe peripheral vascular disease,
             significantly relevant pericardial effusion

          -  History of a cerebral vascular accident, transient ischemic attack or subarachnoid
             hemorrhage within the past 6 months

          -  Radiographic evidence of cavitating or necrotic tumours with invasion of adjacent
             major blood vessels

          -  Laboratory values indicating an increased risk for adverse events:

               1. calculated GFR < 45 ml/min. Sites can use any calculation method according to
                  local practice.

               2. absolute neutrophil count (ANC) < 1.5x109/L

               3. platelets < 100 x109/L

               4. haemoglobin < 90 g/L

               5. proteinuria CTCAE 2 or greater

               6. total bilirubin > x 2 ULN

               7. ALT and/or AST > 1.5 x ULN

               8. unless liver metastases present when ALT or AST > 2.5 ULN

               9. International normalized ratio (INR) > 2 or activated partial thromboplastin time
                  (APTT) >1.5 x ULN in the absence of therapeutic anticoagulation. INR > 4 or APTT
                  > 2.5 x ULN in presence of therapeutic anticoagulation

          -  Serious infections in particular if requiring systemic antibiotic (antimicrobial,
             antifungal or antiviral therapy), including hepatitis B and/or C infection, HIV-
             infection

          -  Poorly controlled diabetes mellitus or patient on sulphonylurea-type hypoglycaemics
             (e.g. gliclazide) as main diabetic control (as contraindicated with cyclophosphamide)

          -  Previous breast cancer patients are permitted only if diagnosis and any chemotherapy
             treatment for this was > 5 years previously and there is no evidence of metastatic
             breast cancer at trial entry (Please contact UCL CTC / CI if patient still on hormone
             treatment for breast cancer).

          -  Other malignancy diagnosed within the past 5 years. In exception to this rule, the
             following malignancies may be included:

               1. non-melanoma skin cancer (if adequately treated)

               2. cervical carcinoma in situ (if adequately treated)

               3. prior or synchronous endometrial cancer (if adequately treated), provided all of
                  the following criteria are met: G1 or G2, no LVSI and FIGO (2010) stage IA only

          -  Serious illness or concomitant non-oncological disease such as neurologic, psychiatric
             or infectious disease or a laboratory abnormality that may increase the risk
             associated with study participation or study drug administration and in the judgment
             of the investigator would make the patient inappropriate for entry into the study

          -  Psychological, familial, sociological or geographical factors potentially hampering
             compliance with the study protocol and follow-up schedule e.g. active alcohol or drug
             abuse

          -  Any contraindications for therapy with cyclophosphamide, e.g. a history of severe
             hypersensitivity reactions to listed excipients for cyclophosphamide treatment with
             other investigational drugs

          -  Patients should not commence trial treatment within 6 weeks of any major surgical
             procedure

          -  Participation in another clinical trial testing a drug within the past four weeks
             before start of therapy or concomitantly with this trial

          -  Chemotherapy, including immunotherapy or monoclonal antibody treatment (VEGF) within 4
             weeks of starting study treatment

          -  Hormone treatment for ovarian cancer within 2 weeks of starting study treatment
             (ongoing HRT is allowable)

          -  Any previous tyrosine kinase inhibitor treatment that has predominantly
             anti-angiogenic action

          -  Radiotherapy within 3 months not allowed except when given for symptom control >28d
             previously. All patients receiving any radiotherapy will require evidence of recurrent
             ovarian cancer outside the irradiated field either on imaging or via rising CA125

          -  Hypersensitivity to nintedanib, peanut or soya, or to any of the excipients of
             nintedanib
      "
NCT03333746,terminated,"
    study was discontinued due to fda recommendations of the potential toxicities of the
    combination of drugs.
  ",0,phase 2,"['recurrent plasma cell myeloma', 'refractory plasma cell myeloma']","[""['G47.13', 'J01.41', 'K11.22', 'K12.0', 'N96', 'F33.8', 'G03.2']"", ""['D46.4', 'I20.2', 'D46.1', 'D46.A', 'D46.0', 'D46.20', 'D46.21']""]",['lenalidomide'],['C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N'],"
        Inclusion Criteria:

          -  Patients with evidence of relapse or refractory disease as defined by International
             Myeloma Working Group (IMWG) criteria and measurable disease as defined by any of the
             following:

               -  Serum m-protein >= 0.5 g/dl (>= 10 g/l)

               -  Urine monoclonal protein >= 200 mg/24 hour(h)

               -  Involved free light chain (FLC) level >= 10mg/dl (>= 100mg/l) and an abnormal
                  serum free light chain ratio (< 0.26, or > 1.65)

               -  Measurable biopsy proven plasmacytoma (should be measured within 28 days of
                  initial investigational agent dosing)

          -  Patients must have had at least 2 prior line of therapy

          -  Patients must not have had progression of disease on lenalidomide 25 mg; stable
             disease on lenalidomide is permitted

          -  Patient may be enrolled at any time from last line of therapy

          -  Patients must have absolute neutrophil count (ANC) > 1000/uL

          -  Platelets >= 75,000/uL, if plasma cell percentage on bone marrow biopsy aspirate or
             core is > 30%, platelet eligibility requirement will be adjusted to 60,000/ul

          -  Total bilirubin =< 1.5 mg/dL

          -  Alkaline phosphatase =< 3 X the upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2 X the ULN

          -  Patients must have adequate renal function as evidenced by serum creatinine =< 2 mg/dL
             or calculated creatinine clearance of >= 40 ml/min within 14 days of registration
             using Modification of Diet in Renal Disease (MDRD) formula

          -  Patient must be able to swallow capsule or tablet

          -  Patients must provide informed consent

          -  Patients must have a left ventricular ejection fraction > 30%, no uncontrolled
             arrhythmias or New York Heart Association class III-IV heart failure

          -  Patients must have a Karnofsky performance status >= 70

          -  A negative pregnancy test will be required for all women of child bearing potential;
             breast feeding is not permitted

          -  Fertility requirements

               -  Female patients with child bearing potential must have a negative pregnancy test
                  at least 7 days before starting treatment drugs

               -  Male patients must agree to use an adequate method of contraception for the
                  duration of the study and for 7 months afterwards

               -  Female patients must be either posy-menopausal, free from menses >= 2 years
                  (yrs), surgically sterilized, willing to use two adequate barrier methods of
                  contraception to prevent pregnancy, or agree to abstain from sexual activity
                  starting from screening and for 5 months afterwards

               -  Female patients of child bearing potential must agree to comply with the
                  fertility and pregnancy test requirements dictated by the Rev-Assist program

        Exclusion Criteria:

          -  Patients with peripheral neuropathy > Common Terminology Criteria for Adverse Events
             (CTCAE) grade 2

          -  Patients receiving concurrent corticosteroids at the time protocol therapy is
             initiated other than for physiologic maintenance treatment

          -  History of allergic reaction (including erythema nodosum) to lenalidomide

          -  Concurrent use of complementary or alternative medicines that would confound the
             interpretation of toxicities and antitumor activity of the study drugs

          -  Patients with contraindication to thromboprophylaxis

          -  Unacceptable cardiac risk factors defined by any of the following criteria: patients
             with congenital long QT syndrome, any history of ventricular fibrillation or torsade
             de pointes, bradycardia defined as heart rate (HR) < 50 bpm, left ventricular ejection
             fraction < 30%

          -  Patients who have received targeted or investigational agents within 2 weeks or within
             5 half-lives of the agent and active metabolites (whichever is longer) and who have
             not recovered from side effects of those therapies

          -  Patients who have undergone major surgery =< 2 weeks prior to starting study drug or
             who have not recovered from the side-effects of surgery

          -  Patients with known positivity for human immunodeficiency virus (HIV), or hepatitis C;
             baseline testing for HIV and hepatitis C is not required

          -  Patients with a history of another primary malignancy that is currently clinically
             significant or currently requires active intervention, other than non-melanoma skin
             cancer and carcinoma in situ of the cervix should not be enrolled; patients are not
             considered to have a ?currently active? malignancy if they have completed therapy for
             a prior malignancy, are disease free from a prior malignancy for >= 5 yrs and are
             considered by their physician to be less than 30% risk of relapse

          -  Patients with active (untreated or relapsed) central nervous system (CNS) metastasis
             of the patient?s myeloma

          -  Patients with a history of gastrointestinal surgery or other procedure that might, in
             the opinion of the investigator(s), interfere with the absorption or swallowing of the
             study drugs

          -  Patients with any significant history of non-compliance to medical regimens or
             unwilling or unable to comply with the instructions given to them by the study staff

          -  Any other medical condition, including mental illness or substance abuse, deemed by
             the investigator(s) to likely interfere with the patient?s ability to sign informed
             consent, cooperate and participate in the study, or interfere with the interpretation
             of the results
      "
NCT02282358,terminated,"
    lack of accrual
  ",0,phase 1/phase 2,"['lymphoma', 'relapsed and refractory', 'diffuse large b-cell lymphoma and follicular lymphoma']","[""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['D46.4', 'I20.2', 'D46.1', 'D46.A', 'D46.0', 'D46.20', 'D46.21']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']""]",['mocetinostat'],['C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC3=NC=CC(=N3)C4=CN=CC=C4'],"
        Inclusion Criteria:

          -  Patient has provided a signed study Informed Consent Form prior to performance of any
             study related procedurePatient is ≥ 18 years of age

          -  Patient has histologically confirmed diagnosis of diffuse large B cell lymphoma or
             follicular lymphoma harboring mutations in CREBBP or EP300 with relapsed or refractory
             disease

          -  Patients with diffuse large B cell lymphoma must have received at least two prior
             therapies and have received, declined or be ineligible for autologous or allogeneic
             stem cell transplant.

          -  Patients with follicular lymphoma must have received at least two prior therapies.

          -  Patients with either diffuse large B cell lymphoma or follicular lymphoma will be
             allowed to enroll after receiving only 1 prior therapy if they are felt to not be a
             candidate for further systemic chemotherapy.

          -  Patient has at least one measurable lesion (≥ 2 cm) according to Cheson criteria [45].
             Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 -
             Patient has adequate bone marrow and organ function by:

        Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L

          -  Platelets ≥ 75 x 10^9/L (no platelet transfusion within past 14 days)

          -  Hemoglobin (Hgb) ≥ 9.0 g/dL (no RBC transfusion within past 14 days)

          -  International Normalized Ratio (INR) ≤ 1.5

          -  Serum Creatinine ≤ 1.5 x upper limit of normal (ULN)

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within 2.5 x ULN,
             or ≤ 5.0 x ULN for patients with documented hepatic involvement

          -  Serum bilirubin ≤ 1.5 x ULN or ≤ 3.0 x ULN for patients with Gilbert Syndrome or
             documented hepatic involvement.

          -  Patients must have fully recovered from major surgery and from the acute toxic effects
             of prior chemotherapy and radiotherapy (residual grade 1 toxicity, e.g. grade 1
             peripheral neuropathy, and residual alopecia are allowed)

        Exclusion Criteria:

          -  Patient has received previous treatment with HDAC inhibitors

          -  Patient has evidence of graft versus host disease (GVHD)

          -  Patient has active or history of central nervous system (CNS) disease

          -  Patient has impaired cardiac function including any of the following:

          -  Presence or history of pericardial effusion (definitions are provided in and/or
             pericarditis.

          -  Acute myocardial infarction, symptomatic angina pectoris ≤ 6 months prior to starting
             study drug

          -  Presence of congestive heart failure ≥ NYHA class 3

          -  QTc > 480 ms on a screening ECG

          -  Screening LVEF < 45% by echocardiography or MUGA

          -  Uncontrolled cardiac arrhythmia including uncontrolled atrial fibrillation/atrial
             flutter/sinus tachycardia, complete left bundle branch block, congenital long QT
             syndrome

          -  Presence of permanent cardiac pacemaker

          -  Other clinically significant heart disease

          -  Subject is taking warfarin at start of treatment or within 6 months prior to start of
             study treatment.

          -  Patient has a concurrent malignancy or has a malignancy within 3 years of study
             enrollment (with the exception of adequately treated basal or squamous cell carcinoma
             or nonmelanomatous skin cancer)

          -  Patient is concurrently using other approved or investigational antineoplastic agent

          -  Patient has received chemotherapy, targeted anticancer therapy, pelvic and/or
             para-aortic radiotherapy or has had major surgery ≤ 4 weeks (6 weeks for nitrosourea,
             monoclonal antibodies or mitomycin-C) prior to starting study drug or who have not
             recovered from side effects of such therapy

          -  Patient has impairment of gastrointestinal (GI) function or GI disease that may
             significantly alter the absorption of mocetinostat (e.g., ulcerative diseases,
             uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel
             resection)

          -  Patient is currently receiving increasing or chronic treatment (> 10 days) with
             corticosteroids or another immunosuppressive agent. The following uses of
             corticosteroids are permitted: single dose, topical applications (e.g., rash), inhaled
             sprays (e.g., obstructive airways diseases), eye drops or local injections (e.g.,
             intra-articular).

          -  Patient has a history of non-compliance to medical regimen or inability to grant
             consent.

          -  Concomitant medications causing prolonged QT which cannot be discontinued or changed
             to a different medication prior to initiating study

          -  Patient is currently being treated with drugs known to be moderate or strong
             inhibitors or inducers of isoenzyme CYP3A, and the treatment cannot be discontinued or
             switched to a different medication prior to starting study drug. Patients must have
             discontinued strong inducers for at least one week and must have discontinued strong
             inhibitors before the start of treatment.

        Note: the oral anti-diabetic drugs troglitazone and pioglitazone are CYP3A inducers.

          -  Patient has a known history of HIV (testing not mandatory), active Hepatitis B or C
             infection.

          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive serum hCG laboratory test (> 5 mIU/mL)

          -  Women of child bearing potential and men with reproductive potential, if they are
             unwilling to use adequate contraception while on study therapy and for 3 months
             thereafter
      "
NCT02289898,completed,,0,phase 2,['pancreatic cancer'],"[""['C25.3']""]","['demcizumab', 'abraxane®', 'gemcitabine', 'placebo']",['Status: 503'],"
        Inclusion Criteria:

          1. Subjects must have histologically confirmed metastatic pancreatic ductal
             adenocarcinoma.. Prior chemotherapy and/or radiotherapy either in the adjuvant or
             neoadjuvant setting or for metastatic disease is not allowed.

          2. Availability of formalin-fixed paraffin-embedded (FFPE) tumor tissue (from either the
             primary tumor, locoregional disease or a metastatic site), either fresh
             core-needle-biopsied or archived (two FFPE cores preferred whenever possible). If
             fresh tissue is obtained, the core biopsy must be done at least 7 days prior to
             randomization.

          3. Age ≥21 years

          4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 5. Measurable
             disease per RECIST v1.1

          5. Adequate organ and marrow function

          6. Signed Informed Consent Form

          7. For women of childbearing potential, agreement to use two effective forms of
             contraception

        Exclusion Criteria:

          1. Subjects with a neuroendocrine tumor of the pancreas, an acinar tumor of the pancreas
             or a pancreatic tumor with mixed histologies.

          2. Subjects receiving heparin, warfarin, factor Xa inhibitors or other similar
             anticoagulants. Note: Subjects may be receiving low-dose aspirin and/or non-steroidal
             anti-inflammatory agents.

          3. Subjects with brain metastases, leptomeningeal disease, uncontrolled seizure disorder,
             or active neurologic disease

          4. Subjects with Grade >2 peripheral neuropathy

          5. Subjects with clinically significant ascites

          6. Malignancies other than pancreatic cancer successfully treated within 3 years prior to
             randomization, except for adequately treated carcinoma in situ of the cervix, basal or
             squamous cell skin cancer, treated superficial bladder cancer, localized prostate
             cancer treated surgically with curative intent, ductal carcinoma in situ treated
             surgically with curative intent

          7. Significant intercurrent illness that will limit the patient's ability to participate
             in the study or may result in their death over the next 18 months

          8. History of a significant allergic reaction attributed to humanized or human monoclonal
             antibody therapy

          9. Subjects with known clinically significant gastrointestinal disease including, but not
             limited to, inflammatory bowel disease

         10. Pregnant women or nursing women

         11. Subjects with known HIV infection

         12. Known bleeding disorder or coagulopathy
      "
NCT02285855,terminated,"
    poor accrual
  ",0,phase 2,['lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]",['metformin'],['CN(C)C(=N)N=C(N)N'],"
        Inclusion Criteria:

          1. Patients with pathologic diagnosis of lung NSCLC or squamous cell carcinoma.

          2. Patients are to be treated with hypofractionated RT.

          3. Patient is not a surgical candidate due to medical comorbidities determined by a
             thoracic surgeon or patient refusal

          4. Patient plans to receive treatment at MD Anderson

          5. Patients must sign informed consent

          6. Patient must have adequate renal function within 30 days prior to registration,
             defined as serum creatinine within normal institutional limits or creatinine clearance
             at least 60 ml/min

        Exclusion Criteria:

          1. Patient has: random glucose >200 mg/dl or is taking an oral hypoglycemic agent or
             insulin at the time of study entry

          2. Patient has a history of lactic acidosis, chronic kidney disease or a creatinine >/=
             1.2 mg/dl

          3. Women who are pregnant or breast feeding, as treatment involves unforeseeable risks to
             the participant, embryo, fetus, or nursing infant

          4. Patients with history of allergic reaction to metformin
      "
NCT02288936,completed,,0,phase 2,['hormone-refractory prostate cancer'],"[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]",['enzalutamide'],['CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C'],"
        Inclusion Criteria:

          -  Patients aged 18 years and above, willing and able to provide written informed
             consent.

          -  Prostate adenocarcinoma with histological or cytological confirmation without
             neuroendocrine differentiation nor small cell characteristics

          -  Androgen deprivation therapy with GnRH analogs or bilateral orchiectomy
             (pharmacological or surgical castration). Patients without bilateral orchiectomy must
             follow a GnRH analog therapy during the trial.

          -  Testosterone serum level <= 1,73 nmol/L (50 ng/dL) in screening visit.

          -  Patients under bisphosphonate therapy must have received stable doses for the last 4
             weeks.

          -  Progression disease at inclusion, defined by one or more of the following three
             criteria during androgen deprivation therapy (according with the criterion nº 3): -
             PSA progression defined as two elevation of the PSA serum level with >=1 week between
             each measure. Patients who have received an antiandrogen must present disease
             progression (>=4 weeks since the last dose of flutamide or >=6 weeks since the last
             dose of bicalutamide or nilutamide). PSA value in screening visit must be >=2 μg/L (2
             ng/mL). - Soft tissue progression defined by RECIST 1.1 criteria - Bone lesion
             progression defined by PCWG2 criteria, with two or more new lesions in a scintigraphy

          -  Metastatic disease with bone lesions detected by scintigraphy, or measurable soft
             tissue lesions by CT/MR. Patients with ganglionar disease will be suitable if they
             have at least one ganglionar lesion with smallest diameter > 2,5 cm.

          -  Patients without previous cytotoxic chemotherapy for prostate cancer

          -  Patients without previous abiraterone acetate therapy for prostate cancer - -
             Asymptomatic patient or mild symptomatic about prostate cancer, (answer in the
             question nº 3 of the Brief Pain Inventory Short From < 4) 11. ECOG = 0-1.

          -  Life expectancy of at least 6 months

          -  Patient must be able to swallow the investigation product and to follow the protocol
             requirements.

          -  Biomarker study informed consent

        Exclusion Criteria:

          -  Active infection or other medical condition which, in the opinion of the investigator,
             would preclude participation in this trial.

          -  Known brain metastasis or leptomeningeal active involvement

          -  Other malignancy in the last five years, except non-melanoma skin cancer treated and
             resolved.

          -  Hematologic parameters: - Absolute neutrophil count <=1500/μL - Platelet count <100
             000/μL - Haemoglobin < 5,6 mmol/L (9 g/dL)

          -  Liver function: Serum bilirubin, SGPT/ALT or SGOT/AST > 2,5 x ULN

          -  Renal function: Creatinine >177 μmol/L (2 mg/dL).

          -  Serum albumin <30 g/L (3,0 g/dL)

          -  History of epilepsy or other medical condition which could cause an epileptic crisis
             as syncope or transient ischemic attack in the last twelve months.

          -  Clinically significant cardiovascular disease.

          -  Known gastrointestinal (GI) disease that could interfere with the GI absorption.

          -  Significant surgery within 4 weeks before enrollment.

          -  Use of opioids to control cancer pain within 4 weeks before enrollment.

          -  Radiation therapy for treatment of the primary tumor in the last 3 weeks before
             enrollment

          -  Radiation therapy for treatment of metastases in the last two months

          -  Radionuclide therapy for treatment of bone metastasis

          -  Prior flutamide treatment within 4 weeks before enrollment

          -  Bicalutamide or nilutamide therapy within 6 weeks before enrollment

          -  5-a reductase inhibitors, estrogen o cyproterone therapy within 4 weeks before
             enrollment

          -  Biologic therapy or other antitumoral drugs for the treatment of CRPC in the last 4
             weeks

          -  History of cancer progression with ketoconazole

          -  Prior therapy or enrollment in a trial with an investigational product which blocks
             androgen synthesis (abiraterone, TAK-700, TAK-683, TAK-448) or blocks androgen
             receptors (ARN507, BMS 641988).

          -  Included in a previous trial with enzalutamide (MDV3100).

          -  Administration of an investigational drug in the last 4 weeks before enrollment

          -  Use of phytotherapy products which hormonal activity against prostate cancer or which
             reduce PSA levels, or systemic corticosteroids in a dose greater than the equivalent
             of prednisone 10mg/day, within 4 weeks before enrollment

          -  Hereditary fructose intolerance

          -  Any condition which, in the opinion of the investigator, would preclude participation
             in this trial.
      "
NCT02289222,terminated,"
    due to the inclusion of an imid in combination with pembrolizumab, study sponsor terminated the
    study.
  ",1,phase 1/phase 2,['multiple myeloma'],"[""['C90.01', 'C90.02', 'C90.00']""]","['mk-3475', 'pomalidomide', 'dexamethasone']","['C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N', 'CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C']","
        Inclusion Criteria:

          1. Confirmed diagnosis of relapsed and/or refractory MM according to International
             Myeloma Working Group guidelines (2003)

          2. Received two lines of prior therapy that includes an IMiD (lenalidomide or
             thalidomide) and a proteasome inhibitor (bortezomib and/or carfilzomib) (used either
             separately or in combination). (a). Prior pomalidomide therapy is permitted, provided
             the patient achieved at least a partial remission and had not progressed for 3 months
             after stopping therapy.

          3. Measureable disease as defined by the protocol (assessed within 28 days prior to
             registration).

          4. Be willing and able to provide written informed consent/assent for the trial.

          5. Be over 18 years of age on day of signing informed consent.

          6. Have a performance status of 2 on the ECOG Performance Scale.

          7. Demonstrate adequate organ function as defined by the protocol.

          8. Female subject of childbearing potential should have a negative serum pregnancy within
             72 hours prior to receiving the first dose of study drug.

          9. Male subjects should agree to use an adequate method of contraception.

        Exclusion Criteria:

          1. Is currently participating in or has participated in a study of an investigational
             agent or using an investigational device within 4 weeks of the first dose of
             treatment.

          2. Has a diagnosis of immunodeficiency (HIV) or is receiving systemic steroid therapy or
             any other form of immunosuppressive therapy within 7 days prior to the first dose of
             trial treatment.

          3. Has had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not
             recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents
             administered more than 4 weeks earlier.

          4. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy
             within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at
             baseline) from adverse events due to a previously administered agent. (Subjects with ≤
             Grade 2 neuropathy are an exception to this criterion and may qualify for the study.)

          5. Has a known additional malignancy that is progressing or requires active treatment.
             Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the
             skin, or situ cervical cancer that has undergone potentially curative therapy.

          6. Has known active central nervous system disease and/or carcinomatous meningitis.

          7. Has an active autoimmune disease requiring systemic treatment within the past 3 months
             or a documented history of clinically severe autoimmune disease, or a syndrome that
             requires systemic steroids or immunosuppressive agents.

          8. Has evidence of interstitial lung disease or active, non-infectious pneumonitis.

          9. Has an active infection requiring systemic therapy.

         10. Has a history or current evidence of any condition, therapy, or lab abnormality that
             might confound the results of the trial, interfere with the subject's participation
             for the full duration of the trial, or is not in the best interest of the subject to
             participate, in the opinion of the treating investigator.

         11. Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial.

         12. Pregnant or breastfeeding, or expecting to conceive or father children during study
             participation.

         13. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or
             anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody as per the
             protocol.

         14. has known active Hepatitis B or Hepatitis C.

         15. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)

         16. Has received a live vaccine within 30 days prior to the first dose of trial treatment.
      "
NCT02283658,completed,,1,phase 2,"['ovarian endometrioid adenocarcinoma', 'ovarian seromucinous carcinoma', 'ovarian serous cystadenocarcinoma', 'ovarian serous surface papillary adenocarcinoma', 'recurrent fallopian tube carcinoma', 'recurrent ovarian carcinoma', 'recurrent ovarian germ cell tumor', 'recurrent primary peritoneal carcinoma', 'undifferentiated ovarian carcinoma']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['G47.13', 'J01.41', 'K11.22', 'K12.0', 'N96', 'F33.8', 'G03.2']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['everolimus', 'letrozole']","['CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC', 'C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3']","
        Inclusion Criteria:

          -  Histologically confirmed estrogen receptor positive (greater than 10%) recurrent
             ovarian, fallopian tube or primary peritoneal carcinoma in post-menopausal women;
             note: pure clear cell and pure mucinous carcinomas are ineligible; both platinum
             sensitive, platinum resistant and platinum refractory disease are eligible; no
             limitations in the number of prior regimens

          -  Patient has disease amenable to biopsy and is agreeable to undergo a biopsy; note:
             under unusual circumstances, submission of ascites material may be acceptable if a
             biopsy is not possible; this will require approval by one of the study principal
             investigators

          -  Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2

          -  Absolute neutrophil count (ANC) >= 1500/mm^3

          -  Platelet count >= 100,000/mm^3

          -  Hemoglobin > 9.0 g/dL

          -  Total serum bilirubin =< 2 mg/dL

          -  Aspartate transaminase (AST) =< 2.5 x upper limit of normal (ULN) (=< 5 x ULN in
             patients with liver metastasis)

          -  International normalized ratio (INR) =< 2

          -  Creatinine =< 1.5 x ULN

          -  Fasting serum cholesterol =< 300 mg/dL or =< 7.75 mmol/L and fasting triglycerides =<
             2.5 x ULN; in case of any of these thresholds be exceeded, the patient can only be
             included after initiation of appropriate lipid lowering medications

          -  Provide informed written consent

          -  Willing to return to enrolling institution for follow-up (during the active monitoring
             phase of the study)

          -  Willing to provide tissue samples for correlative research purposes

        Exclusion Criteria:

          -  Any of the following

               -  Pregnant women

               -  Nursing women

          -  Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment
             of the investigator, would make the patient inappropriate for entry into this study or
             interfere significantly with the proper assessment of safety and toxicity of the
             prescribed regimens including but not limited to any of the following that would limit
             compliance with study requirements:

               -  Ongoing or active severe infection

               -  Liver disease such as cirrhosis

               -  Decompensated liver disease

               -  Symptomatic congestive heart failure (New York heart Association class III or IV)

               -  Unstable angina pectoris, serious uncontrolled cardiac arrhythmia, myocardial
                  infarction =< 6 months prior to registration

               -  Known severely impaired lung function (spirometry and diffusing capacity of the
                  lung for carbon monoxide [DLCO] 50% or less of normal and oxygen [O2] saturation
                  88% or less at rest on room air)

               -  Active bleeding diathesis

               -  Psychiatric illness

          -  Known to be human immunodeficiency virus (HIV) positive

          -  Receiving any other investigational agent =< 4 weeks prior to registration which would
             be considered as treatment for the primary neoplasm

          -  Other active malignancy =< 3 years prior to registration; exceptions: non-melanotic
             skin cancer or carcinoma-in-situ of the cervix, uterus or breast; note: if there is a
             history of prior malignancy, they must not be receiving other specific treatment for
             their cancer

          -  Patients currently receiving anticancer therapies or who have received anticancer
             therapies =< 4 weeks prior to registration (including chemotherapy, radiation therapy,
             antibody based therapy, etc.)

          -  Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g.
             sirolimus, temsirolimus)

          -  Known impairment of gastrointestinal (GI) function or GI disease that may
             significantly alter the absorption of oral everolimus

          -  Uncontrolled diabetes mellitus as defined by hemoglobin (Hb)A1c > 8% despite adequate
             therapy; note: patients with a known history of impaired fasting glucose or diabetes
             mellitus (DM) may be included, however blood glucose and antidiabetic treatment must
             be monitored closely throughout the trial and adjusted as necessary

          -  Chronic treatment with corticosteroids or other immunosuppressive agents; note:
             topical or inhaled corticosteroids are allowed

          -  Patients who have received live attenuated vaccines =< 1 week prior to registration
             and during the study; note: patient should also avoid close contact with others who
             have received live attenuated vaccines; examples of live attenuated vaccines include
             intranasal influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Guerin
             (BCG), yellow fever, varicella and TY21a typhoid vaccines

          -  History of non-compliance to medical regimens or who are considered potentially
             unreliable or will not be able to complete the entire study

          -  Prior therapy with everolimus or an aromatase inhibitor

          -  Known brain metastasis

          -  Active and chronic viral hepatitis (i.e. quantifiable serum hepatitis B virus
             [HBV]-deoxyribonucleic acid [DNA] and/or positive hepatitis B virus surface antigen
             [HBsAg], or quantifiable hepatitis C virus [HCV]-ribonucleic acid [RNA] in serum)
      "
NCT02288078,unknown status,,0,phase 2,['rectal cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['dexamethasone', 'regorafenib', 'placebo', 'proton pump inhibitor']","['CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C', 'CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F']","
        Inclusion Criteria:

          -  Capable of granting informed consent in writing for receiving treatment outlined in
             this protocol

          -  The investigators determines that the patient can receive the treatment outlined in
             this protocol

          -  Histological diagnosis of adenocarcinoma of either the colon or the rectum, regardless
             of RAS mutation

          -  Metastatic colorectal cancer scheduled for treatment with regorafenib

          -  Lesions are either measurable or non-measurable according to RECIST ver. 1.1

          -  Contrasted torso CT within 28 days before enrollment

          -  At least 20 years of age

          -  PS 0-1

          -  Bone marrow, hepatic, and renal functions have all been confirmed as normal within 14
             days prior to initiation of regorafenib treatment

          -  Life expectancy of at least 3 months

        Exclusion Criteria:

          -  Used regorafenib previously

          -  Blood transfusion or granulocyte-colony stimulating factor (G-CSF) administration
             within 14 days

          -  Grade 2 or higher fatigue or malaise or asthenia according to NCI-CTCAE ver. 4.0

          -  History of a different type of cancer according to histological findings or cancer of
             a different primary focus within the past 5 years. The following are excluded:
             carcinoma in situ of the cervix, non-melanoma skin cancer, superficial bladder cancer
             (Ta, Tis, and T1), gastric cancer,non-invasive breast cancer, etc

          -  Highly invasive surgery, an open biopsy, or who have received significant trauma
             within 28 days of initiating regorafenib treatment

          -  Congestive cardiac failure of New York Heart Association (NYHA) >=Class 2

          -  Unstable angina (symptoms at rest),new-onset angina (onset within past 3 months), or a
             history of myocardial infarction within 6 months of initiating treatment

          -  Arrhythmia requiring treatment with anti-arrhythmia drugs

          -  Uncontrollable hypertension

          -  Pleural effusion or ascites causing dyspnea (NCI-CTCAE >=Grade 2)

          -  History of venous or arterial thrombosis or embolism within 6 months prior to
             initiation of treatment, including cerebrovascular accidents, deep vein thrombosis, or
             pulmonary embolism

          -  Patients with active infections of NCI-CTCAE >=Grade 3

          -  Positive for either hepatitis B (HB)s antigen or hepatitis C virus (HCV) antibody

          -  Seizure disorders requiring drug treatment

          -  Cerebral metastases or history of such

          -  History of organ transplant

          -  Symptoms or history of hemorrhagic tendency, regardless of severity

          -  Some form of hemorrhaging (NCI-CTCAE >=Grade 2) within 4 weeks prior to initiating
             treatment

          -  Incurable wound, fracture or ulcer

          -  Renal failure requiring either hemodialysis or peritoneal dialysis

          -  Dehydration symptoms of NCI-CTCAE >=Grade 1

          -  Abusing drugs or who are in a physical, psychological, or social state which might
             impair study participation or evaluation of results

          -  Interstitial lung disease with active signs or symptoms

          -  Have difficulty taking oral drugs

          -  Digestion absorption disorders

          -  Adverse events resulting from previous treatments or procedures which have not yet
             resolved (NCI-CTCAE >=Grade 2)

          -  Received systemic anti-cancer treatments within 2 weeks prior to initiation of
             regorafenib treatment, including chemotherapy, molecular target drugs, immunotherapy,
             or hormone therapy

          -  Poorly controlled glucose tolerance abnormalities due to diabetes mellitus (patients
             using insulin)

          -  Active GI ulcers or a history of such

          -  Glaucoma

          -  Oral steroids are otherwise contraindicated

          -  Either pregnant or nursing. Women who may become pregnant must have a negative
             pregnancy test within 7 days prior to initiating treatment

          -  Women who may become pregnant, or men whose partners may become pregnant, must agree
             to use appropriate contraceptives from granting of consent to 3 months after
             conclusion of regorafenib therapy

          -  Other illnesses or conditions which, according to the judgment of the investigator,
             may result in physical harm caused by the study, or which may impair study compliance
      "
NCT02289456,completed,,0,phase 2,"['carcinoma, non-small-cell lung']","[""['D02.20', 'D02.21', 'D02.22']""]","['nab-paclitaxel', 'carboplatin']","['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C', 'C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]']","
        Inclusion Criteria:

          -  General and Demographics

               1. Age ≥ 18 years of age at the time of signing the Informed Consent Form.

               2. Understand and voluntarily provide written consent to the Informed Consent Form
                  prior to conducting any study related assessments/procedures.

               3. Able to adhere to the study visit schedule and other protocol requirements.
                  Disease Specific

               4. Histologically or cytologically confirmed Stage IIIB or IV Non-Small Cell Lung
                  Cancer.

               5. Radiographically documented measurable disease at study entry per response
                  evaluation criteria in solid tumours ( RECIST) v1.1.

               6. No prior anti-cancer therapy for the treatment of metastatic disease at the time
                  of signing the ICF. Adjuvant treatment is permitted providing cytotoxic
                  chemotherapy was completed 12 months prior to signing the ICF and without disease
                  recurrence.

               7. Absolute neutrophil count (ANC) ≥ 1500 cells/mm3.

               8. Platelets ≥ 100,000 cells/mm3.

               9. Hemoglobin (Hgb) ≥ 9 g/dL.

              10. Aspartate transaminase (AST/serum glutamic oxaloacetic transaminase [SGOT]),
                  alanine transaminase (ALT/serum glutamic pyruvic transaminase [SGPT]) ≤ 2.5 ×
                  upper limit of normal range (ULN) or ≤ 5.0 × ULN if liver metastases.

              11. Total bilirubin ≤ 1.5 × ULN except in cases of Gilbert's disease and liver
                  metastases.

              12. Serum creatinine ≤ 1.5 x ULN, or calculated creatinine clearance ≥ 40 mL/min (if
                  renal impairment is suspected 24-hour urine collection for measurement is
                  required).

              13. Eastern Cooperative Oncology Group Performance Status 2.

              14. Females of childbearing potential [defined as a sexually mature woman who (1)
                  have not undergone hysterectomy (the surgical removal of the uterus) or bilateral
                  oophorectomy (the surgical removal of both ovaries) or (2) have not been
                  naturally postmenopausal for at least 24 consecutive months (ie, has had menses
                  at any time during the preceding 24 consecutive months)] must:

                    1. Have a negative pregnancy test Beta Human Chorionic Gonaditrophin(ß-hCG) as
                       verified by the study doctor within 72 hours prior to starting study
                       therapy.

                    2. You must commit to complete abstinence from heterosexual contact, or agree
                       to use medical doctor-approved contraception throughout the study without
                       interruption; while receiving study medication or for a longer period if
                       required by local regulations.

                       Male subjects must:

                    3. practice true abstinence* or agree to use a condom during sexual contact
                       with a pregnant female or a female of childbearing potential while
                       participating in the study, during dose interruptions and for at least 6
                       months following study drug discontinuation, even if he has undergone a
                       successful vasectomy.

        Exclusion Criteria:

          -  The presence of any of the following will exclude a subject from enrollment:

               1. Evidence of active brain metastases, including leptomeningeal involvement (prior
                  evidence of brain metastasis are permitted only if treated and stable and off
                  therapy for at least 21days prior to signing ICF). MRI of the brain (or CT scan
                  w/contrast) is preferred for diagnosis.

               2. History of leptomeningeal disease.

               3. Only evidence of disease is non-measurable.

               4. Pre-existing peripheral neuropathy of Grade 2, 3, or 4 (per Criteria for Adverse
                  Events (CTCAE) v4.0).

               5. Subject has received radiotherapy ≤ 4 weeks or limited field radiation for
                  palliation ≤ 2 weeks prior to starting investigational product (IP), and/or from
                  whom ≥ 30% of the bone marrow was irradiated. Prior radiation therapy to a target
                  lesion is permitted only if there has been clear progression of the lesion since
                  radiation was completed.

               6. Venous thromboembolism within 1 month prior to signing ICF.

               7. Current congestive heart failure (New York Heart Association Class II-IV).

               8. History of the following within 6 months prior to first administration of
                  investigational product: a myocardial infarction, severe/unstable angina
                  pectoris, coronary/peripheral artery bypass graft, New York Heart Association
                  (NYHA) Class III-IV heart failure, uncontrolled hypertension, clinically
                  significant cardiac dysrhythmia or clinically significant ECG abnormality,
                  cerebrovascular accident, transient ischemic attack, or seizure disorder.

               9. Subject has a known infection with hepatitis B or C, or history of human
                  immunodeficiency virus (HIV) infection, or subject receiving immunosuppressive or
                  myelosuppressive medications that would in the opinion of the investigator,
                  increase the risk of serious neutropenic complications.

              10. Subject has an active, uncontrolled bacterial, viral, or fungal infection(s)
                  requiring systemic therapy, defined as ongoing signs/symptoms related to the
                  infection without improvement despite appropriate antibiotics, antiviral therapy,
                  and/or other treatment.

              11. History of interstitial lung disease, sarcoidosis, silicosis, idiopathic
                  pulmonary fibrosis, or pulmonary hypersensitivity pneumonitis.

              12. Treatment with any investigational product within 28 days prior to signing the
                  ICF.

              13. History of or suspected allergy to nab-paclitaxel, carboplatin and human albumin
                  or any other platinum-based therapy.

              14. Currently enrolled in any other clinical protocol or investigational trial that
                  involves administration of experimental therapy and/or therapeutic devices.

              15. Any other clinically significant medical condition, psychiatric illness, and/or
                  organ dysfunction that will interfere with the administration of the therapy
                  according to this protocol or which, in the views of investigator, preclude
                  combination chemotherapy.

              16. Subject has any other malignancy within 5 years prior to signing the ICF.
                  Exceptions include the following: squamous cell carcinoma of the skin, in-situ
                  carcinoma of the cervix, uteri, non-melanomatous skin cancer, carcinoma in situ
                  of the breast, or incidental histological finding of prostate cancer (Tumor, node
                  and metastasis (TNM) stage of T1a or T1b). All treatment should have been
                  completed 6 months prior to signing ICF.

              17. Any condition including the presence of laboratory abnormalities, which places
                  the subject at unacceptable risk if he/she were to participate in the study.

              18. Any medical condition that confounds the ability to interpret data from the
                  study. This includes subjects with known psychiatric disorders.

              19. Pregnant or breast-feeding females.

              20. Subjects with an ECOG PS other than 2
      "
NCT02282345,completed,,1,phase 2,"['breast adenocarcinoma', 'deleterious brca1 gene mutation', 'deleterious brca2 gene mutation', 'her2/neu negative', 'invasive breast carcinoma']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['A41.50', 'A41.59', 'E70.320', 'Z17.1', 'Z67.11', 'Z67.21', 'Z67.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]",['talazoparib'],['CN1C(=NC=N1)C2C(NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F'],"
        Inclusion Criteria:

          -  Signed written informed consent

          -  Histologically confirmed primary invasive adenocarcinoma of the breast with the size
             of the primary tumor being at least 1 cm on imaging by either mammography, ultrasound
             or breast magnetic resonance imaging (MRI)

          -  Negative human epidermal growth factor receptor 2 (HER-2)/neu- disease defined as
             patients with fluorescence in situ hybridization (FISH) ratio < 2.0 or < 6.0 HER2 gene
             copies per nucleus, and IHC staining scores of 0, 1+, or 2+

          -  No treatment for current primary invasive adenocarcinoma of the breast such as
             irradiation, chemotherapy, immunotherapy, investigational therapy or surgery; previous
             treatment for breast and/or ovarian cancer with chemotherapy, endocrine therapy,
             surgery and radiation are allowed if >= 3 years prior to current diagnosis and there
             is no clinical evidence of metastatic disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

          -  Baseline multi gated acquisition scan (MUGA) or echocardiogram scans with left
             ventricular ejection fraction (LVEF) of > 50%

          -  Absolute neutrophil count (ANC) >= 1,500/uL

          -  Platelets >= 100,000/uL

          -  Hemoglobin (Hgb) >= 9 g/dL

          -  Creatinine clearance > 50 ml/min

          -  Total bilirubin =< 1.5 X upper limit of normal (ULN)

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 X ULN

          -  Negative serum or urine pregnancy test for women within 7 days of receiving the first
             dose of the study medication for women of childbearing potential; women will be
             considered not of childbearing potential and exempt from pregnancy testing if they are
             either a) older than 50 and amenorrheic for at least 12 consecutive months following
             cessation of all exogenous hormonal treatments, or b) have documentation of
             irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or
             bilateral salpingectomy, but not tubal ligation

          -  Women of childbearing potential (WOCBP) must be using an adequate method of
             contraception to avoid pregnancy throughout the study and for up to 8 weeks after the
             last dose of investigational product; men on study also must be using contraception

          -  Identified deleterious mutation in BRCA 1 or 2 genes (this does not include variants
             of uncertain significance)

          -  Eligible to receive standard of care chemotherapy and/or surgery based upon standard
             practices or institutional guidelines

        Exclusion Criteria:

          -  Women who are pregnant (including positive pregnancy test at enrollment or prior to
             study drug administration) or breast-feeding

          -  Disease free of prior malignancy for < 3 years with the exception of curatively
             treated basal carcinoma of the skin or carcinoma in situ of the cervix

          -  Any other previous antitumor therapies for the current cancer event

          -  Has had major surgery within 21 days before cycle 1 day 1

          -  Gastrointestinal tract disease or defect with associated malabsorption syndrome

          -  Uncontrolled inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)

          -  Myocardial infarction within 6 months before starting therapy, symptomatic congestive
             heart failure (New York Heart Association > class II), unstable angina, or unstable
             cardiac arrhythmia requiring medication

          -  Serious intercurrent infections or non-malignant medical illness that are uncontrolled
             or the control of which may be jeopardized by this therapy

          -  Psychiatric disorders or other conditions rendering the subject incapable of complying
             with the requirements of the protocols

          -  Unable to take oral medications

          -  Known to be human immunodeficiency virus positive

          -  Known active hepatitis C virus, or known active hepatitis B virus

          -  Concurrent disease or condition that would interfere with study participation or
             safety, such as any of the following:

               -  Active, clinically significant infection either grade > 2 by National Cancer
                  Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version
                  (v)4.03 or requiring the use of parenteral anti-microbial agents within 14 days
                  before day 1 of study drug

               -  Clinically significant bleeding diathesis or coagulopathy, including known
                  platelet function disorders

               -  Non-healing wound, ulcer, or bone fracture

          -  Known hypersensitivity to any of the components of talazoparib
      "
NCT02899728,terminated,"
    inadequate accrual rate
  ",0,phase 2,['extensive stage lung small cell carcinoma'],"[""['D02.20', 'D02.21', 'D02.22']""]","['carboplatin', 'cediranib', 'cediranib maleate', 'cisplatin', 'etoposide', 'olaparib']","['C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]', 'CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5', 'CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5.C(=CC(=O)O)C(=O)O', 'N.N.Cl[Pt]Cl', 'CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O', 'C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F']","
        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of extensive-stage small cell lung
             cancer with no prior systemic treatment

          -  Patients must have measurable disease, defined as at least one lesion that can be
             accurately measured in at least one dimension (longest diameter to be recorded for
             non-nodal lesions and short axis for nodal lesions) as >= 20 mm (>= 2 cm) with
             conventional techniques or as >= 10 mm (>= 1 cm) with spiral computed tomography (CT)
             scan, magnetic resonance imaging (MRI), or calipers by clinical exam

          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)

          -  White blood cell count (WBC) >= 3 x 10^9/L (within 28 days prior to administration of
             therapy)

          -  No features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)
             on peripheral blood smear (within 28 days prior to administration of therapy)

          -  Absolute neutrophil count >= 1,500/mcL (within 28 days prior to administration of
             therapy)

          -  Platelets >= 100,000/mcL (within 28 days prior to administration of therapy)

          -  Hemoglobin >= 10 g/dL with no blood transfusion within 28 days of initiation of
             therapy (within 28 days prior to administration of therapy)

          -  Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (within 28 days
             prior to administration of therapy)

          -  Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase
             (SGOT)/alanine aminotransferase (ALT) serum glutamate pyruvate transaminase (SGPT) =<
             2.5 x institutional ULN, unless liver metastases are present and then =< 5 x
             institutional ULN is acceptable (within 28 days prior to administration of therapy)

          -  Creatinine clearance >= 50 mL/min (within 28 days prior to administration of therapy)

          -  Proteinuria - urine protein:creatinine ratio (UPC) of =< 1 OR =< 2+ proteinuria on two
             consecutive urinalysis/dipstick tests taken no less than 1 week apart; patients with
             2+ proteinuria on dipstick must also have a UPC of =< 0.5 on 2 consecutive samples
             (within 28 days prior to administration of therapy)

          -  Ability to swallow and retain oral medication

          -  The effects of olaparib and cediranib on the developing human fetus are unknown; for
             this reason and because other therapeutic agents used in this trial are known to be
             teratogenic, women of child-bearing potential and male patients and their partners who
             are sexually active must agree to use two highly effective forms of contraception in
             combination for the duration of study participation and for 3 months after completion
             of olaparib and cediranib administration; should a woman become pregnant or suspect
             she is pregnant while she or her partner is participating in this study, she should
             inform her treating physician immediately

          -  Postmenopausal or evidence of non-pregnant status for women of childbearing potential
             as confirmed by a negative urine or serum pregnancy test within 7 days prior to the
             start of therapy; postmenopausal status is defined as:

               -  Age >= 60 years, or

               -  Age < 60 with any one or more of the conditions below:

                    -  Amenorrheic for >= 1 year in the absence of chemotherapy and/or hormonal
                       treatments,

                    -  Luteinizing hormone and/or follicle stimulating hormone and/or estradiol
                       levels in the post-menopausal range,

                    -  Radiation-induced oophorectomy with last menses > 1 year ago,

                    -  Chemotherapy-induced menopause with > 1 year interval since last menses,

                    -  Surgical sterilization (bilateral oophorectomy or hysterectomy)

          -  Ability to understand and the willingness to sign a written informed consent document

          -  Participants must have archival tumor tissue available for analysis (minimum 20 5 um
             slide) or be able to undergo a baseline fresh tumor tissue biopsy

          -  Adequately controlled blood pressure; (defined as systolic blood pressure [SBP] of =<
             140 mmHg and diastolic blood pressure [DBP] of =< 90 mmHg) on maximum of three
             antihypertensive medications; participants must have a blood pressure (BP) of =<
             140/90 taken in the clinic or hospital setting by a medical professional within 2
             weeks prior to starting on study; it is strongly recommended that participants who are
             on 3 antihypertensive medications be followed by a cardiologist or a primary care
             physician for management of BP while on study

          -  Adequately controlled thyroid function, with no symptoms of thyroid dysfunction;
             patients can be on thyroid hormone replacement medication; asymptomatic patients with
             elevated thyroid stimulating hormone (TSH) with normal T4/T3 are allowed to enroll,
             and recommended to follow with routine thyroid function test

        Exclusion Criteria:

          -  Patients who have had major surgery or trauma within 28 days prior to entering the
             study; patients must have recovered from any effects of any major surgery and surgical
             wound should have healed prior to starting treatment

          -  Patients who have had radiotherapy within 14 days prior to entering the study

          -  Patients with a non-healing wound, fracture, or ulcer

          -  Patients who have not recovered from adverse events due to prior anti-cancer therapy
             (i.e., have residual toxicities > Common Terminology Criteria for Adverse Events
             [CTCAE] grade 1 or baseline, with the exception of alopecia)

          -  Patients who are receiving any other investigational agents

          -  Patients with symptomatic central nervous system (CNS) metastases or leptomeningeal
             carcinomatosis should be excluded from this clinical trial because of their poor
             prognosis and because they often develop progressive neurologic dysfunction that would
             confound the evaluation of neurologic and other adverse events; exceptions include
             patients with previously-treated CNS metastases or those with are asymptomatic,
             subcentimeter metastases, and have no requirement for steroids or anti-seizure
             medication for at least one week prior to study entry; screening with CNS imaging
             studies (CT scan or MRI) is required

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to olaparib, cediranib, carboplatin, cisplatin, or etoposide

          -  Patients with a history of myelodysplastic syndrome (MDS)

          -  Patients with a history of acute myeloid leukemia (AML), or patients with a history of
             any other primary malignancy within 3 years prior to initiation of treatment on this
             study; exceptions include: patients with a history of malignancies (other than AML)
             that were treated curatively and have not recurred within 3 years prior to study
             entry; resected basal and squamous cell carcinomas of the skin; and completely
             resected carcinoma in situ of any type

          -  Patients with clinically significant gastrointestinal abnormalities including, but not
             limited to:

               -  Clinically significant signs and/or symptoms of bowel obstruction within 3 months
                  prior to starting treatment

               -  History of intra-abdominal abscess within 3 months prior to starting treatment

               -  History of gastrointestinal (GI) perforation within 6 months prior to starting
                  treatment

               -  Evidence of abdominal fistula within 6 months prior to starting treatment;
                  history of abdominal fistula will be considered eligible if the fistula was
                  surgically repaired, and there has been no evidence of fistula for at least 6
                  months prior to starting treatment, and patient is deemed to be at low risk of
                  recurrent fistula

          -  Patients with a history of cerebrovascular accident including transient ischemic
             attack (TIA), pulmonary embolism or insufficiently treated deep venous thrombosis
             (DVT) within the past 3 months; Note: Participants with recent DVT who have been
             treated with therapeutic anti-coagulants for at least 6 weeks are eligible, with the
             exception of participants being treated with warfarin, which is prohibited on this
             study; other oral anti-coagulants may be allowed after discussion with overall
             principal investigator (PI), but short half-life low molecular weight heparins are
             strongly preferred

          -  Patients with evidence of active bleeding diathesis

          -  Patients with hemoptysis in excess of 2.5 mL within 6 weeks prior to the first dose of
             study medication

          -  Patients receiving any medications or substances that are potent inhibitors or
             inducers of CYP3A4 are ineligible; the required washout period for strong inhibitors
             is 2 weeks and at least one week for moderate inhibitors; the required washout period
             prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 4 weeks
             for other agents

          -  Patients requiring concomitant therapy with phenytoin, phenobarbital, carbamazepine,
             or valproic acid

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements; specifically, patients with any of the following within 6 months
             prior to starting treatment are excluded:

               -  Acute myocardial infarction

               -  Unstable angina

               -  New York Heart Association functional classification of III or IV

               -  Left ventricular ejection fraction (LVEF) < lower limit of normal (LLN) per
                  institutional guidelines, or 55%

               -  Prior allogeneic bone marrow transplant or double umbilical cord blood
                  transplantation

               -  Patients with active hepatitis (B or C)

               -  Patients with active pneumonitis

          -  Pregnant women are excluded from this study because olaparib and cediranib are agents
             with the potential for teratogenic or abortifacient effects; because there is an
             unknown but potential risk for adverse events in nursing infants secondary to
             treatment of the mother with olaparib or cediranib, breastfeeding should be
             discontinued if the mother is treated with olaparib or cediranib; these potential
             risks may also apply to other agents used in this study

          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
             therapy are ineligible because of the potential for pharmacokinetic interactions with
             olaparib and cediranib; in addition, these patients are at increased risk of lethal
             infections when treated with marrow-suppressive therapy; appropriate studies will be
             undertaken in patients receiving combination antiretroviral therapy when indicated

          -  Patients must be willing and able to check and record daily blood pressure readings if
             receiving cediranib
      "
NCT02898116,completed,,0,phase 1/phase 2,"['non-small cell lung cancer', 'carcinoma', 'nsclc']","[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['ensartinib', 'durvalumab']",['CC1CN(CC(N1)C)C(=O)C2=CC=C(C=C2)NC(=O)C3=NN=C(C(=C3)OC(C)C4=C(C=CC(=C4Cl)F)Cl)N'],"
        Inclusion Criteria:

          1. Histologic confirmation of metastatic NSCLC. Subjects must have had confirmed ALK
             rearrangement as assessed by immunohistochemistry. Subjects may have had prior therapy
             with ALK inhibitors (other than ensartinib) or been ALK inhibitor naïve. ALK inhibitor
             naïve subjects were informed of the availability of approved ALK inhibitors.

          2. Measurable disease according to RECIST 1.1, defined as ≥ 1 lesion that could be
             accurately measured in ≥ 1 dimension (longest diameter to be recorded for non-lymph
             node lesions, shortest diameter to be recorded for lymph node lesions). Each lesion
             must have been ≥ 10 mm when measured by computed tomography, magnetic resonance
             imaging, or caliper measurement by clinical examination or ≥ 20 mm when measured by
             chest x-ray.

          3. Willing to provide a fresh pre-treatment biopsy; however, if subject was ALK inhibitor
             naïve, either archival or pre-treatment biopsy was acceptable.

          4. Asymptomatic subjects with surgically treated brain metastases must have been ≥ 14
             days post surgery at the time of first dosing, while clinically stable with no
             requirement for steroids. Asymptomatic subjects with radiation-treated brain
             metastases may have entered the study immediately after completion of the radiation
             (and been off steroids, if applicable). Symptomatic subjects (those experiencing
             headache, seizure etc.), must have been relieved from all symptoms of their central
             nervous system disease, and must have completed radiation and been off steroids prior
             to first dosing (anti seizure medicine permitted).

          5. Laboratory parameters for vital functions should have been in the normal range.
             Laboratory abnormalities that were not clinically significant were generally
             permitted, except for the following laboratory parameters, which must have been within
             the ranges specified, regardless of clinical significance:

               -  Hemoglobin: ≥ 9 g/dL

               -  Neutrophil count: ≥ 1.5 x 10^9/L

               -  Platelet count: ≥ 100,000/mm^3

               -  Serum creatinine: ≤ 1.5 x institutional upper limit of normal (ULN), OR
                  creatinine clearance: ≥ 50 mL/min (by Cockcroft-Gault formula)

               -  Serum total bilirubin: ≤ 1.5 × ULN (except for subjects with Gilbert's syndrome
                  who were allowed after consultation with their physician)

               -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT): ≤ 2.5 x ULN

               -  Alkaline phosphatase: ≤ 2.5 x ULN

          6. Eastern Cooperative Oncology Group Performance Status ≤ 2.

          7. Age ≥ 18 years.

          8. Able and willing to provide valid written informed consent.

          9. Able and willing to comply with the protocol for the duration of the study including
             undergoing treatment and scheduled visits and examinations including follow-up.

         10. Body weight > 30 kg.

        Exclusion criteria:

          1. Treatment with an investigational agent within 4 weeks of starting treatment, and any
             prior drug-related toxicity (except alopecia) should have recovered to Grade 1 or
             less.

          2. Prior treatment with anti-PD-1, PD-L1 (including durvalumab), or cytotoxic
             T-lymphocyte-associated antigen-4 (CTLA-4), or ensartinib (X-396).

          3. Active, suspected or prior documented autoimmune disease (including but not restricted
             to inflammatory bowel disease, celiac disease, Wegner's granulomatosis, Hashimoto's
             thyroiditis, rheumatoid arthritis, systemic lupus, scleroderma and its variants,
             multiple sclerosis, myasthenia gravis). Vitiligo, residual hypothyroidism due to
             autoimmune condition only requiring hormone replacement, psoriasis not requiring
             systemic treatment, or conditions not expected to recur in the absence of an external
             trigger were permitted.

          4. Subjects with clinically significant cardiovascular disease, including:

               1. New York Heart Association Class II or higher congestive heart failure.

               2. Myocardial infarction, unstable angina, cerebrovascular accident or transient
                  ischemic attack within 6 months of start of study drug (Day -28).

               3. Clinically significant supraventricular or ventricular arrhythmia.

               4. QT interval corrected using Fridericia's formula (QTcF) ≥ 450 ms (male) or QTcF ≥
                  470 ms (female).

               5. Clinically uncontrolled hypertension.

          5. History of pneumonitis or interstitial lung disease, or any unresolved immune-related
             adverse events following prior therapy.

          6. Major surgery within 4 weeks of starting treatment (or scheduled for surgery during
             the projected course of the study).

          7. Women of child bearing potential who were pregnant as evidenced by positive serum
             pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic
             gonadotropin) or nursing.

          8. Female subjects of childbearing potential who were sexually active with a
             non-sterilized male partner must have used at least one highly effective method of
             contraception (see table below) from the time of screening and must have agreed to
             continue using such precautions for 90 days after the final dose of investigational
             products. Non-sterilized male partners of a female subject must have used male condoms
             plus spermicide throughout this period. Cessation of birth control after this point
             should have been discussed with a responsible physician. Not engaging in sexual
             activity for the total duration of the trial and the drug washout period was an
             acceptable practice; however, periodic abstinence, the rhythm method, and the
             withdrawal method were not acceptable methods of birth control.

             Female subjects should have refrained from breastfeeding throughout the period
             described above.

             Females of childbearing potential were defined as those who were not surgically
             sterile (i.e., bilateral tubal ligation, bilateral oophorectomy, or complete
             hysterectomy) or post-menopausal.

             Females were considered post-menopausal if they had been amenorrheic for 12 months
             without an alternative medical cause. The following age-specific requirements applied:

               -  Females <50 years of age were considered post-menopausal if they had been
                  amenorrheic for 12 months or more following cessation of exogenous hormonal
                  treatments and if they had luteinizing hormone and follicle-stimulating hormone
                  levels in the post-menopausal range for the institution or underwent surgical
                  sterilization (bilateral oophorectomy or hysterectomy).

               -  Females ≥50 years of age were considered post-menopausal if they had been
                  amenorrheic for 12 months or more following cessation of all exogenous hormonal
                  treatments, had radiation-induced menopause with last menses >1 year prior to
                  study entry, had chemotherapy-induced menopause with last menses >1 year prior to
                  study entry, or underwent surgical sterilization (bilateral oophorectomy,
                  bilateral salpingectomy or hysterectomy).

             Non-sterilized male subjects who were sexually active with a female partner of
             childbearing potential must have used male condoms plus spermicide from screening
             through 90 days after receipt of the final dose of investigational products. Male
             subjects were to refrain from sperm donation throughout this period. Female partners
             (of childbearing potential) of a male subject must have used a highly effective method
             of contraception (see table below) throughout this period. Cessation of birth control
             after this point was to be discussed with a responsible physician. Not engaging in
             sexual activity for the total duration of the trial and the drug washout period was an
             acceptable practice; however, periodic abstinence, the rhythm method, and the
             withdrawal method were not acceptable methods of birth control.

             A highly effective method of contraception was defined as one that resulted in a low
             failure rate (i.e. less than 1% per year) when used consistently and correctly. Note
             that some contraception methods were not considered highly effective (e.g. male or
             female condom with or without spermicide; female cap, diaphragm, or sponge with or
             without spermicide; non-copper containing intrauterine device; progestogen-only oral
             hormonal contraceptive pills where inhibition of ovulation was not the primary mode of
             action [excluding Cerazette/desogestrel which was considered highly effective]; and
             triphasic combined oral contraceptive pills).

          9. Subjects who were immunosuppressed, including those with known immunodeficiency.

         10. Active infection including tuberculosis (clinical evaluation that included clinical
             history, physical examination and radiographic findings, and tuberculosis testing in
             line with local practice), hepatitis B (known positive hepatitis B virus surface
             antigen result), hepatitis C, or human immunodeficiency virus (positive 1/2
             antibodies). Subjects with a past or resolved hepatitis B virus infection (defined as
             the presence of hepatitis B core antibody and absence of hepatitis B virus surface
             antigen) were eligible. Subjects positive for hepatitis C antibody were eligible only
             if polymerase chain reaction was negative for hepatitis C virus ribonucleic acid.

         11. History of severe allergic reactions to any unknown allergens or components of the
             study drugs.

         12. Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding
             disorders).

         13. Mental impairment that may have compromised compliance with the requirements of the
             study.

         14. Lack of availability for immunological and clinical follow-up assessment.

         15. Inability to swallow or retain oral medication, presence of active gastrointestinal
             disease or other condition that would have interfered significantly with the
             absorption, distribution, metabolism, or excretion of ensartinib.

         16. Any condition that, in the clinical judgment of the treating physician, was likely to
             prevent the subject from complying with any aspect of the protocol or that may have
             put the subject at unacceptable risk.

         17. History of allogeneic organ transplant.

         18. Subjects must not have donated blood while on study and for at least 90 days following
             the last durvalumab treatment.
      "
NCT02890355,"active, not recruiting",,0,phase 2,"['metastatic pancreatic adenocarcinoma', 'recurrent pancreatic carcinoma', 'stage iv pancreatic cancer ajcc v6 and v7']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C25.3']""]","['fluorouracil', 'fluorouracil', 'irinotecan hydrochloride', 'leucovorin calcium', 'veliparib']","['C1=C(C(=O)NC(=O)N1)F', 'C1=C(C(=O)NC(=O)N1)F', 'CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl', 'C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)[O-])C(=O)[O-].[Ca+2]', 'CC1(CCCN1)C2=NC3=C(C=CC=C3N2)C(=O)N']","
        Inclusion Criteria:

          -  Patients must have histologically or cytologically documented pancreatic
             adenocarcinoma; patients with pancreatic neuroendocrine tumors, lymphoma of the
             pancreas, or ampullary cancer are not eligible

          -  Patients must have metastatic disease that is measurable; computed tomography (CT)
             scans or magnetic resonance imaging (MRI)s used to assess measurable disease must have
             been completed within 28 days prior to registration; CT scans or MRIs used to assess
             non-measurable disease must have been completed within 42 days prior to registration;
             all disease must be assessed and documented on the Baseline Tumor Assessment Form

          -  Patients must not have history of brain metastases

          -  Patients must have had one and only one prior regimen of systemic therapy for
             metastatic disease unless the patient meets the criteria below

          -  Prior systemic therapy and chemoradiotherapy for treatment of resectable, borderline
             resectable or locally advanced unresectable disease is allowed and does not count
             toward prior therapy for metastatic disease

          -  Patients who received systemic therapy with gemcitabine/nab-paclitaxel for resectable
             or borderline/locally advanced unresectable disease and progressed with metastatic
             disease within 3 months of the past dose of systemic therapy are eligible

          -  Patients must have completed systemic therapy at least 14 days prior to registration,
             any surgical procedure must have been performed at least 14 days prior to
             registration, and radiation therapy must be completed at least 7 days prior to
             registration; patients must have recovered from major side effects of prior therapies
             or procedures in the opinion of the local site investigator prior to registration

          -  Patients must not have received prior irinotecan-based chemotherapy (e.g. irinotecan
             hydrochloride, leucovorin calcium, fluorouracil, and oxaliplatin [FOLFIRINOX] or
             FOLFIRI)

          -  Patients must not have received prior PARP inhibitor therapy including, but not
             limited to ABT-888, olaparib, rucaparib, and talazoparib (BMN637)

          -  Patients must have a Zubrod performance status of 0-1

          -  Within 14 days prior to registration: Absolute neutrophil count (ANC) >= 1,500/mcL

          -  Within 14 days prior to registration: Hemoglobin >= 9 g/dL

          -  Within 14 days prior to registration: Platelets >= 100,000/mcL

          -  Within 14 days prior to registration: Total bilirubin =< 1.5 x institutional upper
             limit of normal (IULN)

          -  Within 14 days prior to registration: Serum albumin >= 3.0 g/dL

          -  Within 14 days prior to registration: Aspartate aminotransferase (AST) and alanine
             aminotransferase (ALT) =< 2.5 x IULN; patients with liver metastases may have AST and
             ALT of =< 5.0 x IULN

          -  Within 14 days prior to registration: Serum creatinine =< 2.0 mg/dL

          -  Patients must have CA19-9 obtained within 14 days prior to registration; if CA19-9 is
             normal a carcinoembryonic antigen (CEA) must be tested within 14 days prior to
             registration

          -  Patients must have blood urea nitrogen (BUN), alkaline phosphatase, sodium, potassium,
             calcium, glucose, chloride, and bicarbonate levels obtained within 14 days prior to
             registration

          -  Patients must not have any clinically significant and uncontrolled major medical
             condition(s) including, but not limited to uncontrolled nausea/vomiting/diarrhea;
             active uncontrolled infection; symptomatic congestive heart failure (New York Heart
             Association [NYHA] class >= II); unstable angina pectoris or cardiac arrhythmia;
             psychiatric illness/social situation that would limit compliance with study
             requirements

          -  Patients must not have active seizure or history of seizure

          -  Patients must be able to swallow whole capsule

          -  Patients must have a complete physical examination and medical history within 28 days
             prior to registration

          -  Patients must not have known Gilbert's syndrome

          -  Patients must not have known hypersensitivity to irinotecan, fluorouracil, or
             leucovorin

          -  Patients of childbearing potential must have a negative pregnancy test within 28 days
             prior to registration and must not be nursing; women/men of reproductive potential
             must have agreed to use an effective contraceptive method during the study and for 6
             months following completion of treatment; a woman is considered to be of ""reproductive
             potential"" if she has had menses at any time in the preceding 12 consecutive months;
             in addition to routine contraceptive methods, ""effective contraception"" also includes
             heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect
             of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or
             bilateral tubal ligation; however, if at any point a previously celibate patient
             chooses to become heterosexually active during the time period for use of
             contraceptive measures outlined in the protocol, he/she is responsible for beginning
             contraceptive measures

          -  Patients must be willing and able to undergo a biopsy after signed consent and prior
             to registration; patients must have tumor tissue and blood samples available and be
             willing to submit tumor and blood samples; NOTE: core biopsy required; fine needle
             aspiration (FNA) is not an acceptable substitute for core biopsy

          -  If archival tumor is available for submission, patients must be willing to submit
             tumor sample

          -  Patients must be offered the opportunity to participate in specimen banking for future
             use

          -  Patients must be informed of the investigational nature of this study and must sign
             and give written informed consent in accordance with institutional and federal
             guidelines

          -  As a part of the Oncology Patient Enrollment Network (OPEN) registration process the
             treating institution's identity is provided in order to ensure that the current
             (within 365 days) date of institutional review board approval for this study has been
             entered in the system
      "
NCT05233696,withdrawn,"
    low accrual
  ",0,phase 2,"['triple negative breast cancer', 'locally advanced breast cancer', 'unresectable breast carcinoma', 'metastatic breast cancer', 'pd-l1 gene mutation']","[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['nab-paclitaxel', 'paclitaxel', 'pembrolizumab']","['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C']","
        Inclusion Criteria:

          1. Provision to sign and date the consent form including non-English speaking and
             non-reading participants.

          2. Stated willingness to comply with all study procedures and be available for the
             duration of the study.

          3. Male or female aged ≥ 18 years.

          4. Metastatic or locally advanced unresectable histologically documented TNBC as defined
             by absence of estrogen receptor (ER) and progesterone receptor (PR) expression and no
             HER2 amplification or over-expression by local pathology report.

               1. HER2 negativity is defined as either: in situ hybridization non-amplified (ratio
                  of HER2 to CEP17 < 2 or single probe average HER2 gene copy number < 4
                  signals/cell OR IHC 0 or 1+).

               2. ER and PR negativity is defined as < 1% positive by IHC.

          5. Treatment with < 1 prior line of systemic therapy in the metastatic setting or
             adjuvant/neoadjuvant setting if metastatic recurrence within 12 months of treatment.

          6. Confirmed PD-L1 positive as defined by Combined Positive Score (CPS) > 10% by a
             CLIA-certified lab

          7. At least one site of disease amenable to radiation therapy.

          8. Clinically appropriate for treatment with nab-paclitaxel/paclitaxel plus pembrolizumab
             in the opinion of the treating investigator.

          9. If the maximum number of non-biopsy subjects has accrued to the study, willingness to
             undergo 2 tumor biopsies and disease amenable to safe biopsy in the opinion of the
             treating investigator. NOTE: Tumor biopsies may be required, depending on the number
             of subjects who have agreed to undergo correlative studies.

         10. Life expectancy of > 3 months per treating investigator.

         11. ECOG performance status ≤ 1.

         12. Baseline labs must meet the following criteria within 21 days of radiation initiation:

               1. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L.

               2. Platelets ≥ 100,000/mcL.

               3. Hemoglobin ≥ 9.0 g/dL.

               4. Total bilirubin ≤1.5 x institutional upper limit of normal (ULN) or ≤ 3 x ULN for
                  subjects with Gilbert's disease.

               5. AST (SGOT)/ALT (SGPT) ≤ 3 X institutional ULN or ≤ 5 X institutional ULN in liver
                  metastasis are present.

               6. Serum creatinine < 1.5 X institutional ULN.

               7. INR and PTT < 1.5 X institutional ULN. This applies only to patients undergoing
                  serial tumor biopsies.

         13. All prior reversible treatment-related toxicities must have resolved to CTCAE v5.0
             criteria of grade 1 or less (except alopecia).

         14. Women must not be pregnant or breastfeeding.

         15. Women of childbearing potential must have a negative pregnancy test before enrollment.
             Women who are not of childbearing potential defined as post- menopausal (amenorrheic
             for > 12 months) or undergone prior hysterectomy or bilateral salpingo-oophorectomy do
             not require pregnancy testing.

         16. Willingness of male and females who are of childbearing potential to use medically
             acceptable contraception for the duration of the study, including 30 days after last
             dose of nab-paclitaxel/paclitaxel and 6 months after last pembrolizumab, whichever is
             longer. Male patients must refrain from donating sperm during these periods.

         17. Availability of archival tumor tissue (core biopsy or surgical tumor blocks) for
             analysis. Sites will be asked to submit archival tissue (subjects may start the study
             if tissue is available at an outside hospital, but not yet requested or received).

        Exclusion Criteria:

          1. Any of the following interventions within the specified time frame prior to radiation:

               1. Radiation therapy within 21 days.

               2. Cytotoxic chemotherapy within 21 days (capecitabine within 14 days).

               3. Monoclonal antibodies within 21 days.

               4. Administration of an investigational agent that is not expected to be cleared
                  prior to initiation of radiation.

          2. More than one prior line of chemotherapy in the locally advanced unresectable or
             metastatic setting.

          3. Prior treatment with a taxane in the metastatic setting. Prior taxane in the curative
             setting is allowed if treatment was completed ≥ 6 months prior to metastatic
             recurrence.

          4. Prior receipt of immune checkpoint inhibitor (PD-L1, PD-1 or CTLA-4 inhibitors) less
             than 12 mos from metastatic recurrence.

          5. Patients with active collagen vascular disease (CVD), specifically systemic lupus
             erythematosus or scleroderma. Patients with a history of CVD without evidence of
             active disease are eligible for enrollment at the discretion of the study PI.

          6. History of immunodeficiency, hypersensitivity to pembrolizumab or other medical
             contraindication to receipt of immunotherapy.

          7. Has active, or history of, pneumonitis requiring treatment with corticosteroids.

          8. Has a known history of active tuberculosis.

          9. Has a known history of human immunodeficiency virus (HIV) or acquired immunodeficiency
             syndrome - related illness (testing not required at screening).

         10. Has known active hepatitis B (hepatitis B surface antigen reactive) or hepatitis C
             (qualitative HCV RNA is detected) (testing not required at screening).

         11. Has received a live vaccine within 30 days prior to enrollment.

         12. Has an active infection requiring treatment with oral or IV medication. Patients on
             antimicrobial, antifungal or antiviral prophylaxis are not specifically excluded if
             all other criteria are met.

         13. Autoimmune disease that has required systemic treatment in the past 2 years (ie. with
             the use of disease modifying agents, systemic corticosteroids, or immunosuppressive
             drugs). Replacement therapy (eg. thyroxine, insulin, or physiologic corticosteroid
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
             form of systemic treatment.

         14. Symptomatic or uncontrolled central nervous system (CNS) metastases. Patients with
             treated brain metastasis with stable CNS imaging > 28 days after radiation and no
             requirement for corticosteroids are eligible.

         15. Receipt of corticosteroid therapy at greater than physiologic dosing in the
             investigator's opinion within 14 days of the start of radiation therapy.

         16. For patients undergoing serial tumor biopsies, known bleeding diathesis or history of
             abnormal bleeding or require anti-coagulation therapy that cannot be interrupted for
             biopsy.

         17. Patients with a separate active cancer diagnosis for which the patient has not been
             without evidence of disease for at least 2 years.

         18. Medical, psychiatric, cognitive or other conditions that compromise the patient's
             ability to understand the patient information, to give informed consent, to comply
             with the study protocol, or to complete the study.

         19. Any severe concurrent disease or condition (including uncontrolled diabetes mellitus,
             symptomatic congestive heart failure, uncontrolled hypertension, unstable angina
             pectoris, or cardiac arrythmia) which, in judgment of the Investigator, would make the
             patient inappropriate for study participation.
      "
NCT03042780,terminated,"
    slow accrual
  ",0,phase 2,"['gastro-enteropancreatic neuroendocrine tumor', 'pancreatic cancer', 'neuroendocrine carcinomas of pancreas', 'islet cell carcinoma']","[""['C7A.1', 'C7A.8', 'C7B.8', 'D3A.8']"", ""['C25.3']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]","['folfirinox', 'granulocyte colony-stimulating factor (g-csf)']",['CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.C1CCC(C(C1)[NH-])[NH-].C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O.C1=C(C(=O)NC(=O)N1)F.C(=O)(C(=O)[O-])[O-].[Pt+4]'],"
        Inclusion Criteria:

          -  Histologically or cytologically confirmed neuroendocrine carcinoma of the
             gastrointestinal (GI) tract. Potential participants with unknown origin for the
             neuroendocrine carcinoma in which a gastroenteropancreatic origin is suspected (per
             pathologist or investigator discretion) will be eligible for the study.

          -  Tumors must have a Ki-67 index greater than 20% and/or >20 mitotic figures/10
             high-power fields.

          -  Must have metastatic disease.

          -  Must measurable disease, as defined by Response Evaluation Criteria in Solid Tumors
             (RECIST) 1.1.

          -  Any line of treatment (first line versus beyond first line).

          -  Age >18 years.

          -  Life expectancy of greater than 12 weeks.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.

          -  Must have adequate organ and marrow function.

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Have had chemotherapy or radiotherapy within 3 weeks prior to entering the study.

          -  Receiving any other investigational agents.

          -  Untreated brain or meningeal metastases.

          -  Prior treatment with 5-fluorouracil (5-FU), irinotecan or oxaliplatin.

          -  Pre-treatment peripheral neuropathy greater than grade 1 per the CTCAE, version 4.0.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  A secondary primary cancer (excluding baso/squamous cell carcinoma of skin) within 1
             year.

          -  Active viral hepatitis or autoimmune hepatitis. The work-up to confirm active
             hepatitis or autoimmune hepatitis will only be done if clinical suspicion based on
             investigator discretion.

          -  Potential participants with childbearing potential who are not willing to use adequate
             contraception precautions during the study and for 3 months after stopping study
             chemotherapy.
      "
NCT03044730,unknown status,,0,phase 2,"['estrogen receptor negative', 'her2/neu negative', 'progesterone receptor negative', 'recurrent breast carcinoma', 'stage iii breast cancer', 'stage iiia breast cancer', 'stage iiib breast cancer', 'stage iiic breast cancer', 'stage iv breast cancer', 'triple-negative breast carcinoma']","[""['Z17.1']"", ""['A41.50', 'A41.59', 'E70.320', 'Z17.1', 'Z67.11', 'Z67.21', 'Z67.31']"", ""['Z17.0', 'Z17.1', 'T47.0X6S', 'T50.7X6S', 'T47.0X3S', 'T47.0X4S', 'T47.0X5S']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]",['capecitabine'],['CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O'],"
        Inclusion Criteria:

          -  Patients must have histologically-confirmed unresectable, locally advanced or
             metastatic breast cancer that meets one of the following:

               -  Triple negative, defined as estrogen receptor (ER) negative, progesterone
                  receptor (PR) negative, human epidermal growth factor receptor 2 (HER2) negative;
                  HER2 negative defined as immunohistochemistry (IHC) 0 or 1+ or fluorescence in
                  situ hybridization (FISH) negative

               -  Hormone-refractory breast cancer which denotes progression to endocrine therapy
                  (e.g., tamoxifen, aromatase inhibitors, fulvestrant) unless contraindicated

          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status =<
             2

          -  Patients must have a life expectancy of >= 90 days

          -  Patients must have baseline laboratory tests within the following parameters at least
             4 weeks (28 days) prior to registration:

          -  Absolute neutrophil count (ANC) >= 1,500/mcL

          -  Platelets >= 100,000/mcL

          -  Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO)
             dependency

          -  Serum creatinine =< 1.5 x upper limit of normal (ULN) OR measured or calculated
             creatinine clearance (GFR can also be used in place of creatinine or CrCl) >= 60
             mL/min for subject with creatinine levels > 1.5 x institutional ULN

          -  Serum total bilirubin =< 1.5 x ULN OR direct bilirubin =< ULN for subjects with total
             bilirubin levels > 1.5 ULN

          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x
             ULN OR =< 5 x ULN for subjects with liver metastases

          -  Albumin >= 2.5 mg/dL

          -  International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN unless
             subject is receiving anticoagulant therapy as long as PT or partial thromboplastin
             time (PTT) is within therapeutic range of intended use of anticoagulants

          -  Activated partial thromboplastin time (aPTT) =< 1.5 X ULN unless subject is receiving
             anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use
             of anticoagulants

          -  Females of child-bearing potential (FOCBP) must have a negative serum or urine
             pregnancy test within 7 days prior to registration and must be at least within 3 days
             prior to first dose of study drug. If the urine test is positive or cannot be
             confirmed as negative, a serum pregnancy test will be required

               -  (Note: a FOCBP is any woman [regardless of sexual orientation, having undergone a
                  tubal ligation, or remaining celibate by choice] who meets the following
                  criteria:

               -  Has not undergone a hysterectomy or bilateral oophorectomy

               -  Has had menses at any time in the preceding 12 consecutive months (and therefore
                  has not been naturally postmenopausal for > 12 months)

          -  Female subjects of childbearing potential (FOCBP) must be willing to use an adequate
             method of contraception; contraception must be used for the course of the study
             through 120 days after the last dose of study medication

               -  Note: abstinence is acceptable if this is the usual lifestyle and preferred
                  contraception for the subject

          -  Male subjects of childbearing potential must agree to use an adequate method of
             contraception; contraception must be used starting with the first dose of study
             therapy through 120 days after the last dose of study therapy

               -  Note: abstinence is acceptable if this is the usual lifestyle and preferred
                  contraception for the subject

          -  Patients must have the ability to understand and the willingness to sign a written
             informed consent prior to registration on study

          -  Patients must be willing and able to comply with scheduled visits, treatment plan and
             laboratory tests

          -  Patient must be able to swallow and retain oral medication

        Exclusion Criteria:

          -  Patients with documented HER2-positive metastatic disease are not eligible, even if
             their primary breast cancer was HER2-negative

          -  Patients who have received prior anti-cancer therapy (e.g., biologic or other targeted
             therapy, chemotherapy) within 2 weeks prior to registration; hormone therapy is
             permitted until registration

               -  Note: patients who received prior anti-PD-1, PD-L1 or PD-L2 agents are still
                  eligible

          -  Patients who have not recovered from adverse events to grade 1 severity or lower due
             to agents administered more than 2 weeks earlier than registration, are not eligible,
             except for stable sensory neuropathy (=< grade 2) and alopecia

          -  Patients who have received radiotherapy =< 4 weeks prior to registration, with the
             exception of palliative radiotherapy, who have not recovered from side effects of such
             therapy to baseline or grade =< 1 are not eligible for participation

          -  Patients with central nervous system (CNS) involvement may participate if they meet
             all the following criteria:

               -  At least 4 weeks from prior therapy completion (including radiation and/or
                  surgery) to starting the study treatment,

               -  Clinically stable with respect to the CNS tumor at the time of screening

          -  Patients who have undergone major surgery =< 4 weeks prior to registration or have not
             recovered from side effects of such procedure are not eligible for participation

          -  Patients may not be receiving any other investigational agents

          -  Patients who have a history of allergic reactions or hypersensitivity reactions
             attributed to compounds of similar chemical or biologic composition to pembrolizumab
             and/or humanized antibodies are not eligible

          -  Known hypersensitivity to capecitabine, fluorouracil, or any component of the
             formulation

               -  Note: prior capecitabine is permitted

          -  History of autoimmune disease, including but not limited to myasthenia gravis,
             myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis,
             inflammatory bowel disease, vascular thrombosis associated with antiphospholipid
             syndrome, Wegener's granulomatosis, Sjogren's syndrome, Guillain-Barre syndrome,
             multiple sclerosis, vasculitis or glomerulonephritis

               -  Patients with history of autoimmune-related hypothyroidism on a stable dose of
                  thyroid replacement hormone may be eligible for this study

               -  Patients with controlled type I diabetes mellitus on a stable dose of insulin
                  regimen for more than a month may be eligible for this study

          -  Patients who have evidence of active, noninfectious pneumonitis or have a history of
             severe pneumonitis that required treatment with steroids are not eligible for this
             study; (Note: replacement physiologic dose of steroids [prednisone 10 mg daily or
             equivalent] are allowed)

          -  Patients who have an uncontrolled intercurrent illness including, but not limited to
             any of the following, are not eligible:

               -  Hypertension that is not controlled on medication (defined as >= 140/100 at rest,
                  average of 3 consecutive readings)

               -  Ongoing or active infection requiring systemic treatment

               -  Symptomatic congestive heart failure

               -  Unstable angina pectoris

               -  Cardiac arrhythmia

               -  Clinically significant electrocardiogram (ECG) abnormality, e.g., a repeated
                  demonstration of a QTc interval > 500 ms

               -  Psychiatric illness/social situations that would limit compliance with study
                  requirements

               -  Known positive test for human immunodeficiency virus (HIV)

               -  Has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive)
                  or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA]
                  [qualitative] is detected)

               -  Active tuberculosis

               -  Prior allogeneic bone marrow transplantation or solid organ transplant

               -  Administration of a live, attenuated vaccine within 4 weeks before starting the
                  study treatment or anticipation that a live attenuated vaccine will be required
                  during the study

               -  Any other illness or condition that the treating investigator feels would
                  interfere with study compliance or would compromise the patient's safety or study
                  endpoints

          -  Female patients who are pregnant or nursing (lactating) are not eligible

          -  Patients exhibiting any other condition that would, in the Investigator's judgment,
             preclude patient's participation in the clinical study due to safety concerns or
             compliance with clinical study procedures are not eligible for participation; this
             might include, but is not limited to, infection/inflammation, intestinal obstruction,
             and/or social/psychological complications

          -  Patients with impaired gastrointestinal (GI) function or GI disease that may
             significantly alter absorption of oral capecitabine (e.g. ulcerative disease,
             uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel
             resection) are not eligible for participation

          -  Patients with a history of another malignancy that progressed or required treatment
             within 5 years prior to registration are not eligible for participation; Note: the
             exceptions to this include non-melanoma skin cancer or excised carcinoma in situ of
             the cervix
      "
NCT03042702,completed,,1,phase 2,['ovarian cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['kevetrin', 'kevetrin']","['C(CC#N)CSC(=N)N', 'C(CC#N)CSC(=N)N']","
        Inclusion Criteria:

          1. Evidence of a personally signed and dated written informed consent to participate in
             the clinical study

          2. Non-pregnant female adults at least 18 years of age at time of informed consent

          3. Histologically confirmed serous epithelial ovarian cancer with peritoneal metastases

          4. Platinum resistant/refractory disease, defined as disease progression/relapse within 6
             months following the last administered dose of platinum therapy (resistant), or lack
             of response or disease progression while receiving the most recent platinum based
             therapy (refractory), respectively

          5. Measurable disease, as determined by radiologist evaluator, with at least 1
             unidimensional measurable lesion (target lesion) by RECIST v.1.1 that has not
             previously been irradiated or biopsied

          6. Presence of non-target lesions that have not previously been irradiated or biopsied;
             to allow for collection of needle-biopsies at Screening and after completion of
             Kevetrin treatment

          7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          8. Adequate hematologic and organ function as confirmed by laboratory values at
             Screening:

               1. Bone marrow function: Absolute neutrophil count (ANC) ≥ 1500 Cells/μL (with no
                  evidence that this ANC was induced or supported by granulocyte colony stimulating
                  factors)

               2. Hemoglobin ≥ 9 g/dL (with no RBC transfusions within 7 days of Screening)

               3. Platelets ≥ 100,000 cells/μL (with no evidence that this platelet count was
                  induced or supported by a platelet-stimulating agent)

               4. Renal function: creatinine ≤ 1.5 x ULN

               5. Hepatic function: total bilirubin ≤ 1.5 x ULN; ALT and AST ≤ 3 x ULN; alkaline
                  phosphatase ≤ 2.5 x ULN

               6. Neurologic function: neuropathy (sensory and motor) ≤ CTCAE Grade 1

               7. Coagulation status: prothrombin time (PT) ≤ 1.5 ULN or INR within normal limits;
                  and partial thromboplastin time (PTT) ≤ 1.2 × ULN

          9. Women of child-bearing potential are required to use effective contraception
             throughout the study period. Effective contraception methods include:

               1. Total abstinence (if this is the usual lifestyle of the subject). Periodic
                  abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and
                  withdrawal are not acceptable methods of contraception. (Subject must agree to
                  use contraception should they become sexually active while on the study.)

               2. Surgical sterilization (hysterectomy and/or bilateral oophorectomy) or tubal
                  ligation at least six weeks before start of study treatment.

               3. Male partner sterilization, occurring at least 6 months prior to screening. For
                  female subjects on the study, the vasectomized male partner should be their sole
                  partner.

               4. Double barrier method: Condom or Occlusive cap (diaphragm or cervical/vault caps)
                  with spermicidal foam/gel/film/cream/vaginal suppository.

               5. Oral*/ injected/ implanted/ transdermal hormonal contraception or other forms of
                  hormonal contraception that have comparable efficacy (failure rate <1%), e.g.,
                  hormone vaginal ring.

               6. Intrauterine device or intrauterine system. *Stable oral contraception use (on
                  the same pill) for a minimum of 3 months before taking study treatment.

             Women are considered post-menopausal and not of child-bearing potential if they have
             had 12 consecutive months of natural (spontaneous) amenorrhea with an appropriate
             clinical profile (e.g., age appropriate, history of vasomotor symptoms) or have had
             surgical hysterectomy and/or bilateral oophorectomy or tubal ligation at least six
             weeks ago.

         10. Estimated life expectancy of at least 6 months, in the Investigator's opinion

         11. Willing and able to comply with scheduled visits, study assessments and laboratory
             tests, and other study procedures

        Exclusion Criteria:

          1. Unwilling to allow removal of tumor biological samples for analysis, i.e., biopsies of
             tumor lesions, and/or collection of ascites fluid from abdominal ascites (if present)

          2. Non epithelial tumor, including malignant mixed Müllerian tumors without high grade
             serous component, or ovarian tumors with low malignant potential (i.e., borderline
             tumors)

          3. Known presence of central nervous system metastases

          4. Presence of tumor metastases causing significant pleural disease/effusion unilaterally
             or bilaterally (significant pleural effusion is defined by need for thoracentesis more
             frequently than once every 21 days)

          5. Presence of ascites that requires paracentesis more frequently than once every 21
             days.

          6. A history of another primary cancer that has been active or treated within the past 3
             years prior to start of study treatment, with the exception of adequately
             treated/resected: basal cell or squamous cell skin carcinoma or actinic keratoses; or
             carcinoma in situ of the breast or of the cervix; or non-invasive malignant colon
             polyps

          7. Persistent toxic effects with severity of CTCAE grade 2 or greater (excluding
             alopecia) caused by previous treatment

          8. History of arterial or deep venous thromboembolism within the 12 months prior to
             enrollment

          9. Clinically significant cardiac disease, including:

               1. Myocardial infarction or unstable angina < 6 months prior to enrollment

               2. New York Heart Association (NYHA) Grade II or greater congestive heart failure

               3. Cardiac arrhythmia requiring medication (does not include asymptomatic atrial
                  fibrillation with controlled ventricular rate)

         10. Electrocardiogram (ECG) obtained at Screening which shows QTc prolongation or other
             medically relevant abnormalities which may affect subject safety or interpretation of
             study results

         11. At a higher than average risk, in the Investigator's opinion, of bowel perforation
             (e.g., symptoms of partial or complete bowel obstruction, recent (within 6 months)
             history of fistula or bowel perforation, requirement for total parenteral nutrition
             and continuous hydration)

         12. Active or chronic recurrent systemic infections that require continuous antimicrobial
             therapy during the Kevetrin study period

         13. Past medical history of infection with HIV, hepatitis B or hepatitis C

         14. Ongoing or recent history of any other uncontrolled and/or clinically significant
             systemic disease or condition which, in the Investigator's medical opinion, should
             exclude participation in the study

         15. Less than 3 weeks between major surgery and planned start of study treatment; major
             incisions must have healed

         16. Less than 4 weeks since last treatment for ovarian cancer

         17. Any investigational or experimental therapy or procedure or participation in any
             interventional trial within 4 weeks or 5 half-lives (whichever is longer) prior to
             start of study treatment

         18. Women of child-bearing potential who are pregnant or nursing (lactating)

         19. Previous participation in a clinical study of Kevetrin

         20. History of alcohol or substance abuse, unless in full remission for more than 6 months
             prior to start of study treatment

         21. Any other severe acute or chronic medical or psychiatric condition or test
             abnormality(ies) that, in the Investigator's opinion, puts the subject at significant
             risk, could confound the study results, or may interfere significantly with the
             subject's participation in the study
      "
NCT03041181,terminated,"
    funder decision - lack of accrual
  ",0,phase 2,"['non-squamous non-small cell lung cancer (nsclc)', 'adenocarcinoma of the lung', 'lung cancer', 'squamous cell lung cancer']","[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['D02.20', 'D02.21', 'D02.22']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['docetaxel', 'nivolumab', 'gemcitabine', 'pemetrexed']","['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F', 'C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O']","
        Inclusion Criteria:

        Subject must meet all of the following applicable inclusion criteria to participate in this
        study:

          1. Written informed consent and HIPAA authorization for release of personal health
             information prior to registration. NOTE: HIPAA authorization may be included in the
             informed consent or obtained separately.

          2. Age ≥ 18 years at the time of consent.

          3. ECOG Performance Status of 0-2 within 28 days prior to randomization.

          4. Histological or cytological confirmed squamous or non-squamous non-small cell lung
             cancer.

          5. Measurable disease according to RECIST 1.1 within 28 days prior to randomization.

          6. A subject with prior brain metastasis may be considered if they have completed their
             treatment for brain metastasis at least 4 weeks prior to randomization, have been off
             of corticosteroids for ≥ 2 weeks, and are asymptomatic.

          7. Subjects must have primary resistance to PD-1 or PDL-1 inhibitors; defined as PD after
             3 or fewer treatments with a PD-1 or PDL-1 inhibitor

          8. Subjects must have progressed on or after previous platinum-based chemotherapy.
             Chemotherapy may have previously been given with a PD-1 or PD-L1 inhibitor. Subjects
             must have also progressed on or after receiving any PD-1 or PD-L1 inhibitor (including
             nivolumab) as their most recent therapy.

          9. Most recent PD-1 or PD-L1 inhibitor infusion must be completed at least 6 weeks of
             randomization. The subject must have recovered from all reversible acute toxic effects
             (other than alopecia) to ≤ Grade 1 or baseline.

         10. Demonstrate adequate organ function as defined in the table below. All screening labs
             to be obtained within 28 days prior to randomization.

             White blood cell (WBC) ≥ 2 k/mm3 Absolute Neutrophil Count (ANC) ≥ 1.5 K/mm3
             Hemoglobin (Hgb) ≥ 9 g/dL Platelet >100k Estimated creatinine clearance OR ≥ 40 cc/min
             Serum creatinine ≤ 1.5 x upper limit of normal (ULN) Bilirubin 1.5 ≤ (ULN)2 Aspartate
             aminotransferase (AST) ≤ 1.5 × ULN Alanine aminotransferase (ALT) ≤ 1.5 × ULN
             International Normalized Ratio (INR) or Prothrombin Time (PT) Activated Partial
             Thromboplastin Time (aPTT) ≤ 2 × ULN (Note: use of vitamin K antagonist is not
             allowed)

         11. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test
             within 14 days prior to registration. These women must also have a negative serum or
             urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within
             24 hours prior to the start of Nivolumab then every 6 weeks thereafter. NOTE: Women
             are considered of child bearing potential unless they are surgically sterile (have
             undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are
             post-menopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman
             over 45 in the absence of other biological or physiological causes. In addition, women
             under the age of 62 must have a documented serum follicle stimulating hormone (FSH)
             level less than 40 mIU/mL.

         12. Women of childbearing potential must be willing to abstain from heterosexual activity
             or use an effective method of contraception from the time of informed consent until 5
             months after treatment discontinuation. Women cannot breast feed from the time of
             informed consent to 5 months after last dose of study treatment. See below for
             adequate methods of contraception.

         13. Men who are sexually active with WOCBP must use any contraceptive method with a
             failure rate of less than 1% per year. Men receiving Nivolumab and who are sexually
             active with WOCBP will be instructed to adhere to contraception for a period of 7
             months after the last dose of investigational product. See below for methods of
             contraception.

         14. As determined by the enrolling physician or protocol designee, ability of the subject
             to understand and comply with study procedures for the entire length of the study

        Exclusion Criteria

          1. Prior treatment with the single agent chemotherapy the site investigator chooses to
             use for this protocol (pemetrexed, taxotere or gemcitabine).

          2. Previous autoimmune complication from PD-1 or PD-L1 requiring discontinuation of
             therapy or treatment with steroids (ongoing treatment with more than 10 mg of
             prednisone or steroid equivalent daily, excluding inhaled or topical steroids).

          3. Previous discontinuation from PD-1 or PD-L1 due to an adverse event.

          4. Any serious or uncontrolled medical disorder or active infection that would impair the
             ability of the subject to receive protocol therapy.

          5. Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the
             mother is being treated on study).

          6. Known additional malignancy that is active and/or progressive requiring treatment;
             exceptions include basal cell or squamous cell skin cancer, in situ cervical or
             bladder cancer, or other cancer for which the subject has been disease-free for at
             least five years.

          7. Active central nervous system (CNS) metastases. Subjects with brain metastases are
             eligible if metastases have been treated and there is no magnetic resonance imaging
             (MRI) evidence of progression for [lowest minimum is 4 weeks or more] after treatment
             is complete and within 28 days prior to the first dose of Nivolumab administration.
             There must also be no requirement for immunosuppressive doses of systemic
             corticosteroids (> 10 mg/day prednisone equivalents) for at least 2 weeks prior to
             study drug administration.

          8. Treatment with any investigational drug within 30 days prior to registration.

          9. Subjects whose tumors express EGFR mutations on exons 19 and 21, ALK rearrangement, or
             ROS1 rearrangement who still have other FDA approved targeted agents available for
             treatment.

         10. Subjects with an active or recent history of a known or suspected autoimmune disease
             or recent history of a syndrome that required systemic
             corticosteroids/immunosuppressive medications EXCEPT for syndromes which would not be
             expected to recur in the absence of an external trigger. (Subjects with vitiligo,
             autoimmune thyroiditis, or type I diabetes mellitus are permitted to enroll.)

         11. As there is potential for hepatic toxicity with Nivolumab, drugs with a predisposition
             to hepatoxicity should be used with caution in subjects treated with
             Nivolumab-containing regimen.

         12. Subjects should be excluded if they are positive test for hepatitis B virus surface
             antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating
             acute or chronic infection.

         13. Subjects should be excluded if they have known history of testing positive for human
             immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).

         14. History of allergy to study drug components.

         15. Prior solid organ or stem cell transplant
      "
NCT03281083,terminated,"
    difficult recruitment and end of funding.
  ",0,phase 2,"['non-alcoholic fatty liver disease', 'diabetes mellitus, type 2']","[""['Z52.6', 'K71.8', 'K71.7', 'A06.4', 'C22.0', 'C22.3', 'K70.0']"", ""['E11.65', 'E11.9', 'E11.21', 'E11.36', 'E11.41', 'E11.42', 'E11.44']""]",['levothyroxine sodium'],['C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)[O-])N.[Na+]'],"
        Inclusion Criteria:

          1. Male between 21 to 60 years of age

          2. Diagnosed with stable Type II diabetes mellitus (DM) with no changes in oral
             hypoglycaemic medications or dose for the last 2 months from the time of start LT4,
             and if on insulin < 10 units change in insulin dosage, documented by patient's medical
             records. The most recent HbA1C for the last 6 months from the time of start LT4 should
             be no more than 10%.

          3. If the subject is on statin medication, there should be no change in the medication or
             dose of statin for the last 2 months from the time of start LT4

          4. Baseline ALT <3 times upper limit of normal as per the institution's specified
             reference range , with a liver ultrasound showing presence of fatty liver (liver
             ultrasound will not be requested if a prior scan has been done within the past 6
             months from the time of screening)

          5. The IHL content on the MRI/MRS should be more than 10% to allow enrollment in the
             trial.

          6. Baseline TSH levels between 1 - 10 mIU/L

          7. Baseline heart rate <90 beats/min

          8. Ability to provide informed consent

        Exclusion Criteria:

          1. Subject with history of viral hepatitis (except subject with history of viral A
             hepatitis or history of viral E hepatitis that was diagnosed at least 1 year before),
             hepatocellular carcinoma, liver cirrhosis, heart disease, osteoporosis,
             hyper/hypothyroidism, anxiety disorder, Graves' disease, thyroid/liver surgery,
             lactose intolerance, or malabsorption

          2. Baseline estimated glomerular filtration rate (eGFR) < 60 ml/min

          3. Currently on or within 6 months from the time of screening on either thyroxine,
             thiazolidinedione (TZD), oral T4/T3, anticoagulants (coumadin and warfarin),
             anti-viral drugs such as the protease inhibitors (ritonavir, indinavir, lopinavir),
             phenytoin, colestyramine, aluminium containing drugs (antacids, sucralfate),
             salicylates (> 100mg/day), dicumarol, furosemide, or sevelamer

          4. Consumption of ethanol greater than 30g/day (i.e. 3 drinks/day or 21 drinks/week, with
             about 10g of alcohol per drink)

          5. Has advanced liver disease with a baseline NAFLD fibrosis score of >0.675 (stage 3 or
             4 fibrosis)

          6. Has an implant or device in the body which is not safe for MRI scan

          7. Baseline ECG findings considered to be clinically significant (e.g., ischemic changes,
             arrhythmias) by the Investigator(s)

          8. Subject with history of claustrophobia

          9. Baseline free T4 of more than the institution's specified reference range If a sole
             blood test result is deemed borderline according to the laboratory reference interval
             and not clinically significant, the investigator is authorized to exercise discretion.
      "
NCT03289039,terminated,"
    slow accrual
  ",0,phase 2,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['neratinib', 'fulvestrant']","['CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C', 'CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F']","
        Inclusion Criteria:

          -  Participants must have histologically or cytologically confirmed inoperable locally
             advanced or metastatic ER+ breast cancer. To fulfill the requirement for ER+ disease,
             a breast cancer must express, by immunohistochemistry (IHC), ER in ≥10% of cells, on
             the most recent biopsy. If ER quantification is not available, a determination of ER+
             by IHC will suffice. Central confirmation of ER status is not required.

          -  Participants must have documented HER2+ disease by overexpression and/or gene
             amplification on the most recent biopsy, per current ASCO-CAP (American Society of
             Clinical Oncology - College of American Pathologists) guidelines. Central confirmation
             of HER2 status is not required.

          -  Participants must have received prior therapy with the following agents in any
             combination, and in setting (i.e., neoadjuvant, adjuvant, metastatic, etc.). These
             therapies do not need to be the most recent line of therapy.

               -  Trastuzumab

               -  Pertuzumab

               -  Ado-trastuzumab emtansine (T-DM1)

          -  Participants must agree to undergo a research biopsy of a reasonably accessible
             metastatic lesion (chest wall, skin, subcutaneous tissue, lymph nodes, skin, breast,
             bones, lung, and liver metastases). If a reasonably accessible metastatic lesion is
             not available, the patient may go on study provided that archived tissue is available.
             However, if a reasonably accessible site is available for biopsy, the patient must
             agree to biopsy. Any patients not undergoing biopsy must be approved for study
             enrollment by the Overall Principal Investigator at DFCI. Biopsies may be done with
             local anesthesia or intravenous conscious sedation, according to institutional
             guidelines. If a biopsy requires general anesthesia, then it is only allowed if
             acquisition of tissue is clinically indicated, and excess tissue may be collected for
             research purposes. Patients without sites available for biopsy must have available
             tissue [archived formalin-fixed paraffin embedded blocks (FFPB), blocks from which
             slides can be created, or fresh frozen tissue from original diagnosis or metastatic
             setting] for correlative studies. Tissue needs to be located and available at the time
             of registration See Section 9.3 for more details.

          -  Women ≥ 18 years of age. Men are not eligible.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (see Appendix A).

          -  Participants must have normal organ and marrow function as described below:

               -  Absolute neutrophil count ≥1,000/uL

               -  Platelets ≥75,000/uL

               -  Hemoglobin ≥8g/dL

               -  Total bilirubin ≤ 1.5 X institutional upper limit of normal (ULN); in case of
                  known Gilbert's syndrome, <2 x ULN is allowed

               -  AST(SGOT)/ALT(SGPT) ≤3X institutional ULN without liver metastases, or ≤5X
                  institutional ULN with liver metastases

               -  Creatinine clearance ≥ 50 mL/min

               -  Left ventricular ejection fraction ≥50%, as determined by RVG (MUGA) or
                  echocardiogram (ECHO) within 60 days prior to initiation of protocol therapy

          -  Participants may have received any number of prior therapies as long as they have
             adequate performance status and meet all other eligibility criteria.

          -  Women of childbearing potential (including premenopausal women and women less than 12
             months after menopause) must have a negative β-human chorionic gonadotropin (hCG)
             urine pregnancy test within 4 weeks of registration.

          -  The effects of neratinib and fulvestrant on the developing human fetus are unknown.
             For this reason and because SERD agents are known to be teratogenic, women of
             child-bearing potential must agree to be abstinent, or to use a highly effective
             double barrier method of contraception (e.g, a combination of male condom with an
             intravaginal device such as the cervical cap, diaphragm, or vaginal sponge with
             spermicide) or a non-hormonal method, while enrolled in the study, until at least 28
             days after the last dose of neratinib or 1 year after the last dose of fulvestrant.
             Should a woman become pregnant or suspect she is pregnant while she is participating
             in this study, she should inform her treating physician immediately. If a woman is of
             childbearing potential, she must agree to use adequate contraception prior to the
             study, for the duration of study participation, and for one year after completion of
             the study drug.

          -  Ability to understand and willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Participants who have a history of allergic reactions attributed to compounds of
             similar chemical or biologic composition to neratinib or fulvestrant.

          -  Participants who have known hypersensitivity to any component of loperamide or
             colestipol.

          -  Participants who have received previous therapy with neratinib.

          -  Participants who have received anti-cancer therapy (including chemotherapy, biological
             therapy, investigational agents, hormonal therapy, or other anti-cancer therapy) or
             radiotherapy within ≤14 days prior to the planned initiation of investigational
             products, or those who have not recovered to grade ≤1from adverse events due to their
             most recent therapy (excepting alopecia).

          -  Participants who have had any major surgery ≤28 days prior to the planned initiation
             of study therapy, or those who have not recovered from adverse events due to
             agents/surgery administered more than 4 weeks earlier.

          -  Participants who are receiving any other investigational agents.

          -  Participants with known brain metastases that are untreated, symptomatic, or require
             therapy to control symptoms. Participants with a history of treated central nervous
             system (CNS) metastases are eligible. Treated brain metastases are defined as those
             without ongoing requirement for corticosteroids, as ascertained by clinical
             examination and/or brain imaging (magnetic resonance imaging or CT scan) completed
             during screening. Any corticosteroid use for brain metastases must have been
             discontinued without the subsequent appearance of symptoms for ≥ 7 days prior to
             registration. Treatment for brain metastases may include whole brain radiotherapy,
             radiosurgery, surgery or a combination as deemed appropriate by the treating
             physician. Radiation therapy must be completed at least 14 days prior to registration.

          -  Participant has active, uncontrolled cardiac disease, including cardiomyopathy,
             congestive heart failure (New York Heart Association functional classification of ≥2),
             unstable angina, myocardial infarction within 12 months of enrollment, or ventricular
             arrhythmia.

          -  Participant has a QTc interval >470 ms or known history of QTc prolongation or Torsade
             de Pointes.

          -  Participant has an active infection or unexplained fever >38.5°C (101.3°F).

          -  Participant has had another malignancy within the past 5 years with the exception of
             a) adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid
             cancer; b) carcinoma in situ of the breast, cervix or vulva; or c) cancer considered
             cured by surgical resection or unlikely to impact survival during the duration of the
             study, such as localized transitional cell carcinoma of the bladder, or benign tumors
             of the adrenal or pancreas.

          -  Participant has significant chronic gastrointestinal disorder with diarrhea as a major
             symptom (e.g., Crohn's disease, malabsorption, or Grade ≥2 (NCI CTCAE v.4.0) diarrhea
             of any etiology at screening).

          -  Participant has known active infection with hepatitis B or hepatitis C virus.
             Hepatitis B and C serology testing is not required, unless active infection is
             suspected.

          -  Participant is unable or unwilling to swallow tablets.

          -  Participant has evidence of significant medical illness, abnormal laboratory finding,
             or psychiatric illness/social situations that would, in the Investigator's judgment,
             limit compliance with study requirements.

          -  Pregnant women are excluded from this study because fulvestrant is a SERD agent with
             the potential for teratogenic or abortifacient effects. Because there is an unknown
             but potential risk for adverse events in nursing infants secondary to treatment of the
             mother with neratinib and/or fulvestrant, breastfeeding should be discontinued if the
             mother is treated with neratinib and/or fulvestrant.
      "
NCT04671901,terminated,"
    lack of accrual
  ",0,phase 2,"['solid tumor', 'solid tumor, childhood', 'solid carcinoma']","[""['F80.81', 'F84.3', 'F93.8', 'F93.9', 'R62.0', 'E71.520', 'F64.2']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]",['romiplostim'],['CC1=CC(=C(N1)C=C2C3=CC=CC=C3NC2=O)C'],"
        Inclusion Criteria:

          -  Documented diagnosis of a primary solid tumor. Patients must have histological
             verification of malignancy at MSKCC.

          -  Male and female patients aged 1-21 years with a primary solid tumor undergoing
             treatment with the pre-defined chemotherapy regimens of EFT, MAP, D9803. Prior to
             enrollment patient could have been undergoing induction therapy with a similarly
             myelosuppressive regimen as long as they will be continuing with EFT, MAP, D9803 at
             the time of study enrollment.

          -  Patients undergoing treatment with MAP chemotherapy w ho have had ≥ 1 platelet
             transfusion during induction stage of treatment.

          -  Total Bilirubin (sum of conjugated + unconjugated) ≤ 3 times institutional upper limit
             of normal (ULN) for age and ALT/AST ≤ 3 times institutional ULN for age.

          -  Normal cardiac function:

               -  Shortening fraction greater than or equal to 28% by echocardiogram OR Left
                  ventricular ejection fraction (LVEF) greater than or equal to 50% on technetium-
                  99m pertechnetate radionuclide cineangiography (MUGA) or echocardiogram.

               -  Screening ECG with corrected QT (QTc) interval of < 470 msec.

               -  Timing of cardiac assessment: We will utilize the most recent EKG/ECHO when
                  assessing cardiac function. See section 9.0 for additional details.

          -  Adequate renal function, defined as an estimated Creatinine Clearance or GFR >40ml/min
             or an normal creatine for age (see below)

        Serum Creatinine by age:

        Age (years) <6: Maximum Serum Creatinine (mg/dL), Male 0.8, Female 0.8 Age (years) 6 to
        <10: Maximum Serum Creatinine (mg/dL), Male 1, Female 1 Age (years) 10 to <13: Maximum
        Serum Creatinine (mg/dL), Male 1.2, Female 1.2 Age (years) 13 to <16: Maximum Serum
        Creatinine (mg/dL), Male 1.5, Female 1.4 Age (years) >16: Maximum Serum Creatinine (mg/dL),
        Male 1.7, Female 1.4

        These threshold creatine values were derived from the Scwartz formula estimating GFR,
        utilizing child length and statured published by the CDC.

        Exclusion Criteria:

          -  Patients with history of hematologic malignancies or allogenic/autogenic stem cell
             transplant.

          -  Patients with a currently known predisposition to a myeloid stem cell disorder,
             myeloid leukemia, and/or bone marrow failure syndrome including, but not limited to:

               -  Aplastic anemia

               -  Ataxia telangiectasia

               -  Bloom syndrome

               -  Congenital amegakaryocytic thrombocytopenia

               -  Cyclic neutropenia

               -  Diamond Blackfan anemia

               -  Dyskeratosis congenita

               -  Familial AML/MDS syndromes (including ANKRD26, CEBPA, DDX41, ETV6, GATA2, RUNX1,
                  SRP72)

               -  Fanconi anemia

               -  Kostmann disease

               -  Li-Fraumeni syndrome

               -  Neurofibromatosis

               -  Nijmegen breakage syndrome

               -  Noonan syndrome

               -  Paroxysmal nocturnal hemoglobinuria

               -  Pearson syndrome

               -  Poland syndrome

               -  Rothmund-Thomson syndrome

               -  Severe congenital neutropenia

               -  Thrombocytopenia absent radii syndrome

               -  Trisomy 8

               -  Trisomy 21

               -  WHIM syndrome

               -  Wiskott Aldrich syndrome

               -  Xeroderma pigmentosa

          -  Secondary malignancy in the past 5 years.

          -  Patients who have previously undergone up-front chemotherapy and have relapsed or
             progressed through therapy.

          -  Patients who have received 4 or more cycles of induction chemotherapy for their
             current malignancy prior to time of enrollment.

          -  Previous use of romiplostim, eltrombopag, recombinant human TPO, or any other TPO
             receptor agonist, or any investigational platelet producing agent.

          -  Patients receiving other investigational agents are not eligible for study entry.

        History of uncontrolled arrhythmias, clinically significant electrocardiogram (ECG)
        abnormalities, active heart failure or pericardial disease.

          -  Patients with current or prior venous thrombotic event or arterial thrombotic event at
             time of enrollment will be ineligible for this study.

          -  Pregnant women/lactating mothers.

          -  Patients unwilling to use effective contraception method, which includes abstinence.

          -  Patients with an inability to return for follow-up visits or obtain follow-up studies
             required to assess toxicity to therapy.
      "
NCT02055690,terminated,"
    safety
  ",0,phase 1/phase 2,"['ovarian neoplasms', 'neoplasms, ovarian', 'ovarian cancer']","[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['pazopanib', 'fosbretabulin']","['CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N', 'COC1=C(C=C(C=C1)C=CC2=CC(=C(C(=C2)OC)OC)OC)OP(=O)(O)O']","
        Inclusion Criteria:

          -  Advanced, progressive, recurrent epithelial ovarian, fallopian tube or primary
             peritoneal carcinoma, which has recurred following at least one platinum-containing
             regimen.

          -  Progressive disease according to RECIST 1.1 or GCIG criteria within 3-12 months of
             completing platinum containing therapy, although this need not be the immediately
             preceding regimen.

          -  World Health Organisation (WHO) performance status of 0 or 1 (Appendix 1).

          -  Measurable disease (RECIST 1.1 (Appendix 2) or Progressive Disease (PD) according to
             CA125 GCIG criteria with non-measurable disease on CT scan.

          -  Life expectancy of at least 12 weeks.

          -  Haematological and biochemical indices within the ranges shown below. These
             measurements must be performed within one week (Day -7 to Day 1) before the patient
             receives the first dose of Investigational Medicinal Product (IMP):

               -  Haemoglobin (Hb) ≥ 90 g/L

               -  Absolute neutrophil count ≥ 1.5 x 109/L

               -  Platelet count ≥ 100 x 109/L

               -  Serum potassium within normal range

               -  Bilirubin ≤ 1.5 x upper limit of normal (ULN)

               -  Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) ≤ 2.5 x ULN
                  unless raised due to hepatic metastatic disease in which case up to 5 x ULN is
                  permissible

               -  Either: Calculated creatinine clearance ≥ 40 mL/min (uncorrected value) Or:
                  Isotope clearance measurement ≥ 40 mL/min (corrected)

               -  Activated partial thromboplastin time (aPTT) ≤ 1.2 x ULN

               -  Prothrombin Time (PT) or International normalised ratio (INR) ≤ 1.3 x ULN

               -  Urine protein dipstick of less than or equal to 2+, or if 2+ or greater the
                  patient must have a 24 hour urinary protein value of less than 2 g.

               -  Clinically euthyroid.

               -  Aged 18 years or over at the time of consent.

               -  Written (signed and dated) informed consent and capable of co-operating with
                  treatment and follow-up.

               -  Patients can have received bevacizumab prior to trial entry providing that the
                  last dose was administered at least 6 months before the first dose of IMP.

        Exclusion Criteria:

          -  Radiotherapy, surgery or tumour embolisation within 28 days before the first dose of
             IMP

          -  Endocrine therapy, immunotherapy or chemotherapy during the previous four weeks (six
             weeks for nitrosoureas, Mitomycin-C and six weeks for investigational medicinal
             products) before the first dose of IMP.

          -  Ongoing grade ≥ 2 toxic manifestations of previous treatments. Exceptions to this are
             alopecia or certain Grade 1 toxicities, which in the opinion of the Chief and
             Principal Investigators should not exclude the patient; and grade 1 or 2 neurotoxicity
             considered to be due to paclitaxel.

          -  Female patients who are able to become pregnant (or are already pregnant or
             lactating). Those who have a negative serum or urine pregnancy test before enrolment
             and agree to use two highly effective forms of contraception (oral, injected or
             implanted hormonal contraception and condom, have an intra-uterine device and condom,
             diaphragm with spermicidal gel and condom) for four weeks before entering the trial,
             during the trial and for six months afterwards are considered eligible.

          -  Major thoracic or abdominal surgery from which the patient has not yet recovered.

          -  At high medical risk because of non-malignant systemic disease including active
             uncontrolled infection.

          -  Known to be serologically positive for hepatitis B, hepatitis C or human
             immunodeficiency virus (HIV).

          -  History of any of the following cardiovascular conditions within the last six months:

               -  Coronary revascularisation (percutaneous coronary intervention (PCI) or coronary
                  artery bypass graft (CABG))

               -  Acute coronary syndrome (myocardial infarction (MI), unstable angina)

               -  Symptomatic peripheral vascular disease

               -  Class III or IV congestive heart failure, as defined by the New York Heart
                  Association (NYHA) (Appendix 4)

          -  Patients who have sustained hypertension, defined as a systolic blood pressure (SBP)
             of > 140 mm Hg or diastolic blood pressure (DBP) of > 90 mm Hg, on three occasions.

          -  ECG with evidence of clinically significant abnormalities.

          -  Patients with a QTc> 480ms or taking any drug known to prolong the QTc interval that
             cannot be stopped for the duration of the trial (Appendix 4).

          -  Patients with pathologic bradycardia (<60 b/m in non-athletes), heart block (excluding
             first-degree block, being PR interval prolongation only).

          -  History of cerebrovascular accident (including transient ischaemic attack (TIA)),
             pulmonary embolism or untreated deep vein thrombosis (DVT) within the past six months.
             Patients with recent DVT or pulmonary embolism who have been treated with therapeutic
             anti-coagulant agents for at least six weeks will be eligible, provided their INR (if
             taking oral anti-coagulants) has been stable for this period of time.

          -  History or clinical evidence of central nervous system (CNS) metastases or
             leptomeningeal carcinomatosis, except for individuals who have previously treated CNS
             metastases, are asymptomatic and have had no requirement for steroids or
             anti-convulsant medication for six months prior to the first dose of IMP.

          -  Clinically significant abnormalities that may increase the risk of gastrointestinal
             bleeding or perforation, including but not limited to:

               -  Bleeding: Active peptic ulcer disease, known intraluminal metastatic lesions with
                  risk of bleeding, Inflammatory bowel disease (Crohn's disease, ulcerative
                  colitis);

               -  Perforation: History of abdominal fistula or large pelvic mass; gastrointestinal
                  perforation or intra-abdominal abscess within four weeks prior to first dose of
                  IMP; previous bowel surgery which is judged by the investigator to increase
                  significantly the risk of gastrointestinal complications from trial treatment

          -  Evidence of active bleeding or bleeding diathesis.

          -  Transfusion within one week prior to first dose of IMP.

          -  Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels.

          -  Clinically significant haemoptysis, within eight weeks before the first dose of IMP.

          -  Previous treatment with pazopanib.

          -  Any participant that is participating in (or plans to participate in) another
             interventional clinical trial, whilst taking part in this Phase Ib/II study of
             fosbretabulin and pazopanib. Participation in an observational trial would be
             acceptable.

          -  Any other condition which in the Investigator's opinion would not make the patient a
             good candidate for the clinical trial.

          -  Current malignancies of other types, with the exception of adequately treated
             cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell
             carcinoma of the skin and no evidence of recurrence of other malignancy for at least 2
             years.

          -  Hypersensitivity to Pazopanib or any of it's excipients
      "
NCT02057939,completed,,1,phase 2,['prostate cancer'],"[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]","['enzalutamide', 'androgen deprivation']","['CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C', 'Status: 503']","
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of prostate adenocarcinoma. Variants of prostate
             cancer, including neuroendocrine features and small cell carcinoma of the prostate,
             are not permitted.

          -  Gleason sum of 7, 8, 9, or 10 at the time of prostatectomy.

          -  PSA relapse within 4 years of prostatectomy defined by persistently detectable or
             rising PSA after surgery.

          -  Evidence of disease recurrence or progression as evidenced by a PSA > 0.20. This
             requires 2 consecutive rises in PSA, at least 1 week apart, over the
             post-prostatectomy nadir or one PSA value above 0.20 ng/mL if the patient failed to
             achieve a post-prostatectomy nadir of < 0.2 ng/mL.

          -  Age ≥ 18 years

          -  Karnofsky performance status ≥ 70

          -  Adequate laboratory parameters

          -  Adequate bone marrow function: ANC ≥1.5 x 109/L, Platelets ≥100 x 109/L, Hb >9g/dL

          -  AST/SGOT and ALT/SGPT ≤ 2.5 x Institutional Upper Limit of Normal (ULN)

          -  Serum bilirubin ≤ 1.5 x Institutional ULN

          -  Serum creatinine ≤ 1.5 x Institutional ULN or 24-hour clearance ≥ 50 mL/min

          -  A minimum of 4 weeks from any major surgery prior to registration.

          -  Ability to swallow, retain, and absorb oral medication.

          -  Ability to understand and the willingness to sign a written informed consent document.

          -  Must use a condom if having sex with a pregnant woman.

          -  Male patient and his female partner who is of childbearing potential must use 2
             acceptable methods of birth control (one of which must include a condom as a barrier
             method of contraception) starting at screening and continuing throughout the study
             period and for 3 months after final study drug administration.

        Exclusion Criteria:

          -  Radiographic evidence of metastatic disease. Patients with node-positive disease (<2
             positive nodes) at the time of radical prostatectomy are eligible. Patients with
             pelvic nodes up to 2 cm by short axis at the time of screening are eligible. Patients
             with any enlarged lymph nodes in the retroperitoneum or above the aortic bifurcation
             or with pelvic nodes ≥ 2 cm must be excluded.

          -  PSA > 4.0 ng/mL.

          -  Testosterone level ≤ 100 ng/dL.

          -  More than 1 month of prior hormone exposure or hormone exposure within 30 days of
             registration. Prior enzalutamide, ketoconazole, abiraterone, or TAK700 prohibited.
             Prior 5α reductase inhibitors are allowed.

          -  Prior immunotherapy including sipuleucel-T.

          -  Prior systemic chemotherapy (docetaxel, cabazitaxel, estramustine, other cytotoxic
             agents)

          -  History of solid organ or stem cell transplantation.

          -  History of seizure or any condition that may predispose to seizure (e.g., prior
             cortical stroke, prior head or traumatic brain injury with loss of consciousness,
             prior or current space-occupying lesion in the brain). Also, history of loss of
             consciousness or transient ischemic attack within 12 months of Day 1 visit.

          -  Known or suspected brain metastasis or active leptomeningeal disease.

          -  Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g.,
             active or uncontrolled infection) that could cause unacceptable safety risks or
             compromise compliance with the protocol.

          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly
             alter the absorption of enzalutamide or increase the risk of radiation (e.g.,
             uncontrolled nausea, vomiting, diarrhea, malabsorption syndromes, prior small bowel
             resection, or inflammatory bowel disease).

          -  Patients who have received prior prostate or pelvic radiotherapy, including external
             beam or brachytherapy.

          -  Patients who have undergone major surgery ≤ 4 weeks prior to starting study drug or
             who have not recovered from side effects of such therapy prior to registration.

          -  Patients unable or unwilling to abide by the study protocol or cooperate fully with
             the investigator.
      "
NCT02058706,completed,,1,phase 2,"['adenocarcinoma of the prostate', 'recurrent prostate cancer', 'stage iv prostate cancer']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']"", ""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]","['enzalutamide', 'bicalutamide', 'leuprolide acetate', 'goserelin acetate']","['CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C', 'CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O', 'CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O', 'CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O']","
        Inclusion Criteria:

          -  Histologically confirmed prostate adenocarcinoma with metastasis either starting or
             recently started on LHRH analogue therapy. [Late induction permitted within 3 months
             of starting LHRH analogue therapy or antiandrogen]

          -  All patients who have not initiated hormone therapy (Early induction patients) must
             have elevated PSA ≥ 4 ng/ml within 28 days prior to registration. For late induction
             registrations, PSA must be ≥ 4 ng/ml prior to start of androgen deprivation therapy;
             either antiandrogen or LHRH analogue or GNRH antagonist .If patients are on
             antiandrogen, this will need to be discontinued for at least 7 days prior to
             registration.

          -  Patients with a history of prior neoadjuvant or adjuvant hormone therapy are eligible
             provided they have received twenty four or less months of hormone treatment (single or
             combination treatment, excluding orchiectomy). Both therapies (neoadjuvant/adjuvant
             hormone therapy) must have been discontinued at least 6 months prior to registration.
             This is intended to exclude patients who might have been rendered indirectly androgen
             insensitive.

          -  There must be no plans to receive concomitant chemotherapy, biological response
             modifiers, radiation therapy or hormonal therapy. Concomitant radiation therapy is
             allowed for the palliation of severe pain/neuropathic compression. Prior or
             concomitant use of megestrol acetate for the treatment of hot flashes is allowed.

          -  Patients must have a performance status of 0 - 2 by Zubrod Criteria.

          -  Patients must have recovered from any major infections and/or surgical procedures
             and,in the opinion of the investigator, not have significant active medical illness
             precluding protocol treatment or survival.

          -  No prior malignancy is allowed except for adequately treated basal cell (or squamous
             cell) skin cancer, superficial or in situ cancer of the bladder. For an invasive
             cancer the patients should be disease free for at least 3 years prior to enrollment on
             study.

          -  For all patients a bone scan must be performed within 60 days prior to registration
             for tumor assessment. CT scans (abdomen and pelvis) and chest x-ray are optional, but
             must be repeated if used for disease assessment. For late induction registrations,
             tumor assessment imaging showing metastatic disease must be available prior to start
             of androgen deprivation therapy.

          -  Age 18 or older and willing and able to provide informed consent.

          -  Willingness to swallow pills and no medical condition that would interfere with this.

          -  Male patient and his female partner who is of childbearing potential must use 2
             acceptable methods of birth control (one of which must include a condom as a barrier
             method of contraception) starting at screening and continuing throughout the study
             period and for 3 months after final study drug administration. Patients are also
             required to use a condom if having sex with a pregnant woman.

          -  Patient should agree to a tumor tissue biopsy prior to protocol enrollment. Post
             therapy biopsy is optional.

          -  Patients who are being treated with a GNRH antagonist should be willing to switch to a
             LHRH analogue after registration.

          -  Patients must have one of the following a) Low volume disease (defined as no visceral
             metastases and < 4 bone metastases) or b) are not candidates for docetaxel based
             chemotherapy or 3) refused docetaxel chemotherapy

        Exclusion Criteria:

          -  History of seizure or any condition that may predispose to seizure (e.g., prior
             cortical stroke, significant brain trauma) at any time in the past. Also, history of
             loss of consciousness or transient ischemic attack within 12 months of Day 1 visit;

          -  Known or suspected brain metastasis or active leptomeningeal disease;

          -  Severe concurrent disease, infection, or co-morbidity that, in the judgment of the
             Investigator, would make the patient inappropriate for enrollment;

          -  Absolute neutrophil count < 1,000/μL, or platelet count < 50,000/μL, or hemoglobin<8
             g/dL) at the Screening visit.

          -  Total bilirubin, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >
             2.5 times the upper limit of normal

          -  Creatinine > 177 μmol/L (2 mg/dL)

          -  Clinically significant cardiovascular disease including: Myocardial infarction within
             6 months; Uncontrolled angina within 3 months; Congestive heart failure New York Heart
             Association (NYHA) class 3 or 4, or patients with history of congestive heart failure
             (NYHA) class 3 or 4 in the past, unless screening echocardiogram or multi-gated
             acquisition scan performed within 3 months results in a left ventricular ejection
             fraction that is greater or equal to 45%; History of clinically significant
             ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation,
             torsades de pointes); History of Mobitz II second degree or third degree heart block
             without a permanent pacemaker in place; Hypotension as indicated by systolic blood
             pressure < 86 millimeters of mercury (mmHg) at the Screening visit; Bradycardia as
             indicated by a heart rate of < 50 beats per minute on the Screening ECG; Uncontrolled
             hypertension as indicated by systolic blood pressure > 170 mmHg or diastolic blood
             pressure > 105 mmHg

          -  Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer
             disease within last 3 months);

          -  Treatment with concurrent 5-α reductase inhibitors (finasteride, dutasteride),
             estrogens, and/or cyproterone

          -  Treatment with systemic biologic therapy for prostate cancer (other than approved bone
             targeted agents and GnRH-analogue therapy) or other agents with anti-tumor activity
             within 4 weeks of enrollment (Day 1 visit);

          -  History of prostate cancer progression on ketoconazole;

          -  Prior use, or participation in a clinical trial, of an investigational agent that
             blocks androgen synthesis (e.g., abiraterone acetate, TAK-700, TAK-683, TAK-448) or
             agents that block the androgen receptor (e.g.,ARN-509)

          -  Previous enzalutamide therapy;

          -  Use of an investigational agent within 2 weeks of enrollment (Day 1 visit);

          -  Use of herbal products that may have hormonal anti-prostate cancer activity and/or are
             known to decrease PSA levels (e.g., saw palmetto) or systemic corticosteroids greater
             than the equivalent of replacement steroids or > equivalent of 10 mg of prednisone per
             day within 4 weeks of enrollment (Day 1 visit);

          -  Any condition or reason that, in the opinion of the Investigator, interferes with the
             ability of the patient to participate in the trial, which places the patient at undue
             risk, or complicates the interpretation of safety data.

          -  Prior chemotherapy for metastatic disease.

          -  >30 days of antiandrogen therapy monotherapy without androgen deprivation therapy.

          -  Life expectancy of 6 months or less.
      "
NCT02056756,"active, not recruiting",,1,phase 1/phase 2,['multiple myeloma'],"[""['C90.01', 'C90.02', 'C90.00']""]",['carfilzomib'],['CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3)NC(=O)CN4CCOCC4'],"
        Inclusion Criteria:

          -  Patient ≥ 18 years old.

               -  Patient is, in the investigator(s) opinion, willing and able to comply with the
                  protocol requirements.

               -  Patient has given voluntary written informed consent before performance of any
                  study-related procedure not part of normal medical care, with the understanding
                  that consent may be withdrawn by the patient at any time without prejudice to
                  their future medical care.

               -  Female patient is either post-menopausal or surgically sterilized or commits
                  continued abstinence from heterosexual intercourse during the duration of the
                  study or is willing to use two methods of birth control, one highly effective
                  method and one additional effective method at the same time, at least 4 weeks
                  before starting carfilzomib and bendamustine therapy, during carfilzomib and
                  bendamustine therapy and for at least 4 weeks after stopping carfilzomib and
                  bendamustine therapy. Highly effective methods are hormonal contraceptives (birth
                  control pills, injections, and implants), intrauterine device, tubal ligation and
                  partner's vasectomy. Additional effective methods are condom, diaphragm, and
                  cervical cap. Women with child bearing potential must have two negative pregnancy
                  tests (sensitivity at least 50 mIU/mL) prior starting carfilzomib and
                  bendamustine therapy. The first pregnancy test must be performed 10 - 14 days and
                  the second within 24 hours before starting carfilzomib and bendamustine therapy.
                  Pregnancy testing for the first 4 weeks of study therapy must be performed weekly
                  and thereafter every 4 weeks if menstrual cycles are regular or every 2 weeks if
                  menstrual cycles are irregular.

               -  Male patient agrees to use an acceptable method for contraception (i.e., condom
                  or abstinence) for the duration of the study and for 6 months after stopping
                  study therapy.

               -  Patient with relapsed or/and refractory multiple myeloma after failure of two or
                  more treatment regimens (previous bortezomib is allowed).

               -  Patient has measurable disease, defined as follows: any quantifiable serum
                  monoclonal protein (M-protein) value (generally, but not necessarily, ≥ 0.5 g/dL
                  of M-protein) and, where applicable, urine light-chain excretion of >200 mg/24
                  hours. For patients with oligo- or non-secretory MM, it is required that they
                  have measurable plasmacytoma > 2 cm as determined by clinical examination or
                  applicable radiographs (i.e. MRI, CT-Scan) or an abnormal free light chain ratio
                  (n.v.: 0.26-1.65). We anticipate that less than 10% of patients admitted to this
                  study will be oligo- or non-secretory MM with free light chains only in order to
                  maximize interpretation of benefit results.

               -  Patient has a Karnofsky performance status ≥60%.

               -  Patient has a life expectancy >6 months.

               -  Patient has the following laboratory values within 14 days before Baseline (day 1
                  of the Cycle 1, before study drug administration):

          -  Platelet count ≥70 x 109/L (≥50 x 109 /L if myeloma involvement in the bone marrow is
             > 50%) within 14 days prior to drug administration).

          -  Absolute neutrophil count (ANC) ≥ 1 x 109/L without the use of growth factors.

          -  Corrected serum calcium ≤14 mg/dL (3.5 mmol/L).

          -  Alanine transaminase (ALT): ≤ 3 x the ULN.

          -  Total bilirubin: ≤ 2 x the ULN.

          -  Calculated or measured creatinine clearance ≥ 15 mL/min (or, as alternative serum
             creatinine <2 mg/dL).

          -  LVEF ≥ 40%. 2-D transthoracic echocardiogram (ECHO) is the preferred method of
             evaluation. Multigated Acquisition Scan (MUGA) is acceptable if ECHO is not available
             (not applicable in Germany).

        Exclusion Criteria:

          -  Pregnant or lactating females

               -  Patient has active infectious hepatitis type B or C or HIV.

               -  Patients with active congestive heart failure (New York Heart Association [NYHA]
                  Class III to IV), symptomatic ischemia, or conduction abnormalities uncontrolled
                  by conventional intervention.

               -  Peripheral neuropathy (PN) > CTCAE grade 2 and ≥ grade 2 painful PN (with the
                  difference being in the exclusion of patients with Grade 2 painful PN).

               -  Known history of allergy to Captisol (a cyclodextrin derivative used to
                  solubilize carfilzomib)

               -  Known history of intolerability to high dose dexamethasone

               -  Contraindication to any of the required concomitant drugs or supportive
                  treatments, including hypersensitivity to all anticoagulation and anti-platelet
                  options, antiviral drugs, or intolerance to hydration due to preexisting
                  pulmonary or cardiac impairment.

               -  Subject with pleural effusions requiring thoracentesis or ascites requiring
                  paracentesis within 14 days prior to baseline;

               -  Patient has any other clinically significant illness that would, in the
                  investigator's opinion, increase the patient's risk for toxicity.

               -  Patient with a prior malignancy within the last 5 years (except for basal or
                  squamous cell carcinoma of the skin, or in situ cancer of the cervix or breast,
                  or localized prostate cancer of Gleason score <7 with a stable PSA).
      "
NCT02055963,terminated,"
    early termination due to the protocol lack of progress in improving accrual rate
  ",0,phase 2,['head and neck cancer'],"[""['C76.0', 'C47.0', 'C49.0', 'C77.0', 'D17.0', 'D21.0', 'D36.11']""]","['minocycline', 'placebo']",['CN(C)C1C2CC3CC4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C'],"
        Inclusion Criteria:

          1. Patients with head and neck cancer who are undergoing either flap or nonflap surgery
             (limited to parotidectomy, hard palate maxillectomy and glossectomy, mandibulectomy,
             and any procedure with neck dissection) at MD Anderson Cancer Center.

          2. Patients > 18 years old.

          3. Patients who have not undergone surgery in the past 6 months. Patients may have had
             neoadjuvant chemotherapy prior to surgery.

          4. Patients must have normal renal function test and no prior renal disease. The
             screening cut off for serum creatinine is < 1.5mg/dL.

          5. Patients must have normal hepatic function test and no prior liver disease: (1) The
             screening results for alanine aminotransferase (ALT) must be < 2 times the upper limit
             of normal. (2) The screening results for aspartate aminotransferase (AST), if
             available, must be < 2 times the upper limit of normal.

          6. Patients who speak English or Spanish (due to the novel research and its complexity,
             we are only accruing English-speaking or Spanish-speaking patients to the protocol).

          7. Patients must be willing and able to review, understand, and provide written consent.

          8. Patients must be willing to discontinue taking dong quai and/or St. John's wort.

        Exclusion Criteria:

          1. Patients who are taking medications (including minocycline) or have conditions that
             potentially preclude use of the study medication or intervention as determined by the
             treating physician.

          2. Patients who are enrolled in another symptom management trial or receiving active
             treatment under another clinical trial.

          3. Patients with a history of clinically significant cutaneous drug reaction,
             hypersensitivity reaction, anaphylaxis or any other serious adverse reaction to any of
             the anesthetics or analgesics medications used in the study.

          4. Patients with hypersensitivity to any tetracycline.

          5. Patients on vitamin K antagonist (i.e., warfarin).

          6. Patients taking any tetracycline within the last 15 days.

          7. Patients who have been on opioid therapy for the last 4 weeks or more.

          8. Patients with bile duct obstruction.

          9. Patients who are pregnant.

         10. Patients with INR > 1.5.

         11. Patients with autoimmune disease.
      "
NCT02054442,unknown status,,1,phase 1/phase 2,['squamous cell carcinoma of the head and neck'],"[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]","['cetuximab', 'methotrexate']",['CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O'],"
        Inclusion Criteria:

          -  Cytologically/histologically-proven SCCHN

          -  Recurrent or metastatic SCCHN

          -  At least one measurable lesion as determined by RECIST v1.1 is required. Lesions in
             previously irradiated areas should not be considered measurable unless there is clear
             evidence of progression in such lesions since the radiotherapy.

          -  No prior systemic treatment for recurrent or metastatic disease

          -  Primary site: (1) oral cavity, (2) oropharynx, (3) hypopharynx, (4) larynx, or (5)
             unknown primary squamous cell carcinoma in the head and neck region presenting
             originally with lymph node metastases (N1-N3).

          -  Time between prior treatment and inclusion in the study (> 3 months). Palliative RT in
             case of painful bone metastases is allowed in phase II and after 4 weeks in phase Ib

          -  Ineligible (due to medical co-morbidities) or intolerant to platinum-based therapy per
             medical history or refusing cisplatin-based chemotherapy by the patient

          -  WHO performance status 0-2.

          -  Age >18 years

          -  Adequate organ function and laboratory parameters as defined by:

               -  Absolute neutrophil count (ANC) ≥ 1.5 x 109 /L

               -  Hemoglobin (Hb) ≥ 9 g/dl 5.6 mmol/l (which may be achieved by transfusion)

               -  Platelets (PLT) ≥ 100 x 109/L

               -  AST and ALT ≤ 2.5 x ULN (upper limit of normal)

               -  Serum bilirubin ≤ 1.5 x ULN

               -  Calculated creatinine clearance or MDRD > 60ml/min

          -  Recovered from all adverse events (AEs) of previous anti-cancer therapies. AEs related
             to prior radiotherapy are allowed.

          -  Written informed consent

        Exclusion Criteria:

          -  Serious active infections

          -  Patients (M/F) with reproductive potential not implementing adequate contraceptives
             measures

          -  Prior treatment with EGFR inhibitors or MTX

          -  Concomitant (or within 4 weeks before randomization) administration of any other
             experimental drug under investigation

          -  Concurrent treatment with any other anti-cancer therapy.

          -  Central nervous system involvement

          -  Lung fibrosis

          -  Pleural effusion or ascites or other third space effusions

          -  History of another malignancy within 2 years prior to starting study treatment, except
             cured basal cell carcinoma of the skin, excised carcinoma in situ of the cervix, or
             other head and neck cancer.

          -  Pregnancy or lactation

          -  Any other condition that would, in the Investigator's judgment, preclude patient's
             participation in the clinical study due to safety concerns or compliance with clinical
             study procedures, e.g. infection/inflammation, intestinal obstruction,
             social/psychological complications.
      "
NCT02059213,completed,,0,phase 2,['prostate cancer'],"[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]","['ibrance', 'bicalutamide', 'zoladex', 'lupron depot']","['CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C', 'CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O', 'CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6', 'CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O']","
        Inclusion Criteria:

          -  Have pathologic diagnosis of prostate cancer.

          -  Have hormone-sensitive metastatic disease (M1) as evidenced by soft tissue and/or bony
             metastases.

          -  Patients may either be untreated for their newly diagnosed metastatic disease
             (preferred as much as possible) or have started androgen deprivation therapy. Patients
             who have started androgen deprivation therapy for the treatment of their newly
             diagnosed metastatic disease are eligible as long as the duration of treatment is less
             than or equal to 2 weeks (14days) prior to registration. The start date of androgen
             deprivation is considered the day the patient first received an injection of a LHRH
             agonist/antagonist (or orchiectomy), not the date when an oral antiandrogen started.

          -  Patients must have a minimum PSA (Prostate-Specific Antigen) ≥ 5 ng/mL within 60 days
             of registration or prior to the initiation of androgen deprivation for patients who
             have started androgen deprivation therapy.

          -  Agree to undergo a biopsy of at least one metastatic site for RB (Retinoblastoma
             Protein) status evaluation. Adequate metastatic tissue from prior biopsy/resection can
             be used if available in lieu of a biopsy.

          -  ECOG performance status of 0-2 (Eastern Cooperative Oncology Group scoring system used
             to quantify general well-being and activities of daily life; scores range from 0 to 5
             where 0 represents perfect health and 5 represents death).

          -  Patients may have received prior neoadjuvant and/or adjuvant hormonal therapy, for
             non-metastatic disease but it must not have lasted for more than 36 months. At least
             12 months must have elapsed since completion of androgen deprivation therapy in the
             neoadjuvant and/or adjuvant setting.

          -  Within 14 days prior to registration patients must have adequate organ and marrow
             function: White Blood Cell (WBC) count ≥ 3,000/μl, Absolute Neutrophil Count (ANC) ≥
             1,500/μl, Platelet Count ≥ 100,000/μl, Serum Creatinine ≥1.5 x the institutional upper
             limits of normal or corrected creatinine clearance of ≥ 50 mg/ml/hr/1.73 m2 BSA (Body
             Surface Area), Bilirubin within the institutional limits of normal, AST (Aspartate
             Aminotransferase) ≤ 2 x upper limits of normal, ALT (Alanine Aminotransferase) ≤ 2 x
             upper limits of normal.

          -  Patients must be able to take oral medication without crushing, dissolving or chewing
             tablets.

          -  Patients may have received prior radiation therapy or surgery. However, at least 14
             days must have elapsed since completion of radiation therapy or surgery and patient
             must have only grade 2 or less adverse effects at the time of registration.

          -  Patients must agree to use highly effective contraception during treatment and for a
             period of 90 days after ending treatment with PD 0332991.

          -  Ability to understand and the willingness to sign a written informed consent document
             that is approved by an institutional review board.

        Exclusion Criteria:

          -  Patients who have received androgen deprivation therapy for greater than 14 days
             (LHRH-agonist or antagonist) for the treatment of their newly diagnosed metastatic
             disease prior to enrollment are not eligible for this study.

          -  Patients who are currently being treated with strong CYP3A4 inhibitors (e.g.,
             amprenavir, fosamprenavir, indinavir, itraconazole, ketoconazole, lopinavir,
             mibefradil, miconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir,
             telaprevir, telithromycin, verapamil, voriconazole, and grapefruit) or strong inducers
             (e.g., carbamazepine, felbamate, nevirapine, phenobarbital, phenytoin, primidone,
             rifabutin, rifampin, rifapentine and St. John's wort) must either discontinue these
             drugs or are ineligible.

          -  Patients must refrain from the use of proton pump inhibitors. If needed, alternative
             antacid therapies may be used including H2-receptor antagonists, and locally acting
             antacids.

          -  Patients with known brain metastases should be excluded from this clinical trial
             because of their poor prognosis and because they often develop progressive neurologic
             dysfunction that would confound the evaluation of neurologic and other adverse events.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure (New York Heart Association Class III
             and IV heart failure), unstable angina pectoris, cardiac arrhythmia, or psychiatric
             illness/social situations that would limit compliance with study requirements.

          -  Patients with a ""currently active"" second malignancy other than non-melanoma skin
             cancers are not eligible. Patients are not considered to have a ""currently active""
             malignancy if they have completed all therapy and are now considered without evidence
             of disease for 1 year.

          -  HIV-positive patients on combination antiretroviral therapy are ineligible .
      "
NCT02970682,completed,,1,phase 2,['breast neoplasm'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['sfx-01', 'fulvestrant', 'tamoxifen', 'aromatase inhibitors']","['CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F', 'CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3']","
        Inclusion Criteria:

          1. Male or female patients 18 years or older (the patient must be the legal age limit to
             give informed consent within the jurisdiction the study is taking place in);

          2. Patients with histologically confirmed estrogen receptor positive (ER+) breast cancer.
             ER is considered positive if a percentage score of ≥10% of tumour cells staining
             positive for ER;

          3. Histological confirmation of HER2 negative breast cancer on primary tumour at
             diagnosis or on biopsy of a metastasis. HER2 negative is defined by the ASCO/CAP
             guidelines;

          4. Patients with clinical or histological confirmation of metastatic or locally advanced
             disease not amenable to curative surgical resection;

          5. Patients must have at least one site of measurable disease, defined as at least one
             lesion that can be accurately measured in at least one dimension (longest diameter to
             be recorded) ≥ 10 mm with spiral CT scan or MRI scan (malignant lymph nodes should be
             ≥15mm to be considered measurable); all sites of disease should be noted and followed
             in accordance with RECIST v1.1. (A lytic or mixed lytic-blastic bone lesion with a
             soft tissue component assessed on CT/MRI can be measurable if the minimum size
             criteria are met. Blastic bone lesions and bone lesions assessed on bone scan,
             positron emission therapy (PET) or plain films are non-measurable);

          6. Patients must have an anticipated life expectancy of at least 12 weeks;

          7. Adequate bone marrow, renal and hepatic function defined as:

               -  Haemoglobin > 9 g/dL;

               -  Absolute neutrophil count > 1.0 x 109/L;

               -  Platelets > 100 x 109/L;

               -  Total bilirubin within normal limits, except those with Gilberts syndrome for
                  whom this must be <2.5 x ULN;

               -  AST(SGOT) or ALT(SGPT) < 2.5 x ULN;

               -  Calculated creatinine clearance > 30 ml/min (Appendix 2);

          8. Eastern Cooperative Oncology Group (ECOG) performance status < 2;

          9. Must currently be on either a third generation aromatase inhibitor, tamoxifen or
             fulvestrant and have a documented evidence of progressive disease after:

               1. taking ET as adjuvant therapy for >2 years or

               2. achieving a best response of stable disease (for at least 6 months) or an
                  objective response of CR or PR on the current treatment both indicating the
                  development of secondary resistance to current therapy;

         10. Suitable for continuing endocrine therapy according to the treating clinician. The
             window of discontinuation must not exceed 4 weeks.

         11. All patients (or their legally acceptable representatives) must have signed an
             informed consent document indicating that they understand the purpose of and
             procedures required for the study and are willing to participate in the study.

         12. No more than 3 lines of endocrine therapy for metastatic/locally advanced breast
             cancer including the treatment that the patient is receiving at the time of study
             entry. This can include targeted agents alongside endocrine therapy such as, but not
             limited to, everolimus and palbociclib. Ovarian function suppression therapy is not an
             exclusion for females who are premenopausal and on an ET that can be continued
             throughout the study.

         13. No more than one prior line of chemotherapy/targeted therapy for metastatic/locally
             advanced breast cancer.

         14. Patients with adequately controlled hepatitis C or hepatitis B surface antigen.

         15. No residual toxicity > grade 1 from prior antineoplastic therapy with the exception of
             peripheral neuropathy or neuropathic pain which must be stable (as per investigator
             assessment);

         16. Sexually active male and female patients of childbearing potential must agree to use
             an effective method of birth control (e.g., barrier methods with spermicides, oral or
             parenteral contraceptives and/or intrauterine devices) during the entire duration of
             the study and for 6 months after final administration of study drug. Note that
             sterility in female patients must be confirmed in the patients' medical records and be
             defined as any of the following: surgical hysterectomy or bilateral oophorectomy,
             bilateral tubular ligation, natural menopause with last menses >1 year ago; radiation
             induced oophorectomy with last menses >1 year ago; chemotherapy induced menopause with
             1 year interval since last menses; male patients whose female partner(s) is (are)
             pregnant must use a condom from the time of the first administration of SFX-01 until 3
             months following administration of last dose;

         17. Female patients of childbearing potential must have a negative serum or urine
             pregnancy test at day 1 of the study.

        Exclusion Criteria:

          1. Rapidly progressive visceral disease not suitable for further endocrine therapy;

          2. Currently on chemotherapy or any other combination treatment for their MBC other than
             AI, tamoxifen or fulvestrant;

          3. Radiotherapy less than 2 weeks prior to study entry;

          4. Major surgery (excluding placement of vascular access) within 4 weeks before the first
             dose of study treatment;

          5. Spinal cord compression or brain metastases unless treated and radiologically stable
             for > 6weeks post treatment and not requiring steroids for at least 4 weeks prior to
             start of study treatment;

          6. As judged by the Investigator, any evidence of severe or uncontrolled systemic
             diseases, including active infection including hepatitis B, hepatitis C and human
             immunodeficiency virus (HIV). Screening for chronic conditions is not required;

          7. Refractory nausea and vomiting, patients with malabsorption syndrome, diseases
             significantly affecting gastrointestinal function, resection of the stomach or small
             bowel, or difficulty in swallowing and retaining oral medications;

          8. An existing serious disease, illness, or condition that will prevent participation or
             compliance with study procedures;

          9. Patients with unresolved or unstable serious toxicity from prior administration of
             another investigational drug and/or prior cancer treatment;

         10. Diagnosed or treated for a malignancy other than breast cancer within 1 year, or who
             were previously diagnosed with a malignancy other than breast cancer and have any
             radiographic or biochemical marker evidence of malignancy. Patients with completely
             resected basal cell carcinoma, squamous cell carcinoma of the skin, or in situ
             malignancy (other than breast) are not excluded.

         11. Concurrent treatment with another investigational agent or participated in another
             investigational trial unless adequate washout period per the investigational drug PK
             has been achieved (usually this is 5 half lives of a product);

         12. Females who are pregnant, wishing to become pregnant or breast feeding.
      "
NCT02974803,terminated,"
    very slow accrual
  ",0,phase 2,"['melanoma', 'brain metastases']","[""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']""]","['dabrafenib', 'trametinib']","['CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F', 'CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5']","
        Inclusion Criteria:

          -  Histologically confirmed melanoma metastatic to brain and determined to be BRAF V600
             mutated.

          -  Age ≥ 18 years.

          -  Karnofsky Performance Status of 70-100 (Appendix I).

          -  Patients must have a life expectancy of at least 12 weeks.

          -  Presence of measurable disease (i.e. present with at least one measurable CNS lesion
             per RECIST 1.1).

          -  Presence of 1-10 brain metastases as confirmed on a thin slice axial T1
             post-gadolinium MRI sequence. The maximum diameter of a single brain lesion should be
             ≤ 4 cm and presence of a measurable lesion ≥ 1cm based on baseline MRI of brain.

          -  All CNS metastases amenable to single fraction SRS and or fractionated SRS.
             Hemorrhagic lesions are allowed if the treating radiation oncologist deems the lesion
             amenable to focal SRS.

          -  Able to swallow and retain oral medication and must not have any clinically
             significant gastrointestinal abnormalities that may alter absorption such as
             malabsorption syndrome or major resection of the stomach or bowels.

          -  Laboratory requirements (within 14 days prior to registration):

               -  ANC ≥ 1.2 x 10^9/L

               -  Hemoglobin ≥ 90 g/L

               -  Platelet count ≥ 100 x 10^9/L

               -  PT/INR & PTT ≤ 1.3 x ULN

               -  Total bilirubin ≤ 1.5 x ULN

               -  AST and ALT ≤ 2.5 x ULN

               -  Serum creatinine or ≤ 1.5 x ULN or Creatinine Clearance ≥ 50 ml/min (calculated
                  by Cockcroft and Gault)

               -  LVEF ≥ LLN (within 28 days prior to registration)

               -  No prior treatment with a BRAF inhibitor or MEK inhibitor.

               -  No known ocular or primary mucosal melanoma.

               -  No prior systemic anti-cancer treatment within the last 2 weeks preceding the
                  frist dose of dabrafenib and trametinib. Patients must have recoved from clinical
                  manifestations of toxicity related to prior systemic therapy and have adequate
                  washout as follows: Longest of one of the following:

                    -  two weeks

                    -  5 half-lives for investigational agents

                    -  Standard cycle length of standard therapies

               -  Prior systemic treatment in the adjuvant setting is allowed.

               -  No current use of a prohibited medication as described in section 7.2.

               -  No history of malignancy with confirmed activating RAS mutation at any time.

               -  No history of malignancy other than disease under study within 3 years of study
                  enrollment.

               -  No leptomeningeal metastases or metastases causing spinal cord compression that
                  are symptomatic or untreated or not stable for ≥ 3 months. Subjects on stable
                  dose of corticosteroids > 2 weeks or who have been off of corticosteroids for at
                  least 2 weeks can be enrolled with approval of CCTG.

               -  No serious or unstable pre-existing medical conditions, psychiatric disorders or
                  other conditions that could interfere with the subject's safety, obtaining
                  informed consent or compliance with study procedures.

               -  No history of Hepatitis B Virus or Hepatitis C Virus infection

               -  No history or evidence of cardiovascular risk No history or current
                  eveidence/risk of retinal vein occlusion or central serous retinopathy

               -  No known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
                  chemically related to the study treatments, their excipients, and/or dimethyl
                  sulfoxide.

               -  No pregnant or lactating women.

               -  No hisotry of interstitial lung disease or active pneumonitis.

               -  Presence of any one brain metastases >4cm in maximal diameter, and/or presence of
                  brain metastase of less than 1cm.

               -  No prior whole brain radiation

               -  No brainstem metastses

               -  No contrindications to MRI and/or Gadolinimum contrast or sterotactic brain
                  radiation therapy.
      "
NCT02849990,completed,,0,phase 2,"['stage iii prostate adenocarcinoma ajcc v7', 'stage iii prostate cancer ajcc v7', 'stage iv prostate adenocarcinoma ajcc v7', 'stage iv prostate cancer ajcc v7']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]","['abiraterone acetate', 'apalutamide', 'degarelix', 'indomethacin', 'prednisone']","['CC(=O)OC1CCC2(C3CCC4(C(C3CC=C2C1)CC=C4C5=CN=CC=C5)C)C', 'CNC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CC(=C(N=C4)C#N)C(F)(F)F)F', 'CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)NC(=O)N)NC(=O)C(CC3=CC=C(C=C3)NC(=O)C4CC(=O)NC(=O)N4)NC(=O)C(CO)NC(=O)C(CC5=CN=CC=C5)NC(=O)C(CC6=CC=C(C=C6)Cl)NC(=O)C(CC7=CC8=CC=CC=C8C=C7)NC(=O)C', 'CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O', 'CC12CC(=O)C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C']","
        Inclusion Criteria:

          -  Willing and able to provide written informed consent

          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 2

          -  Documented histologically confirmed adenocarcinoma of the prostate

          -  Willing to undergo prostatectomy as primary treatment for localized prostate cancer

          -  High risk prostate cancer (per National Comprehensive Cancer Network [NCCN] criteria):
             Gleason score 8-10 or T3a or PSA > 20 ng/mL or very-high risk prostate cancer (per
             NCCN criteria): T3b-T4

          -  Serum testosterone >= 150 ng/dL

          -  Able to swallow the study drugs whole

          -  Willing to take abiraterone acetate on an empty stomach (no food should be consumed at
             least two hours before and for one hour after dosing)

          -  Agrees to use a condom (even men with vasectomies) and another effective method of
             birth control if he is having sex with a woman of childbearing potential or agrees to
             use a condom if he is having sex with a woman who is pregnant while on study drug and
             for 3 months following the last dose of study drug; must also agree not to donate
             sperm during the study and for 3 months after receiving the last dose of study drug

          -  Medications known to lower the seizure threshold (see list under prohibited meds) must
             be discontinued or substituted at least 4 weeks prior to study entry

        Exclusion Criteria:

          -  Prior local therapy to treat prostate cancer (e.g. radical prostatectomy, radiation
             therapy, brachytherapy)

          -  Prior use of apalutamide, abiraterone acetate or degarelix

          -  Prior or ongoing systemic therapy for prostate cancer including, but not limited to:

               -  Hormonal therapy (for example [e.g.] leuprolide, goserelin, triptorelin,
                  degarelix)

               -  Cytochrome P450 (CYP)-17 inhibitors (e.g. ketoconazole)

               -  Antiandrogens (e.g. bicalutamide, nilutamide)

               -  Second generation antiandrogens (e.g. enzalutamide, apalutamide)

               -  Immunotherapy (e.g. sipuleucel-T, ipilimumab)

               -  Chemotherapy (e.g. docetaxel, cabazitaxel)

          -  Evidence of serious and/or unstable pre-existing medical, psychiatric or other
             condition (including laboratory abnormalities) that could interfere with patient
             safety or provision of informed consent to participate in this study

          -  Any psychological, familial, sociological, or geographical condition that could
             potentially interfere with compliance with the study protocol and follow-up schedule

          -  Absolute neutrophil count [ANC] < 1500/mm^3

          -  Platelet count < 100,000/mm^3

          -  Hemoglobin < 9 g/dL

          -  Total bilirubin > 1.5 x upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >= 2.5 x ULN; Note:
             in subjects with Gilbert's syndrome, if total bilirubin is > 1.5 x ULN, measure direct
             and indirect bilirubin and if direct bilirubin is =< 1.5 x ULN, subject may be
             eligible

          -  Abnormal kidney function (glomerular filtration rate GFR < 45 mL/min)

          -  Serum albumin < 3 g/dL

          -  Serum potassium < 3.5 mmol/L

          -  Seizure or known condition that may pre-dispose to seizure (e.g. prior stroke within 1
             year to randomization, brain arteriovenous malformation, schwannoma, meningioma, or
             other benign central nervous system [CNS] or meningeal disease which may require
             treatment with surgery or radiation therapy)

          -  Severe or unstable angina, myocardial infarction, symptomatic congestive heart
             failure, arterial or venous thromboembolic events (eg, pulmonary embolism,
             cerebrovascular accident including transient ischemic attacks), or clinically
             significant ventricular arrhythmias within 6 months prior to randomization

          -  History of stroke within the last 5-years

          -  History of gastrointestinal (GI) bleed requiring transfusion

          -  History of peptic ulcer disease requiring treatment within the last 5-years

          -  History of asthma that is nonsteroidal anti-inflammatory drug (NSAID)-induced or with
             asthma that is classified as 'mild-persistent' or worse (based on symptoms occurring
             more than 2 days per week)

          -  Uncontrolled hypertension

          -  Gastrointestinal disorder affecting absorption

          -  Active infection (eg, human immunodeficiency virus [HIV] or viral hepatitis)

          -  Any chronic medical condition requiring a higher dose of corticosteroid than 10 mg
             prednisone/ prednisolone once daily

          -  Any condition that in the opinion of the investigator, would preclude participation in
             this study

          -  Child Pugh class B & C

          -  Pre-existing viral hepatitis
      "
NCT02844582,terminated,"
    poor accrual of subjects onto study
  ",0,phase 2,"['hormone-resistant prostate cancer', 'stage iv prostate adenocarcinoma']","[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['cabazitaxel', 'prednisone']","['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC)C)OC', 'CC12CC(=O)C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C']","
        Inclusion Criteria:

          -  Histologically confirmed prostate adenocarcinoma

          -  Metastatic disease

          -  Able and willing to provide informed consent and to comply with the study procedures

          -  Castration resistant disease defined as evidence of radiological and/or prostate
             specific antigen (PSA) progression despite castrate levels of testosterone (serum
             testosterone < 50 ng/dL [1.7 nmol/L]); for PSA progression, there must be at least 2
             sequential rises at a minimum of 1-week intervals; the first PSA value must be >= 4
             (Prostate Cancer Working Group 2 [PCWG2] criteria)

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  At least 21 days have passed since completing radiotherapy (exception for
             radiotherapy: at least 7 days since completing a single fraction of =< 800 cGy to a
             restricted field or limited-field radiotherapy to non-marrow bearing area such as an
             extremity or orbit) at the time of registration

          -  At least 21 days have passed since receiving any investigational agent at the time of
             registration

          -  At least 21 days have passed since major surgery

          -  Neuropathy =< grade 1 at the time of registration

          -  Has recovered from all therapy-related toxicity to =< grade 2 (except alopecia, anemia
             and any signs or symptoms of androgen deprivation therapy) at the time of registration

          -  Poor prognosis disease as defined by any of the following:

               -  PSA nadir >=4.0, or

               -  Gleason score 8-10, or

               -  Time from ADT initiation to CRPC of =< 16 months

          -  Hemoglobin >= 90 g/L

          -  Neutrophils >= 1.5 x 10^9 /L

          -  Platelets >= 100 x 10^9/L

          -  Aspartate aminotransferase (AST) < 1.5 x upper limit of normal (ULN)

          -  Alanine aminotransferase (ALT) < 1.5 x ULN

          -  Bilirubin =< 1.0 x ULN (exceptions for Gilbert's syndrome)

          -  Creatinine =< 1.5 x ULN

        Exclusion Criteria:

          -  Prior therapy with cabazitaxel or to other drugs formulated with polysorbate 80

          -  Prior taxanes for CRPC

          -  Prior enzalutamide, abiraterone or ketoconazole

          -  Other condition, illness, psychiatric condition, or laboratory abnormality that may
             increase the risk associated with administration of cabazitaxel, study participation,
             or may interfere with the interpretation of study results and in the judgment of the
             investigator would make the patient inappropriate for entry into this study

          -  Histologic evidence of small cell/neuroendocrine prostate cancer

          -  Patients with reproductive potential who do not agree to use accepted and effective
             method of contraception during the study treatment period and up to 6 months after the
             last administered dose; the definition of ""effective method of contraception"" will be
             based on the investigator's judgment
      "
NCT02842580,terminated,"
    inclusion rythm too slow.
  ",0,phase 2,['colorectal neoplasms'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['5 fluorouracyl', 'acide folinique', 'irinotecan', 'oxaliplatin', 'capécitabine', 'bevacizumab']","['C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O', 'CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7', 'C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]']","
        Inclusion Criteria:

          -  Metastatic colorectal cancer, histologically proven (on primary tumour and/or
             metastases)

          -  Unresectable and non-pretreated metastases

          -  BRAF wild-type

          -  Patient considered able to receive 3 lines of chemotherapy

          -  At least one measurable target lesion > 1 cm according to RECIST 1.1 (Appendix 4)

          -  Tumour assessment according to RECIST, performed 4 weeks or less prior to
             randomization

          -  Age ≥ 18 years

          -  WHO performance status ≤ 2 (Appendix 5)

          -  No major surgery within 4 weeks prior to randomisation. Wound healing must be complete

          -  Life expectancy greater than 3 months

          -  Laboratory tests: Neutrophils ≥ 1500/mm3, platelets ≥ 100,000/mm3, haemoglobin > 9
             g/dL

          -  Creatinine clearance > 30 mL /min (capecitabine dose modification if the creatinine
             clearance < 30-50 mL/min), serum creatinine < 1.25 x ULN

          -  Liver function tests: bilirubin < 1.25 x ULN, AST/ALT < 5 x ULN

          -  Women of childbearing age and men (who have sexual relations with women of
             childbearing age) must agree to use effective contraception without interruption
             throughout the duration of treatment and for 6 months after the last administration

          -  Signed informed consent

        Exclusion Criteria:

          -  Patient with a potentially resectable colorectal cancer; i.e. for whom the goal of
             chemotherapy would be to make all metastases resectable

          -  Patients with symptomatic metastases

          -  Patient with aggressive disease and a large tumour volume

          -  Active gastroduodenal ulcer, wound or bone fracture

          -  At least one of the following laboratory values: Neutrophils <1500/mm3, platelets <
             100,000/mm3, haemoglobin < 9 g/dL, total bilirubin > 1.5 N, alkaline phosphatase > 2.5
             N (or > 5 N in case of hepatic involvement), serum creatinine > 1.5 N, 24 hr
             proteinuria > 1 g

          -  Chronic inflammatory bowel disease, extensive resection of the small bowel

          -  Clinically significant coronary artery disease or a history of myocardial infraction
             within the last 6 months. Uncontrolled hypertension while receiving chronic medication

          -  Abdominal or major extra-abdominal surgical procedure (except diagnostic biopsy) or
             radiation within 4 weeks before starting treatment

          -  Previous treatment with an anti-angiogenic or irinotecan

          -  Known or suspected central nervous system metastasis CNS metastases, or suspected CNS
             metastases

          -  Other previous malignancies within 5 years, except for basal cell carcinoma of the
             skin or pre-invasive carcinoma of the cervix - Peritoneal macro-nodular carcinomatosis

          -  History of haemoptysis ≥ grade 2 (defined as ≥ 2.5 mL of bright red blood per episode)
             in the month prior to inclusion

          -  Known hypersensitivity to any component of bevacizumab or to one of the study
             treatments

          -  Active infection requiring intravenous antibiotics at start of treatment

          -  History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess or
             active gastrointestinal bleeding within 6 months prior to treatment start

          -  Pregnant or breastfeeding women

          -  Concomitant participation in another clinical study involving a drug during the
             treatment phase and 30 days before starting the study treatment

          -  Patient unable to undergo medical treatment for geographical, social, psychological or
             legal reasons.
      "
NCT02845050,withdrawn,"
    no participants found
  ",0,phase 1/phase 2,['bladder cancer'],"[""['D30.3', 'C67.5', 'C67.9', 'C79.11', 'C67.0', 'C67.1', 'D41.4']""]","['vinflunine', 'cisplatin']","['CCC12C=CCN3C1C4(CC3)C(C(C2OC(=O)C)(C(=O)OC)O)N(C5=CC(=C(C=C45)C6(CC7CC(CN(C7)CC8=C6NC9=CC=CC=C89)C(C)(F)F)C(=O)OC)OC)C', 'N.N.Cl[Pt]Cl']","
        Inclusion Criteria:

          1. Male or female patients aged ≥ 18 years and ≤ 75 years with legal capacity

          2. Signed written informed consent

          3. Histologically confirmed muscle-invasive urothelial cell carcinoma of the bladder
             (MIBC) with clinical T2-T4a (N0/Nx, M0) assessed by primary PDD-guided TUR-B and by
             the screening imaging (MRI pelvis and CT chest/abdomen) which both must include the
             use of contrast medium

          4. Confirmed adequate complete resection of all visible tumor during TUR-B according to
             current treatment guidelines before registration; the latest TUR-B must have been done
             ≤ 8 weeks before registration

          5. ECOG performance status of 0 or 1

          6. Adequate bone marrow, renal and hepatic functions as evidenced by the following:

               -  Absolute Neutrophil Count ≥ 2,000 mm3 and ≤ 7,500 mm3

               -  Hemoglobin ≥ 12 g/dL for the safety phase of the study; if the study treatment
                  proved to be adequate tolerated during this safety phase, the threshold can be
                  lowered to ≥ 10 g/dL according to the decision of the study steering committee

               -  Platelet count ≥ 100,000 mm3

               -  Serum albumin within normal range

               -  Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN)

               -  Transaminases (ALT, AST) ≤ 1.5 x ULN

               -  Creatinine clearance ≥ 60 mL/min, calculated based on a 24h-measured creatinine
                  clearance

               -  Serum Urea < 25 mg/100 ml

          7. Absence of psychological, familial, sociological or geographical condition potentially
             hampering compliance with the study protocol and follow-up schedule; these conditions
             should be assessed with the patient before registration

          8. Electrocardiogram (ECG) without modifications that suggest a high risk of occurrence
             of an acute clinical event (such as signs of angina pectoris or high-risk arrhythmia,
             etc.); cardiologist consultation is required, if relevant abnormalities are observed
             in the screening ECG-assessment

        Exclusion Criteria:

          1. Prior systemic chemotherapy for any kind of malignancy; prior intravesical
             chemotherapy or treatment with BCG is allowed

          2. Prior radiation of the pelvis or any prior radiation to ≥ 30 % of the bone marrow

          3. Evidence of lymph node (N+) or distant metastasis (M1) in the screening imaging
             assessment, including known brain metastases or leptomeningeal involvement (however,
             brain-MRI-scans are not required to rule out CNS-involvement, unless there is clinical
             suspicion of central nervous system (CNS) disease)

          4. Any contraindication with regard to contrasted imaging (MRI or CT)

          5. Other malignancies except adequately treated basal carcinoma of the skin, localized
             prostate cancer Gleason ≤ 6, in-situ cervix carcinoma or any other tumor with a
             disease free interval ≥ 5 years

          6. Peripheral neuropathy Grade ≥ 2 NCI CTCAE v4.03 or hearing impairment Grade ≥ 2 NCI
             CTCAE v.4.03

          7. Any concurrent chronic system immune therapy or previous organ allograft

          8. Weight loss > 5 % within the last 3 months before registration

          9. Any other serious illness or medical condition including:

               -  Infection requiring systemic anti-infective therapy within the last 2 weeks
                  before registration

               -  History of cardio-vascular disease that might compromise the safe administration
                  of cisplatin

               -  Dehydration requiring IV fluid substitution

               -  Any medical condition that might not be controlled, e.g. patients with unstable
                  angina pectoris, myocardial infarction < 6 months before registration or
                  uncontrolled diabetes, congestive cardiac failure > NYHA grade I

         10. Known hypersensitivity to the study drugs or to drugs with similar chemical structures

         11. Treatment with any potent CYP3A4 inhibitor or inductor (e.g. ketoconazole,
             itraconazole, ritonavir, amprenavir, indinavir, rifampicine) or phenytoine;
             replacement of such treatment with alternative treatment options before start of study
             treatment is acceptable, if medically feasible and ethically acceptable

         12. 12. Treatment with any medication that is known to prolong the QT/QTc interval and/or
             to cause Torsades de Pointes (e.g. azithromycine, amitryptiline, imipramine,
             clozapine, flu-ox¬etine, cisapride); replacement of such treatment with alter¬na¬ti¬ve
             options before start of study treatment is acceptable, if medically feasible and
             ethically acceptable

         13. Treatment with hexamethylmelamin, pyridoxine, penicillamine or any other drug with
             known potential to affect the efficacy of cisplatin

         14. Treatment with any other investigational or anti-cancer therapy ≤ 30 days before
             registration

         15. Pregnant or lactating female patients or female patients of childbearing potential
             with positive pregnancy test at screening

         16. Women of child-bearing potential who are unwilling or unable to use an acceptable
             method to avoid pregnancy for the entire study period and for up to 6 months after the
             study

         17. Sexually active fertile men, who are unwilling or unable to use an effective birth
             control from day of informed consent and for up to 6 months after the last cycle of
             chemotherapy, if their partners are women of child-bearing potential (if cystectomy is
             not performed) effective birth control means the use of condoms ideally combined with
             any acceptable contraception of the male patient's partner as described in exclusion
             criterion 16
      "
NCT02846987,"active, not recruiting",,1,phase 2,"['sarcoma', 'dedifferentiated liposarcoma']","[""['C96.A', 'C46.9', 'C96.22', 'C46.0', 'C46.2', 'C92.31', 'C92.32']""]",['abemaciclib'],['CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F'],"
        Inclusion Criteria:

          -  A diagnosis of dedifferentiated liposarcoma confirmed at MSKCC.

          -  Metastatic and/or locally advanced or locally recurrent disease that is not surgically
             resectable.

          -  All patients must have measurable disease as defined by RECIST 1.1. Patients must also
             have evidence of disease progression by RECIST 1.1 within 6 months of first dose of
             study drug.

          -  Any number of prior therapies (including none) is permitted. The last dose of systemic
             therapy (include targeted therapies) must have been given at least 2 4 weeks prior to
             initiation of therapy. Patients receiving BCNU or mitomycin C must have received their
             last dose of such therapy at least 6 weeks prior to initiation of therapy.

          -  Patients with brain metastasis that have been treated with definitive surgery or
             radiation and have been clinically stable for 3 months are eligible.

          -  Age ≥ 18 years.

          -  ECOG performance status 0 or 1

          -  Adequate organ and marrow function as defined below (ULN indicates institutional upper
             limit of normal):

          -  Absolute neutrophil count ≥ 1.510^9/L

          -  Hemoglobin ≥ 8.0 g/dL

          -  WBC ≥ 3.0 x 10^9/L

          -  Platelets ≥ 100 x 10^9/L

          -  Total bilirubin ≤ 1.5 x ULN except for patients with known Gilbert syndrome

          -  AST(SGOT)/ALT(SGPT) ≤ 3 x institutional ULN

          -  Creatinine ≤ 1.5 x ULN or Creatinine Clearance > 50 mL/min (calculated by
             Cockcroft-Gault method)

          -  Patients must not have current evidence of another malignancy that requires treatment.

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence). Women must not breast feed
             while on study.

          -  Ability to understand and the willingness to sign a written informed consent document.

          -  Ability to swallow capsules

        Exclusion Criteria:

          -  Patients who have not recovered from adverse events of prior therapy to ≤ NCI
             CTCAEv4.0 Grade 1.

          -  Patients receiving any other investigational agents.

          -  Patients who have received prior treatment with a selective CDK4 inhibitor

          -  Uncontrolled intercurrent illness including, but not limited to, known ongoing or
             active infection, including HIV, active hepatitis B or C, symptomatic congestive heart
             failure, unstable angina pectoris, cardiac arrhythmia (specifically, atrial
             fibrillation or ventricular dysrhythmias except ventricular premature contractions),
             or psychiatric illness/social situations that would limit compliance with study
             requirements.

          -  Pregnant women and women who are breast-feeding.
      "
NCT03206918,completed,,1,phase 2,"['relapsed or refractory chronic lymphocytic leukemia', 'relapsed or refractory small lymphocytic lymphoma']","[""['A87.2', 'K52.832', 'D72.111', 'C91.11', 'C91.12', 'C91.10']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']""]",['zanubrutinib'],['C=CC(=O)N1CCC(CC1)C2CCNC3=C(C(=NN23)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=O)N'],"
        Key Inclusion Criteria:

          1. Confirmed diagnosis with at least one criterion for treatment according to
             International workshop on chronic lymphocytic leukemia (IWCLL)

          2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          3. Measurable disease by contrast enhanced computerized tomography / magnetic resonance
             imaging (CT/MRI).

          4. Previously treated with a minimum of 1 prior line of standard chemotherapy-containing
             regimen (with completion of ≥2 treatment cycles).

          5. Documented failure to achieve at least partial response (PR) or documented disease
             progression after response to the most recent treatment regimen. Refractory disease is
             defined as treatment failure (stable disease, non-response, progressive disease [PD])
             or disease progression within 6 months after the most recent prior therapy (Hallek et
             al, 2008).

          6. Neutrophils ≥ 0.75 x 109/L independent of growth factor support within 7 days of study
             entry

          7. Platelets ≥ 50 x 109/L, independent of growth factor support or transfusion within 7
             days of study entry

          8. Creatinine clearance of ≥ 30 ml/min (as estimated by the Cockcroft-Gault equation or
             estimated glomerular filtration rate [eGFR] from the Modification of Diet in Renal
             Disease [MDRD])

          9. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 x ULN

         10. Bilirubin ≤2 x ULN (unless documented Gilbert's syndrome)

         11. International normalized ratio (INR) ≤1.5 and activated partial thromboplastin time
             (APTT) ≤1.5 x ULN.

         12. Participants may be enrolled who relapse after autologous stem cell transplant if they
             are at least 6 months after transplant.

         13. Life expectancy of >4 months

         14. Echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) ≥50%;
             (AHA, 2016)

        Key Exclusion Criteria:

          1. Current or history of central nervous system (CNS) lymphoma

          2. Prior exposure to a Bruton's tyrosine kinase (BTK) inhibitor

          3. Prior corticosteroids given in excess of prednisone 10 mg/day or its equivalent with
             antineoplastic intent within 7 days.

          4. Major surgery within 4 weeks of screening

          5. Not recovered from toxicity of any prior anti-cancer therapy to <Grade 1 (except for
             alopecia, absolute neutrophil count (ANC) and platelets.

          6. History of other active malignancies within 2 years of study entry, with exception of
             (1) adequately treated in-situ carcinoma of cervix; (2) localized basal cell or
             squamous cell carcinoma of skin; (3) previous malignancy confined and treated locally
             (surgery or other modality) with curative intent

          7. Currently active clinically significant cardiovascular disease

          8. QTcF >480 msecs based on Fridericia's formula or other significant electrocardiogram
             abnormalities including second degree atrioventricular (AV) block Type II, or third
             degree AV block

          9. Unable to swallow capsules or disease significantly affecting gastrointestinal
             function such as malabsorption syndrome, resection of the stomach or small bowel,
             symptomatic inflammatory bowel disease, or partial or complete bowel obstruction

         10. Active infection including infections requiring oral or intravenous anti-microbials

         11. Known human immunodeficiency virus (HIV), or active hepatitis B or hepatitis C
             infection (detected positive by polymerase chain reaction [PCR]).

         12. Has received allogenic hematopoietic stem cell transplantation prior to enrollment

         13. Any life-threatening illness, medical condition or organ system dysfunction which, in
             the investigator's opinion, could compromise the participants's safety, or put the
             study at risk

         14. Requires ongoing treatment with any medication which is a strong cytochrome P450,
             family 3, subfamily A (CYP3A) inhibitor or strong CYP3A inducer

         15. Known or clinically suspected Richter's transformation at the time of study entry

         16. History of stroke or intracranial hemorrhage within 6 months prior to enrollment

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      "
NCT03206749,completed,,1,phase 2,['acute pain'],"[""['G89.12', 'G89.18', 'G89.11', 'G89.3']""]","['vx-150', 'hb/apap', 'placebo']",['CC1=C(C=CC(=C1)F)OC2=C(C=CC(=C2)C(F)(F)F)C(=O)NC3=CC(=O)N(C=C3)COP(=O)(O)O'],"
        Inclusion Criteria:

        Prior to Surgery:

          -  Body mass index (BMI) of 18.0 to 38.0 kg/m2, inclusive

          -  Be scheduled to undergo a primary unilateral first metatarsal bunionectomy repair,
             without collateral procedures, under regional anesthesia (Mayo and popliteal sciatic
             block) not to include base wedge procedure

        After Surgery:

          -  Subject reported pain of ≥4 on the NPRS, and moderate or severe pain on the Verbal
             Categorical Rating Scale (VRS) within 9 hours after removal of the popliteal sciatic
             block on Day 1

          -  Subject is lucid and able to follow commands

          -  All analgesic guidelines were followed during and after the bunionectomy

        Exclusion Criteria:

        Prior to Surgery:

          -  History in the past 10 years of malignancy, except for squamous cell skin cancer,
             basal cell skin cancer, and Stage 0 cervical carcinoma in situ

          -  History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s)

          -  History of abnormal laboratory results ≥2.5 × upper limit of normal (ULN)

          -  History of peripheral neuropathy

          -  A known or clinically suspected infection with human immunodeficiency virus or
             hepatitis B or C viruses

          -  Prior medical history of bunionectomy or other foot surgery

          -  Intolerant of or unwilling to receive hydrocodone, acetaminophen, or ibuprofen

          -  For female subjects: Pregnant, nursing, or planning to become pregnant during the
             study or within 90 days after the last study drug dose

          -  For male subjects: Male subjects with a female partner who is pregnant, nursing, or
             planning to become pregnant during the study or within 90 days after the last study
             drug dose

        After Surgery:

          -  Subject had a type 3 deformity requiring a base wedge osteotomy or concomitant surgery
             such as hammertoe repair; or experienced medical complications during the bunionectomy
             that, in the opinion of the investigator, should preclude randomization

        Other protocol defined inclusion/exclusion criteria may apply.
      "
NCT01930864,unknown status,,1,phase 2,"['colorectal neoplasms', 'adenocarcinoma']","[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['metformin', 'irinotecan']","['Status: 503', 'CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7']","
        Inclusion Criteria:

          -  18 years or older

          -  Biopsy-proven colorectal adenocarcinoma

          -  Ineligibility for curative intent therapy, e.g., surgery or radiation

          -  Disease progression after oxaliplatin (either adjuvant or palliative),
             fluoropyrimidine (either adjuvant or palliative), irinotecan, and if Kras wild type a
             anti-EGFR therapy

          -  Assessable disease according to RECIST v1.1

        Exclusion Criteria:

          -  known hypersensitivity to metformin or irinotecan

          -  Uncontrolled Central nervous system metastasis

          -  Acute or chronic severe infection
      "
NCT03614065,unknown status,,1,phase 2,['non-small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['endostar', 'placebos']",['CN(CC(=O)C1=CC=CC=C1)N=O'],"
        Inclusion Criteria:

          -  NSCLC Brain metastasis

        Exclusion Criteria:

          -  KPS<60
      "
NCT02178241,completed,,1,phase 2,"['metastatic ureter carcinoma', 'metastatic urethral carcinoma', 'stage iii bladder urothelial carcinoma ajcc v6 and v7', 'stage iii ureter cancer ajcc v7', 'stage iii urethral cancer ajcc v7', 'stage iv bladder urothelial carcinoma ajcc v7', 'stage iv ureter cancer ajcc v7', 'stage iv urethral cancer ajcc v7', 'ureter urothelial carcinoma', 'urethral urothelial carcinoma']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C66.1', 'C66.2', 'C66.9', 'D30.20', 'D30.21', 'D30.22', 'D41.20']"", ""['N34.0', 'N36.0', 'N36.1', 'N36.2', 'N34.3', 'N36.5', 'N36.9']""]","['eribulin mesylate', 'gemcitabine hydrochloride']","['CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O2)OC(C9OC)CC(CN)O.CS(=O)(=O)O', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F.Cl']","
        Inclusion Criteria:

          -  Patients must have locally advanced or metastatic predominantly urothelial carcinoma
             of the bladder, ureter, or urethra that is not amenable to curative surgical treatment

          -  Patients must have histologically confirmed predominantly urothelial carcinoma of the
             bladder, ureter, or urethra

          -  Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors
             (RECIST) criteria, defined as at least one lesion that can be accurately measured in
             at least one dimension (longest diameter to be recorded for non-nodal lesions and
             short axis for nodal lesions) as >= 20 mm with conventional techniques or as >= 10 mm
             with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or
             calipers by clinical exam

          -  Patients must be ineligible for treatment with cisplatin, based on one of:

               -  Calculated creatinine clearance (CrCl) >= 30 and < 60 mL/min (Cockcroft-Gault)

               -  CTCAE grade (Gr) >= 2 hearing loss

               -  CTCAE Gr >= 2 neuropathy

          -  Patients must not have received prior systemic therapy for their advanced cancer;
             prior intravesical therapy completed 4 weeks prior to enrollment and
             adjuvant/neoadjuvant chemotherapy completed more than 6 months prior to diagnosis of
             advanced disease are permitted

          -  Zubrod performance status =< 2 (Karnofsky >= 60%)

          -  Life expectancy of greater than 3 months

          -  Leukocytes >= 3,000/mcL

          -  Absolute neutrophil count >= 1,500/mcL

          -  Platelets >= 100,000/mcL

          -  Total bilirubin < 1.5 times the upper limit of normal (x ULN) for the institution

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =< 3 x institutional upper limit of normal

          -  Creatinine clearance; calculated creatinine clearance (CrCl) >= 30 mL/min and < 60
             mL/min (Cockroft-Gault) unless the patient qualified based on hearing loss or
             neuropathy

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for
             the duration of study participation; should a woman become pregnant or suspect she is
             pregnant while she or her partner is participating in this study, she should inform
             her treating physician immediately; men treated or enrolled on this protocol must also
             agree to use adequate contraception prior to the study, for the duration of study
             participation, and 4 months after completion of gemcitabine and eribulin
             administration

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients with a small cell component in their histology are excluded

          -  Patients who have had chemotherapy for the treatment of the advanced or unresectable
             urothelial cancer of the bladder are not eligible; patients who were previously
             treated for local disease must not have received radiotherapy or chemotherapy within 4
             weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study and must
             have recovered from adverse events due to agents administered more than 4 weeks
             earlier; patients who have received neoadjuvant or adjuvant chemotherapy must have
             completed treatment at least 6 months prior to diagnosis of metastatic disease

          -  Patients who are receiving any other investigational agents

          -  Patients with known brain metastases should be excluded from this clinical trial

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to gemcitabine and eribulin

          -  Uncontrolled intercurrent illness including, but not limited to, a second cancer
             diagnosis within the past 5 years, or a cancer undergoing any treatment, ongoing or
             active infection, symptomatic congestive heart failure, unstable angina pectoris,
             cardiac arrhythmia, or psychiatric illness/social situations that would limit
             compliance with study requirements

          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if
             the mother is treated with eribulin and gemcitabine

          -  Human immunodeficiency virus (HIV)-positive patients with inadequate cluster of
             differentiation (CD)4 counts or those who are on combination antiretroviral therapy
             with strong cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) effects are
             ineligible for this trial

          -  Patients with baseline corrected QT (QTc) prolongation greater than grade 1 are
             excluded from this study; patients with grade 1 QTc elevation are eligible but must be
             monitored with electrocardiogram (ECG) (EKG) exams, for the first 3 cycles of
             treatment; eribulin time to maximum concentration (Cmax) after infusion is about 10
             minutes, and half life is 40 minutes; ECG (EKG) should be performed between 10 to 40
             minutes after eribulin administration (on day 1 and day 8 of treatment); continued ECG
             (EKG) monitoring beyond cycle 3 can be done at the discretion of the treating
             physician

          -  Patients with congenital long QT syndrome are excluded from this study

          -  Other medications known to prolong QT interval should be discontinued and if not
             possible, patient is excluded from this study
      "
NCT02177695,completed,,0,phase 2,['bladder cancer'],"[""['D30.3', 'C67.5', 'C67.9', 'C79.11', 'C67.0', 'C67.1', 'D41.4']""]","['gemcitabine', 'cisplatin', 'methotrexate', 'vinblastine', 'doxorubicin', 'filgrastim']","['C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F', 'N.N.Cl[Pt]Cl', 'CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O', 'CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O', 'CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O']","
        Inclusion Criteria:

          -  Histologically proven bladder cancer (pure small cell carcinoma, pure adenocarcinoma,
             and pure squamous cell carcinoma histologies are excluded).

          -  Stage cT2-T4a N0 M0 disease.

          -  Documented muscle invasive disease with at least one of the following: disease
             measuring at least 10 mm on cross-sectional imaging OR the presence of
             tumor-associated hydronephrosis.

          -  Staging scans with abdominal/pelvic CT or MRI scan and CT scan or x-ray of the chest
             within 56 days prior to registration. If alkaline phosphatase is above the treating
             institution's upper limit of normal (ULN), presence of suspicious bone pain, or if
             other clinical suspicion, a whole body bone scan is required within 56 days prior to
             registration.

          -  Performance status = 0 or 1

          -  18 years of age or older

          -  Must have tumor tissue from transurethral resection of the bladder tumor (TURBT)
             available for submission that is sufficient for COXEN testing and must agree to
             submission of 20 (10 micron) slides plus 2 (5 micron) slides from the start and end of
             the 20 slides for a total of 22 unstained slides.

          -  Must agree to collection of tissue (if residual disease is present), urine, and whole
             blood.

          -  Must agree to participate in the translational medicine studies outlined in the
             protocol

        Exclusion Criteria:

          -  Prior systemic cytotoxic chemotherapy or systemic anthracycline

          -  Peripheral neuropathy >/= Grade 2

          -  Class III/IV heart failure or known left ventricular ejection fraction (LVEF) < 50%

          -  Clinically relevant hearing impairment > Grade 2

          -  Renal function, calculated creatinine clearance < 60 mL/min

          -  Hepatic function, total bilirubin > 1.5 x institutional upper limit of normal (IULN)
             (or > 2.5 x IULN with Gilbert's disease); AST & ALT > 2 X IULN

          -  Hematologic function, absolute neutrophil count (ANC) < 1,500/mcL, hemoglobin < 9
             g/dL, and platelets < 100,000/mcL

          -  Hypersensitivity to cisplatin, gemcitabine, doxorubicin, vinblastine, methotrexate, or
             filgrastim/pegfilgrastim

          -  Incidence of or uncontrolled medical illness (e.g. active cardiac symptoms, active
             systemic infection, etc.)

          -  Pregnant or nursing females

          -  No other prior malignancy is allowed except for the following: adequately treated
             basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated
             Stage I or II cancer from which the patient is currently in complete remission, or any
             other cancer from which the patient has been disease free for five years. However,
             patients with localized prostate cancer who are being followed by an active
             surveillance program are eligible.
      "
NCT02175654,terminated,"
    the trial was prematurely closed due to lack of accrual
  ",0,phase 2,"['colorectal neoplasms', 'metastatic disease']","[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]",['regorafenib'],['CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F'],"
        Inclusion Criteria:

          1. Signing of the informed consent form.

          2. The patient must be able to understand the information and state expressly his or her
             desire to take part in the study.

          3. Age ≥ 18 years.

          4. Histologically or cytologically documented adenocarcinoma of the colon or rectum.

          5. Patients with metastatic colorectal cancer (stage IV) with any RAS or BRAF mutation.

          6. To have received first_line treatment with bevacizumab in combination with
             chemotherapy with the three drugs 5FU/leucovorin (LV), irinotecan and oxaliplatin
             (FOLFOXIRI), and

               -  have had radiological progression of the disease during the first_line treatment,
                  or

               -  have had radiological progression of the disease within a period of ≤ 6 months
                  after the last dose of first-line treatment, or

               -  have discontinued part or all of the first_line treatment due to toxicity and
                  have had radiological progression of the disease within a period of ≤ 6 months
                  after the last dose of first-line treatment.

             The patient will have to have received at least one cycle of bevacizumab in
             combination with FOLFOXIRI + bevacizumab as part of the first_line treatment.

             Patients may have received fluoropyrimidine_based adjuvant treatment with or without
             oxaliplatin.

          7. Existence of at least one measurable unidimensional lesion using CT or MRI based on
             the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1

          8. Overall Eastern Cooperative Oncology Group (ECOG) performance ≤1.

          9. Patient's commitment to compliance with the oral medication throughout the duration of
             the study

         10. Life expectancy of at least 3 months

         11. Adequate bone marrow, renal and hepatic function, defined as:

               -  Neutrophils ≥ 1500/mm3

               -  Platelets ≥100,000/mm3

               -  Haemoglobin ≥ 9,0 g/dL

               -  Serum Creatinine ≤ 1.5 x LSN

               -  Bilirubin levels ≤ 1.5 x LSN

               -  AST and ALT levels ≤ 2.5 x ULN (if liver metastases < 5 x ULN)

        Exclusion Criteria:

          1. Prior treatment with regorafenib.

          2. Assignment prior to treatment during this study. Patients who are permanently
             withdrawn from participation in the study treatment will not be allowed to return to
             it.

          3. Prior or concurrent presence of another neoplastic disease that is different in terms
             of tumour site and histology of the colorectal cancer in the 5 years prior to the
             inclusion of the patient in the study, except in situ cervical cancer, superficial
             bladder carcinoma [Ta (non-invasive), Tis (carcinoma in situ) and T1 (tumour invades
             lamina propria)] and non-melanoma skin tumours.

          4. Presence or history of brain metastases or meningeal tumours.

          5. Major surgery, open biopsy or traumatic injury within 28 days prior to the start of
             patient treatment with the study medication.

          6. Extended-field radiotherapy within 4 weeks prior to inclusion or limited-field
             radiotherapy in the previous 2 weeks. Patients must have recovered from all
             treatment-related toxicities.

          7. Pregnant or breastfeeding women. Women of childbearing age must use adequate
             contraception. Women of childbearing age must have a negative pregnancy test within 7
             days prior to starting with the study medication.

          8. Women of childbearing age and men who wish to take part in the study must agree to use
             adequate contraception from the signing of the informed consent until at least 3
             months after stopping the study medication. The investigator or the person designated
             by him or her will ensure and advise as to the contraceptive methods that should be
             used.

             Appropriate contraceptive methods include abstinence, oral contraceptives, transdermal
             patches and injections of sustained-release progestin (starting at least 4 weeks
             before administration of the IMP), double-barrier method: condom or female condom
             (diaphragm or cervical/vaginal condom) plus spermicide, intrauterine device (IUD),
             intrauterine system, implant or vaginal ring (in place at least 4 weeks before
             administration of the IMP) or male partner sterilisation (vasectomy with documentation
             of azoospermia) prior to inclusion of the woman in the trial if he is the woman's only
             sexual partner.

          9. Active congestive heart failure class 2 or higher on the New York Heart Association
             (NYHA) scale.

         10. Unstable angina (angina symptoms at rest), new_onset angina (having appeared in the
             past 3 months) or acute myocardial infarction that has occurred in the 6 months prior
             to starting with the study medication.

         11. Cardiac arrhythmias that require anti-arrhythmic therapy (only beta blockers and
             digoxin would be allowed as concomitant medication for these patients).

         12. Uncontrolled hypertension (systolic blood pressure > 150 mmHg or diastolic blood
             pressure > 90 mmHg) despite proper medical management.

         13. Patients with phaeochromocytoma.

         14. Pleural effusion or ascites that cause breathing difficulties (dyspnoea of grade ≥ 2
             of the CTC).

         15. Venous or arterial thromboembolism or embolic events such as cerebrovascular accidents
             (including transient ischaemic attacks), deep vein thrombosis or pulmonary
             thromboembolism that have occurred in the 6 months prior to starting with the study
             medication.

         16. Active infection > grade 2 based on the NCI CTC, v. 4.0.

         17. Human immunodeficiency virus (HIV) infection.

         18. Active hepatitis B or C, or hepatitis B or C infection that requires treatment with
             antiviral drugs.

         19. Patients with mental disorders that require medication.

         20. History of organ transplants.

         21. Patients with evidence or history of bleeding diathesis. Any bleeding or bleeding
             event > Common Toxicity Criteria for Adverse Effects (CTCAE) grade 3 in the 4 weeks
             prior to starting with the study medication.

         22. Presence of unhealed wounds, ulcers or bone fractures.

         23. Kidney failure requiring haemodialysis or peritoneal dialysis.

         24. Dehydration based on NCI CTC criteria, version 4, of > 1.

         25. Substance abuse or a history of medical, social or psychological conditions that may
             interfere with study participation or compliance with the efficacy and safety
             assessments planned in the study.

         26. Known hypersensitivity to regorafenib or any of its excipients.

         27. Presence of any disease or medical condition that might interfere with patient safety
             or may compromise treatment compliance with it.

         28. Interstitial lung disease with signs and symptoms present at the time of signing the
             informed consent.

         29. Patients who are unable to swallow oral medication.

         30. Persistent proteinuria > grade 3 based on the NCI CTC, version 4.0 (> 3.5 g/24 hours).

         31. Intestinal malabsorption syndrome.

         32. Close personal relationship with the research staff, such as family members of the
             investigator or dependents (e.g. employees or students of the research centre).

         33. Unresolved toxicity grade > 1 based on the NCI CTC, version 4.0 (except alopecia),
             related to any previous therapy or procedure.
      "
NCT02456714,completed,,1,phase 2,['cholangiocarcinoma'],"[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]",['folfirinox'],['CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.C1CCC(C(C1)[NH-])[NH-].C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O.C1=C(C(=O)NC(=O)N1)F.C(=O)(C(=O)[O-])[O-].[Pt+4]'],"
        Inclusion Criteria:

          -  Histological or cytological diagnosis of cholangiocarcinoma.

          -  Metastatic disease or irresectable locally advanced cholangiocarcinoma.

          -  Measurable disease according RECIST criteria version 1.1.

          -  Age from 18 to 75 year.

          -  WHO/ECOG performance status 0-2.

          -  Patients who received at least 3 cycles of gemcitabine/cisplatin in the first line.

          -  Adequate hematological function (WBC > 3.0 x 109/L, platelets > 100 x109/L)

          -  Adequate hepatic function (bilirubin ≤ 1.5 x upper normal limit (ULN); ALAT or ASAT
             <5x ULN in case of liver metastases and < 2.5 x ULN in absence of liver metastases.

          -  Adequate renal function (creatinine clearance > 60 ml/min; creatinine <120 µmol/L)

          -  Absence of cardiac insufficiency, chest pain (not medically controlled) and myocardial
             infarction in the 12 months preceding study entry.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Concurrent secondary malignancies or other malignancies within 3 years prior to enter
             this study with the exception of non-metastatic basal cell or squamous cell skin
             cancer or carcinoma in situ of the cervix treated by cone-biopsy or resection

          -  Presence of cerebral or meningeal metastases

          -  Contraindication to any of the substances of the planned treatment.

          -  History of chronic diarrhea or colorectal inflammatory conditions, or of unresolved
             occlusion or sub-occlusion for which symptomatic treatment is being administered

          -  Active infection or other serious underlying conditions which may prevent the patient
             from receiving the planned treatment. For example: prolonged unresolved bacterial
             cholangitis with destruction of bile duct branches (e.g. after endoprosthesis
             insertion) or two or more cholangitis in the last 6 months. Patients with other active
             or uncontrolled severe infection, cirrhosis or chronic active hepatitis will be
             excluded.

          -  Presence of cardiac insufficiency, unstable angina pectoris, symptomatic congestive
             heart, failure myocardial infarction 6 months prior to randomization, serious
             uncontrolled cardiac arrhythmia.

          -  Inclusion in another investigational clinical trial

          -  Women who are pregnant, breast-feeding or not using adequate contraceptive

          -  Age younger than 18 or older than 76 years

          -  Individuals under correctional supervision or guardianship
      "
NCT02450903,completed,,1,phase 2,['non-small-cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]",['ldk378'],['CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl'],"
        Key Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of Stage IIIb or IV NSCLC that
             carries an ALK rearrangement as determined locally by Vysis ALK Break Apart FISH Probe
             Kit (Abbott Molecular Inc.) test.

          -  Patients must have NSCLC that has progressed at study enrollment.

          -  Patients must have received previous treatment with alectinib for treatment of locally
             advanced or metastatic NSCLC. Prior therapy with crizotinib as ALK inhibitor therapy
             in addition to alectinib is allowed. Alectinib doesn't need to be the last therapy
             prior to study enrollment. No particular sequence of prior alectinib and crizotinib is
             required for enrollment.

          -  Patients must be chemotherapy-naïve or have received only one line of prior cytotoxic
             chemotherapy.

          -  Age 18 years or older at the time of informed consent.

        Key Exclusion Criteria:

          -  Patients with known hypersensitivity to any of the excipients of LDK378.

          -  Prior therapy with other ALK inhibitor investigational agents except crizotinib and
             alectinib.

          -  Prior systemic anti-cancer (including investigational) therapy aside from alectinib,
             crizotinib and one regimen of previous cytotoxic chemotherapy for locally advanced or
             metastatic NSCLC.

          -  Patients with symptomatic central nervous system (CNS) metastases who are
             neurologically unstable or have required increasing doses of steroids within the 2
             weeks prior to study entry to manage CNS symptoms.

          -  Patient with history of interstitial lung disease or interstitial pneumonitis,
             including clinically significant radiation pneumonitis.

          -  Patients with history of carcinomatous meningitis.

          -  Patient with a concurrent malignancy or history of a malignant disease other than
             NSCLC that has been diagnosed and/or required therapy within the past 3 years.

          -  Patient has clinically significant, uncontrolled heart disease and/or recent cardiac
             event (within 6 months)
      "
NCT02452463,terminated,"
    low accrual
  ",0,phase 2,"['lung non-squamous non-small cell carcinoma', 'radiation-induced pneumonitis', 'stage ii lung non-small cell cancer ajcc v7', 'stage iia lung non-small cell carcinoma ajcc v7', 'stage iib lung non-small cell carcinoma ajcc v7', 'stage iii lung non-small cell cancer ajcc v7', 'stage iiia lung non-small cell cancer ajcc v7', 'stage iiib lung non-small cell cancer ajcc v7', 'stage iv lung non-small cell cancer ajcc v7']","[""['D02.20', 'D02.21', 'D02.22']"", ""['G62.82']"", ""['C96.20', 'C96.29', 'D47.09']"", ""['D02.20', 'D02.21', 'D02.22']"", ""['D02.20', 'D02.21', 'D02.22']"", ""['C96.20', 'C96.29', 'D47.09']"", ""['C96.20', 'C96.29', 'D47.09']"", ""['C96.20', 'C96.29', 'D47.09']"", ""['C96.20', 'C96.29', 'D47.09']""]",['nintedanib'],['CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O'],"
        Inclusion Criteria:

          -  Histologically or cytologically-proven non squamous cell NSCLC; mixed histology with
             small cell lung carcinoma (SCLC) component not allowed

          -  Patients with stage II ? IV non squamous cell NSCLC who received at least 54 Gy of
             total planned thoracic radiation dose will be eligible; patients must have received at
             least one cycle of chemotherapy concurrently during the course of thoracic radiation;
             regimens allowed are platinum combinations with either etoposide or a taxane
             regardless of histology subtype; platinum with pemetrexed for patients with
             non-squamous NSCLC only; patients with oligometastatic stage IV cancer are eligible if
             they have received only one line of systemic therapy for their stage IV cancer prior
             to the concurrent chemoradiation phase

          -  Patient must have had a complete response (CR)/partial response (PR)/stable disease
             (SD), 4-6 weeks after completing last fraction of radiation therapy

          -  Eastern Cooperative Oncology Group (ECOG) performance score 0-2

          -  Absolute neutrophil count (ANC) >= 1,500/uL

          -  Platelet count >= 100,000/uL

          -  Hemoglobin >= 9 g/dL

          -  Total bilirubin =< normal or for those with Gilbert?s syndrome =< 1.5 times upper
             limit of normal (ULN) OR direct bilirubin normal (per institute standards)

          -  Aspartate aminotransferase (AST) =< 1.5 x ULN; alanine aminotransferase (ALT) and AST
             =< 2.5 x ULN is acceptable if there is liver metastasis

          -  Fertile patients must use adequate contraception

        Exclusion Criteria:

          -  Whole-brain radiotherapy (WBRT) < 14 days from the anticipated start of
             nintedanib/placebo administration

          -  Squamous cell NSCLC

          -  Unable to start nintedanib/placebo treatment between 4-8 weeks after completing the
             last dose of thoracic radiation

          -  Active untreated brain or leptomeningeal metastases; in patients with treated central
             nervous system (CNS) metastases, eligible if symptoms controlled for at least 4 weeks;
             dexamethasone allowed if total daily dose does not exceed 2 mg

          -  Major injuries or surgery (e.g., craniotomy) < 28 days from the start of
             nintedanib/placebo administration; wound should be healed prior to starting therapy

          -  Second malignancies are allowed as long as the disease does not require active
             treatment with concomitant systemic cytotoxic chemotherapy, investigational or
             biologic therapy (e.g., anti-cytotoxic T-lymphocyte-associated protein 4 [CTLA4] or
             human epidermal growth factor receptor 2 [HER2] monoclonal antibodies);
             hormone-related therapies (e.g., gonadotrophin releasing hormone (LHRH) agonists,
             tamoxifen, etc.) are allowed

          -  Concurrent uncontrolled illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situation that would increase the risk
             associated with study participation and/or limit compliance with study requirements

          -  Inability to swallow study medication

          -  Presence of active malabsorption disorder (e.g., flare episodes documented within the
             preceding 3 months, presence of symptoms requiring daily medications for control) or
             history of extensive small bowel resection

          -  Known bleeding or thrombotic diathesis

          -  History of arterial or venous thromboembolic event within 12 months prior to study
             participation

          -  Active hemoptysis or history of clinically relevant hemoptysis as determined by the
             treating physician; patients who had history of transient minor hemoptysis after
             bronchoscopic biopsy are eligible unless deemed otherwise by the treating physician

          -  Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or higher proteinuria

          -  Investigational agent administered < 28 days prior to treatment with nintedanib. Last
             dose of systemic chemotherapy administered < 14 days prior to treatment with
             nintedanib

          -  Known chronic active hepatitis B or hepatitis C; human immunodeficiency virus
             (HIV)-positive patients receiving or are candidates for antiretroviral therapy are
             also excluded

          -  Pregnancy or breast feeding; female patients with child-bearing potential must have a
             negative pregnancy test (beta-human chorionic gonadotropin [B-HCG] test in urine or
             serum) prior to commencing study treatment

          -  Creatinine > 1.5 x ULN or creatinine clearance levels (CrCL) < 45 mL/min

          -  Centrally located tumors with radiographic evidence (computed tomography [CT] or
             magnetic resonance imaging [MRI]) of local invasion of major blood vessels

          -  Therapeutic anticoagulation (except low-dose heparin and/or heparin flush as needed
             for maintenance of an in-dwelling intravenous devise) or anti-platelet therapy (except
             for low-dose therapy with acetylsalicylic acid < 325 mg per day)

          -  Active or previous autoimmune disease requiring treatment within the past 2 years will
             exclude patients from receiving immune checkpoint inhibitor in this study. Exception
             allowed: endocrine conditions treated with necessary hormone replacement or other
             supportive medication; vitiligo, alopecia
      "
NCT02450539,completed,,0,phase 2,['non-small cell lung cancer stage iv'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['abemaciclib', 'docetaxel']","['CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O']","
        Inclusion Criteria:

          -  Confirmed diagnosis of stage IV NSCLC.

          -  Have progressed during or after platinum-based chemotherapy for advanced disease.

          -  Have not received prior treatment with docetaxel.

          -  Have availability of adequate formalin-fixed paraffin-embedded (FFPE) tumor derived
             material.

          -  Have adequate organ function including hematology, renal, and liver.

          -  Have good performance score (0-1).

          -  Have measurable disease per RECIST 1.1.

          -  Agree to use a reliable medically approved method of birth control.

        Exclusion Criteria:

          -  Have received prior treatment with any cyclin dependent kinase (CDK) 4 and 6 inhibitor
             or participated in a clinical trial with a CDK 4 and 6 inhibitor and the treatment
             administered is not known.

          -  Are currently receiving treatment in a clinical trial involving an investigational
             product or non-approved use of a drug or device.

          -  Have the presence of unstable central nervous system (CNS) metastasis.

          -  Have had major surgery (excluding biopsy) < 28 days of the initial dose of study drug.
      "
NCT02433483,terminated,"
    the study was closed due to poor accrual and because of competing protocols.
  ",0,phase 2,"['acute myeloid leukemia (aml)', 'myelodysplastic syndrome (mds)']","[""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']"", ""['D46.Z', 'D46.9', 'C94.6', 'D46.C']""]","['cytarabine', 'intrathecal triples']",['C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O'],"
        INCLUSION CRITERIA - AML and MDS PARTICIPANTS

          -  Participants must have a diagnosis of AML or myelodysplastic syndrome (MDS), ALL, and
             must have disease that has relapsed or is refractory to chemotherapy, or that has
             relapsed after HSCT.

               -  Refractory disease is defined as persistent disease after at least two courses of
                  induction chemotherapy.

               -  Patients with AML must have ≥ 5% leukemic blasts in the bone marrow or have
                  converted from negative minimal residual disease (MRD) status to positive MRD
                  status in the bone marrow as assessed by flow cytometry. If an adequate bone
                  marrow sample cannot be obtained, patients may be enrolled if there is
                  unequivocal evidence of leukemia in the peripheral blood.

          -  Participant is ≤ 21 years of age (i.e., has not reached 22nd birthday).

          -  Adequate organ function defined as the following:

               -  Total bilirubin ≤ upper limit of normal (ULN) for age, or if total bilirubin is >
                  ULN, direct bilirubin is ≤ 1.5 mg/dL

               -  AST (SGOT)/ALT (SGPT) < 5 x ULN

               -  Calculated creatinine clearance > 50 ml/min/1.73m^2 as calculated by the Schwartz
                  formula for estimated glomerular filtration rate >

               -  Left ventricular ejection fraction ≥ 40% or shortening fraction ≥ 25%.

          -  Has an available HPC-A donor.

          -  Performance status: Lansky ≥ 50 for patients who are ≤ 16 years old and Karnofsky ≥
             50% for patients who are > 16 years old.

          -  Does not have an uncontrolled infection requiring parenteral antibiotics, antivirals,
             or antifungals within one week prior to first dose. Infections controlled on
             concurrent anti-microbial agents are acceptable, and anti-microbial prophylaxis per
             institutional guidelines is acceptable.

          -  Patient has fully recovered from the acute effects of all prior therapy and must meet
             the following criteria.

               -  At least 14 days must have elapsed since the completion of myelosuppressive
                  therapy.

               -  At least 24 hours must have elapsed since the completion of hydroxyurea, low-dose
                  cytarabine (up to 200 mg/m^2/day), and intrathecal chemotherapy.

               -  At least 30 days must have elapsed since the use of investigational agents.

               -  For patients who have received prior HSCT, there can be no evidence of GVHD and
                  greater than 60 days must have elapsed since the HSCT. Patients cannot be
                  receiving therapy, including steroids, for GVHD.

          -  Post-menarchal female has had negative serum pregnancy test within 7 days prior to
             enrollment.

          -  Male or female of reproductive potential has agreed to use effective contraception for
             the duration of study participation.

          -  Not breastfeeding

        INCLUSION CRITERIA - HPC-A CELL DONOR

          -  At least 18 years of age.

          -  Family member (first degree relatives).

          -  Not pregnant as confirmed by negative serum or urine pregnancy test within 7 days
             prior to enrollment (if female).

          -  Not breast feeding.

          -  Meets donation eligibility requirements as outlined by 21 CFR 1271.
      "
NCT02432846,completed,,0,phase 2,"['renal cell carcinoma, metastatic']","[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]",['sunitinib'],['CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C'],"
        Inclusion Criteria:

          1. Newly (<6 months) diagnosed RCC (histological/cytological verification is optional)
             with at least one (1) CT-verified metastasis ≥10mm for which complete metastasectomy
             is not planned. US patients must have verified clear-cell tumor histology

          2. Planned resection of primary tumor

          3. Primary tumor diameter ≥40 mm

          4. Candidate for first-line therapy with sunitinib initiated 5-8 weeks after nephrectomy

          5. Female or male ≥18 years of age

          6. Willing and able to provide informed consent

          7. Adequate hematological parameters, i.e:

               -  B-Leukocyte count ≥4.5 x10e9/L

               -  B-Platelet count ≥150 x10e9/L

               -  B-Hemoglobin ≥90 g/L

          8. S-creatinine and S-bilirubin ≤ 1.5 x upper limit of normal (ULN). Serum alanine
             aminotransferase (S-ALAT) and serum aspartate aminotransferase (S-ASAT) ≤ 2.5 x ULN
             (or ≤5 in case of liver metastases)

          9. Female who has been post-menopausal for more than one (1) year or female of
             childbearing potential agreeing to use a highly efficient method of contraception
             (i.e. a method with less than 1% failure rate [e.g. sterilization, hormone implants,
             hormone injections, some intrauterine devices, or vasectomized partner or combined
             birth control pills]) Female of childbearing potential must have a negative from
             Screening until 90 days after last dose of Intuvax and/or until completed sunitinib
             treatment whichever occurs later.blood pregnancy test at Screening, and if randomized
             to vaccination a negative blood or urine pregnancy test within one (1) day before each
             dose of Intuvax) and must not be lactating.

        or Male agreeing to use condoms from Screening until 90 days after last dose of Intuvax
        and/or until completed sunitinib treatment whichever occurs later, or male having a female
        partner who is using a highly efficient method of contraception as described above.

        Exclusion Criteria:

          1. Life expectancy less than 4 months

          2. Central nervous system (CNS) metastasis that is symptomatic or progressing or
             untreated or that required current therapy (e.g. evidence of new or enlarging CNS
             metastasis or new neurological symptoms attributable to CNS metastases)

          3. Active autoimmune disease which requires treatment with systemic immunosuppressive
             agents, e.g. inflammatory bowel disease, multiple sclerosis, sarcoidosis, psoriasis,
             autoimmune hemolytic anemia, rheumatoid arthritis, systemic lupus erythematosus (SLE),
             vasculitis, Sjögren's syndrome, scleroderma, autoimmune hepatitis, and other
             rheumatological diseases

          4. Treatment with per oral systemic corticosteroids exceeding 10mg/day within seven (7)
             days before Screening until nephrectomy (inhaled, intranasal and local steroids
             accepted irrespective of dose)

          5. Known cardiomyopathy and/or clinical significant abnormal ECG findings at Screening
             disqualifying the patient from nephrectomy and from subsequent sunitinib treatment

          6. Karnofsky performance status <70%

          7. National Cancer Institute (NCI) Common Terminology criteria for Adverse Events (CTCAE)
             Grade 3 hemorrhage within 28 days before Screening

          8. Pre-existing thyroid abnormality with thyroid function that cannot be maintained in
             the normal range with medication

          9. Clinically significant gastrointestinal abnormalities

         10. Uncontrolled hypertension, or uncontrolled diabetes mellitus

         11. Pulmonary embolism within 12 months before screening

         12. Prior history of invasive cancer within 5 years before screening, except for
             adequately treated in situ carcinomas or non-melanoma skin cancer

         13. Ongoing infection that requires parenteral treatment with antibiotics

         14. Active or latent virus disease (HIV, hepatitis B and hepatitis C)

         15. Eastern Cooperative Oncology Group (ECOG) performance status >2 after optimization of
             analgesics

         16. Abnormal and clinical significant coagulation parameters at the discretion of the
             Investigator, i.e.:

               -  Prothrombin Time - International Normalized Ratio (PT-INR)

               -  Activated Partial Thromboplastin Time (APTT) patients being treated with
                  anticoagulants are excluded if the coagulation parameters are outside the
                  therapeutic intervals as described in the summary of product characteristics
                  (SmPC) / United States prescribing information (USPI) for the administered
                  treatment

         17. Known major adverse reaction/event in connection with previously made vaccination
             (e.g. asthma, anaphylaxis or other serious reaction)

         18. Known hypersensitivity or allergy sunitinib or to chemically related products or
             likely to be exacerbated to by any component of the study products

         19. Prior systemic antitumour therapy within 28 days before Screening Visit. However,
             local radiation therapy to any area except for the abdominal/retroperitoneal area
             including the kidney tumour is allowed

         20. Exposure to other investigational products within 28 days prior to Screening Visit

         21. patients on anticoagulants for whom temporarily stop and start, supported by low
             molecular weight heparin (or other anticoagulation therapy at the discretion of the
             investigator and or per local standard of care) during vaccination and nephrectomy, is
             not an option

         22. History of alcohol or substance abuse

         23. Any reason that, in the opinion of the Investigator, contraindicates that the patient
             participates in the study
      "
NCT02439138,terminated,"
    safety issues from trials in cll
  ",0,phase 2,"[""waldenstrom's macroglobulinemia""]","[""['C88.0']""]",['gs-1101'],['CCC(C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5'],"
        Inclusion Criteria:

          -  Participants must meet the following criteria on screening examination to be eligible
             to participate in the study:

          -  Clinicopathological diagnosis of Waldenstrom's Macroglobulinemia and meeting criteria
             for treatment using consensus panel criteria from the Second International Workshop on
             Waldenstrom's macroglobulinemia (Owen 2003; Kyle 2003).

          -  Measurable disease, defined as presence of serum immunoglobulin M (IgM) with a minimum
             IgM level of > 2 times the upper limit of normal of each institution is required.

          -  Have received at least one prior therapy for WM.

          -  Age ≥18 years.

          -  ECOG performance status <2 (see Appendix A.).

          -  Participants must have normal organ and marrow function as defined below:

               -  Absolute neutrophil count > 1,000/mm3

               -  Platelets > 50,000/mm3

               -  Hemoglobin > 8 g/dL

               -  Total bilirubin ≤1.5 mg/dL or < 2 mg/dL if attributable to hepatic infiltration
                  by neoplastic disease

               -  AST (SGOT) and ALT (SGPT) < 2.5 X institutional upper limit of normal

               -  Creatinine ≤ 2 mg/dL

          -  Not on any active therapy for other malignancies with the exception of topical
             therapies for basal cell or squamous cell cancers of the skin.

          -  Females of childbearing potential (FCBP) must agree to use two reliable forms of
             contraception simultaneously or have or will have complete abstinence from
             heterosexual intercourse during the following time periods related to this study:

             1) while participating in the study; and 2) for at least 28 days after discontinuation
             from the study. Men must agree to use a latex condom during sexual contact with a FCBP
             even if they have had a successful vasectomy. FCBP must be referred to a qualified
             provider of contraceptive methods if needed.

          -  Able to adhere to the study visit schedule and other protocol requirements.

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Any serious medical condition, laboratory abnormality, uncontrolled intercurrent
             illness, or psychiatric illness/social condition that would prevent the participant
             from signing the informed consent form

          -  Concurrent use of any other anti-cancer agents or treatments or any other study agents

          -  Prior exposure to idelalisib

          -  Prior or ongoing clinically significant illness, medical condition, surgical history,
             physical finding, ECG finding, or laboratory abnormality that, in the investigator's
             opinion, could affect the safety of the patient; alter the absorption, distribution,
             metabolism or excretion of Idelalisib; or impair the assessment of study results

          -  Grade > 2 toxicity (other than alopecia) continuing from prior anti-cancer therapy

          -  Known central nervous system lymphoma

          -  Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias,
             congestive heart failure, or myocardial infarction within 6 months of screening

          -  New York Heart Association classification III or IV heart failure.

          -  Malabsorption syndrome, disease significantly affecting gastrointestinal function, or
             resection of the stomach or small bowel, ulcerative colitis, symptomatic inflammatory
             bowel disease, or partial or complete bowel obstruction.

          -  Known history of Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), and/or
             Hepatitis C Virus (HCV) infection

          -  Lactating or pregnant women

          -  Inability to swallow capsules

          -  History of non-compliance to medical regimens

          -  Unwilling or unable to comply with the protocol
      "
NCT02438722,"active, not recruiting",,0,phase 2/phase 3,"['recurrent non-small cell lung carcinoma', 'stage iv non-small cell lung cancer']","[""['D02.20', 'D02.21', 'D02.22']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]",['afatinib dimaleate'],['CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O'],"
        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed stage IV (American Joint
             Committee on Cancer [AJCC] 7th Edition) or recurrent non-small cell lung cancer
             (NSCLC)

          -  Patients must have documented presence of an EGFR exon 19 deltion or exon 21 (L858R)
             substitution mutation; T790M mutation or other molecular abnormality will be allowed
             as long as it accompanies one of the mutations listed above; EGFR testing must be
             performed using a Food and Drug Administration (FDA)-approved test or in a Clinical
             Laboratory Improvement Amendments (CLIA)-certified laboratory.

          -  Patients must have tissue available and must agree to submission of tissue and blood;
             one to two paraffin-embedded tissue blocks or 15-20 unstained slides are requested (a
             minimum of 12 slides is required); cytology (i.e. fine-needle aspirations, pleural
             effusion specimens) is acceptable if a cell block or sufficient unstained slides are
             available; tumor material must be reviewed by a local pathologist who must confirm
             that at least 100 viable tumor cells are present in the sample and sign the S1403
             Pathology Review Form; patients must also be willing to submit blood samples for
             correlative research at baseline, during treatment and at progression

          -  Patients enrolled at sites participating in the Repeat Biopsy Study must agree to
             submission of tissue obtained by a repeat biopsy performed at the time of disease
             progression

          -  Patients must not have received any prior systemic anticancer therapy for advanced or
             metastatic disease including chemotherapy or EGFR tyrosine kinase inhibitor therapy
             (including gefitinib, erlotinib, afatinib, or any experimental EGFR tyrosine kinase
             inhibitors [TKI] agents); prior chemotherapy for non-metastatic disease (i.e. adjuvant
             therapy or concurrent chemo-radiotherapy) is allowed as long as > 12 months has passed
             since completion of therapy; adjuvant EGFR-directed therapy is not allowed; local
             therapy (i.e. palliative radiotherapy) is allowed as long as a period of 7 days has
             passed since the last dose was received and the patient has recovered from any
             associated toxicity at the time of registration

          -  Patients may have measurable or non-measurable disease documented by computed
             tomography (CT) or magnetic resonance imaging (MRI) within 42 days prior to
             registration; the CT from a combined positron emission tomography (PET)/CT may be used
             only if it is of diagnostic quality; laboratory parameters are not acceptable as the
             only evidence of disease; in order to qualify as measurable, measurable disease must
             be outside previous radiation field; all disease must be assessed and documented on
             the Baseline Tumor Assessment Form (Response Evaluation Criteria in Solid Tumors
             [RECIST] 1.1)

          -  Patients must have a CT or MRI scan of the brain to evaluate for central nervous
             system (CNS) disease within 42 days prior to registration; patient must not have
             symptomatic brain metastases or evidence of leptomeningeal carcinomatosis; patients
             with asymptomatic brain metastases are eligible if off of steroids for at least 7 days
             prior to registration without development of symptoms

          -  Patients must not have any known clinically active interstitial lung disease

          -  Absolute neutrophil count (ANC) >= 1,500/mcL

          -  Platelets >= 75,000/mcL

          -  Hemoglobin >= 9 g/dL

          -  Total bilirubin =< 1.5 x institutional upper limit of normal (IULN)

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN (or
             =< 5 x IULN for patients with known liver metastases)

          -  Serum creatinine =< 1.5 x IULN OR measured or calculated creatinine clearance >= 60
             mL/min

          -  Patients must not have significant gastrointestinal disorders with diarrhea as a major
             symptom (e.g. Crohn's disease, malabsorption, etc)

          -  Patients must be able to swallow medication by oral route

          -  Patients must not have a history of clinically relevant cardiovascular abnormalities
             such as uncontrolled hypertension, congestive heart failure New York Heart Association
             (NYHA) classification of 3, unstable angina or poorly controlled arrhythmia or
             myocardial infarction within 6 months prior to registration; if clinically indicated,
             echocardiogram or multigated acquisition (MUGA) must be performed and cardiac ejection
             fraction must be >= 50%

          -  Patients must not have had major surgery within 28 days prior to registration or be
             scheduled for surgery during the projected course of protocol treatment; tumor biopsy
             is allowed

          -  Patients must not have a known history of active hepatitis B infection (defined as
             presence of hepatitis B surface antigen [Hep B sAg] and/ or Hep B deoxyribonucleic
             acid [DNA]), active hepatitis C infection (defined as presence of hepatitis C [Hep C]
             ribonucleic acid [RNA]) and/or known human immunodeficiency virus (HIV) seropositive

          -  Patients must not have any other concomitant serious illness or organ system
             dysfunction which in the opinion of the investigator would either compromise patient
             safety or interfere with the evaluation of the safety of the study drug

          -  Patients must not be planning to receive any other investigational agents during the
             course of protocol treatment

          -  Patients must not have a history of allergic reactions attributed to compounds of
             similar chemical or biologic composition to afatinib and/or cetuximab

          -  Prestudy history and physical must be obtained with 28 days prior to registration

          -  Patients must have Zubrod performance status of 0 - 2

          -  No other prior malignancy is allowed except for the following: adequately treated
             basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated
             stage I or II cancer from which the patient is currently in complete remission, or any
             other cancer from which the patient has been disease free for three years

          -  Patients must not be pregnant or nursing; women/men of reproductive potential must
             have agreed to use an effective contraceptive method; a woman is considered to be of
             ""reproductive potential"" if she has had menses at any time in the preceding 12
             consecutive months; in addition to routine contraceptive methods, ""effective
             contraception"" also includes heterosexual celibacy and surgery intended to prevent
             pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy,
             bilateral oophorectomy or bilateral tubal ligation; however, if at any point a
             previously celibate patient chooses to become heterosexually active during the time
             period for use of contraceptive measures outlined in the protocol, he/she is
             responsible for beginning contraceptive measures

          -  Patients must be informed of the investigational nature of this study and must sign
             and give written informed consent in accordance with institutional and federal
             guidelines

          -  As a part of the Oncology Patient Enrollment Network (OPEN) registration process the
             treating institution's identity is provided in order to ensure that the current
             (within 365 days) date of institutional review board approval for this study has been
             entered in the system
      "
NCT02166658,terminated,"
    after a recruitment of more than 2 years, only 8 patients have been registered.
  ",0,phase 2,"['breast cancer', 'lung cancer', 'recurrent brain metastases', 'progressive brain metastases']","[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]",['cabazitaxel'],['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC)C)OC'],"
        Inclusion Criteria:

          1. Adult patients (≥ 18 years of age)

          2. Histologically or cytologically confirmed stage IV lung or breast cancer with
             progressive or recurrent brain metastases

          3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          4. Prior external beam radiotherapy (WBRT or SRS) of BM Patients suffering from small
             cell lung cancer (SCLC) who have been treated with chemotherapy and prophylactic
             cranial radiotherapy may be also enrolled.

          5. At least one two-dimensional measurable lesion on brain MRI

          6. Life expectancy at least 3 months

          7. Females of childbearing potential (FCBP) must have a negative pregnancy test within 7
             days of the first application of study treatment and must agree to use effective
             contraceptive birth control measures (Pearl Index < 1) during the course of the Trial.
             A female subject is considered to be of childbearing potential unless she is age ≥ 50
             years and naturally amenorrhoeic for ≥ 2 year, or unless she is surgically sterile.

          8. Males must agree to use effective contraception (Pearl Index < 1) during the course of
             the trial and for at least 6 months after last administration of study medication
             cabazitaxel. In addition males must agree to prevent contact with the ejaculate by
             another person throughout study treatment.

        Exclusion Criteria:

          1. Prior chemotherapy or targeted therapy (e.g. erlotinib, bevacizumab) for brain
             metastases

          2. Any chemotherapy or targeted tumor therapy within two weeks of study inclusion or
             concomitantly

          3. Any antihormonal tumor treatment within two weeks of study inclusion or concomitantly

          4. Time interval to prior external beam radiotherapy less than 2 weeks

          5. Suspected or known leptomeningeal disease

          6. Peripheral neuropathy ≥ grade 2

          7. Inadequate organ and bone marrow function as evidenced by:

               -  Absolute neutrophil count (ANC) < 1.5 x 10*9/L;

               -  Hemoglobin < 10.0 g/dL;

               -  Platelet count < 100 x 10*9/L;

               -  Total bilirubin ≥ 1 x upper limit of normal (ULN);

               -  AST/GOT and/or ALT/GPT ≥ 1.5 x ULN;

               -  Serum creatinine > 1.5 x ULN. If creatinine 1.0 - 1.5 x ULN; creatinine clearance
                  has to be calculated according to Chronic Kidney Disease Epidemiology
                  Collaboration (CKD-EPI) formula and patients with creatinine clearance < 60
                  mL/min must be excluded

          8. Other inadequate organ function according to investigator's discretion

          9. History of hypersensitivity reaction to docetaxel

         10. History of hypersensitivity reaction to polysorbate 80 containing drugs

         11. Uncontrolled severe illness or medical condition (including uncontrolled diabetes
             mellitus)

         12. Concurrent or planned treatment with strong inhibitors or strong inducers of
             cytochrome P450 3A4/5 (a one week washout period is necessary for patients who are
             already on these treatments; see also Section 10 and Appendix 3 and 4; dexamethasone
             is allowed)

         13. Recently received or planned vaccination against yellow fever during study treatment

         14. Pregnant or breast feeding females

         15. Participation in any other clinical trial or treatment with any experimental drug
             within 28 day before enrolment to the study or during study participation until the
             end of treatment visit

         16. Previous or concurrent tumor other than underlying tumor disease (breast or lung
             cancer) with the exception of cervical cancer in situ, adequately treated basal cell
             carcinoma or squamous cell carcinoma of the skin, superficial bladder tumors (Ta,Tis,
             and T1) or any curatively treated tumors > 5 years prior to enrolment
      "
NCT02162914,unknown status,,1,phase 2,['cholangiocarcinoma'],"[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['regorafenib/active', 'regorafenib/placebo']","['Status: 400', 'Status: 400']","
        Inclusion Criteria:

          -  histologically proven intra-hepatic or hilum cholangiocarcinoma (mass forming, not
             ""liniting"" tumor), locally advanced unresectable or metastatic

          -  progression documented after GEM-CDDP (or GEM-OX), or gemcitabine alone followed or
             preceded by platinum-based (CDDP or oxaliplatin) chemotherapy

          -  age > 18 years

          -  ECOG PS 0/1 at study entry

          -  measurable disease according to RECIST version 1.1

          -  Adequate bone marrow, liver and renal function as assessed by the following laboratory
             requirementsconducted within 7 days of starting to study treatment:

        oSerum creatinine <1.5x upper reference range

        oTotal bilirubin <1.5x ULN

        oAlanine transaminase (ALT) and aspartate aminotransferase (AST) < 2.5x ULN (<5x ULN
        forpatients with liver involvement of their cancer).

        oAmylase and lipase <1.5x ULN.

          -  life expectancy of at least 12 weeks

          -  effective contraception for both male and female patients if the risk of conception
             exists

          -  negative proteinuria on dipstick or 24 hours proteinuria<1000mg

          -  signed written informed consent

        Exclusion Criteria:

          -  unability to take oral medication

          -  any malabsorption condition

          -  patients taking strong cytochrome P (CYP) CYP3A4 inhibitors (eg. Clarithromycin,
             indinavir,itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir,
             saquinavir, telithromycin,voriconazole) or strong CYP3A4 inducers (eg. Carbamazepine,
             phenobarbital, phenytoin, rifampin, St-John's Wort) (see section 8)

          -  persistent proteinuria >3.5g/24 hours measured by urine protein-creatinine ratio from
             a random urinesample (persistent proteinuria >3 non-healing woud, ulcer, or bone
             fracture

          -  any hemorrhage or bleeding event ≥ CTCAE Grade 3 within 4 weeks prior to the start of
             studymedication

          -  interstitial lund disease with ongoing signs and symptoms at the time of informed
             consent

          -  uncontrolled concurrent CNS, cardiac, infectious diseases, hypertension

          -  history of myocardial infarction, deep venous or arterial thrombosis, cerebrovascular
             accident (CVA) during the last 6 months

          -  previous exposure to anti-VEGF targeting therapy (including Regorafenib) and to signal
             transduction inhibitors

          -  known hypersensitivity to any of the components of study treatments

          -  previous malignancy in the last past 5 years except basal cell cancer of the skin or
             preinvasive cancer of the cervix

          -  pregnant or lactating women, or patients of both genders with procreative potential
             not using adequate contraceptive methods

          -  medical or psychological conditions that would not permit the patient to complete the
             study or sign inform consent

          -  unstable angina, congestive heart failure ≥NYHA class II

          -  uncontrolled hypertension despite optimal management (systolic blood pressure >150
             mmHg or diastolic pressure > 90mmHg)

          -  pheochromocytoma

          -  HIV infection

          -  active chronic hepatitis B or C with a need for antiviral treatment

          -  liver failure, cirrhosis Chil Pugh B or C

          -  brain metastasis

          -  major surgery, open biopsy or significant traumatic injury within 4 weeks prior to the
             first dose of treatment

          -  intra-hepatic locoregional therapy (DC Beads, SIRT)

          -  history of organ allograft

          -  ongoing infection

          -  renal failure requiring dialysis

          -  patients receiving or having received any investigational treatment within 4 weeks
             prior to study entry, or participating to another clinical study
      "
NCT02162719,completed,,1,phase 2,['breast neoplasms'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['ipatasertib', 'paclitaxel', 'placebo']","['CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C']","
        Inclusion Criteria:

          -  Histologically documented triple-negative adenocarcinoma of the breast that is
             inoperable locally advanced or metastatic and is not amenable to resection with
             curative intent

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor
             specimen, required prior to randomization

          -  Measurable disease, according to the RECIST v1.1

          -  Adequate hematologic and organ function within 14 days before the first study
             treatment

          -  For female participants of childbearing potential, agreement (by both participant and
             partner) to use an effective form of contraception for the duration of the study and
             for 6 months after last dose of study treatment

        Exclusion Criteria:

          -  Any previous therapy, including chemotherapy or hormonal or targeted therapy, for
             inoperable locally advanced or metastatic triple-negative adenocarcinoma of the
             breast. Participants may have received prior neoadjuvant or adjuvant chemotherapy
             and/or radiation treatment for locally advanced triple negative adenocarcinoma,
             provided all treatments were completed greater than or equal to (>/=) 6 months prior
             to Cycle 1 Day 1. Locally recurrent disease must not be amenable to resection with
             curative intent

          -  Any radiation treatment to metastatic site within 28 days of Cycle 1, Day 1

          -  Known Human Epidermal Growth Factor Receptor 2 (HER2) positive, erythrocyte receptor
             (ER) positive, or progesterone receptor (PR) positive breast cancer

          -  Previous therapy with Akt, PI3K, and/or mTOR inhibitors

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 30 days
             prior to Cycle 1, Day 1 or anticipation of need for a major surgical procedure during
             the course of the study

          -  Known presence of the brain or spinal cord metastasis, as determined by computed
             tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening or
             prior radiographic assessments
      "
NCT02164916,completed,,1,phase 2,['colorectal cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['irinotecan hydrochloride', 'vemurafenib']","['CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl', 'CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F']","
        -  STEP I INITIAL REGISTRATION: BRAFV600E TESTING:

          -  Patients must have histologically or cytologically documented adenocarcinoma of the
             colon or rectum that is either metastatic, or locally advanced and unresectable

          -  Patients must have BRAFV600E mutant status documented by a Clinical Laboratory
             Improvements Amendments (CLIA) certified laboratory on a pathology report prior to
             Step 2 registration; use of an Food and Drug Administration (FDA)-approved test is
             preferred although other BRAF tests at a CLIA-certified laboratory may also be
             accepted; if a BRAFV600E mutation is known, then the patient must be registered to
             Step 2 Randomization immediately following Step 1 Initial Registration; if testing has
             not been performed locally, BRAFV600E testing must be completed by the central lab
             prior to Step 2 Randomization; if the specimen does not have a BRAFV600E mutation, the
             patient is ineligible for Step 2 Randomization

          -  Brain metastases are allowed if they have been adequately treated with radiotherapy or
             surgery and stable for at least 90 days prior to Step 1 Initial Registration; eligible
             patients should be neurologically asymptomatic and without corticosteroid treatment
             for at least 7 days prior to Step 1 Initial Registration

          -  Patients must have had one or two prior regimens of systemic chemotherapy for
             metastatic disease; prior treatment with irinotecan is allowed; a maintenance regimen
             of 5-fluorouracil or capecitabine, with or without bevacizumab, should not be counted
             as a separate line of treatment; prior treatment for metastatic disease is not
             required for patients who experienced disease recurrence during or within 6 months of
             completion of adjuvant chemotherapy

          -  Patients must not have been treated with any of the following prior to Step 2
             Randomization:

               -  Cetuximab, panitumumab, or any other monoclonal antibody against EGFR or
                  inhibitor of EGFR

               -  BRAF inhibitor including, but not limited to, vemurafenib or dabrafenib;
                  regorafenib is not considered a BRAF inhibitor for the purpose of determining
                  trial eligibility

               -  Mitogen-activated protein/extracellular signal-regulated kinase (MEK) inhibitor
                  including, but not limited to, trametinib or selumetinib

          -  Previous chemotherapy, immunotherapy, or radiation therapy must have been completed at
             least 14 days prior to Step 1 Initial Registration and all toxicity must be resolved
             to Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0) grade 1
             (with the exception of CTCAE v4.0 grade 2 neuropathy) prior to Step 1 Initial
             Registration

          -  Patients must not have a tumor with a mutation detected in codons 12 or 13 in KRAS;
             patients must not have a tumor with a known mutation detected in codons 61, 117, or
             146 of KRAS or NRAS

          -  SPECIMEN SUBMISSION CRITERIA:

          -  Patients must have tumor (slides or block) available for submission for V600E BRAF
             testing

          -  Patients must have additional tumor available and be willing to submit tissue and
             blood samples

          -  SPECIMEN SUBMISSION CRITERIA REGULATORY CRITERIA:

          -  Patients or their legally authorized representative must be informed of the
             investigational nature of this study and must sign and give written informed consent
             in accordance with institutional and federal guidelines; for Step 1 Initial
             Registration of patients who have not yet submitted specimens for the central
             BRAFV600E testing, the appropriate consent form is the Step 1 Consent Form; for both
             Step 1 Initial Registration and Step 2 Randomization of patients whose BRAF mutation
             status is already known, the appropriate consent form is the Step 2 Consent Form

          -  STEP 2 RANDOMIZATION:

          -  Patients must have BRAFV600E mutation

          -  Patients must have measurable or non-measurable metastatic disease; computed
             tomography (CT) scans or magnetic resonance imaging (MRIs) used to assess all disease
             must have been completed within 28 days prior to Step 2 Randomization; CT scans or
             MRIs must be assessed and documented on the Baseline Tumor Assessment Form (Response
             Evaluation Criteria in Solid Tumors [RECIST] 1.1)

          -  Patients must have a Zubrod performance status of 0-1

          -  Absolute neutrophil count (ANC) >= 1,500/mcL

          -  Platelets >= 100,00/mcL

          -  Hemoglobin >= 9 g/dL

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x
             institutional upper limit of normal (IULN) or =< 5 x IULN if liver metastases are
             present

          -  Total bilirubin =< 1.5 x IULN

          -  Serum creatinine =< 1.5 x IULN within 14 days prior to Step 2 Randomization OR

          -  Calculated creatinine clearance > 60 ml/min; the serum creatinine value used in the
             calculation must have been obtained within 14 days prior to Step 2 Randomization

          -  Patients must have an electrocardiogram (ECG) within 14 days prior to Step 2
             Randomization

          -  Patients must have corrected QT (QTc) =< 500 msec

          -  Patients must not have a known history of Gilbert's Syndrome or known homozygosity for
             the UDP glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1)*28 allele

          -  Patients must not have interstitial pneumonia or extensive symptomatic interstitial
             fibrosis of the lung

          -  Patients must not have an uncontrolled intercurrent illness including, but not limited
             to, active bleeding diathesis, uncontrolled infection/disorders, nonmalignant medical
             illnesses that are uncontrolled or whose control may be jeopardized by the treatment
             with the study therapy, or psychiatric illness/social situations which would limit
             compliance with study requirements

          -  Patients must be able to swallow pill/tablet and have no refractory nausea, vomiting,
             malabsorption, external biliary shunt, or significant small bowel resection that would
             preclude adequate absorption

          -  Patients must not be pregnant or nursing; women/men of reproductive potential must
             have agreed to use an effective contraceptive method while on study and for 30 days
             after study treatment; a woman is considered to be of ""reproductive potential"" if she
             has had menses at any time in the preceding 12 consecutive months; in addition to
             routine contraceptive methods, ""effective contraception"" also includes heterosexual
             celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy
             prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal
             ligation; however, if at any point a previously celibate patient chooses to become
             heterosexually active during the time period for use of contraceptive measures, he/she
             is responsible for beginning contraceptive measures

          -  No other prior malignancy is allowed except for the following: adequately treated
             basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated
             stage I or II cancer from which the patient is currently in complete remission, or any
             other cancer from which the patient has been disease free for three years

          -  STEP 2 RANDOMIZATION REGULATORY CRITERIA:

          -  Patients or their legally authorized representative must be informed of the
             investigational nature of this study and must sign and give written informed consent
             in accordance with institutional and federal guidelines; for all patients, the
             appropriate consent form for this registration is the Step 2 Consent Form

          -  As a part of the OPEN registration process the treating institution's identity is
             provided in order to ensure that the current (within 365 days) date of institutional
             review board approval for this study has been entered in the system

          -  STEP 3 CROSSOVER REGISTRATION:

          -  Patients must have documented disease progression while on Arm 1 of this protocol; the
             follow-up tumor assessment form documenting disease progression must be submitted to
             Southwestern Oncology Group (SWOG) prior to Step 3

          -  Registration to Step 3 Crossover must be within 28 days of discontinuation of Arm 1
             protocol treatment; patients going off treatment for any other reason are not eligible

          -  ANC >= 1,500/mcL within 14 days prior to Step 3 registration

          -  Platelets >= 100,00/mcL within 14 days prior to Step 3 registration

          -  Hemoglobin >= 9 g/dL within 14 days prior to Step 3 registration

          -  AST and ALT =< 2.5 x institutional upper limit of normal (IULN) or =< 5 x IULN if
             liver metastases are present within 14 days prior to Step 3 registration

          -  Total bilirubin =< 1.5 x IULN within 14 days prior to Step 3 registration

          -  Serum creatinine =< 1.5 x IULN within 14 days prior to Step 3 registration OR

          -  Calculated creatinine clearance > 60 ml/min; the serum creatinine value used in the
             calculation must have been obtained within 14 days prior to Step 3 registration
      "
NCT02069093,completed,,1,phase 2,['advanced breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['dexamethasone based mouthwash', 'everolimus', 'exemestane']","['CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC', 'CC12CCC3C(C1CCC2=O)CC(=C)C4=CC(=O)C=CC34C']","
        Inclusion Criteria:

          1. Adult women > 18 years of age with metastatic or locally advanced breast cancer not
             amenable to curative treatment by surgery or radiotherapy

          2. Histological or cytological confirmation of hormone-receptor positive (HR+) human
             epidermal growth factor receptor 2 negative (HER2-) breast cancer

          3. Postmenopausal women. Postmenopausal status is defined either by:

               -  Age ≥ 55 years and one year or more of amenorrhea

               -  Age < 55 years and one year or more of amenorrhea, with an estradiol assay < 20
                  pg/ml

               -  Surgical menopause with bilateral oophorectomy

               -  Note: Ovarian radiation or treatment with a luteinizing hormone-releasing hormone
                  (LH-RH) agonist (goserelin acetate or leuprolide acetate) is not permitted for
                  induction of ovarian suppression

          4. Patient has been assessed by treating physician to be appropriate candidate for
             everolimus plus exemestane therapy as treatment of advanced or metastatic breast
             cancer and plans to prescribe everolimus 10mg PO QD in combination with exemestane
             25mg PO QD

          5. Patient must start everolimus 10mg plus exemestane 25mg treatment on Cycle 1 Day 1 of
             trial

          6. ECOG Performance status ≤ 2

          7. Adequate renal function: serum creatinine ≤ 1.5x ULN;

          8. Willingness to self-report level of oral pain using Visual Analog Scale (VAS) and the
             Normalcy Diet Scale (NDS) throughout each stomatitis event, as required in the patient
             diary. At baseline, patient's self-reported oral pain level, using VAS, must be 0 and
             the normalcy diet scale score should ≥ 60

          9. Signed informed consent obtained prior to any screening procedure

        Exclusion criteria:

          1. Patients currently receiving anticancer therapies (except biphosphonate, denosumab);

          2. Patients who currently have stomatitis/oral mucositis/mouth ulcers;

          3. Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g.
             sirolimus, temsirolimus);

          4. Known impairment of gastrointestinal (GI) function or GI disease that may
             significantly alter the absorption of oral Everolimus;

          5. Uncontrolled diabetes mellitus as defined by HbA1c >8% despite adequate therapy.
             Patients with a known history of impaired fasting glucose or diabetes mellitus (DM)
             may be included, however blood glucose and antidiabetic treatment must be monitored
             closely throughout the trial and adjusted as necessary;

          6. Patients who have any severe and/or uncontrolled medical conditions such as:

               -  Unstable angina pectoris, symptomatic congestive heart failure, myocardial
                  infarction ≤6 months prior to start of everolimus, serious uncontrolled cardiac
                  arrhythmia, or any other clinically significant cardiac disease

               -  Symptomatic congestive heart failure of New York heart Association Class III or
                  IV

               -  active (acute or chronic) or uncontrolled severe infection, liver disease such as
                  cirrhosis, decompensated liver disease (except for Hep B and Hep C positive
                  patients)

               -  Known severely impaired lung function (spirometry and DLCO 50% or less of normal
                  and O2 saturation 88% or less at rest on room air)

               -  active, bleeding diathesis;

          7. Chronic treatment with corticosteroids or other immunosuppressive agents. Topical or
             inhaled corticosteroids are allowed;

          8. Known history of HIV seropositivity;

          9. Patients who have received live attenuated vaccines within 1 week of start of
             everolimus and during the study. Patient should also avoid close contact with others
             who have received live attenuated vaccines. Examples of live attenuated vaccines
             include intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow fever,
             varicella and TY21a typhoid vaccines;

         10. Patients who have a history of another primary malignancy, with the exceptions of:
             non-melanoma skin cancer, and carcinoma in situ of the cervix, uteri, or breast from
             which the patient has been disease free for ≥3 years;

         11. Patients with a history of non-compliance to medical regimens or who are considered
             potentially unreliable or will not be able to complete the entire study or patient
             diaries;

         12. Patients who are currently part of any clinical investigation or who has not had
             resolution of all acute toxic effects or prior anti-cancer therapy to NCI CTCAE
             version 4.03 Grade 1 (except alopecia or other toxicities not considered a safety risk
             for the patient at investigator's discretion).
      "
NCT02064426,completed,,1,phase 2,"['anemia', 'renal insufficiency, chronic']","[""['D53.2', 'D64.9', 'D46.4', 'D53.0', 'D53.9', 'D61.3', 'D61.9']"", ""['N25.0', 'Q61.4', 'N23', 'N26.9', 'P96.0', 'Q60.0', 'Q60.1']""]",['molidustat (bay85-3934)'],['C1COCCN1C2=NC=NC(=C2)N3C(=O)C(=CN3)N4C=CN=N4'],"
        Inclusion Criteria:

          -  Eligible male or female subjects were previously enrolled in Study 16208, have a
             diagnosis of anemia associated with CKD, and are on hemodialysis.

          -  Men who agree to use adequate contraception when sexually active or women without
             childbearing potential

          -  Participation and completion of treatment in Study 16208; subjects must have received
             16 weeks of study medication and completed the end of treatment visit (Day 113) in the
             parent study

          -  Mean Hb concentration of 9.5 to 11.5 g/dL, inclusive, during the evaluation period
             (i.e., the last 4 weeks of the parent study) when the subject completed 16 weeks of
             treatment with BAY85-3934, epoetin alfa, or epoetin beta in Study 16208

        Exclusion Criteria:

          -  A scheduled kidney transplant or any other organ transplant within the next 6 months
             (being on a waiting list does not exclude the subject)

          -  Updates to medical and surgical history which meet the exclusion criteria in the
             parent study

          -  Subjects treated with immunosuppressive therapy and the breast cancer resistant
             protein (BCRP) substrates, irinotecan, topotecan, methotrexate, imatinib, and
             lapatinib

          -  Sustained, poorly controlled arterial hypertension or hypotension at baseline, defined
             as mean BP ≥ 180/110 mmHg or systolic BP < 95 mmHg, respectively

          -  Severe rhythm or conduction disorder (e.g., HR < 50 or > 110 bpm, atrial fibrillation
             or flutter, prolonged QT > 500 msec, second or third degree atrioventricular [AV]
             block)

          -  New York Heart Association Class III or IV congestive heart failure

          -  Severe hepatic insufficiency (defined as alanine aminotransferase [ALT], aspartate
             aminotransferase [AST], or gamma-glutamyl transferase > 3 x the upper limit of norma
             [ULN], total bilirubin > 2 mg/dL, or Child-Pugh B or C) or active hepatitis in the
             investigator's opinion

          -  An ongoing SAE from Study 16208 that is assessed as related to study drug

          -  Alcohol or drug abuse
      "
NCT02061631,completed,,1,phase 2,['squamous cell carcinoma of head and neck'],"[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]","['cisplatin', 'docetaxel xrp6976', 'dexamethasone', 'dexamethasone']","['N.N.Cl[Pt]Cl', 'CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C', 'CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C']","
        Inclusion criteria :

          -  Histologically confirmed, unresectable locally advanced squamous cell carcinoma of
             head and neck of oral cavity in stage III-IV without evidence of distant metastases.

          -  No prior chemotherapy or radiation therapy.

          -  Having at least one measurable lesion in one dimension.

          -  Age ≥18 and <65 years with Eastern Cooperative Oncology Group ≤ 1.

          -  Adequate organ function:

          -  Adequate hematological function

          -  Adequate hepatic function

          -  Renal function within normal limits

        Exclusion criteria:

          -  Peripheral neuropathy > grade 1 or other serious diseases (unstable ischaemic heart
             disease, acute myocardial infarction six months prior to inclusion, history of
             significant neurological or psychiatric disorder or active peptic ulcer).

          -  Being treated concomitantly with corticosteroids (except as pre-medication).

          -  Patients having another type of cancer.

          -  Previous chemotherapy or radiotherapy.

          -  Any previous definitive surgery for squamous cell carcinoma of head and neck.

          -  Severe weight loss (> 20 % of body weight) in the preceding 3 months.

          -  Hearing loss (> grade 2).

          -  Pregnancy (pregnancy test result for women of childbearing potential).

          -  Sexually active females with lack of adequate contraception.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      "
NCT02065466,withdrawn,"
    lack of accrual
  ",0,phase 1/phase 2,"['metastatic melanoma', 'brain metastases']","[""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']""]","['nab-paclitaxel', 'temozolomide', 'bevacizumab']","['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C', 'CN1C(=O)N2C=NC(=C2N=N1)C(=O)N']","
        Inclusion Criteria:

          -  Histologically or cytologically confirmed malignant melanoma and clinical evidence of
             metastatic disease to the brain. Mucosal and ocular melanomas are included.

          -  Newly developed inoperable brain metastases without associated hemorrhage or midline
             shift.

          -  Inoperable or metastatic extra cranial stage III or IV disease.

          -  Diagnostic quality MRI of the brain or if contraindicated then contrast CT scan of the
             head performed within 28 days prior to registration.

          -  Measurable metastases to the brain, defined as at least one lesion that can be
             accurately measured in at least one dimension (longest diameter to be recorded) as >10
             mm in the brain MRI/CT scan.

          -  CT scan chest, abdomen and pelvis or PET CT scan performed within 28 days of study
             registration. For disease outside the brain, tumors must be > 10 mm by CT scan.

          -  Prior therapy allowed but no prior therapy with nab-paclitaxel, paclitaxel,
             temozolomide, DTIC or bevacizumab.

          -  Bevacizumab may not be initiated until 4 weeks after surgical resection or radiation
             therapy completion.

          -  Age 18 or older.

          -  Pre-existing peripheral neuropathy must have < Grade 2 (per CTCAE 4.0) at the time of
             registration.

          -  Negative serum or urine β-hCG pregnancy test at screening for patients of childbearing
             potential.

          -  Women of childbearing potential and sexually active males must use an effective
             contraception method during treatment and for three months after completing treatment.

          -  ECOG Performance status 0-1.

          -  Estimated life expectancy of greater than 2 months.

          -  Patients must have adequate organ function as defined below (these must be evaluated
             within 14 days prior to registration):

          -  leukocytes >3,000/mcL

          -  absolute neutrophil count >1,500/mcL

          -  platelets >100,000/mcL

          -  Hemoglobin >9.0 g/dL

          -  AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit

          -  Alkaline phosphatase <2.5 X institutional upper limit

          -  Total bilirubin <1.5 X institutional upper limit of normal (unless associated with
             Gilbert's syndrome)

          -  serum creatinine < 1.5 mg/dL OR 1.5 x institutional normal

          -  LDH there is no restriction

          -  INR <1.5 PTT WNL

          -  Urine protein (UPC) ratio 1.0 OR

          -  Urine dipstick for proteinuria. Urine dipstick for proteinuria ≥ 2+ (patients
             discovered to have ≥2+ proteinuria on dipstick urinalysis at baseline should undergo a
             24 hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be
             eligible).

          -  Able to render informed consent.

        Exclusion Criteria:

          -  Prior surgical resection for brain metastases.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to bevacizumab, nab-paclitaxel or temozolomide.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection requiring parenteral antibiotics, symptomatic congestive heart failure,
             unstable angina pectoris, untreated cardiac arrhythmia and peripheral vascular
             disease.

          -  History of myocardial infarction or unstable angina within 6 months prior to Day 1.

          -  History of stroke or transient ischemic attack within 6 months prior to Day 1.

          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
             within 6 months prior to study screening.

          -  Serious, non-healed wound, ulcer, or bone fracture.

          -  History of hepatitis B, C or HIV.

          -  Uncontrolled hypertension or chronic renal disease. No known bleeding diathesis.

          -  Known hypersensitivity to human albumin.

          -  Surgery within 4 weeks of study registration. Must be fully recovered and fully healed
             from any prior surgery.

          -  Patients having chemotherapy or extra cranial radiotherapy within 4 weeks prior to
             study screening or those who have not recovered from adverse events due to agents
             administered more than 4 weeks prior to the completion of study screening.

          -  Evidence of other concurrent active malignancy.

          -  Pregnant or nursing.

          -  Not be receiving any other investigational agent.
      "
NCT02062359,terminated,"
    study was closed due to poor accrual.
  ",0,phase 2,"['metastatic cancer', 'metastatic melanoma']","[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']""]","['aldesleukin', 'cyclophosphamide', 'fludarabine']","['C1CNP(=O)(OC1)N(CCCl)CCCl', 'C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N']","
        -INCLUSION CRITERIA:

          1. Measurable metastatic melanoma that expresses ESO as assessed by one of the following
             methods: reverse transcription-polymerase chain reaction (RT-PCR) on tumor tissue, or
             by immunohistochemistry of resected tissue, or serum antibody reactive with ESO.

          2. Confirmation of diagnosis of metastatic melanoma by the Laboratory of Pathology of the
             National Cancer Institute (NCI).

          3. Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and
             asymptomatic are eligible. Lesions that have been treated with stereotactic
             radiosurgery must be clinically stable for 1 month after treatment for the patient to
             be eligible. Patients with surgically resected brain metastases are eligible.

          4. Greater than or equal to 18 years of age and less than or equal to 70 years of age.

          5. Willing to sign a durable power of attorney

          6. Able to understand and sign the Informed Consent Document

          7. Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1

          8. Life expectancy of greater than three months

          9. Patients must be human leukocyte antigen (HLA)-A*0201 positive

         10. Patients of both genders must be willing to practice birth control from the time of
             enrollment on this study and for up to four months after treatment

         11. Serology:

               -  Seronegative for human immunodeficiency virus (HIV) antibody. (The experimental
                  treatment being evaluated in this protocol depends on an intact immune system.
                  Patients who are HIV seropositive can have decreased immune-competence and thus
                  be less responsive to the experimental treatment and more susceptible to its
                  toxicities.)

               -  Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody.
                  If hepatitis C antibody test is positive, then patient must be tested for the
                  presence of antigen by RT-PCR and be hepatitis C virus (HCV) ribonucleic acid
                  (RNA) negative.

         12. Women of child-bearing potential must have a negative pregnancy test because of the
             potentially dangerous effects of the treatment on the fetus.

         13. Hematology

               -  Absolute neutrophil count greater than 1000/mm(3) without the support of
                  filgrastim

               -  White blood cell (WBC) greater than or equal to 3000/mm(3)

               -  Platelet count greater than or equal 100,000/mm(3)

               -  Hemoglobin > 8.0 g/dl

         14. Chemistry:

               -  Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less than
                  or equal to 2.5 times the upper limit of normal

               -  Serum creatinine less than or equal to 1.6 mg/dl

               -  Total bilirubin less than or equal to 1.5 mg/dl, except in patients with Gilberts
                  Syndrome who must have a total bilirubin less than 3.0 mg/dl.

         15. More than four weeks must have elapsed since any prior systemic therapy at the time
             the patient receives the preparative regimen, and patients toxicities must have
             recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo).

             Note: Patients may have undergone minor surgical procedures within the past 3 weeks,
             as long as all toxicities have recovered to grade 1 or less or as specified in the
             eligibility criteria in Section 2.1.

         16. Six weeks must have elapsed from the time of any antibody therapy that could affect an
             anti cancer immune response, including anti-cytotoxic T-lymphocyte antigen 4 (CTLA4)
             antibody therapy, toat the time the patient receives the preparative regimen to allow
             antibody levels to decline.

        Note: Patients who have previously received ipilimumab and have documented gastrointestinal
        (GI) toxicity must have a normal colonoscopy with normal colonic biopsies.

        EXCLUSION CRITERIA:

          1. Women of child-bearing potential who are pregnant or breastfeeding because of the
             potentially dangerous effects of the treatment on the fetus or infant.

          2. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency
             Disease).

          3. Active systemic infections, coagulation disorders or other major medical illnesses of
             the cardiovascular, respiratory or immune system, myocardial infarction, cardiac
             arrhythmias, obstructive or restrictive pulmonary disease.

          4. Concurrent opportunistic infections (The experimental treatment being evaluated in
             this protocol depends on an intact immune system. Patients who have decreased immune
             competence may be less responsive to the experimental treatment and more susceptible
             to its toxicities).

          5. Concurrent systemic steroid therapy.

          6. History of severe immediate hypersensitivity reaction to any of the agents used in
             this study.

          7. History of coronary revascularization or ischemic symptoms

          8. Documented left ventricular ejection fraction (LVEF) of less than or equal to 45%.
             Testing is required in patients with:

               -  Clinically significant atrial and/or ventricular arrhythmias including but not
                  limited to: atrial fibrillation, ventricular tachycardia, second or third degree
                  heart block

               -  Age greater than or equal to 60 years old
      "
NCT02065869,"active, not recruiting",,1,phase 1/phase 2,"['acute lymphoblastic leukemia', 'leukemia, acute myeloid (aml), child', 'lymphoma, non-hodgkin', 'myelodysplastic syndrome', 'primary immunodeficiency', 'anemia, aplastic', 'osteopetrosis', 'hemoglobinopathies', 'cytopenia', 'fanconi anemia', 'diamond blackfan anemia', 'thalassemia', 'anemia, sickle cell']","[""['C91.01', 'C91.02', 'C91.00']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['D46.9', 'D46.C', 'D46.Z']"", ""['D56.0', 'D56.1', 'D56.3', 'D56.9', 'D56.2', 'D56.5', 'D57.40']""]",['rimiducid'],['CCC(C1=CC(=C(C(=C1)OC)OC)OC)C(=O)N2CCCCC2C(=O)OC(CCC3=CC(=C(C=C3)OC)OC)C4=CC(=CC=C4)OCC(=O)NCCNC(=O)COC5=CC=CC(=C5)C(CCC6=CC(=C(C=C6)OC)OC)OC(=O)C7CCCCN7C(=O)C(CC)C8=CC(=C(C(=C8)OC)OC)OC'],"
        Inclusion Criteria:

          1. Age < 18 years and > 1 month (< 1 month upon approval by Sponsor)

          2. Life expectancy > 10 weeks

          3. Patients deemed clinically eligible for allogeneic stem cell transplantation.

          4. Patients may have failed prior allograft

          5. Patients with life-threatening acute leukemia (high-risk ALL in 1st CR, ALL in 2nd CR,
             high-risk AML in 1st CR, AML in 2nd CR.) or myelodysplastic syndromes. Morphological
             CR must be documented and minimal residual disease measurement before transplantation
             is recommended.

          6. Non-malignant disorders deemed curable by allogeneic transplantation: (a) primary
             immune deficiencies, (b) severe aplastic anemia not responding to immune suppressive
             therapy, (c) osteopetrosis, (d) selected cases of erythroid disorders such as β0 β0
             thalassemia major, sickle cell disease, Diamond-Blackfan anemia, (e)
             congenital/hereditary cytopenia, including Fanconi Anemia before any clonal malignant
             evolution (MDS, AML).

             Note: Subjects will be eligible if they meet either item 5 OR item 6.

          7. Lack of suitable conventional donor (HLA identical sibling or HLA phenotypically
             identical relative or 10/10 unrelated donor evaluated using high resolution molecular
             typing) or presence of rapidly progressive disease not permitting time to identify an
             unrelated donor

          8. A minimum genotypic identical match of 5/10 is required.

          9. The donor and recipient must be identical, as determined by high resolution typing, on
             at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-
             DRB1 and HLA-DQB1.

         10. Lansky/Karnofsky score > 50

         11. Signed informed consent by the patient or the patient's parent or guardian for
             patients who are minors

        Exclusion Criteria:

          1. Greater than active Grade II acute GvHD or chronic extensive GvHD due to a previous
             allograft at the time of screening

          2. Patient receiving an immunosuppressive treatment for GvHD treatment due to a previous
             allograft at the time of screening

          3. Dysfunction of liver (ALT/AST > 5 times normal value, or bilirubin > 3 times normal
             value), or of renal function (creatinine clearance <30ml/min/1.73m2)

          4. Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive
             heart failure or left ventricular ejection fraction < 40%)

          5. Current clinically active infectious disease (including positive HIV serology or viral
             RNA)

          6. Serious concurrent uncontrolled medical disorder

          7. Pregnant or breast feeding female patient

          8. Lack of parents'/guardian's informed consent for children who are minors.
      "
NCT02062632,terminated,"
    poor accrual
  ",0,phase 2,"['esophageal carcinoma', 'hypopharyngeal carcinoma', 'laryngeal carcinoma', 'lymphoma', 'mesothelioma', 'metastatic malignant neoplasm in the lung', 'metastatic malignant neoplasm in the pleura', 'metastatic malignant neoplasm in the spinal cord', 'non-small cell lung carcinoma', 'sarcoma', 'small cell lung carcinoma', 'thymic carcinoma', 'thymoma', 'thyroid gland carcinoma']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['C45.9', 'C45.0', 'C45.1', 'C45.2', 'C45.7']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['D02.20', 'D02.21', 'D02.22']"", ""['C96.A', 'C46.9', 'C96.22', 'C46.0', 'C46.2', 'C92.31', 'C92.32']"", ""['D02.20', 'D02.21', 'D02.22']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['D09.3']""]",['doxepin hydrochloride'],['CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31.Cl'],"
        Inclusion Criteria:

          -  Histological confirmation of thoracic malignancies including non-small cell lung
             cancer (NSCLC), small lung cancer (SCLC), esophageal cancer, hypopharyngeal and
             laryngeal cancers (for which esophagitis symptoms can be relieved by doxepin swallow),
             lymphoma, thyroid, thymoma, thymic carcinoma, mesothelioma, sarcoma, and spinal,
             pulmonary or pleural-based metastases

          -  Planned RT (with or without chemotherapy) to a dose of >= 20 Gray (Gy) using 1.60 Gy
             per daily fraction; if radiation is given twice daily, a cumulative planned dose of >=
             15 Gy using at least 1.25 Gy per fraction is required; hypofractionated and
             stereotactic body radiation therapy regimen are allowed

          -  At least 5 cm of the esophagus must be planned to receive radiotherapy, with a minimum
             dose of at least 10 Gy

          -  >= 3 esophageal pain, either at rest or during swallowing, felt to be related to
             esophagitis for which the patient wants relief, as measured by asking the following
             question

               -  ?On a scale of 0 to 10 (0 = no pain; 10 = worst pain), what number best describes
                  your chest pain* (right now) due to your radiation treatment??

                    -  Radiation can cause inflammation in your esophagus which can feel like a
                       chest pain, either at rest or during swallowing

          -  Able to swallow the study medication

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2

          -  Negative pregnancy test done =< 28 days prior to registration, for women of
             childbearing potential only

          -  Ability to complete questionnaire(s) by themselves or with assistance

          -  Provide informed written consent

          -  Willingness to complete evaluation and questionnaires per protocol at the
             participating institution for follow-up (during the active monitoring phase of the
             study)

        Exclusion Criteria:

          -  Known allergy to doxepin, tricyclic antidepressants, or any known component of the
             drug formulation

          -  Histologic proof of and getting treatment for esophageal, stomach, spinal cord,
             thyroid, breast, and head and neck cancers and vertebral metastases

          -  Use of a tricyclic antidepressant or monoamine oxidase inhibitor within the 2 weeks
             prior to registration

          -  The presence or strong clinical suspicion of a tracheoesophageal fistula, or known
             esophageal invasion by cancer

          -  Current untreated or unresolved esophageal candidiasis or herpes simplex virus (HSV)
             infection

          -  Current untreated narrow angle glaucoma

          -  Current untreated urinary retention =< 6 weeks prior to registration

          -  Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment
             of the investigator, would make the patient inappropriate for entry into this study or
             interfere significantly with the proper assessment of safety and toxicity of the
             prescribed regimens

          -  Any of the following

               -  Pregnant women

               -  Nursing women

          -  Current use of doxepin or doxepin rinse as a swallow preparation
      "
NCT02060370,completed,,0,phase 2,"['genitourinary cancer', 'kidney cancer']","[""['D17.71', 'D30.00', 'D30.01', 'D30.02', 'D41.00', 'D41.01', 'D41.02']""]",['sunitinib'],['CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C'],"
        Inclusion Criteria:

          1. Histologically or cytologically-confirmed metastatic renal cell carcinoma of clear
             cell histology. Prior nephrectomy is not a requirement for eligibility

          2. Age >/=18 years

          3. Measurable or evaluable metastatic disease per RECIST v 1

          4. ECOG performance status 0-1

          5. Normal organ and bone marrow function as defined by: Serum aspartate transaminase
             (AST) or serum glutamic oxaloacetic transaminase (SGOT) and serum alanine transaminase
             (ALT) or serum glutamic pyruvic transaminase (SGPT) </= 2.5 x laboratory upper limit
             of normal (ULN); Total serum bilirubin </= 2.0 x ULN; Absolute neutrophil count (ANC)
             >/= 1500/µL; Platelets >/= 100,000/µL; Hemoglobin >/= 9.0 g/dL (transfusion
             permitted); Serum calcium </= 12.0 mg/dL; Serum creatinine </= 2.5 mg/dL

          6. Patients with a history of deep venous thromboembolism or pulmonary embolism on
             treatment with anticoagulation are eligible for the study.

          7. Subjects must have the ability to understand and the willingness to sign a written
             informed consent document

        Exclusion Criteria:

          1. Prior treatment with sunitinib or any other systemic therapy in the metastatic setting
             (prior neo/adjuvant therapy will be allowed if completed > 6 months prior to
             registration and therapy not discontinued for toxicity)

          2. Uncontrolled hypertension (defined as blood pressure >140/90 mm Hg not controlled with
             anti-hypertensives)

          3. Prior intraabdominal, intrathoracic, vascular, spinal or intracranial surgery or
             radiation therapy within 4 weeks of starting treatment

          4. History of or known brain metastases, spinal cord compression, or carcinomatous
             meningitis

          5. New York Heart Association (NYHA) grade II or greater congestive heart failure

          6. Current treatment on another therapeutic clinical trial

          7. Any of the following within the preceding 6 months- myocardial infarction,
             severe/unstable angina, severe peripheral vascular disease (claudication) or procedure
             on peripheral vasculature, coronary/peripheral artery bypass, graft, cerebrovascular
             accident or transient ischemic attack, clinically significant bleeding

          8. Pregnant or breastfeeding women are excluded from this study because there is an
             unknown, but potential risk for adverse events in nursing infants secondary to
             treatment of the mother with sunitinib. Breastfeeding must be discontinued if the
             mother is treated with sunitinib

          9. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome
             (AIDS)-related illness

         10. HIV-positive patients on combination antiretroviral therapy are ineligible because of
             the potential for pharmacokinetic interactions with sunitinib. In addition, these
             patients are at increased risk of lethal infections when treated with marrow
             suppressive therapy
      "
NCT02067104,terminated,"
    low enrollment
  ",0,phase 2,['basal cell carcinomas'],"[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]","['vismodegib', 'placebo']",['CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl'],"
        Inclusion Criteria:

          -  Signed and dated informed consent document indicating that the subject (or legally
             acceptable representative) has been informed of all pertinent aspects

          -  Comply with scheduled visits, treatment plan, laboratory tests, and other study
             procedures.

          -  At least 18 years of age at the time of informed consent.

          -  History of 3 or more biopsy confirmed BCCs in the preceding 2 years, calculated from 2
             years prior to the screening visit.

          -  No active skin cancers.

          -  Women of reproductive potential must agree to use two forms of acceptable
             contraception

          -  Male subjects must agree to use condoms at all times, even after a vasectomy, during
             sexual intercourse with female partners of reproductive potential during treatment
             with vismodegib and for 2 months after the last dose to avoid exposing a pregnant
             partner and the unborn fetus to vismodegib.

          -  Male patients must agree not to donate sperm during the study and for 2 months after
             discontinuation of vismodegib

          -  Agreement not to donate blood or blood products during the study and for 7 months
             after the last dose.

          -  Ability to understand and the willingness to sign a written informed consent document
             in English

        Exclusion Criteria:

          -  Women who are pregnant or lactating, or planning pregnancy while enrolled in the study
             or for 7 months after the last dose of the study drug.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements. Subjects with clinically stable chronic medical conditions
             including, but not limited to, controlled hypertension, diabetes mellitus type II,
             hypercholesterolemia, or osteoarthritis, will be allowed to enter the study.

          -  Inability or unwillingness to swallow capsules.

          -  Have a history of alcohol of substance abuse, unless in full remission for greater
             than 6 months prior to the screening visit (Day 0) when the consent form is signed.

          -  Known to be infected with human immunodeficiency virus (HIV), hepatitis B or hepatitis
             C viruses.

          -  Currently receiving vismodegib, biologics or chemotherapy

          -  Currently undergoing treatment with photodynamic therapy, topical chemotherapy agents
             including Imiquimod, fluorouracil

          -  Subjects who have Gorlins syndrome

          -  Subjects who have received any type of solid organ transplant

          -  Subjects taking immunosuppressive medications at the screening visit. (Day 0)

          -  Participation in other study using an investigational or experimental therapy or
             procedure within 4 weeks or 5 half-lives (whichever is longer) before the screening
             visit and/or during study participation. Subjects cannot participate in studies of
             other investigational or experimental therapies or procedures at any time during their
             participation in this study.

          -  Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or
             investigational product administration or may interfere with the interpretation of
             study results and, in the judgment of the investigator, would make the subject
             inappropriate for entry into this study.

          -  Subjects unable or unwilling to comply with the study visit schedule and requirements
             of the study

          -  Subjects unable to speak and read the English language

          -  A subject who, in the opinion of the sponsor-investigator will be uncooperative or
             unable to comply with study procedures.
      "
NCT03652493,terminated,"
    lack of efficacy
  ",0,phase 2,"['castration-resistant prostate cancer', 'metastasis']","[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]",['carboplatin'],['C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]'],"
        Inclusion Criteria:

          -  Patients > 18 years old

          -  Patients with adenocarcinoma or poorly differentiated prostate carcinoma,
             histologically confirmed (small-cell histology or high-grade neuroendocrine histology
             excluded)

          -  Tumor presenting a somatic pathogenic variant likely to alter the homologous
             recombination pathway previously detected on a tumor biopsy or on circulating tumor
             DNA, or germinal mutation among the list of genes defined in the study

          -  Castration-resistant tumor defined by progression despite well-conducted androgen
             deprivation treatment: testosterone ≤50ng /dL agonist / antagonist of luteinizing
             hormone-releasing hormone (LHRH) or surgical castration. The patient must agree to
             continue concomitant LHRH-mediated (agonist or antagonist) therapy throughout the
             duration of the study regimen for patients with no history of surgical castration.

          -  Patients must have performed at least one line of chemotherapy by taxane in case of
             castration resistance:

               -  Patients who have received docetaxel treatment in a hormone-sensitive situation
                  must have received at least treatment with cabazitaxel in case of castration
                  resistance

               -  Patients who have not received chemotherapy in a hormone-sensitive situation must
                  have received docetaxel AND cabazitaxel or have a contraindication to discontinue
                  treatment.

          -  Patients must have been treated with at least 2nd generation hormone therapy (eg,
             abiraterone acetate or enzalutamide)

          -  Patients may have been treated with a poly (ADP-ribose) polymerase inhibitor (PARP)

          -  Performance Status <2

          -  Metastatic disease progressive

        Exclusion Criteria:

          -  Absence of previous treatment with taxane in situation of sensitivity or resistance to
             castration.

          -  Absence of previous treatment with cabazitaxel in case of resistance to castration
             (except contraindication explaining the non-administration of treatment)

          -  No treatment with 2nd generation hormone therapy (eg abiraterone acetate or
             enzalutamide) unless contraindicated to explain non-administration of treatment

          -  Previous treatment with platinum

          -  Symptomatic and untreated central nervous system (CNS) metastases. Patients with
             asymptomatic and pre-treated CNS metastases are included if they are clinically stable
             (not requiring corticosteroid therapy for 28 days) and must have a brain MRI
             evaluation at screening and during follow-up.
      "
NCT03592407,withdrawn,"
    safety concerns
  ",0,phase 2,"['esophageal squamous cell carcinoma', 'esophageal adenocarcinoma', 'gastroesophageal junction adenocarcinoma']","[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]",['epacadostat'],['C1=CC(=C(C=C1N=C(C2=NON=C2NCCNS(=O)(=O)N)NO)Br)F'],"
        Inclusion Criteria:

          -  Documented informed consent of the participant and/or legally authorized
             representative

          -  Agreement to allow the use of archival tissue from diagnostic tumor biopsies

               -  If unavailable, exceptions may be granted only with study principal investigator
                  (PI) approval

          -  Eastern Cooperative Oncology Group (ECOG) =< 2

          -  Non-metastatic cancer of the esophagus OR esophagus and gastroesophageal junction
             (GEJ; tumor extending =< 2 cm into the stomach)

          -  Confirmed stage II-III diagnosis of one of the following:

               -  Squamous cell; OR

               -  Adenocarcinoma; OR

               -  Mixed adenosquamous carcinoma

          -  Deemed appropriate for neoadjuvant chemoradiation by the multidisciplinary team
             (surgeon, medical oncologist, and radiation oncologist)

               -  Chemotherapy defined as weekly carboplatin/paclitaxel; AND

               -  Radiation defined as external beam radiotherapy defined as: 50.4 gray (Gy) as per
                  institutional and national treatment guidelines

          -  Deemed appropriate for esophagectomy or repeat endoscopic biopsies if non-operative
             management is pursued

          -  Absolute neutrophil count (ANC) >= 1500/mm^3 within 14 days prior to day 1 of study
             participation/1st endoscopic biopsy

          -  Platelets >= 100,000/mm^3 within 14 days prior to day 1 of study participation/1st
             endoscopic biopsy

          -  Serum total bilirubin =< 1.5 x upper limit of normal (ULN) OR direct bilirubin =< ULN
             if total bilirubin levels > 1.5 x ULN within 14 days prior to day 1 of study
             participation/1st endoscopic biopsy

          -  Aspartate aminotransferase (AST) =< 2 x ULN within 14 days prior to day 1 of study
             participation/1st endoscopic biopsy

          -  Alanine aminotransferase (ALT) =< 2 x ULN within 14 days prior to day 1 of study
             participation/1st endoscopic biopsy

          -  Creatinine =<1.5 x ULN OR for patients with Creatinine >1.5 x ULN Creatinine clearance
             of >=60 ml/min per 24 hour urine test or the Cockcroft-Gault formula

          -  International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN within 14
             days prior to day 1 of study participation/1st endoscopic biopsy

          -  Activated partial thromboplastin time (aPTT) =< 1.5 x ULN

          -  Female of childbearing potential only: negative urine or serum pregnancy test; if the
             urine test is positive or cannot be confirmed as negative, a serum pregnancy test will
             be required

          -  Agreement by women of childbearing potential (WOCBP) and males of childbearing
             potential to use an effective method of birth control or abstain from heterosexual
             activity for the course of the study through at least 120 days after the last dose of
             protocol therapy

               -  Childbearing potential defined as not being surgically sterilized (men and women)
                  or have not been free from menses for > 1 year (women only)

        Exclusion Criteria:

          -  Immune checkpoint inhibitor(s) (e.g. anti-PD-1, anti-CTLA4)

          -  Indoleamine-2,3-dioxygenase (IDO) inhibitors

          -  Radiotherapy within 21 days prior to day 1 of study participation

          -  Investigational agent within 21 days prior to Day 1 of study participation

          -  Live-virus vaccination within 30 days prior to Day 1 of study participation

          -  Systemic cytotoxic chemotherapy, antineoplastic biologic therapy, or major surgery
             within 21 days of study participation

          -  Chronic systemic steroid therapy or on any other form of immunosuppressive medication

          -  Monoamine oxidase inhibitors (MAOI) or any drug associated with MAOI activity

          -  Any UGT1A9 inhibitors (including acitretin, amitriptyline, androsterone, cyclosporine,
             dasatinib, diclofenac, diflunisal, efavirenz, erlotinib, estradiol (17-beta),
             flutamide, gefitinib, gemfibrozil, glycyrrhetinic acid glycyrrhizin, imatinib,
             imipramine, ketoconazole, linoleic acid supplements, mefenamic acid, and mycophenolic
             acid, niflumic acid, nilotinib, phenobarbital, phenylbutazone, phenytoin, probenecid)

          -  Coumarin-based anticoagulants

          -  Unstable or untreated brain/leptomeningeal metastasis

          -  Clinically active diverticulitis, intra-abdominal abscess, gastrointestinal (GI)
             obstruction, or abdominal carcinomatosis (known risks factors for bowel perforation)

          -  Severe hypersensitivity reaction to treatment with another antibody and/or
             hypersensitivity to epacadostat excipients

          -  Active autoimmune disease that has required systemic treatment in the past 2 years

          -  Known history of human immunodeficiency virus (HIV), hepatitis B or hepatitis C (with
             confirmation of negative hepatitis B surface antigen [HBsAg], hepatitis B virus [HBV]
             polymerase chain reaction [PCR], and hepatitis C virus [HCV] PCR)

          -  History of pneumonitis (non-infectious) that required steroids or current pneumonitis

          -  Known history of active tuberculosis

          -  Diagnosed with or treated for cancer within the previous two years, other than
             histologies listed in inclusion criteria or non-melanoma carcinoma of the skin

          -  Female only: pregnant or breastfeeding

          -  Any othr condition that would, in the Investigator's judgement, contraindicate the
             patient's participation in the clinical study due to safety concerns with clinical
             study procedures

          -  Prospective participants who, in the opinion of the investigator, may not be able to
             comply with all study procedures (including compliance issues related to
             feasibility/logistics)
      "
NCT03113071,terminated,"
    slow accrual
  ",0,phase 1/phase 2,"['acute myeloid leukemia', 'myelodysplastic syndromes']","[""['C92.A1', 'C92.A2', 'C92.61', 'C92.62', 'C92.A0', 'C92.60']"", ""['D46.9', 'D46.C', 'D46.Z']""]","['decitabine', 'digoxin']","['C1C(C(OC1N2C=NC(=NC2=O)N)CO)O', 'CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CC(C7(C6(CCC7C8=CC(=O)OC8)O)C)O)C)C)C)O)O']","
        Inclusion Criteria:

          1. Patients must have a confirmed diagnosis of one of the following:

               -  Newly diagnosed AML (excluding APL)

               -  Newly diagnosed intermediate-2 (INT-2) or high-risk MDS

               -  Relapsed or Refractory AML, or INT-2 or high-risk MDS

          2. For patients with refractory disease they must be at least 4 weeks out from most
             recent therapeutic intervention.

          3. Age > 18 years.

          4. ECOG performance status 0 - 2.

          5. Patients must have normal organ function as defined below:

               -  Total bilirubin within normal institutional limits

               -  AST/ALT (SGOT/SGPT) < 2 times institutional normal limits

               -  Creatinine within normal institutional limits OR

               -  Creatinine clearance > 60 mL/min/1.73 m2 for patients with creatinine levels
                  above institutional normal

          6. Ability to understand and willingness to sign a written informed consent and HIPAA
             consent document.

          7. Agreement on the part of any male participant to use effective contraception during
             sexual activity throughout the duration of treatment and for 2 months after
             discontinuation, for protection against the risk of embryofetal toxicity.

        Exclusion Criteria:

          1. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering
             the study or those who have not recovered from adverse events (less than or equal to
             Grade 1 toxicity) due to agents administered more than 4 weeks earlier.

          2. Patients receiving any other investigational agents.

          3. Patients with known brain metastases, active infection, or untreated CNS leukemia.

          4. Patients with prior or current history of digoxin exposure.

          5. Patients requiring treatment with one or more medications known to interact adversely
             with digoxin, namely thiazide and/or loop diuretics, quinidine, ritonavir, amiodarone,
             cyclosporine, itraconazole, propafenone, spironolactone, verapamil.

          6. Patients requiring treatment with one or more beta-blockers (metoprolol, atenolol,
             propranolol) or calcium channel blockers with AV-nodal blocking activity (verapamil,
             diltiazem).

          7. Patient with history of prior exposure to decitabine.

          8. Patients eligible for intensive induction chemotherapy and ""Medically unfit"" based on
             a TRM score ≥ 13.1*

               -  TRM Score= A scoring model which predicts early death following intensive
                  induction chemotherapy in newly diagnosed AML.

                    -  Model looks at ECOG PS, Age, Platelet Count, Albumin, 2nd AML, WBC, %
                       Peripheral Blasts, Creatinine

                    -  Score above 13.1 associated with 31%+ chance of death after induction

          9. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

         10. Known HIV-positive patients on combination anti-retroviral therapy are ineligible
             because of the potential for pharmacokinetic interactions with digoxin. In addition,
             these patients are at increased risk of lethal infections when treated with
             marrow-suppressive therapy.

         11. Pregnant or breast feeding
      "
NCT03117361,terminated,"
    pharmamar has decided to end this study due to the slow recruitment rate of the trial
  ",0,phase 2,['multiple myeloma'],"[""['C90.01', 'C90.02', 'C90.00']""]","['plitidepsin', 'bortezomib', 'dexamethasone']","['CCC(C)C1C(CC(=O)OC(C(=O)C(C(=O)NC(C(=O)N2CCCC2C(=O)N(C(C(=O)OC(C(C(=O)N1)NC(=O)C(CC(C)C)N(C)C(=O)C3CCCN3C(=O)C(=O)C)C)CC4=CC=C(C=C4)OC)C)CC(C)C)C)C(C)C)O', 'B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O', 'CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C']","
        Inclusion Criteria:

          1. Patients must give written informed consent (IC) in accordance with institutional and
             local guidelines.

          2. Age ≥ 18 years.

          3. Patients must have a confirmed diagnosis of MM according to the Durie and Salmon
             criteria.

          4. Patients must have measurable disease defined as any of the following:

               1. Serum M-protein ≥ 0.5 g/dL or ≥ 0.2 g/24-h urine light chain (UFLC) excretion.

               2. In patients who lack measureable M-protein in serum or urine, i.e., serum
                  M-protein < 0.5 g/dL and urine M-protein < 0.2 g/24 h, serum free light chain
                  (SFLC) levels are most informative. SFLC levels can be used only if the baseline
                  SFLC ratio is abnormal (<0.26 or >1.65), indicating clonality. In addition, the
                  baseline SFLC level must be ≥10 mg/dl of the appropriate involved light chain
                  isotype.

               3. When applicable, measurable soft tissue plasmacytoma ≥ 2 cm, by either physical
                  examination and/or applicable radiological evaluation (i.e., magnetic resonance
                  imaging [MRI], computed tomography [CT]-scan).

          5. Prior autologous and/or allogeneic hematopoietic stem cell transplantation (HSCT)
             patients are allowed. Patients must not have acute/chronic graft-versus-host disease
             (GVHD) or be receiving immunosuppressive therapy at least 90 days before the onset of
             treatment with the trial drug(s).

          6. Patients must have received previous treatment with bortezomib and lenalidomide and be
             refractory to both.

          7. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status
             (PS) ≤ 2.

          8. Recovery to grade ≤ 1 from any non-hematological adverse event (AE) derived from
             previous treatment (if present, alopecia and peripheral neuropathy must be grade <1).

          9. Laboratory data:

               1. Hemoglobin ≥ 8 g/dL.

               2. Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3 (1.0 x 109/L) (≥ 0.5 x 109/L if
                  due to extensive bone marrow [BM] involvement by ≥ 50% of plasma cells in BM
                  biopsy). Screening of ANC should be independent of granulocyte- and
                  granulocyte/macrophage-colony stimulating factor (G-CSF and GM-CSF) support for
                  at least one week and of pegylated G-CSF for at least two weeks.

               3. Platelet count ≥ 50,000/mm3 (50.0 x 109/L) for patients in whom < 50% of the BM
                  nucleated cells are plasma cells.

               4. Platelet count ≥ 25,000/mm3 (25.0 x 109/L) for patients in whom ≥ 50% of BM
                  nucleated cells are plasma cells.

               5. Serum total bilirubin < 1.5 x institutional upper limit of normal (ULN) (except
                  when Gilbert syndrome is clearly documented and other liver function tests are
                  within normal levels).

               6. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x
                  institutional ULN and alkaline phosphatase (AP) ≤ 2.5 x institutional ULN.

               7. Creatinine clearance (CrCl) > 30 mL/min, measured or calculated according to
                  Cockcroft and Gault's formula.

               8. Albumin ≥ 2.5 g/dl.

         10. Evidence of non-childbearing status for women of childbearing potential (WOCBP): WOCBP
             must have a negative serum or urine pregnancy test within seven days prior to
             enrolment and must agree to use a highly effective contraceptive measure throughout
             the trial and during six months after treatment discontinuation. Male patients
             enrolled in the study should also use contraceptive methods during and after treatment
             discontinuation.

         11. Left ventricular ejection fraction (LVEF) ≥ 45%.

         12. Patients must have a BM assessment within three weeks prior to enrolment.

        Exclusion Criteria:

          1. Previous treatment with plitidepsin.

          2. Active or metastatic primary malignancy other than MM.

          3. Serious concomitant systemic disorders that would compromise the safety of the patient
             or the patient's ability to complete the trial, including the following specific
             conditions:

               1. Uncontrolled psychiatric illness or medical illness that the Investigator feels
                  will compromise the patient's tolerance of the trial medication.

               2. Significant non-neoplastic liver disease.

               3. Uncontrolled endocrine diseases (i.e., requiring relevant changes in medication
                  within the last month, or hospital admission within the last three months).

               4. Uncontrolled systemic infection.

               5. Acute infiltrative pulmonary and pericardial disease.

          4. Other relevant cardiac conditions:

               1. Symptomatic arrhythmia (excluding anemia-related grade ≤ 2 sinusal tachycardia)
                  or any arrhythmia requiring ongoing treatment, and/or prolonged grade ≥ 2 QT-QTc;
                  or presence of unstable atrial fibrillation (according to the National Cancer
                  Institute Common Terminology Criteria for the Classification of Adverse Events
                  [NCI-CTCAE] v4.0). Patients on treatment for stable atrial fibrillation are
                  allowed, provided they do not meet any other cardiac or prohibited drug exclusion
                  criterion.

               2. History or presence of unstable angina, myocardial infarction, valvular heart
                  disease, cardiac amyloidosis or congestive heart failure within the last 12
                  months.

               3. Uncontrolled arterial hypertension (≥ 150/100 mmHg) despite optimal medical
                  therapy.

               4. Previous treatment with doxorubicin at cumulative doses of > 400 mg/m², or
                  equivalent.

          5. History of hypersensitivity reactions and/or intolerance to bortezomib, polyoxyl 35
             castor oil, mannitol, boron or dexamethasone.

          6. Myopathy or any clinical situation that causes significant and persistent elevation of
             creatine phosphokinase (CPK) (> 2.5 ULN) in two different determinations performed
             within one week of each other.

          7. Grade ≥ 1 neuropathy (either bortezomib-related or not) according to NCI-CTCAE v4.0.

          8. Any other major illness that, in the Investigator's judgment, will substantially
             increase the risk associated with the patients' participation in this trial.

          9. Pregnant and/or lactating women.

         10. Known active human immunodeficiency virus (HIV) infection (HIV testing is not required
             unless infection is clinically suspected).

         11. Active hepatitis B or C virus (HBV or HCV) infection.

         12. Treatment with any Investigational Medicinal Product (IMP) in the 30 days before
             inclusion in the trial.

         13. Concomitant medications that include corticosteroids, chemotherapy (CT), or other
             therapy that is or may be active against myeloma. Concurrent corticosteroids are
             allowed as an equivalent to a prednisone dose of ≤ 10 mg daily, administered as an
             antiemetic or as premedication for blood products.

         14. Wash-out periods after the end of the previous therapy:

               1. Nitrosoureas must be discontinued six weeks prior to Cycle (C) 1, D1.

               2. Thirty days for other CTs and 15 days for other biological agents prior to C1 D1.

               3. Thirty days after the end of any prior radiation or radionuclide therapy (six
                  weeks in the case of prior extensive external beam radiation, with more than 25%
                  of BM distribution).

         15. Plasma cell leukemia at the time of trial entry.

         16. Disease-related symptomatic hypercalcemia despite optimal medical therapy.

         17. Limitation of the patient's ability to comply with the treatment or follow-up
             protocol.

         18. Contraindication to use steroids.
      "
NCT01812616,completed,,1,phase 1/phase 2,['cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['sativex', 'placebo']",['CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O.CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O'],"
        Inclusion Criteria:

          -  Patient is willing and able to give informed consent for participation in the study.

          -  Patient is aged 18 years or above.

          -  Histopathologically confirmed diagnosis of grade four Glioblastoma Multiforme as per
             World Health Organisation classification.

          -  Evidence of patients first tumour progression (as determined by Revised Assessment in
             Neuro-Oncology) following radiation and first line chemotherapy with Temozolomide.

          -  If taking steroids, then the dose must be stable or decreasing.

          -  Karnofsky performance scale of 60% or greater.

          -  Patient is able (in the investigators opinion) and willing to comply with all study
             requirements.

          -  Patient is willing for his or her name to be notified to the responsible authorities
             for participation in this study, as applicable in individual countries.

          -  Patient is willing to allow his or her primary care practitioner and consultant, if
             appropriate, to be notified of participation in the study.

        Exclusion Criteria:

          -  Patients with Glioblastoma Multiforme secondary to low-grade glioma or anaplastic
             glioma (anaplastic astrocytoma or anaplastic oligodendroglioma).

          -  Patients currently receiving treatment for recurrent Glioblastoma Multiforme.

          -  Less than a four week interval since prior chemotherapy.

          -  Less than a 12 week interval since prior radiotherapy unless there is either: a)
             histopathology confirmation of recurrent tumour, or b) new enhancement on Magnetic
             Resonance Imaging outside of the radiotherapy treatment field.

          -  Presence of extra-cranial metastatic disease.

          -  Any surgery, including intracranial biopsy (not including minor diagnostic procedures
             such as lymph node biopsy) within two weeks of baseline disease assessments; or not
             fully recovered from any side effects of previous procedures.

          -  Any history of a different malignancy unless the patient has remained disease-free for
             at least three years and are at low risk for recurrence of that malignancy (cervical
             cancer in situ, and basal cell or squamous cell carcinoma of the skin are exempt from
             this criterion if treatment has occurred).

          -  Have previously received first line chemotherapy other than Temozolomide.

          -  Presents with Leptomeningeal dissemination.

          -  Have previously received stereotactic radiotherapy, convection enhanced delivery or
             brachytherapy (as gliosis/scarring from these modalities may limit delivery).

          -  The patient is currently using or has used cannabis or cannabinoid based medications
             within 30 days of study entry and is unwilling to abstain for the duration of the
             study.

          -  Any known or suspected history of a substance abuse/dependence disorder, current heavy
             alcohol consumption (>60g of pure alcohol per day for men, >40 g of pure alcohol per
             day for women), current use of an illicit drug or current non prescribed use of any
             prescription drug.

          -  Any history or immediate family history of schizophrenia, other psychotic illness,
             severe personality disorder or other significant psychiatric disorder other than
             depression associated with their underlying condition.

          -  Has experienced myocardial infarction or clinically significant dysfunction within the
             last 12 months or has a cardiac disorder that, in the opinion of the investigator
             would put the patient at risk of clinically significant arrhythmia or myocardial
             infarction.

          -  Has grade 3 or above toxicity by Common Terminology Criteria for Adverse Events
             criteria.

          -  Female patients of child bearing potential and male patients whose partner is of child
             bearing potential, unless willing to ensure that they or their partner use effective
             contraception, for example, oral contraception, double barrier, intra-uterine device,
             during the study and for three months thereafter (however a male condom should not be
             used in conjunction with a female condom).

          -  Female patients who are pregnant, lactating or planning pregnancy during the course of
             the study and for three months thereafter.

          -  Patient who have received an Investigational Medicinal Product within the four weeks
             prior to the screening visit.

          -  Any other significant disease or disorder which, in the opinion of the investigator,
             may either put the patient at risk because of participation in the study, or may
             influence the result of the study, or the patient's ability to participate in the
             study.

          -  Travel outside the country of residence planned during the study.

          -  Patients previously enrolled into this study and received either Investigational
             Medicinal Product or Dose-Intense Temozolomide.

          -  Any known or suspected hypersensitivity to cannabinoids or any of the excipients of
             the Investigational Medicinal Product.

          -  Any known allergy to or other intolerability to Temozolomide.

          -  Following a physical examination, the patient has any abnormalities that, in the
             opinion of the investigator would prevent the patient from safe participation in the
             study.

          -  Unwilling to abstain from donation of blood during the study.
      "
NCT03881735,withdrawn,"
    no accrual
  ",0,phase 2,"['blasts under 5 percent of peripheral blood white cells', 'bone marrow blasts decreased by 50 percent or more compared to pretreatment level', 'idh2 gene mutation', 'recurrent acute myeloid leukemia', 'refractory acute myeloid leukemia']","[""['A18.2', 'H11.043', 'H11.053', 'H18.463', 'H35.40', 'H81.393', 'I73.9']"", ""['R68.82', 'D72.818', 'D72.819', 'H47.12', 'O36.8121', 'O36.8122', 'O36.8123']"", ""['D68.52', 'J84.83']"", ""['G47.13', 'J01.41', 'K11.22', 'K12.0', 'N96', 'F33.8', 'G03.2']"", ""['D46.4', 'I20.2', 'D46.1', 'D46.A', 'D46.0', 'D46.20', 'D46.21']""]",['enasidenib'],['CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O'],"
        Inclusion Criteria:

          -  Confirmed diagnosis of AML harboring a mutation in IDH2 relapsed or refractory to
             first line cytarabine/anthracycline induction chemotherapy, failed to respond to or
             relapsed following at least 2 cycles of hypomethylating agent (azacitidine,
             decitabine, sgi-110) or at least 1 cycle of hypomenthylating agent with venetoclax or
             other targeted therapies

               -  Patients will be identified and deemed eligible based upon the identification of
                  an IDH2 mutation identified at either at the time of disease relapse prior to
                  re-induction chemotherapy or following 1-2 cycles of chemotherapy induction. Each
                  institution will test using their standard local FDA-approved or cleared assay
                  per the institutional standard of care workup for relapsed disease.

               -  First relapse defined as untreated hematologic relapse (according to
                  International Working Group criteria) after one line of intensive regimen for AML
                  including at least one cytarabine containing induction block with a total dose no
                  less than 700 mg/m^2 per cycle and 3 days of an anthracycline that induced a
                  complete remission (CR)/complete remission with incomplete hematologic recovery
                  (CRi)/complete remission with incomplete platelet recovery (CRp). Subjects are
                  allowed to receive induction, consolidation, transplant and/or maintenance
                  therapy prior to achieving their first CR/CRi/CRp

               -  Refractory to induction therapy is defined as never achieving CR, CRi or CRp
                  (according to International Working Group criteria) after one line of intensive
                  regimen for AML (reinduction, consolidation and/or transplant allowed) including
                  at least one cytarabine containing induction block with a total dose no less than
                  700 mg/m^2 per cycle and 3 days of an anthracycline

          -  Subjects considered eligible for intensive chemotherapy

          -  Subjects had received a first salvage within the last 60 days (day 15 to 60 following
             most recent cytarabine-based standard salvage number [#] 1 therapy) who achieved
             either > 50% reduction in blast percentage from the pre-treatment bone marrow OR < 20%
             cellularity with any blast percentage AND < 5% peripheral blood blasts

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2

          -  Adequate liver function within 72 hours of enrollment, defined as:

             o Blood total bilirubin ≤ 1.5 x ULN, unless considered due to Gilbert's syndrome (eg,
             a gene mutation in UGT1A1) or leukemic organ involvement, following review by the
             Investigator

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x upper
             limit of normal (ULN) (within 72 hours of enrollment)

          -  Adequate renal function within 72 hours of enrollment, defined as blood creatinine =<
             2.5 x ULN

          -  Females of childbearing potential (FCBP) may participate, providing they meet the
             following conditions:

               -  Agree to practice true abstinence from sexual intercourse or to use highly
                  effective contraceptive methods (eg, combined [containing estrogen and
                  progestogen] or progestogen-only associated with inhibition of ovulation, oral,
                  injectable, intravaginal, patch, or implantable hormonal contraceptive; bilateral
                  tubal occlusion; intra-uterine device; intrauterine hormone-releasing system; or
                  male partner sterilization [note that vasectomized partner is a highly effective
                  birth control method provided that partner is the sole sexual partner of the FCBP
                  trial participant and that the vasectomized partner has received medical
                  assessment of the surgical success]) at screening and throughout the study, and
                  for 4 months following the last study treatment (6 months following the last dose
                  of cytarabine); and

               -  Have a negative serumblood β-subunit of human chorionic gonadotropin (β-hCG)
                  pregnancy test (sensitivity of at least 25 mIU/mL) at screening; and

               -  Have a negative serum or urine (investigator's discretion under local
                  regulations) β hCG pregnancy test (sensitivity of at least 25 mIU/mL) within 72
                  hours prior to the start of study treatment in the Treatment Phase (note that the
                  screening serumblood pregnancy test can be used as the test prior to the start of
                  study treatment in the Treatment Phase if it is performed within the 72 hour
                  timeframe).

          -  Men must use a latex condom during any sexual contact with women of childbearing
             potential

          -  Willing to adhere to protocol specific requirements

          -  Clinically significant toxic effects of prior therapy (except hydroxyurea) resolved to
             grade =< 1 before the start of study

          -  Participant or legal representative must understand the investigational nature of this
             study and sign an Independent Ethics Committee/Institutional Review Board approved
             written informed consent form prior to receiving any study related procedure

        Exclusion Criteria:

          -  Acute promyelocytic leukemia (APL)

          -  Subject has or is suspected of having central nervous system (CNS) leukemia.
             Evaluation of cerebrospinal fluid is only required if CNS involvement by leukemia is
             suspected during screening

          -  Clinically active or unstable graft-versus-host disease (GVHD) requiring treatment
             that precludes administration of chemotherapy as defined in this protocol

          -  Prior anti-leukemia therapy within 5 x the half-life for other investigational agents

               -  Prior use of hydroxyurea or isolated doses of cytarabine for palliation (i.e.,
                  control of white blood count [WBC]) are allowed but should be discontinued at
                  least 24 hours prior to enrollment. Other agents used strictly with palliative
                  intent might be allowed during this period after discussing with principal
                  investigator

          -  Pre-existing liver disease (e.g. cirrhosis, chronic hepatitis B or C, nonalcoholic
             steatohepatitis, sclerosing cholangitis)

          -  Subject is known seropositive or active infection with human immunodeficiency virus
             (HIV), or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)

          -  Subject has active uncontrolled systemic fungal, bacterial, or viral infection
             (defined as ongoing signs/symptoms related to the infection without improvement
             despite appropriate antibiotics, antiviral therapy, and/or other treatment)

          -  Pregnant or nursing female participants

          -  Subjects of childbearing potential not willing to use adequate contraception

          -  Subject has significant active cardiac disease within 6 months prior to the start of
             study treatment, including New York Heart Association (NYHA) class III or IV
             congestive heart failure; acute coronary syndrome (ACS); and/or stroke; or left
             ventricular ejection fraction (LVEF) < 40% by echocardiogram (ECHO) or multi-gated
             acquisition (MUGA) scan obtained within 28 days prior to the start of study treatment

          -  Subject with concurrent severe and/or uncontrolled medical or psychiatric conditions
             that in the opinion of the investigator may impair the participation in the study or
             the evaluation of safety and/or efficacy

          -  Subject has immediately life-threatening, severe complications of leukemia such as
             uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated
             intravascular coagulation

          -  Subject is known to have dysphagia, short-gut syndrome, gastroparesis, or other
             conditions that limit the ingestion or gastrointestinal absorption of drugs
             administered orally

          -  Subjects has uncontrolled hypertension (systolic blood pressure [BP] > 180 mmHg or
             diastolic BP > 90 mmHg)

          -  Subject has known (or suspected to have) hypersensitivity to any of the components of
             study treatment

          -  Subject has corrected QT (QTc) interval (i.e., Fridericia's correction [QTcF]) >= 450
             ms or other factors that increase the risk of QT prolongation or arrhythmic events
             (e.g., heart failure, hypokalemia, family history of long QT interval syndrome) at
             screening

          -  Subject is taking the following sensitive CYP substrate medications that have a narrow
             therapeutic range are excluded from the study unless the subject can be transferred to
             other medications at least 5 half-lives prior to the start of study treatment:
             phenytoin (CYP2C9), S-mephenytoin (CYP2C19), thioridazine (CYP2D6), theophylline, and
             tizanidine (CYP1A2)

          -  Subject who is taking the breast cancer resistance protein (BCRP)
             transporter-sensitive substrate (i.e., rosuvastatin) should be excluded from the study
             unless the subject can be transferred to other medications at least 5 half-lives prior
             to the start of study treatment

          -  Subject with prior history of malignancy, other than myelodysplastic syndrome (MDS),
             myeloproliferative neoplasm (MPN) or AML may be eligible after discussion with the
             study doctor. Diagnoses of basal or squamous cell carcinoma of the skin, carcinoma in
             situ of the cervix, carcinoma in situ of the breast, and previously treated prostate
             cancer (T1a/T1b by TNM staging) are not exclusionary :

          -  Concurrent participation in another therapeutic clinical trial

          -  Unwilling or unable to follow protocol requirements

          -  Any condition which in the investigator's opinion deems the participant an unsuitable
             candidate to receive study drug Subject has any condition including the presence of
             laboratory abnormalities, which places the subject at unacceptable risk if he/she were
             to participate in the study.
      "
NCT03397394,terminated,"
    efficacy did not meet the continuance criteria and dmc recommended to stop enrollment.
  ",0,phase 2,"['bladder cancer', 'urothelial carcinoma', 'metastatic urothelial carcinoma', 'renal pelvis carcinoma', 'ureter carcinoma', 'urinary bladder carcinoma', 'urethra carcinoma', 'muscle invasive bladder cancer']","[""['D30.3', 'C67.5', 'C67.9', 'C79.11', 'C67.0', 'C67.1', 'D41.4']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]",['rucaparib'],['CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2'],"
        Inclusion Criteria:

          -  Have histologically or cytologically confirmed locally advanced unresectable or
             metastatic transitional cell carcinoma of the urothelium (renal pelvis, ureter,
             urinary bladder or urethra)

          -  Received 1 or 2 prior treatment regimens for advanced or metastatic disease

          -  Confirmed radiologic disease progression during or following recent treatment

          -  Mandatory biopsy is required during screening

          -  Measurable disease per RECIST v1.1

          -  Adequate organ function

          -  ECOG 0 or 1

        Exclusion Criteria:

          -  Prior treatment with a PARP inhibitor

          -  Symptomatic and/or untreated CNS metastases

          -  Duodenal stent and/or any gastrointestinal disorder that may interfere with absorption
             of rucaparib
      "
NCT03391050,terminated,"
    target patient population - difficult to find patientes
  ",0,phase 1/phase 2,['melanoma'],"[""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']""]","['apr-246', 'dabrafenib']","['COCC1(C(=O)C2CCN1CC2)CO', 'CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F']","
        Inclusion Criteria:

          -  Patients with confirmed BRAF V600 mutation-positive unresectable and/or metastatic
             malignant cutaneous melanoma, as determined locally by a validated test and treated
             with dabrafenib/trametinib first line combination therapy or second line after first
             line immunotherapy.

          -  Patients that have progressed according to RECIST 1.1 after at least 4 weeks of
             treatment with dabrafenib/trametinib and remained on dabrafenib full dose (150mg bid)
             treatment for the study.

          -  Measurable disease according to RECIST 1.1 criteria. For phase II only, metabolic
             measurable disease (according to PERCIST).

          -  Availability of tissue from a metastatic lesion. A new biopsy is required unless
             inaccessible. An archival sample is accepted in that case after discussion with the
             sponsor.

          -  ECOG Performance Status of 0 or 1.

          -  Patients able to swallow and retain oral medication.

          -  Capable of giving written informed consent, which includes compliance with the
             requirements and restrictions listed in the consent form.

          -  For female patients of childbearing potential, a pregnancy test (serum) will be
             performed within 7 days before inclusion. Woman of childbearing potential must be
             willing to use one highly effective form of contraception during anticancer treatment
             and for at least six months thereafter. Men must agree to use condom during the course
             of this study and at least six months after the last administration of the study
             treatment and contraception should be considered for partner of childbearing
             potential.

          -  Adequate organ system function.

          -  Signed informed consent before any study specific procedure and/or treatment happens.

        Exclusion Criteria:

          -  Presence of uveal melanoma and/or other non-cutaneous melanomas.

          -  Current use of a prohibited medication or need for any of these medications during
             treatment with study drug and within 28 days before the first administration of
             APR-246. I.e., no anti-cancer other than that given in this clinical trial, no
             immunotherapy, no hormonal cancer therapy, no radiation therapy (except palliative)
             and no experimental medications are permitted during the trial. All alternative
             therapies must first be approved by the sponsor. Supportive care therapies are
             allowed.

          -  Unresolved toxicity greater than NCI-CTCAE(v4) Grade 1 from previous anti-cancer
             therapy except alopecia.

          -  Presence of active gastrointestinal disease or other condition that will interfere
             significantly with the absorption, distribution, metabolism, or excretion of drugs.

          -  Known HIV, active hepatitis B or hepatitis C infection.

          -  Primary malignancy of the central nervous system.

          -  History of familial long QT, serious ventricular arrhythmia (no VT > 130 bpm and > 5
             extra beats per minute), no QTc ≥ 480 msec calculated from a single ECG reading or a
             mean of 3 ECG readings using Fridericia's correction (QTcF = QT/RR0.33) or bradycardia
             (< 45 bpm).

          -  Untreated or symptomatic brain metastasis, leptomeningeal disease or spinal cord
             compression. Patients who are on a stable dose of corticosteroids > 1 month or off
             corticosteroids for 2 weeks can be enrolled.

          -  History of acute coronary syndromes (including unstable angina), coronary angioplasty,
             or stenting, or thrombo-embolic event within the past 24 weeks from signature of ICF.

          -  Class II, III, or IV heart failure as defined by the New York Heart Association (NYHA)
             functional classification system.

          -  Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
             chemically related to the study drugs, or excipients.

          -  Uncontrolled diabetes, hypertension or other medical conditions that may interfere
             with assessment of toxicity.

          -  Pregnant or lactating woman.
      "
NCT03393117,withdrawn,"
    no accrual
  ",0,phase 2,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['liposomal bupivacaine', 'bupivacaine', 'patient-controlled analgesia pump', 'oral narcotic']","['CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C', 'CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C']","
        Inclusion Criteria:

          -  Patients scheduled to have a unilateral, immediate breast reconstruction

        Exclusion Criteria:

          -  Pregnant

          -  Concurrent or recent medical condition that could interfere with study participation
             including:

               -  Hepatitis

               -  Alcohol/substance abuse

               -  Uncontrolled psychiatric disorders

               -  Known allergy

               -  Contraindication to amide-type local anesthetics, opioids, or propofol.

          -  Body weight of less than 50 kg

          -  Participated in another study involving an investigational medication within the prior
             30 days

          -  Taking analgesics (i.e., nonsteroidal anti-inflammatory drugs, acetaminophen, or
             opioids), antidepressants, or glucocorticoids within the 3 days before surgery.
      "
NCT03399669,unknown status,,1,phase 2,['non-small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]",['gefitinib'],['COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4'],"
        Inclusion Criteria:

          -  Histologically confirmed stage IIIB/IV or recurrent NSCLC with activating EGFR
             mutation in exon 18 through exon 21 except T790M

          -  Patients who achieved complete/partial response more than 4 months or stable disease
             more than 6 months with first-line or second line gefitinib

          -  Patients who experience disease progression by RECIST 1.1 criteria

          -  Age ≥ 18years

          -  ECOG performance status of 0 to 2

          -  Adequate organ function as evidenced by the following; Absolute neutrophil count > 1.5
             x 109/L; platelets > 100 x 109/L; total bilirubin ≤1.5 UNL; AST and/or ALT < 5 UNL,
             CCr ≥ 50mL/min

          -  Baseline adverse event of gefitinib ≤ Grade 2

          -  Written informed consent form

        Exclusion Criteria:

          -  Prior treatment with EGFR TKI

          -  Patients who required dose reduction of gefitinib

          -  Surgery undertaken less than 4 weeks before the study

          -  Localized radiotherapy unless completed more than 2 weeks before the study

          -  Uncontrolled systemic illness such as DM, CHF, unstable angina, hypertension or
             arrhythmia

          -  Pregnant or nursing women ( Women of reproductive potential have to agree to use an
             effective contraceptive method (hormonal or barrier methods))

          -  Uncontrolled symptomatic brain metastasis

          -  Prior history of malignancy within 5 years from study entry except for adequately
             treated basal cell or squamous cell skin cancer or in situ cervical cancer,
             well-treated thyroid cancer

          -  Concomitant use of CYP3A4 inducers/inhibitors

          -  Prolonged QT interval in ECG (QTc >450 msec)

          -  Patients who cannot take a medicine orally or who have a gastrointestinal absorption
             disorder
      "
NCT02981498,completed,,1,phase 2,['hepatocellular carcinoma'],"[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]",['folfox protocol'],['[CH2-]C1CCCCC1[CH2-].C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O.C1=C(C(=O)NC(=O)N1)F.C(=O)(C(=O)O)O.[Pt+2]'],"
        Criteria:

        Inclusion Criteria:

          -  The diagnosis of HCC was based on the diagnostic criteria for HCC used by the European
             Association for the Study of the Liver (EASL)

          -  Patients must have at least one tumor lesion that can be accurately measured according
             to EASL criteria.

          -  diagnosed with major or main portal vein invasion (Vp3 or Vp4)

          -  KPS≥70；

          -  with no previous treatment

          -  No Cirrhosis or cirrhotic status of Child-Pugh class A only

          -  Not amendable to surgical resection ,local ablative therapy and any other cured
             treatment.

          -  The following laboratory parameters:

               -  Platelet count ≥ 75,000/µL

               -  Hemoglobin ≥ 8.5 g/dL

               -  Total bilirubin ≤ 30mmol/L

               -  Serum albumin ≥ 30 g/L

               -  ASL and AST ≤ 5 x upper limit of normal

               -  Serum creatinine ≤ 1.5 x upper limit of normal

               -  INR ≤ 1.5 or PT/APTT within normal limits

               -  Absolute neutrophil count (ANC) >1,500/mm3

          -  Ability to understand the protocol and to agree to and sign a written informed consent
             document

        Exclusion Criteria:

          -  Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or
             hepatic encephalopathy

          -  Known history of HIV

          -  History of organ allograft

          -  Known or suspected allergy to the investigational agents or any agent given in
             association with this trial.

          -  Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy

          -  Evidence of bleeding diathesis.

          -  Patients with clinically significant gastrointestinal bleeding within 30 days prior to
             study entry.

          -  Any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of first dose of
             study drug

          -  Serious non-healing wound, ulcer, or bone fracture

          -  Known central nervous system tumors including metastatic brain disease
      "
NCT02981524,completed,,0,phase 2,['metastatic colorectal cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['cy', 'pembrolizumab']",['C1CNP(=O)(OC1)N(CCCl)CCCl'],"
        Inclusion Criteria:

          1. Documented mismatch repair-proficient cancer of colorectum, who have received at least
             two prior lines of therapy for metastatic disease

          2. Measurable disease by RECIST v1.1

          3. Age >18 years

          4. ECOG Performance Status of 0 to 1

          5. Estimated life expectancy of greater than 3 months.

          6. Adequate organ function as defined by study-specified laboratory tests

          7. Must use acceptable form of birth control through the study and for 120 days after
             final dose of study drug

          8. Signed informed consent form

          9. Willing and able to comply with study procedures

        Exclusion Criteria:

          1. Has a known additional malignancy that is progressing or requires active treatment.

          2. Has known central nervous system (CNS) metastases and/or carcinomatous meningitis.

          3. Has known malignant small bowel obstruction within the last 6 months.

          4. Currently have or have history of certain study-specified heart, liver, kidney, lung,
             neurological, immune or other medical conditions.

          5. Systemically active steroid use.

          6. Has an active infection requiring systemic therapy.

          7. Has a known history of active TB (Bacillus Tuberculosis).

          8. Infection with HIV or hepatitis B or C.

          9. Has history of (non-infectious) pneumonitis that required steroids.

         10. Must not require supplemental oxygen or have a pulse oximetry < 92% on room air.

         11. Conditions, including therapy, laboratory abnormalities, psychiatric or substance
             abuse disorders, intercurrent illness, or lack of sufficient peripheral venous access,
             that would affect the patient's ability to comply with study visits and procedures.

         12. Pregnant or lactating.

         13. Another investigational product within 28 days prior to receiving study drug.

         14. Major surgery or significant traumatic injury (or unhealed surgical wounds) occurring
             within 28 days prior to receiving study drug.

         15. Chemotherapy, radiation, hormonal, or biological cancer therapy within 28 days prior
             to receiving study drug.

         16. Has received a live vaccine within 30 days of planned start of study therapy.

         17. Prior treatment with immunotherapy agents (including, anti-PD-1, anti-PD-L1,
             anti-PD-L2, anti-CTLA4, etc.).

         18. Patients receiving growth factors including, but not limited to, granulocyte-colony
             stimulating factor (G-CSF), GM-CSF, erythropoietin, within 14 days of study drug
             administration.

         19. Hypersensitivity to pembrolizumab or any of its excipients.

         20. Patient has a known or suspected hypersensitivity to GM-CSF, hetastarch, corn,
             dimethyl sulfoxide, fetal bovine serum, trypsin (porcine origin), yeast or any other
             component of GVAX vaccine.

         21. Presence of any tissue or organ allograft and history of allogeneic hematopoietic stem
             cell transplant.

         22. Unwilling or unable to comply with study procedures.
      "
NCT02988986,completed,,1,phase 2,['estrogen receptor positive breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['tak-228', 'tamoxifen']","['CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N', 'CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3']","
        Inclusion Criteria:

          1. Female or male ≥ 18 years of age.

          2. Newly diagnosed ER-positive, HER2-negative breast cancer. ER-positive is defined as ≥
             1% immunohistochemical (IHC) staining of any intensity. HER2 test result is negative
             if a single test (or both tests) performed show:

               -  IHC 1+ or 0

               -  In situ hybridization negative based on:

                    -  Single-probe average HER2 copy number < 4.0 signals/cell

                    -  Dual-probe HER2/CEP17 ratio < 2 with an average HER2 copy number < 4.0
                       signals/cell.

          3. Patients with stage II-III breast cancer are eligible if they are deemed appropriate
             for neoadjuvant endocrine therapy by the referring or treating medical oncologist.
             Patients with stage I disease are eligible if they are deemed borderline candidates
             for breast conservation and the treating surgeon recommends preoperative therapy to
             increase the chances of breast conservation.

          4. Eastern Cooperative Oncology Group performance status and/or other performance status
             of ≤ 1.

          5. Female patients who:

               -  Are postmenopausal for at least 1 year before the screening visit, OR

               -  Are surgically sterile, OR

               -  If they are of childbearing potential, agree to practice 1 effective method of
                  contraception and 1 additional effective (barrier) method, at the same time, from
                  the time of signing the ICF through 90 days (or longer, as mandated by local
                  labeling [e.g., United Surgical Partners International, summary of product
                  characteristics, etc.] after the last dose of the study drugs, OR

               -  Agree to practice true abstinence, when this is in line with the preferred and
                  usual lifestyle of the patient (periodic abstinence [e.g., calendar, ovulation,
                  symptothermal, postovulation methods] and withdrawal, spermicides only, and
                  lactational amenorrhea are not acceptable methods of contraception. Female and
                  male condom should not be used together).

          6. Male patients, even if surgically sterilized (i.e., status post-vasectomy), who:

               -  Agree to practice highly effective barrier contraception during the entire study
                  treatment period and through 120 days after the last dose of the study drugs, OR

               -  Agree to practice true abstinence, when this is in line with the preferred and
                  usual lifestyle of the patient

               -  Agree not to donate sperm during the course of this study or within 120 days
                  after receiving their last dose of the study drugs.

          7. Screening clinical laboratory values as specified below:

               1. Bone marrow reserve consistent with: absolute neutrophil count ≥ 1.5 x 109/L,
                  platelet count ≥ 100 x 109/L, and hemoglobin ≥ 9 g/dL (without transfusion)
                  within 1 week preceding the administration of the study drugs;

               2. Hepatic status: Serum total bilirubin ≤ 1 x upper limit of normal (ULN; in the
                  case of known Gilbert's syndrome, a higher serum total bilirubin [< 1.5 x ULN] is
                  allowed), aspartate aminotransferase and alanine aminotransferase ≤ 1.5 x ULN,
                  and alkaline phosphatase ≤ 1.5 x ULN;

               3. Renal status: Creatinine clearance ≥50 mL/min based on Cockcroft-Gault estimate
                  or based on urine collection (12 or 24 hour);

               4. Metabolic status: HbA1c < 7.0%, fasting serum glucose ≤ 130 mg/dL, and fasting
                  triglycerides ≤ 300 mg/dL.

          8. Ability to swallow oral medications.

          9. Voluntary written consent must be given before performance of any study-related
             procedure not part of standard medical care, with the understanding that consent may
             be withdrawn by the patient at any time without prejudice to future medical care.

         10. Negative serum pregnancy test within 7 days prior to the administration of the study
             drugs for female patients of childbearing potential.

         11. Patient must be accessible for treatment and follow-up.

         12. Patient must be willing to undergo breast biopsies as required by the study protocol.

        Exclusion Criteria:

          1. Any patient with metastatic disease.

          2. Other clinically significant comorbidities, such as uncontrolled pulmonary disease,
             active central nervous system disease, active infection, or any other condition that
             could compromise the patient's participation in the study.

          3. Known human immunodeficiency virus infection.

          4. Known hepatitis B surface antigen-positive or known or suspected active hepatitis C
             infection.

          5. Any serious medical or psychiatric illness that could, in the investigator's opinion,
             potentially interfere with the completion of the protocol-specified treatment.

          6. Diagnosed or treated for another malignancy within 2 years before administration of
             the first dose of the study drugs or previously diagnosed with another malignancy and
             have any evidence of residual disease. Patients with non-melanoma skin cancer or
             carcinoma in situ of any type are not excluded if they have undergone complete
             resection.

          7. Breastfeeding or pregnant.

          8. Manifestations of malabsorption due to prior gastrointestinal surgery,
             gastrointestinal disease, or an unknown reason that may alter the absorption of
             TAK-228. Patients with enteric stomata are also excluded.

          9. Treatment with any investigational products within 2 weeks before administration of
             the first dose of the study drugs.

         10. Poorly controlled diabetes mellitus (defined as HbA1c > 7%). Patients with a history
             of transient glucose intolerance due to corticosteroid administration may be enrolled
             in the study if all other inclusion criteria and none of the other exclusion criteria
             are met.

         11. History of any of the following within the last 6 months before administration of the
             first dose of the study drugs:

               -  Ischemic myocardial event, including angina requiring therapy and artery
                  revascularization procedures

               -  Ischemic cerebrovascular event, including transient ischemic attack and artery
                  revascularization procedures

               -  Requirement for inotropic support (excluding digoxin) or serious (uncontrolled)
                  cardiac arrhythmia (including atrial flutter/fibrillation, ventricular
                  fibrillation, and ventricular tachycardia)

               -  Placement of a pacemaker for control of rhythm

               -  New York Heart Association Class III or IV heart failure

               -  Pulmonary embolism

         12. Significant active cardiovascular or pulmonary disease including:

               -  Uncontrolled hypertension (i.e., systolic blood pressure > 180 mm Hg, diastolic
                  blood pressure > 95 mm Hg). Use of antihypertensive agents to control
                  hypertension before week 1, day 1 is allowed.

               -  Pulmonary hypertension

               -  Uncontrolled asthma or O2 saturation < 90% by arterial blood gas analysis or
                  pulse oximetry on room air

               -  Significant valvular disease, severe regurgitation, or stenosis by imaging
                  independent of symptom control with medical intervention or history of valve
                  replacement

               -  Medically significant (symptomatic) bradycardia

               -  History of arrhythmia requiring an implantable cardiac defibrillator

               -  Baseline QTc prolongation (e.g., repeated demonstration of QTc interval > 480
                  milliseconds or history of congenital long QT syndrome or torsades de pointes)

         13. Treatment with strong inhibitors and/or inducers of CYP3A4, CYP2C9, or CYP2C19 within
             7 days preceding the first dose of the study drugs.

         14. Patients receiving systemic corticosteroids (either IV or oral steroids, excluding
             inhalers or low-dose hormone replacement therapy) within 1 week before administration
             of the first dose of the study drugs.

         15. Daily or chronic use of a proton pump inhibitor (PPI) and/or having taken a PPI within
             7 days before receiving the first dose of the study drugs.

         16. Patients unwilling or unable to comply with the study protocol.

         17. Patients previously treated with hormonal therapy (tamoxifen, AI) or PI3K, AKT, dual
             PI3K/mTOR, TORC1/2, or mTORC1 inhibitors.

         18. Patients who are currently being treated with cancer therapy (chemotherapy, radiation
             therapy, immunotherapy, or biologic therapy) other than the trial therapy.

         19. Patients with hypersensitivity to mTOR inhibitors or tamoxifen.
      "
NCT02987959,terminated,"
    closed to accrual due to funding sponsor withdrawing support due to low accrual
  ",0,phase 2,['soft-tissue sarcoma'],"[""['C46.1']""]",['tak-228'],['CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N'],"
        Inclusion Criteria:

          -  This trial has two step inclusion criteria.

        Step 1 Inclusion Criteria

          1. Male or female patients 18 years or older.

          2. Patients must have a diagnosis of a locally advanced or metastatic sarcoma that is
             progressing. The following subtypes (considered genomically complex) will be eligible:
             leiomyosarcoma (well differentiated or poorly differentiated), undifferentiated
             pleomorphic sarcoma, myxofibrosarcoma, pleomorphic rhabdomyosarcoma, pleomorphic
             liposarcoma, malignant peripheral nerve sheath tumor, angiosarcoma or extraskeletal
             osteosarcoma. Other potentially genomically complex Soft Tissue Sarcomas (STS)
             subtypes may be included on a case-by-case basis after discussion with the principal
             investigator.

          3. Measurable disease by RECIST 1.1 criteria (at least one target lesion outside of
             previous radiation fields or progressed within a previous radiation field), described
             in detail in section 15.

          4. Progression of disease by radiographic imaging (10% increase in size by RECIST v1.1
             within 6 months of registration) or presence of new lesions.

          5. Must have received at least 1 prior systemic therapy for advanced disease (does not
             include adjuvant/neoadjuvant therapy in a curative setting).

          6. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

          7. Adequate contraception as follows:

             For women:

             Postmenopausal for at least 1 year before the screening visit, OR Surgically sterile,
             OR If they are of childbearing potential, agree to practice 1 effective method of
             contraception, and 1 additional (barrier) method, at the same time, from the time of
             signing the informed consent through 90 days (or longer, as mandated by local labeling
             [eg. United Surgical Partners Internationals (USPI), Summary of Product
             Characteristics (SmPC), etc;]) after the last dose of study drug OR agree to practice
             true abstinence, when this is in line with the preferred and usual lifestyle of the
             patient (Periodic abstinence [e.g, calendar, ovulation, symptothermal, postovulation
             methods] and withdrawal, spermicides only, and lactational amenorrhea are not
             acceptable methods of contraception. Female and male condoms should not be used
             together.)

             Highly effective methods:

             Intra-uterine devices (IUD) Hormonal (birth control pills/oral contraceptives,
             injectable contraceptives, contraceptive patches, or contraceptive implants)

             Other effective Methods:

             Latex Condoms Diaphragm with spermicide; Cervical cap;Sponge

             For men, even if surgically sterilized (ie, status post-vasectomy), they must:

             Agree to practice highly effective barrier contraception during the entire study
             treatment period and through 120 days after the last dose of study drug, OR agree to
             practice true abstinence, when this is in line with the preferred and usual lifestyle
             of the patient (Periodic abstinence [e.g, calendar, ovulation, symptothermal,
             postovulation methods for the female partner] and withdrawal, spermicides only, and
             lactational amenorrhea are not acceptable methods of contraception. Female and male
             condoms should not be used together.)

             Agree not to donate sperm during the course of this study or 120 days after receiving
             their last dose of study drug

          8. Screening clinical laboratory values as specified below:

             a) Bone marrow reserve consistent with: i. absolute neutrophil count (ANC) ≥ 1.5 x
             10(9)/L; ii. platelet count ≥ 100 x 10(9)/L; iii. hemoglobin ≥ 9 g/dL without
             transfusion within 1 week preceding study drug administration b) Hepatic: i. total
             bilirubin ≤ 1.5 x upper limit of normal (ULN), ii. transaminases (Aspartate
             aminotransferase/Serum Glutamic Oxaloacetic Transaminase (AST/SGOT) and Alanine
             aminotransferase/Serum Glutamic Pyruvic Transaminase (ALT/SGPT) ≤ 2.5 x ULN (≤ 5 x ULN
             if liver metastases are present); c) Renal: creatinine clearance ≥ 50 mL/min based
             either on Cockcroft-Gault estimate or based on urine collection (12 or 24 hour); d)
             Metabolic: i. Glycosylated hemoglobin (HbA1c) ≤ 7.0%, ii. fasting serum glucose ≤ 130
             mg/dL iii. fasting triglycerides ≤ 300 mg/dL

          9. Ability to swallow oral medications.

         10. Voluntary written consent must be given before performance of any study related
             procedure not part of standard medical care, with the understanding that consent may
             be withdrawn by the patient at any time without prejudice to future medical care.

         11. Patients who have a history of brain metastasis are eligible for the study provided
             that all the following criteria are met:

               1. Brain metastases which have been treated

               2. No evidence of disease progression for ≥ 3 months or hemorrhage after treatment

               3. Off-treatment with dexamethasone for 4 weeks before administration of the first
                  dose of TAK-228

               4. No ongoing requirement for dexamethasone or anti-epileptic drugs

        Step 2 Inclusion Criteria: Must be met after meeting step1inclusion and exclusion criteria.

        1. Tumor must have dysregulation of the PI3K/AKT/mTOR pathway. For the purposes of this
        study, patients must have either PTEN protein or genomic loss, or
        phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA)/
        Phosphatase and tensin homolog (PTEN) mutation. Patients must be willing to provide
        sufficient archival tissue. If this is not available fresh tumor for biopsy is required. In
        the event that a patient has had tumor analyzed for PTEN/PIK3CA status through commercial
        means, their eligibility and need for additional tissue will be determined on a case by
        case basis by the principle investigator.

        Exclusion Criteria:

          -  Step 1 Exclusion Criteria

               1. Any clinically significant co-morbidities, such as uncontrolled pulmonary
                  disease, active central nervous system disease, active infection, or any other
                  condition that could compromise the patient's participation in the study.

               2. Known human immunodeficiency virus infection.

               3. Known hepatitis B surface antigen-positive, or known or suspected active
                  hepatitis C infection.

               4. Any serious medical or psychiatric illness that could, in the investigator's
                  opinion, potentially interfere with the completion of treatment according to this
                  protocol.

               5. Diagnosed or treated for another malignancy within 2 years before administration
                  of the first dose of study drug, or previously diagnosed with another malignancy
                  and have any evidence of residual disease. Patients with nonmelanoma skin cancer
                  or carcinoma in situ of any type are not excluded if they have undergone complete
                  resection.

               6. Breast feeding or pregnant.

               7. Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI
                  disease, or for an unknown reason that may alter the absorption of TAK-228. In
                  addition, patients with enteric stomata are also excluded.

               8. Treatment with any investigational products, radiation therapy, surgery, tumor
                  embolization, chemotherapy or immunotherapy within 21 days before the first dose
                  of the study drug. For biologic or hormonal therapy treatment within 14 days or
                  five half-lives of a drug (whichever is longer) before the first dose of study
                  drug.

               9. History of any of the following within the last 6 months before administration of
                  the first dose of the drug:

                    1. Ischemic myocardial event, including angina requiring therapy and artery
                       revascularization procedures

                    2. Ischemic cerebrovascular event, including transient ischemic attack and
                       artery revascularization procedures

                    3. Requirement for inotropic support (excluding digoxin) or serious
                       (uncontrolled) cardiac arrhythmia (including atrial flutter/fibrillation,
                       ventricular fibrillation or ventricular tachycardia)

                    4. Placement of a pacemaker for control of rhythm

                    5. New York Heart Association (NYHA) Class III or IV heart failure

                    6. Pulmonary embolism

              10. Significant active cardiovascular or pulmonary disease including:

                    1. Uncontrolled hypertension (i.e., systolic blood pressure >180 mm Hg,
                       diastolic blood pressure >95 mm Hg). Use of anti-hypertensive agents to
                       control hypertension before Cycle1 Day 1 is allowed.

                    2. Pulmonary hypertension

                    3. Uncontrolled asthma or O2 saturation < 90% by arterial blood gas analysis or
                       pulse oximetry on room air

                    4. Significant valvular disease; severe regurgitation or stenosis by imaging
                       independent of symptom control with medical intervention, or history of
                       valve replacement

                    5. Medically significant (symptomatic) bradycardia

                    6. History of arrhythmia requiring an implantable cardiac defibrillator

                    7. Baseline prolongation of the rate-corrected QT interval (QTc) (e.g.,
                       repeated demonstration of QTc interval >480 milliseconds, or history of
                       congenital long QT syndrome, or torsades de pointes)

              11. Poorly controlled diabetes mellitus defined as glycosylated hemoglobin (HbA1c)
                  >7% ; patients with a history of transient glucose intolerance due to
                  corticosteroid administration or gestational diabetes may be enrolled in this
                  study if all other inclusion/exclusion criteria are met.

              12. Treatment with strong inhibitors and/or inducers of cytochrome P450 (CYP) 3A4,
                  CYP2C19 or CYP2C9 within 1 week preceding the first dose of study drug.

              13. Patients receiving systemic corticosteroids (either IV or oral steroids,
                  excluding inhalers or low-dose hormone replacement therapy) within 1 week before
                  administration of the first dose of study drug.

              14. Daily or chronic use of a proton pump inhibitor (PPI) and/or having taken a PPI
                  within 7 days before receiving the first dose of study drug.
      "
NCT02984995,completed,,1,phase 2,"['leukemia, myeloid, acute']","[""['C92.A1', 'C92.A2', 'C92.61', 'C92.62', 'C92.A0', 'C92.60']""]",['quizartinib'],['CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C=C2)C3=CN4C5=C(C=C(C=C5)OCCN6CCOCC6)SC4=N3'],"
        Inclusion Criteria:

          -  AML patients in first relapse or refractory after all prior therapy

          -  Presence of the FLT3-ITD activating mutation in bone marrow or peripheral blood

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2

        Exclusion Criteria:

          -  Diagnosis of acute promyelocytic leukemia

          -  AML secondary to prior chemotherapy for other neoplasms.

          -  Persistent, clinically significant > Grade 1 non-hematologic toxicity from prior AML
             therapy

          -  Prior treatment with a FLT3 targeted therapy

          -  Active infection not well controlled by antibacterial, antifungal and/or antiviral
             therapy
      "
NCT02092909,terminated,"
    lack of efficacy
  ",0,phase 1/phase 2,"[""waldenstrom's macroglobulinemia""]","[""['C88.0']""]",['imo-8400'],['CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3CC(OC3COP(=S)(O)OC4CC(OC4COP(=S)(O)OC5C(OC(C5OC)N6C=CC(=O)NC6=O)COP(=S)(O)OC7C(OC(C7OC)N8C=NC9=C8N=C(NC9=O)N)COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=O)(OC1CC(OC1COP(=S)(O)OC1CC(OC1CO)N1C=CC(=NC1=O)N)N1C=C(C(=O)NC1=O)C)S)N1C=NC2=C(N=CN=C21)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=C(C(=O)NC1=O)C)N1C=C(C(=NC1=O)N)C)N1C=CC2=C1N=C(NC2=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C1N=C(NC2=O)N)OC)OP(=S)(O)OCC1C(C(C(O1)N1C=CC(=O)NC1=O)OC)O'],"
        Inclusion Criteria:

        Patients must have a diagnosis of relapsed Waldenstrom's Macroglobulinemia.

        In addition to the above, key inclusion and exclusion criteria are listed below.

        Inclusion Criteria:

          1. At least 18 years of age.

          2. Agree to use contraception

          3. Hemoglobin ≥ 7.5 g/dL, - Absolute neutrophil count ≥ 1.0 x 109/L (1000/mm3), -
             Platelets ≥ 50,000/μL

        Exclusion Criteria:

          1. Is nursing or pregnant

          2. Has BMI > 34.9 kg/m2.

          3. Has a positive test for human immunodeficiency virus (HIV-1 or -2) hepatitis C virus
             (HCV) or hepatitis B surface antigen (HBsAg).

          4. Receiving chronic systemic corticosteroid therapy > 20 mg of prednisone daily.

          5. Being treated with other anti-cancer therapies (approved or investigational).

          6. Has, at the initiation of study drug, received cytotoxic chemotherapy or a Bruton's
             tyrosine kinase (BTK)-inhibitor (e.g. ibrutinib) within the past 3 weeks or rituximab
             within the past 2 months

          7. Has an active infection requiring systemic antibiotics.

          8. Has had surgery requiring general anesthesia within 4 weeks of starting the study.

          9. Has autoimmune cytopenia (anemia, thrombocytopenia, leukopenia).

         10. Has heart failure of Class III or IV.

         11. Has sensory or motor neuropathy limiting daily activities.
      "
NCT02094261,"active, not recruiting",,1,phase 2,['non small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]",['azd9291'],['CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC'],"
        Inclusion:

          -  Aged at least 18 years. Japan patients aged at least 20 years.

          -  Locally advanced/metastatic NSCLC not amenable to curative surgery or radiotherapy

          -  Radiological documentation of disease progression:

        following 1st line EGFR TKI treatment but who have not received further treatment OR
        following prior therapy with an EGFR TKI and a platinum-based doublet chemotherapy.
        Patients who received prior EGFR TKI and platinum-based doublet chemotherapy may have also
        received additional lines of treatment. All patients must have documented radiological
        progression on the last treatment administered prior to enrolling in the study.

          -  Disease progression following 1st line EGFR TKI treatment or following prior EGFR TKI
             and platinum-containing doublet chemotherapy.

          -  Confirmation that the tumour harbours an EGFR mutation known to be associated with
             EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q). Patients must
             have central confirmation of tumour T790M mutation positive status from a biopsy
             sample taken after confirmation of disease progression on the most recent treatment
             regimen.

          -  World Health Organisation (WHO) performance status 0-1 with no deterioration over the
             previous 2 weeks and a minimum life expectancy of 12 weeks.

          -  At least one lesion, not previously irradiated and not chosen for biopsy during the
             study screening period, that can be accurately measured at baseline as ≥ 10mm in the
             longest diameter (except lymph nodes which must have short axis ≥ 15mm) with
             computerised tomography (CT) or magnetic resonance imaging (MRI) which is suitable for
             accurate repeated measurements.

          -  Females of child-bearing potential using contraception; negative pregnancy test.

        Exclusion:

          -  Treatment with an EGFR-TKI within 8 days of study entry; any cytotoxic chemotherapy,
             investigational agents or other anticancer drugs within 14 days of study entry;
             previous treatment with AZD9291 (or 3rd generation TKIs); major surgery within 4
             weeks; radiotherapy treatment to more than 30% of the bone marrow or with a wide field
             of radiation within 4 weeks; current treatment with potent inhibitors of CYP2C8 and
             potent inhibitors/inducers of CYP3A4.

          -  Unresolved toxicities from prior therapy.

          -  Unstable spinal cord compression/brain metastases.

          -  Severe/uncontrolled systemic diseases, including uncontrolled hypertension, bleeding
             diatheses or infection.

          -  Refractory nausea/vomiting, chronic gastrointestinal diseases or bowel resection.

          -  Cardiac disease.

          -  Past history of ILD, drug-induced ILD, radiation pneumonitis which required steroid
             treatment, or any evidence of clinically active interstitial lung disease.

          -  Inadequate bone marrow reserve or organ function.
      "
NCT02094794,recruiting,,1,phase 2,"['adult acute myeloid leukemia with 11q23 (mll) abnormalities', 'adult acute myeloid leukemia with del(5q)', 'adult acute myeloid leukemia with inv(16)(p13;q22)', 'adult acute myeloid leukemia with t(15;17)(q22;q12)', 'adult acute myeloid leukemia with t(16;16)(p13;q22)', 'adult acute myeloid leukemia with t(8;21)(q22;q22)', 'recurrent adult acute lymphoblastic leukemia', 'recurrent adult acute myeloid leukemia', 'recurrent childhood acute lymphoblastic leukemia', 'recurrent childhood acute myeloid leukemia']","[""['R19.5', 'H35.09', 'M26.50', 'M26.59', 'Q99.8', 'R06.89', 'R06.9']"", ""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']"", ""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']"", ""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']"", ""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']"", ""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']"", ""['C83.57', 'C83.50', 'C91.01', 'C91.02', 'C83.52', 'C83.56', 'C83.53']"", ""['G47.13', 'J01.41', 'K11.22', 'K12.0', 'N96', 'F33.8', 'G03.2']"", ""['C83.57', 'C83.50', 'C91.01', 'C91.02', 'C83.52', 'C83.56', 'C83.53']"", ""['G47.13', 'J01.41', 'K11.22', 'K12.0', 'N96', 'F33.8', 'G03.2']""]","['etoposide', 'cyclophosphamide']","['CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O', 'C1CNP(=O)(OC1)N(CCCl)CCCl']","
        Inclusion Criteria:

          -  Participant has the ability and the willingness to sign the informed consent document
             (for adults only, for participants with mild cognitive abilities may use a legally
             authorized representative)

          -  Documented (signed) informed consent; the patient, family member and transplant staff
             physician (physician, nurse, and social worker) meet at least once prior to starting
             the transplant procedure; during this meeting all pertinent information with respect
             to risks and benefits to donor and recipient will be presented; alternative treatment
             modalities will be discussed; the risks are explained in detail in the enclosed
             consent forms

          -  Karnofsky performance status >= 70% =< 2

          -  Acute lymphocytic leukemia or acute myelogenous leukemia who are not in first
             remission or second remission i.e. after failing induction therapy, or in relapse or
             beyond second remission; (prior therapy with VP-16 and Cytoxan is allowed)

          -  All candidates for this study must have a human leukocyte antigen (HLA) (A, B, C, DR)
             identical siblings who is willing to donate bone marrow or primed blood stem cells or
             a 10/10 allele matched unrelated donor; a single allele mismatch at A, B, C, DR or DQ
             and a killer immunoglobulin-like receptor (KIR) mismatch at C will be allowed; all ABO
             blood group combinations of the donor/recipient are acceptable

          -  The time from the end last induction, re-induction, or consolidation regimen should be
             greater than or equal to 14 days from planned start of study treatment; Note:
             Chemotherapy given within 14 days of planned study enrollment for the purpose of
             controlling counts is permitted

          -  Total bilirubin =< 1.5 x upper limit of normal (ULN) OR 3 x ULN for Gilbert's disease

          -  Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate
             transaminase (SGPT) =< 5 x ULN

          -  Measured creatinine clearance >= 80 ml/min per 24 hour urine collection OR serum
             creatinine =< 1.3 mg/dL

          -  Women of child bearing potential only: Negative urine or serum pregnancy test

          -  Pulmonary function tests: Forced expiratory volume in one second (FEV1) and carbon
             monoxide diffusion capacity (DLCO) (adjusted for Hb) >= 50% adjusted of predicted
             normal value

          -  Echocardiogram (ECHO) or multi gated acquisition scan (MUGA): ejection fraction of >=
             50% AND no finding of abnormal wall motion (i.e. report does not indicate that wall
             motion is ""abnormal"" or ""altered"")

          -  Electrocardiogram (EKG) showing no ischemic changes and no abnormal rhythm

          -  Agreement of men AND women-of-child-bearing-potential to use adequate contraception
             (hormonal or barrier method of birth control or abstinence) prior to study entry and
             for six months following duration of study participation; should a woman become
             pregnant or suspect that she is pregnant while participating on the trial, she should
             inform her treating physician immediately

          -  DONOR ELIGIBILITY: Donor evaluation and eligibility will be assessed as per current
             City of Hope standard operating procedure (SOP)

        Exclusion Criteria:

          -  Prior autologous or allogeneic hematopoietic stem cell

          -  Prior radiation therapy that would exclude the use of TMLI

          -  Plans during the trial to receive any other (non-trial) investigational agents, or
             concurrent biological, chemotherapy, or radiation therapy; (chemotherapy for white
             blood count control is permitted)

          -  Uncontrolled illness including ongoing or active infection

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to etoposide

          -  Patients with other active malignancies are ineligible for this study, other than
             localized malignancies

          -  Patients with psychological or medical condition that patient's physician deems
             unacceptable to proceed to allogeneic hematopoietic stem cell transplantation

          -  Women who are planning to become pregnant or breast feed during the trial

          -  Subjects, who in the opinion of the investigator, may not be able to comply with the
             safety monitoring requirements of the study
      "
NCT02091531,completed,,0,phase 2,['metastatic castration-resistant prostate cancer'],"[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]",['mln0128'],['CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N'],"
        To be included in this study, patients should have histologically confirmed castration
        resistant metastatic prostate cancer with evidence of disease progression. Patients must
        have been in a castrate state either by orchiectomy or by GnRH analogues. In detail, they
        should meet all of the following criteria

        Inclusion Criteria:

          -  Histologically confirmed prostate cancer with progressive metastatic disease based on
             any of the following: i) a rise in PSA, ii) transaxial imaging, or iii) radionuclide
             bone scan.

               1. PSA - a minimum of 3 consecutive rising levels, with an interval of ≥

                  1 week between each determination. The last determination must have a minimal
                  value of ≥ 2 ng/mL and be determined within two weeks prior to enrollment.

               2. Measurable Disease - patients showing new or progressive soft tissue masses on CT
                  or MRI scans as defined by the PCWG2 criteria21

               3. Radionuclide bone scan - at least two new metastatic lesions.

          -  Detectable metastases by bone scan, CT-scan or MRI.

          -  Ongoing androgen depletion therapy with a Gonadotropin Releasing Hormone (GnRH)
             analogue or inhibitor, or orchiectomy (i.e., surgical or medical castration).

        For patients who have not had an orchiectomy, there must be a plan to maintain effective
        GnRH-analogue therapy for the duration of the trial.

          -  Castrate levels of serum testosterone < 50 ng/dL determined within 4 weeks prior to
             starting treatment.

          -  Patients who are receiving an anti-androgen as part of their first-line hormonal
             therapy must have shown progression of disease off the anti-androgen prior to
             enrollment.

          -  At least 4 weeks must have elapsed from the use of androgen receptor antagonists
             (i.e., flutamide, nilutamide, bicalutamide, enzalutamide ); 5-α reductase inhibitors
             (i.e., finasteride, aminoglutethimide); abiraterone acetate; estrogens; nitrosoureas,
             mitomycin C, isotype therapy, ketoconazole, chemotherapy and other anti-cancer
             pharmacologic therapy prior to beginning protocol therapy.

          -  At least 8 weeks must have elapsed from the use of Strontium-89, Radium-223,
             Samarium-153, or immunotherapy (e.g., Provenge) prior to beginning protocol therapy.

          -  At least 4 weeks must have elapsed from the use of any investigational agent prior to
             beginning protocol therapy.

             a. Note: Prior treatment with PI3K/mTOR pathway inhibitors prohibited.

          -  At least 4 weeks must have elapsed from major surgery.

          -  Toxicities related to prior therapy must either have returned to ≤ Grade 1, baseline
             or deemed irreversible.

          -  Patients with treated, non-progressive epidural disease are eligible.

          -  KPS performance status 70-100% (50-60% is allowed only if due to bone pain)

          -  At least 18 years of age, with a life expectancy at least 3 months.

          -  Patient must be willing to comply with study procedures.

          -  Physical and laboratory test findings

               1. Adequate hepatic function with serum bilirubin ≤ 1.5 times the upper
                  institutional limits of normal (ULN), ALT and AST ≤ 2.5 x ULN. Patients with a
                  history of Gilbert's syndrome may be enrolled if the total bilirubin is < 3 mg/dL
                  with a predominance of indirect bilirubin

               2. Adequate renal function with serum creatinine ≤ 1.5 x ULN.

               3. Adequate hematologic function with absolute neutrophil counts ≥ 1,500 cell/mm3
                  and platelets ≥ 100,000 cells/mm3 and hemoglobin value ≥ 9 g/dL (Note: patients
                  whose anemia has been corrected to a hemoglobin value ≥ 9 g/dL with blood
                  transfusions are allowed).

               4. Electrolytes (including potassium, sodium, and serum calcium corrected for
                  albumin or ionized calcium) must be within normal limits.

          -  Left ventricular ejection fraction (LVEF) no more than 5 absolute percentage points
             below the institutional standard of normal as measured by echocardiogram (ECHO) or
             multiple gated acquisition scan (MUGA) within 4 weeks prior to first study drug
             administration (ie, if the institutional normal is 50%, subject's LVEF may be as low
             as 45% to be eligible for the study)

        Exclusion Criteria:

        Patients that meet any of the criteria listed below will not be eligible for study entry:

          -  History of, or current known metastases in the brain or untreated spinal cord
             compression;

          -  History of another malignancy within the previous 2 years except for the following:

               1. Adequately treated basal cell or squamous cell skin cancer, superficial bladder
                  cancer,

               2. Adequately treated Stage I or II cancer currently in complete remission, or any
                  other cancer that has been in complete remission for at least 2 years;

          -  Prior treatment with PI3K/mTOR pathway inhibitors;

        Diabetes mellitus on active treatment, or subjects with either of the following:

          1. Fasting blood glucose (FBG) ≥ 126 mg/dL (7.0 mmol/L), or

          2. HbA1c ≥ 6.5%;

               -  Use of herbal products that may decrease PSA levels (i.e., saw palmetto) or
                  systemic corticosteroid greater than the equivalent of 10 mg of prednisone per
                  day during the 4 weeks prior to screening or plans to initiate treatment with the
                  above during the entire duration of the study;

               -  Any history of unstable angina, myocardial infarction, New York Heart Association
                  (NYHA) Class III or IV heart failure, and/or pulmonary hypertension;

               -  Significant active cardiovascular disease including:

        a. Uncontrolled high blood pressure (ie, systolic blood pressure > 180 mmHg, diastolic
        blood pressure > 95 mmHg) b. Grade 3 or higher valvular disease c. Grade 3 or higher atrial
        fibrillation d. Grade 3 or higher bradycardia e. Endocarditis f. Pulmonary embolism g.
        Recent cerebrovascular accident within 6 months prior to enrollment

          -  A requirement for positive inotropic support (excluding digoxin) or serious
             uncontrolled cardiac arrhythmia (including atrial flutter/fibrillation) within 1 year
             prior to screening

          -  A pacemaker or implantable cardiac defibrillator

          -  Known history of infection with human immunodeficiency virus (HIV), based on medical
             history (screening labs to rule out HIV infection are not required);

          -  Any other condition that, in the opinion of the Investigator, would impair the
             patient's ability to comply with study procedures.
      "
NCT02096354,completed,,1,phase 2,['colorectal neoplasms'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['rrx-001', 'regorafenib', 'irinotecan']","['C1C(CN1C(=O)CBr)([N+](=O)[O-])[N+](=O)[O-]', 'CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F', 'CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7']","
        Inclusion Criteria:

          -  Histological or cytological documentation of adenocarcinoma of the colon or rectum;

          -  Subject must have received at least oxaliplatin-, and irinotecan-based regimens with
             bevacizumab and with, cetuximab or panitumumab if KRAS wildtype and are refractory to
             irinotecan;

          -  Subject has measurable disease by radiographic techniques (computerized tomography
             [CT] or magnetic resonance imaging [MRI]);

          -  Subjects with a history of brain metastasis are eligible for the study as long as they
             meet all the following criteria: their brain metastases have been treated, they have
             no evidence of progression or hemorrhage after treatment, have been off dexamethasone
             for 4 weeks prior to first study drug administration, and have no ongoing requirement
             for dexamethasone or anti-epileptic drugs;

          -  Life expectancy of at least 12 weeks

          -  Subject's Eastern Cooperative Group (ECOG) performance status is 0 or 1;

          -  Adequate organ function

          -  Fertile subjects must use effective contraception during the course of the study and
             for 30 days following withdrawal from the study;

        Exclusion Criteria:

          -  Clinically significant cardiovascular disease;

          -  Unresolved toxicity higher attributed to any prior therapy/procedure excluding
             alopecia, hypothyroidism and oxaliplatin- induced neurotoxicity ≤ Grade 2 for at least
             14 days;

          -  Evidence or history of tendency or predisposition to active bleeding. Any hemorrhage
             or bleeding event of Grade 3 or higher within 4 weeks of start of study medication;

          -  Symptoms or signs of active brain metastases;

          -  History of an allergic reaction or intolerance to irinotecan

          -  Hepatic encephalopathy

          -  Cholangitis that required treatment or intervention within 4 weeks of study enrollment

          -  Concurrent anticancer therapy or any cytotoxic therapy within 1 month prior to Day 1.
             Corticosteroid therapy is not allowed except on dosing days;

          -  Subject has previously received regorafenib;

          -  Clear contraindication for systemic corticosteroids (diabetes mellitus is not per se a
             clear contraindication);

          -  Severe hypoalbuminemia (albumin < 3.0 g/dL);

          -  Subjects who are pregnant or lactating or who are planning to become pregnant during
             the course of the study are excluded.
      "
NCT02091752,terminated,"
    the study was terminated due to low enrollment.
  ",0,phase 2,['primary myelofibrosis'],"[""['D75.81', 'C94.41', 'C94.42', 'C94.40']""]",['ruxolitinib'],['C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3'],"
        Inclusion Criteria:

          -  Confirmed diagnosis of PMF, PPV MF or PET-MF, irrespective of JAK2 mutational status
             according to the 2008 revised International Standard Criteria

          -  Peripheral blast count < 10%

          -  Requires therapy for MF in the opinion of the investigator

          -  Received prior monotherapy treatment with ruxolitinib for at least 12 consecutive
             weeks and experienced treatment interruption because of lossof response or adverse
             event

          -  Patients adhering to the Screening phase assessments and undergoing a a
             ruxolitinib-free washout period of a minimum of 1 week and a maximum of 8 weeks

          -  ECOG performance status 0, 1, 2, or 3

          -  Adequate bone marrow function

          -  Written informed consent

        Exclusion Criteria:

          -  Patients not initially responding (primary resistance) to ruxolitinib therapy

          -  Patients who underwent a splenectomy or spleen radiation

          -  Patients currently scheduled for bone marrow transplant

          -  Patients who have discontinued ruxolitinib < 14 days prior to screening

          -  Patients who are not able to receive a starting dose of ruxolitinib of at least 15 mg
             total daily dose

          -  Leukemic transformation

          -  Inadequate renal function

          -  Presence of clinically meaningful active bacterial, fungal, parasitic or viral
             infection which requires therapy

          -  Previous history of Progressive Multifocal Leuko-encephalopathy (PML)

          -  Clinically significant cardiac disease or significant concurrent medical condition
      "
NCT02094573,completed,,1,phase 2,"['carcinoma, non-small-cell lung']","[""['D02.20', 'D02.21', 'D02.22']""]",['brigatinib'],['CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)NC4=NC=C(C(=N4)NC5=CC=CC=C5P(=O)(C)C)Cl)OC'],"
        Inclusion Criteria:

          1. Have histologically or cytologically confirmed locally advanced or metastatic
             Non-small Cell Lung Cancer (NSCLC) that is anaplastic lymphoma kinase (ALK+).

          2. Must meet one of the following two criteria:

               1. Have documented ALK rearrangement by a positive result from the Vysis® ALK
                  Break-Apart fluorescence in situ hybridization (FISH) Probe Kit; or

               2. Have documented ALK positivity by a different test and tissue available for the
                  Vysis® FISH test. Tissue should be derived preferably from a biopsy taken after
                  progression with crizotinib. If such a sample is not available, testing may be
                  performed with archived tumor tissue.

          3. Had progressive disease while on crizotinib, as assessed by the investigator or
             treating physician.

          4. Have at least 1 measurable lesion per RECIST v1.1. Note: Previously irradiated lesions
             may not be used for target lesions, unless there is unambiguous radiological
             progression after radiotherapy. Brain lesions may not be used as target lesions if
             they were: 1) previously treated with whole brain radiation therapy (WBRT) within 3
             months, or 2) previously treated by stereotactic radiosurgery (SRS) or surgical
             resection.

          5. Recovered from toxicities related to prior anticancer therapy to National Cancer
             Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, v4.0) grade ≤2.

          6. Are a male or female participants ≥18 years old.

          7. Have a life expectancy ≥3 months.

          8. Have adequate organ and hematologic function, as determined by:

               1. Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤2.5 x upper
                  limit of normal (ULN; ≤5 x ULN is acceptable if liver metastases are present)

               2. Total serum bilirubin ≤1.5 x ULN (<3.0 x ULN for participants with Gilbert
                  syndrome)

               3. Serum creatinine ≤1.5 x ULN

               4. Serum lipase/amylase ≤1.5 x ULN

               5. Absolute neutrophil count (ANC) ≥1500/µL

               6. Platelets ≥75000/µL

               7. Hemoglobin ≥10 g/dL

          9. Have Eastern Cooperative Oncology Group (ECOG) performance status ≤2.

         10. Have normal QT interval on screening electrocardiogram (ECG) evaluation, defined as QT
             interval corrected (Fridericia) (QTcF) of ≤450 ms in males or ≤470 ms in females.

         11. For female participants of childbearing potential, a negative pregnancy test must be
             documented prior to enrollment.

         12. Female and male participants who are fertile must agree to use a highly effective form
             of contraception with their sexual partners throughout study participation.

         13. Must provide a signed and dated informed consent indicating that the participants has
             been informed of all pertinent aspects of the study, including the potential risks,
             and is willingly participating.

         14. Have the willingness and ability to comply with scheduled visits and study procedures.

        Exclusion Criteria:

          1. Received any prior ALK-targeted TKI other than crizotinib.

          2. Received crizotinib within 3 days of the first dose of brigatinib (Day 1, Cycle 1).

          3. Received cytotoxic chemotherapy, investigational agents, or radiation within 14 days,
             except SRS or stereotactic body radiosurgery.

          4. Received monoclonal antibodies or had major surgery within 30 days of the first dose
             of brigatinib (Day 1, Cycle 1).

          5. Have been diagnosed with another primary malignancy within the past 3 years (except
             for adequately treated non-melanoma skin cancer, cervical cancer in situ, or prostate
             cancer, which are allowed within 3 years).

          6. Have symptomatic CNS metastases that are neurologically unstable or require an
             increasing dose of corticosteroids.

          7. Have current spinal cord compression.

          8. Have significant, uncontrolled, or active cardiovascular disease, specifically
             including, but not restricted to:

               1. Myocardial infarction (MI) within 6 months prior to the first dose of brigatinib

               2. Unstable angina within 6 months prior to first dose

               3. Congestive heart failure (CHF) within 6 months prior to first dose

               4. History of clinically significant (as determined by the treating physician)
                  atrial arrhythmia

               5. Any history of ventricular arrhythmia

               6. Cerebrovascular accident or transient ischemic attack within 6 months prior to
                  first dose

          9. Have a history or the presence of pulmonary interstitial disease or drug-related
             pneumonitis.

         10. Have an ongoing or active infection. The requirement for intravenous (IV) antibiotics
             is considered active infection.

         11. Have a known history of human immunodeficiency virus (HIV). Testing is not required in
             the absence of history.

         12. Have a history of or active significant gastrointestinal (GI) bleeding within 3 months
             of the first dose of brigatinib.

         13. Have a known or suspected hypersensitivity to brigatinib or its excipients.

         14. Have malabsorption syndrome or other GI illness that could affect oral absorption of
             the study drug.

         15. Have any condition or illness that, in the opinion of the investigator, would
             compromise participants safety or interfere with evaluation of the drug study.

         16. Be pregnant or breastfeeding.
      "
NCT02096133,terminated,"
    difficulties with inclusion
  ",0,phase 2,['multiple sclerosis'],"[""['G35', 'C81.18']""]",['cholecalciferol'],['CC(C)CCCC(C)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C'],"
        Inclusion Criteria:

          -  Female

          -  Relapsing Remitting MS

          -  At start of study > 6 weeks in clinical remission of disease

          -  Age > 18 years.

          -  Premenopausal

          -  Treated with either no immune-modulating treatment, or the currently registered MS
             modulating treatments: Interferon beta 1a (Rebif®), Interferon Beta 1b (Betaferon® or
             Avonex®), Glatiramer Acetate (Copaxone®), dimethylfumarate (Tecfidera®), teriflunomide
             (Aubagio®)) or fingolimod (Gilenya®).

        Exclusion Criteria:

          -  Any contraindication to vitamin D according to Summary of Product Characteristics:
             Hypercalcaemia, hypervitaminosis D, nephrolithiasis, diseases or conditions resulting
             in hypercalcaemia and/or hypercalciuria (incl. primary hyperparathyroidism), severe
             renal impairment .

          -  Use of dexamethasone or other systemic glucocorticosteroids <2 months prior to first
             study visit

          -  Supplementation of >=1000 IU/d (25µg) vitamin D2 or D3

          -  Medical history of disturbed vitamin D/ calcium metabolism other than low intake

          -  Present clinical (major)depression

          -  Present treatment with anti-depressants, benzodiazepines, or neuroleptics.

          -  Treatment with high-dose dexamethasone for MS exacerbation during study.

          -  Pregnancy or the intention to become pregnant during the study period.
      "
NCT02096042,terminated,"
    slow accrual.
  ",0,phase 1/phase 2,['leukemia'],"[""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']""]","['brentuximab vedotin', '5-azacytidine']","['Status: 503', 'C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N']","
        Inclusion Criteria:

          1. Histologically or cytologically confirmed AML, other than acute promyelocytic
             leukemia, as defined by the 2008 World Health Organization (WHO) criteria that is
             relapsed or refractory to standard chemotherapy. Note: Newly-diagnosed AML patients
             who are 60 years or older and are not candidates for or have refused standard
             chemotherapy are also eligible for this trial.

          2. AML blasts must express CD30 (>/=10% expression as assessed by flow-cytometry or 2+
             expression by immunohistochemistry) (whenever possible CD30 expression will be
             assessed by both methods)

          3. Age 18 years or older

          4. Eastern Cooperative Oncology Group (ECOG) Performance Status score of </=3

          5. The following baseline laboratory data: Serum bilirubin </=1.5 x upper limit of normal
             (ULN) or </= 3 x ULN for patients with Gilbert's disease; Serum creatinine </=1.5 x
             ULN AND creatinine clearance >30 ml/min; Alanine aminotransferase (ALT) and aspartate
             aminotransferase (AST) </=3 x ULN

          6. Females of childbearing potential must have a negative serum or urine beta human
             chorionic gonadotrophin (beta-hCG) pregnancy test result within 14 days prior to the
             first dose of brentuximab vedotin and must agree to use an effective contraception
             method during the study and for 30 days following the last dose of study drug. Females
             of non- childbearing potential are those who are postmenopausal greater than 1 year or
             who have had a bilateral tubal ligation or hysterectomy.

          7. Males who have partners of childbearing potential must agree to use an effective
             contraceptive method during the study and for 30 days following the last dose of study
             drug

          8. Patients or their legally authorized representative must provide written informed
             consent.

        Exclusion Criteria:

          1. History of another primary invasive malignancy that has not been definitively treated
             or in remission for at least 2 years. Patients with non-melanoma skin cancers or with
             carcinomas in situ are eligible regardless of the time from diagnosis (including
             concomitant diagnoses).

          2. Documented history of a cerebral vascular event (stroke or transient ischemic attack),
             unstable angina, myocardial infarction, or cardiac symptoms consistent with New York
             Heart Association Class III-IV within 6 months prior to their first dose of
             brentuximab vedotin

          3. Evidence of active cerebral/meningeal disease. Patients may have history of central
             nervous system (CNS) leukemic involvement if definitively treated with prior therapy
             and no evidence of active disease at the time of registration.

          4. Previous treatment with any anti-CD30 directed therapy

          5. Patients with previous allogeneic stem cell transplant (SCT) if they meet either of
             the following criteria: <100 days from allogeneic SCT, Acute or chronic
             graft-versus-host disease (GvHD), or Receiving immunosuppressive therapy as treatment
             for or prophylaxis against GvHD within the last 7 days

          6. Patients with uncontrolled active infections (viral, bacterial, and fungal) are not
             eligible.

          7. Known to be positive for hepatitis B by surface antigen expression

          8. Known to have active hepatitis C infection (positive by polymerase chain reaction or
             on antiviral therapy for hepatitis C within the last 6 months)

          9. Preexisting grade >/=2 peripheral neuropathy

         10. Patients with uncontrolled diabetes mellitus

         11. Current therapy with other systemic anti-neoplastic or anti-neoplastic investigational
             agents.

         12. Chemotherapy (except hydroxyurea or emergent use of single-agent cytarabine for
             cytoreduction), radiotherapy, biologics, and/or other treatment with immunotherapy
             that is not completed 2 weeks prior to first dose of study drug, unless progressive
             disease is documented. NOTE: Hydroxyurea will be allowed during the first cycle of
             treatment

         13. Females who are pregnant or lactating

         14. Known hypersensitivity to any excipient contained in the drug formulation of
             brentuximab vedotin

         15. History of progressive multifocal leukoencephalopathy (PML)
      "
NCT02699073,completed,,1,phase 2,['metastatic colorectal cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]",['regorafenib'],['CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F'],"
        Inclusion Criteria:

          1. Signed and dated informed consent.

          2. Patients with histologically proven metastatic colorectal cancer

          3. Patients previously treated with, or who are not considered candidates for available
             therapies, i.e., fluoropyrimidine-based chemotherapy, anti-VEGF therapy and anti-EGFR
             therapy (if patients were RAS wild-type).

          4. ECOG PS = 0 or 1

          5. Aged 18-years or older

          6. Life expectancy of at least 3 months

          7. Adequate renal, bone marrow, liver and pancreatic functions:

               -  Estimated creatinine clearance ≥ 30 mL/min as calculated using the
                  Cockcroft-Gault equation

               -  Platelet count ≥ 100.000/mm3; hemoglobin ≥ 9 g/dL; absolute neutrophil count ≥
                  1500/mm3. Transfusion to meet the inclusion criteria will not be allowed

               -  Total bilirubin ≤ 1.5 the upper limit of normal value (ULN); alanine
                  aminotransferase (ALAT) and aspartame aminotransferase (ASAT) ≤ 3.0 x ULN (≤ 5.0
                  x ULN for patients with liver involvement of their cancer); alkaline phosphatase
                  (ALP) ≤ 2.5 x ULN (≤ 5.0 x ULN for patients with liver involvement of their
                  cancer and/or have bone metastases)

          8. International normalized ratio (INR) ≤ 1.5 x ULN and partial thromboplastin time (PTT)
             or activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN unless receiving treatment
             with therapeutic anticoagulation. Patients being treated with anticoagulant, e.g.,
             heparin, will be allowed to participate provided no prior evidence of an underlying
             abnormality in these parameters exists. Close monitoring of at least weekly evaluation
             will be performed until INR and PTT are stable based on a pre-dose measurement as
             defined by the local standard of care

          9. At least one target lesion on CT scan

         10. No contraindication to Iodine contrast media injection during CT.

         11. For women of childbearing potential, blood or urine pregnancy test performed a maximum
             of 7 days before start of study treatment and negative result documented before start
             of study treatment

         12. When applicable, i.e., women of childbearing potential having sexual activity, men
             having sexual activity, must agree to use an adequate contraception before entering
             the study, until at least 8 weeks after the last study drug administration

         13. Registration in a national health care system (CMU included).

        Exclusion Criteria:

          1. Any psychological, familial, sociological or geographical condition potentially
             hampering compliance with the study protocol and follow-up schedule; those conditions
             should be discussed with the patient before inclusion in the trial ; planned surgical
             procedure within the first month of treatment or any procedure that might change the
             timing of regorafenib administration during the first month of treatment

          2. Patients under judicial protection (curatorship, tutorship) and/or deprived of freedom

          3. Major surgical procedure, open biopsy or significant traumatic injury within 28 days
             before start of study medication

          4. Pregnancy or breastfeeding

          5. Congestive heart failure ≥ New York Heart Association (NYHA) class 2

          6. Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3
             months)

          7. Myocardial infarction less than 6 months before the start of study medication

          8. Cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or digoxin are
             permitted)

          9. Uncontrolled hypertension (systolic blood pressure >140 mmHg or diastolic pressure >90
             mmHg despite optimal medical management)

         10. Arterial or venous thrombotic or embolic events such as cerebrovascular accident
             (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism
             within 6 months before the start of study medication (except for adequately treated
             catheter-related venous thrombosis occurring more than one month before the start of
             study medication

         11. Pleural effusion or ascites that causes respiratory compromise (≥ CTCAE grade 2,
             NCI-CTCAE v 4.0 dyspnea)

         12. Ongoing infection >grade 2, NCI- CTCAE v 4.0

         13. Previous or concurrent cancer that is distinct in primary site or histology from
             colorectal cancer within 5 years prior to inclusion, except for curatively treated
             cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors (Ta
             [non-invasive tumor], Tis [carcinoma in situ] and T1 [tumor invades lamina propria])

         14. Known history of human immunodeficiency virus (HIV) infection

         15. Active hepatitis B or C or chronic hepatitis B or C requiring treatment with antiviral
             therapy

         16. Patients with seizure disorder requiring medication

         17. History of organ allograft

         18. Patients with evidence or history of any bleeding diathesis, irrespective of severity

         19. Any hemorrhage or bleeding event ≥ Grade 3, NCI-CTCAE v 4.0 within 4 weeks prior to
             the start of study medication

         20. Non-healing wound, non-healing ulcer or non-healing bone fracture

         21. Dehydration grade ≥1, NCI-CTCAE v 4.0

         22. Known hypersensitivity to the study drug, study drug classes or excipient in the
             formulation

         23. Interstitial lung disease with ongoing signs or symptoms at the time of inclusion

         24. Persistent proteinuria >3.5 g/24 hour measured by urine protein-creatinine ratio from
             a random urine sample (≥ Grade 3, NCI-CTCAE v 4.0)

         25. Patients unable to swallow oral medication

         26. Any malabsorption condition

         27. Unresolved toxicity higher than Grade 1, NCI-CTCAE v 4.0, attributed to any prior
             therapy/procedure excluding alopecia and oxaliplatin induced neuropathy

         28. Systemic anticancer therapy including cytotoxic therapy, signal transduction
             inhibitors, immunotherapy, and hormonal therapy during this trial or within 3 weeks

         29. Treatment with any other investigational medicinal product within 28 days prior to
             study entry

         30. Chronic treatment potentially interacting with the study medication, i.e. strong
             CYP3A4 inducers/inhibitors, strong UGT1A9 inhibitors
      "
NCT04543279,terminated,"
    low accrual
  ",0,phase 2,['myelofibrosis'],"[""['D75.81', 'C94.41', 'C94.42', 'C94.40']""]","['fostamatinib', 'ruxolitinib']","['CC1(C(=O)N(C2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)COP(=O)(O)O)C', 'C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3']","
        Inclusion Criteria:

          -  Confirmed diagnosis of primary myelofibrosis or post-polycythemia vera/essential
             thrombocythemia myelofibrosis classified as high risk, intermediate-2 risk, or
             intermediate 1 risk by IPSS.

          -  Severe thrombocytopenia defined as platelet count < 50,000/microL (confirmed on at
             least two measurements over an 8-week period prior to start of study).

          -  At least 18 years of age.

          -  ECOG performance status ≤ 2

          -  Able to swallow pills

          -  Adequate bone marrow and organ function as defined below:

               -  ANC ≥ 1000/microL

               -  Peripheral blood blasts ≤ 10%

               -  Albumin > 2.7 g/dL

               -  Total bilirubin ≤ 1.5 x IULN; patients with Gilbert's syndrome may enroll if
                  direct bilirubin ≤ 1.5 x IULN

               -  AST(SGOT)/ALT(SGPT) ≤ 1.5 x IULN

               -  Creatinine clearance > 30 mL/min by Cockcroft-Gault

          -  Female subjects must be either post-menopausal for at least 1 year or surgically
             sterile; or, if of childbearing potential, must not be pregnant or lactating and must
             agree to use a highly effective method of birth control throughout the duration of the
             trial and for 30 days following the last dose. Acceptable methods of birth control are
             defined as: hormonal contraception (pill, injection or implant) used consistently for
             at least 30 days prior to screening, an intrauterine device (IUD), or intrauterine
             hormone-releasing system (IUS), or true abstinence (i.e. abstinence is in line with
             the preferred and usual lifestyle of the subject.). Male subjects do not need to use
             contraception for fostamatinib because human studies showed minimal R406 in sperm.

          -  Ability to understand and willingness to sign an IRB approved written informed consent
             document (or that of legally authorized representative, if applicable).

        Exclusion Criteria:

          -  History of allogeneic stem cell transplant.

          -  Any solid tumor or hematologic malignancy (other than myelofibrosis) requiring active
             treatment at the time of study entry

          -  Currently receiving any other investigational agents.

          -  A history of allergic reactions attributed to compounds of similar chemical or
             biologic composition to fostamatinib, ruxolitinib, or other agents used in the study.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable
             angina pectoris, or cardiac arrhythmia.

          -  Subject has uncontrolled or poorly controlled hypertension, defined as systolic blood
             pressure ≥130 mmHg or diastolic blood pressure ≥80 mmHg, whether or not the subject is
             receiving anti-hypertensive treatment.

          -  Pregnant and/or breastfeeding. Women of childbearing potential must have a negative
             pregnancy test within 14 days of study entry and prior to the first dose of
             fostamatinib.

          -  Known positive status for human immunodeficiency virus (HIV)

          -  Chronic, active, or acute viral hepatitis A, B, or C infection, or hepatitis B or C
             carrier.

          -  Treatment with strong CYP3A inhibitors or inducers within 14 days before the first
             dose of study drug. Strong CYP3A inhibitors and CYP3A inducers are not permitted
             during the study.

          -  Ongoing gastrointestinal medical condition such as Crohn's disease, inflammatory bowel
             disease, or chronic diarrhea that is not well controlled and could interfere with
             absorption of oral medication or be exacerbated by study medication

          -  Known hepatic cirrhosis or severe pre-existing hepatic impairment.

          -  Uncontrolled coagulopathy or bleeding disorder.

          -  Female patients who intend to donate eggs and male patients who intend to donate sperm
             during the course of this study or for 4 months after receiving the last dose of study
             treatment.
      "
NCT03837353,terminated,"
    terminated early due to slow accrual in the context of changing practice patterns.
  ",0,phase 1/phase 2,['prostate cancer'],"[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]","['dkn-01', 'docetaxel']",['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O'],"
        Inclusion Criteria:

          -  Age >18 years.

          -  Have a histologically or cytologically confirmed cancer of prostate origin
             (adenocarcinoma, poorly differentiated carcinoma, or neuroendocrine carcinoma are all
             allowed).

               -  Patients with pure neuroendocrine carcinoma must have had at least one line of
                  platinum-based chemotherapy unless the patient is intolerant of or is refusing
                  chemotherapy.

               -  Patients with pure neuroendocrine carcinoma do not need to have been previously
                  treated with androgen receptor (AR) signaling inhibitors (abiraterone or
                  enzalutamide or apalutamide or darolutamide) but must have castrate testosterone
                  and have castration-resistant disease.

          -  Surgically or medically castrated, with testosterone levels of < 50 ng/dL (< 2.0 nM).
             If the patient is being treated with luteinizing hormone-releasing hormone (LHRH)
             agonists (patient who have not undergone orchiectomy), this therapy must have been
             initiated at least 4 weeks prior to C1D1 and must be continued throughout the study.

          -  Cohorts 1A, 1B: Patients must have progressed despite 1 or more androgen receptor (AR)
             signaling inhibitors (abiraterone or enzalutamide or apalutamide or darolutamide) and
             have not received prior taxane-based chemotherapy for prostate cancer. Prior treatment
             with an AR signaling inhibitor for castration-sensitive disease will be allowed if the
             time to progression was within 1 year after starting drug. Prior treatment with a
             taxane-based chemotherapy for castration-sensitive disease will be exclusionary.
             (Prior treatment with an AR signaling inhibitor is not required for pure prostate
             neuroendocrine carcinoma as in inclusion 2.)

          -  Cohorts 2A and 2B: Patients must have progressed despite 1 or more AR signaling
             inhibitor (abiraterone or enzalutamide or apalutamide or darolutamide) and either had
             disease progression, were intolerant of, or refused 1 or more taxane-based
             chemotherapies for mCRPC. (Prior treatment with an AR signaling inhibitor is not
             required for pure prostate neuroendocrine carcinoma as in inclusion 2.)

          -  Cohort 1B. Patients must have measurable disease per RECIST v1.1 guidelines AND must
             have either:

               -  PSA progression is defined by Prostate Cancer Working Group 3 (PCWG3) criteria as
                  a minimum of two consecutive rising levels, with an interval of ≥1 week between
                  each determination with a minimum PSA of 1 ng/mL, if PSA is the sole evidence of
                  progression, OR

               -  Radionuclide bone progression as defined by at least two new metastatic lesions
                  (per PCWG3), OR

               -  Soft tissue progression on transaxial imaging: new or progressive soft tissue
                  masses on computed tomography (CT) or magnetic resonance imaging (MRI) scans as
                  defined by RECIST v1.1.

          -  Cohorts 1A, 2A, 2B. Patients must have baseline progression defined as one of the
             following:

               -  PSA progression is defined by PCWG3 criteria as a minimum of two consecutive
                  rising levels, with an interval of ≥1 week between each determination with a
                  minimum PSA of 2 ng/mL.

               -  Radionuclide bone progression as defined by at least two new metastatic lesions
                  (per PCWG3).

               -  Soft tissue progression on transaxial imaging: new or progressive soft tissue
                  masses on computed tomography (CT) or magnetic resonance imaging (MRI) scans as
                  defined by RECIST v1.1.

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.

          -  Estimated life expectancy of at least 3 months, in the judgment of the Investigator.

          -  Required initial laboratory values within 14 days of C1D1:

               -  Total bilirubin within normal limits for the institution. (For Cohorts 2A and 2B,
                  total bilirubin < 3 × ULN is acceptable with known liver metastases).

               -  For Cohorts 1A, 1B transaminases [aspartate aminotransferase (AST) and alanine
                  aminotransferase (ALT)] ≤1.5 × the upper limit of normal (ULN). For Cohorts 2A
                  and 2B, AST and ALT ≤ 5.0 × ULN is acceptable with known liver metastases.

               -  Creatinine ≤2.0 or calculated creatinine clearance ≥50 mL/min using the Cockcroft
                  and Gault Method (Cockroft and Gault 1976).

               -  Absolute neutrophil count ≥1000 cells/µl.

               -  Absolute lymphocyte count ≥500/µl.

               -  Hemoglobin ≥8.5 g/dL.

               -  Platelet count ≥100,000 cells/µl. (For Cohorts 2A and 2B, Platelet count ≥75,000
                  cells/µl).

               -  International normalized ratio (INR) (prothrombin time [PT])/partial
                  thromboplastin time (PTT) ≤1.5 × ULN unless receiving anticoagulant, in which
                  case INR ≤3.0 and no active bleeding, (ie, no clinically significant bleeding
                  within 14 days prior to first dose of study therapy.

          -  Sexually active male patients must agree to use adequate contraception (hormonal or
             barrier method of birth control) during the study and for 6 months after their last
             dose of study drug. Should a patient's partner become pregnant or suspect she is
             pregnant while participating in the study, the Investigator should be immediately
             informed.

          -  Reliable and willing to make themselves available for the duration of the study and
             are willing to follow study-specific procedures.

          -  Provided written informed consent prior to any study-specific procedures.

          -  Submission of a next-generation sequencing report from prostate cancer tissue or ctDNA
             from a CLIA certified lab if available. If no such report is available, a statement
             attesting to the lack of such a report is sufficient for eligibility.

        Exclusion Criteria:

          -  Any anti-cancer therapy (with the exception of luteinizing hormone-releasing hormone
             [LHRH] analog or antagonist) within 2 weeks prior to initiation of study treatment.

          -  Any investigational anti-cancer therapy within 4 weeks of initiation of study
             treatment.

          -  New York Heart Association Class III or IV heart failure, or myocardial infarction
             within the past 6 months, or unstable arrhythmia within 3 months.

          -  Uncontrolled bacterial, viral, or fungal infections, within 7 days of study entry.

          -  History of malignancy other than prostate cancer within 2 years prior to screening,
             except for malignancies with a negligible risk of metastasis or death (e.g., 5-year OS
             rate > 90%), such as non-melanoma skin carcinoma or ductal carcinoma in situ.

          -  Known to be human immunodeficiency virus (HIV) positive, have positive hepatitis B
             surface antigen (HBSAg), or positive hepatitis C antibody (HCAb) test. (Hepatitis C
             antibody-positive patients with an undetectable hepatitis C virus (HCV) RNA will be
             eligible.)

          -  History of solid organ transplant (ie, heart, lungs, liver, or kidney).

          -  History of autologous/allogenic bone marrow transplant.

          -  Serious nonmalignant disease that could compromise protocol objectives in the opinion
             of the Investigator and/or Sponsor.

          -  Major surgical procedures or significant traumatic injury within 4 weeks prior to
             study entry (minor surgical procedures within 1 week of study entry). Note: Diagnostic
             cystoscopy is not exclusionary at any time during screening. History of osteonecrosis
             of the hip. Other hip pathology such as degenerative disease or malignant involvement
             are not exclusionary. Screening of asymptomatic patients is not required.

          -  Active or untreated central nervous system (CNS) malignancy or metastasis. Screening
             for CNS metastases of asymptomatic patients without a history of CNS metastases is not
             required. Patients with treated CNS metastases are eligible provided they meet all of
             the following criteria:

               -  Evaluable disease outside the CNS.

               -  No history of intracranial or intraspinal hemorrhage.

               -  No evidence of significant vasogenic edema.

               -  No ongoing requirement for corticosteroids as therapy for CNS disease.
                  (Anti-convulsants at a stable dose for > one month is allowed.)

               -  No stereotactic radiation, whole brain radiation within 4 weeks of C1D1.

               -  Patients with CNS metastases treated by neurosurgical resection or brain biopsy
                  within 3 month prior to C1D1 will not be allowed.

               -  Radiographic demonstration of interim stability (ie, no progression) between
                  completion of CNS-directed therapy and the screening radiographic study.

               -  Screening CNS radiographic study ≥4 weeks since completion of radiotherapy or
                  surgical resection and ≥2 weeks since discontinuation of corticosteroids.

          -  Any other condition, disease, metabolic dysfunction, physical examination finding, or
             clinical laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates the use of an investigational drug or that may affect the
             interpretation of the results or render the patient at high risk from treatment
             complications.

          -  Active substance abuse.

          -  Receipt of any live vaccine within 30 days before the first dose of study treatment or
             anticipation that such a live vaccine will be required during study participation.

          -  Previously treated with an anti-DKK1 therapy.
      "
NCT03514836,terminated,"
    insufficient accrual
  ",0,phase 1/phase 2,['castration-resistant prostate cancer'],"[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]",['cyclophosphamide'],['C1CNP(=O)(OC1)N(CCCl)CCCl'],"
        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate

          -  Radiographically documented metastatic disease with evidence of disease progression
             Laboratory parameters per protocol

          -  Surgically or medically castrate

          -  Patients who have progressed following:

          -  a. at least initial therapy (chemotherapy or treatment with a hormonal agent known to
             impact survival such as abiraterone and enzalutamide); or

          -  b. one first-line chemotherapy regimen and one additional hormonal agent known to
             impact survival such as abiraterone and enzalutamide; or

          -  c. failure of two lines of chemotherapy; or

          -  d. failure of pre-chemotherapy abiraterone or enzalutamide and subsequent chemotherapy

        Exclusion Criteria:

          -  Patients with neuroendocrine or small cell cancer of the prostate 2. History of other
             malignant disease (with the exception of the primary prostate cancer and non-melanoma
             skin tumors) in the past 5 years Pre-defined co-morbidities

          -  Administration of experimental therapy within the last 4 weeks before start of
             screening

          -  Treatment with immunotherapy within the last 3 months before start of screening

          -  Treatment with radiopharmaceutical drugs within 8 weeks before start of screening

          -  Receipt of oncolytic virus treatment or vaccination with a live virus within 4 weeks
             of study start

          -  History of organ transplantation
      "
NCT02915523,completed,,0,phase 1/phase 2,"['epithelial ovarian cancer', 'peritoneal cancer', 'fallopian tube cancer']","[""['H18.523', 'H18.521', 'H18.522', 'H18.529']"", ""['K65.1', 'K66.0', 'N99.4', 'N73.6', 'R88.0', 'Z49.32', 'Z49.02']"", ""['C57.00', 'C57.01', 'C57.02']""]","['entinostat', 'avelumab', 'placebo']",['C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3'],"
        Inclusion Criteria:

          -  Histologically or cytologically confirmed epithelial ovarian, fallopian tube, or
             peritoneal cancer

          -  Recurrent or progressive disease on or after initial platinum-based chemotherapy

          -  Evidence of measurable disease based on imaging studies within 28 days before the
             first dose of study drug

          -  Previously received at least 3, but no more than 6, lines of therapy including at
             least 1 course of platinum-based therapy

          -  Patient must have acceptable, applicable laboratory requirements

          -  Patients may have a history of brain metastasis provided certain protocol criteria are
             met

          -  Experienced resolution of toxic effect(s) of the most recent prior anti-cancer therapy
             to Grade ≤1 (except alopecia or neuropathy)

          -  Able to understand and give written informed consent and comply with study procedures.

        Exclusion Criteria:

          -  Non-epithelial ovarian carcinomas or ovarian tumors with low malignant potential
             (i.e., borderline tumors)

          -  Another known malignancy that is progressing or requires active treatment (excluding
             adequately treated basal cell carcinoma or cervical intraepithelial neoplasia/cervical
             carcinoma in situ or melanoma in situ). Prior history of other cancer is allowed, as
             long as there is no active disease within the prior 5 years.

          -  Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form
             of immunosuppressive therapy within 7 days prior to enrollment.

          -  Active autoimmune disease that might deteriorate when receiving an immunostimulatory
             agent

          -  Previously treated with a histone deacetylase inhibitor (i.e., vorinostat, belinostat,
             romidepsin, panobinostat), PD-1/PD-L1-blocking antibody (i.e., atezolizumab,
             nivolumab, pembrolizumab), or a cytotoxic T-lymphocyte associated protein-4 (CTLA-4)
             agent

          -  Currently enrolled in (or completed) another investigational drug study within 30 days
             prior to study drug administration

          -  A medical condition that precludes adequate study treatment or increases patient risk
      "
NCT02910050,unknown status,,0,phase 2,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['bicalutamide', 'aromatase inhibitor']",['CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O'],"
        Inclusion Criteria:

          -  Patients with histologically confirmed estrogen receptor positive, androgen positive
             and HER2 negative breast cancer

          -  Metastatic or unresectable locally advanced disease

          -  Age over 18 years

          -  Postmenopausal status （continuous using luteinizing hormone releasing hormone(LHRH)
             analogue is available）

          -  Patient must have disease progression after treatment of an Aromatase inhibitor.

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS)0-2

          -  Life expectancy over 3 months.

          -  Measurable disease according to RECIST version 1.1 or only bone metastasis

          -  Adequate hematological, hepatic function.

          -  Voluntarily signed and dated written informed consent prior to any study specific
             procedure.

        Exclusion Criteria:

          -  Patient with life-threatening visceral metastasis, such as extensive liver metastasis,
             brain or meningeal metastasis

          -  Concomitant diseases/conditions that is not controllable, and Any other major illness
             that, in the Investigator's judgment, will substantially increase the risk associated
             with the patient's participation in this study.

          -  History of other primary malignancy

          -  Resistant to steroidal or nonsteroidal aromatase Inhibitor
      "
NCT02919462,terminated,"
    low recruitement rate
  ",0,phase 2,"['carcinoma, non-small-cell lung', 'secondary', 'advanced stage iiib', 'high thymidylate synthase expression']","[""['D02.20', 'D02.21', 'D02.22']""]","['oral vinorelbine', 'cisplatin', 'maintenance with metronomic oral vinorelbine', 'pemetrexed', 'cisplatin', 'maintenance with pemetrexed']","['N.N.Cl[Pt]Cl', 'C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O', 'N.N.Cl[Pt]Cl']","
        Inclusion Criteria:

          1. Patients must have histologically or cytologically Non-squamous NSCLC, (including
             those with a non-specified tumor type).

          2. Metastatic (stage IV, both M1A or M1B) or locally advanced (stage IIIB, with
             metastasis to supraclavicular nodes) according to TNM VII edition.

          3. TS nuclear H-score ≥ 70 or with TS nuclear and cytoplasmatic H-score ≥ 210.

          4. Patients at first diagnosis or those with disease recurrence after former surgery are
             eligible.

          5. Patients must have measurable disease, defined as at least one lesion that can be
             accurately measured in at least one dimension (longest diameter to be recorded) as ≥20
             mm with conventional techniques or as ≥10 mm with spiral CT scan. See section 9.2 and
             Appendix E for the evaluation of measurable disease.

          6. At least one target or non-target lesion not previously irradiated according to RECIST
             version 1.1

          7. Male or Female, aged ≥18 years.

          8. Life expectancy greater than 3 months.

          9. ECOG performance status ≤2 (see Appendix C).

         10. Patients must have normal organ and marrow function as defined below:

               -  leukocytes ≥3,000/µL

               -  absolute neutrophil count ≥1,000µL

               -  platelets ≥100,000/µL

               -  total bilirubin within normal institutional limits

               -  AST(SGOT)/ALT(SGPT) ≤2.5 X institutional upper limit of normal

               -  creatinine within normal institutional limits OR

               -  creatinine clearance ≥60 mL/min/1.73 m2 for patients with creatinine levels above
                  institutional normal

         11. Female participants of child bearing potential and male participants whose partner is
             of child bearing potential must be willing to ensure that they or their partner use
             effective contraception during the study and for 3 months thereafter

         12. Participant is willing and able to give informed consent for participation in the
             study.

        Exclusion Criteria:

          1. Prior chemotherapy or therapy with systemic anti-neoplastic therapy for advanced
             disease.

          2. Prior surgery and/or localised irradiation is permitted if delivered outside to the
             target lesion.

          3. Prior adjuvant chemotherapy is permitted if it did not contain vinorelbine and
             pemetrexed and if administered at least 6 months prior entering the study.

          4. Participation in another clinical trial with any investigational agents within 30 days
             prior to study screening.

          5. Patients with symptomatic brain metastasis or spinal cord compression that has not yet
             been treated with surgery and/or radiation. Patients with CNS metastases or spinal
             cord compression previously treated with surgery and/or radiation are eligible if they
             are asymptomatic and do not require escalating high dose steroids (anti-seizure
             medications are allowed)

          6. History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to pemetrexed, vinorelbine, cisplatin, carboplatin or other agents used in
             the study.

          7. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          8. Other known malignant neoplastic diseases in the patient's medical history with a
             disease-free interval of less than 5 years (except for previously treated basal cell
             carcinoma and in situ carcinoma of the uterine cervix or surgically resected prostate
             cancer with normal PSA);

          9. NSCLC with EGFR mutation (or not able to use EGFR inhibitor) or with anaplastic
             lymphoma kinase (ALK) gene translocation (such as EML4-ALK).

         10. Has a known allergy, hypersensitivity, or contraindication to cisplatin, pemetrexed,
             or vinorelbine or any components used in their preparation or has a contraindication
             specified in section 7.
      "
NCT03163667,completed,,1,phase 2,['clear cell renal cell carcinoma'],"[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]","['placebo', 'cb-839', 'everolimus']","['C1=CC=NC(=C1)CC(=O)NC2=NN=C(S2)CCCCC3=NN=C(C=C3)NC(=O)CC4=CC(=CC=C4)OC(F)(F)F', 'CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC']","
        Inclusion Criteria:

          -  Karnofsky Performance Score (KPS) ≥ 70%

          -  Estimated Life Expectancy of at least 3 months

          -  Documented histological or cytological diagnosis of renal cell carcinoma with a
             clear-cell component.

          -  Measurable Disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as
             determined by the Investigator

          -  Must have received at least two prior lines of systemic therapy, including at least
             one VEGF TKI (e.g., sunitinib, sorafenib, pazopanib, cabozantinib)

             a) Radiographic progression of mRCC must have occurred (per investigator assessment)
             on or after the most recent systemic therapy and within 6 months prior to Cycle 1 Day
             1 (C1D1).

          -  Prior treatment with other anti-cancer therapies including cytokines, monoclonal
             antibodies, immunotherapies, and cytotoxic chemotherapy is allowed

        Exclusion Criteria:

          -  Prior treatment with mammalian target of rapamycin (mTOR) inhibitors (everolimus or
             temsirolimus) or CB-839

          -  Receipt of any anticancer therapy within the following windows before randomization:

               -  TKI therapy within 2 weeks or 5 half-lives, whichever is longer

               -  Any type of anti-cancer antibody within 4 weeks

               -  Cytotoxic chemotherapy within 4 weeks

               -  Investigational therapy within 4 weeks or 5 half-lives, whichever is longer

               -  Radiation therapy for bone metastasis within 2 weeks, any other external
                  radiation therapy within 4 weeks before randomization. Patients with clinically
                  relevant ongoing complications from prior radiation therapy are not eligible.

          -  Unable to receive medications orally (PO) or any condition that may prevent adequate
             absorption of oral study medication

          -  Major surgery within 28 days prior to randomization

          -  Patients with active and/or untreated central nervous system (CNS) cancer are not
             eligible. Patients with treated brain metastasis must have 1) documented radiographic
             stability of at least 4 weeks duration demonstrated on baseline contrast-enhanced CNS
             imaging (eg contrast-enhanced magnetic resonance imaging [MRI] of the brain) prior to
             randomization and 2) must be symptomatically stable and off steroids for at least 2
             weeks before randomization.

          -  Requirement for continued proton pump inhibitor after randomization

          -  Chronic treatment with corticosteroids or other immunosuppressive agents except (i)
             inhaled or topical steroids or replacement dose corticosteroids equivalent to ≤ 10 mg
             prednisone and (ii) patients receiving physiological doses of hydrocortisone for
             adrenal insufficiency
      "
NCT03168100,withdrawn,"
    no study population. no subjects enrolled.
  ",0,phase 2,['multiple myeloma'],"[""['C90.01', 'C90.02', 'C90.00']""]","['elotuzumab', 'lenalidomide', 'dexamethasone', 'bortezomib']","['C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N', 'CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C', 'B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O']","
        Inclusion Criteria:

          -  Patients must be at least 18 years of age and not older than 75 years of age at the
             time of enrollment.

          -  Patients must have completed a stem cell transplant regimen for newly diagnosed
             multiple myeloma (MM) consisting of (at least) induction chemotherapy and single or
             tandem autologous stem cell transplant (ASCT) within eight months of study enrollment.
             The completed regimen may have included post-transplant consolidation therapy, but
             post-transplant consolidation is not required.

          -  Patients must have achieved at least a partial response (PR) (according to
             International Myeloma Working Group (IMWG) criteria) in response to the completed
             transplant regimen.

          -  ECOG ≤ 2 (ECOG of 3 allowed if solely due to symptoms of MM-related bone disease).

          -  Patients must have absolute neutrophil count (ANC) ≥ 1,000/mm3 and a platelet count of
             ≥ 75,000/μL.

          -  Patients must have a baseline serum creatinine level of < 3 mg/dL and baseline alanine
             aminotransferase (ALT) < 3x Upper limit of normal (ULN)

          -  Toxicities related to prior therapies must be resolved to ≤ Grade 2 according to NCI
             Common Terminology for Adverse Events (CTCAE) Version 4.

          -  Female patients must be:

               -  Postmenopausal for at least 1 year before the screening visit, OR

               -  Surgically sterile, OR

               -  If they are of childbearing potential, agree to practice 2 simultaneous effective
                  methods of contraception, from the time of signing the informed consent form
                  through 90 days after the last dose of study drug, OR

               -  Agree to practice true abstinence when this is in line with the preferred and
                  usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation,
                  symptothermal, post-ovulation methods] and withdrawal are not acceptable methods
                  of contraception.)

          -  Male patients, even if surgically sterilized (ie, post-vasectomy) must agree to one of
             the following:

               -  Practice effective barrier contraception during the entire study treatment period
                  and through 90 days after the last dose of study drug, OR

               -  Practice true abstinence when this is in line with the preferred and usual
                  lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation,
                  symptothermal, post-ovulation methods] and withdrawal are not acceptable methods
                  of contraception.)

          -  Patients must sign an Institutional Review Board (IRB)-approved informed consent
             indicating their understanding of the proposed treatment and understanding that the
             protocol has been approved by the IRB.

        Exclusion Criteria:

          -  Female patients who are nursing or pregnant may not participate. Women of childbearing
             potential must have a negative pregnancy documented within one week of beginning study
             treatment. Refer to the Revlimid Risk Evaluation and Mitigation Strategies (REMS)
             program for more information.

          -  History of poorly controlled hypertension, diabetes mellitus, active or uncontrolled
             hepatitis, or other serious medical or psychiatric illness that could potentially
             interfere with the completion of treatment according to this protocol, or that in the
             opinion of the investigator would constitute a hazard for participating in this study.

          -  History of clinically significant cardiac disease as determined by the enrolling
             physician including cardiac amyloidosis.

          -  Prior malignancy, except for adequately treated basal cell or squamous cell skin
             cancer, in situ cervical cancer, or other cancer for which the patient has not
             received treatment for one year prior to enrollment. Other cancers will be acceptable
             if the patient's life expectancy exceeds five years.

          -  Known allergies, hypersensitivity, or intolerance to monoclonal antibodies or human
             proteins or any of the study medications, their analogues, or excipients in the
             various formulations of any agent (refer to the latest versions of the package
             inserts).
      "
NCT05045404,withdrawn,"
    study closed due to funding, 0 patient accrual.
  ",0,phase 2,"['metastatic lung non-small cell carcinoma', 'stage iv lung cancer ajcc v8', 'stage iva lung cancer ajcc v8', 'stage ivb lung cancer ajcc v8']","[""['D02.20', 'D02.21', 'D02.22']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]",['poziotinib hydrochloride'],['COC1=C(C=C2C(=C1)N=CN=C2NC3=C(C(=C(C=C3)Cl)Cl)F)OC4CCN(CC4)C(=O)C=C.Cl'],"
        Inclusion Criteria:

          -  Patient, or patient's authorized representative, must be willing and capable of giving
             written informed consent and must be able to adhere to dosing and visit schedules as
             well as meet all study requirements

               -  Patient has histologically or cytologically confirmed non-small cell lung cancer
                  (NSCLC) not amenable to curative intent therapy or stage IV NSCLC

               -  Documented epidermal growth factor receptor (EGFR) exon 20 point or insertion
                  mutation using a Food and Drug Administration (FDA)-approved in vitro diagnostic
                  test (ie, cobas EGFR mutation test version [v] 2 or therascreen EGFR RGQ
                  polymerase chain reaction [PCR] kit), a Clinical Laboratory Improvement Act
                  (CLIA) certified test (eg, OncoMine Comprehensive Assay (OCA), Guardant360 Assay
                  [using plasma], or FoundationOne Assay), or similarly accredited test for tissue
                  or plasma

               -  Brain metastases are allowed, as long as they are stable and do not require
                  treatment with anticonvulsants or escalating doses of steroids

               -  Previously untreated and/or any number of prior lines of therapy for metastatic
                  disease are allowed in the dose expansion part. Previously untreated patients are
                  now allowed in the dose finding portion of the study

               -  Patient is at least 18 years of age

               -  Patient has measurable disease, as per the Response Evaluation Criteria in Solid
                  Tumors (RECIST, version 1.1)

               -  Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0 or
                  1

               -  Patient has recovered from prior systemic therapy for metastatic disease to grade
                  =< 1 for non-hematologic toxicities (except for grade =< 2 peripheral neuropathy)

               -  Leukocytes >= 3.0 x 10^9/L

               -  Absolute neutrophil count (ANC) must be >= 1.5 x 10^9/L

               -  Platelet count >= 100 x 10^9/L

               -  Hemoglobin >= 9.0 g/dL

               -  Total bilirubin =<1.5 x upper limit of normal (ULN); if hepatic metastases are
                  present, =< 2.5 x ULN

               -  Aspartate aminotransferase/serum glutamic-oxaloacetic transaminase (AST/SGOT),
                  alanine aminotransferase/serum glutamic-pyruvic transaminase (ALT/SGPT), and
                  gamma-glutamyltransferase (GGT) =< 2.5 x ULN; if hepatic metastases are present,
                  =< 0.5 x ULN

               -  Creatinine clearance >= 50 mL/min

               -  Adequate coagulation function as defined by international normalized ratio (INR)
                  1.5 and a partial thromboplastin time (PTT) (PTT/activated partial thromboplastin
                  time [aPTT]) < 1.5 x ULN. Patients on full-dose anticoagulation must be on a
                  stable dose (minimum duration 14 days) of oral anticoagulant or low molecular
                  weight heparin (LMWH). If receiving warfarin, the patient must have an INR =<
                  3.0. For heparin and LMWH there should be no active bleeding (that is, no
                  bleeding within 14 days prior to first dose of protocol therapy) or pathological
                  condition present that carries a high risk of bleeding (for example, tumor
                  involving major vessels or known varices)

               -  Patient is willing to practice 2 forms of contraception, one of which must be a
                  barrier method, from study entry until at least 30 days after the last dose of
                  study combination

               -  Females of childbearing potential must have a negative pregnancy test within 7
                  days prior to enrollment. Females who are postmenopausal for at least 1 year
                  (defined as more than 12 months since last menses) or who are surgically
                  sterilized do not require this test

               -  The patient's urinary protein is =< 1+ on dipstick or routine urinalysis (UA; if
                  urine dipstick or routine analysis is >= 2+, a 24-hour urine collection for
                  protein must demonstrate < 1000 mg of protein in 24 hours to allow participation
                  in this protocol)

        Exclusion Criteria:

          -  • Patient has EGFR T790M mutation or other acquired EGFR exon 20point mutation
             following prior treatment with an EGFR-tyrosine kinase inhibitor (TKI)

               -  Previous treatment with poziotinib or ramucirumab

               -  Patient is concurrently receiving chemotherapy, biologics, immunotherapy for
                  cancer treatment; systemic anti-cancer treatment or investigational treatment
                  should not be used within 2 weeks; local radiation therapy for bone pain may be
                  allowed

               -  Patient has a history of congestive heart failure (CHF) class III/IV according to
                  the New York Heart Association (NYHA) functional classification or serious
                  cardiac arrhythmias requiring treatment

               -  Patient has a high risk of cardiac disease, as determined by the investigator,
                  may undergo either echocardiogram (ECHO) or multi-gated acquisition (MUGA) during
                  screening and if the patient has a cardiac ejection fraction < 50%, the patient
                  will be excluded

               -  Patient has a history of other malignancies within the last 3 years, except for
                  non-melanoma skin cancer or carcinoma in situ of the cervix

               -  Patient is confirmed to have clinically significant or recent (within 14 days
                  prior to starting treatment) acute gastrointestinal disease presenting as
                  diarrhea and/or coloenteritis as a main symptom (ie, acute enteritis,
                  malabsorption, or Common Terminology Criteria for Adverse Events [CTCAE, version
                  5.0] grade 2 or above diarrhea due to other etiologies)

               -  Patient is unable to take drugs orally due to disorders or diseases that may
                  affect gastrointestinal (GI) function, such as inflammatory bowel diseases (eg,
                  Crohn's disease, ulcerative colitis) or malabsorption syndrome, or procedures
                  that may affect gastrointestinal function, such as gastrectomy, enterectomy, or
                  colectomy

               -  Patient has an active liver disease or biliary tract disease (except for
                  Gilbert's disease, asymptomatic biliary stones, liver metastasis, or stabilized
                  chronic liver diseases). Patients with liver cirrhosis at a level of Child-Pugh B
                  (or worse) or history of hepatic encephalopathy or clinically meaningful ascites
                  resulting from cirrhosis are excluded.

               -  Patient has known hypersensitivity to poziotinib or ramucirumab

               -  Patient has an active uncontrolled infection, underlying medical condition, or
                  other serious illness that would impair the ability of the patient to receive
                  protocol treatment

               -  Patient has experienced any grade 3-4 GI bleeding within 3 months prior to first
                  dose of protocol therapy.

               -  Patient has a history of deep vein thrombosis (DVT), pulmonary embolism (PE), or
                  any other significant thromboembolism (venous port or catheter thrombosis or
                  superficial venous thrombosis are not considered ""significant"") during the 3
                  months prior to first dose of protocol therapy

               -  The patient has experienced any arterial thromboembolic events, including but not
                  limited to myocardial infarction, transient ischemic attack, cerebrovascular
                  accident, or unstable angina, within 6 months prior to first dose of protocol
                  therapy

               -  The patient has uncontrolled or poorly-controlled hypertension (> 160 mmHg
                  systolic or > 100 mmHg diastolic for > 4 weeks) despite standard medical
                  management

               -  If they experience hemoptysis (defined as bright red blood or >= 1/2 teaspoon)
                  within 2 months prior to first dose of protocol therapy or with radiographic
                  evidence of intratumor cavitation or has radiologically documented evidence of
                  major blood vessel invasion or encasement by cancer

               -  Patient has had recent major surgery within 28 days prior to starting study
                  treatment, or minor surgery/subcutaneous venous access device placement within 7
                  days prior to the first dose of protocol therapy. The patient has elective or
                  planned major surgery to be performed during the course of the clinical trial.

               -  The patient has a prior history of GI perforation/fistula (within 6 months of
                  first dose of protocol therapy) or risk factors for perforation

               -  The patient has a serious or nonhealing wound, ulcer, or bone fracture within 28
                  days prior to first dose of protocol therapy

               -  Patient has EGFR T790M mutation or other acquired EGFR exon 20point mutation
                  following prior treatment with an EGFR-tyrosine kinase inhibitor (TKI)

               -  Previous treatment with poziotinib or ramucirumab

               -  Patient is concurrently receiving chemotherapy, biologics, immunotherapy for
                  cancer treatment; systemic anti-cancer treatment or investigational treatment
                  should not be used within 2 weeks; local radiation therapy for bone pain may be
                  allowed

               -  Patient has a history of congestive heart failure (CHF) class III/IV according to
                  the New York Heart Association (NYHA) functional classification or serious
                  cardiac arrhythmias requiring treatment

               -  Patient has a high risk of cardiac disease, as determined by the investigator,
                  may undergo either echocardiogram (ECHO) or multi-gated acquisition (MUGA) during
                  screening and if the patient has a cardiac ejection fraction < 50%, the patient
                  will be excluded

               -  Patient has a history of other malignancies within the last 3 years, except for
                  non-melanoma skin cancer or carcinoma in situ of the cervix

               -  Patient is confirmed to have clinically significant or recent (within 14 days
                  prior to starting treatment) acute gastrointestinal disease presenting as
                  diarrhea and/or coloenteritis as a main symptom (ie, acute enteritis,
                  malabsorption, or Common Terminology Criteria for Adverse Events [CTCAE, version
                  5.0] grade 2 or above diarrhea due to other etiologies)

               -  Patient is unable to take drugs orally due to disorders or diseases that may
                  affect gastrointestinal (GI) function, such as inflammatory bowel diseases (eg,
                  Crohn's disease, ulcerative colitis) or malabsorption syndrome, or procedures
                  that may affect gastrointestinal function, such as gastrectomy, enterectomy, or
                  colectomy

               -  Patient has an active liver disease or biliary tract disease (except for
                  Gilbert's disease, asymptomatic biliary stones, liver metastasis, or stabilized
                  chronic liver diseases). Patients with liver cirrhosis at a level of Child-Pugh B
                  (or worse) or history of hepatic encephalopathy or clinically meaningful ascites
                  resulting from cirrhosis are excluded.

               -  Patient has known hypersensitivity to poziotinib or ramucirumab

               -  Patient has an active uncontrolled infection, underlying medical condition, or
                  other serious illness that would impair the ability of the patient to receive
                  protocol treatment

               -  Patient has experienced any grade 3-4 GI bleeding within 3 months prior to first
                  dose of protocol therapy.

               -  Patient has a history of deep vein thrombosis (DVT), pulmonary embolism (PE), or
                  any other significant thromboembolism (venous port or catheter thrombosis or
                  superficial venous thrombosis are not considered ""significant"") during the 3
                  months prior to first dose of protocol therapy

               -  The patient has experienced any arterial thromboembolic events, including but not
                  limited to myocardial infarction, transient ischemic attack, cerebrovascular
                  accident, or unstable angina, within 6 months prior to first dose of protocol
                  therapy

               -  The patient has uncontrolled or poorly-controlled hypertension (> 160 mmHg
                  systolic or > 100 mmHg diastolic for > 4 weeks) despite standard medical
                  management

               -  If they experience hemoptysis (defined as bright red blood or >= 1/2 teaspoon)
                  within 2 months prior to first dose of protocol therapy or with radiographic
                  evidence of intratumor cavitation or has radiologically documented evidence of
                  major blood vessel invasion or encasement by cancer

               -  Patient has had recent major surgery within 28 days prior to starting study
                  treatment, or minor surgery/subcutaneous venous access device placement within 7
                  days prior to the first dose of protocol therapy. The patient has elective or
                  planned major surgery to be performed during the course of the clinical trial.

               -  The patient has a prior history of GI perforation/fistula (within 6 months of
                  first dose of protocol therapy) or risk factors for perforation

               -  The patient has a serious or nonhealing wound, ulcer, or bone fracture within 28
                  days prior to first dose of protocol therapy

               -  Patient is pregnant or breast-feeding

               -  The patient is receiving chronic antiplatelet therapy, including dipyridamole or
                  clopidogrel, or similar agents. Once-daily aspirin use (maximum dose 325 mg/day)
                  is permitted

               -  The presence of interstitial lung disease, drug-related pneumonitis, or radiation
                  pneumonitis at screening
      "
NCT02758132,terminated,"
    low accruals
  ",0,phase 2,['prostate cancer'],"[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]","['enzalutamide', 'abiraterone', 'prednisone']","['CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C', 'CC12CCC(CC1=CCC3C2CCC4(C3CC=C4C5=CN=CC=C5)C)O', 'CC12CC(=O)C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C']","
        Inclusion Criteria:

          -  Histologic proof of adenocarcinoma of the prostate with clinical evidence of
             metastatic disease to the bone.

          -  Castrate resistant progression of prostate carcinoma, as shown by:

               -  Serum testosterone level <50 ng/dL or prior bilateral orchiectomy. Treatment to
                  maintain castrate levels of testosterone should continue, and

                    -  Either symptomatic progression, or, if patient is asymptomatic then a rising
                       serum PSA in two occasions at least 1 week apart, with minimum pre-treatment
                       serum PSA of 5 ng/dL.

          -  Patients with nodal disease are eligible.

          -  Bi-dimensionally measurable disease within the bone.

          -  Life expectancy of at least 12 weeks.

          -  ECOG Performance status < 2

          -  Adequate:

               -  Bone marrow function; absolute neutrophil count > 1,500 mm3, platelet count of >
                  100,000 mm3 and hemoglobin > 9.0 gm/dl.

               -  Hepatic function; SGOT/SGPT and conjugated bilirubin less than twice the upper
                  limit of normal.

               -  Renal function; serum creatinine ≤ 2 mg/dL (or, if creatinine > 2 mg/dL, then a
                  creatinine clearance of at least 35 ml/min (measured or estimated by the Cockroft
                  formula:

        CLcr = [(140-age) x wt (kg)]/[72 x serum creatinine (mg/dL)].

          -  No evidence of coagulopathy as indicated by PT < 1.5X upper limit of normal.

          -  Serum calcium (corrected) from 8 to11.5 mg/dL (2 to 2.9 mmol/L) - Patients must sign
             an informed consent indicating that they are aware of the investigational nature of
             the study.

        Exclusion Criteria:

          -  Patients with variant histologies (e.g., ductal or small cell carcinoma).

          -  Patients with visceral disease are ineligible.

          -  Patients who have had prior Sipuleucel-T, docetaxel, cabazitaxel, abiraterone or
             enzalutamide as a single agent, or in combination therapy.

          -  Concurrent cancer chemotherapy, radiotherapy or surgery.

          -  Concurrent serious infection.

          -  Life threatening illness (e.g., congestive heart failure, uncontrolled angina or
             myocardial infarction in the prior six months).

          -  Hypertension uncontrolled by medication.

          -  Patients who are known to require invasive dental procedures.

          -  No known or suspected brain metastases (NOTE: patients with treated epidural disease
             are allowed)

          -  Administration of any investigational drug within 28 days prior to receipt of
             denosumab.

          -  Age ≤ 18 years of age
      "
NCT02750358,"active, not recruiting",,1,phase 2,"['breast cancer', 'early stage', 'triple negative breast cancer']","[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]",['enzalutamide'],['CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C'],"
        The study population for Step 1 must meet the following eligibility criteria:

        Inclusion Criteria:

          -  Stage 1, 2 or 3 invasive breast cancer which is triple negative. Triple negative
             breast cancer is defined as ER <1, PR <1 and HER2 0 or 1+ or FISH not amplified if IHC
             2+.

          -  AR testing may be performed while patient is undergoing other adjuvant therapy (i.e.,
             surgery, chemotherapy, radiation).

          -  Willing and able to provide informed consent. Woman at least 18 years of age.

          -  Patient is a candidate for treatment of their early stage breast cancer.

        The study population for Step 2 will meet the eligibility criteria:

        Inclusion Criteria:

          -  Stage 1, 2 or 3 invasive breast cancer which is triple negative. Triple negative
             breast cancer is defined as ER <1%, PR <1% and HER2 0 or 1+ or FISH not amplified if
             IHC 2+.

          -  AR(+), defined as ≥1% nuclear staining by IHC testing. The assessment of AR expression
             may have been performed any time in the past and is not limited to participation in
             Step 1.

          -  Any neoadjuvant or adjuvant chemotherapy regimen is permitted. Prior chemotherapy for
             the treatment of this breast cancer is not required.

          -  At least 4 weeks from end of surgery, chemotherapy, or radiotherapy with resolution of
             any toxicity to Grade 1 or less, excluding alopecia.

          -  Patients are eligible to participate within 6 months of completion of therapy for
             their breast cancer. This includes prior radiation therapy if needed.

          -  ECOG performance status of 0 or 1.

          -  Willing and able to provide informed consent.

          -  Woman at least 18 years of age.

          -  Able to swallow study drug and comply with study requirements.

          -  Women of childbearing potential must have a negative pregnancy test and must agree to
             use 2 acceptable methods of birth control (one of which must include a condom as a
             barrier method of contraception) starting at screening and continuing throughout the
             study period and for 3 months after final study drug administration.

          -  Is not breastfeeding at screening and will not breastfeed throughout the study period
             and for at least 3 months after final drug administration.

        Exclusion Criteria:

        Each patient eligible to participate in this study must NOT meet any of the following
        exclusion criteria.

          -  Any severe concurrent disease, infection or comorbid condition that renders the
             patient inappropriate for enrollment in the opinion of the investigator or interferes
             with the patient's ability to participate in the study requirements.

          -  Evidence of metastatic/Stage 4 breast cancer

          -  History of another invasive cancer within 5 years with the exceptions of nonmelanoma
             skin cancers and AJCC Stage 0 or 1 cancers that have a remote probability of
             recurrence in the opinion of the investigator

          -  Absolute neutrophil count < 1500/μL, platelet count < 75,000/μL, or hemoglobin < 9
             g/dL (5.6 mmol/L).

          -  Total bilirubin > 1.5 times upper limit of normal (ULN) unless an alternate
             nonmalignant etiology exists (eg, Gilbert's disease). Aspartate aminotransferase (AST)
             or alanine aminotransferase (ALT) > 3 times ULN.

          -  Creatinine > 1.5 times ULN or an estimated creatinine clearance < 50 mL/minute
             calculated using the Cockcroft-Gault equation.

          -  History of seizure or any condition that may predispose to seizure (e.g., prior
             cortical stroke, significant brain trauma) at any time in the past. Also, history of
             loss of consciousness or transient ischemic attack within 12 months before day 1

          -  An active gastrointestinal disorder affecting absorption (eg, gastrectomy, active
             peptic ulcer disease, uncontrolled celiac)

          -  Hypersensitivity reaction to the active pharmaceutical ingredient or any of the
             capsule components, including Labrasol, butylated hydroxyanisole and butylated
             hydroxytoluene.
      "
NCT02049957,completed,,1,phase 2,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['sapanisertib', 'fulvestrant', 'exemestane']","['CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N', 'CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F', 'CC12CCC3C(C1CCC2=O)CC(=C)C4=CC(=O)C=CC34C']","
        Inclusion Criteria

        Each patient must meet all of the following inclusion criteria to be enrolled in the study:

        Phase 1b and Phase 2

          1. Advanced or metastatic breast cancer.

          2. Histological or cytological confirmation of ER+ status (defined as > 1% positive tumor
             cells), and histological or cytological confirmation of HER2-negative (HER2-) status
             by local laboratory testing using criteria in the American Society of Oncology
             (ASCO)/College of American Pathologists (CAP) Clinical Practice Guideline update.

          3. Female patients 18 years of age or older who are postmenopausal for at least 1 year
             before the Screening visit, where menopause is defined by: Age ≥ 55 years and 1 year
             or more of amenorrhea. Surgical menopause with bilateral oophorectomy

             Age < 55 years and 1 year or more of amenorrhea, with an estradiol assay < 20 pg/mL

             Note: Ovarian radiation or treatment with a luteinizing hormone-releasing hormone
             agonist (goserelin acetate or leuprolide acetate) is not permitted for induction of
             ovarian suppression.

          4. Have a history of brain metastasis are eligible for the study provided that all the
             following criteria are met:

             Brain metastases which have been treated

               -  No evidence of disease progression for ≥ 3 months or hemorrhage after treatment

               -  Off-treatment with dexamethasone for 4 weeks before administration of the first
                  dose of MLN0128

               -  No ongoing requirement for dexamethasone or anti-epileptic drugs

          5. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.

          6. Clinical laboratory values as specified below within 4 weeks before the first dose of
             MLN0128:

               -  Bone marrow reserve consistent with absolute neutrophil count (ANC) ≥ 1.5 x
                  10^9/L; platelet count ≥ 100 x 10^9/L; hemoglobin ≥ 9 g/dL

               -  Total bilirubin ≤ 1.5 x the upper limit of the normal range (ULN), aspartate
                  aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN (≤ 5 x ULN
                  if liver metastases are present)

               -  Creatinine clearance ≥ 50 mL/min based either on Cockcroft-Gault estimate or
                  based on a 12- or 24-hour urine collection

               -  Fasting serum glucose ≤ 130 mg/dL and fasting triglycerides ≤ 300 mg/dL

          7. Left ventricular ejection fraction (LVEF) within 5 absolute percentage points of
             institutional standard of normal as measured by echocardiogram (ECHO) or multiple
             gated acquisition scan (MUGA) within 4 weeks before the first dose of MLN0128 (ie, if
             the institutional standard of normal is 50%, LVEF may be as low as 45% to be eligible
             for the study).

          8. Able to provide paraffin blocks or a minimum of 10 unstained slides of available
             archival tumor tissues (paraffin blocks are preferred). If archival tumor tissue is
             not available, a tumor biopsy may be performed before the patient begins treatment
             with MLN0128. If fewer than 10 slides are available or the tumor content/area
             requirements are not met, study eligibility will be determined upon discussion with
             the sponsor.

          9. Ability to swallow oral medications, willingness to perform mucositis prophylaxis, and
             suitable venous access for the study-required blood sampling.

         10. Voluntary written consent must be given before the performance of any study related
             procedure not part of standard medical care, with the understanding that consent may
             be withdrawn by the patient at any time without prejudice to future medical care.

             Phase 1b Only: In addition to the previously mentioned inclusion criteria, each
             patient must meet the following inclusion criterion to be enrolled in the phase 1b
             portion of the study:

         11. Patients may have SD or disease progression during their most recent treatment with
             exemestane or fulvestrant, or everolimus in combination with either exemestane (any
             country) or fulvestrant (US only). Exemestane or fulvestrant in combination with
             MLN0128 can also be initiated as a new line of therapy.

             Phase 2 Only: In addition to the previously mentioned inclusion criteria, each patient
             must meet all of the following inclusion criteria to be enrolled in the phase 2
             portion of the study:

         12. Measurable disease defined as follows:

               -  At least 1 extra-osseous lesion that can be accurately measured in at least 1
                  dimension. The lesion must measure ≥ 20 mm with conventional imaging techniques
                  or ≥ 10 mm with spiral computed tomography (CT) or magnetic resonance imaging
                  (MRI), or

               -  Bone lesions (lytic or mixed [lytic plus sclerotic]) in the absence of measurable
                  disease as defined above

         13. Patients must have had disease progression during treatment with everolimus in
             combination with either exemestane (any country) or fulvestrant (US only) (duration of
             treatment ≥ 4 weeks) and must have tolerated everolimus treatment in combination with
             exemestane (any country) or fulvestrant (US only) adequately according to the treating
             physician's judgment. Everolimus in combination with exemestane or fulvestrant is not
             required to be the most recent treatment before enrollment, but progression on the
             most recent anticancer therapy is required for enrollment.

        Exclusion Criteria

        Patients meeting any of the following exclusion criteria are not to be enrolled in the
        study:

        Phase 1b and Phase 2

          1. Prior anticancer therapy or other investigational therapy within 2 weeks before
             administration of the first dose of MLN0128 (except for exemestane or fulvestrant,
             which should be continued). Treatment with everolimus must be discontinued 2 weeks
             before administration of the first dose of MLN0128.

          2. Chronic concomitant therapy with bisphosphonates or denosumab for the prevention of
             bone metastases. Concomitant treatment with bisphosphonates or denosumab is permitted
             for treatment of osteoporosis or management of existing bone metastases if initiated
             at least 4 weeks before administration of the first dose of MLN0128.

          3. Initiation of treatment with hematopoietic growth factors, transfusions of blood and
             blood products, or systemic corticosteroids (either IV or oral steroids, excluding
             inhalers) within 1 week before administration of the first dose of MLN0128 (patients
             already receiving erythropoietin on a chronic basis for ≥ 4 weeks are eligible).

          4. Previous treatment with dual PI3K/mTOR inhibitors or TORC1/2 inhibitors.

          5. Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI
             disease, or for an unknown reason that may alter the absorption of MLN0128.

          6. Poorly controlled diabetes mellitus defined as glycosylated hemoglobin (HbA1c) > 7%;
             patients with a history of transient glucose intolerance due to corticosteroid
             administration may be enrolled in this study if all other inclusion/exclusion criteria
             are met.

          7. Other clinically significant co-morbidities, such as uncontrolled pulmonary disease,
             active central nervous system disease, active infection, or any other condition that
             could compromise participation of the patient in the study.

          8. Known human immunodeficiency virus infection.

          9. History of any of the following within the last 6 months before administration of the
             first dose of MLN0128:

               -  Ischemic myocardial event, including angina requiring therapy and artery
                  revascularization procedures

               -  Ischemic cerebrovascular event, including transient ischemic attack and artery
                  revascularization procedures

               -  Requirement for inotropic support (excluding digoxin) or serious (uncontrolled)
                  cardiac arrhythmia (including atrial flutter/fibrillation, ventricular
                  fibrillation, or ventricular tachycardia)

               -  Placement of a pacemaker for control of rhythm

               -  New York Heart Association Class III or IV heart failure

               -  Pulmonary embolism

         10. Significant active cardiovascular or pulmonary disease before administration of the
             first dose of MLN0128, including:

               -  Uncontrolled hypertension (ie, systolic blood pressure > 180 mm Hg; diastolic
                  blood pressure > 95 mm Hg)

               -  Pulmonary hypertension

               -  Uncontrolled asthma or oxygen saturation < 90% by arterial blood gas analysis or
                  pulse oximetry on room air

               -  Significant valvular disease; severe regurgitation or stenosis by imaging
                  independent of symptom control with medical intervention; or history of valve
                  replacement

               -  Medically significant (symptomatic) bradycardia

               -  History of arrhythmia requiring an implantable cardiac defibrillator

               -  Baseline prolongation of the rate-corrected QT interval (QTc; eg, repeated
                  demonstration of QTc interval > 480 ms, or history of congenital long QT
                  syndrome, or torsades de pointes)

         11. Diagnosed or treated for another malignancy within 2 years before administration of
             the first dose of MLN0128 or previously diagnosed with another malignancy and have any
             evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in
             situ of any type are not excluded if they have undergone complete resection.

             Phase 1b Only: In addition to the previously mentioned exclusion criteria, patients
             meeting the following exclusion criterion are not to be enrolled in the phase 1b
             portion of the study:

         12. More than 3 prior chemotherapy regimens for locally advanced or metastatic disease.

             Phase 2 Only: In addition to the previously mentioned exclusion criteria, patients
             meeting the following exclusion criterion are not to be enrolled in the phase 2
             portion of the study:

         13. More than 1 prior chemotherapy regimen for locally advanced or metastatic disease.
      "
NCT02046915,completed,,1,phase 2,['relapsed or refractory multiple myeloma'],"[""['D46.4', 'I20.2', 'D46.1', 'D46.A', 'D46.0', 'D46.20', 'D46.21']""]","['imnovid (pomalidomide)', 'dexamethasone', 'endoxan (cyclophosphamide)']",['CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C'],"
        Inclusion Criteria:

          -  Must be ≥ 18 years at the time of signing the informed consent.

          -  Understand and voluntarily sign an informed consent prior to any study related
             assessments/procedures are conducted.

          -  Able to adhere to the study visit schedule and other protocol requirements.

          -  Subjects must have documented diagnosis of multiple myeloma and have measurable
             disease (serum M-protein ≥ 0.5 g/dL or urine M-protein ≥ 200 mg/24 hours). In case of
             oligosecretory myeloma: involved FLC level ≥ 10 mg/dl, provided sFLC ratio is
             abnormal.

          -  Subjects must have had at least two prior anti-myeloma regimens (incl. bortezomib and
             lenalidomide) and must have been progressed under the last prior treatment. Induction
             therapy followed by ASCT and consolidation/ maintenance will be considered as one
             regimen.

          -  ECOG performance status score of 0, 1, or 2.

          -  Females of childbearing potential (FCBP1) must agree:

        to utilize two reliable forms of contraception simultaneously or practice complete
        abstinence from heterosexual contact for at least 28 days before starting study drug, while
        participating in the study (including dose interruptions), and for at least 28 days after
        study treatment discontinuation and must agree to regular pregnancy testing during this
        timeframe, to abstain from breastfeeding during study participation and 28 days after study
        drug discontinuation.

          -  Males must agree: to use a condom during any sexual contact or practice complete
             abstinence from heterosexual contact with a pregnant female and a FCBP while
             participating in the study, during dose interruptions and for 28 days following
             discontinuation from this study, even if he has undergone a successful vasectomy, to
             refrain from donating semen or sperm while on Pomalidomide and for 28 days after
             discontinuation from this study treatment.

          -  All subjects must agree to refrain from donating blood while on study drug and for 28
             days after discontinuation from this study treatment.

          -  All subjects must agree not to share medication.

        Exclusion Criteria:

          -  -Any of the following laboratory abnormalities: Absolute neutrophil count (ANC) <
             1,000/μL.

          -  Subject with platelet count 30,000/µL are not eligible regardless of the percentage of
             plasma cells in the bone marrow. For subject with platelet count > 30,000/µL and <
             75,000/µL, percentage of plasma cells in bone marrow should be 50%.

          -  Corrected serum calcium > 14 mg/dL (> 3.5 mmol/L).

          -  Hemoglobin < 8 g/dL (< 4.9 mmol/L; prior RBC transfusion or recombinant human
             erythropoietin use is permitted).

          -  Serum SGOT/AST or SGPT/ALT > 3.0 x upper limit of normal (ULN) except due to multiple
             myeloma.

          -  Serum total bilirubin > 2.0 mg/dL (34.2 μmol/L); or > 3.0 x ULN for subjects with
             hereditary benign hyperbilirubinemia.

          -  GFR < 30 ml/min or patient requiring hemodialysis

          -  Prior history of malignancies, other than MM, unless the subject has been free of the
             disease for ≥ 5 years. Exceptions include the following:

          -  Basal or squamous cell carcinoma of the skin

          -  Carcinoma in situ of the cervix or breast

          -  Incidental histological finding of prostate cancer (TNM stage of T1a or T1b).

          -  Previous therapy with Pomalidomide.

          -  Hypersensitivity to thalidomide, lenalidomide, or Dexamethasone (this includes ≥ Grade
             3 rash during prior thalidomide or lenalidomide therapy).

          -  Peripheral neuropathy ≥ Grade 2.

          -  Subjects who received an allogeneic bone marrow or allogeneic peripheral blood stem
             cell transplant less than 12 months prior to initiation of study treatment and who
             have not discontinued immunosuppressive treatment for at least 4 weeks prior to
             initiation of study treatment and are currently dependent on such treatment.

          -  Subjects who are planning for or who are eligible for stem cell transplant.

          -  Subjects with any one of the following:

          -  Congestive heart failure (NY Heart Association Class III or IV)

          -  Myocardial infarction within 12 months prior to starting study treatment

          -  Unstable or poorly controlled angina pectoris, including Prinzmetal variant angina
             pectoris.

          -  Subjects who received any of the following within the last 14 days of initiation of
             study treatment:

          -  Major surgery (kyphoplasty is not considered major surgery)

          -  Use of any anti-myeloma drug therapy.

          -  Use of any investigational agents within 28 days or five half-lives (whichever is
             longer) of treatment.

          -  Incidence of gastrointestinal disease that may significantly alter the absorption of
             Pomalidomide.

          -  Subjects unable or unwilling to undergo antithrombotic prophylactic treatment.

          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subjects from signing the informed consent form.

          -  Pregnant or breastfeeding females.

          -  Known human immunodeficiency virus (HIV) positivity, active infectious hepatitis A, B
             or C or chronic hepatitis B or C.
      "
NCT02041260,"active, not recruiting",,1,phase 2,"['differentiated thyroid cancer (dtc)', 'poorly differentiated thyroid cancer']","[""['C73', 'D34', 'D44.0', 'Z85.850']""]",['cabozantinib'],['COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F'],"
        Inclusion Criteria:

          -  The subject has a histologic or cytologic diagnosis of a DTC tumor (including poorly
             differentiated thyroid cancer but not anaplastic thyroid cancer) that is metastatic or
             unresectable and fulfills the following criteria: a. Subjects must have progressive
             disease as defined by RECIST 1.1 criteria when comparing baseline scans to those
             obtained within the prior 14 months AND b. Subject must have RAIrefractory disease
             based on at least one of the following: i. Prior dose of RAI exceeding 600mCi
             ii.Progression of disease within 18 months following a dose of 100mCi iii. Presence of
             target lesions as defined by modified RECIST criteria which do not take up RAI.

          -  The subject has had an assessment of all known disease sites eg, by computerized
             tomography (CT) scan, magnetic resonance imaging (MRI), bone scan as appropriate,
             within 28 days before the first dose of cabozantinib

          -  The subject is 18 years old on the day of consent.

          -  The subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0
             or 1.

          -  The subject has organ and marrow function and laboratory values as follows within 4
             days prior to the first dose of cabozantinib: a. Absolute neutrophil count (ANC)
             1500/mm3without colony stimulating factor support b. Platelets 100,000/mm3 c.
             Hemoglobin 9 g/dL d.Bilirubin 1.5 the upper limit of normal (ULN). For subjects with
             known Gilberts disease, bilirubin 3.0mg/dL e. Serum albumin 2.0 g/dl f. Serum
             creatinine 1.5 ULN or creatinine clearance (CrCl) 50 mL/Page 9 of 16 min. For
             creatinine clearance estimation, the Cockcroft and Gault equation should be used:
             Male: CrCl(mL/min) = (140 - age) × wt (kg) / (serum creatinine × 72) Female: Multiply
             above result by 0.85 g.Alanine aminotransferase (ALT) and aspartate aminotransferase
             (AST) 3.0 ULN h. Lipase 2.0 x the upper limit of normal and no radiologic or clinical
             evidence of pancreatitis i. Urine protein/creatinine ratio (UPCR) 1 j. Serum
             phosphorus, calcium, magnesium and potassium LLN

          -  The subject is capable of understanding and complying with the protocol requirements
             and has signed the informed consent document.

          -  Sexually active subjects (men and women) must agree to use medically accepted barrier
             methods of contraception (eg, male or female condom) during the course of the study
             and for 4 months after the last dose of study drug(s), even if oral contraceptives are
             also used. All subjects of reproductive potential must agree to use both a barrier
             method and a second method of birth control during the course of the study and for 4
             months after the last dose of study drug(s).

          -  Women of childbearing potential must have a negative pregnancy test at screening.
             Women of childbearing potential include women who have experienced menarche and who
             have not undergone successful surgical sterilization (hysterectomy, bilateral tubal
             ligation, or bilateral oophorectomy) or are not postmenopausal. Postmenopause is
             defined as amenorrhea 12 consecutive months. Note: women who have been amenorrheic for
             12 or more months are still considered to be of childbearing potential if the
             amenorrhea is possibly due to prior chemotherapy, antiestrogens, ovarian suppression
             or any other reversible reason.

          -  An archived tumor specimen is available for collection.

        Exclusion Criteria:

          -  The subject has received cytotoxic chemotherapy (including investigational cytotoxic
             chemotherapy),biologic agents (eg, cytokines or antibodies), or any other anti-cancer
             systemic therapy (including multi-kinase inhibitors).

          -  Prior treatment with cabozantinib

          -  The subject has received radiation therapy: a. to the thoracic cavity, abdomen or
             pelvis within 3 months of the first dose of study treatment thathas with ongoing
             complications or is without complete recovery and healing (CT changes related to
             radiation treatment which are not clinical significant are allowed). b. to bone or
             brain metastasis within 14 days of the first dose of study treatment c. to any other
             site(s) within 28 days of the first dose of study treatment

          -  The subject has received radionuclide treatment within 6 weeks of the first dose of
             study treatment

          -  The subject has received any other type of investigational agent within 28 days before
             the first dose of study treatment.

          -  The subject has not recovered to baseline or CTCAE Grade 1 from toxicity due to all
             prior therapies except alopecia and other non-clinically significant AEs (eg.
             albumin).

          -  The subject has a primary brain tumor.

          -  The subject has active brain metastases or epidural disease who have not been treated
             with radiation therapy (Note: Subjects with brain metastases previously treated with
             whole brain radiation or radiosurgery or subjects with epidural disease previously
             treated with radiation or surgery who are asymptomatic and do not require steroid
             treatment for at least 2 weeks before starting study treatment are eligible.
             Neurosurgical resection of brain metastases or brain biopsy is permitted if completed
             at least 2 months before starting study treatment. (Baseline brain imaging with
             contrast-enhanced CT or MRI scans for subjects with known brain metastases is required
             to confirm eligibility.)

          -  The subject has prothrombin time (PT)/ International Normalized Ratio (INR) or partial
             thromboplastin time (PTT) test 1.3 the laboratory ULN within 7 days before the first
             dose of study treatment.

          -  The subject requires concomitant treatment, in therapeutic doses, with anticoagulants
             such as warfarin or warfarin-related agents, heparin, thrombin or Factor Xa
             inhibitors, or antiplatelet agents (eg, clopidogrel). Low dose aspirin ( 81 mg/day),
             low-dose warfarin (1mg/day), and prophylactic low molecular weight heparin (LMWH) are
             permitted.

          -  The subject requires chronic concomitant treatment of strong CYP3A4 inducers (eg,
             dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin,
             phenobarbital, and St. Johns Wort).

          -  The subject has experienced any of the following: a. clinically-significant
             gastrointestinal bleeding within 6 months before the first dose of study treatment b.
             hemoptysis of 0.5 teaspoon (2.5ml) of red blood within 3 months before the first dose
             of study treatment c. any other signs indicative of pulmonary hemorrhage within 3
             months before the first dose of study treatment

          -  The subject has radiographic evidence of cavitating pulmonary lesion(s)

          -  The subject has tumor in contact with, invading or encasing any major blood vessels

          -  The subject has evidence of tumor invading the GI tract (esophagus, stomach, small or
             large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor
             within 28 days before the first dose of cabozantinib.

          -  The subject has uncontrolled, significant intercurrent or recent illness including,
             but not limited to, the following conditions: a. Cardiovascular disorders including i.
             Congestive heart failure (CHF): New York Heart Association (NYHA) Class III (moderate)
             or Class IV (severe) at the time of screening ii. Concurrent uncontrolled hypertension
             defined as sustained BP 140 mm Hg systolic, or 90 mm Hg diastolic despite optimal
             antihypertensive treatment within 7 days of the first dose of study treatment iii. Any
             history of congenital long QT syndrome iv.

        Any of the following within 6 months before the first dose of study treatment: unstable
        angina pectoris clinically-significant cardiac arrhythmias stroke (including TIA, or other
        ischemic event) myocardial infarction thromboembolic event requiring therapeutic
        anticoagulation (Note: subjects with a venous filter (e.g. vena cava filter) are not
        eligible for this study) b. Gastrointestinal disorders particularly those associated with a
        high risk of perforation or fistula formation including: i. Any of the following within 28
        days before the first dose of study treatment intra-abdominal tumor/metastases invading GI
        mucosa active peptic ulcer disease, inflammatory bowel disease (including ulcerative
        colitis and Crohns disease), diverticulitis, cholecystitis, symptomatic cholangitis or
        appendicitis malabsorption syndrome ii. Any of the following within 6 months before the
        first dose of study treatment: abdominal fistula gastrointestinal perforation bowel
        obstruction or gastric outlet obstruction intra-abdominal abscess.Note: Complete resolution
        of an intra-abdominal abscess must be confirmed prior to initiating treatment with
        cabozantinib even if the abscess occurred more that 6 months before the first dose of study
        treatment. c. Other disorders associated with a high risk of fistula formation including
        PEG tube placement within 3 months before the first dose of study therapy d. Other
        clinically significant disorders such as: i. active infection requiring systemic treatment
        within 28 days before the first dose of study treatment ii. serious non-healing
        wound/ulcer/bone fracture within 28 days before the first dose of study treatment iii.
        history of organ transplant iv. concurrent uncompensated hypothyroidism or thyroid
        dysfunction within 7 days before the first dose of study treatment v. history of major
        surgery as follows: (1) Major surgery within 3 months of the first dose of cabozantinib if
        there were no wound healing complications or within 6 months of the first dose of
        cabozantinib if there were wound complications (2) Minor surgery within 1 months of the
        first dose of cabozantinib if there were no wound healing complications or within 3 months
        of the first dose of cabozantinib if there were wound complications In addition complete
        wound healing from prior surgery must be confirmed at least 28 days before the first dose
        of cabozantinib irrespective of the time from surgery

          -  The subject is unable to swallow tablets

          -  The subject has a corrected QT interval calculated by the Fridericia formula (QTcF)
             500 ms within 28 days before randomization. . Note: if initial QTcF is found to be 500
             ms, two additional EKGs separated by at least 3 minutes should be performed. If the
             average of these three consecutive results for QTcF is 500 ms, the subject meets
             eligibility in this regard

          -  The subject is pregnant or breastfeeding.

          -  The subject has a previously identified allergy or hypersensitivity to components of
             the study treatment formulation. 21. The subject is unable or unwilling to abide by
             the study protocol or cooperate fully with the investigator or designee.
      "
NCT02047253,completed,,0,phase 2,['metastatic castration-resistant prostate cancer'],"[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]","['carfilzomib', 'dexamethasone', 'acyclovir']","['CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3)NC(=O)CN4CCOCC4', 'CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C', 'C1=NC2=C(N1COCCO)N=C(NC2=O)N']","
        Inclusion Criteria:

          -  Histologically proven adenocarcinoma of the prostate

          -  Metastatic disease

          -  Progressive disease (PSA, radiologic, symptomatic) following abiraterone acetate
             and/or Enzalutamide (prior sipuleucel-T and chemotherapy are allowed); PSA progression
             is defined as baseline increase followed by any PSA increase ≥1 week apart.

          -  Voluntary written informed consent before performance of any study-related procedure
             not part of normal medical care, with the understanding that consent may be withdrawn
             by the subject at any time without prejudice to future medical care.

          -  Patients, even if surgically sterilized (i.e., status post-vasectomy) must agree to
             one of the following: practice effective barrier contraception during the entire study
             treatment period and through a minimum of 30 days after the last dose of study drug,
             or completely abstain from heterosexual intercourse if female partner of childbearing
             age.

          -  An elevated PSA level of >2ng/mL for patients progressing by PSA criteria is required
             (last confirmatory sample must be >2ng/mL)

          -  Currently on androgen ablation hormone therapy (a luteinizing hormone- releasing
             hormone (LHRH) agonist/antagonist or orchiectomy) with testosterone level <50ng/dL)

          -  Has an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 - 2

          -  Left ventricular ejection fraction (LVEF) ≥40% on 2-D transthoracic echocardiogram
             (ECHO); Multi-gated Acquisition Scan (MUGA) is acceptable if ECHO is not available.

          -  ≥19 years of age

          -  Resolution of all acute toxic effects of prior chemotherapy or surgical procedures to
             NCI CTCAE Version 4.03 Grade <1, in the opinion of the treating physician.

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patient has a platelet count of <100,000/mm3, or absolute neutrophil count of
             <1500/mm3 or Hemoglobin <8.0gm/dL

          -  Patient has a calculated or measured creatinine clearance of <30 milliliters
             (mL)/minute

          -  Patient has total bilirubin >2 x upper limit of normal (ULN), or aspartate
             aminotransferase (AST), alanine aminotransferase (ALT) >3.5 x ULN

          -  Patient has ≥ Grade 2 peripheral neuropathy within 14 days before enrollment

          -  Myocardial infarction within 6 months prior to enrollment or has New York Heart
             Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe
             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
             ischemia or active conduction system abnormalities. Before study entry, any ECG
             abnormality at screening has to be documented by the investigator as not medically
             relevant.

          -  Participation in clinical trials with other investigational agents not included in
             this trial, within 14 days of the start of this trial and throughout the duration of
             this trial.

          -  Serious medical or psychiatric illness likely to interfere with participation in this
             clinical study.

          -  Diagnosed or treated for another malignancy within 3 years of enrollment, with the
             exception of: a) adequately treated basal cell carcinoma, squamous cell skin cancer,
             or thyroid cancer; b) carcinoma in situ of the breast; c) cancer considered cured by
             surgical resection or unlikely to impact survival during the duration of the study,
             such as localized transitional cell carcinoma of the bladder or benign tumors of the
             adrenal or pancreas.

          -  Known HIV, hepatitis B and hepatitis C infection

          -  Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to
             randomization

          -  Prior treatment with bortezomib

          -  Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize
             Carfilzomib)

          -  Has received prior radiation to >50% of the bone marrow

          -  Has had significant bleeding/thrombosis in previous 4 weeks

          -  Has received treatment with radiation therapy, surgery, chemotherapy, or an
             investigational agent within 4 weeks prior to registration, (6 weeks for radiation
             therapy, radionuclides, nitrosoureas, or Mitomycin C) or who have not recovered from
             adverse events due to agents administered more than 4 weeks earlier

          -  Has evidence of uncontrolled Central Nervous System (CNS) involvement (previous
             radiation and off steroids is acceptable)

          -  Patients may not be receiving any other investigational agents

          -  Has a serious uncontrolled intercurrent medical or psychiatric illness, including
             serious infection

          -  Is unable to comply with study requirements

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.
      "
NCT02047747,terminated,"
    slow enrollment
  ",0,phase 2,['brain cancer'],"[""['C71.7', 'C71.9', 'C79.31', 'D33.0', 'D33.1', 'D33.2', 'D49.6']""]",['dacomitinib'],['COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)C=CCN4CCCCC4'],"
        Inclusion Criteria:

          -  Pathologically (histologically or cytologically) documented extracranial diagnosis of
             primary lung cancer, melanoma, human epidermal growth factor receptor 2
             (HER2)-amplified breast cancer, or HER2-amplified gastric cancer, with brain
             metastasis detected by contrast enhanced MRI or CT is required. Patients with
             concurrent leptomeningeal diseases are eligible.

          -  Has progression and measureable brain disease in the brain by magnetic resonance
             imaging (MRI) or computed tomography (CT).

          -  Has stable, or no evidence of, extracranial disease and not receiving systemic therapy
             for extracranial disease.

        Note: Patients with stable disease must have already received standard therapy or are
        intolerant to standard therapy.

          -  Prior therapy for brain metastasis is not required; patients may either have refused
             radiation therapy or have received prior radiation therapy. Patients having received
             prior standard whole brain radiation therapy (WBRT) or stereotactic radiosurgery (SRS)
             must have completed treatment greater than 4 weeks prior to study initiation.

          -  Has recovered from the toxic effects of prior therapy to Common Toxicity Criteria for
             Adverse Effects (CTCAE) Grade 1 or to their clinical baseline.

          -  Age ≥18.

          -  Life expectancy > 3 months in the opinion of the investigator.

          -  KPS ≥ 60%.

          -  Adequate organ and marrow function.

        Exclusion Criteria:

          -  Current or planned use of systemic therapy for extracranial primary tumor.

          -  Current or anticipated use of other investigational agents.

          -  Presence of uncontrolled seizures ≤ 5 days prior first drug dose, defined as status
             epilepticus or multiple seizures not responding to appropriate therapy.

          -  Current or anticipated use of enzyme-inducing anti-epileptic drugs

          -  Insufficient time for recovery from prior therapy: less than 28 days from WBRT or SRS;
             less than 28 days from any investigational agent; less than 28 days from prior
             cytotoxic therapy (except 23 days from prior temozolomide, 14 days from vincristine,
             42 days from nitrosoureas, 21 days from procarbazine administration), and less than 7
             days for non-cytotoxic agents, e.g., interferon, tamoxifen, thalidomide, cis-retinoic
             acid, etc. When radiation necrosis is suspected, confirmatory imaging will be
             performed, and patients with findings consistent with radiation necrosis will be
             excluded.

          -  Current use or anticipated need for treatment with Coumadin® or other agents
             containing warfarin (except low dose Coumadin (1 mg or less daily) administered
             prophylactically for maintenance of in-dwelling lines or ports). Heparin, low
             molecular weight heparin (LWMH), direct thrombin inhibitors and factor Xa inhibitors
             are allowed. Rivaroxaban should be used with caution. Antiplatelet agents are allowed.

          -  Current or anticipated need for treatment with drugs that are known substrates of
             CYP2D6

          -  Current or anticipated need for treatment with proton pump inhibitors. Patients on
             proton pump inhibitors who can be switched to H2-blockers before the start of the
             study are still eligible.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to dacomitinib.

          -  Known severe and/or uncontrolled medical disorder that would impair ability to receive
             study treatment (i.e., uncontrolled diabetes, chronic renal disease, chronic pulmonary
             disease, HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), or active infection).

          -  Impaired cardiac function including any of the following: Congenital long QT syndrome
             or a known family history of long QT syndrome; corrected QT interval (QTc) > 450 msec;
             history or presence of clinically significant ventricular or atrial tachyarrhythmias;
             clinically significant resting bradycardia (< 50 beats per minute); myocardial
             infarction within 1 year of starting study drug; other clinically significant heart
             disease (e.g., unstable angina, congestive heart failure, or uncontrolled
             hypertension)

          -  Pregnant or nursing. There is a potential for congenital abnormalities and for this
             regimen to harm nursing infants.
      "
NCT02048865,completed,,1,phase 2,"['venous thromboembolism', 'cancer']","[""['O88.22', 'O88.23', 'O88.211', 'O88.212', 'O88.213', 'O88.219']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['apixaban', 'placebo drug']",['COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N'],"
        Inclusion Criteria:

          -  A newly diagnosed cancer site or progression of the malignant disease after complete
             or partial remission.

          -  Initiating a new course of chemotherapy with a minimum intent of 3 months therapy

          -  A VTE risk stratification score of ≥ 2, according to the scoring method

          -  Age 18 years old or older

          -  Provide written informed consent

        Exclusion Criteria:

          -  Lesions or conditions at increased risk of clinically significant bleeding (eg. active
             peptic ulcer disease)

          -  Objectively confirmed substantial liver insufficiency as defined by clinical
             manifestations of ascites, cirrhosis, encephalopathy and/or jaundice and/or
             biochemical abnormalities in liver function tests including hypoalbuminemia (< 3.5
             gr/dL), elevated levels of total bilirubin (> 25 umol/L), elevated liver transaminases
             (2 times the upper limit of normal) and/or biochemical diagnosis of biliary tract
             obstruction (elevated levels of gamma-glutamyl transferase and alkaline phosphatase, 3
             times the upper limit of normal). *

          -  Diagnosis of basal cell or squamous cell carcinoma of the skin or acute leukemia or
             myelodysplastic syndrome**

          -  Planned stem cell transplant

          -  Life expectancy less than 6 months

          -  Acute or chronic renal insufficiency with glomerular filtration rate (GFR) < 30 ml/min
             calculated by the Cockroft and Gault formula.

          -  Pregnancy***

          -  Continuous anticoagulation with vitamin K antagonists, low-molecular-weight heparin
             (LMWH), or other oral anticoagulants

          -  Weight < 40 Kg

          -  Platelet count < 50 x 109/L

          -  Known allergies to ingredients contained in apixaban

          -  Use of any contraindicated medications with apixaban
      "
NCT02040870,completed,,1,phase 1/phase 2,['non-small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]",['ldk378'],['CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl'],"
        Inclusion criteria:

          -  Histologically or cytologically confirmed diagnosis of NSCLC that carries an ALK
             rearrangement defined as positive using the FDA approved Vysis ALK Break Apart FISH
             Probe Kit (Abbott Molecular Inc.) test and scoring algorithm (including positivity
             criteria) or positive as assessed by the CFDA approved immunohistochemistry (IHC) test
             (Ventana Medical Systems, Inc)

          -  Age 18 years or older at the time of informed consent.

          -  Patients must have stage IIIB or IV NSCLC at the time of study entry and have had
             progressive disease during or after crizotinib treatment whether or not previously
             treated with cytotoxic chemotherapy. If treated with chemotherapy, maximum 2 lines are
             allowed.

        Exclusion Criteria:

          -  Patients with known hypersensitivity to any of the excipients of LDK378

          -  Patients with symptomatic central nervous system (CNS) metastases who are
             neurologically unstable or have required increasing doses of steroids within the 2
             weeks prior to study entry to manage CNS symptoms

          -  History of carcinomatous meningitis

          -  Presence or history of a malignant disease other than NSCLC that has been diagnosed
             and/or required therapy within the past 3 years.

          -  clinically significant, uncontrolled heart disease.
      "
NCT02047552,withdrawn,"
    no participants enrolled
  ",0,phase 2,"['functional iron deficiency', 'trauma', 'anemia']","[""['K08.81', 'K08.82', 'O71.9', 'N48.31', 'O71.89', 'G89.11', 'G89.21']"", ""['D53.2', 'D64.9', 'D46.4', 'D53.0', 'D53.9', 'D61.3', 'D61.9']""]","['iron sucrose', 'oxandrolone', 'iv iron placebo', 'oxandrolone placebo']","['C(C1C(C(C(C(O1)OC2(C(C(C(O2)CO)O)O)CO)O)O)O)O.O.O.O.[OH-].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3]', 'CC12CCC3C(C1CCC2(C)O)CCC4C3(COC(=O)C4)C']","
        Inclusion Criteria:

          1. Informed consent from patient or patient representative.

          2. Trauma patient

          3. Anemia (hemoglobin < 12 g/dL).

          4. Functional iron deficiency:

               1. Serum iron concentration < 40 ug/dL

               2. TSAT < 25%

               3. Serum ferritin concentration > 28 ng/mL

          5. < 72 hours from ICU admission.

          6. Expected ICU length of stay ≥ 7 days.

        Exclusion Criteria:

          1. Age < 18 years.

          2. Active bleeding requiring pRBCs transfusion.

          3. Iron overload (serum ferritin concentration ≥ 1,500 ng/mL). The serum ferritin
             concentration is an acute phase reactant that is increased during critical illness
             regardless of total body iron. Substantial levels of hyperferritinemia (serum ferritin
             concentration > 1,000 ng/dL) were observed in both NCT00450177 and NCT01180894 without
             increased risk of infection and despite both low TSAT and IDE. For these reasons, we
             believe that relative hyperferritinemia (serum ferritin concentration 500 - 1,500
             ng/dL) is neither harmful nor indicative of bone marrow iron availability.

          4. Infection, defined using US Centers for Disease Control and Prevention (CDC)
             guidelines, with the exception of ventilator-associated pneumonia (VAP), which is
             defined as clinical suspicion for pneumonia along with a lower respiratory tract
             culture with ≥ 105 colony forming units per mL.

          5. Chronic inflammatory conditions (e.g., systemic lupus erythematosis, rheumatoid
             arthritis, ankylosing spondylitis).

          6. Pre-existing hematologic disorders (e.g., thalassemia, sickle cell disease,
             hemophilia, von Willibrand's disease, or myeloproliferative disease).

          7. Pre-existing hepatic dysfunction (cirrhosis, non-alcoholic steatohepatitis, hepatitis)

          8. Current or recent (within 30 days) use of immunosuppressive agents.

          9. Use of any recombinant human erythropoietin formulation within the previous 30 days.

         10. Known or suspected carcinoma of the breast or prostate.

         11. Nephrosis, the nephrotic phase of nephritis.

         12. Hypercalcemia (serum calcium concentration > 10.5 mg/dL).

         13. Pregnancy or lactation.

         14. Legal arrest or incarceration.

         15. Prohibition of pRBCs transfusion.

         16. Stay of ≥ 48 hours duration in the ICU of a transferring hospital.

         17. History of intolerance or hypersensitivity to either iron or oxandrolone.

         18. Moribund state in which death was imminent.
      "
NCT02044796,completed,,1,phase 1/phase 2,"['acute biphenotypic leukemia', 'de novo myelodysplastic syndrome', 'previously treated myelodysplastic syndrome', 'recurrent adult acute myeloid leukemia', 'untreated adult acute myeloid leukemia', 'secondary acute myeloid leukemia']","[""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']"", ""['D46.Z', 'D46.9', 'C94.6', 'D46.C']"", ""['D46.Z', 'D46.9', 'C94.6', 'D46.C']"", ""['G47.13', 'J01.41', 'K11.22', 'K12.0', 'N96', 'F33.8', 'G03.2']"", ""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']"", ""['D75.1', 'E26.1', 'N91.1', 'N91.4', 'N94.5', 'A51.41', 'A51.43']""]","['cladribine', 'cytarabine', 'mitoxantrone hydrochloride']","['C1C(C(OC1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O', 'C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl']","
        Inclusion Criteria:

          -  For patients with newly diagnosed disease: diagnosis of ""high-risk"" myelodysplastic
             syndrome (MDS) (>= 10% blasts) or AML other than acute promyelocytic leukemia (APL)
             with t(15;17)(q22;q12) or variants according to the 2008 World Health Organization
             (WHO) classification; for patients with relapsed/refractory disease: prior diagnosis
             of ""high-risk"" MDS or non-APL AML, with relapsed/refractory disease according to
             standard criteria requiring first or subsequent salvage therapy; patients with
             biphenotypic AML are eligible

          -  Outside diagnostic material is acceptable as long as peripheral blood and/or bone
             marrow slides are reviewed at the study institution; flow cytometric analysis of
             peripheral blood and/or bone marrow should be performed according to institutional
             practice guidelines

          -  For patients with relapsed/refractory disease: patients with prior autologous or
             allogeneic hematopoietic cell transplantation (HCT) for MDS/AML are eligible if
             relapse occurs provided symptoms of graft-versus host disease are well controlled with
             stable use of immunosuppressive agents

          -  Treatment-related mortality (TRM) score =< 6.9 as calculated with simplified model

          -  The use of hydroxyurea prior to study registration is allowed; patients with
             symptoms/signs of hyperleukocytosis or white blood cell (WBC) > 100,000/uL can be
             treated with leukapheresis or may receive up to 2 doses of cytarabine (up to 500
             mg/m^2/dose) prior to enrollment

          -  For patients with relapsed/refractory disease: patients may have previously received
             chemotherapy with a mitoxantrone- or cladribine-based regimen for MDS or AML; if that
             patient has received G-CLAM before and has been sensitive to this regimen, eligibility
             will be determined on a case-by-case basis by the study principal investigator (PI)

          -  Should be off any active systemic therapy for AML with the exception of hydroxyurea
             for at least 14 days prior to study registration unless patient has rapidly
             progressive disease, and all grade 2-4 non-hematologic toxicities should have resolved

          -  Bilirubin =< 2.5 x institutional upper limit of normal (IULN) unless elevation is
             thought to be due to hepatic infiltration by AML, Gilbert's syndrome, or hemolysis
             (assessed within 14 days prior to study day 0)

          -  Serum creatinine =< 2.0 mg/dL (assessed within 14 days prior to study day 0)

          -  Left ventricular ejection fraction >= 45%, assessed within 3 months prior to study day
             0, e.g. by multi gated acquisition scan (MUGA) scan or echocardiography, or other
             appropriate diagnostic modality and no clinical evidence of congestive heart failure;
             if the patient had anthracycline-based therapy since the most recent cardiac
             assessment, cardiac evaluation should be repeated if there is clinical or radiographic
             suspicion of cardiac dysfunction, or if the previous cardiac assessment was abnormal

          -  Women of childbearing potential and men must agree to use adequate contraception

          -  Provide written informed consent

        Exclusion Criteria:

          -  Myeloid blast crisis of chronic myeloid leukemia (CML), unless patient is not
             considered candidate for tyrosine kinase inhibitor treatment

          -  Concomitant illness associated with a likely survival of < 1 year

          -  Active systemic fungal, bacterial, viral, or other infection, unless disease is under
             treatment with anti-microbials and/or controlled or stable (e.g. if specific,
             effective therapy is not available/feasible or desired [e.g. chronic viral hepatitis,
             human immunodeficiency virus (HIV)]); patient needs to be clinically stable as defined
             as being afebrile and hemodynamically stable for 24 hours; patients with fever thought
             to be likely secondary to leukemia are eligible

          -  Known hypersensitivity to any study drug

          -  Pregnancy or lactation

          -  Treatment with any other investigational agent
      "
NCT02040857,completed,,1,phase 2,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['palbociclib', 'aromatase inhibitor']",['CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C'],"
        Inclusion Criteria:

          -  Participants must have histologically confirmed hormone receptor positive (HR+) HER2
             negative stage II (except T2N0) or stage III invasive breast cancer. Evaluation for
             metastatic disease is not required in the absence of symptoms.

          -  Men and both pre- and postmenopausal women are eligible.

          -  Prior Treatment:

               -  Participants may have received (neo)adjuvant chemotherapy, but must be at least
                  30 days after last dose, with no more than grade 1 residual toxicity at time of
                  screening.

               -  Participants may have received adjuvant radiotherapy, but must be at least 30
                  days after last dose , with no more than grade 1 residual toxicity at the time of
                  screening.

               -  If most recent therapy was surgery, participants must be at least 30 days out
                  from definitive surgery with no active wound healing complications.

          -  Participants must have demonstrated ability to tolerate endocrine therapy by prior
             successful completion of at least 1 month of tamoxifen or aromatase inhibitor (AI)
             therapy without significant adverse events, and in the opinion of the treating
             physician any ongoing toxicity does not preclude ability to continue on tamoxifen or
             AI for at least a projected 2 year continuous duration. Ongoing use of any endocrine
             therapy, including tamoxifen, letrozole, anastrozole, or exemestane, is allowed.
             Patients may enroll within 2 years of beginning endocrine therapy, as long as there is
             a plan for at least 2 more years of adjuvant endocrine therapy.

          -  ECOG performance status 0-1

          -  Age ≥18 years.

          -  Normal organ and marrow function

          -  Baseline QTc ≤ 480 ms

          -  The effects of palbociclib on the developing human fetus are unknown. Women who might
             become pregnant must use adequate contraception

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Concurrent therapy with other investigational agents.

          -  Prior therapy with any CDK4/6 inhibitor.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to palbociclib.

          -  Participants receiving any medications or substances that are strong inhibitors or
             inducers of CYP3A isoenzymes are ineligible.

          -  Current use of drugs that are known to prolong the QT interval

          -  Subjects with organ allograft requiring immunosuppression.

          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Pregnant women are excluded from this study. Breastfeeding should be discontinued
             prior to entry onto the study.

          -  Individuals with a history of a different malignancy are ineligible except for the
             following circumstances. Individuals with a history of other malignancies are eligible
             if they have been disease-free for at least 5 years and are deemed by the investigator
             to be at low risk for recurrence of that malignancy. Individuals with the following
             cancers are eligible if diagnosed and treated within the past 5 years: ductal
             carcinoma in situ of the breast, cervical cancer in situ, and basal cell or squamous
             cell carcinoma of the skin.

          -  No ongoing combination antiretroviral therapy
      "
NCT02046928,terminated,"
    slow enrollment
  ",0,phase 2,"['chronic lymphocytic leukemia', 'small lymphocytic lymphoma', 'cll', 'sll']","[""['C91.11', 'C91.12', 'C91.10']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']""]",['a6'],['C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO[P+](=O)O)OP(=O)(O)OCC4C(C(C(O4)N5C=NC6=C5N=C(NC6=O)N)O)O)O)N'],"
        Inclusion Criteria:

          -  Confirmed diagnosis of CLL or SLL based on IWCLL Criteria

          -  Measurable or evaluable disease based on IWCLL criteria

          -  Previously untreated patients who have been counseled on approved alternative
             therapeutic options. Not a candidate for fludarabine/cyclophosphamide/rituximab (FCR)
             or has preference to not receive chemotherapy.

          -  Eastern Cooperative Oncology Group (ECOG) status of 0-2.

          -  Adequate bone marrow, renal, liver, cardiac and pulmonary function.

          -  Life expectancy of greater than or equal to 6 months.

        Exclusion Criteria:

          -  Receipt of other cancer therapy, immunomodulatory drug therapy or immunosuppressive
             therapy within 4 weeks prior to 1st dose.

          -  Receipt of corticosteroids > 20 mg/day within 4 weeks prior to1st dose

          -  Major surgery or radiation within 4 weeks prior to 1st dose

          -  Presence of uncontrolled infection requiring systemic therapy

          -  Active second malignancy other than non-melanoma skin cancer

          -  Uncontrolled autoimmune anemia or thrombocytopenia

          -  Receipt of any investigational agent within 4 weeks prior to 1st dose

          -  Pregnant or lactating female

          -  Any severe, acute or chronic medical or psychiatric condition, or lab abnormality that
             may increase the risk associated with trial participation, study drug administration
             or interfere with informed consent process or compliance with requirements of the
             trial.
      "
NCT03366675,terminated,"
    early detection of the purpose of the study.
  ",1,phase 2,['small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]",['azd2811'],['CCN(CCCOC1=CC2=C(C=C1)C(=NC=N2)NC3=NNC(=C3)CC(=O)NC4=CC(=CC=C4)F)CCO'],"
        Inclusion Criteria:

          1. Provision of fully informed consent prior to any study specific procedures.

          2. Patients must be ≥20 years of age.

          3. Small cell lung cancer(SCLC) that has progressed during or after first-line therapy.

               -  The 1st line regimen must have contained platinum based regimen.

               -  Refractory to first-line chemotherapy or relapse within 6 months since the last
                  dose of first-line chemotherapy

               -  If the patient correspond to sensitive relapse (relapse more than 6 months since
                  the last dose of first-line chemotherapy), she/he should get second-line
                  treatment.

          4. Provision of tumor sample (from either archival or fresh biopsy)

          5. Patients are willing and able to comply with the protocol for the duration of the
             study including undergoing treatment and scheduled visits and examinations including
             follow up.

          6. ECOG performance status of 0-2

          7. Patients must have a life expectancy ≥ 3 months from proposed first dose date.

          8. Patients must have acceptable bone marrow, liver and renal function measured within
             28days prior to administration of study treatment as defined below:

               -  Haemoglobin > 9.0 g/dL

               -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L

               -  White blood cells (WBC) ≥ 3 x 109/L

               -  Platelet count ≥100 x 109/L

               -  Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) except for
                  subject with liver metastases for whom total bilirubin is ≤ 3 x ULN

               -  AST(SGOT)/ALT(SGPT) ≤ 2.5 x institutional upper limit of normal(ULN) except for
                  subject with liver metastases for whom AST(SGOT)/ALT(SGPT) is ≤ 5x ULN

               -  Alkaline phosphatase(ALP) ≤ 2.5 x institutional upper limit of normal(ULN) except
                  for subject with liver metastases for whom ALP is ≤ 5 x ULN. ALP is not
                  exclusionary if due to the presence of bone metastasis and liver function is
                  otherwise considered adequate in the investigator's judgement.

               -  Patients must have creatinine clearance estimated using the Cockcroft-Gault
                  equation of ≥51 mL/min:

             Estimated creatinine clearance = (140-age [years]) x weight (kg) (x F)a serum
             creatinine (mg/dL) x 72 a where F=0.85 for females and F=1 for males.

             - Albumin ≥ 33g/L

          9. At least one measurable lesion that can be accurately assessed by imaging or physical
             examination.

         10. Evidence of non-childbearing status for women of childbearing potential: A woman of
             childbearing potential must have a negative or urine pregnancy test at screening and
             confirmed prior to treatment on Cycle 1 Day 1

         11. Female patients who are not of childbearing potential and fertile female patients of
             childbearing potential who agree to use adequate contraceptive measures, who are not
             breastfeeding. Fertile female patients of childbearing potential should use enhanced
             methods of contraception from the time of screening until 6 months after discontinuing
             study treatment. Acceptable methods of contraception include: combined oral or
             transdermal contraceptives, copper-banded intra-uterine devices and vasectomised
             partner. All methods of contraception (with the exception of total abstinence) should
             be used in combination with the use of a condom by their male sexual partner for
             intercourse. Male patients should be asked to avoid unprotected sex with all sexual
             partners (by use of condoms) during the study, and for a washout period of 6 months
             after the last dose of study drug. Where a sexual partner of a male participant is a
             fertile female patient of childbearing potential, patients should avoid procreation
             for 6 months after completion of study drug treatment. Patients should refrain from
             donating sperm from the start of dosing until 6 months after discontinuing study
             treatment. If male patients wish to father children they should be advised to arrange
             for freezing of sperm samples prior to the start of study treatment

        Exclusion Criteria:

          1. Previous enrolment in the present study

          2. More than two prior chemotherapy regimen for the treatment of small cell lung cancer

          3. Previous treatment with Alisertib

          4. Patients with second primary cancer, except: adequately treated non-melanoma skin
             cancer, curatively treated in-situ cancer of the cervix, or other solid tumours
             curatively treated with no evidence of disease for >2 years.

          5. Treatment with any investigational product during the last 14 days before the
             enrollment (or a longer period depending on the defined characteristics of the agents
             used).

          6. Patients receiving any systemic chemotherapy, radiotherapy (except for palliative
             reasons), within 2 weeks from the last dose prior to study treatment The patient can
             receive a stable dose of bisphosphonates or denosumab for bone metastases, before and
             during the study as long as these were started at least 4 weeks prior to treatment.

          7. Patient has had prescription or non-prescription drugs or other products known to be
             strong inhibitors/inducers of CYP3A4 which cannot be discontinued prior to Day 1 of
             dosing and withheld throughout the study until 2 weeks after the last dose of study
             drug. Washout periods vary between 1 to 5 weeks depending on the medication.

          8. With the exception of alopecia, any ongoing toxicities (>CTCAE 4.03 grade 1) caused by
             previous cancer therapy.

          9. Intestinal obstruction or CTCAE 4.03 grade 3 or grade 4 upper GI bleeding within 4
             weeks before the enrollment.

         10. Resting ECG with measurable QTc > 470 msec on 3 or more time points within a 24 hour
             period or any factors that increase the risk of QTc prolongation or risk of arrhythmic
             events such as heart failure, hypokalaemia, congenital long QT syndrome, immediate
             family history of long QT syndrome or unexplained sudden death under 40 years of age.

         11. Patients with cardiac problem as follows: unstable angina pectoris, congestive heart
             failure, acute myocardial infarction, conduction abnormality not controlled with
             pacemaker or medication, significant ventricular or supraventricular arrhythmias
             (patients with chronic rate controlled atrial fibrillation in the absence of other
             cardiac abnormalities are eligible).

         12. Patients at risk of brain perfusion problems(e.g., carotid stenosis hypotension,
             including a fall in blood pressure of >20mm Hg)

         13. Uncontrolled hypertension requiring clinical intervention.

         14. Female patients who are breast-feeding or child-bearing

         15. Any evidence of severe or uncontrolled systemic disease, active infection, active
             bleeding diatheses or renal transplant, including any patient known to have human
             immunodeficiency virus (HIV), active hepatitis B or active hepatitis C

         16. Major surgical procedures ≤28 days of beginning study treatment, or minor surgical
             procedures ≤7 days

         17. Known malignant central nervous system (CNS) disease other than neurologically stable,
             treated brain metastases - defined as metastasis having no evidence of progression or
             haemorrhage for at least 2 weeks after treatment (including brain radiotherapy).
      "
NCT02135445,completed,,1,phase 2,['prostate cancer'],"[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]","['tak-385', 'degarelix']","['CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC', 'CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)NC(=O)N)NC(=O)C(CC3=CC=C(C=C3)NC(=O)C4CC(=O)NC(=O)N4)NC(=O)C(CO)NC(=O)C(CC5=CN=CC=C5)NC(=O)C(CC6=CC=C(C=C6)Cl)NC(=O)C(CC7=CC8=CC=CC=C8C=C7)NC(=O)C']","
        Inclusion Criteria:

          1. Is male, 18 years of age or older.

          2. Has histologically confirmed diagnosis of localized prostate adenocarcinoma of
             intermediate risk for which 6-month neoadjuvant and adjuvant androgen deprivation
             therapy (ADT) to EBRT is indicated. Intermediate risk per National Comprehensive
             Cancer Network (NCCN) guidelines includes one of the following:

               1. T2b-T2c disease, or

               2. Gleason score 7, or

               3. Prostate-specific antigen (PSA) 10-20 nanogram per milliliter (ng/mL).

          3. Is scheduled for EBRT to begin greater than or equal to (>=) 12 weeks after the
             Baseline visit.

          4. Has serum testosterone at screening greater then (>) 150 nanogram per deciliter
             (ng/dL) (5.2 nanomoles per liter [nmol/L]).

          5. Has screening serum PSA concentration >2 ng/mL.

          6. Has body mass index (BMI) >=18.0 at screening or baseline.

          7. Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at
             screening or baseline.

          8. Is a male participant, even if surgically sterilized (that is, status postvasectomy),
             who: Agrees to practice effective barrier contraception during the entire study
             treatment period and through 4 months after the last dose of study drug, or, Agrees to
             practice true abstinence, when this is in line with the preferred and usual lifestyle
             of the participant. (Periodic abstinence [example, calendar, ovulation, symptothermal,
             postovulation methods for the female partner] and withdrawal are not acceptable
             methods of contraception.).

          9. Has given voluntary written consent before performance of any study-related procedure
             not part of standard medical care, with the understanding that consent may be
             withdrawn by the participant at any time without prejudice to future medical care.

         10. Has suitable venous access for the study-required blood sampling, including
             pharmacokinetic (PK) and pharmacodynamic sampling.

        Exclusion Criteria:

          1. Has metastatic disease (based on investigator evaluation and assuming no likely
             metastatic pelvic lymph nodes >1.0 cm in long axis diameter).

          2. Had prior or current use of a gonadotropin-releasing hormone (GnRH) analog or androgen
             receptor antagonist as first-line hormone therapy, unless total use was less than 6
             months and not more recently than 1 year before the planned baseline visit.

          3. Had diagnosis of or treatment for another malignancy within 2 years before the first
             dose of study drug, or previous diagnosis of another malignancy with evidence of
             residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of
             any type are not excluded if they have undergone complete resection.

          4. Has abnormal screening and/or baseline laboratory values that suggest a clinically
             significant underlying disease, or the following laboratory values:

               1. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >1.5 *
                  institutional upper limit of the normal range (ULN);

               2. Serum creatinine >2.0 milligram per deciliter (mg/dL);

               3. Total bilirubin >2.0 * institutional ULN (unless documented Gilbert's disease);

               4. Uncontrolled diabetes (Hemoglobin A1c [HbA1c] >10 [percent] %) or previously
                  undiagnosed diabetes mellitus with HbA1c >8%.

          5. Has history of myocardial infarction, unstable symptomatic ischemic heart disease, any
             ongoing cardiac arrhythmias of Grade >2 (chronic stable atrial fibrillation on stable
             anticoagulant therapy is allowed), thromboembolic events (example, deep vein
             thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), or any other
             significant cardiac condition (example, pericardial effusion, restrictive
             cardiomyopathy) within 6 months before receiving the first dose of study drug.

          6. Has electrocardiogram (ECG) abnormalities of:

               1. Q-wave infarction, unless identified 6 or more months before screening;

               2. Heart rate-corrected QT interval millisecond (msec) (QTcF interval) >480 msec. If
                  QTcF is prolonged in a participant with a pacemaker, the participant may be
                  enrolled in the study upon discussion with the project clinician;

               3. If the QTcF interval is 450-480 msec, inclusive, in a participant with current
                  use of medications with known effects on QT interval, the participant may be
                  enrolled in the study following discussion with the project clinician.

          7. Has congenital long QT syndrome.

          8. Is currently using Class IA (example, quinidine, procainamide) or Class III (example,
             amiodarone, sotalol) antiarrhythmic medications.

          9. Has uncontrolled hypertension despite appropriate medical therapy (sitting blood
             pressure [BP] of greater than 160 millimeters of mercury (mmHg) systolic and 90 mmHg
             diastolic at 2 separate measurements no more than 60 minutes apart during the
             Screening visit). Participants with systolic BP measurements >160 mmHg may be
             rescreened. Participants with systolic BP measurements 141-160 mmHg, although
             eligible, should be referred for further management of hypertension if indicated.

         10. Has known, previously diagnosed human immunodeficiency virus (HIV) infection, active
             chronic hepatitis B or C, life-threatening illness unrelated to prostate cancer, or
             any serious medical or psychiatric illness that could, in the investigator's opinion,
             potentially interfere with participation in this study. Specific screening for chronic
             viral illness is at the discretion of the site and/or local institutional review board
             (IRB).

         11. Has received treatment with any investigational products within 3 months before the
             first dose of study drug.

         12. Is a primary family member (spouse, parent, child, or sibling) of anyone involved in
             the conduct of the study or is a study site employee.

         13. Has known gastrointestinal (GI) disease, condition or procedure that could interfere
             with the oral absorption or tolerance of TAK-385, including difficulty swallowing
             tablets.

         14. Is using any medication or food products listed in the excluded medications and
             dietary products table within 2 weeks before the first dose of study drug. This list
             includes moderate and strong inhibitors or inducers of cytochrome P450 (CYP3A4/5) and
             P-glycoprotein (P-gp). Participants must have no history of amiodarone use in the 6
             months before the first dose of TAK-385.

         15. Has admission or evidence of alcohol or drug abuse or use of illicit drugs.
      "
NCT02132468,completed,,0,phase 2,['neuroendocrine tumors'],"[""['C7A.1', 'C7A.8', 'C7B.8', 'D3A.8']""]",['fosbretabulin tromethamine'],['COC1=C(C=C(C=C1)C=CC2=CC(=C(C(=C2)OC)OC)OC)OP(=O)(O)O.C(C(CO)(CO)N)O'],"
        Inclusion Criteria:

          -  Ability to read, understand and provide written consent to participate in the study

          -  Age ≥ 18 years

          -  Biopsy-proven well-differentiated, low-to-intermediate-grade PNET or GI-NET with
             elevated (> ULN) biomarkers (serotonin, 5-hydroxyindoleacetic acid (5-HIAA),
             chromogranin A (CgA), neurokinin A, and neuron-specific enolase (NSE))

          -  Life expectancy > 12 weeks

          -  Must have received or may still be receiving one or more therapies including
             octreotide or serotonin synthesis inhibitor (SSI) or other somatostatin analogues

          -  Confirmed progressive disease within 18 months of enrollment on study

          -  Recovered from prior radiation therapy or surgery

          -  Eastern Cooperative Oncology Group (ECOG) performance score 0-2

          -  Absolute neutrophil count (ANC) ≥ 1,500/µL (without growth factors)

          -  Platelet count ≥ 100,000/µL

          -  Adequate renal function as evidenced by serum creatinine

             ≤ 2.0 mg/dL (177 µmol/L)

          -  Adequate hepatic function: serum total bilirubin ≤ 2X greater than the upper limit of
             normal (ULN) (≤ 3X ULN in subjects with liver metastases), aspartate aminotransferase)
             AST) / alanine aminotransferase (AST) ≤ 2X the ULN for the local reference lab (≤ 5X
             the ULN for subjects with liver metastases)

          -  Disease that can be assessed (evaluable) with imaging (CT, MRI, PET, radionuclide
             imaging or other imaging modality)

          -  Women of childbearing potential as well as fertile men and their partners must use an
             effective method of birth control

        Exclusion Criteria:

          -  Inadequately controlled hypertension defined as BP > 150/100 mm Hg despite medication

          -  Prior history of hypertensive crisis or hypertensive encephalopathy

          -  Recent history (within 6 months of start of screening) of unstable angina pectoris
             pattern, myocardial infarction (including non-Q wave MI), or NYHA (New York Heart
             Association) Class III and IV Congestive Heart Failure (CHF)

          -  Subjects who have clinical evidence of carcinoid-induced heart disease

          -  History of prior cerebrovascular accident (CVA), including transient ischemic attach
             (TIA)

          -  Known central nervous system (CNS) disease except for treated brain metastasis

          -  History of torsade de pointes, ventricular tachycardia or fibrillation, pathologic
             sinus bradycardia (<60 bpm), heart block (excluding 1st degree block, being PR
             interval prolongation only), congenital long QT syndrome or new ST segment elevation
             or depression or new Q wave on ECG

          -  Corrected QT interval (QTc) > 480 msec

          -  Ongoing treatment with any drugs known to prolong the QTc interval, including
             anti-arrhythmic medications (stable regimen of antidepressants of the selective
             serotonin reuptake inhibitor (SSRI) class is allowed))

          -  Evidence of bleeding diathesis or significant coagulopathy (in the absence of
             therapeutic anticoagulation)

          -  Significant vascular disease or recent peripheral arterial thrombosis

          -  Known intolerance of or hypersensitivity to fosbretabulin

          -  History of solid organ transplant or bone marrow transplant

          -  Any other intercurrent medical condition, including mental illness or substance abuse,
             deemed by the Investigator to be likely to interfere with a subject's ability to sign
             informed consent, cooperate and participate in the study, or interfere with the
             interpretation of the results

          -  High grade or poorly differentiated NET

          -  NET tumor other than PNET or GI-NET

          -  No elevated biomarker (>ULN) that can be followed

          -  Received regional hepatic infusion therapy within 6 months of enrollment (RFA allowed
             >6 months prior to enrollment)
      "
NCT02135133,"active, not recruiting",,0,phase 2,"['chronic lymphocytic leukemia', 'small lymphocytic lymphoma']","[""['C91.11', 'C91.12', 'C91.10']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']""]","['idelalisib', 'ofatumumab']",['CCC(C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5'],"
        Inclusion Criteria:

          -  Participants must meet the following criteria on screening examination to be eligible
             to participate in the study:

          -  Subjects must have CLL / SLL, as documented by a history at some point of an absolute
             peripheral blood B cell count > 5000, with a monoclonal B cell population
             co-expressing CD19, CD5, and CD23, or if CD23 negative, then documentation of the
             absence of t(11;14) or cyclin D1 overexpression. Alternatively patients with
             lymphadenopathy in the absence of circulating disease will also be eligible for this
             study if lymph node biopsy establishes the diagnosis of CLL with the above
             immunophenotype.

          -  Participants must have measurable disease (lymphocytosis > 5,000, or palpable or CT
             measurable lymphadenopathy > 1.5 cm, or bone marrow involvement >30%).

          -  Subjects must not have received any prior systemic therapy for CLL and currently have
             an indication for treatment as defined by the IWCLL 2008 Guidelines:

          -  Massive or progressive splenomegaly; OR

          -  Massive lymph nodes, nodal clusters, or progressive lymphadenopathy; OR

          -  Grade 2 or 3 fatigue; OR

          -  Fever ≥ 100.5°F or night sweats for greater than 2 weeks without documented infection;
             OR

          -  Presence of weight loss ≥ 10% over the preceding 6 months; OR

          -  Progressive lymphocytosis with an increase of ≥ 50% over a 2-month period or an
             anticipated doubling time of less than 6 months; OR

          -  Evidence of progressive marrow failure as manifested by the development of or
             worsening of anemia and or thrombocytopenia.

          -  ECOG performance status <2 (see Appendix A).

          -  Age ≥ 18 years. Because no dosing or adverse event data are currently available on the
             use of idelalisib or ofatumumab in participants <18 years of age, children are
             excluded from this study.

          -  Participants must have normal organ and marrow function as defined below:

          -  creatinine <2.0 times upper normal limit, total bilirubin <1.5 times upper normal
             limit (unless due to disease involvement of liver, hemolysis or a known history of
             Gilbert's disease)

          -  ALT <2.5 times upper normal limit (unless due to disease involvement of liver)
             alkaline phosphatase <2.5 times upper normal limit (unless due to disease involvement
             of the liver or bone marrow)

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Participants who exhibit any of the following conditions at screening will not be
             eligible for admission into the study.

          -  Participants who have had any prior systemic therapy for CLL, or chemotherapy or
             radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) for some other
             indication prior to entering the study or those who have not recovered from adverse
             events due to agents administered more than 4 weeks earlier.

          -  History of severe allergic reactions attributed to compounds of similar chemical or
             biologic composition to ofatumumab or idelalisib.

          -  Subjects who have current active hepatic or biliary disease (with exception of
             participants with Gilbert's syndrome, asymptomatic gallstones, liver metastases or
             stable chronic liver disease per investigator assessment)

          -  Treatment with any known non-marketed drug substance or experimental therapy within 5
             terminal half lives or 4 weeks prior to enrollment, whichever is longer, or currently
             participating in any other interventional clinical study

          -  Other past or current malignancy that could interfere with the interpretation of
             outcome. Subjects who have been free of active malignancy for at least 2 years, or
             have a history of completely resected non-melanoma skin cancer or successfully treated
             in situ carcinoma, or whose malignancy will not interfere with the interpretation of
             study results, are eligible.

          -  Chronic or current infectious disease requiring systemic antibiotics, antifungal, or
             antiviral treatment such as, but not limited to, chronic renal infection, chronic
             chest infection with bronchiectasis, tuberculosis and active Hepatitis C.

          -  History of significant cerebrovascular disease in the past 6 months or ongoing event
             with active symptoms or sequelae

          -  Known HIV positive. HIV-positive individuals on combination antiretroviral therapy are
             ineligible because of the potential for pharmacokinetic interactions with idelalisib.
             In addition, these individuals are at increased risk of lethal infections when treated
             with marrow-suppressive therapy. Appropriate studies will be undertaken in
             participants receiving combination antiretroviral therapy when indicated.

          -  Clinically significant cardiac disease including unstable angina, acute myocardial
             infarction within six months prior to randomization, congestive heart failure (NYHA
             III-IV), and arrhythmia unless controlled by therapy, with the exception of extra
             systoles or minor conduction abnormalities.

          -  Significant concurrent, uncontrolled medical condition including, but not limited to,
             renal, hepatic, gastrointestinal, endocrine, pulmonary, neurological, cerebral or
             psychiatric disease which in the opinion of the investigator may represent a risk for
             the participant.

          -  Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg. In
             addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a HB
             DNA test will be performed and if positive the subject will be excluded.

          -  If HBV DNA is negative, subject may be included but must undergo HBV DNA PCR testing
             at least every 2 months from the start of treatment until 12 months post treatment.
             Prophylactic antiviral therapy may be initiated at the discretion of the investigator.

          -  Positive serology for hepatitis C (HC) defined as a positive test for HepC Ab, in
             which case reflexively perform an HC RIBA immunoblot assay or hepatitis C viral load
             to confirm the result. If the confirmatory test is negative the subject will be
             eligible.

          -  Pregnant or lactating women.

          -  Women of childbearing potential, including women whose last menstrual period was less
             than one year prior to screening, unable or unwilling to use adequate contraception
             from study start to 30 days after the last dose of protocol therapy. Adequate
             contraception is defined as hormonal birth control, intrauterine device, double
             barrier method or total abstinence.

          -  Male subjects unable or unwilling to use adequate contraception methods from study
             start to 30 days after the last dose of protocol therapy.

          -  Participants using concomitant corticosteroids are allowed as long as the subject is
             on the equivalent of 20mg/day or less of prednisone and has been on a stable dose for
             at least two weeks prior to initiating therapy.
      "
NCT02131662,completed,,1,phase 2,['leiomyoma'],"[""['D25.0', 'D25.1', 'D25.2', 'D25.9']""]","['bay1002670', 'bay1002670', 'bay1002670', 'bay1002670', 'placebo']","['CC12CC(C3=C4CCC(=O)C=C4CCC3C1CCC2(C(C(F)(F)F)(F)F)O)C5=CC=C(C=C5)S(=O)(=O)C', 'CC12CC(C3=C4CCC(=O)C=C4CCC3C1CCC2(C(C(F)(F)F)(F)F)O)C5=CC=C(C=C5)S(=O)(=O)C', 'CC12CC(C3=C4CCC(=O)C=C4CCC3C1CCC2(C(C(F)(F)F)(F)F)O)C5=CC=C(C=C5)S(=O)(=O)C', 'CC12CC(C3=C4CCC(=O)C=C4CCC3C1CCC2(C(C(F)(F)F)(F)F)O)C5=CC=C(C=C5)S(=O)(=O)C']","
        Inclusion Criteria:

          -  Signed and dated informed consent

          -  Diagnosis of uterine fibroid(s) documented by transvaginal or abdominal ultrasound at
             screening with at least 1 fibroid with largest diameter 3.0 cm

          -  18 to 50 years of age at the time of screening

          -  Heavy menstrual bleeding >80 mL documented by MP during the bleeding episode following
             the screening visit

          -  Normal or clinically insignificant cervical smear not requiring further follow-up

          -  An endometrial biopsy performed at the screening visit 1 (Visit 1), without
             significant histological disorder such as endometrial hyperplasia or other significant
             endometrial pathology

          -  Use of a non-hormonal barrier method of contraception starting at the bleeding episode
             following the screening visit 1 (Visit 1) until the end of the study

          -  Good general health (except for findings related to uterine fibroids)

        Exclusion Criteria:

          -  Pregnancy or lactation

          -  Uterine fibroid with largest diameter >10.0 cm

          -  Hypersensitivity to any ingredient of the study drug

          -  Laboratory values outside inclusion range before randomization and considered as
             clinically relevant

          -  Hemoglobin values <6 g/dL or any condition requiring immediate blood transfusion
             (subjects with hemoglobin values <10.9 g/dL will receive iron supplementation)

          -  Any diseases or conditions that can compromise the function of the body systems and
             could result in altered absorption, excessive accumulation, impaired metabolism, or
             altered excretion of the study drug
      "
NCT02132949,completed,,1,phase 2,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['5-fluorouracil', 'cyclophosphamide', 'docetaxel', 'doxorubicin', 'epirubicin', 'paclitaxel', 'pertuzumab', 'trastuzumab']","['C1=C(C(=O)NC(=O)N1)F', 'Status: 503', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O', 'CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O', 'CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C']","
        Inclusion Criteria:

          -  Male and female participants with locally advanced, inflammatory, or early-stage,
             unilateral, and histologically confirmed invasive breast cancer. Participants with
             inflammatory breast cancer must be able to have a core needle biopsy

          -  Primary tumor greater than (>) 2 centimeters (cm) in diameter, or > 5 millimeters (mm)
             in diameter and node-positive

          -  HER2-positive breast cancer confirmed by a central laboratory

          -  Availability of tumor tissue specimen

          -  Baseline LVEF greater than or equal to (>/=) 55%

          -  Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to
             (</=) 1

          -  At least 4 weeks since major unrelated surgery, with full recovery

          -  Women of childbearing potential and male participants with partners of childbearing
             potential must agree to use a ""highly effective"" non-hormonal form of contraception or
             two ""effective"" forms of non-hormonal contraception by the patient and/or partner.
             Contraception must continue for the duration of study treatment and for at least 7
             months after the last dose of study treatment

        Exclusion Criteria:

          -  Metastatic disease (Stage IV) or bilateral breast cancer

          -  Participants who have had an incisional biopsy of the primary tumor or the primary
             tumor excised

          -  Prior breast or non-breast malignancy within 5 years prior to study entry, except for
             carcinoma in situ and basal cell and squamous cell carcinoma of the skin. Participants
             with malignancies occurring more than 5 years prior to study entry are permitted if
             curatively treated

          -  Any previous systemic therapy (including chemotherapy, immunotherapy, HER2 targeted
             agents, and antitumor vaccines) for cancer, or radiation therapy for cancer

          -  Participants with a past history of ductal carcinoma in situ (DCIS) or lobular
             carcinoma in situ (LCIS) are not allowed to enter the study if they have received any
             systemic therapy for its treatment or radiation therapy to the ipsilateral breast
             (they are allowed to enter the study if treated with surgery alone)

          -  High-risk participants who have received chemopreventive drugs in the past are not
             allowed to enter the study

          -  Inadequate bone marrow, renal, or liver function

          -  History or evidence of cardiovascular condition

          -  Dyspnea at rest or other diseases that require continuous oxygen therapy

          -  Severe, uncontrolled systemic disease

          -  Participants with poorly controlled diabetes or with evidence of clinically
             significant diabetic vascular complications

          -  Pregnancy or breast-feeding women

          -  Participants who received any investigational treatment within 4 weeks of study start

          -  Participants with known infection with human immunodeficiency virus (HIV), hepatitis B
             virus, or hepatitis C virus

          -  Current chronic daily treatment with corticosteroids (dose >10 mg methylprednisolone
             or equivalent [excluding inhaled steroids])

          -  Known hypersensitivity to any of the study drugs or excipients
      "
NCT02137083,completed,,0,phase 2,['metastatic breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['docetaxel', 'fulvestrant']","['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O', 'CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F']","
        Inclusion Criteria:

          -  Postmenopausal female between 18 and 70 years old

          -  ECOG performance status of ≤ 1

          -  Life expectancy more than 3 months

          -  Histologically confirmed metastatic breast cancer

          -  ER and&or PR pqositive, HER2-negative

          -  Disease progression during adjuvant or first-line endocrine therapy, or endocrine
             naive but unsuitable for endocrine therapy alone

          -  No pretreated chemotherapy for metastatic disease

          -  Have at least one target lesion according to RECIST 1.1

          -  No therapy (chemotherapy, endocrine therapy, target therapy and operation) within 4
             weeks before enrollment

          -  Hemoglobin ≥ 90 g/L, Absolute Neutrophil Count ≥ 1.5×10^9/L, Platelet Count ≥
             75×10^9/L, Serum Bilirubin ≤ 1.5×ULN, ALT and AST ≤ 1.5×ULN, Serum Creatinine ≤ 1×ULN,
             Endogenous Creatinine Clearance>50ml/min

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Evidence of CNS metastasis

          -  Seriously uncontrolled infection

          -  History of another malignancies except cured basal cell carcinoma of skin and
             carcinoma in-situ of uterine cervix

          -  Pretreated with Fulvestrant

          -  Pretreated with two or more lines of endocrine therapy
      "
NCT02132598,terminated,"
    trial stopped due to slow patient accrual.
  ",0,phase 2,"['non small cell lung cancer (nsclc)', 'metastases to the brain']","[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]",['cabozantinib'],['COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F'],"
        Inclusion Criteria:

          1. Previously treated patients with non-squamous NSCLC who have had brain metastases at
             any point in their treatment history are eligible for enrollment on this clinical
             trial. (Patients must have received at least one regimen for systemic disease which
             may be cytotoxic or oral tyrosine kinase inhibitor therapy.)

               -  Patients with clinically asymptomatic untreated brain metastases will be allowed
                  on trial at the discretion of the treating physician

               -  Patients who have undergone treatment for their brain metastases with whole brain
                  radiotherapy, stereotactic radiosurgery, or surgical resection must be clinically
                  stable and recovered from all procedures at the time of study enrollment.

          2. Patients must have tumor tissue available for submission that is sufficient to
             complete c-MET Fluorescence in Situ Hybridization (FISH) studies as well as routine
             molecular profiling at the UPMC. Patients must agree to submission of these specimens
             as defined in Section 9.

               -  c-MET amplification will be determined by FISH ratio (c-MET/CEP7) > 2.0, based on
                  testing of the primary tumor and/or site of metastatic disease

               -  Patients' tumors must undergo testing for Epidermal Growth Factor Receptor (EGFR)
                  exon 19 deletion, EGFR exon 21 L858R substitution, and anaplastic lymphoma kinase
                  (ALK) rearrangements. If positive, patients must have been treated with an
                  appropriate tyrosine kinase inhibitors (TKI) prior to enrolling to the study.

          3. The subject has had an assessment of all extracranial disease sites (e.g., by
             computerized tomography (CT) scan, positron emission tomography-CT, and bone scan as
             appropriate) within 28 days before the first dose of cabozantinib.

          4. The subject must have a baseline brain MRI scan or CT scan of the head (in patients
             unable to obtain an MRI) within 14 days prior to first dose of cabozantinib.

               -  Patients receiving glucocorticoids must be on a stable dose of glucocorticoids
                  during the 5 days prior to the baseline brain imaging.

          5. Patients must have measurable disease as defined by Response Evaluation Criteria in
             Solid Tumors (RECIST) v1.1

          6. Subjects having undergone recent resection or biopsy of an intracranial tumor will be
             eligible as long as all of the following conditions apply:

               -  First dose of cabozantinib occurs at least 28 days after surgery, and the subject
                  has recovered from the effects of surgery

          7. Age ≥18 years

          8. Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (Karnofsky ≥60%)

          9. Patients must have normal organ and marrow function as defined below: (within 4 days
             of beginning treatment unless noted otherwise)

               -  Hemoglobin ≥9 g/dL

               -  Absolute Neutrophil Count (ANC) ≥1,500/mm3 (no CSF support)

               -  Platelets ≥100,000/mm3

               -  Bilirubin ≤ 1.5 x upper limit of normal (ULN)

               -  Bilirubin (Gilbert's Disease) < 3.0 mg/dL

               -  Aspartate Aminotransferase (AST) (SGOT) ≤3.0 × ULN

               -  Alanine Aminotransferase (ALT) (SGPT) ≤3.0 × ULN

               -  Serum creatinine ≤ 1.5 x ULN

               -  Creatinine clearance (CrCl) ≥40 mL/min

               -  For creatinine clearance estimation, the Cockcroft and Gault equation should be
                  used:

               -  Male: CrCl (mL/min) = (140 - age) × wt (kg) / (serum creatinine × 72)

               -  Female: Multiply above result by 0.85 ≤ 1.5 x ULN

               -  Lipase (no radiologic or clinical evidence of pancreatitis) < 2.0 x ULN

               -  Urine protein/creatinine ratio (UPCR) ≤1

               -  Serum phosphorus, calcium, magnesium and potassium ≥ LLN

         10. The subject is capable of understanding and complying with the protocol requirements
             and has signed the informed consent document.

         11. Women of childbearing potential must have a negative serum pregnancy test at
             screening.

         12. The effects of cabozantinib on the developing human fetus are unknown. For this reason
             women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for
             4 months after the last dose of study drug, even if oral contraceptives are used.

        Exclusion Criteria:

          1. The subject has received cytotoxic chemotherapy (including investigational cytotoxic
             chemotherapy) or biologic agents (e.g., cytokines or antibodies; including
             investigational biologic agents) within 3 weeks, or nitrosoureas/ mitomycin C within 6
             weeks before the first dose of study treatment.

          2. The subject has received prior treatment with a small molecule kinase inhibitor or a
             hormonal therapy (including investigational kinase inhibitors or hormones) within 14
             days or five half-lives of the compound or active metabolites, whichever is longer,
             before the first dose of study treatment.

          3. Prior treatment with cabozantinib or other c-MET directed therapy.

          4. The subject has received radiation therapy as follows:

               -  To the thoracic cavity, abdomen or pelvis within 3 months of the first dose of
                  study treatment or has with ongoing complications or is without complete recovery
                  and healing from prior radiation therapy

               -  To bone or brain metastasis within 14 days of the first dose of study treatment

               -  To any other site(s) within 28 days of the first dose of study treatment

          5. The subject has received radionuclide treatment within 6 weeks of the first dose of
             study treatment.

          6. The subject has evidence of acute intracranial or intratumoral hemorrhage either by
             MRI or computerized tomography (CT) scan. The subject has not recovered to baseline or
             CTCAE ≤ Grade 1 from toxicity due to all prior therapies except alopecia and other
             non-clinically significant AEs.

          7. The subject has prothrombin time (PT)/ International Normalized Ratio (INR) or partial
             thromboplastin time (PTT) test ≥ 1.3 x the laboratory ULN within 7 days before the
             first dose of study treatment.

          8. The subject is receiving concomitant treatment with warfarin, warfarin-related agents,
             or low molecular weight heparin (LMWH) at the time of study entry at therapeutic
             doses. Low-dose warfarin (≤ 1 mg/day) or LMWH at prophylactic doses are permitted.

          9. The subject has received enzyme-inducing anti-epileptic agents within 2 weeks before
             the first dose of cabozantinib (e.g., carbamazepine, phenytoin, phenobarbital,
             primidone). Other enzyme inducing agents prohibited within 2 weeks before the first
             dose of cabozantinib include rifampin, rifabutin, rifapentin, and St. John's Wort.

         10. The subject has experienced any of the following:

               -  Clinically-significant gastrointestinal bleeding within 6 months before the first
                  dose of study treatment b.Hemoptysis of ≥ 0.5 teaspoon (2.5ml) of red blood
                  within 3 months before the first dose of study treatment

               -  Any other signs indicative of pulmonary hemorrhage within 3 months before the
                  first dose of study treatment

         11. The subject has radiographic evidence of cavitating pulmonary lesion(s)

         12. The subject has tumor abutting, invading or encasing any major blood vessels.

         13. The subject has evidence of tumor invading the Gastro Intestinal (GI) tract
             (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of
             endotracheal or endobronchial tumor within 28 days before the first dose of
             cabozantinib.

         14. The subject has uncontrolled, significant intercurrent or recent illness including,
             but not limited to, the following conditions:

               -  Cardiovascular disorders including:

                    -  Congestive heart failure (CHF): New York Heart Association (NYHA) Class III
                       (moderate) or Class IV (severe) at the time of screening

                    -  Concurrent uncontrolled hypertension defined as sustained BP > 140 mm Hg
                       systolic, or > 90 mm Hg diastolic despite optimal antihypertensive treatment
                       within 7 days of the first dose of study treatment

                    -  Any history of congenital long QT syndrome

                    -  Any of the following within 6 months before the first dose of study
                       treatment:

        1.unstable angina pectoris 2.clinically-significant cardiac arrhythmias 3.stroke (including
        Transient Ischemic Attack (TIA), or other ischemic event) 4.myocardial infarction (MI)
        5.thromboembolic event requiring therapeutic anticoagulation (Note: subjects with a venous
        filter (e.g. vena cava filter) are not eligible for this study)

          -  Gastrointestinal disorders particularly those associated with a high risk of
             perforation or fistula formation including:

          -  Any of the following within 28 days before the first dose of study treatment

               1. Intra-abdominal tumor/metastases invading GI mucosa

               2. Active peptic ulcer disease,

               3. Inflammatory bowel disease (including ulcerative colitis and Crohn's disease),
                  diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis

               4. Malabsorption syndrome

          -  Any of the following within 6 months before the first dose of study treatment:

               1. Abdominal fistula

               2. Gastrointestinal perforation

               3. Bowel obstruction or gastric outlet obstruction

               4. Intra-abdominal abscess. Note: Complete resolution of an intra-abdominal abscess
                  must be confirmed prior to initiating treatment with cabozantinib even if the
                  abscess occurred more than 6 months before the first dose of study treatment.

          -  Other disorders associated with a high risk of fistula formation including
             Percutaneous Endoscopic Gastrostomy (PEG) tube placement within 3 months before the
             first dose of study therapy.

          -  Other clinically significant disorders such as:

               -  Serious active infection requiring systemic treatment within 28 days before the
                  first dose of study treatment.

               -  Serious non-healing wound/ulcer/bone fracture within 28 days before the first
                  dose of study treatment.

               -  History of organ transplant

               -  Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days
                  before the first dose of study treatment.

          -  History of surgery as follows:

               1. Subjects having undergone recent resection or biopsy of an intracranial tumor
                  will be eligible as long as all of the following conditions apply: First dose of
                  cabozantinib occurs at least 28 days after surgery, and the subject has recovered
                  from the effects of surgery.

               2. Other minor surgery within 28 days of the first dose of cabozantinib if there
                  were no wound healing complications. If there is evidence of wound dehiscence,
                  subjects will be eligible for trial after a minimum of 3 months after surgery to
                  the first dose of cabozantinib, provided complete wound healing is confirmed at
                  least 28 days before the first dose of cabozantinib.

               3. Other major surgery within 2 months of the first dose of cabozantinib if there
                  were no wound healing complications. If there is evidence of wound dehiscence,
                  subjects will be eligible for trial after a minimum of 6 months after surgery to
                  the first dose of cabozantinib, provided complete wound healing in confirmed at
                  least 28 days before the first dose of cabozantinib.

               4. The subject is unable to swallow tablets.

               5. The subject has a corrected QT interval calculated by the Fridericia formula
                  (QTcF) >500 ms within 28 days before randomization. Note: if initial QTcF is
                  found to be > 500 ms, two additional EKGs separated by at least 3 minutes should
                  be performed. If the average of these three consecutive results for QTcF is ≤ 500
                  ms, the subject meets eligibility in this regard.

               6. The subject is pregnant or breastfeeding.

               7. The subject has a previously identified allergy or hypersensitivity to components
                  of the study treatment formulation.

               8. The subject is unable or unwilling to abide by the study protocol or cooperate
                  fully with the investigator or designee.

               9. The subject has had evidence within 2 years of the start of study treatment of
                  another malignancy which required systemic treatment. Note: Subjects with a
                  history of early stage or locally advanced non-metastatic prostate cancer within
                  2 years of the start of study treatment may be included in the study.
      "
NCT02268175,completed,,1,phase 2,"['prostate adenocarcinoma', 'prostate cancer', 'high risk prostate cancer']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']"", ""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]","['enzalutamide', 'abiraterone acetate', 'prednisone', 'leuprolide acetate']","['CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C', 'CC(=O)OC1CCC2(C3CCC4(C(C3CC=C2C1)CC=C4C5=CN=CC=C5)C)C', 'CC12CC(=O)C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C', 'CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O']","
        Inclusion Criteria:

          -  Male greater than or equal 18 years of age.

          -  Histologically confirmed adenocarcinoma of the prostate without histological variants
             (including overt neuroendocrine differentiation, small cell neuroendocrine carcinoma
             features, sarcomatoid features, pure ductal adenocarcinoma, squamous or transitional
             cell carcinoma).

          -  Must have tissue available from the pre-treatment diagnostic biopsy (tissue blocks if
             possible; if not possible, 10 unstained slides from each positive core sample for a
             total of 30 slides).

          -  Must have three core biopsies involved with cancer (a minimum of 6 core biopsies must
             be obtained). Prostate biopsy must be within three months from screening.

          -  Participants must have the following features:

               -  Intermediate-risk disease defined as Gleason 4+3=7 disease OR

               -  High-risk disease defined as Gleason 8-10 OR PSA > 20 ng/dL OR T3 disease (by
                  prostate MRI)

          -  No evidence of metastatic or nodal disease as determined by radionuclide bone scans
             CT/MRI.

          -  Participants must be candidates for RP and considered surgically resectable by
             urologic evaluation.

          -  ECOG performance status 0 to 1 (Appendix A).

          -  Participants must have normal organ and marrow function as defined below:

               -  WBC ≥ 3,000/mcL

               -  ANC ≥ 1,500/mcL

               -  Platelets ≥ 100,000/mcL

               -  Serum potassium ≥ 3.5 mmol/L

               -  AST, ALT, and total bilirubin ≤ 1.5 x Institutional ULN

               -  Calculated creatinine clearance ≥ 60 mL/min

               -  PTT ≤ 60, INR ≤ 1.5 x Institutional ULN unless on warfarin therapy (investigator
                  would need to determine if safe for participant to stop warfarin prior to biopsy
                  and warfarin therapy)

               -  Controlled blood pressure defined as a systolic blood pressure ≤ 140 mmHg and
                  diastolic blood pressure ≤ 90 mmHg on no more than three anti-hypertensive
                  agents. Drug formulations containing two or more anti-hypertensive agents will be
                  counted based on the number of active agents in each formulation.

        Exclusion Criteria:

          -  Prior hormone therapy for prostate cancer including orchiectomy, antiandrogens
             (including first-generation antiandrogens, enzalutamide, ARN-509 and others), CYP17
             inhibitors (including abiraterone, TAK-700, galeterone, ketoconazole, and others),
             estrogens, LHRH agonist/antagonists. Prior therapy with 5α-reductace inhibitors is
             allowed. LHRH therapy allowed if begun within 4 weeks of day 1.

          -  Prior chemotherapy, radiation therapy, or immunotherapy for prostate cancer.

          -  Prior systemic treatment with an azole drug within four weeks of screening visit.

          -  Hypogonadism or severe androgen deficiency as defined by screening serum testosterone
             < 200 ng/dL.

          -  Clinically significant cardiovascular disease including:

          -  Acute coronary syndrome within 6 months of screening visit;

               -  Hypotension defined as a systolic blood pressure < 86 mmHg;

               -  Bradycardia defined as a heart rate of < 50 beats per minute, unless
                  pharmaceutically induced and thus reversible (i.e. beta blockers);

               -  Uncontrolled angina (requiring escalating doses of nitrates) within 3 months of
                  screening visit;

               -  Congestive heart failure NYHA Class III or IV or subjects with a history of
                  congestive heart failure NYHA Class III or IV, unless screening ECHO results in
                  left ventricular ejection fraction that ≥ 45%;

               -  History of clinically significant ventricular arrhythmias (e.g. ventricular
                  tachycardia, ventricular fibrillation, torsades de pointes);

               -  Prolonged corrected QT interval by the Fridericia correction formula (QTcF) on
                  screening EKG > 470 msec;

               -  History of Mobitz II second degree or third degree heart block without a
                  permanent pacemaker in place;

          -  History of seizure or any condition or concurrent medication that may predispose to
             seizure.

          -  Thromboembolism within 6 months of screening visit.

          -  Severe hepatic impairment (Child-Pugh Class C).

          -  Active or symptomatic viral hepatitis or chronic liver disease.

          -  History of pituitary or adrenal dysfunction.

          -  GI disorders which may interfere with the absorption of the study drug.

          -  Pre-existing condition that warrants long-term corticosteroid use.

          -  Concomitant use of medications that may alter pharmacokinetics of abiraterone or
             enzalutamide.

          -  Individuals with a history of a different malignancy are ineligible except for the
             following circumstances: 1) individuals with a history of other malignancies are
             eligible if they have been disease-free for at least 5 years and are deemed by the
             investigator to be at low risk for recurrence of that malignancy, or 2) individuals
             with the following cancers are eligible if diagnosed and treated within the past 5
             years: non-muscle invasive bladder cancer, basal cell or squamous cell carcinoma of
             the skin.

          -  Major surgery or radiation therapy within 30 days of screening.
      "
NCT02269670,terminated,"
    slow to accrual
  ",0,phase 2,"['estrogen receptor-positive breast cancer', 'her2-negative breast cancer', 'progesterone receptor-positive breast cancer', 'recurrent breast cancer', 'stage iiia breast cancer', 'stage iiib breast cancer', 'stage iiic breast cancer', 'stage iv breast cancer']","[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['everolimus', 'anastrozole', 'letrozole', 'tamoxifen citrate', 'fulvestrant', 'megestrol acetate']","['CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC', 'Status: 503', 'C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3', 'CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O', 'CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F', 'CC1=CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C']","
        Inclusion Criteria:

          -  Estrogen (ER) and/or progesterone (PR)-positive at primary diagnosis and at metastatic
             diagnosis where tissue is available (defined as > or = 1% of staining nuclei)

          -  Progressive or recurrent breast cancer defined as disease progression or recurrence
             while on a combination of exemestane with everolimus

          -  Human epidermal growth factor receptor 2 (HER2)/neu-negative breast cancer by standard
             criteria (immunohistochemistry [IHC] < 3+ or fluorescence in situ hybridization [FISH]
             negative if IHC 2+) at primary diagnosis

          -  Histologically confirmed, measurable or evaluable disease; patients should have at
             least one measurable lesion; if applicable, Response Evaluation Criteria in Solid
             Tumors (RECIST) criteria should be used

          -  Life expectancy > 6 months

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

          -  Absolute neutrophil count (ANC) > 1,500/µL

          -  Platelets ≥ 100,000/µL

          -  Hemoglobin > 10 g/dL

          -  Creatinine ≤ 1.5 x upper limit of normal (ULN)

          -  Bilirubin ≤ 1.5 x ULN

          -  International normalized ratio ≤ 1.3 (or ≤ 3 on anticoagulants)

          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2 x ULN unless
             related to primary disease

          -  Signed informed consent

          -  Adequate birth control

          -  Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 mmol/L AND fasting triglycerides ≤ 2.5
             x ULN; NOTE: in case one or both of these thresholds are exceeded, the patient can
             only be included after initiation of appropriate lipid lowering medication

        Exclusion Criteria:

          -  Prior treatment with everolimus other than in combination with hormonal therapy for
             treatment of breast cancer or prior treatment with another mammalian target of
             rapamycin (mTOR) inhibitor (sirolimus, temsirolimus) for any indication

          -  HER2 positive disease as defined by 3+ IHC or positive FISH (both in primary and
             metastatic sites)

          -  Active infection: temperature > 100 Fahrenheit (F), fever of unknown origin, active
             symptoms or signs of infection as defined by the investigator

          -  Uncontrolled central nervous system metastases

          -  Life-threatening, visceral metastases

          -  Pregnant or lactating women

          -  Prior chemotherapy within the last 4 weeks

          -  Prior radiation therapy within the last 4 weeks; prior radiation therapy to indicator
             lesion (unless objective disease recurrence or progression within the radiation portal
             has been documented since completion of radiation)

          -  Concomitant malignancies or previous malignancies within the last 5 years, with the
             exception of adequately treated basal or squamous cell carcinoma of the skin or
             carcinoma in situ of the cervix

          -  History of significant cardiac disease, cardiac risk factors or uncontrolled
             arrhythmias

          -  Hypersensitivity to trial medications (everolimus)

          -  Emotional limitations, which the investigator judges could limit the patient's ability
             to follow up and comply with study procedures

          -  Patients receiving chronic, systemic treatment with corticosteroids or another
             immunosuppressive agent

          -  Uncontrolled diabetes as defined by fasting serum glucose > 1.5 x ULN

          -  Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent
             hepatitis

          -  A known history of human immunodeficiency virus (HIV) seropositivity

          -  Impairment of gastrointestinal function or gastrointestinal disease that may
             significantly alter the absorption of EVEROLIMUS (e.g., ulcerative disease,
             uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel
             resection)

          -  Patients with an active, bleeding diathesis

          -  Female patients who are pregnant or breast feeding, or adults of reproductive
             potential who are not using effective birth control methods; if barrier contraceptives
             are being used, these must be continued throughout the trial by both sexes; hormonal
             contraceptives are not acceptable as a sole method of contraception; (women of
             childbearing potential must have a negative urine or serum pregnancy test within 7
             days prior to administration of EVEROLIMUS)

          -  Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs,
             resulting in dyspnea at rest

          -  Taking any of the following agents:

               -  Chronic treatment with systemic steroids or another immunosuppressive agent (use
                  of steroids as part of management of everolimus toxicities will be allowed)

               -  Live vaccines

               -  Patients who have received live attenuated vaccines within 1 week of start of
                  everolimus and during the study; patient should also avoid close contact with
                  others who have received live attenuated vaccines; examples of live attenuated
                  vaccines include intranasal influenza, measles, mumps, rubella, oral polio,
                  bacillus Calmette-Guérin (BCG), yellow fever, varicella and TY21a typhoid
                  vaccines

               -  Drugs or substances known to be inhibitors or inducers of the isoenzyme
                  cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A)
      "
NCT02263495,completed,,1,phase 2,['metastatic breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['paclitaxel', 'eribulin', 'gemcitabine']","['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C', 'CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O2)OC(C9OC)CC(CN)O', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F']","
        Inclusion Criteria:

          1. Histologically confirmed metastatic, or recurrent breast cancer

          2. HER2-negative breast cancer

          3. age > 18 years

          4. ECOG performance status 0 - 2

          5. Pre- or postmenopausal breast cancer patients with measurable or non-measurable
             lesions, who are candidates for chemotherapy

          6. Life expectancy ≥ 3 months

          7. No prior history of chemotherapy for metastatic, recurrent breast cancer

          8. Patients may have received prior neoadjuvant or adjuvant taxane regimen as long as it
             has been 12 months since completion of regimen.

          9. Patients either may or may not have a prior anthracycline containing regimen.

         10. Prior hormonal therapy as a treatment of metastatic disease is allowed. But
             antitumoral hormonal therapy must be terminated prior to enrollment(up to the date of
             randomization)

         11. Prior radiation therapy allowed as long as < 25% of the bone marrow has been treated,
             and the patients must have recovered from the acute toxic effects of the treatment
             prior to study enrollment. Prior radiation to the whole pelvis is not allowed. Prior
             radiotherapy must be completed 2 weeks before study entry.

         12. Bisphosphonates for the treatment of bone metastases should not be initiated following
             the first dose of randomized therapy. It must be initiated prior to day of treatment
             (cycle 1, day 1). Patients may continue on bisphosphonates who already established on
             bisphosphonate therapy for bone metastases

         13. Adequate bone marrow function (≥ ANC 1,500/ul, ≥ platelet 100,000/ul, ≥ Hemoglobin 9.0
             g/dl)

         14. Adequate renal function (≤ serum creatinine 1.5 mg/dl or CCr ≥ 50 ml/min)

         15. Adequate liver function (≤ serum bilirubin 1.5 mg/dl, ≤ AST & ALTX3 upper normal limit
             or AST and ALT ≤ 5.0XULN if judged by the investigator to be related to liver
             metastases)

         16. Written informed consent

        Exclusion Criteria:

          1. Serious uncontrolled intercurrent infections

          2. Serious intercurrent medical or psychiatric illness, including active cardiac disease

          3. Pregnancy or breast feeding

          4. Second primary malignancy(except in situ carcinoma of the cervix or adequately treated
             nonmelanomatous carcinoma of the skin or other malignancy treated at least 5 years
             previously with no evidence of recurrence)

          5. Documented parenchymal or leptomeningeal brain metastasis

          6. Peripheral neuropathy ≥ grade 2

          7. Prior treatment with gemcitabine will not be allowed.

          8. HER-2 overexpressing breast cancer and concomitant trastuzumab treatment is not
             allowed

          9. Women of childbearing potential, unwilling to use a medically acceptable method of
             contraception during the trial
      "
NCT02260531,completed,,0,phase 2,"['breast cancer', 'brain tumor - metastatic']","[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['cabozantinib', 'trastuzumab']",['COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F'],"
        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed invasive breast cancer,
             with stage IV disease.

          -  New or progressive CNS lesions, as assessed by the patient's treating physician.

          -  For patients who have received prior cranial radiation, no increase in corticosteroid
             dose in the week prior to the baseline brain MRI

          -  Discontinued prior therapy (with the exception of trastuzumab for patients with HER2+
             breast cancer)

          -  Recovery to baseline or ≤ Grade 1 CTCAE v.4.0 from toxicities related to any prior
             treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive
             therapy;

          -  The subject has an ECOG performance status of 0 or 1

          -  Patients must have normal organ and marrow function and laboratory values as follows
             within 14 days before the first dose of cabozantinib

          -  Sexually active subjects (men and women) must agree to use medically accepted barrier
             methods of contraception (e.g., male or female condom) during the course of the study
             and for 4 months after the last dose of study drug(s)

          -  Subjects of childbearing potential must not be pregnant at screening.

          -  Patients on bisphosphonates may continue receiving bisphosphonate therapy during
             study. Patients wanting to initiate bisphosphonate therapy may do so.

          -  The subject has had an assessment of all known disease sites eg, by computerized
             tomography (CT) scan, magnetic resonance imaging (MRI), bone scan as appropriate,
             within 28 days before the first dose of cabozantinib

        Exclusion Criteria:

          -  The subject has received cabozantinib or another c-Met inhibitor (please note ARQ 197
             is not considered a MET inhibitor for purposes of this study given data to suggest it
             inhibits tubulin)

          -  The subject has uncontrolled, significant intercurrent or recent illness

          -  Leptomeningeal disease as the only site of CNS involvement

          -  Known contraindication to MRI with gadolinium contrast, such as cardiac pacemaker,
             shrapnel, or ocular foreign body

          -  More than 2 seizures over the last 4 weeks prior to study entry

          -  Grade 1 or higher CNS hemorrhage on baseline brain MRI, or history of grade 2 or
             higher CNS hemorrhage within 12 months

          -  Has experienced clinically-significant GI bleeding within 6 months before first dose
             of cabozantinib; hemoptysis of ≥ 0.5 teaspoon (2.5ml) of red blood within 3 months
             before the first dose of cabozantinib; any other signs indicative of pulmonary
             hemorrhage within 3 months before the first dose of cabozantinib

          -  The subject has tumor in contact with, invading or encasing any major blood vessels

          -  The subject has evidence of tumor invading the GI tract (esophagus, stomach, small or
             large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor
             within 28 days before the first dose of cabozantinib

          -  The subject requires concomitant treatment, in therapeutic doses, with anticoagulants.
             Low dose aspirin (≤ 81 mg/day), low-dose warfarin ( ≤1 mg/day), and prophylactic LMWH
             are permitted.

          -  The subject has prothrombin time (PT)/INR or partial thromboplastin time (PTT) test
             ≥1.3 × the laboratory ULN within 7 days before the first dose of cabozantinib.

          -  Inability to swallow intact tablets

          -  Pregnant or lactating females

          -  Diagnosis of another malignancy within 2 years before the first dose of cabozantinib,
             except for superficial skin cancers, or localized, low grade tumors deemed cured and
             not treated with systemic therapy

          -  Subjects with clinically relevant ongoing complications from prior radiation therapy
             are not eligible

          -  The subject is known to be positive for the human immunodeficiency virus (HIV)

          -  Subjects with clinically relevant ongoing complications from prior surgery are not
             eligible

          -  QTcF > 500 msec on average of screening EKGs performed within 28 days of first dose of
             cabozantinib. Three EKGs must be performed at screening. If the average of these three
             consecutive results for QTcF is > 500 msec, the subject is ineligible.

          -  Active infection requiring IV antibiotics at Day 1 of cycle 1

          -  No prior lapatinib within 7 days prior to initiation of protocol treatment

          -  Receive concurrent investigational agents while on study

          -  Receive any concurrent chemotherapy, radiotherapy, or hormonal therapy while on study

          -  Previously identified allergy or hypersensitivity to components of the cabozantinib
             formulations

          -  The subject requires chronic concomitant treatment with strong CYP3A4 inducers
      "
NCT02260440,completed,,0,phase 2,['metastatic colorectal cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['pembrolizumab', 'azacitidine']",['Status: 503'],"
        Inclusion Criteria:

          1. Be willing and able to provide written informed consent/assent for the trial.

          2. Be 18 years of age or older on day of signing informed consent.

          3. The diagnosis of mCRC will be based on histologic or cytologic confirmation.

          4. Have mCRC that has been previously treated with currently approved standard therapies.

          5. Have measurable disease based on RECIST 1.1.

          6. At least 1 of the tumor sites must be amenable to core needle biopsy and this may not
             be the site of disease used to measure antitumor response. Patient must agree to this
             mandatory biopsy.

          7. Have a performance status of 0 or 1 on the ECOG Performance Scale.

          8. Demonstrate adequate organ function, all screening labs should be performed within 14
             days of treatment initiation.

          9. Female subject of childbearing potential should have a negative urine or serum
             pregnancy within 72 hours prior to receiving the first dose of study medication. If
             the urine test is positive or cannot be confirmed as negative, a serum pregnancy test
             will be required.

         10. Female subjects of childbearing potential should be willing to use 2 methods of birth
             control or be surgically sterile, or abstain from heterosexual activity for the course
             of the study through 120 days after the last dose of study medication. Subjects of
             childbearing potential are those who have not been surgically sterilized or have not
             been free from menses for > 1 year.

         11. Male subjects should agree to use an adequate method of contraception starting with
             the first dose of study therapy through 120 days after the last dose of study therapy.

        Exclusion Criteria:

          1. Is currently participating in or has participated in a study of an investigational
             agent or using an investigational device within 4 weeks of the first dose of
             treatment.

          2. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
             other form of immunosuppressive therapy within 7 days prior to the first dose of trial
             treatment.

          3. Has had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not
             recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents
             administered more than 4 weeks earlier.

          4. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy
             within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at
             baseline) from adverse events due to a previously administered agent.

             - Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may
             qualify for the study.

          5. Has a known additional malignancy that is progressing or requires active treatment.
             Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the
             skin, or in situ cervical cancer that has undergone potentially curative therapy..

          6. Has extensive metastatic tumor burden in the liver with serum albumin <3.0 g/dL.

          7. Has known renal tubular acidosis with serum bicarbonate <20 mEq/L.

          8. Has a known hypersensitivity to azacitidine or mannitol.

          9. Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis. Subjects with previously treated brain metastases may participate provided
             they are stable (without evidence of progression by imaging for at least four weeks
             prior to the first dose of trial treatment and any neurologic symptoms have returned
             to baseline), have no evidence of new or enlarging brain metastases, and are not using
             steroids for at least 7 days prior to trial treatment.

         10. Has an active autoimmune disease requiring systemic treatment within the past 3 months
             or a documented history of clinically severe autoimmune disease, or a syndrome that
             requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or
             resolved childhood asthma/atopy would be an exception to this rule. Subjects that
             require intermittent use of bronchodilators or local steroid injections would not be
             excluded from the study. Subjects with hypothyroidism stable on hormone replacement or
             Sjorgen's syndrome will not be excluded from the study.

         11. Has evidence of interstitial lung disease or active, non-infectious pneumonitis.

         12. Has an active infection requiring systemic therapy.

         13. Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the subject's
             participation for the full duration of the trial, or is not in the best interest of
             the subject to participate, in the opinion of the treating investigator.

         14. Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial.

         15. Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the pre-screening or screening visit
             through 120 days after the last dose of trial treatment.

         16. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or
             anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including
             ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation
             or checkpoint pathways).

         17. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).

         18. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA
             [qualitative] is detected).

        Has received a live vaccine within 30 days prior to the first dose of trial treatment.
      "
NCT02260193,completed,,1,phase 2,"['anemia', 'end stage renal disease']","[""['D53.2', 'D64.9', 'D46.4', 'D53.0', 'D53.9', 'D61.3', 'D61.9']"", ""['N18.6', 'I12.0', 'I13.11', 'I13.2']""]","['akb-6548', 'akb-6548', 'akb-6548']","['C1=CC(=CC(=C1)Cl)C2=CC(=C(N=C2)C(=O)NCC(=O)O)O', 'C1=CC(=CC(=C1)Cl)C2=CC(=C(N=C2)C(=O)NCC(=O)O)O', 'C1=CC(=CC(=C1)Cl)C2=CC(=C(N=C2)C(=O)NCC(=O)O)O']","
        Key Inclusion Criteria:

          -  18 to 79 years inclusive

          -  Chronic Kidney Disease (CKD) Stage 5 on chronic hemodialysis for at least 3 months

          -  Anemia secondary to CKD treated with erythropoiesis stimulating agent and intravenous
             iron

        Key Exclusion Criteria:

          -  Body mass index >44.0 kilograms per meter squared (kg/m^2)

          -  Transfusion within 8 weeks prior to Screening

          -  Alanine transaminase or total bilirubin >1.25x ULN

          -  Uncontrolled hypertension

          -  Class III or IV congestive heart failure

          -  Myocardial infarction, acute coronary syndrome, stroke or transient ischemic attack
             within 6 months prior to Screening
      "
NCT02263898,withdrawn,"
    closed without enrollment
  ",0,phase 2,"['recurrent melanoma', 'stage iv melanoma']","[""['G47.13', 'J01.41', 'K11.22', 'K12.0', 'N96', 'F33.8', 'G03.2']"", ""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']""]","['raf kinase inhibitor lgx818', 'binimetinib']",['CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO'],"
        Inclusion Criteria:

          -  Signed written informed consent

          -  Histologically confirmed diagnosis of metastatic melanoma with the presence of the
             B-Raf proto-oncogene, serine/threonine kinase (BRAFV600) mutation

          -  Eastern Cooperative Oncology Group (ECOG) performance status < 3

          -  Absolute neutrophil count (ANC) >= 1.0 x 10^9/L

          -  Hemoglobin (Hgb) >= 9 g/dL without transfusions

          -  Platelets (PLT) >= 90 x 10^9/L without transfusions

          -  Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 2.5 x upper
             limit of normal (ULN); patient with liver metastases =< 5 x ULN

          -  Total bilirubin =< 2 x ULN, or < 5 ULN if Gilbertâ€™s disease

          -  Creatinine =< 1.5 mg/dL, or calculated creatinine clearance (determined as per
             Cockcroft-Gault) >= 50 mL/min

          -  Left ventricular ejection fraction (LVEF) >= 50% as determined by a multigated
             acquisition (MUGA) scan or echocardiogram (ECHO)

          -  Corrected QT (QTc) interval =< 480 ms

          -  Able to take oral medications

          -  Patient is deemed by the Investigator to have the initiative and means to be compliant
             with the protocol (treatment and follow-up)

          -  Negative serum beta (Î²) human chorionic gonadotropin (HCG) test (female patient of
             childbearing potential only) within 72 hours prior to first dose

        Exclusion Criteria:

          -  Prior exposure to BRAF or MEK inhibitors

          -  Any active central nervous system (CNS) lesion (i.e., those with radiographically
             unstable, symptomatic lesions) and/or leptomeningeal metastases; however, patient
             treated with stereotactic radiotherapy, whole brain radiation or surgery are eligible
             if patient remained without evidence of CNS disease progression >= 4 weeks; patients
             must be off corticosteroid therapy for >= 2 weeks

          -  History or current evidence of retinal vein occlusion (RVO) or predisposing factors to
             RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or
             hypercoagulability syndromes)

          -  History of retinal degenerative disease

          -  History of Gilbertâ€™s syndrome

          -  Previous or concurrent malignancy is not an exclusion provided that the other
             malignancy is considered under control and target lesions from melanoma are clearly
             defined for response assessment

          -  Impaired cardiovascular function or clinically significant cardiovascular diseases,
             including any of the following:

               -  History of acute coronary syndromes (including myocardial infarction, unstable
                  angina, coronary artery bypass grafting, coronary angioplasty, or stenting) < 6
                  months prior to screening,

               -  Symptomatic chronic heart failure, history or current evidence of clinically
                  significant cardiac arrhythmia and/or conduction abnormality < 6 months prior to
                  screening except atrial fibrillation and paroxysmal supraventricular tachycardia

          -  Uncontrolled arterial hypertension despite medical treatment

          -  Known positive serology for HIV (human immunodeficiency virus), active hepatitis B,
             and/or active hepatitis C infection

          -  Patients who have neuromuscular disorders that are associated with elevated creatine
             kinase (CK) (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral
             sclerosis, spinal muscular atrophy)

          -  Patients who are planning on embarking on a new strenuous exercise regimen after first
             dose of study treatment; muscular activities, such as strenuous exercise, that can
             result in significant increases in plasma CK levels should be avoided while on MEK162
             treatment

          -  Impairment of gastrointestinal function or gastrointestinal disease (e.g., ulcerative
             disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel
             resection)

          -  Patients taking non-topical medication known to be a strong inhibitor of cytochrome
             P450, family 3, subfamily A, polypeptide 4 (CYP3A4); however patients who either
             discontinue their treatment or switch to another medication at least three days prior
             to randomization are eligible

          -  Any other condition that would, in the Investigatorâ€™s judgment, contraindicate the
             patientâ€™s participation in the clinical study due to safety concerns or compliance
             with clinical study procedures, e.g., infection/inflammation, intestinal obstruction,
             unable to swallow medication, social/psychological issues, etc.

          -  Patients who have undergone major surgery =< 3 weeks prior to starting study drug or
             who have not recovered from side effects of such procedure

          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive hCG laboratory test

          -  Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant, unless they are using highly effective methods of contraception
             throughout the study and for 8 weeks after study drug discontinuation; highly
             effective contraception methods include:

               -  Total abstinence when this is in line with the preferred and usual lifestyle of
                  the patient; periodic abstinence (e.g., calendar, ovulation, symptothermal,
                  post-ovulation methods) and withdrawal are not acceptable methods of
                  contraception

               -  Female sterilization (have had surgical bilateral oophorectomy with or without
                  hysterectomy) or tubal ligation at least six weeks before taking study treatment;
                  in case of oophorectomy alone, only when the reproductive status of the woman has
                  been confirmed by follow up hormone level assessment

               -  Male sterilization (at least 6 months prior to screening); for female patients on
                  the study, the vasectomized male partner should be the sole partner for that
                  patient

               -  Combination of any of the two following (a+b or a+c or b+c)

                    -  a. Use of oral, injected or implanted hormonal methods of contraception or
                       other forms of hormonal contraception that have comparable efficacy (failure
                       rate < 1%), for example hormone vaginal ring or transdermal hormone
                       contraception

                    -  b. Placement of an intrauterine device (IUD) or intrauterine system (IUS)

                    -  c. Barrier methods of contraception: Condom or occlusive cap (diaphragm or
                       cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal
                       suppository

               -  In case of use of oral contraception, women should have been stable on the same
                  pill before taking study treatment

               -  Note: Oral contraceptives are allowed but should be used in conjunction with a
                  barrier method of contraception

               -  Women are considered post-menopausal and not of child bearing potential if they
                  have had 12 months of natural (spontaneous) amenorrhea with an appropriate
                  clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have
                  had surgical bilateral oophorectomy (with or without hysterectomy) or tubal
                  ligation at least six weeks ago; in the case of oophorectomy alone, only when the
                  reproductive status of the woman has been confirmed by follow up hormone level
                  assessment is she considered not of child bearing potential

          -  Sexually active males unless they use a condom during intercourse while taking the
             drug and for 8 weeks after stopping treatment and should not father a child in this
             period; a condom is required to be used also by vasectomized men

          -  Medical, psychiatric, cognitive or other conditions that may compromise the patient's
             ability to understand the patient information, give informed consent, comply with the
             study protocol or complete the study
      "
NCT02268695,completed,,1,phase 2,['head and neck squamous cell carcinoma'],"[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]","['cisplatin', '5-fluorouracile', 'docetaxel', 'cetuximab', 'granulocyte colony-stimulating factor (g-csf)']","['N.N.Cl[Pt]Cl', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O']","
        Inclusion Criteria:

          -  Histologically confirmed diagnosis squamous cell carcinoma of head and neck: oral
             cavity, oropharynx, hypopharynx, larynx (histological confirmation is mandatory at
             least for initial diagnosis)

          -  Recurrence and/or metastatic disease not suitable for local therapy

          -  At least one measurable lesion (RECIST) by CT or MRI

          -  PS < 2

          -  Age ≥ 18 years and < 71 years

          -  Clearance of creatinine > 60ml/mn (MDRD)

          -  Haematological function as follows: absolute neutrophil count > 1.5 x 109/l, platelet
             > 100 x 109/l, hemoglobin ≥ 9.5 g/dl

          -  Hepatic function as followed: bilirubin ≤ Upper limit of normal (ULN); SGOT/SGPT < 1.5
             ULN; AP < 2.5 ULN

          -  Estimated life expectancy > 12 weeks

          -  Informed Consent Form signed

          -  Affiliation to an health insurance

          -  Negative pregnancy test in women of childbearing potential within 14 days prior to
             treatment initiation (premenopausal or less than 12 months of amenorrhea
             post-menopause, and who have not undergone surgical sterilization). Both men and women
             (of childbearing potential) who are sexually active must use adequate contraception,
             during and for at least 6 months post-treatment.

        Exclusion Criteria:

          -  Patients with nasopharyngeal cancer, paranasal sinus cancer or unknown primary

          -  Prior systemic chemotherapy for the head and neck carcinoma, except if given as part
             of a multimodal treatment for locally advanced disease which was completed more than 6
             months prior to study entry

          -  Surgery (excluding diagnostic biopsy) or radiotherapy within 6 weeks before study
             entry

          -  Contra-indication to receive cisplatin

          -  Known dihydropyrimidine dehydrogenase (DPD) deficiency

          -  Administration of prophylactic phenytoin

          -  Recent or planed yellow fever vaccination

          -  Prior dose of cisplatin > 300 mg/m² (a patient who received prior RT + 3 cycles of
             cisplatin or 3 cycles induction TPF, i.e. total dose of cisplatin ≤ 300 mg/m², for
             locally advanced primary HN cancer can be included)

          -  Prior anti-EGFR treatment received less than 12 months before enrolment in the trial

          -  Known hypersensitivity reaction to 5FU, cisplatin, carboplatin, docetaxel or cetuximab

          -  Documented or symptomatic brain or leptomeningeal metastasis

          -  Clinically significant cardiovascular disease, e.g. cardiac failure of New York Heart
             Association classes III-IV, uncontrolled coronary artery disease, cardiomyopathy,
             uncontrolled arrhythmia, uncontrolled hypertension, or history of myocardial
             infarction in the last 12 months

          -  Malignancies within 5 years prior to randomization, with the exception of adequately
             treated basal or squamous cell skin cancer and carcinoma in situ of the cervix

          -  Active infection (infection requiring IV antibiotics), including active tuberculosis
             and known and declared human immunodeficiency virus (HIV).

          -  Significant disease which, in the judgment of the investigator, would make the patient
             inappropriate for entry into the trial.

          -  Any social, personal, medical and/or psychologic factor(s) that could interfere with
             the observance of the patient to the protocol and/or the follow-up and/or the
             signature of the informed consent.

          -  Pregnant or breast feeding women
      "
NCT02268006,unknown status,,1,phase 2,['rectal carcinoma'],"[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]",['capecitabine'],['CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O'],"
        Inclusion Criteria:

          -  Biopsy-proven newly diagnosed primary rectal adenocarcinoma

          -  Locally advanced tumor fulfilling at least one of the following criteria on pelvic
             MRI:

               -  T ≥ 3 or

               -  N ≥ 1

               -  Positive mesorectal fascia (MRF), i.e. tumor or lymph node one mm or less from
                  the mesorectal fascia

               -  Tumor located od 0 - 15 cm above anocutaneous junction or below peritoneum

          -  Age 18 years and more

          -  Signed informed consent

          -  WHO Performance Status 0-2

          -  Patients is considered to be mentally and physically ft for chemotherapy as judged by
             oncologist

          -  Adequate hematological, hepatic and renal function (WBC ≥ 3.0 x 109/L, neu ≥ 1.5 x
             109/L, platelet count ≥ 100 x 109/L, renal clearance ≥ 50 ml/min, bilirubin ≤ 3x
             normal value, aspartate transaminase/alanine transaminase (AST/ALT) ≤ 2,5x normal
             value)

        Exclusion Criteria:

          -  T4 inoperable tumor - extensive growth into cranial part of the sacrum (above S3) or
             the lumbosacral nerve roots

          -  Metastatic or recurrent rectal cancer

          -  Other co-existing malignancy or malignancy within the past 5 years, with the exception
             of adequately treated in situ carcinoma of the cervix or basal cell carcinoma of the
             skin

          -  Chronic bowel inflammatory disease

          -  Pregnant or lactating patient

          -  Significant heart disease (uncontrolled hypertension despite of medication (> 150/100
             mmHg), New York Heart Association (NYHA) class III or IV heart disease,unstable angina
             or myocardial infarction within the past 1 year prior the study entry, history of
             significant ventricular arrhythmia requiring treatment)

          -  Inability to consciously sign the consent form due to physical or psychological
             disabilities
      "
NCT03679624,terminated,"
    low accrual
  ",0,phase 2,"['waldenstrom macroglobulinemia', ""waldenstrom's disease"", 'waldenström; hypergammaglobulinemia', ""waldenstrom's macroglobulinemia recurrent"", ""waldenstrom's macroglobulinemia of lymph nodes"", ""waldenstrom's macroglobulinaemia, without mention of remission"", ""waldenstrom's macroglobulinemia refractory""]","[""['C88.0']"", ""['C88.0']"", ""['D89.0', 'D89.2']"", ""['C88.0']"", ""['C88.0']"", ""['C88.0']"", ""['C88.0']""]","['ibrutinib', 'daratumumab']",['C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N'],"
        Inclusion Criteria:

          -  Subjects must have a diagnosis of WM and meet the requirements for active therapy as
             defined by the 2nd International Workshop on Waldenstrom's Macroglobulinemia

          -  Age ≥18 years of age

          -  Ibrutinib naïve or previously treated patients currently on ibrutinib with a plateau
             in disease response are eligible to participate.

               1. Ibrutinib naïve subjects may be either treatment naïve or previously treated but
                  ibrutinib naïve to enter cohort A.

               2. Subjects entering cohort B must have a plateau response on ibrutinib defined as ≥
                  6 months of ibrutinib treatment with 2 IgM measurements at least 2 months apart
                  with ≤ 15% change from the previous measurement. Subjects with IgM level < 0.7
                  g/dL will be eligible if their IgM level increases < 0.15 g/dL over two
                  subsequent IgM measurements as defined above.

          -  Subjects must have measurable disease defined by a serum IgM level ≥0.5g/dL

          -  Eastern Cooperative Oncology Group performance status of 0-2

          -  Hematology values must be within the following limits:

               1. Absolute neutrophil count (ANC) ≥ 1000/mm3 independent of growth factor support
                  for 7 days of study entry if cytopenias are due to marrow involvement.

               2. Platelets ≥ 50,000/mm3 independent of transfusion support within 7 days of study
                  entry. TPO mimetics are not allowed to meet eligibility criteria.

               3. Hemoglobin ≥ 8g/dL, independent of transfusion support within 7 days of study
                  entry

          -  Biochemical values within the following limits:

             d. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x upper
             limit of normal (ULN)

             e. Total bilirubin ≤ 2 x ULN unless bilirubin rise is due to Gilbert's syndrome or of
             non-hepatic origin

             f. Creatinine clearance (CLcr) > 25 ml/min

          -  Women of childbearing potential and men who are sexually active must be practicing a
             highly effective method of birth control during and after the study consistent with
             local regulations regarding the use of birth control methods for subjects
             participating in clinical trials. Men must agree to not donate sperm during and after
             the study. For females, these restrictions apply for 1 month after the last dose of
             study drug. For males, these restrictions apply for 3 months after the last dose of
             study drug.

          -  Women of childbearing potential must have a negative serum (beta-human chorionic
             gonadotropin (beta-hCG) or urine beta hCG pregnancy test at Screening. Women who are
             pregnant or breastfeeding are ineligible for this study.

          -  Subjects must be able to sign (or their legally-acceptable representatives must sign)
             an informed consent indicating that they understand the rational of the study and can
             participate in all study procedures.

        Exclusion Criteria:

          -  Subject does not have a recorded IgM level recorded within 3 months prior to ibrutinib
             initiation.

          -  Subject meeting definition of disease progression while on ibrutinib. Subjects with
             IgM levels < 0.7gdL are given special consideration. Please see inclusion criteria for
             2b.

          -  Subjects in cohort B experiencing ongoing non hematologic toxicities attributable to
             ibrutinib > Grade 1 will be excluded from study entry.

          -  Major surgery or a wound that has not fully healed within 4 weeks of enrollment.

          -  Evidence of disease transformation at time of enrollment.

          -  Waldenstrom's complicated by amyloidosis

          -  Known central nervous system lymphoma.

          -  History of stroke or intracranial hemorrhage within 6 months prior to randomization.

          -  Requires anticoagulation with warfarin or equivalent vitamin K antagonists (eg,
             phenprocoumon).

          -  Requires chronic treatment with strong CYP3A inhibitors. Subjects that required strong
             CYP3A inhibitors but completed a course of treatment can be considered for enrollment
             after a washout period of 14 days prior to study drug administration.

          -  Requires strong CYP3A inducers. Subjects that required strong CYP3A inducers but
             completed a course of treatment can be considered for enrollment after a washout
             period of 14 days prior to study drug administration.

          -  Patients with history of Chronic Obstructive Pulmonary Disease or Reactive Airway
             disease must have PFTs with FEV1 calculated. Patients with a FEV1 ≤ 50% of predicted
             normal will be excluded.

          -  Clinically significant cardiovascular disease such as uncontrolled or symptomatic
             arrhythmias, congestive heart failure, or myocardial infarction within 6 months of
             Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by
             the New York Heart Association Functional Classification.

          -  Vaccinated with live, attenuated vaccines within 4 weeks of randomization.

          -  Seropositive for human immunodeficiency virus (HIV).

          -  Seropositive for hepatitis B (defined by a positive test for hepatitis B surface
             antigen [HBsAg]). Subjects with resolved infection (i.e., subjects who are HBsAg
             negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or
             antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time
             polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels.
             Those who are PCR positive will be excluded. EXCEPTION: Subjects with serologic
             findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic
             marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV
             DNA by PCR.

          -  Seropositive for hepatitis C (except in the setting of a sustained virologic response
             [SVR], defined as aviremia at least 12 weeks after completion of antiviral therapy).

          -  Any life-threatening illness, medical condition, or organ system dysfunction which, in
             the investigator's opinion, could compromise the subject's safety, interfere with the
             absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue
             risk.

          -  Active malignancy not treated with curative intent within 2 years of study entry.
             Nonmelanotic skin cancers and cervical carcinoma in situ are excluded from this
             criteria.
      "
NCT02529878,unknown status,,1,phase 2,['gastric cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]",['s1/paclitaxel chemotherapy plus apatinib'],['Status: 400'],"
        Inclusion Criteria:

          -  unresectable gastric cancer as proven histologically(AJCC, version 7) under any
             following condition: unable radical excision due to the local metastasis of invasion
             metastasis to the lymph node beside the abdominal aorta, non-extensive metastasis to
             liver( not more than three metastatic foci of radical excision), Peritoneal
             metastasis(CY1,P1,P2), kukerburg tumor

          -  Definitely diagnosed as above stage of gastric cancer before operation via CT of MRI,
             ultrasonic endoscopy, PET-CT, or through the laparoscopic exploration if necessary

          -  Untreated(e.g. radiotherapy, chemotherapy, target therapy and immunotherapy)

          -  Negative HER-2 state

          -  ECOG(Eastern Cooperative Oncology Group) :0~2

          -  Age: 18~75 years old

          -  Normal hemodynamic indices before the recruitment(including blood cell count and
             liver/kidney function ). For example: WBC>4.0*109/L, NE>1.5*109/L, PLT>100*109/L,
             BIL<1.5 times of upper limit of normal reference value, ALT and AST<2.5 times of upper
             limit of normal reference value, and CRE<1.2mg/dl

          -  Good cardiac function before the recruitment, no seizure of myocardial infarction in
             past half years, and controllable hypertension and other coronary heart disease

          -  Not concomitant with other uncontrollable benign disease before the recruitment(e.g.
             the infection in the kidney, lung and liver)

          -  Not participating in other clinical trials before and during the treatment

          -  Signed the Informed Consent Form

        Exclusion Criteria:

          -  not conforming above inclusion conditions

          -  Distal metastasis to lung, brain, and bone

          -  Ever operation on the stomach

          -  Operation intolerance due to other systemic basic disease

          -  Ever administrated with other drugs(including TCM drugs) before the recruitment, or no
             guarantee of progress according to the study requirement after recruitment

          -  Allergy to the drugs in this protocol

          -  Pregnant and lactating women

          -  Women at childbearing age and of pregnancy desire during the study
      "
NCT02525757,"active, not recruiting",,1,phase 2,"['lung cancer', 'non-small cell lung cancer']","[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['mpdl3280a', 'carboplatin', 'paclitaxel']","['C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C']","
        Inclusion Criteria:

          1. Ability and willingness to provide informed consent

          2. Ability and willingness to comply with the requirements of the study protocol

          3. Age >/= 18 years.

          4. Representative tumor specimens in paraffin blocks (preferred) or at least 10 unstained
             slides, with an associated pathology report, requested at any time prior to study
             entry. Only tissue from core needle, punch, or excisional biopsy sample collection
             will be accepted. Fine-needle aspiration, brushing, and lavage samples are not
             acceptable. For all biopsy types, submitted blocks should have sufficient tissue to
             generate at least 10 sections, and tissue for which the pathology report specifies
             that the overall tumor content is low (e.g., ""sparse"" or ""scant"") is not acceptable.

          5. Cont'd from #4: If archival tissue is either insufficient or unavailable, the patient
             will need to consent to and undergo a pre treatment core or excisional biopsy sample
             collection of the tumor. Fine needle aspiration, brushing, and lavage samples are not
             acceptable. The immediate unavailability of tissue blocks or unstained slides aside
             from the slides needed for diagnostic confirmation of lung cancer does not exclude
             patients from this trial. If the patient chooses to not undergo a repeat biopsy aside
             from biopsy for diagnostic purposes, the patient will still be eligible to enroll on
             2014-0722. However, availability of core or excisional biopsy samples must be
             ascertained prior to enrollment.

          6. Patients must have histologically confirmed, untreated non-small cell lung cancer that
             are considered non-metastatic, unresectable for which chemoradiation is the definitive
             therapy.

          7. Patients will have the option to enroll on blood collection protocol, LAB09-0983, for
             serial collections of blood before, during intervals of treatment, and at follow up
             visits. Enrolling on the LAB09-0983 protocol is not required to enroll on the
             2014-0722 study.

          8. Adequate hematologic and end organ function, defined by the following laboratory
             results obtained within 14 days prior to the first study treatment (Cycle 1, Day 1):
             Absolute neutrophil count (ANC) >/= 1500 cells/uL *White Blood Cells (WBC) counts >
             2500/uL *Lymphocyte count >/= 500/uL *Platelet count >/= 100,000/uL; for patients with
             hematologic malignancies, platelet count >/= 75,000/uL *Hemoglobin >/= 9.0 g/dL *Total
             bilirubin </= 1.5 x Upper Limit of Normal (ULN) with the following exception: Patients
             with known Gilbert disease who have serum bilirubin level </= 3 x ULN may be enrolled.
             *Aspartate Aminotransferase (AST) and Alanine transaminase (ALT) </= 3.0 x ULN

          9. Cont'd from #8: Serum creatinine </= 1.5 x ULN or creatinine clearance >/= 50 mL/min
             on the basis of the Cockcroft-Gault glomerular filtration rate estimation: (140 - age)
             x (weight in kg) x (0.85 if female) / 72 x (serum creatinine in mg/dL)

         10. Measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1

         11. For female patients of childbearing potential and male patients with partners of
             childbearing potential, agreement (by patient and/or partner) to use highly effective
             form(s) of contraception (i.e., one that results in a low failure rate [< 1% per year]
             when used consistently and correctly) and to continue its use for 12 months after the
             last dose of MPDL3280A, and for male patients continued use of contraception must be
             for a minimum of 3 months post-treatment.

         12. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 as long as
             patients are eligible to receive chemotherapy along with concurrent radiotherapy

         13. International Normalized (INR) and aPTT </= 1.5 x ULN * This applies only to patients
             who do not receive therapeutic anticoagulation; patients receiving therapeutic
             anticoagulation (such as low-molecular weight heparin or warfarin) should be on a
             stable dose.

        Exclusion Criteria:

          1. Patients with any distant metastasis (liver, lung, bone, brain).

          2. Any approved anticancer therapy, including chemotherapy, hormonal therapy, or
             radiotherapy, within 3 weeks prior to initiation of study treatment; however, the
             following are allowed: *Hormone-replacement therapy or oral contraceptives *Herbal
             therapy > 1 week prior to Cycle 1, Day 1 (herbal therapy intended as anticancer
             therapy must be discontinued at least 1 week prior to Cycle 1, Day 1)

          3. Known clinically significant liver disease, including active viral, alcoholic, or
             other hepatitis, cirrhosis, fatty liver, and inherited liver disease

          4. Patients with acute leukemias, accelerated/blast phase chronic myelogenous leukemia,
             chronic lymphocytic leukemia, Burkitt lymphoma, plasma cell leukemia, or non-secretory
             myeloma

          5. Pregnancy, lactation, or breastfeeding

          6. Known hypersensitivity to Chinese hamster ovary cell products or other recombinant
             human antibodies

          7. Inability to comply with study and follow-up procedures

          8. History or risk of autoimmune disease, including but not limited to systemic lupus
             erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis
             associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's
             syndrome, Bell's palsy, Guillain-Barré syndrome, multiple sclerosis, autoimmune
             thyroid disease, vasculitis, or glomerulonephritis *Patients with a history of
             autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be
             eligible. *Patients with controlled Type 1 diabetes mellitus on a stable insulin
             regimen may be eligible. *Patients with eczema, psoriasis, lichen simplex chronicus of
             vitiligo with dermatologic manifestations only (e.g., patients with psoriatic
             arthritis would be excluded) are permitted provided that they meet the following
             conditions: *Patients with psoriasis must have a baseline ophthalmologic exam to rule
             out ocular manifestations *Rash must cover less than 10% of body surface area (BSA)

          9. Cont'd from #9: *Disease is well controlled at baseline and only requiring low potency
             topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%,
             fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%) *No acute
             exacerbations of underlying condition within the last 12 months (not requiring PUVA
             [psoralen plus ultraviolet A radiation], methotrexate, retinoids, biologic agents,
             oral calcineurin inhibitors, high potency or oral steroids)

         10. History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced),
             organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing
             pneumonia, etc.), or evidence of active pneumonitis on screening chest computed
             tomography (CT) scan

         11. Any other diseases, metabolic dysfunction, physical examination finding, or clinical
             laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates the use of an investigational drug or that may affect the
             interpretation of the results or render the patient at high risk from treatment
             complications

         12. History of human immunodeficiency virus (HIV) infection or active hepatitis B (chronic
             or acute) or hepatitis C infection *Patients with past or resolved hepatitis B
             infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a
             positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible.
             *Patients positive for hepatitis C virus (HCV) antibody are eligible only if
             polymerase chain reaction (PCR) is negative for hepatitis C virus ribonucleic acid
             (HCV RNA).

         13. Active tuberculosis

         14. Severe infections within 4 weeks prior to Cycle 1, Day 1 including but not limited to
             hospitalization for complications of infection, bacteremia, or severe pneumonia

         15. Signs or symptoms of severe infection (sepsis) within 2 weeks prior to treatment
             start.

         16. Major surgical procedure within 28 days prior to treatment start or anticipation of
             need for a major surgical procedure during the course of the study (EBUS and
             mediastinoscopy and VATS are not considered major surgical procedures).

         17. Administration of a live, attenuated vaccine within 4 weeks before treatment start or
             anticipation that such a live attenuated vaccine will be required during the study
             *Influenza vaccination should be given during influenza season only (approximately
             October to March). Patients must not receive live, attenuated influenza vaccine (e.g.,
             FluMist) within 4 weeks prior to treatment start or at any time during the study.

         18. Malignancies within 3 years prior to treatment start, with the exception of those with
             a negligible risk of metastasis or death and with expected curative outcome (such as
             adequately treated carcinoma in situ of the cervix, basal or squamous cell skin
             cancer, localized prostate cancer treated surgically with curative intent, or ductal
             carcinoma in situ treated surgically with curative intent) or undergoing active
             surveillance per standard-of-care management (e.g., CLL Rai Stage 0, prostate cancer
             with Gleason score </= 6, and PSA </= 10 mg/mL, etc.)

         19. FOLLOWING ARE Medication-Related Exclusion Criteria: *Treatment with systemic
             immunostimulatory agents (including but not limited to IFN-a, IL-2) within 6 weeks or
             five half-lives of the drug (whichever is shorter) prior to the start of
             chemoradiation.Treatment with investigational agent within 4 weeks prior to Cycle 1,
             Day 1 (or within five half lives of the investigational product, whichever is longer)

         20. Treatment with systemic immunosuppressive medications (including but not limited to
             prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor
             necrosis factor [TNF] agents) within 2 weeks prior to Cycle 1, Day 1 *Patients who
             have received acute, low dose, systemic immunosuppressant medications (e.g., a
             one-time dose of dexamethasone for nausea) may be enrolled. *The use of inhaled
             corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with
             orthostatic hypotension or adrenocortical insufficiency is allowed.

         21. History of severe allergic, anaphylactic, or other hypersensitivity reactions to
             chimeric or humanized antibodies or fusion proteins

         22. Patients with prior allogeneic bone marrow transplantation or prior solid organ
             transplantation
      "
NCT01717053,completed,,1,phase 2,['prostate cancer'],"[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]","['abiraterone acetate', 'androgen deprivation', 'prednisone']","['Status: 503', 'CC12CC(=O)C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C']","
        Inclusion Criteria:

          -  One of the following high risk criteria:

          -  Gleason Score 7 with PSA ≤ 20 ng/ml and clinical T1-2, or

          -  Gleason Score 8-10, PSA ≤ 20 ng/ml and clinical T1-2a, or

          -  PSA 10.1-40 ng/ml with GS < 7 and clinical T1-2, or

          -  Clinical T3 with Gleason Score < 7 and PSA ≤ 10 ng/ml.

          -  ECOG Performance Status ≤ 1

          -  Digital rectal exam within 90 days of registration on study

          -  CBC with differential with adequate bone marrow function defined as follows:

          -  Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3, Platelets > 100,000/µL and
             Hemoglobin ≥ 9g/dL

          -  Serum potassium ≥ 3.5 mEq/L

          -  Serum albumin > 3.0 g/dl

          -  Total bilirubin < 1.5 X of institutional upper limit of normal (ULN)

          -  AST(SGOT)/ALT(SGPT) < 1.5 X ULN

          -  Calculated creatinine clearance > 60 mL/min

          -  Age > 18 years

          -  Able to swallow a whole tablet and take abiraterone acetate on an empty stomach
             (defined as no food for two hours before and one hour after abiraterone acetate
             ingestion)

          -  Ability to understand and sign a written informed consent document

          -  Written authorization for use and release of health and research study information has
             been obtained

          -  Be willing/able to adhere to the prohibitions and restrictions specified in this
             protocol

          -  Subjects who have partners of childbearing potential must be willing to use a method
             of birth control with adequate barrier protections as determined acceptable by the
             principal investigator during the study and for 1 week after the last dose of
             abiraterone acetate.

        Exclusion Criteria:

          -  Bone, visceral or soft tissue metastasis, including lymph nodes (>2 cm in longest
             diameter)

          -  Prior therapy for prostate cancer [Exceptions: LHRH agonist or antagonist may have
             been initiated within 30 days prior to enrollment. Bicalutamide may have been given
             within 60 days of enrollment as long as it has been stopped at least 7 days before
             enrollment and total duration was no longer than 30 days. This is to allow enrollment
             of those who have been given bicalutamide as a bridge for LHRH agonist/antagonist. It
             is highly unlikely a short non-overlapping course of bicalutamide will interact with
             abiraterone acetate in a measurable way. Previous alpha-reductase inhibitor use
             allowed IF patient has not been taking for at least 30 days prior to abiraterone
             acetate initiation, OR if alpha reductase inhibitor was not used as a primary
             treatment of prostate cancer and the PSA on alpha-reductase inhibitor remains within
             eligibility when doubled. ]

          -  Known serum testosterone ≤ 150 ng/dl or symptoms of hypogonadism (fatigue, hot
             flashes, hair loss, loss of muscle mass, osteoporosis, low libido, depression) prior
             to ADT initiation not explained by other medical co-morbidity OR history of
             testosterone supplement. If questionable, serum testosterone level greater than 150
             ng/dl can be used to exclude hypogonadism.

          -  Previous malignancy within 3 years other than non-melanomatous skin cancer and
             non-muscle invasive bladder cancer

          -  Previous pelvic radiotherapy that would prevent prostate/SV irradiation

          -  Uncontrolled hypertension (systolic BP ≥ 160 mmHg or diastolic BP ≥ 95 mmHg). Patients
             with a history of hypertension are allowed provided blood pressure is controlled by
             anti-hypertensive therapy

          -  History of gastrointestinal disorders that may interfere with the absorption of study
             drug (including gastric bypass surgery)

          -  Concurrent spironolactone use

          -  Significant concurrent medical condition that would make prednisone/prednisolone use
             contraindicated or would interfere with the patient's ability to participate in the
             trial

          -  Receiving any investigational agents currently or within 30 days prior to study
             screening

          -  Prior demonstrated hypersensitivity, intolerance or allergy to abiraterone acetate,
             prednisone or their excipients

          -  Active co-morbidity, defined as follows:

               -  Chronic liver disease with cirrhosis (Child-Pugh B or C) or active hepatitis B or
                  C

               -  History of pituitary or adrenal dysfunction

               -  Poorly controlled diabetes mellitus (A1c >9% or history of complications
                  including peripheral neuropathy, end organ damage, hospitalization, amputation)

               -  Poorly controlled glaucoma

               -  Clinically significant heart disease as evidenced by myocardial infarction, or
                  arterial thrombotic events in the past 6 months, severe or unstable angina, or
                  New York Heart Association (NYHA) Class III-IV heart disease or known cardiac
                  ejection fraction measurement of < 50% at baseline.

               -  Clinical evidence of active infection of any type, including active or
                  symptomatic viral hepatitis.

               -  Known immune deficiency and/or HIV-positive patients

               -  Any medical condition that warrants long-term corticosteroid use in excess of
                  study dose

          -  Patients taking strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin,
             rifabutin, rifapentine, phenobarbital)

          -  Any condition that in the opinion of the Principal Investigator, would compromise the
             well-being of the subject or the study or prevent the subject from meeting or
             performing the study requirements
      "
NCT03572478,terminated,"
    the study was terminated due to lack of efficacy.
  ",0,phase 1/phase 2,"['prostate cancer', 'endometrial cancer']","[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']"", ""['N85.00', 'N85.01', 'N85.02', 'N99.85']""]","['rucaparib', 'nivolumab']",['CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2'],"
        Inclusion Criteria:

          -  Patients must have the ability to understand and the willingness to signed a written
             informed consent document.

          -  Patients must have histologically or cytologically confirmed CRPC or endometrial
             cancer that is metastatic. Evidence of disease progression on a prior therapy is not
             required.

          -  Patients must have at least one lesion that is amenable to biopsy and the treating
             physician must deem this safe.

          -  Patient must be willing to undergo two mandatory research-only biopsies.

          -  Prostate cancer patients:

               -  Patients must be surgically or medically castrated, with serum testosterone
                  levels ≤ 50 ng/mL Patients being treated with Gonadotropin-releasing hormone
                  (GnRH) agonists must have such therapy continued throughout the study.

               -  Patients should have received at least one androgen receptor (AR)-targeted
                  therapy with abiraterone acetate or enzalutamide. Multiple lines of prior
                  AR-targeted therapy and chemotherapy are permitted. A washout of two weeks from
                  prior endocrine therapy (other than GnRH agonist); four weeks washout period from
                  prior cytotoxic chemotherapy or other anticancer agents is required (prior to day
                  1 of study therapy); six weeks washout period to allow for anti-androgen
                  withdrawal for patients managed with antiandrogen therapy such as bicalutamide.

          -  Endometrial cancer patients:

               -  An unlimited number of prior hormonal and/or chemotherapy regimens are permitted.
                  A washout of two weeks from prior endocrine therapy (other than GnRH agonist) and
                  four weeks from prior cytotoxic chemotherapy or other anticancer agents is
                  required (prior to day 1 of study therapy).

          -  At least 5 days should have elapsed since any non-study related minor surgical
             procedure and at least 21 days since any major surgical procedure prior to the first
             dose of rucaparib and the first dose of nivolumab.

          -  Must have an ability to swallow pills or capsules. Patients should have no current
             clinical evidence of bowel obstruction.

          -  Age must be ≥ 18 years.

          -  Eastern Cooperative Oncology Group (ECOG) performance status must be ≤ 1

          -  Patients must have normal hepatic, renal and marrow function as defined below:

               -  hemoglobin > 10 g/dL

               -  leukocytes ≥ 3,000/mcL

               -  absolute neutrophil count ≥ 1,500/mcL

               -  platelets ≥ 150,000/mcL

               -  total bilirubin within normal institutional limits

               -  alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 1.5 ×
                  institutional upper limit of normal

               -  creatinine within normal institutional limits OR creatinine clearance ≥ 60
                  mL/min/1.73 m2 for patients with creatinine levels above institutional normal.

          -  Prior palliative radiotherapy must have been completed at least 2 weeks prior to first
             dose of study drug. Subjects with symptomatic tumor lesions at baseline that may
             require palliative radiotherapy within 4 weeks of first dose of study drug are
             strongly encouraged to receive palliative radiotherapy prior to enrollment.

          -  Reproductive Status: Rucaparib caused post-implantation loss (100% early resorptions)
             at all doses administered in an embryo-fetal development study. Based on its mechanism
             of action, nivolumab can cause fetal harm when administered to a pregnant woman.
             Pregnant women are therefore not eligible for this study.

               -  Women of child-bearing potential (WOCBP) must have a negative serum pregnancy
                  test result less than 3 days prior to administration of the first dose of
                  rucaparib.

               -  WOCBP must not be considering getting pregnant during the study.

               -  WOCBP and their male partners must agree to use a highly effective, reliable form
                  of contraception during treatment; for 6 months following the last dose of
                  rucaparib; and for at least 5 months following the last dose of nivolumab.

               -  Men who are sexually active with WOCBP must agree to use a highly effective,
                  reliable form of contraception during treatment; 6 months following the last dose
                  of rucaparib; and for a period of 7 months after the last dose of nivolumab .

               -  In addition to the above methods of contraception, use of a condom by male
                  patients is recommended to prevent transfer of drug through semen.

        Exclusion Criteria:

          -  Patients with active, known, or suspected autoimmune disease. Subjects with vitiligo,
             type I diabetes, mellitus, residual hypothyroidism due to autoimmune condition only
             requiring hormone replacement, psoriasis not requiring systemic treatment, childhood
             asthma that is not currently active, or conditions not expected to recur in the
             absence of an external trigger are permitted to enroll.

          -  Patients with a condition requiring systemic treatment with either corticosteroids (>
             10 mg daily prednisone equivalents) or other immunosuppressive medications within 14
             days of study drug administration except for adrenal replacement steroid doses > 10 mg
             daily prednisone equivalent in the absence of active autoimmune disease. Note:
             Treatment with a short course of steroids (< 5 days) up to 7 days prior to initiating
             study drug is permitted.

          -  Patients who are receiving any other investigational agents.

          -  Prior exposure to PD-1 or PD-L1 inhibitors, other immune checkpoint inhibitors (e.g.
             anti-LAG-3, and anti-CTLA-4 antibodies), or PARP inhibitors.

          -  Patients with a ""currently active"" second invasive malignancy other than non-melanoma
             skin cancers. Patients are not considered to have a ""currently active"" malignancy if
             they have completed therapy and have been free of disease for ≥ 1 years.

          -  Patients with known and untreated or progressing brain metastases are excluded from
             this clinical trial because of their poor prognosis and because they often develop
             progressive neurologic dysfunction that would confound the evaluation of neurologic
             and other adverse events. Patients whose brain metastases have been treated with
             surgery and/or radiotherapy and are without evidence of progression on scan for at
             least 4 weeks, and are off steroids or antiseizure medications, will be eligible .

          -  Patients with symptomatic or impending spinal cord compression are not eligible unless
             appropriately treated.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to nivolumab or rucaparib.

          -  Based on in vitro CYP interaction studies, caution should be used for concomitant
             medications with a narrow therapeutic window that are substrates of CYP2C19, CYP2C9,
             and/or CYP3A. Selection of an alternate concomitant medication is recommended. Caution
             should also be exercised for concomitant use of certain statin drugs (e.g.
             rosuvastatin and fluvastatin) due to potential increase in exposure from inhibition of
             BCRP and CYP2C9. An updated list of clinically relevant P450 drug interactions (e.g:
             Flockhart Table http://medicine.iupui.edu/clinpharm/ddis/main-table/) should be
             reviewed while screening patients for study.

               -  Patients taking warfarin should have international normalized ration (INR)
                  monitored regularly according to standard institutional practices

               -  Because rucaparib is a moderate inhibitor of P-gp in vitro, caution should be
                  exercised for patients receiving rucaparib and requiring concomitant medication
                  with digoxin. Patients taking digoxin should have their digoxin levels monitored
                  after starting rucaparib and then regularly per standard clinical practice.

          -  Patients on parenteral nutrition are not eligible. Patients must not have a
             pre-existing duodenal stent or any gastrointestinal disorder or defect that would, in
             the opinion of the treating investigator, interfere with absorption of rucaparib.

          -  Uncontrolled intercurrent illness including, but not limited to, requirement for
             oxygen therapy, ongoing or active infection other than minor urinary tract infection,
             symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or
             psychiatric illness/social situations that would limit compliance with study
             requirements.

          -  Known history of chronic hepatitis B or C as evidenced by:

               -  Positive test for hepatitis B surface antigen

               -  Positive test for qualitative hepatitis C viral load (by polymerase chain
                  reaction [PCR])

               -  Note: Subjects with positive hepatitis C antibody and negative quantitative
                  hepatitis C by polymerase chain reaction (PCR) are eligible.

          -  Human Immunodeficiency Virus (HIV)-positive patients on combination antiretroviral
             therapy are ineligible because of the potential for pharmacokinetic interactions with
             rucaparib. In addition, these patients are at increased risk of lethal infections when
             treated with marrow-suppressive therapy.

          -  Prior organ allograft or allogeneic bone marrow transplantation.

          -  Adverse effect of prior therapy not improved to Common Terminology Criteria for
             Adverse Events (CTCAE) Grade 1 or below with the exception of alopecia or lymphopenia.
             Ongoing Grade 2 non-hematologic toxicity (e.g. neuropathy) related to most recent
             treatment regimen may be permitted with prior advanced approval from the Lead
             Principal Investigator.

          -  Initiated denosumab or bisphosphonate therapy or adjusted denosumab or bisphosphonate
             dose/regimen within 4 weeks prior to first dose of rucaparib. Patients on a stable
             denosumab or bisphosphonate regimen are eligible and may continue treatment.

          -  Evidence or history of active or latent tuberculosis infection including purified
             protein derivative (PPD) recently converted to positive.

          -  Use of non-oncology vaccines containing live virus for prevention of infectious
             diseases within 12 weeks prior to study drug. The use of inactivated seasonal
             influenza vaccines, e.g., Fluzone®, will be permitted on study without restriction.
      "
NCT03570476,terminated,"
    terminated due to slow accrual
  ",0,phase 2,"['prostate adenocarcinoma without neuroendocrine differentiation', 'stage i prostate cancer ajcc v8', 'stage ii prostate cancer ajcc v8', 'stage iia prostate cancer ajcc v8', 'stage iib prostate cancer ajcc v8', 'stage iic prostate cancer ajcc v8']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']"", ""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']"", ""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']"", ""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']"", ""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]",['olaparib'],['C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F'],"
        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures.

          -  Histologically confirmed adenocarcinoma of the prostate without morphologic
             neuroendocrine differentiation or small cell features.

          -  The presence of homologous recombination deficiency defined by either; A) Inherited
             pathogenic variant of BRCA2, ATM, BRCA1, PALB2 by a Clinical Laboratory Improvement
             Act (CLIA) level germline assay or B) have evidence by somatic sequencing using a CLIA
             level assay of biallelic inactivation of BRCA1, BRCA2, PALB2, FANCA or biallelic
             inactivation or monoallelic inactivating mutation of ATM. It is anticipated that the
             majority of patients will be germline carriers of a pathogenic variant of BRCA1, BRCA2
             or ATM. Other germline mutations will be considered at investigator's discretion.

          -  Must be candidates for radical prostatectomy and considered surgically resectable by
             urologic evaluation.

          -  No evidence of metastatic disease or nodal disease as determined by radionuclide bone
             scans and computed tomography (CT)/magnetic resonance imaging (MRI); non-pathological
             lymph nodes must be less than 20 mm in the short (transverse) axis.

          -  Provided written authorization for use and release of health and research study
             information.

          -  Hemoglobin >= 10.0 g/dL with no blood transfusion in the past 28 days.

          -  Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (within 28 days prior to
             administration of study treatment).

          -  Platelet count >= 100 x 10^9/L (within 28 days prior to administration of study
             treatment).

          -  Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (within 28 days
             prior to administration of study treatment).

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) /
             alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.5 x
             institutional upper limit of normal unless liver metastases are present in which case
             they must be =< 5 x ULN (within 28 days prior to administration of study treatment).

          -  Patients must have creatinine clearance estimated using the Cockcroft-Gault equation
             of >= 51 mL/min (within 28 days prior to administration of study treatment).

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

          -  Patients must have a life expectancy >= 16 weeks.

          -  Male patients and their partners, who are sexually active and of childbearing
             potential, must agree to the use of two highly effective forms of contraception in
             combination throughout the period of taking study treatment and for 3 months after
             last dose of study drug(s) to prevent pregnancy in a partner.

          -  Patient is willing and able to comply with the protocol for the duration of the study
             including undergoing treatment and scheduled visits and examinations.

        Exclusion Criteria:

          -  Involvement in the planning and/or conduct of the study (applies to both AstraZeneca
             staff and/or staff at the study site).

          -  Any previous treatment with PARP inhibitor, including olaparib.

          -  Other malignancy within the last 5 years except: adequately treated non-melanoma skin
             cancer, or other solid tumors including lymphomas (without bone marrow involvement)
             curatively treated with no evidence of disease for >= 5 years.

          -  Resting electrocardiogram (ECG) with corrected QT interval (QTc) > 470 msec on 2 or
             more time points within a 24-hour period or family history of long QT syndrome.

          -  Patients receiving any systemic chemotherapy, hormonal therapy or radiotherapy.

          -  Concomitant use of known strong CYP3A inhibitors (e.g. itraconazole, telithromycin,
             clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir,
             saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (e.g.
             ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout
             period prior to starting olaparib is 2 weeks.

          -  Concomitant use of known strong (e.g. phenobarbital, phenytoin, rifampicin, rifabutin,
             rifapentine, carbamazepine, nevirapine and St John's wort) or moderate CYP3A inducers
             (e.g. bosentan, efavirenz, modafinil). The required washout period prior to starting
             olaparib is 5 weeks for phenobarbital and 3 weeks for other agents.

          -  Patients with myelodysplastic syndrome/acute myeloid leukemia or with features
             suggestive of myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML).

          -  Major surgery within 2 weeks of starting study treatment and patients must have
             recovered from any effects of any major surgery.

          -  Patients considered a poor medical risk due to a serious, uncontrolled medical
             disorder, non-malignant systemic disease or active, uncontrolled infection. Examples
             include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3
             months) myocardial infarction, uncontrolled major seizure disorder, extensive
             interstitial bilateral lung disease on high resolution computed tomography (HRCT) scan
             or any psychiatric disorder that prohibits obtaining informed consent.

          -  Patients unable to swallow orally administered medication and patients with
             gastrointestinal disorders likely to interfere with absorption of the study
             medication.

          -  Immunocompromised patients, e.g., patients who are known to be serologically positive
             for human immunodeficiency virus (HIV).

          -  Patients with a known hypersensitivity to olaparib or any of the excipients of the
             product.

          -  Patients with known active hepatitis (i.e., hepatitis B or C) due to risk of
             transmitting the infection through blood or other body fluids.

          -  Previous allogenic bone marrow transplant or cord blood transplantation.

          -  Whole blood transfusions in the last 120 days prior to entry to the study (packed red
             blood cells and platelet transfusions are acceptable).
      "
NCT02859415,terminated,"
    slow/insufficient accrual
  ",0,phase 1/phase 2,"['esophageal neoplasms', 'lung neoplasms', 'mesothelioma', 'thymus neoplasms', 'neoplasms, germ cell and embryonal']","[""['K22.2', 'K22.81', 'Q39.4', 'P78.83', 'I85.00', 'I85.01', 'I85.10']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C45.9', 'C45.0', 'C45.1', 'C45.2', 'C45.7']"", ""['C37', 'D15.0', 'D38.4', 'Z85.238']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]",['mithramycin'],['Status: 503'],"
        -  INCLUSION CRITERIA:

          -  Patients with measurable inoperable, histologically confirmed non-small cell lung
             cancer (NSCLC), small cell lung cancer (SCLC), esophageal carcinomas, thymic
             neoplasms, germ cell tumors, malignant pleural mesotheliomas or chest wall sarcomas,
             as well as patients with gastric, colorectal, pancreas or renal cancers, and sarcomas
             metastatic to thorax.

          -  Histologic confirmation of disease in the Laboratory of Pathology, Center for Cancer
             Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH).

          -  Disease amenable to biopsy via percutaneous approach or other minimally invasive
             procedures such as thoracoscopy, bronchoscopy, laparoscopy, or gastrointestinal (GI)
             endoscopy.

          -  Age >= 18.

          -  Eastern Cooperative Oncology Group (ECOG) status 0-2.

          -  Patients must have had, or refused first-line standard chemotherapy for their
             inoperable malignancies.

          -  Patients must have had no chemotherapy, biologic therapy, or radiation therapy for
             their malignancy for at least 30 days prior to treatment. Patients may have received
             localized radiation therapy to non-target lesions provided that the radiotherapy is
             completed 14 days prior to commencing therapy, and the patient has recovered from any
             toxicity. At least 3 half-lives must have elapsed since monoclonal antibody treatment.
             At least 6 weeks must have elapsed between mitomycin C or nitrosourea treatment.

          -  Patients must have adequate organ and marrow function as defined below:

               1. Hematologic and Coagulation Parameters

                    -  Peripheral absolute neutrophil count (ANC) greater than or equal to
                       1500/mm(3)

                    -  Platelets greater than or equal to 100,000/ mm(3) (transfusion independent)

                    -  Hemoglobin greater than or equal to 8 g/dL (PRBC transfusions permitted)

                    -  Prothrombin Time (PT)/partial thromboplastin time (PTT) within normal limits
                       (patient may be eligible for trial if abnormality is deemed clinically
                       insignificant and cleared for protocol therapy by Hematology Consult
                       service)

               2. Hepatic Function

                    -  Bilirubin (total) < 1.5 times upper limit of normal (ULN)

                    -  Alanine aminotransferase (ALT) Serum glutamic pyruvic transaminase(SGPT)
                       less than or equal to 3.0 times ULN

                    -  Albumin > 2 g/dL

               3. Renal Function

                    -  Creatinine within normal institutional limits or creatinine clearance
                       greater than or equal to 60 mL/min/1.73 m(2) for patients with creatinine
                       levels above institutional normal.

                    -  Normal ionized calcium, magnesium and phosphorus (can be on oral
                       supplementation)

          -  Cardiac Function: Left ventricular ejection fraction (EF) >40% by echocardiogram,
             multigated acquisition scan (MUGA), or cardiac magnetic resonance (MR).

          -  Ability of subject to understand, and be willing to sign informed consent.

          -  Female and male patients (and when relevant their partners) must be willing to
             practice birth control (including abstinence) during and for 2 months after treatment
             if female of childbearing potential or male having sexual contact with a female of
             childbearing potential.

          -  Patients must be willing to undergo 2 tumor biopsies.

        EXCLUSION CRITERIA:

          -  Patients with unfavorable ATP Binding Cassette Subfamily B Member 4 (ABCB11), Ral
             binding protein (RALBP) or Cytochrome P450 Family 8 Subfamily B Member 1 (CYP8B1)
             genotypes associated with mithramycin-mediated hepatotoxicity

          -  Clinically significant systemic illness (e.g. serious active infections or significant
             cardiac, pulmonary, hepatic or other organ dysfunction), that in the judgment of the
             PI would compromise the patient's ability to tolerate protocol therapy or
             significantly increase the risk of complications.

          -  Patients with cerebral metastases.

          -  Patients with any of the following pulmonary function abnormalities will be excluded:
             forced expiratory volume (FEV), < 30% predicted; diffusing capacity for carbon
             monoxide (DLCO), < 30% predicted (post-bronchodilator); Oxygen saturation less than or
             equal to 92% on room air (per vital sign measurement). Arterial blood gas will be
             drawn if clinically indicated.

          -  Patients with evidence of active bleeding, intratumoral hemorrhage or history of
             bleeding diatheses, unless specifically occurring as an isolated incident during
             reversible chemotherapy-induced thrombocytopenia.

          -  Patients on therapeutic anticoagulation. Note: Prophylactic anticoagulation (i.e.
             intraluminal heparin) for venous or arterial access devices is allowed.

          -  Patients who are concurrently receiving or requiring any of the following agents,
             which may increase the risk for mithramycin related toxicities, such as hemorrhage:

               -  Thrombolytic agents

               -  Aspirin or salicylate-containing products, which may increase risk of hemorrhage

               -  Dextran

               -  Dipyridamole

               -  Sulfinpyrazone

               -  Valproic acid

               -  Clopidogrel

          -  Lactating or pregnant females (due to risk to fetus or newborn, and lack of testing
             for excretion in breast milk).

          -  Patients with history of human immunodeficiency virus (HIV), hepatitis B virus (HBV)
             or hepatitis C virus (HCV) due to potentially increased risk of mithramycin toxicity
             in this population.

          -  Hypersensitivity to mithramycin.

          -  Patients who in the opinion of the investigator may not be able to comply with the
             safety monitoring requirements of the study.
      "
NCT02859064,terminated,"
    closed due to slow accrual
  ",0,phase 2,"['neuroendocrine tumors', 'gastrointestinal neoplasms', 'carcinoid tumors']","[""['C7A.1', 'C7A.8', 'C7B.8', 'D3A.8']"", ""['C49.A0', 'C49.A1', 'C49.A2', 'C49.A5', 'C49.A3', 'C49.A4', 'C49.A9']"", ""['C7A.00', 'C7A.010', 'C7A.011', 'C7A.012', 'C7A.020', 'C7A.021', 'C7A.026']""]",['lanreotide'],['CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)N)C(=O)NC(C(C)O)C(=O)N'],"
        Inclusion Criteria:

          -  Metastatic well-to-moderately differentiated (or low-grade) neuroendocrine carcinoma,
             including typical carcinoid or pancreatic islet cell carcinoma.

          -  Computerized tomography (CT) scan evidence of liver metastases which are not treatable
             by surgical resection or local ablation with curative intent at the time of study
             entry. If a CT scan is not possible, then an MRI may be used.

          -  Patients who are currently receiving or have previously received lanreotide or another
             somatostatin analogue are eligible. Previous treatment with lanreotide or another
             somatostatin analogue is not required for study entry.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.

          -  Adequate hematologic, hepatic and renal function.

          -  Male patients with female partners of childbearing potential and women patients of
             childbearing potential are required to use two forms of acceptable contraception,
             including one barrier method, during their participation in the study and for 3 months
             (90 days) following last dose of study drug(s). Male patients must also refrain from
             donating sperm during their participation in the study and for 3 months after last
             dose of study drug(s).

          -  Life expectancy ≥ 3 months.

          -  Willingness and ability to comply with study and follow-up procedures.

          -  Ability to understand the nature of this study and give written informed consent.

        Exclusion Criteria:

          -  Anti-cancer therapy with the exception of lanreotide or another somatostatin analogue
             within 21 days or 5 half-lives (whichever is shorter) of starting study treatment.

          -  Wide field radiotherapy (including therapeutic radioisotopes such as strontium 89)
             administered ≤28 days or limited field radiation for palliation ≤7 days prior to Cycle
             1 Day 1 or has not recovered from side effects of such therapy.

          -  Major surgical procedures ≤28 days of beginning study drug, or minor surgical
             procedures ≤7 days. No waiting required following port-a-cath placement.

          -  Previously untreated brain metastases. Patients who have received radiation or surgery
             for brain metastases are eligible if therapy was completed at least 2 weeks prior to
             study entry and there is no evidence of central nervous system disease progression,
             mild neurologic symptoms, and no requirement for chronic corticosteroid therapy.

          -  Clinically significant ascites, cirrhosis, portal hypertension, or thrombosis as
             determined by clinical or radiologic assessment.

          -  Pregnant or lactating.

          -  Acute or chronic liver, renal, or pancreas disease.

          -  Any of the following cardiac diseases currently or within the last 6 months:

               -  Left Ventricular Ejection Fraction (LVEF) <45% as determined by Multiple Gated
                  Acquisition (MUGA) scan or echocardiogram (ECHO)

               -  QTc interval >480 ms on screening electrocardiogram (ECG)

               -  Unstable angina pectoris

               -  Congestive heart failure (New York Heart Association (NYHA) ≥ Grade 2

               -  Acute myocardial infarction

               -  Conduction abnormality not controlled with pacemaker or medication

               -  Significant ventricular or supraventricular arrhythmias (patients with chronic
                  rate-controlled atrial fibrillation in the absence of other cardiac abnormalities
                  are eligible)

               -  Valvular disease with significant compromise in cardiac function

          -  Inadequately controlled hypertension (i.e., systolic blood pressure [SBP] greater than
             180 mmHg or diastolic blood pressure (DBP) greater than100 mmHg) (patients with values
             above these levels must have their blood pressure (BP) controlled with medication
             prior to starting treatment).

          -  Currently receiving treatment with therapeutic doses of warfarin sodium. Low molecular
             weight heparin is allowed.

          -  Serious active infection at the time of treatment, or another serious underlying
             medical condition that would impair the ability of the patient to receive protocol
             treatment.

          -  Known diagnosis of human immunodeficiency virus, hepatitis B or hepatitis C. Lab test
             results will be confirmed by the treating physician prior to study enrollment using
             patient's records not more than 1 year old.

          -  Presence of other active cancers, or history of treatment for invasive cancer ≤5
             years. Patients with Stage I cancer who have received definitive local treatment and
             are considered unlikely to recur are eligible. All patients with previously treated in
             situ carcinoma (i.e., non-invasive) are eligible, as are patients with history of
             non-melanoma skin cancer.

          -  Psychological, familial, sociological, or geographical conditions that do not permit
             compliance with the protocol.
      "
NCT02850874,withdrawn,"
    no accrual rate
  ",0,phase 2,"['pancreatic neoplasms', 'pancreatic adenocarcinoma']","[""['C25.3']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]",['gemcitabine'],['Status: 503'],"
        Inclusion Criteria:

          -  Primary diagnosis of pancreatic ductal adenocarcinoma (PDAC) confined to the head of
             the pancreas classified as T1-T3 with one or more of the following high-risk clinical
             features:

               -  Carbohydrate antigen (CA) 19-9 greater than 1,000 U/mL with a normal bilirubin;

               -  Vascular involvement; and/or

               -  Suspicious regional lymphadenopathy

          -  Intention to undergo open pancreaticoduodenectomy (standard Whipple or
             pylorus-preserving pancreaticoduodenectomy) as treatment for PDAC

          -  Adequate clinical condition to undergo preoperative (neoadjuvant) hyperthermic
             intraperitoneal chemotherapy

          -  Adequate clinical condition to undergo perioperative systemic chemotherapy

          -  White blood cell count of at least 3000/mL

          -  Platelet count of at least 100,000/mL

          -  Normal creatinine (< 2 mg/dL) or creatinine clearance of at least 50 mL/min

          -  Willing and able to give informed consent

        Exclusion Criteria:

          -  Evidence of locoregional spread (carcinomatosis of peritoneal surfaces, mesenteric
             arteries, or body/tail of pancreas) or distant (liver, lung, or other) metastases
             (histological, CT, or MRI confirmation)

          -  Non-curative intent of treatment (≥R2 resection)

          -  Body mass index (BMI) > 35

          -  Previous history of pancreatic resections for tumors in the body and/or tail of the
             pancreas, distal cholangiocarcinoma, duodenal carcinoma, neuroendocrine tumors,
             cyst-adenocarcinoma, or solid and papillary tumors.

          -  Unstable or uncompensated respiratory or cardiac disease

          -  Severe hepatic or renal dysfunction

          -  Bleeding diathesis or coagulopathy

          -  Pregnant or nursing women
      "
NCT02716311,completed,,0,phase 2,['non small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['afatinib', 'cetuximab']","['Status: 503', 'Status: 503']","
        Principal Inclusion Criteria:

          -  Stage III or IV NSCLC, non irradiable non operable

          -  Non squamous NSCLC histologically or cytologically confirmed

          -  No previous treatment of NSCLC

          -  EGFR mutation (exon 19 deletion, L858R mutation, G719X , L861Q or S768I mutations or
             exon 19 insertion)

          -  Presence of at least one lesion that can be measured

          -  PS 0 or 1

        Principal Exclusion Criteria:

          -  Symptomatic brain metastasis or requiring immediate radiotherapy

          -  T790M mutation or exon 20 insertion

          -  Radiotherapy less than 2 weeks prior randomization including symptomatic radiotherapy

          -  Interstitial pneumopathy
      "
NCT02714530,terminated,"
    slow accrual
  ",0,phase 2,['cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]",['erlotinib'],['Status: 503'],"
        Inclusion Criteria:

          -  Age >18 years

          -  Histological or cytological verified NSCLC

          -  Palliative radiotherapy to thorax indicated

          -  ECOG Performance status 0-2

          -  Fertile patients must use contraception

          -  Signed informed consent

          -  Ability to understand and fill in QoL questionnaires

          -  Capability to take per os medication

          -  Serum bilirubin < 2 times upper limit of normal (ULN)

          -  AST and ALT < 2 times ULN (< 5 times ULN if liver metastases are present)

          -  Creatinine < 5 times ULN

        Exclusion Criteria:

          -  Pregnancy or nursing

          -  Other prior or concurrent malignant disease likely to interfere with study treatment
             or comparisons

          -  No evidence of other significant laboratory finding or concurrent uncontrolled medical
             illness, that in the opinion of the investigator, would interfere with study treatment
             or results comparison or render the patient at high risk for treatment complications

          -  No prior radiotherapy to the same organ / place

          -  No concurrent treatment with other experimental drugs

          -  Known brain metastases in need of radiotherapy

          -  Known hypersensitivity to erlotinib or other substances in the erlotinib tablets.
      "
NCT02716766,completed,,0,phase 2,"['carcinoma, hepatocellular', 'secondary']","[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]","['sorafenib', 'capecitabine', 'oxaliplatin']","['CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Advanced or metastatic hepatocellular carcinoma (HCC) not suitable for surgery or
             various loco-regional therapies.

          -  Diagnosis of HCC confirmed either by cyto-histological confirmation or by non-invasive
             criteria according to the European Association for Study of Liver disease (EASL)
             criteria.

          -  Child-Pugh A or B7 cirrhosis.

          -  Eastern Co-Operative Group (ECOG) performance status ≤ 2.

          -  Life expectancy of ≥ 12 weeks.

          -  Adequate organ function (blood transfusion or use of biologic response modifiers is
             not permitted).

          -  Measurable disease with at least one lesion, which is at least 1 cm in one dimension
             on computed tomography (CT) or magnetic resonance imaging (MRI).

          -  Able and willing to meet all protocol-required treatments, investigations and visits.

          -  Signed written informed consent form.

        Exclusion Criteria:

          -  Prior systemic therapy for advanced HCC.

          -  Central nervous system (CNS) metastasis.

          -  History of liver transplantation.

          -  Peripheral sensory neuropathy with functional impairment before the first cycle of
             treatment.

          -  History of cardiac disease.

          -  Uncontrolled hypertension.

          -  Women who are pregnant or breast-feeding, or women of child-bearing potential who are
             unable or unwilling to practice a highly effective means of contraception.

          -  Substance abuse, medical, psychological or social conditions that may interfere with
             the patient's participation in the study or evaluation of study results.
      "
NCT02716272,completed,,1,phase 2,['mesothelioma'],"[""['C45.9', 'C45.0', 'C45.1', 'C45.2', 'C45.7']""]","['nivolumab', 'nivolumab + ipilimumab']",['Status: 503'],"
        Inclusion Criteria:

          1. Histologically proved diagnosis of unresectable malignant pleural Mesothelioma (MPM)

          2. Available (archival and/or fresh) pathological samples for centralized PD-L1
             expression assessment by immunohistochemistry

          3. Age ≥ 18 years old; male and female

          4. ECOG Performance status 0-1

          5. Weight loss < 10% during last 3 months

          6. Life expectancy > 12 weeks

          7. Documented progression of the MPM, assessed by computed tomography (CT) -Scan.

          8. Measurable disease, defined as at least 1 lesion (measurable) that can be accurately
             assessed at baseline by CT-Scan and is suitable for repeated assessment using modified
             Response Evaluation Criteria in Solid Tumors [RECIST] for pleural mesothelioma (Byrne
             2004; Therasse 2006).

          9. Previous treatment by 1 or 2 systemic chemotherapy lines (1 line of chemotherapy
             considered if the patient received ≥2 cycles of this chemotherapy), including at least
             one line with pemetrexed in combination with platinum agent (i.e. ""gold standard
             chemotherapy in MPM; triplet including bevacizumab also accepted)

         10. Written informed consent

         11. Patients must have adequate organ function : creatinine clearance > 50 mL/min
             (Cockcroft formula), Neutrophiles count > 1500/mm3; Platelets > 100 000/mm3 ;
             Hemoglobin > 9 g/dL; hepatic enzymes < 3N with total bilirubin ≤ 1.5 × ULN (upper
             limit of normal) except subjects with documented Gilbert's syndrome (≤ 5 × ULN) or
             liver metastasis, who must have a baseline total bilirubin ≤ 3.0 mg/dL

         12. Recovered from all toxicities associated with prior treatment, to acceptable baseline
             status, or a National Cancer Institute Common Terminology Criteria for Adverse Events
             (NCI CTCAE v4.0) Grade of 0 or 1, except for toxicities not considered a safety risk,
             such as alopecia or vitiligo

         13. Females of childbearing potential who are sexually active with a nonsterilized male
             partner must use a highly effective method of contraception for 28 days prior to the
             first dose of investigational product, and must agree to continue using such
             precautions for 6 months after the final dose of investigational product; cessation of
             contraception after this point should be discussed with a responsible physician.
             Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable
             methods of contraception. They must also refrain from egg cell donation for 6 months
             after the final dose of investigational product. Men receiving nivolumab and who are
             sexually active with women of childbearing potential will be instructed to adhere to
             contraception for a period of 31 weeks after the last dose of nivolumab.

        Exclusion Criteria:

          1. Patients with primitive peritoneal, pericardial, testis or tunica vaginalis
             mesothelioma

          2. Patients with a recent history of other malignancies except adequately treated
             non-melanoma skin cancer, and curatively treated in-situ cancer. Patients with
             prostate adenocarcinoma diagnosed less than 5 years could be included in case of
             localized prostate cancer with good outcome according the Amico classification: ≤ T2a
             and Gleason Score ≤6 and PSA blood level ≤10 ng/ml, and treated with curative intent
             (surgery or radiotherapy) without chemotherapy. Patients with history of solid tumors,
             including adenocarcinoma, treated with curative intent and without any evidence of
             disease >5 years can be included as well.

          3. Brain metastasis, except if surgically resected or treated with stereotaxic
             radiotherapy with no evolution within the 3 months before inclusion, and asymptomatic
             patient

          4. History of primary immunodeficiency, history of organ transplant that requires
             therapeutic immunosuppression and the use of immunosuppressive agents within 28 days
             of randomization or a prior history of severe (grade 3 or 4) immune mediated toxicity
             from other immune therapy.

          5. Subjects with a condition requiring systemic treatment with either corticosteroids (>
             10 mg daily prednisone equivalent) or other immunosuppressive medications within 14
             days of randomization. Intranasal/inhaled or topical steroids, and adrenal replacement
             steroid doses ≤ 10 mg daily prednisone equivalent, are permitted in the absence of
             active autoimmune disease.

          6. Live attenuated vaccination administered within 30 days prior to randomization.

          7. Known history of interstitial lung disease (asbestosis…) or CT-scan signs of
             interstitial lung disease.

          8. Subjects with an active, known or suspected autoimmune disease, including systemic
             lupus erythematosis or Wegener's granulomatosis. Subjects with type I diabetes
             mellitis, or hypothyroidism only requiring hormone replacement, or skin disorders
             (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, are
             permitted to enroll.

          9. Active or history of inflammatory bowel disease (eg, diverticulitis, colitis,
             Crohn's), irritable bowel disease, celiac disease or other serious gastrointestinal
             chronic conditions associated with diarrhea. Note that diverticulosis is permitted.

         10. Patients with active or uncontrolled infections or with serious illnesses or medical
             conditions which would not permit the patient to be managed according to the protocol.
             This includes but is not limited to:

               -  known prior history of active tuberculosis-disease;

               -  known acute or chronic B or C hepatitis by serological evaluation. Patients with
                  serological sequelae of hepatitis (antibodies test serologically positive for
                  virus) without hepatitis could be included.

               -  known Human immunodeficiency virus infection.

         11. Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or
             any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint
             pathways

         12. The last dose of prior chemotherapy or radiation therapy (with the exception of
             palliative radiotherapy) was received less than 3 weeks prior to randomization
      "
NCT02717611,"active, not recruiting",,1,phase 2,['chronic lymphocytic leukemia'],"[""['C91.11', 'C91.12', 'C91.10']""]",['acp-196 (acalabrutinib)'],['Status: 503'],"
        Inclusion Criteria:

          1. Men and women ≥ 18 years of age.

          2. Prior diagnosis of CLL

          3. Must have received ≥ 1 prior therapy for CLL

          4. Intolerant of ibrutinib

          5. Documented disease progression after stopping ibrutinib therapy as defined by the
             IWCLL 2008 criteria

          6. Willing and able to participate in all required evaluations and procedures in this
             study protocol including swallowing capsules without difficulty.

          7. ECOG performance status of ≤ 2.

        Exclusion Criteria:

          1. Ongoing AE attributed to ibrutinib therapy

          2. Treatment with systemic anticancer therapy for CLL is prohibited between
             discontinuation of ibrutinib and enrollment on this trial.

          3. Prior exposure to a BCL-2 inhibitor (eg, venetoclax/ABT- 199)

          4. Prior malignancy (other than CLL), except for adequately treated basal cell or
             squamous cell skin cancer, in situ cancer, or other cancer from which the subject has
             been disease free for ≥ 2 years.

          5. Significant cardiovascular disease such as uncontrolled or symptomatic untreated
             arrhythmias, congestive heart failure, or myocardial infarction within 6 months of
             screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart
             Association Functional Classification, or QTc > 480 msec at screening. Exception:
             Subjects with controlled, asymptomatic atrial fibrillation during screening are
             allowed to enroll on study.

          6. Malabsorption syndrome, disease significantly affecting gastrointestinal function,
             resection of the stomach, extensive small bowel resection that is likely to affect
             absorption, symptomatic inflammatory bowel disease, partial or complete bowel
             obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.

          7. Evidence of active Richter's transformation or any evidence of disease progression on
             ibrutinib therapy or any BTK inhibitor.

          8. CNS involvement by CLL or related Richter's transformation.

          9. Known history of human immunodeficiency virus (HIV), serologic status reflecting
             active hepatitis B or C infection, or any uncontrolled active systemic infection.

         10. Uncontrolled autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura
             (ITP)

         11. History of stroke or intracranial hemorrhage within 2 months before the first dose of
             study drug.

         12. History of bleeding diathesis.

         13. Presence of a gastrointestinal ulcer diagnosed by endoscopy within 3 months before
             screening.

         14. Major surgical procedure within 28 days of first dose of study drug.

         15. Requires treatment with a strong CYP3A inhibitor
      "
NCT03600909,terminated,"
    accrual has been slow
  ",0,phase 2,"['fanconi anemia', 'myelodysplastic syndrome (mds)', 'acute myelogenous leukemia (aml)']","[""['D46.Z', 'D46.9', 'C94.6', 'D46.C']""]","['busulfan', 'fludarabine', 'cyclophosphamide', 'anti-thymocyte globulin (rabbit)', 'g-csf']","['Status: 503', 'C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N', 'Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Patients must have a diagnosis of Fanconi anemia (confirmed by mitomycin C or
             diepoxybutane [DEB] chromosomal breakage testing at a CLIA approved laboratory).

        Patients must have one of the following hematologic diagnoses:

        1. Severe Aplastic Anemia (SAA), with bone marrow cellularity of <25% OR Severe Isolated
        Single lineage Cytopenia

        AND at least one of the following features:

          1. Platelet count <20 x 10^9/L or platelet transfusion dependence*

          2. ANC <1000 x 10^9/L

          3. Hgb <8 gm/dl or red cell transfusion dependence*

        2. Myelodysplastic Syndrome (MDS) (Appendix 1: MDS Classification)

        MDS at any stage, based on either one of the following classifications:

          -  WHO Classification

          -  Refractory anemia and transfusion dependence*

          -  Any of other stages

          -  IPSS Classification

          -  Low risk (score 0) and transfusion dependence*

          -  Any other risk groups Score > 0.5 Note that patients with chromosome 1q cytogenetic
             abnormalities in the absence of morphologic dysplasia will not be considered to have
             MDS.

             3. Acute Myelogenous Leukemia Patients with acute leukemia are included in this trial
             untreated, in remission or with refractory or relapsed disease.

             * Transfusion dependence will be defined as greater than ONE transfusion of platelets
             or red blood cells in the last year prior to evaluation on protocol.

        Donor

        Donor choices will be determined by the investigators according to institutional criteria.
        Patients who will be enrolled on this protocol must have one of the following donor
        choices:

        HLA-compatible unrelated volunteer donors Patients who do not have a related HLA-matched
        donor but have an unrelated donor who is either matched at all A, B, C and DRB1 (8/8) loci
        or who is mismatched at no more than 2/8 loci (A, B, C or DRB1) (6/8) as tested by DNA
        analysis (high resolution), will be eligible for entry on this protocol.

        HLA-mismatched Related donors Patients who do not have a related or unrelated
        HLA-compatible donor must have a healthy family member who is at least HLA-haplotype
        identical to the recipient. First degree related donors must have a normal DEB test.

        The donor must be healthy and willing and able to receive a 4-6 day course of G-CSF and
        undergo 1-3 daily leukaphereses, as per institutional guidelines.

        Related and unrelated donors must be medically evaluated and fulfill the criteria for
        collection of PBSCs as per institutional guidelines.

        Patients and donors may be of either gender or any ethnic background. Patients must have a
        Karnofsky adult, or Lansky pediatric performance scale status ≥ 70%.

        Patients must have adequate physical function measured by :

          1. Cardiac: asymptomatic or if symptomatic then 1) LVEF at rest must be ≥ 50% and must
             improve with exercise or 2) Shortening Fraction ≥ 29%

          2. Hepatic: < 5 x ULN alanine transaminase (ALT) and < 2.0 mg/dl total serum bilirubin.

          3. Renal: serum creatinine ≤1.5 mg/dl or if serum creatinine is outside the normal range,
             then CrCl > 50 ml/min/1.73 m^2

          4. Pulmonary: asymptomatic or if symptomatic, DLCO > 50% of predicted (corrected for
             hemoglobin) Each patient must be willing to participate as a research subject and must
             sign an informed consent form. Parent or legal guardians of patients who are minors
             will sign the informed consent form. Assents will be obtained as per institutional
             guidelines.

        Female patients and donors must not be pregnant or breastfeeding at the time of signing
        consent. Women must be willing to undergo a pregnancy test prior to transplant and avoid
        becoming pregnant while on study. Positive pregnancy test results will be reported to the
        parent(s) or guardian of minor participants, as required per institutional guidelines.

        Exclusion Criteria:

        Active CNS leukemia Female patients who are pregnant (positive serum or urine HCG) or
        breast-feeding. Women of childbearing age must avoid becoming pregnant while on study.

        Active uncontrolled viral, bacterial or fungal infection Patient seropositive for HIV-I/II;
        HTLV -I/II
      "
NCT03608501,withdrawn,"
    business decision (no safety or efficacy concerns)
  ",0,phase 2,['multiple myeloma'],"[""['C90.01', 'C90.02', 'C90.00']""]","['ixazomib', 'thalidomide', 'dexamethasone']","['Status: 503', 'Status: 503', 'CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C']","
        Inclusion Criteria:

          1. Clonal bone marrow plasma cells >=10% or biopsy-proven bony or extramedullary
             plasmacytoma and any one or more of the following myeloma defining events:

               -  Evidence of end organ damage that can be attributed to the underlying plasma cell
                  proliferative disorder, specifically:

                    -  Hypercalcaemia: serum calcium greater than (>) 1 mg/dL higher than the upper
                       limit of normal (ULN) or >11 mg/dL;

                    -  Renal insufficiency: creatinine clearance <40 milliliter (mL) per minute (as
                       per validated equations) or serum creatinine >2 mg/dL;

                    -  Anemia: haemoglobin value of >20 gram per liter (g/L) below the lower limit
                       of normal, or a haemoglobin value <100 g/L;

                    -  Bone lesions: one or more osteolytic lesions on skeletal radiography,
                       computed tomography (CT), or positron emission tomography (PET)-CT.

               -  Any one or more of the following biomarkers of malignancy:

                    -  Clonal bone marrow plasma cell percentage >=60%.

                    -  Involved: uninvolved serum free light chain ratio >=100.

                    -  Greater than (>) 1 focal lesions on magnetic resonance imaging (MRI)
                       studies. Note: clonality should be established by showing kappa to lambda
                       ratio (κ/λ)-light-chain restriction on flow cytometry, immunohistochemistry,
                       or immunofluorescence. Bone marrow plasma cell percentage should preferably
                       be estimated from a core biopsy specimen; in case of a disparity between the
                       aspirate and core biopsy, the highest value should be used.

          2. Ineligibility to autologous transplantation, as per investigator's discretion,
             regardless of age (the reason for such ineligibility should be recorded on the
             electronic case report form [eCRF]).

          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

          4. Ability to take concurrent aspirin daily (or enoxaparin subcutaneously daily), per
             published standard or institutional standard of care, as prophylactic anticoagulation.

          5. Note: For participants with prior history of deep vein thrombosis (DVT), low molecular
             weight heparin (LMWH) is mandatory.

          6. Left ventricular ejection fraction (LVEF) >=50%.

          7. Clinical laboratory values as specified below within 7 days before the first dose of
             study drug:

               -  Absolute neutrophil count (ANC) >=1,500 per cubic millimeter (/mm^3), unless
                  related to bone marrow infiltration by malignant plasma cells.

               -  Hemoglobin >=8.0 g/dL

               -  Platelet count >=75,000/mm^3, unless related to bone marrow infiltration by
                  malignant plasma cells (platelet transfusions to help participants meet
                  eligibility criteria are not allowed).

               -  Aspartate aminotransferase (AST) and alanine aminotransferase (AST) less than or
                  equal to (<=) 1.5 times the institutional ULN.

               -  Bilirubin <=1.5 mg/dL (or <=2.5 mg/dL in case of Gilbert-Meulengracht syndrome).

               -  Glomerular filtration rate >=30 milliliter per minute per (mL/min/) 1.73 square
                  meter (m^2) according to the Modification of Diet in Renal Disease (MDRD) study
                  abbreviated formula. If not on target, this evaluation may be repeated once after
                  at least 24 hours.

               -  Prothrombin time (PT) or activated partial thromboplastin time (aPTT) within
                  normal limits.

        Exclusion Criteria:

          1. Presence of non-secretory or oligo-secretory myeloma, smoldering MM, monoclonal
             gammopathy of undetermined significance, plasma-cell leukemia, Waldenstrom's
             macroglobulinemia, primary amyloidosis, or polyneuropathy, organomegaly,
             endocrinopathy, monoclonal protein, and skin changes (POEMS) syndrome.

          2. Central nervous system involvement by MM.

          3. Prior radiation therapy involving an estimated >=25% of the hematopoietically active
             bone marrow. Radiotherapy should not be given within 14 days before enrollment. In
             case of palliative radiotherapy for pain control and if the involved field is small, 7
             days will be considered a sufficient interval between the radiation treatment and
             administration of the study drugs.

          4. Treatment with any investigational products within 1 (one) year before the first dose
             of the study drug regimen.

          5. Presence of peripheral neuropathy of grade 1 with pain or grade 2 or higher.

          6. Previous or concurrent history of malignancies other than MM except for curatively
             treated cervical carcinoma in situ, non-melanoma skin cancer, superficial bladder
             cancer (Ta [non-invasive tumor], Tis [carcinoma in situ] and T1 [tumor invades lamina
             propria]), or localized prostate cancer.

          7. With evidence or history of bleeding diathesis. Any hemorrhage or bleeding event
             >=common terminology criteria for adverse events (CTCAE) Grade 3 within 4 weeks of
             start of study medication.

          8. Major surgery within 14 days before randomization.

          9. Non-healing wound or ulcer.

         10. Seizure disorder requiring medication.

         11. Systemic treatment with strong cytochrome P-450 3A (CYP3A) inducers (rifampin,
             rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo
             biloba or St. John's wort from Day-14 of cycle 1 until the safety follow-up.

         12. Arterial or venous thrombotic or embolic events such as cerebrovascular accident
             (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism
             within 3 months before the start of study medication.
      "
NCT04442581,terminated,"
    terminated due to slow accrual
  ",0,phase 2,"['advanced hepatocellular carcinoma', 'bclc stage b hepatocellular carcinoma', 'bclc stage c hepatocellular carcinoma']","[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]",['cabozantinib s-malate'],['COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O'],"
        Inclusion Criteria:

          -  Must have a histologically confirmed diagnosis of HCC or a non-invasive diagnosis of
             HCC as per the American Association for the Study of Liver Diseases (AASLD) criteria

               -  If available, archival tissue must be submitted

               -  Mixed HCC-cholangiocarcinoma is not allowed

          -  Patient has Barcelona Clinic Liver Cancer (BCLC) stage C disease, or BCLC stage B
             disease that is not amenable to locoregional therapy or refractory to locoregional
             therapy, and not amenable to curative treatment

               -  Previous locoregional therapy is allowed (e.g. surgical resection, external beam
                  radiation, catheter-based therapy), and patients must have evidence of disease
                  progression from locoregional therapy

          -  Must have measurable disease by RECIST v1.1

               -  Lesions that were previously radiated or ablated cannot be target lesions unless
                  there was subsequent radiographic progression at those sites

          -  No prior systemic therapy for HCC. Prior chemotherapy given locally into the liver
             (e.g. transarterial chemoembolization [TACE]) is allowed

          -  Must have Child-Pugh class A hepatic function within 7 days prior to first dose of
             study intervention

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Life expectancy of at least 12 weeks

          -  Recovery to baseline or =< grade 1 toxicities (CTCAE v5) related to any prior
             treatments, unless adverse events (AEs) are clinically nonsignificant and/or stable on
             supportive therapy

          -  Absolute neutrophil count (ANC) >= 1500/mm^3 without granulocyte colony-stimulating
             factor support (within 14 days before first dose of study treatment)

          -  Platelets >= 60,000/mm^3 without transfusion (within 14 days before first dose of
             study treatment)

          -  Hemoglobin >= 9 g/dL (>= 90 g/L) without transfusion or erythropoietin (EPO)
             dependency (within 14 days before first dose of study treatment)

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 x upper limit
             of normal (ULN) (within 14 days before first dose of study treatment)

          -  Total bilirubin =< 2 mg/dL OR direct bilirubin =< ULN for participants with total
             bilirubin levels > 2 mg/dL (within 14 days before first dose of study treatment)

          -  Serum albumin >= 2.8 g/dl (>= 28 g/L) without albumin infusion (within 14 days before
             first dose of study treatment)

          -  Prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin
             time (PTT) test =< 1.5 x ULN (within 14 days before first dose of study treatment)

          -  Serum creatinine =< 1.5 x ULN or calculated creatinine clearance >= 40 mL/min using
             the Cockcroft-Gault equation (within 14 days before first dose of study treatment)

          -  Urine protein/creatinine ratio (UPCR) =< 1 mg/mg (=< 113.2 mg/mmol) or 24 hour(h)
             urine protein =< 1 g (within 14 days before first dose of study treatment)

          -  Hemoglobin A1c (HbA1c) =< 8% within 28 days before randomization or fasting serum
             glucose =< 160 mg/dL (within 14 days before first dose of study treatment)

          -  Patients with positive hepatitis B surface antigen (HBsAg) and/or hepatitis B virus
             (HBV) viral load > 100 IU/mL at the time of enrollment are eligible to enroll on study
             if they meet the following criteria:

               -  Anti-HBV therapy as per institutional practice must be given at least 4 weeks and
                  HBV viral load must be < 100 IU/mL prior to initiating study treatment. Patients
                  on active HBV therapy with viral loads < 100 IU/mL should remain on the same
                  therapy throughout study treatment

               -  Note: Patients with positive anti-hepatitis B core antibody (HBcAb), negative
                  HBsAg, and negative or positive anti-hepatitis B surface antibody, and who have
                  an HBV viral load < 100 IU/mL do not require anti-viral prophylaxis

          -  Patients with past or ongoing hepatitis C infection (HCV) are eligible to enroll on
             study, with or without prior anti-viral treatment, as long as the other eligibility
             criteria are met. Treated patients must have completed their anti-viral treatment at
             least 1 month prior to initiating study treatment

          -  Sexually active fertile subjects and their partners must agree to use effective
             methods of contraception during the course of the study and for at least 4 months
             after the last dose cabozantinib. They must also refrain from donating sperm during
             this time period

          -  Female subjects of childbearing potential must not be pregnant at screening and not
             breastfeeding. Females of childbearing potential are defined as premenopausal females
             capable of becoming pregnant (i.e. females who have had any evidence of menses in the
             past 12 months, with the exception of those who had prior hysterectomy)

               -  Women who have been amenorrheic for 12 or more months are still considered to be
                  of childbearing potential if the amenorrhea is possibly due to prior
                  chemotherapy, antiestrogens, low body weight, ovarian suppression or other
                  reasons

          -  Capable of understanding and complying with the protocol requirements and must provide
             written informed consent/assent for the study

        Exclusion Criteria:

          -  Prior treatment with any systemic therapy for HCC, including anti-VEGF therapy or any
             systemic investigational agent

               -  If the patient previously received systemic treatment for reasons other than HCC:
                  small molecule kinase inhibitors are not allowed within 2 weeks and
                  cytotoxic/biologic agents are not allowed within 4 weeks of study treatment

          -  Prior exposure to immune checkpoint inhibitors or other immunotherapeutic agents

          -  Currently participating in or has participated in a study of an investigational agent
             or device within 4 weeks prior to the first dose of study treatment

          -  Major surgery within 6 weeks or minor surgery (e.g. dental extraction) within 10 days
             prior to first dose of study treatment

               -  Complete wound healing from major surgery must have occurred at least 1 month
                  before first dose and from minor surgery (e.g. simple excision, tooth extraction)
                  at least 7 days before first dose. Subjects with clinically relevant ongoing
                  complications from prior surgery are not eligible

          -  Local liver-directed therapy within 4 weeks of initiating study treatment

          -  Palliative radiation for the purpose of symptomatic relief to non-liver and
             non-central nervous system (CNS) disease within 2 weeks of starting treatment. Other
             radiation treatments within 4 weeks of starting treatment

               -  Patients must have recovered from all radiation-related toxicities, not require
                  corticosteroids, and have not had radiation pneumonitis

          -  Prior liver or other allogenic tissue/organ transplantation

          -  History of primary immunodeficiency

          -  Active autoimmune or inflammatory disease that has required systemic treatment in the
             past 2 years (i.e. with use of disease-modifying agents, corticosteroids or
             immunosuppressive drugs). This includes, but is not limited to, inflammatory bowel
             disease, celiac disease, systemic lupus erythematosus, rheumatoid arthritis,
             myasthenia gravis, Graves' disease, etc.

               -  The following autoimmune conditions are allowed: vitiligo or alopecia;
                  hypothyroidism on stable hormone replacement therapy; psoriasis/eczema not
                  requiring systemic treatment

               -  Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid
                  replacement therapy for adrenal or pituitary insufficiency) is not considered a
                  form of systemic treatment and is allowed

          -  Chronic use of systemic steroid (in dosing exceeding 10 mg daily of prednisone
             equivalent) or immunosuppressive therapy or use within 14 days prior to enrollment

               -  The following treatments are allowed: intranasal, inhaled, topical or local
                  steroid injections; systemic corticosteroids at physiologic doses equivalent to
                  no more than prednisone 10 mg/day; steroids as premedication for contrast dye
                  allergy

          -  History of (non-infectious) pneumonitis that required steroids or has current
             pneumonitis

          -  History of hepatic encephalopathy or treatment to prevent or control encephalopathy
             within the past 12 months. Subjects on lactulose and/or rifaximin to control hepatic
             encephalopathy are not allowed

          -  Esophageal or gastric variceal bleeding within the past 6 months. All subjects will be
             screened for esophageal varices unless performed in the last 6 months before study
             treatment. If varices are present, they should be treated according to institutional
             standards before starting study treatment

          -  Uncontrolled ascites, clinically significant or symptomatic ascites requiring
             paracenteses or increasing doses of diuretics within the past 3 months

               -  Patients who are on stable diuretic doses for at least 3 months are eligible if
                  they meet other eligibility criteria

               -  Asymptomatic ascites detected on imaging are allowed

          -  Has known history or any evidence of CNS metastases and/or carcinomatous meningitis.
             Subjects with previously treated brain metastases may participate provided they are
             asymptomatic and radiologically stable (i.e. without progression for at least 4 weeks
             by repeat imaging [which must be performed during study screening], clinically stable,
             and without the need steroids for at least 4 weeks prior to first dose of study
             treatment)

          -  Concomitant anticoagulation with oral anticoagulants (e.g. warfarin, direct thrombin
             and factor Xa inhibitors) or platelet inhibitors (e.g. clopidogrel). Allowed
             anticoagulants are the following:

               -  Low-dose aspirin for cardioprotection (per local applicable guidelines) is
                  permitted

               -  Low molecular weight heparin (LMWH) is permitted

               -  Anticoagulation with therapeutic doses of LMWH is allowed in subjects without
                  known brain metastases who are on a stable dose of LMWH for at least 4 weeks
                  before first dose of study treatment, and who have had no clinically significant
                  hemorrhagic complications from the anticoagulation regimen or the tumor

          -  The subject has uncontrolled, significant intercurrent or recent illness including,
             but not limited to, the following conditions:

               -  Cardiovascular disorders:

                    -  Congestive heart failure New York Heart Association class 3 or 4, unstable
                       angina pectoris, serious cardiac arrhythmias with risk of hemodynamic
                       instability within 12 months before the first dose of study treatment

                    -  Uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mm
                       Hg systolic or > 95 mm Hg diastolic despite optimal antihypertensive
                       treatment, and/or change in antihypertensive medications within 1 week
                       before starting treatment. Note: eligibility of a subject receiving 4 or
                       more antihypertensive medications prior to study entry will require approval
                       from the principal investigator (PI)

                    -  Stroke (including transient ischemic attack [TIA]), myocardial infarction
                       (MI), or other ischemic event, or arterial thromboembolic within 12 months
                       before the first dose

                    -  Asymptomatic venous thromboembolic event (e.g. deep venous thrombosis,
                       pulmonary embolism) is allowed if the patient has been stable on
                       anticoagulation with LMWH for at least 4 weeks

               -  Gastrointestinal (GI) disorders including those associated with a high risk of
                  perforation or fistula formation:

                    -  The subject has evidence of tumor invading the GI tract, active peptic ulcer
                       disease, inflammatory bowel disease (e.g. Crohn's disease), GI
                       malabsorption, diverticulitis, cholecystitis, symptomatic cholangitis or
                       appendicitis, acute pancreatitis, acute obstruction of the pancreatic duct
                       or common bile duct, or gastric outlet obstruction

                    -  Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal
                       abscess within 6 months before first dose

                         -  Note: Complete healing of an intra-abdominal abscess must be confirmed
                            before first dose

               -  Clinically significant hematuria, hematemesis, or hemoptysis of > 0.5 teaspoon
                  (2.5 ml) of red blood, other history of significant bleeding (e.g. pulmonary
                  hemorrhage) within 12 weeks before first dose, or known thrombotic disorder

               -  Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease
                  manifestation

               -  Lesions invading any major blood vessels, including main portal vein, inferior
                  vena cava, or cardiac involvement of HCC based on imaging

                    -  Note: Main and branch portal vein and hepatic vein invasion is allowed

               -  Ongoing active infection requiring antibiotics. Antibiotics must be completed at
                  least 7 days before initiating study treatment

               -  Known active tuberculosis

               -  Serious non-healing wound, ulcer, or bone fracture

          -  Patients with proteinuria > 1+ on urine dipstick testing will undergo 24-hour urine
             collection for quantitative assessment of proteinuria. Participants with urine protein
             >= 1 g/24 hours will be ineligible

          -  Corrected QT interval calculated by the Fridericia formula (QTcF) > 480 ms per
             electrocardiogram (EKG) within 28 days before first dose of study treatment

               -  Note: If a single EKG shows a QTcF with an absolute value > 500 ms, two
                  additional EKGs at intervals of approximately 3 min must be performed within 30
                  min after the initial EKG, and the average of these three consecutive results for
                  QTcF will be used to determine eligibility

          -  Inability to swallow tablets or any other condition that might interfere with oral
             absorption of medications

          -  Previously identified allergy or hypersensitivity to study drugs and/or any of their
             excipients

          -  Ongoing secondary malignancy that is progressing and/or has required active treatment
             within the past year. Adjuvant treatment for resected breast cancer is allowed

               -  Subjects with basal cell carcinoma of the skin, squamous cell carcinoma or the
                  skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that
                  have undergone potentially therapy are allowed

          -  Has a known history of human immunodeficiency virus (HIV) infection. Note: HIV testing
             is not mandated for screening

          -  Co-infection with HBV (HBsAg [+] and /or detectable HBV DNA) and HCV (anti-HCV Ab [+]
             and detectable HCV ribonucleic acid [RNA]) at study entry

          -  Co-infection with HBV and hepatitis D virus (HDV) at study entry

          -  Live attenuated vaccine within 30 days prior to first dose of study treatment.
             Examples of live vaccines include, but are not limited to, the following: measles,
             mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus
             Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection
             are generally killed virus vaccines and are allowed; however, intranasal influenza
             vaccines (e.g. FluMist) are live attenuated vaccines and are not allowed

          -  Pregnant or lactating females

          -  Known psychiatric illness, substance abuse disorder, or other condition that would
             interfere with the ability to comply with the requirements of the study

          -  Has history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the study, interfere with the subject's
             participation for the full duration of the study, or is not in the best interest of
             the subject to participate, in the opinion of the treating investigator
      "
NCT05465941,suspended,"
    for interim analysis due to rapid accrual
  ",0,phase 2,"['platinum-resistant fallopian tube carcinoma', 'platinum-resistant ovarian carcinoma', 'platinum-resistant primary peritoneal carcinoma', 'recurrent ovarian carcinoma', 'stage iv fallopian tube cancer ajcc v8', 'stage iv ovarian cancer ajcc v8', 'stage iv primary peritoneal cancer ajcc v8']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C57.00', 'C57.01', 'C57.02', 'D28.2']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['K65.1', 'K66.0', 'N99.4', 'N73.6', 'R88.0', 'Z49.32', 'Z49.02']""]",['pegylated sn-38 conjugate plx038'],['Status: 503'],"
        Inclusion Criteria:

          -  Age >= 18 years NOTE: Because no dosing or adverse event data are currently available
             on the use of PLX038 in patients < 18 years of age, children are excluded from this
             study, but will be eligible for future pediatric trials

          -  Histological confirmed high grade serous ovarian cancer consistent with ovarian,
             fallopian tube, or primary peritoneal carcinoma (NOTE: Any of these diseases are
             referred to in this protocol as ""ovarian cancer"")

          -  Recurrent high grade serous ovarian cancer that was initially platinum sensitive
             (i.e., had at least one platinum-free interval of at least 6 months before
             progression) is now platinum resistant

          -  No more than one prior line of therapy for platinum resistant disease. NOTE: Prior
             poly adenosine diphosphate-ribose polymerase (PARP) inhibitor therapy is allowed

          -  Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

          -  Disease that is amenable to two biopsies

          -  Life expectancy greater >= 12 weeks

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2

          -  Hemoglobin >= 8.0 g/dL (obtained =< 28 days prior to registration)

          -  Absolute neutrophil count (ANC) >= 1500/mm^3 (obtained =< 28 days prior to
             registration)

          -  Platelet count >= 100,000/mm^3 (obtained =< 28 days prior to registration)

          -  Total bilirubin >= 1.5 x upper limit of normal (ULN) (obtained =< 28 days prior to
             registration)

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN (=< 5 x
             ULN for patients with liver involvement) (obtained =< 28 days prior to registration)

          -  Calculated creatinine clearance >= 45 ml/min using the Cockcroft-Gault formula
             (obtained =< 28 days prior to registration)

          -  Negative pregnancy test done =< 7 days prior to registration, for persons of
             childbearing potential only

          -  Provide written informed consent

          -  Willing to return to enrolling institution for follow-up (during the Active Monitoring
             Phase of the study)

          -  Willingness to provide mandatory blood specimens for correlative research

          -  Willingness to provide mandatory tissue specimens for correlative research

        Exclusion Criteria:

          -  Any of the following because this study involves an agent that has known genotoxic,
             mutagenic and teratogenic effects:

               -  Pregnant persons

               -  Nursing persons

               -  Persons of childbearing potential who are unwilling to employ adequate
                  contraception

          -  Histology other than high grade serous carcinoma

          -  Prior treatment restrictions

               -  Chemotherapy =< 4 weeks prior to registration

               -  Immunotherapy =< 4 weeks prior to registration

               -  Radiotherapy =< 4 weeks prior to registration

               -  Any other investigational therapy =< 4 weeks prior to registration

          -  History of prior or concurrent malignancy =< 2 years prior to registration

               -  Exceptions: If natural history or treatment does not have the potential to
                  interfere with the safety or efficacy assessment of the investigational regimen

          -  Uncontrolled intercurrent illness including, but not limited to:

               -  Myocardial infarction within 6 months of study entry

               -  New York Heart Association (NYHA) class III or IV heart failure

               -  Uncontrolled dysrhythmias or poorly controlled angina

               -  History of serious ventricular arrhythmia (ventricular tachycardia [VT] or
                  ventricular fibrillation [VF]) and/or factors that predispose to arrhythmia
                  (e.g., heart failure, hypokalemia, family history of long QT syndrome)

          -  Known history or current symptoms of cardiac disease, or history of treatment with
             cardiotoxic agents, Exception: Patients should have a clinical risk assessment of
             cardiac function using the New York Heart Association functional classification. To be
             eligible for this trial, patients should be class 2B or better

          -  Known human immunodeficiency virus (HIV) Exception: Patients on effective
             anti-retroviral therapy with undetectable viral load =< 6 months prior to registration
             are eligible for this trial

          -  Known hepatitis

               -  Exception: For patients with evidence of chronic hepatitis B virus infection the
                  HepB viral load must be undetectable on suppressive therapy, if indicated, to be
                  eligible

               -  Exception: Patients with a history of hepatitis C virus infection must have been
                  treated and cured. Patients with HCV infection who are currently on treatment are
                  eligible if they have an undetectable HCV viral load

          -  Receiving any other investigational agent

          -  History of clinically significant gastrointestinal bleeding, colitis, or
             gastrointestinal perforation

          -  Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment
             of the investigator, would make the patient inappropriate for entry into this study or
             interfere significantly with the proper assessment of safety and toxicity of the
             prescribed regimen

          -  Requirement for anticoagulation treatment that increases international normalized
             ratio (INR) or activated partial thromboplastin time (APTT) above the normal range
             (Exceptions: low dose deep vein thrombosis (DVT) or line prophylaxis allowed

          -  Known central nervous system (CNS) disease Exception: Patients with treated brain
             metastases are eligible if follow-up brain imaging after CNS directed therapy shows no
             evidence of progression. Patients with new or progressive brain metastases (active
             brain metastases) or leptomeningeal disease are eligible if the treating physician
             determined that immediate CNS specific treatment is not required and is unlikely to be
             required during the 1st cycle of therapy

          -  Known Gilbert's syndrome or homozygous for the UGT1A1*28 variant allele or other
             relevant alleles with severely reduced UGT1A1 activity

          -  Patients who require treatment with UGT1A1 inhibitors during the planned period of
             investigational treatment with PLX038
      "
NCT03323710,withdrawn,"
    poor patient recruitment.
  ",0,phase 2,['renal cell carcinoma'],"[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]","['propranolol', 'sunitinib']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

        Patients are eligible to be included in the study only if they meet all of the following
        criteria:

          1. Histological diagnosis of clear-cell renal cell carcinoma (RCC) or mixed-type RCC with
             more than 60% of clear-cell component.

          2. Diagnosis of stage IV RCC (primary metastatic or recurrence after surgical procedure).

          3. Prior nephrectomy (complete or partial).

          4. Presence of measurable disease per Response Evaluation Criteria in Solid Tumors
             version 1.1.

          5. Karnofsky performance status score of 80-100%.

          6. Favourable- or intermediate-risk according to Memorial Sloan Kettering Cancer Center
             criteria.

          7. Adequate organ function, including the following:

               1. hepatic: total bilirubin ≤ 2 times the upper limit of normal (excluding patients
                  with Gilbert syndrome), aspartate aminotransferase and alanine aminotransferase ≤
                  5 times the upper limit of normal,

               2. renal: serum creatinine ≤ 2 times the upper limit of normal,

               3. bone marrow: absolute neutrophil count ≥ 1500/mm3, platelets ≥ 100000/mm3,
                  hemoglobin ≥ 9.5 g/dl.

          8. Normal thyroid function (natural or with supplementation of thyroid hormones) defined
             as thyroid-stimulating hormone within limits of normal.

          9. Age eighteen years or older on the day of consent.

         10. Written informed consent prior to study entry.

        Exclusion Criteria:

        Patients will be excluded from the study if they meet any of the following criteria:

          1. Prior systemic pharmacotherapy of RCC.

          2. Treatment with propranolol within 6 months of study entry.

          3. Metastases in central nervous system (patients who had central nervous system
             metastases that were surgically resected and/or treated with radiotherapy in the past
             and now are without neurological symptoms, are allowed on protocol).

          4. Female patients who are pregnant or breast feeding or adults of reproductive potential
             who are not using effective birth control methods.

          5. Presence of other malignancies (patients with carcinoma in situ of the cervix or basal
             cell carcinoma of the skin are allowed on protocol).

          6. Presence of any severe and/or uncontrolled medical conditions or other conditions that
             could affect their participation in the study such as:

               1. heart failure of New York Heart Association Class III or IV, significant cardiac
                  arrhythmia or any other clinically significant cardiovascular disease,

               2. unstable angina pectoris, symptomatic congestive heart failure, myocardial
                  infarction within 6 months of entering the study,

               3. severely impaired respiration as defined as O2 saturation that is ≤ 90% at rest
                  on room air,

               4. uncontrolled diabetes as defined by fasting serum glucose > 1.5 times the upper
                  limit of normal,

               5. ejection fraction less than 40% (measured at echocardiography),

               6. significant liver disease such as cirrhosis, active hepatitis or chronic
                  persistent hepatitis,

               7. active (acute or chronic) infections requiring antimicrobial intervention.

          7. Concomitant treatment with:

               1. chronic, systemic corticosteroids or another immunosuppressive agent; topical or
                  inhaled corticosteroids are allowed,

               2. strong CYP3A4 inducers/inhibitors: carbamazepine, phenytoin, rifabutin, rifampin,
                  nafcillin, phenobarbital, St John's wort, itraconazole, ketoconazole,
                  erythromycin, clarithromycin, nefazodone.

          8. Known allergy/sensitivity to sunitinib and/or propranolol.

          9. Galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.

         10. Immunization with attenuated live vaccines within 30 days of study entry.

         11. Human immunodeficiency virus sero-positivity at the study entry or in the past.

         12. Impairment of gastrointestinal function or gastrointestinal disease that may
             significantly alter the absorption of sunitinib and/or propranolol (e.g., ulcerative
             disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small
             bowel resection).

         13. Presence of active, bleeding diathesis.

         14. Major surgery (defined as requiring general anesthesia) and/or significant traumatic
             injury (requiring > 28 days to heal) within 28 days of the study entry; presence of
             side effects due to any surgery or probable requirement of major surgery during the
             course of the study.

         15. Present contraindications to propranolol, that include: bronchial asthma, prolonged
             fasting, acidosis, hypotension (systolic blood pressure less than 90 mmHg, diastolic
             blood pressure less than 60 mmHg), severe peripheral arterial circulatory disturbance,
             cardiogenic shock, bradycardia, Prinzmetal's angina, uncontrolled heart failure,
             second or third degree heart block, untreated phaeochromocytoma, sick sinus syndrome.

         16. Inability or unwillingness of subject or legal guardian/representative to give written
             informed consent.
      "
NCT03325166,terminated,"
    low accrual
  ",0,phase 2,"['lung carcinoma metastatic in the brain', 'stage iv lung non-small cell cancer ajcc v7']","[""['D02.20', 'D02.21', 'D02.22']"", ""['C96.20', 'C96.29', 'D47.09']""]",['ferumoxytol'],['O[Fe]=O.O[Fe]=O.[Fe]'],"
        Inclusion Criteria:

          -  Be willing and able to provide written informed consent/assent for the trial

          -  Have a histologically confirmed diagnosis of NSCLC

          -  Have up to ten measurable (by Response Assessment in Neuro-Oncology Criteria [RANO])
             brain metastasis planned for stereotactic radiosurgery

          -  Have PD-L1 expression of greater than 1%

          -  Subjects may already be receiving PD-(L)1 (including pembrolizumab or other PD-[L]1
             inhibitors such as nivolumab, atezolizumab, avelumab, durvalumab) for the treatment of
             systemic disease; a washout period of at least 3 weeks is required from the last dose
             of PD-(L)1 inhibitor

          -  Subjects with EGFR or ALK genomic tumor aberrations should have documented disease
             progression on Food and Drug Administration (FDA)-approved therapy for these
             aberrations; subjects with EGFR or ALK genomic tumor aberrations who develop new brain
             metastases may be included at the discretion of the treating physician

          -  Have a performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG)
             performance scale

          -  Absolute neutrophil count (ANC) >= 1,500 /mcL

          -  Platelets >= 100,000/mcL

          -  Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO)
             dependency (within 7 days of assessment)

          -  Serum creatinine =< 1.5 X upper limit of normal (ULN) OR measured or calculated
             creatinine clearance (glomerular filtration rate [GFR] can also be used in place of
             creatinine or creatinine clearance [CrCl]) >= 60 mL/min for subject with creatinine
             levels > 1.5 X institutional ULN

               -  Creatinine clearance should be calculated per institutional standard

          -  Serum total bilirubin =< 1.5 X ULN OR direct bilirubin =< ULN for subjects with total
             bilirubin levels > 1.5 ULN

          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X
             ULN OR =< 5 X ULN for subjects with liver metastases

          -  Albumin >= 2.5 mg/dL

          -  International normalized ratio (INR) or prothrombin rime (PT) =< 1.5 X ULN unless
             subject is receiving anticoagulant therapy as long as PT or partial thromboplastin
             time (PTT) is within therapeutic range of intended use of anticoagulants

          -  Activated partial thromboplastin time (aPTT) =< 1.5 X ULN unless subject is receiving
             anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use
             of anticoagulants

          -  Female subject of childbearing potential should have a negative urine or serum
             pregnancy within 72 hours prior to receiving the first dose of study medication; if
             the urine test is positive or cannot be confirmed as negative, a serum pregnancy test
             will be required

          -  Female subjects of childbearing potential should be willing to use 2 methods of birth
             control or be surgically sterile, or abstain from heterosexual activity for the course
             of the study through 120 days after the last dose of study medication; subjects of
             childbearing potential are those who have not been surgically sterilized or have not
             been free from menses for > 1 year; male subjects should agree to use an adequate
             method of contraception starting with the first dose of study therapy through 120 days
             after the last dose of study therapy

        Exclusion Criteria:

          -  Has evidence of leptomeningeal disease on MRI or in cerebrospinal fluid (CSF)

          -  If tumor demonstrates EGFR or ALK genomic tumor aberrations, subject should have
             documented disease progression on FDA-approved therapy for these aberrations

          -  Has a diagnosis of immunodeficiency and is not on continuous daily immunosuppressive
             therapy within 7 days prior to the first dose of trial treatment; (subjects may
             receive steroids before or after SRS to prevent or manage cerebral edema; inhalational
             steroids are permitted)

          -  Has previously progressed on a PD-1 or PD-L1 checkpoint inhibitor for systemic disease

          -  Has a known history of active TB (Bacillus tuberculosis)

          -  Has hypersensitivity to pembrolizumab, gadolinium, or ferumoxytol or any of their
             excipients

          -  Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study
             day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events
             due to agents administered more than 4 weeks earlier

               -  Note: The use of denosumab is an exception to this criterion

          -  Subject who has not recovered (i.e., =< grade 1 or at baseline) from adverse events
             due to a previously administered agent

               -  Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and
                  may qualify for the study

               -  Note: Subjects with =< grade 2 hematologic toxicities are an exception to this
                  criterion and may qualify for the study

               -  Note: Subjects with =< grade 2 fatigue are an exception to this criterion and may
                  qualify for the study

          -  Has a known additional malignancy that is progressing or requires active treatment;
             exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the
             skin that has undergone potentially curative therapy or in situ cervical cancer

          -  Has active autoimmune disease that has required systemic treatment in the past 2 years
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive
             drugs); replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
             form of systemic treatment

          -  Has known history of, or any evidence of active, non-infectious pneumonitis

          -  Has an active infection requiring systemic therapy

          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the subject's
             participation for the full duration of the trial, or is not in the best interest of
             the subject to participate, in the opinion of the treating investigator

          -  Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial

          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the pre-screening or screening visit
             through 120 days after the last dose of trial treatment

          -  Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)

          -  Has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or
             hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is
             detected)

          -  Has received a live vaccine within 30 days of planned start of study therapy

               -  Note: Seasonal influenza vaccines for injection are generally inactivated flu
                  vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist)
                  are live attenuated vaccines, and are not allowed

          -  Subjects with clinically significant signs of uncal herniation, such as acute
             pupillary enlargement, rapidly developing motor changes (over hours), or rapidly
             decreasing level of consciousness, are not eligible

          -  Subjects with known allergic or hypersensitivity reactions to parenteral iron,
             parenteral dextran, parenteral iron-dextran, or parenteral iron-polysaccharide
             preparations; subjects with significant drug or other allergies or autoimmune diseases
             may be enrolled at the investigator's discretion

          -  Subjects who have a contraindication for 3 tesla (3T) MRI: metal in their bodies (a
             cardiac pacemaker or other incompatible device), are severely agitated, or have an
             allergy to gadolinium containing contrast material

          -  Subjects with known iron overload (genetic hemochromatosis); in subjects with a family
             history of hemochromatosis, hemochromatosis must be ruled out prior to study entry
             with normal values of the following blood tests: transferrin saturation (TS) test and
             serum ferritin (SF) test; all associated costs will be paid by the study

          -  Subject who have received ferumoxytol within 3 weeks of study entry

          -  Subjects with three or more drug allergies from separate drug classes
      "
NCT02788773,"active, not recruiting",,0,phase 2,['prostate cancer'],"[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]","['durvalumab', 'tremelimumab']",['Status: 503'],"
        Inclusion Criteria:

          -  Patients must have histologically confirmed adenocarcinoma of the prostate that is
             castrate resistant.

          -  Disease progression as defined as one or both of the following: PSA Progression: A
             rising PSA with 2 subsequent rises over a reference value (not necessarily
             consecutively), measured a minimum of one week apart. The PSA that confirms
             progression must have a value of ≥ 2 ng/ml (ug/L).

        OR Objective Progression:

          -  RECIST 1.1

          -  PCWG 3 Criteria for bone progression

          -  Patients must be surgically or medically castrated, with testosterone levels of < 50
             ng/dL (< 1.7 nM). Patients who have not undergone orchiectomy must continue (or
             restart if previously discontinued) LHRH therapy throughout the study.

          -  All patients must have a tumour block from their primary or metastatic tumour
             available and consent to release the block/recently cut slides for correlative
             analyses and the centre/pathologist must have agreed to the submission of the
             specimen(s). The site of planned biopsy must not be the measurable lesion.

          -  Presence of clinically and/or radiologically documented disease. All radiology studies
             must be performed within 28 days prior to randomization (within 35 days if negative).

          -  All patients must have at least one measurable lesion as defined by RECIST 1.1 that
             has not been the site of the protocol mandated biopsy. The criteria for defining
             measurable disease are as follows: CT scan (with slice thickness of 5 mm) ≥ 10 mm -->
             longest diameter; Lymph nodes by CT scan ≥ 15 mm --> measured in short axis

          -  Patients must be ≥ 18 years of age.

          -  ECOG performance status 0 or 1.

          -  Prior Therapy

        Systemic Therapy:

        0-1 prior regimen of cytotoxic chemotherapy in the CRPC setting is permitted.

        Hormonal Therapy:

          -  Patients must be castrate resistant.

          -  Have failed/progressed on prior abiraterone and/or enzalutamide.

          -  Patients must have discontinued anti-androgens for at least 4 weeks prior to study
             entry (at least 6 weeks for bicalutamide).

        Other therapy:

        Prior treatment with other agents, such as tyrosine kinase or other targeted agents is
        permissible.

          -  Systemic corticosteroids are permitted at a dose equivalent to ≤10 mg prednisone daily
             and are only permitted for reasons other than prostate cancer treatment (ex: fatigue,
             anorexia, etc); topical applications (e.g. rash), inhaled sprays (e.g. obstructive
             airways diseases), eye drops or local injections (e.g. intra-articular) are permitted.

          -  Bisphosphonates/denosumab are permitted for treatment of hypercalcemia, osteoporosis
             and skeletal-related events.

        Immunotherapy:

        Patients may not have received prior immune check point inhibitors (anti PDL1 and anti
        CTL-4). Vaccines and treatment with oncolytic viruses is permissible.

        Patients must have recovered from all reversible toxicity related to prior systemic therapy
        (chemotherapy and hormone) and have adequate washout as follows:

        Longest of one of the following:

          -  Two weeks;

          -  The longer of 30 days or 5 half-lives for investigational agents;

          -  Standard cycle length of standard therapies.

        Radiation:

        Prior external beam radiation or radium-223 is permitted provided a minimum of 28 days (4
        weeks) have elapsed between the last dose of radiation and the date of randomization.
        Exceptions may be made for low-dose non-myelosuppressive radiotherapy after consultation
        with CCTG. Concurrent radiotherapy is not permitted. Prior strontium-89 at any time is not
        permitted

        Prior Surgery:

        Prior major surgery is permitted provided that a minimum of 28 days (4 weeks) have elapsed
        between any major surgery and date of randomization, and that wound healing has occurred.

          -  Laboratory Requirements (Must be done within 7 days prior to randomization):

        Abs Neutrophils ≥ 1.5 x 10^9/L Platelets ≥ 100 x 10^9/L Hemoglobin ≥ 90 g/L Bilirubin ≤ 1.5
        x ULN AST and ALT ≤ 2.5 x ULN ≤ 5.0 ULN (if patient has liver mets) Serum Creatinine < 1.25
        x ULN or Creatinine clearance ≥ 40mL/min

          -  Non-sterilized male patients who are sexually active with a female partner of
             childbearing potential must use male condom plus spermicide while on study and for 6
             months after the last dose of durvalumab and tremelimumab, or for 3 months after the
             last dose of durvalumab alone. Female partners of a male subject must use a highly
             effective method of contraception throughout this period.

          -  Male patients should also refrain from donating sperm during the study and for 6
             months after the last dose of durvalumab and tremelimumab or for 3 months after the
             last dose of durvalumab alone.

          -  Subjects should not donate blood while participating in this study, or for at least 90
             days following the last infusion of durvalumab or tremelimumab.

          -  Patient consent must be appropriately obtained in accordance with applicable local and
             regulatory requirements. Each patient must sign a consent form prior to enrollment in
             the trial to document their willingness to participate. Patients who cannot give
             informed consent (i.e. mentally incompetent patients, or those physically
             incapacitated such as comatose patients) are not to be recruited into the study.
             Patients competent but physically unable to sign the consent form may have the
             document signed by their nearest relative or legal guardian. Each patient will be
             provided with a full explanation of the study before consent is requested.

          -  Patients must be accessible for treatment and follow up. Patients registered on this
             trial must be treated and followed at the participating centre. This implies there
             must be reasonable geographical limits (for example: 1 ½ hour's driving distance)
             placed on patients being considered for this trial. The patient's city of residence
             may be required to verify their geographical proximity. Investigators must assure
             themselves the patients registered on this trial will be available for complete
             documentation of the tretment, adverse events, and follow-up.

          -  Patients must agree to return to their primary care facility for any adverse events
             which may occur through the course of the trial.

          -  In accordance with CCTG policy, protocol treatment is to begin within 5 working days
             of patient randomization.

        Exclusion Criteria:

          -  Patients with a history of other malignancies requiring concurrent anticancer therapy.

          -  Patients with brain metastases are not eligible.

          -  Active or prior documented autoimmune or inflammatory disorders (including
             inflammatory bowel disease (e.g. colitis or Crohn's disease), diverticulitis with the
             exception of diverticulosis, celiac disease or other serious gastrointestinal chronic
             conditions associated with diarrhea), systemic lupus erythematosus, Sarcoidosis
             syndrome, or Wegener syndrome (granulomatosis with polyangiitis), rheumatoid
             arthritis, hypophysitis, uveitis, etc., within the past 3 years prior to the start of
             treatment. The following are exceptions to this criterion:

               -  Patients with alopecia.

               -  Patients with Grave's disease, vitiligo or psoriasis not requiring systemic
                  treatment (within the last 2 years).

               -  Patients with hypothyroidism (e.g. following Hashimoto syndrome) stable on
                  hormone replacement.

          -  History of primary immunodeficiency, history of allogenic organ transplant that
             requires therapeutic immunosuppression and the use of immunosuppressive agents within
             28 days of randomization or a prior history of severe (grade 3 or 4) immune mediated
             toxicity from other immune therapy or grade ≥ 3 infusion reaction.

          -  Live attenuated vaccination administered within 30 days prior to randomization or
             within 30 days of receiving durvalumab.

          -  History of hypersensitivity to durvalumab or tremelimumab or any excipient. Any
             previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab or an
             anti-CTLA4, including tremelimumab.

          -  Patients who have experienced untreated and/or uncontrolled cardiovascular conditions
             and/or have symptomatic cardiac dysfunction (unstable angina, congestive heart
             failure, myocardial infarction within the previous year or cardiac ventricular
             arrhythmias requiring medication, history of 2nd or 3rd degree atrioventricular
             conduction defects). Patients with a significant cardiac history, even if controlled,
             should have a LVEF ≥ 50%.

          -  Concurrent treatment with other investigational drugs or anti-cancer therapy (except
             LHRH in patients not surgically castrated).

          -  Patients with serious illnesses or medical conditions which would not permit the
             patient to be managed according to the protocol (including corticosteroid
             administration), or would put the patient at risk. This includes but is not limited
             to:

               -  History of significant neurologic or psychiatric disorder which would impair the
                  ability to obtain consent or limit compliance with study requirements.

               -  Active infection requiring systemic therapy; (including any patient known to have
                  active hepatitis B, hepatitis C or human immunodeficiency virus (HIV) or
                  tuberculosis or any infection requiring systemic therapy).

               -  Active peptic ulcer disease or gastritis.

               -  Pneumonitis.
      "
NCT02785913,completed,,0,phase 2,"['recurrent squamous cell lung carcinoma', 'stage iv squamous cell lung carcinoma']","[""['D02.20', 'D02.21', 'D02.22']"", ""['D02.20', 'D02.21', 'D02.22']""]",['taselisib'],['Status: 503'],"
        Inclusion Criteria:

          -  Patients must meet all SCREENING/PRE-SCREENING and SUB-STUDY REGISTRATION COMMON
             ELIGIBILITY CRITERIA as specified in S1400: Phase II/III Biomarker-Driven Master
             Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)

          -  Patients must be assigned to S1400B

          -  Hemoglobin A1c (HbA1c) < 7% obtained within 28 days prior to sub-study registration

          -  Fasting glucose < 125 mg/dL obtained within 28 days prior to sub-study registration

          -  Patients must not have type I or II diabetes that requires anti-hyperglycemic
             medication

          -  Patients must not have active or a history of small or large intestine inflammation
             such as Crohn's disease or ulcerative colitis

          -  Patients must not require daily supplemental oxygen

          -  Patients must be able to take oral medications; patients may not have any impairment
             of gastrointestinal function or gastrointestinal disease that may significantly alter
             the absorption of GDC-0032 (e.g. ulcerative disease, uncontrolled nausea, vomiting,
             diarrhea, malabsorption syndrome, or small bowel resection)

          -  Patients must not be taking, nor plan to take while on protocol treatment and for 14
             days post the last dose of study treatment, drugs, herbal supplements or foods that
             are known to be strong/moderate cytochrome p450, family 3, subfamily A, polypeptide 4
             (CYP3A4) substrates

          -  Patients must also be offered participation in banking for future use of specimens

          -  STEP 2 TO GDC-0032 RE-REGISTRATION:

          -  Patients must have progressed on arm 2 (docetaxel) of this sub-study

          -  Patients must not have received any prior systemic therapy (systemic chemotherapy,
             immunotherapy or investigational drug) within 21 days prior to step 2 re-registration;
             patients must have recovered (< grade 1) from any side effects of prior therapy

          -  Patients must have measurable disease documented by computed tomography (CT) or
             magnetic resonance imaging (MRI); the CT from a combined PET/CT may be used to
             document only non-measurable disease unless it is of diagnostic quality; measurable
             disease must be assessed within 28 days prior to step 2 re-registration; pleural
             effusions, ascites and laboratory parameters are not acceptable as the only evidence
             of disease; non-measurable disease must be assessed within 42 days prior to step 2
             re-registration; all disease must be assessed and documented on the baseline tumor
             assessment form; patients whose only measurable disease is within a previous radiation
             therapy port must demonstrate clearly progressive disease (in the opinion of the
             treating investigator) prior to registration

          -  Patients must have a CT or MRI scan of the brain to evaluate for central nervous
             system (CNS) disease within 42 days prior to step 2 re-registration; patient must not
             have leptomeningeal disease, spinal cord compression or brain metastases unless: (1)
             metastases have been locally treated and have remained clinically controlled and
             asymptomatic for at least 14 days following treatment, AND (2) patient has no residual
             neurological dysfunction and has been off corticosteroids for at least 1 day prior to
             re-registration

          -  Patients must not be planning to receive any concurrent chemotherapy, immunotherapy,
             biologic or hormonal therapy for cancer treatment; concurrent use of hormones for
             non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement
             therapy) is acceptable

          -  Absolute neutrophil count (ANC) >= 1,500/mcl obtained within 28 days prior to step 2
             re-registration

          -  Platelet count >= 100,000 mcl obtained within 28 days prior to step 2 re-registration

          -  Hemoglobin >= 9 g/dL obtained within 28 days prior to step 2 re-registration

          -  Serum bilirubin =< institutional upper limit of normal (IULN); for patients with liver
             metastases, bilirubin must be =< 5 x IULN obtained within 28 days prior to step 2
             re-registration

          -  Either alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 2 x IULN
             within 28 days prior to step 2 re-registration (if both ALT and AST are done, both
             must be < 2 IULN); for patients with liver metastases, either ALT or AST must be =< 5
             x IULN (if both ALT and AST are done, both must be =< 5 x IULN)

          -  HbA1c < 7% obtained within 28 days prior to step 2 re-registration

          -  Fasting glucose < 125 mg/dL obtained within 28 days prior to step 2 re-registration

          -  Serum creatinine =< the IULN OR measured or calculated creatinine clearance >= 50
             mL/min

          -  Patients must have Zubrod performance status of 0-1 documented within 28 days prior to
             step 2 re-registration

          -  Patients must not have any grade III/IV cardiac disease as defined by the New York
             Heart Association Criteria (i.e., patients with cardiac disease resulting in marked
             limitation of physical activity or resulting in inability to carry on any physical
             activity without discomfort), unstable angina pectoris, and myocardial infarction
             within 6 months, or serious uncontrolled cardiac arrhythmia

          -  Patients must not have documented evidence of acute hepatitis or have an active or
             uncontrolled infection

          -  Patients with a known history of human immunodeficiency virus (HIV) seropositivity:
             must have undetectable viral load using standard HIV assays in clinical practice; must
             have cluster of differentiation (CD)4 count >= 400/mcL; must not require prophylaxis
             for any opportunistic infections (i.e., fungal, mycobacterium avium complex [mAC], or
             pneumocystis pneumonia [PCP] prophylaxis); must not be newly diagnosed within 12
             months prior to re-registration

          -  Prestudy history and physical exam must be obtained within 28 days prior to
             re-registration

          -  No other prior malignancy is allowed except for the following: adequately treated
             basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated
             stage I or II cancer from which the patient is currently in complete remission, or any
             other cancer from which the patient has been disease free for five years

          -  Patients must not be pregnant or nursing; women/men of reproductive potential must
             have agreed to use an effective contraceptive method; a woman is considered to be of
             ""reproductive potential"" if she has had menses at any time in the preceding 12
             consecutive months; in addition to routine contraceptive methods, ""effective
             contraception"" also includes heterosexual celibacy and surgery intended to prevent
             pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy,
             bilateral oophorectomy or bilateral tubal ligation; however, if at any point a
             previously celibate patient chooses to become heterosexually active during the time
             period for use of contraceptive measures outlined in the protocol, he/she is
             responsible for beginning contraceptive measures

          -  As a part of the Oncology Patient Enrollment Network (OPEN) registration process the
             treating institution's identity is provided in order to ensure that the current
             (within 365 days) date of institutional review board approval for this study has been
             entered in the system

          -  Patients with impaired decision-making capacity are eligible as long as their
             neurological or psychological condition does not preclude their safe participation in
             the study (e.g., tracking pill consumption and reporting adverse events to the
             investigator)

          -  Patients must be informed of the investigational nature of this study and must sign
             and give written informed consent in accordance with institutional and federal
             guidelines
      "
NCT02780700,terminated,"
    substance discontinued
  ",0,phase 2,['colorectal neoplasms'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['nintedanib', 'capecitabine']","['CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O', 'CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O']","
        Inclusion criteria:

          -  Histologically or cytologically confirmed colorectal adenocarcinoma

          -  Metastatic or locally advanced disease not amenable to curative surgery and/or
             radiotherapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status <= 1

          -  At least one measurable lesion according to RECIST 1.1

          -  Previously treated with all of the following: fluoropyrimidine, (e.g. 5-fluorouracil
             (5-FU), capecitabine or TAS-102); oxaliplatin: Patients treated with oxaliplatin in
             adjuvant setting should have progressed within 6 months of completion of adjuvant
             therapy or they must have been treated with oxaliplatin for metastatic disease;
             Irinotecan; Vascular Endothelial Growth Factor (VEGF) directed treatment (e.g.
             bevacizumab, aflibercept, ramucirumab or regorafenib); cetuximab or panitumumab for
             patients with K-Ras wt or Ras wt tumors

          -  Minimal time interval of 3 weeks between the last administration of Colorectal Cancer
             (CRC) treatment (cytotoxics or targeted agents) and starting of trial therapy

          -  Adequate liver and kidney function

          -  Further inclusion criteria apply

        Exclusion criteria:

          -  Prior treatment with nintedanib.

          -  Any other investigational agent received within 3 weeks prior to randomization

          -  Known hypersensitivity or intolerability to the trial drugs or their excipients

          -  History of other malignancies in the last 5 years, in particular those that could
             interfere with interpretation of results. Patients with adequately treated basal or
             squamous cell skin cancer or cervix carcinoma and other early stage cancer treated
             curatively are eligible

          -  History of severe or unexpected reactions to fluoropyrimidine therapy or any of its
             excipients

          -  Known dihydropyrimidine dehydrogenase (DPD) deficiency

          -  Treatment with sorivudine or its chemically related analogues, such as brivudine

          -  Serious concomitant disease or medical condition affecting compliance with trial
             requirements or which are considered relevant for the evaluation of the efficacy or
             safety of the trial drug, such as neurologic, psychiatric, infectious disease or
             active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may
             increase the risk associated with trial participation or trial drug administration,
             and in the judgment of the investigator would make the patient inappropriate for entry
             into the trial

          -  Major injuries and/or surgery or bone fracture within 4 weeks of trial inclusion
             (signing Informed Consent), or planned surgical procedures during the trial period

          -  Significant cardiovascular diseases (i.e. uncontrolled hypertension, unstable angina,
             history of myocardial infarction within past 6 months of trial inclusion, congestive
             heart failure > New York Heart Association (NYHA) II)

          -  History of severe hemorrhagic or thromboembolic event in the past 6 months (excluding
             central venous catheter thrombosis and peripheral deep vein thrombosis). Known
             inherited predisposition to bleeding or to thrombosis

          -  Bleeding or thrombotic disorders requiring anticoagulant therapy such as warfarin, or
             similar agents requiring therapeuticInternational normalized ratio (INR) monitoring
             (treatment with low molecular weight heparin and/or heparin flush as needed for
             maintenance of an indwelling intravenous device is allowed)

          -  Inflammatory bowel disease and other serious medical conditions increasing the risk of
             perforation or bleeding according to investigator's judgment

          -  Gastrointestinal disorders or abnormalities that would interfere with absorption of
             study drug

          -  Patient with brain metastases that are symptomatic and/or require therapy. Patients
             with previously treated and stable brain metastases are allowed

          -  Further exclusion criteria apply
      "
NCT02785939,completed,,0,phase 2/phase 3,"['ccnd1 gene amplification', 'ccnd2 gene amplification', 'ccnd3 gene amplification', 'cdk4 gene amplification', 'recurrent squamous cell lung carcinoma', 'stage iv squamous cell lung carcinoma ajcc v7']","[""['D02.20', 'D02.21', 'D02.22']""]","['docetaxel', 'palbociclib']","['Status: 503', 'CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C']","
        Inclusion Criteria:

          -  Patients must meet all SCREENING/PRE-SCREENING and SUB-STUDY REGISTRATION COMMON
             ELIGIBILITY CRITERIA as specified in S1400: Phase II/III Biomarker-Driven Master
             Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)

          -  Patients must be assigned to S1400C

          -  Patients must not be taking within 7 days prior to sub-study registration, nor plan to
             take while on protocol treatment and for 14 days after the last dose of study
             treatment, strong CYP3A4 inhibitors and/or strong CYP3A4 inducers; moderate inhibitors
             or inducers of isoenzyme CYP3A4 should be avoided, but if necessary can be used with
             caution

          -  Patients must not be taking within 7 days prior to sub-study registration, nor plan to
             take while on protocol treatment drugs that are known to prolong the QT interval

          -  Patients must not have a screening corrected QT Fridericia?s formula (QTcF) interval >
             480 msec based on the average of the triplicate electrocardiograms (EKGs) performed
             within 28 days prior to registration; NOTE: triplicate EKGs are required at other
             timepoints; patients must not have any family or personal history of long or short QT
             syndrome, Brugada syndrome or known history of QTc prolongation, or torsade de pointes

          -  Patients must be able to take oral medications; patient may not have any impairment of
             gastrointestinal function or gastrointestinal disease that may significantly alter the
             absorption of palbociclib (e.g. ulcerative disease, uncontrolled nausea, vomiting,
             diarrhea, malabsorption syndrome or small bowel resection)

          -  Patients must have a sodium (Na), potassium (K), chlorine (Cl), calcium (Ca),
             magnesium (Mg), and glycosylated hemoglobin measurement (HbA1c) performed within 7
             days prior to sub-study registration

          -  Patients must also be offered participation in banking for future use of specimens

          -  STEP 2 PALBOCICLIB RE-REGISTRATION:

          -  Patients must have progressed on Arm 2 (docetaxel) of this sub-study

          -  Patients must not have received any prior systemic therapy (systemic chemotherapy,
             immunotherapy or investigational drug) within 21 days prior to step 2 re-registration;
             patients must have recovered (< grade 1) from any side effects of prior therapy

          -  Patients must have measurable disease documented by computed tomography (CT) or
             magnetic resonance imaging (MRI); the CT from a combined positron emission tomography
             (PET)/CT may be used to document only non-measurable disease unless it is of
             diagnostic quality; measurable disease must be assessed within 28 days prior to step 2
             re-registration; pleural effusions, ascites and laboratory parameters are not
             acceptable as the only evidence of disease; non-measurable disease must be assessed
             within 42 days prior to step 2 re-registration; all disease must be assessed and
             documented on the Baseline Tumor Assessment Form; patients whose only measurable
             disease is within a previous radiation therapy port must demonstrate clearly
             progressive disease (in the opinion of the treating investigator) prior to
             registration

          -  Patients must have a CT or MRI scan of the brain to evaluate for central nervous
             system (CNS) disease within 42 days prior to step 2 re-registration; patient must not
             have leptomeningeal disease, spinal cord compression or brain metastases unless: (1)
             metastases have been locally treated and have remained clinically controlled and
             asymptomatic for at least 14 days following treatment and prior to re-registration,
             AND (2) patient has no residual neurological dysfunction and has been off
             corticosteroids for at least 24 hours prior to re-registration

          -  Patients must not be planning to receive any concurrent chemotherapy, immunotherapy,
             biologic or hormonal therapy for cancer treatment; concurrent use of hormones for
             non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement
             therapy) is acceptable

          -  Patients must not have a screening QTcF interval > 480 msec based on the average of
             the triplicate EKGs performed within 28 days prior to step 2 re-registration; NOTE:
             triplicate EKGs are required at other timepoints; patients must not have any family or
             personal history of long or short QT syndrome, Brugada syndrome or known history of
             QTc prolongation, or torsade de pointes

          -  Absolute neutrophil count (ANC) >= 1,500/mcl obtained within 28 days prior to step 2
             re-registration

          -  Platelet count >= 100,000 mcl obtained within 28 days prior to step 2 re-registration

          -  Hemoglobin >= 9 g/dL obtained within 28 days prior to step 2 re-registration

          -  Serum bilirubin =< institutional upper limit of normal (IULN); for patients with liver
             metastases, bilirubin must be =< 5 x IULN within 28 days prior to step 2
             re-registration

          -  Either alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 2 x IULN
             within 28 days prior to step 2 re-registration (if both ALT and AST are done, both
             must be < 2 IULN); for patients with liver metastases, either ALT or AST must be =< 5
             x IULN (if both ALT and AST are done, both must be =< 5 x IULN)

          -  Patients must have a serum creatinine =< the IULN OR measured or calculated creatinine
             clearance >= 50 mL/min

          -  Patients must have a Na, K, Cl, Ca, Mg, and HbA1c performed within 7 days prior to
             sub-study registration

          -  Patients must have Zubrod performance status of 0-1 documented within 28 days prior to
             step 2 re-registration

          -  Patients must not have any grade III/IV cardiac disease as defined by the New York
             Heart Association Criteria (i.e., patients with cardiac disease resulting in marked
             limitation of physical activity or resulting in inability to carry on any physical
             activity without discomfort), unstable angina pectoris, and myocardial infarction
             within 6 months, or serious uncontrolled cardiac arrhythmia

          -  Patients must not have documented evidence of acute hepatitis or have an active or
             uncontrolled infection

          -  Patients with a known history of human immunodeficiency virus (HIV) seropositivity:

               -  Must have undetectable viral load using standard HIV assays in clinical practice

               -  Must have cluster of differentiation (CD)4 count >= 400/mcL

               -  Must not require prophylaxis for any opportunistic infections (i.e., fungal,
                  mycobacterium avium complex [mAC], or pneumocystis pneumonia [PCP] prophylaxis)

               -  Must not be newly diagnosed within 12 months prior to re-registration

          -  Pre-study history and physical exam must be obtained within 28 days prior to
             re-registration

          -  No other prior malignancy is allowed except for the following: adequately treated
             basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated
             stage I or II cancer from which the patient is currently in complete remission, or any
             other cancer from which the patient has been disease free for five years

          -  Patients must not be pregnant or nursing; women/men of reproductive potential must
             have agreed to use an effective contraceptive method; a woman is considered to be of
             ""reproductive potential"" if she has had menses at any time in the preceding 12
             consecutive months; in addition to routine contraceptive methods, ""effective
             contraception"" also includes heterosexual celibacy and surgery intended to prevent
             pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy,
             bilateral oophorectomy or bilateral tubal ligation; however, if at any point a
             previously celibate patient chooses to become heterosexually active during the time
             period for use of contraceptive measures outlined in the protocol, he/she is
             responsible for beginning contraceptive measures

          -  As a part of the Oncology Patient Enrollment Network (OPEN) registration process the
             treating institution's identity is provided in order to ensure that the current
             (within 365 days) date of institutional review board approval for this study has been
             entered in the system

          -  Patients with impaired decision-making capacity are eligible as long as their
             neurological or psychological condition does not preclude their safe participation in
             the study (e.g., tracking pill consumption and reporting adverse events to the
             investigator)

          -  Patients must be informed of the investigational nature of this study and must sign
             and give written informed consent in accordance with institutional and federal
             guidelines
      "
NCT04372927,terminated,"
    terminated due to slow accrual
  ",0,phase 2,"['locally advanced lung non-small cell carcinoma', 'stage iii lung cancer ajcc v8', 'stage iiia lung cancer ajcc v8', 'stage iiib lung cancer ajcc v8', 'stage iiic lung cancer ajcc v8']","[""['D02.20', 'D02.21', 'D02.22']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['cisplatin', 'etoposide', 'pemetrexed']","['N.N.Cl[Pt]Cl', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Histologically or cytologically documented non-small cell lung cancer (NSCLC)

          -  Stage III NSCLC according to American Joint Committee on Cancer (AJCC) staging version
             (v)8

          -  At least one mediastinal site of disease that is discontiguous from all other visible
             sites of disease and can be excluded from primary tumor site radiation (i.e. at least
             10 mm separation between tumors)

          -  A maximum of 20 patients with bulky mediastinal disease will be allowed on this trial,
             defined as at least one contiguous mediastinal mass with minimum diameter > 2 cm, that
             is not contiguous with the primary tumor (and therefore would not be irradiated during
             radiation to the primary tumor)

          -  No surgery for lung cancer for at least 3 years

          -  No other malignancies for at least 3 years, excluding low grade or non-invasive
             malignancies such as skin cancers, prostate cancers, and ductal breast carcinoma in
             situ (DCIS)

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Age >= 18 years at time of study entry

          -  Life expectancy of >= at least 3 months

          -  Body weight > 30 kg

          -  Hemoglobin >= 9.0 g/dL

          -  Absolute neutrophil count (ANC) 1.5 (or 1.0) x (>= 1500 per mm^3)

          -  Platelet count >= 100,000 per mm^3

          -  Serum bilirubin =< 1.5 x institutional upper limit of normal (ULN). This will not
             apply to patients with confirmed Gilbert's syndrome (persistent or recurrent
             hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or
             hepatic pathology), who will be allowed only in consultation with their physician

          -  Aspartate transaminase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine
             transferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x
             institutional upper limit of normal unless liver metastases are present, in which case
             it must be =< 5 x upper limit of normal (ULN)

          -  Measured creatinine clearance (CL) > 60 mL/min or calculated creatinine CL > 40 mL/min
             by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine
             collection for determination of creatinine clearance

          -  Capable of giving signed informed consent which includes compliance with the
             requirements and restrictions listed in the informed consent form (ICF) and in this
             protocol. Written informed consent and any locally required authorization (eg, Health
             Insurance Portability and Accountability Act) obtained from the patient/legal
             representative prior to performing any protocol-related procedures, including
             screening evaluations

          -  Evidence of post-menopausal status or negative urinary or serum pregnancy test for
             female pre-menopausal patients. Women will be considered post-menopausal if they have
             been amenorrheic for 12 months without an alternative medical cause. The following
             age-specific requirements apply:

               -  Women < 50 years of age would be considered post-menopausal if they have been
                  amenorrheic for 12 months or more following cessation of exogenous hormonal
                  treatments and if they have luteinizing hormone and follicle-stimulating hormone
                  levels in the post-menopausal range for the institution or underwent surgical
                  sterilization (bilateral oophorectomy or hysterectomy)

               -  Women >= 50 years of age would be considered post-menopausal if they have been
                  amenorrheic for 12 months or more following cessation of all exogenous hormonal
                  treatments, had radiation-induced menopause with last menses > 1 year ago, had
                  chemotherapy-induced menopause with last menses > 1 year ago, or underwent
                  surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or
                  hysterectomy)

          -  Patient is willing and able to comply with the protocol for the duration of the study
             including undergoing treatment and scheduled visits and examinations including follow
             up

        Exclusion Criteria:

          -  Prior anti-CTLA-4, PD-1 or PD-L1 antibodies including durvalumab

          -  Prior chemotherapy in the past 3 years from consent

          -  Any unresolved toxicity National Cancer Institute (NCI) CTCAE grade >= 2 from previous
             anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values
             defined in the inclusion criteria

               -  Patients with grade >= 2 neuropathy will be evaluated on a case-by-case basis
                  after consultation with the study physician

               -  Patients with irreversible toxicity not reasonably expected to be exacerbated by
                  treatment with durvalumab may be included only after consultation with the study
                  physician

          -  Prior thoracic radiation that would preclude curative-intent radiation dose as
             outlined in this study

          -  Concurrent enrolment in another clinical study, unless it is an observational
             (non-interventional) clinical study or during the follow-up period of an
             interventional study

          -  History of allogenic organ transplantation

          -  Active or prior documented autoimmune or inflammatory disorders (including
             inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with
             the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome,
             or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid
             arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this
             criterion:

               -  Patients with vitiligo or alopecia

               -  Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on
                  hormone replacement

               -  Any chronic skin condition that does not require systemic therapy

               -  Patients without active disease in the last 5 years may be included but only
                  after consultation with the study physician

               -  Patients with celiac disease controlled by diet alone

          -  Uncontrolled intercurrent illness, including but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable
             angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic
             gastrointestinal conditions associated with diarrhea, or psychiatric illness/social
             situations that would limit compliance with study requirement, substantially increase
             risk of incurring adverse events (AEs) or compromise the ability of the patient to
             give written informed consent

          -  History of leptomeningeal carcinomatosis

          -  History of active primary immunodeficiency

          -  Active infection including tuberculosis (clinical evaluation that includes clinical
             history, physical examination and radiographic findings, and tuberculosis (TB) testing
             in line with local practice), hepatitis B (known positive hepatitis B virus [HBV]
             surface antigen [HBsAg] result), hepatitis C. Patients with a past or resolved HBV
             infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence
             of HBsAg) are eligible. Patients positive for hepatitis C (hepatitis C virus [HCV])
             antibody are eligible only if polymerase chain reaction is negative for HCV
             ribonucleic acid (RNA)

          -  Current or prior use of immunosuppressive medication within 14 days before the first
             dose of durvalumab. The following are exceptions to this criterion:

               -  Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra
                  articular injection)

               -  Systemic corticosteroids at physiologic doses not to exceed <<10 mg/day>> of
                  prednisone or its equivalent

               -  Steroids as premedication for hypersensitivity reactions (e.g., computed
                  tomography [CT] scan premedication)

          -  Receipt of live attenuated vaccine within 30 days prior to the first dose of
             investigational product (IP). Note: Patients, if enrolled, should not receive live
             vaccine whilst receiving IP and up to 30 days after the last dose of IP

          -  Female patients who are pregnant or breastfeeding or male or female patients of
             reproductive potential who are not willing to employ effective birth control from
             screening to 90 days after the last dose of durvalumab monotherapy

          -  Known allergy or hypersensitivity to any of the study drugs or any of the study drug
             excipients
      "
NCT02486601,unknown status,,1,phase 2,['cancer of stomach'],"[""['D13.1', 'C16.9', 'C16.1', 'C16.2', 'D37.1', 'C16.8', 'C16.5']""]","['nab-paclitaxel', 'folfox']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Signed and dated informed consent, and willing and able to comply with protocol
             requirements,

          -  Histologically or cytologically proven adenocarcinoma of the low oesophagus or of the
             stomach, (from 1/3 inferior of the oesophagus to pylorus)

          -  HER2 negative tumors

          -  Localized and operable disease confirmed (stage I-III),

          -  No prior therapy for localized disease ,

          -  Age ≥18 years,

          -  Performance status (PS) 0-2,

          -  Haematological status: neutrophils (ANC) > 2.0x109/L; platelets >100x109/L;
             haemoglobin ≥9g/dL,

          -  Adequate renal function: serum creatinine level <150µM and creatinine clearance test >
             30mL/min,

          -  Adequate liver function: AST (SGOT) and ALT (SGPT) ≤2.5xULN (Upper Limit of Normal)

          -  Total bilirubin ≤1.5 x ULN,

          -  Albumin ≥25g/L

          -  Baseline evaluations performed before inclusion: clinical and blood evaluations no
             more than 2 weeks (14 days) prior to inclusion, tumor assessment (CT-scan, evaluation
             of non-measurable lesions) no more than 3 weeks (21 days) prior to inclusion,

          -  Female patients must be surgically sterile, or be postmenopausal, or must commit to
             using reliable and appropriate methods of contraception during the study and during at
             least six months after the end of study treatment (when applicable). All female
             patients with reproductive potential must have a negative pregnancy test (β HCG)
             within 72 hours days prior to starting nab-paclitaxel neo-adjuvant and adjuvant
             treatment. Breastfeeding is not allowed. Male patients must agree to use effective
             contraception in addition to having their partner use a contraceptive method as well
             during the trial and during at least six months after the end of the study treatment,

          -  Registration in a national health care system (CMU included for France).

        Exclusion Criteria:

          -  Metastatic disease (stage IV)

          -  Non operable primary tumor

          -  Patient using warfarin,

          -  Uncontrolled hypercalcemia (corrected serum calcium > 2.55 mmol/l),

          -  Pre-existing permanent neuropathy (NCI grade ≥2),

          -  Known dihydropyrimidine dehydrogenase (DPD) deficiency,

          -  Concomitant unplanned antitumor therapy (e.g. chemotherapy, molecular targeted
             therapy, immunotherapy),

          -  Treatment with any other investigational medicinal product within 28 days prior to
             study entry,

          -  Other serious and uncontrolled non-malignant disease (eg. active infection requiring
             systemic therapy, coronary stenting or myocardial infarction or stroke in the past 6
             months),

          -  Known or historical active infection with HIV, or known active infection untreated
             with hepatitis B or hepatitis C.

          -  Other concomitant or previous malignancy, except: i/ adequately treated in-situ
             carcinoma of the uterine cervix, ii/ basal or squamous cell carcinoma of the skin,
             iii/ cancer in complete remission for >5 years,

          -  Patients with known allergy to any excipient of study drugs,

          -  Concomitant administration of live, attenuated virus vaccine such as yellow fever
             vaccine and concomitant administration of prophylactic phenytoin

          -  Patient with any medical or psychological condition, deemed by the investigator to
             likely interfere with patient's ability to sign informed consent or cooperate and
             participate in the study, including tutelage or guardianship.
      "
NCT02481050,completed,,1,phase 2,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]",['eribulin mesylate'],['Status: 503'],"
        Inclusion Criteria:

          1. Histological or cytological adenocarcinoma of the breast.

          2. Females, aged greater than or equal to 18 years at time of informed consent.

          3. HER2-negative as determined by fluorescence in situ hybridization (FISH); or 0 or 1+
             by immunohistochemistry (IHC) staining .

          4. Participants with metastatic breast cancer who have received at least 2 and not more
             than 5 prior chemotherapy regimens.

          5. Participants with at least one measurable lesion greater than or equal to 10 mm in the
             longest diameter for a non-lymph node or greater than or equal to 15 mm in the
             short-axis diameter for a lymph node as determined by investigator using Response
             Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1).

          6. Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to 2.

          7. Life expectancy of greater than or equal to 3 months.

          8. Any neuropathy must recover to Grade less than or equal to 2 prior to enrollment.

          9. Adequate renal function as evidenced by serum creatinine less than or equal to 1.5
             mg/dL or calculated creatinine clearance greater than or equal to 50 mL/minute
             according to the Cockcroft and Gault formula.

         10. Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) greater
             than or equal to 1.5 X 10^9/L, hemoglobin greater than or equal to 10.0 g/dL (can be
             corrected by growth factor or transfusion), and platelet count greater than or equal
             to 100 X 10^9/L.

         11. Adequate liver function as evidenced by total bilirubin less than or equal to 1.5 X
             upper limit of normal (ULN), alkaline phosphatase, alanine aminotransferase (ALT), and
             aspartate aminotransferase (AST) less than or equal to 3 X ULN (less than or equal to
             5 X ULN in the case of liver metastases), unless there are bone metastases, in which
             case liver specific alkaline phosphatase must be separated from the total and used to
             assess the liver function instead of the total alkaline phosphatase.

         12. Are willing and able to comply with all aspects of the treatment protocol.

         13. Provide written informed consent.

        Exclusion Criteria:

          1. Previous treatment with eribulin.

          2. Hypersensitivity to eribulin/excipients or halichondrin B or known intolerance of
             eribulin.

          3. Current enrollment in another clinical study or used of any investigational drug or
             device within the past 28 days preceding informed consent.

          4. Previous treatment with chemotherapy, radiation, biological, or targeted therapy
             within the last 2 weeks or 5 X half-life, whichever is longer, preceding informed
             consent.

          5. Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a
             positive beta-human chorionic gonadotropin ([B-hCG] test). A separate Baseline
             assessment is required if a negative screening pregnancy test was obtained more than
             72 hours before the first dose of study drug.

          6. All females will be considered to be of childbearing potential unless they are
             postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age
             group, and without other known or suspected cause) or have been sterilized surgically
             (ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with
             surgery at least 1 month before dosing).

          7. Females of childbearing potential who had unprotected sexual intercourse within 30
             days before study entry and who do not agree to use a highly effective method of
             contraception (eg, total abstinence, an intrauterine device, a double-barrier method
             [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral
             contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout
             the entire study period or for 28 days after study drug discontinuation.

             Females who are currently abstinent and do not agree to use a double barrier method as
             described above or to refrain from sexual activity during the study period or for 28
             days after study drug discontinuation.

             Females who are using hormonal contraceptives but are not on a stable dose of the same
             hormonal contraceptive product for at least 4 weeks before dosing and who do not agree
             to use the same contraceptive during the study or for 28 days after study drug
             discontinuation.

          8. Known central nervous system (CNS) disease, except for those participants with treated
             brain metastasis who are stable for at least 1 month with no evidence of progression
             or hemorrhage after treatment and no ongoing requirement for corticosteroids.

          9. Known human immunodeficiency virus (HIV) positive.

         10. Existing anticancer, therapy-related toxicities of Grades greater than or equal to 2,
             with the exception of alopecia.

         11. A prior malignancy other than carcinoma in situ of the cervix, or nonmelanoma skin
             cancer, unless the prior malignancy was diagnosed and definitively treated greater
             than 5 years previously with no subsequent evidence of recurrence.

         12. Clinically significant cardiovascular impairment (congestive heart failure of New York
             Heart Association [NYHA] Classification greater than II, unstable angina, myocardial
             infarction within the past 6 months, or serious cardiac arrhythmia).

         13. Clinically significant ECG abnormality, including a marked Baseline prolonged QT/QTc
             interval (ie, a repeated demonstration of a QTc interval greater than 500
             milliseconds).

         14. Pulmonary lymphangitic involvement that resulted in pulmonary dysfunction requiring
             active treatment, including the use of oxygen.

         15. History of concomitant medical condition(s) that, in the opinion of the investigator,
             would compromise the participant's ability to safely complete the study.

         16. The investigator's belief that the participant is medically unfit to receive eribulin
             or unsuitable for any other reason.
      "
NCT02489695,completed,,1,phase 2,['papillary renal cell carcinoma'],"[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]",['axitinib'],['CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4'],"
        Inclusion Criteria:

          1. Age ≥ 18 years.

          2. Metastatic or locally advanced (inoperable) pure type 1 or 2 or mixed PRCC,
             histologically confirmed by central review: relevant slides [and blocks if available]
             with the initial histology report must be sent for central reading before confirmation
             of inclusion.

          3. No prior systemic treatment for metastatic renal cancer (chemotherapy, immunotherapy,
             anti-angiogenic drugs, or treatment under evaluation).

          4. At least one measurable site of disease as defined by RECIST 1.1 criteria.

          5. ECOG performance status of 0, 1.

          6. No toxicity > 1 according to the National Cancer Institute (NCI) Common Terminology
             Criteria for Adverse Events (CTCAE version 4.0)

          7. In case of prior radiation therapy, discontinuation of irradiation for at least 4
             weeks before first dose of study treatment. This period can be reduced to at least 1
             week in case of radiotherapy in a limited field (< 10% of the whole body) while no
             side effects grade ≥ 2 is expected and keeping at least one site for evaluation.

          8. Adequate bone marrow, liver and renal function, as defined below:

               -  Absolute neutrophil count ≥ 1.5 G/L, platelet count ≥ 100 G/L, and hemoglobin ≥ 9
                  g/dL),

               -  AST/ALT ≤ 3 x upper limit of normal (ULN) (or ≤ 5.0 x ULN if liver metastasis)
                  and total bilirubin ≤ 1.5 x ULN (≤ 2.5 x ULN if liver metastases),

               -  Serum creatinine ≤ 2.0 x ULN or creatinine clearance ≥ 50 mL/min according to
                  Cockroft formula or MDRD formula for patients older than 65 years,

          9. Absence of proteinuria confirmed by urinary dipstick test. If the dipstick test is ≥
             2+, proteinuria will be quantitated on a complete 24h urine sample (< 1 g/L of
             protein/24h sample).

         10. Adequate contraceptive methods for fertile female subjects for the whole duration of
             the study and for 7 days after the last dose of study drug.

             Note: Oral, implantable, or injectable contraceptives may be affected by cytochrome
             P450 interactions, and are not considered effective for this study.

         11. Covered by a medical insurance, in countries where applicable.

         12. Written informed consent before any study specific procedures or assessments.

        Exclusion Criteria:

          1. Prior TKI treatment in adjuvant situation for renal cancer.

          2. Significant cardiovascular disease including:

               -  Disorder of left ventricular function with a LVEF < 50%,

               -  Uncontrolled arterial hypertension under adapted medication: systolic blood
                  pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg or both despite
                  appropriate therapy, or patients under 3 antihypertensive therapies at screening,

               -  Myocardial infarction, severe angina, or unstable angina within 6 months prior to
                  inclusion,

               -  History of serious ventricular arrhythmia (ie ventricular tachycardia or
                  ventricular fibrillation),

               -  Cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial
                  fibrillation that is well controlled with anti-arrhythmic medication),

               -  Coronary or peripheral artery bypass graft within 6 months of screening.

          3. Presence of brain metastases on MRI or CT-scan performed within 28 days prior to
             inclusion. Patients with a history of brain metastases treated by surgery or
             stereotactic surgery, with normal brain MRI or CT-scan are allowed to participate.

          4. Major surgical procedure, open biopsy, or serious none healing wound within 28 days
             prior to inclusion.

          5. Any active acute or chronic or uncontrolled infection/disorder that impair the ability
             to evaluate the patient or the ability for the patient to complete the study.

          6. Prior history of other malignancies other than PRCC (except for curatively treated
             basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the uterine
             cervix) unless the subjects has been free of the disease for at least 3 years.

          7. Inability to swallow oral medications, or presence of active inflammatory bowel
             disease, partial or complete bowel obstruction or chronic diarrhea.

          8. Patient included in another clinical trial, except for supportive care trials.

          9. Psychological, familial, sociological, or geographical conditions that would limit
             compliance with study protocol requirements.

         10. Pregnant or breastfeeding women (mandatory negative serum or urinary pregnancy test at
             study entry for all women of childbearing potential).
      "
NCT02485834,terminated,"
    poor accrual
  ",0,phase 2,"['adenocarcinoma of the gastroesophageal junction', 'gastric adenocarcinoma', 'gastric cancer']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['5-fu', 'capecitabine', 'docetaxel', 'irinotecan']","['Status: 503', 'CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O', 'CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7']","
        Pre-Registration Eligibility Criteria

          1. Documentation of Disease

             1.1 Histologically confirmed adenocarcinoma of the stomach or gastroesophageal
             junction (Siewert type II, III)

             1.2 Pre-treatment clinical stage of T3-4N any M0 or T any N positive M0 as determined
             by laparoscopy, CT scan (or PET/CT), or endoscopic ultrasound (histologic confirmation
             of lymph involvement is not required). Therefore, patients can have measurable or
             non-measurable disease.

             1.3 Patients with T1-2N0M0 tumors or patients with metastatic disease are NOT
             eligible.

          2. Patients must be eligible for curative intent surgical resection.

          3. FDG Avid malignancy - Patients must have an FDG avid tumor(s). FDG avid tumors are
             defined as a primary tumor with an increased uptake in the region of the tumor that
             has an SUV of > 5.0 or a tumor:liver SUV ratio of > 1.5.

          4. No prior history of congestive heart failure - NYHA class I to IV or known DPD
             deficiency

          5. No current grade 2, 3, or 4 of neuropathy.

          6. No known hypersensitivity to epirubicin, oxaliplatin and cisplatin, capecitabine and
             5-flurouracil, docetaxel or irinotecan.

          7. Not pregnant and not nursing, because this study involves an agent that has known
             genotoxic, mutagenic and teratogenic effects.

             7.1 Therefore, for women of childbearing potential only, a negative serum pregnancy
             test pregnancy test done ≤ 7 days prior to pre-registration is required.

             7.2 A female of childbearing potential is a sexually mature female who: 1) has not
             undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally
             postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in
             the preceding 12 consecutive months).

          8. Age ≥ 18 years

          9. ECOG Performance Status 0 or 1

         10. Required Initial Laboratory Values:

               -  Absolute Neutrophil Count (ANC) ≥ 1,500/mm^3

               -  Platelet Count ≥ 100,000/mm^3

               -  Creatinine ≤ 1.5 x upper limit of normal (ULN)

               -  Total Bilirubin ≤ 1.5 x ULN, except in patients with Gilbert's disease

               -  AST and ALT ≤ 2.5 x ULN

               -  Alkaline Phosphatase ≤ 2.5 x ULN

        Registration Eligibility Criteria to Treatment Arms A or B

          1. Patient must continue to be eligible for curative intent surgical resection.

          2. Disease Progression: FDG avid malignancy that is classified as an FDG PET non-
             responder. PET non-responders are defined as having < 35% reduction in the FDG uptake
             of the primary tumor when compared to baseline.

          3. Concomitant Medications -

             3.1 Chronic concomitant treatment with strong inhibitors of CYP3A4 is not allowed on
             this trial. Patients on strong CYP3A4 inhibitors must discontinue the drug 14 days
             prior to the start of study treatment.

             3.2 Chronic concomitant treatment with strong CYP3A4 inducers is not allowed. Patients
             must discontinue the drug 14 days prior to the start of study treatment.

          4. Patient must have received only one cycle of the following regimens during the
             pre-registration time period and no other therapy for gastric or gastroesophageal
             junction cancer:

               -  Epirubicin, Oxaliplatin, and Capecitabine

               -  Epirubicin, Oxaliplatin, and Fluorouracil

               -  Epirubicin, Cisplatin, and Capecitabine

               -  Epirubicin, Cisplatin, and Fluorouracil

          5. Toxicity recovery should include the following:

               -  Grade ≤ 2 neuropathy

               -  Grade ≤ 2 diarrhea

               -  Grade ≤ 2 mucositis

          6. Pre-registration chemotherapy given within 42 days of treatment (treatment meaning
             surgery if Arm A, chemotherapy if Arm B)
      "
NCT02487277,terminated,"
    low accrual
  ",0,phase 2,['adenocarcinoma'],"[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['pegph20', 'gemcitabine', 'nab-paclitaxel']","['Status: 503', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C']","
        Inclusion Criteria:

          -  Greater than or equal to 18 years old

          -  Histologically confirmed pancreatic adenocarcinoma

          -  Borderline resectable disease

          -  Performance status of Eastern Cooperative Oncology Group (ECOG) of 0-1

          -  Therapy naïve

          -  Evaluable disease with either:

          -  RECIST-defined measurable disease

          -  An elevated serum CA19-9 >100 u/ml

          -  Adequate organ function including:

          -  Bone marrow: Absolute Neutrophil Count (ANC) ≥1500/mm3, platelets ≥100,000/mm3 and
             hemoglobin ≥ 9 g/dL

          -  Hepatic: Serum total bilirubin ≤1.5 x upper limit of normal (ULN), alanine
             aminotransferase (ALT)/ serum glutamic-pyruvic transaminase (SGPT) and aspartate
             aminotransferase (AST)/ serum glutamic-oxaloacetic transaminase (SGOT) ≤ 2.5 x ULN.

          -  Renal: Serum creatinine (sCr) ≤ 1.5 x ULN, or creatinine clearance (Ccr) ≥ 40 mL/min
             as calculated by the Modified Cockcroft-Gault formula.

          -  Peripheral neuropathy < grade 2

          -  Alkaline phosphatase ≤ 2 times the ULN unless bone metastasis is present in the
             absence of liver metastasis

        Exclusion Criteria:

          -  Age younger than 18 years old

          -  Locally advanced or metastatic disease

          -  Known allergy to hyaluronidase

          -  Contraindications to prophylactic dose low molecular weight heparin (LMWH) , including

          -  Patients with recent gastrointestinal bleeding

          -  History of heparin induce thrombocytopenia on LMWH

          -  Subjects with previous severe hemorrhagic events on LMWH

          -  Known contraindications to heparin including:

          -  Recent central nervous system bleed, intracranial or spinal lesion at high risk for
             bleeding

          -  Active bleeding (major): more than 2 units transfused in 24 hours

          -  Spinal anesthesia/lumbar puncture within the past month

          -  Chronic, clinically significant measurable bleeding > 48 hours

          -  Severe platelet dysfunction (uremia, medications, dysplastic hematopoiesis)

          -  Recent major operation at high risk for bleeding

          -  Underlying hemorrhagic coagulopathy High risk for falls (head trauma)

          -  Presence of metal biliary stents (plastic biliary stents are not an exclusion)

          -  Known status of HIV which is not well-controlled at the time of study eligibility

          -  Untreated Hepatitis B infection

          -  Active infection or antibiotics within 48 hours prior to study

          -  Currently active second primary malignancy or history of malignancy less than 5 years
             prior to the time of study eligibility (Patients with history of skin cancers
             excluding melanoma will be eligible for participation).

          -  Serious medical comorbidities such as New York Heart Association Class III/IV cardiac
             disease, uncontrolled cardiac arrhythmias, myocardial infarction over the past 12
             months.

          -  Patients with aneurysm clips, ear implants, spinal nerve stimulators, pacemaker,
             shrapnel or any other metal in their body (contraindication for MRI scans)

          -  Known, existing uncontrolled coagulopathy. Patients who have had a venous
             thromboembolic event (e.g., pulmonary embolism or deep vein thrombosis) requiring
             anticoagulation are eligible IF: they are appropriately anticoagulated and have not
             had a Grade 2 or greater bleeding episode in the 3 weeks before Day 1.

          -  Current use of warfarin (patients will be eligible if warfarin is discontinued and
             low-molecular weight heparin is used instead).

          -  Intolerance to dexamethasone

          -  Prior history of cerebrovascular accident or transient ischemic attack, or
             pre-existing carotid artery disease.

          -  Known pregnancy, nursing women or positive pregnancy test.

          -  Any condition that would preclude informed consent, consistent follow-up and
             compliance for the study participation.
      "
NCT02115373,completed,,1,phase 1/phase 2,"['carcinoma, hepatocellular']","[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]","['tepotinib', 'tepotinib']","['Status: 503', 'CN1CCC(CC1)COC2=CN=C(N=C2)C3=CC=CC(=C3)CN4C(=O)C=CC(=N4)C5=CC=CC(=C5)C#N']","
        Inclusion Criteria:

          -  Histologically confirmed HCC

          -  Child Pugh Class A liver function score

          -  For Phase 2 only: MET+ status

          -  Male or female, 18 years of age or older

          -  Measurable disease in accordance with Response Evaluation Criteria in Solid Tumors
             (RECIST) version 1.1

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1 (inclusive)

          -  Availability of a pretreatment tumor biopsy (excluding fine needle aspiration and
             cytology samples) taken after the subject has discontinued sorafenib and within 28
             days before the day of first dosing with MSC2156119J. From the pretreatment biopsy
             either a formalin-fixed (formalin fixation is mandatory) paraffin-embedded block with
             tumor tissue (preferred) or at least 15 unstained slides must be sent to the central
             laboratory prior to enrollment. An associated pathology report must also be sent with
             the sample

          -  Previously treated with sorafenib for greater than or equal to 4 weeks and
             discontinued sorafenib treatment at least 14 days prior to Day 1 due to either
             intolerance or radiographic progression

          -  Signed and dated informed consent indicating that the subject (or legally acceptable
             representative if applicable by local laws) has been informed of all the pertinent
             aspects of the trial prior to enrollment

          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory
             tests and other trial procedures

          -  Life expectancy of at least 3 months as judged by the investigator

        Exclusion Criteria:

          -  Prior systemic anticancer treatment for advanced HCC (except for sorafenib as
             described in the inclusion criteria)

          -  Prior treatment with any agent targeting the hepatocyte growth factor (HGF)/c-Met
             pathway

          -  Local-regional therapy within 4 weeks before Day 1

          -  Impaired cardiac function

          -  Other protocol defined exclusion criteria could apply
      "
NCT02111863,terminated,"
    study terminated due to low accrual and change in research focus.
  ",0,phase 2,"['melanoma', 'skin cancer']","[""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']"", ""['C79.2', 'C44.500', 'C44.90', 'D23.9', 'D48.5', 'C44.00', 'C44.301']""]","['aldesleukin', 'fludarabine', 'cyclophosphamide']","['Status: 503', 'C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N', 'C1CNP(=O)(OC1)N(CCCl)CCCl']","
        -INCLUSION CRITERIA:

          1. Measurable metastatic melanoma with at least one lesion that is resectable for tumor
             infiltrating lymphocytes (TIL) generation. The lesion must be at least 1 cm in
             diameter that can be surgically removed with minimal morbidity (defined as any
             operation for which expected hospitalization <less than or equal to days).

          2. Confirmation of diagnosis of metastatic melanoma by the Laboratory of Pathology of the
             National Cancer Institute (NCI).

          3. Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and
             asymptomatic are eligible. Lesions that have been treated with stereotactic
             radiosurgery must be clinically stable for 1 month after treatment for the patient to
             be eligible.

          4. Greater than or equal to 18 years of age and less than or equal to age 70.

          5. Able to understand and sign the Informed Consent Document

          6. Willing to sign a durable power of attorney

          7. Clinical performance status of Easter Cooperative Oncology Group (ECOG) 0 or 1

          8. Oxygen saturation of greater than or equal to 90% on room air

          9. Life expectancy of greater than three months

         10. Patients of both genders must be willing to practice birth control from the time of
             enrollment on this study and for up to four months after treatment.

         11. Serology:

               -  Seronegative for human immunodeficiency virus (HIV) antibody. (The experimental
                  treatment being evaluated in this protocol depends on an intact immune system.
                  Patients who are HIV seropositive can have decreased immune-competence and thus
                  be less responsive to the experimental treatment and more susceptible to its
                  toxicities.)

               -  Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody.
                  If hepatitis C antibody test is positive, then patient must be tested for the
                  presence of antigen by reverse transcription polymerase chain reaction (RT-PCR)
                  and be hepatitis C virus ribonucleic acid (HCV RNA) negative.

         12. Women of child-bearing potential must have a negative pregnancy test because of the
             potentially dangerous effects of the treatment on the fetus.

         13. Hematology

               -  Absolute neutrophil count greater than 1000/mm^3 without the support of
                  filgrastim

               -  White blood cell (WBC) greater than or equal to 3000/mm^3

               -  Platelet count greater than or equal to 100,000/mm^3

               -  Hemoglobin > 8.0 g/dl

         14. Chemistry:

               -  Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less than
                  or equal to 2.5 times the upper limit of normal

               -  Serum creatinine less than or equal to 1.6 mg/dl

               -  Total bilirubin less than or equal to 2.0 mg/dl, except in patients with Gilberts
                  Syndrome who must have a total bilirubin less than 3.0 mg/dl.

         15. More than four weeks must have elapsed since any prior systemic therapy at the time
             the patient receives the preparative regimen, and patients toxicities must have
             recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo).
             Patients must have progressing disease after prior treatment.

             Note: Patients may have undergone minor surgical procedures within the past 3 weeks,
             as long as all toxicities have recovered to grade 1 or less or as specified in the
             eligibility criteria in Section 2.1.1.

         16. Six weeks must have elapsed from the time of any antibody therapy that could affect an
             anti cancer immune response, including anti-cytotoxic T-lymphocyte-associated protein
             4 (CTLA4) antibody therapy at the time the patient receives the preparative regimen to
             allow antibody levels to decline.

        Note: Patients who have previously received ipilimumab and have documented gastrointestinal
        (GI) toxicity must have a normal colonoscopy with normal colonic biopsies.

        EXCLUSION CRITERIA:

          1. Prior treatment with an anti-4-1BB antibody.

          2. Women of child-bearing potential who are pregnant or breastfeeding because of the
             potentially dangerous effects of the treatment on the fetus or infant.

          3. Active systemic infections, coagulation disorders or other active major medical
             illnesses of the cardiovascular, respiratory or immune system, as evidenced by a
             positive stress thallium or comparable test, myocardial infarction, cardiac
             arrhythmias, obstructive or restrictive pulmonary disease.

          4. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency
             Disease).

          5. Concurrent opportunistic infections (The experimental treatment being evaluated in
             this protocol depends on an intact immune system. Patients who have decreased immune
             competence may be less responsive to the experimental treatment and more susceptible
             to its toxicities).

          6. Concurrent systemic steroid therapy.

          7. History of severe immediate hypersensitivity reaction to any of the agents used in
             this study.

          8. History of coronary revascularization or ischemic symptoms.

          9. Documented left ventricular ejection fraction (LVEF) of less than or equal to 45%,
             testing is required in patients with:

               -  Clinically significant atrial and/or ventricular arrhythmias including but not
                  limited to: atrial fibrillation, ventricular tachycardia, second or third degree
                  heart block

               -  Age greater than or equal to 60 years old
      "
NCT02117258,completed,,0,phase 2,['metastatic pancreatic adenocarcinoma'],"[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['z-360', 'placebo']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  1. Subjects with histological or cytological evidence of metastatic Pancreatic
             Adenocarcinoma, Measurable disease or non-measurable disease by Response Evaluation
             Criteria in Solid Tumors (RECIST) version criteria

          -  2. Subjects with a life expectancy of at least 12 weeks,

          -  3. Subjects with an Eastern cooperative oncology group performance status (ECOG PS) of
             0, 1 or 2,

          -  4. Subjects with the following adequate organ functions:

               -  White blood cell count ≥3,000/μL (or absolute neutrophil count ≥1,500/μL) and ≤
                  12,000/μL ,

               -  Platelet count ≥100.0 × 10^9/L,

               -  Hemoglobin ≥9.0 g/dL,

               -  Serum creatinine ≤1.5 × the upper limit normal (ULN),

               -  Total bilirubin ≤2.0 × ULN,

               -  Serum aspartate transaminase levels ≤3.0 × ULN (≤5.0 × ULN in presence of liver
                  metastases), and

               -  Serum alanine aminotransferase levels ≤3.0 × ULN (≤5.0 × ULN in presence of liver
                  metastases).

        Exclusion Criteria:

          -  Subjects received the following previous therapies for Pancreatic Adenocarcinoma:

               -  Surgery within the 4 weeks prior to randomization,

               -  Radiation and chemoradiation within the 12 weeks prior to randomization,

               -  Radiation for pain relief within the 4 weeks prior to randomization,

               -  Gemcitabine used as a neoadjuvant or an adjuvant on surgery within the 24 weeks
                  prior to randomization,

               -  Chemotherapy except GEM used as an adjuvant on surgery within the 4 weeks prior
                  to randomization,

               -  Gemcitabine ≥600 mg/m^2 as sensitizer for chemoradiation,

               -  Gemcitabine <600 mg/m^2 as sensitizer for chemoradiation within the 12 weeks
                  prior to randomization,

               -  Gemcitabine used for systemic chemotherapy, or

               -  Systemic chemotherapies except GEM within the 4 weeks prior to randomization.
      "
NCT02119676,terminated,"
    substudy 1 was terminated for futility at interim analysis and substudy 2 was terminated per
    sponsor decision.
  ",0,phase 2,['crc (colorectal cancer)'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['ruxolitinib', 'regorafenib', 'placebo']","['C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3', 'Status: 503']","
        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the colon or rectum that
             is metastatic.

          -  Previous treatment with fluoropyrimidine-, oxaliplatin- and irinotecan- based
             chemotherapy, an anti-VEGF therapy (if no contraindication) and if KRAS wild type and
             no contraindication, an anti-EGFR therapy.

          -  Radiographically measurable or evaluable disease (per RECIST v1.1)

          -  Life expectancy of ≥ 12 weeks.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

          -  Three or more weeks have elapsed from the completion of previous treatment regimen and
             subjects must have recovered or be at a new stable baseline from any related
             toxicities.

          -  Prior radiotherapy to disease sites is allowed with certain protocol-defined
             restrictions.

        Exclusion Criteria:

          -  Prior treatment with regorafenib.

          -  Presence of active gastrointestinal disease or other condition that will interfere
             significantly with the absorption of drugs.

          -  Active peptic ulcer disease, inflammatory bowel disease (eg, ulcerative colitis,
             Crohn's disease), diverticulitis, or other gastrointestinal conditions with increased
             risk of perforation or gastrointestinal bleeding.

          -  Recent history (≤ 3 months) or ongoing partial or complete bowel obstruction unless
             due to disease under study and corrected with surgery.

          -  Blood pressure ≥ 140/90 mmHg.

          -  Active bleeding diathesis or history of any major bleeding (eg, requiring transfusion
             of red blood cells (RBCs), central nervous system (CNS) bleeding, or significant
             hemoptysis within 6 months of enrollment. Subjects with bleeding secondary to
             underlying disease (including gastrointestinal (GI) perforation or fistula) that has
             been corrected by surgery or alternative procedure may be included.

          -  Clinically significant cardiac disease including unstable angina, acute myocardial
             infarction within 6 months from Day 1 of study drug administration, New York Heart
             Association Class II, III, or IV congestive heart failure, and arrhythmia requiring
             therapy.
      "
NCT02119650,terminated,"
    the study was terminated as other related studies of ruxolitinib did not provide sufficient
    efficacy to warrant continuation.
  ",0,phase 2,['nsclc (non-small cell lung carcinoma)'],"[""['D02.20', 'D02.21', 'D02.22']""]","['ruxolitinib', 'placebo', 'pemetrexed', 'cisplatin']","['Status: 503', 'Status: 503', 'C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O', 'N.N.Cl[Pt]Cl']","
        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of nonsquamous NSCLC that is Stage
             IIIB Stage IV, or recurrent after prior definitive intervention (radiation, surgery,
             or chemoradiation therapy, with or without adjuvant or neoadjuvant chemotherapy).

          -  Radiographically measurable or evaluable disease.

          -  Life expectancy of at least 12 weeks.

          -  Tumor without activating driver mutations for which there is available therapy (eg,
             tumor without mutations in epidermal growth factor receptor or anaplastic lymphoma).

          -  An modified Glasgow Prognostic Score (mGPS) of 1 or 2 as defined below:

               -  Criteria:

                    -  C-reactive protein >10 mg/L AND albumin ≥35 g/L; Score = 1

                    -  C-reactive protein >10 mg L AND albumin <35 g/L; Score = 2

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

          -  Adequate renal, hepatic, and bone marrow function demonstrated by protocol-specified
             laboratory parameters at the screening visit.

        Exclusion Criteria:

          -  Squamous or mixed histology (eg, adenosquamous) NSCLC

          -  Previous systemic therapy for advanced or metastatic disease.

          -  Known active central nervous system (CNS) metastases.

          -  Current or previous other malignancy within 2 years of study entry, except cured basal
             or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial
             neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy
             without sponsor approval.

          -  Current uncontrolled cardiac disease such as angina or myocardial infarction,
             congestive heart failure including New York Heart Association functional
             classification of 3, or arrhythmia requiring treatment.

          -  Uncontrolled concomitant medical conditions, including, but not limited to, renal,
             hepatic, hematologic, gastrointestinal, endocrine, pulmonary, neurological, cerebral,
             or psychiatric diseases.
      "
NCT02112552,terminated,"
    low accrual
  ",0,phase 2,"['endometrial serous adenocarcinoma', 'stage iiia uterine corpus cancer', 'stage iiib uterine corpus cancer', 'stage iiic1 uterine corpus cancer', 'stage iiic2 uterine corpus cancer', 'stage iva uterine corpus cancer', 'stage ivb uterine corpus cancer']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C54.9', 'D26.1', 'C54.8']"", ""['C54.9', 'D26.1', 'C54.8']"", ""['C54.9', 'D26.1', 'C54.8']"", ""['C54.9', 'D26.1', 'C54.8']"", ""['C54.9', 'D26.1', 'C54.8']"", ""['C54.9', 'D26.1', 'C54.8']""]","['paclitaxel', 'carboplatin']","['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C', 'C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]']","
        Inclusion Criteria:

          -  Histological/cytologically documented primary International Federation of Gynecology
             and Obstetrics (FIGO) stage 3C1, 3C2, stage 4A, and 4B uterine serous carcinoma; in
             addition, certain stage 3A and B disease are also allowed

               -  Residual disease after primary surgery:

                    -  Eligible:

                         -  Stage 3A and B (pelvic, but confined to adnexa or vagina), residual
                            disease present

                         -  Stage 3CI (pelvic node positive)

                         -  Stage 3CII (para-aortic node positive)

                         -  Stage 4A (bladder or pelvic bowel)

                         -  Stage 4B (distant metastases [mets] including abdominal mets),
                            completely resected

                    -  Not eligible

                         -  Stage 3A and B (pelvic, but confined to adnexa or vagina), completely
                            resected

                         -  Stage 4B (distant mets including abdominal mets), residual disease
                            present

          -  All patients must have a procedure for determining diagnosis of high-risk uterine
             cancer (HRUC); minimum surgical intervention required is tissue biopsy (may be from
             endometrium), if significant clinical evidence exists to support a stage 3 or 4
             diagnosis; as per the discretion of the surgeon, complete surgical staging should
             include: total abdominal hysterectomy, bilateral salpingo-oophorectomy, peritoneal
             washings, omental biopsy and lymph node samplings; this is typically the standard
             unless the disease is bulky or the clinician feels the patient would be best served by
             chemotherapy and radiation therapy after histologic diagnosis is confirmed

          -  Eastern Cooperative Oncology Group (ECOG) performance status of =< 2

          -  Written voluntary informed consent

        Exclusion Criteria:

          -  Distant metastasis to the lung, bone or brain; typically, most stage 4 uterine
             papillary serous cancer (UPSC) is confined to the abdomen on presentation

          -  Serum glutamic oxaloacetic transaminase (SGOT) and/or serum glutamate pyruvate
             transaminase (SGPT) > 2.5 times the institutional upper limit of normal (ULN)

          -  Total serum bilirubin > 1.5 mg/dl

          -  Serum creatinine > 2.0 mg/dl

          -  Platelets < 100,000/mm^3

          -  Absolute neutrophil count (ANC) < 1500/mm^3

          -  Hemoglobin < 8.0 g/dl (the patient may be transfused prior to study entry)

          -  History of abdominal/pelvic radiation therapy

          -  Severe or uncontrolled, concurrent medical disease (e.g. uncontrolled diabetes,
             unstable angina, myocardial infarction within 6 months, congestive heart failure,
             etc.)

          -  Patients with dementia or altered mental status that would prohibit the giving and
             understanding of informed consent at the time of study entry
      "
NCT02114658,completed,,1,phase 2,['thyroid carcinoma'],"[""['D09.3']""]","['sorafenib (nexavar,bay43-9006)']",['Status: 503'],"
        Inclusion Criteria:

          -  Japanese patients with ATC (Anaplastic thyroid carcinoma) or locally advanced or
             metastatic MTC (medullary thyroid carcinoma)

          -  Not a candidate for surgery or radiotherapy with curative intent

          -  Histologically or cytologically confirmed ATC or MTC

          -  Measurable or non-measurable disease (but clinically evaluable) according to RECIST
             1.1.

          -  Age >= 18 years

          -  Adequate bone marrow, liver and renal function to be conducted within 14 days prior to
             treatment

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1

          -  Life expectancy of at least 12 weeks

        Exclusion Criteria:

          -  Histologic subtypes of thyroid cancer other than anaplastic or medullary carcinoma

          -  Prior anti-cancer treatment with tyrosine kinase inhibitors, monoclonal antibodies
             (licensed or investigational) that target VEGF or VEGF (vascular endothelial growth
             factor) receptors or other targeted agents

          -  Prior chemotherapy for thyroid cancer (only one regimen is allowed)

          -  Major surgery, open biopsy, or significant traumatic injury within 30 days prior to
             enrollment in the study.

          -  Subjects with tracheal, bronchial or esophageal infiltration with significant risk of
             bleeding but without having received local treatment prior to enrollment in the study
      "
NCT03733119,terminated,"
    slow accrual
  ",0,phase 2,['triple negative breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]",['akt/erk inhibitor onc201'],['Status: 503'],"
        Inclusion Criteria:

          -  Metastatic or unresectable TNBC (estrogen receptor [ER] < 10%, progesterone receptor
             [PR] < 10% and HER2 negative either by immunohistochemistry [IHC] or in situ
             hybridization method by American Society of Clinical Oncology [ASCO]-College of
             American Pathologists [CAP] guidelines). For patients with a previous tumor sample
             with positive ER, PR and/or HER2 results, if the most recent biopsy meets study
             criteria, they will be eligible.

          -  Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
             within 28 days prior to registration

          -  Written informed consent and Health Insurance Portability and Accountability Act
             (HIPAA) authorization for release of personal health information. NOTE: HIPAA
             authorization may be included in the informed consent or obtained separately

          -  Any number of prior lines of systemic therapy for metastatic disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1

          -  Prior cancer treatment, including radiotherapy, must be completed at least 14 days
             prior to registration and the subject must have recovered from all reversible acute
             toxic effects of the regimen to =< grade 1 or to baseline prior to initiation of that
             therapy. Grade 2 or higher exceptions include alopecia, up to grade 2 neuropathy, and
             other grade 2 AEs or lab values not constituting a safety risk in the opinion of the
             treating physician. This criteria does not apply to lab tests for normal organ and
             marrow function outlined below.

          -  No active central nervous system (CNS) metastatic disease; subjects with prior
             definitive treatment of their CNS disease by surgical resection, stereotactic body
             radiation therapy (SBRT) or whole-brain radiotherapy (WBRT) > 28 days ago will be
             eligible if asymptomatic and off systemic steroids

          -  Life expectancy of greater than 12 weeks

          -  Normal organ and marrow function as defined per protocol definitions

               -  Absolute neutrophil count (ANC) > 1.5 x 10^3/uL

               -  Platelet count >= 100 x 10^3/uL

               -  Hemoglobin >= 9 g/dL

               -  Total bilirubin < 1.5 x upper limit of normal (ULN)

               -  Aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT)
                  and alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT) ≤
                  2.5 x ULN if participant has liver metastases, ≤5x ULN.

               -  Creatinine < ULN (institutional normal)

          -  Females of childbearing potential must have a negative serum pregnancy test within 7
             days prior to registration. NOTE: Females are considered of childbearing potential
             unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal
             ligation, or bilateral oophorectomy), or they are naturally postmenopausal for at
             least 12 consecutive months

          -  Females of childbearing potential must be willing to abstain from heterosexual
             activity or must agree to use adequate contraception (hormonal or barrier method) for
             the duration of study participation and for 90 days after discontinuation of study
             treatment

          -  Ability of the subject to understand and comply with study procedures for the entire
             length of the study

          -  Able to swallow ONC201

          -  Be willing to discontinue vitamin and mineral supplements for the duration of the
             study if randomized to receive the methionine restricted diet

        Exclusion Criteria:

          -  No prior therapy with TRAIL receptor agonists

          -  Active infection requiring systemic therapy. Patients with a known history of human
             immunodeficiency virus (HIV) must have a CD4 count >= the institutional lower limit of
             normal within 28 days prior to registration. Patients with HIV must also be on a
             stable antiretroviral regimen for >= 28 days before registration

          -  Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the
             mother is being treated on study)

          -  Known additional malignancy that is active and/or progressive requiring treatment;
             exceptions include basal cell or squamous cell skin cancer, in situ cervical or
             bladder cancer, or other cancer for which the subject has been disease-free for at
             least three years

          -  Treatment with any investigational drug agent =< 14 days prior to registration or
             within 5 half-lives of that investigational product, whichever is longer

          -  Participant who has had major surgery =< 14 days prior to registration or has not
             recovered from major side effects of the surgery (tumor biopsy is not considered as
             major surgery)

          -  Known hypersensitivity to any of the excipients of ONC201

          -  Any impairment of gastrointestinal (GI) function or GI disease that may significantly
             alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled
             nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)

          -  Any concurrent severe and/or uncontrolled medical condition that would, in the
             investigator's judgment, cause unacceptable safety risks, contraindicate subject
             participation in the clinical study or compromise compliance with the protocol (e.g.
             chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled
             fungal, bacterial or viral infections, etc.)

          -  Participants who follow a vegan or vegetarian diet
      "
NCT04038489,withdrawn,"
    lack of accrual
  ",0,phase 2,"['breast cancer', 'estrogen receptor-positive breast cancer']","[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['aspirin', 'tamoxifen pill', 'doxorubicin', 'cyclophosphamide', 'paclitaxel']","['CC(=O)OC1=CC=CC=C1C(=O)O', 'Status: 503', 'CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O', 'Status: 503', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C']","
        Inclusion Criteria:

          1. Provision of signed and dated informed consent form

          2. Stated willingness to comply with all study procedures and availability for the
             duration of the study

          3. Male or female, aged 18 or older

          4. Newly diagnosed with ER+/HER2- stage I-III breast cancer according to American Society
             of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines and the
             8th edition of the American Joint Committee on Cancer (AJCC); ER positive is defined
             as ≥ 1% positive nuclear staining

          5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2

          6. Life expectancy ≥ 6 months

          7. Women of childbearing potential and men must agree to use adequate contraception (see
             section 5.4) prior to study entry and for at least 3 months following the last dose of
             tamoxifen

          8. If genomic profiling has been performed (OncotypeDx, Mammaprint or other), then the
             score must be in a medium- or high-risk range.

          9. Adequate Organ Function as described below. There are no requirements regarding recent
             transfusions Absolute Neutrophil Count ≥1000/mm3 Platelets ≥100,000/mm3 Hemoglobin ≥9
             g/dL Serum Creatinine or Glomerular Filtration Rate (GFR) ≤ 1.5 x upper limit of
             normal (ULN) Bilirubin ≤ 1.5 x ULN (except in patients with Gilbert's disease, where
             bilirubin to 4x ULN or direct bilirubin ≤ ULN is allowed) Aspartate aminotransferase
             (AST) and Alanine aminotransferase (ALT) ≤ 2.5 x ULN Alkaline phosphatase ≤ 2.5 x ULN

         10. Ability to take oral medication

        Exclusion Criteria:

          1. Receipt of any systemic treatment for the current diagnosis of breast cancer (breast
             biopsy, excisional biopsy, or other local therapy is acceptable as long as residual
             disease is present and is appropriate for systemic chemotherapy and additional
             curative intent resection)

          2. Current use of anticoagulant (e.g. warfarin (Coumadin), heparin, direct oral
             anticoagulants (DOAC)) within 72 hours of registration

          3. Pregnancy or lactation

          4. Currently in prison

          5. Requirement for supplemental oxygen therapy

          6. Current active cancer other than breast cancer

          7. History of severe bleeding that, in the treating investigator's opinion, would put the
             patient at increased risk with daily 325 mg aspirin use

          8. Known allergic reactions to aspirin, tamoxifen, doxorubicin, cyclophosphamide, or
             paclitaxel

          9. Participants classified according to the New York Heart Association classification as
             having Class II - IV heart disease (section 12.2)

         10. History of thrombosis or cerebrovascular accident
      "
NCT02613221,completed,,0,phase 1/phase 2,['colorectal cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]",['panitumumab + tas-102'],['Status: 503'],"
        Inclusion Criteria:

          1. Investigator and subinvestigator judge a candidate is understand clinical trial and
             comply this protocol.

          2. Participants who have given written consent to take part in the study after detailed
             explanation of the study prior to enrollment

          3. Aged ≥20 to <75 years at the time of informed consent

          4. Participants with unresectable adenocarcinoma originating in the large intestine
             (excluding carcinoma of the appendix and anal canal cancer)

          5. Participants with lesion(s) that can be evaluated. It is essential to be evaluated the
             tumor according to the Response Evaluation Criteria in Solid Tumors (RECIST) ver. 1.1.

          6. Participants who have received chemotherapies for metastatic colorectal cancer and are
             refractory to or failing those chemotherapies* including; fluoropyrimidines,
             irinotecan, oxaliplatin, and an angiogenesis inhibitors.

             *: Refractory to or failing those chemotherapies are defied as following;

               -  If recurrence is observed by imaging during neoadjuvant/adjuvant therapy, or
                  within 6 months of the completion of adjuvant therapy.

               -  If imaging or clinical progression is observed during or within 3 months of the
                  last dose of chemotherapy for advanced cancer.

               -  When it is determined that the drugs (ie, fluropyrimidines, oxaliplatin,
                  irinotecan, and angiogenesis inhibitors) are not allowed to be resume due to
                  intolerable AE toxicities (eg, serious allergic reaction and accumulative
                  neuropathy).

          7. Participants classified as KRAS/NRAS wild-type** by KRAS/NRAS testing*.

             *: KRAS/NRAS test will be performed using the in vitro diagnostic listed in the
             National Health Insurance.

             **: Participants with no mutation in any of the codons shown below are considered wild
             type.

             KRAS: EXON2 (codon 12, 13), EXON3 (codon 59, 61), EXON4 (codon 117, 146) NRAS：EXON2
             (codon 12, 13), EXON3 (codon 59, 61),EXON4 (codon 117, 146)

          8. Participants are able to take medications orally.

          9. Participants who satisfy the following criteria for the major organ function in tests
             performed within 14 days prior to enrollment

               -  Neutrophil count ≥1.5×10^3/µL

               -  Platelet count ≥1.0×10^4/µL

               -  Hemoglobin ≥8.0 g/dL

               -  Total bilirubin ≤1.5 mg/dL

               -  Aspartate aminotransferase (AST) ≤ 100 IU/L ( ≤200 IU/L if liver metastases are
                  present)

               -  Alanine aminotransferase (ALT) ≤ 100 IU/L ( ≤200 IU/L if liver metastases are
                  present)

               -  Serum creatinine ≤ 1.5 mg/dL

         10. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1

         11. Life expectancy of ≥ 3 months (90 days) after enrollment

        Exclusion Criteria:

          1. Has received anti-EGFR antibodies (cetuximab or panitumumab), regorafenib, or TAS-102.

          2. Has had treatment with radiotherapy and/or chemotherapy within 2 weeks (14 days) prior
             to study drug administration (except for limited field radiation in order to rescue of
             pain).

          3. Known brain metastasis or strongly suspected of brain metastasis

          4. Synchronous cancers or metachronous cancers with a disease-free period of ≥ 5 years
             (excluding colorectal cancer) excluding mucosal cancers cured or be possibly cured by
             regional resection (esophageal, stomach, and cervical cancer, non-melanoma skin
             cancer, bladder cancer, etc.).

          5. Body cavity fluid that requires treatment (pleural effusion, ascites, pericardial
             effusion, etc.)

          6. Participants who do not want to use contraception to prevent pregnancy, and women who
             are pregnant or breast-feeding, or test positive for pregnancy

          7. Any investigational agent received within prior 4 weeks (28 days).

          8. Disease requiring systemic steroids for treatment (excluding topical steroids)

          9. History or obvious and extensive CT findings of interstitial pulmonary disease
             (interstitial pneumonia, pulmonary fibrosis, etc.)

         10. Intestinal paralysis, gastrointestinal obstruction, or uncontrollable diarrhea
             (incapacitating symptoms despite adequate treatment.

         11. Serious drug hypersensitivity (without allergy to oxaliplatin)

         12. Local or systemic active infection requiring treatment, or fever indicating infection

         13. NYHA class II or higher heart failure or serious heart disease

         14. Active hepatitis B

         15. Known HIV infection

         16. Adverse event due to previous treatment that has not recovered to Grade 1 (Grade 2 for
             peripheral sensory neuropathy) by CTCAE (Japanese edition JCOG version 4.03)
             (excluding hemoglobin content)

         17. Known BRAF mutation

         18. Other participants judged by the investigator or subinvestigator to be ineligible for
             enrollment in the study (such as patients who were coerced to give consent)
      "
NCT02612610,completed,,1,phase 2,['refractory chronic cough'],"[""['D46.4', 'I20.2', 'D46.1', 'D46.A', 'D46.0', 'D46.20', 'D46.21']""]","['gefapixant', 'placebo (for gefapixant)']",['CC(C)C1=CC(=C(C=C1OC2=CN=C(N=C2N)N)S(=O)(=O)N)OC'],"
        Inclusion Criteria:

          -  Women and Men between 18 and 80 years of age inclusive

          -  Have refractory chronic cough

          -  Women of child-bearing potential must use 2 forms of acceptable birth control - Have
             provided written informed consent.

          -  Are willing and able to comply with all aspects of the protocol

        Exclusion Criteria:

          -  Current smoker

          -  Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) ratio <60%

          -  History of upper or lower respiratory tract infection or recent significant change in
             pulmonary status within 4 weeks of the Baseline Visit

          -  History of opioid use within 1 week of the Baseline Visit

          -  Body mass index (BMI) <18 kg/m^2 or ≥ 40 kg/m^2

          -  History of concurrent malignancy or recurrence of malignancy within 2 years prior to
             Screening (not including subjects with <3 excised basal cell carcinomas)

          -  Screening systolic blood pressure (SBP) >160 mm Hg or a diastolic blood pressure (DBP)
             >90 mm Hg

          -  Clinically significant abnormal electrocardiogram (ECG) at Screening

          -  Significantly abnormal laboratory tests at Screening

          -  Pregnant or Breastfeeding

          -  Other severe, acute, or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with trial participation or
             investigational product administration or may interfere with the interpretation of
             trial results and, in the judgment of the Investigator or Sponsor, would make the
             participant inappropriate for entry into this trial
      "
NCT02610140,completed,,0,phase 2,['mesothelioma'],"[""['C45.9', 'C45.0', 'C45.1', 'C45.2', 'C45.7']""]","['anetumab ravtansine (bay94-9343)', 'vinorelbine']","['Status: 503', 'CCC1=CC2CC(C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC']","
        Inclusion Criteria:

          -  Histological documentation of malignant pleural mesothelioma (MPM) overexpressing
             mesothelin

          -  Unresectable locally advanced or metastatic MPM after locally confirmed progression on
             1st line treatment with platinum in combination with pemetrexed.

          -  Patients must have measurable disease

          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1

          -  Life expectancy of at least 3 months.

          -  Adequate bone marrow, liver and renal function

          -  Left ventricular ejection fraction (LVEF) ≥ 50% or the lower limit of normal (LLN)
             according to local institution ranges of normality.

        Exclusion Criteria:

          -  More than 1 previous systemic anti-cancer therapy line

          -  Patients with corneal epitheliopathy or any eye disorder that may predispose the
             patients to this condition at the discretion of the investigator in consultation with
             the ophthalmologist.

          -  Brain metastases, meningeal tumours or other metastases in the central nervous system

          -  Evidence of history of bleeding diathesis.

          -  Ongoing or active infection (bacterial, fungal, or viral) of National Cancer
             Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03
             Grade > 2.

          -  Pre-existing cardiac conditions
      "
NCT02612194,terminated,"
    study closed to accrual due to low accrual numbers.
  ",0,phase 2,"['urinary bladder neoplasms', 'ureteral neoplasms', 'urethral neoplasms']","[""['D30.3', 'C67.5', 'C67.9', 'C79.11', 'C67.0', 'C67.1', 'D41.4']"", ""['T83.122S', 'N13.1', 'N13.2', 'T83.112S', 'T83.122A', 'T83.122D', 'T83.112A']"", ""['N34.0', 'N36.0', 'N36.1', 'N36.2', 'N34.3', 'N36.5', 'N36.9']""]",['crizotinib'],['CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N'],"
        Inclusion Criteria

        Subjects must meet all of the following criteria:

          1. Histologically confirmed stage IV urothelial carcinoma of the bladder, upper urinary
             tract or urethra.

          2. Prior treatment for metastatic disease with at least one cisplatin or
             carboplatin-based multi-agent chemotherapeutic regimen. Prior immunotherapy with
             anti-PD-L1 or anti-PD1 agents is allowed.

             o Chemotherapy received peri-operatively for non-metastatic bladder cancer will be
             considered a prior regimen if less than 24 months have elapsed since treatment.

          3. Measurable disease per RECIST 1.1. See Section 10 for the evaluation of measurable
             disease.

          4. Tissue Pre-screen: Archived tissue must have been obtained within 60 months of subject
             signing tissue pre-screen consent. Biopsy accessible disease if adequate archival
             tissue does not exist for molecular characterization.

             Treatment: Available tumor specimen C-MET/RON expression results that meet the
             criteria for one of the three molecularly defined cohorts per Section 4.2

          5. Age ≥ 18 years

          6. ECOG performance status ≤ 2

          7. Adequate liver function: AST and ALT ≤ 2x upper limit of normal, bilirubin ≤ 1.5x
             upper limit of normal

          8. Adequate bone marrow function: Platelets ≥ 100,000 cells/mm3, hemoglobin > 8.0 g/dL
             and ANC ≥ 1,500 cells/mm3

          9. Adequate renal function with a creatinine clearance (based on Cockgroft-Gault formula)
             ≥ 45 mL/min

         10. Ability to understand and the willingness to sign a written informed consent document

         11. Able to swallow oral medication

        Exclusion Criteria

        Subjects must not meet any of the following criteria

          1. Currently receiving any other investigational agents, a prior c-MET inhibitor, or
             crizotinib

          2. Pregnant or breast feeding, because crizotinib can cause fetal harm

          3. Uncontrolled and current illness including, but no limited to:

               -  Ongoing or active infection

               -  Symptomatic congestive heart failure

               -  Unstable angina pectoris

               -  Cardiac arrhythmia, or

               -  Psychiatric illness/social situations that would limit compliance with study
                  requirements

          4. Presence of any of the following within the previous 3 months of treatment consent:

               -  Myocardial infarction

               -  Severe/unstable angina

               -  Coronary/peripheral artery bypass graft

               -  Congestive heart failure, or

               -  Cerebrovascular accident including transient ischemia attack

          5. History of active malignancy other than urothelial carcinoma within the prior 12
             months of the date of treatment consent (except non-melanoma skin cancer or localized,
             treated prostate cancer)

          6. Prolonged QT interval (QTc > 480 msec), symptomatic bradycardia, ongoing cardiac
             dysrhythmias of CTCAE version 4.0 grade 2 ≥ or uncontrolled atrial fibrillation of any
             grade

          7. Pulmonary disorder requiring supplemental oxygen or history of pulmonary fibrosis.
             Sleep apnea considered to be a sleep disorder (and not a pulmonary disorder) by the
             investigator will be allowed.

          8. Subjects receiving any medications or substances that are strong inhibitors or
             inducers of CYP3A are ineligible. Because the lists of these agents are constantly
             changing, it is important to regularly consult a frequently updated list such as
             http://medicine.iupui.edu/clinpharm/ddis/table/aspx; medical reference texts such as
             the Physicians' Desk Reference may also provide this information. As part of the
             enrollment/informed consent procedures, the subject will be counseled on the risk of
             interactions with other agents, and what to do if new medications need to be
             prescribed or if the subject is considering a new over-the-counter medicine or herbal
             product.

               -  Medical condition requiring the use of strong CPY3A inhibitors, including but not
                  limited to atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole,
                  nefazodone, nelfinavir, ritonavir, saquinavir, suboxone, telithromycin,
                  troleandomycin, and voriconazole.

               -  Use of grapefruit or grapefruit juice, which are considered strong CYP3A
                  inhibitors.

               -  Medical condition requiring the use of strong CYP3A inducers, including but not
                  limited to carbamazepine, efavirenz, modafinil, nevirapine, oxcarbazepine,
                  phenobarbital, phenytoin, pioglitazone, rifabutin, rifampin, St. John's Wort, and
                  troglitazone.

          9. Receiving any medications that are CYP3A substrates with a narrow therapeutic range
             (alfentanil, cyclosporine, dihydroergotamine, fentanyl, pimozide, quinidine, sirolimus
             and tacrolimus)

         10. Subjects may be screened for study participation though may not begin study treatment:

               -  Within 4 weeks of major surgery

               -  Within 2 weeks of prior systemic therapy

               -  Within 2 weeks of prior non-palliative radiotherapy

               -  Within 48 hours of completion of palliative radiotherapy (≤ 10 fractions)

               -  Until recovery of adverse events due to prior therapies to ≤ 1 (except alopecia)

         11. Presence of untreated brain metastases or ≤ 6 months from prior treatment (from the
             time of enrollment), active neurologic symptoms or the use of prohibited medications
             in subjects with a history of brain metastases
      "
NCT02612285,terminated,"
    recruitment very slow - study could not be enrolled
  ",0,phase 2,['cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]",['snx-5422'],['CC1(CC2=C(C(=O)C1)C(=NN2C3=CC(=C(C=C3)C(=O)N)NC4CCC(CC4)OC(=O)CN)C(F)(F)F)C'],"
        Inclusion Criteria:

          -  Confirmed solid or hematological TP53 null type cancer.

          -  No more than 4 prior lines of systemic anti-cancer therapy.

          -  Males or non-pregnant, non-breastfeeding females 18 years-of-age or older.

          -  Karnofsky performance score 60

          -  Life expectancy of at least 3 months.

          -  Adequate baseline laboratory assessments

          -  Recovered from toxicities of previous anticancer therapy to CTCAE Grade ≤ 1 with the
             exception of alopecia.

        Exclusion Criteria:

          -  Treatment with an investigational agent within 30 days prior to the first dose of
             SNX-5422 or planning to receive an investigational agent during the study.

          -  Treatment with other anticancer drugs within 28 days or 5 half-lives of anticancer
             therapy (whichever is shorter) is prohibited from 30 days prior to the first dose of
             SNX-5422 and throughout the study.

          -  Radiation treatment within 2 weeks.

          -  The need for treatment with medications with clinically relevant metabolism by the
             cytochrome P450 (CYP) 3A4 isoenzyme within 3 hours before or after administration of
             SNX-5422 (Appendix B).

          -  Appropriately corrected screening ECG QTc interval 470 msec for females, 450 msec for
             males.

          -  Currently receiving medications known to cause QT prolongation AND corrected QTc of
             450 msec for females, 430 msec for males.

          -  Patients with chronic diarrhea of grade 2 or greater despite maximal medical
             management.

          -  Gastrointestinal diseases or conditions that could affect drug absorption, including
             gastric bypass.

          -  Gastrointestinal diseases that could alter the assessment of safety, including
             irritable bowel syndrome, ulcerative colitis, Crohn's disease, or hemorrhagic
             coloproctitis.

          -  History of documented adrenal dysfunction not due to malignancy.

          -  Seropositive for human immunodeficiency virus (HIV) or hepatitis C virus (HCV).

          -  History of chronic liver disease.

          -  Active hepatitis A or B.

          -  Current alcohol dependence or drug abuse.

          -  Clinically significant glaucoma, retinitis pigmentosa, or macular degeneration.

          -  Other serious concurrent illness or medical condition.
      "
NCT04262869,withdrawn,"
    due to accrual issues
  ",0,phase 2,"['lung non-small cell carcinoma', 'stage iiib lung cancer ajcc v8', 'stage iv lung cancer ajcc v8', 'stage iva lung cancer ajcc v8', 'stage ivb lung cancer ajcc v8']","[""['D02.20', 'D02.21', 'D02.22']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['carboplatin', 'paclitaxel', 'pemetrexed']","['Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Capable of giving signed informed consent which includes compliance with the
             requirements and restrictions listed in the informed consent form (ICF) and in this
             protocol

          -  Have a histologically confirmed or cytologically confirmed diagnosis of stage IIIB or
             stage IV NSCLC

          -  Have a performance status of 2 on the Eastern Cooperative Oncology Group (ECOG)
             performance status with any age, or age >= 70 with ECOG PS of 0, 1, or 2, on the day
             of signing informed consent

          -  Patients must have measurable disease based on Response Evaluation Criteria in Solid
             Tumors (RECIST) 1.1 as determined by local site investigator/radiology assessment.
             Target lesions situated in previously irradiated area are considered measurable if
             progression has been demonstrated in such lesions

          -  Have not received prior systemic treatment for their advanced/metastatic NSCLC.
             Subjects who received adjuvant or neoadjuvant therapy are eligible if the
             adjuvant/neoadjuvant therapy was completed at least 12 months prior to the development
             of metastatic disease

          -  Body weight > 30 kg

          -  Hemoglobin >= 9.0 g/dL

          -  Absolute neutrophil count (ANC) >= 1.5 (>= 1500 per mm^3)

          -  Platelet count >= 100) x 10^9/L (>= 100,000 per mm^3)

          -  Serum bilirubin =< 1.5 x institutional upper limit of normal (ULN). (This will not
             apply to patients with confirmed Gilbert's syndrome (persistent or recurrent
             hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or
             hepatic pathology), who will be allowed if =< 3.0 x institutional upper limit of
             normal (ULN)

          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =< 2.5 x institutional upper limit of normal unless liver metastases are present, in
             which case it must be =< 5 x ULN

          -  Measured creatinine clearance (CL) > 40 mL/min or calculated creatinine CL > 40 mL/min
             by the Cockcroft-Gault formula (Cockcroft and Gault 1976)

          -  The effects of the study drug on the developing human fetus are unknown. For this
             reason female of child-bearing potential (FCBP) must have a negative serum or urine
             pregnancy test prior to starting therapy

          -  FCBP and men must agree to use adequate contraception (at least one highly effective
             method and one additional method of birth control at the same time or complete
             abstinence) prior to study entry, for the duration of study participation and for at
             least 4 months following study drug discontinuation. Should a woman become pregnant or
             suspect she is pregnant while she or her partner is participating in this study, she
             should inform her treating physician immediately. A female of childbearing potential
             (FCBP) is a sexually mature woman who: 1) has not undergone a hysterectomy or
             bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 12
             consecutive months (if age > 55 years); if the female subject is < 55 years and she
             has been naturally postmenopausal for > 1 year her reproductive status has to be
             verified by additional lab tests (< 20 estradiol OR estradiol < 40 with follicle
             stimulating hormone [FSH] > 40 in women not on estrogen replacement therapy)

          -  Patient is willing and able to comply with the protocol for the duration of the study
             including undergoing treatment and scheduled visits and examinations including follow
             up

        Exclusion Criteria:

          -  Participation in another clinical study with an investigational product during the
             last 4 weeks

          -  ECOG PS 3 or higher

          -  Prior systemic therapy for the treatment of advanced or metastatic NSCLC

          -  Concurrent enrollment in another clinical study, unless it is an observational
             (non-interventional) clinical study or during the follow-up period of an
             interventional study

          -  Completed palliative radiotherapy within 7 days of the first dose of trial treatment

          -  Has a known sensitivity to any component of carboplatin, pemetrexed, paclitaxel, or
             durvalumab

          -  Is unable to unwilling to take folic acid of vitamin b12 supplementation (if
             non-squamous histology)

          -  Any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria
             for Adverse Events (CTCAE) grade >= 2 from previous anticancer therapy with the
             exception of vitiligo, and the laboratory values defined in the inclusion criteria

          -  Patients with grade >= 2 neuropathy will be evaluated on a case-by-case basis after
             consultation with the study physician

          -  Patients with irreversible toxicity not reasonably expected to be exacerbated by
             treatment with durvalumab may be included only after consultation with the study
             physician

          -  Any concurrent chemotherapy, investigational product (IP), biologic, or hormonal
             therapy for cancer treatment. Concurrent use of hormonal therapy for
             non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable

          -  Major surgical procedure (as defined by the Investigator) within 28 days prior to the
             first dose of IP. Note: Local surgery of isolated lesions for palliative intent is
             acceptable

          -  History of allogenic organ transplantation

          -  Active or prior documented autoimmune or inflammatory disorders (including
             inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with
             the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome,
             or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid
             arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this
             criterion:

               -  Patients with vitiligo

               -  Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on
                  hormone replacement

               -  Any chronic skin condition that does not require systemic therapy

               -  Patients without active disease in the last 5 years may be included but only
                  after consultation with the study physician

               -  Patients with celiac disease controlled by diet alone

          -  Uncontrolled intercurrent illness, including but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable
             angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic
             gastrointestinal conditions associated with diarrhea, or psychiatric illness/social
             situations that would limit compliance with study requirement, substantially increase
             risk of incurring adverse events (AEs) or compromise the ability of the patient to
             give written informed consent

          -  Prior invasive malignancy (except non-melanomatous skin cancer, low or intermediate
             risk prostate cancer, or in situ carcinoma fully resected) unless disease free for a
             minimum of one year

          -  History of leptomeningeal carcinomatosis

          -  Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis. Subjects with previously treated brain metastases may participate provided
             they are clinically stable for at least 2 weeks. Subjects with asymptomatic brain
             metastases may participate, but will require regular imaging of the brain as a site of
             disease

          -  History of active primary immunodeficiency

          -  Active infection including tuberculosis (clinical evaluation that includes clinical
             history, physical examination and radiographic findings, and tuberculosis [TB] testing
             in line with local practice), hepatitis B (known positive hepatitis B virus [HBV]
             surface antigen [HBsAg] result), hepatitis C, or human immunodeficiency virus
             (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined
             as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are
             eligible. Patients positive for 20. Active infection including tuberculosis (clinical
             evaluation that includes clinical history, physical examination and radiographic
             findings, and TB testing in line with local practice), hepatitis B (known positive HBV
             surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus
             (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined
             as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are
             eligible. Patients positive for hepatitis C (hepatitis C virus [HCV]) antibody are
             eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA)

          -  Current or prior use of immunosuppressive medication within 14 days before the first
             dose of durvalumab. The following are exceptions to this criterion:

               -  Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra
                  articular injection)

               -  Systemic corticosteroids at physiologic doses not to exceed << 10 mg/day >> of
                  prednisone or its equivalent

               -  Steroids as premedication for hypersensitivity reactions (e.g., computed
                  tomography [CT] scan premedication)

          -  Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note:
             Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to
             30 days after the last dose of IP

          -  Female patients who are pregnant or breastfeeding or male or female patients of
             reproductive potential who are not willing to employ effective birth control from
             screening to 90 days after the last dose of durvalumab monotherapy

          -  Known allergy or hypersensitivity to any of the study drugs or any of the study drug
             excipients

          -  Patients may not have received prior anti-PD-1, anti PD-L1 including durvalumab or
             anti CTLA-4 drugs

          -  Judgment by the investigator that the patient is unsuitable to participate in the
             study and the patient is unlikely to comply with study procedures, restrictions and
             requirements
      "
NCT04267237,withdrawn,"
    accrual timelines
  ",0,phase 2,['non-small cell lung cancer (nsclc)'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['atezolizumab', 'ro7198457']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Age >= 18 years;

          -  Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) per American Joint Committee
             on Cancer staging criteria, 8th revised edition;

          -  Complete R0 resection of Stage II or III NSCLC prior to enrollment and adequate
             recovery from surgery;

          -  Pathological evaluation of mediastinal lymph nodes preoperatively or intraoperatively;

          -  ctDNA (circulating tumor DNA) identified in plasma after resection of Stage II-III
             NSCLC and prior to start of adjuvant platinum-doublet therapy, as determined by
             central testing;

          -  Treatment with at least two cycles of adjuvant platinum-doublet chemotherapy regimens
             for resected NSCLC;

          -  No unequivocal evidence of disease after surgery and adjuvant platinum-doublet
             chemotherapy, as assessed on imaging (computed tomography [CT] scan or magnetic
             resonance imaging [MRI]) within 28 days prior to randomization;

          -  Availability of adequate tumor material;

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1;

          -  Adequate hematologic and end-organ function;

          -  Negative HIV test at screening;

          -  Negative hepatitis B test at screening;

          -  Negative hepatitis C test at screening.

        Exclusion Criteria:

          -  Participants with a known mutation in exons 18-21 of epidermal growth factor receptor
             (EGFR) or with a known anaplastic lymphoma kinase (ALK) or reactive oxygen species
             (ROS) alteration;

          -  History of malignancy other than disease under study within 5 years prior to
             enrollment, with the exception of malignancies with a negligible risk of metastasis or
             death, such as adequately treated carcinoma in situ of the cervix, non-melanoma skin
             cancer, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine
             cancer;

          -  Induction and neoadjuvant systemic therapy prior to resection of NSCLC;

          -  Radiotherapy prior to or after resection of NSCLC;

          -  Prior systemic investigational therapy;

          -  Prior anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies, or a cancer
             vaccine;

          -  Treatment with systemic immunostimulatory agents within 6 weeks or 5 drug elimination
             half-lives, prior to initiation of study treatment;

          -  Treatment with systemic immunosuppressive medication within 2 weeks prior to
             initiation of study treatment or anticipation of need for systemic immunosuppressive
             medication during study treatment;

          -  Treatment with monoamine oxidase inhibitors (MAOIs) within 3 weeks prior to initiation
             of study treatment or requirement for ongoing treatment with MAOIs;

          -  Active or history of autoimmune disease or immune deficiency;

          -  Known primary immunodeficiencies, either cellular or combined T-cell and B-cell
             immunodeficiencies;

          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
             pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening
             chest CT scan;

          -  Significant cardiovascular disease;

          -  Major surgical procedure, other than for diagnosis or for resection of disease under
             current study, within 4 weeks prior to initiation of study treatment, or anticipation
             of need for a major surgical procedure during the study;

          -  Known active or latent tuberculosis infection;

          -  Recent acute infection;

          -  Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study
             treatment, or anticipation of need for such a vaccine during study treatment or within
             5 months after the final dose of study treatment;

          -  Prior allogeneic stem cell or solid organ transplantation;

          -  Any other disease, metabolic dysfunction, physical examination finding, or clinical
             laboratory finding that contraindicates the use of an investigational drug, may affect
             the interpretation of the results, or may render the participants at high risk from
             treatment complications;

          -  Known clinically significant liver disease;

          -  Previous splenectomy;

          -  History of severe allergic anaphylactic reactions to chimeric or humanized antibodies
             or fusion proteins;

          -  Known hypersensitivity to Chinese hamster ovary cell products or any component of the
             atezolizumab formulation;

          -  Known allergy or hypersensitivity to any component of RO7198457;

          -  Pregnant or lactating women.
      "
NCT03087708,terminated,"
    insufficient accrual
  ",0,phase 2,"['stage iiib non-small cell lung cancer', 'stage iv non-small cell lung cancer']","[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]",['naloxegol'],['COCCOCCOCCOCCOCCOCCOCCOC1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC=C)O'],"
        Inclusion Criteria:

          -  Advanced (stage IIIB or IV) non-small cell lung cancer diagnosed by biopsy of the
             primary or metastatic site (American Joint Committee on Cancer 7.0)

          -  No known presence of known EGFR or EML4-ALK driver mutations in the tumor

          -  Started first-line systemic therapy of the investigator's choice within 12 weeks prior
             to registration, or planning to initiate first-line systemic therapy of the
             investigator's choice within 4 weeks after registration; no planned initiation of
             definitive (potentially curative) concurrent chemo-radiation

          -  No prior systemic therapy for advanced NSCLC, including chemotherapy, targeted therapy
             or immunotherapy (other than current treatment); prior palliative radiation permitted;
             prior adjuvant systemic therapy /radiation is permitted

          -  No more than 7 days of prior use of mixed opioid agonist/opioid antagonists or other
             opioid antagonists within 4 weeks before registration; patients should not receive
             such medications after registration and for the entire duration of study treatment

          -  No methadone within 4 weeks prior to registration

          -  Patients must have used opioid medication(s) for pain at some time in the 4 weeks
             prior to registration; current use of opioids (at the time of registration) and/or
             later during the course of the study is permitted but not required

          -  Expected survival > 3 months

          -  No concurrently active second invasive malignancies except non-melanoma skin cancer

          -  No history of gastrointestinal obstruction, or conditions that increase the risk of
             gastrointestinal obstruction, perforation, bleeding or impairment of the
             gastrointestinal wall; no abdominal surgery within 60 days of registration

          -  No acute gastrointestinal conditions, such as: obstruction, fecal impaction,
             obstipation, acute surgical abdomen, ongoing need for manual maneuvers to induce bowel
             movements (such as digital evacuation)

          -  No conditions that may compromise blood-brain barrier permeability (e.g., multiple
             sclerosis, recent brain trauma, Alzheimer's disease, or uncontrolled seizures)

               -  No symptomatic and untreated brain metastases; patients will be eligible for
                  study if radiation therapy for brain metastases was completed at least 7 days
                  prior to registration

               -  Patients having received stereotactic radiation will be eligible if the radiation
                  was completed at least 7 days prior to registration

               -  Patients having undergone surgical resection of brain metastases will be eligible
                  after they have healed and recovered from the surgical intervention sufficiently
                  to start systemic treatment for NSCLC, as determined by a neurosurgeon

               -  No known leptomeningeal carcinomatosis

          -  No history of myocardial infarction =< 6 months prior to registration; no current
             symptomatic congestive heart failure, uncontrolled angina, or uncontrolled cardiac
             arrhythmias

          -  No severe hepatic impairment (Child-Pugh class C) or acute liver disease

          -  No known serious or severe hypersensitivity reaction to naloxegol or any of its
             excipients

          -  No concurrent use of moderate/strong CYP3A4 inhibitors, or strong CYP3A4 inducers

          -  Not pregnant and not nursing, because this study involves an investigational agent
             whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn
             are unknown; therefore, for women of childbearing potential only, a negative pregnancy
             test done =< 7 days prior to registration is required; a female of childbearing
             potential is a sexually mature female who: 1) has not undergone a hysterectomy or
             bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 12
             consecutive months (i.e., has had menses at any time in the preceding 12 consecutive
             months)

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Absolute neutrophil count (ANC) >= 1,500/mm^3

          -  Platelet count >= 100,000/mm^3

          -  Calculated (calc.) creatinine clearance >= 60 mL/min calculated using the
             Cockcroft-Gault formula

          -  Total bilirubin =< 1.2 x upper limit of normal (ULN) unless due to Gilbert's disease

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper
             limit of normal (ULN)
      "
NCT03082833,terminated,"
    lack of efficacy
  ",0,phase 2,['cancer of stomach'],"[""['D13.1', 'C16.9', 'C16.1', 'C16.2', 'D37.1', 'C16.8', 'C16.5']""]",['azd2014'],['CC1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=CC=C4)C(=O)NC)N5CCOCC5C'],"
        Inclusion Criteria:

          1. Provision of fully informed consent prior to any study specific procedures.

          2. Patients must be ≥20 years of age.

          3. Advanced gastric adenocarcinoma (including GEJ) that has progressed during or after
             first-line therapy.

               -  The 1st line regimen must have contained doublet 5-fluoropyrimidine and platinum
                  based regimen.

               -  Relapse within 6 months of completion of adjuvant/neoadjuvant chemotherapy
                  containing doublet 5-fluoropyrimidine and platinum-based regimen could be
                  considered as 1st line therapy.

               -  Acceptable prior chemotherapy regimens for this protocol are chemotherapy
                  regimens that include Immune Target agent therapy. (such as a pembrolizumab,
                  ramucirumab etc)

          4. Previous adjuvant/neoadjuvant chemotherapy is allowed, if completed more than 6 months
             prior to starting the 1st line therapy.

          5. Provision of tumor sample (from eith tumor sample (from eith tumor sample (from eith
             tumor sample (from eith tumor sample (from eith er a resection or biopsy)er a
             resection or biopsy) er a resection or biopsy)er a resection or biopsy) er a resection
             or biopsy)er a resection or biopsy)er a resection or biopsy)er a resection or
             biopsy)er a resection or biopsy) er a resection or biopsy) er a resection or biopsy)
             er a resection or biopsy)er a resection or biopsy)

          6. Patients with TSC1/2 mutation or null through the VIKTORY trial. (The VIKTORY trial
             uses Ion Torrent PGM to screen for a panel of cancer mutations and nanostring copy
             number variation panel (see addendum for the VIKTORY trial). Types of TSC1/2 mutation
             for this trial was defined in VIKTORY lab manual

          7. Patients are willing and able to comply with the protocol for the duration of the
             study including undergoing treatment and scheduled visits and examinations.

          8. ECOG performance status 0-2.

          9. Patients must have a life expectancy ≥ 3 months from proposed first dose date.

         10. Patients must have acceptable bone marrow, liver and renal function measured within 28
             days prior to administration of study treatment as defined below:

             - Haemoglobin ≥9.0 g/dL (transfusion allowed)

               -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L

               -  White blood cells (WBC) > 3 x 109/L

               -  Platelet count ≥100 x 109/L (transfusion allowed)

               -  Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN)

               -  AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal unless liver
                  metastases are present in which case it must be ≤ 5x ULN

               -  Serum creatinine ≤1.5 x institutional ULN

         11. At least one measurable lesion that can be accurately assessed by imaging or physical
             examination at baseline and following up visits.

         12. Negative urine or serum pregnancy test within 28 days of study treatment, confirmed
             prior to treatment on day 1. Patients of child-bearing potential should be using
             adequate contraceptive measures (two forms of highly reliable methods) should not be
             breast feeding and must have a negative pregnancy test prior to start of dosing.Or
             Patients must have evidence of non-child-bearing potential by fulfilling one of the
             following criteria at screening: Post-menopausal - defined as aged more than 50 years
             and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal
             treatments. Documentation of irreversible surgical sterilisation by hysterectomy,
             bilateral oophorectomy or bilateral salpingectomy, but not tubal ligation

        Exclusion Criteria:

          -  1. More than one prior chemotherapy regimen (except for adjuvant/neoadjuvant
             chemotherapy with more than 6 month wash out period) for the treatment of gastric
             cancer in the advanced setting.

             2. Any previous treatment with PIK3CA, AKT or mTOR inhibitor or agents with mixed PI3K
             / mTOR activity.

             3. Patients with second primary cancer, except: adequately treated non-melanoma skin
             cancer, curatively treated in-situ cancer of the cervix, or other solid tumours
             curatively treated with no evidence of disease for ≤5 years.

             4. Patients unable to swallow orally administered medication. 5. Previous major
             surgery within 4 weeks prior to enrollment. 6. For AZD2014: Exposure to potent or
             moderate inhibitors or inducers of CYP3A4/5 if taken within the stated washout periods
             before the first dose of study treatment 8. With the exception of alopecia, any
             ongoing toxicities (>CTCAE grade 1) caused by previous cancer therapy.

             9. Intestinal obstruction or CTCAE grade 3 or grade 4 upper GI bleeding within 4 weeks
             before the enrollment.

             10. Resting ECG with measurable QTcB > 450 msec on 2 or more time points within a 24
             hour period or family history of long QT syndrome.

             11. Patients with cardiac problem as follows: uncontrolled hypertension (BP ≥150/95
             mmHg despite medical therapy) Left ventricular ejection fraction <55% measured by
             echocardiography, Atrial fibrillation with a ventricular rate >100 bpm on ECG at rest
             , Symptomatic heart failure (NYHA grade II-IV), Prior or current cardiomyopathy,
             Severe valvular heart disease, Uncontrolled angina (Canadian Cardiovascular Society
             grade II-IV despite medical therapy), Acute coronary syndrome within 6 months prior to
             starting treatment 12. Active or untreated brain metastases or spinal cord compression
             Patients with treated brain metastases or spinal cord compression are eligible if they
             have minimal neurologic symptoms, evidence of stable disease (for at least 1 month) or
             response on follow-up scan, and require no corticosteroid therapy for ≥ 1 week.

             13. Female patients who are breast-feeding or child-bearing 14. Any evidence of severe
             or uncontrolled systemic disease, active infection, active bleeding diatheses or renal
             transplant, including any patient known to have hepatitis B, hepatitis C or human
             immunodeficiency virus (HIV) 15. Patients with proteinuria (3+ on dipstick analysis )
      "
NCT03848182,terminated,"
    slow accrual
  ",0,phase 2,['pancreatic cancer'],"[""['C25.3']""]",['gemcitabine'],['Status: 503'],"
        Inclusion Criteria:

          1. Histologically or cytologically confirmed adenocarcinoma of the pancreas

          2. Patients is a candidate for gemcitabine chemotherapy (adjuvant, metastatic, locally
             advanced, borderline resectable settings all permitted)

          3. Patients at least 18 years of age

          4. ECOG performance status 0-2

          5. Consent to donate 12 tubes of peripheral blood of 10 mL each

          6. Adequate organ function as defined as -neutrophil count ≥ 1200 -platelets ≥ 75,000
             -hemoglobin ≥ 8.0 -bilirubin ≤ 2.0 -creatinine ≤2.0 or calculated GFR ≥ 30

          7. Ability to understand and willingness to sign a written informed consent document

          8. Prior chemotherapy permitted, as long as 60 days have lapsed since last dose. Prior
             radiation therapy permitted, as long as 28 days lapsed since last treatment.

          9. Patients may receive other concurrent chemotherapy, immunotherapy, or radiotherapy

        Exclusion Criteria:

          1. Patients never been immunized with tetanus toxoid (TT). Patients with a history of
             adverse reaction to tetanus vaccine (with the exception of self-limited fever or local
             tissue reaction

          2. Patients may not be receiving any investigational agents

          3. Pregnant women

          4. Patients with HIV
      "
NCT01953406,withdrawn,"
    no participants were enrolled. therefore, we stop this study, prematurely.
  ",0,phase 2,"['hepatocellular carcinoma', 'lung metastasis']","[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]","['5-fluorouracil', 'mitomycin']","['Status: 503', 'CC1=C(C(=O)C2=C(C1=O)N3CC4C(C3(C2COC(=O)N)OC)N4)N']","
        Inclusion Criteria:

          -  Patients who have received previous local therapy treatments for the intrahepatic
             hepatocellular carcinoma (RFA, PEI, cryoablation, surgery, resection) and who don't
             have any viable intrahepatic tumor within 3 months of imaging (dynamic liver CT or
             liver MRI) after the locoregional therapy

          -  Patients who have measurable lung metastasis

          -  Patients who have received their last dose of sorafenib more than 14 days before and
             who had progressive disease of lung metastasis with sorafenib

          -  Patients who have risk factors of hepatocellular carcinoma (chronic hepatitis B,
             chronic hepatitis C, liver cirrhosis)

          -  Age : 18 years to 80 years

          -  ECOG Performance Status of 0 to 2

          -  Child-Pugh class A,B (Child-Pugh score 5-9)

          -  Adequate bone marrow, liver function as assessed by the following laboratory
             requirements to be conducted within 7 days prior to screening:

               -  WBC count > 1,000/mm3

               -  Absolute neutrophil count > 500/mm3

               -  Hb > 7.0 g/dL

               -  Platelet count > 50,000 /mm3

               -  Bilirubin < 3 mg/dL

               -  Adequate clotting function: INR < 2.3 or < 6sec

        Exclusion Criteria:

          -  Child-Pugh score > 10

          -  ECOG Performance Status > 3

          -  History of organ allograft

          -  Patients with uncontrolled co-morbidity which needs treatment

          -  Patients who have received prior systemic chemotherapy except sorafenib
      "
NCT01858662,terminated,"
    due to poor recrutment
  ",0,phase 2,['metastatic colorectal cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['5-fluorouracile', 'leucovorin l', 'oxaliplatin', 'irinotecan', 'cetuximab']","['Status: 503', 'C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          1. Female or male patients with at least 18 years at the time the informed consent is
             signed

          2. ECOG performance status 0 or 1

          3. Histological or cytological confirmed diagnostic of adenocarcinoma of the colon or
             rectum, with or without primary tumour in situ. Wild-type RAS and B-RAF tumor status.

          4. Patients with potentially resectable metastatic disease at diagnosis and for whom a
             chemotherapy first in a curative intent is recommended . Resectability could be planed
             in one or multiple stage if indicated. As commonly admitted, resectability means the
             surgical clearance (+/- radiofrequency ablation) of all detectable (liver) lesions
             with tumor-free margins and compatible with an adequate hepatic reserve. Practically,
             bilateral tumor location, number and location of lesions, and inadequate hepatic
             reserve remain the main decisional factors.

          5. Partial and minor resection of metastatic disease is allowed within 3 months before
             inclusion if patient has never received chemotherapy for mCRC.

          6. Extra hepatic metastatic location is limited to 1 site.

          7. Patients may have received adjuvant chemotherapy or (neo-) adjuvant chemo-radiotherapy
             to the pelvis, provided the last dose of chemotherapy was administered at least 6
             months prior to inclusion (12 months for oxaliplatin). Previous radiotherapy to the
             pelvis is not an exclusion criterion.

          8. Adequate haematological, renal and hepatic function as follows:

             Haematological:

             haemoglobin >9g/dl Neutrophils > 1.5 x 109/L Platelets > 100 x 109/L

             Renal:

             Creatinine< 1.5 x ULN (Upper Limit of Normal)

             Hepatic:

             Bilirubin < or equal 1.5 X ULN AST (Aspartate Aminotransferase),and ALT (Alanine
             Aminotransferase)< or equal 5 x ULN, Phos Alc< or equal 5 x ULN

          9. Female patients must either be postmenopausal, sterile (surgically or radiation- or
             chemically-induced), or if sexually active using an acceptable method of
             contraception.

         10. Male patients must be surgically sterile or if sexually active and having a
             pre-menopausal partner must be using an acceptable method of contraception.

         11. Life expectancy of at least 3 months without any active treatment.

        Exclusion Criteria:

          -  1.Definitively non resectable mCRC at diagnosis

          -  2.Prior chemotherapy or systemic therapy for mCRC. Adjuvant chemotherapy for
             colorectal cancer is not an exclusion criterion provided that it was completed more
             than 6 months prior to inclusion. Oxaliplatin-based chemotherapy must be completed
             more than 1 year prior to inclusion.

          -  3.Prior utilization of cetuximab, panitumumab (or other anti-EGFR (epidermal growth
             factor receptor)therapy).

          -  4.Previous radiotherapy delivered to the upper abdomen.

          -  5 Non mesurable disease( RECIST 1.1 criteria)

          -  6.Evidence of ascites, cirrhosis, portal hypertension, main portal venous tumour
             involvement or thrombosis as determined by clinical or radiologic assessment.

          -  7.Prior major liver resection: remnant liver < 50% of the initial liver volume.

          -  8.Non-malignant disease that would render the patient unsuitable for treatment
             according to this protocol.

          -  9.Concurrent central nervous systems metastases

          -  10.Peripheric neuropathy ≥ grade 2.

          -  11.Interstitial lung disease

          -  12.Pregnant or breast feeding.

          -  13.The patient has previous or concomitant malignancies, except: Invasive malignancies
             in remission for more than 5 years and non melanoma skin cancer or carcinoma in situ
             of the cervix.
      "
NCT01850004,completed,,1,phase 2,['chronic phase chronic myeloid leukemia'],"[""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']""]",['dasatinib'],['Status: 503'],"
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria

          -  Signed Written Informed Consent

          -  Target Population

               1. Men and women diagnosed with CP-CML, on treatment with dasatinib for a minimum of
                  2 years at the time of enrollment and in dasatinib-induced complete molecular
                  remission ongoing for at least 1 year prior to study entry.

               2. Patients are eligible if they have been in stable dasatinib induced CMR for a
                  minimum of nine months, documented by at least three assessments, conducted 2 -
                  6.5 months apart, at a local lab.

               3. Subjects who have received dasatinib beyond first or second line treatment and
                  meet other enrollment criteria are eligible for the study provided prior
                  Tyrosine-kinase inhibitors (TKI) were discontinued due to intolerance or lack
                  efficacy, although only one instance of lack of efficacy to TKI is allowed.

               4. Eastern Co-Operative Group (ECOG) Performance Status (PS) of 0-1

          -  Age and Reproductive Status

               1. Men and women, ages ≥18

               2. Women of childbearing potential (WOCBP) must have a negative serum or urine
                  pregnancy test within 24 hours prior to the restart of study drug

               3. Women must not be breastfeeding

               4. WOCBP must agree to follow instructions for method(s) of contraception at the
                  restart of treatment with study drug (dasatinib) and for the duration treatment
                  plus 30 days (duration of ovulatory cycle) for a total of 30 days post-treatment
                  completion

               5. Men who are sexually active with WOCBP must agree to follow instructions for
                  method(s) of contraception for 90 days after study entry (withdrawal of
                  dasatinib), at restart of study drug (dasatinib) and for the duration of
                  treatment with study drug (dasatinib) plus 90 days (duration of sperm turnover)
                  for a total of 90 days post-treatment completion

        Exclusion Criteria:

          -  Target Disease Exceptions

               1. Patients who have not achieved a 1-log reduction in BCR-ABL transcript levels
                  compared with baseline as determined by local standards or > 10% IS
                  [International Standard]) documented at 3.0-6.5 months since the initial start of
                  dasatinib therapy.

               2. Patients who have previously undergone hematopoietic stem cell transplantation
                  (SCT) or who are scheduled for SCT

               3. Previous diagnosis of CML accelerated phase or blast crisis

          -  Medical History and Concurrent Diseases

               1. Prior or concurrent malignancy, except the following:

                    -  Curatively treated basal cell or squamous cell skin cancer

                    -  Cervical carcinoma in situ

                    -  Adequately treated Stage I or II cancer from which the subject is currently
                       in complete remission

                    -  Any other cancer from which the subject has been disease free for 3 years

               2. A serious uncontrolled medical disorder or active infection that would impair the
                  ability of the subject to receive protocol therapy in case re-initiation of
                  dasatinib is needed.

               3. Uncontrolled or significant cardiovascular disease

               4. Subjects with prior history of pericardial effusion or pleural effusion that
                  required thoracentesis are excluded. Subjects with prior history of pericardial
                  or pleural effusion that was clinically manageable and a maintained CMR for ≥ 1
                  year on a stable dose of dasatinib are allowed.

               5. History of significant bleeding disorder unrelated to CML

          -  Allergies and Adverse Drug Reaction

             a. Subjects with known hypersensitivity to excipients of Dasatinib tablets

          -  Sex and Reproductive Status

               1. Patients who are pregnant or breastfeeding or likely to become pregnant

               2. Men whose partner is unwilling or unable to avoid pregnancy

          -  Other Exclusion Criteria

               1. Patients with a history of non-compliance to CML treatment and monitoring
                  requirements

               2. Prisoners or subjects who are involuntarily incarcerated

          -  Additional Criteria for Patients Eligible to Restart Dasatinib

               -  Any patient who has lost MMR and is eligible for re-starting dasatinib therapy
                  must not have developed a condition that precludes dasatinib use.

        Other protocol defined inclusion/exclusion criteria could apply
      "
NCT02862145,withdrawn,"
    5 immune related serious adverse events in phase 1 study
  ",0,phase 1/phase 2,['melanoma'],"[""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']""]","['mrx34', 'dexamethasone']",['CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C'],"
        Inclusion Criteria:

          -  ≥18 years of age

          -  Advanced or metastatic cutaneous, acral or mucosal melanoma

          -  Tumor lesions accessible to serial biopsies

          -  ECOG ≤ 1

          -  ANC ≥, Plts ≥100,000 /mm3

        Exclusion Criteria:

          -  Serious active non-malignant disease

          -  Central Nervous System metastasis
      "
NCT02867956,completed,,1,phase 2,['ovarian cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['apatinib', 'etoposide']","['C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4', 'Status: 503']","
        Inclusion Criteria:

          -  Histologically or pathologically confirmed diagnosis of epithelial carcinoma of the
             ovary.

          -  Platinum resistant ovarian cancer (defined as relapsing within 6 months after the last
             administration of platinum-based chemotherapy) OR platinum refractory ovarian cancer
             (defined as progressing while on a platinum-based chemotherapy)

          -  At least treated with one line of platinum-based chemotherapy

          -  Female, age ≥18 years and ≤70 years, signed informed consent.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)
             1.1 version

          -  Patients must have a life expectancy of at least 3 months.

          -  Patients must have adequate organ function as defined by the following criteria:

               -  White blood cell count ≥ 3 x 10^9/L, Absolute neutrophil count (ANC) (≥ 1.5 x
                  10^9/L), Hemoglobin of ≥ 80 g/L, Platelets ≥ 70 x 10^9/L

               -  Total bilirubin ≤ 1 x upper limit of normal (ULN), AST and ALT ≤ 2 x ULN

               -  Serum creatinine ≤ 1 x ULN

        Exclusion Criteria:

          -  Had prior exposure to apatinib or has known allegies to any of the excipients.

          -  History of myocardial infarction, or unstable angina, or New York Heart Association
             (NYHA) Grade III-IV within 6 months prior to Day 1.

          -  Patients with QT interval prolongation

          -  Serious, non-healing wound, active ulcer, bowel obstruction.

          -  History of abdominal fistula or gastrointestinal perforation within 28 days prior to
             Day 1

          -  Evidence of bleeding diathesis or coagulopathy

          -  Inadequately controlled hypertension

          -  Major surgical procedure within 28 days prior to Day 1

          -  Symptomatic central nervous system (CNS) metastasis
      "
NCT02864381,completed,,0,phase 2,"['gastric adenocarcinoma', 'gastroesophageal junction adenocarcinoma']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['andecaliximab', 'nivolumab']",['Status: 503'],"
        Key Inclusion Criteria:

          -  Histologically confirmed inoperable locally advanced or metastatic adenocarcinoma of
             the stomach or GEJ which have progressed on at least 1 prior systemic therapy or line
             of treatment for unresectable/metastatic disease

          -  Eastern Cooperative Oncology Group (ECOG) performance score of ≤ 1

          -  Measurable disease according to Response Criteria in Solid Tumors (RECIST) v1.1

          -  Tumor sites that can be accessed for repeat biopsies

          -  Archival tumor tissue, preferably obtained from the most recent available biopsy;
             there must be adequate tissue for a Cochran-Mantel Haenszel (CMH) test stratified by
             programmed death ligand 1 (PD-L1) stratification test, as assessed by central
             pathologist

          -  Individuals not receiving anticoagulant medication must have an international
             normalized ratio (INR) ≤ 1.5 and activated partial thromboplastin (aPTT) ≤ 1.5 x upper
             limit of normal (ULN)

          -  Required baseline laboratory data as outlined in protocol

        Key Exclusion Criteria:

          -  Individuals who have received only neoadjuvant or adjuvant therapy for gastric
             adenocarcinoma

          -  Radiotherapy within 28 days of randomization

          -  Uncontrolled intercurrent illness as outlined in protocol

          -  History of a concurrent or second malignancy except for those outlined in protocol

          -  Major surgery, within 28 days of first dose of study drug

          -  Known positive status for human immunodeficiency virus (HIV)

          -  Known acute or chronic-active infection with hepatitis B virus (HBV) or hepatitis C
             virus (HCV)

          -  Chronic daily treatment with oral corticosteroids (dose of > 10 mg/day prednisone
             equivalent) or other immunosuppressive medications within 14 days of randomization

          -  Known or suspected central nervous system metastases

          -  Documented myocardial infarction or unstable/uncontrolled cardiac disease within 6
             months of randomization

          -  Serious systemic fungal, bacterial, viral, or other infection that is not controlled
             or requires intravenous antibiotics

          -  Current or history of pneumonitis or interstitial lung disease

          -  Active known or suspected autoimmune disease with exceptions noted in protocol.

          -  History of bone marrow, stem cell, or allogenic organ transplantation

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
      "
NCT02441946,completed,,1,phase 2,"['breast cancer', 'hormone receptor positive tumor', 'early-stage breast carcinoma']","[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['Z17.0', 'Z17.1', 'T47.0X6S', 'T50.7X6S', 'T47.0X3S', 'T47.0X4S', 'T47.0X5S']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['abemaciclib', 'loperamide', 'anastrozole']","['CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F', 'CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4', 'Status: 503']","
        Inclusion Criteria:

          -  Have postmenopausal status.

          -  Adenocarcinoma of the breast.

          -  Breast tumor ≥1 centimeter (cm) in diameter, HR+, HER2-.

          -  Neoadjuvant endocrine monotherapy is deemed to be a suitable therapy.

          -  Primary breast cancer that is suitable for baseline core biopsy.

          -  Have adequate organ function.

        Exclusion Criteria:

          -  Bilateral invasive breast cancer.

          -  Metastatic breast cancer (local spread to axillary lymph nodes is permitted).

          -  Inflammatory breast cancer.

          -  Prior systemic therapy or radiotherapy for invasive or non-invasive breast cancer in
             the same breast as currently being treated.

          -  Prior radiotherapy to the ipsilateral chest wall for any malignancy.

          -  Prior anti-estrogen therapy.
      "
NCT02442349,"active, not recruiting",,1,phase 2,['non-small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]",['azd9291'],['CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC'],"
        Inclusion Criteria:

          -  Aged at least 18 years. Patient from Asia Pacific will be enrolled only.

          -  Locally advanced or metastatic NSCLC, not amenable to curative surgery or
             radiotherapy.

          -  Radiological documentation of disease progression on the last treatment administered
             prior to enrolling in the study: following 1st line EGFR TKI treatment but who have
             not received further treatment OR following prior therapy with an EGFR TKI and a
             platinum-based doublet chemotherapy. Patients may have also received additional lines
             of treatment.

          -  Documented EGFR mutation (at any time since the initial diagnosis of NSCLC) known to
             be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R,
             L861Q).

          -  Patients must have central confirmation of tumour T790M mutation positive status from
             a biopsy sample taken after confirmation of disease progression on the most recent
             treatment regimen.

          -  World Health Organisation (WHO) performance status 0-1 with no deterioration over the
             previous 2 weeks and a minimum life expectancy of 12 weeks.

          -  At least one lesion, not previously irradiated and not chosen for biopsy during the
             study screening period, that can be accurately measured at baseline as ≥10mm in the
             longest diameter (except lymph nodes which must have short axis ≥15mm) with
             computerised tomography (CT) or magnetic resonance imaging (MRI) which is suitable for
             accurate repeated measurements.

          -  Females of child-bearing potential using contraception and must have a negative
             pregnancy test.

        Exclusion Criteria:

          -  Treatment with an EGFR-TKI (eg, erlotinib, gefitinib, icotinib or afatinib) within 8
             days or approximately 5x half-life of study entry; any cytotoxic chemotherapy,
             investigational agents or other anticancer drugs within 14 days of study entry;
             previous treatment with AZD9291 or a 3rd generation EGFR TKIs; Major surgery within 4
             weeks of study entry; radiotherapy treatment to more than 30% of the bone marrow or
             with a wide field of radiation within 4 weeks of study entry; currently receiving
             treatment with potent inhibitors or inducers of CYP3A4.

          -  Any unresolved toxicities from prior therapy.

          -  Unstable spinal cord compression or brain metastases.

          -  Severe or uncontrolled systemic diseases, including uncontrolled hypertension and
             active bleeding diatheses or infection.

          -  Refractory nausea and vomiting, chronic gastrointestinal diseases or bowel resection.

          -  Cardiac disease.

          -  Past medical history of interstitial lung disease, drug-induced interstitial lung
             disease, radiation pneumonitis which required steroid treatment, or any evidence of
             clinically active interstitial lung disease.

          -  Inadequate bone marrow reserve or organ function.
      "
NCT02449343,unknown status,,1,phase 2/phase 3,['soft tissue sarcoma'],"[""['C46.1']""]","['anlotinib', 'placebo']",['Status: 503'],"
        Inclusion Criteria:

          -  Signed and dated informed consent

          -  Histological documentation of Soft Tissue Sarcoma,including Synovial
             sarcoma、Leiomyosarcoma、Alveolar soft part sarcoma、Undifferentiated pleomorphic
             sarcoma/malignant fibrous histiocytoma、Adipocytic Tumors、Fibrosarcoma、Clear cell
             sarcoma、Epithelioid sarcoma，With measurable disease.

          -  Within the past 6 months, using at least one failure of chemotherapy regimens
             (including anthracycline-based) in treating patients(except alveolar soft part
             sarcoma)

          -  18-70years,ECOG PS:0-1,Life expectancy of more than 3 months

          -  Main organs function is normal

          -  The woman patients of childbearing age who must agree to take contraceptive methods
             (e.g. intrauterine device, contraceptive pill or condom) during the research and
             within another 6 months after it; who are not in the lactation period and examined as
             negative in blood serum test or urine pregnancy test within 7 days before the
             research; The man patients who must agree to take contraceptive methods during the
             research and within another 6 months after it

        Exclusion Criteria:

          -  Prior treatment with Anlotinib

          -  With pleural effusion or ascites, cause respiratory syndrome

          -  Accepted the vascular endothelial growth inhibitor class targeted drug treatment of
             patients

          -  Plan to take systemic anti-tumor therapy within 4 weeks before grouping or during the
             medicine-taking period of this research, including Cytotoxic Therapy, Signal
             Transduction Inhibitor, and Immunotherapy (or who use Mitomycin C within 6 weeks
             before taking the treatment with experimental drug); The patients who have already
             taken Extended Field Radiotherapy (EF-RT) within 4 weeks before grouping or Limited
             Field Radiotherapy with proposed assessment of nidus within 2 weeks before grouping

          -  Symptoms of brain metastases cannot be controlled and treated within less than 2
             months

          -  With severe and failed to controlled diseases

          -  Occurred venous thromboembolic events within 6 months
      "
NCT02448290,completed,,1,phase 2,['gastric adenocarcinoma'],"[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]",['docetaxel plus selumetinib'],['Status: 503'],"
        Inclusion Criteria:

          1. Provision of fully informed consent prior to any study specific procedures.

          2. Patients must be ≥20 years of age.

          3. Advanced gastric adenocarcinoma (including GEJ) that has progressed during or after
             firstline therapy.

               -  The 1st line regimen must have contained doublet 5-fluoropyrimidine and platinum
                  based regimen.

               -  Relapse within 6 months of completion of adjuvant/neoadjuvant chemotherapy
                  containing doublet 5-fluoropyrimidine and platinum-based regimen could be
                  considered as 1st line therapy.

          4. Previous adjuvant/neoadjuvant chemotherapy is allowed, if completed more than 6 months
             prior to starting the 1st line therapy.

          5. Provision of tumor sample (from either a resection or biopsy)

          6. Patients with MEK signature, RAS mutation or amplification through the VIKTORY trial.

             (The VIKTORY trial uses Ion Torrent PGM to screen for a panel of cancer mutations and
             nanostring, copy number variation panel (see addendum for the VIKTORY trial)

          7. Patients are willing and able to comply with the protocol for the duration of the
             study including undergoing treatment and scheduled visits and examinations.

          8. ECOG performance status 0-1.

          9. Patients must have a life expectancy ≥ 3 months from proposed first dose date.

         10. Patients must have acceptable bone marrow, liver and renal function measured within 28
             days prior to administration of study treatment as defined below:

               -  Haemoglobin ≥9.0 g/L (transfusion allowed)

               -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L

               -  White blood cells (WBC) > 3 x 109/L

               -  Platelet count ≥100 x 109/L (transfusion allowed)

               -  Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (does not
                  include patients with Glibert's disease)

               -  AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal unless liver
                  metastases are present in which case it must be ≤ 5x ULN

               -  Serum creatinine ≤1.5 x institutional ULN

         11. At least one measurable lesion that can be accurately assessed by imaging or physical
             examination at baseline and following up visits.

         12. Negative urine or serum pregnancy test within 28 days of study treatment, confirmed
             prior to treatment on day 1. for women of childbearing potential.

         13. Provision of consent for mandatory biopsy at progression

        Exclusion Criteria:

          1. More than one prior chemotherapy regimen (except for adjuvant/neoadjuvant chemotherapy
             with more than 6 month wash out period) for the treatment of gastric cancer in the
             advanced setting.

          2. Any previous treatment with MEK, RAS or RAF inhibitors

          3. Any previous treatment with docetaxel.

          4. Patients with second primary cancer, except: adequately treated non-melanoma skin
             cancer, curatively treated in-situ cancer of the cervix, or other solid tumours
             curatively treated with no evidence of disease for ≤5 years.

          5. HER2 positive patients (defined by HER2 3+ by immunohistochemistry or HER2 SISH +)

          6. Patients unable to swallow orally administered medication.

          7. Treatment with any investigational product during the last 14 days before the
             enrollment (or a longer period depending on the defined characteristics of the agents
             used).

          8. Patients receiving any systemic chemotherapy, radiotherapy (except for palliative
             reasons), within 3 weeks from the last dose prior to study treatment (or a longer
             period depending on the defined characteristics of the agents used). The patient can
             receive a stable dose of bisphosphonates or denusomab for bone metastases, before and
             during the study as long as these were started at least 4 weeks prior to treatment.

          9. Concomitant use of known potent CYP3A4 inhibitors such as ketoconazole, itraconazole,
             ritonavir, indinavir, saquinavir, telithromycin, clarithromycin and nelfinavir.

         10. With the exception of alopecia, any ongoing toxicities (>CTCAE grade 1) caused by
             previous cancer therapy.

         11. Intestinal obstruction or CTCAE grade 3 or grade 4 upper GI bleeding within 4 weeks
             before the enrollment.

         12. Resting ECG with measurable QTcB > 480 msec on 2 or more time points within a 24 hour
             period or family history of long QT syndrome.

         13. Patients with cardiac problem as follows: uncontrolled hypertension (BP ≥150/95 mmHg
             despite medical therapy) Baseline Left ventricular ejection fraction below the LLN of
             <55% measured by echocardiography or institution's LLN for MUGA, Atrial fibrillation
             with a ventricular rate >100 bpm on ECG at rest , Symptomatic heart failure (NYHA
             grade II-IV), Prior or current cardiomyopathy, Severe valvular heart disease,
             Uncontrolled angina (Canadian Cardiovascular Society grade II-IV despite medical
             therapy), Acute coronary syndrome within 6 months prior to starting treatment

         14. Ophthalmological conditions as follows:Intra-ocular pressure >21 mmHg, or uncontrolled
             glaucoma (irrespective of intra-ocular pressure), Current or past history of retinal
             pigment epithelial detachment/central serous retinopathy or or current or past history
             retinal vein occlusion

         15. Female patients who are breast-feeding or child-bearing and Male or female patients of
             reproductive potential who are not employing an effective method of contraception

         16. Any evidence of severe or uncontrolled systemic disease, active infection, active
             bleeding diatheses or renal transplant, including any patient known to have hepatitis
             B, hepatitis C or human immunodeficiency virus (HIV)
      "
NCT02443337,terminated,"
    the study stopped due to lack of efficacy.
  ",0,phase 2,['non-small cell lung cancer metastatic'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['ly3023414', 'necitumumab']","['CC(CN1C2=C3C=C(C=CC3=NC=C2N(C1=O)C)C4=CC(=CN=C4)C(C)(C)O)OC', 'Status: 503']","
        Inclusion Criteria:

          -  Histologically confirmed squamous advanced NSCLC (Stage IV).

          -  Participants must have progressed on one prior line of platinum-based chemotherapy in
             the advanced or metastatic setting.

          -  Measurable disease as measured by response evaluation criteria in solid tumors
             (RECIST) criteria v 1.1.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.

          -  Able to swallow the study drugs whole.

          -  Adequate organ function.

          -  Women of childbearing potential must have a negative serum or urine pregnancy test
             performed ≤ 7 days prior to start of treatment. Women of childbearing potential or men
             with partners of childbearing potential must use effective birth control measures
             during treatment and during the 3 months following completion of study treatment.

        Exclusion Criteria:

          -  Participants who have received > 1 prior line of chemotherapy in the advanced or
             metastatic setting. (Immunotherapy will not be considered a line of chemotherapy.)

          -  Prior treatment with a PI3K/mTOR inhibitor, epidermal growth factor receptor (EGFR)
             inhibitor, and/or necitumumab.

          -  History of brain metastases unless irradiated ≥ 2 weeks prior to first study treatment
             and stable without requirement of corticosteroids.

          -  Have serious pre-existing medical conditions.

          -  Have insulin-dependent diabetes mellitus. Participants with a type 2 diabetes mellitus
             are eligible if adequate control of blood glucose level is obtained by oral
             anti-diabetics.

          -  Women who are pregnant or breast-feeding.

          -  Clinically significant electrolyte imbalance ≥ Grade 2.

          -  Currently receiving treatment with therapeutic doses of warfarin sodium. Low molecular
             weight heparin and oral Xa inhibitors are allowed.

          -  Have initiated treatment with bisphosphonates or approved receptor activator of
             nuclear factor kappa-B ligand (RANK-L) targeted agents (e.g. denosumab) ≤ 28 days
             prior to Day 1 of Cycle 1.

          -  Concurrent serious infection requiring parenteral antibiotic therapy.

          -  Have a second primary malignancy that in the judgment of the investigator and Medical
             Monitor may affect the interpretation of results.

          -  Have an active, known fungal, bacterial, and/or known viral infection.

          -  History of arterial or venous embolism within 3 months prior to study enrollment. If
             the embolism occurred >3 and <6 months, the participant is eligible provided
             appropriate treatment according to institutional standard of care is ensured.
      "
NCT02449655,terminated,"
    lack of efficacy
  ",0,phase 2,['advanced gastric adenocarcinoma'],"[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['azd5363', 'paclitaxel', 'azd2014', 'paclitaxel']","['C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C', 'CC1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=CC=C4)C(=O)NC)N5CCOCC5C', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C']","
        Inclusion Criteria:

          1. Provision of fully informed consent prior to any study specific procedures.

          2. Patients must be ≥20 years of age.

          3. Advanced gastric adenocarcinoma that has progressed during or after first-line
             therapy.

               -  The 1st line regimen must have contained doublet 5-fluoropyrimidine and platinum
                  based regimen.

               -  Relapse within 6 months of completion of adjuvant/neoadjuvant chemotherapy
                  containing doublet 5-fluoropyrimidine and platinum-based regimen could be
                  considered as first line therapy.

          4. Previous adjuvant/neoadjuvant chemotherapy is allowed, if completed more than 6 months
             prior to starting the first line therapy.

          5. Provision of tumor sample (from either a resection or biopsy)

          6. Patients with biomarker negative

          7. Patients are willing and able to comply with the protocol for the duration of the
             study including undergoing treatment and scheduled visits and examinations.

          8. Eastern Cooperative Oncology Group performance status 0-1.

          9. Patients must have a life expectancy ≥ 3 months from proposed first dose date.

         10. Patients must have acceptable bone marrow, liver and renal function measured within 28
             days prior to administration of study treatment as defined below:

               -  Haemoglobin ≥9.0 g/dL (transfusion allowed)

               -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L

               -  White blood cells (WBC) > 3 x 109/L

               -  Platelet count ≥100 x 109/L (transfusion allowed)

               -  Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN)

               -  AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal unless liver
                  metastases are present in which case it must be ≤ 5x ULN

               -  Serum creatinine ≤1.5 x institutional ULN

         11. At least one measurable lesion that can be accurately assessed by imaging or physical
             examination at baseline and following up visits.

         12. Negative urine or serum pregnancy test within 28 days of study treatment, confirmed
             prior to treatment on day 1.

        Exclusion Criteria:

          1. More than one prior chemotherapy regimen (except for adjuvant/neoadjuvant chemotherapy
             with more than 6 month wash out period) for the treatment of gastric cancer in the
             advanced setting.

          2. Any previous treatment with PIK3CA, AKT or mTOR inhibitor or agents with mixed PI3K /
             mTOR activity.

          3. Any previous treatment with paclitaxel

          4. Patients with second primary cancer, except: adequately treated non-melanoma skin
             cancer, curatively treated in-situ cancer of the cervix, or other solid tumours
             curatively treated with no evidence of disease for ≤5 years.

          5. HER2 positive patients

          6. Patients unable to swallow orally administered medication.

          7. Any investigational drug or product administered within 30 days or 5 half-lives,
             whichever is longer, of the first dose of AZD5363.

          8. Patients receiving any systemic chemotherapy, radiotherapy (except for palliative
             reasons), within 3 weeks from the last dose prior to study treatment (or a longer
             period depending on the defined characteristics of the agents used). The patient can
             receive a stable dose of bisphosphonates or denusomab for bone metastases, before and
             during the study as long as these were started at least 4 weeks prior to treatment.

          9. Previous major surgery within 4weeks prior to enrollment.

         10. For AZD2014: Exposure to potent or moderate inhibitors or inducers of CYP3A4/5 if
             taken within the stated washout periods before the first dose of study treatment

         11. With the exception of alopecia, any ongoing toxicities (>Common Toxicity Criteria for
             Adverse Effects grade 1) caused by previous cancer therapy.

         12. Intestinal obstruction or Common Toxicity Criteria for Adverse Effects grade 3 or
             grade 4 upper GI bleeding within 4 weeks before the enrollment.

         13. Resting ECG with measurable QTcB > 480 msec on 2 or more time points within a 24 hour
             period or family history of long QT syndrome.

         14. Patients with cardiac problem as follows: uncontrolled hypertension (BP ≥150/95 mmHg
             despite medical therapy) Left ventricular ejection fraction <55% measured by
             echocardiography, Atrial fibrillation with a ventricular rate >100 bpm on ECG at rest
             , Symptomatic heart failure (NYHA grade II-IV), Prior or current cardiomyopathy,
             Severe valvular heart disease, Uncontrolled angina (Canadian Cardiovascular Society
             grade II-IV despite medical therapy), Acute coronary syndrome within 6 months prior to
             starting treatment

         15. Active or untreated brain metastases or spinal cord compression Patients with treated
             brain metastases or spinal cord compression are eligible if they have minimal
             neurologic symptoms, evidence of stable disease (for at least 1 month) or response on
             follow-up scan, and require no corticosteroid therapy for ≥ 1 week.

         16. Female patients who are breast-feeding or child-bearing

         17. Any evidence of severe or uncontrolled systemic disease, active infection, active
             bleeding diatheses or renal transplant, including any patient known to have hepatitis
             B, hepatitis C or human immunodeficiency virus (HIV)

         18. Patients with proteinuria (3+ on dipstick analysis )
      "
NCT02440178,completed,,1,phase 2,['acute leukemia'],"[""['C91.01', 'C91.02', 'C92.01', 'C92.02', 'C92.41', 'C92.42', 'C92.51']""]",['micafungin'],['CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC(=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)C(CC(=O)N)O)C)O)O)O'],"
        Inclusion Criteria:

        A. patients belong to either A-1 or A-2 A-1. patients with newly diagnosed acute myeloid
        leukemia who approve to get induction chemotherapy with (cytarabine plus idarubicin) or
        (modified Fludarabine + cytarabine + idarubicin ) A-2. patients with newly diagnosed acute
        lymphoid leukemia who approve to get induction chemotherapy with VPDL (vincristine +
        prednisolone + daunorubicin + L-asparaginase), C-VPDL (cyclophosphamide + vincristine +
        prednisolone + daunorubicin + L-asparaginase), or (R)-hyperCVAD ((Rituximab) +
        cyclophosphamide + vincristine + Adriamycin + dexamethasone) B. Eastern Cooperative
        Oncology Group performance status score is equal to or more than 2 C. patients who
        voluntarily sign the agreement

        Exclusion Criteria:

        A. evidence of proven/probable/possible fungal infection within 30 days before induction
        chemotherapy B. hypersensitivity to echinocandin C. patients had other malignancy within 5
        years D. previous treatment history with chemotherapy, radiation therapy, or
        immunosuppressive therapy.

        E. pregnant or breast-feeding women F. immunodeficient patients including AIDS G. patients
        with uncontrolled seizure or psychiatric disorder H. clinically significant heart disorder
        (myocardial infarction within 3 months or left ventricular ejection fraction < 40%) I.
        interstitial lung disease J. previous organ transplantation history K. galactose
        intolerance L. patients who participated this study before.
      "
NCT04155840,terminated,"
    terminated due to low accrual
  ",0,phase 2,"['lymphoid leukemia', ""non-hodgkin's lymphoma"", 'chronic lymphocytic leukemia', 'small lymphocytic lymphoma']","[""['C91.Z1', 'C91.Z2', 'C91.91', 'C91.92', 'C91.Z0', 'C91.90']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['C91.11', 'C91.12', 'C91.10']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']""]","['copanlisib', 'bendamustine']","['COC1=C(C=CC2=C3NCCN3C(=NC(=O)C4=CN=C(N=C4)N)N=C21)OCCCN5CCOCC5', 'CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O']","
        Inclusion Criteria:

          -  Histologically confirmed, non-17p del chronic lymphocytic leukemia (CLL)/small
             lymphocytic lymphoma (SLL) with any of the three following conditions:

               -  No prior CLL/SLL directed therapy and Cumulative Illness Rating Scale (CIRS)
                  score >= 7

               -  Age >= 65

               -  At least one prior CLL/SLL directed therapy with any CIRS score

          -  CLL/SLL requiring treatment as defined by at least one of the following criteria based
             on IWCLL 2018 guidelines:

               -  Evidence of progressive marrow failure as manifested by the development of, or
                  worsening of, anemia and/or thrombocytopenia

               -  Massive (> 6 cm below left costal margin), progressive or symptomatic
                  splenomegaly

               -  Massive nodes (> 10 cm in longest diameter), or progressive or symptomatic
                  lymphadenopathy

               -  Progressive lymphocytosis with an increase of > 50% over a 2-month period or
                  lymphocyte-doubling time of < 6 months. Lymphocyte-doubling time may be obtained
                  by linear regression extrapolation of absolute lymphocyte counts obtained at
                  intervals of 2 weeks over an observation period of 2 to 3 months. In patients
                  with initial blood lymphocyte counts of < 30x10^9/L (30,000/uL),
                  lymphocyte-doubling time should not be used as a single parameter to define
                  treatment indication. In addition, factors contributing to lymphocytosis or
                  lymphadenopathy other than CLL/SLL (eg, infection, steroid administration) should
                  be excluded

               -  Constitutional symptoms, defined as any 1 or more of the following
                  disease-related symptoms or signs:

                    -  Unintentional weight loss of > 10% within the previous 6 months

                    -  Significant fatigue (ie, inability to work or perform usual activities)

                    -  Fevers > 100.5 degrees Fahrenheit (F) or 38 degrees Celsius (C) for? 2 weeks
                       without other evidence of infection

               -  Night sweats for > 1 month without evidence of infection

          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 2

          -  Previous exposure to other PI3K inhibitors (except copanlisib) is acceptable provided
             there is no resistance (resistance defined as no response [response defined as partial
             response (PR) or complete response (CR)]) at any time during therapy, or progressive
             disease (PD) after any response (PR/CR) or after stable disease within 6 months from
             the end of the therapy with a PI3K inhibitor

          -  Willingness and ability to comply with study and follow-up procedures, and give
             written informed consent

          -  Female subjects of childbearing potential must be surgically sterile, be
             post-menopausal (per institutional guidelines), or must have a negative serum
             pregnancy test within 7 days prior to cycle 1 day 1 and agree to use medically
             acceptable contraception throughout the study period and for 4 months after the last
             dose of either study drug. Men of reproductive potential may not participate unless
             they agree to use medically acceptable contraception throughout the study period and
             for 4 months after the last dose of either study drug

          -  Patients must be expected to receive at least 2 cycles of therapy

          -  Patients should have an expected survival if untreated of >= 90 days

          -  Total bilirubin =< 1.5 x upper limit of normal (ULN) (< 3 x ULN for patients with
             Gilbert-Meulengracht syndrome or for patients with cholestasis due to compressive
             adenopathies of the hepatic hilum) (collected no more than 7 days before starting
             study treatment)

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5
             x ULN for patients with liver involvement by lymphoma) (no more than 7 days before
             starting study treatment)

          -  Lipase =< 1.5 x ULN (no more than 7 days before starting study treatment)

          -  Glomerular filtration rate (GFR) >= 30 mL/min/1.73 m^2 according to the Modification
             of Diet in Renal Disease (MDRD) abbreviated formula (no more than 7 days before
             starting study treatment). If not on target, this evaluation may be repeated once
             after at least 24 hours either according to the MDRD abbreviated formula or by 24 hour
             sampling. If the later result is within acceptable range, it may be used to fulfill
             the inclusion criteria instead

          -  International normalized ratio (INR) =< 1.5 and partial thromboplastin time (PTT) =<
             1.5 x ULN. Prothrombin time (PT) can be used instead of INR if =< 1.5 x ULN (collected
             no more than 7 days before starting study treatment)

          -  Platelet count >= 75,000 /mm^3. For patients with confirmed lymphomatous bone marrow
             infiltration, platelet count >= 50,000 /mm^3 (collected no more than 7 days before
             starting study treatment)

          -  Hemoglobin (Hb) >= 8 g/dL (collected no more than 7 days before starting study
             treatment). Packed red blood cell transfusion or erythropoietin should not be given
             less than 7 days before the exam collection

          -  Absolute neutrophil count (ANC) >= 1,000/mm^3 (collected no more than 7 days before
             starting study treatment). For patients with confirmed lymphomatous bone marrow
             infiltration, ANC count >= 750/mm^3. Myeloid growth factors should not be given less
             than 7 days before the exam collection

        Exclusion Criteria:

          -  Presence of chromosome 17p deletion, known p53 deletion, or known p53 mutation that
             impairs normal function

          -  Prior treatment including systemic therapy or radiotherapy within 21 days of study
             initiation

          -  Prior treatment with bendamustine within 2 years

          -  Prior treatment with copanlisib

          -  Documented evidence of resistance to prior treatment with idelalisib or other PI3K
             inhibitors defined as: No response (response defined as partial response [PR] or
             complete response [CR]) at any time during therapy, or Progression (PD) after any
             response (PR/CR) or after stable disease within 6 months from the end of the therapy
             with a PI3K inhibitor

          -  Active autoimmune disease or prior autoimmune disease requiring systemic
             immunosuppression within the past 6 months

          -  Poorly controlled diabetes mellitus defined as hemoglobin A1c > 8.5%

          -  Known lymphomatous involvement of the central nervous system

          -  Known history of human immunodeficiency virus (HIV) infection. All patients must be
             screened for HIV up to 28 days prior to study drug start using a blood test for HIV
             according to local regulations

          -  Hepatitis B (hepatitis B virus [HBV]) or C (hepatitis C virus [HCV]) infection. All
             patients must be screened for HBV and HCV up to 28 days prior to study drug start
             using the routine hepatitis virus laboratorial panel. Patients positive for hepatitis
             B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) will be eligible if
             they are negative for HBV-deoxyribonucleic acid (DNA), these patients should receive
             prophylactic antiviral therapy. Patients positive for anti-HCV antibody will be
             eligible if they are negative for HCV-ribonucleic acid (RNA)

          -  Previous or concurrent history of malignancies within 3 years prior to study. Any
             exceptions beyond those listed below must be approved by the principal investigator:

               -  Cervical carcinoma in situ

               -  Non-melanoma skin cancer

               -  Superficial bladder cancer (Ta [non-invasive tumor], Tis [carcinoma in situ] and
                  T1 [tumor invades lamina propria])

               -  Localized prostate cancer

          -  Active, clinically serious infections (> Common Terminology Criteria for Adverse
             Events [CTCAE] grade 2)

          -  Known hypersensitivity to any of the study drugs, study drug classes, or excipients in
             the formulation

          -  Proteinuria of >= CTCAE grade 3 as assessed by a 24 hours (h) total urine protein
             quantification or estimated by urine protein : creatinine ratio > 3.5 on a random
             urine sample

          -  Unresolved toxicity from prior therapy higher than National Cancer Institute
             (NCI)-CTCAE grade 1 attributed to any prior therapy/procedure excluding alopecia or
             sensory neuropathy. Concurrent diagnosis of pheochromocytoma

          -  Pregnant or breast-feeding patients. Women of childbearing potential must have a
             pregnancy test performed a maximum of 7 days before start of treatment, and a negative
             result must be documented before start of treatment

          -  Substance abuse, medical, psychological or social conditions that may interfere with
             the patient's participation in the study or evaluation of the study result

          -  Congestive heart failure > New York Heart Association (NYHA) class 2

          -  Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3
             months)

          -  Myocardial infarction less than 6 months before start of test drug

          -  Uncontrolled arterial hypertension despite optimal medical management (per
             investigator's assessment)

          -  Arterial or venous thrombotic or embolic events such as cerebrovascular accident
             (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism
             within 3 months before the start of study treatment

          -  Non-healing wound, ulcer, or bone fracture

          -  Patients with seizure disorder requiring medication

          -  Patients with evidence or history of bleeding diathesis. Any hemorrhage or bleeding
             event >= CTCAE grade 3 within 4 weeks prior to the start of study treatment

          -  Any illness or medical conditions that are unstable or could jeopardize the safety of
             the patients and their compliance in the study

          -  History of having received an allogeneic bone marrow or organ transplant

          -  Anti-arrhythmic therapy (beta blockers or digoxin are permitted)

          -  Major surgical procedure or significant traumatic injury (as judged by the
             investigator) less than 28 days before start of treatment, open biopsy less than 7
             days before start of treatment

          -  Systemic continuous corticosteroid therapy at a daily dose higher than 15 mg
             prednisone or equivalent is not allowed. Patients may be using topical or inhaled
             corticosteroids. Previous corticosteroid therapy must be stopped or reduced to the
             allowed dose at least 7 days performing the screening computed tomography
             (CT)/magnetic resonance imaging (MRI). If a patient is on chronic corticosteroid
             therapy, corticosteroids should be de-escalated to the maximum allowed dose before the
             screening. Patients may be using topical or inhaled corticosteroids

          -  Use of CYP3A4 inhibitors and inducers. Copanlisib is primarily metabolized by CYP3A4.
             Therefore, concomitant use of strong inhibitors of CYP3A4 (e.g., ketoconazole,
             itraconazole, clarithromycin, ritonavir, indinavir, nelfinavir and saquinavir), and
             strong inducers of CYP3A4 (e.g., rifampin, phenytoin, carbamazepine, phenobarbital,
             St. John's wort) are not permitted from day -14 of cycle 1 until the end of treatment
             visit
      "
NCT02835924,completed,,0,phase 2,['metastatic colorectal cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]",['regorafenib'],['Status: 503'],"
        Inclusion Criteria:

          1. Signed informed consent (IC) obtained before any study specific procedures. Subjects
             must be able to understand and willing to sign a written informed consent.

          2. Male or female subjects 18 years of age.

          3. Life expectancy of at least 3 months.

          4. Histological or cytological documentation of adenocarcinoma of the colon or rectum.
             All other histological types are excluded.

          5. Measurable metastatic stage IV disease with at least 1 measurable metastatic lesion
             following RECIST criteria v 1.1.

          6. Subjects with metastatic colorectal cancer (Stage IV).

          7. Progression during or within 3 months following the last administration of approved
             standard therapies which must include fluoropyrimidine, oxaliplatin, irinotecan, an
             anti-VEGF and an anti-EGFR (if RAS WT)

          8. Subjects treated with oxaliplatin in an adjuvant setting should have progressed during
             or within 6 months of completion of adjuvant therapy

          9. Subjects who progress more than 6 months after completion of oxaliplatin containing
             adjuvant treatment must be retreated with oxaliplatin-based therapy to be eligible.
             Subjects who have withdrawn from standard treatment due to unacceptable toxicity
             warranting discontinuation of treatment and precluding retreatment with the same agent
             prior to progression of disease will also be allowed into the study

         10. ECOG Performance Status of 0 or 1(within 14 days prior to the initiation of study
             treatment)

         11. Adequate bone marrow, liver and renal function as assessed by the following laboratory
             requirements:

               -  Total bilirubin =1.5 x the upper limit of normal (ULN).

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.5 x ULN
                  (5 x ULN for subjects with liver involvement of their cancer).

               -  Alkaline phosphatase limit = 2.5 x ULN (5 x ULN for subjects with liver and/or
                  bone involvement of their cancer).

               -  Lipase = 1.5 x the ULN.

               -  Serum creatinine 1.5 x the ULN or = 30 mL/min as calculated using the
                  Cockcroft-Gault equation.

               -  Platelet count >100000/mm3, hemoglobin >9 g/dL, absolute neutrophil count (ANC)
                  >1500/mm3.

               -  International normalized ratio (INR)/ Partial thromboplastin time (PTT) 1.5 x
                  ULN. (Subjects who are therapeutically treated with an agent such as warfarin or
                  heparin will be allowed to participate provided that no prior evidence of
                  underlying abnormality in coagulation parameters exists. Close monitoring of at
                  least weekly evaluations will be performed until INR/PTT is stable based on a
                  measurement that is pre-dose as defined by the local standard.

               -  Blood transfusion to meet the inclusion criteria will not be allowed.

         12. Women of childbearing potential and men must agree to use adequate contraception
             before entering the program until at least 8 weeks after the last study drug
             administration. The investigator or a designated associate is requested to advise the
             subject on how to achieve an adequate birth control. Adequate contraception is defined
             in the study as any medically recommended method (or combination of methods) as per
             standard of care. Women of childbearing potential must have a blood or urine pregnancy
             test performed a maximum of 7 days before start of study treatment, and a negative
             result must be documented before start of study treatment.

        Exclusion Criteria:

          1. Prior treatment with regorafenib.

          2. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             before start of study drug

          3. Pregnant or breast-feeding subjects:

          4. Congestive heart failure = New York Heart Association (NYHA) class 2.

          5. Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3
             months).

          6. Myocardial infarction less than 6 months before start of study drug.

          7. Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are
             permitted).

          8. Uncontrolled hypertension. (Systolic blood pressure > 140 mmHg or diastolic pressure
             >90 mmHg despite optimal medical management).

          9. Arterial or venous thromboembolism within 6 months prior to randomization.

         10. Pleural effusion or ascites that causes respiratory compromise (CTCAE Grade 2
             dyspnea).

         11. Ongoing infection > Grade 2 CTCAE v. 4.0.

         12. Known history of human immunodeficiency virus (HIV) infection.

         13. Known history of active hepatitis B or C, or chronic hepatitis B or C requiring
             treatment with antiviral therapy.

         14. Subjects with seizure disorder requiring medication.

         15. History of organ allograft.

         16. Subjects with evidence or history of any bleeding diathesis, irrespective of severity.

         17. Any hemorrhage or bleeding event = CTCAE Grade 3 within 4 weeks prior to the start of
             study medication.

         18. Non-healing wound, ulcer, or bone fracture.

         19. Renal failure requiring hemo-or peritoneal dialysis.

         20. Dehydration CTCAE v. 4.0 Grade = 1.

         21. Substance abuse, medical, psychological or social conditions that may interfere with
             the subject's participation in the study or evaluation of the study results.

         22. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in
             the formulation.

         23. Any illness or medical conditions that are unstable or could jeopardize the safety of
             the subject and his/her compliance in the study.

         24. Interstitial lung disease with ongoing signs and symptoms

         25. Persistent proteinuria of CTCAE Grade 3 (>3.5g/24 hours).

         26. Subjects unable to swallow oral medications.

         27. Any malabsorption condition.

         28. Unresolved toxicity higher than CTCAE (v. 4.0) > Grade 1 attributed to any prior
             therapy/procedure excluding alopecia, hypothyroidism and oxaliplatin induced
             neurotoxicity > Grade 2.

         29. Subjects treated with strong CYP3A4 inhibitors or inducers (refer to appendix 8 and to
             section 6.3.8. Prohibited concomitant medication).

         30. Subjects receiving G-CSF within 3 weeks prior to signing the ICF

         31. Concomitant participation or participation within the last 30 days in another clinical
             trial

         32. Systemic anticancer therapy including cytotoxic therapy, signal transduction
             inhibitors, immunotherapy, and hormonal therapy during this trial or within 4 weeks
             (or within 6 weeks for mitomycin C) before starting to receive study medication.
      "
NCT02837042,terminated,"
    poor accrual
  ",0,phase 2,['penile squamous cell carcinoma'],"[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]",['pembrolizumab'],['Status: 503'],"
        Inclusion Criteria:

          1. Locally advanced unresectable or metastatic stage 4 (i.e. T4 or N3 or M1) PSCC

          2. Radiologic evidence for progressive disease after ≥1 prior chemotherapy regimen

          3. Be at least 18 years of age on day of signing informed consent.

          4. Have measurable disease based on RECIST 1.1.

          5. Have a performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG)
             Performance Scale.

          6. Demonstrate adequate organ function with all screening labs being performed within 14
             days of treatment initiation.

               -  Absolute neutrophil count (ANC) ≥1,500 /microLiters (mcL)

               -  Platelets ≥100,000/mcL

               -  Hemoglobin ≥9 g/dL or ≥5.6 mmol/L without transfusion or erythropoietin
                  dependency (within 7 days of assessment)

               -  Serum creatinine ≤1.5 X upper limit of normal (ULN); alternately measured or
                  calculated creatinine clearance ≥30 mL/min with creatinine levels >1.5 X
                  institutional ULN (GFR can also be used in place of creatinine or CrCl)

               -  Serum total bilirubin ≤1.5 X ULN or direct bilirubin ≤ ULN for subjects with
                  total bilirubin levels >1.5 ULN

               -  Aspartate Transaminase (AST), also known as Serum Glutamic-Oxaloacetic
                  Transaminase (SGOT) and Alanine Aminotransferase (ALT), also known as Serum
                  Glutamic-Pyruvic Transaminase (SGPT) ≤ 2.5 X ULN or ≤ 5 X ULN for subjects with
                  liver metastases

               -  Albumin >2.5 mg/dL

               -  International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 X ULN unless
                  subject is receiving anticoagulant therapy as long as PT or PTT is within
                  therapeutic range of intended use of anticoagulants

               -  Activated Partial Thromboplastin Time (aPTT) ≤1.5 X ULN unless subject is
                  receiving anticoagulant therapy as long as PT or PTT is within therapeutic range
                  of intended use of anticoagulants

          7. Subjects should agree to use an adequate method of contraception starting with the
             first dose of study therapy through 120 days after the last dose of study therapy

          8. Formalin-fixed paraffin embedded (FFPE) tumor tissue from previous biopsy is
             requested, but not mandatory.

          9. Be willing and able to provide written informed consent/assent for the trial.

        Exclusion Criteria:

          1. Is currently participating and receiving study therapy or has participated in a study
             of an investigational agent and received study therapy or used an investigational
             device within 4 weeks of the first dose of treatment.

          2. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
             other form of immunosuppressive therapy within 7 days prior to the first dose of trial
             treatment.

          3. Has a known history of active Bacillus Tuberculosis (TB)

          4. Hypersensitivity to Pembrolizumab or any of its excipients.

          5. Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study
             Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events
             due to agents administered more than 4 weeks earlier.

          6. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy
             within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at
             baseline) from adverse events due to a previously administered agent.

               -  Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and
                  may qualify for the study.

               -  Note: If subject received major surgery, they must have recovered adequately from
                  the toxicity and/or complications from the intervention prior to starting
                  therapy.

          7. Has a known additional malignancy that is progressing or requires active treatment.
             Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the
             skin that has undergone potentially curative therapy or in situ cervical cancer.

          8. Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis. Subjects with previously treated brain metastases may participate provided
             they are stable (without evidence of progression by imaging for at least four weeks
             prior to the first dose of trial treatment and any neurologic symptoms have returned
             to baseline), have no evidence of new or enlarging brain metastases, and are not using
             steroids for at least 7 days prior to trial treatment. This exception does not include
             carcinomatous meningitis which is excluded regardless of clinical stability.

          9. Has active autoimmune disease that has required systemic treatment in the past 2 years
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive
             drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
             form of systemic treatment.

         10. Has known history of, or any evidence of active, non-infectious pneumonitis.

         11. Has an active infection requiring systemic therapy.

         12. Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the subject's
             participation for the full duration of the trial, or is not in the best interest of
             the subject to participate, in the opinion of the treating investigator.

         13. Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial.

         14. Is pregnant expecting to father children within the projected duration of the trial,
             starting with the pre-screening or screening visit through 120 days after the last
             dose of trial treatment.

         15. Has received prior therapy with an anti-Programmed Cell Death-1 (PD-1), anti-PD-Ligand
             1 (L1), or anti-PD-Ligand 2 (L2) agent.

         16. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).

         17. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (HCV) (e.g., HCV
             RNA [qualitative] is detected).

         18. Has known active Tuberculosis infection.

         19. Has received a live vaccine within 30 days of planned start of study therapy. Note:
             Seasonal influenza vaccines for injection are generally inactivated flu vaccines and
             are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live
             attenuated vaccines, and are not allowed.
      "
NCT02253212,completed,,1,phase 1/phase 2,"['glioblastoma', 'glioma', 'brain tumor']","[""['C71.7', 'C71.9', 'C79.31', 'D33.0', 'D33.1', 'D33.2', 'D49.6']""]",['carboplatin'],['Status: 503'],"
        Inclusion criteria:

          -  Age greater than 18 years.

          -  Subjects with recurrent glioma who have failed standard therapy with surgery and/or
             treatment with radiation and temozolomide.

          -  Patient eligible for Carboplatin-based chemotherapy

          -  Contrast-enhanced tumor less than 35 mm in diameter

          -  No risk of cerebral herniation

          -  Able to tolerate pre/post procedure steroid treatment

          -  Social security affiliated (in France)

          -  Able and willing to give signed and informed consent

          -  Normal biological status

          -  Hemoglobin ≥ 10 g/dl

          -  Platelets ≥ 100000/mm3

          -  Neutrophils ≥ 1500/mm3

          -  Normal creatine clearance ≥ 60ml/mn

          -  ASAT < 3 N

          -  ALAT < 3 N

          -  Normal Bilirubin Level < 1.5 N

          -  Alkaline Phosphatase < 3 N

          -  INR < 1.5

          -  Prothrombin Level ≥ 70%

        Exclusion criteria:

          -  Allergic to Iodine, Gadolinium, Xylocain

          -  Contra-indications to echographic contrast agent (microbubbles)

          -  Severe Renal insufficiency

          -  Hepatic insufficiency

          -  Possible toxic treatment for CNS

          -  Previously infected surgical field

          -  Uncontrolled epilepsy

          -  MRI contra-indications

          -  Hemostasis troubles thrombopenia <75.000, TP <60%, INR >1.5, anti-platelet or
             anticoagulant therapy on-going)

          -  Active phlebitis or active pulmonary embolism

          -  Pregnant or currently breast-feeding

          -  Patients under judicial protection
      "
NCT02250326,"active, not recruiting",,0,phase 2,"['carcinoma, non-small-cell lung']","[""['D02.20', 'D02.21', 'D02.22']""]","['nab-paclitaxel iv', 'cc-486', 'duravalumab']","['Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria: 1.Age ≥ 18 years the time of signing the Informed Consent Form (ICF).

        2. Understand and voluntarily provide written informed consent prior to the conduct of any
        study related assessments/procedures.

        3. Able to adhere to the study visit schedule and other protocol requirements. 4.
        Histologically or cytologically confirmed advanced NSCLC who will receive study therapy as
        second- or third-line of treatment for advanced disease.

        5. No other current active malignancy requiring anticancer therapy. 6. Radiographically
        documented measurable disease (defined by the presence of ≥ 1 radiographically documented
        measurable lesion).

        7. One prior platinum-containing chemotherapy for metastatic or recurrent NSCLC unless
        patients are ineligible to receive it. Patients may have received no more than one line of
        chemotherapy; immunotherapy in prior line of treatment (first or second line) is allowed.
        Absolute neutrophil count (ANC) ≥ 1500 cells/mm3.

        8. Platelets ≥ 100,000 cells/mm3. 9. Hemoglobin (Hgb) ≥ 9 g/dL. 10. Aspartate transaminase
        (AST/serum glutamic oxaloacetic transaminase [SGOT]) and alanine transaminase (ALT/serum
        glutamic pyruvic transaminase [SGPT]) ≤ 2.5 × upper limit of normal range (ULN) or ≤ 5.0 ×
        ULN if liver metastases.

        11. Total bilirubin ≤ 1.5 ULN (unless there is a known history of Gilberts Syndrome).

        12. Serum creatinine ≤ 1.5 x ULN, or calculated creatinine clearance ≥ 60 mL/min (if renal
        impairment is suspected 24-hour urine collection for measurement is required).

        13. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. 14. Eastern
        Cooperative Oncology Group (ECOG) performance status 0 or 1. 15. Females of childbearing
        potential [defined as a sexually mature woman who (1) have not undergone hysterectomy (the
        surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both
        ovaries) or (2) have not been naturally postmenopausal for at least 24 consecutive months
        (ie, has had menses at any time during the preceding 24 consecutive months)] must:

          1. Have a negative pregnancy test (ß-hCG) as verified by the study doctor within 72 hours
             prior to starting study therapy. She must agree to ongoing pregnancy testing during
             the course of the study, and after end of study therapy. This applies even if the
             subject practices true abstinence* from heterosexual contact.

          2. Either commit to true abstinence* from heterosexual contact (which must be reviewed on
             a monthly basis) or agree to use, and be able to comply with, effective contraception
             without interruption, 28 days prior to starting investigational product (IP), during
             the study therapy (including dose interruptions), and for 3 months after
             discontinuation of study therapy.

        Male subjects must:

          1. Practice true abstinence* or agree to use a condom during sexual contact with a
             pregnant female or a female of childbearing potential while participating in the
             study, during dose interruptions and for at least 6 months following IP
             discontinuation, even if he has undergone a successful vasectomy.

          2. Refrain from semen or sperm donation while taking durvalumab and for at least 3 months
             after the last dose of durvalumab.

             16. Females must abstain from breastfeeding during study participation and 3 months
             after IP discontinuation.

             Exclusion Criteria:

               -  The presence of any of the following will exclude a subject from enrollment:

                    1. Refractory to prior taxane therapy for advanced disease. Prior taxane used
                       in the adjuvant setting does not exclude eligibility, provided there is no
                       disease recurrence within 12 months upon completion of chemotherapy in that
                       setting.

                    2. Evidence of active brain metastases, including leptomeningeal involvement
                       (prior evidence of brain metastasis are permitted only if asymptomatic and
                       clinically stable for at least 8 weeks following completion of therapy). MRI
                       of the brain (or CT scan w/contrast) is preferred.

                    3. Only evidence of disease is non-measurable at study entry.

                    4. Known activating EGFR mutations (such as exon 19 deletions or L858R).

                    5. Known activating EML4-ALK mutations.

                    6. Preexisting peripheral neuropathy of Grade > 2 (per NCI CTCAE v4.0).

                    7. Any unresolved toxicity NCI CTCAE Grade ≥ 2 from previous anticancer therapy
                       with the exception of alopecia, vitiligo, and the laboratory values defined
                       in the inclusion criteria.

                    8. Venous thromboembolism within 1 month prior to Cycle 1 Day 1.

                    9. Current congestive heart failure (New York Heart Association Class II-IV).

                   10. History of the following within 6 months prior to Cycle 1 Day 1: a
                       myocardial infarction, severe/unstable angina pectoris, coronary/peripheral
                       artery bypass graft, New York Heart Association (NYHA) Class III-IV heart
                       failure, uncontrolled hypertension, clinically significant cardiac
                       dysrhythmia or clinically significant electrocardiogram (ECG) abnormality,
                       cerebrovascular accident, transient ischemic attack, or seizure disorder.

                   11. Known hepatitis B or C virus (HBV/HCV) infection, known history of human
                       immunodeficiency virus (HIV) infection, or receiving immunosuppressive or
                       myelosuppressive medications that would in the opinion of the investigator,
                       increase the risk of serious neutropenic complications, history of active
                       primary immunodeficiency, active tuberculosis (clinical evaluation that
                       includes clinical history, physical examination and radiographic findings,
                       and TB testing in line with local practice).

                   12. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring
                       systemic therapy, defined as ongoing signs/symptoms related to the infection
                       without improvement despite appropriate antibiotics, antiviral therapy,
                       and/or other treatment.

                   13. History of interstitial lung disease, history of slowly progressive dyspnea
                       and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary
                       fibrosis, or pulmonary hypersensitivity pneumonitis or multiple allergies.
                       Any lung disease that may interfere with the detection or management of
                       suspected drug-related pulmonary toxicity.

                   14. Subject has a clinically significant malabsorption syndrome, persistent
                       diarrhea, or known sub-acute bowel obstruction > NCI CTCAE Grade 2, despite
                       medical management.

                   15. Treatment with any chemotherapy, investigational product, biologic or
                       hormonal therapy for cancer treatment within 28 days prior to signing the
                       ICF. Concurrent use of hormonal therapy for non-cancer-related conditions
                       (e.g. hormone replacement therapy) is acceptable.

                   16. History of or suspected allergy to any IP or their excipients.

                   17. Major surgical procedure (as defined by the Investigator) within 28 days
                       prior to the first dose of IP. Note: Local surgery of isolated lesions for
                       palliative intent is acceptable.

                   18. Currently enrolled in any other clinical protocol or investigational trial
                       that involves administration of experimental therapy and/or therapeutic
                       devices.

                   19. Any other clinically significant medical condition, psychiatric illness,
                       and/or organ dysfunction that will interfere with the administration of the
                       therapy according to this protocol or which, in the views of investigator,
                       preclude combination chemotherapy.

                   20. Any other malignancy within 5 years prior to randomization/treatment
                       assignement, or advanced malignant hepatic tumors, with the exception of
                       adequately treated squamous cell carcinoma of the skin, in-situ carcinoma of
                       the cervix, uteri, non-melanomatous skin cancer, carcinoma in situ of the
                       breast, or incidental histological finding of prostate cancer (TNM
                       Classification of Malignant Tumours (TNM) stage of T1a or T1b). (All
                       treatment of which should have been completed 6 months prior to signing
                       ICF).

                   21. Radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks
                       prior to starting IP, and/or from whom ≥ 30% of the bone marrow was
                       irradiated. Prior radiation therapy to a target lesion is permitted only if
                       there has been clear progression of the lesion since radiation was
                       completed.

                   22. Any condition including the presence of laboratory abnormalities, which
                       places the subject at unacceptable risk if he/she were to participate in the
                       study.

                   23. Any medical condition that confounds the ability to interpret data from the
                       study.

                   24. Female patients who are pregnant or breastfeeding or female patients of
                       reproductive potential who are not willing to employ effective birth control
                       from screening to 90 days after the last dose of durvalumab.

                   25. Male patients of reproductive potential who are not willing to employ
                       effective birth control from screenin to 90 days after the last dose of
                       durvalumab and from screening to 6 months after the last dose of of
                       nab-paclitaxel.

                   26. History of allogenic organ transplantation.

                   27. Current or prior use of immunosuppressive medication within 14 days before
                       the first dose of durvalumab. The following are exceptions to this
                       criterion:

               -  Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra
                  articular injection)

               -  Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of
                  prednisone or its equivalent

               -  Steroids as premedication for hypersensitivity reactions (eg, CT scan
                  premedication) 28. Receipt of live attenuated vaccine within 30 days prior to the
                  first dose of IP. Note: Patients, if enrolled, should not receive live vaccine
                  during the study and up to 30 days after the last dose of IP.

                  29. Prior enrollment and treatment in a previous durvalumab clinical study. 30.
                  Patients who have received prior anti-PD-1 or anti PD-L1:

               -  Must not have experienced a toxicity that led to permanent discontinuation of
                  prior immunotherapy.

               -  All AEs while receiving prior immunotherapy must have completely resolved or
                  resolved to baseline prior to screening for this study.

               -  Must not have experienced a ≥ Grade 3 immune related AE or an immune related
                  neurologic or ocular AE of any grade while receiving prior immunotherapy. NOTE:
                  Subjects with endocrine AE of ≤ Grade 2 are permitted to enroll if they are
                  stably maintained on appropriate replacement therapy and are asymptomatic.

               -  Must not have required the use of additional immunosuppression other than
                  corticosteroids for the management of an AE, not have experienced recurrence of
                  an AE if re-challenged, and not currently require maintenance doses of > 10 mg
                  prednisone or equivalent per day.
      "
NCT02251548,"active, not recruiting",,1,phase 2,"['chronic lymphocytic leukemia', 'leukemia']","[""['C91.11', 'C91.12', 'C91.10']"", ""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']""]","['ibrutinib', 'fludarabine', 'cyclophosphamide', 'rituximab']","['Status: 503', 'Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Must have a confirmed diagnosis of chronic lymphocytic leukemia or small lymphocytic
             lymphoma. as per IW-CLL 2008 criteria. Patients must also require therapy for that
             diagnosis, based on meeting at least one of the following criteria:

          -  evidence of progressive marrow failure as manifested by the development of, or
             worsening of, anemia (hemoglobin <11.0 g/L) and/or thrombocytopenia (platelets <100 x
             10^9/L)

          -  massive (≥ 6 cm below the left costal margin), progressive, or symptomatic
             splenomegaly

          -  massive nodes (at least 10 cm longest diameter), progressive, or symptomatic
             lymphadenopathy

          -  progressive lymphocytosis with an increase of more than 50% over a 2-month period or
             LDT of <6 months. Lymphocyte doubling time may be obtained by linear regression
             extrapolation of absolute lymphocyte counts obtained at intervals of 2 weeks over an
             observation period of 2 to 3 months. In subjects with initial blood lymphocyte counts
             of <30 x 10^9/L, LDT should not be used as a single parameter to define indication for
             treatment. In addition, factors contributing to lymphocytosis or lymphadenopathy other
             than CLL (eg, infections) should be excluded

          -  autoimmune anemia and/or thrombocytopenia that is poorly responsive to corticosteroids
             or other standard therapy

          -  documented constitutional symptoms, defined as 1 or more of the following
             disease-related symptoms or signs:

               -  unintentional weight loss >10% within 6 months prior to screening

               -  significant fatigue (inability to work or perform usual activities)

               -  fevers >100.5° F or 38.0° C for 2 or more weeks prior to screening without
                  evidence of infection

               -  night sweats for more than 1 month prior to screening without evidence of
                  infection

                    -  No prior CLL-directed therapy that was instituted due to patient previously
                       meeting IW-CLL 2008 criteria for treatment

                    -  Age greater than or equal to 18 years and less than or equal to 65. Because
                       CLL is extremely rare in persons <18 years of age, children are excluded
                       from this study. Because iFCR is an aggressive therapy that is likely to be
                       less well-tolerated even in fit elderly subjects, persons > 65 years of age
                       are excluded

                    -  ECOG performance status ≤ 1

                    -  Adequate hematologic function independent of growth factor support for at
                       least 7 days prior to screening and randomization, with the exception of
                       pegylated G-CSF (pegfilgrastim) and darbepoetin which cannot be administered
                       within 14 days of screening.

          -  Patients must meet the following hematologic criteria at screening:

               -  Absolute neutrophil count ≥ 750 cells/mm3 (0.75 x 109/L).

               -  Platelet count ≥ 50,000 cells/mm3 (50 x 109/L).

               -  Hemoglobin ≥ 8 g/L - Adequate hepatic and renal function defined as:

          -  Serum aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 x upper limit
             of normal (ULN)

               -  Bilirubin ≤ 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of
                  non-hepatic origin)

               -  Adequate renal function defined by serum creatinine >1.5 x ULN

               -  PT/INR <1.5 x ULN and PTT (aPTT) <1.5 x ULN.

               -  The effects of ibrutinib on the developing human fetus are unknown. For this
                  reason and because similar agents are known to be teratogenic, women of
                  child-bearing potential and men must agree to use adequate contraception
                  (hormonal or barrier method of birth control; abstinence) prior to study entry
                  and for the duration of study participation.

        Exclusion Criteria:

          -  Concurrent Conditions:

          -  History of other malignancies, except:

               -  Malignancy treated with curative intent and with no known active disease present
                  for ≥ 3 years before the first dose of study drug and felt to be at low risk for
                  recurrence by treating physician.

               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
                  of disease.

               -  Adequately treated carcinoma in situ without evidence of disease.

          -  Concurrent systemic immunosuppressant therapy (eg, cyclosporine A, tacrolimus, etc.,
             or chronic administration of >20 mg/day of prednisone) within 28 days of the first
             dose of study drug.

          -  Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug.

          -  Recent infection requiring systemic treatment that was completed ≤ 14 days before the
             first dose of study drug.

          -  Known bleeding disorders (eg, von Willebrand's disease) or hemophilia.

          -  History of stroke or intracranial hemorrhage within 6 months prior to enrollment.

          -  Known history of human immunodeficiency virus (HIV) or active with hepatitis C virus
             (HCV) or hepatitis B virus (HBV). Patients who are positive for hepatitis B core
             antibody or hepatitis B surface antigen must have a negative polymerase chain reaction
             (PCR) result before enrollment. Those who are PCR positive will be excluded.

          -  Any uncontrolled active systemic infection.

          -  Major surgery within 4 weeks of first dose of study drug.

          -  Any life-threatening illness, medical condition, or organ system dysfunction that, in
             the investigator's opinion, could compromise the subject's safety or put the study
             outcomes at undue risk.

          -  Currently active, clinically significant cardiovascular disease, such as uncontrolled
             arrhythmia or Class 3 or 4 congestive heart failure as defined by the New York Heart
             Association Functional Classification; or a history of myocardial infarction, unstable
             angina, or acute coronary syndrome within 6 months prior to randomization.

          -  Unable to swallow capsules or malabsorption syndrome, disease significantly affecting
             gastrointestinal function, or resection of the stomach or small bowel, symptomatic
             inflammatory bowel disease or ulcerative colitis, or partial or complete bowel
             obstruction.

          -  Lactating or pregnant.

          -  Patients receiving any other study agents

          -  Patients with known CNS involvement

          -  Baseline QTcF >480 ms. NOTE: This criterion does not apply to patients with a left
             bundle branch block.

          -  Patients who require warfarin or other vitamin K antagonists for anticoagulation
             (other anticoagulants are allowed after consultation with the Principal Investigator).

          -  Concurrent administration of medications or foods that are strong inhibitors or
             inducers of CYP3A

          -  Patients with ongoing use of prophylactic antibiotics are eligible as long as there is
             no evidence of active infection and the antibiotic is not included on the list of
             prohibited medications

          -  Significant co-morbid condition or disease which in the judgment of the Principal
             Investigator would place the patient at undue risk or interfere with the study

          -  Unable to receive prophylactic treatment for pneumocystis

          -  Patients with del(17p) confirmed by FISH in ≥20% of cells or on stimulated
             karyotype3.2.24 Patients with del(17p) confirmed by FISH in ≥20% of cells or on
             stimulated karyotype

          -  Patients with unmutated IGHV who also have a complex karyotype on a stimulated
             karyotype
      "
NCT02257619,terminated,"
    sponsor decision to not initiate part 2 due to slow enrollment and competing trials.
  ",0,phase 2,['nsclc (non-small cell lung carcinoma)'],"[""['D02.20', 'D02.21', 'D02.22']""]","['itacitinib', 'docetaxel']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          1. Histologically or cytologically confirmed diagnosis of NSCLC that is Stage IIIb, IV,
             or recurrent.

          2. Received only 1 prior systemic chemotherapy regimen for Stage IIIb, IV, or recurrent
             disease not including neoadjuvant and/or adjuvant therapy. (NOTE: Exceptions may be
             allowed based on prior treatment regimens and tumor types in agreement with protocol
             requirements.)

          3. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.

          4. Life expectancy of ≥12 weeks.

        Exclusion Criteria:

          1. Received prior treatment with docetaxel.

          2. Known active central nervous system (CNS) metastases. Subjects with CNS metastases who
             have completed a course of therapy would be eligible for the study provided they are
             clinically stable for at least 1 month prior to study entry, defined as:

               1. No evidence of new or enlarging CNS metastasis or new neurological symptoms
                  attributable to CNS metastases.

               2. Subjects who are receiving concomitant corticosteroids must be on a stable or
                  decreasing dose for at least 4 weeks prior to first dose of study treatment and
                  off all anticonvulsants for at least 4 weeks prior to study entry.

          3. Peripheral neuropathy ≥ Grade 3.

          4. Current or previous other malignancy within 2 years of study entry, except cured basal
             or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial
             neoplasm, carcinoma in situ of the cervix, or other noninvasive malignancy.

          5. Significant, concurrent, uncontrolled medical condition including but not limited to,
             renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac,
             neurological, cerebral, or psychiatric disease.

          6. Unwilling to be transfused with blood components.
      "
NCT02257684,terminated,"
    sponsor decision
  ",0,phase 2,"['acute lymphoblastic leukemia', 'lymphoblastic lymphoma']","[""['C91.01', 'C91.02', 'C91.00']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']""]",['pegcrisantaspase'],['Status: 503'],"
        Inclusion Criteria:

          1. Have a diagnosis of ALL/LBL

          2. Be > 1 to ≤ 21 years of age at study enrollment

          3. Have had a ≥ Grade 2 allergic reaction (Common Terminology Criteria for Adverse Events
             [CTCAE] v4.03) to pegaspargase

          4. Have ≥ 1 dose(s) of pegaspargase remaining in his/her treatment plan

          5. Have a documented SAA level that is below the limit of quantitation per the analytical
             method.

          6. Subjects must have, in the opinion of the investigator, fully recovered from prior
             allergic reaction to pegaspargase. Subjects must have completed antihistamine,
             epinephrine, and/or corticosteroid treatment for the allergic reaction ≥ 24 hours
             prior to pegcrisantaspase administration.

          7. Subjects must have a performance status corresponding to:

               -  Karnofsky ≥ 50 (for subjects > 16 years of age)

               -  Lansky ≥ 50 (for subjects ≤ 16 years of age)

          8. Adequate Renal Function Defined as:

               -  Creatinine clearance or radioisotope GFR ≥ 70 mL/min/1.73 m2 or

               -  A serum creatinine based on age/gender as follows:

             Age Maximum Serum Creatinine (mg/dL) Male Female 1 to < 2 years 0.6 0.6 2 to < 6 years
             0.8 0.8 6 to < 10 years 1 1 10 to < 13 years 1.2 1.2 13 to < 16 years 1.5 1.4

             ≥ 16 years 1.7 1.4

             The threshold creatinine values in this table were derived from the Schwartz formula
             for estimating GFR (Schwartz & Gauthier 1985) utilizing child length and stature data
             published by the CDC.

          9. Adequate Liver Function defined as:

             Bilirubin levels ≤ 2.5x ULN for age, and Direct (conjugated) Bilirubin < 0.5 mg/dLSGPT
             (ALT) ≤ 225 U/L. For the purpose of this study, the ULN for SGPT is 45 U/L.

         10. Subjects who are sexually active must agree to use a medically acceptable method of
             contraception throughout the entire study period and for 4 weeks after the study is
             completed. Medically acceptable methods of contraception that may be used by the
             subject and/or the partner include abstinence, birth control pills or patches,
             diaphragm and spermicide, condom and vaginal spermicide, surgical sterilization,
             postmenopausal, vasectomy (>6 months prior to baseline), and progestin implant or
             injection.

         11. Able to understand and to sign a written informed consent. All subjects and/or their
             parent or a legally authorized representative must sign a written informed consent.
             Assent, when appropriate, will be obtained according to institutional guidelines.

        Exclusion Criteria:

          1. Have previously received Erwinia asparaginase

          2. Are receiving another investigational agent or will receive an investigational agent
             in subsequent phases of protocol therapy that include asparaginase

          3. Have a history of ≥ Grade 3 pancreatitis (CTCAE v4.03)

          4. Prior history of a CNS thrombotic event or ≥ Grade 3 (CTCAE v4.03) thrombotic event,
             excluding catheter-associated clots

          5. Prior history of asparaginase-associated ≥ Grade 3 (CTCAE v4.03) hemorrhagic event or
             asparaginase-associated thrombus requiring anticoagulation therapy

          6. Blood triglyceride levels > 500 mg/dL or > 5.6 mmol/L

          7. Hyperglycemia requiring insulin therapy

          8. QTc prolongation ≥ 550 msec

          9. Subjects who in the opinion of the investigator may not be able to comply with the
             safety monitoring requirements of the study

         10. Subjects who have any serious active disease or co-morbid medical condition (according
             to investigator's decision), or psychiatric illness that would prevent the subject
             from signing the informed consent form, assent form or informed consent form by
             parents, pending institutional requirements, or per investigator's opinion, would
             prevent the subject from completing one course of pegcrisantaspase.

        Pregnant or lactating females or females of childbearing potential not willing to use an
        adequate method of birth control for the duration of the study. Female subjects who are
        lactating who do not agree to stop breast-feeding.
      "
NCT02254551,terminated,"
    safety lead-in data did not support continuation of study.
  ",0,phase 2,['multiple myeloma'],"[""['C90.01', 'C90.02', 'C90.00']""]","['lde225', 'bortezomib']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          1. Patients must have measurable MM requiring systemic therapy defined as at least one of
             the following:

               -  Serum M-protein ≥ 0.5 g/dL

               -  Urine M-protein ≥ 200 mg/24 hrs

               -  Serum free light chain assay: involved free light chain level ≥ 10 mg/dL provided
                  the serum free light chain ratio is abnormal

          2. Must have progressed during or after at least two previous treatment regimens.
             Patients who have received previous high dose therapy or autologous stem cell
             transplantation are eligible.

          3. ECOG Performance Status score of 0-2.

          4. Patients with adequate bone marrow, liver and renal function.

          5. Patient is able to swallow and retain oral medication.

          6. QTcF ≤450 msec for males and ≤ 470 msec for females on the screening ECG.

          7. Female patients must not be of childbearing potential or must agree to use adequate
             contraceptive measures.

          8. Male patients willing to use adequate contraceptive measures.

          9. Willingness and ability to comply with study and follow-up procedures.

         10. Ability to understand the nature of this study and give written informed consent.

        Exclusion Criteria:

          1. Received any treatment for myeloma-directed treatment within 21 days. Localized
             radiation and dexamethasone must be completed within 7 days prior to study treatment

          2. Refractory to bortezomib, defined as progression on or within 60 days of last
             bortezomib dose.

          3. Received any investigational drug within 28 days or 5 half-lives (whichever is longer)
             prior to the first dose of LDE225. For other anti-neoplastic therapy (e.g.,
             chemotherapy, targeted therapy or radiation), a minimum of 14 days between termination
             of the study drug and administration of LDE225 is required.

          4. Patients who have previously been treated with systemic LDE225 or with other Hedgehog
             (Hh) pathway inhibitors.

          5. Received major surgical procedures within 28 days of beginning study drug, or minor
             surgical procedures within 7 days. No waiting is required following port-a-cath
             placement.

          6. Those who are pregnant or lactating.

          7. Patients with concurrent uncontrolled medical conditions that may interfere with their
             participation in the study or potentially affect the interpretation of the study data.

          8. Patients with > Grade 2 peripheral neuropathy (per NCI CTCAE V4.0) within 14 days
             prior to study enrollment.

          9. Patients with a presence of active gastrointestinal disease or other condition that
             will interfere significantly with the absorption, distribution, metabolism, or
             excretion of oral therapy (e.g. ulcerative disease, uncontrolled nausea, vomiting,
             diarrhea Grade ≥2, and malabsorption syndrome).

         10. Patients who have neuromuscular disorders (e.g. inflammatory myopathies, muscular
             dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy) or are on
             concomitant treatment with drugs that are recognized to cause rhabdomyolysis, such as
             HMG CoA inhibitors (statins), clofibrate and gemfibrozil, and that cannot be
             discontinued at least 2 weeks prior to starting LDE225 treatment. If it is essential
             that the patient stays on a statin to control hyperlipidemia, only pravastatin may be
             used with extra caution.

         11. Patients who are planning on embarking on a new strenuous exercise regimen after
             initiation of study treatment. Muscular activities, such as strenuous exercise, that
             can result in significant increases in plasma CK levels should be avoided while on
             LDE225 treatment.

         12. Receiving treatment with medications known to be moderate and strong inhibitors or
             inducers of CYP3A4 or CYP3A5, drugs that are BCRP substrates, or drugs metabolized by
             CYP2B6 or CYP2C9 that have narrow therapeutic index, and that cannot be discontinued
             before starting treatment with LDE225. Medications that are strong CYP3A4 or CYP3A5
             inhibitors should be discontinued at least 7 days prior to starting LDE225. Strong
             CYP3A4 or CYP3A5 inducers should be discontinued at least 2 weeks weeks weeks prior to
             starting treatment with LDE225.

         13. Therapeutic doses of warfarin sodium or any other warfarin-derivative anticoagulants
             are not permitted since LDE225 is a competitive inhibitor of CYP2C9 based on the in
             vitro data. In this situation therapeutic anticoagulation may be accomplished using
             low molecular weight heparin (LMWH) or similar agents.

         14. Those diagnosed with cardiac conditions currently or within last 6 months.

         15. Those experiencing angina pectoris within 3 months.

         16. Those who experienced acute myocardial infarction within 3 months.

         17. Those with inadequately controlled hypertension defined as systolic blood pressure
             [SBP] > 180 mmHg or diastolic blood pressure (DBP) > 100 mmHg. Patients with values
             above these levels must have their blood pressure controlled with medication prior to
             starting treatment. Patients with a history of labile hypertension, or a history of
             poor compliance with an antihypertensive regimen are to be excluded.

         18. Pregnant or lactating women, where pregnancy is confirmed by a positive human
             chorionic gonadotropin (hCG) laboratory test.

         19. Patients who are not willing to apply highly effective contraception during the study
             and after the final dose of study treatment.

         20. Sexually active males who are unwilling to use a condom during intercourse while
             taking drug and for 6 months after stopping investigational medications and agree not
             to father a child in this period.

         21. Those with a serious active infection at the time of treatment, or another serious
             underlying medical condition that would impair the ability of the patient to receive
             protocol treatment.

         22. Those presenting with other active cancers, or history of treatment for invasive
             cancer within 3 years. Patients with Stage I cancer who have received definitive local
             treatment and are considered unlikely to recur are eligible. All patients with
             previously treated in situ carcinoma (i.e., non-invasive) are eligible, as are
             patients with history of non-melanoma skin cancer.

         23. Those with psychological, familial, sociological, or geographical conditions that do
             not permit compliance with the protocol.
      "
NCT02258659,"active, not recruiting",,1,phase 2,"['human papilloma virus infection', 'stage iii squamous cell carcinoma of the oropharynx', 'stage iva squamous cell carcinoma of the oropharynx', 'stage ivb squamous cell carcinoma of the oropharynx']","[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]","['paclitaxel albumin-stabilized nanoparticle formulation', 'carboplatin', 'paclitaxel', 'fluorouracil', 'hydroxyurea', 'cisplatin']","['Status: 503', 'Status: 503', 'Status: 503', 'Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Patients must have pathologically confirmed HPV-positive squamous cell carcinoma

          -  HPV testing must follow the following criteria

               -  HPV testing using an E6/E7 based assay is preferred, and does not require any
                  validation (e.g. HPV in situ hybridization [ISH] or HPV E6/E7 polymerase chain
                  reaction [PCR])

               -  For oropharyngeal tumors p16 immunohistochemistry (IHC) positivity is sufficient
                  to enroll and initiate treatment (p16 IHC interpretation to follow guidelines by
                  Jordan/Lingen et al 2012); it is recommended that p16 IHC positivity is validated
                  at a later point (during or after treatment) using an E6/E7 based test at the
                  University of Chicago and provided slides will be used

               -  For non-operative (OP) tumors accurate HPV testing (i.e. ISH, or E6/E7 based
                  testing) is required for enrollment and treatment initiation

          -  Availability of >= 10 unstained 5 micron slides

          -  Patients with American Joint Committee on Cancer (AJCC) (7th edition, 2010) nodal
             stage N2 or N3 or a T4 primary tumor

          -  The primary and nodal involvement must be assessable on clinical exam (mucosal and
             lymph node exam)

          -  The primary and nodal involvement must have been defined bi- or uni-dimensional
             measurements measurable by RECIST

          -  No previous radiation or chemotherapy for a head and neck cancer

          -  No surgical resection for a head and neck cancer within 8 weeks of enrollment
             (although lymph node biopsy including excision of an individual node with presence of
             residual nodal disease, or surgical biopsy of the tumor is acceptable)

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (Karnofsky >= 70%)

          -  Leukocytes >= 3000/mm^3

          -  Platelets >= 100,000/mm^3

          -  Absolute neutrophil count >= 1,500

          -  Hemoglobin > 9.0 gm/dL

          -  Albumin > 2.9 gm/dL

          -  Total bilirubin =< 1.5 mg/dl

          -  Creatinine clearance > 45 mL/min (or serum creatinine [SCr] =< 1.5 mg/dL), normal
             within 2 weeks prior to start of treatment

          -  The standard Cockcroft and Gault formula or the measured glomerular filtration rate
             must be used to calculate creatinine clearance (CrCl) for enrollment or dosing

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X upper
             limit of normal (ULN)

          -  Alkaline phosphatase =< 2.5 X ULN

          -  Patients must sign a study-specific informed consent form prior to study entry;
             patients should have the ability to understand and the willingness to sign a written
             informed consent document

        Exclusion Criteria:

          -  Unequivocal demonstration of distant metastases (M1 disease)

          -  Intercurrent medical illnesses which would impair patient tolerance to therapy or
             limit survival; including but not limited to ongoing or active infection,
             immunodeficiency, symptomatic congestive heart failure, pulmonary dysfunction,
             cardiomyopathy, unstable angina pectoris, cardiac arrhythmia or psychiatric
             illness/social situations that would limit compliance

          -  Pregnant and nursing women are excluded; men and women of child-bearing potential are
             eligible but must consent to using effective contraception during therapy and for at
             least 3 months after completing therapy; women with child-bearing potential must have
             a negative serum or urine beta-human chorionic gonadotropin (B-hCG) pregnancy test at
             screening

          -  Other coexisting malignancies or malignancies diagnosed within the previous 3 years no
             evidence of disease for at least 3 years; exceptions to this include non-melanoma skin
             cancer, cervical cancer in situ, well differentiated thyroid cancer or prostate
             cancer; other cancers that per assessment of the PI are not prognosis limiting can be
             allowed after review by the PI

          -  Prior surgical therapy other than incisional or excisional biopsy and organ-sparing
             procedures such as debulking of airway-compromising tumors or neck dissection in a
             patient with an unknown primary tumor; residual tumor is required for enrollment on
             study

          -  Patients receiving other investigational agents

          -  Peripheral neuropathy >= grade 1
      "
NCT02259621,"active, not recruiting",,1,phase 2,['non-small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['nivolumab', 'carboplatin', 'paclitaxel']","['Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Histologically proven non-small-cell lung cancer (core biopsy required).

               -  Squamous or non-squamous histology

               -  Diagnostic core biopsy specimens must be reviewed by a faculty pathologist at
                  SKCCC or MSKCC

               -  Either a formalin fixed paraffin block or a minimum of fifteen 5-micron tissue
                  sections (slides) of tumor biopsy sample must be available for biomarker
                  evaluation (study pathologist must review for adequacy of sampling). This can be
                  obtained from archived tissues, or from a new biopsy if needed.

          -  Stage - High risk NSCLC with resection option for potential cure, as assessed by a
             faculty surgeon at SKCCC or MSKCC. This may include clinical stage IB (≥4cm), II and
             IIIA(see Appendix A). Subjects with N3 nodal involvement are not included.

        ECOG performance status 0-1

        -Adequate organ function as follows:

          -  Leukocytes ≥ 2,000/mm3

          -  Absolute neutrophil count (ANC) ≥ 1000/mm3

          -  Platelet count ≥ 100,000/mm3

          -  Hemoglobin ≥ 9 g/dL

          -  Creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥40 mL/min (if using the
             Cockcroft-Gault formula below):

        Female CrCl = (140 - age in years) x weight in kg x 0.85 72 x serum creatinine in mg/dL

        Male CrCl = (140 - age in years) x weight in kg x 1.00 72 x serum creatinine in mg/dL

          -  Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total
             bilirubin < 3.0 mg/dL)

          -  AST(SGOT), ALT(SGPT), and alkaline phosphatase ≤ 3 times the upper limit of normal

          -  Subjects must have adequate lung function to permit surgical resection determined by
             pre-enrollment pulmonary function tests to include DLCO

               -  The effects of nivolumab on the developing human fetus are unknown. For this
                  reason, women of child-bearing potential (WOCBP) and men must agree to use
                  adequate contraception (hormonal or barrier method of birth control; abstinence)
                  prior to study entry and for the duration of study participation and for up to 23
                  weeks after the last dose of nivolumab. Should a woman become pregnant or suspect
                  she is pregnant while she or her partner is participating in this study, she
                  should inform her treating physician immediately. Sexually active fertile men
                  must use effective barrier birth control if their partners are WOCBP for up to 31
                  weeks after the last dose of nivolumab. WOCBP must have a negative serum or urine
                  pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within
                  two weeks of registration. Women must not be breastfeeding.

               -  Patient understands the study regimen, its requirements, risks and discomforts
                  and is able and willing to sign the informed consent form. Voluntary signed and
                  dated IRB/IEC approved written informed consent form in accordance with
                  regulatory and institutional guidelines must be obtained before the performance
                  of any protocol related procedures that are not part of normal patient care.
                  Subjects must be competent to report AEs, understand the drug dosing schedule and
                  use of medications to control AEs.

        Exclusion Criteria:

          -  Subjects are excluded if they have an active, known or suspected autoimmune disease.
             Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus,
             residual hypothyroidism due to autoimmune condition only requiring hormone
             replacement, psoriasis not requiring systemic treatment, or conditions not expected to
             recur in the absence of an external trigger.

          -  Subjects are excluded if they have a condition requiring systemic treatment with
             either corticosteroids (> 10 mg daily prednisone equivalents) or other
             immunosuppressive medications within 14 days of study drug administration. Inhaled or
             topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents
             are permitted in the absence of active autoimmune disease. As there is potential for
             hepatic toxicity with nivolumab or nivolumab/ipilimumab combinations, drugs with a
             predisposition to hepatoxicity should be used with caution in patients treated with
             nivolumab-containing regimen.

          -  Administration of chemotherapy or any other cancer therapy in the pre-operative
             period.

          -  Subjects with active concurrent malignancies are excluded i.e. cancers other than
             NSCLC (except non melanoma skin cancers, in situ bladder, gastric, breast, colon or
             cervical cancers/dysplasia).

          -  Subjects with brain metastasis are excluded from this study, and all patients should
             have brain imaging (either MRI brain or CT brain with contrast) prior to enrollment.

          -  Subjects with a history of symptomatic interstitial lung disease.

          -  Active systemic infection requiring therapy, positive tests for Hepatitis B surface
             antigen or Hepatitis C ribonucleic acid (RNA).

          -  Known positive history or positive test for Human Immunodeficiency Virus or Acquired
             ImmunoDeficiency Syndrome (AIDS).

          -  History of allergy to study drug components.

          -  Women who are pregnant or nursing.

          -  Men with female partners (WOCBP) that are not willing to use contraception.

          -  Prior therapy with an anti-PD-1, anti-PD-L1, anti-PDL-2, or anti-CTLA-4 antibody (or
             any other antibody targeting T cell co-regulatory pathways).

          -  Underlying medical conditions that, in the Investigator's opinion, will make the
             administration of study drug hazardous or obscure the interpretation of toxicity or
             adverse events.

          -  Prisoners or subjects who are involuntarily incarcerated or compulsorily detained for
             treatment of either a psychiatric or physical (e.g. infectious disease) illness.
      "
NCT02254278,"active, not recruiting",,1,phase 2,"['stage iii oropharyngeal squamous cell carcinoma', 'stage iva oropharyngeal squamous cell carcinoma', 'stage ivb oropharyngeal squamous cell carcinoma', 'stage ivc oropharyngeal squamous cell carcinoma', 'tongue carcinoma']","[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']"", ""['D00.07']""]",['cisplatin'],['Status: 503'],"
        Inclusion Criteria

        Step 1: Registration:

          1. Pathologically (histologically or cytologically) proven diagnosis of squamous cell
             carcinoma (including the histological variants papillary squamous cell carcinoma and
             basaloid squamous cell carcinoma) of the oropharynx (tonsil, base of tongue, soft
             palate, or oropharyngeal walls); cytologic diagnosis from a cervical lymph node is
             sufficient in the presence of clinical evidence of a primary tumor in the oropharynx.
             Clinical evidence should be documented, may consist of palpation, imaging, or
             endoscopic evaluation, and should be sufficient to estimate the size of the primary
             (for T stage).

          2. Patients must have clinically or radiographically evident measurable disease at the
             primary site or at nodal stations. Tonsillectomy or local excision of the primary
             without removal of nodal disease is permitted, as is excision removing gross nodal
             disease but with intact primary site. Limited neck dissections retrieving ≤ 4 nodes
             are permitted and considered as non-therapeutic nodal excisions.

          3. Immunohistochemical staining for p16 must be performed on tissue, and this tissue must
             be submitted for central review. Fine needle aspiration (FNA) biopsy specimens may be
             used as the sole diagnostic tissue if formalin-fixed paraffin-embedded cell block
             material is available for p16 immunohistochemistry. FNA specimens prepared with
             adequate p16 testing in this manner are acceptable to submit for central review. If
             the p16 preparation is not adequate, additional specimens will be required to
             establish p16 status. Centers are encouraged to contact the pathology chairs for
             clarification.

          4. Clinical stage T1-T2, N1-N2b or T3, N0-N2b (AJCC, 7th ed.) including no distant
             metastases based on the following diagnostic workup:

               -  General history and physical examination within 56 days prior to registration;

               -  Fiberoptic exam with laryngopharyngoscopy (mirror and/or fiberoptic and/or direct
                  procedure) within 70 days prior to registration;

               -  One of the following combinations of imaging is required within 56 days prior to
                  registration:

                    1. A computed tomography (CT) scan of the neck (with contrast) and a chest CT
                       scan (with or without contrast);

                    2. or an MRI of the neck (with contrast) and a chest CT scan (with or without
                       contrast);

                    3. or a CT scan of neck (with contrast) and a PET/CT of neck and chest (with or
                       without contrast);

                    4. or an MRI of the neck (with contrast) and a PET/CT of neck and chest (with
                       or without contrast).

             Note: A CT scan of neck and/or a PET/CT performed for the purposes of radiation
             planning may serve as both staging and planning tools.

          5. Patients must provide their personal smoking history prior to registration. The
             lifetime cumulative history cannot exceed 10 pack-years. The following formula is used
             to calculate the pack-years during the periods of smoking in the patient's life; the
             cumulative total of the number of pack-years during each period of active smoking is
             the lifetime cumulative history.

             Number of pack-years = [Frequency of smoking (number of cigarettes per day) × duration
             of cigarette smoking (years)] / 20

             Note: Twenty cigarettes is considered equivalent to one pack. The effect of
             non-cigarette tobacco products on the survival of patients with p16-positive
             oropharyngeal cancers is undefined. While there are reportedly increased risks of head
             and neck cancer associated with sustained heavy cigar and pipe use (Wyss 2013), such
             sustained use of non-cigarette products is unusual and does not appear to convey added
             risk with synchronous cigarette smoking. Cigar and pipe tobacco consumption is
             therefore not included in calculating the lifetime pack-years. Marijuana consumption
             is likewise not considered in this calculation. There is no clear scientific evidence
             regarding the role of chewing tobacco-containing products in this disease, although
             this is possibly more concerning given the proximity of the oral cavity and
             oropharynx. In any case, investigators are discouraged from enrolling patients with a
             history of very sustained use (such as several years or more) of non-cigarette tobacco
             products alone.

          6. Zubrod Performance Status of 0-1 within 56 days prior to registration;

          7. Age ≥ 18;

          8. The trial is open to both genders;

          9. Adequate hematologic function within 14 days prior to registration, defined as
             follows:

               -  Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3;

               -  Platelets ≥ 100,000 cells/mm3;

               -  Hemoglobin (Hgb) ≥ 8.0 g/dl; Note: The use of transfusion or other intervention
                  to achieve Hgb ≥ 8.0 g/dl is acceptable.

         10. Adequate renal function within 14 days prior to registration, defined as follows:

             • Serum creatinine (Cr) < 1.5 mg/dl or creatinine clearance (CC) ≥ 50 ml/min
             determined by 24-hour collection or estimated by Cockcroft-Gault formula:

               -  CC male = [(140 - age) x (wt in kg)] / [(Serum Cr mg/dl) x (72)]

               -  CC female = 0.85 x (CC male)

         11. Adequate hepatic function within 14 days prior to registration defined as follows:

               -  Bilirubin < 2 mg/dl;

               -  Aspartate transaminase (AST) or alanine transaminase (ALT) < 3 x the upper limit
                  of normal.

         12. Negative serum pregnancy test within 14 days prior to registration for women of
             childbearing potential;

         13. Patients who are HIV positive but have no prior Acquired Immune Deficiency Syndrome
             (AIDS) -defining illness and have CD4 cells of at least 350/mm3 are eligible.
             HIV-positive patients must not have multi-drug resistant HIV infection or other
             concurrent AIDS-defining conditions. Patients must not be sero-positive for Hepatitis
             B (Hepatitis B surface antigen positive or anti-hepatitis B core antigen positive) or
             sero-positive for Hepatitis C (anti-Hepatitis C antibody positive). However, patients
             who are immune to hepatitis B (anti-Hepatitis B surface antibody positive) are
             eligible (e.g. patients immunized against hepatitis B).

         14. The patient must provide study-specific informed consent prior to study entry,
             including consent for mandatory submission of tissue for required, central p16 review.

         15. Patients who speak English (or read one of the languages for which a translation is
             available (see Section 10.2) must consent to complete the mandatory dysphagia-related
             patient reported instrument (MDADI). If the patient cannot understand spoken English
             and reads only languages not available in the MDADI translations, the patient can
             still participate in the trial, as this has been factored into the trial statistics.
             For all other patients, the MDADI is mandatory as it is included in the primary
             endpoint to be studied.

             Step 2: Randomization:

         16. p16 positive by immunohistochemistry (defined as greater than 70% strong nuclear or
             nuclear and cytoplasmic staining of tumor cells), confirmed by central pathology
             review; (see Section 10.1 for details).

        Exclusion Criteria

        Step 1: Registration:

          1. Cancers considered to be from an oral cavity site (oral tongue, floor mouth, alveolar
             ridge, buccal or lip), or the nasopharynx, hypopharynx, or larynx, even if p16
             positive, or histologies of adenosquamous, verrucous, or spindle cell carcinomas;

          2. Carcinoma of the neck of unknown primary site origin (even if p16 positive);

          3. Radiographically matted nodes, defined as 3 abutting nodes with loss of the
             intervening fat plane;

          4. Supraclavicular nodes, defined as nodes visualized on the same axial imaging slice as
             the clavicle;

          5. Definitive clinical or radiologic evidence of metastatic disease or adenopathy below
             the clavicles;

          6. Gross total excision of both primary and nodal disease with curative intent; this
             includes tonsillectomy, local excision of primary site, and nodal excision that
             removes all clinically and radiographically evident disease. In other words, to
             participate in this protocol, the patient must have clinically or radiographically
             evident gross disease for which disease response can be assessed.

          7. Patients with simultaneous primary cancers or separate bilateral primary tumor sites
             are excluded with the exception of patients with bilateral tonsil cancers;

          8. Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free
             for a minimum of 1095 days (3 years) (for example, carcinoma in situ of the breast,
             oral cavity, or cervix are all permissible);

          9. Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a
             different cancer is allowable;

         10. Prior radiotherapy to the region of the study cancer that would result in overlap of
             radiation therapy fields;

         11. Severe, active co-morbidity defined as follows:

               -  Unstable angina and/or congestive heart failure requiring hospitalization within
                  the last 6 months;

               -  Transmural myocardial infarction within the last 6 months;

               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the time
                  of registration;

               -  Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness
                  requiring hospitalization or precluding study therapy within 30 days of
                  registration;

               -  Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects;
                  note, however, that laboratory tests for liver function and coagulation
                  parameters are not required for entry into this protocol other than those
                  requested in Section 3.2.10.

               -  Acquired Immune Deficiency Syndrome (AIDS) based upon current Centers for Disease
                  Control and Prevention (CDC) definition with immune compromise greater than that
                  noted in Inclusion Criterion 13; note, however, that HIV testing is not required
                  for entry into this protocol. The need to exclude patients with AIDS from this
                  protocol is necessary because the treatments involved in this protocol may be
                  significantly immunosuppressive. Protocol-specific requirements may also exclude
                  immuno-compromised patients.

         12. Pregnancy; this exclusion is necessary because the treatment involved in this study
             may be significantly teratogenic.

         13. Prior allergic reaction to cisplatin.
      "
NCT02685059,completed,,1,phase 2,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['medi4736 (anti pd-l1)', 'placebo', 'nab-paclitaxel', 'epirubicin', 'cyclophosphamide']","['Status: 503', 'Status: 503', 'Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Written informed consent for all study according to local regulatory requirements
             prior to beginning specific protocol procedures.

          -  Complete baseline documentation must be sent to GBG Forschungs GmbH.

          -  Unilateral or bilateral primary carcinoma of the breast, confirmed histologically by
             core biopsy. Fine-needle aspiration alone is not sufficient. Incisional biopsy is not
             allowed. In case of bilateral cancer, the investigator has to decide prospectively
             which side will be evaluated for the primary endpoint.

          -  Tumor lesion in the breast or the nodes must be measurable in two dimensions,
             preferably by sonography. In case of inflammatory disease, the extent of inflammation
             can be used as measurable lesion.

          -  Patients must be in the following stages of disease: cT1b - cT4a-d irrespective of
             nodal involvement.

        In patients with multifocal or multicentric breast cancer, the largest lesion should be
        measured.

          -  Triple negative disease with centrally confirmed ER negative/PR negative/HER-2
             negative, and centrally confirmed Ki-67 value. ER negative is defined as <1% stained
             cells, PR negative is defined as <10% stained and HER2-negative is defined as either
             IHC 0/1+ or IHC 2+ and in-situ hybridisation (ISH) of either ratio <2.0 or less than 6
             copies of HER2 per tumor cell. Stromal TILs will be evaluated in three groups: low
             immune infiltrate (0-10% stromal TILs) intermediate immune infiltrate (11-59% stromal
             TILs), LPBC 60-100% stromal TILs. PD-L1 status and other predefined markers will be
             prospectively assessed during the study. Formalin-fixed, paraffin-embedded (FFPE)
             breast tissue from core biopsy has therefore to be sent to the GBG central pathology
             laboratory prior to randomization.

          -  Age >=18 years.

          -  ECOG Performance status 0-1.

          -  Normal cardiac function must be confirmed by ECG and cardiac ultrasound (LVEF or
             shortening fraction) within 3 months prior to randomization. Results must be above the
             normal limit of the institution.

          -  Negative pregnancy test (urine or serum) within 14 days prior to randomization for all
             women of childbearing potential. Female subjects must either be of non-reproductive
             potential (ie, post-menopausal by history: >=60 years old and no menses for >=1 year
             without an alternative medical cause; OR history of hysterectomy, OR history of
             bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a
             negative serum pregnancy test upon study entry.

          -  Complete staging work-up within 3 months prior to randomization. All patients must
             have had breast imaging by breast ultrasound plus either bilateral mammography or
             breast MRI (one of those <= 21 days). All patients must have had chest X-ray (PA and
             lateral), abdominal ultrasound or CT scan or MRI, and bone scan (according to
             guidelines). In case of positive bone scan, bone X-ray is mandatory. Other tests may
             be performed as clinically indicated.

          -  Patients must be available and compliant for central diagnostics, treatment and
             follow-up.

          -  Laboratory requirements: Hematology, Hepatic function, Renal Function, Thyroid
             function

        Exclusion Criteria:

          -  Prior chemotherapy for any malignancy.

          -  Prior radiation therapy for breast cancer.

          -  Pregnant or lactating patients. Patients of childbearing potential must implement
             adequate non-hormonal contraceptive measures (barrier methods, intrauterine
             contraceptive devices, sterilization) during study treatment.

          -  Inadequate general condition (not fit for dose-dense, dose-intensified
             anthracycline-taxane-targeted agents-based chemotherapy).

          -  Previous malignant disease being disease-free for less than 5 years (except CIS of the
             cervix and non-melanomatous skin cancer).

          -  6. Known or suspected congestive heart failure (>NYHA I) and / or coronary heart
             disease, angina pectoris requiring antianginal medication, previous history of
             myocardial infarction, evidence of transmural infarction on ECG, uncontrolled or
             poorly controlled arterial hypertension (i.e. BP >140 / 90 mm Hg under treatment with
             at maximum two antihypertensive drugs), rhythm abnormalities requiring permanent
             treatment, clinically significant valvular heart disease.

          -  Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3
             electrocardiograms (ECGs) using Bazett's Correction

          -  Active or prior documented inflammatory bowel disease (e.g., Crohn's disease,
             ulcerative colitis)

          -  History of primary immunodeficiency

          -  History of allogeneic organ transplant

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, active peptic ulcer disease or gastritis, active bleeding diatheses
             including any subject known to have evidence of acute or chronic hepatitis B,
             hepatitis C or human immunodeficiency virus (HIV).

          -  Known history of previous clinical diagnosis of tuberculosis

          -  Receipt of live attenuated vaccination within 30 days prior to study entry or within
             30 days of receiving MEDI4736

          -  Autoimmune disease and conditions (i.e. inflammatory bowel disease)

          -  History of significant neurological or psychiatric disorders including psychotic
             disorders, dementia or seizures that would prohibit the understanding and giving of
             informed consent

          -  Any condition that, in the opinion of the investigator, would interfere with
             evaluation of study treatment or interpretation of patient safety or study results

          -  Pre-existing motor or sensory neuropathy of a severity >= grade 2 by NCI-CTC criteria
             v 4.0.

          -  Currently active infection.

          -  Incomplete wound healing or unhealed bone fracture.

          -  Definite contraindications for the use of corticosteroids

          -  Known hypersensitivity reaction to one of the compounds or incorporated substances
             used in this protocol;

          -  Concurrent treatment with:

          -  chronic corticosteroids prior to study entry with the exceptions of intranasal and
             inhaled corticosteroids or systemic corticosteroids at physiological doses, which are
             not to exceed 10 mg/day of prednisone, or equivalent corticosteroid.

          -  other immunosuppressive medication (e.g. low dose MTX)

          -  sex hormones (including hormonal contraception) prior treatment must be stopped before
             study entry.

          -  other experimental drugs or any other anti-cancer therapy.

          -  Participation in another clinical trial with any investigational, not marketed drug
             within 30 days prior to study entry.

          -  Any previous treatment with a PD1 or PD-L1 inhibitor, including MEDI4736

          -  Male patients.
      "
NCT02685046,terminated,"
    low accrual rate
  ",0,phase 2,['colonic neoplasms'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]",['imatinib'],['Status: 503'],"
        Inclusion Criteria:

          1. Male or female aged ≥18 years

          2. Histologically proven adenocarcinoma of the colon;

          3. Completed cancer staging with CT-abdomen and CT-thorax/X-thorax according to
             hospital's standard of care;

          4. Confirmed eligibility for surgery with curative intent as deemed by the hospital's
             multidisciplinary board (MDB) review;

          5. An intratumoural gene expression profile of PDGFR-α, PDGFR-β, PDGF-C and KIT,
             indicative of the mesenchymal phenotype, according to our diagnostic RT-qPCR test
             (i.e. more than 50% chance of having the mesenchymal phenotype);

          6. Minimum of four properly stored pre-treatment biopsies for gene expression
             analysis/ELISA;

          7. WHO performance status 0 or 1;

          8. Adequate haematology status and organ function, defined as:

               -  Normal creatinine clearance (≥60 ml/min (MRDR))

               -  ALAT within 2.5x upper limit of normal (ULN)

               -  PT-INR < 1.5

               -  Leukocytes > 1,5*10^9/L; Hb > 6.0 mmol/L; platelets > 100*10^9/L

          9. Willingness and ability to comply with scheduled visits, treatment plans and
             laboratory tests;

         10. Written informed consent.

        Exclusion Criteria:

          1. The presence of synchronous distant metastases;

          2. Current hospital standard of care dictates that subject should undergo any neoadjuvant
             therapy;

          3. Concurrent participation in another clinical trial using any medicinal product, or
             participation in such a trial in the period of three months prior to the current
             trial;

          4. Women who are pregnant, plan to become pregnant or are lactating during the study or
             for up to 30 days after the last dose of imatinib;

          5. Known HIV or Hepatitis B/C infection;

          6. Known symptomatic congestive heart failure;

          7. Co-morbidity requiring concomitant treatment with drugs that act as strong inducers of
             CYP3A4 or with drugs with a narrow therapeutic range influenced by imatinib
      "
NCT02681523,terminated,"
    slow patient recruitment
  ",0,phase 2,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]",['eribulin'],['Status: 503'],"
        Inclusion Criteria:

          -  1. Written informed consent prior to admission to this study

          -  2. Aged 18≥over

          -  3. Histologically confirmed ER+ve metastatic breast cancer according to local criteria

          -  4. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2

          -  5. Have progressed after at least one hormonal therapy regime and at least one
             chemotherapy regime for advanced disease

          -  6. Patients must have had prior treatment with an anthracycline and a taxane (either
             sequential or in combination) unless patients were not suitable for these treatments.
             This treatment can be in the adjuvant setting

          -  7. Measurable sites of locally advanced and/or metastatic disease that can be
             accurately assessed by CT/MRI scan at baseline (RECIST v1.1)¹

          -  8. Life expectancy of ≥6 months

          -  9. Adequate organ function, as defined by:

               -  Haemoglobin (Hb) ≥ 9 g/dL

               -  Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L

               -  Platelet count (Plts) ≥ 100 x 109/L

               -  White Blood Cell (WBC) ≥ 3.0 x 109/L

               -  Serum albumin ≤ 1.5 Upper Limit of Normal (ULN)

               -  Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 3 x ULN if
                  no demonstrable liver metastases or ≤ 5 x ULN in the presence of liver
                  metastases.

               -  Alkaline Phosphatase Level (ALP) ≤ 5 x ULN

               -  Total bilirubin ≤ 1.5 x ULN if no demonstrable liver metastases or ≤ 3 x ULN in
                  the presence of liver metastases

               -  Creatinine ≤ 1.5 x ULN or creatinine clearance >50ml/min

          -  10. Postmenopausal as defined by age >50, no menstruation for >2 years, previous
             oophorectomy or lab results confirming this status

          -  11. Premenopausal if has been subject to ovarian ablation/ suppression at least 3
             weeks prior to commencing AI therapy

               -  RECIST v1.1 updated and now considers bone metastasis with an identifiable soft
                  tissue mass to be measurable disease. Therefore, patients with bone metastasis
                  are eligible, provided they have evaluable disease.

        Exclusion Criteria:

          -  1.Triple negative or Human Epidermal Growth Factor Receptor 2 (HER2) positive cancer

          -  2. Hypersensitivity to the active substance or to any of its excipients

          -  3. History of another primary malignancy within 5 years prior to starting study
             treatment, except adequately treated basal or squamous cell carcinoma of the skin,
             carcinoma in site and the disease under study

          -  4. Evidence of uncontrolled active infection

          -  5. Severe hepatic impairment (Child-Pugh C)

          -  6. Evidence of significant medical condition or laboratory finding which, in the
             opinion of the Investigator, makes it undesirable for the patient to participate in
             the trial

          -  7. Concurrent therapy with any other investigational agent or everolimus

          -  8. Concomitant use within 14 days prior to commencement of study treatment of any
             investigational agent

          -  9. Uncontrolled abnormalities of serum potassium, sodium, calcium (corrected)
             phosphate or magnesium levels

          -  10. Pregnant or lactating women. Effective non-hormonal contraception is mandatory for
             all patients of reproductive potential

          -  11. Evidence of ovarian activity

          -  12. Prior eribulin therapy
      "
NCT02681055,completed,,1,phase 2,"['non-alcoholic steatohepatitis', 'hypertriglyceridemia', 'non-alcoholic fatty liver disease', 'hypercholesterolemia']","[""['K75.81']"", ""['Z52.6', 'K71.8', 'K71.7', 'A06.4', 'C22.0', 'C22.3', 'K70.0']"", ""['E78.01', 'E78.00', 'Z83.42']""]",['mn-001'],['Status: 503'],"
        INCLUSION CRITERIA:

          -  Written informed consent is obtained and willing and able to comply with the protocol
             in the opinion of the Investigator.

          -  Male or female subjects ≥ 18 years of age

          -  Histologically proven NASH (NAFLD activity score of 3 or greater with at least 1 point
             being ballooning) based on liver biopsy performed within the last 36 months or
             abdominal ultrasound confirmation of non-alcoholic fatty liver disease (NAFLD)

          -  Fasting serum triglyceride level > 150 mg/dL (confirmed at screening)

          -  Serum ALT, AST, ALP and total bilirubin levels at Screening (- 120 days to -30 days)
             and Lab Visit values (- 1 week ± 5 days) are stable or changes at the Lab visit are <
             20% of the values from Screening.

          -  BMI ≤ 45 kg/m2

          -  Subjects on the following medications can be enrolled if these medications are
             necessary, cannot be stopped, and the dose has been stable for 4 months or more prior
             to baseline:

               -  Stable doses of anti-diabetic medications

               -  Stable doses of fibrates, statins, niacin, ezetimibe.

               -  Stable doses of Vitamin E for at least 8 weeks

          -  Less than 21 units of alcohol/week for men and 14 units of alcohol/week for women over
             a 2-year time frame

          -  Females of child-bearing potential must have a negative serum ß-hCG at screening and
             must be willing to use appropriate contraception (as defined by the investigator) for
             the duration of study treatment and 30 days after the last dose of study treatment.

          -  Males should practice contraception as follows: condom use and contraception by female
             partner.

          -  Subject is in good physical health on the basis of medical history, physical
             examination, and laboratory screening, as defined by the investigator.

          -  Subject is willing and able to comply with the protocol assessments and visits, in the
             opinion of the study nurse/coordinator and the Investigator.

        EXCLUSION CRITERIA:

          -  Diagnosis of other known cause of liver disease (autoimmune, viral, genetic, drug- or
             alcohol-induced, or storage disease)

          -  Decompensated or severe liver disease defined by one or more of the following:

          -  biopsy-proven cirrhosis

          -  INR >1.5

          -  Total bilirubin (TBL) > 1.5 x ULN, or > 2 x ULN for unconjugated bilirubin

          -  serum albumin <2.8 g/dL

          -  ALT or AST > 10 x ULN

          -  evidence of portal hypertension including splenomegaly, ascites, encephalopathy and/or
             esophageal varices

          -  Current diagnosis of hepatocellular carcinoma (HCC) or suspicion of HCC clinically or
             on ultrasound

          -  Uncontrolled diabetes mellitus Type 2

          -  History of bariatric surgery

          -  Greater than 10-pound weight gain or loss in the last 6 months

          -  Clinically significant cardiovascular/cerebrovascular disease, including myocardial
             infarct within last 6 months, coronary artery intervention, coronary artery bypass,
             unstable ischemic heart disease, heart failure class III or IV, angina or cerebral
             vascular accident.

          -  Resting pulse < 50 bpm, SA or AV block, uncontrolled hypertension, or QTcF > 450 ms

          -  History of stomach or intestinal surgery or any other condition that could interfere
             with or is judged by the Investigator to interfere with absorption, distribution,
             metabolism, or excretion of study drug.

          -  Any significant laboratory abnormality which, in the opinion of the Investigator, may
             put the subject at risk

          -  History of malignancy < 5 years prior to signing the informed consent, except for
             adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.

          -  History of HIV (human immunodeficiency virus), HBV, HCV (cured HCV is not excluded),
             EBV CMV or other active infection.

          -  Currently has a clinically significant medical condition including the following:
             neurological, psychiatric, metabolic, immunologic, hematological, pulmonary,
             cardiovascular (including uncontrolled hypertension), gastrointestinal, urological
             disorder, or central nervous system (CNS) infection that would pose a risk to the
             subject if they were to participate in the study or that might confound the results of
             the study. Note: Active medical conditions that are minor or well-controlled are not
             exclusionary if, in the judgment of the Investigator, they do not affect risk to the
             subject or the study results. In cases in which the impact of the condition upon risk
             to the subject or study results is unclear, the Medical Safety Monitor should be
             consulted.

          -  CYP2C8 substrates with a narrow therapeutic index (e.g., paclitaxel) within 15 days
             prior to study and throughout the study are prohibited.

          -  CYP2C9 substrate with narrow therapeutic index (e.g., phenytoin, S-warfarin,
             tolbutamide) within 15 days prior to study and throughout the study are prohibited.

          -  Macrolide or quinolone class antibiotics within 15 days of Screening Visit and
             throughout the study are prohibited.

          -  Steroids within 30 days prior to study drug dosing and throughout the study unless
             administered for a short term treatment course during the study are prohibited.

          -  History of alcohol or substance abuse (DSM-IV-TR criteria) within 3 months prior to
             screening or alcohol or substance dependence (DSM-IV-TR criteria) within 12 months
             prior to screening. The only exceptions include caffeine or nicotine abuse/dependence.

          -  Poor peripheral venous access that will limit the ability to draw blood as judged by
             the Investigator.

          -  Currently participating, or has participated in, a study with an investigational or
             marketed compound or device within 3 months prior to signing the informed consent.

          -  Unable to cooperate with any study procedures, unlikely to adhere to the study
             procedures and keep appointments, in the opinion of the Investigator, or was planning
             to relocate during the study.
      "
NCT02684591,completed,,0,phase 2,"['nonalcoholic fatty liver disease', 'hiv']","[""['Z52.6', 'K71.8', 'K71.7', 'A06.4', 'C22.0', 'C22.3', 'K70.0']"", ""['B20', 'Z71.7', 'O98.72', 'Z21', 'O98.73', 'R75', 'Z11.4']""]","['aramchol', 'placebo']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          1. Age at entry at least 18 years.

          2. And at least one of the following risk factor for more severe liver disease:
             Hypertriglyceridemia based upon ATP-III guidelines, Increased LDL cholesterol or
             increased total cholesterol based upon ATP-III guidelines, Decreased HDL cholesterol
             based upon ATP-III guidelines, Serum alanine (ALT) or aspartate (AST) aminotransferase
             activities that are above the upper limits of normal. 19 or more in women and 30 or
             more in men, Overweight as defined as BMI: 25 < 30 kg/m2, Obesity as defined BMI ≥ 30
             kg/m2, Hyperuricemia based upon ATP-III guidelines, Prediabetes or Diabetes by
             American Diabetes Association Criteria

          3. Lipodystrophy will be confirmed on both clinical and radiologic assessment and defined
             as: Clinical history and/or exam by the study physician with signs of either
             facial,temporal, upper or lower extremity lipo-atrophy, Documented abdominal fat
             accumulation with presence of hepatic steatosis on MRI

          4. An MRI-determined fat fraction classification threshold (≥5%) will be used to confirm
             subjects. MR examinations will include four research sequences (three imaging
             sequences and one single-voxel spectroscopy sequence) that have been developed and
             refined by Dr. Sirlin, allowing for the measurement of liver fat fraction and newer
             candidate MR biomarkers for future NAFLD studies. MR examinations will last 20-30
             minutes and will be performed without contrast agents. Subjects will be scanned at
             1.5T. To assess sequence repeatability, two sequences per subject, block randomized,
             will be run three times. For MR elastography, MR imaging will be done which will
             include placing a vibrating paddle over the abdomen while images are obtained. A
             comprehensive screening questionnaire will be utilized prior to subjects having an
             MRI. Experienced research MR technologists will perform MR examinations under the
             supervision of Dr. Sirlin.

          5. History of HIV documented by a previously positive HIV Elisa or PCR.

          6. Stable antiretroviral (ART) regimen for at least 12 weeks prior to study inclusion.

          7. Written informed consent.

        Exclusion Criteria:

          1. Evidence of another form of liver disease: Hepatitis B as defined as presence of
             hepatitis B surface antigen (HBsAg), Hepatitis C as defined by presence of hepatitis C
             virus (HCV) RNA in serum, Autoimmune hepatitis as defined by anti-nuclear antibody
             (ANA) of 1:160 or greater and liver histology consistent with autoimmune hepatitis or
             previous response to immunosuppressive therapy, Autoimmune cholestatic liver disorders
             as defined by elevation of alkaline phosphatase and anti-mitochondrial antibody of
             greater than 1:80 or liver histology consistent with rimary biliary cirrhosis or
             elevation of alkaline phosphatase and liver histology consistent with sclerosing
             cholangitis, Wilsons disease as defined by ceruloplasmin below the limits of normal
             and liver histology consistent with Wilsons disease Alpha-1-antitrypsin deficiency as
             defined by alpha-1-antitrypsin level less than normal and liver histology consistent
             with alpha-1-antitrypsin deficiency hemochromatosis as defined by presence of 3+ or 4+
             stainable iron on liver biopsy and homozygosity for C282Y or compound heterozygosity
             for C282Y/H63D, Drug-induced liver disease as defined on the basis of typical exposure
             and history,Bile duct obstruction as shown by imaging studies.

          2. Evidence of liver cirrhosis based upon clinical assessment, imaging or any of the
             following lab abnormalities: INR >1.4, albumin <3.2 g/dL, platelet count <90 x
             103/microliter

          3. History of excess alcohol ingestion, averaging more than 30 gm/day (3 drinks per day)
             in the previous 10 years, or history of alcohol intake averaging greater than 10
             gm/day (1 drink per day or 7 drinks per week) in the previous one year.

          4. Contraindications to MRI: The subject has any contraindication to MR imaging, such as
             patients with pacemakers, metallic cardiac valves, magnetic material such as surgical
             clips, implanted electronic infusion pumps or other conditions that would preclude
             proximity to a strong magnetic field, the subject has a history of extreme
             claustrophobia, The subject cannot fit inside the MR scanner cavity, decompensated
             liver disease, Child-Pugh score greater than or equal to 7 points

        6. History of gastrointestinal bypass surgery or ingestion of drugs known to produce
        hepatic steatosis including corticosteroids, high-dose estrogens, methotrexate,
        tetracycline or amiodarone in the previous 6 months. 7. Recent use (within the last 90
        days) of medications to treat hepatic steatosis such as pioglitazone (or medications in the
        same class) or vitamin E. 8. Use of Aramchol or agents in the same class. 9. Recent use
        (within the last 90 days) of insulin as an outpatient for management of diabetes.

        10. HbA1c > 9 or uncontrolled diabetes. 11. Significant systemic or major illnesses other
        than liver disease, including congestive heart failure, coronary artery disease,
        cerebrovascular disease, pulmonary disease with hypoxia, renal failure, organ
        transplantation, serious psychiatric disease, malignancy that, in the opinion of the
        investigator would preclude treatment with Aramchol and adequate follow up.

        12. Active substance abuse, such as alcohol, inhaled or injection drugs within the previous
        one year. 13. Pregnancy or inability to practice adequate contraception in women of
        childbearing potential.

        14. Evidence of hepatocellular carcinoma: alpha-fetoprotein levels greater than 200 ng/ml
        and/or liver mass on imaging study that is suggestive of liver cancer.

        15. HIV specific exclusions: CD4 count of less than 200 cells/μL, Detectable viral
        load,Changes to ART regimen in the preceding 12 weeks,Lack of alternative ART regimens
        should the patient experience virologic breakthrough,History of opportunistic infection in
        the preceding 12 months

        16. Symptoms of uncontrolled gastrointestinal disorders involving motility, gastric acid or
        gastric emptying malabsorption ,Disorders including but not limited to peptic ulcer
        disease, gastroesophageal reflux, dyspepsia, gastroparesis, chronic diarrhea, chromic
        constipation, gall bladder disease,pancreatitis, lactose intolerance and celiac
        disease.Patients who have used anticholinergic or other drugs known to affect
        gastrointestinal motility within 7 days prior to dosing and throughout the study will also
        be excluded

        17. Patients with hypersensitivity to Aramchol or to any of the excipients in the tablets
        or with hypersensitivity to cholic acid or bile acid sequestrants

        18. Any other condition, which, in the opinion of the investigators would impede competence
        or compliance or possibility hinder completion of the study.
      "
NCT02403271,completed,,1,phase 1/phase 2,"['non-small cell lung cancer', 'breast cancer', 'pancreatic cancer']","[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C25.3']""]","['ibrutinib', 'durvalumab']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          1. Pathologically confirmed: Non-small cell lung cancer (NSCLC, adenocarcinoma or
             squamous-cell carcinoma), Breast Cancer (HER2 positive or triple negative), Pancreatic
             Cancer (adenocarcinoma)

          2. Relapsed or refractory disease (Stage III or IV): NSCLC or pancreatic cancer must have
             failed at least 1 prior treatment. Breast cancer must have failed at least 2 prior
             treatments.

          3. Measurable lesion by RECIST 1.1

          4. Adequate hematologic function:

               -  ANC >1500 cells/mm3

               -  Platelet count >100,000 cells/mm3

               -  HGB >9.0 g/dL

          5. Adequate hepatic and renal function:

               -  AST and ALT ≤2.5 x ULN for subjects without liver metastases and ≤3.5 x ULN for
                  subjects with liver metastases

               -  Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of
                  non-hepatic origin)

               -  Creatinine ≤2.0 x ULN and Creatinine Clearance ≥40 mL/min (Cockcroft-Gault or
                  24-hour creatinine clearance collection)

          6. PT/INR <1.5 x ULN and PTT/ aPTT <1.5 x ULN

        Exclusion Criteria:

          1. Mixed small cell and NSCLC histology

          2. A history of CNS involvement except as follows: Subjects with previously treated CNS
             metastases that are adequately treated with whole brain radiotherapy, that are
             neurologically stable, and do not require corticosteroids for symptomatic management
             for at least 14 days prior to first dose of study drug. There must be no clear
             evidence of radiographically active disease for at least 90 days prior to enrollment.

          3. Anti-tumor therapy within 21 days of study Day 1

          4. Prior treatment with ibrutinib or other BTK inhibitor anti-CD137 or CTLA-4 antibody.
             The following are exceptions to this criterion: Subjects previously treated with an
             anti-PD1, anti-PD-L1, or anti-PD-L2 antibody.

          5. History of allogeneic organ transplant

          6. Treatment with a strong cytochrome P450 (CYP) 3A inhibitor
      "
NCT02403947,terminated,"
    inclusion default
  ",0,phase 1/phase 2,['multiple sclerosis'],"[""['G35', 'C81.18']""]","['mesenchymal stem cells', 'suspension media']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Age 18 to 50 years

          -  Disease duration 2 to 10 years (included)

          -  Diagnosis of MS

        Relapsing remitting MS (RRMS) not responding to at least a year of attempted therapy with
        one or more of the approved therapies (beta-interferon, glatiramer acetate, natalizumab,
        mitoxantrone, fingolimod) as evidenced by one or more of the following:

          -  more or egal 1 clinically documented relapse in past 12 months

          -  more or egal 2 clinically documented relapses in last 24 months

          -  more or egal 1 GEL at MRI performed within the last 12 months

        Secondary progressive MS (SPMS) not responding to at least a year of attempted therapy with
        one or more of the approved therapies (beta-interferon, glatiramer acetate, natalizumab,
        mitoxantrone, fingolimod) as evidenced by both::

          -  With more or egal 1 clinically documented relapse in the last twelve months

          -  Without on-going relapses, but with more or egal 1 GEL at MRI performed within the
             last 12 months.

        Primary progressive MS (PPMS) patients with all the following features:

          -  an increase ofmore or egal 1 EDSS point (if at inclusion EDSS inferior or egal 5.0) or
             0.5 EDSS point (if at inclusion EDSS more or egal 5.5), in the last twelve months

          -  more or egal 1 GEL at MRI performed within the last 12 months

          -  Positive cerebrospinal fluid (CSF) (oligoclonal banding).

               -  EDSS (Expanded Disability Status Scale) 3.0 to 6.5

               -  Women of childbearing age with an effective contraception.

        Exclusion Criteria:

          -  RRMS not fulfilling inclusion criteria

          -  SPMS not fulfilling inclusion criteria

          -  PPMS not fulfilling inclusion criteria

          -  Inferior to 3 months since treatment with any immunosuppressive therapy including
             natalizumab and fingolimod

          -  Inferior or egal to 1 month since last treatment with interferon-beta or glatiramer
             acetate

          -  Corticosteroid treatment Inferior or egal to 30 days

          -  Relapse inferior or egal to 60 days

          -  Any active or chronic infection including infection with HIV1-2 (Human
             Immunodeficiency Virus 2) or HTLV I-II (Human T-lymphotropic virus I-II) or Syphilis
             or chronic Hepatitis B or Hepatitis C inferior to 1 month

          -  Previous history of a malignancy other than basal cell carcinoma of the skin or
             carcinoma in situ that has been in remission for more than one year

          -  Severely limited life expectancy by another co-morbid illness

          -  History of previous diagnosis of myelodysplasia or previous hematologic disease or
             current clinically relevant abnormalities of white blood cell counts

          -  Pregnancy or risk or pregnancy (this includes patients that are unwilling to practice
             active contraception during the duration of the study)**

          -  eGFR (estimated Glomerular Filtration Rate ) inferior to 60 mL/min/1.73m2 or known
             renal failure or inability to undergo MRI examination.

          -  Inability to give written informed consent in accordance with research ethics board
             guidelines.
      "
NCT02407171,suspended,"
    study suspended to determine if enrollment is sufficient to meet endpoints.
  ",1,phase 1/phase 2,"['melanoma', 'lung cancer']","[""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]",['mk-3475'],['Status: 503'],"
        Inclusion Criteria:

          -  Be willing and able to provide written informed consent/assent for the trial.

          -  Have metastatic melanoma or NSCLC, or locally advanced NSCLC not suitable for
             curative-intent local therapy.

          -  For melanoma patients and NSCLC patients treated with prior anti-PD-1 therapy,
             patients must have received prior PD-1 therapy and have progressed (irPD) by irRC.

          -  Have 2 or more measurable sites of disease as defined by either RECIST 1.1, or
             cutaneous lesions at least 1 cm in greatest dimension

          -  Have at least one site of disease that is considered potentially suitable for
             treatment with SBRT

          -  Have provided tissue from an archival or newly obtained tissue sample of a tumor
             lesion, sufficient for analysis of PD-L1 and other biomarkers. Patients who have had
             PD-L1 analysis previously performed at Merck can substitute earlier analysis results
             and are not required to submit additional tissue for PD-L1 testing. Expression of
             PD-L1 is NOT required for study entry.

          -  Have a performance status of 0, 1 or 2 on the ECOG Performance Scale.

          -  Demonstrate adequate organ function as defined in Table 1, all screening labs should
             be performed within 28 days of protocol treatment.

        Table 1. Adequate Organ Function Laboratory Values (System/Laboratory Value)

        Hematological

          -  Absolute neutrophil count (ANC) ≥1,500 /mcL

          -  Platelets ≥100,000 / mcL

          -  Hemoglobin ≥9 g/dL

        Renal

          -  Measured or calculated creatinine** clearance ≤1.5 X upper limit of normal (ULN)

          -  (GFR can also be used in place of creatinine or CrCl) ≥60 mL/min for subject with
             creatinine levels > 1.5 X institutional ULN Hepatic

          -  Serum total bilirubin ≤ 1.5 X ULN OR

          -  Direct bilirubin Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5
             ULN

          -  AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver metastases

             **(Creatinine clearance should be calculated per institutional standard. )

          -  Female subject of childbearing potential should have a negative urine or serum
             pregnancy within 72 hours prior to receiving the first dose of study medication. If
             the urine test is positive or cannot be confirmed as negative, a serum pregnancy test
             will be required.

          -  Female subjects of childbearing potential should be willing to use 2 methods of birth
             control or be surgically sterile, or abstain from heterosexual activity for the course
             of the study through 120 days after the last dose of study medication (Reference
             Section 5.7.2). Subjects of childbearing potential are those who have not been
             surgically sterilized or have not been free from menses for > 1 year.

          -  Male subjects should agree to use an adequate method of contraception starting with
             the first dose of study therapy through 120 days after the last dose of study therapy

        Exclusion Criteria:

          -  Has had radiation therapy within 2 weeks of the first protocol treatment.

          -  Is currently participating in or has participated in a study of an investigational
             agent or using an investigational device within 2 weeks of the first protocol
             treatment.

          -  Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
             other form of immunosuppressive therapy within 2 weeks of the first protocol
             treatment. The use of low-dose steroids for management of chronic conditions is
             allowed.

          -  Non-small cell lung cancer patients enrolling to MK-3475 as first protocol therapy (no
             prior anti-PD-1 therapy): Has had a prior monoclonal antibody within 4 weeks prior to
             first protocol treatment or who has not recovered (i.e., ≤ Grade 1 or at baseline)
             from adverse events due to agents administered more than 4 weeks earlier.

          -  Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy
             within 2 weeks of the first protocol treatment or who has not recovered (i.e., ≤ Grade
             1 or at baseline) from adverse events due to a previously administered agent.

          -  Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may
             qualify for the study.

          -  Note: Patients who have had prior treatments with Tyrosine Kinase Inhibitors (e.g.
             Tarceva) require only a 72-hour washout period prior to starting protocol treatment.

          -  Has a known additional malignancy that is progressing or requires active treatment.
             Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the
             skin, or in situ cervical cancer that has undergone potentially curative therapy.

          -  Has known active and untreated brain (CNS) metastases and/or carcinomatous meningitis.
             Subjects with previously treated brain metastases may participate.

          -  Has an active autoimmune disease requiring systemic treatment within the past 3 months
             or a documented history of clinically severe autoimmune disease, or a syndrome that
             requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or
             resolved childhood asthma/atopy would be an example of an exception to this rule.
             Subjects that require intermittent use of bronchodilators or local steroid injections
             would not be excluded from the study. Those with a history of hypothyroidism who are
             now stable on hormone replacement will not be excluded. Those with Sjorgen's syndrome
             will not be excluded from the study.

          -  Has a history of (non-infectious) pneumonitis that required steroids, current
             pneumonitis or evidence of interstitial lung disease.

          -  Has an active infection requiring systemic therapy.

          -  Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial.

          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the screening visit through 120 days
             after the last dose of trial treatment.

          -  Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).

          -  Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA
             [qualitative] is detected).

          -  Has received a live vaccine within 30 days prior to the first protocol treatment.
      "
NCT02409368,completed,,1,phase 2,['non-small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]",['nivolumab'],['Status: 503'],"
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  ECOG Status: PS 0-1 & PS 2

          -  Subjects with histologically or cytologically-documented SqNSCLC

          -  Subjects must have experienced disease progression or recurrence during or after one
             prior platinum doublet-based chemotherapy regimen

          -  Subjects must have evaluable disease by CT or MRI per RECIST 1.1 criteria

          -  Subjects with treated or asymptomatic CNS metastases

          -  Prior palliative radiotherapy must have been completed at least 14 days prior to study
             drug administration

          -  Prior lines of antineoplastic therapy, including hemotherapy, hormonal therapy,
             immunotherapy, surgical resection of lesions, non-palliative radiation therapy, or
             standard or investigational agents for treatment of NSCLC, must be completed 28 days
             prior to the first dose of nivolumab

          -  Males and Females, ages 18 or older

        Exclusion Criteria:

          -  Subjects with untreated, symptomatic CNS metastases

          -  Subjects with carcinomatous meningitis

          -  Subjects with active, known or suspected autoimmune disease.

          -  Subjects who received prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2,
             anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or
             drug specifically targeting T-cell costimulation or checkpoint pathways) or who have
             previously taken part in a randomized BMS clinical trial for nivolumab or ipilimumab.
      "
NCT02403778,"active, not recruiting",,1,phase 2,['melanoma'],"[""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']""]","['vesanoid', 'ipilimumab']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Patients over the age of 18 year.

          -  Patients diagnosed with advanced melanoma.

          -  Patients that are considered candidates for ipilimumab therapy.

          -  Patients able to understand and willing to sign a written informed consent documents.

          -  Patients willing to have regular blood draws, one before treatment and four during or
             after treatment.

        Exclusion Criteria:

          -  Patients under the age of 18.

          -  Patients with Stage I or II, melanoma who are not candidates for Ipilimumab.

          -  Patients that have received systemic treatments within four weeks prior to the
             beginning of treatment.

          -  Women that are pregnant or nursing.

          -  Patients taking immunosuppressive medications.

          -  Patients with active autoimmune disease.

          -  Patients with known sensitivity to retinoic acid derivatives.

          -  Patients with aspartate aminotransferase (AST), alanine aminotransferase (ALT), or
             bilirubin > 2.5 × ULN.
      "
NCT02400437,completed,,1,phase 2,"[""waldenstrom's macroglobulinemia""]","[""['C88.0']""]","['ixazomib', 'dexamethasone', 'rituximab']","['Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Male or female patients 18 years or older.

          -  Voluntary written consent must be given before performance of any study related
             procedure not part of standard medical care, with the understanding that the patient
             may withdraw consent at any time without prejudice to future medical care.

          -  Female patients who:

               -  Are postmenopausal for at least 1 year before the screening visit, OR

               -  Are surgically sterile, OR

               -  If they are of childbearing potential, agree to practice 2 effective methods of
                  contraception, at the same time, from the time of signing the informed consent
                  form through 90 days after the last dose of study drug, AND

               -  Agree to practice true abstinence when this is in line with the preferred and
                  usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation,
                  symptothermal, post-ovulation methods] and withdrawal are not acceptable methods
                  of contraception.)

          -  Male patients, even if surgically sterilized (ie, status post-vasectomy), must agree
             to one of the following:

               -  Agree to practice effective barrier contraception during the entire study
                  treatment period and through 90 days after the last dose of study drug, OR

               -  Agree to practice true abstinence when this is in line with the preferred and
                  usual lifestyle of the subject. (Periodic abstinence (eg, calendar, ovulation,
                  symptothermal, post-ovulation methods] and withdrawal are not acceptable methods
                  of contraception.)

          -  Clinicopathological diagnosis of WM (Owen 2003), with symptomatic disease meeting
             criteria for treatment using consensus panel criteria from the Second International
             Workshop on WM (Kyle 2003), and measurable disease, defined as presence of
             immunoglobulin M (IgM) paraprotein with a minimum IgM level of >2 times the upper
             limit of normal.

          -  Eastern Cooperative Oncology Group performance status of 0, 1, or 2.

          -  Patients must meet the following clinical laboratory criteria

          -  Absolute neutrophil count ≥1,000/mm3 and platelet count ≥75,000/mm3. Platelet
             transfusions to help patients meet eligibility criteria are not allowed within 3 days
             before study enrollment.

          -  Total bilirubin ≤1.5 x the upper limit of the normal range (ULN).

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 x ULN.

          -  Calculated creatinine clearance ≥30 mL/min.

        Exclusion Criteria:

          -  Female patients who are lactating or have a positive serum pregnancy test during the
             screening period.

          -  Major surgery within 14 days before enrollment.

          -  Central nervous system involvement.

          -  Infection requiring systemic antibiotic therapy or other serious infection within 14
             days before study enrollment.

          -  Evidence of current uncontrolled cardiovascular conditions, including uncontrolled
             hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure,
             unstable angina, or myocardial infarction within the past 6 months.

          -  Systemic treatment, within 14 days before the first dose, with strong inhibitors of
             cytochrome P (CYP) 1A2, strong inhibitors of CYP3A, or strong CYP3A inducers, or use
             of Ginkgo biloba or St. John's wort.

          -  Known hepatitis B or C virus, or HIV infection.

          -  Any serious medical or psychiatric illness that could, in the investigator's opinion,
             potentially interfere with the completion of treatment according to this protocol.

          -  Known allergy to any of the study medications, their analogues, or excipients in the
             various formulations of any agent.

          -  Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral
             absorption or tolerance of ixazomib including difficulty swallowing.

          -  Diagnosed or treated for another malignancy within 2 years before study enrollment or
             previously diagnosed with another malignancy and have any evidence of residual
             disease. Patients with non-melanoma skin cancer or carcinoma in situ of any type are
             not excluded if they have undergone complete resection.

          -  Participation in other clinical trials, including those with other investigational
             agents not included in this trial, within 30 days of the start of this trial and
             throughout the duration of this trial.
      "
NCT02402725,withdrawn,"
    poor accrual
  ",0,phase 2,['multiple myeloma'],"[""['C90.01', 'C90.02', 'C90.00']""]",['dexamethasone'],['Status: 503'],"
        Inclusion Criteria:

          1. Relapsed multiple myeloma (MM) with measurable disease parameters according to the
             International Myeloma Working Group (IMWG) Criteria for the Diagnosis of Multiple
             Myeloma

          2. Relapsed is defined as the development of disease progression following the
             achievement of stable disease (SD), partial response (PR), very good partial response
             (VGPR), complete response (CR) or stringent complete response (sCR) to the most recent
             anti-myeloma regimen

          3. Received ≥ 2 prior regimen for MM

          4. The patient or the patient's legal representative is able to understand the risks of
             the study and provide signed informed consent and authorization to use protected
             health information (in accordance with national and local privacy regulations)

          5. ≥18 years of age

          6. Karnofsky Performance Status score of ≥70

          7. Able to adhere to the study visit schedule and other protocol requirements in the
             Investigator's opinion

          8. Adequate hepatic function, as evidenced by serum bilirubin values <6.0 mg/dL and serum
             alanine transaminase (ALT) and/or aspartate transaminase (AST) values <3 × the upper
             limit of normal (ULN) of the local laboratory reference range. (Patients with isolated
             elevations in alkaline phosphatase [ALP] <5 × ULN in the presence of bony disease are
             not excluded from participating in the study)

          9. If a female participant is of childbearing potential, she must have a negative
             pregnancy test (urine or serum) at baseline (Cycle 1, Day 0). (A female participant is
             considered to be NOT of childbearing potential if she has undergone bilateral
             oophorectomy or if she has been menopausal without a menstrual period for 12
             consecutive months)

        Exclusion Criteria:

          1. Received any of the following therapies: Radiotherapy within 2 weeks of Cycle 1 Day 1;
             Systemic therapy within 3 weeks of Cycle 1 Day 1

          2. Prior peripheral autologous stem cell transplant within 12 weeks of Cycle 1 Day 1

          3. Prior allogeneic stem cell transplant

          4. Active systemic infection requiring treatment

          5. Active malignancy (the following are allowable: patients with basal cell carcinoma of
             the skin; superficial carcinoma of the bladder; carcinoma of the prostate with a
             current prostate-specific antigen <0.1 ng/mL; or cervical intraepithelial neoplasia).

          6. Known or suspected human immunodeficiency virus (HIV) positive or hepatitis B surface
             antigen-positive status or is known or suspected to have an active hepatitis C
             infection

          7. If female, patient is lactating

          8. History of significant cardiovascular, neurological, endocrine, gastrointestinal,
             respiratory, or inflammatory illness that could preclude study participation, pose an
             undue medical hazard, or interfere with the interpretation of the study results,
             including, but not limited to, patients with:

               1. Congestive heart failure (New York Heart Association [NYHA] Class 3 or 4

               2. Unstable angina

               3. Cardiac arrhythmia

               4. Recent (within the preceding 6 months) myocardial infarction or stroke

               5. Hypertension requiring >3 medications for adequate control

               6. Chronic obstructive pulmonary disease

          9. History of uncontrolled diabetes mellitus (Type I or II) (Hemoglobin A1C>8.5)

         10. Any other medical, psychiatric, or social condition that would preclude participation
             in the study, pose an undue medical hazard, interfere with the conduct of the study,
             or interfere with interpretation of the study results

         11. History of adverse reaction to dexamethasone or other corticosteroids.

         12. History of allergic reaction attributable to any of the required prophylactic
             medications (proton pump inhibitor (PPI), fluconazole, trimethoprim-sulfamethoxazole)
             or reasonable alternative medications

         13. Inability to monitor glucose at home with glucometer if glucose is found to be
             abnormal at any study center visit

         14. Known or suspected AL Amyloidosis

         15. Currently receiving an investigational agent for any reason
      "
NCT02402764,completed,,0,phase 2,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]",['selinexor'],['Status: 503'],"
        Inclusion Criteria:

          -  Histologically confirmed triple negative breast cancer (TNBC), defined as negative
             immunohistochemical staining for estrogen and progesterone receptors (≤5% of nuclei
             positive by IHC) and receptor tyrosine-protein kinase erbB-2 (HER2) negative (IHC 0-1+
             or HER2-neu negative according to American Society of Clinical Oncology; College of
             American Pathologists (ASCO-CAP) HER2 Test Guideline Recommendations)

          -  Written informed consent in accordance with federal, local, and institutional
             guidelines

          -  Body surface area ≥1.4 m^2

          -  Age ≥18 years

          -  Estimated life expectancy of >3 months at study entry

          -  TNBC must be either locally recurrent or metastatic. Locally recurrent disease must
             not be amenable to surgical resection or radiation with curative intent.

          -  Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

          -  Documented disease progression at study entry

          -  Must have received at least 1 chemotherapy regimens in the setting of metastatic
             disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤2

          -  Adequate hematological function: Absolute neutrophil count (ANC) > 1500/mm^3,
             platelets count >100,000mm^3

          -  Adequate hepatic function within 14 days prior to Cycle 1 Day 1 (C1D1): total
             bilirubin <2 times the upper limit of normal (ULN) (except patients with Gilbert's
             syndrome who must have a total bilirubin of < 3 times ULN) and aspartate
             aminotransferase (AST), alanine aminotransferase (ALT) ≤2.5 x ULN. In the case of
             known (radiological and/or biopsy documented) liver metastasis, AST/ALT ≤5.0 times ULN
             is acceptable.

          -  Amylase and lipase ≤ 1.5 x ULN

          -  Adequate renal function within 14 days prior to C1D1: estimated creatinine clearance
             of ≥ 30 mL/min

          -  Women of child-bearing potential (WOCBP) must agree to use dual methods of
             contraception and have a negative serum pregnancy test at screening, and male
             participants must use an effective barrier method of contraception if sexually active
             with a female of child-bearing potential. For both male and female participants,
             effective methods of contraception must be used throughout the study and for 3 months
             following the last dose. To be considered of non-childbearing potential,
             postmenopausal women must be amenorrheic for at least 12 months naturally (not in the
             setting of post chemotherapy) or participants must be surgically sterile.

          -  Must have received prior anthracycline and taxane therapy unless clinically
             contraindicated

        Exclusion Criteria:

          -  Significant medical illness that in the investigator's opinion cannot be adequately
             controlled with appropriate therapy or would compromise the participant's ability to
             tolerate this therapy

          -  Women who are pregnant or lactating

          -  Radiation, chemotherapy, or immunotherapy or any other approved anticancer therapy ≤2
             weeks prior to cycle 1 day 1

          -  Major surgery within 4 weeks before Day 1

          -  Unstable cardiovascular function: Electrocardiogram (ECG) abnormalities requiring
             treatment, or congestive heart failure (CHF) of New York Hearth Association (NYHA)
             Class ≥3; myocardial infarction (MI) within 3 months

          -  Uncontrolled infection requiring parenteral antibiotics, antivirals, or antifungals
             within one week prior to first dose. Potential participants with controlled infection
             or on prophylactic antibiotics are permitted in the study.

          -  Known history of HIV

          -  Known active hepatitis A, B, or C infection that requires treatment

          -  Any underlying condition that would significantly interfere with the absorption of an
             oral medication

          -  Grade >2 peripheral neuropathy at baseline (within 14 days prior to cycle 1 day 1)

          -  Participation in an investigational anti-cancer study within 3 weeks prior to Cycle 1
             Day 1

          -  Coagulation problems and active major bleeding within 4 weeks prior to C1D1 (peptic
             ulcer, epistaxis, spontaneous bleeding)

          -  Active central nervous system (CNS) malignancy. Asymptomatic small lesions are not
             considered active. Treated lesions may be considered inactive if they are stable for
             at least 3 months.

          -  Radiation, chemotherapy, or immunotherapy or any other anticancer therapy ≤ 2 weeks
             prior to Cycle 1 Day 1 or radio-immunotherapy ≤ 4 weeks prior to Cycle 1 Day 1

          -  Have not recovered to Grade ≤ 1 or to their baseline from clinically significant
             adverse effects
      "
NCT02402062,completed,,0,phase 2,"['neuroendocrine tumors', 'pancreatic neoplasms']","[""['C7A.1', 'C7A.8', 'C7B.8', 'D3A.8']"", ""['C25.3']""]",['th-302 + sunitinib'],['Status: 503'],"
        Inclusion Criteria:

          -  Male or female, 18 years of age or older.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

          -  Histologically proven diagnosis of pancreatic neuroendocrine tumors (pNET) with Ki67
             assessment of ≤ 20% (well and moderately differentiated)

          -  Evidence of unresectable disease or metastatic disease. Locally advanced disease must
             not be amendable to resection or radiation therapy with curative intent.

          -  Patients may be treated with somatostatin analogues prior or during the trial.
             Concomitant or prior interferon treatment is not permitted.

          -  Documented progression disease by CT scan, magnetic resonance (MR) or Octreoscan in 12
             months prior basal visit.

          -  Measurable disease as per RECIST. Measurable lesions that have been previously
             radiated will not be considered target lesions unless increase in size has been
             observed following completion of radiation therapy.

          -  Patient has to be able to swallow the medication.

          -  Life expectancy greater than 12 weeks.

          -  The definitions of minimum adequacy for organ function required prior to study entry
             are as follows:

               -  Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 2.5 x
                  upper limit of normal (ULN), or AST and ALT ≤ 5 x ULN if liver function
                  abnormalities are due to underlying malignancy

               -  Total serum bilirubin ≤ 1.5 x ULN

               -  Serum albumin ≥ 3.0 g/dL

               -  Absolute neutrophil count (ANC) ≥ 1500/µL

               -  Platelets ≥ 100,000/µL

               -  Hemoglobin ≥ 5,6 mmol/L (9.0 g/dL)

               -  Creatinin clearance > 40 mL/min (Cockcroft and Gault formula)

          -  Adequate cardiac function: 12-lead ECG without pathologic findings (clinically
             significant alterations are allowed) and Echocardiogram / Normal multiple gated
             acquisition scan (MUGA) (LVEF> 50%)

          -  Signed and dated informed consent document indicating that the patient (or legally
             acceptable representative) has been informed of all the pertinent aspects of the trial
             prior to enrollment.

          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory
             tests, and other study procedures.

        Exclusion Criteria:

          -  Previous treatments with chemotherapy, monoclonal antibodies anti-vascular endothelial
             growth factor (VEGF), tyrosine kinase inhibitors, mammalian target of rapamycin (mTOR)
             inhibitors, or interferon are not permitted for the advanced disease.

          -  Prior treatment on another hypoxia-activated prodrug under clinical trial.

          -  Major surgery, radiation therapy, or systemic therapy within 3 weeks of study
             randomization except palliative radiotherapy to non-target metastatic lesions.

          -  Prior high-dose chemotherapy requiring hematopoietic stem cell rescue.

          -  Immunosuppressive drugs such as cyclosporine, tacrolimus, azathioprine, or long-term
             oral glucocorticoids taken concurrently or within last 3 months prior to randomization

          -  Treatment with known inhibitors or inductors of cytochrome P450 3A4 (CYP3A4) or that
             prolong the QT interval in the previous 7 days.

          -  Prior radiation therapy to > 25% of the bone marrow.

          -  Current treatment on another clinical trial.

          -  Uncontrolled brain metastases, spinal cord compression, carcinomatous meningitis, or
             leptomeningeal disease. Patients should have completed surgery or radiation therapy
             for existing brain metastases, should not have documented increase in size over the
             previous 3 months prior to first dose of treatment on study and should be
             asymptomatic.

          -  Diagnosis of any second malignancy within the last 3 years, except for adequately
             treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.

          -  Any of the following within the 12 months prior to starting study treatment:

               -  myocardial infarction,

               -  severe/unstable angina,

               -  coronary/peripheral artery bypass graft,

               -  congestive heart failure class III or IV of the New York Heart Association (NYHA)
                  or patients with clinical history of congestive heart failure class III or IV of
                  the NYHA, unless an echocardiogram or MUGA in the previous 3 months to selection
                  shows a LVEF ? 45 %

               -  significant heart valve disease

               -  cerebrovascular accident including transient ischemic attack

               -  pulmonary embolus.

          -  Ongoing cardiac dysrhythmias of NCI Common Toxicity Criteria for Adverse Effects
             (CTCAE) grade ≥ 2, atrial fibrillation of any grade, or corrected QT interval (QTc)
             interval >450 msec for males or >470 msec for females.

          -  Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal
             medical therapy)

          -  Chronic obstructive pulmonary disease (COPD) or any other disease concurrent with
             hypoxemia or oxygen saturation < 90% after a march of two minutes.

          -  Current treatment with therapeutic doses of Coumadin (low dose Coumadin up to 2 mg PO
             daily for deep vein thrombosis prophylaxis is allowed).

          -  Known human immunodeficiency virus infection.

          -  Pregnancy or breastfeeding. All female patients with reproductive potential must have
             a negative pregnancy test (serum or urine) prior to inclusion.

          -  Previous allergic reaction to components structurally similar to TH-302 or sunitinib
             or any of the excipients of drugs.

          -  Non-healing wound, fistulae, active peptic ulcer or bone fracture.

          -  Other severe acute or chronic medical or psychiatric condition, or laboratory
             abnormality that would impart, in the judgment of the investigator, excess risk
             associated with study participation or study drug administration, or which, in the
             judgment of the investigator, would make the patient inappropriate for entry into this
             study.
      "
NCT02405364,unknown status,,1,phase 2,['multiple myeloma'],"[""['C90.01', 'C90.02', 'C90.00']""]",['carfilzomib/lenalidomide/dexamethasone'],['Status: 503'],"
        Inclusion Criteria:

          -  Patients diagnosed with multiple myeloma based on the new International Myeloma
             Working Group

          -  Subjects must have symptomatic myeloma with at least one CRAB criteria

          -  Subjects must not have been treated previously with any systemic therapy for multiple
             myeloma

        Exclusion Criteria:

          -  Pregnant or lactating females

          -  Evidence of mucosal or internal bleeding and/or platelet refractory

          -  Acute active infection requiring treatment

          -  Treatment by localized radiotherapy if the interval between the end of radiotherapy
             and initiation of protocol therapy lower than 2 weeks

          -  Treatment by corticosteroids if exceed the equivalent of 160 mg of dexamethasone in a
             2-week period before initiation therapy

          -  Subjects not eligible for high dose therapy
      "
NCT02407054,completed,,1,phase 2,['prostate cancer metastatic'],"[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]","['ly3023414', 'enzalutamide', 'placebo']","['Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate.

          -  Metastatic disease documented by positive bone scan or metastatic lesions on computed
             tomography (CT) or magnetic resonance imaging (MRI) scan.

          -  Prostate cancer progression documented by PSA and/or radiographic progression
             according to prostate cancer working group 2 (PCWG2).

          -  Prior abiraterone treatment completed at least 4 weeks prior to cycle 1 day 1.
             Participants must have failed prior abiraterone treatment.

          -  Surgically or medically castrated, with testosterone levels of < 50
             nanograms/deciliter.

          -  Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1.

          -  Ability to swallow the study drugs whole.

          -  Adequate hematologic function.

          -  Adequate coagulation parameters, defined as international normalization ratio (INR) ≤
             2.

          -  Availability of tumor tissue from any time since diagnosis of prostate cancer disease.
             If no tumor samples are available the participant might still be eligible following
             discussion between the investigator and the medical monitor.

        Exclusion Criteria:

          -  Prior cytotoxic chemotherapy, immunotherapy, a PI3K/AKT/mTOR agent (including TORC1
             and TORC2 inhibitors), or RA 223 dichloride for the treatment of castration resistant
             prostate cancer (CRPC). Participants may have received docetaxel in the
             hormone-sensitive setting.

          -  Prior investigational new generation potent anti-androgen therapy (such as ARN 509).

          -  Prior treatment with enzalutamide.

          -  Pathological finding consistent with small cell carcinoma of the prostate.

          -  Prior systemic treatment with an azole drug (fluconazole, itraconazole) within 4 weeks
             of cycle 1 day 1.

          -  Known brain metastasis.

          -  History of (a) seizure or any condition that may predispose to seizure (prior cortical
             stroke or significant brain trauma); (b) loss of consciousness or transient ischemic
             attack within 12 months prior to day 1 of cycle 1.

          -  Uncontrolled hypertension (systolic blood pressure [BP] ≥ 160 millimeters of mercury
             [mmHg] or diastolic BP ≥ 95 mmHg).

          -  Have serious pre-existing medical conditions (at the discretion of the investigator).

          -  Have known acute or chronic leukemia or current hematologic malignancies that, in the
             judgment of the investigator and sponsor, may affect the interpretation of results.

          -  Have insulin-dependent diabetes mellitus. Participants with a type 2 diabetes mellitus
             are eligible if adequate control of blood glucose level is obtained by oral
             anti-diabetics as documented by hemoglobin A1c <7%.

          -  Presence of active gastrointestinal disease or other condition that will interfere
             significantly with the absorption, distribution, metabolism, or excretion of oral
             therapy (e.g. ulcerative disease, uncontrolled nausea, vomiting, grade ≥2 diarrhea,
             and malabsorption syndrome).

          -  Have a history of New York Heart Association (NYHA) Class ≥3, QTc interval > 480
             milliseconds (ms) on screening electrocardiogram (ECG) per Friderica's formula,
             unstable angina, or myocardial infarction (MI) in 6 months prior to study drug
             administration.

          -  Clinically significant electrolyte imbalance ≥ grade 2.

          -  Currently receiving treatment with therapeutic doses of warfarin sodium.

          -  Have initiated treatment with bisphosphonates or approved receptor activator of
             nuclear factor kappa-B ligand (RANK-L) targeted agents (e.g. denosumab) ≤28 days prior
             to day 1 of cycle 1.

          -  Concurrent serious infections requiring parenteral antibiotic therapy.

          -  Have a second primary malignancy that in the judgment of the investigator and medical
             monitor may affect the interpretation of results.

          -  Have an active, known fungal, bacterial, and/or known viral infection.
      "
NCT02406508,withdrawn,"
    no enrollment in the study
  ",0,phase 2,['hepatocellular carcinoma (hcc)'],"[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]",['sorafenib'],['Status: 503'],"
        Inclusion Criteria:

          1. HCC diagnosed by tissue or imaging study

          2. Unresectable HCC without extrahepatic disease based on CT

          3. At least one target lesion. In patients with prior loco-regional therapy, the target
             lesion(s) must be located in area(s) outside previous treatment

          4. Child-Pugh Class A in the absence of hepatoencephalopathy or clinically evident
             ascites

          5. Barcelona Clinic Liver Cancer (BCLC) stage B

          6. MELD Score < 15

          7. Eastern Cooperative Oncology Group Performance Status 0-1

          8. No prior systemic therapy for HCC

          9. No prior radiation therapy to the liver including Y90-, I131-based loco-regional
             therapy. Prior loco-regional therapy based on other technology for HCC, if any, must
             have been completed at least 4 weeks prior to baseline imaging

         10. Age ≥ 18 years

         11. Signed informed consent

        Exclusion Criteria:

          1. Metastatic disease outside of liver

          2. Greater than 50% tumor burden in the liver by imaging

          3. History of orthotopic liver transplantation, clinical symptoms of portal hypertension,
             Whipple's procedure, hepatic artery anatomy incompatible with perfusion or known
             unresolved venous shunting

          4. Evidence of ascites on imaging study, or the use of diuretics for ascites

          5. Clinically significant encephalopathy

          6. History of allergies or known hypersensitivity to any components of melphalan or the
             components of the Melphalan/HDS system

          7. Known hypersensitivity to heparin or the presence of heparin-induced thrombocytopenia

          8. Received an investigational agent for any indication within 30 days prior to first
             treatment

          9. Not recovered from side effects of prior therapy to ≤ grade 1 (according to National
             Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 [NCI
             CTCAE v. 4.03]). Certain side effects that are unlikely to develop into serious or
             life-threatening events (e.g. alopecia) are allowed at > grade 1

         10. Those with New York Heart Association functional classification II, III or IV; active
             cardiac conditions including unstable coronary syndromes (unstable or severe angina,
             recent myocardial infarction), worsening or new-onset congestive heart failure,
             significant arrhythmias and severe valvular disease must be evaluated for risks of
             undergoing general anesthesia

         11. History or evidence of clinically significant pulmonary disease that precludes the use
             of general anesthesia

         12. Uncontrolled diabetes mellitus, hypothyroidism, or hyperthyroidism

         13. Active uncontrolled infection, including Hepatitis B, Hepatitis C infection. Patients
             with anti-HBc positive, or HBsAg but DNA negative are exception(s)

         14. History of bleeding disorders

         15. Brain lesions with a propensity to bleed

         16. Known esophageal varices at risk of bleeding, including medium or large esophageal or
             gastric varices, or active peptic ulcer

         17. Previous malignancy within 3 years prior to enrollment, except for curatively-treated
             basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, bladder
             carcinoma in situ or breast cancer in situ

         18. Inadequate hematologic function as evidenced by any of the following:

               -  Platelets < 125,000/µL

               -  Hemoglobin ≤ 10 g/dL, independent of transfusion or growth factor support

               -  Neutrophils < 1,500/µL

         19. Serum creatinine > 1.5 mg/dL

         20. Inadequate liver function as evidenced by any of the following:

               -  Total serum bilirubin ≥ 2.0 mg/dL

               -  Prothrombin time International Normalized Ratio (INR) > 1.5

               -  Aspartate aminotransferase (AST) or alanine transaminase (ALT) > 5 times ULN

               -  Serum albumin < 3.0 g/dL

         21. Alcohol consumption within 30 days of first study treatment, or refusing to abstain
             from alcohol for the duration of study treatment

         22. For female subjects of childbearing potential (i.e., have had a menstrual period
             within the past 12 months): a positive serum pregnancy test (β-human chorionic
             gonadotropin) within 7 days prior to enrollment; or unwilling or unable to undergo
             hormonal suppression to avoid menstruation during treatment

         23. Sexually active females of childbearing potential and sexually active males with
             partners of reproductive potential: unwilling or unable to use appropriate
             contraception from screening until at least 30 days after last administration of study
             treatment
      "
NCT02159365,completed,,1,phase 2,['multiple myeloma'],"[""['C90.01', 'C90.02', 'C90.00']""]","['elotuzumab', 'lenalidomide', 'dexamethasone']","['Status: 503', 'Status: 503', 'Status: 503']","
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤2

          -  Documented evidence of active multiple myeloma:

               -  Newly diagnosed, not candidate for transplant

               -  Relapsed/refractory who have received up to 3 prior lines of therapy

          -  Prior Lenalidomide exposure is permitted only if the following criteria are fulfilled:

               -  Not refractory to prior Lenalidomide which is defined as no progression while
                  receiving Lenalidomide or within 60 days of last dose of Lenalidomide

               -  Subject did not discontinue Lenalidomide due to a Grade ≥3 related adverse event
                  (AE)

        Exclusion Criteria:

          -  Target Disease Exceptions

               -  Plasma cell leukemia

               -  Monoclonal gammopathy of undetermined significance (MGUS)

               -  Smoldering Myeloma

          -  Primary amyloidosis

          -  Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes
             (POEMS) syndrome
      "
NCT02155465,completed,,1,phase 1/phase 2,['lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['ruxolitinib', 'erlotinib']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Pathologic evidence of advanced (non-operable or metastatic) biopsy-proven stage IV or
             recurrent lung cancer reviewed at MSKCC.

          -  a documented somatic activating mutation in EGFR (including but not limited to Exon 19
             deletion or L858R)

          -  Radiographic progression during treatment with erlotinib. Prior chemotherapy regimens
             are permitted.

          -  Received erlotinib or other EGFR TK treatment for at least 2 weeks prior to enrollment

          -  Measurable (RECIST 1.1) indicator lesion not previously irradiated

          -  Must have undergone biopsy after development of acquired resistance to erlotinib
             (which is performed as standard of care) with adequate tissue to determine EGFR T790M
             and tumor histology. Slides from an outside institution may be used.

          -  KPS ≥ 70%

          -  Age>18 years old

          -  Patients must have adequate organ function:

               -  AST, ALT, Alk phos ≤ 3.0 x ULN

               -  Total bilirubin ≤ 2.0 x ULN

               -  Creatinine <2.0 X upper limit of normal and/or a creatinine clearance ≥ 60ml/min

               -  Absolute neutrophil count (ANC) ≥1,000 cells/mm³.

               -  Platelet count ≥ 100,000/mm³

               -  Hemoglobin ≥ 9.0g/dL.

        Exclusion Criteria:

          -  Concurrent therapy with a potent CYP3A4 inducer or inhibitor. Subjects may enter
             screening when therapy with the potent inhibitor or inducer is completed and may begin
             study treatment after 1 week or 5 half-lives, whichever is longer.

          -  Patients with symptomatic brain metastasis requiring escalating doses of steroids.

          -  Any type of systemic therapy (chemotherapy or experimental drugs) within 3 weeks of
             starting treatment on protocol except for erlotinib or other EGFR TKI.

          -  Any radiation within 2 weeks prior to starting treatment on protocol

          -  Patients with ≥ grade 2 or greater diarrhea despite maximal medical management due to
             medications or a medical condition such as Crohn's disease, malabsorption.

          -  Inadequate recovery from any toxicities related to prior treatment (to Grade 1 or
             baseline).

          -  Pregnant or lactating women

          -  Patients who have received prior treatment with JAK inhibitor

          -  Previously or current malignancies at other sites within the last 2 years, with the
             exception of adequately treated in situ carcinoma of the cervix, basal or squamous
             cell carcinoma of the skin, prostate cancer that does not require active treatment per
             National Comprehensive Cancer Network (NCCN) guidelines, superficial bladder cancer or
             other noninvasive indolent or stage 1 malignancy without sponsor approval.

          -  Clinically significant cardiac disease including unstable angina, acute myocardial
             infarction within 6 months from Day 1 of study drug administration, New York Heart
             Association Class III or IV congestive heart failure, or symptomatic arrythmias
             requiring therapy,

          -  Chronic or current active infections requiring systemic antibiotics, antifungals or
             antiviral therapy.

          -  Known human immunodeficiency virus infection, or hepatitis B virus (HBV) viremia or
             hepatitis C virus (HCV) viremia. Screening for the study does not require assessment
             for these infections if not already known.

          -  Any other condition that, in the opinion of the Investigator, may compromise the
             safety, compliance of the patient, or would preclude the patient from successful
             completion of the study.
      "
NCT02158091,"active, not recruiting",,1,phase 1/phase 2,['chronic lymphocytic leukemia'],"[""['C91.11', 'C91.12', 'C91.10']""]","['ipi-145', 'fludarabine', 'cyclophosphamide', 'rituximab']","['Status: 503', 'Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  confirmed diagnosis of CLL and an indication for treatment as per IW-CLL 2008 criteria

          -  no prior therapy for CLL

          -  age 18-65 -- ECOG performance status ≤1

        Exclusion Criteria:

          -  May not be receiving any other study agents

          -  Known CNS involvement

          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Pregnant women are excluded from this study because IPI-145 has the potential for
             teratogenic or abortifacient effects.

          -  Individuals with a history of a different malignancy are ineligible except for the
             following circumstances. disease-free for at least 5 years and deemed to be at low
             risk for recurrence. Individuals with the following cancers are eligible if diagnosed
             and treated with curative intent within the past 5 years: cervical cancer in situ,
             localized prostate cancer, and basal cell or squamous cell carcinoma of the skin

          -  HIV-positive individuals, because of the potential for pharmacokinetic interactions
             with IPI-145

          -  Inadequate hepatic function defined by aspartate aminotransferase (AST) and/or alanine
             aminotransferase (ALT) >2.5 x upper limit of normal (ULN); direct bilirubin >1.5 x
             ULN, unless due to hemolysis or Gilbert's syndrome

          -  Inadequate renal function defined by serum creatinine >1.5 x ULN.

          -  Baseline QTcF >480 ms. NOTE: This criterion does not apply to patients with a left
             bundle branch block

          -  Concurrent treatment with any agent known to prolong the QTc interval

          -  Patients with a history of active tuberculosis within the preceding two years.

          -  Patients who have had a venous thromboembolic event (e.g., PE/DVT) requiring
             anticoagulation and who meet any of the following criteria:

          -  Have been on a stable dose of anticoagulation for <1 month

          -  Have had a Grade 2, 3 or 4 hemorrhage in the last 30 days

          -  Are experiencing continued symptoms from their event

          -  History of alcohol abuse, chronic hepatitis, or other chronic liver disease (other
             than direct CLL liver involvement)

          -  Foods or medications that are strong or moderate inhibitors or inducers of CYP3A taken
             within 1 week prior to study treatment and for the duration of the study

          -  Unable to receive prophylactic treatment for pneumocystis
      "
NCT02153905,terminated,"
    slow, insufficient accrual.
  ",0,phase 1/phase 2,"['breast cancer', 'cervical cancer', 'renal cancer', 'melanoma', 'bladder cancer']","[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['M50.20', 'M50.21', 'M50.30', 'M50.31', 'M50.80', 'M50.81', 'M50.90']"", ""['C65.1', 'C65.2', 'C65.9', 'D30.10', 'D30.11', 'D30.12', 'C64.1']"", ""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']"", ""['D30.3', 'C67.5', 'C67.9', 'C79.11', 'C67.0', 'C67.1', 'D41.4']""]","['aldesleukin', 'fludarabine', 'cyclophosphamide']","['Status: 503', 'Status: 503', 'Status: 503']","
        -  INCLUSION CRITERIA:

               1. Metastatic or locally advanced refractory/recurrent cancer that expresses MAGE-A3
                  as assessed by one of the following methods: reverse transcription polymerase
                  chain reaction (RT-PCR) on tumor tissue defined as 30,000 copies of MAGE-A3 per
                  106 glyceraldehyde 3-phosphate dehydrogenase (GAPDH) copies, or by
                  immunohistochemistry of resected tissue defined as 10% or greater of tumor cells
                  being 2-3+ for MAGE-A3, or serum antibody reactive with MAGE-A3. Metastatic
                  cancer diagnosis will be confirmed by the Laboratory of Pathology at the National
                  Cancer Institute (NCI).

               2. Patients must have previously received prior first line standard therapy (or
                  effective salvage chemotherapy regimens) for their disease, if known to be
                  effective for that disease, and have been either non-responders (progressive
                  disease) or have recurred.

               3. Patients must be human leukocyte antigen serotype within HLA-A A serotype group
                  (HLA-A*01) positive.

               4. Greater than or equal to 18 years of age and less than or equal to age 70.

               5. Ability of subject to understand and the willingness to sign the Informed Consent
                  Document

               6. Willing to sign a durable power of attorney

               7. Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1

               8. Patients of both genders must be willing to practice birth control from the time
                  of enrollment on this study and for up to four months after treatment.

               9. Serology:

                    -  Seronegative for human immunodeficiency virus (HIV) antibody. (The
                       experimental treatment being evaluated in this protocol depends on an intact
                       immune system. Patients who are HIV seropositive can have decreased
                       immune-competence and thus be less responsive to the experimental treatment
                       and more susceptible to its toxicities.)

                    -  Seronegative for hepatitis B antigen, and seronegative for hepatitis C
                       antibody. If hepatitis C antibody test is positive, then patient must be
                       tested for the presence of antigen by RT-PCR and be hepatitis C virus
                       ribonucleic acid (HCV RNA) negative.

              10. Women of child-bearing potential must have a negative pregnancy test because of
                  the potentially dangerous effects of the treatment on the fetus.

              11. Hematology

                    -  Absolute neutrophil count greater than 1000/mm^3 without the support of
                       filgrastim

                    -  White blood cell (WBC) greater than or equal to 3000/mm^3

                    -  Platelet count greater than or equal to 100,000/mm^3

                    -  Hemoglobin > 8.0 g/dl

              12. Chemistry:

                    -  Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less
                       than or equal to to 2.5 times the upper limit of normal

                    -  Serum creatinine less than or equal to to 1.6 mg/dl

                    -  Total bilirubin less than or equal to to 1.5 mg/dl, except in patients with
                       Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dl.

              13. More than four weeks must have elapsed since any prior systemic therapy at the
                  time the patient receives the preparative regimen, and patients toxicities must
                  have recovered to a grade 1 or less (except for toxicities such as alopecia or
                  vitiligo). Patients must have progressing disease after prior treatment. Note:
                  Patients who have previously received ipilimumab and have documented
                  gastrointestinal (GI) toxicity must have a normal colonoscopy with normal colonic
                  biopsies

              14. Subjects must be co-enrolled in protocol 03-C-0277.

        Note: Patients who have previously received ipilimumab and have documented gastrointestinal
        (GI) toxicity must have a normal colonoscopy with normal colonic biopsies.

        EXCLUSION CRITERIA:

          1. Women of child-bearing potential who are pregnant or breastfeeding because of the
             potentially dangerous effects of the treatment on the fetus or infant.

          2. Active systemic infections (e.g.: requiring anti-infective treatment), coagulation
             disorders or any other active major medical illnesses.

          3. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency
             Disease).

          4. Concurrent opportunistic infections (The experimental treatment being evaluated in
             this protocol depends on an intact immune system. Patients who have decreased immune
             competence may be less responsive to the experimental treatment and more susceptible
             to its toxicities).

          5. Concurrent systemic steroid therapy.

          6. History of severe immediate hypersensitivity reaction to any of the agents used in
             this study.

          7. History of any cardiac events including coronary revascularization or ischemic
             symptoms.

          8. Documented left ventricular ejection fraction (LVEF) of less than or equal to 45%;
             testing is required in patients who are:

               -  Age greater than or equal to 65 years old

               -  Clinically significant atrial and or ventricular arrhythmias including but not
                  limited to: atrial fibrillation, ventricular tachycardia, second or third degree
                  heart block or have a history of ischemic heart disease, or chest pain.

          9. Patients with central nervous system (CNS) metastases or symptomatic CNS involvement
             (including cranial neuropathies or mass lesions).

         10. Patients presenting with lesions that may harbor an occult infectious source.

         11. Documented forced expiratory volume 1 (FEV1) less than or equal to 60% predicted
             tested in patients with:

               -  A prolonged history of cigarette smoking (20 pk/year of smoking within the past 2
                  years).

               -  Symptoms of respiratory dysfunction

         12. Patients who are receiving any other investigational agents.
      "
NCT02151084,"active, not recruiting",,0,phase 2,"['biliary tract carcinoma', 'gallbladder carcinoma']","[""['D01.5']""]","['selumetinib', 'cisplatin', 'gemcitabine']","['Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Unresectable, recurrent or metastatic, measurable biliary tract cancer or gall bladder
             cancer

          -  No prior systemic therapy

          -  Performance status 0, 1, or 2

          -  Age 18 years or older

          -  Estimated life expectancy > 3 months

          -  Adequate hematological, liver, renal function

          -  No evidence of active uncontrolled infection

          -  Capable of giving written consent

          -  Acceptable recovery of previous side effects

        Exclusion Criteria:

          -  Progressing within 3 or 6 months of receiving certain treatments

          -  Prior chemotherapy for non-resectable or metastatic disease or a MEK inhibitor

          -  Progressing within 6 months of adjuvant treatment.

          -  May not have received prior chemotherapy for non-resectable/metastatic disease.

          -  Prior MEK, RAS, or RAF inhibitors or history of hypersensitivity to study drugs.

          -  Ampullary carcinoma

          -  Incomplete recovery from previous surgery

          -  Undergoing treatment with curative intent

          -  Prior malignancy that could interfere with the response evaluation

          -  Severe or uncontrolled systemic diseases or lab finding that makes it undesirable for
             patient to participate

          -  Any psychiatric or other disorder likely to impact consent

          -  Pregnant or breastfeeding

          -  Patients with significant cardiac-related issues

          -  History of eye-related issues.

          -  Systemic disease, active infection, bleeding diatheses or renal transplant, including
             hep B, hep C or HIV

          -  Receiving potent inhibitors or inducers of CYP3A4/5, CYP2C19 and CYP1A2 can continue
             with caution
      "
NCT04149821,terminated,"
    terminated due to low accrual
  ",0,phase 2,"['chronic lymphocytic leukemia', 'cll progression', 'cll/sll']","[""['C91.11', 'C91.12', 'C91.10']""]","['umbralisib', 'ublituximab']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  confirmed diagnosis of CLL based upon 2018 International Workshop on CLL (IWCLL)
             criteria.

          -  Patient must have progressed on a BTK or BCL-2 containing regimen as the prior line of
             therapy. Patients who were treated with a regimen containing both classes of novel
             agents will be allowed to enroll and will be enrolled into Cohort B. Patients who
             receive a temporizing non-experimental treatment such as an anti-CD20 monoclonal
             antibody, corticosteroid including high dose methylprednisolone after progression on a
             BTK or BCL-2 inhibitor will be considered for enrollment after discussion with the
             study sponsor.

          -  Age ≥18 years

          -  ECOG performance status ≤2

          -  Patient must have adequate bone marrow function and meet the below thresholds:

               -  Absolute neutrophil count of ≥ 750 cell/μL in absence of G-CSF for 7 days prior
                  to enrollment.

               -  Platelet count of ≥ 30,000 cells/μL, or ≥ 20,000 cells/μL if there is bone marrow
                  involvement)

          -  Patient must have adequate organ function and meet the thresholds below:

               -  Total bilirubin ≤ 1.5 times the upper limit of normal (ULN). Subjects with
                  bilirubin exceeding this limit due to Gilbert's disease are eligible

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 x ULN if
                  no liver involvement or ≤5 x the ULN if known liver involvement

               -  Creatinine clearance >30 ml/min/1.73m2 as calculated by the MDRD equation

          -  Ability to swallow and retain oral medication.

          -  Females who are not of child-bearing potential, and females of child-bearing potential
             (FCBP) who have a negative serum pregnancy test within 3 days prior to initial trial
             treatment. Males of reproductive potential may not participate unless they agree to
             use medically acceptable contraception. FCBP and all male partners, and male subjects
             must consent to use a medically acceptable method of contraception throughout the
             study period and for 4 months after the last dose of study drug

          -  Willingness and ability to comply with trial and follow-up procedures, and give
             written informed consent

        Exclusion Criteria:

          -  Patient has had prior exposure to a PI3K inhibitor at any point in treatment history

          -  Patient has discontinued the BTK or BCL2 inhibitor due to intolerance. Intolerance
             will be defined as discontinuing prior BTKi or BCL-2 therapy for any reason without
             evidence of progression. Patients who were re-challenged after discontinuation for
             therapeutic reasons will be allowed if the toxicity did not recur or was managed
             without indication for discontinuation. Patients who progress on BTKi or BCL-2 therapy
             who were on a reduced dose due to an AE/intolerance are eligible as long as
             progression has been documented on that reduced dose.

          -  Patient has clinical or radiographic evidence of, or has biopsy proven Richter's
             transformation or prolymphocytic leukemia.

          -  Patient has undergone an allogeneic stem cell transplant.

          -  Patient has received an autologous hematologic stem cell transplant within 6 months of
             study entry.

          -  Prior history of malignancy within 3 years of study enrollment except for adequately
             treated basal, squamous cell carcinoma or non-melanomatous skin cancer, carcinoma in
             situ of the cervix, superficial bladder cancer not treated with intravesical
             chemotherapy or BCG within 6 months, localized prostate cancer and PSA <1.0 mg/dL on 2
             consecutive measurements at least 3 months apart with the most recent one being within
             4 weeks of study entry.

          -  Patient is known to be positive for HIV.

          -  Patient has history of hepatitis C infection, active infection with hepatitis B or
             active cytomegalovirus (CMV) as determined by PCR.

          -  Patient has previous exposure to a BTK inhibitor therapy within 14 days of initiating
             study treatment on Cycle 1 Day 1, or previous exposure to anti-cancer therapy
             including chemotherapy, radiotherapy, or investigational therapy, including other
             targeted small molecule agents within 21 days of initiating study treatment on Cycle 1
             Day 1.

          -  Evidence of ongoing systemic bacterial, fungal or viral infection, except localized
             fungal infections of skin or nails.

          -  History of anaphylaxis (excluding infusion related reactions) in association with
             previous anti-CD20 administration.

          -  Inflammatory bowel disease (such as Crohn's disease or ulcerative colitis).

          -  Malabsorption syndromes.

          -  Irritable bowel syndrome with greater than 3 loose stools per day as a baseline.

          -  Any severe and/or uncontrolled medical conditions or other conditions that could
             affect participation in the study such as:

               -  Symptomatic, or history of documented congestive heart failure (New York Heart
                  Association functional classification III-IV)[see Appendix: NYHA Classifications]

               -  Significant cardiovascular disease such as uncontrolled or symptomatic
                  arrhythmias, CHF, or myocardial infarction within 6 months of enrollment.

               -  Concomitant use of medication known to cause QT prolongation or torsades de
                  pointes should be used with caution and at investigator discretion.

               -  Poorly controlled or clinically significant atherosclerotic vascular disease
                  including cerebrovascular accident (CVA), transient ischemic attack (TIA),
                  angioplasty, cardiac or vascular stenting within 6 months of enrollment.

          -  Females who are pregnant or lactating.
      "
NCT03879811,withdrawn,"
    no accrual
  ",0,phase 2,['colorectal cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['tmz', 'nivolumab']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Subject or legally authorized representative, is willing and able to provide written
             informed consent/assent for the trial

          -  Histologically- or cytologically- confirmed CRC

          -  Locally advanced or metastatic CRC

          -  Confirmation of MGMT promoter methylation on archived tissue by PCR analysis (any
             time).

          -  MGMT promoter methylation is determined using the ARUP laboratory assay (or similar).
             Total methylation is calculated as an average across listed CpG sites. Total
             methylation of 0-9 percent is reported as ""Not detected"" 10-29 percent as ""Low level""
             and equal or more than 30 percent as ""Detected"". Patients will require MGMT promoter
             methylation to be ""detected"" in order to be eligible.

          -  Undergone testing for MSI/dMMR and determined to be MSS or MMR proficient

          -  Subjects must be refractory or intolerant to at least 2 lines of standard
             chemotherapy, according to NCCN guidelines for patients eligible for intensive
             therapy. At a minimum, such therapies should include regimens containing oxaliplatin
             or irinotecan in combination with a fluoropyrimidine (e.g., FOLFOX or FOLFIRI or their
             variants).

          -  At least one index lesion which is measurable based on RECIST 1.1

          -  Be >/= 18 years of age on day of signing informed consent

          -  Consent for tumor biopsies and blood draws for research purposes

          -  Have an ECOG performance status of 0 or 1

          -  Demonstrate adequate organ function as defined in Table 6.1, all screening labs should
             be performed within 28 days of treatment initiation.

        Adequate Organ Function Laboratory Values

        Hematological

          -  Absolute neutrophil count (ANC) >/= 1,500/mcl

          -  Platelets >/= 100,000/mcl

          -  WBC >/= 2000/ul

          -  Hemoglobin >/= 9.0 g/dL

        Renal

          -  Serum creatinine </= 1.5 x upper limit of normal (ULN) OR

          -  Measured or calculated creatinine clearance (GFR can also be used in place of
             creatinine of CrCl) >/= 60 mL/min for subject with creatinine levels > 1.5 x
             institutional ULN (Creatinine clearance should be calculated per institutional
             standard)

        Hepatic

          -  Serum total bilirubin </= 1.5 x ULN -OR- Direct bilirubin </= ULN for subjects with
             total bilirubin levels > 1.5 ULN

          -  AST (SGOT) and ALT (SGPT) </= 2.5 x ULN -OR- </= 5 x ULN for subjects with liver
             metastases

          -  Female subject of childbearing potential should have a negative serum pregnancy within
             2 weeks prior to starting treatment

          -  Female subjects of childbearing potential should be willing to use 2 methods of birth
             control or be surgically sterile, or abstain from heterosexual activity for the course
             of the study through 5 months after the last dose of study medication. Subjects of
             childbearing potential are those who have not been surgically sterilized or have not
             been free from menses for > 1 year

          -  Male subjects should agree to use an adequate method of contraception starting with
             the first dose of study therapy through 7 months after the last dose of study therapy
             (defined in section 7.1). In addition, male subjects must be willing to refrain from
             sperm donation during this time.

        Coagulation

          -  International Normalized Ratio (INR) or Prothrombin Time (PT) </= 1.5 x ULN unless
             subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic
             range of intended use of anticoagulants

          -  Activated Partial Thromboplastin Time (aPTT) </= 1.5 x ULN unless subject is receiving
             anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use
             of anticoagulants

        Exclusion Criteria:

          -  Subject is currently participating in or has participated in a study of an
             investigational agent or using an investigational device within 4 weeks of the first
             dose of treatment.

          -  Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (>10
             mg/day prednisone, or equivalent) or any other form of immunosuppressive therapy
             within 7 days prior to the first dose of trial treatment. inhaled or topical steroids
             are permitted in the absence of active autoimmune disease

          -  Prior chemotherapy, targeted small molecule therapy, or biological therapy, within 2
             weeks prior to study Day 1 or who has not recovered (i.e., </= Grade 1 or at baseline)
             from adverse events due to a previously administered agent (exc. alopecia)

          -  If subject received major surgery, they must have recovered adequately prior to
             starting therapy

          -  Has a known additional malignancy that is progressing or requires active treatment.
             Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the
             skin, or in situ cervical cancer that has undergone potentially curative therapy

          -  Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis. Subjects with previously treated brain metastases may participate provided
             they are stable (without evidence of progression by imaging for at least four weeks
             prior to the first dose of trial treatment any neurologic symptoms have returned to
             baseline), have no evidence of new or enlarging brain metastases, and are not using
             steroids for at least 7 days prior to trial treatment,

          -  Has an active, known or suspected autoimmune disease requiring systemic treatment
             within the past 3 months or a documented history of clinically severe autoimmune
             disease, or a syndrome that requires systemic steroids or immunosuppressive agents.
             Subjects with vitiligo or resolved childhood asthma/atopy, type 1 diabetes mellitus
             are permitted. Subjects that require intermittent use of bronchodilators or local
             steroid injections would not be excluded from the study. Subjects with hypothyroidism
             stable on hormone replacement or Sjorgen's syndrome will not be excluded from the
             study.

          -  Has evidence of known interstitial lung disease or active, non-infectious pneumonitis

          -  Has an active infection requiring systemic therapy

          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the subject's
             participation for the full duration of the trial, or it is not in the best interest of
             the subject to participate, in the opinion of the treating investigator

          -  Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial

          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the pre-screening or screening visit
             through 5 months for females, 7 months for males after the last dose of trial
             treatment

          -  Prior anti-PD-1, anti-PDL-1, anti-PDL-2, anti-Cytotixic T-lymphocyte-associated
             antigen-4 (CTLA-4) antibody or any other antibody or drug specifically targeting
             T-cell co-stimulation or checkpoint pathways

          -  Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)

          -  Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA
             [qualitative] is detected)

          -  Has received a live vaccine within 30 days prior to the first dose of trial treatment

          -  Subjects is a prisoners or compulsory detained
      "
NCT03109301,withdrawn,"
    slow accrual
  ",0,phase 2,"['neoplasms, nerve tissue', 'neurofibromatosis 1', 'heredodegenerative disorders, nervous system', 'peripheral nervous system diseases']","[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['Q85.01']"", ""['F20.81', 'F21', 'F34.0', 'F34.1', 'F42.3', 'F45.0', 'F51.5']"", ""['G64', 'M35.06', 'P14.9', 'P14.8', 'C47.9', 'D36.10', 'R94.138']""]","['selumetinib (azd6244 hyd sulfate) 50mg/dose', 'selumetinib (azd6244 hyd sulfate) 25mg/m2']","['Status: 503', 'Status: 503']","
        -  ELIGIBILITY CRITERIA:

          -  Age: greater than or equal to 3 years of age, BSA greater than or equal to 0.55 m^2,
             and able to swallow intact capsules.

          -  Diagnosis: must have either a clinical diagnosis of NF1 or a germline NF1 mutation, or
             in patients without the NF1 syndrome, demonstrate an NF1 mutation in the GIST verified
             in a CLIA certified laboratory. In patients without the NF1 syndrome, confirmation of
             the NF1 mutation in the GIST is required for enrollment.

               -  a) For a clinical diagnosis of NF1 patients must have at least two of the
                  diagnostic criteria for NF1 listed below

                    -  Six or more cafe-au-lait macules (greater or equal to 0.5cm in prepubertal
                       subjects or greater than or equal to 1.5 cm in post pubertal subjects)

                    -  Freckling in axilla or groin

                    -  A neurofibroma or plexiform neurofibroma

                    -  Optic glioma

                    -  Two or more Lisch nodules

                    -  A distinctive bony lesion (dysplasia of the sphenoid bone or dysplasia or
                       thinning of long bone cortex)

                    -  A first-degree relative with NF1

          -  Patients must have a histologically or cytologically confirmed measurable GIST without
             PDGFRA or KIT mutations. GIST may be newly diagnosed or recurrent provided that it
             meets criteria for progressive or metastatic disease. Metastatic disease refers to
             disease outside the GI tract, not simply a multifocal primary tumor. Testing performed
             by the Laboratory of Pathology, NCI, unless previously conducted by a CLIA/CAP
             external laboratory; analysis will include evaluation of 4 exons of KIT (9, 11, 13,
             17) and 3 exons of PDGFRA (12, 14, 18).

          -  Measurable Disease:

               -  Patients must have measurable GIST as defined by RECIST v 1.1 as at least one
                  lesion not previously irradiated, that can be accurately measured at baseline
                  greater than or equal to 10 mm in the longest diameter (except lymph nodes which
                  must have short axis greater than or equal to 15 mm) with computed tomography
                  (CT) or magnetic resonance imaging (MRI) and which is suitable for accurate
                  repeated measurements.

               -  Progressive disease: GIST has demonstrated progression as defined by RECIST v1.1
                  within the past 12 months. Patients whose tumors do not meet this criterion, and
                  have a diagnosis of NF1, may enroll on the NF1 Natural History study.

          -  Performance Status: ECOG less than or equal to 2 (Patients greater than or equal to 16
             years of age must have a Karnofsky performance level of greater than or equal to 70%
             (or ECOG less than or equal to 2), and children less than or equal to 16 years old
             must have a Lansky performance of greater than or equal to 70%

          -  Patients must have normal organ and marrow function as defined below:

               -  absolute neutrophil count greater than or equal to 1,000/mcL

               -  platelets greater than or equal to 100,000/mcL

               -  hemoglobin (Hgb) greater than or equal to 9.0 g/dL

               -  total bilirubin < 1.5(SqrRoot) institutional upper limit of normal

               -  AST(SGOT)/ALT(SGPT) < 3.0 (SqrRoot) institutional upper limit of normal

               -  creatinine clearance or radioisotope GFR > 60 mL/min/1.73 m^2 by either
                  Cockcroft- Gault formula or analysis normal serum creatinine based on age
                  described below:

                    -  Age (years): less than or equal to 5; Maximum Serum Creatinine (mg/dL): 0.8

                    -  Age (years): 5 or less or equal to 10; Maximum Serum Creatinine (mg/dL): 1.0

                    -  Age (years): 10 or less than or equal to 15; Maximum Serum Creatinine
                       (mg/dL): 1.2

                    -  Age (years): >15; Maximum Serum Creatinine (mg/dL): 1.5

          -  Prior Therapy: Patients will be eligible if tumor is metastatic, unresectable,
             progressive, or if complete tumor resection is not considered to be feasible without
             substantial risk or morbidity.

               -  Since there is no standard effective chemotherapy for patients with NF1 and GIST,
                  patients may be treated on this trial without having received prior medical
                  therapy directed at their GIST. Patients who have had prior GIST-directed surgery
                  may enroll provided they have measurable disease.

               -  Since selumetinib is not expected to cause substantial myelosuppression, there
                  will be no limit to number of prior myelosuppressive regimen for GIST or other
                  tumor manifestations associated with NF1.

               -  Patients who have received previous investigational agents or biologic therapy,
                  such as tipifarnib, pirfenidone, Peg-Intron, sorafenib, imatinib or other
                  targeted therapies are eligible for enrollment. At least 4 weeks must have
                  elapsed since receiving medical therapy directed at the PN and patients who
                  received previous GIST-directed therapy must either demonstrate progression as
                  defined by RECIST, or be unable to tolerate their previous therapy. Patients who
                  received effects of all prior therapy to less than or equal to grade 1 before
                  entering this study.

               -  Cytotoxic chemotherapy last dose must have been received at least 28 days prior
                  to enrollment, their last dose of biological therapy, immunomodulatory agents,
                  vaccines, differentiating agents, used to treat their cancer at least 7 days
                  prior to enrollment, their last dose of a monoclonal antibody at least 30 days
                  prior to enrollment, and their last dose of any investigational agent at least 30
                  days prior

        to enrollment.

          -  Growth factors that support platelet or white cell number or function must not have
             been administered within the 7 days prior to enrollment.

          -  At least 6 weeks must have elapsed prior to enrollment since the patient received any
             prior radiation therapy.

          -  At least 4 weeks must have elapsed since any surgeries, with evidence of good wound
             healing.

               -  The effects of selumetinib on the developing human fetus at the recommended
                  therapeutic dose are unknown. For this reason, women of child-bearing potential
                  and men must agree to use adequate contraception (hormonal or barrier method of
                  birth control; abstinence) prior to study entry, for the duration of study
                  participation, and for 4 weeks after dosing with selumetinib ceases. Women of
                  child-bearing potential must have a negative pregnancy test prior to entry.
                  Should a woman become pregnant or suspect she is pregnant while she or her
                  partner is participating in this study, the patient should inform her treating
                  physician immediately. Please note that the selumetinib

        manufacturer recommends that adequate contraception for male patients should be used for 16
        weeks post-last dose due to sperm life cycle.

          -  All patients and/or their parents or legal guardians must sign a written informed
             consent.

          -  Willingness to avoid excessive sun exposure and use adequate sunscreen protection if
             sun exposure is anticipated.

          -  Willingness to avoid the ingestion of grapefruit and Seville oranges (as well as other
             products containing these fruits, e.g. grapefruit juice or marmalade) during the
             study, as these may affect selumetinib metabolism.

          -  Although not a requirement, participants will be asked to also participate in protocol
             10-C-0086 Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of
             a Repository for Related Biological Studies. Patients with NF1 will be asked to
             coenroll

        on the NF1 Natural History Study and 08-C-0079: Natural History Study and Longitudinal
        Assessment of Children, Adolescents, and Adults with Neurofibromatosis Type 1.

        EXCLUSION CRITERIA:

          -  Patients with evidence of another malignancy or benign tumor requiring chemotherapy or
             radiation therapy are excluded; however, those patients with a plexiform neurofibroma
             requiring treatment will be eligible as selumetinib has documented activity in
             plexiform neurofibromas.

          -  Patients with a diagnosis of NF1 and GIST who do not meet other eligibility criteria
             may enroll on the NF1 Natural History Study, and will be followed on this study.
             Should they require therapy for GIST based on evidence of progression, they may then
             enroll on study.

          -  Patients who are receiving any other investigational agents.

          -  Prior therapy with selumetinib or another specific MEK inhibitor is not permitted.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to selumetinib or other agents used in study.

          -  Previous MEK, RAS, or RAF inhibitor use.

          -  Patients who anticipate the need for surgical intervention within the first three
             cycles (3 months), as surgical intervention during the period of DLT evaluation may
             affect analysis of adherence and/or make the subject inevaluable.

          -  Patients with known brain metastases should be excluded from this clinical trial
             because of their poor prognosis and because they often develop progressive neurologic
             dysfunction that would confound the evaluation of neurologic and other adverse events.

          -  Patients with the following cardiac conditions are excluded:

               -  Uncontrolled hypertension (Adults: blood pressure [BP] of greater than or equal
                  to 150/95 despite medical support/management. Participants 18 years of age and
                  younger should have a blood pressure less than or equal to 95th percentile for
                  age, height and gender. Preexisting hypertension in adults should be controlled
                  (either with pharmacological or nonpharmacological methods) at the time of
                  enrollment.)

               -  Acute coronary syndrome within 6 months prior to starting treatment

               -  Uncontrolled angina - Canadian Cardiovascular Society grade II-IV despite medical
                  support/management

               -  Heart failure NYHA Class II or above

               -  Prior or current cardiomyopathy including but not limited to the following: Known
                  hypertrophic cardiomyopathy

               -  Known arrhythmogenic right ventricular cardiomyopathy

               -  Baseline left ventricular ejection fraction (LVEF) less than or equal to 55%

               -  Previous moderate or severe impairment of left ventricular systolic function
                  (LVEF less than 50% on echocardiography or equivalent on Multi-Gated Acquisition
                  Scan [MUGA]) even if full recovery has occurred.

               -  Severe valvular heart disease

               -  Atrial fibrillation with a ventricular rate greater than 100 bpm on ECG at rest

          -  Ophthalmological conditions as follows:

               -  Current or past history of retinal pigment epithelial detachment (RPED)/central
                  serous retinopathy (CSR) or retinal vein occlusion

               -  Intraocular pressure (IOP) greater than 21 mmHg or uncontrolled glaucoma
                  (irrespective of IOP).

               -  Evidence of optic glioma, malignant glioma, malignant peripheral nerve sheath
                  tumor,

               -  Ophthalmological findings secondary to long-standing optic pathway glioma (such
                  as visual loss, optic nerve pallor or strabismus) or long-standing orbitotemporal
                  PN (such as visual loss, strabismus) will NOT be considered a significant
                  abnormality for the purposes of the study

               -  Subjects with any other significant abnormality on ophthalmic examination
                  (performed by an ophthalmologist) should be discussed with the Study Chair for
                  potential eligibility.

          -  Inability to swallow capsules, since capsules cannot be crushed or broken.

          -  Patients with refractory nausea and vomiting, chronic gastrointestinal (GI) diseases
             (e.g., inflammatory bowel disease) or significant bowel resection that may
             significantly alter the absorption of study agent

          -  Patients receiving any medications or substances that are strong inhibitors or
             inducers of CYP 1A2, 2C8, 2C9, 2C19, 3A4/5 and UGT 1A1 and 1A3, P-glycoprotein, or
             BCRP are ineligible. Because the lists of these agents are constantly changing, it is
             important to regularly consult a frequently-updated medical reference. As part of the
             enrollment/informed consent procedures, the patient will be counseled on the risk of
             interactions with other agents, and what to do if new medications need to be
             prescribed or if the patient is considering a new over-the-counter medicine or herbal
             product.

          -  No supplementation with vitamin E is permitted because the selumetinib capsules
             contain vitamin E

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Pregnant women are excluded from this study because the effects of selumetinib on the
             developing human fetus at the recommended therapeutic dose are unknown. Because there
             is an unknown but potential risk for adverse events in nursing infants secondary to
             treatment of the mother, breastfeeding should be discontinued if the mother is treated
             with selumetinib.

          -  HIV-positive patients on combination antiretroviral therapy are ineligible because of
             the potential for pharmacokinetic interactions with selumetinib. Appropriate studies
             will be undertaken in patients receiving combination antiretroviral therapy when
             indicated.

          -  Ongoing radiation therapy, chemotherapy, hormonal therapy, immunotherapy, or biologic
             therapy directed at the tumor. Those patients with a plexiform neurofibroma requiring
             treatment will be eligible, as selumetinib has documented activity in plexiform
             neurofibromas.

          -  Patients who in the opinion of the investigator may not be able to comply with the
             safety monitoring requirements of the study.
      "
NCT03109886,completed,,1,phase 2,['hepatocellular carcinoma'],"[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]",['milciclib maleate'],['Status: 503'],"
        Inclusion Criteria:

          -  Patients with diagnosis of HCC, confirmed by histology or radiology according to
             American Association for the Study of Liver Diseases/European Association for the
             Study of the Liver (AASLD/EASL) criteria prior to the start of the investigational
             product. Imaging characteristics should be retrieved from at least a 3-phase liver
             protocol CT or MRI with target tumor lesion(s) demonstrating arterial
             hyper-enhancement and wash-out in the venous phase;

          -  Tumor stages eligible for the study are defined as:

               1. HCC within the Barcelona Clinic Liver Cancer (BCLC) stage C. In case of portal
                  vein thrombosis (PVT) an associated target lesion in the liver parenchyma should
                  be clearly defined. PVT without associated target lesion are not eligible to the
                  study;

               2. Untreatable post-chemoembolization (TACE) or post-radioembolization (TARE)
                  progression defined as BCLC stage B or C with radiographic progression according
                  to mRECIST after TACE or TARE not eligible for further surgical or loco-regional
                  therapy;

               3. Recurring HCC non eligible for pre-transplant downstaging protocols or for
                  resection;

          -  Patients must have failed sorafenib treatment or be intolerant to sorafenib or
             actively refusing sorafenib

               1. Failing sorafenib treatment is defined if after ≥ 14 days of therapy (not
                  necessarily consecutive) radiology progression is ascertained according to
                  mRECIST;

               2. Intolerant to sorafenib treatment is defined as a sorafenib related Grade 2 or
                  greater adverse event (CTC-AE) that continues or recurs after sorafenib treatment
                  interruption for 7 days or dose reduction;

               3. Active refusal should be documented by a written and signed patient declaration
                  to be filed in the clinical records;

          -  Child-Pugh score ≤ 6 (class A);

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

          -  Local or loco-regional therapy (i.e., surgery, radiation therapy, hepatic arterial
             embolization, chemoembolization, radioembolization, radiofrequency ablation,
             percutaneous ethanol injection, or cryoablation) must have been completed ≥4 weeks
             prior to study entry with documentation of progressive or recurrent disease;

          -  Signed and dated Investigational Review Board/Independent Ethics Committee (IRB/IEC)
             approved Informed Consent/Genetic Consent.

        Exclusion Criteria:

          -  Prior use of any systemic anti-cancer therapy (including experimental agents and
             immunotherapy) except for sorafenib and second line treatment with regorafenib
             discontinued for intolerance within 14 days;

          -  Known fibrolamellar HCC or mixed hepato-cholangiocarcinoma;

          -  Grade 3 oesophageal varices, regardless of previous bleeding episodes on endoscopy
             performed no more than in the last 12 months;

          -  Clinical meaningful ascites defined as CTCAE Grade≥2. Patient who have been on a
             stable medication regimen for at least 2 months to manage ascites are eligible if they
             show no ascites at the clinical examination. Patients with clinically undetectable
             ascites who are Child A with detectable ascites at CT/MRI are eligible to the
             protocol;
      "
NCT03424759,unknown status,,1,phase 2,['non small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]",['azd9291'],['Status: 503'],"
        Inclusion Criteria:

          -  Histologically confirmed metastatic or recurrent stage IV NSCLC with activating EGFR
             mutation other than deletion in exon 19, L858R, T790M and insertion in exon 20

          -  metastatic or recurrent NSCLC

          -  Be 19years of age on day of signing informed consent

          -  ECOG performance status of 0 to 2

          -  At least one measurable lesion by RECIST 1.1(The part of radiation treatment in the
             palliative setting is excluded.)

          -  Untreated asymptomatic brain metastasis or symptomatic brain metastasis treated with
             local treatment such as operation, whole brain radiotherapy, or gamma-knife surgery

          -  At least 2 weeks later after whole brain radiotherapy or at least 4 weeks later after
             palliative thoracic radiotherapy

          -  Adequate organ function as evidenced by the following; Absolute neutrophil count > 1.5
             x 109/L; Hb > 9.0g/dL; platelets > 100 x 109/L; total bilirubin ≤1.5 UNL; AST and/or
             ALT < 2.5 ULN if no demonstrable liver metastases or < 5 UNL in the presence of liver
             metastases, CCr ≥ 50mL/min

          -  Written informed consent form

        Exclusion Criteria:

          -  Prior treatment with EGFR TKI

          -  Major surgery undertaken less than 4 weeks before the study

          -  Localized palliative radiotherapy unless completed more than 2 weeks before the study

          -  Uncontrolled systemic illness such as DM, CHF, unstable angina, hypertension or
             arrhythmia

          -  Pregnant or nursing women (Women of reproductive potential have to agree to use an
             adequate contraceptive method)

          -  Uncontrolled symptomatic brain metastasis

          -  Prior history of malignancy within 5 years from study entry except for adequately
             treated basal cell or squamous cell skin cancer or in situ cervical cancer, or
             well-treated thyroid cancer

          -  Concomitant use of CYP3A4 inducers/inhibitors

          -  Prolonged QT interval in ECG (QTc >450 msec)

          -  Prior history of interstitial lung disease
      "
NCT03425331,suspended,"
    slow accrual, competing studies, and lack of efficacy
  ",0,phase 2,['non-small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['ipilimumab', 'nivolumab']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Histologically confirmed stage IV NSCLC, with no prior systemic anti-cancer therapy of
             any kind (including EGFR and ALK inhibitors). Prior definitive chemoradiation for
             locally advanced disease is permitted as long as the last administration of
             chemotherapy or radiation (whichever was given last) occurred at least 6 months prior
             to enrollment. Prior adjuvant or neoadjuvant chemotherapy for early stage lung cancer
             is permitted if completed at least 6 months prior to initiating study treatment.

          -  Participants must have measurable disease, defined as at least one lesion that can be
             accurately measured in at least one dimension (longest diameter to be recorded for
             non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional
             techniques or as ≥10 mm with spiral CT scan, MRI, or calipers by clinical exam. See
             Section 11 for the evaluation of measurable disease.

          -  Age ≥ 18 years.

          -  ECOG performance status ≤ 1 (see Appendix A)

          -  Participants must have normal organ and marrow function as defined below:

               -  Absolute neutrophil count ≥ 1,500/mcL

               -  Platelets ≥ 100,000/mcL

               -  Total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN)

               -  AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional ULN, OR

               -  AST(SGOT)/ALT(SGPT) ≤ 5 × institutional ULN if liver metastases are present

               -  Serum creatinine ≤ 1.5 × institutional ULN, OR

               -  Creatinine clearance ≥ 60 mL/min/1.73 m2 for participants with serum creatinine
                  levels above 1.5 × institutional ULN.

          -  Ability to understand and the willingness to sign a written informed consent document.

          -  Participants must have a tumor tissue sample available (formalin-fixed paraffin
             embedded [FFPE] tissue block or unstained slides); may be newly obtained or obtained
             within 6 months prior to enrollment (without systemic therapy given after the sample
             was obtained). Participants without sufficient archival tissue may be enrolled
             following successful completion of the pre-treatment tumor tissue biopsy. Tissue must
             be a core needle biopsy, excisional, or incisional biopsy. Fine needle aspirates (FNA)
             or malignant effusions are not adequate. Bone biopsies without a soft tissue component
             are not adequate.

          -  The effects of nivolumab and ipilimumab on the developing human fetus are unknown. For
             this reason, women of childbearing potential (WOCBP) must agree to follow instructions
             for acceptable contraception from the time of signing consent, and for 23 weeks after
             their last dose of protocol-indicated treatment. Should a woman become pregnant or
             suspect she is pregnant while she or her partner is participating in this study, she
             should inform her treating physician immediately. Men treated or enrolled on this
             protocol who are not azoospermic who are sexually active with WOCBP must agree to
             follow instructions for acceptable contraception from the time of signing consent, and
             for 31 weeks after their last dose of protocol-indicated treatment.

          -  Participants must be able and willing to undergo a pre-treatment tumor tissue biopsy.
             Participants must also be willing to undergo an on-treatment tumor tissue biopsy if
             clinically feasible.

        Exclusion Criteria:

          -  Participants with known EGFR mutations or ALK rearrangements. All subjects must have
             been tested for EGFR mutation and ALK rearrangement prior to study entry, unless they
             are known to have a KRAS mutation.

          -  Participants who have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2,
             anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell
             co-stimulation or checkpoint pathways.

          -  Participants who received prior non-CNS directed palliative radiation therapy within 7
             days of the date of study entry.

          -  Participants who are receiving any other investigational agents.

          -  Participants with known untreated brain metastases should be excluded from this
             clinical trial because of their poor prognosis and because they often develop
             progressive neurologic dysfunction that would confound the evaluation of neurologic
             and other adverse events. Subjects are eligible if CNS metastases are adequately
             treated and subjects are neurologically returned to baseline (except for residual
             signs or symptoms related to the CNS treatment) for at least 2 weeks prior to study
             entry. Subjects must be either off corticosteroids, or on a stable or decreasing dose
             of ≤10 mg daily prednisone (or equivalent) for at least 2 weeks prior to first study
             treatment.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to ipilimumab or nivolumab.

          -  Participants with previous malignancies are excluded unless a complete remission was
             achieved at least 2 years prior to first treatment and no additional therapy is
             required or anticipated to be required during the study period as judged by the
             treating investigator. Exceptions include non-melanoma skin cancers, and in situ
             cancers of any type (e.g. bladder, gastric, colon, cervical/dysplasia, melanoma, or
             breast carcinoma in situ).

          -  Participants with any other active malignancy requiring concurrent intervention.

          -  Participants with an active, known, or suspected autoimmune disease. Subjects with
             type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin
             disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment,
             or conditions not expected to recur in the absence of an external trigger are
             permitted to enroll.

          -  Participants with a condition requiring systemic treatment with corticosteroids of >
             10 mg daily prednisone (or equivalent), or subjects requiring other immunosuppressive
             medications within 14 days of first treatment. Inhaled, topical, ophthalmologic, local
             steroid injections, and adrenal replacement steroid > 10 mg daily prednisone or
             equivalent are permitted in the absence of active autoimmune disease.

          -  Participants with interstitial lung disease that is symptomatic or may interfere with
             the detection or management of suspected drug-related pulmonary toxicity in the
             opinion of the treating investigator.

          -  Participants with a known history of testing positive for human immunodeficiency virus
             (HIV), or known acquired immunodeficiency syndrome (AIDS).

          -  Participants with known positive test for hepatitis B or C indicating acute or chronic
             infection.

          -  Participants with ≥ Grade 2 peripheral neuropathy.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Pregnant women are excluded from this study because ipilimumab and nivolumab are both
             agents with the potential for teratogenic or abortifacient effects. Because there is
             an unknown but potential risk for adverse events in nursing infants secondary to
             treatment of the mother with ipilimumab or nivolumab, breastfeeding should be
             discontinued if the mother is treated with ipilimumab or nivolumab. A negative serum
             pregnancy test is required prior to study entry.
      "
NCT03535961,completed,,1,phase 2,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]",['apatinib+oral etoposide'],['Status: 503'],"
        Inclusion Criteria:

          -  Age between 18 and 75 year-old women; HER2 negative(immunohistochemistry or
             fluorescence in situ hybridization);

          -  ECOG score: 0-1, expected survival time ≥ 3months;

          -  Pathologically or cytologically confirmed breast cancer;

          -  Anthracycline- / taxane- pretreated (adjuvant, neoadjuvant) breast cancer patients who
             have failed from 1-2 standard chemotherapies after recurrence and metastasis;

          -  According to RECIST 1.1, exist at least ≥1 measurable lesion(CT >1cm，other examination
             >2cm);

          -  The patients have enough organ function. The laboratory test indexes must comply with
             the following requirements:

               -  Blood routine: neutrophil≥1.5G/L, platelet count ≥80G/L, hemoglobin ≥90g/L

               -  Liver function: serum bilirubin ≤ 1.5 times the upper limit of normal value; ALT
                  and AST≤2.5 times the upper limit of normal value; ALT and AST≤5 times the upper
                  limit of normal value when liver metastasis

               -  Renal function: serum creatinine ≤ 1.0times the upper limit of normal value,
                  creatinine clearance >50ml/min（Cockcroft-Gault formula)

          -  Women of child-bearing age should be carried out pregnancy test (serum or urine)
             within 7 days before recruit, the results should be negative; and are willing to adopt
             the appropriate methods of contraception during the trial and 8 weeks after last
             administration；

          -  Can swallow oral drugs;

          -  The patients have good compliance to the therapy and follow-up to be scheduled and are
             able to understand the study protocol and sign the Informed Consent Form.

        Exclusion Criteria:

          -  The patients in pregnancy or lactation growth period and did not take effective
             contraception;

          -  The patients who received ≥3 chemotherapies（Do not include endocrine therapy）after
             recurrence and metastasis; involved in other clinical trials four weeks prior to the
             start of the study;

          -  The patients with a variety of factors that affect the oral administration and
             absorption of drugs;

          -  The patients previously received anti-VEFG of anti-VEGFR therapies;

          -  The patients with rapid progression of viscera invasion(liver lesion >1/2 viscera area
             or liver dysfunction);

          -  The patients have uncontrollable mental illness.

          -  The patients who had serious adverse effect to oral etoposide or were allergic to
             etoposide.

          -  The patients who have only bone metastasis without other measurable lesion;

          -  The patients experience severe cardiovascular diseases;

          -  The patients experience severe upper gastrointestinal ulcer or malabsorption syndrome.

          -  Abnormal bone marrow functions(neutrophil<1.5G/L, platelet count <75G/L, hemoglobin
             <90g/L);

          -  Abnormal renal function(serum creatinine > 1.5 times the upper limit of normal value);

          -  Abnormal liver function(serum bilirubin ≤ 1.5 times the upper limit of normal value);

          -  The patients have uncontrollable brain metastasis;

          -  The patients do have good compliance to the therapy.
      "
NCT03246685,terminated,"
    due to enrollment challenges resulting in changing treatment patterns, the study has been
    terminated. no patients remain on study.
  ",0,phase 2,['squamous cell carcinoma of the head and neck'],"[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]",['pembrolizumab'],['Status: 503'],"
        Inclusion Criteria:

          1. Have signed an informed document prior to any study-specific procedures or treatment

          2. Be ≥ 18 years of age at time of consent

          3. Have histologically or cytologically confirmed diagnosis of SCCHN irrespective of
             PD-L1 status, which is either inoperable and recurrent, or metastatic

          4. Up to 3 prior chemotherapy regimens or metastatic disease

          5. Have either:

               1. Investigator determined assessment of disease progression after treatment with
                  pembrolizumab monotherapy, OR

               2. Investigator determined assessment of current stable disease following completion
                  of at least 4 cycles but no more than 8 cycles, of pembrolizumab monotherapy

          6. Have resolution of all previous treatment-related toxicities to Grade 1 severity or
             lower, except for stable sensory neuropathy (less than or equal to Grade 2) or
             alopecia. If subject received major surgery or radiation therapy of > 30 Gy, must have
             recovered from the toxicity and/or complications from the intervention.

          7. Have at least one radiologically measurable lesion as per RECIST v1.1 defined as a
             lesion that is at least 10 mm in longest diameter or lymph node that is at least 15 mm
             in short axis imaged by CT scan or MRI and obtained by imaging within 28 days prior to
             start of study treatment. Tumor lesions situated in a previously irradiated area are
             considered measurable if progression has been demonstrated in such lesions.

          8. Have peripheral blood levels of IgG anti-β-glucan antibody (ABA) of ≥ 20 mcg/mL as
             determined by an ELISA test within 90 days prior to start of study treatment

          9. Be willing to consider providing fresh tissue for biomarker analysis, and, based on
             the adequacy of the tissue sample quality, for assessment of biomarker status. Repeat
             samples may be required if adequate tissue is not provided. Newly obtained biopsy
             specimens are preferred to archived samples and formalin-fixed, paraffin-embedded
             block specimens are preferred to slides.

             Note: Information on 1 tumor biopsy sample is mandatory and is as follows: (1) To
             determine eligibility, historical (diagnostic) tumor biopsy official pathology report
             +/- an archival sample. Additional biopsy samples, preferably obtained from the same
             localized region, are highly desirable when feasible at the following time points: (2)
             Sample before the first dose of study treatment, (3) Sample after completion of Cycle
             2 but before the start of Cycle 3 dosing, and (4) Sample either at the time of
             response or at the End of Study Visit (if no response).

         10. Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (see
             Appendix 14.3)

         11. Have life expectancy of 6 months or greater as determined by the treating physician

         12. Have adequate organ function (all screening labs should be performed within 15 days
             prior to study treatment):

               1. Total bilirubin ≤ 1.5 × upper limit of normal (ULN) OR direct bilirubin ≤ ULN for
                  subjects with total bilirubin levels > 1.5 x ULN

               2. Aspartate aminotransferase (AST) ≤ 2.5 × ULN or ≤ 5 × ULN for subjects with known
                  hepatic metastases

               3. Alanine aminotransferase (ALT) ≤ 2.5 × ULN or ≤ 5 × ULN for subjects with known
                  hepatic metastases

               4. Albumin level ≥3 g/dL

         13. Have adequate renal function within 15 days prior to study treatment, defined by the
             following criteria:

             Creatinine ≤ 1.5 x ULN and CrCl ≥ 30 ml/min per Cockcroft Gault formula:

         14. Have adequate hematologic function within 15 days prior to study treatment, defined as
             meeting all of the following criteria:

               1. Hemoglobin ≥ 9 g/dL (uncorrected by RBC transfusion)

               2. Absolute neutrophil count (ANC) ≥ 1.5 × 109/L

               3. Platelet count ≥ 100 × 109/L

         15. Have adequate coagulation functioning within 15 days prior to start of study
             treatment, defined by either of the following criteria:

               1. INR < 1.5 × ULN

               2. OR for subjects receiving warfarin or low molecular weight heparin (LMWH), the
                  subjects must, in the Investigator's opinion, be clinically stable with no
                  evidence of active bleeding while receiving anticoagulant therapy. The INR for
                  these subjects may exceed 1.5 × ULN if that is the goal of anticoagulant therapy.

               3. Activated Partial Thromboplastin Time (aPTT) < 1.5 × ULN unless subject is
                  receiving anticoagulant therapy as long as PT or PTT is within therapeutic range
                  of intended use of anticoagulants

         16. Female subjects of childbearing potential as defined in Section 5.7.2 must have a
             negative urine or serum pregnancy within 72 hours prior to receiving the first dose of
             study medication. If the urine test is positive or cannot be confirmed as negative, a
             serum pregnancy test will be required.

         17. If of childbearing potential as defined in Section 5.7.2, must be willing to use an
             adequate method of contraception (see Section 5.7.2) from the first dose of study
             medication through 120 days after the last dose of study medication

         18. Be willing and have the ability to comply with scheduled visits (including
             geographical proximity), treatment plans, laboratory tests, and other study procedures

        Exclusion Criteria:

          1. Has disease that is suitable for local therapy administered with curative intent

          2. Is currently participating and receiving study therapy or has participated in a study
             of an investigational agent and received study therapy or used an investigational
             device within 4 weeks of the first dose of treatment

          3. Has a diagnosis of immunodeficiency or receiving systemic steroid therapy (in dosing
             exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive
             therapy within 7 days prior to the first dose of study treatment. The use of
             physiologic doses of corticosteroids may be approved after consultation with the
             Sponsor.

          4. Has known history of active tuberculosis

          5. Has known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)

          6. Has known active Hepatitis B (eg, HBsAg reactive) or Hepatitis C (eg, HCV RNA
             [qualitative] is detected

          7. Has a history of clinically severe autoimmune disease, or history of organ transplant

          8. Has known hypersensitivity to baker's yeast

          9. Had previous exposure to Betafectin® or Imprime PGG

         10. Has severe hypersensitivity to pembrolizumab or any of its excipients

         11. Had a prior anti-cancer monoclonal antibody (other than pembrolizumab) within 30 days
             prior to start of study treatment, or failure to recover to CTCAE Grade 1 or better
             from the adverse events of prior therapies

         12. Had within 2 weeks prior to the first dose of study treatment, received prior
             chemotherapy, targeted small molecule therapy, or radiation therapy, or who has not
             recovered from adverse events due to a previously administered agent or major surgery

         13. Has received transfusion of blood products (including platelets or red blood cells) or
             administration of colony stimulating factors (including G-CSF, GM-CSF, or recombinant
             erythropoietin) within 4 weeks prior to the first dose of study treatment

         14. Has known additional malignancy that is progressing or requires active treatment.
             Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the
             skin that has undergone potentially curative therapy or in situ cervical cancer.

         15. Has known active central nervous system metastases and/or carcinomatous meningitis.
             Subjects with previously treated brain metastases may participate provided they are
             stable (without evidence of progression by imaging for at least 4 weeks prior to the
             first dose of trial treatment and any neurologic symptoms have returned to baseline),
             have no evidence of new or enlarging brain metastases, and are not using steroids for
             at least 7 days prior to trial treatment. This exception does not include
             carcinomatous meningitis, which is excluded regardless of clinical stability.

         16. Has active autoimmune disease requiring systemic treatment in the past 2 years (ie,
             with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
             Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteriod replacement
             therapy for adrenal or pituitary insufficiency) is not considered a form of systemic
             treatment.

         17. Has history of (non-infectious) pneumonitis that required steroids or current
             pneumonitis

         18. Has a history of interstitial lung disease

         19. Has an active infection requiring systemic therapy

         20. Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the subject's
             participation for the full duration of the trial, or is not in the best interest of
             the subject to participate, in the opinion of the treating Investigator

         21. Has a clinically significant cardiovascular disease such as unstable angina,
             myocardial infarction, or acute coronary syndrome within ≤180 days prior to start of
             study treatment, symptomatic or uncontrolled arrhythmia, congestive heart failure, or
             any Class 3 or 4 cardiac disease as defined by the New York Heart Association
             Functional Classification

         22. Has a known psychiatric or substance abuse disorder(s) that would interfere with
             informed consent or cooperation with the requirements of the trial

         23. Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the pre-screening or screening visit
             through 120 days after the last dose of trial treatment

         24. Has received a live-virus vaccination within 30 days of planned treatment start.
             Seasonal flu vaccines that do not contain live virus are permitted
      "
NCT03244358,terminated,"
    difficulty accruing subjects the study accrual was closed
  ",0,phase 2,['triple negative breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]",['epalrestat'],['Status: 503'],"
        Inclusion Criteria:

          -  Female ≥ 18 years, ≤70 years.

          -  Minimum life expectancy 16 weeks

          -  Histologicalconfirmation of hormone receptor negative and HER2 negative breast
             cancer(IHC:ER -, PR-) on primary tumour at diagnosis/on biopsy of metastasis

          -  Clinical or histological confirmation of metastatic or locally advanced disease not
             amenable to curative surgical resection

          -  ECOG 0-2 with no deterioration over previous 2 weeks Measurable disease

          -  Adequate bone marrow and organ function

          -  Availability of archival tumour sample or fresh biopsy Informed consent

          -  Normal organ function

        Exclusion Criteria:

          -  Last dose chemotherapy, immunotherapy targeted therapy, biological therapy or tumour
             embolisation <21 days prior to study treatment

          -  Last dose of palliative radiotherapy <7 days prior to study treatment

          -  Rapidly progressive visceral disease not suitable for further therapy

          -  Spinal cord compression or brain/meningeal metastases unless asymptomatic, treated and
             stable and not requiring steroids for ≥ 4 weeks study treatment

          -  Major surgery (excluding placement of vascular access) within 4 weeks before study
             treatment

          -  Evidence of severe or uncontrolled systemic diseases, including uncontrolled
             hypertension, active bleeding diatheses, or active infection including hepatitis B,
             hepatitis C and HIV

          -  With the exception of alopecia, any unresolved toxicities from previous therapy
             greater than CTCAE grade 1 before study treatment

          -  Elevated ALP in absence of bone metastasis

          -  Evidence of dementia, altered mental status or any psychiatric condition that would
             prohibit understanding or rendering of informed consent

          -  Participation in another study with investigational product during last 30 days

          -  Inability or unwillingness to comply with study procedures, including inability to
             take regular oral medication
      "
NCT03246971,completed,,1,phase 2,"['acute pain', 'bunion', 'abdominoplasty']","[""['G89.12', 'G89.18', 'G89.11', 'G89.3']"", ""['M21.611', 'M21.612', 'M21.619', 'M21.621', 'M21.622', 'M21.629']""]","['wafermine™ 50 mg', 'wafermine™ 75 mg', 'placebos', 'wafermine™ 25 mg']","['Status: 503', 'Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Scheduled for a bunionectomy or mini abdominoplasty with no additional planned
             procedures.

          -  Good general health without clinically significant renal, hepatic, cardiac or
             respiratory disease, as determined by the Investigator.

        Exclusion Criteria:

          -  For those undergoing bunionectomy, other painful conditions involving the surgical
             foot.

          -  Positive lab values for Hepatitis B or C or HIV
      "
NCT03248492,"active, not recruiting",,1,phase 2,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]",['ds-8201a'],['Status: 503'],"
        Inclusion Criteria:

          -  Men or women the age of majority in their country

          -  Has pathologically documented breast cancer that:

               1. is unresectable or metastatic

               2. has HER2 positive expression confirmed per protocol

          -  Has an adequate tumor sample

          -  Has at least one measurable lesion per Response Evaluation Criteria in Solid Tumors
             (RECIST) version 1.1

          -  Has protocol-defined adequate cardiac, renal and hepatic function

          -  Agrees to follow protocol-defined method(s) of contraception

        Exclusion Criteria:

          -  Has a medical history of myocardial infarction, symptomatic congestive heart failure
             (CHF) (NYHA classes II-IV), unstable angina or serious cardiac arrhythmia

          -  Has a corrected QT interval (QTc) prolongation to > 450 millisecond (ms) in males and
             > 470 ms in females

          -  Has a medical history of clinically significant lung disease

          -  Is suspected to have certain other protocol-defined diseases based on imaging at
             screening period

          -  Has history of any disease, metastatic condition, drug/medication use or other
             condition that might, per protocol or in the opinion of the investigator, compromise:

               1. safety or well-being of the participant or offspring

               2. safety of study staff

               3. analysis of results
      "
NCT01288573,completed,,1,phase 1/phase 2,"[""ewing's sarcoma/soft tissue sarcoma"", 'neuroblastoma', 'brain tumors']","[""['C71.7', 'C71.9', 'C79.31', 'D33.0', 'D33.1', 'D33.2', 'D49.6']""]","['plerixafor', 'plerixafor', 'plerixafor']","['Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Age 2 to < 18 years during stage 1 and 1 to < 18 years during stage 2

          -  Ewing's sarcoma, soft tissue sarcoma, lymphoma, neuroblastoma, brain tumors or other
             malignancy (excluding any form of leukemia) requiring treatment with high dose
             chemotherapy and autologous transplant as rescue therapy

          -  Eligible for autologous transplantation

          -  Recovered from all acute significant toxic effects of prior chemotherapy

          -  Adequate performance status (for patients ≥16 years of age, defined as Karnofsky score
             >60 and for patients <16 years of age, defined as Lansky score >60)

          -  Absolute neutrophil count >0.75 × 10^9/L

          -  Platelet count >50 × 10^9/L

          -  Calculated creatinine clearance (using the Schwartz method): during study Stage 1, >80
             mL/min/1.73m^2 and during study Stage 2, >60 mL/min/1.73m^2

          -  Aspartate aminotransferase(AST)/serum glutamic oxaloacetic transaminase(SGOT), alanine
             aminotransferase(ALT)/serum glutamic pyruvic transaminase (SGPT) and total bilirubin
             <3 × upper limit of normal

          -  The patient and/or their parent/legal guardian is willing and able to provide signed
             informed consent

          -  Patients who are sexually active must be willing to abstain from sexual intercourse or
             agree to use an approved form of contraception while receiving plerixafor and/or
             standard mobilization treatment and for at least 3 months following any plerixafor
             treatment

        Exclusion Criteria:

          -  Any form of leukemia

          -  A co-morbid condition which, in the view of the Investigator, renders the patient at
             high-risk from treatment complications

          -  Previous stem cell transplantation

          -  Persistent high percentage marrow involvement prior to mobilization will be
             prohibited.

          -  On-going toxicities (excluding alopecia) Grade ≥2 resulting from prior chemotherapy

          -  Acute infection

          -  Fever (temperature >38.5°C) - if fever is between 37°C and 38.5°C, infection must be
             excluded as a cause

          -  Known HIV seropositivity, AIDS, hepatitis C or active hepatitis B infections

          -  Positive pregnancy test in post pubertal girls

          -  History of clinically significant cardiac abnormality or arrhythmia

          -  Use of an investigational drug which is not approved in any indication either in
             adults or pediatrics within 2 weeks prior to the first dose of G-CSF to be
             administered as part of the patient's planned standard mobilization regimen, and/or
             during the study up until engraftment of the transplant. If patients are on
             investigational drugs as part of their anti-cancer regimen, this should be discussed
             with the Sponsor before screening. Drugs approved for other indications that are being
             used in a manner considered standard of care for this transplant procedure are allowed

          -  The patient (and/or their parent/legal guardian), in the opinion of the Investigator,
             is unable to adhere to the requirements of the study
      "
NCT03007719,terminated,"
    low accrual
  ",0,phase 2,['bladder cancer'],"[""['D30.3', 'C67.5', 'C67.9', 'C79.11', 'C67.0', 'C67.1', 'D41.4']""]",['fluorine f 18 ara-g'],['Status: 503'],"
        Inclusion Criteria:

          -  Histologically or cytologically documented cancer to which anti-PD1 or anti-PDL1 are
             approved therapies

          -  Eligible for with plan to undergo neoadjuvant treatment with atezolizumab followed by
             surgery as part of a companion study (NCT02451423), or planned to undergo treatment
             with anti-PD-1 or anti-PD-L1 per standard of care

          -  Must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST)
             version (v)1.1 regardless of disease stage (e.g. localized, locally advanced, or
             metastatic)

          -  In female patients, negative pregnancy test with no plans to become pregnant during
             the duration of the study

          -  Able to provide informed consent and follow the study guidelines

          -  Archival tumor tissue from biopsy or resection will be required for all patients;
             archival tissue should be of good quality based on total and viable tumor contents;
             fine needle aspiration, brushing, and cytologic cell pellets are not acceptable

        Exclusion Criteria:

          -  History of prior treatment with immune checkpoint antibodies (e.g. anti-PD1,
             anti-PDL1, anti-CTLA4 antibody) or co-stimulatory agonist antibodies (e.g. anti-41BB,
             anti-OX40)

             * Prior intravesical treatment with Bacillus Calmette-Guerin (BCG) is allowed;
             however, the last dose must be at least 6 weeks from time of enrollment and patients
             must have documented progressive disease at least 6 weeks from completion of last BCG

          -  Diagnosis of immunodeficiency including history of human immunodeficiency virus (HIV)

          -  Receiving systemic steroid therapy or any form of immunosuppressive therapy within 7
             days prior to first injection of [18F]F-AraG

             * Topical and inhaled corticosteroids are allowed

          -  Prior allogeneic stem cell or solid organ transplant

          -  Known psychiatric or substance abuse disorders that would interfere with cooperation
             with the requirements of the study

          -  Biopsy or resection of the primary tumor within 14 days the first injection of
             [18F]F-AraG

          -  Contraindication to magnetic resonance (MRI) imaging, as determined through review of
             the University of California, San Francisco (UCSF) MRI screening form by study
             investigator

          -  Evidence of active infection within 14 days of study enrollment

          -  Female patients who are pregnant or breastfeeding

          -  Inability to receive furosemide (Lasix) in the opinion of the treating investigator

          -  Patients that plan to receive off-label use of anti-PD1 or anti-PDL1
      "
NCT03008512,terminated,"
    poor accrual
  ",0,phase 2,"['carcinoma, hepatocellular']","[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]",['genexol-pm'],['Status: 503'],"
        Inclusion Criteria:

          1. A diagnosis of hepatocellular carcinoma (HCC) based on either

               1. histopathologic or cytologic findings

               2. a diagnosis of cirrhosis and HCC with classical imaging characteristics (at least
                  a 3-phase liver protocol CT or MRI and a lesion that demonstrates arterial
                  enhancement and washes out in the venous phase)

          2. Previous sorafenib treatment for at least 14 days and discontinuation of sorafenib
             treatment prior to inclusion

          3. Radiologic confirmation of disease progression during or after discontinuation of
             sorafenib treatment or discontinuation of sorafenib due to intolerance despite
             appropriate supportive care

          4. Barcelona Clinic Liver Cancer (BCLC) stage C or BCLC stage B disease not amenable to
             locoregional therapy or refractory to locoregional therapy

          5. ≥ 1 measurable lesion according to RECIST Version 1.1

          6. ≥ 20 year of age

          7. ECOG performance status ≤ 2

          8. Child-Pugh score ≤ 7

          9. Informed consent prior to study

         10. Adequate organ function

               1. Hepatic: bilirubin ≤ 1.5 times upper limit of institutional normal value (ULN),
                  AST or ALT ≤ 5 x ULN

               2. Renal: estimated creatinine clearance ≥ 60 mL/min

               3. Hematologic: hemoglobin ≥ 9 g/dL, absolute neutrophil count (ANC) ≥ 1,500/μL,
                  platelets ≥ 75,000/μL (In case of thrombocytopenia associated with hypersplenism
                  in chronic liver disease, platelets ≥ 50,000/μL is allowed for participation at
                  the physician's discretion.)

               4. Coagulation: prothrombin time (INR) ≤ 1.5, partial thrombin time (PTT) ≤ 5
                  seconds above the ULN

        Exclusion Criteria:

          1. Previous systemic chemotherapy for advanced disease (except previous biologic agents
             including VEGF inhibitors, TGF-beta inhibitors, or PD-1/PD-L1 blockers)

          2. A history o f or current hepatic encephalopathy or clinically meaningful ascites

          3. Grade 2 or more peripheral neuropathy

          4. Prior liver transplant

          5. History of any other cancer within 2 years (Patients with carcinoma in situ of any
             origin and patients with prior malignancy who are in remission and whose likelihood of
             recurrence is very low, may be eligible.)

          6. A history of treatment with taxanes (paclitaxel or docetaxel)

          7. Females who are pregnant or lactating

          8. A know allergy or hypersensitivity reaction to any of the treatment components

          9. Serious preexisting medical conditions that cannot adequately controlled with
             appropriate therapy
      "
NCT03007407,completed,,1,phase 2,['colorectal cancer metastatic'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['durvalumab', 'tremelimumab']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  The ECOG performance status must be 0 or 1.

          -  There must be histologic confirmation of a diagnosis of colorectal adenocarcinoma.

          -  The tumor must have been determined to be microsatellite stable (MSS).

          -  There must be documentation by positron emission tomography (PET)/computed tomography
             (CT) scan, CT scan, or magnetic resonance imaging (MRI), that the patient has evidence
             of measurable metastatic disease per RECIST 1.1.

          -  Patients must have an accessible metastatic lesion for pretreatment core biopsy.

          -  Unless either drug is medically contraindicated, patients must have received
             oxaliplatin and irinotecan as part of standard metastatic chemotherapy regimens.

          -  The patient must have multiple sites of metastatic disease with at least one lesion
             amenable to treatment with stereotactic radiation therapy (SBRT) in the lung or liver
             and at least one lesion not being irradiated and meeting RECIST 1.1.

          -  At the time of study entry, blood counts performed within 2 weeks prior to study entry
             must meet the following criteria:

               -  ANC (absolute neutrophil count) must be greater than or equal to 1500/mm3,

               -  Platelet count must be greater than or equal to 100,000/mm3; and

               -  Hemoglobin must be greater than or equal to 9 g/dL.

          -  The following criteria for evidence of adequate hepatic function performed within 2
             weeks prior to study entry must be met:

               -  Total bilirubin must be less than or equal to 1.5 x ULN (upper limit of normal)
                  for the lab unless the patient has a bilirubin elevation greater than 1.5 x ULN
                  to 3 x ULN due to Gilbert's disease or similar syndrome involving slow
                  conjugation of bilirubin; and

               -  AST (aspartate aminotransferase)and ALT (alanine transaminase) must be less than
                  or equal to 2.5 x ULN for the lab with the following exception: for patients with
                  documented liver metastases, AST and ALT must be less than or equal to 5 x ULN.

          -  Adequate renal function within 4 weeks prior to study entry, defined as serum
             creatinine less than or equal to 1.5 x ULN for the lab or measured or calculated
             creatinine clearance greater than 40 mL/min by Cockcroft-Gault formula.

          -  All hematologic, gastrointestinal, and genitourinary chemotherapy toxicities must be
             less than Grade 2 at the time study therapy is to begin. (Note: Transfusions may be
             used to correct hemoglobin for patients experiencing anemia from therapy who otherwise
             would be eligible for the study.

          -  Patients with reproductive potential (male/female) must agree to use accepted and
             highly effective methods of contraception while receiving study therapy and for at
             least 6 months after the completion of study therapy. The definition of effective
             method of contraception will be based on the investigator's discretion.

          -  Female patients must either be of non-reproductive potential (i.e., post-menopausal by
             history: greater than or equal to 60 years old and no menses for greater than or equal
             to 1 year without an alternative medical cause; OR history of hysterectomy, OR history
             of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a
             negative serum pregnancy test upon study entry.

        Exclusion Criteria:

          -  Diagnosis of anal or small bowel carcinoma.

          -  Colorectal cancer other than adenocarcinoma, e.g., sarcoma, lymphoma, carcinoid.

          -  Previous therapy with any PD-1 or PD-L1 (programmed cell death-1 (PD-1) protein,
             programmed death ligand-1 (PDL-1) protein inhibitor including durvalumab or anti-CTLA4
             (including tremelimumab) for any malignancy.

          -  Receipt of live attenuated vaccination within 30 days prior to study entry or within
             30 days of receiving study therapy.

          -  Active or chronic hepatitis B or hepatitis C.

          -  Symptomatic or uncontrolled brain metastases requiring concurrent treatments,
             uncontrolled spinal cord compression, carcinomatous meningitis, or new evidence of
             brain or leptomeningeal disease; uncontrolled seizures.

          -  Active infection or chronic infection requiring chronic suppressive antibiotics.

          -  Active or documented inflammatory disease.

          -  Known history of human immunodeficiency virus (HIV) or acquired
             immunodeficiency-related (AIDS) illnesses.

          -  Current or prior use of immunosuppressive medication within 28 days before the first
             dose of study therapy with the exceptions of intranasal corticosteroids or systemic
             corticosteroids at physiological doses that do not exceed 10mg/day of prednisone or an
             equivalent corticosteroid.

          -  History of allogeneic organ transplantation.

          -  Any of the following cardiac conditions:

               -  Documented NYHA (New York Heart Association) Class III or IV congestive heart
                  failure,

               -  Myocardial infarction within 6 months prior to study entry,

               -  Unstable angina within 6 months prior to study entry,

               -  Symptomatic arrhythmia. If QTc (corrected QT interval) greater than or equal to
                  470ms, confirmation of eligible QTc requires mean calculation from 2 additional
                  electrocardiograms (ECGs) 2-5 minutes apart using Fridericia's Correction Formula
                  (mean less than 470 ms).

          -  Uncontrolled high blood pressure defined as systolic blood pressure (BP) greater than
             or equal to 150 mmHg or diastolic BP greater than or equal to 100 mmHg with or without
             anti-hypertensive medication. Patients with initial BP elevations are eligible if
             initiation or adjustment of BP medication lowers pressure to meet entry criteria.

          -  Active or prior documented inflammatory bowel disease (e.g., Crohn's disease,
             ulcerative colitis).

          -  Ongoing or active gastritis or peptic ulcer disease.

          -  Active bleeding diatheses.

          -  Known history of previous diagnosis of tuberculosis.

          -  History of hypersensitivity to durvalumab or tremelimumab or any excipients of these
             drugs.

          -  Known history or confirmation of active pneumonia, pneumonitis, symptomatic
             interstitial lung disease, or definitive evidence of interstitial lung disease
             described on CT scan, MRI, or chest x-ray in asymptomatic patients; dyspnea at rest
             requiring current continuous oxygen therapy.

          -  Active or prior documented autoimmune disease within the past 2 years. (Note: Patients
             with vitiligo, Grave disease, or psoriasis not requiring systemic treatment within the
             past 2 years are eligible.)

          -  Other malignancies unless the patient is considered to be disease-free and has
             completed therapy for the malignancy greater than or equal to 12 months prior to study
             entry. Patients with the following cancers are eligible if diagnosed and treated
             within the past 12 months: carcinoma in situ of the cervix, and basal cell and
             squamous cell carcinoma of the skin.

          -  Psychiatric or addictive disorders or other conditions that, in the opinion of the
             investigator, would preclude the patient from meeting the study requirements or
             interfere with interpretation of study results.

          -  Pregnancy or lactation at the time of study entry. (Note: Pregnancy testing should be
             performed within 14 days prior to study entry according to institutional standards for
             women of childbearing potential.)

          -  Use of any investigational agent. Use and/or receipt of the last dose of anti-cancer
             therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic
             therapy, tumor embolization, monoclonal anti-bodies) within 14 days prior to the first
             dose of study therapy.

          -  Use of any investigational agent within 4 weeks of starting study therapy.
      "
NCT03000179,terminated,"
    low accrual
  ",0,phase 2,['adenocarcinoma'],"[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]",['avelumab'],['Status: 503'],"
        Inclusion Criteria:

          -  Signed and dated written informed consent.

          -  Male or female ≥ 18 years of age.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

          -  Histologically confirmed adenocarcinoma of the small intestine that is advanced (not
             amenable to surgery) or metastatic (clinical stage IV). For the purposes of this
             study, ampullary tumors are considered a part of the duodenum and are classified as
             adenocarcinomas of the small intestine.

          -  At least one measurable lesion as defined by Response Evaluation Criteria in Solid
             Tumors (RECIST) version 1.1 criteria that has not been previously irradiated and which
             can be followed by CT or MRI.

          -  Adequate organ function including:

               -  Absolute neutrophil count (ANC) ≥ 1.5 × 109/L

               -  Platelets ≥ 100 × 109/L

               -  Hemoglobin ≥ 9/g/dL (may have been transfused)

               -  Total serum bilirubin ≤ 1.5 times upper limit of normal (ULN)

               -  Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤
                  2.5 × ULN (or ≤ 5 × ULN if liver metastases are present)

               -  Serum creatinine ≤ 1.5 x ULN or estimated creatinine clearance ≥ 30 mL/min as
                  calculated using the Cockcroft-Gault (CG) equation

          -  Archival tissue [paraffin block(s) or unstained slides from paraffin block(s)] from
             the primary tumor and/or a metastatic site judged reasonably available prior to
             initiating treatment, or willingness to undergo fresh pre-treatment tumor biopsy.
             (Prior to initiating treatment, the screening team must have documentation that an
             archival or fresh tumor specimen has been requested from a local or outside facility.
             However, physical possession of requested tissue or waiting for histological analysis
             or confirmation that an acquired specimen contains tumor tissue sufficient for
             analysis is not a requirement prior to initiating treatment.) If no archival tissue is
             available and patient consents to a fresh biopsy, but the patient's lesion is deemed
             inaccessible to safe biopsy, the patient will be allowed to enroll if otherwise
             eligible.

          -  Female patients of childbearing potential and male patients able to father children
             who have female partners of childbearing potential must agree to use one highly
             effective method (defined as less than 1% failure rate per year) and one additional
             effective method of contraception (Appendix 4) from 15 days prior to first trial
             treatment administration until at least 60 days after study participant's final dose
             of avelumab.

               -  Females of childbearing potential are defined as those who are not surgically
                  sterile or post-menopausal (i.e. patient has not had a bilateral tubal ligation,
                  a bilateral oophorectomy, or a complete hysterectomy; or has not been amenorrheic
                  for 12 months without an alternative medical cause). Post-menopausal status in
                  females under 55 years of age should be confirmed with a serum
                  follicle-stimulating hormone (FSH) level within laboratory reference range for
                  postmenopausal women.

               -  Male patients able to father children are defined as those who are not surgically
                  sterile (i.e. patient has not had a vasectomy).

          -  Serum pregnancy test (for females of childbearing potential) negative at screening.

          -  Re-enrollment of a subject that has discontinued the study as a pre-treatment screen
             failure (i.e. a consented patient who did not receive avelumab) is permitted. If
             re-enrolled, the subject must be re-consented. Only the screening procedures performed
             outside of protocol-specified timing must be repeated.

        Exclusion Criteria:

          -  There is no restriction on the number of prior therapies. However, prior therapy with
             antibody or drug specifically targeting T cell regulatory proteins, including but not
             limited to the following is not allowed: Prior immunotherapy with IL-2 or IFN-α, or an
             anti-PD-1 (including nivolumab), anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic
             T-lymphocyteassociated antigen-4 (CTLA-4) antibody (including ipilimumab), or any
             other antibody or drug specifically targeting T-cell co-stimulation or checkpoint
             pathways.

          -  Within 28 days before first dose of avelumab: Anti-cancer treatment, major surgery
             requiring general anesthesia, or the use of any investigational agent.

          -  Within 14 days before first dose of avelumab: Therapeutic or palliative radiation
             therapy. (Subjects receiving bisphosphonate or denosumab are eligible provided
             treatment was initiated at least 14 days before the first dose of avelumab.)

          -  Current use of immunosuppressive medication, except the following:

               -  Subjects are permitted the use of corticosteroids with minimal systemic
                  absorption (e.g. topical, ocular, intra-articular, intranasal, and inhaled);

               -  Systemic corticosteroids at physiologic doses ≤10 mg/day of prednisone or
                  equivalent are permitted;

               -  A brief (less than 3 weeks) course of corticosteroids for prophylaxis (e.g. CT
                  scan premedication against contrast dye allergy) or for treatment of
                  non-autoimmune conditions (e.g. delayed-type hypersensitivity reaction caused by
                  a contact allergen) is permitted.

          -  Previous malignant disease other than adenocarcinoma of the small intestine within the
             last 5 years, with the exception of basal or squamous cell carcinoma of the skin or
             cervical carcinoma in situ considered curatively treated (i.e. complete remission
             achieved at least 2 years prior to first dose of avelumab AND additional therapy not
             required while receiving study treatment).

          -  All subjects with brain metastases, expect those meeting the following criteria:

               -  Brain metastases that have been treated locally and are clinically stable for at
                  least 2 weeks prior to enrollment

               -  No ongoing neurological symptoms that are related to the brain localization of
                  the disease (sequelae that are a consequence of the treatment of the brain
                  metastases are acceptable.

               -  Subjects must be either off steroids or on a stable or decreasing dose of ≤ 10 mg
                  daily prednisone (or equivalent)

          -  Receipt of any organ transplantation including allogeneic stem-cell transplantation.

          -  Significant acute or chronic infections requiring systemic therapy.

               -  Known history of testing positive for human immunodeficiency virus (HIV), or
                  acquired immunodeficiency syndrome (AIDS).

               -  Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection at screening
                  (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test
                  positive).

          -  Active autoimmune disease with reasonable possibility of clinically significant
             deterioration when receiving an immunostimulatory agent:

               -  Subjects with Type 1 diabetes mellitus, vitiligo, psoriasis, hypo- or
                  hyperthyroid disease not requiring immunosuppressive treatment are eligible.

          -  Interstitial lung disease that is symptomatic or which may interfere with the
             detection or management of suspected drug-related pulmonary toxicity.

          -  Uncontrolled asthma [defined as having 3 or more of the following features of
             partially controlled asthma within 28 days prior to starting study treatment: Daytime
             symptoms more than twice per week, any limitation of activities, any nocturnal
             symptoms/awaking, need for reliever/rescue inhaler more than twice per week, or known
             lung function (PEF or FEV1) without administration of a bronchodilator that is < 80%
             predicted or personal best (if known)].

          -  Current symptomatic congestive heart failure (New York Heart Association > class II),
             unstable cardiac arrhythmia requiring therapy (e.g. medication or pacemaker), unstable
             angina (e.g. new, worsening or persistent chest discomfort), or uncontrolled
             hypertension (systolic > 160 mmHg or diastolic > 100mmHg). Or any of the following
             occurring within 6 months (180 days) prior to first dose of avelumab: Myocardial
             infarction, coronary/peripheral artery bypass graft, cerebrovascular accident or
             transient ischemic attack, or serious cardiac arrhythmia requiring medication. (Use of
             antihypertensive medication to control blood pressure is allowed.)

          -  Concurrent treatment with a non-permitted drug.

          -  Requirement of anticoagulant therapy with oral vitamin K antagonists such as Coumadin
             (warfarin). Low-dose anticoagulants for the maintenance of patency in a central venous
             access device or the prevention of deep vein thrombosis or pulmonary embolism is
             allowed. Therapeutic use of low molecular weight heparin is allowed.

          -  Persisting toxicity related to prior therapy that has not reduced to Grade 1 [National
             Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 4.03;
             however, alopecia and sensory neuropathy Grade ≤ 2 is acceptable.

          -  Known severe (Grade ≥ 3 NCI-CTCAE v4.03) hypersensitivity reactions to monoclonal
             antibodies, including hypersensitivity to the investigational agent or any component
             in its formulations, or history of anaphylaxis.

          -  Vaccination within 28 days of the first dose of avelumab and while on trial is
             prohibited, except for administration of inactivated vaccines (for example,
             inactivated influenza vaccine).

          -  Pregnant or breastfeeding females.

          -  Known alcohol or drug abuse.

          -  Prisoners or subjects who are involuntarily incarcerated.

          -  Other severe acute or chronic medical condition, including colitis, inflammatory bowl
             disease, pneumonitis, pulmonary fibrosis, or psychiatric condition including recent
             (within the past year) or active suicidal ideation or behavior; or laboratory
             abnormalities that may increase the risk associated with study participation or study
             treatment administration or may interfere with the interpretation of study results
             and, in the judgment of the investigator, would make the patient inappropriate for
             entry into this study.
      "
NCT03745352,withdrawn,"
    inadequate accrual rate
  ",0,phase 2,"['recurrent acute myeloid leukemia', 'refractory acute myeloid leukemia']","[""['G47.13', 'J01.41', 'K11.22', 'K12.0', 'N96', 'F33.8', 'G03.2']"", ""['D46.4', 'I20.2', 'D46.1', 'D46.A', 'D46.0', 'D46.20', 'D46.21']""]","['azacitidine', 'pevonedistat']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Patients must have an established and confirmed diagnosis of AML by World Health
             Organization (WHO) criteria, excluding acute promyelocytic leukemia (APL).

          -  Patients must have relapsed or refractory AML, defined as:

               -  Relapsed: >= 5% bone marrow blasts by morphology, reappearance of minimal
                  residual disease (MRD) (> 0.1%) by flow cytometry, reappearance of peripheral
                  blood blasts, or development of extramedullary leukemia after one or more prior
                  lines of therapy. Consolidation regimens, including autologous and allogeneic
                  HCT, do not count as a separate prior line of therapy, (e.g., 7+3 followed by
                  cytarabine consolidation followed by allogeneic hematopoietic cell
                  transplantation (HCT) would be considered one prior line of therapy). Note, there
                  is no restriction on the prior number of relapses and prior treatment of relapsed
                  disease is allowed.

               -  Refractory: no complete response (CR) or complete response with incomplete bone
                  marrow recovery (CRi) after two courses of induction therapy (e.g. therapy with
                  the intent to induce remission). Patients 75 years or older, or patients of any
                  age with comorbidities that prevent the use of further intensive chemotherapy,
                  will be eligible if they did not experience CR or CRi after one course of
                  induction therapy.

          -  Patients must have Karnofsky >= 60%.

          -  Patients must have a white blood cell count (WBC) =< 25 x 10^9 cells/L. Hydroxyurea
             and leukapheresis are permitted to satisfy this criterion.

          -  Total bilirubin =< institutional upper limit of normal (ULN) except in patients with
             Gilbert's syndrome or post-transfusion hemolysis. Patients with Gilbert's syndrome or
             post-transfusion hemolysis may enroll if direct bilirubin =< 1.5 x ULN of the direct
             bilirubin.

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =< 3 x institutional ULN (unless resulting from liver infiltration with leukemia).

          -  Creatinine clearance >= 30 mL/min (If serum creatinine not =< institutional ULN).

          -  Hemoglobin > 8 g/dL. Patients may be transfused to achieve this value.

          -  Human immunodeficiency virus (HIV)-infected patients will be eligible for this trial
             if they are on effective antiretroviral regimens utilizing non-CYP-interacting agents,
             they have an undetectable viral load, they have a CD4 count > 350 cells/mm^3, and they
             have no history of acquired immune deficiency syndrome (AIDS)-defining opportunistic
             infections. If there is evidence of chronic hepatitis B virus (HBV) infection, HBV
             viral load must be undetectable on suppressive therapy, if indicated. If there is
             history of hepatitis C virus (HCV) infection, the patient must have been treated and
             have undetectable HCV viral load.

          -  Patients must be willing to submit blood samples for the integrated biomarker.

          -  Female patients of childbearing potential (i.e. who are not postmenopausal for at
             least 1 year before screening or are not surgically sterile) must have a negative
             serum pregnancy test within 72 hours prior to the first study drug administration and
             must agree to practice one highly effective method and one additional effective
             (barrier) method of contraception, at the same time, from the time of signing the
             informed consent through 4 months after the last dose of study drug, or agree to
             practice true abstinence, when this is in line with the preferred and usual lifestyle
             of the patient. Male patients, even if surgically sterilized, must agree to practice
             effective barrier contraception during the entire study treatment period through 4
             months after the last dose of study drug, or agree to practice true abstinence when
             this is in line with the preferred and usual lifestyle of the patient. Periodic
             abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods),
             withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of
             contraception.

          -  Patients may have had prior allogeneic HCT at least 3 months prior to randomization
             but should not have evidence of active graft versus host disease or require systemic
             immune suppression.

          -  Patients must be able to understand and be willing to sign a written informed consent
             document.

          -  Patients with impaired decision-making capacity (IDMC) will be eligible if they have a
             legal guardian or a close family member available to assist them.

        Exclusion Criteria:

          -  Patients must not have had prior treatment with MLN4924 (pevonedistat), azacitidine,
             or decitabine.

          -  Patients for whom, in the opinion of the treating physician, azacitidine alone is not
             an appropriate treatment will be excluded.

          -  Patients must not have documented active central nervous system (CNS) involvement by
             leukemia. Patients with known brain metastases should be excluded from this clinical
             trial because of their poor prognosis and because they often develop progressive
             neurologic dysfunction that would confound the evaluation of neurologic and other
             adverse events.

          -  Patients must not have received any other investigational or commercial agents or
             therapies administered with the intention to treat their leukemia within 14 days or
             five half-lives (whichever is shorter) of first receipt of study drug, with the
             exception of hydroxyurea used to control WBCs.

          -  All non-hematologic adverse events (AEs) of prior chemotherapy, surgery, or
             radiotherapy, except alopecia, must have resolved to National Cancer Institute (NCI)
             Common Terminology Criteria for Adverse Events (CTCAE) grade =< 2 prior to starting
             therapy.

          -  Patients must not have a history of other malignancies, except:

               -  Any malignancy that was treated with curative intent, has no known active disease
                  present for >= 1 year before the first dose of study drug, and is felt to be at
                  low risk of recurrence by the treating physician;

               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
                  of disease;

               -  Adequately treated carcinoma in situ without evidence of disease;

               -  Low-risk prostate cancer after curative surgery.

          -  Patients must not have a history of allergic reactions attributed to compounds of
             similar chemical or biologic composition to MLN4924 (pevonedistat), azacitidine, or
             mannitol.

          -  Clinically significant metabolic enzyme inducers are not permitted during this study,
             or within 14 days before the first dose of study drugs. As part of the
             enrollment/informed consent procedures, the patient will be counseled on the risk of
             interactions with other agents, and what to do if new medications need to be
             prescribed or if the patient is considering a new over-the-counter medicine or herbal
             product.

          -  Patients must not have severe and/or uncontrolled medical conditions or other
             conditions that, in the opinion of the investigator, could affect their participation
             in the study.

          -  Pregnant women are ineligible because, as an Nedd8 activating enzyme (NAE) inhibitor,
             MLN4924 (pevonedistat) has the potential for teratogenic or abortifacient effects.
             Because there is an unknown but potential risk for AEs in nursing infants secondary to
             treatment of the mother with MLN4924 (pevonedistat), breastfeeding must be
             discontinued if the mother is treated with MLN4924 (pevonedistat). These potential
             risks may also apply to azacitidine.

          -  Patients must not have had major surgery within 14 days before the first dose of any
             study drug or be scheduled for surgery during the study period.

          -  Patients must not have uncontrolled coagulopathy or a bleeding disorder unless
             directly attributable to their AML (e.g., disseminated intravascular coagulation).

          -  Patients must not have known hepatic cirrhosis or severe pre-existing hepatic
             impairment.

          -  Patients must not have known cardiopulmonary disease defined as:

               -  Unstable angina;

               -  Congestive heart failure (New York Heart Association [NYHA] class III or IV;

               -  Myocardial infarction (MI) within 6 months prior to first dose. Patients who had
                  ischemic heart disease such as acute coronary syndrome (ACS), MI, and/or
                  revascularization more than 6 months before screening and who are without cardiac
                  symptoms or those with a prior non-ST elevation MI due to demand-supply mismatch
                  (NSTEM type II) may enroll;

               -  Symptomatic cardiomyopathy;

               -  Clinically significant arrhythmia:

                    -  History of polymorphic ventricular fibrillation or torsade de pointes,

                    -  Permanent atrial fibrillation, defined as continuous atrial fibrillation
                       lasting for >= 6 months;

                    -  Persistent atrial fibrillation, defined as sustained atrial fibrillation
                       lasting > 7 days and/or requiring cardioversion in the 4 weeks before
                       screening;

                    -  Grade 3 atrial fibrillation, defined as symptomatic and incompletely
                       controlled medically, or controlled with a device (e.g., pacemaker) or by
                       ablation;

                    -  Patients with paroxysmal atrial fibrillation or < grade 3 atrial
                       fibrillation for period of at least 6 months are permitted to enroll
                       provided that their heart rate is controlled on a stable regimen;

               -  Moderate or severe pulmonary hypertension.

          -  Patients must not have uncontrolled high blood pressure that cannot be controlled by
             standard therapies.

          -  Patients must not have any life-threatening illness unrelated to cancer.

          -  Patients must not have an active, uncontrolled infection or severe infectious disease,
             (e.g. severe pneumonia, meningitis, or septicemia). Patients with an uncontrolled
             infection must not be enrolled until they have received treatment and the infection is
             under control.

          -  Patients must not have prolonged rate-corrected QT (QTc) interval >= 480 msec,
             calculated according to institutional guidelines.

          -  Patients must not have left ventricular ejection fraction < 40% as assessed by a
             transthoracic echocardiogram or radionuclide angiography within one month prior to
             study entry.

          -  Patients must not have known moderate to severe chronic obstructive pulmonary disease,
             interstitial lung disease, or pulmonary fibrosis.

          -  Female patients who intend to donate eggs (ova) during the course of this study or
             within 4 months of receiving their last dose of study drugs are ineligible.

          -  Male patients who intend to donate sperm during the course of this study or within 4
             months of receiving their last dose of study drugs are ineligible.
      "
NCT03630120,terminated,"
    lack of efficacy
  ",0,phase 2,"['thyroid cancer', 'thyroid cancer, medullary', 'differentiated thyroid cancer', 'papillary thyroid cancer', 'follicular thyroid cancer', 'poorly differentiated thyroid gland carcinoma']","[""['C73', 'D34', 'D44.0', 'Z85.850']"", ""['C73', 'D34', 'D44.0', 'Z85.850']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['lenvatinib', 'sorafenib', 'cabozantinib', 'vandetanib']","['Status: 503', 'Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  All histologically or cytologically confirmed diagnosis of thyroid cancer, other than
             anaplastic or stromal-cell derived cancers.

          -  Participants with differentiated thyroid cancers (DTC) must have negative
             thyroglobulin antibodies.

          -  Measurable disease meeting the following criteria and confirmed by central
             radiographic review:

               -  At least 1 lesion of ≥ 1.0 centimeter (cm) in the longest diameter for a non-
                  lymph node or ≥ 1.5 cm in the short-axis diameter for a lymph node which is
                  serially measurable according to Response Evaluation Criteria in Solid Tumors
                  (RECIST) 1.1 using computerized tomography/magnetic resonance imaging (CT/MRI).
                  If there is only one target lesion and it is a non-lymph node, it should have a
                  longest diameter of ≥ 1.5 cm.

               -  Lesions that have had external beam radiotherapy (EBRT) or locoregional therapies
                  such as radiofrequency (RF) ablation must show evidence of progressive disease
                  (substantial size increase of ≥ 20%) within 12 months to be deemed a target
                  lesion.

          -  Participants must show evidence of disease progression comparing (a) scan in screening
             and (b) historical scan obtained within 12 months prior to signing informed consent,
             according to RECIST 1.1 assessed and confirmed by central radiographic review of CT
             and/or MRI scans.

          -  Participants with DTC must not be eligible for possible curative surgery and must be
             radioiodine (RAI)-refractory / resistant as defined by at least one of the following:

               -  One or more measurable lesions that do not demonstrate iodine uptake on any
                  radioiodine scan

               -  One or more measurable lesions that has progressed by RECIST 1.1 within 12 months
                  of RAI therapy, despite demonstration of radioiodine avidity at the time of that
                  treatment by pre- or post-treatment scanning.

               -  Disease progression in a patient that has received a cumulative activity of RAI
                  of ≥ 550 millicuries (mCi) (22 gigabecquerels), with the last RAI dose
                  administered at least 6 months prior to study entry.

               -  Otherwise deemed not a candidate for further RAI therapy by a multidisciplinary
                  tumor board within 60 days of enrollment.

          -  Participants with DTC must be receiving thyroxine suppression therapy and thyroid
             stimulating hormone (TSH) should not be elevated (TSH should be ≤ 0.1 mU/L).

          -  ""Measurable"" tumor marker (non-stimulated thyroglobulin >10 ng/mL or CEA>10 ng/ML in
             patients with DTC; or serum basal calcitonin >10 pg/mL in patients with MTC)

          -  Participants may have received prior multi-kinase targeted therapy except the TKI used
             in this trial. For example, patients getting Lenvatinib on this study may have been
             previously treated with Sorafenib, Vandetanib, Sunitinib, Pazopanib, etc. Each of the
             TKI targeted agents will be counted individually, regardless of the duration of its
             administration.

          -  Participants with known brain metastases who have completed whole brain radiotherapy,
             stereotactic radiosurgery or complete surgical resection, will be eligible if they
             have remained clinically stable, asymptomatic for 30 days.

          -  All chemotherapy or radiation related toxicities must have resolved to < Grade 2
             severity per Common Terminology Criteria for Adverse Events (CTCAE v 5.0), except
             alopecia infertility, anemia (see separate criteria) and any toxicities deemed
             irreversible by the treating physician.

          -  Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status
             of 0 - 2.

          -  Adequately controlled blood pressure (BP) with or without antihypertensive
             medications, defined as BP ≤ 150/90 mm Hg at screening and no change in
             antihypertensive medications within 1 week prior to Cycle 1/Day 1

          -  Adequate renal function defined as calculated creatinine clearance ≥ 30 mL/min (using
             Cockcroft/Gault formula)

          -  Adequate bone marrow function

          -  Adequate liver function

          -  Males or females age ≥ 18 years at the time of informed consent

          -  Females must not be breastfeeding or pregnant at Screening or Baseline.

          -  Males and females must follow all contraception guidelines as outlined in the protocol
             guidelines.

          -  Voluntary agreement to provide written informed consent and the willingness and
             ability to comply with all aspects of the protocol

        Exclusion Criteria:

          -  Participants who have received any anticancer treatment (including Chinese herbal
             medicine specified for the treatment of tumor) within 21 days or any investigational
             agent within 30 days prior to the first dose of study drug. This does not apply to the
             use of TSH-suppressive thyroid hormone therapy.

          -  Major surgery within 21 days prior to the first dose of study drug.

          -  Palliative radiation therapy within 14 days prior to the first dose of study drug.

          -  Participants having > 30 mg/mL urine protein on urine dipstick testing (Participants
             with urine protein < 1 g/24 hour (h) will be eligible).

          -  Gastrointestinal malabsorption or any other condition that in the opinion of the
             investigator might affect the absorption of Lenvatinib, Sorafenib, Cabozantinib, or
             Vandetanib.

          -  Significant cardiovascular impairment: history of (a) congestive heart failure greater
             than New York Heart association (NYHA) Class II, (b) unstable angina, (c) myocardial
             infarction, (d) stroke, or (e) cardiac arrhythmia associated with impairment within 6
             months of the first dose of study drug.

          -  Bleeding or thrombotic disorders (Treatment with low molecular weight heparin is
             allowed).

          -  Radiographic evidence of major blood vessel invasion/infiltration.

          -  Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 21 days prior to
             the first dose of study drug.

          -  Active infection (any infection requiring systemic treatment).

          -  Active malignancy (except for DTC/MTC or definitively treated basal or squamous cell
             carcinoma of the skin, or carcinoma in-situ of the cervix or bladder) within the past
             24 months.

          -  Known intolerance to any of the study drugs (or any of the excipients).

          -  Any medical or other condition which, in the opinion of the investigator, would
             preclude participation in a clinical trial.

          -  Females who are pregnant or breastfeeding.

          -  Participants who are taking prohibited medications outlined in protocol documentation.
      "
NCT03634800,terminated,"
    lack of patient accruals.
  ",0,phase 2,['multiple myeloma'],"[""['C90.01', 'C90.02', 'C90.00']""]",['nivolumab 240mg'],['Status: 503'],"
        Inclusion Criteria:

          1. Subject is, in the investigator's opinion, willing and able to comply with the
             protocol requirements.

          2. Subject has given voluntary written informed consent before performance of any study
             related procedure not part of normal medical care, with the understanding that consent
             may be withdrawn by the subject at any time without prejudice to their future medical
             care.

          3. Must have received 2 consecutive cycles of systemic myeloma therapy.

          4. Documented refractory or relapsed and refractory (R/R) multiple myeloma

               1. patients had less than minimal response, or had achieved at least a minimal
                  response to previous treatment, but progressed within 6 months

               2. patients must have failed, be intolerant or are ineligible to treatment with an
                  IMiD, proteasome inhibitor and anti-CD38 agent

          5. Targetable plasmacytoma, either intra-or extramedullary that is visualized on imaging
             (PET/CT or MRI) and is causing symptoms (eg. pain, neurological compromise) or
             potential to cause symptom as per clinician's judgement; and measurable disease at
             screening, defined as one or more of the following:

               1. Serum IgG, IgA, or IgM M-protein ≥ 0.5 g/dL

               2. Urine M-Protein ≥ 200 mg excreted in a 24-hour collection sample

               3. Involved serum free light chain (sFLC) > 100 mg/L provided the FLC ratio is
                  abnormal

          6. Males and Females at least 18 years or legal age of consent per local regulations.

          7. Women of childbearing potential (WOCBP) must have two negative serum or urine
             pregnancy tests (minimum sensitivity 25 mIU/mL or equivalent units of HCG). One 10-14
             days prior to start of the study drug and one within 24 hours prior to the start of
             study drug.

          8. Investigators shall counsel WOCBP and male subjects who are sexually active with WOCBP
             on the importance of pregnancy prevention and the implications of an unexpected
             pregnancy Investigators shall advise WOCBP and male subjects who are sexually active
             with WOCBP on the use of highly effective methods of contraception. Highly effective
             methods of contraception have a failure rate of < 1% when used consistently and
             correctly.

          9. No condition which would cause unacceptable risk.

        Exclusion Criteria:

          1. Subjects with solitary bone or extramedullary plasmacytoma as the only evidence of
             plasm cell dyscrasia.

          2. Subjects with monoclonal gammopathy of undetermined significance (MGUS), smoldering
             multiple myeloma (SMM), Waldenstrom's macroglobulinemia, or POEMS syndrome (plasma
             cell dyscrasia with poly neuropathy, organomegaly, endocrinopathy, monoclonal protein,
             and skin changes).

          3. Subjects with active plasma cell leukemia (defined as either 20% of peripheral blood
             white blood cell count comprised of plasma/CD138+ cells or an absolute plasma cell
             count of 2 x 109/L).

          4. Subjects within 100 days of stem cell transplantation.

          5. Subjects within 4 weeks of surgery, unless cleared by surgeon.

          6. Women who are of childbearing potential not complying to the above described
             contraceptive measures or are breastfeeding, and sexually active fertile men whose
             partners are WOCBP if they are not complying to the above described contraceptive
             measures.

          7. Any uncontrolled or severe cardiovascular or pulmonary disease determined by the
             investigator, including:

               1. NYHA functional classification III or IV, congestive heart failure, unstable or
                  poorly controlled angina, uncontrolled hypertension, arrhythmia, or myocardial
                  infarction in the past 12 months

               2. Subjects with interstitial lung disease that is symptomatic or may interfere with
                  the detection or management of suspected drug-related pulmonary toxicity

          8. Active infection or know HBV/HCV/HIV.

          9. Subjects with an active, known or suspected autoimmune disease. Subjects with type I
             diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders
             (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or
             conditions not expected to recur in the absence of an external trigger are permitted
             to enroll.

         10. Subjects with a condition requiring systemic treatment with either corticosteroids (>
             10 mg daily prednisone equivalent) or other immunosuppressive medications within 14
             days of initiation of study drug. Inhaled or topical steroids, and adrenal replacement
             steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of
             active autoimmune disease.

         11. Previous radiotherapy to the area of the target area.

         12. Prior exposure to immunotherapy.
      "
NCT02669615,completed,,1,phase 2,['multiple myeloma'],"[""['C90.01', 'C90.02', 'C90.00']""]",['melphalan hcl for injection (propylene glycol free)'],['Status: 503'],"
        Inclusion Criteria:

          -  Patients with symptomatic multiple myeloma (MM) requiring treatment at or following
             diagnosis.

          -  Patients with MM, who qualify for ASCT therapy, and have received pretransplant
             therapy prior to transplantation.

          -  Adult patients (≥18 years of age) meeting local institutional criteria to receive a
             total Melphalan dose of 200 mg/m^2 as a conditioning regimen.

          -  Patients with an adequate autologous graft, which is defined as an unmanipulated,
             cryopreserved, peripheral blood cell graft containing at least 2 × 106 CD34+ cells/kg,
             based on patient weight.

          -  Patients with adequate organ function, as measured by:

          -  Cardiac: Left ventricular ejection fraction at rest >40% (documented within 30 days
             prior to Day -3).

          -  Hepatic: Bilirubin <2 × the upper limit of normal (ULN) and Alanine
             transaminase/Aspartate transaminase (ALT/AST) <3 × ULN.

          -  Renal: Creatinine clearance >40 mL/min (measured or calculated/estimated).

          -  Pulmonary: Adjusted Diffusing capacity of the lungs for carbon monoxide (DLCO), forced
             expiratory volume in one second (FEV1), forced vital capacity (FVC) >50% of predicted
             value (corrected for hemoglobin level [Hgb]) and documented within prior to day -3.

        Exclusion Criteria:

          -  Patients with systemic AL amyloidosis (immunoglobulin light chain amyloidosis).

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≥2.

          -  Patients with uncontrolled hypertension.

          -  Patients with a serious active bacterial, viral or fungal infection.

          -  Patients with prior malignancies except resected basal cell carcinoma or treated
             cervical carcinoma in situ. Cancer treated with curative intent >5 years previously
             will be allowed. Cancer treated with curative intent <5 years previously will not be
             allowed unless approved by the medical monitor.

          -  Female patients who are pregnant (positive human chorionic gonadotropin [ß-HCG]) or
             breastfeeding.

          -  Female patients of childbearing potential, who are unwilling to use adequate
             contraceptive techniques during and for one month following study treatment with
             Melphalan HCl for injection (propylene glycol free).

          -  Patients seropositive for HIV.

          -  Patients who are unwilling to provide informed consent.

          -  Patients receiving other concurrent anticancer therapy (including chemotherapy,
             radiation, hormonal treatment, or immunotherapy, but excluding corticosteroids) within
             30 days prior to the ASCT or planning to receive any of these treatments prior to
             study discharge.

          -  Patients concurrently participating in any other clinical study.

          -  Patients who are hypersensitive or intolerant to any component of the study drug
             formulation.
      "
NCT02667574,completed,,1,phase 2,['basal cell carcinoma'],"[""['C44.510', 'C44.91', 'C44.01', 'C44.311', 'C44.511', 'C44.81', 'C44.41']""]",['erivedge'],['Status: 503'],"
        Inclusion Criteria:

          1. Patients with BCC, which surgery stage is A, B or C (cf. Appendix 3: Definition of
             surgery stages), with a diameter ≥ 3cm in zones at intermediate risk of tumor
             recurrence and a BCC with a diameter of ≥ 2 cm in the zones at higher risk of tumor
             recurrence. According to the HAS recommendations, two zones are taken into
             consideration:

               -  Zones at intermediate risk of tumor recurrence: forehead, cheek, chin, neck and
                  scalp

               -  Zones at higher risk of tumor recurrence: nose and periorificial sites of the
                  cephalic extremity

          2. The decision to include the patient in this study should be taken during the
             Pluridisciplinary Committee Meeting (RCP). During this RCP, the radiotherapy should be
             considered as an inadequate treatment. (If the radiotherapist is absent during the
             meeting, his opinion should be documented in the patient's medical record).

          3. Written informed consent

          4. Age ≥ 18 years old

          5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0, 1, or 2

          6. At least one histologically confirmed lesion...

          7. Patients with Gorlin syndrome may enroll in this study but must meet the other
             inclusion criteria

          8. Patients with measurable and/or non-measurable disease (as defined by RECIST, v1.1)

          9. Adequate organ function, as evidenced by the following laboratory results:

               -  Hemoglobin > 8.5 g/dL

               -  Granulocyte count ≥ 1000/μL

               -  Platelet count ≥ 75,000/μL

               -  Aspartate transaminase (AST ) and alanine transaminase (ALT) ≤ 3 × upper limit of
                  normal (ULN)

               -  Total bilirubin ≤ 1.5 × ULN or within 3 × ULN for patients with documented
                  Gilbert syndrome

         10. Negative serum pregnancy test within 7 days prior to commencement of dosing in
             premenopausal women. Women of non-childbearing potential may be included if they are
             either surgically sterile or have been postmenopausal for ≥ 1 year.

         11. Women of childbearing potential must use one highly-effective method of contraception
             and one barrier method of contraception during treatment and for 24 months after the
             final dose. Highly-effective methods of contraception are defined as those which
             result in a low failure rate (i.e., less than 1% per year) when used consistently and
             correctly (e.g., implants, injectables, or intra-uterine devices; refer to Appendix 8
             for more details). At the discretion of the Investigator, acceptable methods of
             contraception may include total abstinence. (Periodic abstinence [e.g., calendar,
             ovulation, symptothermal, and postovulation methods] and withdrawal are not acceptable
             methods of contraception.).

         12. For male patients with female partners of childbearing potential, agreement top use a
             condom with spermicide, even after vasectomy, during sexual intercourse with partners
             while being treated with Vismodegib and for two months after completion of study
             treatment

         13. For male patients, agreement not to donate semen during the study and for 24 months
             after discontinuation of Vismodegib

         14. Agreement not to donate blood or blood products during the study and for at least 24
             months after discontinuation of Vismodegib.

         15. Life expectancy > 12 weeks

         16. Patients covered by a Health Insurance System

        Exclusion Criteria:

          1. Inability or unwillingness to swallow capsules

          2. Patients with BCC situated out of the head or the neck area

          3. Pregnancy or lactation

          4. Concurrent non-protocol-specified anti-tumor therapy (e.g., chemotherapy, other
             targeted therapy or photodynamic therapy

          5. Chemotherapy within 4 weeks prior to enrollment

          6. Participation in another clinical trial within 4 weeks prior to enrollment

          7. Radiotherapy within 6 months prior to enrolment

          8. Metastatic BCC

          9. Uncontrolled medical illnesses such as infection requiring treatment with intravenous
             antibiotics.

         10. History of other disease, metabolic dysfunction, physical examination finding, or
             clinical laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates use of an investigational drug or that might affect interpretation of
             the results of the study or that renders the patient at high risk from treatment
             complications.

         11. Patients with a rare hereditary problem of galactose intolerance, primary hypolactasia
             or glucose-galactose malabsorption (according to the product SmPC).

         12. Patients unable or unwilling to comply with the protocol requirements

         13. Patients in emergency situations

         14. Patients kept in detention
      "
NCT02666898,completed,,1,phase 2,"['leukemia, lymphocytic, chronic, b-cell']","[""['C91.11', 'C91.12', 'C91.10']""]","['ga101', 'ibrutinib', 'cyclophosphamide', 'fludarabine']","['Status: 503', 'Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Patient information and written informed consent

          -  Age 18 years or older

          -  Immunophenotypically confirmed B-CLL (IWCLL2008 and Matutes score 4 or 5)

          -  Binet stage C according to IWCLL 2008 criteria or Binet stage A and B with active
             disease could be considered for inclusion.

          -  Patients with no prior treatment (chemotherapy, radiotherapy, immunotherapy) except
             steroids for less than 1 month

          -  Absence of 17p deletion as assessed by FISH (< 10 % positive nuclei)

          -  Performance status ECOG < 2

          -  CIRS (Cumulative Illness Rating Scale) ≤ 6 (see appendix 4 for calculation of CIRS
             score) Mandatory inclusion criteria for treatment with ibrutinib

        Hematology values must be within the following limits:

          -  Absolute neutrophil count (ANC) <1 G/L independent of growth factor support

          -  Platelets <100 G/L or <50 G/L if bone marrow involvement independent of transfusion
             support in either situation

        Biochemical values within the following limits:

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x upper limit
             of normal (ULN)

          -  Total bilirubin ≤ 1.5 x ULN unless bilirubin rise is due to Gilbert's syndrome or of
             non-hepatic origin

          -  Serum creatinine ≤ 2 x ULN or estimated Glomerular Filtration Rate (Cockroft Gault≥ 40
             mL/min/1.73m2

          -  Women of childbearing potential and men who are sexually active must be practicing a
             highly effective method of birth control during and after the study consistent with
             local regulations regarding the use of birth control methods for subjects
             participating in clinical trials. Men must agree to not donate sperm during and after
             the study. For females, these restrictions apply for 1 month after the last dose of
             study drug. For males, these restrictions apply for 3 months after the last dose of
             study drug.

          -  Women of childbearing potential must have a negative serum (beta-human chorionic
             gonadotropin [Beta-hCG]) or urine pregnancy test at Screening. Women who are pregnant
             or breastfeeding are ineligible for this study.

          -  Sign (or their legally-acceptable representatives must sign) an informed consent
             document indicating that they understand the purpose of and procedures required for
             the study, including biomarkers, and are willing to participate in the study

        Exclusion Criteria:

          -  Binet stage A and B without active disease according to IWCLL 2008 criteria

               -  Known HIV seropositivity

               -  Hepatitis B or C seropositivity (unless clearly due to vaccination)

               -  Active hemolysis (isolated positive DAT is not an exclusion criteria)

               -  Life expectancy < 6 months

               -  Patient refusal to perform the bone marrow biopsy for evaluation points

               -  Clinically significant auto-immune anemia

               -  Active second malignancy currently requiring treatment (except basal cell
                  carcinoma in situ endometrial carcinoma and incidental prostate carcinoma) and/or
                  less than 5 years CR after breast cancer

               -  Any severe co-morbid conditions such as Class III or IV heart failure, myocardial
                  infarction within months, unstable angina, ventricular tachyarrhythmias requiring
                  ongoing treatment, severe chronic obstructive pulmonary disease with hypoxemia,
                  uncontrolled diabetes mellitus, or uncontrolled hypertension

               -  Concomitant disease requiring prolonged use of corticosteroids (> 1 month)

               -  Known hypersensitivity with anaphylactic reaction to humanized monoclonal
                  antibodies or any of the study drugs

               -  Contraindication to the use of Obinutuzumab.

               -  Contraindication to use of Ibrutinib

               -  Transformation to aggressive B-cell malignancy (e.g. diffuse large cell lymphoma,
                  Hodgkin lymphoma, or prolymphocytic leukaemia)

               -  Active bacterial, viral or fungal infection

               -  Abnormal renal function with creatinine clearance < 60 ml/min calculated
                  according to the formula of Cockcroft and Gault

               -  Total bilirubin, gamma glutamyltransferase or transaminase levels > 2.5 ULN.

               -  Any coexisting medical or psychological condition that would preclude
                  participation in the required study procedures

               -  Patient with mental deficiency preventing proper understanding of the
                  requirements of treatment.

               -  Pregnant or breastfeeding women.

               -  Adult under law-control

               -  Fertile male and female patients who cannot or do not wish to use an effective
                  method of contraception, during and for 18 months after the final treatment used
                  for the purposes of the study.

               -  No affiliate to social security

        Mandatory exclusion criteria for treatment with Ibrutinib

          -  Major surgery within 4 weeks of randomization.

          -  Known central nervous system lymphoma.

          -  History of stroke or intracranial hemorrhage within 6 months prior to randomization.

          -  Requires anticoagulation with warfarin or equivalent vitamin K antagonists

          -  Requires treatment with strong CYP3A inhibitors.

          -  Clinically significant cardiovascular disease such as uncontrolled or symptomatic
             arrhythmias, congestive heart failure, or myocardial infarction within 6 months of
             Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by
             the New York Heart Association Functional Classification.

          -  Vaccinated with live, attenuated vaccines within 4 weeks of randomization.

          -  Known history of human immunodeficiency virus (HIV) or active Hepatitis C Virus or
             active Hepatitis B Virus infection or any uncontrolled active systemic infection
             requiring intravenous (IV) antibiotics.

          -  Any life-threatening illness, medical condition, or organ system dysfunction which, in
             the investigator's opinion, could compromise the subject's safety, interfere with the
             absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue
             risk.
      "
NCT02662296,withdrawn,"
    low enrollment
  ",0,phase 2,"['prolymphocytic leukemia', 'recurrent chronic lymphocytic leukemia', 'recurrent non-hodgkin lymphoma', 'recurrent small lymphocytic lymphoma']","[""['C91.31', 'C91.32', 'C91.61', 'C91.62', 'C91.30', 'C91.60']"", ""['A87.2', 'K52.832', 'D72.111', 'C91.11', 'C91.12', 'C91.10']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']""]","['ibrutinib', 'idelalisib']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Patients with diagnoses of CLL/SLL or non-Hodgkin lymphoma (NHL) patients, who meet
             the criteria of either relapse or progression at any time point after allogeneic HCT
             or those who experience persistent stable disease or persistent disease with
             regression between days 28 and 100 post-transplant using standard morphologic, flow
             cytometric, and/or imaging studies and following the disease response evaluation
             criteria established by the International Workshop on CLL (IWCLL) for CLL and those
             following Cheson 2007 criteria for NHL

          -  Patients will then be assigned to one of two cohorts:

               -  Cohort 1 will include patients who have relapsed /progressed within the first 180
                  days post-transplant and who are still within 3 months from date of
                  progression-relapse

               -  Cohort 2 will include patients who have either i) relapsed/progressed beyond day
                  180 post-HCT, ii) those with persistent stable disease or persistent disease with
                  regression between days 28-100 after allogeneic HCT, or iii) those who progressed
                  or relapsed within 180 days after HCT but were not started on this protocol
                  within 3 months from date of progression or relapse could also be enrolled under
                  cohort 2

                    -  NOTE: the inclusion of patients with persistent stable or persistent
                       regressing disease in this protocol is not meant to advocate treatment;
                       however, if the attending physician is inclined to offer treatment then
                       these patients would be eligible for this study

          -  Patients must be able to give informed consent

          -  Women of childbearing potential and men who are sexually active must affirm they are
             practicing a highly effective method of birth control during and after the study
             consistent with local regulations regarding the use of birth control methods for
             subjects participating in clinical trials; men must agree to not donate sperm during
             or after the study; for females, these restrictions apply for 1 month after the last
             dose of study drug; for males, these restrictions apply for 3 months after the last
             dose of the study drug

          -  Women of childbearing potential must have a negative serum (beta-human chorionic
             gonadotropin [B-hCG]) or urine pregnancy test at screening

          -  Absolute neutrophil count (ANC) >= 750/mm^3

          -  Platelets >= 30,000/mm^3

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x upper limit
             of normal (ULN)

          -  Total bilirubin =< 1.5 x ULN unless bilirubin rise is due to Gilbert's syndrome or of
             non-hepatic origin

          -  Creatinine clearance (Clcr) > 25 mL/min

        Exclusion Criteria:

          -  Pregnant or breast feeding females; (lactating females must agree not to breast feed
             while taking ibrutinib or idelalisib)

          -  Any condition, including the presence of laboratory abnormalities, which places the
             subject at unacceptable risk if he/she were to participate in the study or confounds
             the ability to interpret data from the study should be first discussed and clarified
             with the study investigators

          -  Concurrent use of other anti-cancer agents or treatments

          -  Known history of human immunodeficiency virus (HIV)

          -  Karnofsky performance status < 50%

          -  Active grades III or IV acute GVHD

          -  Central nervous system (CNS) involvement with disease refractory to intrathecal
             chemotherapy

          -  Vaccinated with live, attenuated vaccines within 4 weeks of initiation of therapy

          -  Patients with other prior malignancies except for adequately treated basal cell
             carcinoma, squamous cell carcinoma of the skin, breast or cervical cancer in situ, or
             other cancer from which the patient has been disease-free for 5 years or greater,
             unless approved by the protocol principal investigators

          -  Unable to swallow capsules or disease significantly affecting gastrointestinal
             function and/or inhibiting small intestine absorption such as; malabsorption syndrome,
             resection of the small bowel, or poorly controlled inflammatory bowel disease
             affecting the small intestine

          -  Uncontrolled active systemic fungal, bacterial, viral, or other infection (defined as
             exhibiting ongoing signs/symptoms related to the infection and without improvement,
             despite appropriate antibiotics or other treatment)

          -  Have uncontrolled hepatitis B or C infection

          -  IBRUTINIB-SPECIFIC EXCLUSION CRITERIA

          -  History of stroke or intracranial hemorrhage within 6 months of screening would be
             exclusion for ibrutinib therapy but idelalisib would be an option

          -  Patients requiring anticoagulation with warfarin or equivalent vitamin K antagonists
             (e.g., phenprocoumon) within 28 days from the start of study drug cannot be treated
             with ibrutinib but idelalisib would be an option

          -  Patients requiring chronic treatment with strong cytochrome P450 family 3, subfamily A
             (CYP3A) inhibitors cannot be treated with ibrutinib but idelalisib would be an option

          -  Clinically significant cardiovascular disease such as uncontrolled or symptomatic
             arrhythmias, congestive heart failure, or myocardial infarction within 6 months of
             screening, or any class 3 (moderate) or class 4 (severe) cardiac disease as defined by
             the New York Heart Association Functional Classification would be exclusion for
             ibrutinib therapy but idelalisib would be an option

          -  IDELALISIB-SPECIFIC EXCLUSION CRITERIA

          -  Ongoing drug-induced liver injury, chronic active hepatitis C (HCV), chronic active
             hepatitis B (HBV), alcoholic liver disease, non-alcoholic steatohepatitis, primary
             biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the
             liver, or portal hypertension would be exclusion for idelalisib therapy but ibrutinib
             would be an option

          -  Ongoing drug-induced pneumonitis would be exclusion for idelalisib therapy but
             ibrutinib would be an option
      "
NCT02669914,terminated,"
    low accrual, funding withdrawn by astrazeneca, and change in clinical practice
  ",0,phase 2,"['non-small cell lung cancer', 'nonsmall cell lung cancer', 'breast cancer', 'cancer of breast', 'cancer of the breast', 'gastroesophageal cancer', 'pancreatic cancer', 'cancer of the pancreas', 'colorectal cancer', 'colorectal carcinoma', 'renal cancer', 'kidney cancer', 'cancer of the kidney', 'cancer of kidney', 'ovarian cancer', 'ovary cancer', 'cancer of the ovary', 'cancer of ovary']","[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['K22.6', 'K21.9', 'K21.00', 'K21.01']"", ""['C25.3']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C65.1', 'C65.2', 'C65.9', 'D30.10', 'D30.11', 'D30.12', 'C64.1']"", ""['D17.71', 'D30.00', 'D30.01', 'D30.02', 'D41.00', 'D41.01', 'D41.02']"", ""['N26.2', 'Q63.0', 'Q63.2', 'Z52.4', 'I75.81', 'N19', 'N20.0']"", ""['D17.71', 'D30.00', 'D30.01', 'D30.02', 'D41.00', 'D41.01', 'D41.02']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['C56.1', 'C56.2', 'C56.9', 'D27.0', 'D27.1', 'D27.9', 'C79.60']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['C56.1', 'C56.2', 'C56.9', 'D27.0', 'D27.1', 'D27.9', 'C79.60']""]",['medi4736'],['Status: 503'],"
        Inclusion Criteria:

          -  Cohort A: Histologically confirmed metastatic non-small cell lung cancer (all
             histologic subtypes allowed) with radiographic evidence by MRI of at least one
             measurable brain lesion as defined by RANO criteria that does not require
             corticosteroids for symptomatic control.

          -  Cohort B: Histologically confirmed metastatic solid tumor of epithelial origin,
             excluding NSCLC, including but not limited to ovarian cancer, colorectal cancer,
             pancreatic cancer, gastric cancer, renal cancer, bladder cancer, or breast cancer with
             radiographic evidence by MRI of at least one measurable brain lesion as defined by
             RANO criteria that does not require corticosteroids for symptomatic control.

          -  Cohort C: Histologically confirmed metastatic solid tumor of epithelial origin,
             including both NSCLC and non-NSCLC, with radiographic evidence by MRI of at least one
             measurable brain lesion as defined by RANO criteria that requires corticosteroids for
             symptomatic control.

          -  At least one prior treatment to a CNS-based lesion is required. Prior therapy must be
             completed > 2 weeks prior to enrollment. A previously treated lesion must be
             demonstrated by MRI to have progressed following treatment in order to be eligible.
             The subsequent development of a new CNS lesion that was not previously treated will be
             permitted and dose not require treatment followed by progression prior to enrollment.
             Treatment of a single CNS lesion with local therapy in the context of multifocal
             disease is permitted as long as at least one untreated lesions meets criteria for
             measurable disease. Patients should have received minimum of one line of systemic
             therapy.

          -  At least 18 years of age.

          -  ECOG performance status of 0 to 2

          -  Adequate bone marrow and organ function as defined below:

               -  Absolute neutrophil count ≥ 1,500/mcL

               -  Platelets ≥ 100,000/mcL

               -  Hemoglobin ≥ 8.0 g/dL

               -  Serum bilirubin ≤ 1.5 x IULN

               -  AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN

               -  Creatinine clearance ≥ 40 mL/min/1.73 m2 by the Cockcroft-Gault formula or by
                  24-hour urine collection for determination of creatinine clearance

          -  Negative antiviral serology:

               -  Negative human immunodeficiency virus (HIV) antibody.

               -  Negative hepatitis B surface antigen (HBsAg) and negative hepatitis B core (HBc)
                  antibody or undetectable hepatitis B (HBV) DNA by quantitative polymerase chain
                  reaction (PCR) testing.

               -  Negative hepatitis C virus (HCV) antibody or negative HCV ribonucleic acid (RNA)
                  by quantitative PCR.

          -  Mean QT interval corrected for heart rate (QTc) < 470 msec calculated from 3 ECGs
             performed at least 2 minutes apart using Frediricia's Correction.

          -  Female subjects must either be of non-reproductive potential (i.e., post-menopausal by
             history: ≥60 years old and no menses for 1 year without an alternative medical cause;
             OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of
             bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry.

          -  Ability to understand and willingness to sign an IRB approved written informed consent
             document (or that of legally authorized representative, if applicable).

        Exclusion Criteria:

          -  Diagnosis of leptomeningeal carcinomatosis.

          -  Diagnosis of melanoma or other non-epithelial based malignancy such as sarcoma,
             neuroendocrine tumor, small cell lung cancer.

          -  Presence of unstable systemic disease (e.g., visceral crisis or rapid progression) in
             the judgment of the investigator.

          -  A history of other malignancy ≤ 5 years previous with the exception of basal cell or
             squamous cell carcinoma of the skin which were treated with local resection only or
             carcinoma in situ of the cervix.

          -  Currently receiving any other investigational agents.

          -  A history of allergic reactions attributed to compounds of similar chemical or
             biologic composition to MEDI4736 or other agents used in the study.

          -  Previous treatment with a PD-1 or PD-L1 inhibitor, including MEDI4736, or a CTLA-4
             inhibitory agent.

          -  Current or prior use of immunosuppressive medication within 28 days before the first
             dose of MEDI4736 with the exceptions of intranasal and inhaled corticosteroids, or
             systemic corticosteroids in Cohort C.

          -  Receipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy,
             endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal
             antibodies, other investigational agent) 21 days prior to the first dose of study
             drug.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, uncontrolled hypertension (>180/110),
             unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or
             gastritis, active bleeding diatheses, or psychiatric illness/social situations that
             would limit compliance with study requirements.

          -  Active or prior documented autoimmune disease within the past 2 years (Note: subjects
             with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within
             the past 2 years) are not excluded).

          -  Active or prior documented inflammatory bowel disease (e.g., Crohn's disease,
             ulcerative colitis).

          -  History of prior immunodeficiency.

          -  History of allogeneic organ transplant.

          -  Known history of previous clinical diagnosis of tuberculosis.

          -  Receipt of live attenuated vaccination within 30 days prior to first dose of MEDI4736.

          -  Pregnant and/or breastfeeding or female patients of reproductive potential who are not
             employing an effective method of birth control.

          -  Any condition that, in the opinion of the investigator, would interfere with
             evaluation of study treatment or interpretation of patient safety or study results
      "
NCT02399137,completed,,0,phase 2,['pancreatic cancer'],"[""['C25.3']""]","['mm-141', 'placebo', 'gemcitabine', 'nab-paclitaxel']","['Status: 503', 'Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Metastatic adenocarcinoma of the pancreas. Patients with islet cell neoplasms are not
             eligible.

          -  Patient must have received no prior radiotherapy, surgery, chemotherapy, or
             investigational therapy for the treatment of metastatic disease.

          -  Blood sample sent for free IGF-1 testing

          -  ECOG performance status (PS) of 0 or 1

        Exclusion Criteria:

          -  Patients who only present with localized disease

          -  Patients with CNS malignancies (primary or metastatic)

          -  Clinically significant cardiac disease
      "
NCT02393209,terminated,"
    lack of efficacy in combination.
  ",0,phase 1/phase 2,['non-small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['docetaxel', 'tak-117']","['Status: 503', 'Status: 503']","
        Inclusion Criteria

          -  Has a histologically and/or cytologically confirmed diagnosis of NSCLC (squamous or
             nonsquamous).

             - For Phase 2 of the study, has a diagnosis of mixed squamous and nonsquamous (or
             adenosquamous) NSLC.

          -  Has locally advanced or metastatic disease (Stage IIIb or Stage IV) with
             radiographically or clinically evaluable lesions.

          -  Has experienced failure of at least 1 prior chemotherapy regimen:

               -  For Phase 2 of the study:

               -  Participants must have received 1 prior platinum-based chemotherapy regimen
                  (excluding a docetaxel-containing regimen) for advanced or metastatic (Stage IIIb
                  or Stage IV) disease followed by documented progressive disease (PD).

               -  A drug provided as maintenance therapy following cytotoxic chemotherapy will be
                  considered to be part of that regimen.

               -  Participants who received prior therapy with paclitaxel as a part of the
                  platinum-based doublet front-line regimen without PD on therapy.

               -  Participants who, after the front-line, platinum-based, non-docetaxel containing
                  chemotherapy, have been treated with 1 line of nivolumab or other
                  immune-checkpoint inhibitors but progressed on or after the therapy.

               -  For Phase 1b of the study: Participants who have experienced failure of multiple
                  lines of prior chemotherapy are eligible.

               -  For Phase 2, has archived or fresh tumor biopsy samples (obtained during
                  screening) sufficient for genotyping.

          -  Has adequate organ function, before the first dose of study drug.

          -  Has Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

          -  Female participants who are postmenopausal for at least 1 year before the screening
             visit or are surgically sterile, or are of childbearing potential, agree to practice 1
             highly effective method and 1 additional effective (barrier) method of contraception,
             at the same time, from the time of signing the informed consent through 30 days (or
             longer, as mandated by local labeling) after the last dose of study drug, or agree to
             practice true abstinence.

          -  Female participants must agree to not donate eggs (ova) during the course of this
             study and for 30 days after receiving their last dose of TAK-117 and, for docetaxel,
             for as long as is mandated by local labeling.

          -  Male participants agree to practice highly effective barrier contraception during the
             entire study treatment period and through 120 days after the last dose of TAK-117 and,
             for docetaxel, for as long as is mandated by local labeling, or agree to practice true
             abstinence.

          -  Male participants must agree to not donate sperm during the course of the study and
             for 120 days after receiving their last dose of TAK-117 and, for docetaxel, for as
             long as is mandated by local labeling.

          -  Has suitable venous access for the study-required blood sampling.

          -  Has recovered (ie, <= Grade 1 toxicity or eligibility per this protocol is met) from
             the reversible effects of prior anticancer therapy.

          -  In the opinion of the investigator, the participant or legal guardian is capable of
             understanding and complying with protocol requirements for the duration of the study.

        Exclusion Criteria:

          -  Previous treatment with a PI3K or AKT inhibitor.

          -  Prior cancer therapy or other investigational therapy within 2 weeks before the first
             administration of study drug or failed to recover from the reversible effects of prior
             anticancer therapies. For prior therapies with a half-life longer than 3 days, the
             interval must be at least 28 days before the first administration of study drug, and
             the participant must have documented progressive disease.

          -  Has poorly controlled diabetes mellitus defined as HbA1c > 6.5%.

          -  Has taken strong inhibitors or strong inducers of CYP3A4 within 14 days before the
             first dose of study drug.

          -  Has taken histamine-H2 receptor antagonists and/or neutralizing antacids within 24
             hours before the first administration of study drug.

          -  Has taken proton pump inhibitors within 7 days before the first administration of
             study drug.

          -  Has a condition that requires the concomitant use of any of the protocol-excluded
             medications, supplements, or food products during the course of the study .

          -  Has any clinically significant co-morbidities.

          -  Has acute myocardial infarction within 6 months before starting study drug, current or
             history of New York Heart Association Class III or IV heart failure; evidence of
             current uncontrolled cardiovascular conditions including cardiac arrhythmias, angina,
             pulmonary hypertension, or electrocardiogram (ECG) evidence of acute ischemia or
             active conduction system abnormalities; Fridericia's corrected QT interval > 475
             milliseconds (msec) (males) or > 450 msec (females) on a 12-lead ECG during the
             Screening period; or abnormalities on 12-lead ECG including, but not limited to,
             changes in rhythm and intervals that in the opinion of the investigator are considered
             to be clinically significant.

          -  Has known, previously diagnosed human immunodeficiency virus infection or active
             chronic hepatitis B or C.

          -  Has brain metastasis, unless has completed definitive therapy, is not on steroids, has
             a stable neurologic status for at least 2 weeks after completion of the definitive
             therapy and steroids, and does not have neurologic dysfunction that would confound the
             evaluation of neurologic and other adverse events.

          -  Has active secondary malignancy that requires treatment.

          -  Has any serious medical or psychiatric illness, including drug or alcohol abuse.

          -  Male participants who intend to donate sperm during the course of this study or 120
             days after receiving their last dose of TAK-117 and, for docetaxel, for as long as is
             mandated by local labeling.

          -  Female participants who are lactating and breastfeeding or have a positive serum
             pregnancy test during the Screening period or a positive urine pregnancy test on Day 1
             before administration of the first dose of study drug.

          -  Is unwilling or unable to abide by the requirements of the study.
      "
NCT02397928,completed,,1,phase 2,['malignant pleural mesothelioma'],"[""['C45.9', 'C45.0', 'C45.1', 'C45.2', 'C45.7']""]","['pemetrexed', 'cisplatin or carboplatin']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          1. Pathological or histological evidence of mesothelioma

          2. ≥ 18 years of age

          3. Not candidate for curative treatment (surgery or radiotherapy)

          4. At least 4 weeks since major surgery

          5. At least one measurable or evaluable lesion according to modified RECIST Criteria

          6. ECOG Performance Status of 0-1

          7. Life expectancy of at least 3 months

          8. Participants of childbearing age must use effective contraception as indicated by the
             investigator

          9. All subjects must sign written informed consent.

         10. Able to operate the NovoTTF-100L System independently or with the help of a caregiver

        Exclusion Criteria:

          1. Patient candidate for surgery or radiotherapy with curative intent

          2. Previous chemotherapy or radiation

          3. Prior malignancy requiring anti-tumor treatment (apart from in-situ cervical cancer,
             in situ breast cancer, non-melanomatous skin cancers, or any malignancy for which
             treatment was received and there is no evidence of disease for at least 5 years) or
             concurrent malignancy

          4. Significant co-morbidities within 4 weeks prior to enrollment, resulting in the
             following laboratory findings:

               1. Significant liver function impairment:

                    -  AST or ALT > 3 times the upper limit of normal

                    -  Total bilirubin ≥ 1.5 times upper limit of normal

               2. Significant renal impairment (serum creatinine > 1.7 mg/dL)

               3. Coagulopathy (as evidenced by PT or APTT >1.5 times control in subjects not
                  undergoing anticoagulation)

               4. Thrombocytopenia (platelet count < 100 x 10^3/μL)

               5. Neutropenia (absolute neutrophil count < 1.5 x 10^3/μL)

               6. Anemia (Hb < 10 g/dL)

               7. Severe acute infection

          5. Significant comorbidity which is expected to affect patient's prognosis or ability to
             receive the combined therapy:

               1. History of significant cardiovascular disease unless the disease is well
                  controlled.

                  Significant cardiac disease includes second/third degree heart block; significant
                  ischemic heart disease; poorly controlled hypertension; congestive heart failure
                  of the New York Heart Association (NYHA) Class II or worse (slight limitation of
                  physical activity; comfortable at rest, but ordinary activity results in fatigue,
                  palpitation or dyspnea)

               2. History of arrhythmia that is symptomatic or requires treatment. Patients with
                  atrial fibrillation or flutter controlled by medication are not excluded from
                  participation in the trial

               3. Active infection or any serious underlying medical condition that would impair
                  the ability of the patient to receive protocol therapy

               4. History of any psychiatric condition that might impair the patient's ability to
                  understand or comply with the requirements of the study or to provide consent

          6. Untreated brain metastases. Asymptomatic, pretreated brain metastases not requiring
             steroids are allowed

          7. Implanted pacemaker, defibrillator or other electrical medical devices

          8. Known allergies to medical adhesives or hydrogel

          9. Pregnant or breast feeding (all patients of childbearing potential must use effective
             contraception method during the entire period of the study based on the recommendation
             of the investigator or a gynecologist)
      "
NCT02392637,completed,,1,phase 2,"['stage iii intrahepatic cholangiocarcinoma ajcc v7', 'stage iiia gallbladder cancer ajcc v7', 'stage iiib gallbladder cancer ajcc v7', 'stage iva gallbladder cancer ajcc v7', 'stage iva intrahepatic cholangiocarcinoma ajcc v7', 'stage ivb gallbladder cancer ajcc v7', 'stage ivb intrahepatic cholangiocarcinoma ajcc v7', 'unresectable extrahepatic bile duct carcinoma', 'unresectable gallbladder carcinoma']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C23', 'D37.6']"", ""['C23', 'D37.6']"", ""['C23', 'D37.6']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C23', 'D37.6']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['cisplatin', 'gemcitabine hydrochloride', 'nab-paclitaxel']","['Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Patient must have histologically or cytologically confirmed intrahepatic
             cholangiocarcinoma, extrahepatic cholangiocarcinoma, or gallbladder cancer or may
             undergo a repeat biopsy for histologic confirmation if pre-existing biopsy is not
             sufficient for diagnosis

          -  Metastatic or unresectable disease documented on diagnostic imaging studies

          -  May not have received prior chemotherapy; if patient has received prior adjuvant
             therapy, must be > 6 months from treatment

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

          -  Absolute neutrophil count (ANC) >= 1,500 cells/mm^3

          -  Platelets >= 100,000/ul

          -  Hemoglobin > 9.0 g/dL

          -  Total bilirubin =< 1.5 mg/dL (in patients with known Gilbert's syndrome direct
             bilirubin =< 1.5 x upper limit of normal [ULN] will be used as organ function
             criteria, instead of total bilirubin)

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = < 5 x ULN

          -  Creatinine =< 1.5 gm/dL

          -  Negative serum or urine pregnancy test in women with childbearing potential (WOCBP)
             defined as not post-menopausal for 12 months or no previous surgical sterilization,
             within one week prior to initiation of treatment; WOCBP must be using an adequate
             method of contraception to avoid pregnancy throughout the study and for up to 12 weeks
             after the last dose of study drug to minimize the risk of pregnancy

          -  A male subject of fathering potential must use an adequate method of contraception to
             avoid conception throughout the study and for up to 12 weeks after the last dose of
             study drug to minimize the risk of pregnancy; if the partner is pregnant or
             breastfeeding, the subject must use a condom

          -  Patients must sign an informed consent and authorization indicating that they are
             aware of the investigational nature of this study and the known risks involved

        Exclusion Criteria:

          -  Peripheral neuropathy of grade 2 or greater by Common Terminology Criteria for Adverse
             Events (CTCAE) 4.0; in CTCAE version 4.0 grade 2 sensory neuropathy is defined as
             ""moderate symptoms; limiting instrumental activities of daily living (ADLs)""

          -  Concurrent severe and/or uncontrolled medical conditions which could compromise
             participation in the study such as unstable angina, myocardial infarction within 6
             months, unstable symptomatic arrhythmia, uncontrolled diabetes, serious active or
             uncontrolled infection

          -  Pregnancy (positive pregnancy test) or lactation

          -  Known central nervous system (CNS) disease, except for treated brain metastasis;
             treated brain metastases are defined as having no evidence of progression or
             hemorrhage after treatment and no ongoing requirement for dexamethasone, as
             ascertained by clinical examination and brain imaging (magnetic resonance imaging
             [MRI] or computed tomography [CT]) during the screening period; anticonvulsants
             (stable dose) are allowed; treatment for brain metastases may include whole brain
             radiotherapy (WBRT), radiosurgery (RS; Gamma Knife, linear accelerator [LINAC], or
             equivalent) or a combination as deemed appropriate by the treating physician; patients
             with CNS metastases treated by neurosurgical resection or brain biopsy performed
             within 3 months prior to day 1 will be excluded
      "
NCT02399592,completed,,0,phase 2,['ovarian cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['bevacizumab', 'tocotrinol']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Histologically confirmed epithelial, primary fallopian or primary peritoneal cancer.

          -  Prior treatment with at least two different cytostatic regimens including platinum.

          -  Progression on previous treatment.

          -  Measurable disease by RECIST 1.1 or evaluable by GCIG CA-125 criteria.

          -  Age ≥ 18 years.

          -  Performance stage 0-2.

          -  Adequate bone marrow function, liver function, and renal function (within 7 days prior
             to inclusion):

               -  WBC ≥ 3.0 * 10^9/l or neutrophils (ANC) ≥ 1.5 * 109/l

               -  Platelet count ≥ 100 * 10^9/l

               -  Hemoglobin ≥ 6 mmol/l

               -  Serum bilirubin < 2.0 * ULN

               -  Serum transaminase ≤ 2.5 * ULN

               -  Serum creatinine ≤ 1.5 ULN

          -  Urine dipstick for protein <2+. If the dipstick shows protein ≥2+ 24 hour urine
             testing must be made with protein contents < 1 g.

          -  Written informed consent.

        Exclusion Criteria:

          -  Other malignant diseases within 5 years prior to inclusion in the study, except
             curatively treated basal cell or squamous cell carcinoma of the skin and other types
             of cancer with minimal risk of recurrence.

          -  Other experimental therapy or participation in another clinical trial within 28 days
             prior to treatment initiation.

          -  Underlying medical disease not adequately treated (diabetes, cardiac disease).

          -  Uncontrolled hypertension (BT >150/100 despite antihypertensive treatment).

          -  Surgery, incl. open biopsy, within 4 weeks prior to first dose of bevacizumab.

          -  Non-healing wounds or fractures.

          -  Cerebral vascular attack, transient ischemic attack or subarachnoidal hemorhage within
             6 months before start of treatment.

          -  Clinically significant cardiovascular disease, including:

               -  Myocardial infarction or unstable angina within 6 months before start of
                  treatment

               -  New York heart Association (NYHA) class ≥ 2

               -  Poorly controlled cardiac arrhythmia despite medication

               -  Periferal vascular disease grade ≥ 3

          -  Allergy to the active substance or any of the auxiliary agents

          -  Bleeding tumor

          -  Pregnant or breast-feeding patients. For fertile women a negative pregnancy test at
             screening is mandatory.

          -  Fertile patients not willing to use effective methods of contraception during
             treatment and for 6 months after the end of treatment
      "
NCT02392377,terminated,"
    slow accrual
  ",0,phase 2,"['stage ib esophageal adenocarcinoma', 'stage iia esophageal adenocarcinoma', 'stage iib esophageal adenocarcinoma', 'stage iiia esophageal adenocarcinoma', 'stage iiib esophageal adenocarcinoma', 'stage iiic esophageal adenocarcinoma']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['paclitaxel', 'carboplatin', 'oxaliplatin', 'leucovorin calcium', 'fluorouracil']","['Status: 503', 'Status: 503', 'Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed localized (T1N1-3M0 or
             T2-4NanyM0, stage IB-III) Siewert type 1 or type 2 esophageal adenocarcinoma that is
             amenable to surgical resection as determined by a thoracic surgeon and for which all
             disease (primary tumor and involved lymph nodes) can be treated with radiation, as
             determined by a radiation oncologist

          -  Patients may not have received any prior chemotherapy, biologic therapy or radiation
             therapy for management of their disease; chemotherapy or biologic therapy administered
             for treatment of another primary malignancy are permitted if treatment was greater
             than 5 years ago

          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status =<
             2

          -  Patients must have a life expectancy of > 3 months, in the opinion of and as
             documented by the investigator

          -  Hemoglobin >= 10.0 g/dl

          -  Absolute neutrophil count >= 1,500/mcL

          -  Platelet count >= 100,000/mcL

          -  Total bilirubin within normal institutional limits

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =<
             2.5 X institutional upper limit of normal

          -  Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X
             institutional upper limit of normal

          -  Serum creatinine within normal institutional limits OR creatinine clearance >= 60
             mL/min/1.73 m^2 for patients with creatinine levels above institutional normal (as
             calculated by Cockcroft-Gault)

          -  Patients must have an avid primary tumor with an standardized uptake value (SUV) of >=
             5 on baseline (18F) FDG-PET/computed tomography (CT) imaging

          -  Men must agree to use adequate contraception (double barrier method of birth control
             or abstinence) 1 week prior to study entry, for the duration of study participation
             and for 1 month after completing combined modality treatment with chemotherapy and
             radiation; should a male patient's female partner become pregnant or suspect that she
             is pregnant while her partner is participating in this study, the treating physician
             should be informed immediately

          -  Patients must have the ability to understand and the willingness to sign a written
             informed consent document

          -  This study will be limited to enrollment of Caucasian males only

        Exclusion Criteria:

          -  Patients who are receiving any chemotherapy, biologic therapy, radiation therapy or
             any investigational agent

          -  Patients with metastatic disease

          -  Patients with a history of allergic reactions attributed to compounds of similar
             chemical or biologic composition to platinums, taxanes or fluoropyrimidines

          -  Patients who have previously received radiation therapy to the chest or abdomen such
             that there would be overlap between the previous and current radiation field

          -  Patients with uncontrolled intercurrent illness including, but not limited to ongoing
             or active infection, symptomatic congestive heart failure, unstable angina pectoris,
             cardiac arrhythmia, or psychiatric illness/social situations that would limit
             compliance with study requirements

          -  Patients with human immunodeficiency virus (HIV) whom are not receiving antiretroviral
             therapy

          -  Patients with another malignancy within the past 5 years
      "
NCT02399215,completed,,1,phase 2,"['carcinoid tumor', 'metastatic carcinoid tumor', 'neuroendocrine neoplasm']","[""['C7A.00', 'C7A.010', 'C7A.011', 'C7A.012', 'C7A.020', 'C7A.021', 'C7A.026']"", ""['C7A.00', 'C7A.010', 'C7A.011', 'C7A.012', 'C7A.020', 'C7A.021', 'C7A.026']"", ""['C7A.1', 'C7A.8', 'C7B.8', 'D3A.8']""]",['nintedanib'],['Status: 503'],"
        Inclusion Criteria:

          -  Patient must be on a stable dose of octreotide (Sandostatin®) long-acting release
             (LAR) or lanreotide for 3 months prior to study enrollment

          -  Patient must have histologically or cytologically confirmed well differentiated or
             moderately differentiated (low grade or intermediate grade) neuroendocrine tumor that
             is locally advanced or metastatic and not of pancreatic origin

          -  Measurable disease determined by computed tomography (CT) or magnetic resonance
             imaging (MRI)

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          -  Life expectancy greater than 3 months

          -  Leukocytes >= 3,000/uL

          -  Absolute neutrophil count >= 1,500/uL

          -  Total bilirubin =< 2 mg/dL

          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 x upper limit
             of normal (ULN) and bilirubin =< ULN for patients without liver metastases

          -  AST/ALT =< 2.5 x ULN and bilirubin =< ULN for patients with liver metastases

          -  Patients with Gilbert syndrome and bilirubin < 2 x ULN and normal AST/ALT

          -  Creatinine =< 1.5 mg/dl

          -  Prior treatment will be permitted including surgery (>= 4 weeks), cytotoxic
             chemotherapy (maximum of 2 prior regimens); radiation, interferon, targeted growth
             factors (>= 4 weeks); and prior treatment with octreotide, will be allowed

          -  Ability to swallow and retain oral medication

          -  Participants of child-bearing potential (both male and female) must agree to use
             adequate contraceptive methods (e.g., hormonal or barrier method of birth control;
             abstinence) prior to study entry; should a woman become pregnant or suspect she is
             pregnant while she or her partner is participating in this study, she should inform
             her treating physician immediately

          -  Participant or legal representative must understand the investigational nature of this
             study and sign an Independent Ethics Committee/Institutional Review Board approved
             written informed consent form prior to receiving any study related procedure

          -  Archival tissue of carcinoid biopsy must be available

        Exclusion Criteria:

          -  Uncontrolled hypertension, unstable angina, New York Heart Association grade II or
             greater congestive heart failure, unstable symptomatic arrhythmia requiring
             medication, or clinically significant peripheral vascular disease (grade II or
             greater)

          -  Presence of brain metastases

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to day 0, or anticipated need for major surgical procedure during the course of
             the study, or fine needle aspirations or core biopsies within 7 days prior to day 0

          -  Significant proteinuria at baseline (>= 500 mg/24 hours [h])

          -  Serious non-healing wound, ulcer or bone fracture

          -  Evidence of bleeding diathesis or coagulopathy

          -  Recent (=< 6 months) arterial thromboembolic events, including transient ischemic
             attack, cerebrovascular accident, unstable angina, or myocardial infarction

          -  Poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma,
             adenocarcinoid, goblet cell carcinoma, or small cell carcinoma

          -  Hepatic artery embolization or ablation of hepatic metastasis within 3 months of
             enrollment, prior peptide receptor radionuclide therapy (PRRT) within 4 months or any
             other cancer therapy within 4 weeks (as long as all toxicities are resolved)

          -  Intolerance or hypersensitivity to octreotide

          -  Severe or uncontrolled medical conditions

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Pregnant or nursing female participants

          -  Unwilling or unable to follow protocol requirements

          -  Any condition which in the investigator's opinion deems the participant an unsuitable
             candidate to receive study drug
      "
NCT02393755,completed,,1,phase 1/phase 2,"['colon adenocarcinoma', 'rectal adenocarcinoma', 'recurrent colon carcinoma', 'recurrent rectal carcinoma', 'stage iva colon cancer', 'stage iva rectal cancer', 'stage ivb colon cancer', 'stage ivb rectal cancer']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C18.2', 'C18.4', 'C18.6', 'C18.7', 'C18.9', 'D12.2', 'D12.3']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['C18.2', 'C18.4', 'C18.6', 'C18.7', 'C18.9', 'D12.2', 'D12.3']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['capecitabine', 'nintedanib']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

          -  Hemoglobin >= 9 g/dL

          -  Absolute neutrophil count >= 1500/mm^3

          -  Platelet count >= 100,000/mm^3

          -  Creatinine =< 1.5 upper limit of normal (ULN) AND creatinine clearance (CrCl) > 50
             mL/min by Cockcroft-Gault equation

          -  Males = (140 -age (yrs) (body weight (kg)/(72) (serum creatinine) (mg/dL)

          -  Females = 0.85 * (140-age (yrs) (body weight (kg)/(72)(serum creatinine (mg/dL)

          -  Bilirubin < ULN

          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 ULN if without
             liver metastases

          -  AST/ALT =< 2.5 x ULN if with liver metastases

          -  Coagulation parameters: international normalized ratio (INR) =< 2, prothrombin time
             (PT) and partial thromboplastin time (PTT) < 1.5 X institutional ULN

          -  Have measurable disease per RECIST 1.1 criteria

          -  Histologically or cytologically proven adenocarcinoma of the colon or rectum

          -  Prior progression following a fluoropyrimidine-based therapy and progression following
             or intolerance to irinotecan and oxaliplatin, as well as anti-epidermal growth factor
             receptor (EGFR) therapy (e.g., panitumumab or cetuximab) for rat sarcoma viral
             oncogene homolog (RAS) wild-type patients

          -  Ability to swallow and retain oral medication

          -  Participants of child-bearing potential must agree to use adequate contraceptive
             methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study
             entry and for three months following completion of therapy; should a woman become
             pregnant or suspect she is pregnant while she or her partner is participating in this
             study, she should inform her treating physician immediately

          -  Participant or legal representative must understand the investigational nature of this
             study and sign an Independent Ethics Committee/Institutional Review Board approved
             written informed consent form prior to receiving any study related procedure

        Exclusion Criteria:

          -  Prior treatment with nintedanib

          -  Prior treatment with regorafenib

          -  Major injuries or surgery within the 4 weeks prior to initiation of therapy with
             incomplete wound healing or planned surgery during the on-study treatment period

          -  Uncontrolled hypertension: systolic blood pressure >= 160, diastolic blood pressure >=
             90

          -  Urine protein/creatinine ratio >= 1.0

          -  History of clinically significant hemorrhagic or thrombotic event within the past 6
             months, not including uncomplicated catheter-associated venous thrombosis; patients on
             anti-coagulation are not permitted to be on any oral formulations (warfarin,
             rivaroxaban, dabigatran, etc.) due to concern for drug-drug interaction

          -  Unstable angina, symptomatic congestive heart failure or cardiac arrhythmia requiring
             anti-arrhythmic therapy (beta-blockers, calcium channel blockers and digoxin are
             allowed)

          -  History of cerebrovascular or myocardial ischemia within 6 months of initiation

          -  Known inherited predisposition to bleeding or thrombosis

          -  Known active or chronic hepatitis B or C or human immunodeficiency virus (HIV)

          -  Untreated brain metastases

          -  History of second primary malignancy diagnosed within 3 years prior to enrollment,
             excluding:

               -  In-situ cervical carcinoma

               -  Superficial bladder cancer

               -  Non-melanoma skin cancer

               -  Stage I breast cancer

               -  Low grade (Gleason =< 6) localized prostate cancer

               -  Any additional malignancy which has been in clinical remission for at least 1
                  year

          -  Pregnant or nursing female participants

          -  Unwilling or unable to follow protocol requirements

          -  Any condition which in the Investigator's opinion deems the participant an unsuitable
             candidate to receive study drug

          -  Received an investigational agent within 4 weeks prior to enrollment

          -  PHASE I: History of intolerance to capecitabine at doses =< 1000 mg/m^2 BID, as
             defined by documented >= grade 3 hand-foot syndrome, documented severe diarrhea
             requiring hospitalization, or other documented severe adverse events (AEs)
             attributable to capecitabine

          -  PHASE II: History of intolerance to capecitabine at doses below 1000 mg/m^2 BID, as
             defined by documented >= grade 3 hand-foot syndrome; documented severe diarrhea
             requiring hospitalization; or other documented severe AEs attributable to capecitabine
      "
NCT04002115,terminated,"
    terminated due to low accrual
  ",0,phase 2,['acute myeloid leukemia'],"[""['C92.A1', 'C92.A2', 'C92.61', 'C92.62', 'C92.A0', 'C92.60']""]","['clofarabine', 'fludarabine', 'busulfan', 'cyclophosphamide', 'granulocyte colony-stimulating factor', 'tacrolimus', 'cellcept']","['Status: 503', 'Status: 503', 'Status: 503', 'Status: 503', 'Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          1. Diagnostic criteria of AML, induction failure without having achieved remission after
             at least 2 attempts at induction chemotherapy, or relapsed after any complete
             remission (CR).

          2. 18 to 75 years of age.

          3. Planned or scheduled to receive an allogeneic HSCT from haploidentical related donors,
             matched and mismatched unrelated donors.

          4. All organ function testing should be done within 28 days of study registration.

               -  Performance status: Karnofsky ≥ 70% (Appendix A).

               -  Cardiac: LVEF ≥ 50% by MUGA or echocardiogram.

               -  Pulmonary: FEV1 and FVC ≥ 50% predicted, DLCO (corrected for hemoglobin) ≥ 50% of
                  predicted.

               -  Renal: Creatinine clearance (CrCl) ≥ 60 mL/min/1.73 m2

               -  Hepatic: Serum bilirubin ≤1.5 x upper limit of normal (ULN); (AST)/(ALT) ≤ 2.5 x
                  ULN; Alkaline phosphatase ≤ 2.5 x ULN.

          5. Both men and women need to use an approved method of birth control and/or abstinence
             due to unknown risks to the fetus.

        Exclusion Criteria:

          1. Acute promyelocytic leukemia (APL)

          2. Known history of non-compliance with medication regimens, scheduled clinic visits, or
             self-care.

          3. In the opinion of the investigator, no appropriate caregivers identified.

          4. HIV1 (Human Immunodeficiency Virus-1) or HIV2 positive

          5. Active Hepatitis B and Hepatitis C orepatitis positive serology including HBsAg,
             hepatitis B core antibody, and hepatitis C antibody. Hepatitis B surface antibody
             positive due to vaccination or natural immunity are permitted.

          6. In the opinion of the physician investigator, uncontrolled medical or psychiatric
             disorders.

          7. Uncontrolled infections requiring treatment within 14 days of registration.

          8. Active central nervous system (CNS) leukemia.

          9. Cord blood transplant excluded.

         10. Prior allogeneic HSCT within last 6 months.

         11. Patients with >= grade 2 acute GVHD.

         12. Patients with >=moderate chronic GVHD.

         13. Pregnant or Breastfeeding. Women of child bearing potential (WCBP) are required to
             have a negative serum or urine pregnancy test prior to initiation of conditioning
             regimen.

         14. Haploidentical related donors who are positive for DSA ≥ 5000 MFI by solid phase
             microarray method (Luminex).

         15. Any patient with steroid dose more than 10 mg/day within a week of registration .

         16. Autoimmune disorder requiring any active immunosuppression therapy.
      "
NCT04007588,withdrawn,"
    slow accrual
  ",0,phase 2,"['melanoma stage iii', 'melanoma stage iv']","[""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']"", ""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']""]","['nivolumab', 'bms-986205', 'ipilimumab']","['Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Histologic or cytologic diagnosis of resectable stage III or IV cutaneous melanoma.
             Patients with melanoma of mucosal origin are not eligible. Patients with acral
             melanoma that fit criteria are eligible. Patients must have clinically detectable
             stage III (clinically detectable N1b, N1c, N2b, N2c, N3b or N3c) or stage IV
             resectable melanoma.

          -  Age ≥ 18 years.

          -  ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)

          -  Participants must have normal organ and marrow function as defined below:

               -  leukocytes ≥2,000/mcL

               -  absolute neutrophil count ≥1,500/mcL

               -  platelets ≥100,000/mcL

               -  hemoglobin ≥9.0g/dL

               -  total bilirubin within normal institutional limits

               -  AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal

               -  creatinine within normal institutional limits OR

               -  creatinine clearance ≥40 mL/min/1.73 m2 for participants with creatinine levels
                  above institutional normal.

               -  C-Reactive Protein < institutional ULN

          -  Quantitative or qualitative G6PD assay results must not suggest underlying G6PD
             deficiency

          -  Measurable disease (by CT, PET/CT or MRI)

          -  Prior therapies including targeted therapy and immunotherapy are not allowed, with the
             exception of adjuvant Ipilimumab or Interferon-α-2b.

          -  Ability to understand and the willingness to sign a written informed consent document.

          -  Ability to swallow pills intact and without GI issues which may impact medication
             absorption.

          -  Women of childbearing potential (WOCBP) must agree to follow instructions for
             method(s) of contraception (Refer to Appendix B) for the duration of treatment with
             study treatment(s) plus 5 months post-treatment completion (i.e. 30 days plus the time
             required for nivolumab to undergo approximately 5 half-lives).

          -  Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy
             test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to
             the start of study treatment.

          -  Males who are sexually active with WOCBP must agree to follow instructions for
             method(s) of contraception for the duration of treatment with study treatment(s) plus
             7 months post-treatment completion (i.e. 90 days plus the time required for nivolumab
             to undergo approximately 5 half-lives). In addition, male participants must be willing
             to refrain from sperm donation during this time. This criterion applies to azoospermic
             males as well.

        Exclusion Criteria:

          -  A history of prior treatment with PD-1 inhibitor, CTLA-4 inhibitor or IDO inhibition.
             Prior therapy with ipilimumab or Interferon-α-2b in the adjuvant setting is permitted.
             Participants may not have received live/attenuated vaccines within 30 days of first
             treatment.

          -  Participants with uveal or mucosal melanoma

          -  Participants with known brain metastases must have documented stability for at least
             30 days directly prior to study enrollment and not be requiring active treatment for
             these. Prior radiation, surgery and stereotactic radiosurgery are allowed but must be
             completed four weeks prior to initiating therapy.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to nivolumab, ipilimumab, methylene blue or BMS-986205. History or
             presence of hypersensitivity or idiosyncratic reaction to methylene blue.

          -  Need for systemic steroids at the time of enrollment. Physiologic replacements at a
             dose of less than 10 mg daily prednisone equivalent is allowed.

          -  Blood Methemoglobin > ULN, assessed in an arterial or venous blood sample or by
             co-oximetry

          -  Participants with active ILD/pneumonitis or history of ILD/ pneumonitis requiring
             steroids.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Pregnant women are excluded from this study because there is an unknown but potential
             risk for adverse events in nursing infants secondary to treatment of the mother with
             nivolumab or BMS-986205, breastfeeding should be discontinued if the mother is treated
             with nivolumab or BMS-986205. These potential risks may also apply to other agents
             used in this study.

          -  Known active HIV, Hepatitis B or Hepatitis C patients. HIV-positive participants on
             combination antiretroviral therapy are ineligible because of the potential for an
             immunologic effect with the therapy. Appropriate studies will be undertaken in
             participants receiving combination antiretroviral therapy when indicated.

          -  Autoimmune disease that requires treatment at the time of enrollment. Participants
             with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin
             disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment
             or conditions not expected to recur in the absence of an external trigger are
             permitted to enroll.

          -  Participant with a personal or family (ie, in a first-degree relative) history of
             cytochrome b5 reductase deficiency (previously called methemoglobin reductase
             deficiency) or other diseases that put them at risk of methemoglobinemia. All
             participants will be screened for methemoglobin levels prior to randomization.

          -  Participant with a history of G6PD deficiency or other congenital or autoimmune
             hemolytic disorders. All participants will be screened for G6PD levels prior to
             randomization.

          -  Participants must not have a history of life-threatening toxicity related to prior
             immune therapy (eg. anti-CTLA-4 or any other antibody or drug specifically targeting
             T-cell co-stimulation or immune checkpoint pathways) except those that are unlikely to
             re-occur with standard countermeasures (eg. hormone replacement after adrenal crisis).

          -  Treatment with botanical preparations (eg, herbal supplements or traditional Chinese
             medicines) intended for general health support or to treat the disease under study
             within 2 weeks prior to randomization.

          -  History of other malignancy within 3 years prior to screening, with the exception of
             those with a negligible risk of metastasis or death (e.g., 5-year OS of > 90%), such
             as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma,
             localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer.

          -  Participants who have had major surgery requiring general anesthesia or significant
             trauma who have not recovered per physician determination for at least 14 days prior
             to randomization.

          -  Participants with conditions known to interfere significantly with the absorption of
             oral medication, as per investigator judgment.

          -  Participants with uncontrolled adrenal insufficiency.

          -  Prior history of serotonin syndrome.
      "
NCT03063671,completed,,1,phase 2/phase 3,['acute pain'],"[""['G89.12', 'G89.18', 'G89.11', 'G89.3']""]","['ketamine, bupivacine,dexmedetomidine']",['Status: 503'],"
        Inclusion Criteria:

          -  Patients scheduled for modified radical mastectomy.

          -  ASA Physical status I, II and III.

        Exclusion Criteria:

          -  Patients' refusal.

          -  Uncooperative patients & severe psychiatric illness (cannot evaluate their own pain
             intensity using visual analogue scale (VAS).

          -  Patients with history of drug allergy.

          -  severe renal or liver impairment, unstable ischemic heart disease

          -  Any contraindications to epidural analgesia (coagulopathy, recent -less than 1
             week-treatment with thrombolytic or potent antiplatelet drugs as clopidogrel, and
             local infection).
      "
NCT03066947,completed,,1,phase 1/phase 2,"['breastcancer', 'breast neoplasm']","[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]",['cyclophosphamide'],['Status: 503'],"
        Inclusion Criteria:

          -  1. Have histological confirmation of breast cancer with recurrent and/or metastatic
             lesions via investigational site.

               -  Patients with new or progressive breast cancer metastatic to brain will be
                  eligible provided:

                    1. There is no need for steroids and patients have not had steroids at least 2
                       weeks

                    2. No individual tumor size is >50 mm3

                    3. ECOG status <3

                    4. Tumor is not impinging on Middle Cerebral Artery/speech-motor strip

                    5. If surgically debulked, must be healed from surgery and at least 3 weeks
                       have elapsed since general anesthesia

                    6. Patients consent to MRI studies at 3-4 week intervals until evidence of
                       tumor regression on at least 2 imaging studies. In no case, will the
                       interval between MRI studies be longer than 3 months. MRI study may be
                       introduced at any time should the patients develop new or clearly worsening
                       symptoms and/or introduction of steroids

                       2. Have evidence of persistent, recurrent, or progressive disease for which
                       there is no known or established treatment available with curative intent,
                       after failing at least one course of community standard systemic treatment
                       with chemotherapy (and endocrine therapy if appropriate)

                       3. Be 18 years of age or older and female

                       4. Have expected survival of at least 4 months

                       5. Have adequate performance status (ECOG 0-2)

                       6. Patients may be maintained on hormonal therapy provided there is clear
                       evidence of tumor progression

                       7. Have provided written informed consent.

                       Exclusion Criteria:

               1. Concurrent or recent chemotherapy (within 3 weeks), XRT within 3 weeks, may have
                  had immunotherapy in the past (off within 3 weeks), or general anesthesia/major
                  surgery (within 3 weeks). Patients must have recovered from all known or expected
                  toxicities from previous treatment and passed a treatment-free ""washout"" period
                  of 3 weeks before starting this program (8 weeks for persons receiving
                  nitrosourea or mitomycin).

               2. History of clinical hypersensitivity to GM-CSF, Interferon-alpha-2b (Merck),
                  yeast, beef, or to any components used in the preparation of the experimental
                  vaccine.

               3. BUN >30 and a creatinine >2.

               4. Absolute granulocyte count < 1000; platelets <100,000.

               5. Bilirubin >2.0; alkaline phosphatase >5x upper limit of normal (ULN); ALT/AST >2x
                  ULN.

               6. Proteinuria >1+ on urinalysis or >1 gm/24hr.

               7. Left ventricular ejection fraction (LVEF as determined by cardiac echo or MUGA
                  scan) below the normal limits of the institutions specific testing range. This
                  assessment may be repeated once at the discretion of the Investigator with the
                  approval of the Sponsor.

               8. New York Heart Association stage 3 or 4 cardiac disease.

               9. A pleural effusion of moderate severity or worse.

              10. Any woman of childbearing potential, unless she:

                    1. Agrees to take measures to avoid becoming pregnant during the study and

                    2. Has a negative serum pregnancy test within 7 days prior to starting
                       treatment.

              11. Women who are pregnant or nursing.

              12. Patients with concurrent second malignancy. Persons with previous malignancies
                  effectively treated and not requiring treatment for >24 months are eligible,
                  provided there is unambiguous documentation that current local recurrence or
                  metastatic site represents recurrence of the primary breast malignancy.

              13. Patients who are HIV positive (by self-report) or have clinical or laboratory
                  features indicative of AIDS.

              14. 14. Patients who require systemic steroids at a dose equivalent of >10 mg/day of
                  prednisone. Beta-blocker therapy, while not exclusionary, is discouraged and
                  alternatives should be sought if possible. The beta-blocker might compromise use
                  of epinephrine for the rare possibility of anaphylaxis. Anticoagulants must be
                  approved by the Investigator with notification of the Sponsor.

              15. Patients who are on treatment for rheumatological or autoimmune disease unless
                  approved by the Investigator in consultation with the Sponsor (e.g., as for
                  replacement therapy for autoimmune thyroiditis or diabetes).

              16. Patients with severe psychiatric (i.e. schizophrenia, bipolar, or borderline
                  personality disorder) or other clinically progressive major medical problems,
                  unless approved by the PI.

              17. Male breast cancer patients.

              18. Patients may not be on a concurrent clinical trial, unless approved by PI.
      "
NCT03069950,withdrawn,"
    lack of accrual
  ",0,phase 2,['colorectal adenocarcinoma metastatic to the liver'],"[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['floxuridine (fudr)', 'irinotecan (cpt-11)', 'fluorouracil', 'panitumumab', 'dexamethasone', 'leucovorin']","['Status: 503', 'Status: 503', 'Status: 503', 'Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  History of histologically confirmed colorectal adenocarcinoma metastatic to the liver
             with no clinical or radiographic evidence of extrahepatic disease. Confirmation of
             diagnosis must be performed by the enrolling institution.

          -  Patients must have a primary L sided colorectal cancer, (at or distal to the splenic
             flexure)

          -  Confirmed RAS/RAF wild type tumor. Paraffin-embedded tumor tissue obtained from the
             primary tumor or metastasis

          -  Have received prior treatment for metastatic disease with oxaliplatin-based regimen
             and either

               -  Had disease progression OR

               -  Had stable disease OR

               -  Discontinued oxaliplatin due to neuropathy

          -  Patients must meet the following criteria for unresectability as determined by two
             hepatobiliary surgeons and one radiologist:

               -  When a margin negative resection would require resection of all three hepatic
                  veins, both portal veins, or the retrohepatic vena cava.

               -  Requiring a resection that leaves less than 2 hepatic segments (not including the
                  caudate lobe) behind with adequate arterial/portal inflow, venous outflow and
                  biliary drainage. **

                  **A patient is considered resectable if the procedure includes a minor wedge or
                  thermo-ablation encompassing 10% or less of the volume of the remaining 2
                  segments.

               -  Patient""s liver metastases must comprise <70% of the liver parenchyma. All
                  patients must be clinically fit to undergo surgery as determined by the
                  pre-operative evaluation

          -  Lab values within 14 days prior to enrollment/randomization:

               -  WBC ≥ 3.0 K/uL

               -  ANC > 1.5 K/uL

               -  Platelets ≥ 100,000/uL

          -  Renal function (≤ 10 days prior to enrollment/randomization) °Creatinine ≤ 1.5 mg/dL
             or creatinine clearance ≥ 50 mL/min calculated by the Cockcroft-Gault method as
             follows:

        Cockcroft-Gault method as follows:

          -  Male creatinine clearance = (140 -age in years) x (weight in Kg) / (serum Cr in mg/dl
             x 72)

          -  Female creatinine clearance = (140 - age in years) x (weight in Kg) x 0.85 / (serum Cr
             in mg/dl x 72) (use of creatinine clearance per protocol based on chemotherapy
             regimen)

               -  Hepatic function, as follows: (≤ 10 days prior to enrollment/randomization)

          -  Total Bilirubin ≤ 1.5 mg/dl

               -  Calcium ≥ lower limit of normal (≤ 48 hours prior to enrollment/randomization)

               -  KPS ≥ 60% (ECOG (or Karnofsky) performance status (preferably 0 or 1/≥ 60% for
                  Karnofsky))

        Exclusion Criteria:

          -  Patients < 18 years of age

          -  Patients who have received more than one chemotherapy regimen for metastatic disease

          -  Patients who are chemotherapy naïve

          -  Prior radiation to the liver (Prior radiation therapy to the pelvis is acceptable if
             completed at least 4 weeks prior to registration)

          -  Active infection

             °Active infection includes patients with positive blood cultures

          -  Prior treatment with HAI FUDR

          -  Prior TACE

          -  Female patients who are pregnant or lactating - or planning to become pregnant within
             6 months after the end of the treatment (female patients of child-bearing potential
             must have negative pregnancy test ≤ 72 hours before enrollment and randomization, and
             must have a negative pregnancy test ≤ 72 hours prior to treatment start)

          -  If a patient has any serious medical problems which may preclude receiving this type
             of treatment

          -  Patients with history or known presence of primary CNS tumors, seizures not
             well-controlled with standard medical therapy, or history of stroke will also be
             excluded.

          -  Serious or non-healing active wound, ulcer, or bone fracture

          -  History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or
             evidence of interstitial lung disease on baseline chest CT scan

          -  Patients who have a diagnosis of Gilbert""s disease

          -  History of other malignancy, except:

               1. Malignancy treated with curative intent and with no known active disease present
                  for ≥ 3 years prior to randomization and felt to be at low risk for recurrence by
                  the treating physician

               2. Adequately treated non-melanomatous skin cancer or lentigo maligna without
                  evidence of disease

               3. Adequately treated cervical carcinoma in situ without evidence of disease
      "
NCT03061708,terminated,"
    lack of efficacy
  ",0,phase 2,['stomach neoplasms'],"[""['D13.1', 'C16.9', 'C16.1', 'C16.2', 'D37.1', 'C16.8', 'C16.5']""]",['azd2014'],['Status: 503'],"
        Inclusion Criteria:

          1. Provision of fully informed consent prior to any study specific procedures.

          2. Patients must be ≥20 years of age.

          3. Advanced gastric adenocarcinoma (including GEJ) that has progressed during or after
             firstline therapy.

          4. Previous adjuvant/neoadjuvant chemotherapy is allowed, if completed more than 6 months
             prior to starting the 1st line therapy.

          5. Provision of tumor sample (from either a resection or biopsy)

          6. Patients with RICTOR amplification or overexpression through the VIKTORY trial.

          7. Patients are willing and able to comply with the protocol for the duration of the
             study including undergoing treatment and scheduled visits and examinations.

          8. ECOG performance status 0-2.

          9. Patients must have a life expectancy ≥ 3 months from proposed first dose date.

         10. Patients must have acceptable bone marrow, liver and renal function -

         11. At least one measurable lesion that can be accurately assessed by imaging or physical
             examination at baseline and following up visits.

         12. Negative urine or serum pregnancy test within 28 days of study treatment, confirmed
             prior to treatment on day 1.

        Exclusion Criteria:

          1. More than one prior chemotherapy regimen for the treatment of gastric cancer in the
             advanced setting.

          2. Any previous treatment with PIK3CA, AKT or mTOR inhibitor or agents with mixed PI3K /
             mTOR activity.

          3. Patients with second primary cancer,

          4. Patients unable to swallow orally administered medication.

          5. Previous major surgery within 4weeks prior to enrollment.

          6. For AZD2014: Exposure to potent or moderate inhibitors or inducers of CYP3A4/5 if
             taken within the stated washout periods before the first dose of study treatment
             Inhibitors

          7. Exposure to potent or moderate inhibitors or inducers of CYP2C8 if taken within the
             stated washout periods before the first dose of study treatment

          8. With the exception of alopecia, any ongoing toxicities (>CTCAE grade 1) caused by
             previous cancer therapy.

          9. Intestinal obstruction or CTCAE grade 3 or grade 4 upper GI bleeding within 4 weeks
             before the enrollment.

         10. Resting ECG with measurable QTcB > 450 msec on 2 or more time points within a 24 hour
             period or family history of long QT syndrome.

         11. Patients with cardiac problem

         12. Active or untreated brain metastases or spinal cord compression Patients with treated
             brain metastases or spinal cord compression are eligible if they have minimal
             neurologic symptoms, evidence of stable disease (for at least 1 month) or response on
             follow-up scan, and require no corticosteroid therapy for ≥ 1 week.

         13. Female patients who are breast-feeding or child-bearing

         14. Any evidence of severe or uncontrolled systemic disease, active infection, active
             bleeding diatheses or renal transplant, including any patient known to have hepatitis
             B, hepatitis C or human immunodeficiency virus (HIV)

         15. Patients with proteinuria (3+ on dipstick analysis )
      "
NCT03061721,completed,,1,phase 2,"['non-alcoholic fatty liver disease', 'nonalcoholic steatohepatitis']","[""['Z52.6', 'K71.8', 'K71.7', 'A06.4', 'C22.0', 'C22.3', 'K70.0']"", ""['K75.81']""]","['saroglitazar magnesium 1 mg', 'saroglitazar magnesium 2 mg', 'saroglitazar magnesium 4 mg', 'placebos']","['Status: 503', 'Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          1. Males or females, 18 to 75 years of age, with body mass index (BMI) ≥ 25 kg/m2.

          2. Documented diagnosis of NAFLD established either by imaging (ultrasound, CT scan or
             MRI) or liver biopsy showing NASH or simple steatosis, within the 24 months preceding
             Visit 1. The diagnosis of NAFLD is made according to the American Association for the
             Study of Liver Diseases (AASLD) criteria (Chalasani et al. Hepatology 2012;
             55:2005-2023).

          3. ALT level of ≥50 U/L at Visit 1 and Visit 2 with ≤30% variance between the levels at
             Visit 1 and Visit 2.

          4. Patient's demonstration of understanding of study requirements and treatment
             procedures, willingness to comply with all protocol-required evaluations; provision of
             written informed consent before any study specific tests or procedures are performed.

        Exclusion Criteria:

          1. Consumption of > 3 units of alcohol per day (> 21 units per week) if male and > 2
             units of alcohol per day (>14 units per week) if female for at least 3 consecutive
             months in the 5 years preceding Visit 1 (Note: 1 unit = 12 ounces of beer, 4 ounces of
             wine or 1 ounce of spirits/hard liquor).

          2. Presence of alternative causes of fatty liver, including:

               1. Weight change >5% within the 3 months preceding Visit 1

               2. Total parenteral nutrition, starvation or protein-calorie malnutrition within the
                  90 days preceding Visit 1.

               3. Use of drugs associated with NAFLD for more than 12 consecutive weeks in the 1
                  year before Visit 1, including amiodarone, tamoxifen, methotrexate, systemic
                  glucocorticoids, anabolic steroids, tetracycline, estrogens in doses higher than
                  used in oral contraceptives, vitamin A, L asparaginase, valproate, chloroquine or
                  antiretroviral drugs

          3. Initiation of vitamin E at doses > 100 IU/day, or multivitamins containing > 100
             IU/day of vitamin E in the 3 months preceding Visit 1.

          4. Use of drugs with potential effect on NASH such as ursodeoxycholic acid,
             S-adenosylmethionine (SAM-e), betaine, pentoxifylline, obeticholic acid or milk
             thistle in the 3 months prior to Visit 1.

          5. Changing doses of statins (simvastatin, pitavastatin, pravastatin, atorvastatin,
             fluvastatin, lovastatin, rosuvastatin) or fibrates (clofibrate, fenofibrate) in the 3
             months preceding Visit 1.

          6. Use of thiazolidinediones (pioglitazone, rosiglitazone).

          7. Use of drugs that are known CYP2C8 inhibitors/substrate

          8. History of bowel surgery (gastrointestinal (bariatric) surgery or undergoing
             evaluation for bariatric surgery for obesity, extensive small-bowel resection or
             orthotopic liver transplant (OLT) or listed for OLT.

          9. History of other chronic liver disease (chronic hepatitis C, (HCV) infection,
             irrespective of their mRNA HCV assay status or active hepatitis B infection, (i.e.,
             serum positive for hepatitis B surface antigen) or autoimmune hepatitis, cholestatic
             and metabolic liver diseases) or hemochromatosis

         10. Patient has known cirrhosis, either based on clinical criteria or liver histology.

         11. Patient with INR >1.3.

         12. Type 1 diabetes mellitus.

         13. Poorly controlled type 2 diabetes mellitus, i.e., glycosylated hemoglobin (HbA1c) >
             9%.

         14. Unstable cardiovascular disease, including:

               1. unstable angina, (i.e., new or worsening symptoms of coronary heart disease
                  within the 3 months preceding Visit 1), acute coronary syndrome within the 6
                  months preceding Visit 1, acute myocardial infarction within the 3 months
                  preceding Visit 1 or heart failure of New York Heart Association class (III - IV)
                  or worsening congestive heart failure, or coronary artery intervention, within
                  the 6 months preceding Visit 1

               2. history of (within 3 months preceding Visit 1) or current unstable cardiac
                  dysrhythmias

               3. uncontrolled hypertension (systolic blood pressure [BP] > 160 mmHg and/or
                  diastolic BP > 100 mmHg)

               4. stroke or transient ischemic attack within the 6 months preceding Visit 1.

         15. History of myopathies or evidence of active muscle disease.

         16. History of malignancy in the 5 years preceding Visit 1 and/or active neoplasm with the
             exception of resolved superficial nonmelanoma skin cancer.

         17. Any of the following laboratory values:

               1. Hemoglobin < 9 g/dL

               2. White blood cell count < 2.5 × 103/μL

               3. Neutrophil count < 1.5 × 103/μL

               4. Platelets < 100 × 103/μL

               5. Total Serum bilirubin > 1.5 mg/dL (except in patient with known Gilbert bilirubin
                  where TB up to 2.5 mg/dL is allowed), if it is <1.5 mg/dL at screening and >30%
                  variance in the levels at Visit 1 and Visit 2

               6. Albumin < 3.2 g/dL

               7. Serum creatinine >1.5 mg/dL

               8. Serum ALT or AST > 250 IU/L at Visit 1 or Visit 2 .

         18. Contraindications to Saroglitazar Magnesium or has any conditions affecting the
             ability to evaluate the effects of Saroglitazar Magnesium.

         19. Known allergy, sensitivity or intolerance to the study drug, placebo or formulation
             ingredients.

         20. Participation in any other therapeutic clinical study within the 3 months preceding
             Visit 1, including participation in any other NAFLD/NASH clinical trials.

         21. History of bladder disease and/or hematuria or has current hematuria except due to a
             urinary tract infection.

         22. Illicit substance abuse within the 12 months preceding Visit 1.

         23. Pregnancy-related exclusions, including:

               1. Pregnant/lactating female (including a positive serum pregnancy test at Visit 1)

               2. A male patient has to use a condom with spermicide, and the female partner of the
                  male patient has to use an intrauterine device OR a diaphragm with spermicide OR
                  oral contraceptive pills.

               3. If a male patient has undergone a vasectomy, the female partner does not have to
                  use any contraception.

               4. A female patient has to use either an intrauterine device OR a diaphragm with
                  spermicide OR oral contraceptive pills. The male partner of the female patient
                  has to use a condom with spermicide.

               5. If the female patient is surgically sterilized for at least the 6 months
                  preceding Visit 1 or postmenopausal, defined as at least 12 months with no menses
                  and without an alternative cause, the male partner of the female patient does not
                  have to use any contraception.

         24. History or other evidence of severe illness or any other conditions that would make
             the patient, in the opinion of the investigator, unsuitable for the study (such as
             poorly controlled psychiatric disease, HIV, coronary artery disease or active
             gastrointestinal conditions that might interfere with drug absorption).
      "
NCT02302846,terminated,"
    slow accrual
  ",0,phase 2,['leukemia'],"[""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']""]",['ixazomib'],['Status: 503'],"
        Inclusion Criteria:

          1. Male or female patients 18 years of age or older.

          2. Voluntary written consent must be given before performance of any study related
             procedure not part of standard medical care, with the understanding that consent may
             be withdrawn by the patient at any time without prejudice to future medical care.

          3. Female patients who: Are postmenopausal for at least 1 year, OR Are surgically
             sterile, OR If they are of childbearing potential, agree to practice 2 effective
             methods of contraception, from the time of signing the informed consent through 90
             days after the last dose of study drug, OR Agree to practice true abstinence when this
             is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence
             [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are
             not acceptable methods of contraception.) Male patients, even if surgically
             sterilized, must agree to one of the following: Agree to practice effective barrier
             contraception during the entire study treatment period and through 90 days after the
             last dose of study drug, OR agree to practice true abstinence when this is in line
             with the preferred and usual lifestyle of the subject.

          4. Patients must have a history of de novo or therapy-related AML (defined by World
             Health Organization (WHO) classification of >/= 20% bone marrow blasts) or high-risk
             MDS (defined by International Prostate Symptom Score (IPSS) or IPSS-R)

          5. 5. Patients must be in a documented complete response/incomplete blood count recovery
             (CR/CRi) from either their front-line or first salvage therapy as evidenced by </= 5%
             bone marrow blasts and absence of extramedullary disease. (For patients with prior MDS
             who then transformed to AML, therapy received for MDS is not considered prior therapy
             for AML)

          6. Patients should have received at least 2 cycles of induction therapy or 1 induction
             and 1 consolidation cycle, OR patient should be considered to have completed all
             planned chemotherapy, OR patient is considered to be unable, unfit or unwilling to
             receive additional chemotherapy.

          7. Eastern Cooperative Oncology Group (ECOG) performance 0, 1, or 2.

          8. Patients must meet the following clinical laboratory criteria: - Absolute neutrophil
             count (ANC) >/= 500/mm3 and platelet count >/= 50,000/mm3. Platelet transfusions to
             help patients meet eligibility criteria are not allowed within 3 days before study
             enrollment - Total bilirubin </= 1.5 x the upper limit of the normal range (ULN). -
             Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)</= 3 x ULN. -
             Calculated creatinine clearance >/= 30 mL/min

        Exclusion Criteria:

          1. Female patients who are lactating or have a positive serum pregnancy test during the
             screening period.

          2. Failure to have fully recovered (ie, </= Grade 1 toxicity) from the reversible effects
             of prior chemotherapy.

          3. Major surgery within 14 days before enrollment.

          4. Radiotherapy within 14 days before enrollment. If the involved field is small, 7 days
             will be considered a sufficient interval between treatment and administration of the
             MLN9708.

          5. Known central nervous system involvement

          6. Infection requiring systemic antibiotic therapy or other serious infection within 14
             days before study enrollment.

          7. Evidence of current uncontrolled cardiovascular conditions, including sustained
             hypertension (SBP >150mmHg on two or more readings one week apart without
             normalization in between), clinically significant uncontrolled cardiac arrhythmias,
             symptomatic Class III-IV New York Heart Association (NYHA) congestive heart failure,
             unstable angina, or myocardial infarction within the past 6 months.

          8. Systemic treatment, within 7 days, or the half life of the treatment, whichever is
             longer before the first dose of MLN9708, with strong inhibitors of CYP1A2
             (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of cytochrome P CYP3A
             (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone,
             posaconazole) or strong CYP3A inducers (rifampin, rifapentine, rifabutin,
             carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort.

          9. Ongoing or active systemic infection, history of hepatitis B or C virus infection, or
             known human immunodeficiency virus (HIV) positive.

         10. Any serious medical or psychiatric illness that could, in the investigator's opinion,
             potentially interfere with the completion of treatment according to this protocol.

         11. Known allergy to any of the study medications, their analogues, or excipients in the
             various formulations of any agent.

         12. Known GI disease or GI procedure that is expected to interfere with the oral
             absorption or tolerance of MLN9708 including difficulty swallowing. As determined by
             the investigator.

         13. Diagnosed or treated for another malignancy within 2 years before study enrollment or
             previously diagnosed with another malignancy and have any evidence of residual
             disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are
             not excluded if they have undergone complete resection

         14. Patient has >/= Grade 3 peripheral neuropathy, or Grade 2 with pain on clinical
             examination during the screening period.

         15. Administration of other investigational agents for the treatment of AML/MDS within
             21days (or 5 times the terminal half life of the investigational treatment whichever
             is longer) of the start of this trial and throughout the duration of this trial.

         16. At the time of registration, stem cell transplantation is not planned within the next
             3 months.
      "
NCT02305563,terminated,"
    business objectives have changed, slow accrual, the standard of care for the patient population
    changed and we were unable to accrue any longer.
  ",0,phase 1/phase 2,['leukemia'],"[""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']""]","['bms-936564', 'cytarabine']","['Status: 503', 'Status: 503']","
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Newly Diagnosed Acute Myeloid Leukemia (AML)

          -  Considered inappropriate for intensive remission induction therapy by an investigator

          -  Not eligible for stem cell transplantation

        Exclusion Criteria:

          -  Acute promyelocytic leukemia

          -  Current Myelodysplastic syndrome only subjects

          -  Unstable angina or uncontrolled congestive heart failure

          -  Any other malignancy, excluding basal or squamous cell carcinoma of the skin, in situ
             melanoma, cervical carcinoma in situ, localized prostate cancer, or superficial
             bladder cancer stage 0, from which the subject has not been disease-free for at least
             3 years

          -  Respiratory disease requiring continuous supplemental oxygen

        Other protocol defined inclusion/exclusion criteria could apply
      "
NCT02301481,completed,,1,phase 2,"['stomach neoplasms', 'neoadjuvant therapy', 'chemoradiotherapy', 'chemotherapy']","[""['D13.1', 'C16.9', 'C16.1', 'C16.2', 'D37.1', 'C16.8', 'C16.5']"", ""['D61.810', 'Z51.11', 'D64.81', 'D70.1', 'Z92.21', 'P04.11', 'T80.810S']""]","['s-1', 'sox']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Histologically or cytologically proven locally advanced gastric adenocarcinoma in
             patients staged as cT3-4N0M0 or anyTN+M0

          -  No distant metastasis in liver,lung,bone,central nervous system(CNS),no peritoneal
             transplantation

          -  No prior abdominal or pelvic radiotherapy

          -  Karnofsky performance status(KPS)≥ 70, predictive life span no less than 6 months

          -  Patients must have normal organ and marrow function as defined below: Leukocytes:
             greater than or equal to 3,000 G/L; Platelets: greater than or equal to 100,000/mm3
             .Hemoglobin:greater than or equal to 10g/L .Total bilirubin: within normal
             institutional limits; AST/ALT: less than or equal to 1.5 times the upper limit;
             Creatinine within normal upper limits

          -  Informed consent

        Exclusion Criteria:

          -  Any prior chemotherapy or other cancer treatment prior to this protocol

          -  Patients with other cancer history except cervical carcinoma in situ and non-malignant
             melanoma skin cancer

          -  With any distant metastasis in liver,lung,bone,CNS,or peritoneal transplantation

          -  History of allergic reactions attributed to similar chemical or biologic complex to
             S-1 or Xeloda or Oxaliplatin

          -  Uncontrolled illness including, but not limited to, active infection, symptomatic
             heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness

          -  History of myocardial infarction within the past 6 months or history of ventricular
             arrhythmia

          -  History of prior radiation to the abdomen

          -  Pregnant or lactating females
      "
NCT02301039,completed,,0,phase 2,"['soft tissue sarcoma', 'bone sarcoma']","[""['C46.1']""]",['pembrolizumab'],['Status: 503'],"
        Inclusion Criteria:

          -  Age ≥ 18 years (Age ≥ 12 years for patients with bone sarcomas).

          -  Histologically confirmed diagnosis of unresectable, recurrent, and/or metastatic high
             grade soft-tissue or bone sarcoma of one of the following subtypes: soft tissue
             sarcomas (leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high
             grade pleomorphic undifferentiated sarcoma/MFH and synovial sarcoma), and bone
             sarcomas (Ewing sarcoma, osteosarcoma, and chondrosarcoma [de-differentiated or
             mesenchymal]).

          -  ECOG Performance Status of 0 or 1.

          -  At least one site of measurable disease on CT/MRI scans as defined by RECIST 1.1.
             Baseline imaging must be performed within 30 days of dosing.

          -  At least one site of accessible disease for pre- and post-treatment core biopsies for
             at least 20 patients per arm on the expansion cohorts.

          -  Patients may have received 1-3 prior systemic therapies in the metastatic setting.

          -  Adequate organ function within 14 days of dosing

          -  Must be willing to provide and have available archival tissue for PD-L1 testing.

          -  Written, voluntary informed consent.

          -  Fertile men and women of childbearing potential must agree to use an effective method
             of birth control from providing signed consent and for 120 days after last study drug
             administration. Women of childbearing potential include pre-menopausal women and women
             within the first 2 years of the onset of menopause. Women of childbearing potential
             must have a negative pregnancy test ≤ 72 hours prior to Day 1 of study.

          -  Effective methods of birth control include: surgically sterile, barrier device
             (condom, diaphragm), contraceptive coil, intrauterine device (IUD), and abstinence.

          -  Life expectancy of >12 weeks.

          -  Patients with central nervous system disease are eligible for enrollment if they have
             received prior radiotherapy or surgery to sites of CNS metastatic disease and are
             without evidence of clinical progression for at least 4 weeks prior to screening, have
             no evidence of new or enlarging brain metastases, and are off steroids for at least 7
             days before first dose of pembrolizumab.

        Exclusion Criteria:

          -  Prior systemic therapy targeting PD-1: PD-L1 axis.

          -  Patients who are curable by conventional multidisciplinary management.

          -  Patients with severe and/or uncontrolled concurrent medical disease that in the
             opinion of the investigator could cause unacceptable safety risks or compromise
             compliance with the protocol.

          -  Patients who have received wide field radiotherapy ≤ 4 weeks or limited field
             radiation for palliation < 2 weeks prior to screening or who have not recovered
             adequately from side effects of such therapy.

          -  Patients who have active infections requiring therapy.

          -  Patients that are known to be positive for Human Immunodeficiency Virus (HIV) (HIV 1/2
             antibodies), active Hepatitis B (HBsAg reactive), or Hepatitis C (HCV RNA
             [qualitative] is detected); patients with negative Hepatitis C antibody testing may
             not need RNA testing.

          -  Patients that have a known psychiatric or substance abuse disorder that would
             interfere with cooperation with the requirements of the trial.

          -  Patients who received systemic anti-cancer treatment prior to the first dose of study
             drug within the following time frames:

          -  Patients with active autoimmune disease or a documented history of autoimmune disease
             or syndrome that requires systemic steroids or immunosuppressive agents. Patients with
             vitiligo or resolved childhood asthma/atopy would be exception to this rule. Patients
             that require inhaled steroids or local steroid injections would not be excluded from
             the study. Patients with hypothyroidism not from autoimmune disease that is stable on
             hormone replacement will not be excluded from the study.

          -  Women who are pregnant or nursing/breastfeeding.

          -  Known hypersensitivity to pembrolizumab or another mAb.

          -  Has a history of (non-infectious) pneumonitis that required steroids or current
             pneumonitis.

          -  Patients with untreated central nervous system disease. Patients with controlled
             treated CNS lesions who have undergone surgery or stereotactic radiosurgery and stable
             for 4 weeks are eligible.

          -  Inability to comply with protocol required procedures.

          -  Patients with medical conditions that require chronic systemic corticosteroid therapy
             or require any other form of immunosuppressive medication. However, patients using
             physiologic replacement doses of hydrocortisone, or its equivalent, will be considered
             eligible for this study: up to 20 mg hydrocortisone (or 5 mg of prednisone) in the
             morning and 10 mg hydrocortisone (or 2.5 mg prednisone) in the evening.

          -  Patients with the risk factors for bowel obstruction or bowel perforation (examples
             include but not limited to a history of acute diverticulitis, intra-abdominal abscess,
             abdominal carcinomatosis).

          -  Patients who have received a live vaccine within 30 days prior to the first dose of
             trial treatment.
      "
NCT02301143,completed,,1,phase 2,['pancreatic neoplasms'],"[""['C25.3']""]","['nab-paclitaxel', 'gemcitabine', 'chemoradiation', 'capecitabine']","['Status: 503', 'Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Non- metastasis, unresectable, adenocarcinoma pancreatic cancer patients

          -  No prior anticancer therapy for pancreatic cancer

             •≥ 18 years of age with a performance status of 0 or 1•Adequate complete blood counts,
             hepatic function, and renal function

          -  Signed informed Consent

        Exclusion Criteria:

          -  Active bacterial, viral, or fungal infection

          -  Infection with hepatitis B or C, or history of human immunodeficiency virus (HIV)
             infection, or receiving immunosuppressive or myelosuppressive

          -  Subjects with sensory neuropathy, ascites, or plastic biliary stent.

          -  Serious medical risk factors involving any of the major organ systems, or serious
             psychiatric disorders (including but not limited to connective tissue disorders, lung
             disease, and cardiac or seizure disorders)

          -  Women who are pregnant or breast feeding
      "
NCT02301611,completed,,1,phase 2,['melanoma'],"[""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']""]","['tlpldc', 'placebo']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  18 years or older

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0,1 (Appendix D)

          -  AJCC stage III or IV completely resectable melanoma identified before surgery

          -  Approximately 1 mg (1 cm3) of accessible and dispensable tumor that will not interfere
             with pathologic staging

          -  Clinically disease-free after surgery

          -  Completing SoC adjuvant therapy per NCCN guidelines to include chemotherapy, radiation
             therapy, and/or biologic therapy as clinically indicated. (Consent #2 should be signed
             as close to completion of SoC as possible but may overlap completion by up to one
             month.)

          -  Vaccinations initiated between 3 weeks and 3 months from completion of SoC
             multi-modality cancer care

          -  Adequate organ function as determined by the following laboratory values:

          -  ANC ≥ 1,000/μL

          -  Platelets ≥ 75,000/μL

          -  Hgb ≥ 9 g/dL

          -  Creatinine ≤ 1.5 x upper limit of normal (ULN) or Creatinine clearance ≥ 50%

          -  Total bilirubin ≤ 1.5 ULN

          -  ALT and AST ≤ 1.5 ULN

          -  For women of child-bearing potential, agreement to use adequate birth control
             (abstinence, hysterectomy, bilateral oophorectomy, bilateral tubal ligation, oral
             contraception, IUD, or use of condoms or diaphragms)

          -  Signed informed consent

        Exclusion Criteria:

          -  Evidence of residual disease after surgery and SoC adjuvant therapies

          -  Insufficient tumor available to produce vaccine

          -  ECOG >2 performance status (Appendix D)

          -  Immune deficiency disease or known history of HIV, HBV, HCV

          -  Receiving immunosuppressive therapy including chronic steroids, methotrexate, or other
             known immunosuppressive agents

          -  Pregnancy (assessed by urine HCG)

          -  Breast feeding

          -  Active pulmonary disease requiring medication to include multiple inhalers (>2
             inhalers and one containing steroids)

          -  Involved in other experimental protocols (except with permission of the other study
             PI)
      "
NCT02303041,terminated,"
    business decision
  ",0,phase 2,"['carcinoma, basal cell', 'recurrent skin cancer', 'skin neoplasms', 'basal cell nevus syndrome']","[""['C44.510', 'C44.91', 'C44.01', 'C44.311', 'C44.511', 'C44.81', 'C44.41']"", ""['C79.2', 'C44.500', 'C44.90', 'D23.9', 'D48.5', 'C44.00', 'C44.301']"", ""['C79.2', 'C44.500', 'C44.90', 'D23.9', 'D48.5', 'C44.00', 'C44.301']"", ""['D68.61', 'D69.41', 'D81.4', 'E24.1', 'E26.01', 'E26.81', 'E34.0']""]","['buparlisib', 'sonidegib']","['Status: 503', 'Status: 503']","
        INCLUSION CRITERIA:

          -  Able to understand and sign informed consent

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

          -  Metastatic BCC, histologic confirmation of distant BCC metastasis

          -  Metastatic disease, target lesion must be measurable using computed tomography (CT) or
             magnetic resonance imaging (MRI)

          -  Locally advanced BCC are required to have disease that is considered inoperable due to
             significant functional compromise or to have a medical contraindication to surgery

          -  Nevoid BCC syndrome (Gorlin syndrome) may enroll in this study but must meet the
             criteria for locally advanced or metastatic disease listed above

          -  COHORT 2 ONLY: A Smoothened inhibitor must have been previously administered as
             monotherapy

          -  Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L

          -  Platelets ≥ 80 x10^9/L

          -  Hemoglobin (Hb) > 9 g/dL or values ≥ lower limit of normal (LLN) for site-specific lab

          -  Total calcium (corrected for serum albumin) within normal limits (biphosphonate use
             for malignant hypercalcemia control is not allowed)

          -  Magnesium ≥ the lower limit of normal

          -  Potassium within normal limits for the institution

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal
             range [or ≤ 3.0 x upper limit of normal (ULN) if liver metastases are present]

          -  Serum bilirubin within normal range (or ≤ 1.5 x ULN if liver metastases are present;
             or total bilirubin ≤ 3.0 x ULN with direct bilirubin within normal range in patients
             with well-documented Gilbert Syndrome)

          -  Serum creatinine ≤ 1.5 x ULN or 24-hour clearance ≥ 50 mL/min

          -  Serum amylase ≤ ULN

          -  Serum lipase ≤ ULN

          -  Fasting plasma glucose ≤ 120 mg/dL (6.7 mmol/L)

          -  Negative serum pregnancy test within 72 hours before starting study treatment in women
             with childbearing potential

          -  International normalized ratio (INR) ≤ 2

        EXCLUSION CRITERIA:

          -  Prior treatment with a P13K inhibitor

          -  Known hypersensitivity to buparlisib or to its excipients

          -  Untreated brain metastases are excluded; however, patients with metastatic central
             nervous system (CNS) tumors may participate in this trial, if the patient is > 4 weeks
             from therapy completion (including radiation and/or surgery), is clinically stable at
             the time of study entry and is not receiving corticosteroid therapy

          -  Acute or chronic liver, renal disease or pancreatitis

          -  Baseline creatinine kinase (CK) > ULN

          -  The following mood disorders as judged by the Investigator or a psychiatrist, or as a
             result of patient's mood assessment questionnaire:

               -  Medically documented history of or active major depressive episode, bipolar
                  disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of
                  suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm
                  to others)

               -  ≥ Common Terminology Criteria for Adverse Events (CTCAE) grade 3 anxiety

               -  Meets the cut-off score of ≥ 12 in the Patient Health Questionnaire (PHQ)-9 or a
                  cut-off of ≥ 15 in the Generalized Anxiety Disorder 7-item (GAD-7) mood scale,
                  respectively, or selects a positive response of ""1, 2, or 3"" to question number 9
                  regarding potential for suicidal thoughts in the PHQ-9 (independent of the total
                  score of the PHQ-9)

          -  Diarrhea ≥ CTCAE grade 2

          -  Active cardiac disease including any of the following:

               -  Left ventricular ejection fraction (LVEF) < 50% as determined by multiple gated
                  acquisition (MUGA) scan or echocardiogram (ECHO)

               -  QTc > 450 msec on screening electrocardiogram (ECG) (using the QTcF formula)

               -  Angina pectoris that requires the use of anti-anginal medication

               -  Ventricular arrhythmias except for benign premature ventricular contractions

               -  Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled
                  with medication

               -  Conduction abnormality requiring a pacemaker

               -  Valvular disease with document compromise in cardiac function

               -  Symptomatic pericarditis

          -  Patient has a history of cardiac dysfunction including any of the following:

               -  Myocardial infraction within the last 6 months, documented by persistent elevated
                  cardiac enzymes or persistent regional wall abnormalities on assessment of LVEF
                  function

               -  History of documented congestive heart failure (New York Heart Association
                  functional classification 3-4)

               -  Documented cardiomyopathy

          -  Patient has poorly controlled diabetes mellitus [defined as hemoglobin A1C (HgA1c) >
             ULN], steroid-induced diabetes mellitus, or insulin dependent diabetes mellitus

          -  Other concurrent severe and/or uncontrolled concomitant medical conditions (eg, active
             or uncontrolled infection) that could cause unacceptable safety risks or compromise
             compliance with the protocol

          -  Significant symptomatic deterioration of lung function; if clinically indicated,
             pulmonary function tests including measures of predicted lung volumes, diffusing
             capacity of the lung for carbon monoxide (DLco), oxygen (O2) saturation at rest on
             room air should be considered to exclude pneumonitis or pulmonary infiltrates

          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly
             alter the absorption of buparlisib (eg, ulcerative diseases, uncontrolled nausea,
             vomiting, diarrhea, malabsorption syndrome, or small bowel resection); patients with
             unresolved diarrhea will be excluded as previously indicated

          -  Patients who have been treated with any hematopoietic colony-stimulating growth
             factors (eg, filgrastim (granulocyte-colony stimulating factor, G-CSF), sargramostim
             (granulocyte-macrophage colony-stimulating factor, GM-CSF) ≤ 2 weeks prior to starting
             study drug; erythropoietin or darbepoetin therapy, if initiated at least 2 weeks prior
             to enrollment, may be continued

          -  Patients who are currently receiving treatment with medication with a known risk to
             prolong the QT interval or inducing Torsades de Pointes and the treatment cannot
             either be discontinued or switched to a different medication prior to starting study
             drug

          -  Patients receiving chronic treatment with steroids or another immunosuppressive agent

               -  Note: topical applications (eg, rash), inhaled sprays (eg, obstructive airways
                  diseases), eye drops or local injections (eg, intr-articular) are allowed;
                  patients with previously treated brain metastases, who are on stable low dose
                  corticosteroids treatment (eg, dexamethasone 2 mg/day, prednisolone 10 mg/day)
                  for at least 14 days before start of study treatment are eligible

          -  Patients who have taken herbal medications and certain fruits within 7 days prior to
             starting study drug; herbal medications include, but are not limited to St. John's
             Wort, Kava, ephedra (ma huang), dehydroepiandrosterone (DHEA), gingko biloba, yohimbe,
             saw palmetto, and ginseng; fruits include the cytochrome P450, family 3, subfamily A
             (CYP3A) inhibitors Seville oranges, grapefruit, pummelos, or exotic citrus fruits

          -  Patients who are currently treated with drugs known to be moderate and strong
             inhibitors or inducers of isoenzyme CYP3A, and the treatment cannot be discontinued or
             switched to a different medication prior to starting study drug; please note that
             co-treatment with weak inhibitors of CYP3A is allowed

          -  Patients who have received chemotherapy or targeted anticancer therapy ≤ 4 weeks (6
             weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug must
             recover to a grade 1 before starting the trial

          -  Patients who have received any continuous or intermittent small molecule therapeutics
             (excluding monoclonal antibodies) ≤ 5 effective half lives prior to starting study
             drug or who have not recovered from side effects of such therapy

          -  Use of statin drugs or other medications known to associate with rhabdomyolysis; these
             drugs must be discontinued at enrollment

          -  Patients who have received wide field radiotherapy ≤ 4 weeks or limited field
             radiation for palliation ≤ 2 weeks prior to starting study drug or who have not
             recovered from side effects of such therapy

          -  Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or
             who have not recovered from side effects of such therapy

          -  Patients who are currently taking therapeutic doses of warfarin sodium or any other
             coumadin-derivative anticoagulant; low molecular weight heparin is allowed

          -  Women who are pregnant or breast feeding or adults of reproductive potential not
             employing an effective method of birth control; double barrier contraceptives must be
             used through the trial by both sexes; oral, implantable, or injectable contraceptives
             may be affected by cytochrome P450 interactions, and are therefore not considered
             effective for this study; women of child-bearing potential, defined as sexually mature
             women who have not undergone a hysterectomy or who have not been naturally
             postmenopausal for at least 12 consecutive months (ie, who has had menses any time in
             the preceding 12 consecutive months), must have a negative serum pregnancy test ≤ 72
             hours prior to initiating treatment

               -  Women are considered post-menopausal and not of child bearing potential if they
                  have had 12 months of natural (spontaneous) amenorrhea with an appropriate
                  clinical profile (eg, age appropriate, history of vasomotor symptoms) or 6 months
                  of spontaneous amenorrhea with serum follicle stimulating hormone (FSH) levels >
                  40 mIU/mL (for US only: and estradiol < 20 pg/mL) or have had surgical bilateral
                  oophorectomy (with or without hysterectomy) at least 6 weeks prior; in the case
                  of oophorectomy alone, only when the reproductive status of the woman has been
                  confirmed by follow up hormone level assessment is she considered not of child
                  bearing potential

               -  Women of child-bearing potential, defined as all women physiologically capable of
                  becoming pregnant, must use highly effective contraception during the study and
                  through 20 months after the final dose of study treatment; for males with
                  partners with childbearing potential, highly effective contraception is required
                  for 6 months; the highly effective contraception is defined as either:

                    -  True abstinence: when this is in line with the preferred and usual lifestyle
                       of the subject; periodic abstinence (eg, calendar, ovulation, symptothermal,
                       post-ovulation methods) and withdrawal are not acceptable methods of
                       contraception

                    -  Sterilization: have had surgical bilateral oophorectomy (with or without
                       hysterectomy) or tubal ligation at least six weeks ago; in case of
                       oophorectomy alone, only when the reproductive status of the woman has been
                       confirmed by follow up hormone level assessment

                    -  Male partner sterilization (with the appropriate post-vasectomy
                       documentation of the absence of sperm in the ejaculate); for female subjects
                       on the study, the vasectomized male partner should be the sole partner for
                       that patient

                    -  Use of a combination of any two of the following (a+b):

                         -  a. Placement of an intrauterine device (IUD) or intrauterine system
                            (IUS)

                         -  b. Barrier methods of contraception: condom or occlusive cap (diaphragm
                            or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal
                            suppository

               -  Oral contraception, injected or implanted hormonal methods are not allowed

               -  Fertile males, must use highly effective (double barrier) methods of
                  contraception (eg, spermicidal gel plus condom) for the entire duration of the
                  study, and continuing using contraception and refrain from fathering a child for
                  6 months following the study drug; a condom is required to be used also by
                  vasectomized men as well as during intercourse with a male partner in order to
                  prevent delivery of the study treatment via seminal fluid; female partner of male
                  study subject should use highly effective contraception during dosing of any
                  study agent and for 16 weeks after final dose of study therapy

               -  Note: hormonal contraception methods (eg, oral, injected, implanted) are not
                  allowed

               -  Note: woman are considered post-menopausal and not child bearing potential if
                  they have had 12 months of natural (spontaneous) amenorrhea with an appropriate
                  clinical profile (eg, age appropriate, history of vasomotor symptoms) or six
                  months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL and estradiol
                  < 20 pg/mL or have had surgical bilateral oophorectomy (with or without
                  hysterectomy) at least six weeks ago; in the case of oophorectomy alone, only
                  when the reproductive status of the woman has been confirmed by follow up hormone
                  level assessment is she considered not of child bearing potential

          -  Known diagnosis of human immunodeficiency virus (HIV) infection, hepatitis B or
             hepatitis C

          -  History of another malignancy within 3 years, except cured basal cell carcinoma of the
             skin or excised carcinoma in situ of the cervix

          -  Patient is unable or unwilling to abide by the study protocol or cooperate fully with
             the investigator
      "
NCT02306291,completed,,1,phase 1/phase 2,"['leukemia, myeloid, acute']","[""['C92.A1', 'C92.A2', 'C92.61', 'C92.62', 'C92.A0', 'C92.60']""]","['gmi-1271', 'mitoxantrone', 'etoposide', 'cytarabine', 'idarubicin']","['Status: 503', 'Status: 503', 'Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion criteria:

          1. AML (including secondary AML) diagnosed as per WHO criteria

          2. For relapsed/refractory subjects only:

               -  Subjects age ≥ 18 years with relapsed or refractory AML after ≤ 2 prior induction
                  regimens, at least one containing anthracyclines

               -  Medically eligible to receive MEC

               -  Absolute blast count (ABC) ≤ 40,000/mm

          3. For treatment-naïve subjects only:

               -  Subjects ≥ 60 years of age with newly diagnosed AML

               -  Medically eligible to receive ""7+3"" cytarabine/idarubicin

               -  ABC count ≤ 40,000/mm

          4. ECOG performance status 0-2

          5. Hemodynamically stable and adequate organ function

        Exclusion criteria:

          1. Acute promyelocytic leukemia

          2. Acute leukemia of ambiguous lineage (biphenotypic leukemia)

          3. Active signs or symptoms of CNS involvement by malignancy

          4. No prior G-CSF, GM-CSF or plerixafor within 14 days of study drug dosing

          5. Known history or evidence of active hepatitis A, B, or C or HIV

          6. Uncontrolled acute life threatening bacterial, viral or fungal infection

          7. Active graft versus host disease (GVHD) ≥ Grade 2 or extensive chronic GVHD requiring
             immunosuppressive therapy

          8. Hematopoietic stem cell transplantation ≤ 4 months of dosing

          9. Clinically significant cardiovascular disease
      "
NCT02309515,terminated,"
    slow accrual
  ",0,phase 2,"['monoclonal b-cell lymphocytosis', 'stage 0 chronic lymphocytic leukemia', 'stage i chronic lymphocytic leukemia', 'stage i small lymphocytic lymphoma']","[""['C91.11', 'C91.12', 'C91.10']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']""]",['lenalidomide'],['Status: 503'],"
        Inclusion Criteria:

          -  Diagnosis of:

               1. CLL according to the National Cancer Institute (NCI) criteria

               2. Small lymphocytic lymphoma (SLL) according to the World Health Organization (WHO)
                  criteria

               3. MBL according to the consensus criteria

                    -  This includes previous documentation of:

                         -  Biopsy-proven small lymphocytic lymphoma or

                         -  Diagnosis of CLL or MBL as evidenced by all of the following:

                              -  Clonal B-cell population in the peripheral blood with
                                 immunophenotyping consistent with CLL defined as:

                                   -  The population of lymphocytes share both B-cell antigens
                                      (cluster of differentiation [CD]19, CD20 [typically dim
                                      expression], or CD23) as well as CD5 in the absence of other
                                      pan-T-cell markers (CD3, CD2, etc)

                                   -  Clonality as evidenced by k (kappa) or lambda light chain
                                      expression (typically dim immunoglobulin expression) or other
                                      genetic method (e.g. immunoglobulin heavy chain variable
                                      [IGHV] analysis) NOTE: splenomegaly, hepatomegaly, or
                                      lymphadenopathy are not required for the diagnosis of CLL

                              -  Patients with a peripheral blood B-cell lymphocyte count of < 5 x
                                 10^9/L and no evidence of lymphadenopathy or organomegaly will be
                                 classified as MBL; patients with a peripheral blood B-cell
                                 lymphocyte count of < 5 x 10^9/L who have evidence of
                                 lymphadenopathy will be classified as SLL; patients with a
                                 peripheral blood B-cell lymphocyte count >= 5 x 10^9/L will be
                                 considered to have CLL

                              -  Before diagnosing MBL, CLL or SLL, mantle cell lymphoma must be
                                 excluded by demonstrating a negative fluorescence in situ
                                 hybridization (FISH) analysis for t(11;14)(IgH/cyclin D 1 [CCND1])
                                 on peripheral blood or tissue biopsy or negative
                                 immunohistochemical stains for cyclin D1 on involved tissue biopsy

          -  CLL or SLL patients only (does not apply to MBL patients): Rai stage 0-1 (both CLL and
             SLL patients can be staged using the Rai system)

          -  Patients must not previously have received the Prevnar 13 pneumococcal vaccination;
             NOTE: previous vaccination with Pneumovax (PCV23) is permitted but must have been at
             least 365 days prior to registration

          -  Patients must be previously untreated and must NOT have any of the following
             indications for chemotherapy:

               -  Evidence of progressive marrow failure as manifested by the development of or
                  worsening anemia (=< 11 g/dL) and/or thrombocytopenia (=< 100 x 10^9/L) not due
                  to autoimmune disease

               -  Symptomatic or progressive lymphadenopathy, splenomegaly or hepatomegaly

               -  One or more of the following disease-related symptoms:

                    -  Weight loss >= 10% within the previous 6 months

                    -  Extreme fatigue attributed to CLL

                    -  Fevers > 100.4 degree Fahrenheit (o^F) for 2 weeks without evidence of
                       infection

                    -  Drenching night sweats without evidence of infection Note: 1) Prior
                       chemotherapy or monoclonal antibody based therapy for treatment of CLL or
                       SLL will be considered prior therapy; nutraceutical treatments with no
                       established benefit in CLL (such as epigallocatechin gallate or EGCG, found
                       in green tea or other herbal treatments) will not be considered ""prior
                       treatment"" 2) Prior corticosteroid therapy for an indication other than
                       CLL/SLL will not be considered ""prior treatment""; previous use of
                       corticosteroids for treatment of autoimmune complications of CLL/SLL does
                       not constitute prior therapy for CLL/SLL

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

          -  Absolute neutrophil count (ANC) >= 1000/mm^3

          -  Platelet count >= 100,000/mm^3

          -  Hemoglobin >= 11.0 g/dL

          -  Total bilirubin =< 1.5 x upper limit of normal (ULN) unless due to Gilbert's disease;
             if total bilirubin is > 1.5 x ULN, a direct bilirubin should be performed and must be
             < 1.5 mg/dL for Gilbert's to be diagnosed

          -  Aspartate transaminase (AST) =< 3 x ULN

          -  Calculated creatinine clearance must be >= 50 ml/min using the Cockcroft-Gault formula

          -  Provide informed written consent

          -  Willing to return to enrolling institution for follow-up (during the active monitoring
             phase of the study)

          -  All study participants must be willing to be registered into the mandatory Revlimid
             Risk Evaluation and Mitigation Strategy (REMS)® program, and be willing and able to
             comply with the requirements of the REMS® program; NOTE: Actual registration in the
             Revlimid REMS® program may occur after the patient is randomized since this
             requirement only applies to patients randomized to Arm A

          -  Females of reproductive potential must be willing to adhere to the scheduled pregnancy
             testing as required in the Revlimid REMS® program; NOTE: This requirement only applies
             to patients randomized to Arm A

          -  Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients
             intolerant to acetylsalicylic acid [ASA] may use warfarin or low molecular weight
             heparin)

          -  Willing to provide blood samples for correlative research purposes

        Exclusion Criteria:

          -  Palpable lymph nodes > 3 cm in maximal dimension

          -  Any of the following:

               -  Pregnant women

               -  Nursing women

               -  Men or women of childbearing potential who are unwilling to employ adequate
                  contraception

          -  Any of the following comorbid conditions:

               -  New York Heart Association classification III or IV cardiovascular disease

               -  Recent myocardial infarction (=< 30 days)

               -  Uncontrolled infection

          -  Immunocompromised patients and patients known to be human immunodeficiency virus (HIV)
             positive and currently receiving antiretroviral therapy; NOTE: patients known to be
             HIV positive, but without clinical evidence of an immunocompromised state, are
             eligible for this trial

          -  Other active primary malignancy requiring treatment or limiting survival to =< 2 years
             prior to registration

          -  Any radiation therapy =< 28 days prior to registration

          -  Any major surgery =< 28 days prior to registration

          -  Current use of corticosteroids; EXCEPTION: low doses of steroids (=< 10 mg of
             prednisone or equivalent dose of other steroid) used for treatment of nonhematologic
             medical conditions; NOTE: previous use of corticosteroids is allowed

          -  Active hemolytic anemia requiring immunosuppressive therapy or other pharmacologic
             treatment; NOTE: patients who have a positive Coombs test but no evidence of hemolysis
             are NOT excluded from participation

          -  History of deep venous thromboses or pulmonary embolism =< 365 days prior to
             registration

          -  Co-existent diffuse large B-cell lymphoma (Richter's transformation)
      "
NCT02301988,completed,,0,phase 2,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['ipatasertib', 'paclitaxel', 'placebo']","['Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Premenopausal or postmenopausal women

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Histologically documented, Stage Ia to operable Stage IIIa, triple-negative carcinoma
             of the breast with primary tumor greter than or equal to (>/=) 1.5 centimeters (cm) in
             largest diameter (cT1-3) by MRI

          -  Adequate hematologic and organ function within 14 days before the first study
             treatment

          -  Availability of tumor tissue from formalin-fixed, paraffin-embedded (FFPE) core biopsy
             of breast primary tumor

          -  For female participants of childbearing potential, agreement to use highly effective
             form(s) of contraception for the duration of the study and for at least 6 months after
             last dose of study treatment

        Exclusion Criteria:

          -  Known human epidermal growth factor 2 (HER2)-positive, estrogen receptor
             (ER)-positive, or progesterone receptor (PgR)-positive breast cancer

          -  Any prior treatment for the current primary invasive breast cancer

          -  Participants with cT4 or cN3 stage breast tumors

          -  Metastatic (Stage IV) breast cancer

          -  Bilateral invasive breast cancer

          -  Multicentric breast cancer

          -  Any disease, metabolic dysfunction, physical examination finding, or clinical
             laboratory finding that contraindicates the use of an investigational drug or that may
             affect the interpretation of the results or render the participant at high risk from
             treatment complications
      "
NCT04685915,withdrawn,"
    bayer is no longer funding due to lack of accrual
  ",0,phase 2,['chronic lymphocytic leukemia (cll)'],"[""['A87.2', 'K52.832', 'D72.111', 'C91.11', 'C91.12', 'C91.10']""]","['ibrutinib', 'copanlisib', 'acalabrutinib']","['Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Must have a confirmed diagnosis of chronic lymphocytic leukemia or small lymphocytic
             lymphoma as per 2018 IWCLL criteria with evidence of persistent disease, defined as
             measurable adenopathy or splenomegaly, circulating disease, or marrow disease

          -  On ibrutinib or acalabrutinib which was instituted due to patient previously meeting
             2018 IWCLL criteria for treatment, started at least 6 months prior to study entry for
             any patient who have received at least one prior line of therapy prior to ibrutinib or
             acalabrutinib. Reduced dose of ibrutinib or acalabrutinib is allowed as long as the
             dose has been stable for at least 4 weeks and all toxicities are ≤ grade 1

          -  Must have achieved either SD, PR or PR-L on ibrutinib or acalabrutinib by 2018 IWCLL
             criteria

          -  ECOG performance status < 2

          -  Patients must meet the following hematologic criteria at screening, unless they have
             significant bone marrow involvement of CLL confirmed on biopsy:

               -  Absolute neutrophil count ≥500 cells/mm3 (0.5 x 109/L). Growth factor is allowed
                  in order to achieve this

               -  Platelet count ≥50,000 cells/mm3 independent of transfusion within 7 days of
                  screening

          -  Adequate hepatic function defined as: Serum aspartate transaminase (AST) and alanine
             transaminase (ALT) ≤ 3.0 x upper limit of normal (ULN), bilirubin ≤2.0 x ULN (unless
             bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin including
             hemolysis)

          -  Adequate renal function defined by serum creatinine ≤1.5 x ULN or creatinine clearance
             (by Cockroft-Gauldt ≥ 50 ml/min

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for
             the duration of study participation

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients receiving cancer therapy (i.e., chemotherapy, radiation therapy,
             immunotherapy, biologic therapy, hormonal therapy, surgery and/or tumor embolization)
             other than ibrutinib or acalabrutinib within 2 weeks of Cycle 1/Day 1 with the
             following exceptions:

               -  Limited palliative radiation is allowed if completed > 1 weeks of C1D1

               -  Hormonal therapy given in the adjuvant setting

               -  Corticosteroid therapy (prednisone or equivalent <15 mg daily) is allowed as
                  clinically warranted as long as the dose is stabilized at least for 7 days prior
                  to initial dosing.Topical or inhaled corticosteroids are permitted

          -  Within six months of allogeneic hematologic stem cell transplant at the time of
             starting study treatment or active graft vs. host disease requiring systemic treatment
             or prophylaxis within 6 weeks of starting study treatment

          -  Prior treatment with copanlisib

          -  Patients in CR on ibrutinib or acalabrutinib

          -  History of other malignancies, except:

               -  Malignancy treated with curative intent and with no known active disease present
                  for ≥2 years before the first dose of study drug and felt to be at low risk for
                  recurrence by treating physician

               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
                  of disease

               -  Adequately treated carcinoma in situ without evidence of disease.

               -  Low-risk prostate cancer on active surveillance

          -  Vaccinated with live, attenuated vaccines <4 weeks before first dose of study drug

          -  Active autoimmune disease requiring systemic treatment

          -  Recent infection requiring intravenous antibiotics that was completed ≤7 days before
             the first dose of study drug, or any uncontrolled active systemic infection

          -  Known bleeding disorders (eg, von Willebrand's disease) or hemophilia

          -  History of stroke or intracranial hemorrhage within 6 months prior to enrollment

          -  Human immunodeficiency virus (HIV) or active hepatitis C virus (HCV) or hepatitis B
             virus (HBV) infection

          -  CMV PCR positive at baseline

          -  Major surgery within 4 weeks of first dose of study drug

          -  History of or concurrent condition of interstitial lung disease of any severity and/or
             severely impaired lung function (as judged by the investigator)

          -  Concurrent diagnosis of pheochromocytoma

          -  Uncontrolled arterial hypertension despite optimal medical management

          -  Type 1 or type 2 diabetes mellitus with a HgbA1c > 8.5%

          -  Any life-threatening illness, medical condition, or organ system dysfunction that, in
             the investigator's opinion, could compromise the subject's safety

          -  Currently active, clinically significant cardiovascular disease, such as uncontrolled
             arrhythmia or Class 3 or 4 congestive heart failure as defined by the New York Heart
             Association Functional Classification; or a history of myocardial infarction, unstable
             angina, or acute coronary syndrome within 6 months prior to randomization

          -  Unable to swallow capsules or malabsorption syndrome, disease significantly affecting
             gastrointestinal function, or resection of the stomach or small bowel, symptomatic
             inflammatory bowel disease or ulcerative colitis, or partial or complete bowel
             obstruction

          -  Lactating or pregnant

          -  Patients with known CNS involvement

          -  Concurrent administration of medications or foods that are strong inhibitors or
             inducers of CYP3A

          -  Known hypersensitivity to copanlisib, ibrutinib, or acalabrutinib
      "
NCT02147873,terminated,"
    study terminated due to lack of efficacy
  ",0,phase 2,"['myelodysplastic syndrome (mds)', 'chronic myelomonocytic leukemia (cmml)']","[""['D46.Z', 'D46.9', 'C94.6', 'D46.C']"", ""['C92.51', 'C92.52', 'C93.11', 'C93.12', 'C93.31', 'C93.32', 'C92.50']""]","['birinapant', 'azacitidine', 'placebo']","['Status: 503', 'Status: 503', 'Status: 503']","
        key Inclusion Criteria:

          -  Morphologically confirmed diagnosis of MDS/CMMoL according to FAB or WHO
             classification, including RAEB-t and MDS/MPN

          -  International prognostic score-revised (IPSS-R) of >3.5 (Intermediate, High or Very
             High)

          -  Previously untreated with hypomethylating agents for MDS/CMMoL

          -  Performance status of 0, 1 or 2 by the ECOG scale

          -  Adequate renal and liver function

          -  Female subjects of childbearing potential must have a negative serum pregnancy test at
             screening within 96 hours prior to the first study dose.

          -  Female subjects of childbearing potential and male subjects with partners of
             childbearing potential should ensure use of a highly effective method of birth control
             as defined by the investigator, for example, those which result in a low failure rate
             (i.e., less than 1% per year) when used consistently and correctly during the study
             and for a period of 3 months following the last dose of any drug administered during
             the study.

        Key Exclusion Criteria:

          -  Relapsed or refractory to hypomethylating agents

          -  Acute myeloid leukemia (AML), except those patients with RAEB-t who are not candidates
             for intensive AML therapy.

          -  Participated in any interventional study within 4 weeks of randomization or 5 half
             lives (whichever is longer).

          -  Received any hematopoietic growth factors within 14 days prior to screening.

          -  Prior malignancy or secondary malignancy within the prior 2 years (except in situ
             cervical cancer, squamous cell carcinoma or basal cell carcinoma of the skin).

          -  known diagnosis of human immunodeficiency virus or chronic active Hep B or C.

          -  Uncontrolled hypertension

          -  Impaired cardiac function, uncontrolled cardiac arrhythmias despite medications, or
             clinically significant cardiac disease

          -  Lack of recovery of prior adverse events to Grade ≤1 severity (National Cancer
             Institute Common Terminology Criteria for Adverse Events version 4) (except alopecia)
             due to therapy administered prior to the initiation of study drug dosing.

          -  Nursing or pregnant.

          -  Known allergy or hypersensitivity to any of the formulation components

          -  Any concurrent disease and/or medical condition that, in the opinion of the
             Investigator, would prevent the subject's participation.

          -  History of cranial nerve palsy.

          -  Being treated with anti-TNF therapies or has been treated with an anti-TNF therapy
             within 5 half-lives of randomization.
      "
NCT02146937,withdrawn,"
    due to lack of accrual for this study. pi decided to close the study.
  ",0,phase 2,['detectable prostate nodules'],"[""['A18.14', 'N41.2', 'N42.0', 'N42.83', 'C61', 'D29.1', 'N42.30']""]",['bicalutamide plus finasteride- combination therapy'],['Status: 503'],"
        Inclusion Criteria:

          1. Willing and able to provide written informed consent.

          2. Age ≥ 18 years

          3. Eastern cooperative group (ECOG) performance status ≤2

          4. Documented histologically confirmed adenocarcinoma of the prostate (minimum 12 core
             prostate biopsy completed within 90 days of screening)

          5. Very low-risk prostate cancer as defined by:

               -  Gleason score ≤ 6

               -  PSA density ≤ 0.15 ng/mL/mL

               -  PSA < 10 ng/mL

               -  Clinical tumor stage T1 (cT1) (i.e., no palpable nodule by digital rectal exam)

               -  ≤2 prostate cores positive for prostatic adenocarcinoma

               -  ≤50% of any given core involved by prostatic adenocarcinoma

          6. Willing and qualified for active surveillance at Johns Hopkins

          7. Presence of at least one MRI significant visible prostate tumor (i.e., ≥5 mm in at
             least one dimension) that has been biopsy proven to be prostatic adenocarcinoma Note:
             MRI may occur pre- or post-prostate biopsy. If done post-biopsy, the MRI must not
             occur <8 weeks post-prostate biopsy.

          8. Serum testosterone ≥150 ng/dL

          9. Able to swallow the study drugs whole as a tablet

        Exclusion Criteria:

          1. Prior local therapy to treat prostate cancer (e.g., radical prostatectomy, radiation
             therapy, brachytherapy)

          2. Prior use of bicalutamide

          3. Prior use of finasteride within the past year

          4. Prior or ongoing systemic therapy for prostate cancer including, but not limited to:

               -  Hormonal therapy (e.g., leuprolide, goserelin, triptorelin)

               -  CYP-17 inhibitors (e.g., abiraterone, ketoconazole)

               -  Antiandrogens (e.g., bicalutamide, flutamide, nilutamide)

               -  Second generation antiandrogens (e.g., enzalutamide, ARN-509)

               -  Immunotherapy (e.g., sipuleucel-T, ipilimumab)

               -  Chemotherapy (e.g., docetaxel, cabazitaxel)

          5. Evidence of serious and/or unstable pre-existing medical, psychiatric or other
             condition (including laboratory abnormalities) that could interfere with patient
             safety or provision of informed consent to participate in this study.

          6. Any psychological, familial, sociological, or geographical condition that could
             potentially interfere with compliance with the study protocol and follow-up schedule.

          7. Abnormal bone marrow function [absolute neutrophil count (ANC)<1500/mm3, platelet
             count <100,000/mm3, hemoglobin <9 g/dL]

          8. Abnormal liver function (bilirubin, AST, ALT ≥ 3 x upper limit of normal)

          9. Abnormal kidney function (serum creatinine ≥ 2 x upper limit of normal)

         10. Abnormal cardiac function as manifested by NYHA (New York Heart Association) class III
             or IV heart failure or history of a prior myocardial infarction (MI) within the last
             five years prior to enrollment in the study.
      "
NCT02140437,withdrawn,"
    the progress of enrollment is too slow.
  ",0,phase 2,['carcinoma breast stage iv'],"[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['fulvestrant', 'anastrozole']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          1. Signed informed consent

          2. Histologically confirmed breast cancer

          3. Luminal A-like breast cancer (primary or metastatic tumor), defined as: ER-positive,
             PR-positive (> 20%), Her-2 negative and Ki67 <14%.

          4. Advanced breast cancer is eligible:

               -  Endocrine therapy-naive patients with locally advanced disease, who are not
                  suitable for radical surgery or radiotherapy (the decision made by the
                  multidisciplinary breast cancer team). Prior first-line cytotoxic chemotherapy is
                  acceptable. or

               -  Patients with recurrent or metastatic disease, who have not received adjuvant
                  endocrine therapy or who have been 2 years or longer after stop of adjuvant
                  endocrine therapy. Patients who had disease progression from first-line cytotoxic
                  chemotherapy are allowed.

          5. At least one lesion (measurable and / or non-measurable) can be assessed at baseline,
             and is suitable for repeated assessments with CT and/or MRI.

          6. Postmenopausal women, defined as any one of the following criteria (as defined in the
             NCCN's menopause definition):

               -  previous bilateral oophorectomy

               -  60 years old or older

               -  less than 60 years old, amenorrheic for 12 months or longer in the absence of
                  chemotherapy, tamoxifen, toremifene, or ovarian suppression and
                  follicle-stimulating hormone and estradiol in the postmenopausal range.

               -  If taking tamoxifen, or toremifene and age < 60, then FSH and E in the
                  postmenopausal range

          7. ECOG 0, 1 or 2.

          8. Patients with good compliance.

          9. Must be able to swallow tablets.

         10. Without any significant gastrointestinal obstruction or dysfunction of absorption for
             oral drug.

        Exclusion Criteria:

          1. Life-threatening metastatic visceral disease, defined as extensive liver involvement
             or any degree of brain or leptomeningeal involvement (past or present) or symptomatic
             pulmonary lymphatic metastasis. If the investigator believe that their respiratory
             function is not significantly impaired due to illness, patients with scattered
             parenchymal metastases are qualified.

          2. Have received any systemic treatment other than first-line cytotoxic chemotherapy.

          3. Radiation therapy within 28 days prior to randomization (exception: radiotherapy to
             control bone pain, but should be completed before the randomization).

          4. Use any other anti-cancer therapy at the same time (except bisphosphonate).

          5. Previous endocrine treatment for advanced breast cancer.

          6. Current or previous malignancy ( except for breast cancer, basal cell or squamous cell
             carcinoma of the skin with adequate treatment, cervical carcinoma in situ).

          7. Inadequate blood or liver or renal function within one week prior to randomization:
             Platelets < 80 × 10^9/L; Total bilirubin > 1.5 × (ULRR) (patients with Gilbert's
             syndrome is eligible); or ALT or AST > 2.5 × ULRR (without liver metastases) or > 5 ×
             ULRR (with liver metastases).

          8. History with hemorrhagic constitution (e.g. disseminated intravascular coagulation,
             clotting factor deficiency) or long-term anticoagulant therapy.

          9. Hypersensitivity history to excipients or castor oil of fulvestrant or anastrozole.

         10. Any other severe co-existing medical disorders, ie uncontrolled heart disease.

         11. Participation in any clinical trial and / or exposure to any investigational
             medication within 28 days before randomization.
      "
NCT02141295,terminated,,0,phase 2,['colorectal cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['5-fu', 'bevacizumab', 'folinic acid', 'oxaliplatin', 'vanucizumab']","['Status: 503', 'Status: 503', 'Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Histologically or cytologically confirmed mCRC not amenable to potentially curative
             resection with at least one measurable metastatic lesion, as defined by RECIST v1.1

          -  Eastern Cooperative Oncology Group (World Health Organization) performance status of 0
             or 1

          -  Adequate hematologic, liver, coagulation, renal, and cardiovascular function

          -  Recovery from all reversible AEs of previous medical therapies to baseline or National
             Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade 1,
             except for alopecia (any grade)

          -  Negative serum pregnancy test within 7 days prior to starting study treatment in
             premenopausal women and women less than (< 2) years after the onset of menopause

        Exclusion Criteria:

          -  Any prior systemic therapy (including chemotherapy, antibody therapy, tyrosine kinase
             inhibitors, immunotherapy, hormonal therapy) before Day 1 of Cycle 1 for treatment of
             mCRC

          -  Malignancies other than CRC within 5 years prior to randomization, except for those
             with a minimal risk of metastasis or death, such as adequately treated carcinoma in
             situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer,
             ductal carcinoma in situ treated surgically with curative intent

          -  Radiotherapy within 28 days and abdominal/ pelvic radiotherapy within 60 days prior to
             Day 1 of Cycle 1, except palliative radiotherapy to bone lesions within 7 days prior
             to Day 1 of Cycle 1

          -  Treatment with any other investigational agent or participation in another clinical
             trial with therapeutic intent within 28 days prior to Day 1 of Cycle

          -  Pregnant or lactating women

          -  Symptomatic central nervous system (CNS) metastases or carcinomatous meningitis.
             Asymptomatic patients must be clinically stable with regard to their CNS/ meningeal
             metastatic involvement, have completed previous therapy (including radiation and/ or
             surgery) at least 4 weeks prior to study drug administration, are not receiving
             steroid therapy or taper, and are not receiving anti-convulsive medication for any CNS
             involvement

          -  Active infection requiring IV antibiotics

          -  Active autoimmune disease that is not controlled by nonsteroidal anti-inflammatory
             drugs (NSAIDs), inhaled corticosteroids, or the equivalent of less than or equal to
             (</=) 10 mg/day prednisone

          -  Sensory peripheral neuropathy greater than or equal to (>/=) Grade 2

          -  Significant cardiovascular or cerebrovascular disease within 6 months prior to Day 1
             of Cycle 1

          -  Evidence of bleeding diathesis or significant coagulopathy (in the absence of
             therapeutic anticoagulation

          -  Current use of anticoagulants at therapeutic doses within 7 days prior to study drug
             administration. Prophylactic use of unfractioned heparin or low molecular weight
             heparin is permitted

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to Day 1 of Cycle 1 or abdominal surgery, abdominal interventions or significant
             abdominal traumatic injury within 60 days prior to Day 1 of Cycle 1

          -  History of intra-abdominal inflammatory process within 6 months prior to Day 1 of
             Cycle 1 including but not limited to peptic ulcer disease, diverticulitis, or colitis

          -  Colonic prosthesis (stent) implant in place

          -  History of abdominal or tracheo-oesophageal fistula or gastrointestinal (GI)
             perforation or intra abdominal abscess within 6 months prior to Day 1 of Cycle 1

          -  History of intestinal obstruction and/or clinical signs or symptoms of GI obstruction
             including sub-occlusive disease related to the underlying disease or a requirement for
             routine parenteral hydration, parenteral nutrition, or tube feeding within 6 months
             prior to Day 1 of Cycle 1

          -  Chronic daily treatment with NSAID (occasional use for the symptomatic relief of
             medical conditions, for example headache or fever is allowed)

          -  Chronic daily treatment with corticosteroids (dose > 10 mg/day methylprednisolone
             equivalent) excluding inhaled steroids

          -  Evidence of abdominal free air not explained by paracentesis or recent surgical
             procedure

          -  Metastatic disease that involve major airways or blood vessels, or centrally located
             mediastinal tumor masses (< 30 millimeter from the carina) of large volume

          -  History of bronchopulmonary hemorrhage NCI CTCAE >/= Grade 2 within 2 months prior to
             randomization

          -  Severe, nonhealing or open wound, active ulcer, or untreated bone fracture

          -  Known dihydropyrimidine dehydrogenase deficiency or thymidylate synthase gene
             polymorphism predisposing the patient for 5-FU toxicity

          -  Any other condition, diseases, metabolic dysfunction, active or uncontrolled
             infections/inflammation, physical examination finding, mental status or clinical
             laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates participation in the clinical study due to safety concerns, compliance
             with clinical study procedures or that may affect the interpretation of the results
      "
NCT02146833,terminated,"
    due to enrollment challenges. the termination is not a consequence of any safety concern.
  ",0,phase 2,['prostate cancer'],"[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]",['selinexor'],['Status: 503'],"
        Inclusion Criteria:

          -  Histologically proven adenocarcinoma of the prostate with evidence for skeletal
             metastases on bone scan and/or CT scan.

          -  Must have received at least one agent known to impact survival (abiraterone,
             enzalutamide, etc.).

          -  Eastern Cooperative Oncology Group (ECOG) less than or equal to (≤ 2) or a Karnofsky
             Performance Status (KPS) ≥ 60%.

          -  Serum testosterone levels less than (<) 50 ng/ml.

          -  Ongoing gonadal androgen deprivation therapy with luteinising hormone-releasing
             hormone (LHRH) analogues or orchiectomy. Participants, who have not had an
             orchiectomy, must be maintained on standard dosing of LHRH analogue therapy at
             appropriate frequency for the duration of the study.

          -  Progression of disease despite androgen ablation shown by objective, documented
             evidence of disease progression (excluding prostate-specific antigen [PSA]), defined
             as one or both of the following:

               1. Soft tissue disease progression defined by Response Evaluation Criteria in Solid
                  Tumors (RECIST) version 1.1

               2. Bone disease progression defined by modified Prostate Cancer Clinical Trials
                  Working Group 2 (PCWG2) with two or more new lesions or bone scan

          -  Discontinuation of all glucocorticoids prescribed to specifically treat prostate
             cancer (e.g., as a secondary hormonal manipulation) greater than (>) 4 weeks prior to
             receiving first dose of study drug. Glucocorticoids prescribed for a chronic
             non-cancer-related illness (e.g., asthma or chronic obstructive pulmonary disease
             [COPD]) that is well controlled with medical management are permissible to an
             equivalent of ≤ 10 milligrams (mg) prednisone daily.

          -  Laboratory requirements:

               1. White blood cell (WBC) count > 3,000/microliter (μL)

               2. Absolute neutrophil count (ANC) > 1,500/μL

               3. Hemoglobin ≥8.0 gram per deciliter (g/dL)

               4. Platelet count ≥150,000/μL

               5. Serum albumin ≥3.0 g/dL

               6. Calculated or measured creatinine clearance > 30 milliliter per minute (mL/min)

          -  A biopsy documenting prostate cancer in a target lesion (e.g., lymph node, bone
             lesion, or soft tissue lesion) within 3 months prior to study entry.

          -  No evidence of chronic or acute disseminated intravascular coagulation or bleeding
             tendency.

          -  Participant must be willing and able to comply with protocol requirements. All
             participants must sign an informed consent indicating that they are aware of the
             investigational nature of this study.

          -  Participant must be willing and able to sign an authorization for the release of their
             protected health information for study purposes.

        Exclusion Criteria:

          -  Histologic variants other than adenocarcinoma in the primary tumor.

          -  Participants who require or may be expected to require urgent treatment with docetaxel
             during the study (e.g., participants with visceral metastases).

          -  Abnormal hepatic function:

               1. Bilirubin > 2 times the upper limit of normal (2 x ULN) (except participants with
                  Gilbert's syndrome [hereditary indirect hyperbilirubinemia] who must not have a
                  total bilirubin of > 3 x ULN)

               2. Aspartate transaminase (AST) and alanine transaminase (ALT) > 2.5 x ULN (except
                  participants with known liver involvement of their mCRPC who must not have an AST
                  and ALT > 5 x ULN)

          -  Therapy with other hormonal therapy, including any herbal product known to decrease
             PSA levels (e.g., Saw Palmetto and PC-SPES) within 4 weeks prior to receiving first
             dose of study drug.

          -  Therapy with samarium-153, strontium-89, or radium-223 within 8 weeks prior to first
             dose of study drug.

          -  Uncontrolled infection or concomitant illness that is not controlled with medical
             management.

          -  Prior external beam radiation therapy completed < 3 weeks or single fraction of
             palliative radiotherapy within 14 days prior to first dose of study drug.

          -  Any ""currently active"" second malignancy, other than non-melanoma skin cancer.
             Participants are not considered to have a ""currently active"" malignancy, if they have
             completed therapy and are considered by their physician to be at least less than 30%
             risk of relapse over next 3 months.

          -  Active psychiatric illnesses/social situations that would limit compliance with
             protocol requirements.

          -  Active or uncontrolled autoimmune disease that may require corticosteroid therapy
             during study.

          -  Severely compromised immunological state, including known human immunodeficiency virus
             (HIV).

          -  Known acute or chronic hepatitis B or C.

          -  Chemotherapy and other investigational therapies (targeted or immunotherapy) will
             require a 3-week washout period before treatment initiation.

          -  Initiation of bisphosphonate therapy within 4 weeks prior to first dose of study
             treatment. Participants receiving ongoing bisphosphonate or denosumab therapy must
             have been on stable doses for at least 4 weeks prior to receiving first dose of study
             treatment. Participants on stable doses of bisphosphonates who show subsequent tumor
             progression may continue on this medication.

          -  Impaired cardiac function or clinically significant cardiac diseases, including any of
             the following:

               1. History or presence of serious uncontrolled ventricular arrhythmias or presence
                  of uncontrolled atrial fibrillation.

               2. Clinically significant resting bradycardia (< 50 beats per minute).

               3. Any of the following within 3 months prior to study entry: myocardial infarction
                  severe/unstable angina, Coronary Artery Bypass Graft, Grade 3 or 4 Congestive
                  Heart Failure, Cerebrovascular Accident, Transient Ischemic Attack, or Pulmonary
                  Embolism.

               4. Uncontrolled hypertension, as defined by a systolic blood pressure > 160 mm Hg
                  and/or a diastolic blood pressure > 90 mm Hg with or without anti-hypertensive
                  medication.

               5. Previous pericarditis; clinically significant pleural effusion in the previous 12
                  months or current ascites requiring 2 or more interventions per month.

               6. Angina at rest.

          -  Any acute toxicities due to prior chemotherapy and/or radiotherapy that have not
             resolved to a National Cancer Institute (NCI) common terminology criteria for adverse
             events (CTCAE), version 4.03 Grade of ≤ 1. Chemotherapy induced alopecia or Grade 2
             neuropathy is allowed.

          -  Any condition or situation, which in the Investigator's opinion, may put the
             participant at significant risk, confound the study results, or interfere
             significantly with the participant's participation in the study.

          -  Men with a female partner of child-bearing potential, (defined as a sexually mature
             woman who has not undergone a hysterectomy or who has not been naturally
             postmenopausal for at least 12 consecutive months), who as a couple are unable or
             unwilling to employ two forms of highly effective contraception (e.g., male condom
             with spermicide, diaphragm with spermicide, intra-uterine device). Two methods of
             contraception must be used by participants and their partners through the study and
             for 3 months after the end of study treatment.

          -  Body mass index (BMI) < 1.2 m^2, in order to prevent a participant from receiving a
             dose of selinexor > 70 mg/m^2.
      "
NCT02651415,completed,,0,phase 2,['metastatic colorectal cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['regorafenib', 'perindopril']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

        Patients with metastatic colorectal cancer (mCRC) who have progressed on/after, or are
        intolerant to all approved drugs for CRC and are eligible for regorafenib.

        In order to be eligible, all inclusion criteria must be met.

        A patient must:

          -  Understand, be willing to give consent, and sign a written informed consent form (ICF)
             prior to undergoing any study-specific procedure

          -  Be male or female and ≥ 18 years of age

          -  Histological or cytological documentation of adenocarcinoma of the colon or rectum.

          -  Patients with metastatic colorectal cancer (Stage IV) previously treated with
             fluoropyrimidine-based chemotherapy, oxaliplatin, irinotecan, an anti-VEGF therapy,
             and, if KRAS wild type, an anti-EGFR therapy.

          -  Progression during or within 3 months following the last administration of approved
             standard therapies, or have experienced intolerance to previous therapy.

          -  Metastatic CRC patients with measurable or non-measurable disease

          -  Life expectancy of at least 3 months

          -  Have an Eastern Cooperative Oncology Group performance status of 0 or 1 (within 14
             days prior to the initiation of study treatment)

          -  Have adequate bone marrow, liver function, and renal function as measured by the
             following laboratory assessments conducted within 7 days prior to the initiation of
             study treatment:

               -  Total bilirubin < 1.5 times the upper limit of normal (ULN)

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 times
                  the ULN (< 5 times ULN for patients with liver involvement of their cancer)

               -  Lipase < 1.5 times the ULN

               -  Serum creatinine < 1.5 times the ULN

               -  Glomerular filtration rate > 30 mL/min/1.73 m2 according to the modified diet in
                  renal disease abbreviated formula

               -  International normalized ratio (INR) of prothrombin time (PT; PT-INR) and partial
                  thromboplastin time (PTT) < 1.5 times the ULN

               -  Platelet count > 100000 /mm3, hemoglobin > 9 g/dL, absolute neutrophil count >
                  1500/mm3.

               -  Alkaline phosphatase limit ≤ 2.5 times the ULN (< 5 times ULN for patients with
                  liver involvement of their cancer)

          -  If female and of childbearing potential, have a NEGATIVE result on a pregnancy test
             performed a maximum of 7 days before initiation of study treatment.

          -  If female and of childbearing potential or if male, must agree to use adequate
             contraception (e.g., abstinence, intrauterine device, oral contraceptive, or
             double-barrier method) based on the judgment of the investigator or a designated
             associate from the date on which the ICF is signed until 6 months after the last dose
             of study drug.

        Exclusion Criteria:

        Patients who meet the following criteria at the time of screening will be excluded:

          -  Patients with hypotension (less than 90/60mm Hg) or at risk of symptomatic hypotension
             (fainting or dizziness) will be excluded.

          -  Prior treatment with regorafenib or any VEGFR-targeting kinase inhibitor.

          -  Previous assignment to treatment during this study. Patients permanently withdrawn
             from study participation will not be allowed to re-enter the study.

          -  Concurrent cancer requiring treatment that is distinct in primary site or histology
             from colorectal cancer.

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             before start of study medication.

          -  Unstable/uncontrolled cardiac disease including: congestive heart failure > New York
             Heart Association (NYHA) class 2; unstable angina (angina symptoms at rest), new-onset
             angina (begun within the last 3 months); myocardial infarction less than 6 months
             before start of study drug; cardiac arrhythmias requiring anti-arrhythmic therapy
             (beta blockers or digoxin are permitted).

          -  Uncontrolled hypertension. (Systolic blood pressure > 150 mmHg or diastolic pressure >
             90 mmHg despite optimal medical management).

          -  Patients with phaeochromocytoma.

          -  Arterial or venous thrombotic or embolic events such as cerebrovascular accident
             (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism
             within the 6 months before start of study medication.

          -  Ongoing infection > grade 2 NCI-CTCAE version 4.03

          -  Known history of human immunodeficiency virus (HIV) infection.

          -  Known history of chronic hepatitis B or C.

          -  Patients with seizure disorder requiring medication.

          -  Symptomatic metastatic brain or meningeal tumors unless the patient is > 6 months from
             definitive therapy, has a negative imaging study within 4 weeks of study entry and is
             clinically stable with respect to the tumor at the time of study entry. Also the
             patient must not be undergoing acute steroid therapy or taper (chronic steroid therapy
             is acceptable provided that the dose is stable for one month prior to and following
             screening radiographic studies)

          -  History of organ allograft

          -  Patients with evidence or history of bleeding diasthesis, including patients who have
             had a transfusion and/or radiographic endoscopic or elective operative interaction to
             control the bleeding or hemorrhage event within four weeks prior to the study

          -  Non-healing wound, ulcer, or bone fracture.

          -  Renal impairment or failure requiring hemo-or peritoneal dialysis.

          -  Patients with severe hepatic impairment.

          -  Dehydration NCI-CTC version 4.03 grade > 1.

          -  Substance abuse, medical, psychological or social conditions that may interfere with
             the patient's participation in the study or evaluation of the study results

          -  Any illness or medical conditions that are unstable or could jeopardize the safety of
             the study

          -  Interstitial lung disease with ongoing signs and symptoms at the time of informed
             consent.

          -  Persistent proteinuria of Common Terminology Criteria (CTC) Grade 3 or higher.
             Quantification of proteinuria done by urinary protein/creatinine ratio on a random
             urine sample preferably taken at mid-morning. If protein/creatinine ratio is greater
             than 30g/mol Creat, then a 24-hour urine protein test should be performed to confirmed
             Grade 3 or higher proteinuria (> 3.5 g/24 hours).

          -  Patients unable to swallow oral medications

          -  Any malabsorption condition

          -  Unresolved toxicity higher than NCI-CTCAE (version 4.03) Grade 1 attributed to any
             prior therapy/procedure excluding alopecia and oxaliplatin induced neurotoxicity
             ≤Grade 2

          -  Patients who are hypersensitive to perindopril, as well as those hypersensitive to
             regorafenib, sorafenib, drugs in the same class or any ingredient in the formulation.

          -  Patients who cannot tolerate the full dose of perindopril (4 mg) for any reason.

          -  Patients receiving systemic anticancer therapy including cytotoxic therapy, signal
             transduction inhibitors, immunotherapy, hormonal therapy and experimental or approved
             therapies during this trial or within 14 days before starting to receive study
             medication.

        In addition, patients will be excluded for the following reasons (From perindopril
        monograph).

          -  Patients with a history of hereditary/idiopathic angioedema, or angioedema related to
             previous treatment with an angiotensin converting enzyme inhibitor.

          -  Pregnant women or those planning to become pregnant, nursing women.

          -  Patients with hereditary problems of galactose intolerance, glucose-galactose
             malabsorption, or the Lapp lactase deficiency.

          -  Patients with pre-existing anti-hypertension treatment with an angiotensin-converting
             enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) are to be excluded.
             Co-administration of ACE inhibitors, including COVERSYL®, with other agents blocking
             the Renin-Angiotensin System (RAS), such as ARBs or aliskiren-containing drugs, will
             not be allowed, since such treatment has been associated with an increased incidence
             of severe hypotension, renal failure, and hyperkalemia.
      "
NCT02656615,terminated,"
    lack of patient accrual
  ",0,phase 2,['prostate cancer'],"[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]",['abiraterone acetate'],['Status: 503'],"
        Inclusion Criteria:

          1. Written prostate cancer.

          2. Adult patients with histological or cytological diagnosis of adenocarcinoma of the
             prostate.

          3. Men with castration-resistant metastatic decline maintained for at least 3 weeks as
             per PCWG2 criteria).

          4. Confirmed biochemical response to prior abiraterone acetate (≥50% PSA Informed Consent
             (including consent for biomarker studies including the fresh tumour biopsies)

          5. Progressive disease according to PCWG2 criteria during prior therapy with standard
             dose of abiraterone acetate (confirmed increase of PSA ≥25% over nadir) or soft-tissue
             or bone progression. Patients that have stopped abiraterone acetate for reasons other
             than progression are not eligible.

          6. Documented progression of disease by any of the criteria listed here:

               -  PSA

               -  Soft tissue

               -  Bone scan all as per PCWG2 criteria

          7. Patients may have received treatment with docetaxel, enzalutamide or radium-223

          8. PSA of ≥10ug/l

          9. ECOG performance status 0 - 2

         10. At least 3 months (90 days) since stop of prior abiraterone acetate.

        Exclusion Criteria:

          1. Major surgery within 28 days weeks prior to start of treatment

          2. Prior treatment with cabazitaxel or the CYP-17 inhibitor TAK-700/orteronel

          3. Any concurrent treatment or prior treatment with an investigational drug within 28
             days prior to start of treatment.

          4. Known brain or leptomeningeal disease

          5. Concurrent use of steroids other than prednisone >10mg/d

          6. Inadequate bone marrow and organ function as evidenced by:

             Platelet count <75 x 10 G/L ASAT and/or ALAT ≥ 2.5 x ULN Total bilirubin ≥ 1.5 x ULN
             (≥ 2.0 x ULN for patients with Gilbert's disease) Hypokalaemia despite adequate
             supplementation Creatinine Clearance <30ml/min

          7. Uncontrolled hypertension or cardiac failure or LVEF <50%

        creatinine clearance is to be calculated by using the formula of Cockcroft-Gault in
        appendix 4 of the protocol
      "
NCT02657928,completed,,1,phase 2,"['estrogen receptor positive', 'postmenopausal', 'recurrent fallopian tube carcinoma', 'recurrent ovarian carcinoma', 'recurrent primary peritoneal carcinoma', 'recurrent uterine corpus carcinoma']","[""['Z17.0']"", ""['N95.0', 'N95.2']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['letrozole', 'ribociclib']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Ability to understand and the willingness to sign a written informed consent document

          -  Post-menopausal

          -  Histologically confirmed recurrent ovarian, fallopian tube or primary peritoneal
             carcinoma or endometrial cancer in post-menopausal women; NOTE: pure clear cell and
             pure mucinous carcinomas are ineligible; platinum sensitive, platinum resistant and
             platinum refractory disease are eligible; no limitations in the number of prior
             regimens

          -  Patient has disease amenable to biopsy and is agreeable to undergo a biopsy; NOTE:
             under unusual circumstances, submission of ascites material may be acceptable if a
             biopsy is not possible; this exception will require approval by one of the study
             principal investigators

          -  Willing to provide tissue samples for ER and retinoblastoma (RB) staining

          -  Measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST) criteria

          -  Tumors must stain positive for estrogen receptor (>= 10%) by immunohistochemistry
             (IHC)

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2

          -  Absolute neutrophil count (ANC) >= 1000/mm^3

          -  Platelet count >= 100,000/mm^3

          -  Hemoglobin >= 9.0 g/dL

          -  Total bilirubin =< 1 x upper limit of normal (ULN); or total bilirubin =< 3.0 x ULN
             with direct bilirubin =< 1.5 x ULN in patients with well-documented Gilbert's syndrome

          -  Aspartate transaminase (aspartate aminotransferase [AST]) =< 2.5 x ULN (=< 5 x ULN in
             patients with liver metastasis)

          -  International normalized ratio (INR) =< 2

          -  Creatinine =< 1.5 mg/dL

          -  Potassium =< ULN (or corrected to =< ULN with supplements prior to registration)

          -  Total calcium (corrected for serum calcium) =< ULN (or corrected to =< ULN with
             supplements prior to registration)

          -  Magnesium =< ULN (or corrected to =< ULN with supplements prior to registration)

          -  Sodium =< ULN (or corrected to =< ULN with supplements prior to registration)

          -  Phosphorus =< ULN (or corrected to =< ULN with supplements prior to registration)

          -  Ability to swallow study medication

          -  Provide informed written consent

          -  Willing to return to enrolling institution for follow-up (during the active monitoring
             phase of the study)

          -  Willing to provide tissue samples for correlative research purposes

        Exclusion Criteria:

          -  Patients who have central nervous system (CNS) involvement unless they meet ALL of the
             following criteria:

               -  >= 4 weeks from prior therapy completion (including radiation and/or surgery) to
                  starting the study treatment

               -  Clinically stable CNS tumor at the time of screening and not receiving steroids
                  and/or enzyme-inducing anti-epileptic medications for brain metastases

          -  Patient has any other concurrent severe and/or uncontrolled medical condition that
             would, in the investigator's judgment, cause unacceptable safety risks, contraindicate
             patient participation in the clinical study or compromise compliance with the protocol
             (e.g. chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled
             fungal, bacterial or viral infections, etc.)

          -  Clinically significant, uncontrolled heart disease or cardiac repolarization
             abnormalities and/or recent events including any of the following:

               -  History of acute coronary syndromes (including myocardial infarction, unstable
                  angina, coronary artery bypass grafting, coronary angioplasty, or stenting) or
                  symptomatic pericarditis within 6 months prior to screening

               -  History of documented congestive heart failure (New York Heart Association
                  functional classification III-IV)

               -  Documented cardiomyopathy

               -  Left ventricular ejection fraction (LVEF) < 50% as determined by multiple gated
                  acquisition (MUGA) scan or echocardiogram (ECHO) at screening

               -  Clinically significant cardiac arrhythmias (e.g. ventricular tachycardia),
                  complete left bundle branch block, high-grade atrioventricular (AV) block (e.g.
                  bifascicular block, Mobitz type II and third-degree AV block) long QT syndrome or
                  family history of long QT syndrome

               -  Idiopathic sudden death or congenital long QT syndrome

               -  Risk factors for torsades de pointe (TdP) including uncorrected hypokalemia or
                  hypomagnesemia, history of cardiac failure, or history of clinically
                  significant/symptomatic bradycardia

               -  Concomitant use of medication(s) with a known risk to prolong the QT interval
                  and/or known to cause torsades de pointe that cannot be discontinued (within 5
                  half-lives or 7 days prior to starting study drug) or replaced by safe
                  alternative medication

               -  Inability to determine the QT interval on screening (corrected QT interval
                  [QTcF], using Fridericia's correction)

               -  Systolic blood pressure (SBP) > 160 mmHg or < 90 mmHg at screening

               -  Bradycardia (heart rate < 50 at rest), by electrocardiogram (ECG) or pulse, at
                  screening

               -  Tachycardia (heart rate > 110 at rest), by ECG or pulse at screening

          -  Inability to determine the QTcF interval on the ECG (i.e.: unreadable or not
             interpretable) or QTcF > 450 msec (using Fridericia's correction); NOTE: all as
             determined by screening ECG

          -  Patient is currently receiving any of the following medications and cannot be
             discontinued =< 7 days prior to starting study drug: known strong inducers or
             inhibitors of cytochrome P450 family 3, subfamily A, polypeptide 4/5 (CYP3A4/5)
             including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges or
             that have a narrow therapeutic window and are predominantly metabolized through
             CYP3A4/5 or herbal preparations/medications or dietary supplements

          -  Patient is currently receiving or has received systemic corticosteroids within =< 2
             weeks prior to starting study drug, or who have not fully recovered from side effects
             of such treatment; NOTE: the following uses of corticosteroids are permitted: single
             doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive
             airways diseases), eye drops or local injections (e.g., intra-articular)

          -  Patient has received radiotherapy =< 4 weeks or limited field radiation for palliation
             =< 2 weeks prior to starting study drug, and who has not recovered to grade 1 or
             better from related side effects of such therapy (exceptions include alopecia) and/or
             in whom >= 30% of the bone marrow was irradiated

          -  Patient has had major surgery =< 14 days prior to registration or has not recovered
             from major side effects (tumor biopsy is not considered as major surgery)

          -  Known to be human immunodeficiency virus (HIV) positive (testing not mandatory)

          -  Patient has a known hypersensitivity to any of the excipients of ribociclib

          -  Patient is currently receiving warfarin or other Coumarin-derived anticoagulant for
             treatment, prophylaxis or otherwise; NOTE: therapy with apixaban, dabigatran, heparin,
             low molecular weight heparin (LMWH) or fondaparinux is allowed

          -  Participation in a prior investigational study within 30 days prior to enrollment or
             =< 5 half-lives of the investigational product, whichever is longer

          -  Patient has not recovered from all toxicities related to prior anticancer therapies to
             National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE)
             version 4.0 grade < 3 (exception to this criterion: patients with any grade of
             alopecia or neuropathy are allowed to enter the study)

          -  Patient with a Child-Pugh score B or C

          -  Patient has impairment of gastrointestinal (GI) function or GI disease that may
             significantly alter the absorption of the study drugs (e.g., ulcerative diseases,
             uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or significant small
             bowel resection)

          -  Prior therapy with ribociclib or an aromatase inhibitor (letrozole, anastrozole or
             exemestane)

          -  Patient has received systemic chemotherapy =< 3 weeks prior to registration
      "
NCT02658084,terminated,"
    terminated due to low accrual and toxicity concerns.
  ",0,phase 1/phase 2,"['breast cancer', 'metastatic breast cancer']","[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['vinorelbine', 'trastuzumab emtansine']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          1. Histologically or cytologically documented breast cancer.

          2. Metastatic or unresectable locally advanced/recurrent breast cancer.

          3. HER2-positive disease documented as: Immunohistochemistry (IHC) 3+ positive, and/or
             Fluorescence in situ hybridization (FISH) ≥ 2.0, and/or gene copy number greater than
             6, on previously collected tumor or metastatic site. IHC testing, FISH assay(s), and
             gene copy number may all have been performed; however, a positive result from only one
             of the above is required for eligibility.

          4. Documented disease progression on the last regimen by radiographic measurement
             (progression demonstrated by tumor markers only is unacceptable).

          5. Documented disease progression (by investigator assessment) after at least one regimen
             of HER2-directed therapy in the metastatic or unresectable locally advanced/recurrent
             setting.

          6. For patients with hormone receptor-positive disease: disease progression or recurrence
             in any setting on prior hormonal therapy, given with or without HER2 directed therapy.

          7. Measurable or bone only disease.

          8. Prior treatment with a taxane, in the neoadjuvant, adjuvant, locally advanced or
             metastatic setting.

          9. A minimum of 6 weeks of prior trastuzumab for the treatment of metastatic or
             unresectable locally advanced/recurrent disease is required.

         10. Prior use of Pertuzumab in any setting is permitted (but not required).

         11. Prior use of Lapatinib in any setting is permitted (but not required).

         12. Age ≥ 18 years

         13. Life expectancy ≥ 3 months

         14. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. See Appendix C
             for details.

         15. Patients must have normal organ and marrow function as defined below:

               -  absolute neutrophil count (ANC) >1,500 cells/mm3

               -  platelets >100,000 cells/mm3

               -  hemoglobin > 9.0 g/dL (Patients are permitted to receive transfused red blood
                  cells to achieve this level.)

               -  total bilirubin ≤1.5 X institutional upper limit of normal (ULN) [Note: For
                  patients with previously documented Gilbert's syndrome, total bilirubin ≤ 3
                  mg/dL.]

               -  Aspartate aminotransferase (AST/SGOT) ≤ 2.5 X ULN

               -  Alanine aminotransferase (ALT/SGPT) ≤ 2.5 X ULN

               -  alkaline phosphatase (alk phos) ≤ 2.5 X ULN

               -  serum creatinine < 1.5 X ULN

         16. International normalized ratio (INR) < 1.5 X ULN

         17. Left ventricular ejection fraction (LVEF) ≥ 50% by either echocardiogram (ECHO) or
             multiple-gated acquisition scan (MUGA).

         18. Negative results of serum pregnancy test for premenopausal women of reproductive
             capacity and for women < 12 months after menopause. For men and women of childbearing
             potential, agreement by the patient and/or partner to use two effective non-hormonal
             forms of barrier contraception at the same time, throughout treatment on study. Women
             should agree to continued use for at least 90 days after the end of treatment. Men
             should agree to continued use for at least 7 months after the end of treatment.
             Examples of non-hormonal barrier contraception include: condom or occlusive cap
             (diaphragm or cervical/vault caps) with spermicide.

         19. Ability to understand and willingness to sign a written informed consent and HIPAA
             document.

        Exclusion Criteria:

          1. Chemotherapy ≤21 days prior to first dose of study treatment

          2. If last dose of trastuzumab was:

               -  6mg/kg then ≤21 days prior to first dose of study treatment

               -  4mg/kg then ≤14 days prior to first dose of study treatment

               -  2mg/kg then ≤7 days prior to first dose of study treatment

          3. Lapatinib ≤14 days prior to first dose of study treatment

          4. Pertuzumab ≤21 days prior to first dose of study treatment

          5. Hormone therapy ≤7 days prior to first dose of study treatment

          6. Investigational therapy or any other such experimental therapy ≤28 days prior to first
             dose of study treatment

          7. Prior treatment with trastuzumab emtansine, (on or off a study protocol)

          8. Prior use of vinorelbine (in any setting).

          9. Previous radiotherapy for the treatment of unresectable, locally advanced, recurrent
             or metastatic breast cancer is not allowed if:

               -  The last fraction of radiotherapy has been administered within 14 days prior to
                  study enrollment

               -  More than 25% of marrow-bearing bone has been irradiated

         10. Brain metastases that are untreated or symptomatic, or require any radiation, surgery,
             or continued steroid therapy to control symptoms from brain metastases within 14 days
             of study enrollment.

         11. History of intolerance (including Grade 3 or 4 infusion reaction) or hypersensitivity
             to trastuzumab or murine proteins.

         12. History of exposure to the following cumulative doses of anthracyclines:

               -  Doxorubicin ≥550mg/m2

               -  Liposomal doxorubicin >500 mg/m2

               -  Epirubicin >900 mg/m2

               -  Mitoxantrone > 120 mg/m2

               -  If another anthracycline, or more than one anthracycline, has been used, the
                  cumulative dose must not exceed the equivalent of ≥550 mg/m2 doxorubicin.

         13. Current peripheral neuropathy of Grade ≥3 per the NCI CTCAE, v4.0

         14. The patient has not recovered from any other acute toxicity (to Grade ≤1 as per NCI
             CTCAE v4.03) prior to study enrollment.

         15. History of other malignancy within the last 3 years, except for appropriately treated
             carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer,
             or other cancers with a similar outcome.

         16. Cardiopulmonary Function Criteria:

               -  Current unstable ventricular arrhythmia requiring treatment

               -  History of symptomatic congestive heart failure (CHF) as per New York Heart
                  Association (NYHA) Classes II-IV; see Appendix D for details.

               -  History of myocardial infarction or unstable angina within 6 months of study
                  enrollment

               -  History of a decrease in LVEF to < 40% or symptomatic CHF with previous
                  trastuzumab treatment

               -  Severe dyspnea at rest due to complications of advanced malignancy or requiring
                  current continuous oxygen therapy

         17. Current severe, uncontrolled systemic disease (e.g., clinically significant
             cardiovascular, pulmonary, or metabolic disease)

               -  Major surgical procedure or significant traumatic injury within 28 days -before
                  enrollment or anticipation of the need for major surgery during the course of
                  study treatment

               -  Current pregnancy or lactation

               -  Current known uncontrolled active infection with HIV, hepatitis B, and/or
                  hepatitis C virus

         18. Any uncontrolled, intercurrent illness including but not limited to ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia.

         19. Any other serious medical or psychiatric illness/condition likely in the judgment of
             the Investigator(s) to interfere or limit compliance with study
             requirements/treatment.
      "
NCT02654132,completed,,1,phase 2,['multiple myeloma'],"[""['C90.01', 'C90.02', 'C90.00']""]","['elotuzumab', 'pomalidomide', 'dexamethasone']","['Status: 503', 'Status: 503', 'Status: 503']","
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  ≥ 2 prior lines of therapy which must have included at least 2 consecutive cycles of
             lenalidomide and a proteosome inhibitor alone or in combination

          -  Documented refractory or relapsed and refractory multiple myeloma

          -  Refractory to proteosome inhibitor and lenalidomide, and to last treatment

          -  Relapsed and refractory patients must have achieved at least a partial response to
             previous treatment with proteosome inhibitor or lenalidomide, or both, but progressed
             within 6 months, and were refractory to their last treatment

          -  Measurable disease at screening

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

        Exclusion Criteria:

          -  Active plasma cell leukemia

          -  Prior treatment with pomalidomide

          -  Unable to tolerate thromboembolic prophylaxis while on the study

          -  Prior autologous stem cell transplant within 12 weeks

          -  Known Human Immunodeficiency Virus (HIV) infection or active hepatitis A, B, or C
      "
NCT01641107,completed,,0,phase 2,"['philadelphia positive', 'bcr-abl positive', 'acute lymphoblastic leukemia']","[""['C91.01', 'C91.02', 'C91.00']""]",['ponatinib'],['Status: 503'],"
        Inclusion Criteria:

          1. To be classified as having Ph+ ALL, patients must have >20% blasts in bone marrow at
             the time of diagnosis and no prior history of CML.

          2. Patients with previously untreated Ph+ and/or BCR/ABL + ALL:

               -  age ≥ 60 years old or

               -  age ≥ 18 years old, but unfit for program of intensive therapy and allogeneic SCT

          3. Adequate hepatic function as defined by the following criteria:

               -  total serum bilirubin ≤1.5 x upper limit of normal (ULN), unless due to Gilbert's
                  syndrome

               -  alanine aminotransferase (ALT) ≤2.5 × ULN

               -  aspartate aminotransferase (AST) ≤2.5 × ULN.

          4. Adequate pancreatic function as defined by the following criterion:

             - serum lipase and amylase ≤1.5 × ULN.

          5. For females of childbearing potential, a negative pregnancy test must be documented
             prior to randomization.

          6. Female and male patients who are fertile must agree to use an effective form of
             contraception with their sexual partners from randomization through 4 months after the
             end of treatment.

          7. Signed written informed consent according to ICH/EU/GCP and national local laws.

        Exclusion Criteria:

          1. WHO performance status ≤ 50% (Karnofsky) or ≥ 3 (ECOG).

          2. Active HBV or HCV hepatitis, or AST/ALT ≥ 2.5 x ULN and bilirubin ≥ 1.5 x ULN.

          3. History of acute pancreatitis within 1 year of study or history of chronic
             pancreatitis.

          4. History of alcohol abuse.

          5. Ongoing or active infections.

          6. Uncontrolled hypertriglyceridemia (triglycerides >450 mg/dL).

          7. Clinically significant, uncontrolled, or active cardiovascular disease, specifically
             including, but not restricted to:

               -  any history of myocardial infarction, stroke, or revascularization

               -  unstable angina or transient ischemic attack within 6 months prior to enrollment

               -  congestive heart failure within 6 months prior to enrollment, or left ventricular
                  ejection fraction (LVEF) less than lower limit of normal per local institutional
                  standards within 6 months prior to enrollment

               -  history of clinically significant (as determined by the treating physician)
                  atrial arrhythmia

               -  any history of ventricular arrhythmia

               -  any history of venous thromboembolism including deep venous thrombosis or
                  pulmonary embolism .

          8. Uncontrolled hypertension (diastolic blood pressure >90 mm Hg; systolic >140 mm Hg).
             Patients with hypertension should be under treatment on study entry to effect blood
             pressure control.

          9. Taking medications that are known to be associated with Torsades de Pointes.

         10. Taking any medications or herbal supplements that are known to be strong inhibitors of
             CYP3A4 within at least 14 days before the first dose of ponatinib.

         11. Creatinine level > 2.5mg/dl or Glomerular Filtration Rate (GFR) < 20 ml/min or
             proteinuria > 3.5 g/day.

         12. Impairment of gastrointestinal (GI) function, or a GI disease that may significantly
             alter the absorption of study drugs (e.g. rare hereditary problems of galactose
             intolerance , the Lapp lactase deficiency or glucose-galactose malabsorption, severe
             malabsorption syndrome, or extended small bowel resection).

         13. Patients who are currently receiving treatment with any of the medications listed in
             Appendix E if the medications cannot be either discontinued or switched to a different
             medication prior to starting study drug. The medications listed in Appendix E have the
             potential to prolong QT.

         14. Patients who have received any investigational drug ≤ 4 weeks.

         15. Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or
             who have not recovered from side effects of such therapy.

         16. Patients who are pregnant or breast feeding and adults of reproductive potential not
             employing an effective method of birth control (women of childbearing potential must
             have a negative serum pregnancy test within 48 hrs prior to administration of
             Ponatinib). Post menopausal women must be amenorrhoeic for at least 12 months to be
             considered of non-childbearing potential. Male and female patients must agree to
             employ an effective barrier method of birth control throughout the study and for up to
             4 months following discontinuation of study drugs.

         17. Patients with a history of another primary malignancy that is currently clinically
             significant or currently requires active intervention.

         18. Patients unwilling or unable to comply with the protocol.
      "
